,Broader,N,PUBMEDID,AUTHOR,parentterm,STAGE,DATE,ACCESSION,DiseaseOrTrait
4722,European,146.0,15761122.0,Klein RJ,Neurological disorder,initial,2005-03-10,GCST000001,Age-related macular degeneration
13510,Other/Mixed,122.0,16252231.0,Maraganore DM,Neurological disorder,replication,2005-09-09,GCST000002,Parkinson's disease
13517,Other/Mixed,141.0,16252231.0,Maraganore DM,Neurological disorder,initial,2005-09-09,GCST000002,Parkinson's disease
1515,Asian,1.0,16252231.0,Maraganore DM,Neurological disorder,initial,2005-09-09,GCST000002,Parkinson's disease
1516,Asian,1.0,16252231.0,Maraganore DM,Neurological disorder,replication,2005-09-09,GCST000002,Parkinson's disease
5688,European,744.0,16252231.0,Maraganore DM,Neurological disorder,initial,2005-09-09,GCST000002,Parkinson's disease
5399,European,541.0,16252231.0,Maraganore DM,Neurological disorder,replication,2005-09-09,GCST000002,Parkinson's disease
750,African American or Afro-Caribbean,866.0,16614226.0,Herbert A,"Other measurement, Metabolic disorder",replication,2006-04-14,GCST000003,Obesity
9640,European,10527.0,16614226.0,Herbert A,"Other measurement, Metabolic disorder",replication,2006-04-14,GCST000003,Obesity
4818,European,200.0,16648850.0,Arking DE,Cardiovascular measurement,initial,2006-04-30,GCST000004,QT interval
8375,European,4851.0,16648850.0,Arking DE,Cardiovascular measurement,replication,2006-04-30,GCST000004,QT interval
5394,European,537.0,17052657.0,Fung HC,Neurological disorder,initial,2006-09-28,GCST000005,Parkinson's disease
1838,Asian,226.0,17053108.0,Dewan A,Neurological disorder,initial,2006-10-19,GCST000006,Age-related macular degeneration (wet)
5571,European,662.0,17053149.0,Papassotiropoulos A,Other measurement,replication,2006-10-20,GCST000007,Memory performance
13415,Other/Mixed,18.0,17053149.0,Papassotiropoulos A,Other measurement,replication,2006-10-20,GCST000007,Memory performance
5022,European,341.0,17053149.0,Papassotiropoulos A,Other measurement,initial,2006-10-20,GCST000007,Memory performance
6191,European,1095.0,17068223.0,Duerr RH,"Digestive system disorder, Immune system disorder",initial,2006-10-26,GCST000008,Inflammatory bowel disease
13877,Other/Mixed,1584.0,17068223.0,Duerr RH,"Digestive system disorder, Immune system disorder",replication,2006-10-26,GCST000008,Inflammatory bowel disease
5677,European,740.0,17099884.0,Liu QR,Neurological disorder,initial,2006-12-05,GCST000009,Addiction
762,African American or Afro-Caribbean,920.0,17099884.0,Liu QR,Neurological disorder,initial,2006-12-05,GCST000009,Addiction
6037,European,981.0,17158188.0,Bierut LJ,Neurological disorder,replication,2006-12-07,GCST000010,Nicotine dependence
5979,European,948.0,17158188.0,Bierut LJ,Neurological disorder,initial,2006-12-07,GCST000010,Nicotine dependence
5593,European,673.0,17223258.0,Spinola M,Cancer,initial,2007-01-16,GCST000011,Lung cancer
5513,European,621.0,17223258.0,Spinola M,Cancer,replication,2007-01-16,GCST000011,Lung cancer
6348,European,1275.0,17293876.0,Sladek R,Metabolic disorder,initial,2007-02-11,GCST000012,Type 2 diabetes
8628,European,5511.0,17293876.0,Sladek R,Metabolic disorder,replication,2007-02-11,GCST000012,Type 2 diabetes
5406,European,547.0,17362836.0,Schymick JC,Neurological disorder,initial,2007-02-20,GCST000013,Amyotrophic lateral sclerosis
7646,European,3109.0,17447842.0,Libioulle C,Digestive system disorder,replication,2007-03-05,GCST000014,Crohn's disease
6509,European,1475.0,17447842.0,Libioulle C,Digestive system disorder,initial,2007-03-05,GCST000014,Crohn's disease
5488,European,604.0,17357082.0,Melquist S,Neurological disorder,replication,2007-03-08,GCST000015,Progressive supranuclear palsy
5526,European,632.0,17357082.0,Melquist S,Neurological disorder,initial,2007-03-08,GCST000015,Progressive supranuclear palsy
4992,European,322.0,17522711.0,Lencz T,Neurological disorder,initial,2007-03-20,GCST000016,Schizophrenia
13565,Other/Mixed,207.0,17395743.0,Hanson RL,Other disease,initial,2007-04-01,GCST000020,End-stage renal disease
8259,European,4517.0,17401366.0,Gudmundsson J,Cancer,initial,2007-04-01,GCST000019,Prostate cancer
7956,European,3655.0,17401366.0,Gudmundsson J,Cancer,replication,2007-04-01,GCST000019,Prostate cancer
6177,European,1086.0,17474819.0,Coon KD,Neurological disorder,initial,2007-04-01,GCST000018,Alzheimer's disease (late onset)
718,African American or Afro-Caribbean,745.0,17401366.0,Gudmundsson J,Cancer,replication,2007-04-01,GCST000019,Prostate cancer
8801,European,6266.0,17401363.0,Yeager M,Cancer,replication,2007-04-01,GCST000017,Prostate cancer
7204,European,2329.0,17401363.0,Yeager M,Cancer,initial,2007-04-01,GCST000017,Prostate cancer
5222,European,454.0,17407593.0,Uhl GR,Neurological disorder,initial,2007-04-03,GCST000021,Nicotine dependence
9666,European,10657.0,17434869.0,Frayling TM,"Body measurement, Other measurement",initial,2007-04-12,GCST000022,Body mass index
10681,European,29596.0,17434869.0,Frayling TM,"Body measurement, Other measurement",replication,2007-04-12,GCST000022,Body mass index
9432,European,9103.0,17463249.0,Zeggini E,Metabolic disorder,replication,2007-04-26,GCST000025,Type 2 diabetes
7393,European,2601.0,17463246.0,Saxena R,Lipid or lipoprotein measurement,initial,2007-04-26,GCST004920,LDL cholesterol levels
9696,European,10850.0,17463246.0,Saxena R,Metabolic disorder,replication,2007-04-26,GCST000028,Type 2 diabetes
7569,European,2931.0,17463246.0,Saxena R,Metabolic disorder,initial,2007-04-26,GCST000028,Type 2 diabetes
9377,European,8686.0,17460697.0,Steinthorsdottir V,Metabolic disorder,initial,2007-04-26,GCST000027,Type 2 diabetes
7293,European,2473.0,17463248.0,Scott LJ,Metabolic disorder,replication,2007-04-26,GCST000024,Type 2 diabetes
8378,European,4862.0,17463249.0,Zeggini E,Metabolic disorder,initial,2007-04-26,GCST000025,Type 2 diabetes
6490,European,1451.0,17463246.0,Saxena R,Lipid or lipoprotein measurement,initial,2007-04-26,GCST004921,Apolipoprotein A1 levels
9493,European,9461.0,17460697.0,Steinthorsdottir V,Metabolic disorder,replication,2007-04-26,GCST000027,Type 2 diabetes
7209,European,2335.0,17463248.0,Scott LJ,Metabolic disorder,initial,2007-04-26,GCST000024,Type 2 diabetes
7409,European,2623.0,17463246.0,Saxena R,Lipid or lipoprotein measurement,initial,2007-04-26,GCST004919,HDL cholesterol levels
7427,European,2659.0,17463246.0,Saxena R,Lipid or lipoprotein measurement,initial,2007-04-26,GCST000026,Triglycerides
8535,European,5217.0,17463246.0,Saxena R,Lipid or lipoprotein measurement,replication,2007-04-26,GCST000026,Triglycerides
5023,European,341.0,17470457.0,Huentelman MJ,Biological process,initial,2007-04-30,GCST000029,Episodic memory
5251,European,472.0,17470457.0,Huentelman MJ,Biological process,replication,2007-04-30,GCST000029,Episodic memory
9456,European,9289.0,17478679.0,Helgadottir A,Cardiovascular disease,replication,2007-05-03,GCST000030,Myocardial infarction
9242,European,8335.0,17478679.0,Helgadottir A,Cardiovascular disease,initial,2007-05-03,GCST000030,Myocardial infarction
10514,European,23791.0,17478681.0,McPherson R,Cardiovascular disease,replication,2007-05-03,GCST000031,Coronary heart disease
5530,European,634.0,17478681.0,McPherson R,Cardiovascular disease,initial,2007-05-03,GCST000031,Coronary heart disease
5358,European,517.0,17434096.0,Matarin M,Cardiovascular disease,initial,2007-05-06,GCST000032,Stroke
6121,European,1024.0,17486107.0,Baum AE,Neurological disorder,initial,2007-05-08,GCST000033,Bipolar disorder
6664,European,1648.0,17486107.0,Baum AE,Neurological disorder,replication,2007-05-08,GCST000033,Bipolar disorder
4827,European,204.0,17505501.0,Kindmark A,"Liver enzyme measurement, Response to drug",initial,2007-05-15,GCST000034,Response to ximelagatran treatment (increased serum alanine aminotransferase levels)
4563,European,26.0,17505501.0,Kindmark A,"Liver enzyme measurement, Response to drug",replication,2007-05-15,GCST000034,Response to ximelagatran treatment (increased serum alanine aminotransferase levels)
13806,Other/Mixed,896.0,17529973.0,Hunter DJ,Cancer,replication,2007-05-27,GCST000036,Breast cancer
9880,European,13145.0,17529974.0,Stacey SN,Cancer,initial,2007-05-27,GCST000037,Breast cancer
5706,European,754.0,17529967.0,Easton DF,Cancer,initial,2007-05-27,GCST000035,Breast cancer
13664,Other/Mixed,441.0,17529974.0,Stacey SN,Cancer,replication,2007-05-27,GCST000037,Breast cancer
3873,Asian,7928.0,17529967.0,Easton DF,Cancer,replication,2007-05-27,GCST000035,Breast cancer
7167,European,2287.0,17529973.0,Hunter DJ,Cancer,initial,2007-05-27,GCST000036,Breast cancer
751,African American or Afro-Caribbean,870.0,17529974.0,Stacey SN,Cancer,replication,2007-05-27,GCST000037,Breast cancer
11087,European,48565.0,17529967.0,Easton DF,Cancer,replication,2007-05-27,GCST000035,Breast cancer
2493,Asian,1126.0,17529974.0,Stacey SN,Cancer,replication,2007-05-27,GCST000037,Breast cancer
7216,European,2352.0,17529973.0,Hunter DJ,Cancer,replication,2007-05-27,GCST000036,Breast cancer
9410,European,8921.0,17529974.0,Stacey SN,Cancer,replication,2007-05-27,GCST000037,Breast cancer
12755,Hispanic or Latin American,840.0,17529974.0,Stacey SN,Cancer,replication,2007-05-27,GCST000037,Breast cancer
7687,European,3206.0,17554261.0,Parkes M,Digestive system disorder,replication,2007-06-06,GCST000039,Crohn's disease
8456,European,5000.0,17554260.0,Todd JA,Metabolic disorder,initial,2007-06-06,GCST000038,Type 1 diabetes
10234,European,17991.0,17554260.0,Todd JA,Metabolic disorder,replication,2007-06-06,GCST000038,Type 1 diabetes
8317,European,4686.0,17554300.0,Wellcome Trust Case Control Consortium,Digestive system disorder,initial,2007-06-07,GCST000042,Crohn's disease
8395,European,4901.0,17554300.0,Wellcome Trust Case Control Consortium,Metabolic disorder,initial,2007-06-07,GCST000043,Type 1 diabetes
8353,European,4798.0,17554300.0,Wellcome Trust Case Control Consortium,Immune system disorder,initial,2007-06-07,GCST000040,Rheumatoid arthritis
8381,European,4864.0,17554300.0,Wellcome Trust Case Control Consortium,Cardiovascular disease,initial,2007-06-07,GCST000045,Coronary heart disease
8379,European,4862.0,17554300.0,Wellcome Trust Case Control Consortium,Metabolic disorder,initial,2007-06-07,GCST000047,Type 2 diabetes
8356,European,4806.0,17554300.0,Wellcome Trust Case Control Consortium,Neurological disorder,initial,2007-06-07,GCST000044,Bipolar disorder
8392,European,4890.0,17554300.0,Wellcome Trust Case Control Consortium,Cardiovascular disease,initial,2007-06-07,GCST000041,Hypertension
7299,European,2480.0,17558408.0,van Heel DA,Immune system disorder,replication,2007-06-10,GCST000048,Celiac disease
7115,European,2200.0,17558408.0,van Heel DA,Immune system disorder,initial,2007-06-10,GCST000048,Celiac disease
8584,European,5349.0,17668382.0,Salonen JT,Metabolic disorder,replication,2007-06-26,GCST000049,Type 2 diabetes
6067,European,997.0,17668382.0,Salonen JT,Metabolic disorder,initial,2007-06-26,GCST000049,Type 2 diabetes
9864,European,12791.0,17603485.0,Gudmundsson J,Cancer,initial,2007-07-01,GCST000050,Prostate cancer
8474,European,5050.0,17603485.0,Gudmundsson J,Cancer,replication,2007-07-01,GCST000050,Prostate cancer
3265,Asian,3169.0,17603472.0,Gudbjartsson DF,Cardiovascular disease,replication,2007-07-01,GCST000051,Atrial fibrillation/atrial flutter
10228,European,17810.0,17603472.0,Gudbjartsson DF,Cardiovascular disease,replication,2007-07-01,GCST000051,Atrial fibrillation/atrial flutter
8464,European,5026.0,17603472.0,Gudbjartsson DF,Cardiovascular disease,initial,2007-07-01,GCST000051,Atrial fibrillation/atrial flutter
9849,European,12580.0,17618284.0,Tomlinson I,Cancer,replication,2007-07-08,GCST000053,Colorectal cancer
9635,European,10472.0,17618283.0,Zanke BW,Cancer,replication,2007-07-08,GCST000052,Colorectal cancer
6852,European,1890.0,17618284.0,Tomlinson I,Cancer,initial,2007-07-08,GCST000053,Colorectal cancer
7536,European,2868.0,17632509.0,Buch S,Digestive system disorder,replication,2007-07-15,GCST000055,Gallstone disease
7310,European,2503.0,17632545.0,Hakonarson H,Metabolic disorder,replication,2007-07-15,GCST000054,Type 1 diabetes
5534,European,640.0,17632509.0,Buch S,Digestive system disorder,initial,2007-07-15,GCST000055,Gallstone disease
12604,Hispanic or Latin American,334.0,17632509.0,Buch S,Digestive system disorder,replication,2007-07-15,GCST000055,Gallstone disease
7642,European,3105.0,17632545.0,Hakonarson H,Metabolic disorder,initial,2007-07-15,GCST000054,Type 1 diabetes
7210,European,2336.0,17637780.0,Winkelmann J,Neurological disorder,replication,2007-07-18,GCST000056,Restless legs syndrome
7328,European,2519.0,17634449.0,Samani NJ,Cardiovascular disease,replication,2007-07-18,GCST000057,Coronary heart disease
6958,European,2045.0,17637780.0,Winkelmann J,Neurological disorder,initial,2007-07-18,GCST000056,Restless legs syndrome
8382,European,4864.0,17634449.0,Samani NJ,Cardiovascular disease,initial,2007-07-18,GCST000057,Coronary heart disease
5273,European,486.0,17641165.0,Fellay J,"Biological process, Other measurement, Other disease",initial,2007-07-19,GCST000059,HIV-1 viral setpoint
10085,European,15970.0,17634447.0,Stefansson H,Neurological disorder,initial,2007-07-19,GCST000058,Restless legs syndrome
7117,European,2206.0,17634447.0,Stefansson H,Neurological disorder,replication,2007-07-19,GCST000058,Restless legs syndrome
4715,European,140.0,17641165.0,Fellay J,"Biological process, Other measurement, Other disease",replication,2007-07-19,GCST000059,HIV-1 viral setpoint
8335,European,4741.0,17658951.0,Scuteri A,"Other measurement, Liver enzyme measurement, Body measurement, Cardiovascular measurement, Inflammatory measurement, Lipid or lipoprotein measurement, Biological process, Metabolic disorder",initial,2007-07-20,GCST000060,Obesity-related traits
6505,European,1471.0,17658951.0,Scuteri A,"Other measurement, Liver enzyme measurement, Body measurement, Cardiovascular measurement, Inflammatory measurement, Lipid or lipoprotein measurement, Biological process, Metabolic disorder",replication,2007-07-20,GCST000060,Obesity-related traits
772,African American or Afro-Caribbean,968.0,17658951.0,Scuteri A,"Other measurement, Liver enzyme measurement, Body measurement, Cardiovascular measurement, Inflammatory measurement, Lipid or lipoprotein measurement, Biological process, Metabolic disorder",replication,2007-07-20,GCST000060,Obesity-related traits
12752,Hispanic or Latin American,824.0,17658951.0,Scuteri A,"Other measurement, Liver enzyme measurement, Body measurement, Cardiovascular measurement, Inflammatory measurement, Lipid or lipoprotein measurement, Biological process, Metabolic disorder",replication,2007-07-20,GCST000060,Obesity-related traits
7081,European,2187.0,17611496.0,Moffatt MF,Other disease,initial,2007-07-26,GCST000061,Asthma
7195,European,2320.0,17611496.0,Moffatt MF,Other disease,replication,2007-07-26,GCST000061,Asthma
9006,European,7136.0,17660530.0,Hafler DA,Immune system disorder,replication,2007-07-29,GCST000062,Multiple sclerosis
8538,European,5224.0,17660530.0,Hafler DA,Immune system disorder,initial,2007-07-29,GCST000062,Multiple sclerosis
6980,European,2054.0,17667963.0,Shifman S,"Neurological disorder, Other measurement",initial,2007-07-31,GCST000063,Neuroticism
6551,European,1533.0,17667963.0,Shifman S,"Neurological disorder, Other measurement",replication,2007-07-31,GCST000063,Neuroticism
1780,Asian,188.0,17653210.0,Maeda S,Metabolic disorder,initial,2007-08-01,GCST000064,Type 2 diabetes nephropathy
13364,Other/Mixed,3.0,17671248.0,Dunckley T,"Neurological disorder, Neurological disorder",replication,2007-08-01,GCST000065,Amyotrophic lateral sclerosis
1542,Asian,8.0,17671248.0,Dunckley T,Neurological disorder,replication,2007-08-01,GCST000065,Amyotrophic lateral sclerosis
13559,Other/Mixed,192.0,17671248.0,Dunckley T,Neurological disorder,replication,2007-08-01,GCST000065,Amyotrophic lateral sclerosis
5196,European,438.0,17671248.0,Dunckley T,Neurological disorder,replication,2007-08-01,GCST000065,Amyotrophic lateral sclerosis
5938,European,928.0,17671248.0,Dunckley T,Neurological disorder,initial,2007-08-01,GCST000065,Amyotrophic lateral sclerosis
12538,Hispanic or Latin American,87.0,17671248.0,Dunckley T,Neurological disorder,replication,2007-08-01,GCST000065,Amyotrophic lateral sclerosis
17,African,35.0,17671248.0,Dunckley T,Neurological disorder,replication,2007-08-01,GCST000065,Amyotrophic lateral sclerosis
8814,European,6309.0,17684544.0,Franke A,Digestive system disorder,replication,2007-08-08,GCST000066,Crohn's disease
5750,European,792.0,17684544.0,Franke A,Digestive system disorder,initial,2007-08-08,GCST000066,Crohn's disease
9996,European,14649.0,17690259.0,Thorleifsson G,Neurological disorder,initial,2007-08-09,GCST000067,Glaucoma (exfoliation)
5100,European,397.0,17690259.0,Thorleifsson G,Neurological disorder,replication,2007-08-09,GCST000067,Glaucoma (exfoliation)
4772,European,179.0,17767159.0,Menzel S,Hematological measurement,initial,2007-09-02,GCST000069,F-cell distribution
8417,European,4921.0,17767157.0,Weedon MN,"Other measurement, Body measurement",initial,2007-09-02,GCST000068,Height
4649,European,90.0,17767159.0,Menzel S,Hematological measurement,replication,2007-09-02,GCST000069,F-cell distribution
10669,European,29098.0,17767157.0,Weedon MN,"Other measurement, Body measurement",replication,2007-09-02,GCST000068,Height
7828,European,3380.0,17804836.0,Plenge RM,Immune system disorder,initial,2007-09-05,GCST000070,Rheumatoid arthritis
7555,European,2911.0,17804836.0,Plenge RM,Immune system disorder,replication,2007-09-05,GCST000070,Rheumatoid arthritis
6231,European,1146.0,17804789.0,Raelson JV,Digestive system disorder,initial,2007-09-05,GCST000071,Crohn's disease
7658,European,3141.0,17804789.0,Raelson JV,Digestive system disorder,replication,2007-09-05,GCST000071,Crohn's disease
6776,European,1782.0,17827064.0,van Es MA,Neurological disorder,replication,2007-09-07,GCST000072,Amyotrophic lateral sclerosis
5916,European,911.0,17827064.0,van Es MA,Neurological disorder,initial,2007-09-07,GCST000072,Amyotrophic lateral sclerosis
12688,Hispanic or Latin American,603.0,17846126.0,Rampersaud E,Metabolic disorder,replication,2007-09-10,GCST000076,Type 2 diabetes
6524,European,1506.0,17846124.0,Hayes MG,Metabolic disorder,replication,2007-09-10,GCST000075,Type 2 diabetes
13715,Other/Mixed,634.0,17848626.0,Florez JC,"Metabolic disorder, Other measurement",replication,2007-09-10,GCST000073,Type 2 diabetes and 6 quantitative traits
7611,European,3022.0,17846126.0,Rampersaud E,Metabolic disorder,replication,2007-09-10,GCST000076,Type 2 diabetes
12673,Hispanic or Latin American,561.0,17846124.0,Hayes MG,Metabolic disorder,initial,2007-09-10,GCST000075,Type 2 diabetes
12689,Hispanic or Latin American,603.0,17848626.0,Florez JC,"Metabolic disorder, Other measurement",replication,2007-09-10,GCST000073,Type 2 diabetes and 6 quantitative traits
13714,Other/Mixed,634.0,17846126.0,Rampersaud E,Metabolic disorder,replication,2007-09-10,GCST000076,Type 2 diabetes
5144,European,419.0,17846126.0,Rampersaud E,Metabolic disorder,initial,2007-09-10,GCST000076,Type 2 diabetes
13805,Other/Mixed,895.0,17846125.0,Hanson RL,Metabolic disorder,initial,2007-09-10,GCST000074,Type 2 diabetes
12729,Hispanic or Latin American,760.0,17846125.0,Hanson RL,Metabolic disorder,replication,2007-09-10,GCST000074,Type 2 diabetes
6855,European,1892.0,17846125.0,Hanson RL,Metabolic disorder,replication,2007-09-10,GCST000074,Type 2 diabetes
6178,European,1087.0,17848626.0,Florez JC,"Metabolic disorder, Other measurement",initial,2007-09-10,GCST000073,Type 2 diabetes and 6 quantitative traits
8362,European,4815.0,17848626.0,Florez JC,"Metabolic disorder, Other measurement",replication,2007-09-10,GCST000073,Type 2 diabetes and 6 quantitative traits
13932,Other/Mixed,2834.0,17846125.0,Hanson RL,Metabolic disorder,replication,2007-09-10,GCST000074,Type 2 diabetes
13804,Other/Mixed,895.0,17846124.0,Hayes MG,Metabolic disorder,replication,2007-09-10,GCST000075,Type 2 diabetes
6889,European,1951.0,17903306.0,Newton-Cheh C,Cardiovascular measurement,initial,2007-09-19,GCST000111,Electrocardiographic traits
5613,European,694.0,17903297.0,Seshadri S,Other measurement,initial,2007-09-19,GCST000098,Cognitive test performance
5890,European,886.0,17903294.0,Yang Q,Other measurement,initial,2007-09-19,GCST000082,Factor VII
5699,European,747.0,17903306.0,Newton-Cheh C,Cardiovascular measurement,initial,2007-09-19,GCST000086,Heart rate variability traits
6321,European,1238.0,17903301.0,Vasan RS,Cardiovascular measurement,initial,2007-09-19,GCST000089,Exercise treadmill test traits
6108,European,1012.0,17903293.0,Benjamin EJ,"Other measurement, Liver enzyme measurement, Cardiovascular measurement, Inflammatory measurement",initial,2007-09-19,GCST000083,Select biomarker traits
6393,European,1341.0,17903300.0,Fox CS,"Body measurement, Other measurement",initial,2007-09-19,GCST000090,Body mass index
6171,European,1079.0,17903300.0,Fox CS,Body measurement,initial,2007-09-19,GCST000084,Waist circumference
6179,European,1087.0,17903299.0,Kathiresan S,"Lipid or lipoprotein measurement, Other measurement",initial,2007-09-19,GCST000078,Lipid traits
6323,European,1238.0,17903301.0,Vasan RS,"Other trait, Other measurement",initial,2007-09-19,GCST000110,Echocardiographic traits
9203,European,8100.0,17903299.0,Kathiresan S,"Lipid or lipoprotein measurement, Other measurement",replication,2007-09-19,GCST000078,Lipid traits
6152,European,1062.0,17903294.0,Yang Q,"Hematological measurement, Inflammatory measurement, Other measurement, Cardiovascular measurement, Biological process",initial,2007-09-19,GCST000080,Hemostatic factors and hematological phenotypes
5626,European,705.0,17903297.0,Seshadri S,Other measurement,initial,2007-09-19,GCST000088,Volumetric brain MRI
6322,European,1238.0,17903301.0,Vasan RS,Other measurement,initial,2007-09-19,GCST000102,Endothelial function traits
4744,European,165.0,17911428.0,Cervino AC,Immune system disorder,initial,2007-10-08,GCST000112,Lupus
6853,European,1890.0,17934461.0,Broderick P,Cancer,initial,2007-10-14,GCST000113,Colorectal cancer
9910,European,13475.0,17934461.0,Broderick P,Cancer,replication,2007-10-14,GCST000113,Colorectal cancer
2267,Asian,737.0,17999355.0,Stokowski RP,"Other trait, Other measurement",initial,2007-10-15,GCST000114,Skin pigmentation
1857,Asian,231.0,17999355.0,Stokowski RP,"Other trait, Other measurement",replication,2007-10-15,GCST000114,Skin pigmentation
8057,European,3932.0,17952075.0,Sulem P,Other trait,replication,2007-10-21,GCST000118,Blond vs. brown hair color
7590,European,2986.0,17952075.0,Sulem P,Other trait,initial,2007-10-21,GCST000118,Blond vs. brown hair color
5101,European,397.0,17982456.0,Plenge RM,Immune system disorder,initial,2007-11-04,GCST000122,Rheumatoid arthritis
6703,European,1707.0,17982456.0,Plenge RM,Immune system disorder,replication,2007-11-04,GCST000122,Rheumatoid arthritis
6367,European,1301.0,17997608.0,Li S,"Metabolic disorder, Other measurement",replication,2007-11-09,GCST000123,Urate levels
8195,European,4305.0,17997608.0,Li S,"Metabolic disorder, Other measurement",initial,2007-11-09,GCST000123,Urate levels
6514,European,1489.0,17998437.0,Li H,Neurological disorder,initial,2007-11-12,GCST000124,Alzheimer's disease
5579,European,667.0,17998437.0,Li H,Neurological disorder,replication,2007-11-12,GCST000124,Alzheimer's disease
1933,Asian,311.0,18075462.0,Suzuki S,Cardiovascular disease,replication,2007-11-17,GCST000125,Coronary spasm
1669,Asian,100.0,18075462.0,Suzuki S,Cardiovascular disease,initial,2007-11-17,GCST000125,Coronary spasm
5175,European,432.0,18057069.0,Cronin S,Neurological disorder,initial,2007-12-07,GCST000126,Amyotrophic lateral sclerosis
6495,European,1458.0,18057069.0,Cronin S,Neurological disorder,replication,2007-12-07,GCST000126,Amyotrophic lateral sclerosis
6496,European,1458.0,18084291.0,van Es MA,Neurological disorder,initial,2007-12-16,GCST000127,Amyotrophic lateral sclerosis
7126,European,2225.0,18084291.0,van Es MA,Neurological disorder,replication,2007-12-16,GCST000127,Amyotrophic lateral sclerosis
679,African American or Afro-Caribbean,556.0,18073375.0,Duggan D,Cancer,replication,2007-12-19,GCST000128,Prostate cancer
7525,European,2834.0,18073375.0,Duggan D,Cancer,initial,2007-12-19,GCST000128,Prostate cancer
6622,European,1603.0,18073375.0,Duggan D,Cancer,replication,2007-12-19,GCST000128,Prostate cancer
5943,European,929.0,18159244.0,Hinney A,Metabolic disorder,initial,2007-12-26,GCST000129,Obesity (early onset extreme)
7149,European,2269.0,18159244.0,Hinney A,Metabolic disorder,replication,2007-12-26,GCST000129,Obesity (early onset extreme)
8438,European,4955.0,18179892.0,Wallace C,"Metabolic disorder, Other measurement",replication,2008-01-10,GCST000130,Urate levels
8437,European,4955.0,18179892.0,Wallace C,"Lipid or lipoprotein measurement, Other measurement",replication,2008-01-10,GCST000131,LDL cholesterol
6895,European,1955.0,18179892.0,Wallace C,"Metabolic disorder, Other measurement",initial,2008-01-10,GCST000130,Urate levels
6894,European,1955.0,18179892.0,Wallace C,"Lipid or lipoprotein measurement, Other measurement",initial,2008-01-10,GCST000131,LDL cholesterol
9376,European,8684.0,18193043.0,Willer CJ,Lipid or lipoprotein measurement,initial,2008-01-13,GCST000139,Triglycerides
10261,European,18544.0,18193044.0,Kathiresan S,"Lipid or lipoprotein measurement, Other measurement",replication,2008-01-13,GCST000134,LDL cholesterol
9371,European,8656.0,18193043.0,Willer CJ,Lipid or lipoprotein measurement,initial,2008-01-13,GCST000135,HDL cholesterol
9357,European,8589.0,18193043.0,Willer CJ,"Lipid or lipoprotein measurement, Other measurement",initial,2008-01-13,GCST000132,LDL cholesterol
9748,European,11437.0,18193043.0,Willer CJ,Lipid or lipoprotein measurement,replication,2008-01-13,GCST000135,HDL cholesterol
2514,Asian,1181.0,18193046.0,Kooner JS,Lipid or lipoprotein measurement,replication,2008-01-13,GCST000137,Triglycerides
9874,European,12981.0,18193043.0,Willer CJ,"Lipid or lipoprotein measurement, Other measurement",replication,2008-01-13,GCST000132,LDL cholesterol
10262,European,18554.0,18193044.0,Kathiresan S,Lipid or lipoprotein measurement,replication,2008-01-13,GCST000133,HDL cholesterol
10263,European,18554.0,18193044.0,Kathiresan S,Lipid or lipoprotein measurement,replication,2008-01-13,GCST000138,Triglycerides
7483,European,2758.0,18193044.0,Kathiresan S,"Lipid or lipoprotein measurement, Other measurement",initial,2008-01-13,GCST000134,LDL cholesterol
13914,Other/Mixed,2528.0,18193046.0,Kooner JS,Lipid or lipoprotein measurement,replication,2008-01-13,GCST000137,Triglycerides
7481,European,2758.0,18193044.0,Kathiresan S,Lipid or lipoprotein measurement,initial,2008-01-13,GCST000133,HDL cholesterol
1163,African American or Afro-Caribbean,3860.0,18193045.0,Sanna S,"Other measurement, Body measurement",replication,2008-01-13,GCST000136,Height
9537,European,9741.0,18193043.0,Willer CJ,Lipid or lipoprotein measurement,replication,2008-01-13,GCST000139,Triglycerides
6101,European,1005.0,18193046.0,Kooner JS,Lipid or lipoprotein measurement,initial,2008-01-13,GCST000137,Triglycerides
8887,European,6669.0,18193045.0,Sanna S,"Other measurement, Body measurement",initial,2008-01-13,GCST000136,Height
10511,European,23684.0,18193045.0,Sanna S,"Other measurement, Body measurement",replication,2008-01-13,GCST000136,Height
8936,European,6827.0,18193046.0,Kooner JS,Lipid or lipoprotein measurement,replication,2008-01-13,GCST000137,Triglycerides
2441,Asian,1006.0,18193046.0,Kooner JS,Lipid or lipoprotein measurement,initial,2008-01-13,GCST000137,Triglycerides
7482,European,2758.0,18193044.0,Kathiresan S,Lipid or lipoprotein measurement,initial,2008-01-13,GCST000138,Triglycerides
4835,European,206.0,18195134.0,Byun E,Response to drug,initial,2008-01-14,GCST000140,Response to interferon beta therapy
4625,European,81.0,18195134.0,Byun E,Response to drug,replication,2008-01-14,GCST000140,Response to interferon beta therapy
7643,European,3105.0,18198356.0,Hakonarson H,Metabolic disorder,initial,2008-01-15,GCST000141,Type 1 diabetes
7656,European,3136.0,18198356.0,Hakonarson H,Metabolic disorder,replication,2008-01-15,GCST000141,Type 1 diabetes
7768,European,3297.0,18204447.0,Kozyrev SV,Immune system disorder,replication,2008-01-20,GCST000143,Systemic lupus erythematosus
7962,European,3671.0,18204446.0,Harley JB,Immune system disorder,replication,2008-01-20,GCST000142,Systemic lupus erythematosus
5752,European,794.0,18204447.0,Kozyrev SV,Immune system disorder,initial,2008-01-20,GCST000143,Systemic lupus erythematosus
7623,European,3037.0,18204446.0,Harley JB,Immune system disorder,initial,2008-01-20,GCST000142,Systemic lupus erythematosus
8301,European,4651.0,18204098.0,Hom G,Immune system disorder,initial,2008-01-20,GCST000144,Systemic lupus erythematosus
6666,European,1650.0,18204098.0,Hom G,Immune system disorder,replication,2008-01-20,GCST000144,Systemic lupus erythematosus
7681,European,3195.0,18067574.0,Butcher LM,Biological process,replication,2008-01-22,GCST000145,General cognitive ability
5855,European,860.0,18067574.0,Butcher LM,Biological process,initial,2008-01-22,GCST000145,General cognitive ability
6466,European,1406.0,18252221.0,Kayser M,Other trait,initial,2008-01-24,GCST000146,Iris color
8944,European,6867.0,18252221.0,Kayser M,Other trait,replication,2008-01-24,GCST000146,Iris color
9080,European,7481.0,18227835.0,Berrettini W,Neurological disorder,initial,2008-01-29,GCST000147,Nicotine dependence
6927,European,2000.0,18227835.0,Berrettini W,Neurological disorder,replication,2008-01-29,GCST000147,Nicotine dependence
8196,European,4305.0,18245381.0,Uda M,Hematological measurement,initial,2008-02-05,GCST000150,Fetal hemoglobin levels
5367,European,521.0,18245381.0,Uda M,Hematological measurement,replication,2008-02-05,GCST000150,Fetal hemoglobin levels
8444,European,4979.0,18262040.0,Sandhu MS,"Lipid or lipoprotein measurement, Other measurement",replication,2008-02-09,GCST000151,LDL cholesterol
9773,European,11685.0,18262040.0,Sandhu MS,"Lipid or lipoprotein measurement, Other measurement",initial,2008-02-09,GCST000151,LDL cholesterol
7205,European,2329.0,18264096.0,Thomas G,Cancer,initial,2008-02-10,GCST000154,Prostate cancer
10077,European,15829.0,18264098.0,Gudmundsson J,Cancer,replication,2008-02-10,GCST000153,Prostate cancer
8877,European,6634.0,18264097.0,Eeles RA,Cancer,replication,2008-02-10,GCST000152,Prostate cancer
10496,European,23226.0,18264098.0,Gudmundsson J,Cancer,initial,2008-02-10,GCST000153,Prostate cancer
9155,European,7905.0,18264096.0,Thomas G,Cancer,replication,2008-02-10,GCST000154,Prostate cancer
7988,European,3748.0,18264097.0,Eeles RA,Cancer,initial,2008-02-10,GCST000152,Prostate cancer
8686,European,5802.0,18282107.0,Shifman S,Neurological disorder,replication,2008-02-15,GCST000155,Schizophrenia
2368,Asian,873.0,18282107.0,Shifman S,Neurological disorder,replication,2008-02-15,GCST000155,Schizophrenia
13972,Other/Mixed,4148.0,18282107.0,Shifman S,Neurological disorder,replication,2008-02-15,GCST000155,Schizophrenia
13936,Other/Mixed,2931.0,18282107.0,Shifman S,Neurological disorder,initial,2008-02-15,GCST000155,Schizophrenia
2170,Asian,580.0,18316681.0,Uhl GR,Neurological disorder,initial,2008-03-01,GCST000156,Methamphetamine dependence
7105,European,2189.0,18311140.0,Hunt KA,Immune system disorder,initial,2008-03-02,GCST000157,Celiac disease
8472,European,5049.0,18311140.0,Hunt KA,Immune system disorder,replication,2008-03-02,GCST000157,Celiac disease
7878,European,3469.0,18317468.0,Sklar P,Neurological disorder,initial,2008-03-04,GCST000158,Bipolar disorder
6878,European,1943.0,18317468.0,Sklar P,Neurological disorder,replication,2008-03-04,GCST000158,Bipolar disorder
8009,European,3812.0,18325910.0,Liu YJ,"Other measurement, Metabolic disorder",replication,2008-03-05,GCST000159,Obesity
6070,European,1000.0,18325910.0,Liu YJ,"Other measurement, Metabolic disorder",initial,2008-03-05,GCST000159,Obesity
9592,European,9947.0,18327256.0,Doring A,"Metabolic disorder, Other measurement",replication,2008-03-09,GCST000161,Urate levels
5753,European,794.0,18327257.0,Vitart V,"Metabolic disorder, Other measurement",initial,2008-03-09,GCST000160,Urate levels
6658,European,1644.0,18327256.0,Doring A,"Metabolic disorder, Other measurement",initial,2008-03-09,GCST000161,Urate levels
5628,European,706.0,18327257.0,Vitart V,"Metabolic disorder, Other measurement",replication,2008-03-09,GCST000160,Urate levels
7221,European,2359.0,18326623.0,Gold B,Cancer,replication,2008-03-11,GCST000162,Breast cancer
5409,European,548.0,18326623.0,Gold B,Cancer,initial,2008-03-11,GCST000162,Breast cancer
7203,European,2327.0,18332876.0,Kirov G,Neurological disorder,initial,2008-03-11,GCST000163,Schizophrenia
5805,European,828.0,18347602.0,Sullivan PF,Neurological disorder,initial,2008-03-18,GCST000164,Schizophrenia
637,African American or Afro-Caribbean,436.0,18347602.0,Sullivan PF,Neurological disorder,initial,2008-03-18,GCST000164,Schizophrenia
13566,Other/Mixed,207.0,18347602.0,Sullivan PF,Neurological disorder,initial,2008-03-18,GCST000164,Schizophrenia
8188,European,4288.0,18364390.0,Capon F,Immune system disorder,replication,2008-03-25,GCST000165,Psoriasis
5494,European,606.0,18364390.0,Capon F,Immune system disorder,initial,2008-03-25,GCST000165,Psoriasis
7909,European,3529.0,18360741.0,Butcher LM,Other measurement,replication,2008-03-25,GCST000166,Environmental confusion in the home
5818,European,838.0,18360741.0,Butcher LM,Other measurement,initial,2008-03-25,GCST000166,Environmental confusion in the home
11406,European,79792.0,18372903.0,Zeggini E,Metabolic disorder,replication,2008-03-30,GCST000167,Type 2 diabetes
6917,European,1983.0,18372901.0,Tenesa A,Cancer,initial,2008-03-30,GCST000168,Colorectal cancer
10374,European,20688.0,18372901.0,Tenesa A,Cancer,replication,2008-03-30,GCST000168,Colorectal cancer
10815,European,33951.0,18372905.0,Tomlinson IP,Cancer,replication,2008-03-30,GCST000169,Colorectal cancer
3827,Asian,7579.0,18372901.0,Tenesa A,Cancer,replication,2008-03-30,GCST000168,Colorectal cancer
6824,European,1849.0,18372905.0,Tomlinson IP,Cancer,initial,2008-03-30,GCST000169,Colorectal cancer
9611,European,10128.0,18372903.0,Zeggini E,Metabolic disorder,initial,2008-03-30,GCST000167,Type 2 diabetes
8373,European,4848.0,18385739.0,Thorgeirsson TE,Neurological disorder,replication,2008-04-03,GCST000171,Nicotine dependence
13984,Other/Mixed,6471.0,18385738.0,Hung RJ,Cancer,replication,2008-04-03,GCST000170,Lung cancer
8833,European,6418.0,18385676.0,Amos CI,Cancer,replication,2008-04-03,GCST000172,Lung cancer
5754,European,794.0,18385738.0,Hung RJ,Cancer,replication,2008-04-03,GCST000170,Lung cancer
7174,European,2291.0,18385676.0,Amos CI,Cancer,initial,2008-04-03,GCST000172,Lung cancer
9706,European,10995.0,18385739.0,Thorgeirsson TE,Neurological disorder,initial,2008-04-03,GCST000171,Nicotine dependence
13977,Other/Mixed,4448.0,18385738.0,Hung RJ,Cancer,initial,2008-04-03,GCST000170,Lung cancer
5668,European,737.0,18369459.0,Liu Y,Immune system disorder,initial,2008-04-04,GCST000173,Psoriasis
7230,European,2370.0,18369459.0,Liu Y,Immune system disorder,replication,2008-04-04,GCST000173,Psoriasis
9349,European,8541.0,18391951.0,Gudbjartsson DF,"Other measurement, Body measurement",replication,2008-04-06,GCST000175,Height
10076,European,15821.0,18391950.0,Lettre G,"Other measurement, Body measurement",initial,2008-04-06,GCST000176,Height
10715,European,30968.0,18391951.0,Gudbjartsson DF,"Other measurement, Body measurement",initial,2008-04-06,GCST000175,Height
10130,European,16482.0,18391952.0,Weedon MN,"Other measurement, Body measurement",replication,2008-04-06,GCST000174,Height
10225,European,17801.0,18391950.0,Lettre G,"Other measurement, Body measurement",replication,2008-04-06,GCST000176,Height
9935,European,13665.0,18391952.0,Weedon MN,"Other measurement, Body measurement",initial,2008-04-06,GCST000174,Height
5527,European,632.0,18403759.0,Ober C,Inflammatory measurement,initial,2008-04-09,GCST000177,YKL-40 levels
6215,European,1140.0,18403759.0,Ober C,Inflammatory measurement,replication,2008-04-09,GCST000177,YKL-40 levels
8820,European,6345.0,18439548.0,Ridker PM,Inflammatory measurement,initial,2008-04-24,GCST000178,C-reactive protein
5915,European,909.0,18439552.0,Reiner AP,Inflammatory measurement,initial,2008-04-24,GCST000179,C-reactive protein
8497,European,5106.0,18439552.0,Reiner AP,Inflammatory measurement,replication,2008-04-24,GCST000179,C-reactive protein
9164,European,7925.0,18445777.0,Styrkarsdottir U,Other measurement,replication,2008-04-29,GCST000181,Bone mineral density (hip)
7010,European,2094.0,18455228.0,Richards JB,Other measurement,initial,2008-04-29,GCST000182,Bone mineral density
8701,European,5861.0,18445777.0,Styrkarsdottir U,Other measurement,initial,2008-04-29,GCST000180,Bone mineral density (spine)
8840,European,6463.0,18455228.0,Richards JB,Other measurement,replication,2008-04-29,GCST000182,Bone mineral density
9163,European,7925.0,18445777.0,Styrkarsdottir U,Other measurement,replication,2008-04-29,GCST000180,Bone mineral density (spine)
8702,European,5861.0,18445777.0,Styrkarsdottir U,Other measurement,initial,2008-04-29,GCST000181,Bone mineral density (hip)
4565,European,30.0,18449908.0,Poduslo SE,Neurological disorder,initial,2008-04-30,GCST000183,Alzheimer's disease
4931,European,284.0,18449908.0,Poduslo SE,Neurological disorder,replication,2008-04-30,GCST000183,Alzheimer's disease
11283,European,66340.0,18454148.0,Loos RJ,"Body measurement, Other measurement",replication,2008-05-04,GCST000185,Body mass index
3803,Asian,7394.0,18454146.0,Chambers JC,"Body measurement, Lipid or lipoprotein measurement",replication,2008-05-04,GCST000184,Waist circumference and related phenotypes
10163,European,16876.0,18454148.0,Loos RJ,"Body measurement, Other measurement",initial,2008-05-04,GCST000185,Body mass index
8272,European,4561.0,18454146.0,Chambers JC,"Body measurement, Lipid or lipoprotein measurement",replication,2008-05-04,GCST000184,Waist circumference and related phenotypes
3154,Asian,2684.0,18454146.0,Chambers JC,"Body measurement, Lipid or lipoprotein measurement",initial,2008-05-04,GCST000184,Waist circumference and related phenotypes
361,African American or Afro-Caribbean,2.0,18463975.0,Kibriya MG,Cancer,initial,2008-05-08,GCST000187,Breast cancer
12491,Hispanic or Latin American,6.0,18463975.0,Kibriya MG,Cancer,initial,2008-05-08,GCST000187,Breast cancer
4584,European,52.0,18463975.0,Kibriya MG,Cancer,initial,2008-05-08,GCST000187,Breast cancer
5535,European,642.0,18471798.0,Valdes AM,Other disease,initial,2008-05-08,GCST000186,Knee osteoarthritis
7915,European,3549.0,18471798.0,Valdes AM,Other disease,replication,2008-05-08,GCST000186,Knee osteoarthritis
7630,European,3075.0,18463370.0,Maris JM,Cancer,initial,2008-05-09,GCST000188,Neuroblastoma
8279,European,4590.0,18464913.0,Melzer D,"Other measurement, Inflammatory measurement, Liver enzyme measurement, Hematological measurement, Lipid or lipoprotein measurement",replication,2008-05-09,GCST000189,Protein quantitative trait loci
6288,European,1200.0,18464913.0,Melzer D,"Other measurement, Inflammatory measurement, Liver enzyme measurement, Hematological measurement, Lipid or lipoprotein measurement",initial,2008-05-09,GCST000189,Protein quantitative trait loci
7532,European,2848.0,18463370.0,Maris JM,Cancer,replication,2008-05-09,GCST000188,Neuroblastoma
7169,European,2287.0,18483556.0,Han J,Other trait,initial,2008-05-16,GCST000191,Black vs. red hair color
9337,European,8465.0,18483556.0,Han J,Other trait,replication,2008-05-16,GCST000191,Black vs. red hair color
9336,European,8465.0,18483556.0,Han J,Other trait,replication,2008-05-16,GCST000190,Black vs. blond hair color
7168,European,2287.0,18483556.0,Han J,Other trait,initial,2008-05-16,GCST000190,Black vs. blond hair color
7787,European,3330.0,18488028.0,Sulem P,Immune system disorder,replication,2008-05-18,GCST000195,Skin sensitivity to sun
8508,European,5130.0,18488028.0,Sulem P,Other trait,initial,2008-05-18,GCST000192,Blue vs. green eyes
7300,European,2481.0,18488026.0,Brown KM,Cancer,replication,2008-05-18,GCST000198,Melanoma
7791,European,3330.0,18488028.0,Sulem P,Other trait,replication,2008-05-18,GCST000194,Blond vs. brown hair color
7792,European,3330.0,18488028.0,Sulem P,Other trait,replication,2008-05-18,GCST000197,Freckles
6735,European,1728.0,18488026.0,Brown KM,Cancer,initial,2008-05-18,GCST000198,Melanoma
7788,European,3330.0,18488028.0,Sulem P,"Other disease, Other trait",replication,2008-05-18,GCST000196,Burning and freckling
8510,European,5130.0,18488028.0,Sulem P,Other trait,initial,2008-05-18,GCST000194,Blond vs. brown hair color
8509,European,5130.0,18488028.0,Sulem P,Other trait,initial,2008-05-18,GCST000193,Red vs. non-red hair color
7790,European,3330.0,18488028.0,Sulem P,Other trait,replication,2008-05-18,GCST000193,Red vs. non-red hair color
7789,European,3330.0,18488028.0,Sulem P,Other trait,replication,2008-05-18,GCST000192,Blue vs. green eyes
8511,European,5130.0,18488028.0,Sulem P,Other trait,initial,2008-05-18,GCST000197,Freckles
8506,European,5130.0,18488028.0,Sulem P,Immune system disorder,initial,2008-05-18,GCST000195,Skin sensitivity to sun
8507,European,5130.0,18488028.0,Sulem P,"Other disease, Other trait",initial,2008-05-18,GCST000196,Burning and freckling
8142,European,4158.0,18514160.0,Arnaud-Lopez L,"Other measurement, Other trait",replication,2008-06-01,GCST000199,Thyroid stimulating hormone levels
8197,European,4305.0,18514160.0,Arnaud-Lopez L,"Other measurement, Other trait",initial,2008-06-01,GCST000199,Thyroid stimulating hormone levels
1563,Asian,16.0,18521091.0,Volpi S,Response to drug,initial,2008-06-03,GCST000201,Response to iloperidone treatment (QT prolongation)
13502,Other/Mixed,104.0,18521090.0,Lavedan C,Response to drug,replication,2008-06-03,GCST000200,Response to iloperidone treatment (PANSS-T score)
13503,Other/Mixed,106.0,18521090.0,Lavedan C,Response to drug,initial,2008-06-03,GCST000200,Response to iloperidone treatment (PANSS-T score)
450,African American or Afro-Caribbean,91.0,18521091.0,Volpi S,Response to drug,initial,2008-06-03,GCST000201,Response to iloperidone treatment (QT prolongation)
13387,Other/Mixed,7.0,18521091.0,Volpi S,Response to drug,initial,2008-06-03,GCST000201,Response to iloperidone treatment (QT prolongation)
4608,European,69.0,18521091.0,Volpi S,Response to drug,initial,2008-06-03,GCST000201,Response to iloperidone treatment (QT prolongation)
10256,European,18436.0,18521185.0,Chen WM,Other measurement,replication,2008-06-04,GCST000202,Fasting plasma glucose
5417,European,550.0,18519826.0,Uhl GR,Biological process,initial,2008-06-04,GCST000203,Smoking cessation
8494,European,5088.0,18521185.0,Chen WM,Other measurement,initial,2008-06-04,GCST000202,Fasting plasma glucose
5070,European,374.0,18535201.0,Cooper GM,Response to drug,replication,2008-06-05,GCST000204,Warfarin maintenance dose
4775,European,181.0,18535201.0,Cooper GM,Response to drug,initial,2008-06-05,GCST000204,Warfarin maintenance dose
5557,European,654.0,18451265.0,Bouatia-Naji N,Other measurement,initial,2008-06-19,GCST000205,Fasting plasma glucose
9471,European,9353.0,18451265.0,Bouatia-Naji N,Other measurement,replication,2008-06-19,GCST000205,Fasting plasma glucose
6939,European,2019.0,18576341.0,Behrens EM,Immune system disorder,initial,2008-06-24,GCST000206,Arthritis (juvenile idiopathic)
9504,European,9541.0,18587394.0,Barrett JC,Digestive system disorder,initial,2008-06-29,GCST000207,Crohn's disease
9208,European,8151.0,18587394.0,Barrett JC,Digestive system disorder,replication,2008-06-29,GCST000207,Crohn's disease
4810,European,195.0,18591461.0,Turner ST,Response to drug,initial,2008-06-30,GCST000208,Response to diuretic therapy
519,African American or Afro-Caribbean,194.0,18591461.0,Turner ST,Response to drug,initial,2008-06-30,GCST000208,Response to diuretic therapy
4640,European,87.0,18594024.0,Sarasquete ME,Other disease,initial,2008-07-01,GCST000209,Osteonecrosis of the jaw
8275,European,4570.0,18604267.0,Pare G,Cardiovascular measurement,initial,2008-07-04,GCST000210,Soluble ICAM-1
6933,European,2008.0,18604267.0,Pare G,Cardiovascular measurement,replication,2008-07-04,GCST000210,Soluble ICAM-1
4646,European,89.0,18615156.0,Liu C,Response to drug,initial,2008-07-10,GCST000211,Response to TNF antagonist treatment
6260,European,1174.0,18723019.0,Franke A,"Digestive system disorder, Other disease",initial,2008-07-21,GCST000212,Crohn's disease and sarcoidosis (combined)
7251,European,2408.0,18723019.0,Franke A,"Digestive system disorder, Other disease",replication,2008-07-21,GCST000212,Crohn's disease and sarcoidosis (combined)
4762,European,175.0,18650507.0,Link E,Response to drug,initial,2008-07-23,GCST000213,Response to statin therapy
10146,European,16664.0,18650507.0,Link E,Response to drug,replication,2008-07-23,GCST000213,Response to statin therapy
8432,European,4946.0,18660810.0,Schormair B,Neurological disorder,replication,2008-07-27,GCST000214,Restless legs syndrome
7152,European,2272.0,18660810.0,Schormair B,Neurological disorder,initial,2008-07-27,GCST000214,Restless legs syndrome
9667,European,10658.0,18677311.0,O'Donovan MC,Neurological disorder,replication,2008-07-30,GCST000215,Schizophrenia
3332,Asian,3647.0,18677311.0,O'Donovan MC,Neurological disorder,replication,2008-07-30,GCST000215,Schizophrenia
7852,European,3416.0,18677311.0,O'Donovan MC,Neurological disorder,initial,2008-07-30,GCST000215,Schizophrenia
5764,European,804.0,18668548.0,Julia A,Immune system disorder,replication,2008-08-01,GCST000217,Rheumatoid arthritis
5761,European,800.0,18668548.0,Julia A,Immune system disorder,initial,2008-08-01,GCST000217,Rheumatoid arthritis
7386,European,2586.0,19165918.0,Graham RR,Immune system disorder,initial,2008-08-01,GCST000216,Systemic lupus erythematosus
6394,European,1341.0,19165918.0,Graham RR,Immune system disorder,replication,2008-08-01,GCST000216,Systemic lupus erythematosus
9652,European,10596.0,18711365.0,Ferreira MA,Neurological disorder,initial,2008-08-17,GCST000220,Bipolar disorder
9479,European,9387.0,18711366.0,Unoki H,Metabolic disorder,replication,2008-08-17,GCST000221,Type 2 diabetes
4111,Asian,12361.0,18711366.0,Unoki H,Metabolic disorder,replication,2008-08-17,GCST000221,Type 2 diabetes
8866,European,6570.0,18711367.0,Yasuda K,Metabolic disorder,replication,2008-08-17,GCST000219,Type 2 diabetes
2783,Asian,1752.0,18711366.0,Unoki H,Metabolic disorder,initial,2008-08-17,GCST000221,Type 2 diabetes
2745,Asian,1691.0,18711367.0,Yasuda K,Metabolic disorder,initial,2008-08-17,GCST000219,Type 2 diabetes
4162,Asian,13173.0,18711367.0,Yasuda K,Metabolic disorder,replication,2008-08-17,GCST000219,Type 2 diabetes
9542,European,9769.0,18846228.0,Weidinger S,Other measurement,replication,2008-08-22,GCST000222,IgE levels
6548,European,1530.0,18846228.0,Weidinger S,Other measurement,initial,2008-08-22,GCST000222,IgE levels
6099,European,1004.0,18729187.0,Galvan A,Cancer,initial,2008-08-26,GCST000223,Lung adenocarcinoma
8546,European,5261.0,18758464.0,Kugathasan S,"Digestive system disorder, Immune system disorder",initial,2008-08-31,GCST000225,Inflammatory bowel disease
6879,European,1943.0,18758461.0,Di Bernardo MC,Cancer,initial,2008-08-31,GCST000224,Chronic lymphocytic leukemia
10087,European,16046.0,18758464.0,Kugathasan S,"Digestive system disorder, Immune system disorder",replication,2008-08-31,GCST000225,Inflammatory bowel disease
7454,European,2701.0,18758461.0,Di Bernardo MC,Cancer,replication,2008-08-31,GCST000224,Chronic lymphocytic leukemia
6847,European,1880.0,18762592.0,van den Oord EJ,"Neurological disorder, Other measurement",replication,2008-09-01,GCST000226,Neuroticism
13800,Other/Mixed,868.0,18759275.0,McArdle PF,Cardiovascular measurement,initial,2008-09-01,GCST000227,Uric acid levels
6311,European,1227.0,18762592.0,van den Oord EJ,"Neurological disorder, Other measurement",initial,2008-09-01,GCST000226,Neuroticism
6672,European,1658.0,18776911.0,Hazra A,Other measurement,initial,2008-09-07,GCST000228,Vitamin B12 levels
6149,European,1059.0,18776911.0,Hazra A,Other measurement,replication,2008-09-07,GCST000228,Vitamin B12 levels
6305,European,1216.0,18776929.0,Liu YZ,Body measurement,replication,2008-09-08,GCST000229,Hip bone size
6071,European,1000.0,18776929.0,Liu YZ,Body measurement,initial,2008-09-08,GCST000229,Hip bone size
6173,European,1081.0,18760390.0,Huyghe JR,Neurological disorder,initial,2008-09-12,GCST000230,Hearing impairment
10080,European,15853.0,18794853.0,Raychaudhuri S,Immune system disorder,initial,2008-09-14,GCST000232,Rheumatoid arthritis
10871,European,36139.0,18794855.0,Kiemeney LA,Cancer,initial,2008-09-14,GCST000231,Urinary bladder cancer
9536,European,9736.0,18794853.0,Raychaudhuri S,Immune system disorder,replication,2008-09-14,GCST000232,Rheumatoid arthritis
8734,European,5965.0,18794855.0,Kiemeney LA,Cancer,replication,2008-09-14,GCST000231,Urinary bladder cancer
5138,European,413.0,18780872.0,Liu P,Cancer,initial,2008-09-17,GCST000233,Lung cancer
13909,Other/Mixed,2346.0,18802019.0,Burkhardt R,"Lipid or lipoprotein measurement, Other measurement",initial,2008-09-18,GCST000234,LDL cholesterol
13427,Other/Mixed,22.0,18821564.0,Mick E,Neurological disorder,initial,2008-09-26,GCST000235,Attention deficit hyperactivity disorder
4687,European,105.0,18821564.0,Mick E,Neurological disorder,initial,2008-09-26,GCST000235,Attention deficit hyperactivity disorder
12515,Hispanic or Latin American,34.0,18821564.0,Mick E,Neurological disorder,initial,2008-09-26,GCST000235,Attention deficit hyperactivity disorder
389,African American or Afro-Caribbean,26.0,18821564.0,Mick E,Neurological disorder,initial,2008-09-26,GCST000235,Attention deficit hyperactivity disorder
5744,European,785.0,18820697.0,Miyagawa T,Neurological disorder,replication,2008-09-28,GCST000236,Narcolepsy
2177,Asian,611.0,18820697.0,Miyagawa T,Neurological disorder,initial,2008-09-28,GCST000236,Narcolepsy
512,African American or Afro-Caribbean,184.0,18820697.0,Miyagawa T,Neurological disorder,replication,2008-09-28,GCST000236,Narcolepsy
2298,Asian,773.0,18820697.0,Miyagawa T,Neurological disorder,replication,2008-09-28,GCST000236,Narcolepsy
7196,European,2321.0,18823527.0,Abraham R,Neurological disorder,initial,2008-09-29,GCST000237,Alzheimer's disease
2180,Asian,618.0,18835860.0,Mushiroda T,Cancer,replication,2008-10-01,GCST000238,Idiopathic pulmonary fibrosis
8184,European,4274.0,20031538.0,Heid IM,Lipid or lipoprotein measurement,initial,2008-10-01,GCST000240,HDL cholesterol
9843,European,12476.0,18991354.0,Gretarsdottir S,Cardiovascular disease,initial,2008-10-01,GCST000239,Stroke (ischemic)
1161,African American or Afro-Caribbean,3843.0,18834626.0,Dehghan A,"Metabolic disorder, Other measurement",replication,2008-10-01,GCST000242,Urate levels
10525,European,23919.0,18991354.0,Gretarsdottir S,Cardiovascular disease,replication,2008-10-01,GCST000239,Stroke (ischemic)
9800,European,11847.0,18834626.0,Dehghan A,"Metabolic disorder, Other measurement",initial,2008-10-01,GCST000242,Urate levels
10083,European,15873.0,20031538.0,Heid IM,Lipid or lipoprotein measurement,replication,2008-10-01,GCST000240,HDL cholesterol
6016,European,970.0,19802338.0,Chasman DI,"Lipid or lipoprotein measurement, Other measurement",replication,2008-10-01,GCST000241,Lipid traits
9710,European,11024.0,18834626.0,Dehghan A,"Metabolic disorder, Other measurement",replication,2008-10-01,GCST000242,Urate levels
8827,European,6382.0,19802338.0,Chasman DI,"Lipid or lipoprotein measurement, Other measurement",initial,2008-10-01,GCST000241,Lipid traits
2477,Asian,1093.0,18835860.0,Mushiroda T,Cancer,initial,2008-10-01,GCST000238,Idiopathic pulmonary fibrosis
6881,European,1944.0,18836448.0,Franke A,Immune system disorder,initial,2008-10-05,GCST000243,Ulcerative colitis
8433,European,4946.0,18836448.0,Franke A,Immune system disorder,replication,2008-10-05,GCST000243,Ulcerative colitis
7508,European,2803.0,18846501.0,Sonuga-Barke EJ,"Neurological disorder, Other measurement",initial,2008-10-07,GCST000245,Conduct disorder (maternal expressed emotions interaction)
7509,European,2803.0,18846501.0,Sonuga-Barke EJ,"Neurological disorder, Other measurement",initial,2008-10-07,GCST000247,Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction)
5475,European,593.0,18839057.0,Lesch KP,Neurological disorder,initial,2008-10-07,GCST000246,Attention deficit hyperactivity disorder
9173,European,7976.0,18840781.0,Grant SF,Metabolic disorder,replication,2008-10-07,GCST000244,Type 1 diabetes
7669,European,3158.0,18840781.0,Grant SF,Metabolic disorder,initial,2008-10-07,GCST000244,Type 1 diabetes
6102,European,1005.0,18940312.0,Yuan X,"Liver enzyme measurement, Other measurement",replication,2008-10-10,GCST000248,Liver enzyme levels
3339,Asian,3669.0,18940312.0,Yuan X,"Liver enzyme measurement, Other measurement",replication,2008-10-10,GCST000248,Liver enzyme levels
9132,European,7751.0,18940312.0,Yuan X,"Liver enzyme measurement, Other measurement",initial,2008-10-10,GCST000248,Liver enzyme levels
8020,European,3836.0,18849991.0,Richards JB,"Other measurement, Other disease",replication,2008-10-12,GCST000250,Male-pattern baldness
6207,European,1125.0,18849991.0,Richards JB,"Other measurement, Other disease",initial,2008-10-12,GCST000250,Male-pattern baldness
10823,European,34047.0,18849993.0,Stacey SN,Cancer,initial,2008-10-12,GCST000249,Basal cell carcinoma
8111,European,4060.0,18849993.0,Stacey SN,Cancer,replication,2008-10-12,GCST000249,Basal cell carcinoma
5421,European,553.0,18849994.0,Hillmer AM,"Other measurement, Other disease",replication,2008-10-12,GCST000251,Male-pattern baldness
5770,European,808.0,18849994.0,Hillmer AM,"Other measurement, Other disease",initial,2008-10-12,GCST000251,Male-pattern baldness
6610,European,1586.0,18941528.0,Comabella M,Immune system disorder,replication,2008-10-22,GCST000252,Multiple sclerosis
5269,European,484.0,18941528.0,Comabella M,Immune system disorder,initial,2008-10-22,GCST000252,Multiple sclerosis
7516,European,2814.0,18951430.0,Anney RJ,Neurological disorder,initial,2008-10-24,GCST000253,Attention deficit hyperactivity disorder and conduct disorder
8050,European,3925.0,18952825.0,Johansson A,"Other measurement, Body measurement",initial,2008-10-24,GCST000254,Height
10950,European,39859.0,18952825.0,Johansson A,"Other measurement, Body measurement",replication,2008-10-24,GCST000254,Height
811,African American or Afro-Caribbean,1148.0,18952825.0,Johansson A,"Other measurement, Body measurement",replication,2008-10-24,GCST000254,Height
7397,European,2605.0,18976728.0,Bertram L,Neurological disorder,replication,2008-10-29,GCST000255,Alzheimer's disease
6397,European,1345.0,18976728.0,Bertram L,Neurological disorder,initial,2008-10-29,GCST000255,Alzheimer's disease
8906,European,6717.0,18978790.0,McKay JD,Cancer,initial,2008-11-02,GCST000256,Lung cancer
9218,European,8207.0,18978792.0,Cooper JD,Metabolic disorder,initial,2008-11-02,GCST000258,Type 1 diabetes
9623,European,10295.0,18978787.0,Wang Y,Cancer,initial,2008-11-02,GCST000257,Lung cancer
9338,European,8472.0,18978790.0,McKay JD,Cancer,replication,2008-11-02,GCST000256,Lung cancer
10107,European,16235.0,18978792.0,Cooper JD,Metabolic disorder,replication,2008-11-02,GCST000258,Type 1 diabetes
8600,European,5431.0,18978787.0,Wang Y,Cancer,replication,2008-11-02,GCST000257,Lung cancer
7510,European,2803.0,18980221.0,Neale BM,Neurological disorder,initial,2008-11-03,GCST000259,Attention deficit hyperactivity disorder
6854,European,1890.0,18987618.0,Cronin S,Neurological disorder,initial,2008-11-05,GCST000260,Amyotrophic lateral sclerosis
7139,European,2246.0,18985386.0,Pankratz N,Neurological disorder,initial,2008-11-06,GCST000261,Parkinson's disease (familial)
5263,European,480.0,19009022.0,Drgon T,Neurological disorder,initial,2008-11-09,GCST000264,Nicotine dependence
7473,European,2739.0,18997785.0,Aulchenko YS,Immune system disorder,replication,2008-11-09,GCST000263,Multiple sclerosis
9147,European,7856.0,18997786.0,Bilguvar K,Cardiovascular disease,initial,2008-11-09,GCST000262,Intracranial aneurysm
2507,Asian,1171.0,18997786.0,Bilguvar K,Cardiovascular disease,replication,2008-11-09,GCST000262,Intracranial aneurysm
4883,European,240.0,18997785.0,Aulchenko YS,Immune system disorder,initial,2008-11-09,GCST000263,Multiple sclerosis
6680,European,1674.0,19010793.0,Baranzini SE,Immune system disorder,initial,2008-11-14,GCST000265,Brain lesion load
6650,European,1636.0,19010793.0,Baranzini SE,Immune system disorder,initial,2008-11-14,GCST000268,Normalized brain volume
6831,European,1861.0,19010793.0,Baranzini SE,"Immune system disorder, Other measurement",initial,2008-11-14,GCST000267,Multiple sclerosis (age of onset)
6830,European,1861.0,19010793.0,Baranzini SE,Immune system disorder,initial,2008-11-14,GCST000269,Multiple sclerosis
6681,European,1677.0,19010793.0,Baranzini SE,Immune system disorder,initial,2008-11-14,GCST000266,Multiple sclerosis (severity)
10884,European,37210.0,19011631.0,Houlston RS,Cancer,replication,2008-11-16,GCST000270,Colorectal cancer
8018,European,3831.0,19011631.0,Houlston RS,Cancer,initial,2008-11-16,GCST000270,Colorectal cancer
4689,European,106.0,19023125.0,Potkin SG,"Neurological disorder, Other measurement",initial,2008-11-20,GCST000271,Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction)
2181,Asian,618.0,19030899.0,Lei SF,"Other measurement, Body measurement",initial,2008-11-23,GCST000272,Height
3225,Asian,2953.0,19030899.0,Lei SF,"Other measurement, Body measurement",replication,2008-11-23,GCST000272,Height
8072,European,3972.0,18957941.0,Terracciano A,Other trait,initial,2008-11-24,GCST000273,Personality dimensions
4932,European,284.0,19043545.0,Gieger C,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",initial,2008-11-28,GCST000274,Metabolite levels
4705,European,130.0,19047183.0,Friedman RA,Neurological disorder,replication,2008-12-01,GCST000275,Hearing impairment
10860,European,35812.0,19060907.0,Prokopenko I,Other measurement,initial,2008-12-01,GCST000276,Fasting plasma glucose
6688,European,1692.0,19047183.0,Friedman RA,Neurological disorder,initial,2008-12-01,GCST000275,Hearing impairment
8380,European,4862.0,19056611.0,Timpson NJ,Metabolic disorder,initial,2008-12-03,GCST000277,Type 2 diabetes
9433,European,9103.0,19056611.0,Timpson NJ,Metabolic disorder,replication,2008-12-03,GCST000277,Type 2 diabetes
7497,European,2790.0,18821565.0,Lasky-Su J,Neurological disorder,initial,2008-12-05,GCST000281,Attention deficit hyperactivity disorder
7496,European,2790.0,18821565.0,Lasky-Su J,Biological process,initial,2008-12-05,GCST000279,Inattentive symptoms
7498,European,2790.0,18937294.0,Lasky-Su J,Neurological disorder,initial,2008-12-05,GCST000280,Attention deficit hyperactivity disorder (time to onset)
7495,European,2790.0,18821565.0,Lasky-Su J,Biological process,initial,2008-12-05,GCST000278,Hyperactive-impulsive symptoms
10229,European,17815.0,19060911.0,Aulchenko YS,Lipid or lipoprotein measurement,initial,2008-12-07,GCST000289,Triglycerides
10369,European,20623.0,19060906.0,Kathiresan S,Lipid or lipoprotein measurement,replication,2008-12-07,GCST000286,Triglycerides
10090,European,16094.0,19060909.0,Bouatia-Naji N,Other measurement,replication,2008-12-07,GCST000291,Fasting plasma glucose
8338,European,4763.0,19060910.0,Sabatti C,"Lipid or lipoprotein measurement, Other measurement",initial,2008-12-07,GCST000283,LDL cholesterol
10341,European,19840.0,19060906.0,Kathiresan S,"Lipid or lipoprotein measurement, Other measurement",initial,2008-12-07,GCST000287,LDL cholesterol
10371,European,20623.0,19060906.0,Kathiresan S,"Lipid or lipoprotein measurement, Other measurement",replication,2008-12-07,GCST000287,LDL cholesterol
10427,European,21412.0,19060911.0,Aulchenko YS,Lipid or lipoprotein measurement,initial,2008-12-07,GCST000288,HDL cholesterol
10474,European,22562.0,19060911.0,Aulchenko YS,Lipid or lipoprotein measurement,initial,2008-12-07,GCST000285,"Cholesterol, total"
10339,European,19840.0,19060906.0,Kathiresan S,Lipid or lipoprotein measurement,initial,2008-12-07,GCST000286,Triglycerides
8337,European,4763.0,19060910.0,Sabatti C,Lipid or lipoprotein measurement,initial,2008-12-07,GCST000284,HDL cholesterol
7045,European,2151.0,19060909.0,Bouatia-Naji N,Other measurement,initial,2008-12-07,GCST000291,Fasting plasma glucose
10224,European,17797.0,19060911.0,Aulchenko YS,"Lipid or lipoprotein measurement, Other measurement",initial,2008-12-07,GCST000282,LDL cholesterol
10340,European,19840.0,19060906.0,Kathiresan S,Lipid or lipoprotein measurement,initial,2008-12-07,GCST000290,HDL cholesterol
8339,European,4763.0,19060910.0,Sabatti C,"Other measurement, Biological process, Lipid or lipoprotein measurement",initial,2008-12-07,GCST000292,Metabolic traits
10370,European,20623.0,19060906.0,Kathiresan S,Lipid or lipoprotein measurement,replication,2008-12-07,GCST000290,HDL cholesterol
9806,European,11972.0,19065144.0,Sullivan PF,Neurological disorder,replication,2008-12-09,GCST000293,Major depressive disorder
7912,European,3540.0,19065144.0,Sullivan PF,Neurological disorder,initial,2008-12-09,GCST000293,Major depressive disorder
13790,Other/Mixed,810.0,19081515.0,Mead S,Neurological disorder,replication,2008-12-11,GCST000294,Creutzfeldt-Jakob disease
7684,European,3200.0,19081515.0,Mead S,Neurological disorder,initial,2008-12-11,GCST000294,Creutzfeldt-Jakob disease
7941,European,3610.0,19081515.0,Mead S,Neurological disorder,replication,2008-12-11,GCST000294,Creutzfeldt-Jakob disease
815,African American or Afro-Caribbean,1160.0,19079260.0,Thorleifsson G,"Body measurement, Other measurement",initial,2008-12-14,GCST000296,Body mass index
11349,European,72598.0,19079260.0,Thorleifsson G,"Body measurement, Other measurement",initial,2008-12-14,GCST000296,Body mass index
9346,European,8510.0,19079262.0,Styrkarsdottir U,Other measurement,replication,2008-12-14,GCST000297,Bone mineral density (hip)
10750,European,32387.0,19079261.0,Willer CJ,"Body measurement, Other measurement",initial,2008-12-14,GCST000298,Body mass index
9713,European,11036.0,19079260.0,Thorleifsson G,"Body measurement, Other measurement",replication,2008-12-14,GCST000296,Body mass index
11348,European,72598.0,19079260.0,Thorleifsson G,Body measurement,initial,2008-12-14,GCST000299,Weight
9345,European,8510.0,19079262.0,Styrkarsdottir U,Other measurement,replication,2008-12-14,GCST000295,Bone mineral density (spine)
8943,European,6865.0,19079262.0,Styrkarsdottir U,Other measurement,initial,2008-12-14,GCST000297,Bone mineral density (hip)
11219,European,59082.0,19079261.0,Willer CJ,"Body measurement, Other measurement",replication,2008-12-14,GCST000298,Body mass index
9712,European,11036.0,19079260.0,Thorleifsson G,Body measurement,replication,2008-12-14,GCST000299,Weight
8942,European,6865.0,19079262.0,Styrkarsdottir U,Other measurement,initial,2008-12-14,GCST000295,Bone mineral density (spine)
814,African American or Afro-Caribbean,1160.0,19079260.0,Thorleifsson G,Body measurement,initial,2008-12-14,GCST000299,Weight
13757,Other/Mixed,698.0,19074352.0,Pollin TI,Lipid or lipoprotein measurement,replication,2008-12-17,GCST000300,Triglycerides
5134,European,411.0,19084217.0,Benyamin B,Other measurement,initial,2008-12-17,GCST000302,Iron status biomarkers
5924,European,918.0,19084217.0,Benyamin B,Other measurement,initial,2008-12-17,GCST000301,Iron status biomarkers
13789,Other/Mixed,809.0,19074352.0,Pollin TI,Lipid or lipoprotein measurement,initial,2008-12-17,GCST000300,Triglycerides
9994,European,14618.0,19096518.0,Pare G,Other measurement,initial,2008-12-19,GCST000303,Glycated hemoglobin levels
5226,European,455.0,19096518.0,Pare G,Other measurement,replication,2008-12-19,GCST000303,Glycated hemoglobin levels
7659,European,3141.0,19107115.0,Muglia P,Neurological disorder,initial,2008-12-23,GCST000304,Major depressive disorder
6623,European,1606.0,19110211.0,Meisinger C,Hematological measurement,initial,2008-12-24,GCST000305,Mean platelet volume
9361,European,8617.0,19110211.0,Meisinger C,Hematological measurement,replication,2008-12-24,GCST000305,Mean platelet volume
13695,Other/Mixed,575.0,19114657.0,Wang Y,"Other measurement, Cardiovascular measurement",replication,2008-12-29,GCST000306,Blood pressure
5402,European,542.0,19114657.0,Wang Y,"Other measurement, Cardiovascular measurement",initial,2008-12-29,GCST000306,Blood pressure
8823,European,6361.0,19114657.0,Wang Y,"Other measurement, Cardiovascular measurement",replication,2008-12-29,GCST000306,Blood pressure
6641,European,1627.0,19115949.0,Limou S,Immune system disorder,initial,2009-01-01,GCST000308,AIDS progression
8298,European,4636.0,19117981.0,Sun J,Cancer,replication,2009-01-01,GCST000307,Prostate cancer
7437,European,2678.0,19116933.0,Hinks A,Immune system disorder,replication,2009-01-01,GCST000309,Arthritis (juvenile idiopathic)
7526,European,2834.0,19117981.0,Sun J,Cancer,initial,2009-01-01,GCST000307,Prostate cancer
5237,European,463.0,19116933.0,Hinks A,Immune system disorder,initial,2009-01-01,GCST000309,Arthritis (juvenile idiopathic)
5230,European,458.0,19118814.0,Beecham GW,Neurological disorder,replication,2009-01-03,GCST000310,Alzheimer's disease
6054,European,988.0,19118814.0,Beecham GW,Neurological disorder,initial,2009-01-03,GCST000310,Alzheimer's disease
7309,European,2502.0,19122664.0,Silverberg MS,Immune system disorder,replication,2009-01-04,GCST000311,Ulcerative colitis
7904,European,3525.0,19122664.0,Silverberg MS,Immune system disorder,initial,2009-01-04,GCST000311,Ulcerative colitis
6015,European,970.0,19125160.0,Feulner TM,Neurological disorder,initial,2009-01-07,GCST000313,Alzheimer's disease
6145,European,1054.0,19124843.0,Ober C,Lipid or lipoprotein measurement,replication,2009-01-07,GCST000312,Lp (a) levels
13637,Other/Mixed,357.0,19124843.0,Ober C,Lipid or lipoprotein measurement,initial,2009-01-07,GCST000312,Lp (a) levels
4886,European,241.0,19132087.0,Burgner D,Immune system disorder,initial,2009-01-09,GCST000314,Kawasaki disease
6875,European,1940.0,19132087.0,Burgner D,Immune system disorder,replication,2009-01-09,GCST000314,Kawasaki disease
7480,European,2756.0,19136949.0,Carrasquillo MM,Neurological disorder,replication,2009-01-11,GCST000315,Alzheimer's disease
7013,European,2099.0,19136949.0,Carrasquillo MM,Neurological disorder,initial,2009-01-11,GCST000315,Alzheimer's disease
6160,European,1075.0,19148276.0,Tanaka T,Other measurement,initial,2009-01-16,GCST000316,Polyunsaturated fatty acid levels
6163,European,1076.0,19148276.0,Tanaka T,Other measurement,replication,2009-01-16,GCST000316,Polyunsaturated fatty acid levels
10704,European,30395.0,19151717.0,Rafnar T,Cancer,initial,2009-01-18,GCST000318,Basal cell carcinoma
6600,European,1575.0,19151717.0,Rafnar T,Cancer,replication,2009-01-18,GCST000318,Basal cell carcinoma
7502,European,2796.0,19151714.0,Meyre D,"Other measurement, Metabolic disorder",initial,2009-01-18,GCST000317,Obesity
9975,European,14186.0,19151714.0,Meyre D,"Other measurement, Metabolic disorder",replication,2009-01-18,GCST000317,Obesity
6921,European,1986.0,19165155.0,Ling H,Other measurement,initial,2009-01-22,GCST000319,Adiponectin levels
2019,Asian,400.0,19165232.0,Otowa T,Neurological disorder,initial,2009-01-23,GCST000320,Panic disorder
3041,Asian,2271.0,19169255.0,Zhang XJ,Immune system disorder,initial,2009-01-25,GCST000321,Psoriasis
9605,European,10089.0,19169254.0,Nair RP,Immune system disorder,replication,2009-01-25,GCST000322,Psoriasis
4145,Asian,13061.0,19169255.0,Zhang XJ,Immune system disorder,replication,2009-01-25,GCST000321,Psoriasis
7484,European,2759.0,19169254.0,Nair RP,Immune system disorder,initial,2009-01-25,GCST000322,Psoriasis
25,African,53.0,19176441.0,Yang JJ,"Response to drug, Cancer",initial,2009-01-28,GCST000323,Response to treatment for acute lymphoblastic leukemia
13485,Other/Mixed,78.0,19176441.0,Yang JJ,"Response to drug, Cancer",initial,2009-01-28,GCST000323,Response to treatment for acute lymphoblastic leukemia
5044,European,356.0,19176441.0,Yang JJ,"Response to drug, Cancer",initial,2009-01-28,GCST000323,Response to treatment for acute lymphoblastic leukemia
6279,European,1191.0,19185284.0,Ferrucci L,Other measurement,initial,2009-01-29,GCST000324,Carotenoid and tocopherol levels
7356,European,2540.0,19185284.0,Ferrucci L,Other measurement,replication,2009-01-29,GCST000324,Carotenoid and tocopherol levels
8034,European,3875.0,19181680.0,Timpson NJ,Other measurement,replication,2009-01-30,GCST000325,Bone mineral density
6579,European,1552.0,19181680.0,Timpson NJ,Other measurement,initial,2009-01-30,GCST000325,Bone mineral density
10018,European,14830.0,19182806.0,Stefansson H,Other trait,initial,2009-02-01,GCST000329,Essential tremor
6719,European,1720.0,19182806.0,Stefansson H,Other trait,replication,2009-02-01,GCST000329,Essential tremor
10245,European,18245.0,20031564.0,Ridker PM,Lipid or lipoprotein measurement,initial,2009-02-01,GCST000331,HDL cholesterol
1962,Asian,347.0,19187332.0,Kim SH,Other disease,initial,2009-02-01,GCST000330,Asthma (toluene diisocyanate-induced)
4694,European,112.0,19207018.0,Kim H,Other trait,initial,2009-02-01,GCST000326,Pain
5903,European,898.0,19260141.0,Zemunik T,"Cardiovascular measurement, Hematological measurement, Lipid or lipoprotein measurement, Other measurement",initial,2009-02-01,GCST000328,Biochemical measures
5902,European,898.0,19260139.0,Polasek O,"Other measurement, Body measurement",initial,2009-02-01,GCST000327,Anthropometric traits
9112,European,7623.0,19188921.0,Liu YZ,Biological process,replication,2009-02-03,GCST000332,Smoking behavior
838,African American or Afro-Caribbean,1251.0,19188921.0,Liu YZ,Biological process,replication,2009-02-03,GCST000332,Smoking behavior
5821,European,840.0,19188921.0,Liu YZ,Biological process,initial,2009-02-03,GCST000332,Smoking behavior
8644,European,5616.0,19193627.0,Chio A,Neurological disorder,replication,2009-02-04,GCST000333,Amyotrophic lateral sclerosis
7330,European,2521.0,19193627.0,Chio A,Neurological disorder,initial,2009-02-04,GCST000333,Amyotrophic lateral sclerosis
2238,Asian,700.0,19196962.0,Garcia-Barcelo MM,Digestive system disorder,replication,2009-02-05,GCST000334,Hirschsprung disease
2135,Asian,527.0,19196962.0,Garcia-Barcelo MM,Digestive system disorder,initial,2009-02-05,GCST000334,Hirschsprung disease
13934,Other/Mixed,2906.0,19197348.0,Lowe JK,"Other measurement, Body measurement, Lipid or lipoprotein measurement, Inflammatory measurement",initial,2009-02-06,GCST000337,Quantitative traits
10889,European,37388.0,19198613.0,Gudmundsson J,Cancer,initial,2009-02-06,GCST000335,Thyroid cancer
9989,European,14455.0,19197363.0,Need AC,Neurological disorder,replication,2009-02-06,GCST000336,Schizophrenia
7064,European,2159.0,19198613.0,Gudmundsson J,Cancer,replication,2009-02-06,GCST000335,Thyroid cancer
6744,European,1734.0,19197363.0,Need AC,Neurological disorder,initial,2009-02-06,GCST000336,Schizophrenia
9818,European,12118.0,19198610.0,Gudbjartsson DF,Hematological measurement,replication,2009-02-08,GCST000339,Eosinophil counts
10924,European,38253.0,19198612.0,Erdmann J,Cardiovascular disease,replication,2009-02-08,GCST000338,Coronary heart disease
9985,European,14398.0,19198611.0,Tregouet DA,Cardiovascular disease,replication,2009-02-08,GCST000341,Coronary heart disease
3541,Asian,5212.0,19198610.0,Gudbjartsson DF,Hematological measurement,replication,2009-02-08,GCST000339,Eosinophil counts
9480,European,9392.0,19198610.0,Gudbjartsson DF,Hematological measurement,initial,2009-02-08,GCST000339,Eosinophil counts
10316,European,19492.0,19198609.0,Kathiresan S,Cardiovascular disease,replication,2009-02-08,GCST000340,Myocardial infarction (early onset)
8383,European,4864.0,19198611.0,Tregouet DA,Cardiovascular disease,initial,2009-02-08,GCST000341,Coronary heart disease
7329,European,2520.0,19198612.0,Erdmann J,Cardiovascular disease,initial,2009-02-08,GCST000338,Coronary heart disease
8753,European,6042.0,19198609.0,Kathiresan S,Cardiovascular disease,initial,2009-02-08,GCST000340,Myocardial infarction (early onset)
6621,European,1601.0,19221038.0,Soranzo N,Hematological measurement,replication,2009-02-12,GCST000342,Mean platelet volume
3247,Asian,3027.0,19219042.0,Zheng W,Cancer,initial,2009-02-15,GCST000343,Breast cancer
13842,Other/Mixed,1262.0,19389651.0,Smith JG,Cardiovascular measurement,initial,2009-02-15,GCST000344,Electrocardiographic conduction measures
7624,European,3057.0,19219042.0,Zheng W,Cancer,replication,2009-02-15,GCST000343,Breast cancer
3813,Asian,7502.0,19219042.0,Zheng W,Cancer,replication,2009-02-15,GCST000343,Breast cancer
13880,Other/Mixed,1719.0,19230858.0,Schrauwen I,Neurological disorder,replication,2009-02-18,GCST000345,Otosclerosis
13706,Other/Mixed,604.0,19230858.0,Schrauwen I,Neurological disorder,initial,2009-02-18,GCST000345,Otosclerosis
4989,European,320.0,19242412.0,Gu Y,Other disease,initial,2009-02-25,GCST000346,Cystic fibrosis severity
3338,Asian,3655.0,19249006.0,Xiong DH,Other measurement,replication,2009-02-25,GCST000347,Bone mineral density
5271,European,485.0,19242412.0,Gu Y,Other disease,replication,2009-02-25,GCST000346,Cystic fibrosis severity
8418,European,4925.0,19249006.0,Xiong DH,Other measurement,replication,2009-02-25,GCST000347,Bone mineral density
149,African,908.0,19249006.0,Xiong DH,Other measurement,replication,2009-02-25,GCST000347,Bone mineral density
6072,European,1000.0,19249006.0,Xiong DH,Other measurement,initial,2009-02-25,GCST000347,Bone mineral density
6701,European,1705.0,19252134.0,Pezzolesi MG,Metabolic disorder,initial,2009-02-27,GCST000348,Type 2 diabetes nephropathy
6371,European,1304.0,19252134.0,Pezzolesi MG,Metabolic disorder,replication,2009-02-27,GCST000348,Type 2 diabetes nephropathy
8208,European,4342.0,19247474.0,Caporaso N,Biological process,initial,2009-02-27,GCST000349,Smoking behavior
1817,Asian,214.0,19259986.0,Hattori E,Neurological disorder,initial,2009-03-02,GCST000350,Bipolar disorder
2335,Asian,804.0,19259986.0,Hattori E,Neurological disorder,replication,2009-03-02,GCST000350,Bipolar disorder
6023,European,973.0,19268274.0,Liu XG,Other measurement,initial,2009-03-04,GCST000352,Body mass (lean)
3226,Asian,2955.0,19268274.0,Liu XG,Other measurement,replication,2009-03-04,GCST000352,Body mass (lean)
7891,European,3497.0,19268276.0,Vink JM,Biological process,initial,2009-03-04,GCST000351,Smoking behavior
9108,European,7614.0,19268276.0,Vink JM,Biological process,replication,2009-03-04,GCST000351,Smoking behavior
7871,European,3460.0,19268274.0,Liu XG,Other measurement,replication,2009-03-04,GCST000352,Body mass (lean)
13588,Other/Mixed,249.0,19268276.0,Vink JM,Biological process,replication,2009-03-04,GCST000351,Smoking behavior
5498,European,607.0,19270707.0,Birnbaum S,"Other trait, Other measurement, Other disease",initial,2009-03-08,GCST000353,Orofacial clefts
7734,European,3237.0,19278955.0,Tregouet DA,Cardiovascular disease,replication,2009-03-10,GCST000354,Venous thromboembolism
6663,European,1647.0,19278955.0,Tregouet DA,Cardiovascular disease,initial,2009-03-10,GCST000354,Venous thromboembolism
6633,European,1616.0,19282985.0,Liu YZ,Other measurement,replication,2009-03-13,GCST000355,Menarche (age at onset)
2602,Asian,1387.0,19282985.0,Liu YZ,Other measurement,replication,2009-03-13,GCST000355,Menarche (age at onset)
5257,European,477.0,19282985.0,Liu YZ,Other measurement,initial,2009-03-13,GCST000355,Menarche (age at onset)
5390,European,531.0,19287509.0,Cui J,Other measurement,initial,2009-03-14,GCST000356,Anti-cyclic Citrullinated Peptide Antibody
5840,European,849.0,19287509.0,Cui J,Other measurement,replication,2009-03-14,GCST000356,Anti-cyclic Citrullinated Peptide Antibody
7785,European,3323.0,19287384.0,Kilpivaara O,Cancer,initial,2009-03-15,GCST000357,Myeloproliferative neoplasms
7571,European,2934.0,19303062.0,Tanaka T,"Other measurement, Cardiovascular measurement",initial,2009-03-18,GCST000358,Folate pathway vitamin levels
5609,European,686.0,19303062.0,Tanaka T,"Other measurement, Cardiovascular measurement",replication,2009-03-18,GCST000358,Folate pathway vitamin levels
9126,European,7691.0,19300500.0,Wilk JB,Other measurement,initial,2009-03-20,GCST000362,Pulmonary function
5814,European,835.0,19300500.0,Wilk JB,Other measurement,replication,2009-03-20,GCST000362,Pulmonary function
6647,European,1633.0,19300482.0,Pillai SG,Other disease,initial,2009-03-20,GCST000359,Chronic obstructive pulmonary disease
5997,European,954.0,19304780.0,Org E,Cardiovascular disease,initial,2009-03-20,GCST000361,Hypertension
7515,European,2812.0,19304780.0,Org E,Cardiovascular disease,replication,2009-03-20,GCST000361,Hypertension
6143,European,1053.0,19300499.0,Takeuchi F,Response to drug,initial,2009-03-20,GCST000360,Warfarin maintenance dose
7478,European,2752.0,19300482.0,Pillai SG,Other disease,replication,2009-03-20,GCST000359,Chronic obstructive pulmonary disease
5471,European,588.0,19300499.0,Takeuchi F,Response to drug,replication,2009-03-20,GCST000360,Warfarin maintenance dose
9936,European,13685.0,19305408.0,Newton-Cheh C,Cardiovascular measurement,initial,2009-03-22,GCST000363,QT interval
10081,European,15854.0,19305408.0,Newton-Cheh C,Cardiovascular measurement,replication,2009-03-22,GCST000363,QT interval
10078,European,15842.0,19305409.0,Pfeufer A,Cardiovascular measurement,initial,2009-03-22,GCST000364,QT interval
10248,European,18282.0,19330030.0,Thomas G,Cancer,replication,2009-03-29,GCST000365,Breast cancer
7170,European,2287.0,19330030.0,Thomas G,Cancer,initial,2009-03-29,GCST000365,Breast cancer
8164,European,4221.0,20031579.0,Tarasov KV,Cardiovascular measurement,initial,2009-04-01,GCST000370,Arterial stiffness
10211,European,17686.0,20031576.0,Dehghan A,Hematological measurement,replication,2009-04-01,GCST000366,Fibrinogen
10454,European,22096.0,20031576.0,Dehghan A,Hematological measurement,initial,2009-04-01,GCST000366,Fibrinogen
7992,European,3761.0,20031582.0,Thompson JF,Response to drug,replication,2009-04-01,GCST000369,Response to statin therapy
7425,European,2654.0,20031579.0,Tarasov KV,Cardiovascular measurement,replication,2009-04-01,GCST000370,Arterial stiffness
6919,European,1984.0,20031582.0,Thompson JF,Response to drug,initial,2009-04-01,GCST000369,Response to statin therapy
9955,European,13974.0,20031578.0,Pare G,Cardiovascular measurement,initial,2009-04-01,GCST000367,Homocysteine levels
10212,European,17686.0,20031577.0,Danik JS,Hematological measurement,initial,2009-04-01,GCST000368,Fibrinogen
5822,European,840.0,20031578.0,Pare G,Cardiovascular measurement,replication,2009-04-01,GCST000367,Homocysteine levels
5867,European,870.0,19340012.0,Nan H,Other trait,replication,2009-04-02,GCST000371,Tanning
7171,European,2287.0,19340012.0,Nan H,Other trait,initial,2009-04-02,GCST000371,Tanning
9015,European,7187.0,19343178.0,Soranzo N,"Other measurement, Body measurement",replication,2009-04-03,GCST000372,Height
9856,European,12611.0,19343178.0,Soranzo N,"Other measurement, Body measurement",initial,2009-04-03,GCST000372,Height
3671,Asian,5981.0,19403135.0,Yamada Y,Cardiovascular disease,replication,2009-04-05,GCST000373,Stroke (ischemic)
1886,Asian,266.0,19403135.0,Yamada Y,Cardiovascular disease,initial,2009-04-05,GCST000373,Stroke (ischemic)
8869,European,6594.0,19349984.0,Esparza-Gordillo J,Immune system disorder,replication,2009-04-06,GCST000374,Atopic dermatitis
7605,European,3011.0,19349984.0,Esparza-Gordillo J,Immune system disorder,initial,2009-04-06,GCST000374,Atopic dermatitis
2487,Asian,1113.0,19349983.0,Kamatani Y,"Digestive system disorder, Other measurement",initial,2009-04-06,GCST000375,Hepatitis B
3437,Asian,4420.0,19349983.0,Kamatani Y,"Digestive system disorder, Other measurement",replication,2009-04-06,GCST000375,Hepatitis B
2364,Asian,854.0,19349983.0,Kamatani Y,"Digestive system disorder, Other measurement",replication,2009-04-06,GCST000375,Hepatitis B
6639,European,1625.0,19359265.0,Mangino M,Other measurement,initial,2009-04-08,GCST000376,Telomere length
6251,European,1165.0,19359265.0,Mangino M,Other measurement,replication,2009-04-08,GCST000376,Telomere length
2383,Asian,900.0,19359809.0,Hiura Y,Lipid or lipoprotein measurement,initial,2009-04-10,GCST000377,HDL cholesterol
2829,Asian,1810.0,19359809.0,Hiura Y,Lipid or lipoprotein measurement,replication,2009-04-10,GCST000377,HDL cholesterol
4980,European,314.0,19367585.0,Poduslo SE,Biological process,initial,2009-04-14,GCST000378,Aging
362,African American or Afro-Caribbean,2.0,19367585.0,Poduslo SE,Biological process,initial,2009-04-14,GCST000378,Aging
10330,European,19602.0,19369658.0,Ikram MA,Cardiovascular disease,initial,2009-04-15,GCST000379,Stroke
1068,African American or Afro-Caribbean,3004.0,19369658.0,Ikram MA,Cardiovascular disease,replication,2009-04-15,GCST000379,Stroke
8181,European,4265.0,19369658.0,Ikram MA,Cardiovascular disease,replication,2009-04-15,GCST000379,Stroke
3869,Asian,7861.0,19396169.0,Cho YS,"Other measurement, Body measurement",replication,2009-04-26,GCST000380,Height
3868,Asian,7861.0,19396169.0,Cho YS,"Body measurement, Cardiovascular measurement, Other measurement",replication,2009-04-26,GCST000381,Biomedical quantitative traits
3948,Asian,8842.0,19396169.0,Cho YS,"Other measurement, Body measurement",initial,2009-04-26,GCST000380,Height
3947,Asian,8842.0,19396169.0,Cho YS,"Body measurement, Cardiovascular measurement, Other measurement",initial,2009-04-26,GCST000381,Biomedical quantitative traits
9692,European,10796.0,19404256.0,Wang K,Neurological disorder,initial,2009-04-28,GCST000382,Autism
6955,European,2038.0,19404256.0,Wang K,Neurological disorder,replication,2009-04-28,GCST000382,Autism
4107,Asian,11977.0,19401414.0,Takeuchi F,Metabolic disorder,replication,2009-04-29,GCST000383,Type 2 diabetes
2447,Asian,1022.0,19401414.0,Takeuchi F,Metabolic disorder,initial,2009-04-29,GCST000383,Type 2 diabetes
5707,European,754.0,19330027.0,Ahmed S,Cancer,initial,2009-05-01,GCST004948,Breast cancer
3468,Asian,4631.0,19330027.0,Ahmed S,Cancer,replication,2009-05-01,GCST004948,Breast cancer
5708,European,754.0,19330027.0,Ahmed S,Cancer,initial,2009-05-01,GCST004949,Breast cancer
10508,European,23660.0,19330027.0,Ahmed S,Cancer,replication,2009-05-01,GCST004949,Breast cancer
11410,European,80356.0,19330027.0,Ahmed S,Cancer,replication,2009-05-01,GCST004948,Breast cancer
2504,Asian,1166.0,19412176.0,Hallmayer J,Neurological disorder,replication,2009-05-03,GCST000385,Narcolepsy
6848,European,1881.0,19412176.0,Hallmayer J,Neurological disorder,initial,2009-05-03,GCST000385,Narcolepsy
7305,European,2490.0,19412175.0,Capasso M,Cancer,replication,2009-05-03,GCST000384,Neuroblastoma (high-risk)
7270,European,2440.0,19412175.0,Capasso M,Cancer,initial,2009-05-03,GCST000384,Neuroblastoma (high-risk)
5643,European,718.0,19412176.0,Hallmayer J,Neurological disorder,replication,2009-05-03,GCST000385,Narcolepsy
567,African American or Afro-Caribbean,277.0,19412176.0,Hallmayer J,Neurological disorder,replication,2009-05-03,GCST000385,Narcolepsy
13993,Other/Mixed,9464.0,19414484.0,Johnson AD,Other measurement,initial,2009-05-04,GCST000386,Bilirubin levels
10239,European,18190.0,19416921.0,Scott LJ,Neurological disorder,initial,2009-05-05,GCST000387,Bipolar disorder
8194,European,4300.0,19419973.0,Sanna S,Other measurement,initial,2009-05-06,GCST000388,Bilirubin levels
7442,European,2692.0,19419973.0,Sanna S,Other measurement,replication,2009-05-06,GCST000388,Bilirubin levels
6297,European,1205.0,19426955.0,Himes BE,Other disease,initial,2009-05-07,GCST000389,Asthma
10051,European,15339.0,19426955.0,Himes BE,Other disease,replication,2009-05-07,GCST000389,Asthma
1222,African American or Afro-Caribbean,5264.0,19426955.0,Himes BE,Other disease,replication,2009-05-07,GCST000389,Asthma
2735,Asian,1666.0,19421330.0,Yang HC,Cardiovascular disease,replication,2009-05-07,GCST000390,Hypertension (young onset)
1965,Asian,350.0,19421330.0,Yang HC,Cardiovascular disease,initial,2009-05-07,GCST000390,Hypertension (young onset)
12852,Hispanic or Latin American,1776.0,19426955.0,Himes BE,Other disease,replication,2009-05-07,GCST000389,Asthma
13884,Other/Mixed,1776.0,19426955.0,Himes BE,Other disease,replication,2009-05-07,GCST000389,Asthma
12779,Hispanic or Latin American,961.0,19430760.0,Rich SS,Other trait,replication,2009-05-09,GCST000391,Insulin resistance/response
12585,Hispanic or Latin American,229.0,19430760.0,Rich SS,Other trait,initial,2009-05-09,GCST000391,Insulin resistance/response
4141,Asian,12889.0,19430483.0,Newton-Cheh C,Other measurement,replication,2009-05-10,GCST000395,Systolic blood pressure
10832,European,34433.0,19430479.0,Levy D,Cardiovascular disease,replication,2009-05-10,GCST000398,Hypertension
4140,Asian,12889.0,19430483.0,Newton-Cheh C,Other measurement,replication,2009-05-10,GCST000394,Diastolic blood pressure
11579,European,100347.0,19430483.0,Newton-Cheh C,Other measurement,replication,2009-05-10,GCST000395,Systolic blood pressure
10833,European,34433.0,19430479.0,Levy D,Other measurement,replication,2009-05-10,GCST000393,Systolic blood pressure
10834,European,34433.0,19430479.0,Levy D,Other measurement,replication,2009-05-10,GCST000396,Diastolic blood pressure
10835,European,34433.0,19430483.0,Newton-Cheh C,Other measurement,initial,2009-05-10,GCST000394,Diastolic blood pressure
11578,European,100347.0,19430483.0,Newton-Cheh C,Other measurement,replication,2009-05-10,GCST000394,Diastolic blood pressure
10671,European,29136.0,19430479.0,Levy D,Other measurement,initial,2009-05-10,GCST000393,Systolic blood pressure
10343,European,19877.0,19430482.0,Kottgen A,"Other measurement, Other disease",initial,2009-05-10,GCST000397,Renal function and chronic kidney disease
10670,European,29136.0,19430479.0,Levy D,Cardiovascular disease,initial,2009-05-10,GCST000398,Hypertension
10836,European,34433.0,19430483.0,Newton-Cheh C,Other measurement,initial,2009-05-10,GCST000395,Systolic blood pressure
10136,European,16559.0,19430480.0,Barrett JC,Metabolic disorder,initial,2009-05-10,GCST000392,Type 1 diabetes
9893,European,13279.0,19430480.0,Barrett JC,Metabolic disorder,replication,2009-05-10,GCST000392,Type 1 diabetes
7725,European,3219.0,19430482.0,Kottgen A,"Other measurement, Other disease",replication,2009-05-10,GCST000397,Renal function and chronic kidney disease
10672,European,29136.0,19430479.0,Levy D,Other measurement,initial,2009-05-10,GCST000396,Diastolic blood pressure
13612,Other/Mixed,322.0,19442274.0,Fei Y,Cardiovascular disease,initial,2009-05-14,GCST000399,Behcet's disease
10050,European,15297.0,19448622.0,Sulem P,Other measurement,initial,2009-05-15,GCST000400,Menarche (age at onset)
7373,European,2560.0,19448619.0,Stolk L,Other measurement,replication,2009-05-15,GCST000401,Menopause (age at onset)
9599,European,10040.0,19448622.0,Sulem P,Other measurement,replication,2009-05-15,GCST000400,Menarche (age at onset)
7588,European,2979.0,19448619.0,Stolk L,Other measurement,initial,2009-05-15,GCST000401,Menopause (age at onset)
13833,Other/Mixed,1177.0,19448189.0,Perlis RH,"Response to drug, Neurological disorder",initial,2009-05-15,GCST000402,Response to lithium treatment in bipolar disorder
5053,European,359.0,19448189.0,Perlis RH,"Response to drug, Neurological disorder",replication,2009-05-15,GCST000402,Response to lithium treatment in bipolar disorder
10115,European,16373.0,19448623.0,Ong KK,Other measurement,replication,2009-05-17,GCST000405,Menarche (age at onset)
8326,European,4714.0,19448623.0,Ong KK,Other measurement,initial,2009-05-17,GCST000405,Menarche (age at onset)
10200,European,17438.0,19448621.0,He C,Other measurement,initial,2009-05-17,GCST000403,Menarche and menopause (age at onset)
10203,European,17510.0,19448620.0,Perry JR,Other measurement,initial,2009-05-17,GCST000404,Menarche (age at onset)
13822,Other/Mixed,1094.0,19451621.0,Landers JE,Neurological disorder,replication,2009-05-18,GCST000406,Amyotrophic lateral sclerosis
13969,Other/Mixed,4079.0,19451621.0,Landers JE,Neurological disorder,initial,2009-05-18,GCST000406,Amyotrophic lateral sclerosis
882,African American or Afro-Caribbean,1467.0,19454037.0,Arnett DK,Cardiovascular measurement,replication,2009-05-19,GCST000407,Left ventricular mass
4824,European,202.0,19454037.0,Arnett DK,Cardiovascular measurement,initial,2009-05-19,GCST000407,Left ventricular mass
5625,European,704.0,19454037.0,Arnett DK,Cardiovascular measurement,replication,2009-05-19,GCST000407,Left ventricular mass
6936,European,2012.0,19458352.0,Hirschfield GM,Cancer,initial,2009-05-20,GCST000408,Primary biliary cholangitis
6743,European,1732.0,19458352.0,Hirschfield GM,Cancer,replication,2009-05-20,GCST000408,Primary biliary cholangitis
12586,Hispanic or Latin American,229.0,19461586.0,Norris JM,"Other measurement, Liver enzyme measurement, Body measurement, Cardiovascular measurement, Inflammatory measurement, Lipid or lipoprotein measurement, Biological process, Metabolic disorder",initial,2009-05-21,GCST000409,Obesity-related traits
12780,Hispanic or Latin American,961.0,19461586.0,Norris JM,"Other measurement, Liver enzyme measurement, Body measurement, Cardiovascular measurement, Inflammatory measurement, Lipid or lipoprotein measurement, Biological process, Metabolic disorder",replication,2009-05-21,GCST000409,Obesity-related traits
232,African,2040.0,19465909.0,Jallow M,Digestive system disorder,initial,2009-05-24,GCST000410,Malaria
257,African,3463.0,19465909.0,Jallow M,Digestive system disorder,replication,2009-05-24,GCST000410,Malaria
4752,European,172.0,19478329.0,Aston KI,Other disease,initial,2009-05-28,GCST000412,Male infertility
7247,European,2390.0,19456320.0,Ma D,Neurological disorder,replication,2009-05-28,GCST000411,Autism
6449,European,1390.0,19456320.0,Ma D,Neurological disorder,initial,2009-05-28,GCST000411,Autism
1988,Asian,371.0,19478819.0,Ng CC,Cancer,initial,2009-05-29,GCST000413,Nasopharyngeal carcinoma
2037,Asian,420.0,19478819.0,Ng CC,Cancer,replication,2009-05-29,GCST000413,Nasopharyngeal carcinoma
6283,European,1196.0,19483682.0,Kanetsky PA,Cancer,initial,2009-05-31,GCST000416,Testicular cancer
6652,European,1639.0,19483682.0,Kanetsky PA,Cancer,replication,2009-05-31,GCST000416,Testicular cancer
5038,European,350.0,19483685.0,Daly AK,Digestive system disorder,initial,2009-05-31,GCST000415,Drug-induced liver injury (flucloxacillin)
7238,European,2377.0,19483681.0,Rapley EA,Cancer,replication,2009-05-31,GCST000414,Testicular germ cell tumor
7069,European,2165.0,19483681.0,Rapley EA,Cancer,initial,2009-05-31,GCST000414,Testicular germ cell tumor
7740,European,3244.0,19488044.0,Smith EN,Neurological disorder,replication,2009-06-02,GCST000417,Bipolar disorder
779,African American or Afro-Caribbean,1015.0,19488044.0,Smith EN,Neurological disorder,initial,2009-06-02,GCST000417,Bipolar disorder
6949,European,2034.0,19488044.0,Smith EN,Neurological disorder,initial,2009-06-02,GCST000417,Bipolar disorder
10638,European,28141.0,19503597.0,Kolz M,Cardiovascular measurement,initial,2009-06-05,GCST000418,Uric acid levels
13888,Other/Mixed,1861.0,19497516.0,Elmore JR,Cardiovascular disease,replication,2009-06-06,GCST000419,Abdominal aortic aneurysm
13981,Other/Mixed,5486.0,19503088.0,Gregersen PK,Immune system disorder,replication,2009-06-07,GCST000420,Rheumatoid arthritis
8965,European,6922.0,19503088.0,Gregersen PK,Immune system disorder,initial,2009-06-07,GCST000420,Rheumatoid arthritis
6795,European,1804.0,19508968.0,Zhai G,Other disease,initial,2009-06-08,GCST000421,Osteoarthritis
7748,European,3266.0,19508968.0,Zhai G,Other disease,replication,2009-06-08,GCST000421,Osteoarthritis
4724,European,150.0,19508998.0,Knauff EA,Other disease,replication,2009-06-09,GCST000422,Premature ovarian failure
5012,European,334.0,19508998.0,Knauff EA,Other disease,initial,2009-06-09,GCST000422,Premature ovarian failure
5086,European,387.0,19525478.0,Malarstig A,Cardiovascular measurement,initial,2009-06-12,GCST000423,Homocysteine levels
6324,European,1238.0,19525478.0,Malarstig A,Cardiovascular measurement,replication,2009-06-12,GCST000423,Homocysteine levels
9560,European,9844.0,19525953.0,De Jager PL,Immune system disorder,initial,2009-06-14,GCST000424,Multiple sclerosis
8467,European,5031.0,19525955.0,Bahlo M,Immune system disorder,initial,2009-06-14,GCST000425,Multiple sclerosis
8273,European,4566.0,19525955.0,Bahlo M,Immune system disorder,replication,2009-06-14,GCST000425,Multiple sclerosis
8204,European,4331.0,19525953.0,De Jager PL,Immune system disorder,replication,2009-06-14,GCST000424,Multiple sclerosis
8073,European,3972.0,19553259.0,Cotsapas C,"Metabolic disorder, Body measurement",initial,2009-06-24,GCST000426,Obesity (extreme)
11585,European,102064.0,19557161.0,Lindgren CM,Metabolic disorder,replication,2009-06-26,GCST000428,Adiposity
10725,European,31373.0,19557197.0,Heard-Costa NL,Body measurement,initial,2009-06-26,GCST000427,Waist circumference
10931,European,38580.0,19557161.0,Lindgren CM,Metabolic disorder,initial,2009-06-26,GCST000428,Adiposity
10858,European,35540.0,19561606.0,Thorleifsson G,Other disease,initial,2009-06-28,GCST000429,Kidney stones
9683,European,10743.0,19561606.0,Thorleifsson G,Other disease,replication,2009-06-28,GCST000429,Kidney stones
9601,European,10074.0,19570815.0,Estrada K,"Other measurement, Body measurement",initial,2009-07-01,GCST000431,Height
8963,European,6912.0,19570815.0,Estrada K,"Other measurement, Body measurement",replication,2009-07-01,GCST000431,Height
988,African American or Afro-Caribbean,2259.0,19571809.0,Shi J,Neurological disorder,initial,2009-07-01,GCST000433,Schizophrenia
14011,Other/Mixed,17967.0,19567438.0,Elliott P,Inflammatory measurement,initial,2009-07-01,GCST000430,C-reactive protein
14000,Other/Mixed,13615.0,19567438.0,Elliott P,Inflammatory measurement,replication,2009-07-01,GCST000430,C-reactive protein
8961,European,6909.0,19571811.0,Purcell SM,Neurological disorder,initial,2009-07-01,GCST000434,Schizophrenia
10096,European,16161.0,19571808.0,Stefansson H,Neurological disorder,initial,2009-07-01,GCST000435,Schizophrenia
10354,European,20185.0,19571811.0,Purcell SM,Neurological disorder,replication,2009-07-01,GCST000434,Schizophrenia
6815,European,1834.0,19581569.0,Treutlein J,"Other measurement, Neurological disorder",initial,2009-07-01,GCST000432,Alcohol dependence
6942,European,2020.0,19581569.0,Treutlein J,"Other measurement, Neurological disorder",replication,2009-07-01,GCST000432,Alcohol dependence
10726,European,31375.0,19571808.0,Stefansson H,Neurological disorder,replication,2009-07-01,GCST000435,Schizophrenia
8581,European,5334.0,19571809.0,Shi J,Neurological disorder,initial,2009-07-01,GCST000433,Schizophrenia
10435,European,21751.0,19571809.0,Shi J,Neurological disorder,replication,2009-07-01,GCST000433,Schizophrenia
6491,European,1451.0,19578179.0,Teichert M,Response to drug,initial,2009-07-04,GCST000436,Acenocoumarol maintenance dosage
8631,European,5548.0,19578367.0,Shete S,Cancer,initial,2009-07-05,GCST000439,Glioma
9758,European,11514.0,19578365.0,Falchi M,Cancer,replication,2009-07-05,GCST000438,Cutaneous nevi
13547,Other/Mixed,174.0,19578366.0,Wrensch M,Cancer,replication,2009-07-05,GCST000440,Glioma (high-grade)
8627,European,5498.0,19578367.0,Shete S,Cancer,replication,2009-07-05,GCST000439,Glioma
8315,European,4684.0,19578366.0,Wrensch M,Cancer,initial,2009-07-05,GCST000440,Glioma (high-grade)
6538,European,1524.0,19578365.0,Falchi M,Cancer,initial,2009-07-05,GCST000438,Cutaneous nevi
8612,European,5456.0,19578364.0,Bishop DT,Cancer,initial,2009-07-05,GCST000437,Melanoma
13347,Other/Mixed,2.0,19578366.0,Wrensch M,Cancer,replication,2009-07-05,GCST000440,Glioma (high-grade)
8153,European,4179.0,19578364.0,Bishop DT,Cancer,replication,2009-07-05,GCST000437,Melanoma
4756,European,174.0,19578366.0,Wrensch M,Cancer,replication,2009-07-05,GCST000440,Glioma (high-grade)
8119,European,4094.0,19584346.0,Vasan RS,Other measurement,replication,2009-07-08,GCST000441,Cardiac structure and function
5980,European,948.0,19584900.0,Tonjes A,"Other measurement, Body measurement",initial,2009-07-08,GCST000443,Body mass index and fat mass
8118,European,4094.0,19584346.0,Vasan RS,Cardiovascular measurement,replication,2009-07-08,GCST000442,Aortic root size
9858,European,12612.0,19584346.0,Vasan RS,Other measurement,initial,2009-07-08,GCST000441,Cardiac structure and function
9857,European,12612.0,19584346.0,Vasan RS,Cardiovascular measurement,initial,2009-07-08,GCST000442,Aortic root size
10678,European,29527.0,19587794.0,Nolte IM,Cardiovascular measurement,replication,2009-07-09,GCST000444,QT interval
7919,European,3558.0,19587794.0,Nolte IM,Cardiovascular measurement,initial,2009-07-09,GCST000444,QT interval
8687,European,5806.0,19597491.0,Gudbjartsson DF,Cardiovascular disease,replication,2009-07-13,GCST000446,Atrial fibrillation
3253,Asian,3049.0,19597491.0,Gudbjartsson DF,Cardiovascular disease,replication,2009-07-13,GCST000446,Atrial fibrillation
8787,European,6218.0,19597492.0,Benjamin EJ,Cardiovascular disease,replication,2009-07-13,GCST000445,Atrial fibrillation
10976,European,40518.0,19597492.0,Benjamin EJ,Cardiovascular disease,initial,2009-07-13,GCST000445,Atrial fibrillation
10870,European,36137.0,19597491.0,Gudbjartsson DF,Cardiovascular disease,initial,2009-07-13,GCST000446,Atrial fibrillation
157,African,980.0,19609347.0,Adeyemo A,Cardiovascular disease,replication,2009-07-17,GCST000447,Hypertension
781,African American or Afro-Caribbean,1017.0,19609347.0,Adeyemo A,Cardiovascular disease,initial,2009-07-17,GCST000447,Hypertension
5736,European,781.0,19620980.0,Skibola CF,Cancer,initial,2009-07-20,GCST000448,Follicular lymphoma
7739,European,3241.0,19620980.0,Skibola CF,Cancer,replication,2009-07-20,GCST000448,Follicular lymphoma
2260,Asian,718.0,19625618.0,Nakano M,Neurological disorder,initial,2009-07-22,GCST000449,Glaucoma (primary open-angle)
2365,Asian,857.0,19625618.0,Nakano M,Neurological disorder,replication,2009-07-22,GCST000449,Glaucoma (primary open-angle)
5733,European,778.0,20031604.0,Cheng YC,Other measurement,initial,2009-08-01,GCST000450,Matrix metalloproteinase levels
4690,European,106.0,19667218.0,Comabella M,Response to drug,initial,2009-08-01,GCST000453,Response to interferon beta therapy
4660,European,94.0,19667218.0,Comabella M,Response to drug,replication,2009-08-01,GCST000453,Response to interferon beta therapy
7202,European,2325.0,20031603.0,Marroni F,Cardiovascular measurement,initial,2009-08-01,GCST000452,QT interval
7201,European,2325.0,20031603.0,Marroni F,Cardiovascular measurement,initial,2009-08-01,GCST000451,RR interval (heart rate)
6868,European,1926.0,19648920.0,Wu X,Cancer,initial,2009-08-02,GCST000454,Bladder cancer
8147,European,4170.0,19648919.0,Song H,Cancer,initial,2009-08-02,GCST000455,Ovarian cancer
7927,European,3576.0,19648918.0,Amundadottir L,Cancer,initial,2009-08-02,GCST000456,Pancreatic cancer
10125,European,16421.0,19648919.0,Song H,Cancer,replication,2009-08-02,GCST000455,Ovarian cancer
8177,European,4247.0,19648918.0,Amundadottir L,Cancer,replication,2009-08-02,GCST000456,Pancreatic cancer
11029,European,44331.0,19648920.0,Wu X,Cancer,replication,2009-08-02,GCST000454,Bladder cancer
8755,European,6062.0,19656524.0,Grant SF,"Other trait, Other measurement, Other disease",initial,2009-08-03,GCST000458,Orofacial clefts
8239,European,4462.0,19651812.0,Chambers JC,Other measurement,replication,2009-08-03,GCST000457,Fasting plasma glucose
3810,Asian,7474.0,19651812.0,Chambers JC,Other measurement,initial,2009-08-03,GCST000457,Fasting plasma glucose
7832,European,3390.0,19654303.0,Broderick P,Cancer,initial,2009-08-04,GCST000459,Lung cancer
8617,European,5470.0,19654303.0,Broderick P,Cancer,replication,2009-08-04,GCST000459,Lung cancer
2160,Asian,562.0,19664746.0,Tse KP,Cancer,initial,2009-08-05,GCST000460,Nasopharyngeal carcinoma
3044,Asian,2275.0,19664746.0,Tse KP,Cancer,replication,2009-08-05,GCST000460,Nasopharyngeal carcinoma
380,African American or Afro-Caribbean,21.0,19668339.0,Potkin SG,Neurological disorder,initial,2009-08-07,GCST000461,Hippocampal atrophy
1535,Asian,4.0,19668339.0,Potkin SG,Neurological disorder,initial,2009-08-07,GCST000461,Hippocampal atrophy
13348,Other/Mixed,2.0,19668339.0,Potkin SG,Neurological disorder,initial,2009-08-07,GCST000461,Hippocampal atrophy
5042,European,354.0,19668339.0,Potkin SG,Neurological disorder,initial,2009-08-07,GCST000461,Hippocampal atrophy
13400,Other/Mixed,11.0,19680635.0,Alkelai A,Response to drug,initial,2009-08-13,GCST000462,Response to antipsychotic treatment
4902,European,257.0,19680635.0,Alkelai A,Response to drug,initial,2009-08-13,GCST000462,Response to antipsychotic treatment
473,African American or Afro-Caribbean,129.0,19680635.0,Alkelai A,Response to drug,initial,2009-08-13,GCST000462,Response to antipsychotic treatment
7775,European,3305.0,19684604.0,Papaemmanuil E,Cancer,initial,2009-08-16,GCST000463,Acute lymphoblastic leukemia (childhood)
12532,Hispanic or Latin American,75.0,19684573.0,Ge D,Digestive system disorder,initial,2009-08-16,GCST000465,Response to hepatitis C treatment
10305,European,19275.0,19684603.0,Trevino LR,Cancer,initial,2009-08-16,GCST000464,Acute lymphoblastic leukemia (childhood)
5868,European,871.0,19684573.0,Ge D,Digestive system disorder,initial,2009-08-16,GCST000465,Response to hepatitis C treatment
515,African American or Afro-Caribbean,191.0,19684573.0,Ge D,Digestive system disorder,initial,2009-08-16,GCST000465,Response to hepatitis C treatment
3153,Asian,2680.0,19698717.0,Cui R,Cancer,replication,2009-08-18,GCST000466,Esophageal cancer
2484,Asian,1109.0,19698717.0,Cui R,Cancer,initial,2009-08-18,GCST000466,Esophageal cancer
5160,European,429.0,19706858.0,Shuldiner AR,"Response to drug, Cardiovascular measurement",initial,2009-08-26,GCST000467,Response to clopidogrel therapy
13368,Other/Mixed,4.0,19706858.0,Shuldiner AR,"Response to drug, Cardiovascular measurement",replication,2009-08-26,GCST000467,Response to clopidogrel therapy
4716,European,140.0,19706858.0,Shuldiner AR,"Response to drug, Cardiovascular measurement",replication,2009-08-26,GCST000467,Response to clopidogrel therapy
442,African American or Afro-Caribbean,83.0,19706858.0,Shuldiner AR,"Response to drug, Cardiovascular measurement",replication,2009-08-26,GCST000467,Response to clopidogrel therapy
7814,European,3355.0,19714249.0,Liu YZ,"Other disease, Metabolic disorder",replication,2009-08-28,GCST000469,Obesity and osteoporosis
12839,Hispanic or Latin American,1476.0,19714205.0,Hancock DB,Other disease,initial,2009-08-28,GCST000468,Asthma (childhood onset)
12666,Hispanic or Latin American,531.0,19714205.0,Hancock DB,Other disease,replication,2009-08-28,GCST000468,Asthma (childhood onset)
6073,European,1000.0,19714249.0,Liu YZ,"Other disease, Metabolic disorder",initial,2009-08-28,GCST000469,Obesity and osteoporosis
13878,Other/Mixed,1682.0,19724244.0,Laje G,Response to drug,replication,2009-08-31,GCST000470,Response to antidepressant treatment
13554,Other/Mixed,180.0,19724244.0,Laje G,Response to drug,initial,2009-08-31,GCST000470,Response to antidepressant treatment
5620,European,700.0,19736353.0,Ising M,Response to drug,initial,2009-09-01,GCST000471,Response to antidepressant treatment
7422,European,2649.0,19723657.0,Spain SL,Cancer,replication,2009-09-01,GCST000472,Colorectal cancer
5306,European,494.0,19721433.0,McClay JL,Response to drug,initial,2009-09-01,GCST000473,Response to antipsychotic treatment
13587,Other/Mixed,244.0,19721433.0,McClay JL,Response to drug,initial,2009-09-01,GCST000473,Response to antipsychotic treatment
6285,European,1198.0,19736353.0,Ising M,Response to drug,replication,2009-09-01,GCST000471,Response to antidepressant treatment
6826,European,1850.0,19723657.0,Spain SL,Cancer,initial,2009-09-01,GCST000472,Colorectal cancer
7408,European,2622.0,19727025.0,De Moor MH,Biological process,initial,2009-09-02,GCST000474,Leisure-time exercise behaviour
5258,European,477.0,19729612.0,Paterson AD,Inflammatory measurement,replication,2009-09-03,GCST000476,Soluble E-selectin levels
5606,European,685.0,19729612.0,Paterson AD,Inflammatory measurement,initial,2009-09-03,GCST000476,Soluble E-selectin levels
5944,European,929.0,19729412.0,Tonjes A,"Other measurement, Body measurement",initial,2009-09-03,GCST000475,Height
8678,European,5758.0,19729412.0,Tonjes A,"Other measurement, Body measurement",replication,2009-09-03,GCST000475,Height
1808,Asian,207.0,19734545.0,Need AC,Other measurement,initial,2009-09-04,GCST000477,Cognitive performance
6000,European,958.0,19734545.0,Need AC,Other measurement,initial,2009-09-04,GCST000477,Cognitive performance
1680,Asian,104.0,19734545.0,Need AC,Other measurement,initial,2009-09-04,GCST000477,Cognitive performance
6440,European,1376.0,19734900.0,Rung J,Metabolic disorder,initial,2009-09-06,GCST000478,Type 2 diabetes
9028,European,7275.0,19734903.0,Lambert JC,Neurological disorder,replication,2009-09-06,GCST000480,Alzheimer's disease
9050,European,7360.0,19734903.0,Lambert JC,Neurological disorder,initial,2009-09-06,GCST000480,Alzheimer's disease
8211,European,4363.0,19734902.0,Harold D,Neurological disorder,replication,2009-09-06,GCST000479,Alzheimer's disease
9741,European,11336.0,19734901.0,van Es MA,Neurological disorder,initial,2009-09-06,GCST000481,Amyotrophic lateral sclerosis
9782,European,11789.0,19734902.0,Harold D,Neurological disorder,initial,2009-09-06,GCST000479,Alzheimer's disease
9339,European,8472.0,19734901.0,van Es MA,Neurological disorder,replication,2009-09-06,GCST000481,Amyotrophic lateral sclerosis
9862,European,12676.0,19734900.0,Rung J,Metabolic disorder,replication,2009-09-06,GCST000478,Type 2 diabetes
5407,European,547.0,19740415.0,Sha Q,Neurological disorder,initial,2009-09-09,GCST000482,Amyotrophic lateral sclerosis (SNP x SNP interaction)
8340,European,4763.0,19744961.0,Hazra A,"Other measurement, Cardiovascular measurement",initial,2009-09-10,GCST000483,Folate pathway vitamin levels
5618,European,699.0,20061627.0,Heinzen EL,Neurological disorder,initial,2009-09-11,GCST000484,Alzheimer's disease
5422,European,555.0,19749758.0,Suppiah V,Digestive system disorder,replication,2009-09-13,GCST000485,Response to hepatitis C treatment
4953,European,293.0,19749758.0,Suppiah V,Digestive system disorder,initial,2009-09-13,GCST000485,Response to hepatitis C treatment
1763,Asian,172.0,19749757.0,Tanaka Y,Digestive system disorder,replication,2009-09-13,GCST000486,Response to hepatitis C treatment
1735,Asian,142.0,19749757.0,Tanaka Y,Digestive system disorder,initial,2009-09-13,GCST000486,Response to hepatitis C treatment
7029,European,2134.0,19754311.0,Le Clerc S,Immune system disorder,initial,2009-09-15,GCST000487,AIDS
7989,European,3748.0,19767753.0,Eeles RA,Cancer,initial,2009-09-20,GCST000488,Prostate cancer
14027,Other/Mixed,38640.0,19767753.0,Eeles RA,Cancer,replication,2009-09-20,GCST000488,Prostate cancer
10887,European,37350.0,19767754.0,Gudmundsson J,Cancer,initial,2009-09-20,GCST000489,Prostate cancer
10546,European,24193.0,19767754.0,Gudmundsson J,Cancer,replication,2009-09-20,GCST000489,Prostate cancer
5700,European,747.0,19772629.0,Latourelle JC,"Neurological disorder, Other measurement",replication,2009-09-22,GCST000490,Parkinson's disease (age of onset)
5848,European,857.0,19772629.0,Latourelle JC,"Neurological disorder, Other measurement",initial,2009-09-22,GCST000490,Parkinson's disease (age of onset)
2548,Asian,1231.0,19779542.0,Nakanishi H,Other trait,initial,2009-09-25,GCST000491,Myopia (pathological)
2672,Asian,1510.0,19779542.0,Nakanishi H,Other trait,replication,2009-09-25,GCST000491,Myopia (pathological)
4819,European,200.0,19786962.0,Roeske D,Biological process,initial,2009-09-29,GCST000492,Speech perception in dyslexia
4782,European,186.0,19786962.0,Roeske D,Biological process,replication,2009-09-29,GCST000492,Speech perception in dyslexia
8128,European,4110.0,19798445.0,Hicks AA,"Other measurement, Lipid or lipoprotein measurement",initial,2009-10-02,GCST000493,Sphingolipid levels
10299,European,19195.0,19801982.0,Rivadeneira F,Other measurement,initial,2009-10-04,GCST000495,Bone mineral density (hip)
10298,European,19195.0,19801982.0,Rivadeneira F,Other measurement,initial,2009-10-04,GCST000494,Bone mineral density (spine)
13980,Other/Mixed,5265.0,19812673.0,Weiss LA,Neurological disorder,replication,2009-10-08,GCST000496,Autism
13875,Other/Mixed,1553.0,19812673.0,Weiss LA,Neurological disorder,initial,2009-10-08,GCST000496,Autism
9490,European,9456.0,19862010.0,Ganesh SK,Hematological measurement,replication,2009-10-11,GCST000503,Mean corpuscular volume
9489,European,9456.0,19862010.0,Ganesh SK,Hematological measurement,replication,2009-10-11,GCST000502,Hematocrit
10542,European,24167.0,19862010.0,Ganesh SK,Hematological measurement,initial,2009-10-11,GCST000502,Hematocrit
8816,European,6316.0,19820698.0,Chambers JC,Hematological measurement,initial,2009-10-11,GCST000501,Hemoglobin
7879,European,3470.0,19820699.0,Benyamin B,Other measurement,replication,2009-10-11,GCST000505,Iron status biomarkers
9488,European,9456.0,19862010.0,Ganesh SK,Hematological measurement,replication,2009-10-11,GCST000500,Other erythrocyte phenotypes
9491,European,9456.0,19862010.0,Ganesh SK,Hematological measurement,replication,2009-10-11,GCST000504,Mean corpuscular hemoglobin
10540,European,24167.0,19862010.0,Ganesh SK,Hematological measurement,initial,2009-10-11,GCST000499,Hemoglobin
9487,European,9456.0,19862010.0,Ganesh SK,Hematological measurement,replication,2009-10-11,GCST000499,Hemoglobin
10543,European,24167.0,19862010.0,Ganesh SK,Hematological measurement,initial,2009-10-11,GCST000503,Mean corpuscular volume
8363,European,4818.0,19820699.0,Benyamin B,Other measurement,initial,2009-10-11,GCST000505,Iron status biomarkers
4005,Asian,9685.0,19820698.0,Chambers JC,Hematological measurement,initial,2009-10-11,GCST000501,Hemoglobin
9462,European,9316.0,19820697.0,Soranzo N,Hematological measurement,replication,2009-10-11,GCST000497,Mean platelet volume
8291,European,4627.0,19820697.0,Soranzo N,Hematological measurement,initial,2009-10-11,GCST000497,Mean platelet volume
8292,European,4627.0,19820697.0,Soranzo N,Hematological measurement,initial,2009-10-11,GCST000498,Hematological parameters
10541,European,24167.0,19862010.0,Ganesh SK,Hematological measurement,initial,2009-10-11,GCST000500,Other erythrocyte phenotypes
3746,Asian,6721.0,19820698.0,Chambers JC,Hematological measurement,replication,2009-10-11,GCST000501,Hemoglobin
8530,European,5187.0,19820698.0,Chambers JC,Hematological measurement,replication,2009-10-11,GCST000501,Hemoglobin
10544,European,24167.0,19862010.0,Ganesh SK,Hematological measurement,initial,2009-10-11,GCST000504,Mean corpuscular hemoglobin
9463,European,9316.0,19820697.0,Soranzo N,Hematological measurement,replication,2009-10-11,GCST000498,Hematological parameters
10425,European,21379.0,19836008.0,Landi MT,Cancer,replication,2009-10-15,GCST000506,Lung adenocarcinoma
9766,European,11587.0,19836008.0,Landi MT,Cancer,initial,2009-10-15,GCST000506,Lung adenocarcinoma
3035,Asian,2252.0,19838193.0,Han JW,Immune system disorder,initial,2009-10-18,GCST000507,Systemic lupus erythematosus
4035,Asian,10202.0,19838193.0,Han JW,Immune system disorder,replication,2009-10-18,GCST000507,Systemic lupus erythematosus
1916,Asian,293.0,19850125.0,Kim HJ,Immune system disorder,initial,2009-10-19,GCST000508,Neuromyelitis optica
552,African American or Afro-Caribbean,241.0,19846067.0,Garriock HA,Response to drug,initial,2009-10-19,GCST000509,Response to citalopram treatment
6153,European,1067.0,19846067.0,Garriock HA,Response to drug,initial,2009-10-19,GCST000509,Response to citalopram treatment
12571,Hispanic or Latin American,183.0,19846067.0,Garriock HA,Response to drug,initial,2009-10-19,GCST000509,Response to citalopram treatment
1591,Asian,37.0,19850125.0,Kim HJ,Immune system disorder,replication,2009-10-19,GCST000508,Neuromyelitis optica
7340,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008425,Neutrophil count
7341,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008426,Red blood cell count
8052,European,3925.0,19851299.0,Johansson A,"Body measurement, Other measurement",initial,2009-10-22,GCST000512,Body mass index
6564,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008428,Eosinophil counts
6565,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008429,Hemoglobin levels
8051,European,3925.0,19851299.0,Johansson A,Body measurement,initial,2009-10-22,GCST000511,Weight
6567,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008431,Lymphocyte counts
7342,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008428,Eosinophil counts
7343,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008429,Hemoglobin levels
7348,European,2538.0,19853236.0,Ferreira MA,Inflammatory measurement,initial,2009-10-22,GCST008427,Basophil count
7347,European,2538.0,19853236.0,Ferreira MA,"Hematological measurement, Inflammatory measurement",initial,2009-10-22,GCST008419,White blood cell count
7346,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008432,Mean corpuscular hemoglobin
6566,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008430,Hematocrit
6568,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008432,Mean corpuscular hemoglobin
6570,European,1543.0,19853236.0,Ferreira MA,Inflammatory measurement,replication,2009-10-22,GCST008427,Basophil count
6563,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008426,Red blood cell count
7339,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008421,Monocyte count
7338,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008420,Mean corpuscular volume
7337,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008418,Mean corpuscular hemoglobin concentration
6562,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008425,Neutrophil count
7336,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST000510,Platelet count
6561,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008421,Monocyte count
6560,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008420,Mean corpuscular volume
6559,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST008418,Mean corpuscular hemoglobin concentration
6558,European,1543.0,19853236.0,Ferreira MA,Hematological measurement,replication,2009-10-22,GCST000510,Platelet count
7345,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008431,Lymphocyte counts
6569,European,1543.0,19853236.0,Ferreira MA,"Hematological measurement, Inflammatory measurement",replication,2009-10-22,GCST008419,White blood cell count
7344,European,2538.0,19853236.0,Ferreira MA,Hematological measurement,initial,2009-10-22,GCST008430,Hematocrit
849,African American or Afro-Caribbean,1265.0,20029952.0,Sebastiani P,Neurological disorder,initial,2009-10-23,GCST000513,Sickle cell anemia (severity)
505,African American or Afro-Caribbean,163.0,20029952.0,Sebastiani P,Neurological disorder,replication,2009-10-23,GCST000513,Sickle cell anemia (severity)
13500,Other/Mixed,103.0,19875103.0,Aberg K,Response to drug,initial,2009-10-27,GCST000514,Response to antipsychotic therapy (extrapyramidal side effects)
543,African American or Afro-Caribbean,214.0,19875103.0,Aberg K,Response to drug,initial,2009-10-27,GCST000514,Response to antipsychotic therapy (extrapyramidal side effects)
5147,European,421.0,19875103.0,Aberg K,Response to drug,initial,2009-10-27,GCST000514,Response to antipsychotic therapy (extrapyramidal side effects)
7371,European,2557.0,19874204.0,Guo Y,Other measurement,replication,2009-10-29,GCST000515,Bone mineral density
6446,European,1382.0,19875614.0,Paterson AD,Other measurement,replication,2009-10-29,GCST000516,Glycemic control in type 1 diabetes (HbA1c)
6372,European,1304.0,19875614.0,Paterson AD,Other measurement,initial,2009-10-29,GCST000516,Glycemic control in type 1 diabetes (HbA1c)
6039,European,983.0,19874204.0,Guo Y,Other measurement,initial,2009-10-29,GCST000515,Bone mineral density
6864,European,1919.0,19880490.0,Tanaka T,Other measurement,initial,2009-10-30,GCST000517,Iron levels
6192,European,1096.0,19929986.0,Craig DW,Other disease,initial,2009-11-01,GCST000518,End-stage renal disease
9441,European,9169.0,19838195.0,Gateva V,Immune system disorder,initial,2009-11-01,GCST004867,Systemic lupus erythematosus
8804,European,6292.0,19838195.0,Gateva V,Immune system disorder,replication,2009-11-01,GCST004867,Systemic lupus erythematosus
10389,European,20985.0,19896111.0,Medland SE,Other trait,initial,2009-11-04,GCST000519,Hair morphology
4614,European,76.0,19890347.0,Birlea SA,Immune system disorder,initial,2009-11-05,GCST000520,Vitiligo
5310,European,496.0,19897590.0,Schaefer AS,Digestive system disorder,replication,2009-11-06,GCST000521,Periodontitis
6337,European,1255.0,19897590.0,Schaefer AS,Digestive system disorder,initial,2009-11-06,GCST000521,Periodontitis
3949,Asian,8842.0,19893584.0,Kim JJ,"Other measurement, Body measurement",initial,2009-11-06,GCST000522,Height
430,African American or Afro-Caribbean,73.0,19901119.0,Trevino LR,Response to drug,initial,2009-11-09,GCST000523,Methotrexate phramacokinetics (acute lymphoblastic leukemia)
4985,European,315.0,19901119.0,Trevino LR,Response to drug,initial,2009-11-09,GCST000523,Methotrexate phramacokinetics (acute lymphoblastic leukemia)
1538,Asian,5.0,19901119.0,Trevino LR,Response to drug,initial,2009-11-09,GCST000523,Methotrexate phramacokinetics (acute lymphoblastic leukemia)
13454,Other/Mixed,41.0,19901119.0,Trevino LR,Response to drug,initial,2009-11-09,GCST000523,Methotrexate phramacokinetics (acute lymphoblastic leukemia)
1221,African American or Afro-Caribbean,5205.0,19910028.0,Mathias RA,Other disease,replication,2009-11-10,GCST000525,Asthma
6289,European,1200.0,20039944.0,Docherty SJ,Biological process,initial,2009-11-10,GCST000524,Mathematical ability
926,African American or Afro-Caribbean,1864.0,19910028.0,Mathias RA,Other disease,initial,2009-11-10,GCST000525,Asthma
12748,Hispanic or Latin American,814.0,19902172.0,Palmer ND,"Other measurement, Other trait",replication,2009-11-10,GCST000526,Insulin-related traits
7135,European,2237.0,19910028.0,Mathias RA,Other disease,replication,2009-11-10,GCST000525,Asthma
6892,European,1954.0,20039944.0,Docherty SJ,Biological process,replication,2009-11-10,GCST000524,Mathematical ability
12587,Hispanic or Latin American,229.0,19902172.0,Palmer ND,"Other measurement, Other trait",initial,2009-11-10,GCST000526,Insulin-related traits
8663,European,5691.0,19915575.0,Simon-Sanchez J,Neurological disorder,initial,2009-11-15,GCST000528,Parkinson's disease
9355,European,8571.0,19915574.0,Imielinski M,Digestive system disorder,initial,2009-11-15,GCST000531,Inflammatory bowel disease (early onset)
2632,Asian,1473.0,19915573.0,Asano K,Immune system disorder,replication,2009-11-15,GCST000529,Ulcerative colitis
9169,European,7934.0,19915575.0,Simon-Sanchez J,Neurological disorder,replication,2009-11-15,GCST000528,Parkinson's disease
9007,European,7139.0,19915572.0,Barrett JC,Immune system disorder,replication,2009-11-15,GCST000527,Ulcerative colitis
2575,Asian,1310.0,19915573.0,Asano K,Immune system disorder,initial,2009-11-15,GCST000529,Ulcerative colitis
8931,European,6818.0,19915574.0,Imielinski M,Digestive system disorder,replication,2009-11-15,GCST000531,Inflammatory bowel disease (early onset)
4240,Asian,16686.0,19915576.0,Satake W,Neurological disorder,replication,2009-11-15,GCST000530,Parkinson's disease
9136,European,7778.0,19915572.0,Barrett JC,Immune system disorder,initial,2009-11-15,GCST000527,Ulcerative colitis
3312,Asian,3509.0,19915576.0,Satake W,Neurological disorder,initial,2009-11-15,GCST000530,Parkinson's disease
1764,Asian,174.0,20183929.0,Nuinoon M,Other disease,replication,2009-11-19,GCST000532,Beta thalassemia/hemoglobin E disease
2182,Asian,618.0,20183929.0,Nuinoon M,Other disease,initial,2009-11-19,GCST000532,Beta thalassemia/hemoglobin E disease
6928,European,2000.0,19936222.0,Chasman DI,Other measurement,replication,2009-11-20,GCST000533,Lipid metabolism phenotypes
10186,European,17296.0,19936222.0,Chasman DI,Other measurement,initial,2009-11-20,GCST000533,Lipid metabolism phenotypes
7972,European,3701.0,19944697.0,Karlsen TH,Digestive system disorder,replication,2009-11-25,GCST000534,Primary sclerosing cholangitis
5465,European,583.0,19944697.0,Karlsen TH,Digestive system disorder,initial,2009-11-25,GCST000534,Primary sclerosing cholangitis
8027,European,3854.0,19950302.0,Zhou X,Neurological disorder,replication,2009-11-30,GCST000535,Systemic sclerosis
2232,Asian,690.0,19950302.0,Zhou X,Neurological disorder,initial,2009-11-30,GCST000535,Systemic sclerosis
1612,Asian,60.0,19954339.0,Yin CS,Other trait,initial,2009-12-01,GCST000536,Sasang constitutional medicine type
9940,European,13795.0,20018283.0,Heid IM,Other measurement,replication,2009-12-02,GCST000537,Adiponectin levels
8304,European,4659.0,20018283.0,Heid IM,Other measurement,initial,2009-12-02,GCST000537,Adiponectin levels
8784,European,6202.0,20011104.0,Richards JB,Other measurement,replication,2009-12-05,GCST000538,Adiponectin levels
9348,European,8531.0,20011104.0,Richards JB,Other measurement,initial,2009-12-05,GCST000538,Adiponectin levels
9892,European,13276.0,19966805.0,Wallace C,Metabolic disorder,replication,2009-12-06,GCST000539,Type 1 diabetes
5550,European,651.0,19961619.0,Castro-Giner F,Immune system disorder,replication,2009-12-06,GCST000540,Atopy
10137,European,16559.0,19966805.0,Wallace C,Metabolic disorder,initial,2009-12-06,GCST000539,Type 1 diabetes
4861,European,225.0,19961619.0,Castro-Giner F,Immune system disorder,initial,2009-12-06,GCST000540,Atopy
2968,Asian,2118.0,20175129.0,Zhao LJ,Other measurement,replication,2009-12-11,GCST000541,Femoral neck bone geometry
6052,European,987.0,20175129.0,Zhao LJ,Other measurement,initial,2009-12-11,GCST000541,Femoral neck bone geometry
6513,European,1488.0,20175129.0,Zhao LJ,Other measurement,replication,2009-12-11,GCST000541,Femoral neck bone geometry
10101,European,16178.0,20010835.0,Hancock DB,Other measurement,replication,2009-12-13,GCST000542,Pulmonary function
11164,European,54276.0,20010834.0,Repapi E,Other measurement,replication,2009-12-13,GCST000544,Pulmonary function
10385,European,20890.0,20010835.0,Hancock DB,Other measurement,initial,2009-12-13,GCST000542,Pulmonary function
10355,European,20288.0,20010834.0,Repapi E,Other measurement,initial,2009-12-13,GCST000544,Pulmonary function
6499,European,1462.0,20012890.0,Ronald A,Other measurement,initial,2009-12-13,GCST000543,Social and non-social autistic-like traits
7888,European,3494.0,20012890.0,Ronald A,Other measurement,replication,2009-12-13,GCST000543,Social and non-social autistic-like traits
145,African,848.0,20018918.0,Solovieff N,Hematological measurement,initial,2009-12-16,GCST000545,Fetal hemoglobin levels
2895,Asian,1931.0,20018961.0,Zhang FR,Neurological disorder,initial,2009-12-16,GCST000546,Leprosy
1689,Asian,113.0,20018918.0,Solovieff N,Hematological measurement,replication,2009-12-16,GCST000545,Fetal hemoglobin levels
3983,Asian,9209.0,20018961.0,Zhang FR,Neurological disorder,replication,2009-12-16,GCST000546,Leprosy
2027,Asian,406.0,20018918.0,Solovieff N,Hematological measurement,replication,2009-12-16,GCST000545,Fetal hemoglobin levels
87,African,305.0,20018918.0,Solovieff N,Hematological measurement,replication,2009-12-16,GCST000545,Fetal hemoglobin levels
5558,European,655.0,20023658.0,Mangold E,"Other trait, Other measurement, Other disease",replication,2009-12-20,GCST000547,Orofacial clefts
6716,European,1717.0,20023658.0,Mangold E,"Other trait, Other measurement, Other disease",initial,2009-12-20,GCST000547,Orofacial clefts
7287,European,2463.0,20032318.0,Sleiman PM,Other disease,replication,2009-12-23,GCST000548,Asthma
7491,European,2781.0,20032318.0,Sleiman PM,Other disease,initial,2009-12-23,GCST000548,Asthma
1145,African American or Afro-Caribbean,3712.0,20032318.0,Sleiman PM,Other disease,replication,2009-12-23,GCST000548,Asthma
7223,European,2362.0,20041166.0,Fellay J,Other disease,initial,2009-12-24,GCST000549,HIV-1 control
6292,European,1202.0,20037589.0,Illig T,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",replication,2009-12-27,GCST000550,Metabolite levels
6126,European,1029.0,20037589.0,Illig T,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",initial,2009-12-27,GCST000550,Metabolite levels
6695,European,1699.0,20038948.0,Papassotiropoulos A,Biological process,replication,2009-12-29,GCST000552,Memory (short-term)
5010,European,333.0,20038948.0,Papassotiropoulos A,Biological process,initial,2009-12-29,GCST000552,Memory (short-term)
9056,European,7385.0,20038947.0,Shyn SI,Neurological disorder,initial,2009-12-29,GCST000551,Major depressive disorder (broad)
7349,European,2538.0,20045101.0,Ferreira MA,Hematological measurement,initial,2009-12-31,GCST008636,CD3-positive T-lymphocyte count
9481,European,9401.0,20044523.0,Debette S,Cardiovascular disease,initial,2009-12-31,GCST000554,Subclinical brain infarct
7354,European,2538.0,20045101.0,Ferreira MA,Inflammatory measurement,initial,2009-12-31,GCST000553,CD4:CD8 lymphocyte ratio
7353,European,2538.0,20045101.0,Ferreira MA,Hematological measurement,initial,2009-12-31,GCST008640,CD56-positive NK-lymphocyte cell count
6055,European,988.0,20045101.0,Ferreira MA,Hematological measurement,replication,2009-12-31,GCST008636,CD3-positive T-lymphocyte count
7352,European,2538.0,20045101.0,Ferreira MA,Hematological measurement,initial,2009-12-31,GCST008639,CD19-positive B-lymphocyte count
6060,European,988.0,20045101.0,Ferreira MA,Inflammatory measurement,replication,2009-12-31,GCST000553,CD4:CD8 lymphocyte ratio
7350,European,2538.0,20045101.0,Ferreira MA,Hematological measurement,initial,2009-12-31,GCST008637,CD4-positive T-lymphocyte count
6806,European,1822.0,20044523.0,Debette S,Cardiovascular disease,replication,2009-12-31,GCST000554,Subclinical brain infarct
6058,European,988.0,20045101.0,Ferreira MA,Hematological measurement,replication,2009-12-31,GCST008639,CD19-positive B-lymphocyte count
7351,European,2538.0,20045101.0,Ferreira MA,Hematological measurement,initial,2009-12-31,GCST008638,CD8-positive T-lymphocyte count
6059,European,988.0,20045101.0,Ferreira MA,Hematological measurement,replication,2009-12-31,GCST008640,CD56-positive NK-lymphocyte cell count
692,African American or Afro-Caribbean,644.0,20044523.0,Debette S,Cardiovascular disease,replication,2009-12-31,GCST000554,Subclinical brain infarct
6057,European,988.0,20045101.0,Ferreira MA,Hematological measurement,replication,2009-12-31,GCST008638,CD8-positive T-lymphocyte count
6056,European,988.0,20045101.0,Ferreira MA,Hematological measurement,replication,2009-12-31,GCST008637,CD4-positive T-lymphocyte count
13382,Other/Mixed,5.0,20215924.0,Liu X,Other measurement,initial,2010-01-01,GCST000556,Functional MRI
4592,European,57.0,20215924.0,Liu X,Other measurement,initial,2010-01-01,GCST000556,Functional MRI
4770,European,177.0,20009918.0,Shrestha S,"Cardiovascular disease, Cardiovascular measurement, Other disease",initial,2010-01-01,GCST000555,Carotid atherosclerosis in HIV infection
366,African American or Afro-Caribbean,6.0,20215924.0,Liu X,Other measurement,initial,2010-01-01,GCST000556,Functional MRI
10989,European,41597.0,20112360.0,Kerkhof HJ,Other disease,replication,2010-01-07,GCST000558,Osteoarthritis
8370,European,4837.0,20112360.0,Kerkhof HJ,Other disease,initial,2010-01-07,GCST000558,Osteoarthritis
13987,Other/Mixed,7397.0,20112360.0,Kerkhof HJ,Other disease,replication,2010-01-07,GCST000558,Osteoarthritis
6414,European,1362.0,20060832.0,Rauch A,Digestive system disorder,initial,2010-01-07,GCST000557,Chronic hepatitis C infection
2387,Asian,906.0,20072603.0,Guo Y,Other disease,replication,2010-01-08,GCST000560,Osteoporosis
2239,Asian,700.0,20072603.0,Guo Y,Other disease,initial,2010-01-08,GCST000560,Osteoporosis
5560,European,656.0,20066028.0,Igl W,Lipid or lipoprotein measurement,initial,2010-01-08,GCST000559,Cholesterol
7758,European,3282.0,20066028.0,Igl W,Lipid or lipoprotein measurement,replication,2010-01-08,GCST000559,Cholesterol
9024,European,7193.0,20062062.0,Reveille JD,Immune system disorder,initial,2010-01-10,GCST000563,Ankylosing spondylitis
3704,Asian,6243.0,20062061.0,Chambers JC,Cardiovascular measurement,replication,2010-01-10,GCST000564,Electrocardiographic traits
3739,Asian,6543.0,20062061.0,Chambers JC,Cardiovascular measurement,initial,2010-01-10,GCST000564,Electrocardiographic traits
9861,European,12670.0,20062063.0,Holm H,Cardiovascular measurement,initial,2010-01-10,GCST000561,Electrocardiographic traits
7256,European,2416.0,20062062.0,Reveille JD,Immune system disorder,replication,2010-01-10,GCST000563,Ankylosing spondylitis
9628,European,10352.0,20062063.0,Holm H,Cardiovascular measurement,replication,2010-01-10,GCST000561,Electrocardiographic traits
10647,European,28517.0,20062060.0,Pfeufer A,Cardiovascular measurement,initial,2010-01-10,GCST000562,PR interval
8588,European,5370.0,20062061.0,Chambers JC,Cardiovascular measurement,replication,2010-01-10,GCST000564,Electrocardiographic traits
2189,Asian,623.0,20066004.0,Chung CM,Other measurement,replication,2010-01-12,GCST000565,Angiotensin-converting enzyme activity
2020,Asian,400.0,20066004.0,Chung CM,Other measurement,initial,2010-01-12,GCST000565,Angiotensin-converting enzyme activity
7892,European,3497.0,20070850.0,Edwards TL,Neurological disorder,initial,2010-01-13,GCST000567,Parkinson's disease
5036,European,347.0,20068591.0,Van Laer L,Neurological disorder,initial,2010-01-13,GCST000566,Hearing impairment
8310,European,4677.0,20081856.0,McMahon FJ,Neurological disorder,replication,2010-01-17,GCST000570,Major mood disorders
10923,European,38238.0,20081858.0,Dupuis J,Other measurement,initial,2010-01-17,GCST000571,Fasting blood insulin
10882,European,37037.0,20081858.0,Dupuis J,"Other measurement, Other trait",initial,2010-01-17,GCST005179,Homeostasis model assessment of insulin resistance
10707,European,30620.0,20081857.0,Saxena R,Other measurement,replication,2010-01-17,GCST000569,Two-hour glucose challenge
10073,European,15754.0,20081856.0,McMahon FJ,Neurological disorder,initial,2010-01-17,GCST000570,Major mood disorders
11043,European,46186.0,20081858.0,Dupuis J,Other measurement,initial,2010-01-17,GCST000568,Fasting blood glucose
11246,European,62264.0,20081858.0,Dupuis J,Other measurement,replication,2010-01-17,GCST005180,Homeostasis model assessment of beta-cell function
14001,Other/Mixed,15234.0,20081857.0,Saxena R,Other measurement,initial,2010-01-17,GCST000569,Two-hour glucose challenge
11245,European,62264.0,20081858.0,Dupuis J,Other measurement,replication,2010-01-17,GCST000571,Fasting blood insulin
10875,European,36466.0,20081858.0,Dupuis J,Other measurement,initial,2010-01-17,GCST005180,Homeostasis model assessment of beta-cell function
11247,European,62264.0,20081858.0,Dupuis J,"Other measurement, Other trait",replication,2010-01-17,GCST005179,Homeostasis model assessment of insulin resistance
11371,European,76558.0,20081858.0,Dupuis J,Other measurement,replication,2010-01-17,GCST000568,Fasting blood glucose
2323,Asian,785.0,20096396.0,Kung AW,Other measurement,initial,2010-01-20,GCST000572,Bone mineral density
3410,Asian,4185.0,20096396.0,Kung AW,Other measurement,replication,2010-01-20,GCST000572,Bone mineral density
9950,European,13913.0,20096396.0,Kung AW,Other measurement,replication,2010-01-20,GCST000572,Bone mineral density
5659,European,733.0,20100581.0,Shen L,Other measurement,initial,2010-01-22,GCST000573,Brain imaging
1708,Asian,126.0,20101243.0,Petersen GM,Cancer,initial,2010-01-24,GCST000574,Pancreatic cancer
9062,European,7416.0,20101243.0,Petersen GM,Cancer,initial,2010-01-24,GCST000574,Pancreatic cancer
13642,Other/Mixed,369.0,20101243.0,Petersen GM,Cancer,initial,2010-01-24,GCST000574,Pancreatic cancer
8044,European,3901.0,20159242.0,Li X,Other disease,initial,2010-02-01,GCST000576,Asthma
5872,European,873.0,20117844.0,Brynedal B,Immune system disorder,replication,2010-02-01,GCST000577,Multiple sclerosis (severity)
6134,European,1040.0,20117844.0,Brynedal B,Immune system disorder,initial,2010-02-01,GCST000577,Multiple sclerosis (severity)
7426,European,2656.0,20125088.0,Shi J,Neurological disorder,initial,2010-02-02,GCST000578,Major depressive disorder
5776,European,813.0,20125193.0,Cirulli ET,Other measurement,initial,2010-02-03,GCST000579,Cognitive performance
1629,Asian,74.0,20125193.0,Cirulli ET,Other measurement,initial,2010-02-03,GCST000579,Cognitive performance
1759,Asian,167.0,20125193.0,Cirulli ET,Other measurement,initial,2010-02-03,GCST000579,Cognitive performance
12492,Hispanic or Latin American,7.0,20125193.0,Cirulli ET,Other measurement,initial,2010-02-03,GCST000579,Cognitive performance
4192,Asian,14392.0,20139978.0,Kamatani Y,Hematological measurement,initial,2010-02-07,GCST000588,Red blood cell count
4208,Asian,14806.0,20139978.0,Kamatani Y,Hematological measurement,initial,2010-02-07,GCST000580,Platelet count
7557,European,2917.0,20139977.0,Codd V,Other measurement,initial,2010-02-07,GCST000586,Telomere length
4189,Asian,14362.0,20139978.0,Kamatani Y,Hematological measurement,initial,2010-02-07,GCST000587,Mean corpuscular hemoglobin
4190,Asian,14364.0,20139978.0,Kamatani Y,Hematological measurement,initial,2010-02-07,GCST000585,Mean corpuscular volume
4191,Asian,14377.0,20139978.0,Kamatani Y,Hematological measurement,initial,2010-02-07,GCST000582,Mean corpuscular hemoglobin concentration
3964,Asian,8868.0,20139978.0,Kamatani Y,"Metabolic disorder, Other measurement",initial,2010-02-07,GCST000581,Urate levels
4193,Asian,14402.0,20139978.0,Kamatani Y,"Other measurement, Liver enzyme measurement, Cardiovascular measurement, Hematological measurement, Lipid or lipoprotein measurement",initial,2010-02-07,GCST000583,Hematological and biochemical traits
3969,Asian,8993.0,20139978.0,Kamatani Y,Lipid or lipoprotein measurement,initial,2010-02-07,GCST000584,Triglycerides
4196,Asian,14677.0,20139978.0,Kamatani Y,"Hematological measurement, Inflammatory measurement",initial,2010-02-07,GCST000589,White blood cell count
9499,European,9492.0,20139977.0,Codd V,Other measurement,replication,2010-02-07,GCST000586,Telomere length
8016,European,3825.0,20152958.0,Xing C,Other measurement,replication,2010-02-11,GCST000591,Fasting plasma glucose
5190,European,435.0,20150558.0,He M,Inflammatory measurement,replication,2010-02-11,GCST000590,Interleukin-18 levels
9064,European,7428.0,20152958.0,Xing C,Other measurement,initial,2010-02-11,GCST000591,Fasting plasma glucose
6536,European,1523.0,20150558.0,He M,Inflammatory measurement,initial,2010-02-11,GCST000590,Interleukin-18 levels
953,African American or Afro-Caribbean,2029.0,20152958.0,Xing C,Other measurement,initial,2010-02-11,GCST000591,Fasting plasma glucose
894,African American or Afro-Caribbean,1571.0,20152958.0,Xing C,Other measurement,replication,2010-02-11,GCST000591,Fasting plasma glucose
9609,European,10112.0,20159113.0,Jakkula E,Immune system disorder,replication,2010-02-12,GCST000593,Multiple sclerosis
2351,Asian,833.0,20169177.0,Yang W,Immune system disorder,replication,2010-02-12,GCST000592,Systemic lupus erythematosus
4828,European,204.0,20159113.0,Jakkula E,Immune system disorder,initial,2010-02-12,GCST000593,Multiple sclerosis
3499,Asian,4785.0,20169177.0,Yang W,Immune system disorder,replication,2010-02-12,GCST000592,Systemic lupus erythematosus
2828,Asian,1798.0,20169177.0,Yang W,Immune system disorder,initial,2010-02-12,GCST000592,Systemic lupus erythematosus
7614,European,3024.0,20154673.0,Van Deerlin VM,Neurological disorder,initial,2010-02-14,GCST000595,Frontotemporal lobar degeneration
5536,European,642.0,20154673.0,Van Deerlin VM,Neurological disorder,replication,2010-02-14,GCST000595,Frontotemporal lobar degeneration
5472,European,590.0,20064070.0,Herbeck JT,Other disease,replication,2010-02-15,GCST000596,HIV-1 progression
4734,European,156.0,20064070.0,Herbeck JT,Other disease,initial,2010-02-15,GCST000596,HIV-1 progression
6539,European,1524.0,20164292.0,Koller DL,Other measurement,initial,2010-02-17,GCST000598,Bone mineral density
5678,European,740.0,20171287.0,Stein JL,Other measurement,initial,2010-02-17,GCST000597,Brain structure
5583,European,669.0,20164292.0,Koller DL,Other measurement,replication,2010-02-17,GCST000598,Bone mineral density
2880,Asian,1894.0,20172861.0,Okada Y,Hematological measurement,replication,2010-02-18,GCST000600,Neutrophil count
9552,European,9813.0,20167578.0,Barbalic M,"Cardiovascular measurement, Other measurement",initial,2010-02-18,GCST000599,Soluble levels of adhesion molecules
3660,Asian,5771.0,20172861.0,Okada Y,Hematological measurement,initial,2010-02-18,GCST000600,Neutrophil count
3277,Asian,3276.0,20174558.0,Tsai FJ,Metabolic disorder,replication,2010-02-19,GCST000601,Type 2 diabetes
2879,Asian,1889.0,20174558.0,Tsai FJ,Metabolic disorder,initial,2010-02-19,GCST000601,Type 2 diabetes
9968,European,14179.0,20173747.0,Ellinor PT,Cardiovascular disease,initial,2010-02-21,GCST000602,Atrial fibrillation
6061,European,988.0,20173735.0,Fellay J,Digestive system disorder,initial,2010-02-21,GCST000604,Chronic hepatitis C infection
8200,European,4320.0,20173748.0,Cho MH,Other disease,initial,2010-02-21,GCST000603,Chronic obstructive pulmonary disease
8343,European,4771.0,20173747.0,Ellinor PT,Cardiovascular disease,replication,2010-02-21,GCST000602,Atrial fibrillation
58,African,198.0,20173735.0,Fellay J,Digestive system disorder,initial,2010-02-21,GCST000604,Chronic hepatitis C infection
6104,European,1006.0,20173748.0,Cho MH,Other disease,replication,2010-02-21,GCST000603,Chronic obstructive pulmonary disease
6521,European,1504.0,20167575.0,Sun Q,Other measurement,initial,2010-02-22,GCST000605,Soluble leptin receptor levels
6103,European,1005.0,20147318.0,Qi L,Inflammatory measurement,initial,2010-02-22,GCST000606,E-selectin levels
5360,European,518.0,20147318.0,Qi L,Inflammatory measurement,replication,2010-02-22,GCST000606,E-selectin levels
5877,European,875.0,20167575.0,Sun Q,Other measurement,replication,2010-02-22,GCST000605,Soluble leptin receptor levels
10127,European,16443.0,20185149.0,Athanasiu L,Neurological disorder,replication,2010-02-23,GCST000607,Schizophrenia
5331,European,506.0,20185149.0,Athanasiu L,Neurological disorder,initial,2010-02-23,GCST000607,Schizophrenia
1652,Asian,93.0,20189245.0,Han S,Cancer,initial,2010-02-25,GCST000608,Acute lymphoblastic leukemia (childhood)
8724,European,5919.0,20195514.0,Pillas D,Biological process,initial,2010-02-26,GCST000609,Primary tooth development (time to first tooth eruption)
4283,Asian,19633.0,20189936.0,Okada Y,"Other measurement, Body measurement",initial,2010-02-26,GCST000611,Height
8675,European,5752.0,20195514.0,Pillas D,Biological process,initial,2010-02-26,GCST000610,Primary tooth development (number of teeth)
9656,European,10602.0,20190752.0,Dubois PC,Immune system disorder,replication,2010-02-28,GCST000612,Celiac disease
10045,European,15283.0,20190752.0,Dubois PC,Immune system disorder,initial,2010-02-28,GCST000612,Celiac disease
4993,European,324.0,20235792.0,Uhl GR,Biological process,initial,2010-03-01,GCST000616,Smoking cessation
5687,European,742.0,20197096.0,Stein JL,Other measurement,initial,2010-03-01,GCST000615,Brain structure (hippocampal volume)
6462,European,1399.0,20201924.0,Edenberg HJ,"Other measurement, Neurological disorder",initial,2010-03-01,GCST000617,Alcohol dependence
5686,European,742.0,20197096.0,Stein JL,Neurological disorder,initial,2010-03-01,GCST000614,Brain structure (temporal lobe volume)
660,African American or Afro-Caribbean,485.0,20201924.0,Edenberg HJ,"Other measurement, Neurological disorder",initial,2010-03-01,GCST000617,Alcohol dependence
67,African,226.0,20487506.0,Joubert BR,Biological process,initial,2010-03-01,GCST000613,HIV (mother-to-child transmission)
13501,Other/Mixed,103.0,20195266.0,Adkins DE,Response to drug,initial,2010-03-02,GCST000618,Response to antipsychotic treatment
6820,European,1845.0,20202923.0,Bierut LJ,"Other measurement, Neurological disorder",replication,2010-03-02,GCST000619,Alcohol dependence
544,African American or Afro-Caribbean,214.0,20195266.0,Adkins DE,Response to drug,initial,2010-03-02,GCST000618,Response to antipsychotic treatment
816,African American or Afro-Caribbean,1161.0,20202923.0,Bierut LJ,"Other measurement, Neurological disorder",initial,2010-03-02,GCST000619,Alcohol dependence
7432,European,2668.0,20202923.0,Bierut LJ,"Other measurement, Neurological disorder",initial,2010-03-02,GCST000619,Alcohol dependence
5148,European,421.0,20195266.0,Adkins DE,Response to drug,initial,2010-03-02,GCST000618,Response to antipsychotic treatment
6364,European,1300.0,20208534.0,Rothenberg ME,Digestive system disorder,replication,2010-03-07,GCST000620,Eosinophilic esophagitis (pediatric)
7049,European,2155.0,20208534.0,Rothenberg ME,Digestive system disorder,initial,2010-03-07,GCST000620,Eosinophilic esophagitis (pediatric)
5041,European,352.0,20212171.0,Buil A,Cardiovascular measurement,initial,2010-03-08,GCST000621,C4b binding protein levels
8087,European,4006.0,20222955.0,Pattaro C,Other measurement,initial,2010-03-11,GCST000622,Creatinine levels
6952,European,2035.0,20222955.0,Pattaro C,Other measurement,replication,2010-03-11,GCST000622,Creatinine levels
9171,European,7967.0,20228798.0,Franke A,Immune system disorder,replication,2010-03-14,GCST000623,Ulcerative colitis
9497,European,9484.0,20228799.0,McGovern DP,Immune system disorder,initial,2010-03-14,GCST000624,Ulcerative colitis
7933,European,3589.0,20228799.0,McGovern DP,Immune system disorder,replication,2010-03-14,GCST000624,Ulcerative colitis
7476,European,2746.0,20228798.0,Franke A,Immune system disorder,initial,2010-03-14,GCST000623,Ulcerative colitis
9105,European,7604.0,20231535.0,Smith NL,Other measurement,replication,2010-03-15,GCST000625,Factor VII levels
10505,European,23608.0,20231535.0,Smith NL,Hematological measurement,initial,2010-03-15,GCST000627,vWF levels
9103,European,7604.0,20231535.0,Smith NL,Hematological measurement,replication,2010-03-15,GCST000626,Factor VIII levels
10043,European,15279.0,20231535.0,Smith NL,Hematological measurement,initial,2010-03-15,GCST000626,Factor VIII levels
9104,European,7604.0,20231535.0,Smith NL,Hematological measurement,replication,2010-03-15,GCST000627,vWF levels
10058,European,15422.0,20231535.0,Smith NL,Other measurement,initial,2010-03-15,GCST000625,Factor VII levels
12759,Hispanic or Latin American,858.0,20237162.0,Bozaoglu K,Cardiovascular measurement,initial,2010-03-17,GCST000628,Chemerin levels
2128,Asian,514.0,20305777.0,Nakajima M,Other disease,replication,2010-03-18,GCST000629,Knee osteoarthritis
6479,European,1431.0,20303064.0,Houlihan LM,Hematological measurement,initial,2010-03-18,GCST000631,Activated partial thromboplastin time
8006,European,3791.0,20304771.0,Newman AB,Other measurement,initial,2010-03-18,GCST000632,Longevity
6849,European,1884.0,20305777.0,Nakajima M,Other disease,replication,2010-03-18,GCST000629,Knee osteoarthritis
7545,European,2889.0,20303062.0,Medland SE,Body measurement,initial,2010-03-18,GCST000630,Digit length ratio
3426,Asian,4295.0,20305777.0,Nakajima M,Other disease,initial,2010-03-18,GCST000629,Knee osteoarthritis
8747,European,6025.0,20304771.0,Newman AB,Other measurement,replication,2010-03-18,GCST000632,Longevity
7957,European,3659.0,20303062.0,Medland SE,Body measurement,replication,2010-03-18,GCST000630,Digit length ratio
5653,European,728.0,20304703.0,Li Y,Cancer,initial,2010-03-19,GCST000633,Lung cancer
13570,Other/Mixed,219.0,20304703.0,Li Y,Cancer,replication,2010-03-19,GCST000633,Lung cancer
13441,Other/Mixed,26.0,20304703.0,Li Y,Cancer,initial,2010-03-19,GCST000633,Lung cancer
6363,European,1299.0,20304703.0,Li Y,Cancer,replication,2010-03-19,GCST000633,Lung cancer
5856,European,860.0,20306291.0,Davis OS,Biological process,initial,2010-03-21,GCST000634,Cognitive ability
7405,European,2619.0,20306291.0,Davis OS,Biological process,replication,2010-03-21,GCST000634,Cognitive ability
8053,European,3928.0,20339536.0,Barber MJ,Response to drug,initial,2010-03-22,GCST000635,Response to statin therapy
4591,European,56.0,20308991.0,Kim S,Other measurement,initial,2010-03-23,GCST000636,Brain cytoarchitecture
8206,European,4335.0,20332263.0,Azzato EM,Cancer,replication,2010-03-23,GCST000637,Breast cancer (prognosis)
14012,Other/Mixed,19611.0,20360844.0,Arking DE,Cardiovascular disease,replication,2010-03-25,GCST000638,Sudden cardiac arrest
5549,European,650.0,20360844.0,Arking DE,Cardiovascular disease,initial,2010-03-25,GCST000638,Sudden cardiac arrest
10983,European,41199.0,20348956.0,Kiemeney LA,Cancer,initial,2010-03-28,GCST000639,Urinary bladder cancer
9426,European,9029.0,20348956.0,Kiemeney LA,Cancer,replication,2010-03-28,GCST000639,Urinary bladder cancer
6118,European,1021.0,20350937.0,Takahashi M,Cancer,initial,2010-03-29,GCST000640,"Thyroid cancer (Papillary, radiation-related)"
5629,European,706.0,20360315.0,Uher R,Response to drug,initial,2010-04-01,GCST000643,Response to antidepressants
9762,European,11536.0,20397748.0,Liu JZ,"Body measurement, Other measurement",initial,2010-04-01,GCST000642,Body mass index
9763,European,11536.0,20397748.0,Liu JZ,"Other measurement, Body measurement",initial,2010-04-01,GCST000644,Height
2204,Asian,660.0,20363506.0,Meguro A,Neurological disorder,initial,2010-04-02,GCST000645,Glaucoma
10048,European,15295.0,20364137.0,Yasuno K,Cardiovascular disease,initial,2010-04-04,GCST000646,Intracranial aneurysm
3498,Asian,4777.0,20364137.0,Yasuno K,Cardiovascular disease,replication,2010-04-04,GCST000646,Intracranial aneurysm
13774,Other/Mixed,746.0,20372150.0,Freathy RM,Body measurement,replication,2010-04-06,GCST000648,Birth weight
9660,European,10623.0,20372150.0,Freathy RM,Body measurement,initial,2010-04-06,GCST000648,Birth weight
13881,Other/Mixed,1748.0,20372150.0,Freathy RM,Body measurement,replication,2010-04-06,GCST000648,Birth weight
10629,European,27591.0,20372150.0,Freathy RM,Body measurement,replication,2010-04-06,GCST000648,Birth weight
6315,European,1231.0,20370913.0,Ma L,Lipid or lipoprotein measurement,replication,2010-04-06,GCST000647,Cholesterol
9043,European,7322.0,20383147.0,Radstake TR,Neurological disorder,replication,2010-04-11,GCST000650,Systemic sclerosis
9071,European,7467.0,20383147.0,Radstake TR,Neurological disorder,initial,2010-04-11,GCST000650,Systemic sclerosis
10517,European,23812.0,20383145.0,Chambers JC,Other measurement,initial,2010-04-11,GCST000651,Creatinine levels
10143,European,16626.0,20383145.0,Chambers JC,Other measurement,replication,2010-04-11,GCST000651,Creatinine levels
11289,European,67093.0,20383146.0,Kottgen A,"Other disease, Other measurement",initial,2010-04-11,GCST000649,Chronic kidney disease
10490,European,22982.0,20383146.0,Kottgen A,"Other disease, Other measurement",replication,2010-04-11,GCST000649,Chronic kidney disease
6350,European,1278.0,20385826.0,Neale BM,Neurological disorder,replication,2010-04-12,GCST000653,Age-related macular degeneration
7776,European,3307.0,20385819.0,Chen W,Neurological disorder,initial,2010-04-12,GCST000652,Age-related macular degeneration
2446,Asian,1014.0,20385819.0,Chen W,Neurological disorder,replication,2010-04-12,GCST000652,Age-related macular degeneration
9948,European,13890.0,20385819.0,Chen W,Neurological disorder,replication,2010-04-12,GCST000652,Age-related macular degeneration
2610,Asian,1409.0,20386566.0,Lee MT,Neurological disorder,replication,2010-04-13,GCST000654,Bipolar I disorder
2926,Asian,2000.0,20386566.0,Lee MT,Neurological disorder,initial,2010-04-13,GCST000654,Bipolar I disorder
666,African American or Afro-Caribbean,515.0,20205591.0,Pelak K,"Biological process, Other measurement, Other disease",initial,2010-04-15,GCST000656,HIV-1 viral setpoint
6428,European,1368.0,20395239.0,Macgregor S,Other measurement,initial,2010-04-15,GCST000658,Optic nerve measurement (rim area)
6429,European,1368.0,20395239.0,Macgregor S,Other measurement,initial,2010-04-15,GCST000659,Optic nerve measurement (cup area)
5839,European,848.0,20395239.0,Macgregor S,Other measurement,replication,2010-04-15,GCST000659,Optic nerve measurement (cup area)
6426,European,1368.0,20395239.0,Macgregor S,Other measurement,initial,2010-04-15,GCST000655,Optic nerve measurement (cup-to-disc ratio)
5838,European,848.0,20395239.0,Macgregor S,Other measurement,replication,2010-04-15,GCST000658,Optic nerve measurement (rim area)
6427,European,1368.0,20395239.0,Macgregor S,Other measurement,initial,2010-04-15,GCST000657,Optic nerve measurement (disc area)
5837,European,848.0,20395239.0,Macgregor S,Other measurement,replication,2010-04-15,GCST000657,Optic nerve measurement (disc area)
5836,European,848.0,20395239.0,Macgregor S,Other measurement,replication,2010-04-15,GCST000655,Optic nerve measurement (cup-to-disc ratio)
1182,African American or Afro-Caribbean,4175.0,20400458.0,Kang SJ,"Other measurement, Body measurement",replication,2010-04-16,GCST000660,Anthropometric traits
716,African American or Afro-Caribbean,743.0,20400458.0,Kang SJ,"Other measurement, Body measurement",initial,2010-04-16,GCST000660,Anthropometric traits
171,African,1188.0,20400458.0,Kang SJ,"Other measurement, Body measurement",initial,2010-04-16,GCST000660,Anthropometric traits
7374,European,2562.0,20400778.0,Morrison AC,"Other measurement, Cardiovascular disease",initial,2010-04-17,GCST000661,Mortality in heart failure
107,African,466.0,20400778.0,Morrison AC,"Other measurement, Cardiovascular disease",initial,2010-04-17,GCST000661,Mortality in heart failure
7950,European,3635.0,20410501.0,Jin Y,Immune system disorder,replication,2010-04-21,GCST000662,Vitiligo
8093,European,4021.0,20410501.0,Jin Y,Immune system disorder,initial,2010-04-21,GCST000662,Vitiligo
8633,European,5552.0,20421936.0,Scherag A,Metabolic disorder,replication,2010-04-22,GCST000663,Obesity (early onset extreme)
7144,European,2258.0,20421936.0,Scherag A,Metabolic disorder,initial,2010-04-22,GCST000663,Obesity (early onset extreme)
8255,European,4501.0,20418485.0,Ahn J,Other measurement,initial,2010-04-23,GCST000664,Vitamin D levels
8654,European,5643.0,20418489.0,Qi L,Metabolic disorder,initial,2010-04-23,GCST000665,Type 2 diabetes
7125,European,2221.0,20418485.0,Ahn J,Other measurement,replication,2010-04-23,GCST000664,Vitamin D levels
11448,European,84605.0,20418489.0,Qi L,Metabolic disorder,replication,2010-04-23,GCST000665,Type 2 diabetes
11357,European,74035.0,20418890.0,Tobacco and Genetics Consortium,Biological process,initial,2010-04-25,GCST000666,Smoking behavior
11704,European,120516.0,20418889.0,Liu JZ,Biological process,replication,2010-04-25,GCST000668,Smoking behavior
10723,European,31266.0,20418888.0,Thorgeirsson TE,Biological process,initial,2010-04-25,GCST000667,Smoking behavior
11173,European,54731.0,20418888.0,Thorgeirsson TE,Biological process,replication,2010-04-25,GCST000667,Smoking behavior
10982,European,41150.0,20418889.0,Liu JZ,Biological process,initial,2010-04-25,GCST000668,Smoking behavior
13613,Other/Mixed,322.0,20421487.0,Hodgkinson CA,Other measurement,initial,2010-04-26,GCST000670,Electroencephalogram traits
7540,European,2876.0,20421499.0,Levy D,Other measurement,replication,2010-04-26,GCST000669,Telomere length
7853,European,3417.0,20421499.0,Levy D,Other measurement,initial,2010-04-26,GCST000669,Telomere length
4780,European,185.0,20421487.0,Hodgkinson CA,Other measurement,replication,2010-04-26,GCST000670,Electroencephalogram traits
13892,Other/Mixed,1893.0,20421499.0,Levy D,Other measurement,replication,2010-04-26,GCST000669,Telomere length
8886,European,6668.0,20442857.0,Suchindran S,Lipid or lipoprotein measurement,initial,2010-04-29,GCST000671,Lipoprotein-associated phospholipase A2 activity and mass
8017,European,3830.0,20436469.0,Beaty TH,Other trait,replication,2010-05-02,GCST000673,Cleft lip
5801,European,825.0,20436469.0,Beaty TH,Other trait,initial,2010-05-02,GCST000673,Cleft lip
13882,Other/Mixed,1769.0,20436469.0,Beaty TH,Other trait,replication,2010-05-02,GCST000673,Cleft lip
3015,Asian,2194.0,20436469.0,Beaty TH,Other trait,replication,2010-05-02,GCST000673,Cleft lip
6690,European,1693.0,20436471.0,Albagha OM,Other disease,initial,2010-05-02,GCST000672,Paget's disease
1944,Asian,322.0,20436469.0,Beaty TH,Other trait,replication,2010-05-02,GCST000673,Cleft lip
2456,Asian,1038.0,20436469.0,Beaty TH,Other trait,initial,2010-05-02,GCST000673,Cleft lip
5689,European,744.0,20436471.0,Albagha OM,Other disease,replication,2010-05-02,GCST000672,Paget's disease
10387,European,20926.0,20445134.0,Smith NL,Cardiovascular disease,initial,2010-05-05,GCST000675,Heart failure
9672,European,10693.0,20451256.0,Djurovic S,Neurological disorder,replication,2010-05-05,GCST000674,Bipolar disorder
1044,African American or Afro-Caribbean,2895.0,20445134.0,Smith NL,Cardiovascular disease,initial,2010-05-05,GCST000675,Heart failure
5717,European,760.0,20451256.0,Djurovic S,Neurological disorder,initial,2010-05-05,GCST000674,Bipolar disorder
4962,European,299.0,20452100.0,Kramer PL,Neurological disorder,initial,2010-05-06,GCST000676,Alzheimer's disease
10559,European,24799.0,20453838.0,Turnbull C,Cancer,replication,2010-05-09,GCST000678,Breast cancer
3629,Asian,5683.0,20453841.0,Kochi Y,Immune system disorder,initial,2010-05-09,GCST000677,Rheumatoid arthritis
9351,European,8556.0,20453838.0,Turnbull C,Cancer,initial,2010-05-09,GCST000678,Breast cancer
10063,European,15574.0,20453842.0,Stahl EA,Immune system disorder,replication,2010-05-09,GCST000679,Rheumatoid arthritis
10586,European,25708.0,20453842.0,Stahl EA,Immune system disorder,initial,2010-05-09,GCST000679,Rheumatoid arthritis
4305,Asian,22127.0,20453841.0,Kochi Y,Immune system disorder,replication,2010-05-09,GCST000677,Rheumatoid arthritis
7999,European,3780.0,20453840.0,Sanna S,Immune system disorder,replication,2010-05-09,GCST000680,Multiple sclerosis
6761,European,1754.0,20453840.0,Sanna S,Immune system disorder,initial,2010-05-09,GCST000680,Multiple sclerosis
2291,Asian,762.0,20460270.0,Garcia-Barcelo MM,Digestive system disorder,initial,2010-05-11,GCST000681,Biliary atresia
1818,Asian,214.0,20460270.0,Garcia-Barcelo MM,Digestive system disorder,replication,2010-05-11,GCST000681,Biliary atresia
10350,European,20037.0,20460622.0,Seshadri S,Neurological disorder,replication,2010-05-12,GCST000682,Alzheimer's disease
14018,Other/Mixed,25610.0,20460622.0,Seshadri S,Neurological disorder,initial,2010-05-12,GCST000682,Alzheimer's disease
8115,European,4075.0,20485516.0,Lu Y,Other measurement,initial,2010-05-13,GCST000683,Central corneal thickness
8733,European,5951.0,20463881.0,Liu F,Other trait,initial,2010-05-16,GCST000685,Eye color traits
7913,European,3543.0,20463881.0,Liu F,Other trait,replication,2010-05-16,GCST000685,Eye color traits
4792,European,190.0,20484958.0,Diergaarde B,Cancer,initial,2010-05-17,GCST000686,Pancreatic cancer
4717,European,142.0,20484958.0,Diergaarde B,Cancer,replication,2010-05-17,GCST000686,Pancreatic cancer
3306,Asian,3477.0,20512145.0,Bei JX,Cancer,initial,2010-05-30,GCST000687,Nasopharyngeal carcinoma
3807,Asian,7407.0,20512145.0,Bei JX,Cancer,replication,2010-05-30,GCST000687,Nasopharyngeal carcinoma
1872,Asian,245.0,20463552.0,Wu C,Response to drug,initial,2010-06-01,GCST000688,Response to platinum-based chemotherapy in small-cell lung cancer
549,African American or Afro-Caribbean,225.0,20520587.0,Nielsen DA,Neurological disorder,initial,2010-06-01,GCST000690,Heroin addiction
7799,European,3336.0,20516156.0,Lewis CM,Neurological disorder,replication,2010-06-01,GCST000689,Major depressive disorder
1777,Asian,183.0,20463552.0,Wu C,Response to drug,replication,2010-06-01,GCST000688,Response to platinum-based chemotherapy in small-cell lung cancer
5039,European,350.0,20520587.0,Nielsen DA,Neurological disorder,initial,2010-06-01,GCST000690,Heroin addiction
7730,European,3230.0,20516156.0,Lewis CM,Neurological disorder,initial,2010-06-01,GCST000689,Major depressive disorder
9629,European,10380.0,20522523.0,Kasperaviciute D,Neurological disorder,initial,2010-06-03,GCST000691,Partial epilepsies
4252,Asian,17363.0,20526339.0,Quan C,Immune system disorder,replication,2010-06-06,GCST000692,Vitiligo
3128,Asian,2546.0,20526339.0,Quan C,Immune system disorder,initial,2010-06-06,GCST000692,Vitiligo
744,African American or Afro-Caribbean,840.0,20526338.0,Johnson AD,Biological process,replication,2010-06-06,GCST000693,Platelet aggregation
8084,European,3991.0,20526338.0,Johnson AD,Biological process,initial,2010-06-06,GCST000693,Platelet aggregation
5227,European,455.0,20528957.0,Oedegaard KJ,"Cardiovascular disease, Neurological disorder",replication,2010-06-07,GCST000695,Migraine in psychiatric disorder
7558,European,2917.0,20529992.0,Teupser D,Other measurement,replication,2010-06-07,GCST000694,Phytosterol levels
6519,European,1495.0,20529992.0,Teupser D,Other measurement,initial,2010-06-07,GCST000694,Phytosterol levels
5709,European,755.0,20528957.0,Oedegaard KJ,"Cardiovascular disease, Neurological disorder",initial,2010-06-07,GCST000695,Migraine in psychiatric disorder
703,African American or Afro-Caribbean,699.0,20532800.0,Bostrom MA,Other disease,replication,2010-06-08,GCST000696,End-stage renal disease (non-diabetic)
767,African American or Afro-Caribbean,942.0,20532800.0,Bostrom MA,Other disease,initial,2010-06-08,GCST000696,End-stage renal disease (non-diabetic)
10231,European,17871.0,20541252.0,Wang TJ,Other trait,replication,2010-06-09,GCST000697,Vitamin D insufficiency
10092,European,16125.0,20541252.0,Wang TJ,Other trait,initial,2010-06-09,GCST000697,Vitamin D insufficiency
7924,European,3569.0,20548944.0,Hsu YH,Other disease,initial,2010-06-10,GCST000698,Osteoporosis-related phenotypes
9052,European,7360.0,20548946.0,Ramdas WD,Other measurement,initial,2010-06-10,GCST000700,Vertical cup-disc ratio
8236,European,4455.0,20548946.0,Ramdas WD,Other measurement,replication,2010-06-10,GCST000699,Optic disc parameters
9051,European,7360.0,20548946.0,Ramdas WD,Other measurement,initial,2010-06-10,GCST000699,Optic disc parameters
9130,European,7721.0,20548944.0,Hsu YH,Other disease,replication,2010-06-10,GCST000698,Osteoporosis-related phenotypes
8237,European,4455.0,20548946.0,Ramdas WD,Other measurement,replication,2010-06-10,GCST000700,Vertical cup-disc ratio
8130,European,4120.0,20543847.0,Turnbull C,Cancer,replication,2010-06-13,GCST000701,Testicular germ cell cancer
8725,European,5926.0,20543847.0,Turnbull C,Cancer,initial,2010-06-13,GCST000701,Testicular germ cell cancer
4571,European,37.0,20558996.0,Ott J,Neurological disorder,initial,2010-06-17,GCST000702,Schizophrenia
8609,European,5444.0,20558539.0,Kestenbaum B,Other measurement,replication,2010-06-17,GCST000703,Phosphorus levels
10109,European,16264.0,20558539.0,Kestenbaum B,Other measurement,initial,2010-06-17,GCST000703,Phosphorus levels
1589,Asian,35.0,20534544.0,Beall CM,Hematological measurement,initial,2010-06-22,GCST000704,Hemoglobin levels
8126,European,4099.0,20570966.0,McGovern DP,Digestive system disorder,initial,2010-06-22,GCST000705,Crohn's disease
1752,Asian,161.0,20534544.0,Beall CM,Hematological measurement,replication,2010-06-22,GCST000704,Hemoglobin levels
6549,European,1531.0,20570966.0,McGovern DP,Digestive system disorder,replication,2010-06-22,GCST000705,Crohn's disease
8613,European,5459.0,20585626.0,Long J,Cancer,replication,2010-06-24,GCST000709,Breast cancer
9437,European,9126.0,20585627.0,Eriksson N,Other trait,initial,2010-06-24,GCST000708,Freckling
9438,European,9126.0,20585627.0,Eriksson N,"Other trait, Biological process",initial,2010-06-24,GCST000706,Common traits (Other)
3407,Asian,4157.0,20585626.0,Long J,Cancer,initial,2010-06-24,GCST000709,Breast cancer
9436,European,9126.0,20585627.0,Eriksson N,"Other measurement, Other trait",initial,2010-06-24,GCST000710,Eye color
9435,European,9126.0,20585627.0,Eriksson N,"Other measurement, Other trait",initial,2010-06-24,GCST000707,Hair color
4343,Asian,28152.0,20585626.0,Long J,Cancer,replication,2010-06-24,GCST000709,Breast cancer
12781,Hispanic or Latin American,961.0,20600896.0,Engelman CD,Other measurement,replication,2010-06-26,GCST000711,Vitamin D levels
12588,Hispanic or Latin American,229.0,20600896.0,Engelman CD,Other measurement,initial,2010-06-26,GCST000711,Vitamin D levels
7448,European,2698.0,20585324.0,Dick DM,Neurological disorder,initial,2010-06-27,GCST000714,Conduct disorder
7447,European,2698.0,20585324.0,Dick DM,Neurological disorder,initial,2010-06-27,GCST000713,Conduct disorder (symptom count)
13395,Other/Mixed,8.0,20585324.0,Dick DM,Neurological disorder,initial,2010-06-27,GCST000713,Conduct disorder (symptom count)
11557,European,94337.0,20581827.0,Voight BF,Metabolic disorder,replication,2010-06-27,GCST000712,Type 2 diabetes
13396,Other/Mixed,8.0,20585324.0,Dick DM,Neurological disorder,initial,2010-06-27,GCST000714,Conduct disorder
11065,European,47117.0,20581827.0,Voight BF,Metabolic disorder,initial,2010-06-27,GCST000712,Type 2 diabetes
839,African American or Afro-Caribbean,1257.0,20585324.0,Dick DM,Neurological disorder,initial,2010-06-27,GCST000713,Conduct disorder (symptom count)
840,African American or Afro-Caribbean,1257.0,20585324.0,Dick DM,Neurological disorder,initial,2010-06-27,GCST000714,Conduct disorder
1536,Asian,4.0,20592726.0,Chen SH,"Cancer, Response to drug",initial,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
12525,Hispanic or Latin American,46.0,20592726.0,Chen SH,"Cancer, Response to drug",initial,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
1527,Asian,2.0,20592726.0,Chen SH,"Cancer, Response to drug",replication,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
21,African,40.0,20592726.0,Chen SH,"Cancer, Response to drug",initial,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
12510,Hispanic or Latin American,24.0,20592726.0,Chen SH,"Cancer, Response to drug",replication,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
6473,European,1415.0,20598377.0,Nischwitz S,Immune system disorder,initial,2010-06-30,GCST000716,Multiple sclerosis
4681,European,99.0,20592726.0,Chen SH,"Cancer, Response to drug",replication,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
13383,Other/Mixed,5.0,20592726.0,Chen SH,"Cancer, Response to drug",replication,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
4845,European,211.0,20592726.0,Chen SH,"Cancer, Response to drug",initial,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
14,African,33.0,20592726.0,Chen SH,"Cancer, Response to drug",replication,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
13423,Other/Mixed,21.0,20592726.0,Chen SH,"Cancer, Response to drug",initial,2010-06-30,GCST000715,Asparaginase hypersensitivity in acute lymphoblastic leukemia
2285,Asian,758.0,20664687.0,Lin HJ,"Neurological disorder, Metabolic disorder",initial,2010-07-01,GCST000717,Cataracts in type 2 diabetes
8205,European,4332.0,20596022.0,Petukhova L,Other disease,initial,2010-07-01,GCST000719,Alopecia areata
8596,European,5411.0,20595679.0,Feehally J,Other disease,initial,2010-07-01,GCST000718,Nephropathy
3033,Asian,2239.0,20610895.0,Koriyama H,Cardiovascular disease,replication,2010-07-02,GCST000720,Peripheral artery disease
2690,Asian,1553.0,20610895.0,Koriyama H,Cardiovascular disease,initial,2010-07-02,GCST000720,Peripheral artery disease
3168,Asian,2741.0,20601957.0,Uno S,Other disease,initial,2010-07-04,GCST000721,Endometriosis
3443,Asian,4458.0,20601957.0,Uno S,Other disease,replication,2010-07-04,GCST000721,Endometriosis
6648,European,1634.0,20610541.0,Lascorz J,Cancer,initial,2010-07-07,GCST000722,Colorectal cancer
9879,European,13074.0,20610541.0,Lascorz J,Cancer,replication,2010-07-07,GCST000722,Colorectal cancer
2606,Asian,1398.0,20613766.0,Akiyama K,Cardiovascular disease,replication,2010-07-08,GCST000723,Intracranial aneurysm
2105,Asian,482.0,20613766.0,Akiyama K,Cardiovascular disease,initial,2010-07-08,GCST000723,Intracranial aneurysm
7132,European,2235.0,20634892.0,Calboli FC,"Neurological disorder, Other measurement",initial,2010-07-09,GCST004569,Neuroticism
7131,European,2235.0,20634892.0,Calboli FC,"Neurological disorder, Other measurement",initial,2010-07-09,GCST000724,Neuroticism (age interaction)
2587,Asian,1348.0,20622879.0,Mizuki N,Cardiovascular disease,initial,2010-07-11,GCST000728,Behcet's disease
1882,Asian,259.0,20622879.0,Mizuki N,Cardiovascular disease,replication,2010-07-11,GCST000728,Behcet's disease
13913,Other/Mixed,2494.0,20622879.0,Mizuki N,Cardiovascular disease,replication,2010-07-11,GCST000728,Behcet's disease
5395,European,537.0,20622880.0,Bezzina CR,Cardiovascular disease,replication,2010-07-11,GCST000725,Ventricular fibrillation
6018,European,972.0,20622880.0,Bezzina CR,Cardiovascular disease,initial,2010-07-11,GCST000725,Ventricular fibrillation
13911,Other/Mixed,2493.0,20622878.0,Remmers EF,Cardiovascular disease,initial,2010-07-11,GCST000726,Behcet's disease
5161,European,430.0,20622878.0,Remmers EF,Cardiovascular disease,replication,2010-07-11,GCST000726,Behcet's disease
13628,Other/Mixed,336.0,20622878.0,Remmers EF,Cardiovascular disease,replication,2010-07-11,GCST000726,Behcet's disease
9677,European,10718.0,20622881.0,Gretarsdottir S,Cardiovascular disease,replication,2010-07-11,GCST000727,Abdominal aortic aneurysm
2633,Asian,1479.0,20622878.0,Remmers EF,Cardiovascular disease,replication,2010-07-11,GCST000726,Behcet's disease
13634,Other/Mixed,352.0,20622878.0,Remmers EF,Cardiovascular disease,replication,2010-07-11,GCST000726,Behcet's disease
10733,European,31795.0,20622881.0,Gretarsdottir S,Cardiovascular disease,initial,2010-07-11,GCST000727,Abdominal aortic aneurysm
2067,Asian,453.0,20637204.0,Ochi H,"Other trait, Response to drug",initial,2010-07-13,GCST000729,Ribavirin-induced anemia
2085,Asian,470.0,20637204.0,Ochi H,"Other trait, Response to drug",replication,2010-07-13,GCST000729,Ribavirin-induced anemia
10939,European,38991.0,20639392.0,Eijgelsheim M,Cardiovascular measurement,initial,2010-07-16,GCST000731,Resting heart rate
2478,Asian,1096.0,20639394.0,Kang TW,Other measurement,replication,2010-07-16,GCST000730,Bilirubin levels
3946,Asian,8841.0,20639394.0,Kang TW,Other measurement,initial,2010-07-16,GCST000730,Bilirubin levels
8504,European,5127.0,20602913.0,Duffy DL,Other measurement,replication,2010-07-17,GCST000732,Nevus count
6797,European,1810.0,20602913.0,Duffy DL,Other measurement,initial,2010-07-17,GCST000732,Nevus count
9476,European,9372.0,20639881.0,Conde L,Cancer,replication,2010-07-18,GCST000734,Follicular lymphoma
6460,European,1398.0,20639880.0,Liu X,Cancer,initial,2010-07-18,GCST000733,Primary biliary cholangitis
12489,Hispanic or Latin American,3.0,20639878.0,Singer JB,Digestive system disorder,initial,2010-07-18,GCST000735,Lumiracoxib-related liver injury
13653,Other/Mixed,405.0,20639878.0,Singer JB,Digestive system disorder,replication,2010-07-18,GCST000735,Lumiracoxib-related liver injury
4572,European,37.0,20639878.0,Singer JB,Digestive system disorder,initial,2010-07-18,GCST000735,Lumiracoxib-related liver injury
12506,Hispanic or Latin American,16.0,20639878.0,Singer JB,Digestive system disorder,replication,2010-07-18,GCST000735,Lumiracoxib-related liver injury
13549,Other/Mixed,176.0,20639878.0,Singer JB,Digestive system disorder,initial,2010-07-18,GCST000735,Lumiracoxib-related liver injury
13339,Other/Mixed,1.0,20639878.0,Singer JB,Digestive system disorder,initial,2010-07-18,GCST000735,Lumiracoxib-related liver injury
8155,European,4187.0,20639880.0,Liu X,Cancer,replication,2010-07-18,GCST000733,Primary biliary cholangitis
13340,Other/Mixed,1.0,20639878.0,Singer JB,Digestive system disorder,replication,2010-07-18,GCST000735,Lumiracoxib-related liver injury
6480,European,1431.0,20639881.0,Conde L,Cancer,initial,2010-07-18,GCST000734,Follicular lymphoma
4620,European,79.0,20639878.0,Singer JB,Digestive system disorder,replication,2010-07-18,GCST000735,Lumiracoxib-related liver injury
8133,European,4126.0,20661308.0,Kapur K,Other measurement,replication,2010-07-22,GCST000736,Calcium levels
9409,European,8919.0,20661308.0,Kapur K,Other measurement,initial,2010-07-22,GCST000736,Calcium levels
3375,Asian,3947.0,20661308.0,Kapur K,Other measurement,initial,2010-07-22,GCST000736,Calcium levels
6674,European,1660.0,20657596.0,Johansen CT,"Metabolic disorder, Lipid or lipoprotein measurement",initial,2010-07-25,GCST000737,Hypertriglyceridemia
568,African American or Afro-Caribbean,280.0,20659327.0,Kariuki SN,Immune system disorder,replication,2010-07-26,GCST000739,Serologic markers in systemic lupus erythematosus
379,African American or Afro-Caribbean,20.0,20659327.0,Kariuki SN,Immune system disorder,initial,2010-07-26,GCST000739,Serologic markers in systemic lupus erythematosus
4570,European,36.0,20659327.0,Kariuki SN,Immune system disorder,initial,2010-07-26,GCST000739,Serologic markers in systemic lupus erythematosus
12536,Hispanic or Latin American,85.0,20659327.0,Kariuki SN,Immune system disorder,replication,2010-07-26,GCST000739,Serologic markers in systemic lupus erythematosus
12512,Hispanic or Latin American,32.0,20659327.0,Kariuki SN,Immune system disorder,initial,2010-07-26,GCST000739,Serologic markers in systemic lupus erythematosus
7874,European,3467.0,20662065.0,Clancy RM,Immune system disorder,initial,2010-07-26,GCST000738,Neonatal lupus
4754,European,173.0,20659327.0,Kariuki SN,Immune system disorder,replication,2010-07-26,GCST000739,Serologic markers in systemic lupus erythematosus
1564,Asian,16.0,20659327.0,Kariuki SN,Immune system disorder,initial,2010-07-26,GCST000739,Serologic markers in systemic lupus erythematosus
5742,European,783.0,20663923.0,Anney R,Neurological disorder,replication,2010-07-27,GCST000740,Autism
6314,European,1230.0,20663923.0,Anney R,Neurological disorder,initial,2010-07-27,GCST000740,Autism
13899,Other/Mixed,1965.0,20663923.0,Anney R,Neurological disorder,replication,2010-07-27,GCST000740,Autism
13519,Other/Mixed,155.0,20663923.0,Anney R,Neurological disorder,initial,2010-07-27,GCST000740,Autism
4963,European,299.0,20668430.0,Genovese G,Other disease,replication,2010-07-28,GCST000741,Glomerulosclerosis
918,African American or Afro-Caribbean,1815.0,20668430.0,Genovese G,Other disease,initial,2010-07-28,GCST000741,Glomerulosclerosis
6614,European,1592.0,20668430.0,Genovese G,Other disease,initial,2010-07-28,GCST000741,Glomerulosclerosis
2129,Asian,518.0,20668459.0,Kim HN,"Other measurement, Body measurement",initial,2010-07-29,GCST000744,Height
9202,European,8097.0,20686651.0,Gudbjartsson DF,"Other disease, Other measurement",replication,2010-07-29,GCST000742,Chronic kidney disease and serum creatinine levels
10936,European,38765.0,20686651.0,Gudbjartsson DF,"Other disease, Other measurement",initial,2010-07-29,GCST000742,Chronic kidney disease and serum creatinine levels
3699,Asian,6200.0,20686608.0,Low SK,Cancer,initial,2010-07-29,GCST000745,Pancreatic cancer
6856,European,1892.0,20673876.0,Rietschel M,Neurological disorder,initial,2010-07-29,GCST000743,Major depressive disorder
5994,European,950.0,20673876.0,Rietschel M,Neurological disorder,replication,2010-07-29,GCST000743,Major depressive disorder
4611,European,73.0,20675712.0,Reed DR,Biological process,replication,2010-07-31,GCST000746,Bitter taste response
6494,European,1457.0,20675712.0,Reed DR,Biological process,initial,2010-07-31,GCST000746,Bitter taste response
1565,Asian,16.0,20670164.0,Horinouchi M,Cancer,replication,2010-08-01,GCST000749,Acute lymphoblastic leukemia (childhood)
2255,Asian,707.0,20676096.0,Zhang H,Cancer,initial,2010-08-01,GCST000752,Hepatocellular carcinoma
3905,Asian,8416.0,20676098.0,Takata R,Cancer,replication,2010-08-01,GCST000750,Prostate cancer
3513,Asian,4969.0,20676098.0,Takata R,Cancer,initial,2010-08-01,GCST000750,Prostate cancer
8597,European,5415.0,20732625.0,Neale BM,Neurological disorder,initial,2010-08-01,GCST000751,Attention deficit hyperactivity disorder
8905,European,6707.0,20707712.0,Mosing MA,Other trait,initial,2010-08-01,GCST000747,Self-rated health
1543,Asian,8.0,20670164.0,Horinouchi M,Cancer,initial,2010-08-01,GCST000749,Acute lymphoblastic leukemia (childhood)
3361,Asian,3869.0,20676096.0,Zhang H,Cancer,replication,2010-08-01,GCST000752,Hepatocellular carcinoma
3034,Asian,2240.0,20694148.0,Zabaneh D,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",replication,2010-08-04,GCST000753,Metabolic syndrome
8501,European,5117.0,20691247.0,Verweij KJ,Other trait,initial,2010-08-04,GCST000754,Personality dimensions
3129,Asian,2554.0,20694148.0,Zabaneh D,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",initial,2010-08-04,GCST000753,Metabolic syndrome
2506,Asian,1169.0,20700438.0,Hsiung CA,Cancer,initial,2010-08-05,GCST000761,Lung adenocarcinoma
3490,Asian,4699.0,20700438.0,Hsiung CA,Cancer,replication,2010-08-05,GCST000761,Lung adenocarcinoma
10055,European,15366.0,20700443.0,Meyer TE,Other measurement,initial,2010-08-05,GCST000756,Magnesium levels
9334,European,8463.0,20700443.0,Meyer TE,Other measurement,replication,2010-08-05,GCST000756,Magnesium levels
11576,European,100184.0,20686565.0,Teslovich TM,Lipid or lipoprotein measurement,initial,2010-08-05,GCST000760,"Cholesterol, total"
11568,European,96598.0,20686565.0,Teslovich TM,Lipid or lipoprotein measurement,initial,2010-08-05,GCST000758,Triglycerides
11575,European,99900.0,20686565.0,Teslovich TM,Lipid or lipoprotein measurement,initial,2010-08-05,GCST000755,HDL cholesterol
11566,European,95454.0,20686565.0,Teslovich TM,"Lipid or lipoprotein measurement, Other measurement",initial,2010-08-05,GCST000759,LDL cholesterol
7811,European,3351.0,20732627.0,Neale BM,Neurological disorder,initial,2010-08-05,GCST000757,Attention deficit hyperactivity disorder
289,African,5359.0,20694014.0,Thye T,"Other disease, Other measurement",initial,2010-08-08,GCST000764,Tuberculosis
7154,European,2280.0,20694013.0,Davila S,Other disease,replication,2010-08-08,GCST000762,Meningococcal disease
6533,European,1520.0,20694011.0,Ferreira RC,Other measurement,initial,2010-08-08,GCST000763,Immunoglobulin A
293,African,6066.0,20694014.0,Thye T,"Other disease, Other measurement",replication,2010-08-08,GCST000764,Tuberculosis
8525,European,5178.0,20694013.0,Davila S,Other disease,initial,2010-08-08,GCST000762,Meningococcal disease
6312,European,1228.0,20694011.0,Ferreira RC,Other measurement,replication,2010-08-08,GCST000763,Immunoglobulin A
4879,European,236.0,20708005.0,Chalasani N,"Cancer, Digestive system disorder",initial,2010-08-10,GCST000767,Non-alcoholic fatty liver disease histology (AST)
4878,European,236.0,20708005.0,Chalasani N,"Cancer, Digestive system disorder",initial,2010-08-10,GCST000766,Non-alcoholic fatty liver disease histology (lobular)
4880,European,236.0,20708005.0,Chalasani N,"Liver enzyme measurement, Cancer, Digestive system disorder",initial,2010-08-10,GCST000765,Non-alcoholic fatty liver disease histology (other)
10367,European,20611.0,20705733.0,O'Seaghdha CM,Other measurement,initial,2010-08-12,GCST000769,Calcium levels
7242,European,2383.0,20709820.0,Kong X,Other disease,initial,2010-08-13,GCST000770,Emphysema-related traits
3212,Asian,2892.0,20711176.0,Nakashima M,Other disease,replication,2010-08-15,GCST000773,Keloid
2490,Asian,1122.0,20711176.0,Nakashima M,Other disease,initial,2010-08-15,GCST000773,Keloid
6346,European,1264.0,20711174.0,Hor H,Neurological disorder,initial,2010-08-15,GCST000771,Narcolepsy
5859,European,865.0,20711174.0,Hor H,Neurological disorder,replication,2010-08-15,GCST000771,Narcolepsy
8080,European,3986.0,20711177.0,Hamza TH,Neurological disorder,initial,2010-08-15,GCST000772,Parkinson's disease
8154,European,4186.0,20713499.0,Huang J,Neurological disorder,initial,2010-08-16,GCST000774,"Schizophrenia, bipolar disorder and depression (combined)"
8709,European,5882.0,20719862.0,Vitart V,Other measurement,replication,2010-08-18,GCST000775,Central corneal thickness
6487,European,1445.0,20719862.0,Vitart V,Other measurement,initial,2010-08-18,GCST000775,Central corneal thickness
4277,Asian,19526.0,20729853.0,Wang LD,Cancer,replication,2010-08-22,GCST000776,Esophageal cancer
3192,Asian,2810.0,20729853.0,Wang LD,Cancer,initial,2010-08-22,GCST000776,Esophageal cancer
3618,Asian,5623.0,20729852.0,Abnet CC,Cancer,initial,2010-08-22,GCST000777,Esophageal cancer and gastric cancer
5066,European,369.0,20811658.0,Uhl GR,Biological process,initial,2010-08-24,GCST000778,Smoking cessation
8360,European,4811.0,20800221.0,Terracciano A,Neurological disorder,initial,2010-08-25,GCST000779,Depression (quantitative trait)
9195,European,8048.0,20802025.0,Tang W,Hematological measurement,initial,2010-08-27,GCST000780,Protein C levels
6441,European,1376.0,20802025.0,Tang W,Hematological measurement,replication,2010-08-27,GCST000780,Protein C levels
5908,European,902.0,20801718.0,Laaksovirta H,Neurological disorder,initial,2010-08-27,GCST000781,Amyotrophic lateral sclerosis
9911,European,13478.0,20802479.0,Anttila V,Cardiovascular disease,initial,2010-08-29,GCST000782,Migraine
11012,European,43264.0,20802479.0,Anttila V,Cardiovascular disease,replication,2010-08-29,GCST000782,Migraine
6472,European,1413.0,20808326.0,Krumbiegel M,Neurological disorder,replication,2010-09-01,GCST000784,Pseudoexfoliation syndrome
4884,European,240.0,20808326.0,Krumbiegel M,Neurological disorder,initial,2010-09-01,GCST000784,Pseudoexfoliation syndrome
12597,Hispanic or Latin American,286.0,20871662.0,Fu YP,Metabolic disorder,initial,2010-09-02,GCST000786,Diabetic retinopathy
3820,Asian,7541.0,20818381.0,Yamauchi T,Metabolic disorder,initial,2010-09-05,GCST000787,Type 2 diabetes
10064,European,15595.0,20818381.0,Yamauchi T,Metabolic disorder,replication,2010-09-05,GCST000787,Type 2 diabetes
4292,Asian,20289.0,20818381.0,Yamauchi T,Metabolic disorder,replication,2010-09-05,GCST000787,Type 2 diabetes
3377,Asian,3962.0,20832056.0,Ikeda M,Neurological disorder,replication,2010-09-08,GCST000788,Schizophrenia
2482,Asian,1108.0,20832056.0,Ikeda M,Neurological disorder,initial,2010-09-08,GCST000788,Schizophrenia
7854,European,3417.0,20832056.0,Ikeda M,Neurological disorder,replication,2010-09-08,GCST000788,Schizophrenia
7272,European,2442.0,20838585.0,Smith EN,"Body measurement, Other disease, Lipid or lipoprotein measurement, Other measurement",replication,2010-09-09,GCST000789,Cardiovascular risk factors (age interaction)
7271,European,2442.0,20838585.0,Smith EN,"Body measurement, Other disease, Lipid or lipoprotein measurement",replication,2010-09-09,GCST004704,Cardiovascular risk factors
5379,European,525.0,20838585.0,Smith EN,"Body measurement, Other disease, Lipid or lipoprotein measurement",initial,2010-09-09,GCST004704,Cardiovascular risk factors
5380,European,525.0,20838585.0,Smith EN,"Body measurement, Other disease, Lipid or lipoprotein measurement, Other measurement",initial,2010-09-09,GCST000789,Cardiovascular risk factors (age interaction)
4945,European,290.0,20825314.0,Baratz KH,Neurological disorder,initial,2010-09-09,GCST000790,Fuchs's corneal dystrophy
6188,European,1093.0,20826269.0,Panicker V,Other trait,replication,2010-09-10,GCST000791,Thyroid function
6938,European,2014.0,20826269.0,Panicker V,Other trait,initial,2010-09-10,GCST000791,Thyroid function
2671,Asian,1508.0,20833655.0,Cha PC,Response to drug,initial,2010-09-10,GCST000792,Warfarin maintenance dose
2061,Asian,444.0,20833655.0,Cha PC,Response to drug,replication,2010-09-10,GCST000792,Warfarin maintenance dose
8579,European,5328.0,20835239.0,Solouki AM,Other trait,initial,2010-09-12,GCST000795,Refractive error
8171,European,4239.0,20835238.0,Thorleifsson G,Neurological disorder,replication,2010-09-12,GCST000793,Glaucoma (primary open-angle)
9621,European,10280.0,20835239.0,Solouki AM,Other trait,replication,2010-09-12,GCST000795,Refractive error
9906,European,13414.0,20835236.0,Hysi PG,Other trait,replication,2010-09-12,GCST000794,Refractive error
8182,European,4270.0,20835236.0,Hysi PG,Other trait,initial,2010-09-12,GCST000794,Refractive error
10872,European,36140.0,20835238.0,Thorleifsson G,Neurological disorder,initial,2010-09-12,GCST000793,Glaucoma (primary open-angle)
6777,European,1782.0,20849430.0,Franklin CS,Other measurement,initial,2010-09-16,GCST000798,Glycated hemoglobin levels
2675,Asian,1521.0,20844546.0,Adachi S,Other disease,initial,2010-09-16,GCST000797,Endometriosis
3157,Asian,2729.0,20862305.0,Shu XO,Metabolic disorder,initial,2010-09-16,GCST000796,Type 2 diabetes
14015,Other/Mixed,21680.0,20862305.0,Shu XO,Metabolic disorder,replication,2010-09-16,GCST000796,Type 2 diabetes
3693,Asian,6132.0,20877124.0,Hiura Y,Cardiovascular disease,replication,2010-09-18,GCST000799,Hypertension
2402,Asian,936.0,20877124.0,Hiura Y,Cardiovascular disease,initial,2010-09-18,GCST000799,Hypertension
11232,European,60473.0,20852632.0,Goode EL,Cancer,replication,2010-09-19,GCST000802,Ovarian cancer
10324,European,19570.0,20852633.0,Bolton KL,Cancer,replication,2010-09-19,GCST000800,Ovarian cancer
8132,European,4122.0,20852632.0,Goode EL,Cancer,initial,2010-09-19,GCST000802,Ovarian cancer
8131,European,4121.0,20852633.0,Bolton KL,Cancer,initial,2010-09-19,GCST000800,Ovarian cancer
7243,European,2383.0,20852631.0,Antoniou AC,Cancer,initial,2010-09-19,GCST000801,Breast cancer
8736,European,5986.0,20852631.0,Antoniou AC,Cancer,replication,2010-09-19,GCST000801,Breast cancer
11051,European,46368.0,20858683.0,Soranzo N,Other measurement,initial,2010-09-21,GCST000803,Glycated hemoglobin levels
10220,European,17723.0,20864672.0,Waterworth DM,"Lipid or lipoprotein measurement, Other measurement",initial,2010-09-23,GCST000807,LDL cholesterol
10911,European,37774.0,20864672.0,Waterworth DM,Lipid or lipoprotein measurement,replication,2010-09-23,GCST000809,Triglycerides
10910,European,37774.0,20864672.0,Waterworth DM,Lipid or lipoprotein measurement,replication,2010-09-23,GCST000805,HDL cholesterol
10912,European,37774.0,20864672.0,Waterworth DM,"Lipid or lipoprotein measurement, Other measurement",replication,2010-09-23,GCST000807,LDL cholesterol
14019,Other/Mixed,26475.0,20860503.0,Moffatt MF,Other disease,initial,2010-09-23,GCST000804,Asthma
10218,European,17723.0,20864672.0,Waterworth DM,Lipid or lipoprotein measurement,initial,2010-09-23,GCST000805,HDL cholesterol
7993,European,3762.0,20861866.0,Kopplin LJ,Neurological disorder,replication,2010-09-23,GCST000806,Age-related macular degeneration
13900,Other/Mixed,2035.0,20885792.0,Naj AC,Neurological disorder,initial,2010-09-23,GCST000808,Alzheimer's disease (late onset)
4002,Asian,9665.0,20864672.0,Waterworth DM,Lipid or lipoprotein measurement,replication,2010-09-23,GCST000805,HDL cholesterol
5870,European,872.0,20861866.0,Kopplin LJ,Neurological disorder,initial,2010-09-23,GCST000806,Age-related macular degeneration
4004,Asian,9665.0,20864672.0,Waterworth DM,"Lipid or lipoprotein measurement, Other measurement",replication,2010-09-23,GCST000807,LDL cholesterol
10219,European,17723.0,20864672.0,Waterworth DM,Lipid or lipoprotein measurement,initial,2010-09-23,GCST000809,Triglycerides
4003,Asian,9665.0,20864672.0,Waterworth DM,Lipid or lipoprotein measurement,replication,2010-09-23,GCST000809,Triglycerides
3216,Asian,2904.0,20871597.0,Miki D,Cancer,initial,2010-09-26,GCST000810,Lung adenocarcinoma
9326,European,8428.0,20872241.0,Li J,Cancer,initial,2010-09-26,GCST000811,Breast cancer
4037,Asian,10242.0,20871597.0,Miki D,Cancer,replication,2010-09-26,GCST000810,Lung adenocarcinoma
5880,European,878.0,20876420.0,Ingle JN,Response to drug,initial,2010-09-27,GCST000813,Adverse response to aromatase inhibitors
7606,European,3012.0,20927387.0,Kullo IJ,Hematological measurement,initial,2010-09-28,GCST000814,Red blood cell traits
2998,Asian,2162.0,20876614.0,Yoon KA,Cancer,initial,2010-09-28,GCST000815,Non-small cell lung cancer
5630,European,706.0,20877300.0,Perroud N,"Biological process, Other measurement",initial,2010-09-28,GCST000816,Suicidal ideation
3043,Asian,2274.0,20876614.0,Yoon KA,Cancer,replication,2010-09-28,GCST000815,Non-small cell lung cancer
11104,European,50074.0,20881960.0,Lango Allen H,"Other measurement, Body measurement",replication,2010-09-29,GCST000817,Height
11768,European,133653.0,20881960.0,Lango Allen H,"Other measurement, Body measurement",initial,2010-09-29,GCST000817,Height
10641,European,28283.0,20884846.0,Yang Q,"Metabolic disorder, Other measurement",initial,2010-09-30,GCST000818,Urate levels
10453,European,22054.0,20884846.0,Yang Q,"Metabolic disorder, Other measurement",replication,2010-09-30,GCST000818,Urate levels
390,African American or Afro-Caribbean,29.0,20920776.0,DeWan AT,Other disease,replication,2010-10-01,GCST000819,Asthma
5084,European,385.0,20920776.0,DeWan AT,Other disease,replication,2010-10-01,GCST000819,Asthma
9944,European,13844.0,20801717.0,Shatunov A,Neurological disorder,initial,2010-10-01,GCST000820,Amyotrophic lateral sclerosis
12513,Hispanic or Latin American,32.0,20920776.0,DeWan AT,Other disease,initial,2010-10-01,GCST000819,Asthma
12516,Hispanic or Latin American,34.0,20920776.0,DeWan AT,Other disease,replication,2010-10-01,GCST000819,Asthma
13406,Other/Mixed,14.0,20920776.0,DeWan AT,Other disease,initial,2010-10-01,GCST000819,Asthma
4578,European,47.0,20920776.0,DeWan AT,Other disease,initial,2010-10-01,GCST000819,Asthma
13466,Other/Mixed,51.0,20920776.0,DeWan AT,Other disease,replication,2010-10-01,GCST000819,Asthma
376,African American or Afro-Caribbean,15.0,20920776.0,DeWan AT,Other disease,initial,2010-10-01,GCST000819,Asthma
8168,European,4234.0,20889312.0,Wang KS,Neurological disorder,initial,2010-10-01,GCST000821,Bipolar disorder and schizophrenia
1658,Asian,95.0,20923822.0,Niu N,Biological process,initial,2010-10-05,GCST000823,Radiation response
4647,European,89.0,20923822.0,Niu N,Biological process,initial,2010-10-05,GCST000823,Radiation response
439,African American or Afro-Caribbean,79.0,20932654.0,Kerns SL,"Cancer, Other disease, Biological process",initial,2010-10-05,GCST000824,Erectile dysfunction and prostate cancer treatment
454,African American or Afro-Caribbean,93.0,20923822.0,Niu N,Biological process,initial,2010-10-05,GCST000823,Radiation response
13767,Other/Mixed,738.0,20921969.0,Aberg K,Response to drug,initial,2010-10-05,GCST000822,Antipsychotic drug-induced QTc interval prolongation
3051,Asian,2304.0,20887962.0,Jee SH,Other measurement,replication,2010-10-08,GCST000828,Adiponectin levels
5090,European,390.0,20932310.0,Han MR,Other measurement,initial,2010-10-08,GCST000827,Cerebrospinal fluid AB1-42 levels
3383,Asian,4001.0,20887962.0,Jee SH,Other measurement,initial,2010-10-08,GCST000828,Adiponectin levels
5089,European,390.0,20932310.0,Han MR,Other measurement,initial,2010-10-08,GCST000826,Cerebrospinal T-tau levels
5088,European,390.0,20932310.0,Han MR,Other measurement,initial,2010-10-08,GCST000825,Cerebrospinal P-tau181p levels
11733,European,125931.0,20935630.0,Speliotes EK,"Body measurement, Other measurement",replication,2010-10-10,GCST000830,Body mass index
11655,European,113636.0,20935629.0,Heid IM,"Other measurement, Body measurement",replication,2010-10-10,GCST000829,Waist-hip ratio
11725,European,123865.0,20935630.0,Speliotes EK,"Body measurement, Other measurement",initial,2010-10-10,GCST000830,Body mass index
11387,European,77167.0,20935629.0,Heid IM,"Other measurement, Body measurement",initial,2010-10-10,GCST000829,Waist-hip ratio
4851,European,217.0,20939080.0,Greenbaum L,Neurological disorder,initial,2010-10-11,GCST000831,Tardive dyskinesia in schizophrenia
13397,Other/Mixed,8.0,20939080.0,Greenbaum L,Neurological disorder,initial,2010-10-11,GCST000831,Tardive dyskinesia in schizophrenia
462,African American or Afro-Caribbean,102.0,20939080.0,Greenbaum L,Neurological disorder,initial,2010-10-11,GCST000831,Tardive dyskinesia in schizophrenia
13522,Other/Mixed,170.0,20939080.0,Greenbaum L,Neurological disorder,replication,2010-10-11,GCST000831,Tardive dyskinesia in schizophrenia
1973,Asian,360.0,20947153.0,Ueta M,Other disease,initial,2010-10-12,GCST000832,Stevens-Johnson syndrome
6634,European,1618.0,20953188.0,Ellinghaus E,Immune system disorder,initial,2010-10-17,GCST000836,Psoriasis
9156,European,7909.0,20953188.0,Ellinghaus E,Immune system disorder,replication,2010-10-17,GCST000836,Psoriasis
8625,European,5488.0,20953186.0,Huffmeier U,Immune system disorder,replication,2010-10-17,GCST000835,Psoriatic arthritis
9367,European,8638.0,20953190.0,Strange A,Immune system disorder,replication,2010-10-17,GCST000833,Psoriasis
6498,European,1460.0,20953186.0,Huffmeier U,Immune system disorder,initial,2010-10-17,GCST000835,Psoriatic arthritis
9047,European,7353.0,20953190.0,Strange A,Immune system disorder,initial,2010-10-17,GCST000833,Psoriasis
2810,Asian,1780.0,20966902.0,Croteau-Chonka DC,"Body measurement, Other measurement",initial,2010-10-21,GCST000840,Body mass index
4612,European,73.0,20971583.0,Ojwang JO,Other disease,initial,2010-10-22,GCST000841,Dupuytren's disease
9170,European,7962.0,20972440.0,Houlston RS,Cancer,initial,2010-10-24,GCST000843,Colorectal cancer
11197,European,56656.0,20972438.0,Rothman N,Cancer,replication,2010-10-24,GCST000842,Bladder cancer
9370,European,8652.0,20972438.0,Rothman N,Cancer,initial,2010-10-24,GCST000842,Bladder cancer
10705,European,30420.0,20972440.0,Houlston RS,Cancer,initial,2010-10-24,GCST000843,Colorectal cancer
5434,European,564.0,20978177.0,Penney KL,"Cancer, Other measurement",initial,2010-10-26,GCST000844,Prostate cancer mortality
5559,European,655.0,20978177.0,Penney KL,"Cancer, Other measurement",replication,2010-10-26,GCST000844,Prostate cancer mortality
6697,European,1703.0,21060860.0,Gaudet MM,Cancer,initial,2010-10-28,GCST000846,Breast cancer in BRCA2 mutation carriers
10054,European,15358.0,21060863.0,Ikram MK,Other measurement,initial,2010-10-28,GCST000847,Retinal vascular caliber
8881,European,6652.0,21060863.0,Ikram MK,Other measurement,replication,2010-10-28,GCST000847,Retinal vascular caliber
10873,European,36386.0,21082022.0,Padmanabhan S,Cardiovascular disease,replication,2010-10-28,GCST000849,Hypertension
8751,European,6041.0,20981099.0,Kong A,Other measurement,initial,2010-10-28,GCST000848,Recombination measurement (females)
7784,European,3320.0,21082022.0,Padmanabhan S,Cardiovascular disease,initial,2010-10-28,GCST000849,Hypertension
7304,European,2486.0,21060860.0,Gaudet MM,Cancer,replication,2010-10-28,GCST000846,Breast cancer in BRCA2 mutation carriers
8215,European,4389.0,20981099.0,Kong A,Other measurement,initial,2010-10-28,GCST000845,Recombination measurement (males)
7577,European,2950.0,21037115.0,Wan ES,"Other disease, Body measurement",initial,2010-10-29,GCST000850,Body mass in chronic obstructive pulmonary disease
5323,European,502.0,21037115.0,Wan ES,"Other disease, Body measurement",replication,2010-10-29,GCST000850,Body mass in chronic obstructive pulmonary disease
8620,European,5473.0,21037568.0,Enciso-Mora V,Cancer,replication,2010-10-31,GCST000851,Hodgkin's lymphoma
8685,European,5788.0,21037568.0,Enciso-Mora V,Cancer,initial,2010-10-31,GCST000851,Hodgkin's lymphoma
7449,European,2698.0,21041247.0,Perlis RH,"Biological process, Neurological disorder",replication,2010-11-01,GCST000854,Suicide risk
7208,European,2334.0,21041692.0,Denny JC,Cardiovascular measurement,initial,2010-11-01,GCST000852,Atrioventricular conduction
7872,European,3462.0,20848476.0,Haritunians T,Immune system disorder,initial,2010-11-01,GCST000853,Ulcerative colitis
8216,European,4390.0,21041247.0,Perlis RH,"Biological process, Neurological disorder",initial,2010-11-01,GCST000854,Suicide risk
2611,Asian,1413.0,21044949.0,Yang J,Immune system disorder,replication,2010-11-02,GCST000858,Systemic lupus erythematosus
3391,Asian,4071.0,21044949.0,Yang J,Immune system disorder,replication,2010-11-02,GCST000858,Systemic lupus erythematosus
5857,European,862.0,21184583.0,Zlojutro M,Other measurement,replication,2010-11-02,GCST000857,Event-related brain oscillations
8762,European,6104.0,21042317.0,Wray NR,Neurological disorder,initial,2010-11-02,GCST000856,Major depressive disorder
495,African American or Afro-Caribbean,153.0,21184583.0,Zlojutro M,Other measurement,replication,2010-11-02,GCST000857,Event-related brain oscillations
7612,European,3023.0,21044948.0,Spencer CC,Neurological disorder,replication,2010-11-02,GCST000855,Parkinson's disease
2794,Asian,1772.0,21044949.0,Yang J,Immune system disorder,initial,2010-11-02,GCST000858,Systemic lupus erythematosus
8947,European,6880.0,21044948.0,Spencer CC,Neurological disorder,initial,2010-11-02,GCST000855,Parkinson's disease
13489,Other/Mixed,80.0,21184583.0,Zlojutro M,Other measurement,replication,2010-11-02,GCST000857,Event-related brain oscillations
576,African American or Afro-Caribbean,293.0,21184583.0,Zlojutro M,Other measurement,initial,2010-11-02,GCST000857,Event-related brain oscillations
8865,European,6560.0,21042317.0,Wray NR,Neurological disorder,replication,2010-11-02,GCST000856,Major depressive disorder
5724,European,771.0,21184583.0,Zlojutro M,Other measurement,initial,2010-11-02,GCST000857,Event-related brain oscillations
2172,Asian,592.0,21072201.0,Kim JH,Other trait,replication,2010-11-03,GCST000859,Aspirin intolerance in asthmatics
1771,Asian,180.0,21072201.0,Kim JH,Other trait,initial,2010-11-03,GCST000859,Aspirin intolerance in asthmatics
1694,Asian,117.0,21048783.0,Kamada F,Cardiovascular disease,initial,2010-11-04,GCST000860,Moyamoya disease
12704,Hispanic or Latin American,677.0,21051598.0,Pereyra F,Other disease,initial,2010-11-04,GCST000863,HIV-1 control
6708,European,1712.0,21051598.0,Pereyra F,Other disease,initial,2010-11-04,GCST000863,HIV-1 control
835,African American or Afro-Caribbean,1233.0,21051598.0,Pereyra F,Other disease,initial,2010-11-04,GCST000863,HIV-1 control
6553,European,1534.0,21057379.0,Curtis D,Neurological disorder,initial,2010-11-04,GCST000862,Bipolar disorder and schizophrenia
1684,Asian,108.0,21048783.0,Kamada F,Cardiovascular disease,replication,2010-11-04,GCST000860,Moyamoya disease
6940,European,2019.0,21668797.0,Agrawal A,Neurological disorder,initial,2010-11-04,GCST000861,Cannabis dependence
788,African American or Afro-Caribbean,1035.0,21668797.0,Agrawal A,Neurological disorder,initial,2010-11-04,GCST000861,Cannabis dependence
5646,European,720.0,21061259.0,Plant D,"Immune system disorder, Response to drug",replication,2010-11-08,GCST000865,Response to anti-TNF therapy in rheumatoid arthritis
5824,European,841.0,21059979.0,Shen H,"Lipid or lipoprotein measurement, Other measurement",initial,2010-11-08,GCST000866,LDL cholesterol
8022,European,3839.0,21059989.0,Lee JH,Neurological disorder,replication,2010-11-08,GCST000864,Alzheimer's disease
5565,European,658.0,21059989.0,Lee JH,Neurological disorder,initial,2010-11-08,GCST000864,Alzheimer's disease
5437,European,566.0,21061259.0,Plant D,"Immune system disorder, Response to drug",initial,2010-11-08,GCST000865,Response to anti-TNF therapy in rheumatoid arthritis
12517,Hispanic or Latin American,34.0,21059989.0,Lee JH,Neurological disorder,initial,2010-11-08,GCST000864,Alzheimer's disease
13556,Other/Mixed,186.0,21059989.0,Lee JH,Neurological disorder,replication,2010-11-08,GCST000864,Alzheimer's disease
5574,European,663.0,21059979.0,Shen H,"Lipid or lipoprotein measurement, Other measurement",replication,2010-11-08,GCST000866,LDL cholesterol
622,African American or Afro-Caribbean,401.0,21059989.0,Lee JH,Neurological disorder,initial,2010-11-08,GCST000864,Alzheimer's disease
8531,European,5200.0,21062454.0,Li J,Cancer,initial,2010-11-09,GCST000867,Breast cancer (estrogen-receptor negative)
5440,European,573.0,21051773.0,Scerri TS,"Other trait, Neurological disorder",replication,2010-11-09,GCST000868,Handedness in dyslexia
9871,European,12868.0,21068099.0,Evangelou E,Other disease,replication,2010-11-10,GCST000869,Osteoarthritis
10925,European,38280.0,21068099.0,Evangelou E,Other disease,initial,2010-11-10,GCST000869,Osteoarthritis
3091,Asian,2428.0,21068099.0,Evangelou E,Other disease,replication,2010-11-10,GCST000869,Osteoarthritis
1682,Asian,105.0,21079520.0,Sato Y,"Other measurement, Cancer",initial,2010-11-12,GCST000871,Non-small cell lung cancer (survival)
9012,European,7170.0,21076409.0,Sotoodehnia N,Cardiovascular measurement,replication,2010-11-14,GCST000872,QRS duration
10971,European,40407.0,21076409.0,Sotoodehnia N,Cardiovascular measurement,initial,2010-11-14,GCST000872,QRS duration
8341,European,4766.0,21079607.0,Wang K,Metabolic disorder,initial,2010-11-16,GCST000873,Anorexia nervosa
7613,European,3023.0,21084426.0,Saad M,Neurological disorder,initial,2010-11-17,GCST000874,Parkinson's disease
9624,European,10296.0,21084426.0,Saad M,Neurological disorder,replication,2010-11-17,GCST000874,Parkinson's disease
8160,European,4212.0,21124955.0,Marzi C,Lipid or lipoprotein measurement,initial,2010-11-18,GCST000876,Amyloid A serum levels
6872,European,1934.0,21124946.0,Paternoster L,Other measurement,initial,2010-11-18,GCST000877,Bone mineral density
7554,European,2905.0,21088011.0,Erdmann J,Cardiovascular disease,initial,2010-11-18,GCST000875,Coronary heart disease
8019,European,3835.0,21124946.0,Paternoster L,Other measurement,replication,2010-11-18,GCST000877,Bone mineral density
7030,European,2136.0,21124955.0,Marzi C,Lipid or lipoprotein measurement,replication,2010-11-18,GCST000876,Amyloid A serum levels
10093,European,16131.0,21088011.0,Erdmann J,Cardiovascular disease,replication,2010-11-18,GCST000875,Coronary heart disease
3257,Asian,3087.0,21095009.0,Li YJ,Other trait,replication,2010-11-20,GCST000878,Myopia (pathological)
2429,Asian,980.0,21095009.0,Li YJ,Other trait,initial,2010-11-20,GCST000878,Myopia (pathological)
10714,European,30962.0,21102463.0,Franke A,Digestive system disorder,replication,2010-11-21,GCST000879,Crohn's disease
10005,European,14731.0,21102462.0,Elks CE,Other measurement,replication,2010-11-21,GCST000880,Menarche (age at onset)
11491,European,87802.0,21102462.0,Elks CE,Other measurement,initial,2010-11-21,GCST000880,Menarche (age at onset)
10426,European,21389.0,21102463.0,Franke A,Digestive system disorder,initial,2010-11-21,GCST000879,Crohn's disease
2721,Asian,1628.0,21104366.0,Tan L,Other measurement,replication,2010-11-23,GCST000881,Bone mineral density (wrist)
6074,European,1000.0,21104366.0,Tan L,Other measurement,initial,2010-11-23,GCST000881,Bone mineral density (wrist)
5594,European,673.0,21106707.0,Gu J,"Response to drug, Other measurement",initial,2010-11-24,GCST000882,Response to bleomycin (chromatid breaks)
13768,Other/Mixed,738.0,21107309.0,McClay JL,Biological process,initial,2010-11-24,GCST000883,Response to antipsychotic treatment in schizophrenia (working memory)
13769,Other/Mixed,738.0,21107309.0,McClay JL,Biological process,initial,2010-11-24,GCST000885,Response to antipsychotic treatment in schizophrenia (reasoning)
5813,European,834.0,21106707.0,Gu J,"Response to drug, Other measurement",replication,2010-11-24,GCST000882,Response to bleomycin (chromatid breaks)
13770,Other/Mixed,738.0,21107309.0,McClay JL,Response to drug,initial,2010-11-24,GCST000884,Response to antipsychotic treatment
2763,Asian,1733.0,21107343.0,Aoki A,Cardiovascular disease,initial,2010-11-25,GCST000887,Myocardial infarction
8553,European,5277.0,21098978.0,Sherva R,Neurological disorder,replication,2010-11-25,GCST000886,Alzheimer's disease
4082,Asian,11397.0,21107343.0,Aoki A,Cardiovascular disease,replication,2010-11-25,GCST000887,Myocardial infarction
13593,Other/Mixed,266.0,21098978.0,Sherva R,Neurological disorder,initial,2010-11-25,GCST000886,Alzheimer's disease
5946,European,930.0,21113153.0,van der Zanden LF,Other disease,initial,2010-11-28,GCST000888,Hypospadias
6154,European,1067.0,21113153.0,van der Zanden LF,Other disease,replication,2010-11-28,GCST000888,Hypospadias
1873,Asian,245.0,21118971.0,Wu C,Cancer,initial,2010-11-30,GCST000896,Small-cell lung cancer (survival)
6005,European,963.0,21116278.0,Furney SJ,"Neurological disorder, Other measurement",initial,2010-11-30,GCST000895,Whole-brain volume (Alzheimer's disease interaction)
5967,European,939.0,21116278.0,Furney SJ,"Neurological disorder, Other measurement",initial,2010-11-30,GCST000889,Entorhinal cortical thickness (Alzheimer's disease interaction)
5969,European,939.0,21116278.0,Furney SJ,"Neurological disorder, Other measurement",initial,2010-11-30,GCST000897,Hippocampal volume (Alzheimer's disease interaction)
5974,European,939.0,21116278.0,Furney SJ,"Other measurement, Neurological disorder",initial,2010-11-30,GCST000892,Total ventricular volume (Alzheimer's disease interaction)
5973,European,939.0,21116278.0,Furney SJ,Other measurement,initial,2010-11-30,GCST000899,Entorhinal cortical volume
1928,Asian,305.0,21118971.0,Wu C,Cancer,replication,2010-11-30,GCST000896,Small-cell lung cancer (survival)
6006,European,963.0,21116278.0,Furney SJ,Other measurement,initial,2010-11-30,GCST000891,Whole-brain volume
5970,European,939.0,21116278.0,Furney SJ,Other measurement,initial,2010-11-30,GCST000890,Hippocampal volume
5972,European,939.0,21116278.0,Furney SJ,Other measurement,initial,2010-11-30,GCST000898,Total ventricular volume
5971,European,939.0,21116278.0,Furney SJ,Other measurement,initial,2010-11-30,GCST000894,Entorhinal cortical thickness
5968,European,939.0,21116278.0,Furney SJ,"Neurological disorder, Other measurement",initial,2010-11-30,GCST000893,Entorhinal cortical volume (Alzheimer's disease interaction)
5071,European,374.0,21123754.0,Kim S,"Other measurement, Neurological disorder",initial,2010-12-01,GCST000900,Alzheimer's disease biomarkers
2066,Asian,451.0,21105107.0,Clifford RJ,Cancer,initial,2010-12-01,GCST000902,Hepatocellular carcinoma
13516,Other/Mixed,140.0,21130132.0,Mick E,Response to drug,initial,2010-12-01,GCST000903,Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)
2188,Asian,622.0,21105107.0,Clifford RJ,Cancer,replication,2010-12-01,GCST000902,Hepatocellular carcinoma
7875,European,3467.0,21124317.0,Wang K,Cancer,replication,2010-12-01,GCST000901,Neuroblastoma
8388,European,4881.0,21124317.0,Wang K,Cancer,initial,2010-12-01,GCST000901,Neuroblastoma
8102,European,4039.0,21130836.0,Luciano M,Biological process,initial,2010-12-03,GCST000905,Information processing speed
6306,European,1217.0,21131588.0,Slager SL,Cancer,replication,2010-12-03,GCST000906,Chronic lymphocytic leukemia
5624,European,703.0,21131588.0,Slager SL,Cancer,initial,2010-12-03,GCST000906,Chronic lymphocytic leukemia
9003,European,7116.0,21131975.0,Purdue MP,Cancer,replication,2010-12-05,GCST000907,Renal cell carcinoma
9825,European,12277.0,21131975.0,Purdue MP,Cancer,initial,2010-12-05,GCST000907,Renal cell carcinoma
5033,European,346.0,21139019.0,Walsh KM,Cancer,initial,2010-12-07,GCST000908,Ileal carcinoids
7524,European,2832.0,21150878.0,Ferreira MA,Other disease,initial,2010-12-08,GCST000910,Asthma
870,African American or Afro-Caribbean,1399.0,21150874.0,McDonough CW,Metabolic disorder,replication,2010-12-08,GCST000909,Type 2 diabetes nephropathy
5489,European,604.0,21150878.0,Ferreira MA,Other disease,replication,2010-12-08,GCST000910,Asthma
935,African American or Afro-Caribbean,1994.0,21150874.0,McDonough CW,Metabolic disorder,initial,2010-12-08,GCST000909,Type 2 diabetes nephropathy
5361,European,518.0,21087763.0,Carrasquillo MM,Other measurement,initial,2010-12-10,GCST000911,Progranulin levels
5232,European,459.0,21087763.0,Carrasquillo MM,Other measurement,replication,2010-12-10,GCST000911,Progranulin levels
8874,European,6616.0,21149283.0,Oexle K,Other measurement,initial,2010-12-10,GCST000913,Iron status biomarkers
2399,Asian,934.0,21149285.0,Ozeki T,Response to drug,initial,2010-12-10,GCST000912,Adverse response to carbamazepine
1622,Asian,67.0,21149285.0,Ozeki T,Response to drug,replication,2010-12-10,GCST000912,Adverse response to carbamazepine
9618,European,10254.0,21151130.0,Painter JN,Other disease,initial,2010-12-12,GCST000916,Endometriosis
8305,European,4663.0,21151130.0,Painter JN,Other disease,replication,2010-12-12,GCST000916,Endometriosis
2724,Asian,1639.0,21151128.0,Chen ZJ,Other disease,initial,2010-12-12,GCST000914,Polycystic ovary syndrome
7683,European,3199.0,21151127.0,Melum E,Digestive system disorder,replication,2010-12-12,GCST000915,Primary sclerosing cholangitis
3975,Asian,9130.0,21151128.0,Chen ZJ,Other disease,replication,2010-12-12,GCST000914,Polycystic ovary syndrome
7963,European,3677.0,21151127.0,Melum E,Digestive system disorder,initial,2010-12-12,GCST000915,Primary sclerosing cholangitis
7601,European,3000.0,21156761.0,Padyukov L,Immune system disorder,initial,2010-12-14,GCST000917,Rheumatoid arthritis
184,African,1379.0,21160409.0,Petrovski S,"Immune system disorder, Other disease",initial,2010-12-14,GCST000918,HIV-1 susceptibility
7016,European,2105.0,21156761.0,Padyukov L,Immune system disorder,replication,2010-12-14,GCST000917,Rheumatoid arthritis
4247,Asian,17176.0,21211798.0,Yamada Y,Cardiovascular disease,replication,2010-12-15,GCST000920,Myocardial infarction
9088,European,7538.0,21160077.0,Gudmundsson J,Other measurement,initial,2010-12-15,GCST000919,Serum prostate-specific antigen levels
1902,Asian,271.0,21211798.0,Yamada Y,Cardiovascular disease,initial,2010-12-15,GCST000920,Myocardial infarction
7236,European,2373.0,21160077.0,Gudmundsson J,Other measurement,replication,2010-12-15,GCST000919,Serum prostate-specific antigen levels
5443,European,576.0,21197116.0,Ryu E,Neurological disorder,initial,2010-12-17,GCST000921,Age-related macular degeneration
13773,Other/Mixed,744.0,21197116.0,Ryu E,Neurological disorder,replication,2010-12-17,GCST000921,Age-related macular degeneration
13349,Other/Mixed,2.0,21197116.0,Ryu E,Neurological disorder,initial,2010-12-17,GCST000921,Age-related macular degeneration
9,African,12.0,21197116.0,Ryu E,Neurological disorder,initial,2010-12-17,GCST000921,Age-related macular degeneration
11184,European,56173.0,21177295.0,Panoutsopoulou K,Other disease,replication,2010-12-21,GCST000923,Osteoarthritis
7767,European,3294.0,21173776.0,de Moor MH,Other measurement,replication,2010-12-21,GCST006329,Agreeableness
7766,European,3294.0,21173776.0,de Moor MH,Other measurement,replication,2010-12-21,GCST006326,Conscientiousness
7765,European,3294.0,21173776.0,de Moor MH,Other measurement,replication,2010-12-21,GCST000922,Openness
7764,European,3294.0,21173776.0,de Moor MH,"Neurological disorder, Other measurement",replication,2010-12-21,GCST006327,Neuroticism
13929,Other/Mixed,2744.0,21177295.0,Panoutsopoulou K,Other disease,replication,2010-12-21,GCST000923,Osteoarthritis
10194,European,17375.0,21173776.0,de Moor MH,"Biological process, Other measurement",initial,2010-12-21,GCST006328,Extraversion
10195,European,17375.0,21173776.0,de Moor MH,"Neurological disorder, Other measurement",initial,2010-12-21,GCST006327,Neuroticism
9200,European,8071.0,21177295.0,Panoutsopoulou K,Other disease,initial,2010-12-21,GCST000923,Osteoarthritis
10196,European,17375.0,21173776.0,de Moor MH,Other measurement,initial,2010-12-21,GCST000922,Openness
10197,European,17375.0,21173776.0,de Moor MH,Other measurement,initial,2010-12-21,GCST006326,Conscientiousness
10198,European,17375.0,21173776.0,de Moor MH,Other measurement,initial,2010-12-21,GCST006329,Agreeableness
7763,European,3294.0,21173776.0,de Moor MH,"Biological process, Other measurement",replication,2010-12-21,GCST006328,Extraversion
1613,Asian,60.0,21177773.0,Moyer AM,Response to drug,initial,2010-12-22,GCST000924,Response to acetaminophen (hepatotoxicity)
420,African American or Afro-Caribbean,56.0,21177773.0,Moyer AM,Response to drug,initial,2010-12-22,GCST000924,Response to acetaminophen (hepatotoxicity)
4593,European,60.0,21177773.0,Moyer AM,Response to drug,initial,2010-12-22,GCST000924,Response to acetaminophen (hepatotoxicity)
5248,European,470.0,21183627.0,Bouchard C,Other measurement,initial,2010-12-23,GCST000926,Maximal oxygen uptake response
72,African,247.0,21183627.0,Bouchard C,Other measurement,replication,2010-12-23,GCST000926,Maximal oxygen uptake response
7372,European,2559.0,21203500.0,Lauc G,Other measurement,initial,2010-12-23,GCST000925,N-glycan levels
6122,European,1024.0,21186350.0,Zhou K,Response to drug,initial,2010-12-26,GCST000927,Response to metformin in type 2 diabetes (glycemic)
7537,European,2872.0,21253498.0,Benjamin AM,"Body measurement, Other measurement",replication,2010-12-26,GCST000929,Body mass index
7538,European,2872.0,21253498.0,Benjamin AM,"Body measurement, Other measurement",replication,2010-12-26,GCST000930,Body mass index (sex interaction)
7186,European,2314.0,21253498.0,Benjamin AM,"Body measurement, Other measurement",initial,2010-12-26,GCST000928,Waist-to-hip ratio (sex interaction)
9430,European,9091.0,21253498.0,Benjamin AM,"Body measurement, Other measurement",initial,2010-12-26,GCST000930,Body mass index (sex interaction)
7539,European,2872.0,21253498.0,Benjamin AM,"Body measurement, Other measurement",replication,2010-12-26,GCST000931,Waist circumference (sex interaction)
9429,European,9091.0,21253498.0,Benjamin AM,"Body measurement, Other measurement",initial,2010-12-26,GCST000929,Body mass index
7187,European,2314.0,21253498.0,Benjamin AM,"Body measurement, Other measurement",initial,2010-12-26,GCST000931,Waist circumference (sex interaction)
7551,European,2896.0,21186350.0,Zhou K,Response to drug,replication,2010-12-26,GCST000927,Response to metformin in type 2 diabetes (glycemic)
7773,European,3304.0,21302353.0,Perroud N,Neurological disorder,initial,2010-12-28,GCST000932,Hoarding
3170,Asian,2742.0,21196492.0,Okada Y,Inflammatory measurement,replication,2010-12-31,GCST000933,C-reactive protein
4030,Asian,10112.0,21196492.0,Okada Y,Inflammatory measurement,initial,2010-12-31,GCST000933,C-reactive protein
6704,European,1708.0,21211648.0,Ege MJ,"Other disease, Other measurement",initial,2011-01-01,GCST000934,Asthma or atopy (farm exposure interaction)
7869,European,3457.0,21208937.0,Pichler I,Other measurement,replication,2011-01-04,GCST000935,Iron status biomarkers
8649,European,5633.0,21208937.0,Pichler I,Other measurement,initial,2011-01-04,GCST000935,Iron status biomarkers
6380,European,1316.0,21212386.0,Arnett DK,"Other trait, Other measurement",replication,2011-01-06,GCST000936,Cardiac muscle measurement
841,African American or Afro-Caribbean,1258.0,21212386.0,Arnett DK,"Other trait, Other measurement",initial,2011-01-06,GCST000936,Cardiac muscle measurement
774,African American or Afro-Caribbean,989.0,21212386.0,Arnett DK,"Other trait, Other measurement",replication,2011-01-06,GCST000936,Cardiac muscle measurement
13824,Other/Mixed,1113.0,21216876.0,Sharma S,Other disease,initial,2011-01-07,GCST000938,Adolescent idiopathic scoliosis
6313,European,1228.0,21216876.0,Sharma S,Other disease,replication,2011-01-07,GCST000938,Adolescent idiopathic scoliosis
9622,European,10280.0,21216879.0,Kaplan RC,Other measurement,initial,2011-01-07,GCST000937,Insulin-like growth factors
2324,Asian,786.0,21221998.0,Kim JJ,Immune system disorder,initial,2011-01-09,GCST000939,Kawasaki disease
2691,Asian,1556.0,21221998.0,Kim JJ,Immune system disorder,replication,2011-01-09,GCST000939,Kawasaki disease
2404,Asian,940.0,21155030.0,Cheong MY,Cardiovascular disease,replication,2011-01-11,GCST000941,Stroke (ischemic)
1653,Asian,93.0,22384361.0,Cheng YC,Cardiovascular disease,initial,2011-01-11,GCST000940,Stroke
8489,European,5074.0,21221126.0,Shen Y,Other disease,initial,2011-01-11,GCST000942,Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)
8185,European,4276.0,22384361.0,Cheng YC,Cardiovascular disease,replication,2011-01-11,GCST000940,Stroke
1940,Asian,320.0,21155030.0,Cheong MY,Cardiovascular disease,initial,2011-01-11,GCST000941,Stroke (ischemic)
714,African American or Afro-Caribbean,734.0,22384361.0,Cheng YC,Cardiovascular disease,initial,2011-01-11,GCST000940,Stroke
6062,European,989.0,22384361.0,Cheng YC,Cardiovascular disease,initial,2011-01-11,GCST000940,Stroke
806,African American or Afro-Caribbean,1086.0,21223598.0,Wineinger NE,Cardiovascular measurement,initial,2011-01-11,GCST000943,Aortic root size
3079,Asian,2383.0,21228123.0,Ochi H,Digestive system disorder,initial,2011-01-12,GCST000944,Response to hepatitis C treatment
7022,European,2116.0,21239051.0,Reilly MP,Cardiovascular disease,replication,2011-01-14,GCST000946,Myocardial infarction in coronary artery disease
10172,European,17053.0,21239051.0,Reilly MP,Cardiovascular disease,replication,2011-01-14,GCST000945,Coronary artery disease
9041,European,7311.0,21239051.0,Reilly MP,Cardiovascular disease,initial,2011-01-14,GCST000946,Myocardial infarction in coronary artery disease
7467,European,2723.0,21239051.0,Reilly MP,Cardiovascular disease,initial,2011-01-14,GCST000945,Coronary artery disease
3308,Asian,3481.0,21242260.0,Cui R,Cancer,initial,2011-01-17,GCST000948,Colorectal cancer
5482,European,600.0,21242121.0,Frullanti E,Cancer,initial,2011-01-17,GCST000947,Lung adenocarcinoma (clinical stage)
4988,European,317.0,21242121.0,Frullanti E,Cancer,replication,2011-01-17,GCST000947,Lung adenocarcinoma (clinical stage)
3860,Asian,7782.0,21242260.0,Cui R,Cancer,replication,2011-01-17,GCST000948,Colorectal cancer
7503,European,2796.0,21248740.0,Simon-Sanchez J,Neurological disorder,initial,2011-01-19,GCST000950,Parkinson's disease
4757,European,174.0,21283782.0,Tore S,Other disease,initial,2011-01-20,GCST000951,Nephrolithiasis
4928,European,282.0,21283782.0,Tore S,Other disease,replication,2011-01-20,GCST000951,Nephrolithiasis
10235,European,18021.0,21263130.0,Fletcher O,Cancer,replication,2011-01-24,GCST000952,Breast cancer
13495,Other/Mixed,87.0,21245432.0,Spraggs CF,Response to drug,initial,2011-01-24,GCST000953,Lapatinib-induced hepatotoxicity in breast cancer
13449,Other/Mixed,31.0,21245432.0,Spraggs CF,Response to drug,replication,2011-01-24,GCST000953,Lapatinib-induced hepatotoxicity in breast cancer
4856,European,222.0,21245432.0,Spraggs CF,Response to drug,initial,2011-01-24,GCST000953,Lapatinib-induced hepatotoxicity in breast cancer
4721,European,144.0,21245432.0,Spraggs CF,Response to drug,replication,2011-01-24,GCST000953,Lapatinib-induced hepatotoxicity in breast cancer
8821,European,6346.0,21263130.0,Fletcher O,Cancer,initial,2011-01-24,GCST000952,Breast cancer
2757,Asian,1721.0,21270382.0,Baik I,"Biological process, Other measurement",initial,2011-01-26,GCST000954,Alcohol consumption
2488,Asian,1113.0,21270382.0,Baik I,"Biological process, Other measurement",replication,2011-01-26,GCST000954,Alcohol consumption
9742,European,11367.0,21298027.0,Festen EA,"Digestive system disorder, Immune system disorder",replication,2011-01-27,GCST000955,Crohn's disease and celiac disease
9617,European,10249.0,21298027.0,Festen EA,"Digestive system disorder, Immune system disorder",initial,2011-01-27,GCST000955,Crohn's disease and celiac disease
169,African,1103.0,21298047.0,Chen X,Neurological disorder,initial,2011-01-27,GCST000956,Substance dependence
6386,European,1325.0,21273288.0,Del Greco M F,Cardiovascular measurement,initial,2011-01-27,GCST000957,Natriuretic peptide levels
7332,European,2524.0,21298047.0,Chen X,Neurological disorder,initial,2011-01-27,GCST000956,Substance dependence
6750,European,1746.0,21273288.0,Del Greco M F,Cardiovascular measurement,replication,2011-01-27,GCST000957,Natriuretic peptide levels
6228,European,1145.0,21278746.0,Lindstrom S,"Other measurement, Cancer",replication,2011-01-30,GCST000958,Percent mammographic density
8387,European,4877.0,21278746.0,Lindstrom S,"Other measurement, Cancer",initial,2011-01-30,GCST000958,Percent mammographic density
5843,European,851.0,21348951.0,Parsa A,Other trait,initial,2011-02-01,GCST000960,Cardiac hypertrophy
8357,European,4806.0,21254220.0,Jiang Y,Neurological disorder,initial,2011-02-01,GCST000961,Bipolar disorder
10190,European,17352.0,21292315.0,Nalls MA,Neurological disorder,initial,2011-02-01,GCST000959,Parkinson's disease
2233,Asian,696.0,21326860.0,Tsai FJ,Immune system disorder,initial,2011-02-04,GCST000962,Kawasaki disease
782,African American or Afro-Caribbean,1017.0,21294900.0,Charles BA,Cardiovascular measurement,initial,2011-02-04,GCST000963,Uric acid levels
2167,Asian,574.0,21326860.0,Tsai FJ,Immune system disorder,replication,2011-02-04,GCST000962,Kawasaki disease
10471,European,22545.0,21297633.0,Anderson CA,Immune system disorder,replication,2011-02-06,GCST000964,Ulcerative colitis
10601,European,26405.0,21297633.0,Anderson CA,Immune system disorder,initial,2011-02-06,GCST000964,Ulcerative colitis
10132,European,16540.0,21300955.0,Dehghan A,Inflammatory measurement,replication,2011-02-07,GCST000965,C-reactive protein levels
11281,European,66185.0,21300955.0,Dehghan A,Inflammatory measurement,initial,2011-02-07,GCST000965,C-reactive protein levels
8634,European,5580.0,21305692.0,Belmonte Mahon P,"Other trait, Neurological disorder, Other measurement",initial,2011-02-08,GCST000969,Bipolar disorder (age of onset and psychotic symptoms)
4650,European,90.0,21497773.0,Ziliak D,Response to drug,initial,2011-02-08,GCST000967,Response to platinum-based chemotherapy in head and neck cancers
1646,Asian,90.0,21497773.0,Ziliak D,Response to drug,initial,2011-02-08,GCST000968,Response to platinum-based chemotherapy in head and neck cancers
27,African,59.0,21497773.0,Ziliak D,Response to drug,replication,2011-02-08,GCST000968,Response to platinum-based chemotherapy in head and neck cancers
4651,European,90.0,21497773.0,Ziliak D,Response to drug,replication,2011-02-08,GCST000968,Response to platinum-based chemotherapy in head and neck cancers
2360,Asian,849.0,21310492.0,Huang YC,Metabolic disorder,initial,2011-02-08,GCST000966,Diabetic retinopathy
9466,European,9326.0,21307088.0,Khor CC,Other measurement,replication,2011-02-09,GCST000970,Optic disc area
3056,Asian,2313.0,21307088.0,Khor CC,Other measurement,initial,2011-02-09,GCST000970,Optic disc area
2976,Asian,2132.0,21307088.0,Khor CC,Other measurement,initial,2011-02-09,GCST000970,Optic disc area
1037,African American or Afro-Caribbean,2854.0,21347282.0,Lettre G,Cardiovascular disease,replication,2011-02-10,GCST000973,Hypertension
1254,African American or Afro-Caribbean,6247.0,21347284.0,Smith JG,Cardiovascular measurement,initial,2011-02-10,GCST000971,PR interval
1296,African American or Afro-Caribbean,7565.0,21347282.0,Lettre G,"Lipid or lipoprotein measurement, Other measurement",initial,2011-02-10,GCST000975,LDL cholesterol
1309,African American or Afro-Caribbean,7813.0,21347282.0,Lettre G,Lipid or lipoprotein measurement,initial,2011-02-10,GCST000974,HDL cholesterol
1188,African American or Afro-Caribbean,4323.0,21347282.0,Lettre G,Lipid or lipoprotein measurement,replication,2011-02-10,GCST000974,HDL cholesterol
985,African American or Afro-Caribbean,2250.0,21347282.0,Lettre G,Cardiovascular disease,replication,2011-02-10,GCST000972,Coronary heart disease
942,African American or Afro-Caribbean,2022.0,21347284.0,Smith JG,Cardiovascular measurement,replication,2011-02-10,GCST000971,PR interval
1282,African American or Afro-Caribbean,6942.0,21347282.0,Lettre G,Metabolic disorder,initial,2011-02-10,GCST000976,Type 2 diabetes
1224,African American or Afro-Caribbean,5313.0,21347282.0,Lettre G,Cardiovascular disease,initial,2011-02-10,GCST000972,Coronary heart disease
1157,African American or Afro-Caribbean,3789.0,21347282.0,Lettre G,"Lipid or lipoprotein measurement, Other measurement",replication,2011-02-10,GCST000975,LDL cholesterol
974,African American or Afro-Caribbean,2159.0,21347282.0,Lettre G,Metabolic disorder,replication,2011-02-10,GCST000976,Type 2 diabetes
1311,African American or Afro-Caribbean,7917.0,21347282.0,Lettre G,Cardiovascular disease,initial,2011-02-10,GCST000973,Hypertension
7219,European,2357.0,21314694.0,Kendler KS,"Other measurement, Neurological disorder",initial,2011-02-11,GCST000977,Alcohol dependence
7527,European,2836.0,21316860.0,Velders FP,Other measurement,replication,2011-02-11,GCST000978,Cortisol secretion
733,African American or Afro-Caribbean,812.0,21314694.0,Kendler KS,"Other measurement, Neurological disorder",initial,2011-02-11,GCST000977,Alcohol dependence
6706,European,1711.0,21316860.0,Velders FP,Other measurement,initial,2011-02-11,GCST000978,Cortisol secretion
4909,European,269.0,21359210.0,Ricci G,Other disease,initial,2011-02-16,GCST000979,Asthma (childhood onset)
6392,European,1339.0,21326295.0,Jin Y,Immune system disorder,initial,2011-02-17,GCST000981,Vitiligo
638,African American or Afro-Caribbean,440.0,21326311.0,Bhatnagar P,"Neurological disorder, Hematological measurement",initial,2011-02-17,GCST000982,F-cell distribution in sickle cell anaemia
12629,Hispanic or Latin American,418.0,21379329.0,Wijsman EM,Neurological disorder,replication,2011-02-17,GCST000980,Alzheimer's disease (late onset)
5596,European,677.0,21326295.0,Jin Y,Immune system disorder,replication,2011-02-17,GCST000981,Vitiligo
8023,European,3839.0,21379329.0,Wijsman EM,Neurological disorder,initial,2011-02-17,GCST000980,Alzheimer's disease (late onset)
5725,European,772.0,21379329.0,Wijsman EM,Neurological disorder,replication,2011-02-17,GCST000980,Alzheimer's disease (late onset)
7548,European,2894.0,21323541.0,Stanescu HC,Other disease,initial,2011-02-22,GCST000984,Idiopathic membranous nephropathy
4583,European,51.0,21339755.0,Liu X,Other measurement,replication,2011-02-22,GCST000983,5-HTT brain serotonin transporter levels
4558,European,13.0,21339755.0,Liu X,Other measurement,initial,2011-02-22,GCST000983,5-HTT brain serotonin transporter levels
374,African American or Afro-Caribbean,13.0,21339755.0,Liu X,Other measurement,initial,2011-02-22,GCST000983,5-HTT brain serotonin transporter levels
12493,Hispanic or Latin American,7.0,21339755.0,Liu X,Other measurement,initial,2011-02-22,GCST000983,5-HTT brain serotonin transporter levels
6916,European,1982.0,21353194.0,Cichon S,Neurological disorder,initial,2011-02-23,GCST000985,Bipolar disorder
10992,European,41821.0,21353194.0,Cichon S,Neurological disorder,replication,2011-02-23,GCST000985,Bipolar disorder
10918,European,38053.0,21383967.0,Zhernakova A,Other disease,initial,2011-02-24,GCST000987,Celiac disease or Rheumatoid arthritis
9823,European,12213.0,21383967.0,Zhernakova A,Other disease,replication,2011-02-24,GCST000987,Celiac disease or Rheumatoid arthritis
7935,European,3595.0,21390209.0,Hu X,Neurological disorder,initial,2011-02-24,GCST000986,Alzheimer's disease (late onset)
6685,European,1682.0,21357381.0,Figueiredo JC,Cancer,replication,2011-02-25,GCST000989,Colorectal cancer
10729,European,31580.0,21355061.0,Boger CA,Other trait,initial,2011-02-25,GCST000988,Urinary albumin excretion
7106,European,2190.0,21357381.0,Figueiredo JC,Cancer,initial,2011-02-25,GCST000989,Colorectal cancer
10724,European,31277.0,21355061.0,Boger CA,Other trait,replication,2011-02-25,GCST000988,Urinary albumin excretion
4799,European,191.0,21364930.0,Bol SM,Other disease,initial,2011-02-25,GCST000990,HIV-1 replication
1709,Asian,126.0,21519539.0,Cho SC,Neurological disorder,initial,2011-02-25,GCST000991,Autism spectrum disorders (language delay)
1985,Asian,368.0,23480133.0,Kim Y,Cardiovascular disease,replication,2011-02-28,GCST000993,Vascular dementia
8873,European,6611.0,21357676.0,Sulem P,"Biological process, Other measurement",initial,2011-02-28,GCST000992,Coffee consumption
8107,European,4050.0,21357676.0,Sulem P,"Biological process, Other measurement",replication,2011-02-28,GCST000992,Coffee consumption
1915,Asian,284.0,23480133.0,Kim Y,Cardiovascular disease,initial,2011-02-28,GCST000993,Vascular dementia
3628,Asian,5666.0,21372407.0,Takeuchi F,Biological process,replication,2011-03-01,GCST000994,Drinking behavior
2630,Asian,1462.0,21372407.0,Takeuchi F,Biological process,initial,2011-03-01,GCST000994,Drinking behavior
6890,European,1951.0,21368711.0,Alliey-Rodriguez N,"Neurological disorder, Other trait",initial,2011-03-02,GCST000995,Personality traits in bipolar disorder
8852,European,6530.0,21408207.0,Chung SA,Immune system disorder,initial,2011-03-03,GCST000996,Systemic lupus erythematosus
11330,European,69899.0,21378095.0,Fox ER,"Other measurement, Cardiovascular measurement",replication,2011-03-04,GCST000997,Blood pressure
1390,African American or Afro-Caribbean,10694.0,21378095.0,Fox ER,"Other measurement, Cardiovascular measurement",replication,2011-03-04,GCST000997,Blood pressure
172,African,1188.0,21378095.0,Fox ER,"Other measurement, Cardiovascular measurement",replication,2011-03-04,GCST000997,Blood pressure
1291,African American or Afro-Caribbean,7473.0,21378095.0,Fox ER,"Other measurement, Cardiovascular measurement",initial,2011-03-04,GCST000997,Blood pressure
2075,Asian,460.0,21378986.0,Wang F,Cardiovascular disease,initial,2011-03-06,GCST001000,Coronary heart disease
10831,European,34406.0,21378988.0,Coronary Artery Disease (C4D) Genetics Consortium,Cardiovascular disease,replication,2011-03-06,GCST000999,Coronary heart disease
4206,Asian,14790.0,21378988.0,Coronary Artery Disease (C4D) Genetics Consortium,Cardiovascular disease,initial,2011-03-06,GCST000999,Coronary heart disease
11483,European,86995.0,21378990.0,Schunkert H,Cardiovascular disease,initial,2011-03-06,GCST000998,Coronary heart disease
6668,European,1654.0,21378987.0,Holm H,Cardiovascular disease,replication,2011-03-06,GCST001001,Sick sinus syndrome
5765,European,804.0,21386754.0,Marciante KD,"Other disease, Response to drug",initial,2011-03-06,GCST001002,Cerivastatin-induced rhabdomyolysis
10071,European,15682.0,21378988.0,Coronary Artery Disease (C4D) Genetics Consortium,Cardiovascular disease,initial,2011-03-06,GCST000999,Coronary heart disease
3828,Asian,7593.0,21378986.0,Wang F,Cardiovascular disease,replication,2011-03-06,GCST001000,Coronary heart disease
3698,Asian,6187.0,21378988.0,Coronary Artery Disease (C4D) Genetics Consortium,Cardiovascular disease,replication,2011-03-06,GCST000999,Coronary heart disease
10928,European,38384.0,21378987.0,Holm H,Cardiovascular disease,initial,2011-03-06,GCST001001,Sick sinus syndrome
11198,European,56682.0,21378990.0,Schunkert H,Cardiovascular disease,replication,2011-03-06,GCST000998,Coronary heart disease
10456,European,22161.0,21386085.0,Kraja AT,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",initial,2011-03-08,GCST001003,Metabolic syndrome
10457,European,22161.0,21386085.0,Kraja AT,Lipid or lipoprotein measurement,initial,2011-03-08,GCST001005,HDL Cholesterol - Triglycerides (HDLC-TG)
10460,European,22161.0,21386085.0,Kraja AT,"Other measurement, Lipid or lipoprotein measurement",initial,2011-03-08,GCST001004,Triglycerides-Blood Pressure (TG-BP)
10459,European,22161.0,21386085.0,Kraja AT,"Metabolic disorder, Lipid or lipoprotein measurement",initial,2011-03-08,GCST001006,Waist Circumference - Triglycerides (WC-TG)
10458,European,22161.0,21386085.0,Kraja AT,Metabolic disorder,initial,2011-03-08,GCST001007,Metabolic syndrome (bivariate traits)
9014,European,7176.0,21423719.0,Speliotes EK,Digestive system disorder,initial,2011-03-10,GCST001008,Nonalcoholic fatty liver disease
6924,European,1997.0,21423719.0,Speliotes EK,Digestive system disorder,replication,2011-03-10,GCST001008,Nonalcoholic fatty liver disease
7252,European,2410.0,21399633.0,Gharavi AG,Other disease,replication,2011-03-13,GCST001009,Nephropathy
7653,European,3134.0,21399635.0,Mells GF,Cancer,replication,2011-03-13,GCST001010,Primary biliary cholangitis
2628,Asian,1460.0,21399633.0,Gharavi AG,Other disease,replication,2011-03-13,GCST001009,Nephropathy
2959,Asian,2096.0,21399633.0,Gharavi AG,Other disease,initial,2011-03-13,GCST001009,Nephropathy
8976,European,7003.0,21399635.0,Mells GF,Cancer,initial,2011-03-13,GCST001010,Primary biliary cholangitis
10379,European,20726.0,21437268.0,McKay JD,Cancer,replication,2011-03-17,GCST001011,Oral cavity and pharyngeal cancer
9634,European,10425.0,21437268.0,McKay JD,Cancer,initial,2011-03-17,GCST001011,Oral cavity and pharyngeal cancer
7228,European,2368.0,21424380.0,Sehrawat B,Cancer,replication,2011-03-19,GCST001012,Breast cancer
5518,European,623.0,21424380.0,Sehrawat B,Cancer,initial,2011-03-19,GCST001012,Breast cancer
6997,European,2073.0,21418511.0,Deelen J,Other measurement,initial,2011-03-21,GCST001013,Longevity
13947,Other/Mixed,3298.0,21418511.0,Deelen J,Other measurement,replication,2011-03-21,GCST001013,Longevity
7926,European,3575.0,21418511.0,Deelen J,Other measurement,replication,2011-03-21,GCST001013,Longevity
5015,European,337.0,21428769.0,McCormack M,Response to drug,replication,2011-03-24,GCST001014,Adverse response to carbamazepine
8108,European,4052.0,21428769.0,McCormack M,Response to drug,initial,2011-03-24,GCST001014,Adverse response to carbamazepine
7450,European,2698.0,21423239.0,Willour VL,"Biological process, Neurological disorder",initial,2011-03-25,GCST001015,Suicide attempts in bipolar disorder
4605,European,67.0,21396408.0,Miller EK,Response to drug,initial,2011-03-25,GCST001016,Vaccine-related adverse events
7521,European,2829.0,21441570.0,Grassi MA,Metabolic disorder,initial,2011-03-26,GCST001017,Diabetic retinopathy
3594,Asian,5581.0,21441931.0,Okamoto K,Other disease,replication,2011-03-27,GCST001018,Nephrotic syndrome (acquired)
2767,Asian,1741.0,21441931.0,Okamoto K,Other disease,initial,2011-03-27,GCST001018,Nephrotic syndrome (acquired)
9382,European,8731.0,21448238.0,Ligthart L,Cardiovascular disease,replication,2011-03-30,GCST001019,Migraine
9705,European,10980.0,21448238.0,Ligthart L,Cardiovascular disease,initial,2011-03-30,GCST001019,Migraine
4873,European,232.0,21483845.0,McLaren CE,Other trait,replication,2011-03-31,GCST001020,Iron deficiency
4872,European,232.0,21483845.0,McLaren CE,Other measurement,replication,2011-03-31,GCST001021,Iron status biomarkers
5601,European,679.0,21483845.0,McLaren CE,Other trait,initial,2011-03-31,GCST001020,Iron deficiency
5600,European,679.0,21483845.0,McLaren CE,Other measurement,initial,2011-03-31,GCST001021,Iron status biomarkers
2692,Asian,1558.0,21452313.0,Freudenberg J,Immune system disorder,initial,2011-04-01,GCST001022,Rheumatoid arthritis
7172,European,2287.0,21459883.0,Villard E,Cardiovascular disease,initial,2011-04-01,GCST001023,Idiopathic dilated cardiomyopathy
7290,European,2467.0,21459883.0,Villard E,Cardiovascular disease,replication,2011-04-01,GCST001023,Idiopathic dilated cardiomyopathy
2620,Asian,1437.0,21452313.0,Freudenberg J,Immune system disorder,replication,2011-04-01,GCST001022,Rheumatoid arthritis
3745,Asian,6683.0,21460842.0,Cha PC,Cancer,replication,2011-04-03,GCST001027,Uterine fibroids
10359,European,20373.0,21460840.0,Hollingworth P,Neurological disorder,initial,2011-04-03,GCST001025,Alzheimer's disease
10070,European,15675.0,21460841.0,Naj AC,Neurological disorder,initial,2011-04-03,GCST001026,Alzheimer's disease (late onset)
10942,European,39342.0,21460840.0,Hollingworth P,Neurological disorder,replication,2011-04-03,GCST001025,Alzheimer's disease
10934,European,38754.0,21460841.0,Naj AC,Neurological disorder,replication,2011-04-03,GCST001026,Alzheimer's disease (late onset)
3251,Asian,3035.0,21460842.0,Cha PC,Cancer,initial,2011-04-03,GCST001027,Uterine fibroids
4965,European,302.0,21467234.0,FitzGerald LM,Cancer,initial,2011-04-05,GCST001028,Prostate cancer
7173,European,2289.0,21467234.0,FitzGerald LM,Cancer,replication,2011-04-05,GCST001028,Prostate cancer
10598,European,26316.0,21471458.0,Schumann G,"Biological process, Other measurement",initial,2011-04-06,GCST001029,Alcohol consumption
10395,European,21185.0,21471458.0,Schumann G,"Biological process, Other measurement",replication,2011-04-06,GCST001029,Alcohol consumption
2938,Asian,2034.0,21490949.0,Sim X,Metabolic disorder,initial,2011-04-07,GCST001033,Type 2 diabetes
4958,European,296.0,21473668.0,Fliers EA,Neurological disorder,replication,2011-04-07,GCST001030,Attention deficit hyperactivity disorder motor coordination
2443,Asian,1008.0,21471979.0,Kumar V,Cancer,initial,2011-04-07,GCST001031,Large B-cell lymphoma
3330,Asian,3634.0,21471979.0,Kumar V,Cancer,replication,2011-04-07,GCST001031,Large B-cell lymphoma
2982,Asian,2146.0,21490949.0,Sim X,Metabolic disorder,initial,2011-04-07,GCST001033,Type 2 diabetes
3376,Asian,3955.0,21490949.0,Sim X,Metabolic disorder,initial,2011-04-07,GCST001033,Type 2 diabetes
11072,European,47431.0,21490707.0,Cornelis MC,Biological process,initial,2011-04-07,GCST001032,Caffeine consumption
5893,European,890.0,21473668.0,Fliers EA,Neurological disorder,initial,2011-04-07,GCST001030,Attention deficit hyperactivity disorder motor coordination
7928,European,3581.0,21478494.0,Nan H,Cancer,replication,2011-04-09,GCST001034,Cutaneous nevi
9440,European,9136.0,21478494.0,Nan H,Cancer,initial,2011-04-09,GCST001034,Cutaneous nevi
5665,European,735.0,21483023.0,Wu X,"Response to drug, Cancer",replication,2011-04-11,GCST001035,Response to platinum-based chemotherapy in non-small-cell lung cancer
4996,European,327.0,21483023.0,Wu X,"Response to drug, Cancer",initial,2011-04-11,GCST001035,Response to platinum-based chemotherapy in non-small-cell lung cancer
5660,European,733.0,21570397.0,Lucena MI,Digestive system disorder,initial,2011-04-12,GCST001036,Drug-induced liver injury (amoxicillin-clavulanate)
12758,Hispanic or Latin American,857.0,21483430.0,Carless MA,Other measurement,initial,2011-04-12,GCST001037,Neuranatomic and neurocognitive phenotypes
10019,European,14846.0,21533175.0,Zhai G,Other measurement,initial,2011-04-14,GCST001038,Dehydroepiandrosterone sulphate levels
6309,European,1223.0,21497890.0,Orange JS,Immune system disorder,replication,2011-04-15,GCST001039,Common variable immunodeficiency
7012,European,2096.0,21497890.0,Orange JS,Immune system disorder,initial,2011-04-15,GCST001039,Common variable immunodeficiency
3276,Asian,3269.0,21499248.0,Kumar V,Cancer,replication,2011-04-17,GCST001041,Hepatocellular carcinoma
9695,European,10843.0,21499250.0,Spurdle AB,Cancer,replication,2011-04-17,GCST001040,Endometrial cancer
3326,Asian,3611.0,21499248.0,Kumar V,Cancer,initial,2011-04-17,GCST001041,Hepatocellular carcinoma
8837,European,6455.0,21499250.0,Spurdle AB,Cancer,initial,2011-04-17,GCST001040,Endometrial cancer
3981,Asian,9171.0,21505073.0,Terao C,Immune system disorder,replication,2011-04-19,GCST001042,Rheumatoid arthritis
3577,Asian,5429.0,21544081.0,Dorajoo R,"Other measurement, Metabolic disorder",initial,2011-04-19,GCST001046,Obesity
3123,Asian,2531.0,21544081.0,Dorajoo R,"Other measurement, Metabolic disorder",initial,2011-04-19,GCST001046,Obesity
5056,European,362.0,21502966.0,Weber F,Response to drug,initial,2011-04-19,GCST001043,Response to interferon beta therapy
5239,European,464.0,21502949.0,Stein JL,Other measurement,replication,2011-04-19,GCST001045,Caudate nucleus volume
3092,Asian,2431.0,21544081.0,Dorajoo R,"Other measurement, Metabolic disorder",initial,2011-04-19,GCST001046,Obesity
2047,Asian,437.0,21505071.0,Li Z,Other trait,initial,2011-04-19,GCST001044,Myopia (pathological)
4144,Asian,12962.0,21505071.0,Li Z,Other trait,replication,2011-04-19,GCST001044,Myopia (pathological)
5781,European,818.0,21502966.0,Weber F,Response to drug,replication,2011-04-19,GCST001043,Response to interferon beta therapy
5664,European,734.0,21502949.0,Stein JL,Other measurement,initial,2011-04-19,GCST001045,Caudate nucleus volume
3161,Asian,2733.0,21505073.0,Terao C,Immune system disorder,initial,2011-04-19,GCST001042,Rheumatoid arthritis
10465,European,22435.0,21533024.0,Pare G,Cardiovascular measurement,initial,2011-04-21,GCST001047,Soluble ICAM-1
6254,European,1170.0,21533074.0,Smedby KE,Cancer,initial,2011-04-21,GCST001051,Follicular lymphoma
6896,European,1955.0,21533022.0,Duncan EL,Other measurement,initial,2011-04-21,GCST001050,Bone mineral density
10393,European,21052.0,21502573.0,Smith NL,Cardiovascular measurement,initial,2011-04-21,GCST001049,D-dimer levels
8459,European,5001.0,21533074.0,Smedby KE,Cancer,replication,2011-04-21,GCST001051,Follicular lymphoma
10386,European,20898.0,21533022.0,Duncan EL,Other measurement,replication,2011-04-21,GCST001050,Bone mineral density
6669,European,1654.0,21493818.0,Shaw SY,Other measurement,initial,2011-04-21,GCST001048,Monocyte early outgrowth colony forming units
7836,European,3393.0,21529783.0,Heath AC,Neurological disorder,replication,2011-04-27,GCST001055,Alcoholism (12-month weekly alcohol consumption)
9388,European,8754.0,21529783.0,Heath AC,Neurological disorder,initial,2011-04-27,GCST001053,Alcoholism (alcohol use disorder factor score)
9387,European,8754.0,21529783.0,Heath AC,Neurological disorder,initial,2011-04-27,GCST001052,Alcoholism (heaviness of drinking)
7835,European,3393.0,21529783.0,Heath AC,Neurological disorder,replication,2011-04-27,GCST001054,Alcoholism (alcohol dependence factor score)
9390,European,8754.0,21529783.0,Heath AC,Neurological disorder,initial,2011-04-27,GCST001055,Alcoholism (12-month weekly alcohol consumption)
7834,European,3393.0,21529783.0,Heath AC,Neurological disorder,replication,2011-04-27,GCST001053,Alcoholism (alcohol use disorder factor score)
7833,European,3393.0,21529783.0,Heath AC,Neurological disorder,replication,2011-04-27,GCST001052,Alcoholism (heaviness of drinking)
9389,European,8754.0,21529783.0,Heath AC,Neurological disorder,initial,2011-04-27,GCST001054,Alcoholism (alcohol dependence factor score)
6150,European,1060.0,21552555.0,Wang K,"Other measurement, Metabolic disorder",initial,2011-04-28,GCST001057,Obesity
775,African American or Afro-Caribbean,991.0,21521612.0,Kohli MA,Neurological disorder,replication,2011-04-28,GCST001056,Major depressive disorder
6284,European,1196.0,21552555.0,Wang K,"Other measurement, Metabolic disorder",replication,2011-04-28,GCST001057,Obesity
5645,European,719.0,21521612.0,Kohli MA,Neurological disorder,initial,2011-04-28,GCST001056,Major depressive disorder
9954,European,13969.0,21521612.0,Kohli MA,Neurological disorder,replication,2011-04-28,GCST001056,Major depressive disorder
9764,European,11582.0,21531791.0,Sanson M,Cancer,initial,2011-04-29,GCST001058,Glioma
48,African,115.0,21507922.0,Ramsuran V,Hematological measurement,initial,2011-05-01,GCST001061,Platelet count
8233,European,4446.0,21532571.0,Burdon KP,Neurological disorder,initial,2011-05-01,GCST001062,Glaucoma
47,African,115.0,21507922.0,Ramsuran V,Hematological measurement,initial,2011-05-01,GCST001059,Neutrophil count
5710,European,755.0,21502085.0,Troyer JL,Immune system disorder,initial,2011-05-01,GCST001060,AIDS progression
8621,European,5474.0,21532571.0,Burdon KP,Neurological disorder,replication,2011-05-01,GCST001062,Glaucoma
2234,Asian,698.0,21540461.0,Kim DH,Cancer,initial,2011-05-03,GCST001063,Chronic myeloid leukemia
5726,European,773.0,21540310.0,Hofmann S,Other disease,initial,2011-05-03,GCST001064,Sarcoidosis
5771,European,808.0,21540461.0,Kim DH,Cancer,replication,2011-05-03,GCST001063,Chronic myeloid leukemia
2549,Asian,1237.0,21540461.0,Kim DH,Cancer,replication,2011-05-03,GCST001063,Chronic myeloid leukemia
7820,European,3365.0,21540310.0,Hofmann S,Other disease,replication,2011-05-03,GCST001064,Sarcoidosis
687,African American or Afro-Caribbean,610.0,21546767.0,Murea M,Other disease,initial,2011-05-05,GCST001066,Dialysis-related mortality
6463,European,1399.0,21551455.0,Kanetsky PA,Cancer,replication,2011-05-06,GCST001067,Testicular cancer
6347,European,1268.0,21551455.0,Kanetsky PA,Cancer,initial,2011-05-06,GCST001067,Testicular cancer
7916,European,3554.0,21573004.0,Prescott J,Other measurement,initial,2011-05-10,GCST001068,Telomere length
7285,European,2460.0,21573004.0,Prescott J,Other measurement,replication,2011-05-10,GCST001068,Telomere length
7945,European,3620.0,21565293.0,Teumer A,Other measurement,initial,2011-05-13,GCST001069,Thyroid volume
6358,European,1290.0,21565293.0,Teumer A,Other measurement,replication,2011-05-13,GCST001069,Thyroid volume
4281,Asian,19608.0,21572416.0,Kato N,"Other measurement, Cardiovascular measurement",initial,2011-05-15,GCST001072,Blood pressure
12912,Hispanic or Latin American,2584.0,21573907.0,Parra EJ,Metabolic disorder,initial,2011-05-15,GCST001070,Type 2 diabetes
4282,Asian,19608.0,21572416.0,Kato N,"Other measurement, Cardiovascular measurement",initial,2011-05-15,GCST001074,Blood pressure
4361,Asian,30765.0,21572416.0,Kato N,"Other measurement, Cardiovascular measurement",replication,2011-05-15,GCST001072,Blood pressure
4362,Asian,30765.0,21572416.0,Kato N,"Other measurement, Cardiovascular measurement",replication,2011-05-15,GCST001074,Blood pressure
3539,Asian,5203.0,21573128.0,Kou I,Other disease,replication,2011-05-15,GCST001071,Osteoporosis
2781,Asian,1747.0,21573128.0,Kou I,Other disease,initial,2011-05-15,GCST001071,Osteoporosis
6832,European,1862.0,21572414.0,Suhre K,Other measurement,replication,2011-05-15,GCST001073,Urinary metabolites
531,African American or Afro-Caribbean,201.0,21703177.0,Thompson AJ,Digestive system disorder,initial,2011-05-20,GCST001076,IFN-related cytopenia
6043,European,984.0,21703177.0,Thompson AJ,Digestive system disorder,initial,2011-05-20,GCST001076,IFN-related cytopenia
3197,Asian,2834.0,21625490.0,Andiappan AK,Immune system disorder,replication,2011-05-20,GCST001075,Atopy
2438,Asian,1001.0,21625490.0,Andiappan AK,Immune system disorder,initial,2011-05-20,GCST001075,Atopy
12542,Hispanic or Latin American,99.0,21703177.0,Thompson AJ,Digestive system disorder,initial,2011-05-20,GCST001076,IFN-related cytopenia
1125,African American or Afro-Caribbean,3408.0,21602798.0,Haiman CA,Cancer,replication,2011-05-22,GCST001078,Prostate cancer
7191,European,2317.0,21602797.0,Wright FA,Other disease,initial,2011-05-22,GCST001077,Cystic fibrosis severity
1272,African American or Afro-Caribbean,6715.0,21602798.0,Haiman CA,Cancer,initial,2011-05-22,GCST001078,Prostate cancer
5904,European,898.0,21602797.0,Wright FA,Other disease,replication,2011-05-22,GCST001077,Cystic fibrosis severity
224,African,1705.0,21602798.0,Haiman CA,Cancer,replication,2011-05-22,GCST001078,Prostate cancer
11174,European,54758.0,21606135.0,Wild PS,Cardiovascular disease,replication,2011-05-23,GCST001079,Coronary heart disease
8468,European,5031.0,21606135.0,Wild PS,Cardiovascular disease,initial,2011-05-23,GCST001079,Coronary heart disease
4923,European,276.0,21612516.0,Malovini A,Other measurement,replication,2011-05-25,GCST001081,Longevity
6007,European,963.0,21612516.0,Malovini A,Other measurement,initial,2011-05-25,GCST001081,Longevity
5777,European,816.0,21618603.0,Beaty TH,"Other disease, Other trait, Other measurement",initial,2011-05-26,GCST001082,Orofacial clefts (maternal alcohol consumption interaction)
2317,Asian,777.0,21618603.0,Beaty TH,"Other disease, Other trait, Other measurement",initial,2011-05-26,GCST001082,Orofacial clefts (maternal alcohol consumption interaction)
13469,Other/Mixed,57.0,21618603.0,Beaty TH,"Other disease, Other trait, Other measurement",initial,2011-05-26,GCST001082,Orofacial clefts (maternal alcohol consumption interaction)
8458,European,5000.0,21626137.0,Slavin TP,Cardiovascular disease,initial,2011-05-28,GCST001085,Hypertension (SNP x SNP interaction)
8457,European,5000.0,21626137.0,Slavin TP,Cardiovascular disease,initial,2011-05-28,GCST001084,Coronary heart disease (SNP X SNP interaction)
7660,European,3145.0,21623375.0,Albagha OM,Other disease,replication,2011-05-29,GCST001086,Paget's disease
7862,European,3440.0,21623375.0,Albagha OM,Other disease,initial,2011-05-29,GCST001086,Paget's disease
9873,European,12943.0,21627779.0,Antunez C,Neurological disorder,replication,2011-05-31,GCST001087,Alzheimer's disease
6184,European,1088.0,21627779.0,Antunez C,Neurological disorder,initial,2011-05-31,GCST001087,Alzheimer's disease
3906,Asian,8445.0,21640322.0,Shi Y,Other trait,replication,2011-06-02,GCST001088,Myopia (pathological)
2474,Asian,1088.0,21640322.0,Shi Y,Other trait,initial,2011-06-02,GCST001088,Myopia (pathological)
3392,Asian,4075.0,21642993.0,Wu C,Cancer,initial,2011-06-05,GCST001089,Esophageal cancer
3884,Asian,8143.0,21642993.0,Wu C,Cancer,replication,2011-06-05,GCST001089,Esophageal cancer
8812,European,6307.0,21646302.0,Bielinski SJ,Other measurement,initial,2011-06-06,GCST001091,Bilirubin levels
3009,Asian,2175.0,21674006.0,Yamada K,Neurological disorder,replication,2011-06-06,GCST001090,Schizophrenia
1974,Asian,360.0,21674006.0,Yamada K,Neurological disorder,initial,2011-06-06,GCST001090,Schizophrenia
12808,Hispanic or Latin American,1273.0,21647700.0,Below JE,Metabolic disorder,initial,2011-06-07,GCST001092,Type 2 diabetes
12812,Hispanic or Latin American,1310.0,21647700.0,Below JE,Metabolic disorder,replication,2011-06-07,GCST001092,Type 2 diabetes
2750,Asian,1709.0,21647738.0,Wu Y,Inflammatory measurement,initial,2011-06-07,GCST001093,C-reactive protein
5045,European,356.0,21659360.0,Wade R,Response to drug,initial,2011-06-09,GCST001095,Response to antineoplastic agents
6501,European,1470.0,21654844.0,Briggs FB,Immune system disorder,initial,2011-06-09,GCST001096,Multiple sclerosis
6014,European,968.0,21694764.0,Martin NW,Other measurement,replication,2011-06-09,GCST001097,Educational attainment
2014,Asian,391.0,21659334.0,Tanaka Y,Digestive system disorder,replication,2011-06-09,GCST001094,Response to hepatitis C treatment
1925,Asian,303.0,21659334.0,Tanaka Y,Digestive system disorder,initial,2011-06-09,GCST001094,Response to hepatitis C treatment
5075,European,380.0,21659360.0,Wade R,Response to drug,replication,2011-06-09,GCST001095,Response to antineoplastic agents
9503,European,9538.0,21694764.0,Martin NW,Other measurement,initial,2011-06-09,GCST001097,Educational attainment
5490,European,605.0,21658281.0,Aouizerat BE,Cardiovascular disease,initial,2011-06-10,GCST001099,Sudden cardiac arrest
3048,Asian,2281.0,21665993.0,Han S,Other measurement,initial,2011-06-10,GCST001101,Corneal curvature
8908,European,6728.0,21665990.0,Yu Y,Neurological disorder,initial,2011-06-10,GCST001100,Age-related macular degeneration
13384,Other/Mixed,5.0,21665988.0,Horne BD,Cardiovascular disease,initial,2011-06-10,GCST001098,Peripartum cardiomyopathy
2980,Asian,2142.0,21665993.0,Han S,Other measurement,replication,2011-06-10,GCST001101,Corneal curvature
5057,European,362.0,21665988.0,Horne BD,Cardiovascular disease,replication,2011-06-10,GCST001098,Peripartum cardiomyopathy
5491,European,605.0,21658281.0,Aouizerat BE,Cardiovascular disease,initial,2011-06-10,GCST001102,Sudden cardiac arrest
2930,Asian,2008.0,21665993.0,Han S,Other measurement,initial,2011-06-10,GCST001101,Corneal curvature
11210,European,57814.0,21665990.0,Yu Y,Neurological disorder,replication,2011-06-10,GCST001100,Age-related macular degeneration
2397,Asian,929.0,21665993.0,Han S,Other measurement,replication,2011-06-10,GCST001101,Corneal curvature
5673,European,739.0,21665988.0,Horne BD,Cardiovascular disease,initial,2011-06-10,GCST001098,Peripartum cardiomyopathy
5492,European,605.0,21658281.0,Aouizerat BE,Cardiovascular disease,initial,2011-06-10,GCST001104,Sudden cardiac arrest
8527,European,5181.0,21665994.0,Kutalik Z,Biological process,initial,2011-06-10,GCST001103,Alcohol consumption (transferrin glycosylation)
10222,European,17777.0,21666692.0,Chasman DI,Cardiovascular disease,replication,2011-06-12,GCST001105,Migraine
10497,European,23230.0,21666692.0,Chasman DI,Cardiovascular disease,initial,2011-06-12,GCST001105,Migraine
8484,European,5062.0,21666691.0,Sun LD,Immune system disorder,replication,2011-06-13,GCST001106,Atopic dermatitis
4225,Asian,15821.0,21666691.0,Sun LD,Immune system disorder,replication,2011-06-13,GCST001106,Atopic dermatitis
3073,Asian,2374.0,21666691.0,Sun LD,Immune system disorder,initial,2011-06-13,GCST001106,Atopic dermatitis
7863,European,3440.0,21685187.0,Siedlinski M,"Other disease, Other measurement",initial,2011-06-16,GCST001112,Lifetime average cigarettes per day in chronic obstructive pulmonary disease
857,African American or Afro-Caribbean,1323.0,21698141.0,Freedman BI,Other disease,replication,2011-06-16,GCST001107,End-stage renal disease
7615,European,3024.0,21681796.0,Fornage M,Other measurement,replication,2011-06-16,GCST001109,White matter hyperintensity burden
7629,European,3071.0,21685187.0,Siedlinski M,"Other disease, Biological process",initial,2011-06-16,GCST001108,Smoking cessation in chronic obstructive pulmonary disease
933,African American or Afro-Caribbean,1940.0,21698141.0,Freedman BI,Other disease,initial,2011-06-16,GCST001107,End-stage renal disease
9475,European,9361.0,21681796.0,Fornage M,Other measurement,initial,2011-06-16,GCST001109,White matter hyperintensity burden
1747,Asian,158.0,21679298.0,Ma X,Neurological disorder,initial,2011-06-16,GCST001110,Schizophrenia
7838,European,3397.0,21685187.0,Siedlinski M,"Other disease, Biological process",initial,2011-06-16,GCST001113,Age at smoking initiation in chronic obstructive pulmonary disease
6202,European,1113.0,21685187.0,Siedlinski M,"Other disease, Other measurement",initial,2011-06-16,GCST001111,Current cigarettes per day in chronic obstructive pulmonary disease
6247,European,1162.0,21688384.0,Wang KS,"Neurological disorder, Other measurement",initial,2011-06-17,GCST001115,Schizophrenia (age at onset)
6246,European,1162.0,21688384.0,Wang KS,"Neurological disorder, Other measurement",initial,2011-06-17,GCST001114,Schizophrenia (age at onset) (sex interaction)
6155,European,1068.0,21688384.0,Wang KS,"Neurological disorder, Other measurement",replication,2011-06-17,GCST001114,Schizophrenia (age at onset) (sex interaction)
6156,European,1068.0,21688384.0,Wang KS,"Neurological disorder, Other measurement",replication,2011-06-17,GCST001115,Schizophrenia (age at onset)
13615,Other/Mixed,329.0,21685912.0,Hoglinger GU,Neurological disorder,initial,2011-06-19,GCST001116,Progressive supranuclear palsy
8286,European,4611.0,21685912.0,Hoglinger GU,Neurological disorder,replication,2011-06-19,GCST001116,Progressive supranuclear palsy
8097,European,4027.0,21685912.0,Hoglinger GU,Neurological disorder,initial,2011-06-19,GCST001116,Progressive supranuclear palsy
13515,Other/Mixed,138.0,21696813.0,Schauberger EM,Other disease,replication,2011-06-20,GCST001117,Asthma (childhood onset)
13557,Other/Mixed,189.0,21682944.0,Alkelai A,Neurological disorder,replication,2011-06-20,GCST001119,Schizophrenia
4924,European,277.0,21696813.0,Schauberger EM,Other disease,initial,2011-06-20,GCST001117,Asthma (childhood onset)
9450,European,9243.0,21696813.0,Schauberger EM,Other disease,replication,2011-06-20,GCST001117,Asthma (childhood onset)
12967,Hispanic or Latin American,3693.0,21696813.0,Schauberger EM,Other disease,replication,2011-06-20,GCST001117,Asthma (childhood onset)
5004,European,331.0,21682944.0,Alkelai A,Neurological disorder,initial,2011-06-20,GCST001119,Schizophrenia
2432,Asian,983.0,21699788.0,Okada Y,"Digestive system disorder, Immune system disorder",replication,2011-06-20,GCST001118,Ulcerative colitis or Crohn's disease
496,African American or Afro-Caribbean,156.0,21696813.0,Schauberger EM,Other disease,replication,2011-06-20,GCST001117,Asthma (childhood onset)
2268,Asian,744.0,21699788.0,Okada Y,"Digestive system disorder, Immune system disorder",initial,2011-06-20,GCST001118,Ulcerative colitis or Crohn's disease
6915,European,1979.0,21700265.0,Kullo IJ,Inflammatory measurement,initial,2011-06-22,GCST001120,Erythrocyte sedimentation rate
7453,European,2699.0,21703634.0,Wang KS,"Other measurement, Neurological disorder",initial,2011-06-22,GCST001121,Alcohol dependence
8646,European,5628.0,21700265.0,Kullo IJ,Inflammatory measurement,replication,2011-06-22,GCST001120,Erythrocyte sedimentation rate
7795,European,3334.0,21703634.0,Wang KS,"Other measurement, Neurological disorder",replication,2011-06-22,GCST001121,Alcohol dependence
1146,African American or Afro-Caribbean,3724.0,21701570.0,Ng MC,"Body measurement, Other measurement",replication,2011-06-23,GCST001125,Body mass index
13825,Other/Mixed,1120.0,21701565.0,Malhotra A,"Body measurement, Other measurement",initial,2011-06-23,GCST001123,Body mass index
9197,European,8058.0,21700618.0,Nan H,Cancer,initial,2011-06-23,GCST001124,Basal cell carcinoma
8803,European,6271.0,21700618.0,Nan H,Cancer,replication,2011-06-23,GCST001124,Basal cell carcinoma
6613,European,1591.0,21700879.0,Qi L,Other measurement,initial,2011-06-23,GCST001122,Adiponectin levels
910,African American or Afro-Caribbean,1715.0,21701570.0,Ng MC,"Body measurement, Other measurement",initial,2011-06-23,GCST001125,Body mass index
10768,European,33050.0,21738487.0,Do CB,Neurological disorder,initial,2011-06-23,GCST001126,Parkinson's disease
13904,Other/Mixed,2133.0,21701565.0,Malhotra A,"Body measurement, Other measurement",replication,2011-06-23,GCST001123,Body mass index
5523,European,626.0,21700879.0,Qi L,Other measurement,replication,2011-06-23,GCST001122,Adiponectin levels
4585,European,52.0,21705454.0,Huang RS,Response to drug,replication,2011-06-24,GCST001127,Response to platinum-based agents
4641,European,87.0,21705454.0,Huang RS,Response to drug,initial,2011-06-24,GCST001127,Response to platinum-based agents
10667,European,29069.0,21706003.0,Kilpelainen TO,Metabolic disorder,initial,2011-06-26,GCST001128,Adiposity
3823,Asian,7557.0,21706003.0,Kilpelainen TO,Metabolic disorder,initial,2011-06-26,GCST001128,Adiposity
7181,European,2306.0,21706340.0,Teerlink C,Cancer,initial,2011-06-26,GCST001129,Melanoma
10948,European,39576.0,21706003.0,Kilpelainen TO,Metabolic disorder,replication,2011-06-26,GCST001128,Adiposity
9627,European,10337.0,21708048.0,Jiao H,"Other measurement, Metabolic disorder",replication,2011-06-28,GCST001130,Obesity
4997,European,327.0,21708048.0,Jiao H,"Other measurement, Metabolic disorder",initial,2011-06-28,GCST001130,Obesity
6632,European,1614.0,21740922.0,Nebel A,Other measurement,replication,2011-06-29,GCST001131,Longevity
6804,European,1821.0,21740922.0,Nebel A,Other measurement,initial,2011-06-29,GCST001131,Longevity
1431,African American or Afro-Caribbean,16388.0,21738479.0,Reiner AP,"Hematological measurement, Inflammatory measurement",initial,2011-06-30,GCST001133,White blood cell count
12960,Hispanic or Latin American,3551.0,21738479.0,Reiner AP,"Hematological measurement, Inflammatory measurement",replication,2011-06-30,GCST001133,White blood cell count
3673,Asian,5998.0,21738478.0,Okada Y,"Hematological measurement, Inflammatory measurement",replication,2011-06-30,GCST001134,White blood cell types
9979,European,14265.0,21738491.0,Arking DE,Cardiovascular disease,replication,2011-06-30,GCST001132,Sudden cardiac arrest
3934,Asian,8794.0,21738478.0,Okada Y,"Hematological measurement, Inflammatory measurement",initial,2011-06-30,GCST001134,White blood cell types
10317,European,19509.0,21738479.0,Reiner AP,"Hematological measurement, Inflammatory measurement",replication,2011-06-30,GCST001133,White blood cell count
10397,European,21283.0,21738491.0,Arking DE,Cardiovascular disease,initial,2011-06-30,GCST001132,Sudden cardiac arrest
4205,Asian,14767.0,21738479.0,Reiner AP,"Hematological measurement, Inflammatory measurement",replication,2011-06-30,GCST001133,White blood cell count
9799,European,11823.0,21738480.0,Nalls MA,"Hematological measurement, Inflammatory measurement",replication,2011-07-01,GCST001137,White blood cell count
10318,European,19509.0,21738480.0,Nalls MA,"Hematological measurement, Inflammatory measurement",initial,2011-07-01,GCST001137,White blood cell count
1905,Asian,274.0,21787189.0,Nyberg F,Other disease,initial,2011-07-01,GCST001136,Interstitial lung disease
4897,European,251.0,21694509.0,Janicki PK,Other trait,initial,2011-07-01,GCST001138,Postoperative nausea and vomiting
4836,European,208.0,21694509.0,Janicki PK,Other trait,replication,2011-07-01,GCST001138,Postoperative nausea and vomiting
2427,Asian,977.0,21725309.0,Miki D,Digestive system disorder,initial,2011-07-03,GCST001139,Chronic hepatitis C infection
3064,Asian,2335.0,21725309.0,Miki D,Digestive system disorder,replication,2011-07-03,GCST001139,Chronic hepatitis C infection
4139,Asian,12722.0,21725308.0,Hu Z,Cancer,replication,2011-07-03,GCST001140,Lung cancer
3571,Asian,5408.0,21725308.0,Hu Z,Cancer,initial,2011-07-03,GCST001140,Lung cancer
6483,European,1437.0,22303337.0,Wang K,Lipid or lipoprotein measurement,initial,2011-07-05,GCST001143,HDL cholesterol
8090,European,4014.0,21729881.0,Major JM,Other measurement,initial,2011-07-05,GCST001142,Vitamin E levels
13931,Other/Mixed,2775.0,21729881.0,Major JM,Other measurement,replication,2011-07-05,GCST001142,Vitamin E levels
6550,European,1531.0,21750702.0,Schosser A,"Biological process, Other measurement",replication,2011-07-05,GCST001141,Suicidal ideation
7048,European,2154.0,21750702.0,Schosser A,"Biological process, Other measurement",initial,2011-07-05,GCST001141,Suicidal ideation
6063,European,992.0,21729881.0,Major JM,Other measurement,replication,2011-07-05,GCST001142,Vitamin E levels
5866,European,869.0,22303337.0,Wang K,Lipid or lipoprotein measurement,replication,2011-07-05,GCST001143,HDL cholesterol
54,African,176.0,21755009.0,Wheeler HE,Response to drug,initial,2011-07-06,GCST001145,Chemotherapeutic susceptibility
443,African American or Afro-Caribbean,83.0,21755009.0,Wheeler HE,Response to drug,initial,2011-07-06,GCST001145,Chemotherapeutic susceptibility
9329,European,8434.0,21732829.0,Dolmans GH,Other disease,replication,2011-07-06,GCST001144,Dupuytren's disease
7970,European,3692.0,21732829.0,Dolmans GH,Other disease,initial,2011-07-06,GCST001144,Dupuytren's disease
7212,European,2340.0,21750679.0,Allanore Y,Neurological disorder,initial,2011-07-07,GCST001146,Systemic sclerosis
8641,European,5608.0,21750679.0,Allanore Y,Neurological disorder,replication,2011-07-07,GCST001146,Systemic sclerosis
9963,European,14090.0,21743057.0,Schumacher FR,Cancer,replication,2011-07-08,GCST001147,Prostate cancer
9027,European,7240.0,21743057.0,Schumacher FR,Cancer,initial,2011-07-08,GCST001147,Prostate cancer
9797,European,11802.0,21743469.0,Evans DM,Immune system disorder,initial,2011-07-10,GCST001149,Ankylosing spondylitis
9915,European,13560.0,21743467.0,Kote-Jarai Z,Cancer,initial,2011-07-10,GCST001148,Prostate cancer
11045,European,46191.0,21743467.0,Kote-Jarai Z,Cancer,replication,2011-07-10,GCST001148,Prostate cancer
13999,Other/Mixed,12595.0,21743467.0,Kote-Jarai Z,Cancer,replication,2011-07-10,GCST001148,Prostate cancer
627,African American or Afro-Caribbean,410.0,21743467.0,Kote-Jarai Z,Cancer,replication,2011-07-10,GCST001148,Prostate cancer
2362,Asian,853.0,21743467.0,Kote-Jarai Z,Cancer,replication,2011-07-10,GCST001148,Prostate cancer
8870,European,6594.0,21743469.0,Evans DM,Immune system disorder,replication,2011-07-10,GCST001149,Ankylosing spondylitis
970,African American or Afro-Caribbean,2127.0,21752600.0,Chen J,Neurological disorder,replication,2011-07-12,GCST001151,Schizophrenia
9932,European,13632.0,21750109.0,Rafnar T,Cancer,replication,2011-07-12,GCST001153,Bladder cancer
3743,Asian,6649.0,21750111.0,Mbarek H,"Digestive system disorder, Other measurement",replication,2011-07-12,GCST001150,Hepatitis B
13683,Other/Mixed,515.0,21750109.0,Rafnar T,Cancer,replication,2011-07-12,GCST001153,Bladder cancer
10802,European,33577.0,21747397.0,Rietschel M,Neurological disorder,replication,2011-07-12,GCST001152,Schizophrenia
3116,Asian,2514.0,21750111.0,Mbarek H,"Digestive system disorder, Other measurement",initial,2011-07-12,GCST001150,Hepatitis B
8389,European,4883.0,21747397.0,Rietschel M,Neurological disorder,initial,2011-07-12,GCST001152,Schizophrenia
11022,European,43837.0,21750109.0,Rafnar T,Cancer,initial,2011-07-12,GCST001153,Bladder cancer
7780,European,3313.0,21752600.0,Chen J,Neurological disorder,initial,2011-07-12,GCST001151,Schizophrenia
9832,European,12352.0,21752600.0,Chen J,Neurological disorder,replication,2011-07-12,GCST001151,Schizophrenia
8503,European,5122.0,21779381.0,Schurks M,"Liver enzyme measurement, Cardiovascular measurement, Other measurement, Other disease, Lipid or lipoprotein measurement, Inflammatory measurement",initial,2011-07-14,GCST001157,Cardiovascular disease risk factors
9058,European,7385.0,21779181.0,Gorlova O,Neurological disorder,replication,2011-07-14,GCST001160,Systemic sclerosis
9073,European,7468.0,21779181.0,Gorlova O,Neurological disorder,initial,2011-07-14,GCST001160,Systemic sclerosis
7906,European,3527.0,21757650.0,Debette S,Cardiovascular measurement,initial,2011-07-14,GCST001155,Vascular endothelial growth factor levels
7282,European,2448.0,21779176.0,Winkelmann J,Neurological disorder,initial,2011-07-14,GCST001159,Restless legs syndrome
9057,European,7385.0,21779181.0,Gorlova O,Neurological disorder,replication,2011-07-14,GCST001156,Systemic sclerosis
9528,European,9689.0,21779176.0,Winkelmann J,Neurological disorder,replication,2011-07-14,GCST001159,Restless legs syndrome
9072,European,7468.0,21779181.0,Gorlova O,Neurological disorder,initial,2011-07-14,GCST001156,Systemic sclerosis
6734,European,1727.0,21757650.0,Debette S,Cardiovascular measurement,replication,2011-07-14,GCST001155,Vascular endothelial growth factor levels
2896,Asian,1931.0,21764829.0,Png E,Response to drug,replication,2011-07-15,GCST001162,Hepatitis B vaccine response
2740,Asian,1683.0,21764829.0,Png E,Response to drug,initial,2011-07-15,GCST001162,Hepatitis B vaccine response
8817,European,6322.0,21761138.0,Peters U,Cancer,initial,2011-07-15,GCST001161,Colorectal cancer
10185,European,17262.0,21761138.0,Peters U,Cancer,replication,2011-07-15,GCST001161,Colorectal cancer
1347,African American or Afro-Caribbean,8651.0,21768215.0,Tin A,"Metabolic disorder, Other measurement",initial,2011-07-18,GCST001163,Urate levels
937,African American or Afro-Caribbean,1996.0,21768215.0,Tin A,"Metabolic disorder, Other measurement",replication,2011-07-18,GCST001163,Urate levels
13689,Other/Mixed,564.0,21771265.0,Yosifova A,Neurological disorder,initial,2011-07-19,GCST001164,Bipolar disorder
2003,Asian,382.0,21771975.0,Chung CM,Other measurement,initial,2011-07-19,GCST001165,Adiponectin levels
2155,Asian,559.0,21771975.0,Chung CM,Other measurement,replication,2011-07-19,GCST001165,Adiponectin levels
13666,Other/Mixed,450.0,21771265.0,Yosifova A,Neurological disorder,replication,2011-07-19,GCST001164,Bipolar disorder
451,African American or Afro-Caribbean,91.0,21775533.0,Tan XL,Response to drug,initial,2011-07-20,GCST001169,Response to platinum-based chemotherapy in small cell and non-small cell lung cancers
6272,European,1183.0,21775533.0,Tan XL,Response to drug,replication,2011-07-20,GCST001169,Response to platinum-based chemotherapy in small cell and non-small cell lung cancers
1502,African American or Afro-Caribbean,30033.0,21775986.0,Hinch AG,Other measurement,initial,2011-07-20,GCST001168,Recombination measurement
1660,Asian,96.0,21775533.0,Tan XL,Response to drug,initial,2011-07-20,GCST001169,Response to platinum-based chemotherapy in small cell and non-small cell lung cancers
10168,European,16995.0,21782286.0,Walter S,Biological process,initial,2011-07-20,GCST001166,Aging (time to event)
9632,European,10411.0,21782286.0,Walter S,"Other measurement, Biological process",replication,2011-07-20,GCST001167,Aging (time to death)
4663,European,96.0,21775533.0,Tan XL,Response to drug,initial,2011-07-20,GCST001169,Response to platinum-based chemotherapy in small cell and non-small cell lung cancers
10570,European,25007.0,21782286.0,Walter S,"Other measurement, Biological process",initial,2011-07-20,GCST001167,Aging (time to death)
3260,Asian,3106.0,21814517.0,Noguchi E,Other disease,initial,2011-07-21,GCST001172,Asthma
6642,European,1627.0,21777205.0,Dumitrescu L,"Lipid or lipoprotein measurement, Other measurement",replication,2011-07-21,GCST001170,Lipid traits
198,African,1478.0,21777205.0,Dumitrescu L,"Lipid or lipoprotein measurement, Other measurement",replication,2011-07-21,GCST001170,Lipid traits
3261,Asian,3106.0,21814517.0,Noguchi E,Other disease,replication,2011-07-21,GCST001172,Asthma
4929,European,282.0,21777205.0,Dumitrescu L,"Lipid or lipoprotein measurement, Other measurement",initial,2011-07-21,GCST001170,Lipid traits
12529,Hispanic or Latin American,63.0,21777205.0,Dumitrescu L,"Lipid or lipoprotein measurement, Other measurement",initial,2011-07-21,GCST001170,Lipid traits
12831,Hispanic or Latin American,1443.0,21777205.0,Dumitrescu L,"Lipid or lipoprotein measurement, Other measurement",replication,2011-07-21,GCST001170,Lipid traits
424,African American or Afro-Caribbean,66.0,21777205.0,Dumitrescu L,"Lipid or lipoprotein measurement, Other measurement",initial,2011-07-21,GCST001170,Lipid traits
2703,Asian,1599.0,21799836.0,Cui B,Metabolic disorder,initial,2011-07-22,GCST001173,Type 2 diabetes
3966,Asian,8903.0,21799836.0,Cui B,Metabolic disorder,replication,2011-07-22,GCST001173,Type 2 diabetes
6671,European,1657.0,21785125.0,Traglia M,Other measurement,initial,2011-07-25,GCST001174,Hepcidin levels
6252,European,1168.0,21795503.0,Alkelai A,Neurological disorder,replication,2011-07-27,GCST001176,Schizophrenia
1595,Asian,48.0,21799462.0,Srinivasan Y,Other trait,replication,2011-07-27,GCST001175,Epirubicin-induced leukopenia
13558,Other/Mixed,189.0,21795503.0,Alkelai A,Neurological disorder,initial,2011-07-27,GCST001176,Schizophrenia
1901,Asian,270.0,21799462.0,Srinivasan Y,Other trait,initial,2011-07-27,GCST001175,Epirubicin-induced leukopenia
9403,European,8866.0,21829377.0,Lemaitre RN,Lipid or lipoprotein measurement,initial,2011-07-28,GCST001177,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)
9405,European,8866.0,21829377.0,Lemaitre RN,Lipid or lipoprotein measurement,initial,2011-07-28,GCST001179,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid)
9406,European,8866.0,21829377.0,Lemaitre RN,Lipid or lipoprotein measurement,initial,2011-07-28,GCST001180,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid)
9404,European,8866.0,21829377.0,Lemaitre RN,Lipid or lipoprotein measurement,initial,2011-07-28,GCST001178,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid)
7180,European,2305.0,21801394.0,Genin E,Other disease,initial,2011-07-29,GCST001181,Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)
12878,Hispanic or Latin American,2299.0,21804549.0,Torgerson DG,Other disease,replication,2011-07-31,GCST001182,Asthma
7468,European,2727.0,21804549.0,Torgerson DG,Other disease,replication,2011-07-31,GCST001182,Asthma
7007,European,2088.0,21804549.0,Torgerson DG,Other disease,initial,2011-07-31,GCST001182,Asthma
7355,European,2538.0,21804547.0,Dobbins SE,Cancer,replication,2011-07-31,GCST001184,Meningioma
4355,Asian,30247.0,21804548.0,Hirota T,Other disease,replication,2011-07-31,GCST001183,Asthma
3507,Asian,4836.0,21804548.0,Hirota T,Other disease,initial,2011-07-31,GCST001183,Asthma
6591,European,1563.0,21804547.0,Dobbins SE,Cancer,initial,2011-07-31,GCST001184,Meningioma
971,African American or Afro-Caribbean,2147.0,21804549.0,Torgerson DG,Other disease,replication,2011-07-31,GCST001182,Asthma
12850,Hispanic or Latin American,1688.0,21804549.0,Torgerson DG,Other disease,initial,2011-07-31,GCST001182,Asthma
900,African American or Afro-Caribbean,1612.0,21804549.0,Torgerson DG,Other disease,initial,2011-07-31,GCST001182,Asthma
1739,Asian,149.0,21810746.0,Chantarangsu S,Response to drug,initial,2011-08-01,GCST001186,Nevirapine-induced rash
1858,Asian,233.0,21810746.0,Chantarangsu S,Response to drug,replication,2011-08-01,GCST001186,Nevirapine-induced rash
9324,European,8424.0,21846871.0,Mehta NN,Cardiovascular disease,initial,2011-08-01,GCST001185,Coronary heart disease
6146,European,1054.0,21810643.0,Bakken TE,Other measurement,initial,2011-08-01,GCST001187,Cortical thickness
3773,Asian,6996.0,21846871.0,Mehta NN,Cardiovascular disease,initial,2011-08-01,GCST001185,Coronary heart disease
6638,European,1624.0,21810271.0,Antoni G,"Hematological measurement, Other measurement",initial,2011-08-02,GCST001188,vWF and FVIII levels
5211,European,446.0,21812969.0,Liu X,Neurological disorder,initial,2011-08-03,GCST001189,Parkinson's disease
7864,European,3440.0,21812969.0,Liu X,Neurological disorder,replication,2011-08-03,GCST001189,Parkinson's disease
8202,European,4328.0,21829393.0,Plagnol V,"Other measurement, Metabolic disorder",initial,2011-08-04,GCST004382,Gastric parietal cell autoantibody levels in type 1 diabetes
10290,European,19102.0,21829393.0,Plagnol V,Metabolic disorder,initial,2011-08-04,GCST001191,Type 1 diabetes
7312,European,2506.0,21829393.0,Plagnol V,"Other measurement, Metabolic disorder",initial,2011-08-04,GCST004380,Glutamate decarboxylase autoantibody levels in type 1 diabetes
9237,European,8300.0,21829393.0,Plagnol V,"Other measurement, Metabolic disorder",initial,2011-08-04,GCST004383,Thyroid peroxidase autoantibody levels in type 1 diabetes
1321,African American or Afro-Caribbean,8155.0,21829389.0,Barbalic M,Cardiovascular disease,replication,2011-08-04,GCST001190,Coronary heart disease
1046,African American or Afro-Caribbean,2905.0,21829389.0,Barbalic M,Cardiovascular disease,initial,2011-08-04,GCST001190,Coronary heart disease
7307,European,2498.0,21829393.0,Plagnol V,"Other measurement, Metabolic disorder",initial,2011-08-04,GCST004381,Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes
9650,European,10577.0,21824976.0,Garcia-Closas M,Cancer,initial,2011-08-08,GCST001193,Bladder cancer
4621,European,79.0,21826682.0,Isackson PJ,Response to drug,initial,2011-08-08,GCST001192,Response to statin therapy
7930,European,3583.0,21824976.0,Garcia-Closas M,Cancer,replication,2011-08-08,GCST001193,Bladder cancer
4693,European,109.0,21826682.0,Isackson PJ,Response to drug,replication,2011-08-08,GCST001192,Response to statin therapy
5584,European,670.0,21826061.0,Davies G,Biological process,replication,2011-08-09,GCST001195,Intelligence
1765,Asian,174.0,21826085.0,Tanaka S,Neurological disorder,replication,2011-08-09,GCST001196,Tardive dyskinesia
7895,European,3511.0,21826061.0,Davies G,Biological process,initial,2011-08-09,GCST001195,Intelligence
1702,Asian,122.0,21826085.0,Tanaka S,Neurological disorder,initial,2011-08-09,GCST001196,Tardive dyskinesia
8345,European,4773.0,21827660.0,Yang TH,Cancer,initial,2011-08-09,GCST001194,Glioma
9759,European,11514.0,21833088.0,Sawcer S,Immune system disorder,replication,2011-08-11,GCST001198,Multiple sclerosis
10609,European,26621.0,21833088.0,Sawcer S,Immune system disorder,initial,2011-08-11,GCST001198,Multiple sclerosis
23,African,47.0,21836138.0,Hadchouel A,Other disease,replication,2011-08-11,GCST001197,Bronchopulmonary dysplasia
5040,European,351.0,21836138.0,Hadchouel A,Other disease,replication,2011-08-11,GCST001197,Bronchopulmonary dysplasia
42,African,107.0,21836138.0,Hadchouel A,Other disease,initial,2011-08-11,GCST001197,Bronchopulmonary dysplasia
4670,European,98.0,21836138.0,Hadchouel A,Other disease,initial,2011-08-11,GCST001197,Bronchopulmonary dysplasia
5438,European,572.0,21835309.0,Larsson M,Other measurement,replication,2011-08-12,GCST001199,Iris characteristics
7023,European,2121.0,21835309.0,Larsson M,Other measurement,initial,2011-08-12,GCST001199,Iris characteristics
3231,Asian,2958.0,21841780.0,Chu X,Immune system disorder,initial,2011-08-14,GCST001200,Graves' disease
3814,Asian,7504.0,21841780.0,Chu X,Immune system disorder,replication,2011-08-14,GCST001200,Graves' disease
2240,Asian,700.0,21844665.0,Hu HJ,Immune system disorder,initial,2011-08-16,GCST001203,Rheumatoid arthritis
34,African,83.0,21844884.0,Wheeler HE,Response to drug,initial,2011-08-16,GCST001204,Response to platinum-based chemotherapy (carboplatin)
4758,European,174.0,21844884.0,Wheeler HE,Response to drug,initial,2011-08-16,GCST001201,Response to platinum-based chemotherapy (cisplatin)
4759,European,174.0,21844884.0,Wheeler HE,Response to drug,initial,2011-08-16,GCST001204,Response to platinum-based chemotherapy (carboplatin)
1767,Asian,175.0,21844884.0,Wheeler HE,Response to drug,initial,2011-08-16,GCST001204,Response to platinum-based chemotherapy (carboplatin)
55,African,176.0,21844884.0,Wheeler HE,Response to drug,initial,2011-08-16,GCST001201,Response to platinum-based chemotherapy (cisplatin)
33,African,83.0,21844884.0,Wheeler HE,Response to drug,initial,2011-08-16,GCST001201,Response to platinum-based chemotherapy (cisplatin)
56,African,176.0,21844884.0,Wheeler HE,Response to drug,initial,2011-08-16,GCST001204,Response to platinum-based chemotherapy (carboplatin)
2566,Asian,1289.0,21844665.0,Hu HJ,Immune system disorder,replication,2011-08-16,GCST001203,Rheumatoid arthritis
1766,Asian,175.0,21844884.0,Wheeler HE,Response to drug,initial,2011-08-16,GCST001201,Response to platinum-based chemotherapy (cisplatin)
7570,European,2931.0,21876681.0,Hamza TH,"Neurological disorder, Biological process",replication,2011-08-18,GCST001205,Parkinson's disease (coffee consumption interaction)
7246,European,2389.0,21876681.0,Hamza TH,"Neurological disorder, Biological process",initial,2011-08-18,GCST001205,Parkinson's disease (coffee consumption interaction)
6290,European,1201.0,21886828.0,Wei W,Cardiovascular measurement,initial,2011-08-19,GCST001206,Uric acid levels (SNP x SNP interaction)
8299,European,4641.0,21886828.0,Wei W,Cardiovascular measurement,replication,2011-08-19,GCST001206,Uric acid levels (SNP x SNP interaction)
8945,European,6879.0,21862451.0,Benyamin B,Liver enzyme measurement,initial,2011-08-23,GCST001207,Butyrylcholinesterase levels
6863,European,1912.0,21862451.0,Benyamin B,Liver enzyme measurement,replication,2011-08-23,GCST001207,Butyrylcholinesterase levels
792,African American or Afro-Caribbean,1040.0,21901158.0,Irvin MR,Other trait,initial,2011-08-25,GCST001208,Insulin resistance/response
2604,Asian,1394.0,21866343.0,Ahn MJ,Cancer,replication,2011-08-25,GCST001210,Non-small cell lung cancer
10857,European,35474.0,21871595.0,Day-Williams AG,Other disease,replication,2011-08-25,GCST001209,Osteoarthritis
2405,Asian,942.0,21866343.0,Ahn MJ,Cancer,initial,2011-08-25,GCST001210,Non-small cell lung cancer
9201,European,8071.0,21871595.0,Day-Williams AG,Other disease,initial,2011-08-25,GCST001209,Osteoarthritis
9673,European,10701.0,21873549.0,Strawbridge RJ,Other measurement,initial,2011-08-26,GCST001212,Proinsulin levels
10124,European,16378.0,21873549.0,Strawbridge RJ,Other measurement,replication,2011-08-26,GCST001212,Proinsulin levels
6113,European,1016.0,21876473.0,Lydall GJ,"Other measurement, Neurological disorder",initial,2011-08-26,GCST001211,Alcohol dependence
4288,Asian,20019.0,21874001.0,Kooner JS,Metabolic disorder,initial,2011-08-28,GCST001213,Type 2 diabetes
4409,Asian,38568.0,21874001.0,Kooner JS,Metabolic disorder,replication,2011-08-28,GCST001213,Type 2 diabetes
7796,European,3335.0,21878436.0,Sampietro ML,Cardiovascular disease,replication,2011-08-30,GCST001214,Coronary restenosis
8462,European,5006.0,21878437.0,Mondul AM,Other measurement,initial,2011-08-30,GCST001216,Retinol levels
5860,European,866.0,21878436.0,Sampietro ML,Cardiovascular disease,initial,2011-08-30,GCST001214,Coronary restenosis
10269,European,18716.0,21876539.0,Amin N,"Biological process, Other measurement",initial,2011-08-30,GCST001215,Coffee consumption
6206,European,1124.0,21878437.0,Mondul AM,Other measurement,replication,2011-08-30,GCST001216,Retinol levels
9167,European,7929.0,21876539.0,Amin N,"Biological process, Other measurement",replication,2011-08-30,GCST001215,Coffee consumption
7517,European,2820.0,21886157.0,Suhre K,"Other measurement, Biological process, Lipid or lipoprotein measurement",initial,2011-08-31,GCST001217,Metabolic traits
6489,European,1450.0,21900290.0,Qi Q,Lipid or lipoprotein measurement,initial,2011-09-06,GCST001218,Lp (a) levels
3358,Asian,3837.0,21900946.0,Nakabayashi K,Immune system disorder,initial,2011-09-08,GCST001219,Graves' disease
5861,European,866.0,21900944.0,Shen H,Liver enzyme measurement,initial,2011-09-08,GCST001222,Aspartate aminotransferase levels
7596,European,2994.0,21931568.0,Geller F,Biological process,replication,2011-09-08,GCST001221,Permanent tooth development
4718,European,142.0,21931564.0,Nicholson G,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",initial,2011-09-08,GCST001220,Metabolite levels
2699,Asian,1589.0,21900946.0,Nakabayashi K,Immune system disorder,replication,2011-09-08,GCST001219,Graves' disease
4825,European,202.0,21931564.0,Nicholson G,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",replication,2011-09-08,GCST001220,Metabolite levels
8495,European,5088.0,21931568.0,Geller F,Biological process,initial,2011-09-08,GCST001221,Permanent tooth development
3400,Asian,4128.0,21908515.0,Cai Q,Cancer,initial,2011-09-09,GCST001224,Breast cancer
4354,Asian,29968.0,21908515.0,Cai Q,Cancer,replication,2011-09-09,GCST001224,Breast cancer
4623,European,80.0,21912186.0,Smith AK,Immune system disorder,initial,2011-09-09,GCST001223,Chronic fatigue syndrome
8361,European,4811.0,21896673.0,Chen D,Other measurement,initial,2011-09-10,GCST001225,HPV seropositivity
10576,European,25358.0,21907864.0,Ferreira MA,Other disease,replication,2011-09-10,GCST001226,Asthma
12884,Hispanic or Latin American,2344.0,21896673.0,Chen D,Other measurement,replication,2011-09-10,GCST001225,HPV seropositivity
10752,European,32442.0,21907864.0,Ferreira MA,Other disease,initial,2011-09-10,GCST001226,Asthma
13734,Other/Mixed,687.0,21909108.0,Bis JC,"Other measurement, Cardiovascular measurement, Cardiovascular disease",replication,2011-09-11,GCST001231,Carotid intima media thickness
6261,European,1174.0,21909107.0,LeMaire SA,Cardiovascular disease,replication,2011-09-11,GCST001229,Thoracic aortic aneurysms and dissections
11324,European,69395.0,21909115.0,Ehret GB,Other measurement,initial,2011-09-11,GCST001228,Diastolic blood pressure
11323,European,69395.0,21909115.0,Ehret GB,Other measurement,initial,2011-09-11,GCST001227,Systolic blood pressure
11769,European,133661.0,21909115.0,Ehret GB,Cardiovascular disease,replication,2011-09-11,GCST001238,Hypertension
11359,European,74064.0,21909110.0,Wain LV,"Other measurement, Cardiovascular measurement",initial,2011-09-11,GCST001236,Blood pressure
10722,European,31211.0,21909108.0,Bis JC,"Other measurement, Cardiovascular measurement, Cardiovascular disease",initial,2011-09-11,GCST001231,Carotid intima media thickness
11322,European,69395.0,21909115.0,Ehret GB,Cardiovascular disease,initial,2011-09-11,GCST001238,Hypertension
4129,Asian,12545.0,21909109.0,Kim YJ,Liver enzyme measurement,initial,2011-09-11,GCST001234,Gamma glutamyl transpeptidase
4128,Asian,12545.0,21909109.0,Kim YJ,Lipid or lipoprotein measurement,initial,2011-09-11,GCST001237,HDL cholesterol
4127,Asian,12545.0,21909109.0,Kim YJ,Lipid or lipoprotein measurement,initial,2011-09-11,GCST001230,Triglycerides
11088,European,48607.0,21909110.0,Wain LV,"Other measurement, Cardiovascular measurement",replication,2011-09-11,GCST001235,Blood pressure
11089,European,48607.0,21909110.0,Wain LV,"Other measurement, Cardiovascular measurement",replication,2011-09-11,GCST001236,Blood pressure
4357,Asian,30395.0,21909109.0,Kim YJ,Lipid or lipoprotein measurement,replication,2011-09-11,GCST001230,Triglycerides
4358,Asian,30395.0,21909109.0,Kim YJ,Lipid or lipoprotein measurement,replication,2011-09-11,GCST001237,HDL cholesterol
4359,Asian,30395.0,21909109.0,Kim YJ,Liver enzyme measurement,replication,2011-09-11,GCST001234,Gamma glutamyl transpeptidase
4360,Asian,30395.0,21909109.0,Kim YJ,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",replication,2011-09-11,GCST001233,Metabolite levels
11771,European,133661.0,21909115.0,Ehret GB,Other measurement,replication,2011-09-11,GCST001228,Diastolic blood pressure
11770,European,133661.0,21909115.0,Ehret GB,Other measurement,replication,2011-09-11,GCST001227,Systolic blood pressure
11358,European,74064.0,21909110.0,Wain LV,"Other measurement, Cardiovascular measurement",initial,2011-09-11,GCST001235,Blood pressure
4130,Asian,12545.0,21909109.0,Kim YJ,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",initial,2011-09-11,GCST001233,Metabolite levels
4232,Asian,16280.0,21909106.0,Arakawa S,Neurological disorder,replication,2011-09-11,GCST001232,Age-related macular degeneration
6653,European,1639.0,21909107.0,LeMaire SA,Cardiovascular disease,initial,2011-09-11,GCST001229,Thoracic aortic aneurysms and dissections
3405,Asian,4150.0,21909106.0,Arakawa S,Neurological disorder,initial,2011-09-11,GCST001232,Age-related macular degeneration
2440,Asian,1005.0,21912425.0,Tohkin M,Other disease,initial,2011-09-13,GCST001239,Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)
8589,European,5373.0,21935397.0,Paternoster L,"Metabolic disorder, Body measurement",initial,2011-09-15,GCST001240,Obesity (extreme)
10673,European,29181.0,21935397.0,Paternoster L,"Metabolic disorder, Body measurement",replication,2011-09-15,GCST001240,Obesity (extreme)
10449,European,21856.0,21926974.0,Ripke S,Neurological disorder,initial,2011-09-18,GCST001242,Schizophrenia
10685,European,29839.0,21926974.0,Ripke S,Neurological disorder,replication,2011-09-18,GCST001242,Schizophrenia
10149,European,16731.0,21926972.0,Sklar P,Neurological disorder,initial,2011-09-18,GCST001241,Bipolar disorder
11063,European,46918.0,21926972.0,Sklar P,Neurological disorder,replication,2011-09-18,GCST001241,Bipolar disorder
6691,European,1695.0,21940522.0,Shaffer JR,Digestive system disorder,replication,2011-09-21,GCST001244,Dental caries
6375,European,1305.0,21940522.0,Shaffer JR,Digestive system disorder,initial,2011-09-21,GCST001244,Dental caries
7842,European,3402.0,21957438.0,Meschia JF,Cardiovascular disease,initial,2011-09-21,GCST001243,Stroke
7522,European,2830.0,21926416.0,Amos CI,Cancer,initial,2011-09-22,GCST001245,Melanoma
14020,Other/Mixed,29807.0,21926416.0,Amos CI,Cancer,replication,2011-09-22,GCST001245,Melanoma
9772,European,11683.0,21943158.0,Middelberg RP,"Liver enzyme measurement, Cardiovascular measurement, Other measurement, Other disease, Lipid or lipoprotein measurement, Inflammatory measurement",initial,2011-09-24,GCST001247,Cardiovascular disease risk factors
10991,European,41735.0,21946351.0,Stacey SN,Cancer,initial,2011-09-25,GCST001250,Basal cell carcinoma
14010,Other/Mixed,17607.0,21946351.0,Stacey SN,Cancer,replication,2011-09-25,GCST001250,Basal cell carcinoma
11053,European,46411.0,21946350.0,Soler Artigas M,Other measurement,replication,2011-09-25,GCST001251,Pulmonary function
11052,European,46411.0,21946350.0,Soler Artigas M,Other measurement,replication,2011-09-25,GCST001248,Pulmonary function
2716,Asian,1627.0,21947420.0,Lei SF,Other measurement,initial,2011-09-25,GCST001249,Spine bone size
6736,European,1728.0,21947420.0,Lei SF,Other measurement,replication,2011-09-25,GCST001249,Spine bone size
11081,European,48201.0,21946350.0,Soler Artigas M,Other measurement,initial,2011-09-25,GCST001248,Pulmonary function
11082,European,48201.0,21946350.0,Soler Artigas M,Other measurement,initial,2011-09-25,GCST001251,Pulmonary function
5961,European,935.0,21991891.0,Tantisira KG,Response to drug,replication,2011-09-26,GCST001252,Asthma treatment response
6253,European,1169.0,21991891.0,Tantisira KG,Response to drug,initial,2011-09-26,GCST001252,Asthma treatment response
7423,European,2652.0,21980494.0,Germain M,Cardiovascular disease,initial,2011-09-27,GCST001253,Venous thromboembolism
7563,European,2927.0,21956439.0,Zuo L,"Other measurement, Neurological disorder",initial,2011-09-28,GCST001254,Alcohol dependence
821,African American or Afro-Caribbean,1189.0,21956439.0,Zuo L,"Other measurement, Neurological disorder",initial,2011-09-28,GCST001254,Alcohol dependence
10619,European,26890.0,21980299.0,Bradfield JP,Metabolic disorder,initial,2011-09-29,GCST001255,Type 1 diabetes
7817,European,3360.0,21980299.0,Bradfield JP,Metabolic disorder,replication,2011-09-29,GCST001255,Type 1 diabetes
6448,European,1388.0,21980348.0,Fox AA,Cardiovascular disease,replication,2011-09-30,GCST001256,Postoperative ventricular dysfunction
6287,European,1199.0,21980348.0,Fox AA,Cardiovascular disease,initial,2011-09-30,GCST001256,Postoperative ventricular dysfunction
3189,Asian,2798.0,22004137.0,Liu L,"Digestive system disorder, Other measurement",initial,2011-10-01,GCST001257,Hepatitis B
10999,European,42247.0,21964575.0,Rafnar T,Cancer,initial,2011-10-02,GCST001258,Ovarian cancer
4586,European,52.0,21961650.0,Squassina A,"Response to drug, Neurological disorder",initial,2011-10-03,GCST001259,Response to lithium treatment in bipolar disorder
4727,European,152.0,21961650.0,Squassina A,"Response to drug, Neurological disorder",replication,2011-10-03,GCST001259,Response to lithium treatment in bipolar disorder
3334,Asian,3648.0,21971053.0,Takeuchi F,Cardiovascular disease,initial,2011-10-05,GCST001260,Coronary heart disease
4010,Asian,9928.0,21971053.0,Takeuchi F,Cardiovascular disease,replication,2011-10-05,GCST001260,Coronary heart disease
7914,European,3546.0,21979947.0,Li X,"Other measurement, Neurological disorder",initial,2011-10-06,GCST001261,Corneal structure
6208,European,1129.0,21979947.0,Li X,"Other measurement, Neurological disorder",replication,2011-10-06,GCST001261,Corneal structure
8540,European,5244.0,21977987.0,Trompet S,"Lipid or lipoprotein measurement, Other measurement",initial,2011-10-06,GCST001262,LDL cholesterol
8626,European,5491.0,21998597.0,Ohlsson C,Other measurement,replication,2011-10-06,GCST001264,Testosterone levels
1435,African American or Afro-Caribbean,16436.0,21998595.0,N'Diaye A,"Other measurement, Body measurement",replication,2011-10-06,GCST001263,Height
14013,Other/Mixed,20427.0,21998595.0,N'Diaye A,"Other measurement, Body measurement",initial,2011-10-06,GCST001263,Height
9411,European,8938.0,21998597.0,Ohlsson C,Other measurement,initial,2011-10-06,GCST001264,Testosterone levels
6846,European,1879.0,21981779.0,Denny JC,Other disease,replication,2011-10-07,GCST001265,Hypothyroidism
8824,European,6370.0,21981779.0,Denny JC,Other disease,initial,2011-10-07,GCST001265,Hypothyroidism
8863,European,6555.0,21983785.0,Macgregor S,Cancer,initial,2011-10-09,GCST001266,Melanoma
9633,European,10422.0,21983787.0,Barrett JH,Cancer,initial,2011-10-09,GCST001267,Melanoma
10979,European,40968.0,21983786.0,Sulem P,Metabolic disorder,initial,2011-10-09,GCST001268,Gout
10358,European,20337.0,21983785.0,Macgregor S,Cancer,replication,2011-10-09,GCST001266,Melanoma
10060,European,15506.0,21983786.0,Sulem P,Cardiovascular measurement,initial,2011-10-09,GCST001269,Serum uric acid levels
9875,European,13000.0,21983787.0,Barrett JH,Cancer,replication,2011-10-09,GCST001267,Melanoma
6031,European,977.0,21996601.0,Das K,"Other measurement, Cardiovascular measurement",initial,2011-10-11,GCST001270,Blood pressure
13655,Other/Mixed,409.0,21990027.0,Drago A,Response to drug,initial,2011-10-11,GCST001271,Response to antipsychotic therapy (extrapyramidal side effects)
7028,European,2133.0,21993531.0,Kuparinen T,Biological process,initial,2011-10-13,GCST001272,Cytomegalovirus antibody response
8000,European,3781.0,22003120.0,Burdon KP,"Other measurement, Neurological disorder",initial,2011-10-14,GCST001274,Corneal structure
6381,European,1317.0,22003120.0,Burdon KP,"Other measurement, Neurological disorder",replication,2011-10-14,GCST001274,Corneal structure
9819,European,12126.0,22003152.0,Grallert H,Lipid or lipoprotein measurement,initial,2011-10-14,GCST001273,Lipoprotein-associated phospholipase A2 activity and mass
3926,Asian,8739.0,22001757.0,Chambers JC,Liver enzyme measurement,initial,2011-10-16,GCST001275,Liver enzyme levels (alanine transaminase)
11131,European,52350.0,22001757.0,Chambers JC,Liver enzyme measurement,initial,2011-10-16,GCST001276,Liver enzyme levels (alkaline phosphatase)
3927,Asian,8739.0,22001757.0,Chambers JC,Liver enzyme measurement,initial,2011-10-16,GCST001276,Liver enzyme levels (alkaline phosphatase)
3485,Asian,4671.0,22001756.0,Khor CC,Other disease,replication,2011-10-16,GCST001278,Dengue shock syndrome
3386,Asian,4026.0,22001756.0,Khor CC,Other disease,initial,2011-10-16,GCST001278,Dengue shock syndrome
11130,European,52350.0,22001757.0,Chambers JC,Liver enzyme measurement,initial,2011-10-16,GCST001275,Liver enzyme levels (alanine transaminase)
11132,European,52350.0,22001757.0,Chambers JC,Liver enzyme measurement,initial,2011-10-16,GCST001277,Liver enzyme levels (gamma-glutamyl transferase)
3928,Asian,8739.0,22001757.0,Chambers JC,Liver enzyme measurement,initial,2011-10-16,GCST001277,Liver enzyme levels (gamma-glutamyl transferase)
2621,Asian,1443.0,22004975.0,Li R,Immune system disorder,replication,2011-10-17,GCST001279,Systemic lupus erythematosus
3830,Asian,7674.0,22004975.0,Li R,Immune system disorder,replication,2011-10-17,GCST001279,Systemic lupus erythematosus
3191,Asian,2805.0,22004975.0,Li R,Immune system disorder,initial,2011-10-17,GCST001279,Systemic lupus erythematosus
2523,Asian,1200.0,21989058.0,Qin Y,Other disease,replication,2011-10-18,GCST001284,Premature ovarian failure
3950,Asian,8842.0,22006218.0,Yoon D,Biological process,initial,2011-10-18,GCST001286,Smoking behavior
6277,European,1190.0,22005931.0,Kamboh MI,"Neurological disorder, Other measurement",initial,2011-10-18,GCST001280,Alzheimer's disease (age of onset)
8969,European,6944.0,22005930.0,Hollingworth P,"Neurological disorder, Other trait",initial,2011-10-18,GCST001285,Psychosis and Alzheimer's disease
2564,Asian,1286.0,21989058.0,Qin Y,Other disease,initial,2011-10-18,GCST001284,Premature ovarian failure
864,African American or Afro-Caribbean,1366.0,22006218.0,Yoon D,Biological process,replication,2011-10-18,GCST001286,Smoking behavior
7893,European,3501.0,22004471.0,Frank J,"Other measurement, Neurological disorder",initial,2011-10-18,GCST001281,Alcohol dependence
372,African American or Afro-Caribbean,12.0,22005930.0,Hollingworth P,"Neurological disorder, Other trait",initial,2011-10-18,GCST001282,Psychosis in Alzheimer's disease
373,African American or Afro-Caribbean,12.0,22005930.0,Hollingworth P,"Neurological disorder, Other trait",initial,2011-10-18,GCST001285,Psychosis and Alzheimer's disease
13350,Other/Mixed,2.0,22005930.0,Hollingworth P,"Neurological disorder, Other trait",initial,2011-10-18,GCST001282,Psychosis in Alzheimer's disease
13351,Other/Mixed,2.0,22005930.0,Hollingworth P,"Neurological disorder, Other trait",initial,2011-10-18,GCST001285,Psychosis and Alzheimer's disease
9826,European,12277.0,22010048.0,Wu X,Cancer,replication,2011-10-18,GCST001283,Renal cell carcinoma
5585,European,671.0,22006218.0,Yoon D,Biological process,replication,2011-10-18,GCST001286,Smoking behavior
7253,European,2410.0,22010048.0,Wu X,Cancer,initial,2011-10-18,GCST001283,Renal cell carcinoma
9148,European,7860.0,22833195.0,Terracciano A,Other measurement,initial,2011-10-18,GCST006796,Excitement-seeking behaviour
6987,European,2062.0,22833195.0,Terracciano A,Other measurement,replication,2011-10-18,GCST006796,Excitement-seeking behaviour
6943,European,2020.0,22005930.0,Hollingworth P,"Neurological disorder, Other trait",initial,2011-10-18,GCST001282,Psychosis in Alzheimer's disease
8213,European,4374.0,22012869.0,Hinney A,Neurological disorder,replication,2011-10-19,GCST001287,Attention deficit hyperactivity disorder
5478,European,598.0,22013104.0,Melka MG,"Other measurement, Liver enzyme measurement, Body measurement, Cardiovascular measurement, Inflammatory measurement, Lipid or lipoprotein measurement, Biological process, Metabolic disorder",initial,2011-10-19,GCST001288,Obesity-related traits
6792,European,1795.0,22012869.0,Hinney A,Neurological disorder,initial,2011-10-19,GCST001287,Attention deficit hyperactivity disorder
10743,European,32225.0,22028671.0,Surakka I,"Lipid or lipoprotein measurement, Other measurement",initial,2011-10-20,GCST001289,Lipid traits
9756,European,11509.0,22028671.0,Surakka I,"Lipid or lipoprotein measurement, Other measurement",replication,2011-10-20,GCST001289,Lipid traits
13998,Other/Mixed,11163.0,22028671.0,Surakka I,"Lipid or lipoprotein measurement, Other measurement",replication,2011-10-20,GCST001289,Lipid traits
1320,African American or Afro-Caribbean,8149.0,22021425.0,Carty CL,"Other measurement, Body measurement",initial,2011-10-21,GCST001290,Height
1457,African American or Afro-Caribbean,20809.0,22021425.0,Carty CL,"Other measurement, Body measurement",replication,2011-10-21,GCST001290,Height
3707,Asian,6287.0,22019778.0,Zhang F,Neurological disorder,initial,2011-10-23,GCST001292,Leprosy
3109,Asian,2506.0,22019779.0,Takahashi Y,Other disease,initial,2011-10-23,GCST001293,Scoliosis
4031,Asian,10149.0,22019779.0,Takahashi Y,Other disease,replication,2011-10-23,GCST001293,Scoliosis
3909,Asian,8600.0,22019778.0,Zhang F,Neurological disorder,replication,2011-10-23,GCST001292,Leprosy
13883,Other/Mixed,1772.0,22029572.0,Simonson MA,"Liver enzyme measurement, Cardiovascular measurement, Other measurement, Other disease, Lipid or lipoprotein measurement, Inflammatory measurement",initial,2011-10-26,GCST001294,Cardiovascular disease risk factors
5321,European,501.0,22030708.0,Menke A,"Biological process, Other measurement",replication,2011-10-26,GCST001296,Suicidal ideation
5102,European,397.0,22030708.0,Menke A,"Biological process, Other measurement",initial,2011-10-26,GCST001296,Suicidal ideation
7607,European,3012.0,22027810.0,Forstbauer LM,Other disease,replication,2011-10-26,GCST001295,Alopecia areata
6447,European,1385.0,22027810.0,Forstbauer LM,Other disease,initial,2011-10-26,GCST001295,Alopecia areata
6286,European,1198.0,22032556.0,Brockschmidt FF,"Other measurement, Other disease",initial,2011-10-27,GCST001297,Male-pattern baldness
5507,European,612.0,22032556.0,Brockschmidt FF,"Other measurement, Other disease",replication,2011-10-27,GCST001297,Male-pattern baldness
4001,Asian,9630.0,22037552.0,Yue WH,Neurological disorder,replication,2011-10-30,GCST001299,Schizophrenia
199,African,1487.0,22037903.0,Crosslin DR,"Hematological measurement, Inflammatory measurement",initial,2011-10-30,GCST001302,White blood cell count
10297,European,19193.0,22037553.0,Haiman CA,Cancer,replication,2011-10-30,GCST001298,Breast cancer
3967,Asian,8922.0,22037555.0,Shi Y,Neurological disorder,replication,2011-10-30,GCST001301,Schizophrenia
1150,African American or Afro-Caribbean,3749.0,22037553.0,Haiman CA,Cancer,initial,2011-10-30,GCST001298,Breast cancer
3066,Asian,2345.0,22037552.0,Yue WH,Neurological disorder,initial,2011-10-30,GCST001299,Schizophrenia
3278,Asian,3279.0,22037551.0,Shi Y,Cancer,initial,2011-10-30,GCST001300,Gastric cancer
4036,Asian,10218.0,22037555.0,Shi Y,Neurological disorder,initial,2011-10-30,GCST001301,Schizophrenia
9815,European,12046.0,22037903.0,Crosslin DR,"Hematological measurement, Inflammatory measurement",initial,2011-10-30,GCST001302,White blood cell count
8592,European,5388.0,22037553.0,Haiman CA,Cancer,initial,2011-10-30,GCST001298,Breast cancer
3759,Asian,6897.0,22037551.0,Shi Y,Cancer,replication,2011-10-30,GCST001300,Gastric cancer
5096,European,395.0,22051697.0,Du R,Other disease,initial,2011-11-01,GCST001309,Asthma
574,African American or Afro-Caribbean,288.0,22041458.0,Clark SL,"Response to drug, Other trait",initial,2011-11-01,GCST001308,Response to anti-depressant treatment in major depressive disorder
9872,European,12898.0,22036096.0,Ramasamy A,Immune system disorder,initial,2011-11-01,GCST001310,Allergic rhinitis
12680,Hispanic or Latin American,584.0,22051697.0,Du R,Other disease,replication,2011-11-01,GCST001309,Asthma
9847,European,12526.0,22010049.0,Middelberg RP,Liver enzyme measurement,initial,2011-11-01,GCST001307,Gamma glutamyl transferase levels
7511,European,2809.0,22044751.0,Foster MC,Other measurement,initial,2011-11-01,GCST001304,Renal sinus fat
9831,European,12347.0,22036096.0,Ramasamy A,Immune system disorder,initial,2011-11-01,GCST001303,IgE grass sensitization
13658,Other/Mixed,418.0,22295569.0,Karunas AS,Other disease,replication,2011-11-01,GCST001306,Asthma
6235,European,1151.0,22041458.0,Clark SL,"Response to drug, Other trait",initial,2011-11-01,GCST001308,Response to anti-depressant treatment in major depressive disorder
13729,Other/Mixed,678.0,22295569.0,Karunas AS,Other disease,initial,2011-11-01,GCST001306,Asthma
6589,European,1562.0,22054870.0,De Jager PL,"Other trait, Biological process",replication,2011-11-03,GCST001311,Cognitive decline
5702,European,749.0,22054870.0,De Jager PL,"Other trait, Biological process",initial,2011-11-03,GCST001311,Cognitive decline
13762,Other/Mixed,717.0,22054870.0,De Jager PL,"Other trait, Biological process",replication,2011-11-03,GCST001311,Cognitive decline
9013,European,7172.0,22055160.0,Bown MJ,Cardiovascular disease,initial,2011-11-04,GCST001312,Abdominal aortic aneurysm
10963,European,40011.0,22055160.0,Bown MJ,Cardiovascular disease,replication,2011-11-04,GCST001312,Abdominal aortic aneurysm
5875,European,874.0,22064162.0,Edwards AC,Neurological disorder,initial,2011-11-05,GCST001313,Depression and alcohol dependence
10506,European,23649.0,22057235.0,Trynka G,Immune system disorder,initial,2011-11-06,GCST005523,Celiac disease
2186,Asian,620.0,22057235.0,Trynka G,Immune system disorder,initial,2011-11-06,GCST005523,Celiac disease
7159,European,2286.0,22087292.0,Sun L,Other measurement,replication,2011-11-07,GCST001315,Femoral neck bone geometry
2717,Asian,1627.0,22087292.0,Sun L,Other measurement,initial,2011-11-07,GCST001315,Femoral neck bone geometry
3282,Asian,3310.0,22065538.0,Morisaki H,Other measurement,initial,2011-11-07,GCST001314,Adiponectin levels
10373,European,20634.0,22068335.0,Mitchell GF,Cardiovascular measurement,initial,2011-11-08,GCST001317,Aortic stiffness
9141,European,7809.0,22075330.0,Granada M,Other measurement,replication,2011-11-08,GCST001316,IgE levels
8935,European,6819.0,22075330.0,Granada M,Other measurement,initial,2011-11-08,GCST001316,IgE levels
8576,European,5306.0,22068335.0,Mitchell GF,Cardiovascular measurement,replication,2011-11-08,GCST001317,Aortic stiffness
7417,European,2647.0,22075249.0,Tang WH,Other measurement,initial,2011-11-10,GCST001318,Serum ceruloplasmin levels
6978,European,2050.0,22075249.0,Tang WH,Other measurement,replication,2011-11-10,GCST001318,Serum ceruloplasmin levels
5802,European,825.0,22072270.0,Wang KS,Neurological disorder,replication,2011-11-11,GCST001319,Alcohol withdrawal symptoms
8598,European,5421.0,22080838.0,Cho MH,Other disease,initial,2011-11-11,GCST001321,Chronic obstructive pulmonary disease
8207,European,4338.0,22076464.0,Ellinghaus E,Cancer,replication,2011-11-11,GCST001320,Acute lymphoblastic leukemia (childhood)
5901,European,893.0,22076464.0,Ellinghaus E,Cancer,initial,2011-11-11,GCST001320,Acute lymphoblastic leukemia (childhood)
5865,European,869.0,22072270.0,Wang KS,Neurological disorder,initial,2011-11-11,GCST001319,Alcohol withdrawal symptoms
6893,European,1954.0,22081228.0,Khor CC,Immune system disorder,replication,2011-11-13,GCST001322,Kawasaki disease
13654,Other/Mixed,405.0,22081228.0,Khor CC,Immune system disorder,replication,2011-11-13,GCST001322,Kawasaki disease
8882,European,6657.0,22081228.0,Khor CC,Immune system disorder,initial,2011-11-13,GCST001322,Kawasaki disease
3125,Asian,2540.0,22081228.0,Khor CC,Immune system disorder,replication,2011-11-13,GCST001322,Kawasaki disease
5788,European,822.0,22833209.0,Hu X,"Other measurement, Other trait",initial,2011-11-15,GCST004371,Rate of cognitive decline in mild cognitive impairment (time interaction)
7973,European,3708.0,22086417.0,Cozen W,Cancer,initial,2011-11-15,GCST001323,Nodular sclerosis Hodgkin lymphoma
4998,European,327.0,22086417.0,Cozen W,Cancer,replication,2011-11-15,GCST001323,Nodular sclerosis Hodgkin lymphoma
690,African American or Afro-Caribbean,619.0,22085899.0,Chen G,Other measurement,initial,2011-11-16,GCST001324,Bilirubin levels
5632,European,707.0,22095909.0,Lange CM,Digestive system disorder,initial,2011-11-16,GCST001325,Response to hepatitis C treatment
8355,European,4805.0,22101970.0,Kho AN,Metabolic disorder,initial,2011-11-19,GCST001326,Type 2 diabetes
908,African American or Afro-Caribbean,1683.0,22101970.0,Kho AN,Metabolic disorder,initial,2011-11-19,GCST001326,Type 2 diabetes
6158,European,1073.0,22105620.0,Papassotiropoulos A,Other measurement,initial,2011-11-22,GCST001327,Memory performance
8761,European,6095.0,22116812.0,Schrijvers EM,Cardiovascular disease,replication,2011-11-23,GCST001328,Vascular dementia
8666,European,5700.0,22116812.0,Schrijvers EM,Cardiovascular disease,initial,2011-11-23,GCST001328,Vascular dementia
530,African American or Afro-Caribbean,200.0,22116950.0,Schuh-Huerta SM,Other measurement,initial,2011-11-24,GCST001330,Ovarian reserve
3301,Asian,3451.0,22116939.0,Guo Y,Neurological disorder,initial,2011-11-24,GCST001329,Epilepsy
4874,European,232.0,22116950.0,Schuh-Huerta SM,Other measurement,initial,2011-11-24,GCST001330,Ovarian reserve
2468,Asian,1080.0,22116939.0,Guo Y,Neurological disorder,replication,2011-11-24,GCST001329,Epilepsy
6193,European,1096.0,22120009.0,Broderick P,Cancer,replication,2011-11-27,GCST001331,Multiple myeloma
9099,European,7578.0,22120009.0,Broderick P,Cancer,initial,2011-11-27,GCST001331,Multiple myeloma
1774,Asian,182.0,22118420.0,Datta S,Other measurement,initial,2011-11-28,GCST001333,Bilirubin levels
5621,European,700.0,22126837.0,LeBlanc M,"Biological process, Other measurement",initial,2011-11-28,GCST001332,Cognitive function
4573,European,42.0,22137330.0,Sanchez-Juan P,Neurological disorder,replication,2011-11-30,GCST001334,Creutzfeldt-Jakob disease (variant)
12943,Hispanic or Latin American,3468.0,22131368.0,Chen CT,Other measurement,initial,2011-11-30,GCST001336,Menarche and menopause (age at onset)
11091,European,48666.0,22139419.0,Gieger C,Hematological measurement,initial,2011-11-30,GCST001337,Platelet count
10281,European,18838.0,22139419.0,Gieger C,Hematological measurement,replication,2011-11-30,GCST001337,Platelet count
6619,European,1597.0,22137330.0,Sanchez-Juan P,Neurological disorder,initial,2011-11-30,GCST001334,Creutzfeldt-Jakob disease (variant)
10267,European,18600.0,22139419.0,Gieger C,Hematological measurement,initial,2011-11-30,GCST001335,Mean platelet volume
10280,European,18838.0,22139419.0,Gieger C,Hematological measurement,replication,2011-11-30,GCST001335,Mean platelet volume
2978,Asian,2139.0,22144915.0,Fan Q,"Neurological disorder, Other trait",replication,2011-12-01,GCST001339,Corneal astigmatism
2971,Asian,2120.0,22144915.0,Fan Q,"Neurological disorder, Other trait",replication,2011-12-01,GCST001339,Corneal astigmatism
778,African American or Afro-Caribbean,1009.0,22159054.0,Logue MW,Neurological disorder,initial,2011-12-01,GCST001342,Alzheimer's disease
89,African,311.0,22130093.0,Nam RK,Cancer,replication,2011-12-01,GCST001338,Prostate cancer
1781,Asian,189.0,22130093.0,Nam RK,Cancer,replication,2011-12-01,GCST001338,Prostate cancer
4800,European,192.0,21897333.0,Irvin MR,"Body measurement, Other disease",initial,2011-12-01,GCST001343,Fat distribution (HIV)
3031,Asian,2238.0,22144915.0,Fan Q,"Neurological disorder, Other trait",initial,2011-12-01,GCST001339,Corneal astigmatism
2932,Asian,2016.0,22144915.0,Fan Q,"Neurological disorder, Other trait",initial,2011-12-01,GCST001339,Corneal astigmatism
4615,European,76.0,22105264.0,Allen-Brady K,Other disease,replication,2011-12-01,GCST001340,Pelvic organ prolapse
13514,Other/Mixed,129.0,22130093.0,Nam RK,Cancer,replication,2011-12-01,GCST001338,Prostate cancer
7633,European,3091.0,22105264.0,Allen-Brady K,Other disease,initial,2011-12-01,GCST001340,Pelvic organ prolapse
10214,European,17698.0,22190364.0,Patsopoulos NA,Immune system disorder,initial,2011-12-01,GCST001341,Multiple sclerosis
7512,European,2810.0,22130093.0,Nam RK,Cancer,replication,2011-12-01,GCST001338,Prostate cancer
5586,European,671.0,22140272.0,Dalgaard MD,Other disease,replication,2011-12-03,GCST001344,Testicular dysgenesis syndrome
5937,European,927.0,22140272.0,Dalgaard MD,Other disease,initial,2011-12-03,GCST001344,Testicular dysgenesis syndrome
3595,Asian,5596.0,22138694.0,Lin Z,Immune system disorder,replication,2011-12-04,GCST001345,Ankylosing spondylitis
3687,Asian,6068.0,22138694.0,Lin Z,Immune system disorder,initial,2011-12-04,GCST001345,Ankylosing spondylitis
9595,European,9961.0,22144573.0,O'Donnell CJ,Other trait,initial,2011-12-05,GCST001347,Coronary artery calcification
4955,European,294.0,22142827.0,Innocenti F,"Response to drug, Cancer",initial,2011-12-05,GCST001346,Response to gemcitabine in pancreatic cancer
8748,European,6032.0,22144573.0,O'Donnell CJ,Other trait,replication,2011-12-05,GCST001347,Coronary artery calcification
1788,Asian,192.0,22174901.0,Chan KY,Cancer,initial,2011-12-08,GCST001348,Hepatocellular carcinoma
2547,Asian,1228.0,22174901.0,Chan KY,Cancer,replication,2011-12-08,GCST001348,Hepatocellular carcinoma
7394,European,2601.0,22156575.0,Paus T,Body measurement,replication,2011-12-09,GCST001349,Brain development
5425,European,557.0,22156575.0,Paus T,Body measurement,initial,2011-12-09,GCST001349,Brain development
3234,Asian,2972.0,22158540.0,Wu C,Cancer,initial,2011-12-11,GCST001350,Pancreatic cancer
2812,Asian,1783.0,22158537.0,Cho YS,Metabolic disorder,initial,2011-12-11,GCST001351,Type 2 diabetes
4388,Asian,35873.0,22158537.0,Cho YS,Metabolic disorder,replication,2011-12-11,GCST001351,Type 2 diabetes
3581,Asian,5480.0,22158540.0,Wu C,Cancer,replication,2011-12-11,GCST001350,Pancreatic cancer
2939,Asian,2034.0,22158537.0,Cho YS,Metabolic disorder,initial,2011-12-11,GCST001351,Type 2 diabetes
4210,Asian,15000.0,22158537.0,Cho YS,Metabolic disorder,initial,2011-12-11,GCST001351,Type 2 diabetes
111,African,496.0,22174851.0,Lingappa JR,"Biological process, Other measurement, Other disease",initial,2011-12-12,GCST001352,HIV-1 viral setpoint
141,African,798.0,22174851.0,Lingappa JR,"Immune system disorder, Other disease",initial,2011-12-12,GCST001353,HIV-1 susceptibility
9380,European,8716.0,22170493.0,Ellinghaus E,Immune system disorder,replication,2011-12-15,GCST001355,Psoriatic arthritis
8066,European,3967.0,22170493.0,Ellinghaus E,Immune system disorder,initial,2011-12-15,GCST001355,Psoriatic arthritis
7821,European,3367.0,21908519.0,Huffman JE,Other measurement,initial,2011-12-15,GCST005046,N-glycan levels
5252,European,472.0,22174390.0,Rankinen T,Cardiovascular measurement,initial,2011-12-15,GCST001354,Heart rate variability traits
1621,Asian,62.0,22179738.0,Lai HM,Metabolic disorder,initial,2011-12-16,GCST001356,Gout
1870,Asian,240.0,22180457.0,Kiyotani K,Response to drug,initial,2011-12-16,GCST001357,Response to tamoxifen in breast cancer
1827,Asian,222.0,22180457.0,Kiyotani K,Response to drug,replication,2011-12-16,GCST001357,Response to tamoxifen in breast cancer
8025,European,3843.0,22182935.0,Chen DT,Neurological disorder,replication,2011-12-20,GCST001358,Bipolar disorder
9863,European,12755.0,22182935.0,Chen DT,Neurological disorder,initial,2011-12-20,GCST001358,Bipolar disorder
2927,Asian,2000.0,22182935.0,Chen DT,Neurological disorder,initial,2011-12-20,GCST001358,Bipolar disorder
2457,Asian,1045.0,22188591.0,Anantharaman R,Other disease,replication,2011-12-21,GCST001360,Asthma
6950,European,2034.0,22205951.0,Kerner B,Neurological disorder,initial,2011-12-21,GCST001359,Bipolar disorder
2430,Asian,980.0,22188591.0,Anantharaman R,Other disease,initial,2011-12-21,GCST001360,Asthma
10990,European,41692.0,22199011.0,Murabito JM,Cardiovascular measurement,initial,2011-12-23,GCST001361,Ankle-brachial index
10148,European,16717.0,22199011.0,Murabito JM,Cardiovascular measurement,replication,2011-12-23,GCST001361,Ankle-brachial index
3697,Asian,6167.0,22197929.0,Yu XQ,Other disease,replication,2011-12-25,GCST001364,IgA nephropathy
10593,European,26171.0,22197932.0,Paternoster L,Immune system disorder,initial,2011-12-25,GCST001363,Atopic dermatitis
10573,European,25252.0,22197932.0,Paternoster L,Immune system disorder,replication,2011-12-25,GCST001363,Atopic dermatitis
3144,Asian,2638.0,22197933.0,Hu Z,Other disease,initial,2011-12-25,GCST001362,Non-obstructive azoospermia
3681,Asian,6023.0,22197933.0,Hu Z,Other disease,replication,2011-12-25,GCST001362,Non-obstructive azoospermia
3633,Asian,5704.0,22197929.0,Yu XQ,Other disease,initial,2011-12-25,GCST001364,IgA nephropathy
5103,European,397.0,22216198.0,Athanasiadis G,"Other measurement, Hematological measurement",initial,2011-12-28,GCST001365,Anticoagulant levels
706,African American or Afro-Caribbean,704.0,22205395.0,Tekola Ayele F,Inflammatory measurement,initial,2011-12-29,GCST006103,Interleukin-6 levels
707,African American or Afro-Caribbean,706.0,22205395.0,Tekola Ayele F,Inflammatory measurement,initial,2011-12-29,GCST006104,Interleukin-1-receptor antagonist levels
705,African American or Afro-Caribbean,704.0,22205395.0,Tekola Ayele F,Inflammatory measurement,initial,2011-12-29,GCST006102,Interleukin-10 levels
100,African,425.0,22205395.0,Tekola Ayele F,Inflammatory measurement,replication,2011-12-29,GCST006102,Interleukin-10 levels
9031,European,7296.0,22210626.0,Mead S,Neurological disorder,initial,2011-12-30,GCST001366,Prion diseases
2636,Asian,1496.0,22171074.0,Tan A,Lipid or lipoprotein measurement,replication,2011-12-30,GCST001367,Triglycerides
13696,Other/Mixed,576.0,22210626.0,Mead S,Neurological disorder,initial,2011-12-30,GCST001366,Prion diseases
2913,Asian,1999.0,22171074.0,Tan A,Lipid or lipoprotein measurement,initial,2011-12-30,GCST001367,Triglycerides
441,African American or Afro-Caribbean,82.0,22864933.0,O'Donnell PH,Response to drug,initial,2012-01-03,GCST001368,Capecitabine sensitivity
53,African,173.0,22864933.0,O'Donnell PH,Response to drug,initial,2012-01-03,GCST001368,Capecitabine sensitivity
1643,Asian,84.0,22864933.0,O'Donnell PH,Response to drug,initial,2012-01-03,GCST001368,Capecitabine sensitivity
4742,European,164.0,22864933.0,O'Donnell PH,Response to drug,initial,2012-01-03,GCST001368,Capecitabine sensitivity
936,African American or Afro-Caribbean,1994.0,22238593.0,Palmer ND,Metabolic disorder,initial,2012-01-04,GCST001369,Type 2 diabetes
1191,African American or Afro-Caribbean,4455.0,22238593.0,Palmer ND,Metabolic disorder,replication,2012-01-04,GCST001369,Type 2 diabetes
9500,European,9515.0,22219177.0,Tao S,"Cancer, Other measurement",initial,2012-01-04,GCST001370,Prostate cancer (SNP x SNP interaction)
6187,European,1092.0,22228203.0,Aslibekyan S,"Other measurement, Inflammatory measurement, Response to drug",initial,2012-01-05,GCST001371,Inflammatory biomarkers
5712,European,757.0,22245343.0,Meda SA,Neurological disorder,initial,2012-01-08,GCST001372,Alzheimer's disease
2904,Asian,1950.0,22232737.0,Shu XO,"Other measurement, Cancer",initial,2012-01-09,GCST001373,Breast cancer (survival)
6365,European,1300.0,22229870.0,Karns R,Cardiovascular measurement,initial,2012-01-09,GCST001374,Uric acid levels
3408,Asian,4160.0,22232737.0,Shu XO,"Other measurement, Cancer",replication,2012-01-09,GCST001373,Breast cancer (survival)
2751,Asian,1710.0,22233651.0,Kwak SH,Metabolic disorder,initial,2012-01-10,GCST001375,Diabetes (gestational)
2753,Asian,1714.0,22233651.0,Kwak SH,Metabolic disorder,replication,2012-01-10,GCST001375,Diabetes (gestational)
5911,European,904.0,22247754.0,Murray SS,Cardiovascular disease,initial,2012-01-11,GCST001376,Life threatening arrhythmia
2498,Asian,1140.0,22239941.0,Png E,"Other disease, Other measurement",replication,2012-01-13,GCST001377,Tuberculosis
1830,Asian,223.0,22239941.0,Png E,"Other disease, Other measurement",initial,2012-01-13,GCST001377,Tuberculosis
7942,European,3616.0,22239941.0,Png E,"Other disease, Other measurement",replication,2012-01-13,GCST001377,Tuberculosis
5995,European,951.0,22443383.0,Oudot-Mellakh T,"Hematological measurement, Inflammatory measurement, Other measurement, Cardiovascular measurement, Biological process",initial,2012-01-16,GCST001378,Hemostatic factors and hematological phenotypes
4951,European,292.0,22279548.0,Sebastiani P,Other measurement,replication,2012-01-18,GCST001379,Longevity
6710,European,1715.0,22279548.0,Sebastiani P,Other measurement,initial,2012-01-18,GCST001379,Longevity
4712,European,139.0,22388998.0,Zhang CK,Metabolic disorder,initial,2012-01-19,GCST001380,Gaucher disease severity
9987,European,14435.0,22267201.0,Stolk L,Other measurement,replication,2012-01-22,GCST001381,Menopause (age at onset)
11021,European,43773.0,22267200.0,Gudmundsson J,Cancer,replication,2012-01-22,GCST001382,Thyroid cancer
10632,European,27758.0,22267200.0,Gudmundsson J,Cancer,initial,2012-01-22,GCST001382,Thyroid cancer
10937,European,38968.0,22267201.0,Stolk L,Other measurement,initial,2012-01-22,GCST001381,Menopause (age at onset)
5308,European,495.0,22295056.0,Christie JD,Other disease,replication,2012-01-25,GCST001383,Acute lung injury
7535,European,2866.0,22295056.0,Christie JD,Other disease,initial,2012-01-25,GCST001383,Acute lung injury
8323,European,4694.0,22291609.0,Naitza S,"Other measurement, Inflammatory measurement, Response to drug",initial,2012-01-26,GCST001385,Inflammatory biomarkers
4353,Asian,29951.0,22291604.0,Okada Y,Immune system disorder,replication,2012-01-26,GCST001384,Systemic lupus erythematosus
3425,Asian,4275.0,22291604.0,Okada Y,Immune system disorder,initial,2012-01-26,GCST001384,Systemic lupus erythematosus
6455,European,1392.0,22291609.0,Naitza S,"Other measurement, Inflammatory measurement, Response to drug",replication,2012-01-26,GCST001385,Inflammatory biomarkers
6262,European,1176.0,22286212.0,Urayama KY,Cancer,replication,2012-01-27,GCST001387,Hodgkin's lymphoma
5235,European,462.0,22286170.0,Cusanovich DA,Hematological measurement,initial,2012-01-27,GCST001389,Lymphocyte counts
9109,European,7617.0,22286212.0,Urayama KY,Cancer,initial,2012-01-27,GCST001387,Hodgkin's lymphoma
3757,Asian,6867.0,22286173.0,Low SK,Cardiovascular disease,initial,2012-01-27,GCST001388,Intracranial aneurysm
3890,Asian,8260.0,22286173.0,Low SK,Cardiovascular disease,replication,2012-01-27,GCST001388,Intracranial aneurysm
9240,European,8330.0,22286219.0,Kettunen J,Other measurement,initial,2012-01-29,GCST001392,Lipid metabolism phenotypes
1659,Asian,95.0,22293537.0,Kiyotani K,"Response to drug, Cancer",replication,2012-01-29,GCST001390,Response to gemcitabine in pancreatic cancer
9241,European,8330.0,22286219.0,Kettunen J,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",initial,2012-01-29,GCST001391,Metabolite levels
1637,Asian,79.0,22293537.0,Kiyotani K,"Response to drug, Cancer",initial,2012-01-29,GCST001390,Response to gemcitabine in pancreatic cancer
3352,Asian,3782.0,22290723.0,Ryu J,Other measurement,replication,2012-01-30,GCST001393,Glycated hemoglobin levels
3424,Asian,4275.0,22290723.0,Ryu J,Other measurement,initial,2012-01-30,GCST001393,Glycated hemoglobin levels
10104,European,16179.0,22293688.0,Huang J,Metabolic disorder,initial,2012-02-01,GCST001397,Type 2 diabetes
10103,European,16179.0,22293688.0,Huang J,Metabolic disorder,initial,2012-02-01,GCST001394,Type 1 diabetes
10102,European,16179.0,22293688.0,Huang J,Digestive system disorder,initial,2012-02-01,GCST001396,Crohn's disease
8688,European,5808.0,22420046.0,Stergiakouli E,Neurological disorder,initial,2012-02-01,GCST001395,Attention deficit hyperactivity disorder
6220,European,1142.0,22420046.0,Stergiakouli E,Neurological disorder,replication,2012-02-01,GCST001395,Attention deficit hyperactivity disorder
296,African,7178.0,22306650.0,Thye T,"Other disease, Other measurement",replication,2012-02-05,GCST001398,Tuberculosis
10986,European,41458.0,22306652.0,Bellenguez C,Cardiovascular disease,replication,2012-02-05,GCST001400,Stroke
9501,European,9520.0,22306652.0,Bellenguez C,Cardiovascular disease,initial,2012-02-05,GCST001400,Stroke
6678,European,1672.0,22306654.0,Feenstra B,Digestive system disorder,replication,2012-02-05,GCST001399,Infantile hypertrophic pyloric stenosis
254,African,3176.0,22306650.0,Thye T,"Other disease, Other measurement",initial,2012-02-05,GCST001398,Tuberculosis
7843,European,3402.0,22306654.0,Feenstra B,Digestive system disorder,initial,2012-02-05,GCST001399,Infantile hypertrophic pyloric stenosis
9626,European,10315.0,22306650.0,Thye T,"Other disease, Other measurement",replication,2012-02-05,GCST001398,Tuberculosis
5749,European,791.0,22310351.0,Fernandez-Rozadilla C,Response to drug,replication,2012-02-07,GCST001403,Fluorouracil treatment response in colorectal cancer
9951,European,13949.0,22319020.0,Davies RW,Cardiovascular disease,initial,2012-02-07,GCST001401,Coronary heart disease
9711,European,11032.0,22319020.0,Davies RW,Cardiovascular disease,replication,2012-02-07,GCST001401,Coronary heart disease
4826,European,203.0,22310351.0,Fernandez-Rozadilla C,Response to drug,initial,2012-02-07,GCST001403,Fluorouracil treatment response in colorectal cancer
2388,Asian,907.0,22318345.0,Cha PC,Cancer,initial,2012-02-09,GCST001404,Gallbladder cancer
3512,Asian,4965.0,22322875.0,Kim SJ,"Cardiovascular disease, Other measurement",initial,2012-02-09,GCST001405,Hypertension risk in short sleep duration
2396,Asian,928.0,22318345.0,Cha PC,Cancer,replication,2012-02-09,GCST001404,Gallbladder cancer
8348,European,4779.0,22327514.0,Postel-Vinay S,Cancer,initial,2012-02-12,GCST001407,Ewing sarcoma
6897,European,1960.0,22327514.0,Postel-Vinay S,Cancer,replication,2012-02-12,GCST001407,Ewing sarcoma
8974,European,6989.0,22331829.0,Chasman DI,"Lipid or lipoprotein measurement, Response to drug",initial,2012-02-13,GCST001408,Response to statins (LDL cholesterol change)
7955,European,3653.0,22333899.0,Wei WH,Body measurement,initial,2012-02-15,GCST001409,Body mass index (SNP x SNP interaction)
8488,European,5071.0,22333899.0,Wei WH,Body measurement,replication,2012-02-15,GCST001409,Body mass index (SNP x SNP interaction)
7080,European,2185.0,22341974.0,Paternoster L,"Other trait, Other measurement",initial,2012-02-16,GCST001412,Facial morphology
8100,European,4034.0,22359512.0,Demirkan A,Lipid or lipoprotein measurement,initial,2012-02-16,GCST001414,Phospholipid levels (plasma)
5718,European,760.0,22343285.0,Bakken TE,Other measurement,replication,2012-02-16,GCST001411,Occipital cortical area (total cortical area interaction)
5149,European,421.0,22343285.0,Bakken TE,Other measurement,initial,2012-02-16,GCST001411,Occipital cortical area (total cortical area interaction)
8101,European,4034.0,22359512.0,Demirkan A,"Other measurement, Lipid or lipoprotein measurement",initial,2012-02-16,GCST001413,Sphingolipid levels
6636,European,1622.0,22341974.0,Paternoster L,"Other trait, Other measurement",replication,2012-02-16,GCST001412,Facial morphology
4446,Asian,53215.0,22344219.0,Wen W,"Body measurement, Other measurement",replication,2012-02-19,GCST001415,Body mass index
4334,Asian,26620.0,22344221.0,Okada Y,Body measurement,initial,2012-02-19,GCST001416,Body mass index (SNP x SNP interaction)
2969,Asian,2118.0,22344219.0,Wen W,"Body measurement, Other measurement",replication,2012-02-19,GCST001415,Body mass index
4315,Asian,22762.0,22344219.0,Wen W,"Body measurement, Other measurement",initial,2012-02-19,GCST001415,Body mass index
4387,Asian,35625.0,22344221.0,Okada Y,Body measurement,replication,2012-02-19,GCST001416,Body mass index (SNP x SNP interaction)
3121,Asian,2522.0,22344219.0,Wen W,"Body measurement, Other measurement",initial,2012-02-19,GCST001415,Body mass index
3093,Asian,2431.0,22344219.0,Wen W,"Body measurement, Other measurement",initial,2012-02-19,GCST001415,Body mass index
9391,European,8754.0,22354554.0,Thompson SD,Immune system disorder,replication,2012-02-21,GCST001417,Arthritis (juvenile idiopathic)
6506,European,1472.0,22354554.0,Thompson SD,Immune system disorder,initial,2012-02-21,GCST001417,Arthritis (juvenile idiopathic)
6115,European,1017.0,22497812.0,Clark PJ,"Lipid or lipoprotein measurement, Digestive system disorder",initial,2012-02-22,GCST001418,Lipid levels in hepatitis C treatment
540,African American or Afro-Caribbean,207.0,22497812.0,Clark PJ,"Lipid or lipoprotein measurement, Digestive system disorder",initial,2012-02-22,GCST001418,Lipid levels in hepatitis C treatment
7444,European,2697.0,22365631.0,Greenwood TA,"Other measurement, Neurological disorder, Other trait",initial,2012-02-22,GCST001419,Temperament (bipolar disorder)
12540,Hispanic or Latin American,95.0,22497812.0,Clark PJ,"Lipid or lipoprotein measurement, Digestive system disorder",initial,2012-02-22,GCST001418,Lipid levels in hepatitis C treatment
4384,Asian,34455.0,22383897.0,Long J,Cancer,replication,2012-02-23,GCST001420,Breast cancer
6599,European,1573.0,22362865.0,Knaapila A,Biological process,initial,2012-02-23,GCST001422,Odorant perception
4864,European,226.0,22362865.0,Knaapila A,Biological process,replication,2012-02-23,GCST001422,Odorant perception
2577,Asian,1313.0,22383894.0,Pierce BL,Other measurement,initial,2012-02-23,GCST001421,Arsenic metabolism
3546,Asian,5242.0,22383897.0,Long J,Cancer,initial,2012-02-23,GCST001420,Breast cancer
1935,Asian,315.0,22384028.0,Guo Y,Cardiovascular disease,initial,2012-02-24,GCST001423,Hypertension
2637,Asian,1496.0,22367966.0,Lin X,Other measurement,replication,2012-02-24,GCST001424,Vitamin B12 levels
7367,European,2550.0,22368281.0,Deshmukh HA,Response to drug,replication,2012-02-24,GCST001425,Response to statin therapy
7457,European,2702.0,22368281.0,Deshmukh HA,Response to drug,initial,2012-02-24,GCST001425,Response to statin therapy
2914,Asian,1999.0,22367966.0,Lin X,Other measurement,initial,2012-02-24,GCST001424,Vitamin B12 levels
8515,European,5136.0,22367438.0,Tao S,"Cancer, Other measurement",replication,2012-02-26,GCST001426,Prostate cancer (SNP x SNP interaction)
7259,European,2420.0,22377092.0,Wang KS,Neurological disorder,initial,2012-02-27,GCST001427,Nicotine dependence
7774,European,3304.0,22377092.0,Wang KS,Neurological disorder,replication,2012-02-27,GCST001427,Nicotine dependence
5561,European,656.0,22449649.0,Loo SK,Biological process,initial,2012-02-28,GCST001428,Intelligence
9341,European,8477.0,22451204.0,Pankratz N,Neurological disorder,initial,2012-03-01,GCST001430,Parkinson's disease
6432,European,1372.0,22379998.0,McCormack M,Response to drug,initial,2012-03-01,GCST001431,Adverse response to lamotrigine and phenytoin
3902,Asian,8375.0,22396660.0,Urabe Y,Other disease,initial,2012-03-01,GCST001432,Nephrolithiasis
5912,European,904.0,22613542.0,Chen XD,Biological process,initial,2012-03-01,GCST001429,Drinking behavior
3227,Asian,2955.0,22613542.0,Chen XD,Biological process,replication,2012-03-01,GCST001429,Drinking behavior
4204,Asian,14765.0,22396660.0,Urabe Y,Other disease,replication,2012-03-01,GCST001432,Nephrolithiasis
7471,European,2733.0,22613542.0,Chen XD,Biological process,replication,2012-03-01,GCST001429,Drinking behavior
8699,European,5849.0,22451204.0,Pankratz N,Neurological disorder,replication,2012-03-01,GCST001430,Parkinson's disease
4314,Asian,22737.0,22387998.0,Tanikawa C,Digestive system disorder,initial,2012-03-04,GCST001433,Duodenal ulcer
4000,Asian,9621.0,22387998.0,Tanikawa C,Digestive system disorder,replication,2012-03-04,GCST001433,Duodenal ulcer
8217,European,4391.0,22403646.0,Froguel P,Hematological measurement,replication,2012-03-05,GCST001435,Haptoglobin levels
13499,Other/Mixed,100.0,22391508.0,Jiang R,Other measurement,initial,2012-03-05,GCST001434,Naphthyl-keratin adduct levels
5525,European,631.0,22403646.0,Froguel P,Hematological measurement,initial,2012-03-05,GCST001435,Haptoglobin levels
9649,European,10564.0,22399527.0,Kristiansson K,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",initial,2012-03-07,GCST001436,Metabolic syndrome
7637,European,3095.0,22412388.0,Kenny EE,Digestive system disorder,replication,2012-03-08,GCST001438,Crohn's disease
7597,European,2994.0,22412388.0,Kenny EE,Digestive system disorder,initial,2012-03-08,GCST001438,Crohn's disease
1432,African American or Afro-Caribbean,16388.0,22423221.0,Qayyum R,Hematological measurement,initial,2012-03-08,GCST001439,Mean platelet volume
1631,Asian,76.0,22399142.0,Jongjaroenprasert W,Metabolic disorder,replication,2012-03-08,GCST001437,Thyrotoxic hypokalemic periodic paralysis
1743,Asian,152.0,22399142.0,Jongjaroenprasert W,Metabolic disorder,initial,2012-03-08,GCST001437,Thyrotoxic hypokalemic periodic paralysis
1433,African American or Afro-Caribbean,16388.0,22423221.0,Qayyum R,Hematological measurement,initial,2012-03-08,GCST008047,Platelet count
2673,Asian,1519.0,22428042.0,Nakano M,Neurological disorder,initial,2012-03-12,GCST001441,Glaucoma (primary open-angle)
5476,European,594.0,22417934.0,Athanasiu L,"Body measurement, Biological process, Lipid or lipoprotein measurement",initial,2012-03-12,GCST001440,Body mass index and cholesterol (psychopharmacological treatment)
2241,Asian,700.0,22428042.0,Nakano M,Neurological disorder,replication,2012-03-12,GCST001441,Glaucoma (primary open-angle)
13847,Other/Mixed,1277.0,22419666.0,Shi M,"Other trait, Other measurement, Other disease",initial,2012-03-14,GCST001442,Orofacial clefts
8408,European,4916.0,22432041.0,Johnson MP,Cardiovascular disease,replication,2012-03-14,GCST001443,Preeclampsia
6189,European,1094.0,22419666.0,Shi M,"Other trait, Other measurement, Other disease",initial,2012-03-14,GCST001442,Orofacial clefts
6170,European,1078.0,22432041.0,Johnson MP,Cardiovascular disease,initial,2012-03-14,GCST001443,Preeclampsia
5392,European,535.0,22425255.0,Lopez LM,Other measurement,initial,2012-03-15,GCST001446,White matter integrity
14035,Other/Mixed,98080.0,22438815.0,Lill CM,Neurological disorder,replication,2012-03-15,GCST001445,Parkinson's disease
9809,European,12018.0,22424883.0,Imboden M,Other measurement,replication,2012-03-15,GCST001444,Pulmonary function decline
8129,European,4118.0,22424883.0,Imboden M,Other measurement,initial,2012-03-15,GCST001444,Pulmonary function decline
3313,Asian,3514.0,22426144.0,Long J,Cancer,initial,2012-03-16,GCST001447,Endometrial cancer
10337,European,19800.0,22426144.0,Long J,Cancer,replication,2012-03-16,GCST001447,Endometrial cancer
2808,Asian,1774.0,22426144.0,Long J,Cancer,replication,2012-03-16,GCST001447,Endometrial cancer
8536,European,5218.0,22446040.0,Wang KS,"Body measurement, Other measurement",initial,2012-03-16,GCST001448,Body mass index
13776,Other/Mixed,762.0,22446040.0,Wang KS,"Body measurement, Other measurement",replication,2012-03-16,GCST001448,Body mass index
10251,European,18330.0,22430674.0,Lambert JC,Neurological disorder,replication,2012-03-20,GCST001449,Alzheimer's disease
9048,European,7353.0,22430674.0,Lambert JC,Neurological disorder,initial,2012-03-20,GCST001449,Alzheimer's disease
7020,European,2112.0,22437554.0,Major JM,Biological process,initial,2012-03-21,GCST001450,Response to Vitamin E supplementation
3970,Asian,9014.0,22419738.0,Osman W,Neurological disorder,replication,2012-03-22,GCST001451,Glaucoma (primary open-angle)
13643,Other/Mixed,372.0,22437316.0,Sarig O,Immune system disorder,replication,2012-03-22,GCST001452,Pemphigus vulgaris
5112,European,399.0,22437316.0,Sarig O,Immune system disorder,replication,2012-03-22,GCST001452,Pemphigus vulgaris
3877,Asian,7993.0,22419738.0,Osman W,Neurological disorder,initial,2012-03-22,GCST001451,Glaucoma (primary open-angle)
1800,Asian,201.0,22445761.0,Kurose K,Other trait,initial,2012-03-23,GCST001453,Sexual dysfunction (SSRI/SNRI-related)
2761,Asian,1729.0,22446961.0,Lee YC,Immune system disorder,initial,2012-03-25,GCST001456,Kawasaki disease
4295,Asian,20965.0,22446963.0,Okada Y,Immune system disorder,initial,2012-03-25,GCST001454,Rheumatoid arthritis
2341,Asian,811.0,22446961.0,Lee YC,Immune system disorder,replication,2012-03-25,GCST001456,Kawasaki disease
3353,Asian,3807.0,22446962.0,Onouchi Y,Immune system disorder,initial,2012-03-25,GCST001455,Kawasaki disease
4338,Asian,26961.0,22446963.0,Okada Y,Immune system disorder,replication,2012-03-25,GCST001454,Rheumatoid arthritis
2579,Asian,1328.0,22479419.0,Liou YJ,Neurological disorder,initial,2012-03-27,GCST001458,Schizophrenia (treatment resistant)
3871,Asian,7894.0,22452962.0,Kim HC,Cancer,replication,2012-03-27,GCST001457,Breast cancer
3428,Asian,4325.0,22452962.0,Kim HC,Cancer,initial,2012-03-27,GCST001457,Breast cancer
1904,Asian,273.0,22479419.0,Liou YJ,Neurological disorder,replication,2012-03-27,GCST001458,Schizophrenia (treatment resistant)
6226,European,1144.0,22470424.0,Kwee LC,Neurological disorder,replication,2012-03-28,GCST001460,Amyotrophic lateral sclerosis
5165,European,431.0,22457343.0,Martinelli-Boneschi F,Immune system disorder,initial,2012-03-28,GCST001459,Multiple sclerosis
8954,European,6896.0,22470424.0,Kwee LC,Neurological disorder,initial,2012-03-28,GCST001460,Amyotrophic lateral sclerosis
4068,Asian,11139.0,22456796.0,Imamura M,Metabolic disorder,replication,2012-03-28,GCST001461,Type 2 diabetes
5731,European,777.0,22457343.0,Martinelli-Boneschi F,Immune system disorder,replication,2012-03-28,GCST001459,Multiple sclerosis
3821,Asian,7541.0,22456796.0,Imamura M,Metabolic disorder,initial,2012-03-28,GCST001461,Type 2 diabetes
10273,European,18753.0,22479309.0,Boraska V,Body measurement,initial,2012-03-29,GCST001462,Brachial circumference
2809,Asian,1776.0,22479202.0,Dastani Z,Other measurement,initial,2012-03-29,GCST001463,Adiponectin levels
7946,European,3623.0,22479309.0,Boraska V,Body measurement,replication,2012-03-29,GCST001462,Brachial circumference
10677,European,29347.0,22479202.0,Dastani Z,Other measurement,initial,2012-03-29,GCST001465,Adiponectin levels
1936,Asian,315.0,22479346.0,Yang HC,Cardiovascular disease,replication,2012-03-29,GCST001467,Hypertension
1185,African American or Afro-Caribbean,4232.0,22479202.0,Dastani Z,Other measurement,initial,2012-03-29,GCST001463,Adiponectin levels
10676,European,29347.0,22479202.0,Dastani Z,Other measurement,initial,2012-03-29,GCST001463,Adiponectin levels
8460,European,5003.0,22479346.0,Yang HC,Cardiovascular disease,replication,2012-03-29,GCST001467,Hypertension
95,African,397.0,22455414.0,Tekola Ayele F,Immune system disorder,initial,2012-03-29,GCST001464,Podoconiosis
127,African,606.0,22455414.0,Tekola Ayele F,Immune system disorder,replication,2012-03-29,GCST001464,Podoconiosis
11361,European,74354.0,22479191.0,Pattaro C,"Other disease, Other measurement",initial,2012-03-29,GCST001466,Chronic kidney disease
2329,Asian,800.0,22479346.0,Yang HC,Cardiovascular disease,initial,2012-03-29,GCST001467,Hypertension
9641,European,10536.0,22479202.0,Dastani Z,Other measurement,replication,2012-03-29,GCST001465,Adiponectin levels
11185,European,56246.0,22479191.0,Pattaro C,"Other disease, Other measurement",replication,2012-03-29,GCST001466,Chronic kidney disease
7994,European,3763.0,22466613.0,Sun L,Digestive system disorder,initial,2012-04-01,GCST001468,Cystic fibrosis (meconium ileus)
7234,European,2372.0,22466613.0,Sun L,Digestive system disorder,replication,2012-04-01,GCST001468,Cystic fibrosis (meconium ileus)
5187,European,434.0,22472174.0,Xiao Y,Cancer,replication,2012-04-03,GCST001470,Glioblastoma
4986,European,315.0,22472174.0,Xiao Y,Cancer,initial,2012-04-03,GCST001470,Glioblastoma
11209,European,57478.0,22472876.0,Sullivan PF,Neurological disorder,replication,2012-04-03,GCST001469,Major depressive disorder
10274,European,18759.0,22472876.0,Sullivan PF,Neurological disorder,initial,2012-04-03,GCST001469,Major depressive disorder
7123,European,2214.0,22488850.0,Zuo L,Neurological disorder,initial,2012-04-04,GCST001471,Alcohol and nicotine co-dependence
764,African American or Afro-Caribbean,929.0,22488850.0,Zuo L,Neurological disorder,initial,2012-04-04,GCST001471,Alcohol and nicotine co-dependence
743,African American or Afro-Caribbean,837.0,22492993.0,Doumatey AP,Inflammatory measurement,initial,2012-04-05,GCST001472,C-reactive protein
110,African,486.0,22492993.0,Doumatey AP,Inflammatory measurement,replication,2012-04-05,GCST001472,C-reactive protein
10941,European,39282.0,22493691.0,Eriksson N,Other disease,initial,2012-04-06,GCST001474,Hypothyroidism
10193,European,17360.0,22482804.0,Ellinghaus D,"Digestive system disorder, Immune system disorder",replication,2012-04-06,GCST001473,Crohn's disease and psoriasis
10032,European,15131.0,22482804.0,Ellinghaus D,"Digestive system disorder, Immune system disorder",initial,2012-04-06,GCST001473,Crohn's disease and psoriasis
9945,European,13848.0,22484627.0,Bradfield JP,"Other measurement, Metabolic disorder",initial,2012-04-08,GCST001475,Obesity
8391,European,4888.0,22484627.0,Bradfield JP,"Other measurement, Metabolic disorder",replication,2012-04-08,GCST001475,Obesity
13684,Other/Mixed,526.0,22491018.0,Wang J,"Immune system disorder, Biological process",replication,2012-04-10,GCST001476,Response to tocilizumab in rheumatoid arthritis
13826,Other/Mixed,1157.0,22491018.0,Wang J,"Immune system disorder, Biological process",initial,2012-04-10,GCST001476,Response to tocilizumab in rheumatoid arthritis
6196,European,1104.0,22509378.0,Burri A,Other trait,initial,2012-04-11,GCST001477,Sexual dysfunction (female)
7036,European,2142.0,22526605.0,Howson JM,"Other measurement, Metabolic disorder",initial,2012-04-12,GCST001479,Type 1 diabetes autoantibodies
1737,Asian,147.0,22503698.0,Bhatnagar R,"Cancer, Other measurement",initial,2012-04-12,GCST001480,Oral cancers (chewing tobacco related)
5845,European,855.0,22526605.0,Howson JM,"Other measurement, Metabolic disorder",replication,2012-04-12,GCST001479,Type 1 diabetes autoantibodies
13992,Other/Mixed,8175.0,22504418.0,Ikram MA,Other measurement,initial,2012-04-15,GCST001483,Intracranial volume
7193,European,2318.0,22504421.0,Bis JC,Other measurement,replication,2012-04-15,GCST001485,Hippocampal volume
14023,Other/Mixed,32961.0,22504420.0,Estrada K,Other measurement,initial,2012-04-15,GCST007691,Femoral neck bone mineral density
9844,European,12514.0,22504417.0,Stein JL,Other measurement,replication,2012-04-15,GCST001481,Brain structure
9448,European,9232.0,22504421.0,Bis JC,Other measurement,initial,2012-04-15,GCST001485,Hippocampal volume
11111,European,50933.0,22504420.0,Estrada K,Other measurement,replication,2012-04-15,GCST001482,Lumbar spine bone mineral density
9688,European,10768.0,22504419.0,Taal HR,Body measurement,initial,2012-04-15,GCST001484,Head circumference (infant)
13584,Other/Mixed,237.0,22504417.0,Stein JL,Other measurement,replication,2012-04-15,GCST001481,Brain structure
6760,European,1752.0,22504418.0,Ikram MA,Other measurement,replication,2012-04-15,GCST001483,Intracranial volume
9140,European,7795.0,22504417.0,Stein JL,Other measurement,initial,2012-04-15,GCST001481,Brain structure
14022,Other/Mixed,32961.0,22504420.0,Estrada K,Other measurement,initial,2012-04-15,GCST001482,Lumbar spine bone mineral density
12690,Hispanic or Latin American,605.0,22504417.0,Stein JL,Other measurement,replication,2012-04-15,GCST001481,Brain structure
11112,European,50933.0,22504420.0,Estrada K,Other measurement,replication,2012-04-15,GCST007691,Femoral neck bone mineral density
9239,European,8321.0,22504419.0,Taal HR,Body measurement,replication,2012-04-15,GCST001484,Head circumference (infant)
7982,European,3736.0,22494929.0,Rawal R,Other trait,initial,2012-04-16,GCST001487,Thyroid function
12799,Hispanic or Latin American,1171.0,22508271.0,Rasmussen-Torvik LJ,Other measurement,initial,2012-04-16,GCST001486,Fasting plasma glucose
865,African American or Afro-Caribbean,1366.0,22508271.0,Rasmussen-Torvik LJ,Other measurement,initial,2012-04-16,GCST001486,Fasting plasma glucose
7978,European,3727.0,22494929.0,Rawal R,Other trait,replication,2012-04-16,GCST001487,Thyroid function
2215,Asian,664.0,22508271.0,Rasmussen-Torvik LJ,Other measurement,initial,2012-04-16,GCST001486,Fasting plasma glucose
7215,European,2349.0,22508271.0,Rasmussen-Torvik LJ,Other measurement,initial,2012-04-16,GCST001486,Fasting plasma glucose
3941,Asian,8834.0,22513714.0,Shin J,Metabolic disorder,initial,2012-04-19,GCST001488,Gout
12543,Hispanic or Latin American,99.0,22524403.0,Rice JP,Neurological disorder,initial,2012-04-24,GCST001490,Nicotine dependence
9439,European,9126.0,22532574.0,Stevens KN,"Other measurement, Cancer",replication,2012-04-24,GCST001489,Percent mammographic density
6326,European,1241.0,22532574.0,Stevens KN,"Other measurement, Cancer",initial,2012-04-24,GCST001489,Percent mammographic density
7145,European,2267.0,22524403.0,Rice JP,Neurological disorder,initial,2012-04-24,GCST001490,Nicotine dependence
777,African American or Afro-Caribbean,999.0,22524403.0,Rice JP,Neurological disorder,initial,2012-04-24,GCST001490,Nicotine dependence
547,African American or Afro-Caribbean,217.0,22542470.0,Ovsyannikova IG,"Response to drug, Other measurement",initial,2012-04-25,GCST001491,Immune response to smallpox vaccine (IL-6)
5449,European,580.0,22542470.0,Ovsyannikova IG,"Response to drug, Other measurement",initial,2012-04-25,GCST001491,Immune response to smallpox vaccine (IL-6)
12584,Hispanic or Latin American,217.0,22542470.0,Ovsyannikova IG,"Response to drug, Other measurement",initial,2012-04-25,GCST001491,Immune response to smallpox vaccine (IL-6)
3151,Asian,2665.0,22541561.0,Zhao H,Other disease,initial,2012-04-26,GCST001494,Non-obstructive azoospermia
8876,European,6633.0,22570617.0,Wiggs JL,Neurological disorder,initial,2012-04-26,GCST001493,Glaucoma (primary open-angle)
3404,Asian,4137.0,22541561.0,Zhao H,Other disease,replication,2012-04-26,GCST001494,Non-obstructive azoospermia
5142,European,418.0,22538805.0,Tantisira KG,Other disease,initial,2012-04-26,GCST001495,Asthma
5119,European,407.0,22538805.0,Tantisira KG,Other disease,replication,2012-04-26,GCST001495,Asthma
972,African American or Afro-Caribbean,2152.0,22558097.0,Milton JN,"Digestive system disorder, Neurological disorder, Other measurement",replication,2012-04-27,GCST001497,Cholelithiasis-related traits in sickle cell anemia
2722,Asian,1629.0,22558069.0,Osman W,Other measurement,replication,2012-04-27,GCST001496,Non-albumin protein levels
760,African American or Afro-Caribbean,905.0,22558097.0,Milton JN,"Digestive system disorder, Neurological disorder, Other measurement",initial,2012-04-27,GCST001497,Cholelithiasis-related traits in sickle cell anemia
3971,Asian,9103.0,22558069.0,Osman W,Other measurement,initial,2012-04-27,GCST001496,Non-albumin protein levels
8682,European,5767.0,22605921.0,Gibson J,Neurological disorder,initial,2012-04-28,GCST001498,Glaucoma (primary open-angle)
5032,European,344.0,22605921.0,Gibson J,Neurological disorder,replication,2012-04-28,GCST001498,Glaucoma (primary open-angle)
8582,European,5339.0,22544364.0,Turnbull C,Cancer,replication,2012-04-29,GCST001500,Wilms tumor
10057,European,15411.0,22544366.0,Ellinor PT,Cardiovascular disease,replication,2012-04-29,GCST001499,Atrial fibrillation
11221,European,59133.0,22544366.0,Ellinor PT,Cardiovascular disease,initial,2012-04-29,GCST001499,Atrial fibrillation
7415,European,2636.0,22544364.0,Turnbull C,Cancer,initial,2012-04-29,GCST001500,Wilms tumor
4701,European,125.0,22550155.0,Edelstein LC,"Cardiovascular measurement, Hematological measurement",initial,2012-05-01,GCST001501,Platelet thrombus formation
467,African American or Afro-Caribbean,116.0,22550155.0,Edelstein LC,"Cardiovascular measurement, Hematological measurement",initial,2012-05-01,GCST001501,Platelet thrombus formation
5441,European,573.0,22560479.0,Forno E,Other disease,initial,2012-05-02,GCST001502,Asthma (childhood onset)
12684,Hispanic or Latin American,591.0,22560479.0,Forno E,Other disease,replication,2012-05-02,GCST001502,Asthma (childhood onset)
4691,European,107.0,22560479.0,Forno E,Other disease,replication,2012-05-02,GCST001502,Asthma (childhood onset)
9807,European,11972.0,22570627.0,van Koolwijk LM,Other measurement,initial,2012-05-03,GCST001506,Intraocular pressure
9081,European,7482.0,22570627.0,van Koolwijk LM,Other measurement,replication,2012-05-03,GCST001506,Intraocular pressure
8668,European,5725.0,22570697.0,Matesanz F,Immune system disorder,replication,2012-05-03,GCST001505,Multiple sclerosis
2524,Asian,1201.0,22551897.0,Mahasirimongkol S,"Other disease, Other measurement",replication,2012-05-03,GCST001504,Tuberculosis
8888,European,6685.0,22570697.0,Matesanz F,Immune system disorder,initial,2012-05-03,GCST001505,Multiple sclerosis
2264,Asian,728.0,22551897.0,Mahasirimongkol S,"Other disease, Other measurement",initial,2012-05-03,GCST001504,Tuberculosis
2491,Asian,1122.0,22551897.0,Mahasirimongkol S,"Other disease, Other measurement",initial,2012-05-03,GCST001504,Tuberculosis
6587,European,1560.0,22554406.0,Kang SJ,"Neurological disorder, Other measurement",initial,2012-05-03,GCST001503,Electroencephalographic traits in alcoholism
2337,Asian,808.0,22551897.0,Mahasirimongkol S,"Other disease, Other measurement",replication,2012-05-03,GCST001504,Tuberculosis
13494,Other/Mixed,85.0,22556244.0,Kenny EE,"Other measurement, Other trait",initial,2012-05-04,GCST001507,Hair color
8186,European,4279.0,22561531.0,Wan YI,Other disease,initial,2012-05-05,GCST001508,Asthma
6601,European,1576.0,22561531.0,Wan YI,Other disease,replication,2012-05-05,GCST001508,Asthma
7729,European,3228.0,22561518.0,Jin Y,Immune system disorder,initial,2012-05-06,GCST001509,Vitiligo
7429,European,2661.0,22561518.0,Jin Y,Immune system disorder,replication,2012-05-06,GCST001509,Vitiligo
4813,European,196.0,22569225.0,Krintel SB,"Immune system disorder, Response to drug",initial,2012-05-06,GCST001510,Response to TNF-alpha inhibitors in rheumatoid arthritis
4778,European,183.0,22566560.0,Malhotra AK,Other trait,replication,2012-05-07,GCST001517,Antipsychotic drug-induced weight gain
9513,European,9617.0,22566634.0,Benjamin DJ,Other trait,initial,2012-05-07,GCST001519,Economic and political preferences
9508,European,9617.0,22566634.0,Benjamin DJ,Other trait,initial,2012-05-07,GCST001511,Economic and political preferences (time)
9512,European,9617.0,22566634.0,Benjamin DJ,Other trait,initial,2012-05-07,GCST001515,Economic and political preferences (immigration/crime)
4812,European,196.0,22566498.0,Turner ST,"Response to drug, Cardiovascular disease",replication,2012-05-07,GCST001518,Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)
8846,European,6523.0,22566624.0,Castano Betancourt MC,Other disease,initial,2012-05-07,GCST001516,Osteoarthritis
520,African American or Afro-Caribbean,194.0,22566498.0,Turner ST,"Response to drug, Cardiovascular disease",replication,2012-05-07,GCST001518,Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)
518,African American or Afro-Caribbean,193.0,22566498.0,Turner ST,"Response to drug, Cardiovascular disease",initial,2012-05-07,GCST001520,Response to angiotensin II receptor blocker therapy
517,African American or Afro-Caribbean,193.0,22566498.0,Turner ST,"Response to drug, Cardiovascular disease",initial,2012-05-07,GCST001518,Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)
9510,European,9617.0,22566634.0,Benjamin DJ,Other trait,initial,2012-05-07,GCST001513,Economic and political preferences (fairness)
8231,European,4442.0,22566624.0,Castano Betancourt MC,Other disease,replication,2012-05-07,GCST001516,Osteoarthritis
397,African American or Afro-Caribbean,32.0,22566560.0,Malhotra AK,Other trait,initial,2012-05-07,GCST001517,Antipsychotic drug-induced weight gain
385,African American or Afro-Caribbean,22.0,22566560.0,Malhotra AK,Other trait,replication,2012-05-07,GCST001517,Antipsychotic drug-induced weight gain
5095,European,394.0,22566498.0,Turner ST,"Response to drug, Cardiovascular disease",initial,2012-05-07,GCST001518,Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)
4814,European,198.0,22566498.0,Turner ST,"Response to drug, Cardiovascular disease",initial,2012-05-07,GCST001520,Response to angiotensin II receptor blocker therapy
9509,European,9617.0,22566634.0,Benjamin DJ,Other trait,initial,2012-05-07,GCST001512,Economic and political preferences (environmentalism)
9511,European,9617.0,22566634.0,Benjamin DJ,Other trait,initial,2012-05-07,GCST001514,Economic and political preferences (feminism/equality)
4616,European,77.0,22566560.0,Malhotra AK,Other trait,initial,2012-05-07,GCST001517,Antipsychotic drug-induced weight gain
2290,Asian,761.0,22589742.0,Fox CS,Other measurement,replication,2012-05-10,GCST001522,Pericardial fat
8624,European,5487.0,22589742.0,Fox CS,Other measurement,initial,2012-05-10,GCST001522,Pericardial fat
9648,European,10557.0,22589738.0,Fox CS,"Other measurement, Body measurement",initial,2012-05-10,GCST001523,Visceral adipose tissue adjusted for BMI
9647,European,10557.0,22589738.0,Fox CS,Other measurement,initial,2012-05-10,GCST001525,Visceral fat
9645,European,10557.0,22589738.0,Fox CS,Other measurement,initial,2012-05-10,GCST001521,Subcutaneous adipose tissue
9646,European,10557.0,22589738.0,Fox CS,Other measurement,initial,2012-05-10,GCST001524,Visceral adipose tissue/subcutaneous adipose tissue ratio
876,African American or Afro-Caribbean,1442.0,22589742.0,Fox CS,Other measurement,replication,2012-05-10,GCST001522,Pericardial fat
12821,Hispanic or Latin American,1399.0,22589742.0,Fox CS,Other measurement,replication,2012-05-10,GCST001522,Pericardial fat
11122,European,51750.0,22581228.0,Manning AK,"Body measurement, Other measurement",initial,2012-05-13,GCST001526,Fasting blood insulin (BMI interaction)
10809,European,33823.0,22581228.0,Manning AK,"Body measurement, Other measurement",replication,2012-05-13,GCST001526,Fasting blood insulin (BMI interaction)
11123,European,51750.0,22581228.0,Manning AK,Other measurement,initial,2012-05-13,GCST005185,Fasting blood insulin
11213,European,58074.0,22581228.0,Manning AK,Other measurement,initial,2012-05-13,GCST005186,Fasting blood glucose
11212,European,58074.0,22581228.0,Manning AK,"Body measurement, Other measurement",initial,2012-05-13,GCST001527,Fasting blood glucose (BMI interaction)
10810,European,33823.0,22581228.0,Manning AK,Other measurement,replication,2012-05-13,GCST005185,Fasting blood insulin
10930,European,38422.0,22581228.0,Manning AK,Other measurement,replication,2012-05-13,GCST005186,Fasting blood glucose
10929,European,38422.0,22581228.0,Manning AK,"Body measurement, Other measurement",replication,2012-05-13,GCST001527,Fasting blood glucose (BMI interaction)
1729,Asian,136.0,22584459.0,Sasayama D,Response to drug,replication,2012-05-15,GCST001528,Response to antidepressants
7127,European,2229.0,22832961.0,Kamboh MI,Neurological disorder,initial,2012-05-15,GCST001529,Alzheimer's disease
6679,European,1673.0,22745009.0,Melville SA,Neurological disorder,initial,2012-05-15,GCST001530,Hippocampal atrophy
9838,European,12433.0,22832960.0,Service SK,Other measurement,initial,2012-05-15,GCST001531,Temperament
1650,Asian,92.0,22584459.0,Sasayama D,Response to drug,initial,2012-05-15,GCST001528,Response to antidepressants
6344,European,1262.0,22832961.0,Kamboh MI,Neurological disorder,replication,2012-05-15,GCST001529,Alzheimer's disease
630,African American or Afro-Caribbean,419.0,22745009.0,Melville SA,Neurological disorder,replication,2012-05-15,GCST001530,Hippocampal atrophy
525,African American or Afro-Caribbean,199.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001534,Immune reponse to smallpox (secreted IL-10)
529,African American or Afro-Caribbean,199.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001538,Immune reponse to smallpox (secreted IFN-alpha)
5345,European,512.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001532,Immune response to smallpox vaccine (IL-6)
5346,European,512.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001533,Immune reponse to smallpox (secreted IL-1beta)
5347,European,512.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001534,Immune reponse to smallpox (secreted IL-10)
5348,European,512.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001535,Immune reponse to smallpox (secreted IL-2)
5349,European,512.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001536,Immune reponse to smallpox (secreted TNF-alpha)
5350,European,512.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001537,Immune reponse to smallpox (secreted IL-12p40)
5351,European,512.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001538,Immune reponse to smallpox (secreted IFN-alpha)
528,African American or Afro-Caribbean,199.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001537,Immune reponse to smallpox (secreted IL-12p40)
523,African American or Afro-Caribbean,199.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001532,Immune response to smallpox vaccine (IL-6)
524,African American or Afro-Caribbean,199.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001533,Immune reponse to smallpox (secreted IL-1beta)
527,African American or Afro-Caribbean,199.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001536,Immune reponse to smallpox (secreted TNF-alpha)
526,African American or Afro-Caribbean,199.0,22610502.0,Kennedy RB,"Response to drug, Other measurement",initial,2012-05-19,GCST001535,Immune reponse to smallpox (secreted IL-2)
1503,African American or Afro-Caribbean,32389.0,22832964.0,David SP,Biological process,initial,2012-05-22,GCST001539,Smoking behavior
4910,European,269.0,22633400.0,Kosova G,"Other measurement, Other trait",initial,2012-05-23,GCST001540,Male fertility
9451,European,9244.0,22628180.0,Luciano M,Other trait,replication,2012-05-24,GCST001541,Personality dimensions
6355,European,1287.0,22628157.0,Levine AJ,Neurological disorder,initial,2012-05-24,GCST001542,HIV-associated dementia
8802,European,6268.0,22628180.0,Luciano M,Other trait,initial,2012-05-24,GCST001541,Personality dimensions
10223,European,17780.0,22634755.0,Dunlop MG,Cancer,initial,2012-05-27,GCST001544,Colorectal cancer
10883,European,37170.0,22634755.0,Dunlop MG,Cancer,replication,2012-05-27,GCST001544,Colorectal cancer
7175,European,2291.0,22637743.0,Wei S,"Cancer, Other measurement",initial,2012-05-27,GCST001543,Lung cancer (asbestos exposure interaction)
3309,Asian,3481.0,22634755.0,Dunlop MG,Cancer,replication,2012-05-27,GCST001544,Colorectal cancer
5651,European,726.0,22658931.0,Pajewski NM,Response to drug,initial,2012-05-30,GCST001547,Immune response to anthrax vaccine
13730,Other/Mixed,682.0,22666496.0,Shiffman D,"Cardiovascular disease, Response to drug",initial,2012-05-30,GCST001545,Coronary heart disease event reduction (statin therapy interaction)
5204,European,443.0,22658654.0,Chung SJ,Neurological disorder,initial,2012-05-30,GCST001546,Parkinson's disease (motor and cognition)
13910,Other/Mixed,2427.0,22666496.0,Shiffman D,"Cardiovascular disease, Response to drug",replication,2012-05-30,GCST001545,Coronary heart disease event reduction (statin therapy interaction)
9865,European,12806.0,22693459.0,Li R,"Other measurement, Other disease",initial,2012-05-31,GCST001548,Male-pattern baldness
7910,European,3529.0,22648509.0,Wang KS,Other trait,initial,2012-05-31,GCST001549,Formal thought disorder in schizophrenia
6204,European,1117.0,22661486.0,Ulmer M,Other measurement,initial,2012-06-01,GCST001552,Central corneal thickness
4860,European,224.0,22856363.0,Ousdal OT,Other measurement,initial,2012-06-01,GCST001551,Amygdala reactivity
1583,Asian,29.0,22856363.0,Ousdal OT,Other measurement,replication,2012-06-01,GCST001551,Amygdala reactivity
13388,Other/Mixed,7.0,22856363.0,Ousdal OT,Other measurement,replication,2012-06-01,GCST001551,Amygdala reactivity
4582,European,50.0,22856363.0,Ousdal OT,Other measurement,replication,2012-06-01,GCST001551,Amygdala reactivity
375,African American or Afro-Caribbean,13.0,22856363.0,Ousdal OT,Other measurement,replication,2012-06-01,GCST001551,Amygdala reactivity
381,African American or Afro-Caribbean,21.0,22665904.0,Willis JA,Cancer,replication,2012-06-04,GCST001556,Pancreatic cancer
1550,Asian,10.0,22665904.0,Willis JA,Cancer,replication,2012-06-04,GCST001556,Pancreatic cancer
5756,European,798.0,22665904.0,Willis JA,Cancer,replication,2012-06-04,GCST001556,Pancreatic cancer
6620,European,1598.0,22675492.0,Prescott J,Other measurement,initial,2012-06-04,GCST001554,Sex hormone-binding globulin levels
4899,European,252.0,22665904.0,Willis JA,Cancer,initial,2012-06-04,GCST001556,Pancreatic cancer
6606,European,1583.0,22675492.0,Prescott J,Other measurement,initial,2012-06-04,GCST001553,Estradiol levels
6611,European,1589.0,22675492.0,Prescott J,Other measurement,initial,2012-06-04,GCST001555,Testosterone levels
1537,Asian,4.0,22665904.0,Willis JA,Cancer,replication,2012-06-04,GCST001556,Pancreatic cancer
13938,Other/Mixed,2962.0,22672568.0,Heit JA,Cardiovascular disease,initial,2012-06-05,GCST001557,Venous thromboembolism
12797,Hispanic or Latin American,1108.0,22673963.0,Lasky-Su J,Other measurement,replication,2012-06-07,GCST001560,Vitamin D levels
3176,Asian,2789.0,22685421.0,Fan Q,Other trait,initial,2012-06-07,GCST001561,Myopia (pathological)
6474,European,1416.0,22673963.0,Lasky-Su J,Other measurement,initial,2012-06-07,GCST001560,Vitamin D levels
2995,Asian,2155.0,22685421.0,Fan Q,Other trait,initial,2012-06-07,GCST001561,Myopia (pathological)
13601,Other/Mixed,285.0,22678113.0,Cox HC,Cardiovascular disease,initial,2012-06-08,GCST001562,Migraine
10588,European,25713.0,22678113.0,Cox HC,Cardiovascular disease,replication,2012-06-08,GCST001562,Migraine
8519,European,5160.0,22683712.0,Freilinger T,Cardiovascular disease,replication,2012-06-10,GCST001563,Migraine
6808,European,1824.0,22694930.0,Li X,Other disease,initial,2012-06-11,GCST001564,Asthma
10575,European,25353.0,22692763.0,Liu CT,Other measurement,initial,2012-06-12,GCST001566,Bone mineral density (sex interaction)
7566,European,2929.0,22688191.0,Bergen SE,Neurological disorder,initial,2012-06-12,GCST001569,Bipolar disorder
1989,Asian,374.0,22693232.0,Zhou J,Biological process,replication,2012-06-12,GCST001568,Influenza (severity)
8623,European,5482.0,22688191.0,Bergen SE,Neurological disorder,initial,2012-06-12,GCST001567,Bipolar disorder and schizophrenia
14017,Other/Mixed,24763.0,22692763.0,Liu CT,Other measurement,replication,2012-06-12,GCST001566,Bone mineral density (sex interaction)
1599,Asian,51.0,22693232.0,Zhou J,Biological process,initial,2012-06-12,GCST001568,Influenza (severity)
8300,European,4646.0,22688191.0,Bergen SE,Neurological disorder,initial,2012-06-12,GCST001565,Schizophrenia
7634,European,3092.0,22694956.0,Cipriani V,Neurological disorder,initial,2012-06-13,GCST001571,Age-related macular degeneration
7528,European,2842.0,22694956.0,Cipriani V,Neurological disorder,replication,2012-06-13,GCST001571,Age-related macular degeneration
5387,European,528.0,22704111.0,Hotaling JM,"Other disease, Metabolic disorder",initial,2012-06-13,GCST001572,Erectile dysfunction in type 1 diabetes
7549,European,2894.0,22700719.0,Slager SL,Cancer,replication,2012-06-13,GCST001570,Chronic lymphocytic leukemia
8385,European,4866.0,22700719.0,Slager SL,Cancer,initial,2012-06-13,GCST001570,Chronic lymphocytic leukemia
7399,European,2611.0,22703881.0,Tang W,Hematological measurement,replication,2012-06-14,GCST001574,Activated partial thromboplastin time
5018,European,339.0,22701019.0,Sabater-Lleal M,Hematological measurement,initial,2012-06-14,GCST001575,Factor XI
9449,European,9240.0,22703881.0,Tang W,Hematological measurement,initial,2012-06-14,GCST001574,Activated partial thromboplastin time
2629,Asian,1461.0,22719876.0,Kawaguchi T,Digestive system disorder,initial,2012-06-14,GCST001576,Nonalcoholic fatty liver disease
5566,European,658.0,22701019.0,Sabater-Lleal M,Hematological measurement,replication,2012-06-14,GCST001575,Factor XI
6049,European,986.0,22703881.0,Tang W,Hematological measurement,replication,2012-06-14,GCST001573,Prothrombin time
7384,European,2583.0,22703881.0,Tang W,Hematological measurement,initial,2012-06-14,GCST001573,Prothrombin time
8436,European,4953.0,22705344.0,Sobrin L,Neurological disorder,initial,2012-06-15,GCST001578,Age-related macular degeneration (geographic atrophy)
8722,European,5909.0,22705344.0,Sobrin L,Neurological disorder,initial,2012-06-15,GCST001579,Age-related macular degeneration (choroidal neovascularisation)
7391,European,2594.0,22705344.0,Sobrin L,Neurological disorder,initial,2012-06-15,GCST001577,Age-related macular degeneration (CNV vs. GA)
3802,Asian,7373.0,22726844.0,Kim JW,Cardiovascular measurement,replication,2012-06-20,GCST001580,QT interval
13897,Other/Mixed,1949.0,22745674.0,Hager J,Cardiovascular disease,initial,2012-06-20,GCST001581,Coronary heart disease
3749,Asian,6805.0,22726844.0,Kim JW,Cardiovascular measurement,initial,2012-06-20,GCST001580,QT interval
13915,Other/Mixed,2547.0,22745674.0,Hager J,Cardiovascular disease,replication,2012-06-20,GCST001581,Coronary heart disease
2151,Asian,550.0,22737229.0,Nishida N,"Biological process, Digestive system disorder",initial,2012-06-21,GCST001582,Hepatitis B (viral clearance)
4296,Asian,21043.0,22737229.0,Nishida N,"Biological process, Digestive system disorder",replication,2012-06-21,GCST001582,Hepatitis B (viral clearance)
13816,Other/Mixed,928.0,23505185.0,Plourde M,Metabolic disorder,initial,2012-06-28,GCST001583,Adiposity
6689,European,1692.0,22744181.0,Hai R,"Other measurement, Body measurement",replication,2012-06-29,GCST001584,Lean body mass and age at menarche (combined)
2333,Asian,801.0,22744181.0,Hai R,"Other measurement, Body measurement",initial,2012-06-29,GCST001584,Lean body mass and age at menarche (combined)
10100,European,16175.0,22747683.0,Eriksson N,Body measurement,initial,2012-06-30,GCST001585,Breast size
6047,European,985.0,22794196.0,Lu Y,Cancer,initial,2012-07-01,GCST001589,Ovarian cancer
7249,European,2402.0,22754043.0,Byrne EM,Other measurement,initial,2012-07-01,GCST001586,Insomnia (caffeine-induced)
6117,European,1020.0,22699663.0,Divaris K,Digestive system disorder,initial,2012-07-01,GCST001588,Periodontal microbiota
9768,European,11617.0,22794196.0,Lu Y,Cancer,replication,2012-07-01,GCST001589,Ovarian cancer
3736,Asian,6534.0,22751097.0,Lu X,Cardiovascular disease,initial,2012-07-01,GCST001587,Coronary heart disease
4337,Asian,26932.0,22751097.0,Lu X,Cardiovascular disease,replication,2012-07-01,GCST001587,Coronary heart disease
11106,European,50411.0,22763110.0,Zeggini E,Other disease,replication,2012-07-03,GCST001592,Osteoarthritis
6456,European,1392.0,22760553.0,Adkins DE,Response to drug,initial,2012-07-03,GCST001591,Response to citalopram treatment
563,African American or Afro-Caribbean,264.0,22760553.0,Adkins DE,Response to drug,initial,2012-07-03,GCST001591,Response to citalopram treatment
6418,European,1364.0,22764253.0,Thier S,Other trait,initial,2012-07-03,GCST001590,Essential tremor
13504,Other/Mixed,106.0,22760553.0,Adkins DE,Response to drug,initial,2012-07-03,GCST001591,Response to citalopram treatment
10254,European,18419.0,22763110.0,Zeggini E,Other disease,initial,2012-07-03,GCST001592,Osteoarthritis
6248,European,1163.0,22764253.0,Thier S,Other trait,replication,2012-07-03,GCST001590,Essential tremor
6659,European,1644.0,22792082.0,Himes BE,"Response to drug, Other disease",initial,2012-07-05,GCST001597,Asthma (bronchodilator response)
9714,European,11052.0,22792070.0,Medina-Gomez C,Other measurement,replication,2012-07-05,GCST001594,Bone mineral density
6141,European,1051.0,22792082.0,Himes BE,"Response to drug, Other disease",replication,2012-07-05,GCST001597,Asthma (bronchodilator response)
8662,European,5672.0,22792071.0,Zheng HF,Other measurement,initial,2012-07-05,GCST001595,Bone mineral density
6816,European,1834.0,22792070.0,Medina-Gomez C,Other measurement,initial,2012-07-05,GCST001594,Bone mineral density
1710,Asian,126.0,22763476.0,Zhang D,"Other measurement, Cardiovascular measurement",initial,2012-07-05,GCST001598,Blood pressure
2451,Asian,1035.0,22792221.0,Takamoto M,Neurological disorder,replication,2012-07-05,GCST001596,Glaucoma
2357,Asian,843.0,22792221.0,Takamoto M,Neurological disorder,initial,2012-07-05,GCST001596,Glaucoma
6129,European,1032.0,22792071.0,Zheng HF,Other measurement,replication,2012-07-05,GCST001593,Cortical thickness
8706,European,5878.0,22792071.0,Zheng HF,Other measurement,initial,2012-07-05,GCST001593,Cortical thickness
4905,European,263.0,22773346.0,Edwards DR,Biological process,initial,2012-07-07,GCST001599,Aging
2915,Asian,1999.0,22673310.0,Liao M,Other measurement,initial,2012-07-07,GCST001600,IgG levels
2638,Asian,1496.0,22673310.0,Liao M,Other measurement,replication,2012-07-07,GCST001600,IgG levels
4930,European,282.0,22785395.0,Gaj P,Neurological disorder,initial,2012-07-11,GCST001602,Alzheimer's disease
6378,European,1312.0,22780124.0,Lind PA,Biological process,initial,2012-07-11,GCST001601,Gambling
3980,Asian,9156.0,22807686.0,Li S,Cancer,replication,2012-07-12,GCST001603,Hepatocellular carcinoma
763,African American or Afro-Caribbean,927.0,22791750.0,Chen G,"Other measurement, Other trait",initial,2012-07-12,GCST001604,Insulin-related traits
125,African,570.0,22791750.0,Chen G,"Other measurement, Other trait",replication,2012-07-12,GCST001604,Insulin-related traits
3245,Asian,3003.0,22807686.0,Li S,Cancer,initial,2012-07-12,GCST001603,Hepatocellular carcinoma
4126,Asian,12536.0,22797724.0,Shiraishi K,Cancer,replication,2012-07-15,GCST001609,Lung adenocarcinoma
4300,Asian,21417.0,22797727.0,Okada Y,"Other measurement, Cardiovascular measurement",initial,2012-07-15,GCST001608,Renal function-related traits (urea)
4092,Asian,11657.0,22797727.0,Okada Y,"Other measurement, Cardiovascular measurement",replication,2012-07-15,GCST001608,Renal function-related traits (urea)
4284,Asian,19636.0,22797727.0,Okada Y,Other measurement,replication,2012-07-15,GCST001607,Renal function-related traits (eGRFcrea)
3778,Asian,7028.0,22797724.0,Shiraishi K,Cancer,initial,2012-07-15,GCST001609,Lung adenocarcinoma
4413,Asian,39717.0,22797727.0,Okada Y,Other measurement,initial,2012-07-15,GCST001610,Renal function-related traits (BUN)
4254,Asian,17461.0,22797727.0,Okada Y,Other measurement,replication,2012-07-15,GCST001610,Renal function-related traits (BUN)
4285,Asian,19662.0,22797727.0,Okada Y,Other measurement,replication,2012-07-15,GCST001606,Renal function-related traits (sCR)
4418,Asian,42257.0,22797727.0,Okada Y,Other measurement,initial,2012-07-15,GCST001606,Renal function-related traits (sCR)
4420,Asian,42451.0,22797727.0,Okada Y,Other measurement,initial,2012-07-15,GCST001607,Renal function-related traits (eGRFcrea)
7958,European,3664.0,23055271.0,Gregersen PK,"Neurological disorder, Other disease",replication,2012-07-16,GCST001611,Myasthenia gravis
8720,European,5905.0,23055271.0,Gregersen PK,"Neurological disorder, Other disease",initial,2012-07-16,GCST001611,Myasthenia gravis
8780,European,6173.0,22808956.0,Lyons PA,Immune system disorder,initial,2012-07-19,GCST001613,Antineutrophil cytoplasmic antibody-associated vasculitis
9213,European,8175.0,22829776.0,Coviello AD,Other measurement,replication,2012-07-19,GCST001612,Sex hormone-binding globulin levels
7649,European,3120.0,22808956.0,Lyons PA,Immune system disorder,replication,2012-07-19,GCST001613,Antineutrophil cytoplasmic antibody-associated vasculitis
10437,European,21791.0,22829776.0,Coviello AD,Other measurement,initial,2012-07-19,GCST001612,Sex hormone-binding globulin levels
8056,European,3931.0,22814818.0,Hoehn R,Other measurement,initial,2012-07-20,GCST001614,Central corneal thickness
6475,European,1418.0,22814818.0,Hoehn R,Other measurement,replication,2012-07-20,GCST001614,Central corneal thickness
8210,European,4356.0,22821403.0,Ellinghaus D,"Digestive system disorder, Immune system disorder",initial,2012-07-23,GCST001615,Sclerosing cholangitis and ulcerative colitis (combined)
5884,European,883.0,22911860.0,Hernandez DG,Neurological disorder,initial,2012-07-24,GCST001617,Parkinson's disease
4896,European,246.0,22828495.0,Brown AA,Other measurement,initial,2012-07-24,GCST001618,Neural processing (facial expression)
4636,European,85.0,22828495.0,Brown AA,Other measurement,replication,2012-07-24,GCST001618,Neural processing (facial expression)
6245,European,1161.0,22841784.0,Patin E,"Cancer, Digestive system disorder",initial,2012-07-26,GCST001623,Hepatitis C induced liver fibrosis
8910,European,6739.0,22837380.0,Fischer A,Other disease,replication,2012-07-26,GCST001622,Sarcoidosis
6266,European,1181.0,22841784.0,Patin E,"Cancer, Digestive system disorder",replication,2012-07-26,GCST001623,Hepatitis C induced liver fibrosis
10765,European,32875.0,22837378.0,Wilk JB,Other measurement,initial,2012-07-26,GCST001621,Airflow obstruction
5567,European,659.0,22843503.0,Qi Q,Other measurement,replication,2012-07-26,GCST001620,Resistin levels
7542,European,2881.0,22837378.0,Wilk JB,Other measurement,replication,2012-07-26,GCST001621,Airflow obstruction
13852,Other/Mixed,1314.0,22843504.0,Anney R,Neurological disorder,replication,2012-07-26,GCST001619,Autism
13864,Other/Mixed,1419.0,22843504.0,Anney R,Neurological disorder,initial,2012-07-26,GCST001619,Autism
7744,European,3248.0,22843503.0,Qi Q,Other measurement,initial,2012-07-26,GCST001620,Resistin levels
7035,European,2139.0,22837380.0,Fischer A,Other disease,initial,2012-07-26,GCST001622,Sarcoidosis
5846,European,855.0,22843789.0,Baldwin RM,"Response to drug, Neurological disorder, Other measurement",initial,2012-07-27,GCST001624,Paclitaxel-induced neuropathy
469,African American or Afro-Caribbean,117.0,22843789.0,Baldwin RM,"Response to drug, Neurological disorder, Other measurement",replication,2012-07-27,GCST001624,Paclitaxel-induced neuropathy
11658,European,114863.0,22843499.0,Boraska V,Other measurement,initial,2012-07-27,GCST001625,Sex ratio at birth
4732,European,154.0,22843789.0,Baldwin RM,"Response to drug, Neurological disorder, Other measurement",replication,2012-07-27,GCST001624,Paclitaxel-induced neuropathy
2639,Asian,1496.0,22864923.0,Yang C,Other measurement,replication,2012-08-03,GCST001626,IgA levels
2916,Asian,1999.0,22864923.0,Yang C,Other measurement,initial,2012-08-03,GCST001626,IgA levels
7975,European,3715.0,22863734.0,Ludwig KU,"Other trait, Other measurement, Other disease",initial,2012-08-05,GCST001628,Orofacial clefts
3080,Asian,2385.0,22863734.0,Ludwig KU,"Other trait, Other measurement, Other disease",replication,2012-08-05,GCST001628,Orofacial clefts
2069,Asian,454.0,22863731.0,Cheung CL,Metabolic disorder,replication,2012-08-05,GCST001627,Thyrotoxic hypokalemic periodic paralysis
2550,Asian,1239.0,22863731.0,Cheung CL,Metabolic disorder,initial,2012-08-05,GCST001627,Thyrotoxic hypokalemic periodic paralysis
2136,Asian,528.0,22872573.0,Hu L,"Response to drug, Cancer",initial,2012-08-07,GCST001629,Response to platinum-based chemotherapy in non-small-cell lung cancer
686,African American or Afro-Caribbean,605.0,22869035.0,Logue MW,Neurological disorder,replication,2012-08-07,GCST001630,Post-traumatic stress disorder
11028,European,44216.0,22883433.0,Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium 2,Neurological disorder,replication,2012-08-07,GCST001631,Schizophrenia
7841,European,3400.0,22883433.0,Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium 2,Neurological disorder,initial,2012-08-07,GCST001631,Schizophrenia
5296,European,491.0,22869035.0,Logue MW,Neurological disorder,initial,2012-08-07,GCST001630,Post-traumatic stress disorder
5128,European,409.0,22872573.0,Hu L,"Response to drug, Cancer",replication,2012-08-07,GCST001629,Response to platinum-based chemotherapy in non-small-cell lung cancer
1956,Asian,340.0,22872573.0,Hu L,"Response to drug, Cancer",replication,2012-08-07,GCST001629,Response to platinum-based chemotherapy in non-small-cell lung cancer
5779,European,817.0,22890011.0,Frazier-Wood AC,Response to drug,initial,2012-08-09,GCST001632,Response to fenofibrate
10141,European,16616.0,22886559.0,Rajaraman P,Cancer,replication,2012-08-11,GCST001633,Glioma
8927,European,6811.0,22886559.0,Rajaraman P,Cancer,initial,2012-08-11,GCST001633,Glioma
4224,Asian,15804.0,22885925.0,Shi Y,Other disease,replication,2012-08-12,GCST001634,Polycystic ovary syndrome
3547,Asian,5255.0,22885925.0,Shi Y,Other disease,initial,2012-08-12,GCST001634,Polycystic ovary syndrome
9162,European,7919.0,22889921.0,Stewart SE,Neurological disorder,initial,2012-08-14,GCST001636,Obsessive-compulsive disorder
8799,European,6249.0,22889924.0,Scharf JM,Neurological disorder,initial,2012-08-14,GCST001635,Tourette syndrome
12661,Hispanic or Latin American,496.0,22889924.0,Scharf JM,Neurological disorder,replication,2012-08-14,GCST001635,Tourette syndrome
292,African,5755.0,22895189.0,Timmann C,Digestive system disorder,replication,2012-08-15,GCST001637,Malaria
239,African,2153.0,22895189.0,Timmann C,Digestive system disorder,initial,2012-08-15,GCST001637,Malaria
8872,European,6608.0,22916037.0,Inouye M,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",initial,2012-08-16,GCST001639,Metabolite levels
11030,European,44385.0,22899653.0,Timofeeva MN,Cancer,initial,2012-08-16,GCST001638,Lung cancer
3575,Asian,5415.0,22899653.0,Timofeeva MN,Cancer,replication,2012-08-16,GCST001638,Lung cancer
6398,European,1345.0,22903471.0,Hibar DP,Other measurement,initial,2012-08-18,GCST001640,Lentiform nucleus volume
5319,European,499.0,22907730.0,Ji Y,Response to drug,initial,2012-08-21,GCST001641,Response to antidepressants
6796,European,1806.0,22907691.0,Breitfeld J,Other measurement,replication,2012-08-21,GCST001642,Vaspin levels
6298,European,1207.0,22907730.0,Ji Y,Response to drug,replication,2012-08-21,GCST001641,Response to antidepressants
5803,European,826.0,22907691.0,Breitfeld J,Other measurement,initial,2012-08-21,GCST001642,Vaspin levels
8203,European,4330.0,22915352.0,Power RA,"Neurological disorder, Other measurement",initial,2012-08-22,GCST001643,Depression (age of onset)
7494,European,2786.0,22915352.0,Power RA,"Neurological disorder, Other measurement",replication,2012-08-22,GCST001643,Depression (age of onset)
7379,European,2567.0,22911880.0,Boraska V,"Metabolic disorder, Neurological disorder",initial,2012-08-22,GCST001644,Eating disorders
5720,European,767.0,22911880.0,Boraska V,"Metabolic disorder, Neurological disorder",replication,2012-08-22,GCST001644,Eating disorders
837,African American or Afro-Caribbean,1249.0,23067351.0,Rasmussen-Torvik LJ,"Lipid or lipoprotein measurement, Other measurement",initial,2012-08-23,GCST001645,LDL cholesterol
12870,Hispanic or Latin American,2100.0,22923026.0,Cheng I,Cancer,initial,2012-08-24,GCST001646,Prostate cancer
2952,Asian,2075.0,22923026.0,Cheng I,Cancer,initial,2012-08-24,GCST001646,Prostate cancer
3514,Asian,4969.0,22923026.0,Cheng I,Cancer,replication,2012-08-24,GCST001646,Prostate cancer
8639,European,5602.0,22923026.0,Cheng I,Cancer,replication,2012-08-24,GCST001646,Prostate cancer
7947,European,3625.0,22925353.0,Lee HJ,Neurological disorder,initial,2012-08-25,GCST001647,Bipolar disorder
1418,African American or Afro-Caribbean,14579.0,22923054.0,Chen F,Cancer,replication,2012-08-25,GCST001648,Breast cancer
1234,African American or Afro-Caribbean,5761.0,22923054.0,Chen F,Cancer,initial,2012-08-25,GCST001648,Breast cancer
3559,Asian,5301.0,22922875.0,Vithana EN,Neurological disorder,replication,2012-08-26,GCST001649,Glaucoma (primary angle closure)
3561,Asian,5319.0,22922875.0,Vithana EN,Neurological disorder,initial,2012-08-26,GCST001649,Glaucoma (primary angle closure)
3275,Asian,3268.0,22922875.0,Vithana EN,Neurological disorder,initial,2012-08-26,GCST001649,Glaucoma (primary angle closure)
2010,Asian,389.0,22922875.0,Vithana EN,Neurological disorder,replication,2012-08-26,GCST001649,Glaucoma (primary angle closure)
8366,European,4830.0,22922875.0,Vithana EN,Neurological disorder,replication,2012-08-26,GCST001649,Glaucoma (primary angle closure)
13630,Other/Mixed,340.0,22922875.0,Vithana EN,Neurological disorder,replication,2012-08-26,GCST001649,Glaucoma (primary angle closure)
3203,Asian,2875.0,22922875.0,Vithana EN,Neurological disorder,initial,2012-08-26,GCST001649,Glaucoma (primary angle closure)
377,African American or Afro-Caribbean,18.0,22952603.0,Hart AB,Biological process,initial,2012-08-28,GCST001651,Response to amphetamines
1336,African American or Afro-Caribbean,8280.0,22939635.0,Reiner AP,Inflammatory measurement,initial,2012-08-28,GCST001650,C-reactive protein
1551,Asian,10.0,22952603.0,Hart AB,Biological process,initial,2012-08-28,GCST001651,Response to amphetamines
1156,African American or Afro-Caribbean,3787.0,22939635.0,Reiner AP,Inflammatory measurement,replication,2012-08-28,GCST001650,C-reactive protein
4994,European,325.0,22952603.0,Hart AB,Biological process,initial,2012-08-28,GCST001651,Response to amphetamines
12958,Hispanic or Latin American,3548.0,22939635.0,Reiner AP,Inflammatory measurement,initial,2012-08-28,GCST001650,C-reactive protein
13386,Other/Mixed,6.0,22952603.0,Hart AB,Biological process,initial,2012-08-28,GCST001651,Response to amphetamines
12959,Hispanic or Latin American,3548.0,22939635.0,Reiner AP,Inflammatory measurement,replication,2012-08-28,GCST001650,C-reactive protein
8660,European,5656.0,22939635.0,Reiner AP,Inflammatory measurement,replication,2012-08-28,GCST001650,C-reactive protein
13341,Other/Mixed,1.0,22952603.0,Hart AB,Biological process,initial,2012-08-28,GCST001651,Response to amphetamines
12507,Hispanic or Latin American,17.0,22952603.0,Hart AB,Biological process,initial,2012-08-28,GCST001651,Response to amphetamines
9060,European,7405.0,22936702.0,Hofmann S,Other disease,replication,2012-08-30,GCST001654,Sarcoidosis
6840,European,1870.0,22936702.0,Hofmann S,Other disease,initial,2012-08-30,GCST001654,Sarcoidosis
7727,European,3225.0,22936694.0,Jin G,Other measurement,initial,2012-08-30,GCST001653,Androgen levels
13905,Other/Mixed,2165.0,22935194.0,Connolly JJ,Neurological disorder,initial,2012-08-30,GCST001655,Autism
7487,European,2765.0,22936669.0,Julia A,Digestive system disorder,initial,2012-08-30,GCST001652,Crohn's disease
7485,European,2761.0,22936669.0,Julia A,Digestive system disorder,replication,2012-08-30,GCST001652,Crohn's disease
2718,Asian,1627.0,22960237.0,Han Y,Other measurement,initial,2012-08-31,GCST001656,Comprehensive strength and appendicular lean mass
7759,European,3286.0,22960237.0,Han Y,Other measurement,replication,2012-08-31,GCST001656,Comprehensive strength and appendicular lean mass
7750,European,3267.0,22885689.0,Levinson DF,Neurological disorder,initial,2012-09-01,GCST001657,Schizophrenia
11314,European,69033.0,22885922.0,Morris AP,Metabolic disorder,initial,2012-09-01,GCST005047,Type 2 diabetes
11385,European,77138.0,22885922.0,Morris AP,Metabolic disorder,replication,2012-09-01,GCST005047,Type 2 diabetes
5757,European,798.0,22881374.0,Cummings AC,Neurological disorder,initial,2012-09-01,GCST001658,Alzheimer's disease (late onset)
3336,Asian,3650.0,22885922.0,Morris AP,Metabolic disorder,replication,2012-09-01,GCST005047,Type 2 diabetes
13590,Other/Mixed,253.0,22885689.0,Levinson DF,Neurological disorder,initial,2012-09-01,GCST001657,Schizophrenia
8809,European,6303.0,22941191.0,Diskin SJ,Cancer,initial,2012-09-02,GCST001660,Neuroblastoma
1038,African American or Afro-Caribbean,2856.0,22941191.0,Diskin SJ,Cancer,replication,2012-09-02,GCST001660,Neuroblastoma
6211,European,1131.0,22941191.0,Diskin SJ,Cancer,replication,2012-09-02,GCST001660,Neuroblastoma
7250,European,2406.0,22941190.0,Holliday EG,Cardiovascular disease,initial,2012-09-02,GCST001659,Stroke (ischemic)
11167,European,54410.0,22941190.0,Holliday EG,Cardiovascular disease,replication,2012-09-02,GCST001659,Stroke (ischemic)
8082,European,3988.0,22949513.0,EPICURE Consortium,Neurological disorder,initial,2012-09-04,GCST001662,Generalized epilepsy
7934,European,3590.0,22949513.0,EPICURE Consortium,Neurological disorder,replication,2012-09-04,GCST001662,Generalized epilepsy
4979,European,310.0,22945461.0,Rahmioglu N,Liver enzyme measurement,initial,2012-09-04,GCST001661,CYP3A4 enzyme activity
9473,European,9355.0,22959728.0,Ahmeti KB,Neurological disorder,initial,2012-09-05,GCST004792,Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals
9474,European,9355.0,22959728.0,Ahmeti KB,Neurological disorder,initial,2012-09-05,GCST004793,Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals
8174,European,4243.0,22959728.0,Ahmeti KB,Neurological disorder,initial,2012-09-05,GCST004791,Amyotrophic lateral sclerosis (C9orf72 mutation interaction)
8175,European,4243.0,22959728.0,Ahmeti KB,"Neurological disorder, Other measurement",initial,2012-09-05,GCST001663,Amyotrophic lateral sclerosis (age of onset)
9472,European,9355.0,22959728.0,Ahmeti KB,Neurological disorder,initial,2012-09-05,GCST001664,Amyotrophic lateral sclerosis
9495,European,9469.0,22956598.0,Peters MJ,Other trait,replication,2012-09-06,GCST001668,Pain
3215,Asian,2902.0,22951594.0,Elgazzar S,Cancer,initial,2012-09-06,GCST001667,Breast cancer
4229,Asian,16064.0,22951725.0,Tang XF,Immune system disorder,replication,2012-09-06,GCST001670,Vitiligo
8999,European,7099.0,22956598.0,Peters MJ,Other trait,initial,2012-09-06,GCST001668,Pain
3344,Asian,3712.0,22961080.0,Li H,Metabolic disorder,initial,2012-09-06,GCST001666,Type 2 diabetes
3193,Asian,2818.0,22951725.0,Tang XF,Immune system disorder,initial,2012-09-06,GCST001670,Vitiligo
3442,Asian,4450.0,22951594.0,Elgazzar S,Cancer,replication,2012-09-06,GCST001667,Breast cancer
7672,European,3166.0,22961961.0,Foroud T,Cardiovascular disease,initial,2012-09-06,GCST001665,Intracranial aneurysm
3013,Asian,2192.0,22951595.0,Hwang JY,Other disease,initial,2012-09-06,GCST001669,Polycystic ovary syndrome
4386,Asian,35339.0,22961080.0,Li H,Metabolic disorder,replication,2012-09-06,GCST001666,Type 2 diabetes
2940,Asian,2034.0,22961080.0,Li H,Metabolic disorder,replication,2012-09-06,GCST001666,Type 2 diabetes
3014,Asian,2192.0,22951595.0,Hwang JY,Other disease,replication,2012-09-06,GCST001669,Polycystic ovary syndrome
2813,Asian,1783.0,22961080.0,Li H,Metabolic disorder,replication,2012-09-06,GCST001666,Type 2 diabetes
5129,European,409.0,23225573.0,Buck D,Other measurement,replication,2012-09-08,GCST001671,IgG levels
4869,European,229.0,23225573.0,Buck D,Other measurement,initial,2012-09-08,GCST001671,IgG levels
7550,European,2894.0,22968431.0,Urban TJ,"Response to drug, Digestive system disorder",replication,2012-09-09,GCST001673,Drug-induced liver injury
4241,Asian,16712.0,22960999.0,Wu C,Cancer,replication,2012-09-09,GCST001672,Esophageal cancer  (alcohol interaction)
8003,European,3784.0,22968431.0,Urban TJ,"Response to drug, Digestive system disorder",initial,2012-09-09,GCST001673,Drug-induced liver injury
10279,European,18811.0,22961001.0,Su Z,Digestive system disorder,replication,2012-09-09,GCST001675,Barrett's esophagus
4242,Asian,16712.0,22960999.0,Wu C,Cancer,replication,2012-09-09,GCST001674,Esophageal cancer (squamous cell)
3394,Asian,4075.0,22960999.0,Wu C,Cancer,initial,2012-09-09,GCST001674,Esophageal cancer (squamous cell)
8982,European,7024.0,22961001.0,Su Z,Digestive system disorder,initial,2012-09-09,GCST001675,Barrett's esophagus
3393,Asian,4075.0,22960999.0,Wu C,Cancer,initial,2012-09-09,GCST001672,Esophageal cancer  (alcohol interaction)
11223,European,59325.0,22982992.0,Yang J,"Body measurement, Other measurement",replication,2012-09-12,GCST001676,Body mass index
11763,European,133154.0,22982992.0,Yang J,"Body measurement, Other measurement",initial,2012-09-12,GCST001676,Body mass index
6075,European,1000.0,22981920.0,Weissflog L,Neurological disorder,initial,2012-09-13,GCST001682,Personality disorders
7031,European,2136.0,22982463.0,Tang WH,Cardiovascular measurement,initial,2012-09-13,GCST001677,Paraoxonase activity
4404,Asian,37586.0,23028356.0,Myouzen K,Immune system disorder,replication,2012-09-13,GCST001681,Rheumatoid arthritis
2391,Asian,914.0,22976474.0,Siddiq A,Cancer,replication,2012-09-13,GCST001683,Breast cancer
8593,European,5388.0,23028347.0,Liu F,"Other trait, Other measurement",initial,2012-09-13,GCST001678,Facial morphology
3630,Asian,5683.0,23028356.0,Myouzen K,Immune system disorder,initial,2012-09-13,GCST001681,Rheumatoid arthritis
12838,Hispanic or Latin American,1464.0,22976474.0,Siddiq A,Cancer,replication,2012-09-13,GCST001683,Breast cancer
1149,African American or Afro-Caribbean,3748.0,22976474.0,Siddiq A,Cancer,initial,2012-09-13,GCST001683,Breast cancer
7507,European,2801.0,22969067.0,Mishra A,Other measurement,initial,2012-09-13,GCST001680,Corneal curvature
2640,Asian,1496.0,23028341.0,Yang X,Other measurement,replication,2012-09-13,GCST001679,Complement C3 and C4 levels
10757,European,32530.0,22976474.0,Siddiq A,Cancer,initial,2012-09-13,GCST001683,Breast cancer
8971,European,6972.0,22976474.0,Siddiq A,Cancer,replication,2012-09-13,GCST001683,Breast cancer
8114,European,4071.0,23028347.0,Liu F,"Other trait, Other measurement",replication,2012-09-13,GCST001678,Facial morphology
2917,Asian,1999.0,23028341.0,Yang X,Other measurement,initial,2012-09-13,GCST001679,Complement C3 and C4 levels
10329,European,19599.0,22990020.0,Huang J,Other measurement,initial,2012-09-18,GCST001684,Plasminogen activator inhibitor type 1 levels (PAI-1)
2420,Asian,963.0,23000144.0,Nakamura M,Cancer,initial,2012-09-18,GCST001685,Primary biliary cholangitis
2608,Asian,1402.0,23000144.0,Nakamura M,Cancer,replication,2012-09-18,GCST001685,Primary biliary cholangitis
8106,European,4048.0,22986903.0,Hansel NN,Other disease,initial,2012-09-18,GCST001686,Chronic obstructive pulmonary disease
6771,European,1772.0,22986903.0,Hansel NN,Other disease,replication,2012-09-18,GCST001686,Chronic obstructive pulmonary disease
9685,European,10764.0,22990020.0,Huang J,Other measurement,replication,2012-09-18,GCST001684,Plasminogen activator inhibitor type 1 levels (PAI-1)
8313,European,4683.0,22993228.0,Williams FM,Other disease,initial,2012-09-19,GCST001687,Disc degeneration (lumbar)
8316,European,4684.0,23028342.0,Sandholm N,Metabolic disorder,replication,2012-09-20,GCST001688,Type 1 diabetes nephropathy
8038,European,3889.0,22997280.0,Ho JE,Hematological measurement,initial,2012-09-20,GCST006519,Growth differentiation factor-15 levels
5772,European,810.0,22990015.0,Arning A,Cardiovascular disease,initial,2012-09-20,GCST001689,Stroke (pediatric)
8791,European,6231.0,23028342.0,Sandholm N,Metabolic disorder,initial,2012-09-20,GCST001688,Type 1 diabetes nephropathy
7943,European,3618.0,23001122.0,Orr N,Cancer,initial,2012-09-23,GCST001690,Breast cancer (male)
5917,European,912.0,23001122.0,Orr N,Cancer,replication,2012-09-23,GCST001690,Breast cancer (male)
1662,Asian,96.0,23006423.0,Niu N,Response to drug,initial,2012-09-24,GCST001694,Response to taxane treatment (placlitaxel)
12749,Hispanic or Latin American,815.0,23017229.0,Voruganti VS,Other measurement,initial,2012-09-24,GCST001691,Monocyte chemoattractant protein-1 levels
1661,Asian,96.0,23006423.0,Niu N,Response to drug,initial,2012-09-24,GCST001692,Response to taxane treatment (docetaxel)
13844,Other/Mixed,1267.0,23007406.0,Yang JJ,Cancer,replication,2012-09-24,GCST001693,Acute lymphoblastic leukemia (childhood)
13845,Other/Mixed,1268.0,23007406.0,Yang JJ,Cancer,initial,2012-09-24,GCST001693,Acute lymphoblastic leukemia (childhood)
459,African American or Afro-Caribbean,96.0,23006423.0,Niu N,Response to drug,initial,2012-09-24,GCST001694,Response to taxane treatment (placlitaxel)
4665,European,96.0,23006423.0,Niu N,Response to drug,initial,2012-09-24,GCST001694,Response to taxane treatment (placlitaxel)
458,African American or Afro-Caribbean,96.0,23006423.0,Niu N,Response to drug,initial,2012-09-24,GCST001692,Response to taxane treatment (docetaxel)
4664,European,96.0,23006423.0,Niu N,Response to drug,initial,2012-09-24,GCST001692,Response to taxane treatment (docetaxel)
9444,European,9190.0,23001564.0,Mangino M,Other measurement,initial,2012-09-25,GCST001697,Telomere length
3579,Asian,5462.0,23049750.0,Kumasaka N,Biological process,replication,2012-09-25,GCST001696,Smoking behavior
7638,European,3095.0,23010768.0,Meier S,Neurological disorder,initial,2012-09-25,GCST001695,Bipolar disorder (Negative mood delusions)
4093,Asian,11696.0,23049750.0,Kumasaka N,Biological process,initial,2012-09-25,GCST001696,Smoking behavior
7439,European,2681.0,23010768.0,Meier S,Neurological disorder,replication,2012-09-25,GCST001695,Bipolar disorder (Negative mood delusions)
3991,Asian,9380.0,23022100.0,Franceschini N,Other measurement,initial,2012-09-26,GCST001699,Serum albumin level
13583,Other/Mixed,235.0,23021708.0,Kerns SL,"Cancer, Other disease, Biological process",initial,2012-09-26,GCST001700,Erectile dysfunction and prostate cancer treatment
4034,Asian,10168.0,23022100.0,Franceschini N,"Hematological measurement, Other measurement",initial,2012-09-26,GCST001698,Serum total protein level
11142,European,53190.0,23022100.0,Franceschini N,Other measurement,initial,2012-09-26,GCST001699,Serum albumin level
13574,Other/Mixed,230.0,23021708.0,Kerns SL,"Cancer, Other disease, Biological process",replication,2012-09-26,GCST001700,Erectile dysfunction and prostate cancer treatment
10585,European,25539.0,23022100.0,Franceschini N,"Hematological measurement, Other measurement",initial,2012-09-26,GCST001698,Serum total protein level
10268,European,18604.0,23028483.0,Ramasamy A,Other disease,initial,2012-09-28,GCST001701,Asthma
10047,European,15286.0,23028483.0,Ramasamy A,Other disease,replication,2012-09-28,GCST001701,Asthma
4064,Asian,10993.0,23023329.0,Xu J,Cancer,replication,2012-09-30,GCST001702,Prostate cancer
3089,Asian,2425.0,23023329.0,Xu J,Cancer,initial,2012-09-30,GCST001702,Prostate cancer
9744,European,11375.0,22961000.0,Liu JZ,Cancer,initial,2012-10-01,GCST005581,Primary biliary cirrhosis
6721,European,1720.0,23031429.0,Surakka I,Other measurement,initial,2012-10-03,GCST001703,Apolipoprotein Levels
6720,European,1720.0,23031429.0,Surakka I,Lipid or lipoprotein measurement,initial,2012-10-03,GCST001704,Cholesterol and Triglycerides
6341,European,1261.0,23031429.0,Surakka I,Lipid or lipoprotein measurement,replication,2012-10-03,GCST001704,Cholesterol and Triglycerides
4941,European,289.0,23054467.0,Postula M,Cardiovascular measurement,initial,2012-10-04,GCST001705,Platelet reactivity
10962,European,39965.0,23041239.0,Traylor M,Cardiovascular disease,replication,2012-10-05,GCST001706,Stroke (ischemic)
11362,European,74393.0,23041239.0,Traylor M,Cardiovascular disease,initial,2012-10-05,GCST001706,Stroke (ischemic)
3098,Asian,2465.0,23041239.0,Traylor M,Cardiovascular disease,replication,2012-10-05,GCST001706,Stroke (ischemic)
2505,Asian,1167.0,23041938.0,Lee YJ,Cardiovascular disease,initial,2012-10-06,GCST001707,Behcet's disease
2194,Asian,635.0,23041938.0,Lee YJ,Cardiovascular disease,replication,2012-10-06,GCST001707,Behcet's disease
8434,European,4948.0,23053960.0,Lee YH,Immune system disorder,initial,2012-10-07,GCST001708,Systemic lupus erythematosus
3965,Asian,8877.0,23042114.0,Hirota T,Immune system disorder,replication,2012-10-07,GCST001709,Atopic dermatitis
3995,Asian,9443.0,23042114.0,Hirota T,Immune system disorder,initial,2012-10-07,GCST001709,Atopic dermatitis
7998,European,3776.0,23056639.0,de Boer RA,Other measurement,initial,2012-10-09,GCST001711,Protein biomarker
7197,European,2322.0,23043469.0,Menzel S,Hematological measurement,initial,2012-10-09,GCST001710,HbA2 levels
6331,European,1251.0,23049088.0,Meng W,Other trait,initial,2012-10-09,GCST001712,Myopia (pathological)
6715,European,1716.0,23043469.0,Menzel S,Hematological measurement,replication,2012-10-09,GCST001710,HbA2 levels
5926,European,920.0,23064961.0,Shaffer JR,Digestive system disorder,initial,2012-10-11,GCST001713,Dental caries
10472,European,22548.0,23065704.0,Amin Al Olama A,Cancer,initial,2012-10-12,GCST001714,Prostate cancer
11097,European,49121.0,23065704.0,Amin Al Olama A,Cancer,replication,2012-10-12,GCST001714,Prostate cancer
6682,European,1678.0,23093944.0,Krumsiek J,Other measurement,initial,2012-10-18,GCST006249,Serum metabolite levels
8041,European,3895.0,23100282.0,Hopewell JC,Response to drug,initial,2012-10-24,GCST001716,Response to statin therapy
3990,Asian,9374.0,23103227.0,Jin G,Cancer,initial,2012-10-25,GCST001718,"Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)"
4294,Asian,20437.0,23103227.0,Jin G,Cancer,replication,2012-10-25,GCST001718,"Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)"
6465,European,1402.0,23133572.0,Rye MS,Neurological disorder,initial,2012-10-25,GCST001717,Otitis media (chronic/recurrent)
9877,European,13053.0,23104005.0,Gudmundsson J,Cancer,replication,2012-10-28,GCST001719,Prostate cancer
3169,Asian,2741.0,23104006.0,Nyholt DR,Other disease,initial,2012-10-28,GCST001720,Endometriosis
11227,European,59585.0,23104005.0,Gudmundsson J,Cancer,initial,2012-10-28,GCST001719,Prostate cancer
3524,Asian,5061.0,23104006.0,Nyholt DR,Other disease,replication,2012-10-28,GCST001720,Endometriosis
9736,European,11256.0,23104006.0,Nyholt DR,Other disease,initial,2012-10-28,GCST001720,Endometriosis
6438,European,1374.0,23108145.0,Wang LE,Cancer,replication,2012-10-29,GCST001721,Lung Cancer (DNA repair capacity)
6774,European,1774.0,23108145.0,Wang LE,Cancer,initial,2012-10-29,GCST001721,Lung Cancer (DNA repair capacity)
2719,Asian,1627.0,23108985.0,Guo YF,Other measurement,initial,2012-10-30,GCST001722,Body mass (lean)
7160,European,2286.0,23108985.0,Guo YF,Other measurement,replication,2012-10-30,GCST001722,Body mass (lean)
4763,European,175.0,23118974.0,Candille SI,"Other measurement, Other trait",initial,2012-10-31,GCST001723,Eye color
2918,Asian,1999.0,23118916.0,Yang M,Other measurement,initial,2012-10-31,GCST001724,IgM levels
2641,Asian,1496.0,23118916.0,Yang M,Other measurement,replication,2012-10-31,GCST001724,IgM levels
4954,European,293.0,23118974.0,Candille SI,"Other measurement, Other trait",replication,2012-10-31,GCST001723,Eye color
9934,European,13664.0,23118302.0,Chu AY,Lipid or lipoprotein measurement,replication,2012-11-01,GCST001727,Lipoprotein-associated phospholipase A2 activity and mass
10830,European,34366.0,23128233.0,Jostins L,Immune system disorder,initial,2012-11-01,GCST001728,Ulcerative colitis
10829,European,34366.0,23128233.0,Jostins L,"Digestive system disorder, Immune system disorder",initial,2012-11-01,GCST001725,Inflammatory bowel disease
8940,European,6851.0,23118302.0,Chu AY,Lipid or lipoprotein measurement,initial,2012-11-01,GCST001727,Lipoprotein-associated phospholipase A2 activity and mass
11008,European,42698.0,23128233.0,Jostins L,Immune system disorder,replication,2012-11-01,GCST001728,Ulcerative colitis
11007,European,42698.0,23128233.0,Jostins L,"Digestive system disorder, Immune system disorder",replication,2012-11-01,GCST001725,Inflammatory bowel disease
11006,European,42698.0,23128233.0,Jostins L,Digestive system disorder,replication,2012-11-01,GCST001729,Crohn's disease
8580,European,5329.0,23118302.0,Chu AY,Lipid or lipoprotein measurement,initial,2012-11-01,GCST001726,Lipoprotein-associated phospholipase A2 activity change in response to statin therapy
10828,European,34366.0,23128233.0,Jostins L,Digestive system disorder,initial,2012-11-01,GCST001729,Crohn's disease
5355,European,516.0,23047291.0,Brown CC,Response to drug,initial,2012-11-01,GCST001730,Response to temozolomide
6342,European,1261.0,23114982.0,Siegert S,"Other measurement, Body measurement, Cancer",replication,2012-11-02,GCST001731,Colorectal cancer (environment interaction)
4981,European,314.0,23114982.0,Siegert S,"Other measurement, Body measurement, Cancer",initial,2012-11-02,GCST001731,Colorectal cancer (environment interaction)
2570,Asian,1301.0,23818313.0,Kim HJ,"Other measurement, Metabolic disorder",replication,2012-11-06,GCST001732,Obesity
2282,Asian,756.0,23818313.0,Kim HJ,"Other measurement, Metabolic disorder",initial,2012-11-06,GCST001732,Obesity
5435,European,564.0,23142968.0,Betcheva ET,Neurological disorder,initial,2012-11-07,GCST001733,Schizophrenia
5159,European,427.0,23142968.0,Betcheva ET,Neurological disorder,replication,2012-11-07,GCST001733,Schizophrenia
1963,Asian,348.0,23144319.0,Lee Y,Cancer,initial,2012-11-08,GCST001734,Non-small cell lung cancer
1413,African American or Afro-Caribbean,13415.0,23139255.0,Butler AM,Cardiovascular measurement,initial,2012-11-08,GCST001735,PR interval
6891,European,1951.0,23144326.0,Kim DK,"Other disease, Hematological measurement, Inflammatory measurement, Other measurement",initial,2012-11-09,GCST001737,Chronic obstructive pulmonary disease-related biomarkers
2286,Asian,758.0,23137000.0,Lin HJ,"Neurological disorder, Metabolic disorder",initial,2012-11-09,GCST001736,Cataracts in type 2 diabetes
5751,European,793.0,23149075.0,Aslibekyan S,Response to drug,initial,2012-11-10,GCST001738,Response to fenofibrate (adiponectin levels)
1067,African American or Afro-Caribbean,2961.0,23146381.0,Levin AM,Other measurement,replication,2012-11-10,GCST001739,IgE levels
12591,Hispanic or Latin American,259.0,23146381.0,Levin AM,Other measurement,initial,2012-11-10,GCST001739,IgE levels
6390,European,1329.0,23146381.0,Levin AM,Other measurement,replication,2012-11-10,GCST001739,IgE levels
12840,Hispanic or Latin American,1477.0,23146381.0,Levin AM,Other measurement,replication,2012-11-10,GCST001739,IgE levels
995,African American or Afro-Caribbean,2469.0,23146381.0,Levin AM,Other measurement,initial,2012-11-10,GCST001739,IgE levels
6593,European,1564.0,23146381.0,Levin AM,Other measurement,initial,2012-11-10,GCST001739,IgE levels
3384,Asian,4012.0,23143601.0,Lan Q,Cancer,replication,2012-11-11,GCST001740,Lung cancer
8528,European,5183.0,23143602.0,Whitcomb DC,Digestive system disorder,initial,2012-11-11,GCST001741,Pancreatitis
8490,European,5080.0,23143602.0,Whitcomb DC,Digestive system disorder,replication,2012-11-11,GCST001741,Pancreatitis
4026,Asian,10054.0,23143601.0,Lan Q,Cancer,initial,2012-11-11,GCST001740,Lung cancer
2519,Asian,1190.0,23149450.0,Otowa T,Neurological disorder,replication,2012-11-13,GCST001742,Panic disorder
3094,Asian,2435.0,23149450.0,Otowa T,Neurological disorder,initial,2012-11-13,GCST001742,Panic disorder
8485,European,5069.0,23150908.0,Jonsson T,Neurological disorder,replication,2012-11-14,GCST001743,Alzheimer's disease
9839,European,12438.0,23150908.0,Jonsson T,Neurological disorder,initial,2012-11-14,GCST001743,Alzheimer's disease
1775,Asian,182.0,23151678.0,Takata R,Response to drug,initial,2012-11-15,GCST001744,Serum tamsulosin hydrochloride concentration
5091,European,390.0,23160099.0,Justice CM,Neurological disorder,initial,2012-11-18,GCST001745,Sagittal craniosynostosis
1403,African American or Afro-Caribbean,13105.0,23166209.0,Smith JG,Cardiovascular measurement,initial,2012-11-19,GCST001746,QT interval
2497,Asian,1138.0,23180272.0,Park BL,Other trait,replication,2012-11-21,GCST001747,Aspirin exacerbated respiratory disease in asthmatics
2334,Asian,802.0,23180272.0,Park BL,Other trait,initial,2012-11-21,GCST001747,Aspirin exacerbated respiratory disease in asthmatics
1412,African American or Afro-Caribbean,13372.0,23183192.0,Deo R,Cardiovascular measurement,initial,2012-11-23,GCST001748,Resting heart rate
5537,European,642.0,23180869.0,Wu C,Cancer,initial,2012-11-24,GCST001749,Pancreatic cancer
1976,Asian,363.0,23180869.0,Wu C,Cancer,replication,2012-11-24,GCST001749,Pancreatic cancer
9691,European,10781.0,23184150.0,Henrion M,Cancer,initial,2012-11-25,GCST001750,Renal cell carcinoma
9846,European,12525.0,23184150.0,Henrion M,Cancer,replication,2012-11-25,GCST001750,Renal cell carcinoma
1862,Asian,235.0,23183491.0,Nishizawa D,Response to drug,replication,2012-11-27,GCST001751,Opioid sensitivity
1697,Asian,118.0,23183491.0,Nishizawa D,Response to drug,initial,2012-11-27,GCST001751,Opioid sensitivity
1324,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004579,Waist-to-hip circumference ratio (alcohol intake interaction)
1323,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST001753,Body mass index (alcohol intake interaction)
1325,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004580,Body mass index (recreational physical activity interaction)
2434,Asian,985.0,23209447.0,Tang M,Cancer,replication,2012-11-29,GCST001752,Nasopharyngeal carcinoma
12952,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Other measurement, Body measurement",initial,2012-11-29,GCST001754,Waist-to-hip circumference ratio (ever vs never smoking interaction)
12944,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST001753,Body mass index (alcohol intake interaction)
12945,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004579,Waist-to-hip circumference ratio (alcohol intake interaction)
12946,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004580,Body mass index (recreational physical activity interaction)
12947,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004581,Body mass index  (smoking years interaction)
12948,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004582,Waist-to-hip circumference ratio (dietary energy interaction)
12949,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004583,Waist-to-hip circumference ratio (recreational physical activity interaction)
12950,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004586,Body mass index (ever vs never smoking interaction)
12953,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Other measurement, Body measurement",initial,2012-11-29,GCST004584,Waist-to-hip circumference ratio (smoking years interaction)
1326,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004581,Body mass index  (smoking years interaction)
12951,Hispanic or Latin American,3484.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004587,Body mass index (dietary energy interaction)
1327,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004582,Waist-to-hip circumference ratio (dietary energy interaction)
1332,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Other measurement, Body measurement",initial,2012-11-29,GCST004584,Waist-to-hip circumference ratio (smoking years interaction)
3388,Asian,4055.0,23209447.0,Tang M,Cancer,initial,2012-11-29,GCST001752,Nasopharyngeal carcinoma
1330,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004587,Body mass index (dietary energy interaction)
1329,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004586,Body mass index (ever vs never smoking interaction)
1328,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Body measurement, Other measurement",initial,2012-11-29,GCST004583,Waist-to-hip circumference ratio (recreational physical activity interaction)
1331,African American or Afro-Caribbean,8203.0,23192594.0,Velez Edwards DR,"Other measurement, Body measurement",initial,2012-11-29,GCST001754,Waist-to-hip circumference ratio (ever vs never smoking interaction)
4617,European,77.0,23204130.0,Wheeler HE,"Response to drug, Neurological disorder, Other measurement",initial,2012-11-30,GCST001755,Paclitaxel-induced neuropathy
7161,European,2286.0,23207799.0,Deng FY,Other measurement,initial,2012-11-30,GCST001756,Spine bone size
37,African,87.0,23204130.0,Wheeler HE,"Response to drug, Neurological disorder, Other measurement",initial,2012-11-30,GCST001755,Paclitaxel-induced neuropathy
2720,Asian,1627.0,23207799.0,Deng FY,Other measurement,replication,2012-11-30,GCST001756,Spine bone size
7311,European,2503.0,23207799.0,Deng FY,Other measurement,replication,2012-11-30,GCST001756,Spine bone size
444,African American or Afro-Caribbean,83.0,23204130.0,Wheeler HE,"Response to drug, Neurological disorder, Other measurement",initial,2012-11-30,GCST001755,Paclitaxel-induced neuropathy
10295,European,19167.0,23143596.0,Eyre S,Immune system disorder,initial,2012-12-01,GCST005567,Rheumatoid arthritis (ACPA-negative)
9817,European,12097.0,22922229.0,Cooper JD,Immune system disorder,initial,2012-12-01,GCST005524,Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis)
7283,European,2454.0,23212062.0,Fanous AH,Neurological disorder,initial,2012-12-01,GCST001757,Schizophrenia
11074,European,47580.0,23143596.0,Eyre S,Immune system disorder,initial,2012-12-01,GCST005569,Rheumatoid arthritis
10778,European,33394.0,23143594.0,Tsoi LC,Immune system disorder,initial,2012-12-01,GCST005527,Psoriasis
9770,European,11649.0,22922229.0,Cooper JD,Immune system disorder,initial,2012-12-01,GCST005526,Graves' disease
9559,European,9826.0,22922229.0,Cooper JD,Immune system disorder,initial,2012-12-01,GCST005525,Hashimoto thyroiditis
11013,European,43327.0,23143596.0,Eyre S,Immune system disorder,initial,2012-12-01,GCST005568,Rheumatoid arthritis (ACPA-positive)
10613,European,26836.0,23202124.0,Horikoshi M,Body measurement,initial,2012-12-02,GCST001758,Birth weight
11005,European,42519.0,23202124.0,Horikoshi M,Body measurement,replication,2012-12-02,GCST001758,Birth weight
10475,European,22570.0,23209189.0,Tabassum R,Metabolic disorder,replication,2012-12-03,GCST001759,Type 2 diabetes
2973,Asian,2128.0,23209189.0,Tabassum R,Metabolic disorder,initial,2012-12-03,GCST001759,Type 2 diabetes
3933,Asian,8776.0,23209189.0,Tabassum R,Metabolic disorder,replication,2012-12-03,GCST001759,Type 2 diabetes
8653,European,5640.0,23181788.0,Lasky-Su J,Other disease,replication,2012-12-04,GCST001763,Asthma
12750,Hispanic or Latin American,815.0,23251661.0,Comuzzie AG,"Other measurement, Liver enzyme measurement, Body measurement, Cardiovascular measurement, Inflammatory measurement, Lipid or lipoprotein measurement, Biological process, Metabolic disorder",initial,2012-12-04,GCST001762,Obesity-related traits
8028,European,3855.0,23181788.0,Lasky-Su J,Other disease,initial,2012-12-04,GCST001763,Asthma
7756,European,3280.0,23207651.0,Davies G,"Other trait, Biological process",initial,2012-12-04,GCST001761,Cognitive decline
12854,Hispanic or Latin American,1809.0,23181788.0,Lasky-Su J,Other disease,replication,2012-12-04,GCST001763,Asthma
6420,European,1367.0,23207651.0,Davies G,"Other trait, Biological process",replication,2012-12-04,GCST001761,Cognitive decline
3988,Asian,9308.0,23222517.0,van der Harst P,Hematological measurement,initial,2012-12-05,GCST001765,Red blood cell traits
11258,European,62553.0,23222517.0,van der Harst P,Hematological measurement,initial,2012-12-05,GCST001765,Red blood cell traits
11262,European,63506.0,23222517.0,van der Harst P,Hematological measurement,replication,2012-12-05,GCST001765,Red blood cell traits
5939,European,928.0,23213074.0,Adams LA,"Liver enzyme measurement, Cancer, Digestive system disorder",initial,2012-12-05,GCST001766,Non-alcoholic fatty liver disease histology (other)
7983,European,3737.0,23216389.0,Zuo L,Neurological disorder,replication,2012-12-06,GCST001769,Alcohol and nicotine co-dependence
765,African American or Afro-Caribbean,929.0,23216389.0,Zuo L,Neurological disorder,replication,2012-12-06,GCST001769,Alcohol and nicotine co-dependence
2479,Asian,1098.0,23001997.0,Hou S,Cardiovascular disease,initial,2012-12-06,GCST001768,Behcet's disease
2752,Asian,1713.0,23001997.0,Hou S,Cardiovascular disease,replication,2012-12-06,GCST001768,Behcet's disease
7124,European,2214.0,23216389.0,Zuo L,Neurological disorder,initial,2012-12-06,GCST001769,Alcohol and nicotine co-dependence
5324,European,502.0,23223146.0,Le Clerc S,Biological process,initial,2012-12-06,GCST001767,Aging (facial)
13513,Other/Mixed,127.0,23233662.0,Ramsey LB,Response to drug,initial,2012-12-11,GCST001770,Methotrexate clearance (acute lymphoblastic leukemia)
6805,European,1821.0,23233654.0,Umicevic Mirkov M,"Immune system disorder, Response to drug",replication,2012-12-11,GCST001772,Response to TNF-alpha inhibitors in rheumatoid arthritis
1568,Asian,22.0,23233662.0,Ramsey LB,Response to drug,initial,2012-12-11,GCST001770,Methotrexate clearance (acute lymphoblastic leukemia)
5767,European,806.0,23233662.0,Ramsey LB,Response to drug,initial,2012-12-11,GCST001770,Methotrexate clearance (acute lymphoblastic leukemia)
12593,Hispanic or Latin American,266.0,23233662.0,Ramsey LB,Response to drug,initial,2012-12-11,GCST001770,Methotrexate clearance (acute lymphoblastic leukemia)
421,African American or Afro-Caribbean,58.0,23233662.0,Ramsey LB,Response to drug,initial,2012-12-11,GCST001770,Methotrexate clearance (acute lymphoblastic leukemia)
5619,European,699.0,23233662.0,Ramsey LB,Response to drug,replication,2012-12-11,GCST001770,Methotrexate clearance (acute lymphoblastic leukemia)
5883,European,882.0,23233654.0,Umicevic Mirkov M,"Immune system disorder, Response to drug",initial,2012-12-11,GCST001772,Response to TNF-alpha inhibitors in rheumatoid arthritis
7477,European,2748.0,23229837.0,Aragam N,"Neurological disorder, Other measurement",initial,2012-12-11,GCST001771,Neuroticism
545,African American or Afro-Caribbean,214.0,23241943.0,Clark SL,Response to drug,initial,2012-12-12,GCST001773,Response to antipsychotic treatment
5150,European,421.0,23241943.0,Clark SL,Response to drug,initial,2012-12-12,GCST001773,Response to antipsychotic treatment
7383,European,2578.0,23237013.0,Power RA,"Other trait, Other measurement",initial,2012-12-14,GCST001774,Reporting of stressful life event
6236,European,1151.0,23237013.0,Power RA,"Other trait, Other measurement",replication,2012-12-14,GCST001774,Reporting of stressful life event
3117,Asian,2514.0,23242368.0,Jiang DK,"Digestive system disorder, Cancer",initial,2012-12-16,GCST001775,Hepatocellular carcinoma in hepatitis B infection
3985,Asian,9285.0,23242368.0,Jiang DK,"Digestive system disorder, Cancer",replication,2012-12-16,GCST001775,Hepatocellular carcinoma in hepatitis B infection
959,African American or Afro-Caribbean,2053.0,23247143.0,Yu B,Cardiovascular measurement,initial,2012-12-16,GCST001776,Cardiac Troponin-T levels
9498,European,9491.0,23247143.0,Yu B,Cardiovascular measurement,initial,2012-12-16,GCST001776,Cardiac Troponin-T levels
8170,European,4238.0,23247145.0,Makela KM,Lipid or lipoprotein measurement,replication,2012-12-17,GCST001777,LDL (oxidized)
7002,European,2080.0,23247145.0,Makela KM,Lipid or lipoprotein measurement,initial,2012-12-17,GCST001777,LDL (oxidized)
7211,European,2338.0,23255317.0,Wooten EC,Cardiovascular disease,replication,2012-12-19,GCST001778,Hypertrophic cardiomyopathy
6068,European,997.0,23255317.0,Wooten EC,Cardiovascular disease,initial,2012-12-19,GCST001778,Hypertrophic cardiomyopathy
1317,African American or Afro-Caribbean,7943.0,23263863.0,Li J,"Hematological measurement, Cardiovascular measurement, Other measurement",initial,2012-12-20,GCST001779,Hematology traits
1316,African American or Afro-Caribbean,7943.0,23263863.0,Li J,Hematological measurement,initial,2012-12-20,GCST001783,Platelet count
1315,African American or Afro-Caribbean,7943.0,23263863.0,Li J,Hematological measurement,initial,2012-12-20,GCST001782,Mean corpuscular hemoglobin concentration
1314,African American or Afro-Caribbean,7943.0,23263863.0,Li J,Hematological measurement,initial,2012-12-20,GCST001781,Mean corpuscular volume
1313,African American or Afro-Caribbean,7943.0,23263863.0,Li J,Hematological measurement,initial,2012-12-20,GCST001780,Mean corpuscular hemoglobin
8793,European,6234.0,23263863.0,Li J,Hematological measurement,initial,2012-12-20,GCST001780,Mean corpuscular hemoglobin
8797,European,6234.0,23263863.0,Li J,"Hematological measurement, Cardiovascular measurement, Other measurement",initial,2012-12-20,GCST001779,Hematology traits
8796,European,6234.0,23263863.0,Li J,Hematological measurement,initial,2012-12-20,GCST001783,Platelet count
8795,European,6234.0,23263863.0,Li J,Hematological measurement,initial,2012-12-20,GCST001782,Mean corpuscular hemoglobin concentration
8794,European,6234.0,23263863.0,Li J,Hematological measurement,initial,2012-12-20,GCST001781,Mean corpuscular volume
11103,European,50047.0,23284291.0,Hancock DB,Other measurement,initial,2012-12-20,GCST001784,Pulmonary function (smoking interaction)
9069,European,7443.0,23259602.0,Wang X,Digestive system disorder,initial,2012-12-21,GCST001786,Dental caries
6834,European,1867.0,23266556.0,Peters U,Cancer,replication,2012-12-21,GCST001787,Colorectal cancer
3348,Asian,3761.0,23266558.0,Yamazaki K,Digestive system disorder,initial,2012-12-21,GCST001785,Crohn's disease
4245,Asian,16951.0,23266558.0,Yamazaki K,Digestive system disorder,replication,2012-12-21,GCST001785,Crohn's disease
3867,Asian,7847.0,23266556.0,Peters U,Cancer,replication,2012-12-21,GCST001787,Colorectal cancer
10633,European,27809.0,23266556.0,Peters U,Cancer,initial,2012-12-21,GCST001787,Colorectal cancer
898,African American or Afro-Caribbean,1594.0,23263444.0,Frazier-Wood AC,Other disease,replication,2012-12-22,GCST001789,Lipoprotein diameter
12827,Hispanic or Latin American,1422.0,23263444.0,Frazier-Wood AC,Other disease,replication,2012-12-22,GCST001789,Lipoprotein diameter
2287,Asian,758.0,23263444.0,Frazier-Wood AC,Other disease,replication,2012-12-22,GCST001789,Lipoprotein diameter
6032,European,979.0,23263445.0,Lawrance-Owen AJ,Body measurement,initial,2012-12-22,GCST001788,Digit length ratio
5780,European,817.0,23263444.0,Frazier-Wood AC,Other disease,initial,2012-12-22,GCST001789,Lipoprotein diameter
7264,European,2430.0,23263444.0,Frazier-Wood AC,Other disease,replication,2012-12-22,GCST001789,Lipoprotein diameter
10762,European,32813.0,23263486.0,Kottgen A,"Metabolic disorder, Other measurement",replication,2012-12-23,GCST001791,Urate levels
9220,European,8229.0,23263489.0,Huyghe JR,Other measurement,initial,2012-12-23,GCST008109,Fasting blood proinsulin levels
6133,European,1036.0,23263486.0,Kottgen A,Metabolic disorder,replication,2012-12-23,GCST001790,Gout
9221,European,8229.0,23263489.0,Huyghe JR,Other measurement,initial,2012-12-23,GCST008110,Insulinogenic index
3866,Asian,7847.0,23263487.0,Jia WH,Cancer,initial,2012-12-23,GCST001792,Colorectal cancer
9223,European,8229.0,23263489.0,Huyghe JR,Other measurement,initial,2012-12-23,GCST008112,Proinsulin levels (early-phase conversion)
4074,Asian,11280.0,23263487.0,Jia WH,Cancer,replication,2012-12-23,GCST001792,Colorectal cancer
10591,European,26060.0,23263487.0,Jia WH,Cancer,replication,2012-12-23,GCST001792,Colorectal cancer
9224,European,8229.0,23263489.0,Huyghe JR,Other measurement,initial,2012-12-23,GCST008113,Proinsulin levels (late-phase conversion)
9222,European,8229.0,23263489.0,Huyghe JR,Other measurement,initial,2012-12-23,GCST008111,Insulin disposition index
11627,European,110347.0,23263486.0,Kottgen A,"Metabolic disorder, Other measurement",initial,2012-12-23,GCST001791,Urate levels
11321,European,69374.0,23263486.0,Kottgen A,Metabolic disorder,initial,2012-12-23,GCST001790,Gout
7745,European,3250.0,23267103.0,Desch KC,Other measurement,initial,2012-12-24,GCST001793,Coagulation factor levels
8529,European,5185.0,23300701.0,Jiao S,Cancer,replication,2012-12-26,GCST001794,Colorectal cancer (SNP x SNP interaction)
10283,European,18938.0,23300701.0,Jiao S,Cancer,initial,2012-12-26,GCST001794,Colorectal cancer (SNP x SNP interaction)
2642,Asian,1496.0,23269536.0,Sun J,Other measurement,replication,2012-12-27,GCST001796,Prostate-specific antigen levels
2612,Asian,1416.0,23273568.0,Yang W,Immune system disorder,replication,2012-12-27,GCST001795,Systemic lupus erythematosus
3520,Asian,5050.0,23273568.0,Yang W,Immune system disorder,initial,2012-12-27,GCST001795,Systemic lupus erythematosus
3968,Asian,8923.0,23273568.0,Yang W,Immune system disorder,replication,2012-12-27,GCST001795,Systemic lupus erythematosus
2919,Asian,1999.0,23269536.0,Sun J,Other measurement,initial,2012-12-27,GCST001796,Prostate-specific antigen levels
994,African American or Afro-Caribbean,2468.0,23275298.0,Fox ER,Other measurement,replication,2012-12-28,GCST001797,Cardiac structure and function
1273,African American or Afro-Caribbean,6765.0,23275298.0,Fox ER,Other measurement,initial,2012-12-28,GCST001797,Cardiac structure and function
9859,European,12612.0,23275298.0,Fox ER,Other measurement,replication,2012-12-28,GCST001797,Cardiac structure and function
6723,European,1722.0,23359319.0,Jin G,Other measurement,replication,2013-01-01,GCST001799,Prostate-specific antigen levels
7680,European,3192.0,23359319.0,Jin G,Other measurement,initial,2013-01-01,GCST001799,Prostate-specific antigen levels
9828,European,12307.0,23459209.0,Faraco J,Neurological disorder,initial,2013-01-01,GCST005522,Narcolepsy
7014,European,2100.0,23381943.0,Williams FM,"Hematological measurement, Other measurement",initial,2013-01-01,GCST001798,End-stage coagulation
5288,European,487.0,23703922.0,Li WD,Cardiovascular measurement,initial,2013-01-02,GCST001801,Uric acid levels
10838,European,34549.0,23290196.0,Hek K,Neurological disorder,initial,2013-01-02,GCST001802,Depression (quantitative trait)
10147,European,16709.0,23290196.0,Hek K,Neurological disorder,replication,2013-01-02,GCST001802,Depression (quantitative trait)
4975,European,306.0,23279374.0,Athanasiadis G,Other measurement,initial,2013-01-02,GCST001800,&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels
3221,Asian,2937.0,23401653.0,Guggenheim JA,Other measurement,replication,2013-01-03,GCST001803,Corneal curvature
2981,Asian,2142.0,23401653.0,Guggenheim JA,Other measurement,replication,2013-01-03,GCST001803,Corneal curvature
6945,European,2023.0,23401653.0,Guggenheim JA,Other measurement,initial,2013-01-03,GCST001803,Corneal curvature
3049,Asian,2281.0,23401653.0,Guggenheim JA,Other measurement,replication,2013-01-03,GCST001803,Corneal curvature
2954,Asian,2078.0,23291585.0,Fakiola M,Other disease,initial,2013-01-06,GCST001805,Leishmaniasis (visceral)
2900,Asian,1941.0,23291585.0,Fakiola M,Other disease,replication,2013-01-06,GCST001805,Leishmaniasis (visceral)
2588,Asian,1352.0,23291587.0,Kirino Y,Cardiovascular disease,replication,2013-01-06,GCST001804,Behcet's disease
2875,Asian,1883.0,23291589.0,Lu Y,"Other measurement, Neurological disorder",initial,2013-01-06,GCST001806,Corneal structure
3124,Asian,2538.0,23291589.0,Lu Y,"Other measurement, Neurological disorder",initial,2013-01-06,GCST001806,Corneal structure
9878,European,13057.0,23291589.0,Lu Y,"Other measurement, Neurological disorder",initial,2013-01-06,GCST001806,Corneal structure
3126,Asian,2542.0,23291589.0,Lu Y,"Other measurement, Neurological disorder",initial,2013-01-06,GCST001806,Corneal structure
13868,Other/Mixed,1468.0,23291587.0,Kirino Y,Cardiovascular disease,replication,2013-01-06,GCST001804,Behcet's disease
12862,Hispanic or Latin American,1970.0,23291585.0,Fakiola M,Other disease,initial,2013-01-06,GCST001805,Leishmaniasis (visceral)
13912,Other/Mixed,2493.0,23291587.0,Kirino Y,Cardiovascular disease,initial,2013-01-06,GCST001804,Behcet's disease
3302,Asian,3451.0,23300138.0,He M,Other measurement,initial,2013-01-07,GCST001808,Tumor biomarkers
8739,European,5994.0,23297363.0,Cordell HJ,Other trait,initial,2013-01-07,GCST001807,Tetralogy of Fallot
7979,European,3729.0,23297363.0,Cordell HJ,Other trait,replication,2013-01-07,GCST001807,Tetralogy of Fallot
4049,Asian,10326.0,23300138.0,He M,Other measurement,replication,2013-01-07,GCST001808,Tumor biomarkers
2707,Asian,1616.0,23300278.0,Saxena R,Metabolic disorder,initial,2013-01-08,GCST001809,Type 2 diabetes
4430,Asian,45687.0,23300278.0,Saxena R,Metabolic disorder,replication,2013-01-08,GCST001809,Type 2 diabetes
11066,European,47117.0,23300278.0,Saxena R,Metabolic disorder,replication,2013-01-08,GCST001809,Type 2 diabetes
4382,Asian,33707.0,23300278.0,Saxena R,Metabolic disorder,replication,2013-01-08,GCST001809,Type 2 diabetes
10177,European,17091.0,23307926.0,Perry JR,Other measurement,initial,2013-01-09,GCST001810,Menopause (age at onset)
9243,European,8340.0,23307926.0,Perry JR,Other measurement,replication,2013-01-09,GCST001810,Menopause (age at onset)
6922,European,1993.0,23326512.0,Greenwood TA,Neurological disorder,initial,2013-01-10,GCST001811,Bipolar disorder (mania)
6232,European,1147.0,23326512.0,Greenwood TA,Neurological disorder,replication,2013-01-10,GCST001811,Bipolar disorder (mania)
12814,Hispanic or Latin American,1367.0,23326239.0,Rubicz R,"Other disease, Other measurement",initial,2013-01-10,GCST001812,Epstein-Barr virus immune response (EBNA-1)
3412,Asian,4205.0,23303382.0,Hong KW,"Hematological measurement, Cardiovascular measurement, Other measurement",replication,2013-01-10,GCST001813,Hematology traits
3471,Asian,4637.0,23303382.0,Hong KW,"Hematological measurement, Cardiovascular measurement, Other measurement",initial,2013-01-10,GCST001813,Hematology traits
12683,Hispanic or Latin American,589.0,23326239.0,Rubicz R,"Other disease, Other measurement",replication,2013-01-10,GCST001812,Epstein-Barr virus immune response (EBNA-1)
10338,European,19805.0,23326517.0,Holliday EG,Neurological disorder,initial,2013-01-11,GCST001814,Age-related macular degeneration
3411,Asian,4190.0,23326517.0,Holliday EG,Neurological disorder,replication,2013-01-11,GCST001814,Age-related macular degeneration
2759,Asian,1727.0,23321320.0,Urabe Y,Cancer,initial,2013-01-12,GCST001815,Hepatitis C induced liver cirrhosis
3494,Asian,4745.0,23321320.0,Urabe Y,Cancer,replication,2013-01-12,GCST001815,Hepatitis C induced liver cirrhosis
5393,European,536.0,23319801.0,Rafiq S,Cancer,initial,2013-01-14,GCST001816,Breast cancer (prognosis)
6528,European,1516.0,23319801.0,Rafiq S,Cancer,replication,2013-01-14,GCST001816,Breast cancer (prognosis)
10455,European,22100.0,23322567.0,Lopes MC,"Neurological disorder, Other trait",initial,2013-01-15,GCST001819,Corneal astigmatism
5109,European,398.0,23319000.0,Luykx JJ,Other measurement,initial,2013-01-15,GCST001822,Metabolite levels (MHPG)
5108,European,398.0,23319000.0,Luykx JJ,Other measurement,initial,2013-01-15,GCST001821,Metabolite levels (5-HIAA/ MHPG Ratio)
5111,European,398.0,23319000.0,Luykx JJ,Other measurement,initial,2013-01-15,GCST001824,Metabolite levels (HVA)
5107,European,398.0,23319000.0,Luykx JJ,Other measurement,initial,2013-01-15,GCST001820,Metabolite levels (5-HIAA)
5106,European,398.0,23319000.0,Luykx JJ,Other measurement,initial,2013-01-15,GCST001818,Metabolite levels (HVA/5-HIAA ratio)
5105,European,398.0,23319000.0,Luykx JJ,Other measurement,initial,2013-01-15,GCST001817,Metabolite levels (HVA-5-HIAA Factor score)
5110,European,398.0,23319000.0,Luykx JJ,Other measurement,initial,2013-01-15,GCST001823,Metabolite levels (HVA/MHPG ratio)
8907,European,6720.0,23328707.0,Tin A,Other measurement,initial,2013-01-16,GCST001825,Beta-trace protein levels
913,African American or Afro-Caribbean,1734.0,23328707.0,Tin A,Other measurement,replication,2013-01-16,GCST001825,Beta-trace protein levels
8024,European,3841.0,23349640.0,Vijai J,Cancer,replication,2013-01-17,GCST001826,Lymphoma
3912,Asian,8632.0,23341777.0,Dong J,Cancer,replication,2013-01-17,GCST001827,Squamous cell carcinoma
3373,Asian,3927.0,23341777.0,Dong J,Cancer,initial,2013-01-17,GCST001827,Squamous cell carcinoma
4600,European,64.0,23337848.0,Posti JP,Other disease,initial,2013-01-18,GCST001828,Vascular constriction
13480,Other/Mixed,68.0,23337848.0,Posti JP,Other disease,replication,2013-01-18,GCST001828,Vascular constriction
5479,European,598.0,23337944.0,Haghighi A,Biological process,initial,2013-01-22,GCST001829,Fat intake
5295,European,490.0,23337944.0,Haghighi A,Biological process,replication,2013-01-22,GCST001829,Fat intake
2618,Asian,1427.0,23349225.0,Hwang JY,Other disease,initial,2013-01-24,GCST001830,Osteoporosis
3263,Asian,3136.0,23349225.0,Hwang JY,Other disease,replication,2013-01-24,GCST001830,Osteoporosis
6098,European,1001.0,23354978.0,Rinella ES,Cancer,initial,2013-01-25,GCST001831,Breast cancer
5242,European,466.0,23354978.0,Rinella ES,Cancer,replication,2013-01-25,GCST001831,Breast cancer
6406,European,1355.0,23350875.0,Fernandez-Rozadilla C,Cancer,initial,2013-01-26,GCST001832,Colorectal cancer
7724,European,3216.0,23350875.0,Fernandez-Rozadilla C,Cancer,replication,2013-01-26,GCST001832,Colorectal cancer
6770,European,1770.0,23358160.0,Borglum AD,"Neurological disorder, Other disease",initial,2013-01-29,GCST001833,Schizophrenia (cytomegalovirus infection interaction)
8632,European,5548.0,23358156.0,Benyamin B,Biological process,replication,2013-01-29,GCST001837,Intelligence (childhood)
9192,European,8025.0,23358160.0,Borglum AD,"Neurological disorder, Other disease",replication,2013-01-29,GCST001833,Schizophrenia (cytomegalovirus infection interaction)
6769,European,1770.0,23358160.0,Borglum AD,Neurological disorder,initial,2013-01-29,GCST001839,Schizophrenia
4746,European,168.0,23374588.0,Martinelli-Boneschi F,"Response to drug, Neurological disorder",replication,2013-01-29,GCST001835,Response to cholinesterase inhibitors in Alzheimer's disease
4747,European,169.0,23374588.0,Martinelli-Boneschi F,"Response to drug, Neurological disorder",initial,2013-01-29,GCST001835,Response to cholinesterase inhibitors in Alzheimer's disease
9191,European,8025.0,23358160.0,Borglum AD,Neurological disorder,replication,2013-01-29,GCST001839,Schizophrenia
9840,European,12441.0,23358156.0,Benyamin B,Biological process,initial,2013-01-29,GCST001837,Intelligence (childhood)
8254,European,4500.0,23382809.0,Xu C,Neurological disorder,initial,2013-01-29,GCST001836,Schizophrenia (negative symptoms)
9415,European,8961.0,23362303.0,Wu JH,Lipid or lipoprotein measurement,initial,2013-01-29,GCST001834,Oleic acid (18:1n-9) levels
9418,European,8961.0,23362303.0,Wu JH,Lipid or lipoprotein measurement,initial,2013-01-29,GCST001841,Palmitoleic acid (16:1n-7) levels
9417,European,8961.0,23362303.0,Wu JH,Lipid or lipoprotein measurement,initial,2013-01-29,GCST001840,Stearic acid (18:0) levels
9416,European,8961.0,23362303.0,Wu JH,Lipid or lipoprotein measurement,initial,2013-01-29,GCST001838,Palmitic acid (16:0) levels
3517,Asian,5010.0,23364009.0,Yang X,Biological process,initial,2013-01-30,GCST001842,Drinking behavior
4258,Asian,18189.0,23364009.0,Yang X,Biological process,replication,2013-01-30,GCST001842,Drinking behavior
10799,European,33533.0,23372041.0,Chu AY,Biological process,initial,2013-01-30,GCST001844,Dietary macronutrient intake
8344,European,4771.0,23386860.0,Pasquale LR,"Metabolic disorder, Other measurement",initial,2013-01-30,GCST001843,Type 2 diabetes (dietary heme iron intake interaction)
10927,European,38360.0,23372041.0,Chu AY,Biological process,replication,2013-01-30,GCST001844,Dietary macronutrient intake
3936,Asian,8830.0,23371916.0,Dai X,Other measurement,replication,2013-01-31,GCST001846,Bilirubin levels
2625,Asian,1452.0,23371916.0,Dai X,Other measurement,initial,2013-01-31,GCST001846,Bilirubin levels
7141,European,2247.0,23382691.0,Lauc G,Other measurement,initial,2013-01-31,GCST001848,IgG glycosylation
3635,Asian,5714.0,23364394.0,Lee JY,Cardiovascular disease,initial,2013-01-31,GCST001845,Coronary heart disease
13645,Other/Mixed,377.0,23376709.0,Kerns SL,"Cancer, Biological process, Other trait",replication,2013-01-31,GCST001847,Urinary symptoms in response to radiotherapy in prostate cancer
3878,Asian,8028.0,23364394.0,Lee JY,Cardiovascular disease,replication,2013-01-31,GCST001845,Coronary heart disease
6823,European,1848.0,23382691.0,Lauc G,Other measurement,initial,2013-01-31,GCST001849,IgG glycosylation
13631,Other/Mixed,346.0,23376709.0,Kerns SL,"Cancer, Biological process, Other trait",initial,2013-01-31,GCST001847,Urinary symptoms in response to radiotherapy in prostate cancer
6100,European,1004.0,23378610.0,Xie W,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",initial,2013-02-01,GCST001852,Metabolite levels
3050,Asian,2296.0,23894747.0,Aberg KA,Neurological disorder,replication,2013-02-01,GCST001851,Schizophrenia
847,African American or Afro-Caribbean,1262.0,23894747.0,Aberg KA,Neurological disorder,replication,2013-02-01,GCST001851,Schizophrenia
7474,European,2740.0,23894747.0,Aberg KA,Neurological disorder,replication,2013-02-01,GCST001851,Schizophrenia
5019,European,339.0,23378610.0,Xie W,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",replication,2013-02-01,GCST001852,Metabolite levels
7142,European,2256.0,23377640.0,GENDEP Investigators,Neurological disorder,initial,2013-02-01,GCST001850,Major depressive disorder
10451,European,21953.0,23894747.0,Aberg KA,Neurological disorder,initial,2013-02-01,GCST001851,Schizophrenia
7731,European,3230.0,23381795.0,Verweij N,Cardiovascular measurement,replication,2013-02-04,GCST001853,Circulating vasoactive peptide levels
7865,European,3444.0,23381795.0,Verweij N,Cardiovascular measurement,initial,2013-02-04,GCST001853,Circulating vasoactive peptide levels
10312,European,19411.0,23393555.0,Jensen RA,Neurological disorder,initial,2013-02-05,GCST001854,Retinopathy in non-diabetics
10602,European,26420.0,23408906.0,Porcu E,Other measurement,initial,2013-02-07,GCST001856,Thyroid hormone levels
5436,European,565.0,23392654.0,Lewis JP,Biological process,initial,2013-02-07,GCST001855,Response to antiplatelet therapy
5639,European,710.0,23392654.0,Lewis JP,Biological process,replication,2013-02-07,GCST001855,Response to antiplatelet therapy
13369,Other/Mixed,4.0,23392654.0,Lewis JP,Biological process,replication,2013-02-07,GCST001855,Response to antiplatelet therapy
12595,Hispanic or Latin American,276.0,23392654.0,Lewis JP,Biological process,replication,2013-02-07,GCST001855,Response to antiplatelet therapy
551,African American or Afro-Caribbean,237.0,23392654.0,Lewis JP,Biological process,replication,2013-02-07,GCST001855,Response to antiplatelet therapy
6282,European,1195.0,23372042.0,Lane J,"Immune system disorder, Other disease",initial,2013-02-10,GCST001857,HIV-1 susceptibility
3042,Asian,2273.0,23396134.0,Verhoeven VJ,Other trait,initial,2013-02-10,GCST001858,Refractive error
3381,Asian,3995.0,23396134.0,Verhoeven VJ,Other trait,initial,2013-02-10,GCST001858,Refractive error
10888,European,37382.0,23396134.0,Verhoeven VJ,Other trait,initial,2013-02-10,GCST001858,Refractive error
2964,Asian,2108.0,23396134.0,Verhoeven VJ,Other trait,initial,2013-02-10,GCST001858,Refractive error
600,African American or Afro-Caribbean,342.0,23400010.0,Del-Aguila JL,"Response to drug, Lipid or lipoprotein measurement, Other measurement",initial,2013-02-12,GCST001859,Thiazide-induced adverse metabolic effects in hypertensive patients
5154,European,425.0,23400010.0,Del-Aguila JL,"Response to drug, Lipid or lipoprotein measurement, Other measurement",initial,2013-02-12,GCST001859,Thiazide-induced adverse metabolic effects in hypertensive patients
4933,European,284.0,23412934.0,Gourraud PA,Immune system disorder,initial,2013-02-13,GCST001860,Multiple sclerosis
2403,Asian,939.0,23408455.0,Wakai K,Biological process,initial,2013-02-14,GCST001861,Confectionary intake
13569,Other/Mixed,213.0,23406172.0,Milton JN,Neurological disorder,replication,2013-02-14,GCST001862,Sickle cell anemia (haemolysis)
3452,Asian,4491.0,23408455.0,Wakai K,Biological process,replication,2013-02-14,GCST001861,Confectionary intake
8909,European,6728.0,23417110.0,Tin A,Other measurement,initial,2013-02-16,GCST001863,Beta-2 microglubulin plasma levels
2302,Asian,774.0,23388002.0,Thanassoulis G,Other trait,replication,2013-02-17,GCST001864,Mitral annular calcification
1002,African American or Afro-Caribbean,2497.0,23388002.0,Thanassoulis G,Other trait,replication,2013-02-17,GCST001864,Mitral annular calcification
8968,European,6942.0,23388002.0,Thanassoulis G,Cardiovascular disease,initial,2013-02-17,GCST001865,Aortic-valve calcification
5693,European,745.0,23388002.0,Thanassoulis G,Other trait,replication,2013-02-17,GCST001864,Mitral annular calcification
1001,African American or Afro-Caribbean,2497.0,23388002.0,Thanassoulis G,Cardiovascular disease,replication,2013-02-17,GCST001865,Aortic-valve calcification
8007,European,3795.0,23388002.0,Thanassoulis G,Other trait,initial,2013-02-17,GCST001864,Mitral annular calcification
12865,Hispanic or Latin American,2027.0,23388002.0,Thanassoulis G,Other trait,replication,2013-02-17,GCST001864,Mitral annular calcification
2301,Asian,774.0,23388002.0,Thanassoulis G,Cardiovascular disease,replication,2013-02-17,GCST001865,Aortic-valve calcification
5692,European,745.0,23388002.0,Thanassoulis G,Cardiovascular disease,replication,2013-02-17,GCST001865,Aortic-valve calcification
12864,Hispanic or Latin American,2027.0,23388002.0,Thanassoulis G,Cardiovascular disease,replication,2013-02-17,GCST001865,Aortic-valve calcification
5423,European,555.0,23419831.0,Ramanan VK,"Other measurement, Neurological disorder",initial,2013-02-19,GCST001868,Alzheimer's disease biomarkers
13644,Other/Mixed,373.0,23420232.0,Duggal P,Digestive system disorder,initial,2013-02-19,GCST001867,Chronic hepatitis C infection
4952,European,292.0,23420232.0,Duggal P,Digestive system disorder,replication,2013-02-19,GCST001867,Chronic hepatitis C infection
571,African American or Afro-Caribbean,284.0,23420232.0,Duggal P,Digestive system disorder,replication,2013-02-19,GCST001867,Chronic hepatitis C infection
13521,Other/Mixed,169.0,23420232.0,Duggal P,Digestive system disorder,replication,2013-02-19,GCST001867,Chronic hepatitis C infection
4820,European,200.0,23423138.0,Ludwig KU,Biological process,initial,2013-02-19,GCST001866,Mathematical ability in children with dyslexia
6605,European,1581.0,23420232.0,Duggal P,Digestive system disorder,initial,2013-02-19,GCST001867,Chronic hepatitis C infection
13665,Other/Mixed,447.0,23420232.0,Duggal P,Digestive system disorder,initial,2013-02-19,GCST001867,Chronic hepatitis C infection
5340,European,510.0,23423138.0,Ludwig KU,Biological process,replication,2013-02-19,GCST001866,Mathematical ability in children with dyslexia
14002,Other/Mixed,16093.0,23423446.0,Hein R,"Cancer, Other trait",replication,2013-02-20,GCST001869,Breast cancer (menopausal hormone therapy interaction)
5657,European,731.0,23423446.0,Hein R,"Cancer, Other trait",initial,2013-02-20,GCST001869,Breast cancer (menopausal hormone therapy interaction)
6142,European,1052.0,23437003.0,Paternoster L,Other measurement,replication,2013-02-21,GCST001870,Bone mineral density
8707,European,5878.0,23437003.0,Paternoster L,Other measurement,initial,2013-02-21,GCST001870,Bone mineral density
4906,European,263.0,23432519.0,O'Brien RP,Other measurement,initial,2013-02-21,GCST001871,Renal transplant outcome
6843,European,1874.0,23509613.0,Kamboh MI,Other measurement,initial,2013-02-24,GCST001872,Presence of antiphospholipid antibodies
4187,Asian,14088.0,23446634.0,Chen Z,Hematological measurement,replication,2013-02-26,GCST001873,Red blood cell traits
1362,African American or Afro-Caribbean,9692.0,23446634.0,Chen Z,Hematological measurement,replication,2013-02-26,GCST001873,Red blood cell traits
10390,European,21020.0,23446634.0,Chen Z,Hematological measurement,replication,2013-02-26,GCST001873,Red blood cell traits
1436,African American or Afro-Caribbean,16485.0,23446634.0,Chen Z,Hematological measurement,initial,2013-02-26,GCST001873,Red blood cell traits
9531,European,9710.0,23449627.0,Cousminer DL,"Body measurement, Biological process",replication,2013-02-27,GCST001875,Pubertal anthropometrics
11237,European,61220.0,23453885.0,Smoller JW,Neurological disorder,initial,2013-02-27,GCST001877,"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)"
8836,European,6438.0,23455491.0,Zuo L,"Other measurement, Neurological disorder",replication,2013-02-27,GCST001874,Alcohol dependence
1874,Asian,245.0,23454411.0,Lin MT,"Immune system disorder, Cardiovascular disease",replication,2013-02-27,GCST001878,Coronary arterial lesions in patients with Kawasaki disease
7564,European,2927.0,23455491.0,Zuo L,"Other measurement, Neurological disorder",initial,2013-02-27,GCST001874,Alcohol dependence
9961,European,14040.0,23449627.0,Cousminer DL,"Body measurement, Biological process",initial,2013-02-27,GCST001875,Pubertal anthropometrics
9693,European,10799.0,23449627.0,Cousminer DL,"Body measurement, Biological process",initial,2013-02-27,GCST001876,Pubertal anthropometrics
1727,Asian,134.0,23454411.0,Lin MT,"Immune system disorder, Cardiovascular disease",initial,2013-02-27,GCST001878,Coronary arterial lesions in patients with Kawasaki disease
1235,African American or Afro-Caribbean,5761.0,23468962.0,Song C,Cancer,initial,2013-02-28,GCST001879,Breast cancer
2715,Asian,1625.0,23406873.0,Shi Y,Other trait,initial,2013-02-28,GCST001881,Myopia (pathological)
7333,European,2524.0,23533358.0,Liu Z,Neurological disorder,initial,2013-02-28,GCST001880,Addiction
170,African,1103.0,23533358.0,Liu Z,Neurological disorder,initial,2013-02-28,GCST001880,Addiction
3663,Asian,5811.0,23406873.0,Shi Y,Other trait,replication,2013-02-28,GCST001881,Myopia (pathological)
5113,European,402.0,23281178.0,Hong MG,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",initial,2013-03-01,GCST001882,Metabolite levels
5291,European,489.0,23281178.0,Hong MG,"Other trait, Other measurement, Liver enzyme measurement, Cardiovascular measurement, Lipid or lipoprotein measurement",replication,2013-03-01,GCST001882,Metabolite levels
2016,Asian,396.0,23456092.0,Park BL,"Other measurement, Neurological disorder",initial,2013-03-01,GCST001883,Alcohol dependence
2424,Asian,975.0,23456092.0,Park BL,"Other measurement, Neurological disorder",replication,2013-03-01,GCST001883,Alcohol dependence
10151,European,16753.0,23455636.0,Fritsche LG,Neurological disorder,replication,2013-03-03,GCST001884,Age-related macular degeneration
3737,Asian,6534.0,23456168.0,Hao Y,"Other measurement, Body measurement",initial,2013-03-03,GCST001885,Height
13594,Other/Mixed,271.0,23314186.0,Crosslin DR,Hematological measurement,initial,2013-03-03,GCST001887,Monocyte count
2871,Asian,1881.0,23456168.0,Hao Y,"Other measurement, Body measurement",replication,2013-03-03,GCST001885,Height
8409,European,4919.0,23455637.0,Iles MM,Cancer,initial,2013-03-03,GCST001886,Melanoma
1855,Asian,229.0,23455636.0,Fritsche LG,Neurological disorder,initial,2013-03-03,GCST001884,Age-related macular degeneration
11178,European,55115.0,23455636.0,Fritsche LG,Neurological disorder,initial,2013-03-03,GCST001884,Age-related macular degeneration
9561,European,9849.0,23314186.0,Crosslin DR,Hematological measurement,initial,2013-03-03,GCST001887,Monocyte count
13803,Other/Mixed,894.0,23314186.0,Crosslin DR,Hematological measurement,initial,2013-03-03,GCST001887,Monocyte count
3406,Asian,4150.0,23455636.0,Fritsche LG,Neurological disorder,initial,2013-03-03,GCST001884,Age-related macular degeneration
11303,European,67980.0,23455637.0,Iles MM,Cancer,replication,2013-03-03,GCST001886,Melanoma
2444,Asian,1008.0,23455636.0,Fritsche LG,Neurological disorder,replication,2013-03-03,GCST001884,Age-related macular degeneration
8257,European,4504.0,23459936.0,Divaris K,Digestive system disorder,initial,2013-03-04,GCST001888,Periodontitis
13727,Other/Mixed,656.0,23459936.0,Divaris K,Digestive system disorder,replication,2013-03-04,GCST001888,Periodontitis
8550,European,5272.0,23463857.0,Ritchie MD,Cardiovascular measurement,initial,2013-03-05,GCST001893,Electrocardiographic conduction measures
7190,European,2316.0,23472165.0,Albertsen HM,Other disease,replication,2013-03-05,GCST001894,Endometriosis
9967,European,14174.0,23472165.0,Albertsen HM,Other disease,initial,2013-03-05,GCST001894,Endometriosis
10972,European,40407.0,23463857.0,Ritchie MD,Cardiovascular measurement,replication,2013-03-05,GCST001893,Electrocardiographic conduction measures
5005,European,331.0,23471985.0,Jahanshad N,Other measurement,initial,2013-03-05,GCST001889,Brain connectivity
7844,European,3403.0,23472185.0,Mero IL,"Immune system disorder, Other measurement",replication,2013-03-05,GCST001891,Multiple sclerosis (OCB status)
6541,European,1528.0,23472185.0,Mero IL,"Immune system disorder, Other measurement",initial,2013-03-05,GCST001892,Multiple sclerosis (OCB status)
6540,European,1528.0,23472185.0,Mero IL,"Immune system disorder, Other measurement",initial,2013-03-05,GCST001891,Multiple sclerosis (OCB status)
10806,European,33781.0,23459443.0,Avery CL,"Cardiovascular measurement, Response to drug",initial,2013-03-05,GCST001890,QT interval (drug interaction)
1574,Asian,25.0,23467860.0,Pare G,Response to drug,replication,2013-03-06,GCST001895,Response to dabigatran etexilate treatment
6,African,6.0,23467860.0,Pare G,Response to drug,replication,2013-03-06,GCST001895,Response to dabigatran etexilate treatment
12530,Hispanic or Latin American,66.0,23467860.0,Pare G,Response to drug,replication,2013-03-06,GCST001895,Response to dabigatran etexilate treatment
6517,European,1490.0,23467860.0,Pare G,Response to drug,initial,2013-03-06,GCST001895,Response to dabigatran etexilate treatment
1557,Asian,15.0,23467860.0,Pare G,Response to drug,replication,2013-03-06,GCST001895,Response to dabigatran etexilate treatment
4829,European,204.0,23467860.0,Pare G,Response to drug,replication,2013-03-06,GCST001895,Response to dabigatran etexilate treatment
13342,Other/Mixed,1.0,23467860.0,Pare G,Response to drug,replication,2013-03-06,GCST001895,Response to dabigatran etexilate treatment
1549,Asian,9.0,23467860.0,Pare G,Response to drug,replication,2013-03-06,GCST001895,Response to dabigatran etexilate treatment
9029,European,7280.0,23474815.0,Stambolian D,Other trait,initial,2013-03-07,GCST001898,Refractive error
10332,European,19763.0,23474815.0,Stambolian D,Other trait,replication,2013-03-07,GCST001898,Refractive error
6038,European,982.0,23470693.0,Zeng Z,Digestive system disorder,initial,2013-03-07,GCST001896,Smooth-surface caries
6066,European,996.0,23470693.0,Zeng Z,Digestive system disorder,initial,2013-03-07,GCST001897,Pit-and-Fissure caries
8447,European,4982.0,23482656.0,Chen D,Cancer,initial,2013-03-12,GCST001900,Cervical cancer
7113,European,2198.0,23482656.0,Chen D,Cancer,replication,2013-03-12,GCST001900,Cervical cancer
7407,European,2620.0,23561647.0,van Setten J,Other trait,initial,2013-03-13,GCST001902,Coronary artery calcification
12849,Hispanic or Latin American,1644.0,23493294.0,Gao X,Other measurement,initial,2013-03-14,GCST001903,Central corneal thickness
12556,Hispanic or Latin American,124.0,23493294.0,Gao X,Other measurement,replication,2013-03-14,GCST001903,Central corneal thickness
12872,Hispanic or Latin American,2121.0,23505323.0,Weissglas-Volkov D,Lipid or lipoprotein measurement,replication,2013-03-15,GCST001904,HDL cholesterol
12876,Hispanic or Latin American,2240.0,23505323.0,Weissglas-Volkov D,"Metabolic disorder, Lipid or lipoprotein measurement",initial,2013-03-15,GCST001905,Hypertriglyceridemia
12875,Hispanic or Latin American,2240.0,23505323.0,Weissglas-Volkov D,Lipid or lipoprotein measurement,initial,2013-03-15,GCST001904,HDL cholesterol
12873,Hispanic or Latin American,2121.0,23505323.0,Weissglas-Volkov D,"Metabolic disorder, Lipid or lipoprotein measurement",replication,2013-03-15,GCST001905,Hypertriglyceridemia
6469,European,1408.0,23502781.0,Germain M,Cardiovascular disease,initial,2013-03-17,GCST001908,Pulmonary arterial hypertension (without BMPR2 mutations)
9420,European,8966.0,23502783.0,Weinhold N,Cancer,initial,2013-03-17,GCST001907,Multiple myeloma (hyperdiploidy)
9419,European,8966.0,23502783.0,Weinhold N,Cancer,initial,2013-03-17,GCST001906,Multiple myeloma (IgH translocation)
5087,European,387.0,23496005.0,Luca G,Neurological disorder,replication,2013-03-18,GCST001909,Narcolepsy with cataplexy
5467,European,585.0,23496005.0,Luca G,Neurological disorder,initial,2013-03-18,GCST001909,Narcolepsy with cataplexy
6981,European,2054.0,23508960.0,Zhou G,Other measurement,initial,2013-03-18,GCST001910,Aspirin hydrolysis (plasma)
12685,Hispanic or Latin American,592.0,23508266.0,Duan QL,"Response to drug, Other disease",replication,2013-03-19,GCST001911,Asthma (bronchodilator response)
12742,Hispanic or Latin American,783.0,23512250.0,Xu H,Cancer,replication,2013-03-19,GCST001912,Acute lymphoblastic leukemia (childhood)
881,African American or Afro-Caribbean,1452.0,23512250.0,Xu H,Cancer,initial,2013-03-19,GCST001912,Acute lymphoblastic leukemia (childhood)
823,African American or Afro-Caribbean,1203.0,23512250.0,Xu H,Cancer,replication,2013-03-19,GCST001912,Acute lymphoblastic leukemia (childhood)
5114,European,403.0,23508266.0,Duan QL,"Response to drug, Other disease",initial,2013-03-19,GCST001911,Asthma (bronchodilator response)
7220,European,2358.0,23512250.0,Xu H,Cancer,initial,2013-03-19,GCST001912,Acute lymphoblastic leukemia (childhood)
6307,European,1220.0,23508266.0,Duan QL,"Response to drug, Other disease",replication,2013-03-19,GCST001911,Asthma (bronchodilator response)
12813,Hispanic or Latin American,1313.0,23512250.0,Xu H,Cancer,initial,2013-03-19,GCST001912,Acute lymphoblastic leukemia (childhood)
7673,European,3175.0,23512250.0,Xu H,Cancer,replication,2013-03-19,GCST001912,Acute lymphoblastic leukemia (childhood)
6654,European,1639.0,23509962.0,Greliche N,Cardiovascular disease,initial,2013-03-20,GCST001913,Venous thromboembolism (SNP x SNP interaction)
7424,European,2652.0,23509962.0,Greliche N,Cardiovascular disease,replication,2013-03-20,GCST001913,Venous thromboembolism (SNP x SNP interaction)
1567,Asian,17.0,23518928.0,Liu M,Other measurement,initial,2013-03-21,GCST001914,Estradiol plasma levels (breast cancer)
24,African,50.0,23518928.0,Liu M,Other measurement,initial,2013-03-21,GCST001914,Estradiol plasma levels (breast cancer)
13385,Other/Mixed,5.0,23518928.0,Liu M,Other measurement,initial,2013-03-21,GCST001914,Estradiol plasma levels (breast cancer)
5622,European,700.0,23518928.0,Liu M,Other measurement,initial,2013-03-21,GCST001914,Estradiol plasma levels (breast cancer)
4968,European,303.0,23535033.0,Sherva R,Neurological disorder,initial,2013-03-24,GCST001915,Alzheimer's disease (cognitive decline)
2725,Asian,1639.0,23532257.0,Ma RC,Metabolic disorder,initial,2013-03-27,GCST001919,Type 2 diabetes
7469,European,2727.0,23544013.0,Couch FJ,"Cancer, Other measurement",initial,2013-03-27,GCST001916,Breast Cancer in BRCA1 mutation carriers
4412,Asian,38983.0,23532257.0,Ma RC,Metabolic disorder,replication,2013-03-27,GCST001919,Type 2 diabetes
9805,European,11964.0,23544013.0,Couch FJ,"Other measurement, Cancer",replication,2013-03-27,GCST001917,Ovarian cancer in BRCA1 mutation carriers
2911,Asian,1998.0,23532257.0,Ma RC,Metabolic disorder,replication,2013-03-27,GCST001919,Type 2 diabetes
11067,European,47117.0,23532257.0,Ma RC,Metabolic disorder,replication,2013-03-27,GCST001919,Type 2 diabetes
9219,European,8211.0,23544012.0,Gaudet MM,Cancer,initial,2013-03-27,GCST007302,Breast cancer in BRCA2 mutation carriers
2983,Asian,2146.0,23532257.0,Ma RC,Metabolic disorder,replication,2013-03-27,GCST001919,Type 2 diabetes
9804,European,11964.0,23544013.0,Couch FJ,"Cancer, Other measurement",replication,2013-03-27,GCST001916,Breast Cancer in BRCA1 mutation carriers
6571,European,1544.0,23541324.0,Li X,"Other measurement, Other disease",initial,2013-03-27,GCST001918,Pulmonary function in asthmatics
7470,European,2727.0,23544013.0,Couch FJ,"Other measurement, Cancer",initial,2013-03-27,GCST001917,Ovarian cancer in BRCA1 mutation carriers
649,African American or Afro-Caribbean,455.0,23534349.0,Jeff JM,Cardiovascular measurement,initial,2013-03-28,GCST001920,QRS duration
1742,Asian,151.0,23555300.0,Cui J,"Immune system disorder, Response to drug",replication,2013-03-28,GCST001926,Response to anti-TNF therapy in rheumatoid arthritis
3284,Asian,3350.0,23539754.0,Yamada Y,"Other disease, Other measurement",replication,2013-03-28,GCST001924,Chronic kidney disease
2518,Asian,1184.0,23535911.0,Kitamoto T,"Cancer, Other measurement, Digestive system disorder",replication,2013-03-28,GCST001928,Pediatric non-alcoholic fatty liver disease activity score
9427,European,9049.0,23535967.0,Tin A,Other measurement,initial,2013-03-28,GCST001923,Glomerular filtration rate
650,African American or Afro-Caribbean,455.0,23534349.0,Jeff JM,Cardiovascular measurement,initial,2013-03-28,GCST001921,Heart rate
2119,Asian,501.0,23539754.0,Yamada Y,"Other disease, Other measurement",initial,2013-03-28,GCST001924,Chronic kidney disease
652,African American or Afro-Caribbean,455.0,23534349.0,Jeff JM,Cardiovascular measurement,initial,2013-03-28,GCST001925,PR interval
2578,Asian,1326.0,23535911.0,Kitamoto T,"Cancer, Other measurement, Digestive system disorder",initial,2013-03-28,GCST001928,Pediatric non-alcoholic fatty liver disease activity score
4713,European,139.0,23555300.0,Cui J,"Immune system disorder, Response to drug",replication,2013-03-28,GCST001926,Response to anti-TNF therapy in rheumatoid arthritis
5661,European,733.0,23555300.0,Cui J,"Immune system disorder, Response to drug",initial,2013-03-28,GCST001926,Response to anti-TNF therapy in rheumatoid arthritis
7458,European,2706.0,23555300.0,Cui J,"Immune system disorder, Response to drug",initial,2013-03-28,GCST001927,Response to anti-TNF therapy in rheumatoid arthritis
651,African American or Afro-Caribbean,455.0,23534349.0,Jeff JM,Cardiovascular measurement,initial,2013-03-28,GCST001922,QT interval
9455,European,9283.0,23548203.0,Zhang M,Other disease,initial,2013-04-01,GCST001933,Sunburns
6033,European,979.0,23517042.0,Melen E,"Body measurement, Other disease",replication,2013-04-01,GCST001945,Body mass index in asthmatics
8915,European,6747.0,23548203.0,Zhang M,"Other trait, Cancer",initial,2013-04-01,GCST001940,Non-melanoma skin cancer
6431,European,1371.0,23555189.0,Chen Z,Other measurement,initial,2013-04-01,GCST001946,PCA3 expression level
2515,Asian,1183.0,23535730.0,Pharoah PD,Cancer,replication,2013-04-01,GCST001941,Ovarian cancer
2494,Asian,1127.0,23511034.0,Yang SK,Immune system disorder,initial,2013-04-01,GCST001934,Ulcerative colitis
3120,Asian,2519.0,23511034.0,Yang SK,Immune system disorder,replication,2013-04-01,GCST001934,Ulcerative colitis
10478,European,22627.0,23535729.0,Michailidou K,Cancer,initial,2013-04-01,GCST001937,Breast cancer
2502,Asian,1149.0,23511034.0,Yang SK,Immune system disorder,replication,2013-04-01,GCST001938,Ulcerative colitis
2495,Asian,1127.0,23511034.0,Yang SK,Immune system disorder,initial,2013-04-01,GCST001938,Ulcerative colitis
8990,European,7070.0,23548203.0,Zhang M,"Other measurement, Other trait",initial,2013-04-01,GCST001932,Hair color
7000,European,2078.0,23548203.0,Zhang M,"Other trait, Cancer",replication,2013-04-01,GCST001940,Non-melanoma skin cancer
9526,European,9678.0,23548203.0,Zhang M,Other trait,initial,2013-04-01,GCST001939,Tanning
7306,European,2496.0,23548203.0,Zhang M,"Other measurement, Other trait",replication,2013-04-01,GCST001929,Eye color
12772,Hispanic or Latin American,921.0,23517042.0,Melen E,"Body measurement, Other disease",replication,2013-04-01,GCST001945,Body mass index in asthmatics
9682,European,10739.0,23535734.0,Codd V,Other measurement,replication,2013-04-01,GCST001936,Telomere length
1815,Asian,212.0,23535730.0,Pharoah PD,Cancer,replication,2013-04-01,GCST001941,Ovarian cancer
9836,European,12359.0,23517042.0,Melen E,Body measurement,initial,2013-04-01,GCST001935,Body mass index in non-asthmatics
8260,European,4524.0,23517042.0,Melen E,"Body measurement, Other disease",initial,2013-04-01,GCST001945,Body mass index in asthmatics
8141,European,4155.0,23548203.0,Zhang M,"Other measurement, Other trait",replication,2013-04-01,GCST001932,Hair color
10943,European,39377.0,23535732.0,Eeles RA,Cancer,replication,2013-04-01,GCST001942,Prostate cancer
10944,European,39387.0,23535733.0,Garcia-Closas M,Cancer,initial,2013-04-01,GCST001930,Breast cancer
8032,European,3871.0,23548203.0,Zhang M,"Other measurement, Other trait",initial,2013-04-01,GCST001929,Eye color
8169,European,4236.0,23548203.0,Zhang M,Other disease,replication,2013-04-01,GCST001933,Sunburns
10949,European,39674.0,23535730.0,Pharoah PD,Cancer,replication,2013-04-01,GCST001941,Ovarian cancer
13618,Other/Mixed,331.0,23517042.0,Melen E,Body measurement,initial,2013-04-01,GCST001935,Body mass index in non-asthmatics
13523,Other/Mixed,171.0,23517042.0,Melen E,"Body measurement, Other disease",initial,2013-04-01,GCST001945,Body mass index in asthmatics
10473,European,22548.0,23535732.0,Eeles RA,Cancer,initial,2013-04-01,GCST001942,Prostate cancer
9211,European,8165.0,23535730.0,Pharoah PD,Cancer,initial,2013-04-01,GCST001941,Ovarian cancer
11079,European,47969.0,23535733.0,Garcia-Closas M,Cancer,replication,2013-04-01,GCST001930,Breast cancer
11485,European,87170.0,23535729.0,Michailidou K,Cancer,replication,2013-04-01,GCST001937,Breast cancer
10908,European,37684.0,23535734.0,Codd V,Other measurement,initial,2013-04-01,GCST001936,Telomere length
6332,European,1252.0,23551011.0,Zhao L,Cardiovascular disease,initial,2013-04-02,GCST001949,Preeclampsia
786,African American or Afro-Caribbean,1031.0,23551011.0,Zhao L,Cardiovascular disease,initial,2013-04-02,GCST001949,Preeclampsia
7513,European,2810.0,23565138.0,Trzaskowski M,"Other measurement, Other trait",initial,2013-04-02,GCST001948,Anxiety
8354,European,4804.0,23565138.0,Trzaskowski M,"Other measurement, Other trait",replication,2013-04-02,GCST001948,Anxiety
12717,Hispanic or Latin American,720.0,23551011.0,Zhao L,Cardiovascular disease,initial,2013-04-02,GCST001949,Preeclampsia
10485,European,22771.0,23565137.0,Miyashita A,Neurological disorder,replication,2013-04-02,GCST001947,Alzheimer's disease (late onset)
3283,Asian,3338.0,23565137.0,Miyashita A,Neurological disorder,replication,2013-04-02,GCST001947,Alzheimer's disease (late onset)
2764,Asian,1735.0,23565137.0,Miyashita A,Neurological disorder,initial,2013-04-02,GCST001947,Alzheimer's disease (late onset)
11108,European,50627.0,23593239.0,van der Loos MJ,Other measurement,initial,2013-04-04,GCST001952,Self-employment
6737,European,1728.0,23593202.0,Ran S,Other measurement,initial,2013-04-04,GCST001950,Femoral neck bone geometry and menarche (age at onset)
6351,European,1278.0,23562540.0,Cruchaga C,"Other measurement, Neurological disorder",initial,2013-04-04,GCST001951,Alzheimer's disease biomarkers
2346,Asian,826.0,23593202.0,Ran S,Other measurement,replication,2013-04-04,GCST001950,Femoral neck bone geometry and menarche (age at onset)
5322,European,501.0,23593202.0,Ran S,Other measurement,replication,2013-04-04,GCST001950,Femoral neck bone geometry and menarche (age at onset)
8892,European,6703.0,23563607.0,Berndt SI,"Other measurement, Body measurement",replication,2013-04-07,GCST001954,Waist-hip ratio
7581,European,2961.0,23563609.0,Wheeler E,Metabolic disorder,replication,2013-04-07,GCST001957,Obesity (early onset extreme)
9530,European,9703.0,23563607.0,Berndt SI,"Other measurement, Body measurement",replication,2013-04-07,GCST001956,Height
8953,European,6889.0,23563609.0,Wheeler E,Metabolic disorder,initial,2013-04-07,GCST001957,Obesity (early onset extreme)
11767,European,133637.0,23563607.0,Berndt SI,"Other measurement, Metabolic disorder",replication,2013-04-07,GCST001953,Obesity
12027,European,204498.0,23563607.0,Berndt SI,"Other measurement, Metabolic disorder",initial,2013-04-07,GCST001953,Obesity
9620,European,10255.0,23563607.0,Berndt SI,"Other measurement, Body measurement",initial,2013-04-07,GCST001954,Waist-hip ratio
10089,European,16068.0,23563607.0,Berndt SI,"Body measurement, Other measurement",initial,2013-04-07,GCST001955,Body mass index
9545,European,9791.0,23563607.0,Berndt SI,"Body measurement, Other measurement",replication,2013-04-07,GCST001955,Body mass index
10105,European,16196.0,23563607.0,Berndt SI,"Other measurement, Body measurement",initial,2013-04-07,GCST001956,Height
7334,European,2524.0,23568457.0,Wade TD,Metabolic disorder,initial,2013-04-09,GCST001961,Anorexia nervosa
8703,European,5866.0,23572186.0,Zheng HF,Other measurement,initial,2013-04-09,GCST001962,Bone mineral density
7273,European,2442.0,23568457.0,Wade TD,Metabolic disorder,initial,2013-04-09,GCST001958,Bulimia nervosa
12715,Hispanic or Latin American,715.0,23572186.0,Zheng HF,Other measurement,replication,2013-04-09,GCST001962,Bone mineral density
6673,European,1659.0,23568457.0,Wade TD,"Metabolic disorder, Neurological disorder",initial,2013-04-09,GCST001960,Eating disorders
7331,European,2521.0,23568457.0,Wade TD,Metabolic disorder,initial,2013-04-09,GCST001959,Eating disorders (purging via substances)
7176,European,2296.0,23575227.0,Urbanek M,"Other measurement, Body measurement, Other trait",replication,2013-04-10,GCST001964,Anthropometric traits in newborns
1240,African American or Afro-Caribbean,5896.0,23571587.0,Reitz C,Neurological disorder,initial,2013-04-10,GCST001963,Alzheimer's disease (late onset)
6416,European,1363.0,23575227.0,Urbanek M,"Other measurement, Body measurement, Other trait",initial,2013-04-10,GCST001964,Anthropometric traits in newborns
12694,Hispanic or Latin American,616.0,23575227.0,Urbanek M,"Other measurement, Body measurement, Other trait",initial,2013-04-10,GCST001964,Anthropometric traits in newborns
2526,Asian,1207.0,23575227.0,Urbanek M,"Other measurement, Body measurement, Other trait",initial,2013-04-10,GCST001964,Anthropometric traits in newborns
808,African American or Afro-Caribbean,1095.0,23575227.0,Urbanek M,"Other measurement, Body measurement, Other trait",initial,2013-04-10,GCST001964,Anthropometric traits in newborns
3839,Asian,7696.0,23575436.0,Go MJ,Metabolic disorder,initial,2013-04-11,GCST001965,Glycemic traits
7518,European,2820.0,23585552.0,Kirin M,Neurological disorder,initial,2013-04-11,GCST001966,Rhegmatogenous retinal detachment
9153,European,7884.0,23585552.0,Kirin M,Neurological disorder,replication,2013-04-11,GCST001966,Rhegmatogenous retinal detachment
3738,Asian,6536.0,23575436.0,Go MJ,Metabolic disorder,replication,2013-04-11,GCST001965,Glycemic traits
1505,African American or Afro-Caribbean,37956.0,23583978.0,Monda KL,"Body measurement, Other measurement",initial,2013-04-14,GCST001967,Body mass index
3741,Asian,6568.0,23583979.0,den Hoed M,Cardiovascular measurement,initial,2013-04-14,GCST001969,Heart rate
11469,European,85787.0,23583979.0,den Hoed M,Cardiovascular measurement,initial,2013-04-14,GCST001969,Heart rate
8808,European,6299.0,23583980.0,Fingerlin TE,Other disease,initial,2013-04-14,GCST001968,Interstitial lung disease
1500,African American or Afro-Caribbean,27661.0,23583978.0,Monda KL,"Body measurement, Other measurement",replication,2013-04-14,GCST001967,Body mass index
173,African,1188.0,23583978.0,Monda KL,"Body measurement, Other measurement",initial,2013-04-14,GCST001967,Body mass index
7488,European,2766.0,23583980.0,Fingerlin TE,Other disease,replication,2013-04-14,GCST001968,Interstitial lung disease
274,African,4607.0,23583978.0,Monda KL,"Body measurement, Other measurement",replication,2013-04-14,GCST001967,Body mass index
11723,European,123706.0,23583978.0,Monda KL,"Body measurement, Other measurement",replication,2013-04-14,GCST001967,Body mass index
11504,European,88823.0,23583979.0,den Hoed M,Cardiovascular measurement,replication,2013-04-14,GCST001969,Heart rate
2229,Asian,687.0,23646285.0,Khor SS,Neurological disorder,initial,2013-04-16,GCST001971,Hypersomnia (HLA-DQB1*06:02 negative)
13692,Other/Mixed,573.0,23592221.0,Rahmani M,Other measurement,replication,2013-04-16,GCST001970,Menopause (age at onset)
10938,European,38968.0,23592221.0,Rahmani M,Other measurement,replication,2013-04-16,GCST001970,Menopause (age at onset)
13635,Other/Mixed,352.0,23592221.0,Rahmani M,Other measurement,initial,2013-04-16,GCST001970,Menopause (age at onset)
7143,European,2257.0,24429156.0,Noth I,Cancer,replication,2013-04-17,GCST001974,Idiopathic pulmonary fibrosis
1442,African American or Afro-Caribbean,18089.0,23599027.0,Demerath EW,Other measurement,initial,2013-04-17,GCST001973,Menarche (age at onset)
1036,African American or Afro-Caribbean,2850.0,23599027.0,Demerath EW,Other measurement,replication,2013-04-17,GCST001973,Menarche (age at onset)
2481,Asian,1100.0,23594818.0,Ikeda M,Neurological disorder,initial,2013-04-17,GCST001972,Methamphetamine dependence
6175,European,1084.0,24429156.0,Noth I,Cancer,initial,2013-04-17,GCST001974,Idiopathic pulmonary fibrosis
11492,European,87802.0,23599027.0,Demerath EW,Other measurement,replication,2013-04-17,GCST001973,Menarche (age at onset)
1859,Asian,234.0,23594818.0,Ikeda M,Neurological disorder,initial,2013-04-17,GCST001975,Psychosis (methamphetamine induced)
6265,European,1180.0,23642732.0,Cox AJ,Other measurement,initial,2013-04-19,GCST001976,Bilirubin levels
12681,Hispanic or Latin American,585.0,23562823.0,Sheu WH,Metabolic disorder,replication,2013-04-19,GCST001977,Diabetic retinopathy
2442,Asian,1007.0,23562823.0,Sheu WH,Metabolic disorder,initial,2013-04-19,GCST001977,Diabetic retinopathy
10082,European,15872.0,23603761.0,Hinks A,Immune system disorder,initial,2013-04-21,GCST005528,Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular)
5713,European,759.0,23626673.0,Matullo G,Cancer,initial,2013-04-23,GCST001978,Malignant pleural mesothelioma
6692,European,1697.0,23626673.0,Matullo G,Cancer,replication,2013-04-23,GCST001978,Malignant pleural mesothelioma
9453,European,9260.0,23620142.0,Reiner AP,Cardiovascular measurement,initial,2013-04-24,GCST001980,Circulating myeloperoxidase levels (plasma)
9459,European,9305.0,23620142.0,Reiner AP,Cardiovascular measurement,initial,2013-04-24,GCST001979,Circulating myeloperoxidase levels (serum)
3103,Asian,2483.0,23624525.0,Deng M,Neurological disorder,replication,2013-04-28,GCST001981,Amyotrophic lateral sclerosis
3070,Asian,2365.0,23624525.0,Deng M,Neurological disorder,initial,2013-04-28,GCST001981,Amyotrophic lateral sclerosis
4146,Asian,13080.0,23612905.0,Zhao SX,Immune system disorder,replication,2013-04-29,GCST001982,Graves' disease
6338,European,1256.0,23620144.0,Sulkava S,Neurological disorder,initial,2013-04-29,GCST001983,Job-related exhaustion
9946,European,13864.0,23620144.0,Sulkava S,Neurological disorder,replication,2013-04-29,GCST001983,Job-related exhaustion
3218,Asian,2910.0,23612905.0,Zhao SX,Immune system disorder,initial,2013-04-29,GCST001982,Graves' disease
4230,Asian,16242.0,23612905.0,Zhao SX,Immune system disorder,replication,2013-04-29,GCST001984,Graves' disease
3219,Asian,2910.0,23612905.0,Zhao SX,Immune system disorder,initial,2013-04-29,GCST001984,Graves' disease
5011,European,333.0,23633212.0,Rinella ES,Other trait,replication,2013-04-30,GCST001985,Weight loss (gastric bypass surgery)
4764,European,175.0,23633212.0,Rinella ES,Other trait,initial,2013-04-30,GCST001985,Weight loss (gastric bypass surgery)
6476,European,1419.0,23577725.0,Naj AC,"Other measurement, Neurological disorder",initial,2013-05-01,GCST001990,Age-related macular degeneration (smoking status interaction)
6316,European,1233.0,23577725.0,Naj AC,Neurological disorder,initial,2013-05-01,GCST001987,Age-related macular degeneration (extreme sampling)
6858,European,1893.0,23577725.0,Naj AC,Neurological disorder,initial,2013-05-01,GCST001986,Age-related macular degeneration
10800,European,33533.0,23636237.0,Tanaka T,Biological process,replication,2013-05-01,GCST001988,Dietary macronutrient intake
10902,European,37537.0,23636237.0,Tanaka T,Biological process,initial,2013-05-01,GCST001989,Dietary macronutrient intake
4837,European,208.0,23577725.0,Naj AC,Neurological disorder,replication,2013-05-01,GCST001986,Age-related macular degeneration
4719,European,143.0,23577725.0,Naj AC,Neurological disorder,replication,2013-05-01,GCST001987,Age-related macular degeneration (extreme sampling)
10901,European,37537.0,23636237.0,Tanaka T,Biological process,initial,2013-05-01,GCST001988,Dietary macronutrient intake
10984,European,41257.0,23636237.0,Tanaka T,Biological process,replication,2013-05-01,GCST001989,Dietary macronutrient intake
1992,Asian,376.0,23678272.0,Cheong KA,Immune system disorder,replication,2013-05-02,GCST001992,Vitiligo (non-segmental)
5612,European,693.0,23643386.0,Hatoum IJ,Other trait,initial,2013-05-02,GCST001991,Weight loss (gastric bypass surgery)
4999,European,327.0,23643386.0,Hatoum IJ,Other trait,replication,2013-05-02,GCST001991,Weight loss (gastric bypass surgery)
1816,Asian,212.0,23678272.0,Cheong KA,Immune system disorder,initial,2013-05-02,GCST001992,Vitiligo (non-segmental)
1740,Asian,149.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002009,Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin)
2197,Asian,643.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002008,Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)
2496,Asian,1129.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST001997,Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil)
2133,Asian,523.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002004,Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)
2122,Asian,503.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002002,Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide)
3127,Asian,2543.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002005,Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)
2171,Asian,582.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST001999,Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)
2001,Asian,380.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST001995,Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)
1654,Asian,93.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002000,Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide)
1929,Asian,306.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002003,Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)
2522,Asian,1196.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002001,Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)
2198,Asian,647.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002007,Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)
1937,Asian,316.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST002006,Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)
2508,Asian,1171.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST001998,Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)
1917,Asian,293.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST001994,Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)
1819,Asian,214.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST001993,Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin)
2068,Asian,453.0,23648065.0,Low SK,Response to drug,initial,2013-05-04,GCST001996,Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin)
11356,European,73965.0,23644456.0,Styrkarsdottir U,Other measurement,initial,2013-05-05,GCST002011,Bone mineral density
2905,Asian,1962.0,23644492.0,Wu C,"Cancer, Other measurement",replication,2013-05-05,GCST002010,Esophageal squamous cell cancer (length of survival)
11031,European,44499.0,23650146.0,Tang W,Cardiovascular disease,initial,2013-05-05,GCST002012,Venous thromboembolism
8916,European,6767.0,23650146.0,Tang W,Cardiovascular disease,replication,2013-05-05,GCST002012,Venous thromboembolism
2580,Asian,1331.0,23644492.0,Wu C,"Cancer, Other measurement",initial,2013-05-05,GCST002010,Esophageal squamous cell cancer (length of survival)
4222,Asian,15495.0,23667675.0,Tanikawa C,Other measurement,initial,2013-05-07,GCST002013,Menarche (age at onset)
9638,European,10485.0,23652523.0,Mayerle J,Other measurement,initial,2013-05-08,GCST002014,Helicobacter pylori serologic status
7413,European,2631.0,23658558.0,Bae HT,Other trait,initial,2013-05-08,GCST002015,Personality dimensions
6356,European,1287.0,23658558.0,Bae HT,Other trait,replication,2013-05-08,GCST002015,Personality dimensions
8283,European,4595.0,23658558.0,Bae HT,Other trait,initial,2013-05-08,GCST002016,Personality dimensions
6040,European,983.0,23665963.0,Dubinsky MC,Digestive system disorder,initial,2013-05-09,GCST002018,Crohn's disease (time to surgery)
5509,European,614.0,23665963.0,Dubinsky MC,Digestive system disorder,initial,2013-05-09,GCST002017,Crohn's disease (need for surgery)
2920,Asian,1999.0,23661040.0,Liao M,Other measurement,initial,2013-05-10,GCST002019,IgE levels
2643,Asian,1496.0,23661040.0,Liao M,Other measurement,replication,2013-05-10,GCST002019,IgE levels
10108,European,16253.0,23669352.0,Graff M,"Body measurement, Other measurement",replication,2013-05-12,GCST002021,Body mass index
8726,European,5932.0,23666240.0,Ruark E,Cancer,initial,2013-05-12,GCST002022,Testicular germ cell tumor
9816,European,12070.0,23666239.0,Chung CC,Cancer,replication,2013-05-12,GCST002023,Testicular germ cell tumor
6651,European,1638.0,23666239.0,Chung CC,Cancer,initial,2013-05-12,GCST002023,Testicular germ cell tumor
4339,Asian,27204.0,23666238.0,Kou I,Other disease,replication,2013-05-12,GCST002020,Scoliosis
9724,European,11146.0,23666240.0,Ruark E,Cancer,replication,2013-05-12,GCST002022,Testicular germ cell tumor
3110,Asian,2506.0,23666238.0,Kou I,Other disease,initial,2013-05-12,GCST002020,Scoliosis
9931,European,13627.0,23669352.0,Graff M,"Body measurement, Other measurement",initial,2013-05-12,GCST002021,Body mass index
6273,European,1184.0,23666238.0,Kou I,Other disease,replication,2013-05-12,GCST002020,Scoliosis
13663,Other/Mixed,438.0,23668334.0,Shan J,Cancer,replication,2013-05-13,GCST002024,Prostate cancer
13571,Other/Mixed,221.0,23668334.0,Shan J,Cancer,initial,2013-05-13,GCST002024,Prostate cancer
1831,Asian,223.0,23677057.0,Kim JJ,"Immune system disorder, Cardiovascular disease",replication,2013-05-16,GCST002026,Coronary arterial lesions in patients with Kawasaki disease
1733,Asian,140.0,23677057.0,Kim JJ,"Immune system disorder, Cardiovascular disease",initial,2013-05-16,GCST002026,Coronary arterial lesions in patients with Kawasaki disease
931,African American or Afro-Caribbean,1904.0,23696099.0,Ding K,Hematological measurement,initial,2013-05-20,GCST002027,Red blood cell traits
628,African American or Afro-Caribbean,411.0,23696099.0,Ding K,Hematological measurement,replication,2013-05-20,GCST002027,Red blood cell traits
6294,European,1203.0,23698163.0,Gong J,Other measurement,initial,2013-05-21,GCST002028,Serum selenium levels
5514,European,621.0,23698163.0,Gong J,Other measurement,replication,2013-05-21,GCST002028,Serum selenium levels
321,African,12316.0,23717212.0,Band G,Digestive system disorder,initial,2013-05-23,GCST002033,Malaria
2557,Asian,1256.0,23704207.0,Wu X,"Other measurement, Cancer",replication,2013-05-23,GCST002032,Non-small cell lung cancer (survival)
2131,Asian,520.0,23746317.0,Yamaguchi T,Other disease,initial,2013-05-23,GCST002029,Temporomandibular joint disorder
9722,European,11118.0,23704328.0,Fatemifar G,Biological process,initial,2013-05-23,GCST002030,Primary tooth development (time to first tooth eruption)
5512,European,620.0,23704207.0,Wu X,"Other measurement, Cancer",initial,2013-05-23,GCST002032,Non-small cell lung cancer (survival)
9757,European,11513.0,23704328.0,Fatemifar G,Biological process,initial,2013-05-23,GCST002031,Primary tooth development (number of teeth)
13782,Other/Mixed,778.0,23719583.0,Kerns SL,Biological process,replication,2013-05-26,GCST002034,Adverse response to radiation therapy
7661,European,3146.0,23708191.0,Cordell HJ,Cardiovascular disease,replication,2013-05-26,GCST002035,Congenital heart disease
3682,Asian,6026.0,23708190.0,Hu Z,Cardiovascular disease,replication,2013-05-26,GCST002036,Congenital heart malformation
3012,Asian,2191.0,23708190.0,Hu Z,Cardiovascular disease,initial,2013-05-26,GCST002036,Congenital heart malformation
8972,European,6978.0,23708191.0,Cordell HJ,Cardiovascular disease,initial,2013-05-26,GCST002035,Congenital heart disease
13611,Other/Mixed,320.0,23719583.0,Kerns SL,Biological process,initial,2013-05-26,GCST002034,Adverse response to radiation therapy
6821,European,1846.0,23726511.0,Xie P,Neurological disorder,initial,2013-05-28,GCST002037,Post-traumatic stress disorder (asjusted for relatedness)
717,African American or Afro-Caribbean,744.0,23726511.0,Xie P,Neurological disorder,replication,2013-05-28,GCST002038,Post-traumatic stress disorder
6604,European,1578.0,23726511.0,Xie P,Neurological disorder,replication,2013-05-28,GCST002038,Post-traumatic stress disorder
6818,European,1838.0,23726511.0,Xie P,Neurological disorder,initial,2013-05-28,GCST002038,Post-traumatic stress disorder
1124,African American or Afro-Caribbean,3392.0,23726511.0,Xie P,Neurological disorder,initial,2013-05-28,GCST002037,Post-traumatic stress disorder (asjusted for relatedness)
1123,African American or Afro-Caribbean,3380.0,23726511.0,Xie P,Neurological disorder,initial,2013-05-28,GCST002038,Post-traumatic stress disorder
7396,European,2603.0,23720494.0,Evans DM,Other measurement,initial,2013-05-29,GCST002041,Blood trace element (Cu levels)
1312,African American or Afro-Caribbean,7917.0,23726366.0,Coram MA,Lipid or lipoprotein measurement,initial,2013-05-29,GCST002043,HDL cholesterol
1310,African American or Afro-Caribbean,7861.0,23726366.0,Coram MA,"Lipid or lipoprotein measurement, Other measurement",initial,2013-05-29,GCST002042,LDL cholesterol
8622,European,5477.0,23720494.0,Evans DM,Other measurement,initial,2013-05-29,GCST002039,Blood trace element (Se levels)
12940,Hispanic or Latin American,3425.0,23726366.0,Coram MA,"Lipid or lipoprotein measurement, Other measurement",initial,2013-05-29,GCST002042,LDL cholesterol
1285,African American or Afro-Caribbean,7138.0,23726366.0,Coram MA,"Lipid or lipoprotein measurement, Other measurement",replication,2013-05-29,GCST002042,LDL cholesterol
1284,African American or Afro-Caribbean,7138.0,23726366.0,Coram MA,Lipid or lipoprotein measurement,replication,2013-05-29,GCST002044,Triglycerides
12957,Hispanic or Latin American,3506.0,23726366.0,Coram MA,Lipid or lipoprotein measurement,initial,2013-05-29,GCST002043,HDL cholesterol
1283,African American or Afro-Caribbean,7138.0,23726366.0,Coram MA,Lipid or lipoprotein measurement,replication,2013-05-29,GCST002043,HDL cholesterol
7395,European,2603.0,23720494.0,Evans DM,Other measurement,initial,2013-05-29,GCST002040,Blood trace element (Zn levels)
12935,Hispanic or Latin American,3335.0,23726366.0,Coram MA,Lipid or lipoprotein measurement,initial,2013-05-29,GCST002044,Triglycerides
1297,African American or Afro-Caribbean,7601.0,23726366.0,Coram MA,Lipid or lipoprotein measurement,initial,2013-05-29,GCST002044,Triglycerides
12557,Hispanic or Latin American,126.0,23726668.0,Hunter AM,Response to drug,initial,2013-05-30,GCST002046,Response to antidepressant treatment (citalopram)
11736,European,126559.0,23722424.0,Rietveld CA,Other measurement,initial,2013-05-30,GCST008396,Educational attainment (years of education)
10581,European,25490.0,23722424.0,Rietveld CA,Other measurement,replication,2013-05-30,GCST002045,Educational attainment
13452,Other/Mixed,39.0,23726668.0,Hunter AM,Response to drug,initial,2013-05-30,GCST002046,Response to antidepressant treatment (citalopram)
490,African American or Afro-Caribbean,145.0,23726668.0,Hunter AM,Response to drug,initial,2013-05-30,GCST002046,Response to antidepressant treatment (citalopram)
1566,Asian,16.0,23726668.0,Hunter AM,Response to drug,initial,2013-05-30,GCST002046,Response to antidepressant treatment (citalopram)
11582,European,101069.0,23722424.0,Rietveld CA,Other measurement,initial,2013-05-30,GCST002045,Educational attainment
5728,European,774.0,23726668.0,Hunter AM,Response to drug,initial,2013-05-30,GCST002046,Response to antidepressant treatment (citalopram)
11735,European,126559.0,23722424.0,Rietveld CA,Other measurement,initial,2013-05-30,GCST002047,Educational attainment (college completion)
5468,European,585.0,23726668.0,Hunter AM,Response to drug,replication,2013-05-30,GCST002046,Response to antidepressant treatment (citalopram)
7198,European,2322.0,23728906.0,Byrne EM,Other measurement,initial,2013-05-31,GCST002050,Sleep time
7189,European,2315.0,23728906.0,Byrne EM,Other measurement,initial,2013-05-31,GCST002049,Sleep quality
7188,European,2314.0,23728906.0,Byrne EM,Other measurement,initial,2013-05-31,GCST002054,Sleep depth
2929,Asian,2003.0,23728934.0,Yang L,Neurological disorder,initial,2013-05-31,GCST002048,Attention deficit hyperactivity disorder
6930,European,2001.0,23728906.0,Byrne EM,Other measurement,replication,2013-05-31,GCST002051,Sleep latency
7146,European,2267.0,23728906.0,Byrne EM,"Neurological disorder, Other measurement",initial,2013-05-31,GCST002052,Insomnia
7153,European,2278.0,23728906.0,Byrne EM,Other measurement,initial,2013-05-31,GCST002053,Sleep duration
7155,European,2280.0,23728906.0,Byrne EM,Other measurement,initial,2013-05-31,GCST002051,Sleep latency
11824,European,143849.0,23603763.0,Liu JZ,"Digestive system disorder, Immune system disorder, Other disease, Metabolic disorder",initial,2013-06-01,GCST005563,"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)"
2114,Asian,489.0,23732972.0,Hashimoto R,"Other trait, Biological process",initial,2013-06-01,GCST002055,Cognitive decline
10655,European,28868.0,23603763.0,Liu JZ,Digestive system disorder,initial,2013-06-01,GCST006670,Primary sclerosing cholangitis
7839,European,3397.0,23727862.0,Savage SA,Cancer,initial,2013-06-02,GCST002056,Osteosarcoma
5755,European,797.0,23727862.0,Savage SA,Cancer,replication,2013-06-02,GCST002056,Osteosarcoma
5083,European,384.0,23725790.0,Renteria ME,Biological process,replication,2013-06-03,GCST002058,DNA methylation (variation)
6123,European,1024.0,23725790.0,Renteria ME,Biological process,initial,2013-06-03,GCST002057,DNA methylation (parent-of-origin)
4901,European,256.0,23725790.0,Renteria ME,Biological process,initial,2013-06-03,GCST002058,DNA methylation (variation)
668,African American or Afro-Caribbean,533.0,23755828.0,Perera MA,Response to drug,initial,2013-06-05,GCST002061,Warfarin maintenance dose
636,African American or Afro-Caribbean,432.0,23755828.0,Perera MA,Response to drug,replication,2013-06-05,GCST002061,Warfarin maintenance dose
8880,European,6649.0,23738518.0,Luciano M,Biological process,initial,2013-06-05,GCST002062,Reading and spelling
8879,European,6649.0,23738518.0,Luciano M,Biological process,initial,2013-06-05,GCST002060,Word reading
8878,European,6649.0,23738518.0,Luciano M,Biological process,initial,2013-06-05,GCST002059,Non-word repetition
11773,European,133723.0,23754948.0,Randall JC,"Other measurement, Body measurement, Other trait",initial,2013-06-06,GCST002063,Sexual dimorphism in anthropometric traits
11791,European,137052.0,23754948.0,Randall JC,"Other measurement, Body measurement, Other trait",replication,2013-06-06,GCST002063,Sexual dimorphism in anthropometric traits
7492,European,2784.0,23761726.0,Yazar S,"Neurological disorder, Other trait",initial,2013-06-06,GCST002064,Corneal astigmatism
8407,European,4915.0,23743675.0,Kapoor M,"Biological process, Other measurement",initial,2013-06-07,GCST002065,Alcohol consumption
3744,Asian,6667.0,23749188.0,Tan DE,Cancer,replication,2013-06-09,GCST002066,B cell non-Hodgkin lymphoma
2746,Asian,1691.0,23749188.0,Tan DE,Cancer,initial,2013-06-09,GCST002066,B cell non-Hodgkin lymphoma
5152,European,424.0,23753411.0,Turner ST,Response to drug,initial,2013-06-10,GCST002067,Response to diuretic therapy in hypertension
9615,European,10198.0,23740937.0,Martin JE,"Neurological disorder, Immune system disorder",replication,2013-06-10,GCST002069,Systemic lupus erythematosus and Systemic sclerosis
3217,Asian,2909.0,23760081.0,Kim YJ,Digestive system disorder,replication,2013-06-10,GCST002068,Chronic hepatitis B infection
5825,European,841.0,23753411.0,Turner ST,Response to drug,replication,2013-06-10,GCST002067,Response to diuretic therapy in hypertension
9702,European,10911.0,23740937.0,Martin JE,"Neurological disorder, Immune system disorder",initial,2013-06-10,GCST002069,Systemic lupus erythematosus and Systemic sclerosis
2607,Asian,1400.0,23760081.0,Kim YJ,Digestive system disorder,initial,2013-06-10,GCST002068,Chronic hepatitis B infection
6203,European,1114.0,23752247.0,Loukola A,Biological process,initial,2013-06-11,GCST002070,Smoking behavior
8571,European,5294.0,23752247.0,Loukola A,Biological process,replication,2013-06-11,GCST002070,Smoking behavior
10270,European,18722.0,23776548.0,Sim X,Other measurement,initial,2013-06-12,GCST002071,Retinal arteriolar caliber
8058,European,3939.0,23776548.0,Sim X,Other measurement,replication,2013-06-12,GCST002071,Retinal arteriolar caliber
6850,European,1884.0,23785401.0,Leone MA,"Immune system disorder, Other measurement",replication,2013-06-13,GCST002072,Multiple sclerosis (OCB status)
5429,European,562.0,23785401.0,Leone MA,"Immune system disorder, Other measurement",initial,2013-06-13,GCST002072,Multiple sclerosis (OCB status)
9193,European,8027.0,23770605.0,Berndt SI,Cancer,replication,2013-06-16,GCST002073,Chronic lymphocytic leukemia
9323,European,8400.0,23770605.0,Berndt SI,Cancer,initial,2013-06-16,GCST002073,Chronic lymphocytic leukemia
4720,European,143.0,23776197.0,Leandro-Garcia LJ,"Response to drug, Neurological disorder, Other measurement",initial,2013-06-17,GCST002074,Paclitaxel-induced neuropathy
5469,European,586.0,23823136.0,Larsen MH,Other measurement,replication,2013-06-18,GCST002075,Lipopolysaccharide induced cytokine levels
4706,European,130.0,23823136.0,Larsen MH,Other measurement,initial,2013-06-18,GCST002075,Lipopolysaccharide induced cytokine levels
9492,European,9458.0,23805179.0,Hass J,"Neurological disorder, Other measurement",replication,2013-06-21,GCST002076,Hippocampal volume in schizophrenia
5758,European,798.0,23793441.0,Davis MF,Neurological disorder,initial,2013-06-21,GCST002077,Parkinson's disease
4749,European,170.0,23805179.0,Hass J,"Neurological disorder, Other measurement",initial,2013-06-21,GCST002076,Hippocampal volume in schizophrenia
11404,European,79357.0,23793025.0,Anttila V,Cardiovascular disease,initial,2013-06-23,GCST002080,Migraine with aura
10294,European,19147.0,23793025.0,Anttila V,Cardiovascular disease,initial,2013-06-23,GCST002079,Migraine - clinic-based
11687,European,118710.0,23793025.0,Anttila V,Cardiovascular disease,initial,2013-06-23,GCST002081,Migraine
11368,European,76534.0,23793025.0,Anttila V,Cardiovascular disease,initial,2013-06-23,GCST002078,Migraine without aura
3432,Asian,4392.0,23817570.0,Shi Y,Cancer,initial,2013-06-30,GCST002082,Cervical cancer
11154,European,53862.0,23817569.0,Hinds DA,Immune system disorder,initial,2013-06-30,GCST002083,Self-reported allergy
10086,European,16034.0,23817571.0,Bonnelykke K,Other measurement,replication,2013-06-30,GCST002084,Allergic sensitization
4080,Asian,11363.0,23817570.0,Shi Y,Cancer,replication,2013-06-30,GCST002082,Cervical cancer
10079,European,15845.0,23817571.0,Bonnelykke K,Other measurement,initial,2013-06-30,GCST002084,Allergic sensitization
3262,Asian,3117.0,23749187.0,Cortes A,Immune system disorder,initial,2013-07-01,GCST005529,Ankylosing spondylitis
10480,European,22647.0,23749187.0,Cortes A,Immune system disorder,initial,2013-07-01,GCST005530,Ankylosing spondylitis (SNP x SNP interaction)
7294,European,2475.0,23827383.0,Cadby G,Cancer,initial,2013-07-01,GCST002085,Malignant mesothelioma
5714,European,759.0,23827383.0,Cadby G,Cancer,replication,2013-07-01,GCST002085,Malignant mesothelioma
10479,European,22647.0,23749187.0,Cortes A,Immune system disorder,initial,2013-07-01,GCST005529,Ankylosing spondylitis
3045,Asian,2275.0,23844046.0,Dorajoo R,Inflammatory measurement,initial,2013-07-02,GCST002086,C-reactive protein
3010,Asian,2179.0,23844046.0,Dorajoo R,Inflammatory measurement,initial,2013-07-02,GCST002086,C-reactive protein
3032,Asian,2238.0,23844046.0,Dorajoo R,Inflammatory measurement,initial,2013-07-02,GCST002086,C-reactive protein
11026,European,44147.0,23824729.0,van Meurs JB,Cardiovascular measurement,initial,2013-07-03,GCST002087,Homocysteine levels
13784,Other/Mixed,788.0,23830517.0,Saruhan-Direskeneli G,Cardiovascular disease,initial,2013-07-03,GCST006863,Takayasu arteritis
5568,European,659.0,23830517.0,Saruhan-Direskeneli G,Cardiovascular disease,initial,2013-07-03,GCST006863,Takayasu arteritis
12560,Hispanic or Latin American,138.0,23829686.0,Ding L,Other disease,replication,2013-07-05,GCST002088,Asthma (childhood onset)
497,African American or Afro-Caribbean,156.0,23829686.0,Ding L,Other disease,replication,2013-07-05,GCST002088,Asthma (childhood onset)
6357,European,1287.0,23829686.0,Ding L,Other disease,initial,2013-07-05,GCST002088,Asthma (childhood onset)
7078,European,2175.0,23836780.0,Blue Mountains Eye Study (BMES),Other measurement,initial,2013-07-07,GCST002089,Intraocular pressure
8386,European,4866.0,23836780.0,Blue Mountains Eye Study (BMES),Other measurement,replication,2013-07-07,GCST002089,Intraocular pressure
13484,Other/Mixed,76.0,23838604.0,Pare G,"Cardiovascular disease, Response to drug",replication,2013-07-08,GCST002091,Angioedema in response to angiotensin-converting enzyme inhibitor
13728,Other/Mixed,664.0,23838604.0,Pare G,"Cardiovascular disease, Response to drug",initial,2013-07-08,GCST002091,Angioedema in response to angiotensin-converting enzyme inhibitor
7567,European,2930.0,23874384.0,Viding E,Biological process,initial,2013-07-09,GCST002092,Callous-unemotional behaviour
7620,European,3029.0,23853074.0,Meder B,Cardiovascular disease,initial,2013-07-12,GCST002093,Idiopathic dilated cardiomyopathy
9400,European,8824.0,23853074.0,Meder B,Cardiovascular disease,replication,2013-07-12,GCST002093,Idiopathic dilated cardiomyopathy
3310,Asian,3488.0,23850713.0,Yang SK,Digestive system disorder,replication,2013-07-14,GCST002094,Crohn's disease
2558,Asian,1265.0,23850713.0,Yang SK,Digestive system disorder,initial,2013-07-14,GCST002094,Crohn's disease
6627,European,1610.0,23857890.0,Power RA,Neurological disorder,initial,2013-07-15,GCST002095,Major depressive disorder
8368,European,4835.0,23871474.0,Psychosis Endophenotypes International Consortium,Neurological disorder,initial,2013-07-17,GCST002096,Psychosis
9598,European,9992.0,23870195.0,Wojczynski MK,Other trait,replication,2013-07-19,GCST002097,Coronary artery calcification
1236,African American or Afro-Caribbean,5823.0,23870195.0,Wojczynski MK,Other trait,initial,2013-07-19,GCST002097,Coronary artery calcification
6464,European,1400.0,23872634.0,Bezzina CR,Cardiovascular disease,replication,2013-07-21,GCST002098,Brugada syndrome
2545,Asian,1224.0,23872634.0,Bezzina CR,Cardiovascular disease,replication,2013-07-21,GCST002098,Brugada syndrome
6477,European,1427.0,23872634.0,Bezzina CR,Cardiovascular disease,initial,2013-07-21,GCST002098,Brugada syndrome
1683,Asian,105.0,23875689.0,Hong SN,Cancer,initial,2013-07-22,GCST002099,Colorectal cancer
2000,Asian,379.0,23875689.0,Hong SN,Cancer,replication,2013-07-22,GCST002099,Colorectal cancer
9928,European,13581.0,23935489.0,McLaren PJ,"Immune system disorder, Other disease",initial,2013-07-25,GCST002101,HIV-1 susceptibility
8610,European,5446.0,23886662.0,Weidinger S,Immune system disorder,replication,2013-07-25,GCST002100,Atopic dermatitis
8645,European,5617.0,23886662.0,Weidinger S,Immune system disorder,initial,2013-07-25,GCST002100,Atopic dermatitis
6276,European,1187.0,23894154.0,Kohler A,Cancer,initial,2013-07-26,GCST002102,Thyroid cancer
8889,European,6685.0,23894154.0,Kohler A,Cancer,replication,2013-07-26,GCST002102,Thyroid cancer
5092,European,390.0,23897914.0,Wang H,Other disease,initial,2013-07-29,GCST002104,Bronchopulmonary dysplasia
7136,European,2240.0,23900074.0,Pooley KA,Other measurement,initial,2013-07-29,GCST002103,Telomere length
12769,Hispanic or Latin American,908.0,23897914.0,Wang H,Other disease,initial,2013-07-29,GCST002104,Bronchopulmonary dysplasia
13787,Other/Mixed,795.0,23897914.0,Wang H,Other disease,replication,2013-07-29,GCST002104,Bronchopulmonary dysplasia
13450,Other/Mixed,36.0,23897914.0,Wang H,Other disease,initial,2013-07-29,GCST002104,Bronchopulmonary dysplasia
13520,Other/Mixed,167.0,23897914.0,Wang H,Other disease,initial,2013-07-29,GCST002104,Bronchopulmonary dysplasia
550,African American or Afro-Caribbean,225.0,23897914.0,Wang H,Other disease,initial,2013-07-29,GCST002104,Bronchopulmonary dysplasia
4788,European,187.0,23910658.0,McRae JF,Biological process,initial,2013-07-31,GCST002107,Odorant perception (&beta;-ionone)
4787,European,187.0,23910658.0,McRae JF,Biological process,initial,2013-07-31,GCST002106,Odorant perception (&beta;-damascenone)
7617,European,3026.0,23903356.0,Hayes MG,Other measurement,replication,2013-07-31,GCST002110,Glycemic traits (pregnancy)
1686,Asian,109.0,23910658.0,McRae JF,Biological process,replication,2013-07-31,GCST002107,Odorant perception (&beta;-ionone)
1685,Asian,109.0,23910658.0,McRae JF,Biological process,replication,2013-07-31,GCST002105,Odorant perception (isobutyraldehyde)
2511,Asian,1178.0,23903356.0,Hayes MG,Other measurement,initial,2013-07-31,GCST002110,Glycemic traits (pregnancy)
6421,European,1367.0,23903356.0,Hayes MG,Other measurement,initial,2013-07-31,GCST002110,Glycemic traits (pregnancy)
4786,European,187.0,23910658.0,McRae JF,Biological process,initial,2013-07-31,GCST002105,Odorant perception (isobutyraldehyde)
12751,Hispanic or Latin American,817.0,23903356.0,Hayes MG,Other measurement,initial,2013-07-31,GCST002110,Glycemic traits (pregnancy)
6677,European,1664.0,23935956.0,Pistis G,Hematological measurement,initial,2013-07-31,GCST002109,Red blood cell traits
10158,European,16764.0,23935956.0,Pistis G,Hematological measurement,replication,2013-07-31,GCST002109,Red blood cell traits
1632,Asian,76.0,23921680.0,Kim DS,Immune system disorder,initial,2013-07-31,GCST002108,Allergic dermatitis (nickel)
4648,European,89.0,23910658.0,McRae JF,Biological process,replication,2013-07-31,GCST002106,Odorant perception (&beta;-damascenone)
799,African American or Afro-Caribbean,1075.0,23903356.0,Hayes MG,Other measurement,initial,2013-07-31,GCST002110,Glycemic traits (pregnancy)
2476,Asian,1089.0,23903073.0,Kim HN,Other trait,initial,2013-08-01,GCST002111,Personality dimensions
2958,Asian,2090.0,23903073.0,Kim HN,Other trait,replication,2013-08-01,GCST002111,Personality dimensions
5510,European,618.0,23936387.0,Ostensson M,Immune system disorder,initial,2013-08-02,GCST002112,Celiac disease
6227,European,1144.0,23932459.0,Yao TC,Other measurement,initial,2013-08-06,GCST002113,Pulmonary function
5581,European,668.0,23918034.0,Kuhnisch J,Other disease,initial,2013-08-07,GCST002114,Molar-incisor hypomineralization
3888,Asian,8216.0,24144296.0,Cheng CY,Other measurement,replication,2013-08-08,GCST002115,Axial length
9848,European,12531.0,24144296.0,Cheng CY,Other measurement,initial,2013-08-08,GCST002115,Axial length
8008,European,3802.0,23929743.0,Yadav S,Other measurement,initial,2013-08-08,GCST002116,Blood pressure variability
8043,European,3900.0,23929743.0,Yadav S,Other measurement,replication,2013-08-08,GCST002116,Blood pressure variability
3506,Asian,4800.0,23933737.0,Khor CC,Other trait,replication,2013-08-09,GCST002117,Myopia (severe)
3518,Asian,5030.0,23933737.0,Khor CC,Other trait,initial,2013-08-09,GCST002117,Myopia (severe)
844,African American or Afro-Caribbean,1260.0,23934736.0,Yu B,Other measurement,initial,2013-08-11,GCST002120,Metabolite levels (Dihydroxy docosatrienoic acid)
842,African American or Afro-Caribbean,1260.0,23934736.0,Yu B,Other measurement,initial,2013-08-11,GCST002118,Metabolite levels (Pyroglutamine)
843,African American or Afro-Caribbean,1260.0,23934736.0,Yu B,Other measurement,initial,2013-08-11,GCST002119,Metabolite levels  (X-11787)
13553,Other/Mixed,178.0,23937595.0,Al Safar HS,Metabolic disorder,initial,2013-08-13,GCST002123,Type 2 diabetes
13610,Other/Mixed,315.0,23937595.0,Al Safar HS,Metabolic disorder,replication,2013-08-13,GCST002123,Type 2 diabetes
7440,European,2687.0,23953852.0,Pan Y,"Biological process, Other measurement",initial,2013-08-13,GCST002121,Alcohol consumption
7657,European,3137.0,23953852.0,Pan Y,"Biological process, Other measurement",replication,2013-08-13,GCST002121,Alcohol consumption
2373,Asian,877.0,23967269.0,Kim JH,"Other disease, Other measurement",initial,2013-08-13,GCST002125,IgE levels in asthmatics (D.f. specific)
2371,Asian,877.0,23967269.0,Kim JH,"Other disease, Other measurement",initial,2013-08-13,GCST002122,IgE levels in asthmatics
2372,Asian,877.0,23967269.0,Kim JH,"Other disease, Other measurement",initial,2013-08-13,GCST002124,IgE levels in asthmatics (D.p. specific)
9016,European,7188.0,23942779.0,McGue M,Biological process,initial,2013-08-14,GCST002132,Non-substance related behavioral disinhibition
4336,Asian,26805.0,23945395.0,Hara K,Metabolic disorder,initial,2013-08-14,GCST002128,Type 2 diabetes
9021,European,7188.0,23942779.0,McGue M,"Other measurement, Neurological disorder",initial,2013-08-14,GCST002134,Alcohol dependence
8046,European,3915.0,24024966.0,Teumer A,Digestive system disorder,initial,2013-08-14,GCST002126,Periodontitis (CDC/AAP)
9020,European,7188.0,23942779.0,McGue M,"Biological process, Other measurement",initial,2013-08-14,GCST002130,Alcohol consumption
9017,European,7188.0,23942779.0,McGue M,Biological process,initial,2013-08-14,GCST002133,Illicit drug use
4408,Asian,38401.0,23945395.0,Hara K,Metabolic disorder,replication,2013-08-14,GCST002128,Type 2 diabetes
9018,European,7188.0,23942779.0,McGue M,Biological process,initial,2013-08-14,GCST002135,Nicotine use
7308,European,2501.0,24024966.0,Teumer A,Digestive system disorder,initial,2013-08-14,GCST002129,Periodontitis (DPAL)
9019,European,7188.0,23942779.0,McGue M,"Biological process, Neurological disorder, Other measurement",initial,2013-08-14,GCST002131,Behavioural disinhibition (generation interaction)
8098,European,4032.0,24024966.0,Teumer A,Digestive system disorder,initial,2013-08-14,GCST002127,Periodontitis (Mean PAL)
7584,European,2969.0,24024966.0,Teumer A,Digestive system disorder,initial,2013-08-14,GCST002136,Periodontitis (PAL4Q3)
1446,African American or Afro-Caribbean,19744.0,23966867.0,Liu CT,"Other measurement, Body measurement",initial,2013-08-15,GCST002138,Waist-hip ratio
1486,African American or Afro-Caribbean,23564.0,23966867.0,Liu CT,Body measurement,initial,2013-08-15,GCST002137,Waist circumference
1376,African American or Afro-Caribbean,10027.0,23966867.0,Liu CT,Body measurement,replication,2013-08-15,GCST002137,Waist circumference
1298,African American or Afro-Caribbean,7606.0,23966867.0,Liu CT,"Other measurement, Body measurement",replication,2013-08-15,GCST002138,Waist-hip ratio
4964,European,301.0,23956247.0,Knevel R,"Immune system disorder, Other measurement",replication,2013-08-16,GCST002139,Joint damage progression in ACPA-positive rheumatoid arthritis
9520,European,9641.0,23955597.0,Chubb D,Cancer,initial,2013-08-18,GCST002140,Multiple myeloma
8752,European,6041.0,23955597.0,Chubb D,Cancer,replication,2013-08-18,GCST002140,Multiple myeloma
11325,European,69395.0,23972371.0,Franceschini N,"Other measurement, Cardiovascular measurement",replication,2013-08-20,GCST002143,Blood pressure
4280,Asian,19601.0,23972371.0,Franceschini N,"Other measurement, Cardiovascular measurement",replication,2013-08-20,GCST002143,Blood pressure
1119,African American or Afro-Caribbean,3318.0,23958962.0,Gelernter J,Neurological disorder,initial,2013-08-20,GCST002142,Cocaine dependence
8252,European,4498.0,23958962.0,Gelernter J,Neurological disorder,replication,2013-08-20,GCST002142,Cocaine dependence
7239,European,2379.0,23958962.0,Gelernter J,Neurological disorder,initial,2013-08-20,GCST002142,Cocaine dependence
1223,African American or Afro-Caribbean,5266.0,23972371.0,Franceschini N,"Other measurement, Cardiovascular measurement",replication,2013-08-20,GCST002143,Blood pressure
12550,Hispanic or Latin American,104.0,23966204.0,Ledda M,Biological process,replication,2013-08-20,GCST002144,Bitter taste perception
1501,African American or Afro-Caribbean,28190.0,23972371.0,Franceschini N,"Other measurement, Cardiovascular measurement",initial,2013-08-20,GCST002143,Blood pressure
174,African,1188.0,23972371.0,Franceschini N,"Other measurement, Cardiovascular measurement",initial,2013-08-20,GCST002143,Blood pressure
283,African,5108.0,23972371.0,Franceschini N,"Other measurement, Cardiovascular measurement",replication,2013-08-20,GCST002143,Blood pressure
185,African,1389.0,23972371.0,Franceschini N,"Other measurement, Cardiovascular measurement",replication,2013-08-20,GCST002143,Blood pressure
12663,Hispanic or Latin American,503.0,23966204.0,Ledda M,Biological process,initial,2013-08-20,GCST002144,Bitter taste perception
966,African American or Afro-Caribbean,2114.0,23958962.0,Gelernter J,Neurological disorder,replication,2013-08-20,GCST002142,Cocaine dependence
13865,Other/Mixed,1435.0,23989729.0,Feenstra B,Digestive system disorder,replication,2013-08-21,GCST002145,Infantile hypertrophic pyloric stenosis
7365,European,2546.0,23989729.0,Feenstra B,Digestive system disorder,replication,2013-08-21,GCST002145,Infantile hypertrophic pyloric stenosis
7822,European,3372.0,23989729.0,Feenstra B,Digestive system disorder,initial,2013-08-21,GCST002145,Infantile hypertrophic pyloric stenosis
9845,European,12518.0,23990791.0,Thun GA,Other measurement,replication,2013-08-22,GCST002146,Serum alpha1-antitrypsin levels
12834,Hispanic or Latin American,1447.0,23969696.0,Sabater-Lleal M,Hematological measurement,replication,2013-08-22,GCST002147,Fibrinogen
11542,European,91323.0,23969696.0,Sabater-Lleal M,Hematological measurement,initial,2013-08-22,GCST002147,Fibrinogen
1338,African American or Afro-Caribbean,8423.0,23969696.0,Sabater-Lleal M,Hematological measurement,replication,2013-08-22,GCST002147,Fibrinogen
6457,European,1392.0,23990791.0,Thun GA,Other measurement,initial,2013-08-22,GCST002146,Serum alpha1-antitrypsin levels
5445,European,577.0,23974705.0,Allen EK,Neurological disorder,initial,2013-08-23,GCST002148,Otitis media (chronic/recurrent)
13438,Other/Mixed,25.0,23974705.0,Allen EK,Neurological disorder,initial,2013-08-23,GCST002148,Otitis media (chronic/recurrent)
6607,European,1584.0,23974705.0,Allen EK,Neurological disorder,replication,2013-08-23,GCST002148,Otitis media (chronic/recurrent)
9735,European,11244.0,23974872.0,Ripke S,Neurological disorder,initial,2013-08-25,GCST002149,Schizophrenia
9506,European,9542.0,23974872.0,Ripke S,Neurological disorder,replication,2013-08-25,GCST002149,Schizophrenia
8719,European,5902.0,23983088.0,Miller FW,Neurological disorder,initial,2013-08-27,GCST002151,Dermatomyositis
6064,European,994.0,23984888.0,Himes BE,Other trait,initial,2013-08-28,GCST002152,Airway hyperresponsiveness
7183,European,2310.0,23982368.0,Qi L,"Other disease, Metabolic disorder",initial,2013-08-28,GCST002153,Cardiovascular heart disease in diabetics
8085,European,4004.0,23984888.0,Himes BE,Other trait,replication,2013-08-28,GCST002152,Airway hyperresponsiveness
6845,European,1878.0,23982368.0,Qi L,"Other disease, Metabolic disorder",replication,2013-08-28,GCST002153,Cardiovascular heart disease in diabetics
11118,European,51537.0,23989986.0,Evangelou E,Other disease,initial,2013-08-29,GCST002155,Osteoarthritis (hip)
12853,Hispanic or Latin American,1782.0,23992748.0,Drake KA,"Response to drug, Other disease",initial,2013-08-29,GCST002154,Asthma (bronchodilator response)
10626,European,27498.0,23989986.0,Evangelou E,Other disease,replication,2013-08-29,GCST002155,Osteoarthritis (hip)
12665,Hispanic or Latin American,529.0,23992748.0,Drake KA,"Response to drug, Other disease",replication,2013-08-29,GCST002154,Asthma (bronchodilator response)
8826,European,6381.0,23996088.0,Migliorini G,Cancer,initial,2013-08-30,GCST002158,Acute lymphoblastic leukemia (B-cell precursor)
1656,Asian,94.0,24009623.0,Jiang J,Response to drug,initial,2013-08-30,GCST002157,Response to mTOR inhibitor (everolimus)
7572,European,2937.0,23996088.0,Migliorini G,Cancer,replication,2013-08-30,GCST002158,Acute lymphoblastic leukemia (B-cell precursor)
453,African American or Afro-Caribbean,91.0,24009623.0,Jiang J,Response to drug,initial,2013-08-30,GCST002157,Response to mTOR inhibitor (everolimus)
452,African American or Afro-Caribbean,91.0,24009623.0,Jiang J,Response to drug,initial,2013-08-30,GCST002156,Response to mTOR inhibitor (rapamycin)
1655,Asian,94.0,24009623.0,Jiang J,Response to drug,initial,2013-08-30,GCST002156,Response to mTOR inhibitor (rapamycin)
4642,European,87.0,24009623.0,Jiang J,Response to drug,initial,2013-08-30,GCST002156,Response to mTOR inhibitor (rapamycin)
4643,European,87.0,24009623.0,Jiang J,Response to drug,initial,2013-08-30,GCST002157,Response to mTOR inhibitor (everolimus)
6762,European,1756.0,23740775.0,Xie G,Cardiovascular disease,replication,2013-09-01,GCST002159,Wegener's granulomatosis
6907,European,1962.0,23740775.0,Xie G,Cardiovascular disease,initial,2013-09-01,GCST002159,Wegener's granulomatosis
5501,European,608.0,23740775.0,Xie G,Cardiovascular disease,replication,2013-09-01,GCST002160,Wegener's granulomatosis
6908,European,1962.0,23740775.0,Xie G,Cardiovascular disease,initial,2013-09-01,GCST002160,Wegener's granulomatosis
672,African American or Afro-Caribbean,541.0,24023788.0,Ong BA,Other measurement,initial,2013-09-02,GCST002162,Lung function (FVC)
6109,European,1015.0,24023788.0,Ong BA,Other measurement,initial,2013-09-02,GCST002162,Lung function (FVC)
6110,European,1015.0,24023788.0,Ong BA,Other measurement,initial,2013-09-02,GCST002163,Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity)
6111,European,1015.0,24023788.0,Ong BA,Other measurement,initial,2013-09-02,GCST002164,Lung function (FEV1/FVC)
674,African American or Afro-Caribbean,541.0,24023788.0,Ong BA,Other measurement,initial,2013-09-02,GCST002164,Lung function (FEV1/FVC)
6112,European,1015.0,24023788.0,Ong BA,Other measurement,initial,2013-09-02,GCST002165,Lung function (FEV1)
673,African American or Afro-Caribbean,541.0,24023788.0,Ong BA,Other measurement,initial,2013-09-02,GCST002163,Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity)
675,African American or Afro-Caribbean,541.0,24023788.0,Ong BA,Other measurement,initial,2013-09-02,GCST002165,Lung function (FEV1)
4346,Asian,28783.0,24001895.0,Kelly TN,"Other measurement, Cardiovascular measurement",replication,2013-09-03,GCST002167,Blood pressure
3429,Asian,4325.0,24001895.0,Kelly TN,"Other measurement, Cardiovascular measurement",initial,2013-09-03,GCST002167,Blood pressure
4307,Asian,22275.0,24001895.0,Kelly TN,"Other measurement, Cardiovascular measurement",initial,2013-09-03,GCST002167,Blood pressure
2937,Asian,2028.0,24023777.0,Miyake A,Other disease,initial,2013-09-04,GCST002169,Adolescent idiopathic scoliosis (severe)
8798,European,6236.0,24002674.0,Ozel AB,Other measurement,initial,2013-09-04,GCST002168,Intraocular pressure
4063,Asian,10988.0,24023777.0,Miyake A,Other disease,replication,2013-09-04,GCST002169,Adolescent idiopathic scoliosis (severe)
8266,European,4550.0,24014518.0,Kasperaviciute D,Neurological disorder,replication,2013-09-06,GCST002170,Mesial temporal lobe epilepsy with hippocampal sclerosis
9354,European,8570.0,24014518.0,Kasperaviciute D,Neurological disorder,initial,2013-09-06,GCST002170,Mesial temporal lobe epilepsy with hippocampal sclerosis
601,African American or Afro-Caribbean,342.0,24080187.0,Guffanti G,Neurological disorder,initial,2013-09-08,GCST002171,Post-traumatic stress disorder
7357,European,2541.0,24080187.0,Guffanti G,Neurological disorder,replication,2013-09-08,GCST002171,Post-traumatic stress disorder
13439,Other/Mixed,25.0,24080187.0,Guffanti G,Neurological disorder,initial,2013-09-08,GCST002171,Post-traumatic stress disorder
4575,European,45.0,24080187.0,Guffanti G,Neurological disorder,initial,2013-09-08,GCST002171,Post-traumatic stress disorder
7418,European,2647.0,24015780.0,Wetherill L,"Other measurement, Neurological disorder",replication,2013-09-09,GCST002172,Alcohol dependence
7199,European,2322.0,24015780.0,Wetherill L,"Other measurement, Neurological disorder",initial,2013-09-09,GCST002172,Alcohol dependence
5820,European,839.0,24023261.0,Keller M,"Lipid or lipoprotein measurement, Other measurement",initial,2013-09-10,GCST002173,Lipid traits
8542,European,5248.0,24023261.0,Keller M,"Lipid or lipoprotein measurement, Other measurement",replication,2013-09-10,GCST002173,Lipid traits
2811,Asian,1782.0,24023260.0,Wu Y,"Lipid or lipoprotein measurement, Other measurement",initial,2013-09-10,GCST002174,Lipid traits
2756,Asian,1719.0,24023260.0,Wu Y,"Lipid or lipoprotein measurement, Other measurement",replication,2013-09-10,GCST002174,Lipid traits
1701,Asian,120.0,24025145.0,Chung S,"Response to drug, Other disease",initial,2013-09-11,GCST002179,Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)
1681,Asian,104.0,24025145.0,Chung S,"Other disease, Response to drug",initial,2013-09-11,GCST002180,Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel)
1649,Asian,91.0,24025145.0,Chung S,"Other disease, Response to drug",initial,2013-09-11,GCST002178,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)
1569,Asian,23.0,24025145.0,Chung S,Other disease,replication,2013-09-11,GCST002181,Adverse response to chemotherapy in breast cancer (alopecia)
1836,Asian,224.0,24025145.0,Chung S,"Other disease, Response to drug",initial,2013-09-11,GCST002177,Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)
8189,European,4291.0,24024963.0,Eicher JD,Neurological disorder,initial,2013-09-11,GCST002175,Reading disability and language impairment
1835,Asian,224.0,24025145.0,Chung S,"Other disease, Response to drug",initial,2013-09-11,GCST002176,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU)
2516,Asian,1183.0,24025145.0,Chung S,Other disease,initial,2013-09-11,GCST002181,Adverse response to chemotherapy in breast cancer (alopecia)
5201,European,440.0,24024963.0,Eicher JD,Neurological disorder,replication,2013-09-11,GCST002175,Reading disability and language impairment
7431,European,2666.0,24068947.0,Brandler WM,Other trait,initial,2013-09-12,GCST002185,Relative hand skill
7133,European,2235.0,24029427.0,Sandholm N,"Other disease, Metabolic disorder",initial,2013-09-12,GCST002182,End-stage renal disease in Type 1 diabetics
9930,European,13582.0,24026423.0,Shameer K,Hematological measurement,initial,2013-09-12,GCST002186,Platelet count
6531,European,1517.0,24029427.0,Sandholm N,"Other disease, Metabolic disorder",replication,2013-09-12,GCST002182,End-stage renal disease in Type 1 diabetics
5654,European,728.0,24068947.0,Brandler WM,"Other trait, Neurological disorder",initial,2013-09-12,GCST002183,Relative hand skill in reading disability
8788,European,6219.0,24026423.0,Shameer K,Hematological measurement,initial,2013-09-12,GCST002184,Mean platelet volume
903,African American or Afro-Caribbean,1617.0,24058526.0,Bhatnagar P,"Neurological disorder, Other measurement",initial,2013-09-13,GCST002187,Systolic blood pressure in sickle cell anemia
13661,Other/Mixed,428.0,24037343.0,Chang ALS,Biological process,initial,2013-09-13,GCST002189,Skin youthfulness
13788,Other/Mixed,807.0,24037343.0,Chang ALS,Biological process,replication,2013-09-13,GCST002189,Skin youthfulness
7140,European,2246.0,24039173.0,McGrath LM,"Neurological disorder, Other measurement",initial,2013-09-13,GCST002188,"Functional impairment in major depressive disorder, bipolar disorder and schizophrenia"
3299,Asian,3437.0,24045676.0,Pyun JA,Other measurement,initial,2013-09-16,GCST002191,Menarche (age at onset)
2832,Asian,1827.0,24045676.0,Pyun JA,Other measurement,initial,2013-09-16,GCST002192,Menopause (age at onset)
2993,Asian,2151.0,24043878.0,Wong EH,Neurological disorder,replication,2013-09-16,GCST002190,Schizophrenia
3111,Asian,2506.0,24043878.0,Wong EH,Neurological disorder,initial,2013-09-16,GCST002190,Schizophrenia
10708,European,30620.0,24046328.0,Bradley DT,Cardiovascular disease,replication,2013-09-17,GCST002193,Abdominal aortic aneurysm
8989,European,7069.0,24046328.0,Bradley DT,Cardiovascular disease,initial,2013-09-17,GCST002193,Abdominal aortic aneurysm
13765,Other/Mixed,733.0,24057671.0,Chimusa ER,"Other disease, Other measurement",initial,2013-09-18,GCST002197,Tuberculosis
2921,Asian,1999.0,24049095.0,Chen Z,Other measurement,initial,2013-09-18,GCST002195,Hormone measurements
2644,Asian,1496.0,24049095.0,Chen Z,Other measurement,replication,2013-09-18,GCST002195,Hormone measurements
13766,Other/Mixed,733.0,24057671.0,Chimusa ER,"Other disease, Other measurement",initial,2013-09-18,GCST002198,Tuberculosis
6508,European,1474.0,24047826.0,Kleber ME,Other measurement,replication,2013-09-18,GCST002196,Homoarginine levels
8516,European,5143.0,24047826.0,Kleber ME,Other measurement,initial,2013-09-18,GCST002196,Homoarginine levels
6419,European,1364.0,24047820.0,St Pourcain B,Other measurement,replication,2013-09-18,GCST002194,Social communication problems
2645,Asian,1496.0,24049095.0,Chen Z,Other measurement,replication,2013-09-18,GCST002199,Follicule stimulating hormone
8635,European,5584.0,24047820.0,St Pourcain B,Other measurement,initial,2013-09-18,GCST002194,Social communication problems
2922,Asian,1999.0,24049095.0,Chen Z,Other measurement,initial,2013-09-18,GCST002199,Follicule stimulating hormone
7433,European,2668.0,24047446.0,Schosser A,"Neurological disorder, Other trait",initial,2013-09-19,GCST002200,Anxiety and major depressive disorder
6535,European,1522.0,24047446.0,Schosser A,"Neurological disorder, Other trait",initial,2013-09-19,GCST002202,Anxiety in major depressive disorder
10434,European,21679.0,24068962.0,O'Seaghdha CM,Other measurement,replication,2013-09-19,GCST002201,Calcium levels
10946,European,39400.0,24068962.0,O'Seaghdha CM,Other measurement,initial,2013-09-19,GCST002201,Calcium levels
13726,Other/Mixed,648.0,24065354.0,Al-Qahtani A,Digestive system disorder,initial,2013-09-24,GCST002204,Liver disease in chronic hepatitis B virus infection
1706,Asian,125.0,24086445.0,Wang Q,"Neurological disorder, Other measurement",initial,2013-09-24,GCST002203,Gray matter volume (schizophrenia interaction)
13572,Other/Mixed,225.0,24065354.0,Al-Qahtani A,Digestive system disorder,replication,2013-09-24,GCST002204,Liver disease in chronic hepatitis B virus infection
6608,European,1585.0,24065183.0,Armour JA,Other trait,initial,2013-09-25,GCST002206,Handedness
7218,European,2355.0,24065183.0,Armour JA,Other trait,initial,2013-09-25,GCST002205,Handedness
3730,Asian,6428.0,24124408.0,Hong KW,Cardiovascular disease,initial,2013-09-30,GCST002209,Orthostatic hypotension
2106,Asian,484.0,24124411.0,Park TJ,Liver enzyme measurement,initial,2013-09-30,GCST002207,Liver enzyme levels (alanine transaminase)
2107,Asian,484.0,24124411.0,Park TJ,Liver enzyme measurement,initial,2013-09-30,GCST002208,Liver enzyme levels (aspartate transaminase)
1698,Asian,118.0,24159609.0,Choi H,Cancer,initial,2013-10-01,GCST002210,Acute myeloid leukemia
1720,Asian,129.0,24159609.0,Choi H,Cancer,replication,2013-10-01,GCST002210,Acute myeloid leukemia
6467,European,1406.0,24084763.0,Wang J,Cancer,initial,2013-10-01,GCST002212,Colorectal adenoma (advanced)
9446,European,9211.0,24084763.0,Wang J,Cancer,replication,2013-10-01,GCST002212,Colorectal adenoma (advanced)
2398,Asian,929.0,24132900.0,Kanazawa T,Neurological disorder,initial,2013-10-01,GCST002211,Psychosis (atypical)
5921,European,915.0,24098343.0,Polfus LM,"Other trait, Other measurement",initial,2013-10-03,GCST002213,Coronary artery calcification (smoking interaction)
6124,European,1025.0,24098343.0,Polfus LM,"Other trait, Other measurement",replication,2013-10-03,GCST002213,Coronary artery calcification (smoking interaction)
3937,Asian,8830.0,24094242.0,Li J,Liver enzyme measurement,replication,2013-10-05,GCST002214,Serum alkaline phosphatase levels
2626,Asian,1452.0,24094242.0,Li J,Liver enzyme measurement,initial,2013-10-05,GCST002214,Serum alkaline phosphatase levels
561,African American or Afro-Caribbean,262.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002215,Endometrial cancer
11553,European,93982.0,24097068.0,Willer CJ,Lipid or lipoprotein measurement,replication,2013-10-06,GCST002221,"Cholesterol, total"
11554,European,93982.0,24097068.0,Willer CJ,Lipid or lipoprotein measurement,replication,2013-10-06,GCST002223,HDL cholesterol
13492,Other/Mixed,81.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002218,Endometrial cancer
12614,Hispanic or Latin American,382.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002218,Endometrial cancer
3387,Asian,4030.0,24097066.0,Li Y,Neurological disorder,replication,2013-10-06,GCST002217,Sjgren's syndrome
562,African American or Afro-Caribbean,262.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002218,Endometrial cancer
11552,European,93982.0,24097068.0,Willer CJ,Lipid or lipoprotein measurement,replication,2013-10-06,GCST002216,Triglycerides
11558,European,94595.0,24097068.0,Willer CJ,Lipid or lipoprotein measurement,initial,2013-10-06,GCST002216,Triglycerides
11559,European,94595.0,24097068.0,Willer CJ,Lipid or lipoprotein measurement,initial,2013-10-06,GCST002219,Triglycerides
13491,Other/Mixed,81.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002215,Endometrial cancer
12613,Hispanic or Latin American,382.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002215,Endometrial cancer
11555,European,93982.0,24097068.0,Willer CJ,"Lipid or lipoprotein measurement, Other measurement",replication,2013-10-06,GCST002222,LDL cholesterol
3264,Asian,3136.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002218,Endometrial cancer
8618,European,5472.0,24096698.0,De Vivo I,Cancer,initial,2013-10-06,GCST002215,Endometrial cancer
11560,European,94595.0,24097068.0,Willer CJ,Lipid or lipoprotein measurement,initial,2013-10-06,GCST002221,"Cholesterol, total"
272,African,4420.0,24097068.0,Willer CJ,"Lipid or lipoprotein measurement, Other measurement",replication,2013-10-06,GCST002220,LDL cholesterol
9743,European,11369.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002218,Endometrial cancer
11561,European,94595.0,24097068.0,Willer CJ,Lipid or lipoprotein measurement,initial,2013-10-06,GCST002223,HDL cholesterol
2702,Asian,1592.0,24097066.0,Li Y,Neurological disorder,initial,2013-10-06,GCST002217,Sjgren's syndrome
11562,European,94595.0,24097068.0,Willer CJ,"Lipid or lipoprotein measurement, Other measurement",initial,2013-10-06,GCST002220,LDL cholesterol
1979,Asian,366.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002215,Endometrial cancer
11563,European,94595.0,24097068.0,Willer CJ,"Lipid or lipoprotein measurement, Other measurement",initial,2013-10-06,GCST002222,LDL cholesterol
8619,European,5472.0,24096698.0,De Vivo I,Cancer,initial,2013-10-06,GCST002218,Endometrial cancer
3930,Asian,8743.0,24097068.0,Willer CJ,Lipid or lipoprotein measurement,replication,2013-10-06,GCST002219,Triglycerides
8183,European,4270.0,24096698.0,De Vivo I,Cancer,replication,2013-10-06,GCST002215,Endometrial cancer
13962,Other/Mixed,3926.0,24101674.0,Hanson RL,Metabolic disorder,replication,2013-10-07,GCST002224,Type 2 diabetes
13935,Other/Mixed,2908.0,24101674.0,Hanson RL,Metabolic disorder,replication,2013-10-07,GCST002224,Type 2 diabetes
13795,Other/Mixed,840.0,24101674.0,Hanson RL,Metabolic disorder,initial,2013-10-07,GCST002224,Type 2 diabetes
3167,Asian,2740.0,24064335.0,Pei YF,Other measurement,replication,2013-10-08,GCST002226,Fat body mass
12936,Hispanic or Latin American,3348.0,24064335.0,Pei YF,"Body measurement, Other measurement",initial,2013-10-08,GCST002227,Body mass index
4271,Asian,19097.0,24216480.0,Song YQ,Other disease,replication,2013-10-08,GCST002225,Disc degeneration (lumbar)
9335,European,8463.0,24064335.0,Pei YF,"Body measurement, Other measurement",initial,2013-10-08,GCST002227,Body mass index
1292,African American or Afro-Caribbean,7478.0,24064335.0,Pei YF,"Body measurement, Other measurement",initial,2013-10-08,GCST002227,Body mass index
3166,Asian,2740.0,24064335.0,Pei YF,"Body measurement, Other measurement",replication,2013-10-08,GCST002227,Body mass index
8445,European,4979.0,24064335.0,Pei YF,"Body measurement, Other measurement",replication,2013-10-08,GCST002227,Body mass index
708,African American or Afro-Caribbean,709.0,24064335.0,Pei YF,Other measurement,initial,2013-10-08,GCST002226,Fat body mass
2714,Asian,1624.0,24064335.0,Pei YF,"Body measurement, Other measurement",initial,2013-10-08,GCST002227,Body mass index
2710,Asian,1622.0,24064335.0,Pei YF,Other measurement,initial,2013-10-08,GCST002226,Fat body mass
3342,Asian,3697.0,24216480.0,Song YQ,Other disease,initial,2013-10-08,GCST002225,Disc degeneration (lumbar)
12621,Hispanic or Latin American,408.0,24064335.0,Pei YF,Other measurement,initial,2013-10-08,GCST002226,Fat body mass
8440,European,4967.0,24064335.0,Pei YF,Other measurement,replication,2013-10-08,GCST002226,Fat body mass
8602,European,5434.0,24216480.0,Song YQ,Other disease,replication,2013-10-08,GCST002225,Disc degeneration (lumbar)
8834,European,6433.0,24064335.0,Pei YF,Other measurement,initial,2013-10-08,GCST002226,Fat body mass
5940,European,928.0,24114350.0,Zhang M,Other disease,initial,2013-10-11,GCST002229,Acne (severe teenage)
6458,European,1392.0,24114350.0,Zhang M,Other disease,replication,2013-10-11,GCST002229,Acne (severe teenage)
6010,European,965.0,24133439.0,Jones RM,Other measurement,initial,2013-10-11,GCST002228,Social autistic-like traits
9005,European,7135.0,24121790.0,Levine DM,"Digestive system disorder, Cancer, Other disease",initial,2013-10-13,GCST002231,Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
9138,European,7785.0,24121790.0,Levine DM,Cancer,replication,2013-10-13,GCST002232,Esophageal adenocarcinoma
9350,European,8547.0,24121790.0,Levine DM,"Digestive system disorder, Cancer, Other disease",replication,2013-10-13,GCST002231,Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
8608,European,5442.0,24121790.0,Levine DM,Digestive system disorder,initial,2013-10-13,GCST002230,Barrett's esophagus
9139,European,7785.0,24121790.0,Levine DM,Digestive system disorder,replication,2013-10-13,GCST002230,Barrett's esophagus
8607,European,5442.0,24121790.0,Levine DM,Cancer,initial,2013-10-13,GCST002232,Esophageal adenocarcinoma
4038,Asian,10250.0,24105470.0,Wu Y,Other measurement,replication,2013-10-14,GCST002233,Adiponectin levels
3862,Asian,7827.0,24105470.0,Wu Y,Other measurement,initial,2013-10-14,GCST002233,Adiponectin levels
3706,Asian,6280.0,24143190.0,Low SK,Cancer,replication,2013-10-15,GCST002234,Breast cancer
3493,Asian,4741.0,24143190.0,Low SK,Cancer,initial,2013-10-15,GCST002234,Breast cancer
7240,European,2379.0,24143882.0,Gelernter J,Response to drug,initial,2013-10-19,GCST002235,Opioid sensitivity
967,African American or Afro-Caribbean,2116.0,24143882.0,Gelernter J,Response to drug,replication,2013-10-19,GCST002235,Opioid sensitivity
8251,European,4496.0,24143882.0,Gelernter J,Response to drug,replication,2013-10-19,GCST002235,Opioid sensitivity
1120,African American or Afro-Caribbean,3318.0,24143882.0,Gelernter J,Response to drug,initial,2013-10-19,GCST002235,Opioid sensitivity
13440,Other/Mixed,25.0,24141364.0,Perez-Andreu V,Cancer,replication,2013-10-20,GCST002236,Acute lymphoblastic leukemia (childhood)
830,African American or Afro-Caribbean,1228.0,24141364.0,Perez-Andreu V,Cancer,replication,2013-10-20,GCST002236,Acute lymphoblastic leukemia (childhood)
6556,European,1541.0,24141364.0,Perez-Andreu V,Cancer,initial,2013-10-20,GCST002236,Acute lymphoblastic leukemia (childhood)
13524,Other/Mixed,171.0,24141364.0,Perez-Andreu V,Cancer,replication,2013-10-20,GCST002236,Acute lymphoblastic leukemia (childhood)
12771,Hispanic or Latin American,920.0,24141364.0,Perez-Andreu V,Cancer,replication,2013-10-20,GCST002236,Acute lymphoblastic leukemia (childhood)
13973,Other/Mixed,4344.0,24141364.0,Perez-Andreu V,Cancer,initial,2013-10-20,GCST002236,Acute lymphoblastic leukemia (childhood)
12811,Hispanic or Latin American,1287.0,24141364.0,Perez-Andreu V,Cancer,initial,2013-10-20,GCST002236,Acute lymphoblastic leukemia (childhood)
7953,European,3647.0,24141364.0,Perez-Andreu V,Cancer,replication,2013-10-20,GCST002236,Acute lymphoblastic leukemia (childhood)
9152,European,7882.0,24149102.0,Frampton M,Cancer,initial,2013-10-22,GCST002237,Hodgkin's lymphoma
6157,European,1071.0,24149102.0,Frampton M,Cancer,replication,2013-10-22,GCST002237,Hodgkin's lymphoma
6048,European,985.0,24152035.0,Goodbourn PT,Other measurement,initial,2013-10-23,GCST002238,Contrast sensitivity
10272,European,18729.0,24163127.0,Figueroa JD,Cancer,initial,2013-10-24,GCST002243,Bladder cancer
8500,European,5110.0,24159190.0,Seppala I,Other measurement,initial,2013-10-24,GCST002242,Serum dimethylarginine levels (asymmetric/symetric ratio)
8785,European,6206.0,24163127.0,Figueroa JD,Cancer,initial,2013-10-24,GCST002240,Bladder cancer
8498,European,5110.0,24159190.0,Seppala I,"Cardiovascular measurement, Other measurement",initial,2013-10-24,GCST002239,Symmetrical dimethylarginine levels
8499,European,5110.0,24159190.0,Seppala I,"Cardiovascular measurement, Other measurement",initial,2013-10-24,GCST002241,Asymmetrical dimethylarginine levels
2567,Asian,1294.0,24513584.0,Oei L,Other disease,replication,2013-10-25,GCST002244,Fractures (vertebral)
7598,European,2995.0,24513584.0,Oei L,Other disease,initial,2013-10-25,GCST002244,Fractures (vertebral)
10594,European,26217.0,24513584.0,Oei L,Other disease,replication,2013-10-25,GCST002244,Fractures (vertebral)
11179,European,55134.0,24162737.0,Lambert JC,Neurological disorder,initial,2013-10-27,GCST002245,Alzheimer's disease (late onset)
2878,Asian,1888.0,24162738.0,Hu Z,"Digestive system disorder, Other measurement",initial,2013-10-27,GCST002246,Hepatitis B
10344,European,19884.0,24162737.0,Lambert JC,Neurological disorder,replication,2013-10-27,GCST002245,Alzheimer's disease (late onset)
4009,Asian,9903.0,24162738.0,Hu Z,"Digestive system disorder, Other measurement",replication,2013-10-27,GCST002246,Hepatitis B
2844,Asian,1840.0,24165912.0,He J,"Other measurement, Biological process",initial,2013-10-28,GCST002249,Blood pressure measurement (high sodium intervention)
2205,Asian,660.0,24165912.0,He J,"Other measurement, Biological process",replication,2013-10-28,GCST002250,Blood pressure measurement (low sodium intervention)
2202,Asian,654.0,24165912.0,He J,"Other measurement, Biological process",replication,2013-10-28,GCST002252,Blood pressure measurement (high sodium and potassium intervention)
2843,Asian,1836.0,24165912.0,He J,"Other measurement, Biological process",initial,2013-10-28,GCST002252,Blood pressure measurement (high sodium and potassium intervention)
2851,Asian,1850.0,24165912.0,He J,"Other measurement, Biological process",initial,2013-10-28,GCST002250,Blood pressure measurement (low sodium intervention)
5783,European,820.0,24204828.0,Zheng JS,Other measurement,initial,2013-10-28,GCST002251,Homeostasis model assessment of beta-cell function (dietary factor interaction)
2872,Asian,1881.0,24165912.0,He J,"Other measurement, Biological process",initial,2013-10-28,GCST002247,Blood pressure measurement (cold pressor test)
5784,European,820.0,24204828.0,Zheng JS,Other measurement,initial,2013-10-28,GCST002253,Homeostasis model assessment of insulin resistance (dietary factor interaction)
5782,European,820.0,24204828.0,Zheng JS,Other measurement,initial,2013-10-28,GCST002248,Fasting insulin (dietary factor interaction)
2203,Asian,659.0,24165912.0,He J,"Other measurement, Biological process",replication,2013-10-28,GCST002249,Blood pressure measurement (high sodium intervention)
2235,Asian,698.0,24165912.0,He J,"Other measurement, Biological process",replication,2013-10-28,GCST002247,Blood pressure measurement (cold pressor test)
8232,European,4443.0,24182552.0,Matteini AM,"Other measurement, Inflammatory measurement, Response to drug",initial,2013-10-29,GCST002255,Inflammatory biomarkers
2113,Asian,487.0,24172245.0,Haga S,Digestive system disorder,initial,2013-10-31,GCST002258,Tooth agenesis (mandibular third molar)
2559,Asian,1266.0,24204295.0,Han F,Neurological disorder,initial,2013-10-31,GCST002259,Narcolepsy (onset before 2009 H1N1 influenza pandemic)
2111,Asian,487.0,24172245.0,Haga S,Digestive system disorder,initial,2013-10-31,GCST002256,Tooth agenesis (third molar)
9976,European,14188.0,24204295.0,Han F,Neurological disorder,replication,2013-10-31,GCST002260,Narcolepsy
2437,Asian,1000.0,24204295.0,Han F,"Neurological disorder, Other measurement",initial,2013-10-31,GCST002261,Narcolepsy (age of onset)
2112,Asian,487.0,24172245.0,Haga S,Digestive system disorder,initial,2013-10-31,GCST002257,Tooth agenesis (maxillary third molar)
3270,Asian,3186.0,24204295.0,Han F,Neurological disorder,initial,2013-10-31,GCST002260,Narcolepsy
8166,European,4229.0,24097067.0,Lessard CJ,Neurological disorder,replication,2013-11-01,GCST004879,Sjgren's syndrome
1638,Asian,79.0,24192120.0,Kamide K,"Other measurement, Response to drug",replication,2013-11-01,GCST002262,Blood pressure (response to antihypertensive medication)
10987,European,41505.0,24076602.0,Beecham AH,Immune system disorder,replication,2013-11-01,GCST005531,Multiple sclerosis
7232,European,2370.0,24097067.0,Lessard CJ,Neurological disorder,initial,2013-11-01,GCST004879,Sjgren's syndrome
4881,European,236.0,24236485.0,Cornejo-Garcia JA,"Other disease, Cardiovascular disease, Response to drug",initial,2013-11-01,GCST002263,Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)
8745,European,6022.0,24097067.0,Lessard CJ,Neurological disorder,replication,2013-11-01,GCST004878,Sjgren's syndrome
8148,European,4175.0,24097067.0,Lessard CJ,Neurological disorder,initial,2013-11-01,GCST005532,Sjgren's syndrome
7231,European,2370.0,24097067.0,Lessard CJ,Neurological disorder,initial,2013-11-01,GCST004878,Sjgren's syndrome
10932,European,38582.0,24076602.0,Beecham AH,Immune system disorder,initial,2013-11-01,GCST005531,Multiple sclerosis
1885,Asian,265.0,24192120.0,Kamide K,"Other measurement, Response to drug",initial,2013-11-01,GCST002262,Blood pressure (response to antihypertensive medication)
1826,Asian,221.0,24236485.0,Cornejo-Garcia JA,"Other disease, Cardiovascular disease, Response to drug",initial,2013-11-01,GCST002263,Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)
153,African,932.0,24185611.0,Cook MB,Cancer,initial,2013-11-02,GCST002264,Prostate cancer
1377,African American or Afro-Caribbean,10068.0,24185611.0,Cook MB,Cancer,replication,2013-11-02,GCST002264,Prostate cancer
5400,European,541.0,24080446.0,Rudolph A,"Cancer, Other trait",initial,2013-11-04,GCST002266,Lobular breast cancer (menopausal hormone therapy interaction)
7559,European,2920.0,24080446.0,Rudolph A,"Cancer, Other trait",initial,2013-11-04,GCST002265,Breast cancer (menopausal hormone therapy interaction)
9591,European,9942.0,24080446.0,Rudolph A,"Cancer, Other trait",replication,2013-11-04,GCST002266,Lobular breast cancer (menopausal hormone therapy interaction)
10165,European,16955.0,24080446.0,Rudolph A,"Cancer, Other trait",replication,2013-11-04,GCST002265,Breast cancer (menopausal hormone therapy interaction)
8042,European,3897.0,24189344.0,Xia K,Neurological disorder,replication,2013-11-05,GCST002268,Autism
10803,European,33689.0,24190013.0,Earp MA,Cancer,replication,2013-11-05,GCST002267,Epithelial ovarian cancer
2902,Asian,1945.0,24189344.0,Xia K,Neurological disorder,initial,2013-11-05,GCST002268,Autism
5976,European,943.0,24190013.0,Earp MA,Cancer,initial,2013-11-05,GCST002267,Epithelial ovarian cancer
6053,European,987.0,24223155.0,Behr ER,"Biological process, Cardiovascular disease",initial,2013-11-06,GCST002269,Drug-induced torsades de pointes
3298,Asian,3427.0,24244560.0,Chen P,Other measurement,initial,2013-11-07,GCST002270,Glycated hemoglobin levels
2680,Asian,1529.0,24244560.0,Chen P,Other measurement,initial,2013-11-07,GCST002270,Glycated hemoglobin levels
2765,Asian,1735.0,24244560.0,Chen P,Other measurement,initial,2013-11-07,GCST002270,Glycated hemoglobin levels
691,African American or Afro-Caribbean,630.0,24220910.0,Purdue MP,Cancer,initial,2013-11-12,GCST002272,Renal cell carcinoma
698,African American or Afro-Caribbean,683.0,24220910.0,Purdue MP,Cancer,replication,2013-11-12,GCST002272,Renal cell carcinoma
2125,Asian,505.0,24265751.0,Li W,Neurological disorder,replication,2013-11-12,GCST002271,Delayed encephalopathy in acute carbon monoxide poisoning
2035,Asian,419.0,24265751.0,Li W,Neurological disorder,initial,2013-11-12,GCST002271,Delayed encephalopathy in acute carbon monoxide poisoning
11318,European,69230.0,24220699.0,Gudmundsson J,Cancer,initial,2013-11-13,GCST002273,Renal cell carcinoma
8312,European,4678.0,24220699.0,Gudmundsson J,Cancer,replication,2013-11-13,GCST002273,Renal cell carcinoma
3532,Asian,5139.0,24249740.0,Zhang L,Other measurement,replication,2013-11-17,GCST002276,Bone mineral density
7966,European,3684.0,24241537.0,Bonnelykke K,Other disease,initial,2013-11-17,GCST002275,Asthma (childhood onset)
12625,Hispanic or Latin American,409.0,24249740.0,Zhang L,Other measurement,initial,2013-11-17,GCST002276,Bone mineral density
9340,European,8472.0,24249740.0,Zhang L,Other measurement,initial,2013-11-17,GCST002276,Bone mineral density
7625,European,3058.0,24241537.0,Bonnelykke K,Other disease,replication,2013-11-17,GCST002275,Asthma (childhood onset)
2685,Asian,1547.0,24249740.0,Zhang L,Other measurement,initial,2013-11-17,GCST002276,Bone mineral density
9679,European,10732.0,24249740.0,Zhang L,Other measurement,replication,2013-11-17,GCST002276,Bone mineral density
712,African American or Afro-Caribbean,712.0,24249740.0,Zhang L,Other measurement,initial,2013-11-17,GCST002276,Bone mineral density
7359,European,2544.0,24253340.0,Lencz T,Neurological disorder,initial,2013-11-19,GCST002277,Schizophrenia
928,African American or Afro-Caribbean,1875.0,24253340.0,Lencz T,Neurological disorder,replication,2013-11-19,GCST002277,Schizophrenia
2469,Asian,1080.0,24253340.0,Lencz T,Neurological disorder,replication,2013-11-19,GCST002277,Schizophrenia
8975,European,6993.0,24253340.0,Lencz T,Neurological disorder,replication,2013-11-19,GCST002277,Schizophrenia
12679,Hispanic or Latin American,580.0,24324551.0,Deng X,"Other measurement, Cardiovascular measurement",initial,2013-11-20,GCST002284,QRS duration in Tripanosoma cruzi seropositivity
12674,Hispanic or Latin American,580.0,24324551.0,Deng X,"Cardiovascular measurement, Other measurement",initial,2013-11-20,GCST002278,QT interval in Tripanosoma cruzi seropositivity
12675,Hispanic or Latin American,580.0,24324551.0,Deng X,"Cardiovascular measurement, Other measurement",initial,2013-11-20,GCST002281,Ejection fraction in Tripanosoma cruzi seropositivity
9885,European,13225.0,24256812.0,Fogh I,Neurological disorder,initial,2013-11-20,GCST002283,Amyotrophic lateral sclerosis (sporadic)
12664,Hispanic or Latin American,513.0,24324551.0,Deng X,"Cardiovascular disease, Other measurement",initial,2013-11-20,GCST002285,Chagas cardiomyopathy in Tripanosoma cruzi seropositivity
12677,Hispanic or Latin American,580.0,24324551.0,Deng X,Other measurement,initial,2013-11-20,GCST002282,Parasitemia in Tripanosoma cruzi seropositivity
12676,Hispanic or Latin American,580.0,24324551.0,Deng X,Other measurement,initial,2013-11-20,GCST002280,Antibody status in Tripanosoma cruzi seropositivity
12678,Hispanic or Latin American,580.0,24324551.0,Deng X,"Other measurement, Cardiovascular measurement",initial,2013-11-20,GCST002279,PR interval in Tripanosoma cruzi seropositivity
8294,European,4630.0,24256812.0,Fogh I,Neurological disorder,replication,2013-11-20,GCST002283,Amyotrophic lateral sclerosis (sporadic)
4866,European,227.0,24280104.0,Wu AC,"Response to drug, Other disease",replication,2013-11-23,GCST002291,Bronchodilator response in asthma (inhaled corticosteroid treatment interaction)
5450,European,581.0,24280104.0,Wu AC,"Response to drug, Other disease",initial,2013-11-23,GCST002291,Bronchodilator response in asthma (inhaled corticosteroid treatment interaction)
1903,Asian,272.0,24277619.0,Quillen EE,"Biological process, Other measurement",initial,2013-11-26,GCST002294,Alcohol consumption (max-drinks)
1922,Asian,298.0,24277619.0,Quillen EE,Biological process,initial,2013-11-26,GCST002292,Response to alcohol consumption (flushing response)
10503,European,23527.0,24280982.0,Ruderfer DM,Neurological disorder,initial,2013-11-26,GCST002295,Schizophrenia or bipolar disorder
1934,Asian,314.0,24277619.0,Quillen EE,"Other measurement, Neurological disorder",initial,2013-11-26,GCST002293,Alcohol dependence
1778,Asian,185.0,24282030.0,Pan L,Response to drug,initial,2013-11-28,GCST002297,Hepatitis B vaccine response
2785,Asian,1756.0,24282030.0,Pan L,Response to drug,replication,2013-11-28,GCST002297,Hepatitis B vaccine response
2953,Asian,2075.0,23918589.0,Negi S,Immune system disorder,replication,2013-12-01,GCST002300,Rheumatoid arthritis
8967,European,6938.0,24292274.0,Speedy HE,Cancer,initial,2013-12-01,GCST002299,Chronic lymphocytic leukemia
8191,European,4295.0,24292274.0,Speedy HE,Cancer,replication,2013-12-01,GCST002299,Chronic lymphocytic leukemia
2631,Asian,1467.0,23918589.0,Negi S,Immune system disorder,initial,2013-12-01,GCST002300,Rheumatoid arthritis
4661,European,94.0,24778558.0,Domarkiene I,Cardiovascular disease,initial,2013-12-01,GCST002298,Coronary heart disease
7534,European,2860.0,24348519.0,Namjou B,"Body measurement, Other measurement",initial,2013-12-03,GCST002301,Body mass index
3099,Asian,2474.0,24324648.0,Yatagai Y,Other measurement,replication,2013-12-04,GCST002302,IgE levels
8117,European,4088.0,24405752.0,An P,Other measurement,initial,2013-12-04,GCST002303,Glycated hemoglobin levels
2512,Asian,1180.0,24324648.0,Yatagai Y,Other measurement,initial,2013-12-04,GCST002302,IgE levels
11077,European,47822.0,24405752.0,An P,Other measurement,replication,2013-12-04,GCST002303,Glycated hemoglobin levels
13920,Other/Mixed,2572.0,24315451.0,van der Valk RJ,Other measurement,initial,2013-12-05,GCST002304,Fractional exhaled nitric oxide (childhood)
8514,European,5131.0,24315451.0,van der Valk RJ,Other measurement,initial,2013-12-05,GCST002304,Fractional exhaled nitric oxide (childhood)
12798,Hispanic or Latin American,1155.0,24315451.0,van der Valk RJ,Other measurement,initial,2013-12-05,GCST002304,Fractional exhaled nitric oxide (childhood)
3572,Asian,5408.0,24325914.0,Chu M,Cancer,initial,2013-12-09,GCST006866,Lung cancer (SNP x SNP interaction)
3876,Asian,7984.0,24325914.0,Chu M,Cancer,replication,2013-12-09,GCST006866,Lung cancer (SNP x SNP interaction)
8419,European,4928.0,24325915.0,Purrington KS,Cancer,initial,2013-12-09,GCST002305,"Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative)"
7870,European,3457.0,24325915.0,Purrington KS,Cancer,replication,2013-12-09,GCST002305,"Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative)"
6470,European,1408.0,24322204.0,Winham SJ,"Body measurement, Neurological disorder",initial,2013-12-10,GCST002306,Bipolar disorder (body mass index interaction)
8949,European,6882.0,24376456.0,Simino J,"Biological process, Cardiovascular measurement",initial,2013-12-12,GCST002310,Pulse pressure (alcohol consumption interaction)
8952,European,6882.0,24376456.0,Simino J,"Biological process, Other measurement",initial,2013-12-12,GCST002309,Diastolic blood pressure (alcohol consumption interaction)
8951,European,6882.0,24376456.0,Simino J,"Biological process, Other measurement",initial,2013-12-12,GCST002308,Mean arterial pressure (alcohol consumption interaction)
8950,European,6882.0,24376456.0,Simino J,"Biological process, Other measurement",initial,2013-12-12,GCST002307,Systolic blood pressure (alcohol consumption interaction)
12697,Hispanic or Latin American,632.0,24379826.0,Voruganti VS,Cardiovascular measurement,initial,2013-12-16,GCST002311,Serum uric acid levels
5595,European,673.0,24347629.0,Shaffer JR,"Other measurement, Digestive system disorder",initial,2013-12-17,GCST002312,Periodontal disease-related phenotype (Socransky)
2169,Asian,577.0,24351856.0,Nanayakkara S,Other measurement,initial,2013-12-18,GCST002314,Glomerular filtration rate
2168,Asian,577.0,24351856.0,Nanayakkara S,"Other disease, Other measurement",initial,2013-12-18,GCST002313,Chronic kidney disease
6339,European,1257.0,24357727.0,Rocanin-Arjo A,Other measurement,replication,2013-12-19,GCST002315,Thrombin generation potential phenotypes
6913,European,1967.0,24357727.0,Rocanin-Arjo A,Other measurement,initial,2013-12-19,GCST002315,Thrombin generation potential phenotypes
3300,Asian,3444.0,24376798.0,Miki D,Digestive system disorder,initial,2013-12-20,GCST002316,Chronic hepatitis C infection
4372,Asian,32668.0,24376798.0,Miki D,Digestive system disorder,replication,2013-12-20,GCST002316,Chronic hepatitis C infection
1986,Asian,368.0,24376627.0,Su WH,Cancer,replication,2013-12-23,GCST006524,Nasopharyngeal carcinoma (SNP x SNP interaction)
2161,Asian,562.0,24376627.0,Su WH,Cancer,initial,2013-12-23,GCST006524,Nasopharyngeal carcinoma (SNP x SNP interaction)
7688,European,3207.0,24390345.0,Williams AL,Metabolic disorder,replication,2013-12-25,GCST002317,Type 2 diabetes
12851,Hispanic or Latin American,1728.0,24390345.0,Williams AL,Metabolic disorder,replication,2013-12-25,GCST002317,Type 2 diabetes
4164,Asian,13263.0,24390342.0,Okada Y,Immune system disorder,replication,2013-12-25,GCST002318,Rheumatoid arthritis
13142,Hispanic or Latin American,8214.0,24390345.0,Williams AL,Metabolic disorder,initial,2013-12-25,GCST002317,Type 2 diabetes
3011,Asian,2187.0,24390345.0,Williams AL,Metabolic disorder,replication,2013-12-25,GCST002317,Type 2 diabetes
3379,Asian,3968.0,24390345.0,Williams AL,Metabolic disorder,replication,2013-12-25,GCST002317,Type 2 diabetes
9507,European,9576.0,24390342.0,Okada Y,Immune system disorder,replication,2013-12-25,GCST002318,Rheumatoid arthritis
13848,Other/Mixed,1277.0,24390345.0,Williams AL,Metabolic disorder,replication,2013-12-25,GCST002317,Type 2 diabetes
11214,European,58284.0,24390342.0,Okada Y,Immune system disorder,initial,2013-12-25,GCST002318,Rheumatoid arthritis
3627,Asian,5648.0,24390345.0,Williams AL,Metabolic disorder,replication,2013-12-25,GCST002317,Type 2 diabetes
1184,African American or Afro-Caribbean,4230.0,24390345.0,Williams AL,Metabolic disorder,replication,2013-12-25,GCST002317,Type 2 diabetes
4311,Asian,22515.0,24390342.0,Okada Y,Immune system disorder,initial,2013-12-25,GCST002318,Rheumatoid arthritis
4887,European,241.0,24375517.0,Lohmann K,Neurological disorder,replication,2013-12-26,GCST002319,Musician's dystonia
758,African American or Afro-Caribbean,890.0,24468470.0,Zhang C,Other trait,initial,2013-12-26,GCST002320,Cognitive decline (age-related)
6199,European,1111.0,24375517.0,Lohmann K,Neurological disorder,initial,2013-12-26,GCST002319,Musician's dystonia
8680,European,5765.0,24468470.0,Zhang C,Other trait,initial,2013-12-26,GCST002320,Cognitive decline (age-related)
3303,Asian,3451.0,24386095.0,Zhou L,"Lipid or lipoprotein measurement, Other measurement",initial,2013-12-30,GCST002321,Lipid traits
10381,European,20776.0,24388013.0,Ferreira MA,"Other disease, Immune system disorder",initial,2013-12-30,GCST002322,Asthma and hay fever
3938,Asian,8830.0,24386095.0,Zhou L,"Lipid or lipoprotein measurement, Other measurement",replication,2013-12-30,GCST002321,Lipid traits
7794,European,3333.0,24388013.0,Ferreira MA,"Other disease, Immune system disorder",replication,2013-12-30,GCST002322,Asthma and hay fever
9238,European,8305.0,24449572.0,Orozco G,Immune system disorder,initial,2014-01-01,GCST002323,Rheumatoid arthritis
8513,European,5131.0,24166409.0,Gelernter J,"Other measurement, Neurological disorder",initial,2014-01-01,GCST004711,Alcohol dependence
9046,European,7351.0,24449572.0,Orozco G,Immune system disorder,replication,2014-01-01,GCST002323,Rheumatoid arthritis
1204,African American or Afro-Caribbean,4629.0,24166409.0,Gelernter J,"Other measurement, Neurological disorder",initial,2014-01-01,GCST004711,Alcohol dependence
6751,European,1746.0,24166409.0,Gelernter J,"Other measurement, Neurological disorder",replication,2014-01-01,GCST004711,Alcohol dependence
693,African American or Afro-Caribbean,651.0,24166409.0,Gelernter J,"Other measurement, Neurological disorder",replication,2014-01-01,GCST004712,Alcohol dependence
1183,African American or Afro-Caribbean,4213.0,24166409.0,Gelernter J,"Other measurement, Neurological disorder",initial,2014-01-01,GCST004712,Alcohol dependence
8541,European,5244.0,24166409.0,Gelernter J,"Other measurement, Neurological disorder",replication,2014-01-01,GCST004712,Alcohol dependence
730,African American or Afro-Caribbean,801.0,24166409.0,Gelernter J,"Other measurement, Neurological disorder",replication,2014-01-01,GCST004711,Alcohol dependence
8309,European,4671.0,24166409.0,Gelernter J,"Other measurement, Neurological disorder",initial,2014-01-01,GCST004712,Alcohol dependence
9385,European,8747.0,24489884.0,Mick E,Biological process,initial,2014-01-01,GCST002324,Anger
8572,European,5299.0,24387989.0,Mayes MD,Neurological disorder,initial,2014-01-02,GCST005534,Systemic sclerosis
8103,European,4040.0,24387989.0,Mayes MD,Neurological disorder,initial,2014-01-02,GCST005535,Diffuse cutaneous systemic sclerosis
9008,European,7152.0,24387989.0,Mayes MD,Neurological disorder,replication,2014-01-02,GCST005535,Diffuse cutaneous systemic sclerosis
8746,European,6023.0,24383474.0,Manichaikul A,Other disease,replication,2014-01-02,GCST002326,Pulmonary emphysema
1004,African American or Afro-Caribbean,2510.0,24383474.0,Manichaikul A,Other disease,initial,2014-01-02,GCST002326,Pulmonary emphysema
6327,European,1241.0,24392092.0,Luksys G,Other measurement,initial,2014-01-02,GCST002325,Memory performance
7387,European,2587.0,24383474.0,Manichaikul A,Other disease,initial,2014-01-02,GCST002326,Pulmonary emphysema
12871,Hispanic or Latin American,2113.0,24383474.0,Manichaikul A,Other disease,initial,2014-01-02,GCST002326,Pulmonary emphysema
2251,Asian,704.0,24383474.0,Manichaikul A,Other disease,initial,2014-01-02,GCST002326,Pulmonary emphysema
9331,European,8442.0,24387989.0,Mayes MD,Neurological disorder,replication,2014-01-02,GCST005533,Limited cutaneous systemic scleroderma
8281,European,4593.0,24387989.0,Mayes MD,Neurological disorder,initial,2014-01-02,GCST005533,Limited cutaneous systemic scleroderma
9593,European,9952.0,24387989.0,Mayes MD,Neurological disorder,replication,2014-01-02,GCST005534,Systemic sclerosis
6801,European,1815.0,24387768.0,Xu W,Neurological disorder,initial,2014-01-04,GCST002327,Bipolar disorder
3701,Asian,6223.0,24387323.0,Kim WJ,Other measurement,initial,2014-01-06,GCST002328,Lung function
3156,Asian,2720.0,24387323.0,Kim WJ,Other measurement,replication,2014-01-06,GCST002328,Lung function
3588,Asian,5520.0,24399259.0,He L,Other disease,replication,2014-01-07,GCST002329,Acne (severe)
12971,Hispanic or Latin American,3774.0,24406073.0,Galanter JM,Other disease,initial,2014-01-07,GCST002330,Asthma
2949,Asian,2062.0,24399259.0,He L,Other disease,initial,2014-01-07,GCST002329,Acne (severe)
8759,European,6090.0,24403052.0,Stacey SN,Cancer,replication,2014-01-08,GCST002331,Basal cell carcinoma
11654,European,113616.0,24403052.0,Stacey SN,Cancer,initial,2014-01-08,GCST002331,Basal cell carcinoma
2330,Asian,800.0,24413707.0,Chiang KM,Cardiovascular disease,initial,2014-01-11,GCST002332,Hypertension (young onset)
8461,European,5003.0,24413707.0,Chiang KM,Cardiovascular disease,replication,2014-01-11,GCST002332,Hypertension (young onset)
2647,Asian,1499.0,24413707.0,Chiang KM,Cardiovascular disease,replication,2014-01-11,GCST002332,Hypertension (young onset)
7241,European,2380.0,24430505.0,Moayyeri A,Other measurement,initial,2014-01-14,GCST002335,Bone properties (heel)
9715,European,11058.0,24430505.0,Moayyeri A,Other measurement,replication,2014-01-14,GCST002335,Bone properties (heel)
9602,European,10074.0,24430505.0,Moayyeri A,Other measurement,replication,2014-01-14,GCST002333,Bone properties (heel)
7134,European,2236.0,24430505.0,Moayyeri A,Other measurement,replication,2014-01-14,GCST002334,Bone properties (heel)
3104,Asian,2483.0,24430505.0,Moayyeri A,Other measurement,initial,2014-01-14,GCST002333,Bone properties (heel)
8271,European,4556.0,24430505.0,Moayyeri A,Other measurement,initial,2014-01-14,GCST002334,Bone properties (heel)
6851,European,1885.0,24430505.0,Moayyeri A,Other measurement,initial,2014-01-14,GCST002333,Bone properties (heel)
2265,Asian,730.0,24430505.0,Moayyeri A,Other measurement,initial,2014-01-14,GCST002335,Bone properties (heel)
8365,European,4829.0,24478790.0,Lee JH,Other measurement,initial,2014-01-17,GCST002336,Telomere length
2117,Asian,500.0,24529757.0,Xie T,Neurological disorder,initial,2014-01-17,GCST002337,Amyotrophic lateral sclerosis (sporadic)
2021,Asian,400.0,24444492.0,Kuo PH,Neurological disorder,initial,2014-01-18,GCST002338,Bipolar I disorder
2297,Asian,772.0,24444492.0,Kuo PH,Neurological disorder,replication,2014-01-18,GCST002338,Bipolar I disorder
1798,Asian,200.0,24465431.0,Ma RC,Metabolic disorder,initial,2014-01-20,GCST002339,Type 2 diabetes (young onset) and obesity
3143,Asian,2632.0,24465473.0,Liu Y,Other measurement,initial,2014-01-21,GCST002341,Telomere length
5615,European,696.0,24465473.0,Liu Y,Other measurement,replication,2014-01-21,GCST002341,Telomere length
3372,Asian,3917.0,24465473.0,Liu Y,Other measurement,replication,2014-01-21,GCST002341,Telomere length
3436,Asian,4415.0,24448986.0,Zhang B,Cancer,initial,2014-01-21,GCST002340,Colorectal cancer
4203,Asian,14764.0,24448986.0,Zhang B,Cancer,replication,2014-01-21,GCST002340,Colorectal cancer
4959,European,297.0,24486069.0,Park HW,"Response to drug, Other disease",replication,2014-01-31,GCST002342,Asthma (corticosteroid response)
4699,European,124.0,24486069.0,Park HW,"Response to drug, Other disease",initial,2014-01-31,GCST002342,Asthma (corticosteroid response)
4594,European,60.0,24483146.0,Li L,Response to drug,initial,2014-02-01,GCST002343,Response to cytidine analogues (gemcitabine)
4595,European,60.0,24483146.0,Li L,Response to drug,initial,2014-02-01,GCST002345,Response to cytadine analogues (cytosine arabinoside)
7416,European,2639.0,24687471.0,Harlaar N,Biological process,replication,2014-02-01,GCST002344,Receptive language ability
324,African,14330.0,24507774.0,Peloso GM,"Lipid or lipoprotein measurement, Other measurement",initial,2014-02-01,GCST007848,LDL cholesterol
7206,European,2329.0,24687471.0,Harlaar N,Biological process,initial,2014-02-01,GCST002344,Receptive language ability
417,African American or Afro-Caribbean,54.0,24483146.0,Li L,Response to drug,initial,2014-02-01,GCST002343,Response to cytidine analogues (gemcitabine)
10998,European,42208.0,24507774.0,Peloso GM,"Lipid or lipoprotein measurement, Other measurement",initial,2014-02-01,GCST007848,LDL cholesterol
322,African,14330.0,24507774.0,Peloso GM,Lipid or lipoprotein measurement,initial,2014-02-01,GCST007849,Triglycerides
323,African,14330.0,24507774.0,Peloso GM,Lipid or lipoprotein measurement,initial,2014-02-01,GCST007850,HDL cholesterol
8393,European,4896.0,24342994.0,Lencz T,Biological process,initial,2014-02-01,GCST006523,General cognitive ability
10996,European,42208.0,24507774.0,Peloso GM,Lipid or lipoprotein measurement,initial,2014-02-01,GCST007849,Triglycerides
418,African American or Afro-Caribbean,54.0,24483146.0,Li L,Response to drug,initial,2014-02-01,GCST002345,Response to cytadine analogues (cytosine arabinoside)
10997,European,42208.0,24507774.0,Peloso GM,Lipid or lipoprotein measurement,initial,2014-02-01,GCST007850,HDL cholesterol
1614,Asian,60.0,24483146.0,Li L,Response to drug,initial,2014-02-01,GCST002343,Response to cytidine analogues (gemcitabine)
1615,Asian,60.0,24483146.0,Li L,Response to drug,initial,2014-02-01,GCST002345,Response to cytadine analogues (cytosine arabinoside)
8789,European,6225.0,24493630.0,Ahsan H,Cancer,initial,2014-02-03,GCST002346,Breast cancer (early onset)
9414,European,8945.0,24493630.0,Ahsan H,Cancer,replication,2014-02-03,GCST002346,Breast cancer (early onset)
4767,European,176.0,24503447.0,Nelson D,"Response to drug, Other measurement, Digestive system disorder",initial,2014-02-06,GCST002347,Response to protease inhibitor treatment in hepatitis c (bilirubin toxicity)
4768,European,176.0,24503447.0,Nelson D,"Response to drug, Other measurement, Digestive system disorder",initial,2014-02-06,GCST002349,Response to protease inhibitor treatment in hepatitis c (peak serum total bilirubin levels)
13470,Other/Mixed,57.0,24516586.0,Wu T,"Other trait, Other measurement",initial,2014-02-06,GCST002348,Cleft plate (environmental tobacco smoke interaction)
2318,Asian,777.0,24516586.0,Wu T,"Other trait, Other measurement",initial,2014-02-06,GCST002348,Cleft plate (environmental tobacco smoke interaction)
5778,European,816.0,24516586.0,Wu T,"Other trait, Other measurement",initial,2014-02-06,GCST002348,Cleft plate (environmental tobacco smoke interaction)
9541,European,9767.0,24621683.0,Cho MH,Other disease,initial,2014-02-07,GCST002351,Chronic obstructive pulmonary disease (moderate to severe)
9000,European,7100.0,24621683.0,Cho MH,Other disease,initial,2014-02-07,GCST002350,Chronic obstructive pulmonary disease (severe)
1006,African American or Afro-Caribbean,2570.0,24621683.0,Cho MH,Other disease,initial,2014-02-07,GCST002350,Chronic obstructive pulmonary disease (severe)
1007,African American or Afro-Caribbean,2570.0,24621683.0,Cho MH,Other disease,initial,2014-02-07,GCST002351,Chronic obstructive pulmonary disease (moderate to severe)
11386,European,77138.0,24509480.0,Mahajan A,Metabolic disorder,replication,2014-02-09,GCST002352,Type 2 diabetes
4267,Asian,18817.0,24509480.0,Mahajan A,Metabolic disorder,initial,2014-02-09,GCST002352,Type 2 diabetes
4289,Asian,20019.0,24509480.0,Mahajan A,Metabolic disorder,initial,2014-02-09,GCST002352,Type 2 diabetes
12910,Hispanic or Latin American,2583.0,24509480.0,Mahajan A,Metabolic disorder,initial,2014-02-09,GCST002352,Type 2 diabetes
11315,European,69033.0,24509480.0,Mahajan A,Metabolic disorder,initial,2014-02-09,GCST002352,Type 2 diabetes
7621,European,3031.0,24511991.0,Hill-Burns EM,Neurological disorder,replication,2014-02-10,GCST002353,Parkinson's disease
8081,European,3986.0,24511991.0,Hill-Burns EM,Neurological disorder,initial,2014-02-10,GCST002353,Parkinson's disease
3304,Asian,3451.0,24513273.0,Yang B,Cardiovascular measurement,initial,2014-02-11,GCST002355,Serum uric acid levels
7489,European,2774.0,24518671.0,Nag A,Other measurement,initial,2014-02-11,GCST002356,Intraocular pressure
2375,Asian,879.0,24514567.0,Boraska V,Metabolic disorder,replication,2014-02-11,GCST002354,Anorexia nervosa
3939,Asian,8830.0,24513273.0,Yang B,Cardiovascular measurement,replication,2014-02-11,GCST002355,Serum uric acid levels
10487,European,22789.0,24518671.0,Nag A,Other measurement,replication,2014-02-11,GCST002356,Intraocular pressure
10221,European,17767.0,24514567.0,Boraska V,Metabolic disorder,initial,2014-02-11,GCST002354,Anorexia nervosa
9739,European,11306.0,24514567.0,Boraska V,Metabolic disorder,replication,2014-02-11,GCST002354,Anorexia nervosa
11040,European,45790.0,24532676.0,Kim K,Immune system disorder,initial,2014-02-14,GCST006048,Rheumatoid arthritis (ACPA-positive)
3987,Asian,9299.0,24532676.0,Kim K,Immune system disorder,initial,2014-02-14,GCST006048,Rheumatoid arthritis (ACPA-positive)
6827,European,1853.0,24532677.0,Bossini-Castillo L,Immune system disorder,replication,2014-02-14,GCST002357,Rheumatoid arthritis (ACPA-negative)
9011,European,7156.0,24532677.0,Bossini-Castillo L,Immune system disorder,initial,2014-02-14,GCST002357,Rheumatoid arthritis (ACPA-negative)
6034,European,979.0,24556642.0,Zeng Z,Digestive system disorder,initial,2014-02-18,GCST002358,Pit-and-Fissure caries
7908,European,3528.0,24535457.0,Chouraki V,Other measurement,initial,2014-02-18,GCST002360,Plasma amyloid beta peptide concentrations (ABx-40)
6105,European,1006.0,24556642.0,Zeng Z,Digestive system disorder,initial,2014-02-18,GCST002361,Smooth-surface caries
7907,European,3528.0,24535457.0,Chouraki V,Other measurement,initial,2014-02-18,GCST002359,Plasma amyloid beta peptide concentrations (ABx-42)
7650,European,3121.0,24839885.0,Benke KS,Other measurement,initial,2014-02-19,GCST002362,Preschool internalizing problems
446,African American or Afro-Caribbean,86.0,24554482.0,Leger PD,"Response to drug, Other disease, Neurological disorder",initial,2014-02-20,GCST002366,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)
423,African American or Afro-Caribbean,61.0,24554482.0,Leger PD,"Response to drug, Other disease, Neurological disorder",initial,2014-02-20,GCST002363,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)
4686,European,104.0,24554482.0,Leger PD,"Response to drug, Other disease, Neurological disorder",initial,2014-02-20,GCST002365,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)
4702,European,125.0,24554482.0,Leger PD,"Response to drug, Other disease, Neurological disorder",initial,2014-02-20,GCST002366,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)
440,African American or Afro-Caribbean,79.0,24554482.0,Leger PD,"Response to drug, Other disease, Neurological disorder",initial,2014-02-20,GCST002365,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)
12523,Hispanic or Latin American,43.0,24554482.0,Leger PD,"Response to drug, Other disease, Neurological disorder",initial,2014-02-20,GCST002366,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)
12520,Hispanic or Latin American,39.0,24554482.0,Leger PD,"Response to drug, Other disease, Neurological disorder",initial,2014-02-20,GCST002365,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)
12514,Hispanic or Latin American,33.0,24554482.0,Leger PD,"Response to drug, Other disease, Neurological disorder",initial,2014-02-20,GCST002363,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)
13702,Other/Mixed,601.0,24586186.0,Rueedi R,Other measurement,replication,2014-02-20,GCST002364,Urinary metabolites (H-NMR features)
4658,European,93.0,24554482.0,Leger PD,"Response to drug, Other disease, Neurological disorder",initial,2014-02-20,GCST002363,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)
5815,European,835.0,24586186.0,Rueedi R,Other measurement,initial,2014-02-20,GCST002364,Urinary metabolites (H-NMR features)
8647,European,5628.0,24564958.0,St Pourcain B,Other measurement,initial,2014-02-24,GCST002367,Social communication problems
5338,European,508.0,24574247.0,Yuan H,"Neurological disorder, Other measurement",initial,2014-02-25,GCST002368,Maternal genotype effects in autism spectrum disorder families
9745,European,11388.0,24569950.0,Hatemi PK,Other trait,initial,2014-02-26,GCST002372,Political ideology
5332,European,506.0,24571439.0,Nudel R,Neurological disorder,replication,2014-02-26,GCST002369,Parent of origin effect on language impairment (maternal)
5503,European,609.0,24571439.0,Nudel R,Neurological disorder,initial,2014-02-26,GCST002371,Parent of origin effect on language impairment (paternal)
5502,European,609.0,24571439.0,Nudel R,Neurological disorder,initial,2014-02-26,GCST002369,Parent of origin effect on language impairment (maternal)
5327,European,503.0,24582949.0,Docampo E,Immune system disorder,initial,2014-02-26,GCST002370,Fibromyalgia
6557,European,1541.0,24582949.0,Docampo E,Immune system disorder,replication,2014-02-26,GCST002370,Fibromyalgia
9210,European,8159.0,24586183.0,Medici M,Other measurement,replication,2014-02-27,GCST002373,Thyroid peroxidase antibody levels
9833,European,12353.0,24586183.0,Medici M,Other measurement,initial,2014-02-27,GCST002373,Thyroid peroxidase antibody levels
10249,European,18297.0,24586183.0,Medici M,Other measurement,initial,2014-02-27,GCST002378,Thyroid peroxidase antibody positivity
10620,European,26929.0,24578379.0,Huang J,Cardiovascular measurement,initial,2014-02-27,GCST002374,Plasma plasminogen activator levels
5243,European,466.0,24578207.0,Opherk C,"Cardiovascular disease, Other measurement",initial,2014-02-27,GCST002377,White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy
9700,European,10884.0,24578125.0,Olden M,Other measurement,initial,2014-02-27,GCST002376,Urinary uromodulin levels
8250,European,4487.0,24578379.0,Huang J,Cardiovascular measurement,replication,2014-02-27,GCST002374,Plasma plasminogen activator levels
2048,Asian,438.0,24583629.0,Senapati S,"Immune system disorder, Response to drug",initial,2014-02-27,GCST002375,Response to methotrexate in rheumatoid arthritis
9422,European,8990.0,24586183.0,Medici M,Other measurement,replication,2014-02-27,GCST002378,Thyroid peroxidase antibody positivity
8677,European,5756.0,24487271.0,Weizman A,"Digestive system disorder, Other trait",initial,2014-03-01,GCST002380,Erythema nodosum in inflammatory bowel disease
8676,European,5756.0,24487271.0,Weizman A,"Digestive system disorder, Other trait",initial,2014-03-01,GCST002379,Pyoderma gangrenosum in inflammatory bowel disease
2004,Asian,382.0,24123702.0,Chung CM,Other measurement,initial,2014-03-03,GCST002381,Resistin levels
2156,Asian,559.0,24123702.0,Chung CM,Other measurement,replication,2014-03-03,GCST002381,Resistin levels
7990,European,3750.0,24595857.0,Sandholm N,"Other measurement, Metabolic disorder",replication,2014-03-05,GCST002382,Urinary albumin excretion rate in type 1 diabetes
6867,European,1925.0,24595857.0,Sandholm N,"Other measurement, Metabolic disorder",initial,2014-03-05,GCST002382,Urinary albumin excretion rate in type 1 diabetes
2855,Asian,1860.0,24603532.0,Nongpiur ME,Other measurement,initial,2014-03-06,GCST002383,Anterior chamber depth
2784,Asian,1752.0,24603532.0,Nongpiur ME,Other measurement,initial,2014-03-06,GCST002383,Anterior chamber depth
2367,Asian,872.0,24603532.0,Nongpiur ME,Other measurement,initial,2014-03-06,GCST002383,Anterior chamber depth
2344,Asian,824.0,24603532.0,Nongpiur ME,Other measurement,replication,2014-03-06,GCST002383,Anterior chamber depth
5941,European,928.0,24604477.0,An P,Lipid or lipoprotein measurement,initial,2014-03-07,GCST002384,NHDL cholesterol
7781,European,3313.0,24604477.0,An P,Lipid or lipoprotein measurement,replication,2014-03-07,GCST002384,NHDL cholesterol
5721,European,767.0,24614497.0,Oikkonen J,Biological process,initial,2014-03-11,GCST002387,Musical aptitude
10534,European,24025.0,24618891.0,Muhleisen TW,Neurological disorder,initial,2014-03-11,GCST002385,Bipolar disorder
845,African American or Afro-Caribbean,1260.0,24625756.0,Yu B,Other measurement,initial,2014-03-13,GCST002388,Serum metabolite levels
6993,European,2065.0,24656865.0,Woo D,Cardiovascular disease,replication,2014-03-18,GCST002389,Intracerebral hemorrhage
12746,Hispanic or Latin American,794.0,24656865.0,Woo D,Cardiovascular disease,replication,2014-03-18,GCST002389,Intracerebral hemorrhage
801,African American or Afro-Caribbean,1083.0,24656865.0,Woo D,Cardiovascular disease,replication,2014-03-18,GCST002389,Intracerebral hemorrhage
7618,European,3026.0,24656865.0,Woo D,Cardiovascular disease,initial,2014-03-18,GCST002389,Intracerebral hemorrhage
2760,Asian,1727.0,24647736.0,Chen P,Other measurement,initial,2014-03-19,GCST002390,Glycated hemoglobin levels
4173,Asian,13585.0,24647736.0,Chen P,Other measurement,replication,2014-03-19,GCST002390,Glycated hemoglobin levels
4249,Asian,17290.0,24647736.0,Chen P,Other measurement,initial,2014-03-19,GCST002390,Glycated hemoglobin levels
73,African,258.0,24651765.0,Williams SR,Cardiovascular measurement,initial,2014-03-20,GCST002391,Plasma homocysteine levels (post-methionine load test)
13508,Other/Mixed,117.0,24651765.0,Williams SR,Cardiovascular measurement,initial,2014-03-20,GCST002391,Plasma homocysteine levels (post-methionine load test)
6726,European,1725.0,24651765.0,Williams SR,Cardiovascular measurement,initial,2014-03-20,GCST002391,Plasma homocysteine levels (post-methionine load test)
3246,Asian,3023.0,24658283.0,Zhang R,"Other measurement, Cancer",replication,2014-03-22,GCST002392,Lung cancer (smoking interaction)
3573,Asian,5408.0,24658283.0,Zhang R,"Other measurement, Cancer",initial,2014-03-22,GCST002392,Lung cancer (smoking interaction)
3563,Asian,5354.0,24665060.0,Argos M,Biological process,initial,2014-03-24,GCST002396,Smoking initiation
9061,European,7413.0,24662972.0,Figueroa JD,Cancer,initial,2014-03-24,GCST002397,Bladder cancer (smoking interaction)
2941,Asian,2035.0,24665060.0,Argos M,Biological process,initial,2014-03-24,GCST002395,Smoking cessation
2942,Asian,2035.0,24665060.0,Argos M,"Biological process, Other measurement",initial,2014-03-24,GCST002394,Age of smoking initiation
9212,European,8168.0,24662972.0,Figueroa JD,Cancer,replication,2014-03-24,GCST002397,Bladder cancer (smoking interaction)
2943,Asian,2035.0,24665060.0,Argos M,Other measurement,initial,2014-03-24,GCST002393,Smoking quantity
5662,European,733.0,24667120.0,Zhang TX,Other disease,replication,2014-03-25,GCST002399,Clubfoot
6459,European,1396.0,24667120.0,Zhang TX,Other disease,initial,2014-03-25,GCST002399,Clubfoot
5847,European,855.0,24680774.0,Mezzavilla M,Cardiovascular measurement,initial,2014-03-25,GCST002398,Resting heart rate
5270,European,484.0,24677629.0,Wolf EJ,Neurological disorder,initial,2014-03-27,GCST002401,Post-traumatic stress disorder
7493,European,2785.0,24676358.0,Viktorin A,Other measurement,replication,2014-03-27,GCST002402,Serum IgA levels
6857,European,1892.0,24675659.0,Hartiala J,Other measurement,replication,2014-03-27,GCST002400,Plasma trimethylamine N-oxide levels
9514,European,9617.0,24676358.0,Viktorin A,Other measurement,initial,2014-03-27,GCST002402,Serum IgA levels
6914,European,1973.0,24675659.0,Hartiala J,Other measurement,initial,2014-03-27,GCST002400,Plasma trimethylamine N-oxide levels
11360,European,74216.0,24688116.0,Deelen J,Other measurement,replication,2014-03-31,GCST002403,Longevity (85 years and older)
11312,European,68486.0,24688116.0,Deelen J,Other measurement,replication,2014-03-31,GCST002404,Longevity (90 years and older)
10366,European,20518.0,24688116.0,Deelen J,Other measurement,initial,2014-03-31,GCST002404,Longevity (90 years and older)
10519,European,23850.0,24688116.0,Deelen J,Other measurement,initial,2014-03-31,GCST002403,Longevity (85 years and older)
8350,European,4789.0,24699409.0,Prokopenko I,Other measurement,initial,2014-04-03,GCST005216,Corrected insulin response adjusted for insulin sensitivity index
8167,European,4231.0,24699409.0,Prokopenko I,Other measurement,initial,2014-04-03,GCST005223,Ratio of the area under the curve for insulin and the area under the curve for glucose
10260,European,18535.0,24699409.0,Prokopenko I,Other measurement,replication,2014-04-03,GCST005217,Insulin levels adjusted for BMI
10378,European,20722.0,24699409.0,Prokopenko I,Other measurement,replication,2014-04-03,GCST005215,Corrected insulin response
10368,European,20620.0,24699409.0,Prokopenko I,Other measurement,replication,2014-04-03,GCST005218,Area under the curve of insulin levels
8512,European,5130.0,24699409.0,Prokopenko I,Other measurement,initial,2014-04-03,GCST005222,Insulin disposition index
10376,European,20706.0,24699409.0,Prokopenko I,Other measurement,replication,2014-04-03,GCST005219,Incremental insulin
8342,European,4768.0,24699409.0,Prokopenko I,Other measurement,initial,2014-04-03,GCST005221,Insulin sensitivity index
8249,European,4483.0,24699409.0,Prokopenko I,Other measurement,initial,2014-04-03,GCST005220,Insulin levels
10365,European,20514.0,24699409.0,Prokopenko I,Other measurement,replication,2014-04-03,GCST005221,Insulin sensitivity index
8222,European,4409.0,24699409.0,Prokopenko I,Other measurement,initial,2014-04-03,GCST005217,Insulin levels adjusted for BMI
8201,European,4324.0,24699409.0,Prokopenko I,Other measurement,initial,2014-04-03,GCST005218,Area under the curve of insulin levels
10362,European,20461.0,24699409.0,Prokopenko I,Other measurement,replication,2014-04-03,GCST005216,Corrected insulin response adjusted for insulin sensitivity index
10364,European,20513.0,24699409.0,Prokopenko I,Other measurement,replication,2014-04-03,GCST005223,Ratio of the area under the curve for insulin and the area under the curve for glucose
10382,European,20792.0,24699409.0,Prokopenko I,Other measurement,replication,2014-04-03,GCST005220,Insulin levels
8577,European,5318.0,24699409.0,Prokopenko I,Other measurement,initial,2014-04-03,GCST005215,Corrected insulin response
8234,European,4447.0,24699409.0,Prokopenko I,Other measurement,initial,2014-04-03,GCST005219,Incremental insulin
10363,European,20461.0,24699409.0,Prokopenko I,Other measurement,replication,2014-04-03,GCST005222,Insulin disposition index
1647,Asian,90.0,24952865.0,Akerblom A,"Cardiovascular disease, Other measurement",initial,2014-04-04,GCST002406,Plasma cystastin c levels in acute coronary syndrome
2030,Asian,412.0,24700089.0,Miura K,Cancer,initial,2014-04-04,GCST002405,Cervical cancer
26,African,57.0,24952865.0,Akerblom A,"Cardiovascular disease, Other measurement",initial,2014-04-04,GCST002406,Plasma cystastin c levels in acute coronary syndrome
9549,European,9801.0,24952865.0,Akerblom A,"Cardiovascular disease, Other measurement",initial,2014-04-04,GCST002406,Plasma cystastin c levels in acute coronary syndrome
5899,European,890.0,24629169.0,Ising M,"Other measurement, Biological process",initial,2014-04-08,GCST007698,perceptual and visual search speed and executive function (trail making test BA) (age interaction)
5898,European,890.0,24629169.0,Ising M,"Other measurement, Biological process",initial,2014-04-08,GCST007695,perceptual and visual search speed and executive function (trail making test BA)
7640,European,3102.0,24714607.0,Dijkstra AE,Other trait,initial,2014-04-08,GCST002407,Chronic mucus hypersecretion
5897,European,890.0,24629169.0,Ising M,Other measurement,initial,2014-04-08,GCST007697,executive function (trail making test B) (age interaction)
5896,European,890.0,24629169.0,Ising M,Other measurement,initial,2014-04-08,GCST007694,executive function (trail making test B)
5895,European,890.0,24629169.0,Ising M,Biological process,initial,2014-04-08,GCST007696,perceptual and visual search speed (trail making test A) (age interaction)
5894,European,890.0,24629169.0,Ising M,Biological process,initial,2014-04-08,GCST007693,perceptual and visual search speed (trail making test A)
5614,European,694.0,24709693.0,Cobb J,"Response to drug, Immune system disorder",initial,2014-04-08,GCST002408,Response to methotrexate in juvenile idiopathic arthritis
9142,European,7816.0,24714607.0,Dijkstra AE,Other trait,replication,2014-04-08,GCST002407,Chronic mucus hypersecretion
12740,Hispanic or Latin American,776.0,24736177.0,Sprooten E,Other measurement,initial,2014-04-13,GCST002409,White matter microstructure (global fractional anisotropy)
11329,European,69776.0,24728293.0,Styrkarsdottir U,Other disease,initial,2014-04-13,GCST002410,"Osteoarthritis (hand, severe)"
9320,European,8386.0,24728293.0,Styrkarsdottir U,Other disease,replication,2014-04-13,GCST002410,"Osteoarthritis (hand, severe)"
10689,European,29974.0,24737748.0,Whiffin N,Cancer,replication,2014-04-15,GCST002411,Colorectal cancer
1876,Asian,250.0,24737549.0,Yoon KA,"Other measurement, Cancer",initial,2014-04-15,GCST002412,Non-small cell lung cancer (recurrence rate)
1932,Asian,308.0,24737549.0,Yoon KA,"Other measurement, Cancer",replication,2014-04-15,GCST002412,Non-small cell lung cancer (recurrence rate)
9907,European,13443.0,24737748.0,Whiffin N,Cancer,initial,2014-04-15,GCST002411,Colorectal cancer
8476,European,5051.0,24740154.0,Lange EM,Cancer,initial,2014-04-16,GCST002413,Prostate cancer (early onset)
7887,European,3492.0,24740154.0,Lange EM,Cancer,replication,2014-04-16,GCST002413,Prostate cancer (early onset)
6444,European,1380.0,24740207.0,Moy KA,Other measurement,initial,2014-04-16,GCST002414,Serum vitamin D-binding protein levels
2349,Asian,829.0,24722205.0,Kwak SH,Other measurement,replication,2014-04-17,GCST002417,Plasma thyroid-stimulating hormone levels
3178,Asian,2789.0,24722205.0,Kwak SH,Other measurement,initial,2014-04-17,GCST002418,Free thyroxine concentration
2350,Asian,829.0,24722205.0,Kwak SH,Other measurement,replication,2014-04-17,GCST002418,Free thyroxine concentration
2356,Asian,842.0,24722205.0,Kwak SH,Other measurement,replication,2014-04-17,GCST002416,Thyroid peroxidase antibody positivity
3177,Asian,2789.0,24722205.0,Kwak SH,Other measurement,initial,2014-04-17,GCST002417,Plasma thyroid-stimulating hormone levels
3292,Asian,3396.0,24722205.0,Kwak SH,Other measurement,initial,2014-04-17,GCST002416,Thyroid peroxidase antibody positivity
10252,European,18404.0,24743840.0,Figueiredo JC,"Other measurement, Cancer",initial,2014-04-17,GCST002415,Colorectal cancer (diet interaction)
6675,European,1660.0,24882193.0,Winham SJ,"Metabolic disorder, Neurological disorder",replication,2014-04-19,GCST002419,Binge eating behaviour and bipolar disorder
5945,European,929.0,24882193.0,Winham SJ,"Metabolic disorder, Neurological disorder",initial,2014-04-19,GCST002420,Binge eating behaviour in bipolar disorder
6910,European,1963.0,24882193.0,Winham SJ,"Metabolic disorder, Neurological disorder",initial,2014-04-19,GCST002419,Binge eating behaviour and bipolar disorder
5806,European,828.0,24882193.0,Winham SJ,"Metabolic disorder, Neurological disorder",replication,2014-04-19,GCST002420,Binge eating behaviour in bipolar disorder
7578,European,2950.0,24753544.0,Knipe DW,Cancer,initial,2014-04-21,GCST002421,Prostate cancer
7762,European,3291.0,24753544.0,Knipe DW,Cancer,replication,2014-04-21,GCST002421,Prostate cancer
8274,European,4569.0,24755620.0,Perez-Palma E,Neurological disorder,initial,2014-04-22,GCST002422,Alzheimer's disease
9962,European,14085.0,24768677.0,de Boer YS,Immune system disorder,initial,2014-04-23,GCST002423,Autoimmune hepatitis type-1
8269,European,4554.0,24768677.0,de Boer YS,Immune system disorder,replication,2014-04-23,GCST002423,Autoimmune hepatitis type-1
3829,Asian,7626.0,24763700.0,Vinayagamoorthy N,Inflammatory measurement,initial,2014-04-24,GCST002424,C-reactive protein levels
2386,Asian,903.0,24763700.0,Vinayagamoorthy N,Inflammatory measurement,replication,2014-04-24,GCST002424,C-reactive protein levels
9590,European,9916.0,24770850.0,Cousminer DL,Other measurement,initial,2014-04-25,GCST002425,Puberty onset
7997,European,3769.0,24770850.0,Cousminer DL,Other measurement,initial,2014-04-25,GCST002426,Puberty onset (genital enlargement)
8775,European,6147.0,24770850.0,Cousminer DL,Other measurement,initial,2014-04-25,GCST002427,Puberty onset (breast development)
4838,European,208.0,24770850.0,Cousminer DL,Other measurement,replication,2014-04-25,GCST002426,Puberty onset (genital enlargement)
6442,European,1376.0,24770850.0,Cousminer DL,Other measurement,replication,2014-04-25,GCST002425,Puberty onset
13979,Other/Mixed,5244.0,24816038.0,Postmus I,Response to drug,initial,2014-04-26,GCST002428,Cardiovascular event reduction in the elderly at risk for vascular disease (statin therapy interaction)
5356,European,516.0,24785509.0,Barnett GC,"Cancer, Biological process",replication,2014-04-28,GCST002431,Response to radiotherapy in cancer (late toxicity)
6773,European,1773.0,24785509.0,Barnett GC,"Cancer, Biological process",initial,2014-04-28,GCST002431,Response to radiotherapy in cancer (late toxicity)
1782,Asian,189.0,24792382.0,Park TJ,"Response to drug, Other measurement, Other disease",initial,2014-04-30,GCST002432,Response to inhaled corticosteroid treatment in asthma (change in FEV1)
10587,European,25708.0,24782177.0,Jiang L,Immune system disorder,replication,2014-05-01,GCST002434,Rheumatoid arthritis
2881,Asian,1895.0,24782177.0,Jiang L,Immune system disorder,initial,2014-05-01,GCST002433,Rheumatoid arthritis
3228,Asian,2955.0,24827717.0,Yang F,"Body measurement, Other measurement",replication,2014-05-01,GCST002435,Body mass index
6596,European,1570.0,24797007.0,Holliday EG,Digestive system disorder,initial,2014-05-01,GCST002436,Irritable bowel syndrome
3488,Asian,4685.0,24782177.0,Jiang L,Immune system disorder,replication,2014-05-01,GCST002433,Rheumatoid arthritis
6291,European,1201.0,24797007.0,Holliday EG,Digestive system disorder,replication,2014-05-01,GCST002436,Irritable bowel syndrome
2173,Asian,597.0,24827717.0,Yang F,"Body measurement, Other measurement",initial,2014-05-01,GCST002435,Body mass index
2882,Asian,1895.0,24782177.0,Jiang L,Immune system disorder,initial,2014-05-01,GCST002434,Rheumatoid arthritis
9894,European,13285.0,24795349.0,Saxena R,Other measurement,replication,2014-05-03,GCST002437,Telomere length
3084,Asian,2397.0,24795349.0,Saxena R,Other measurement,replication,2014-05-03,GCST002437,Telomere length
2708,Asian,1616.0,24795349.0,Saxena R,Other measurement,initial,2014-05-03,GCST002437,Telomere length
5484,European,602.0,24801482.0,Baron-Cohen S,Biological process,initial,2014-05-06,GCST002439,Mathematical ability
6139,European,1044.0,24800985.0,Agopian AJ,"Cardiovascular disease, Other measurement",replication,2014-05-06,GCST002438,Conotruncal heart defects
13445,Other/Mixed,30.0,24800985.0,Agopian AJ,"Cardiovascular disease, Other measurement",replication,2014-05-06,GCST002438,Conotruncal heart defects
13890,Other/Mixed,1868.0,24800985.0,Agopian AJ,"Cardiovascular disease, Other measurement",initial,2014-05-06,GCST002438,Conotruncal heart defects
5885,European,883.0,24811271.0,Kennedy RB,Response to drug,initial,2014-05-09,GCST002441,Immune response to measles-mumps-rubella vaccine
7732,European,3234.0,24847357.0,Ye Z,Other disease,initial,2014-05-09,GCST002440,Staphylococcus aureus infection
9143,European,7824.0,24816252.0,Shin SY,Other measurement,initial,2014-05-11,GCST002443,Blood metabolite levels
6768,European,1767.0,24816252.0,Shin SY,Other measurement,replication,2014-05-11,GCST002442,Blood metabolite ratios
8637,European,5591.0,24816252.0,Shin SY,Other measurement,initial,2014-05-11,GCST002442,Blood metabolite ratios
9362,European,8631.0,24823311.0,Guan W,Lipid or lipoprotein measurement,initial,2014-05-13,GCST002444,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)
7940,European,3606.0,24824216.0,Myers RA,"Other disease, Other measurement",initial,2014-05-13,GCST002445,Asthma (sex interaction)
9363,European,8631.0,24823311.0,Guan W,Lipid or lipoprotein measurement,initial,2014-05-13,GCST002446,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)
9364,European,8631.0,24823311.0,Guan W,Lipid or lipoprotein measurement,initial,2014-05-13,GCST002448,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid)
12893,Hispanic or Latin American,2428.0,24824216.0,Myers RA,"Other disease, Other measurement",initial,2014-05-13,GCST002445,Asthma (sex interaction)
1069,African American or Afro-Caribbean,3015.0,24824216.0,Myers RA,"Other disease, Other measurement",initial,2014-05-13,GCST002445,Asthma (sex interaction)
738,African American or Afro-Caribbean,820.0,24825563.0,McDonald ML,"Other disease, Other measurement",initial,2014-05-13,GCST002447,Resting oxygen saturation in chronic osbtructive pulmonary disease (pulse oxymetry)
9365,European,8631.0,24823311.0,Guan W,Lipid or lipoprotein measurement,initial,2014-05-13,GCST002449,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)
9366,European,8631.0,24823311.0,Guan W,Lipid or lipoprotein measurement,initial,2014-05-13,GCST002450,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)
8303,European,4658.0,24825563.0,McDonald ML,"Other disease, Other measurement",replication,2014-05-13,GCST002447,Resting oxygen saturation in chronic osbtructive pulmonary disease (pulse oxymetry)
7200,European,2322.0,24832863.0,Wetherill L,Neurological disorder,initial,2014-05-16,GCST002452,Substance dependence phenotypes
7419,European,2647.0,24832863.0,Wetherill L,Neurological disorder,replication,2014-05-16,GCST002452,Substance dependence phenotypes
2546,Asian,1225.0,24837172.0,Juyal G,Immune system disorder,initial,2014-05-16,GCST002453,Ulcerative colitis
2873,Asian,1881.0,24837172.0,Juyal G,Immune system disorder,replication,2014-05-16,GCST002453,Ulcerative colitis
3891,Asian,8270.0,24836286.0,Zhang B,Cancer,initial,2014-05-18,GCST002454,Colorectal cancer
4410,Asian,38638.0,24836286.0,Zhang B,Cancer,replication,2014-05-18,GCST002454,Colorectal cancer
10847,European,35246.0,24836286.0,Zhang B,Cancer,replication,2014-05-18,GCST002454,Colorectal cancer
13933,Other/Mixed,2889.0,24842889.0,Vacic V,Neurological disorder,replication,2014-05-19,GCST002455,Parkinson's disease
13960,Other/Mixed,3741.0,24842889.0,Vacic V,Neurological disorder,initial,2014-05-19,GCST002455,Parkinson's disease
10129,European,16468.0,24850809.0,Verweij N,Cardiovascular measurement,initial,2014-05-21,GCST002457,P wave duration
10128,European,16468.0,24850809.0,Verweij N,Cardiovascular measurement,initial,2014-05-21,GCST002456,PR segment
3272,Asian,3235.0,24852370.0,Zhan M,Other measurement,replication,2014-05-22,GCST002458,Serum thyroid-stimulating hormone levels
2586,Asian,1346.0,24852370.0,Zhan M,Other measurement,initial,2014-05-22,GCST002458,Serum thyroid-stimulating hormone levels
1900,Asian,269.0,24863034.0,Urano T,Other measurement,initial,2014-05-23,GCST002459,Lean body mass
2470,Asian,1081.0,24863034.0,Urano T,Other measurement,replication,2014-05-23,GCST002459,Lean body mass
11545,European,91850.0,24861552.0,Rafnar T,Cancer,initial,2014-05-26,GCST002460,Urinary bladder cancer
3427,Asian,4301.0,24861553.0,Wen W,"Body measurement, Other measurement",initial,2014-05-26,GCST002461,Body mass index
4432,Asian,47352.0,24861553.0,Wen W,"Body measurement, Other measurement",replication,2014-05-26,GCST002461,Body mass index
4474,Asian,82438.0,24861553.0,Wen W,"Body measurement, Other measurement",initial,2014-05-26,GCST002461,Body mass index
10072,European,15697.0,24861552.0,Rafnar T,Cancer,replication,2014-05-26,GCST002460,Urinary bladder cancer
8993,European,7076.0,24958192.0,Gusareva ES,Neurological disorder,replication,2014-05-28,GCST002462,Alzheimer's disease (SNP x SNP interaction)
9230,European,8276.0,24958192.0,Gusareva ES,Neurological disorder,initial,2014-05-28,GCST002462,Alzheimer's disease (SNP x SNP interaction)
7671,European,3163.0,24871463.0,Armstrong DL,Immune system disorder,initial,2014-05-29,GCST002463,Systemic lupus erythematosus
7873,European,3464.0,24871321.0,Sambo F,"Other disease, Metabolic disorder",initial,2014-05-29,GCST002464,End-stage renal disease or diabetic nephropathy in type 1 diabetes
4666,European,96.0,24751813.0,Drago A,"Response to drug, Neurological disorder",initial,2014-06-01,GCST002465,Response to haloperidol in psychosis
10622,European,27209.0,24880342.0,Wang Y,Cancer,initial,2014-06-01,GCST002466,Lung cancer
11086,European,48541.0,24880342.0,Wang Y,Cancer,replication,2014-06-01,GCST002466,Lung cancer
12970,Hispanic or Latin American,3701.0,24886709.0,Ko A,Lipid or lipoprotein measurement,initial,2014-06-02,GCST002469,HDL cholesterol
13076,Hispanic or Latin American,6017.0,24886709.0,Ko A,Lipid or lipoprotein measurement,replication,2014-06-02,GCST002469,HDL cholesterol
12933,Hispanic or Latin American,3323.0,24886709.0,Ko A,Lipid or lipoprotein measurement,initial,2014-06-02,GCST002468,Triglycerides
12969,Hispanic or Latin American,3701.0,24886709.0,Ko A,Lipid or lipoprotein measurement,initial,2014-06-02,GCST002467,"Cholesterol, total"
13074,Hispanic or Latin American,6017.0,24886709.0,Ko A,Lipid or lipoprotein measurement,replication,2014-06-02,GCST002467,"Cholesterol, total"
13075,Hispanic or Latin American,6017.0,24886709.0,Ko A,Lipid or lipoprotein measurement,replication,2014-06-02,GCST002468,Triglycerides
3456,Asian,4544.0,24903457.0,Kim YK,"Other measurement, Body measurement",replication,2014-06-05,GCST002471,Blood pressure (anthropometric measures interaction)
427,African American or Afro-Caribbean,70.0,24909733.0,Cook-Sather SD,Response to drug,replication,2014-06-05,GCST002472,Morphine dose requirement in tonsillectomy and adenoidectomy surgery
4613,European,75.0,24909733.0,Cook-Sather SD,Response to drug,replication,2014-06-05,GCST002472,Morphine dose requirement in tonsillectomy and adenoidectomy surgery
3811,Asian,7486.0,24903457.0,Kim YK,"Other measurement, Body measurement",initial,2014-06-05,GCST002471,Blood pressure (anthropometric measures interaction)
3457,Asian,4544.0,24903457.0,Kim YK,"Other measurement, Cardiovascular measurement",replication,2014-06-05,GCST004705,Blood pressure
553,African American or Afro-Caribbean,241.0,24909733.0,Cook-Sather SD,Response to drug,initial,2014-06-05,GCST002472,Morphine dose requirement in tonsillectomy and adenoidectomy surgery
4925,European,277.0,24909733.0,Cook-Sather SD,Response to drug,initial,2014-06-05,GCST002472,Morphine dose requirement in tonsillectomy and adenoidectomy surgery
3812,Asian,7486.0,24903457.0,Kim YK,"Other measurement, Cardiovascular measurement",initial,2014-06-05,GCST004705,Blood pressure
9106,European,7608.0,24908248.0,Walsh KM,Cancer,initial,2014-06-08,GCST002474,Glioma (high-grade)
6772,European,1772.0,24908248.0,Walsh KM,Cancer,replication,2014-06-08,GCST002474,Glioma (high-grade)
5244,European,466.0,24916650.0,Versmissen J,"Cardiovascular disease, Metabolic disorder",initial,2014-06-11,GCST002478,Coronary heart disease in familial hypercholesterolemia
3509,Asian,4864.0,24916648.0,Hirokawa M,Cardiovascular disease,initial,2014-06-11,GCST002475,Myocardial infarction
7268,European,2435.0,24916650.0,Versmissen J,"Cardiovascular disease, Metabolic disorder",replication,2014-06-11,GCST002478,Coronary heart disease in familial hypercholesterolemia
2571,Asian,1302.0,24919509.0,Terao C,Other measurement,replication,2014-06-11,GCST002476,Prostate-specific antigen levels
6783,European,1788.0,24962325.0,Kapoor M,"Neurological disorder, Other measurement",initial,2014-06-11,GCST002477,Alcohol dependence (age at onset)
4414,Asian,39809.0,24916648.0,Hirokawa M,Cardiovascular disease,replication,2014-06-11,GCST002475,Myocardial infarction
2471,Asian,1086.0,24919509.0,Terao C,Other measurement,initial,2014-06-11,GCST002476,Prostate-specific antigen levels
6929,European,2000.0,24925725.0,Chung SA,Immune system disorder,initial,2014-06-12,GCST002479,Lupus nephritis in systemic lupus erythematosus
9529,European,9693.0,24920014.0,Cozen W,Cancer,initial,2014-06-12,GCST002480,Hodgkin's lymphoma
8253,European,4499.0,24920014.0,Cozen W,Cancer,replication,2014-06-12,GCST002480,Hodgkin's lymphoma
8099,European,4033.0,24927181.0,Navarini AA,Other disease,replication,2014-06-13,GCST002481,Acne (severe)
8983,European,7025.0,24927181.0,Navarini AA,Other disease,initial,2014-06-13,GCST002481,Acne (severe)
12592,Hispanic or Latin American,264.0,24954085.0,Della-Morte D,"Other measurement, Cardiovascular measurement",replication,2014-06-14,GCST002482,Carotid plaque burden (smoking interaction)
12702,Hispanic or Latin American,665.0,24954085.0,Della-Morte D,"Other measurement, Cardiovascular measurement",initial,2014-06-14,GCST002482,Carotid plaque burden (smoking interaction)
3913,Asian,8637.0,24929828.0,Loth DW,Other measurement,replication,2014-06-15,GCST002483,Lung function (forced vital capacity)
10766,European,32917.0,24929828.0,Loth DW,Other measurement,replication,2014-06-15,GCST002483,Lung function (forced vital capacity)
12756,Hispanic or Latin American,849.0,24929828.0,Loth DW,Other measurement,replication,2014-06-15,GCST002483,Lung function (forced vital capacity)
11129,European,52253.0,24929828.0,Loth DW,Other measurement,initial,2014-06-15,GCST002483,Lung function (forced vital capacity)
1244,African American or Afro-Caribbean,6070.0,24929828.0,Loth DW,Other measurement,replication,2014-06-15,GCST002483,Lung function (forced vital capacity)
6132,European,1035.0,24934506.0,Eny KM,Other measurement,replication,2014-06-17,GCST002484,Skin fluorescence
9550,European,9803.0,24934506.0,Eny KM,Other measurement,initial,2014-06-17,GCST002484,Skin fluorescence
2382,Asian,898.0,24938310.0,Nakano M,Neurological disorder,initial,2014-06-18,GCST002486,Exfoliation glaucoma or exfoliation syndrome
2923,Asian,1999.0,24941225.0,Liang Y,Other measurement,initial,2014-06-18,GCST002485,Elevated serum carcinoembryonic antigen levels
6515,European,1489.0,24939585.0,Fransen E,Neurological disorder,initial,2014-06-18,GCST002487,Age-related hearing impairment (SNP x SNP interaction)
2950,Asian,2063.0,24940741.0,Chang SW,Digestive system disorder,replication,2014-06-18,GCST002490,Chronic hepatitis B infection
2006,Asian,384.0,24938310.0,Nakano M,Neurological disorder,replication,2014-06-18,GCST002486,Exfoliation glaucoma or exfoliation syndrome
3267,Asian,3170.0,24942650.0,Terao C,Other measurement,initial,2014-06-18,GCST002489,Rheumatoid factor
6516,European,1489.0,24939585.0,Fransen E,Neurological disorder,initial,2014-06-18,GCST002491,Age-related hearing impairment
2190,Asian,625.0,24940741.0,Chang SW,Digestive system disorder,initial,2014-06-18,GCST002490,Chronic hepatitis B infection
3266,Asian,3170.0,24942650.0,Terao C,Other measurement,initial,2014-06-18,GCST002488,Anti-citrullinated peptide antibody
3100,Asian,2476.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002495,Blood pressure (age interaction)
11014,European,43445.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002495,Blood pressure (age interaction)
13835,Other/Mixed,1177.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002493,"Bone mineral density (paediatric, skull)"
9185,European,8007.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002492,"Bone mineral density (paediatric, lower limb)"
2853,Asian,1855.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002495,Blood pressure (age interaction)
11181,European,55796.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",initial,2014-06-19,GCST002495,Blood pressure (age interaction)
11182,European,55796.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",initial,2014-06-19,GCST002497,Blood pressure
2854,Asian,1855.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002497,Blood pressure
9186,European,8007.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002494,"Bone mineral density (paediatric, total body less head)"
13579,Other/Mixed,232.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002492,"Bone mineral density (paediatric, lower limb)"
11015,European,43445.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002497,Blood pressure
2850,Asian,1849.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002497,Blood pressure
3108,Asian,2502.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002497,Blood pressure
3101,Asian,2476.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002497,Blood pressure
2849,Asian,1849.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002495,Blood pressure (age interaction)
13581,Other/Mixed,232.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002494,"Bone mineral density (paediatric, total body less head)"
13582,Other/Mixed,232.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002496,"Bone mineral density (paediatric, upper limb)"
9187,European,8007.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002496,"Bone mineral density (paediatric, upper limb)"
3107,Asian,2502.0,24954895.0,Simino J,"Other measurement, Cardiovascular measurement",replication,2014-06-19,GCST002495,Blood pressure (age interaction)
13834,Other/Mixed,1177.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002492,"Bone mineral density (paediatric, lower limb)"
13836,Other/Mixed,1177.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002494,"Bone mineral density (paediatric, total body less head)"
9174,European,7976.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002493,"Bone mineral density (paediatric, skull)"
13837,Other/Mixed,1177.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002496,"Bone mineral density (paediatric, upper limb)"
13580,Other/Mixed,232.0,24945404.0,Kemp JP,Other measurement,initial,2014-06-19,GCST002493,"Bone mineral density (paediatric, skull)"
3017,Asian,2200.0,24951543.0,Liao J,Other trait,initial,2014-06-20,GCST002498,Age-related nuclear cataracts
8282,European,4593.0,24950379.0,Metrustry SJ,Body measurement,initial,2014-06-20,GCST002499,Birth weight
3072,Asian,2369.0,24951543.0,Liao J,Other trait,initial,2014-06-20,GCST002498,Age-related nuclear cataracts
3135,Asian,2571.0,24951543.0,Liao J,Other trait,initial,2014-06-20,GCST002498,Age-related nuclear cataracts
5773,European,810.0,24957906.0,Kuiper JJ,Cardiovascular disease,initial,2014-06-22,GCST002501,Birdshot chorioretinopathy
7519,European,2823.0,24957906.0,Kuiper JJ,Cardiovascular disease,replication,2014-06-22,GCST002501,Birdshot chorioretinopathy
11337,European,71061.0,24952745.0,Arking DE,Cardiovascular measurement,initial,2014-06-22,GCST002500,QT interval
10775,European,33316.0,24952745.0,Arking DE,Cardiovascular measurement,replication,2014-06-22,GCST002500,QT interval
2977,Asian,2138.0,24963161.0,Chen P,Other measurement,initial,2014-06-24,GCST002502,Corneal curvature
3545,Asian,5220.0,24963161.0,Chen P,Other measurement,replication,2014-06-24,GCST002502,Corneal curvature
3268,Asian,3178.0,24963161.0,Chen P,Other measurement,initial,2014-06-24,GCST002502,Corneal curvature
2972,Asian,2124.0,24963161.0,Chen P,Other measurement,initial,2014-06-24,GCST002502,Corneal curvature
6785,European,1791.0,25009551.0,Kullo IJ,Cardiovascular disease,replication,2014-06-25,GCST002504,Peripheral artery disease
5701,European,747.0,24964207.0,Mullins N,"Biological process, Neurological disorder",initial,2014-06-25,GCST002505,Suicidal ideation in depression or bipolar disorder
7742,European,3245.0,25009551.0,Kullo IJ,Cardiovascular disease,initial,2014-06-25,GCST002504,Peripheral artery disease
7753,European,3270.0,24964207.0,Mullins N,"Biological process, Neurological disorder",initial,2014-06-25,GCST002503,Suicide attempts in depression or bipolar disorder
3596,Asian,5605.0,24975945.0,Ganesh SK,"Other measurement, Cardiovascular measurement",replication,2014-06-26,GCST002506,Blood pressure
11054,European,46553.0,24975945.0,Ganesh SK,"Other measurement, Cardiovascular measurement",initial,2014-06-26,GCST002506,Blood pressure
7627,European,3063.0,24974787.0,Meng W,"Metabolic disorder, Other trait",initial,2014-06-26,GCST002507,Neuropathic pain in type 2 diabetes
10837,European,34433.0,24975945.0,Ganesh SK,"Other measurement, Cardiovascular measurement",replication,2014-06-26,GCST002506,Blood pressure
9190,European,8014.0,24931836.0,Diekstra FP,Neurological disorder,replication,2014-06-27,GCST002510,Amyotrophic lateral sclerosis or frontotemporal dementia
10199,European,17394.0,24931836.0,Diekstra FP,Neurological disorder,initial,2014-06-27,GCST002509,Amyotrophic lateral sclerosis
6825,European,1849.0,24931836.0,Diekstra FP,Neurological disorder,initial,2014-06-27,GCST002508,Frontotemporal dementia
10302,European,19243.0,24931836.0,Diekstra FP,Neurological disorder,initial,2014-06-27,GCST002510,Amyotrophic lateral sclerosis or frontotemporal dementia
5703,European,749.0,24974847.0,Fachal L,"Cancer, Biological process",replication,2014-06-29,GCST002511,Response to radiotherapy in prostate cancer (toxicity)
5551,European,652.0,24974847.0,Fachal L,"Cancer, Biological process",initial,2014-06-29,GCST002511,Response to radiotherapy in prostate cancer (toxicity)
8765,European,6122.0,24980573.0,Song F,Cancer,initial,2014-06-30,GCST002514,Melanoma
6353,European,1281.0,24978480.0,Real LM,Cancer,initial,2014-06-30,GCST002513,Colorectal cancer (SNP x SNP interaction)
7813,European,3354.0,24978480.0,Real LM,Cancer,replication,2014-06-30,GCST002513,Colorectal cancer (SNP x SNP interaction)
7812,European,3354.0,24978480.0,Real LM,Cancer,replication,2014-06-30,GCST002512,Colorectal cancer
10253,European,18416.0,24980573.0,Song F,Cancer,replication,2014-06-30,GCST002514,Melanoma
6352,European,1281.0,24978480.0,Real LM,Cancer,initial,2014-06-30,GCST002512,Colorectal cancer
8839,European,6462.0,24943344.0,Ferrari R,Neurological disorder,initial,2014-07-01,GCST002516,Frontotemporal dementia
8841,European,6466.0,24943344.0,Ferrari R,Neurological disorder,replication,2014-07-01,GCST002516,Frontotemporal dementia
10623,European,27249.0,24983941.0,Tang W,Other measurement,initial,2014-07-01,GCST002517,Rate of change of FEV1 (time interaction)
2450,Asian,1031.0,24986923.0,Chu M,"Other disease, Biological process",replication,2014-07-01,GCST002515,Pneumoconiosis in silica exposure
2022,Asian,400.0,24986923.0,Chu M,"Other disease, Biological process",initial,2014-07-01,GCST002515,Pneumoconiosis in silica exposure
12815,Hispanic or Latin American,1367.0,24962563.0,Rubicz R,"Biological process, Other measurement",initial,2014-07-01,GCST002518,Food antigen IgG levels
6317,European,1235.0,24993907.0,Smolonska J,Other disease,replication,2014-07-03,GCST002519,Asthma or chronic obstructive pulmonary disease
8853,European,6535.0,24993907.0,Smolonska J,Other disease,initial,2014-07-03,GCST002519,Asthma or chronic obstructive pulmonary disease
14014,Other/Mixed,20912.0,24993907.0,Smolonska J,Other disease,replication,2014-07-03,GCST002519,Asthma or chronic obstructive pulmonary disease
8297,European,4634.0,24999842.0,Garner C,Immune system disorder,initial,2014-07-07,GCST002520,Celiac disease
10282,European,18901.0,25043464.0,Jun G,Neurological disorder,replication,2014-07-08,GCST002523,Alzheimer's disease
7047,European,2153.0,25003214.0,Davis OS,Biological process,replication,2014-07-08,GCST002522,Reading or mathematical ability
1209,African American or Afro-Caribbean,4896.0,25043464.0,Jun G,Neurological disorder,replication,2014-07-08,GCST002523,Alzheimer's disease
7500,European,2794.0,25003214.0,Davis OS,Biological process,initial,2014-07-08,GCST002522,Reading or mathematical ability
2846,Asian,1845.0,25043464.0,Jun G,Neurological disorder,replication,2014-07-08,GCST002523,Alzheimer's disease
7451,European,2698.0,25044411.0,Liao SY,Other measurement,initial,2014-07-08,GCST002521,Lung function (forced expiratory volume in 1 second)
1093,African American or Afro-Caribbean,3158.0,25006744.0,Castaldi PJ,Other measurement,initial,2014-07-09,GCST002525,Local histogram emphysema pattern
5495,European,606.0,25008200.0,Feng P,Digestive system disorder,initial,2014-07-09,GCST002524,Chronic periodontitis
92,African,343.0,25008200.0,Feng P,Digestive system disorder,replication,2014-07-09,GCST002524,Chronic periodontitis
6510,European,1476.0,25008200.0,Feng P,Digestive system disorder,replication,2014-07-09,GCST002524,Chronic periodontitis
13481,Other/Mixed,70.0,25008200.0,Feng P,Digestive system disorder,initial,2014-07-09,GCST002524,Chronic periodontitis
514,African American or Afro-Caribbean,190.0,25008200.0,Feng P,Digestive system disorder,initial,2014-07-09,GCST002524,Chronic periodontitis
8838,European,6456.0,25006744.0,Castaldi PJ,Other measurement,initial,2014-07-09,GCST002525,Local histogram emphysema pattern
9853,European,12597.0,25010111.0,Bolton JL,Other measurement,initial,2014-07-10,GCST002526,Cortisol levels (plasma)
7501,European,2795.0,25010111.0,Bolton JL,Other measurement,replication,2014-07-10,GCST002526,Cortisol levels (plasma)
9594,European,9953.0,25017104.0,Kottyan LC,Digestive system disorder,initial,2014-07-13,GCST002527,Eosinophilic esophagitis
13898,Other/Mixed,1962.0,25023989.0,Schmit SL,Cancer,replication,2014-07-14,GCST002528,Colorectal cancer
13820,Other/Mixed,983.0,25023989.0,Schmit SL,Cancer,initial,2014-07-14,GCST002528,Colorectal cancer
7587,European,2976.0,25023989.0,Schmit SL,Cancer,initial,2014-07-14,GCST002528,Colorectal cancer
8064,European,3966.0,25028398.0,Weiss FU,Other measurement,initial,2014-07-15,GCST002530,Serum lipase activity
6485,European,1444.0,25028398.0,Weiss FU,Other measurement,replication,2014-07-15,GCST002530,Serum lipase activity
5058,European,363.0,25027320.0,Ramirez A,"Neurological disorder, Other measurement",initial,2014-07-15,GCST002531,Cerebrospinal AB1-42 levels in Alzheimer's disease dementia
1308,African American or Afro-Caribbean,7787.0,25027321.0,Hoffmann TJ,Neurological disorder,initial,2014-07-15,GCST002529,Glaucoma
8065,European,3966.0,25028398.0,Weiss FU,Other measurement,initial,2014-07-15,GCST002532,High serum lipase activity
6486,European,1444.0,25028398.0,Weiss FU,Other measurement,replication,2014-07-15,GCST002532,High serum lipase activity
12931,Hispanic or Latin American,3174.0,25027321.0,Hoffmann TJ,Neurological disorder,initial,2014-07-15,GCST002529,Glaucoma
3689,Asian,6085.0,25035420.0,Hong KW,Cardiovascular measurement,initial,2014-07-17,GCST002533,QRS duration
3690,Asian,6085.0,25035420.0,Hong KW,Cardiovascular measurement,initial,2014-07-17,GCST002535,PR interval
4918,European,271.0,25030430.0,Zignego AL,"Digestive system disorder, Immune system disorder",replication,2014-07-17,GCST002534,Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection
3795,Asian,7295.0,25035420.0,Hong KW,Cardiovascular measurement,replication,2014-07-17,GCST002535,PR interval
3794,Asian,7295.0,25035420.0,Hong KW,Cardiovascular measurement,replication,2014-07-17,GCST002533,QRS duration
6041,European,983.0,25030430.0,Zignego AL,"Digestive system disorder, Immune system disorder",initial,2014-07-17,GCST002534,Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection
689,African American or Afro-Caribbean,618.0,25042611.0,Griffin PJ,"Neurological disorder, Hematological measurement",initial,2014-07-19,GCST002536,Hemoglobin A2 levels in sickle cell anemia
2018,Asian,398.0,25042611.0,Griffin PJ,"Neurological disorder, Hematological measurement",replication,2014-07-19,GCST002536,Hemoglobin A2 levels in sickle cell anemia
511,African American or Afro-Caribbean,173.0,25042611.0,Griffin PJ,"Neurological disorder, Hematological measurement",replication,2014-07-19,GCST002536,Hemoglobin A2 levels in sickle cell anemia
4403,Asian,37511.0,25038754.0,Cai Q,Cancer,replication,2014-07-20,GCST002537,Breast cancer
11208,European,57338.0,25038754.0,Cai Q,Cancer,replication,2014-07-20,GCST002537,Breast cancer
3996,Asian,9450.0,25038754.0,Cai Q,Cancer,initial,2014-07-20,GCST002537,Breast cancer
7009,European,2089.0,25044758.0,Stergiakouli E,Body measurement,replication,2014-07-21,GCST002538,Height adjusted BMI
11432,European,82315.0,25056061.0,Ripke S,Neurological disorder,initial,2014-07-22,GCST002539,Schizophrenia
3544,Asian,5219.0,25056061.0,Ripke S,Neurological disorder,initial,2014-07-22,GCST002539,Schizophrenia
11300,European,67749.0,25056061.0,Ripke S,Neurological disorder,replication,2014-07-22,GCST002539,Schizophrenia
6008,European,964.0,25057126.0,Ramos YF,Other measurement,replication,2014-07-23,GCST002540,Osteoarthritis biomarkers
11990,European,182413.0,25231870.0,Perry JR,Other measurement,initial,2014-07-23,GCST002541,Menarche (age at onset)
3750,Asian,6805.0,25055868.0,Sano M,Cardiovascular measurement,replication,2014-07-23,GCST002542,Electrocardiographic traits
3238,Asian,2994.0,25055868.0,Sano M,Cardiovascular measurement,initial,2014-07-23,GCST002542,Electrocardiographic traits
8302,European,4654.0,25057126.0,Ramos YF,Other measurement,initial,2014-07-23,GCST002540,Osteoarthritis biomarkers
8280,European,4591.0,25060954.0,Wolber LE,Biological process,initial,2014-07-24,GCST002543,Hearing function
13633,Other/Mixed,348.0,25060954.0,Wolber LE,Biological process,initial,2014-07-24,GCST002543,Hearing function
3775,Asian,7017.0,25064007.0,Nakajima M,Other disease,replication,2014-07-27,GCST002545,Ossification of the posterior longitudinal ligament of the spine
9701,European,10904.0,25064009.0,Nalls MA,Neurological disorder,replication,2014-07-27,GCST002544,Parkinson's disease
3872,Asian,7922.0,25064007.0,Nakajima M,Other disease,initial,2014-07-27,GCST002545,Ossification of the posterior longitudinal ligament of the spine
11621,European,108990.0,25064009.0,Nalls MA,Neurological disorder,initial,2014-07-27,GCST002544,Parkinson's disease
1114,African American or Afro-Caribbean,3273.0,25087078.0,Anney RJ,Neurological disorder,initial,2014-07-30,GCST002547,Epilepsy
9518,European,9634.0,25080503.0,Kwan JS,Cardiovascular measurement,initial,2014-07-30,GCST002546,Osteoprotegerin levels
2244,Asian,702.0,25080503.0,Kwan JS,Cardiovascular measurement,initial,2014-07-30,GCST002546,Osteoprotegerin levels
10501,European,23453.0,25087078.0,Anney RJ,Neurological disorder,initial,2014-07-30,GCST002547,Epilepsy
13843,Other/Mixed,1264.0,25087078.0,Anney RJ,Neurological disorder,initial,2014-07-30,GCST002547,Epilepsy
3285,Asian,3362.0,25087078.0,Anney RJ,Neurological disorder,initial,2014-07-30,GCST002547,Epilepsy
10652,European,28694.0,25082827.0,Julia A,Immune system disorder,initial,2014-07-31,GCST002548,Ulcerative colitis
7217,European,2352.0,25082827.0,Julia A,Immune system disorder,replication,2014-07-31,GCST002548,Ulcerative colitis
5162,European,430.0,24528284.0,Ji Y,"Response to drug, Neurological disorder",initial,2014-08-01,GCST002549,Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)
8875,European,6631.0,24869959.0,Jacobs LC,Other measurement,initial,2014-08-01,GCST006522,Upper eyelid sagging severity
12880,Hispanic or Latin American,2326.0,25085501.0,Bunyavanich S,Immune system disorder,initial,2014-08-02,GCST002550,Allergic rhinitis
13688,Other/Mixed,561.0,25085501.0,Bunyavanich S,"Other disease, Immune system disorder",initial,2014-08-02,GCST002552,Allergic rhinitis in asthma
12844,Hispanic or Latin American,1574.0,25085501.0,Bunyavanich S,"Other disease, Immune system disorder",initial,2014-08-02,GCST002552,Allergic rhinitis in asthma
6951,European,2034.0,25085501.0,Bunyavanich S,Immune system disorder,initial,2014-08-02,GCST002550,Allergic rhinitis
6200,European,1111.0,25085501.0,Bunyavanich S,"Other disease, Immune system disorder",initial,2014-08-02,GCST002552,Allergic rhinitis in asthma
713,African American or Afro-Caribbean,712.0,25085501.0,Bunyavanich S,Immune system disorder,initial,2014-08-02,GCST002551,Allergic rhinitis in non-asthmatics
851,African American or Afro-Caribbean,1273.0,25085501.0,Bunyavanich S,Immune system disorder,initial,2014-08-02,GCST002550,Allergic rhinitis
5930,European,923.0,25085501.0,Bunyavanich S,Immune system disorder,initial,2014-08-02,GCST002551,Allergic rhinitis in non-asthmatics
12727,Hispanic or Latin American,752.0,25085501.0,Bunyavanich S,Immune system disorder,initial,2014-08-02,GCST002551,Allergic rhinitis in non-asthmatics
8919,European,6785.0,25086665.0,Wolpin BM,Cancer,initial,2014-08-03,GCST002553,Pancreatic cancer
10049,European,15295.0,25086665.0,Wolpin BM,Cancer,replication,2014-08-03,GCST002553,Pancreatic cancer
5611,European,690.0,25140149.0,Hohman TJ,Other measurement,initial,2014-08-04,GCST002554,Left inferior lateral ventricle volume (Cerebrospinal fluid biomarker status interaction)
4008,Asian,9810.0,25096241.0,Keller MF,Hematological measurement,initial,2014-08-05,GCST002555,Monocyte count
1434,African American or Afro-Caribbean,16388.0,25096241.0,Keller MF,"Hematological measurement, Inflammatory measurement",initial,2014-08-05,GCST002556,White blood cell count
4007,Asian,9802.0,25096241.0,Keller MF,Hematological measurement,initial,2014-08-05,GCST002557,Neutrophil count
1289,African American or Afro-Caribbean,7391.0,25096241.0,Keller MF,Hematological measurement,initial,2014-08-05,GCST002557,Neutrophil count
1288,African American or Afro-Caribbean,7369.0,25096241.0,Keller MF,Hematological measurement,initial,2014-08-05,GCST002555,Monocyte count
10135,European,16550.0,25096241.0,Keller MF,Hematological measurement,initial,2014-08-05,GCST002557,Neutrophil count
10134,European,16550.0,25096241.0,Keller MF,Hematological measurement,initial,2014-08-05,GCST002555,Monocyte count
10319,European,19509.0,25096241.0,Keller MF,"Hematological measurement, Inflammatory measurement",initial,2014-08-05,GCST002556,White blood cell count
4244,Asian,16843.0,25096241.0,Keller MF,"Hematological measurement, Inflammatory measurement",initial,2014-08-05,GCST002556,White blood cell count
74,African,258.0,25147783.0,Keene KL,"Other measurement, Cardiovascular disease",initial,2014-08-06,GCST002559,Vitamin B levels in ischemic stroke
2002,Asian,380.0,25096692.0,Chung WH,"Response to drug, Other disease",replication,2014-08-06,GCST002558,Phenytoin-induced severe cutaneous adverse reactions
6727,European,1725.0,25147783.0,Keene KL,"Other measurement, Cardiovascular disease",initial,2014-08-06,GCST002559,Vitamin B levels in ischemic stroke
3252,Asian,3038.0,25096692.0,Chung WH,"Response to drug, Other disease",replication,2014-08-06,GCST002558,Phenytoin-induced severe cutaneous adverse reactions
13509,Other/Mixed,117.0,25147783.0,Keene KL,"Other measurement, Cardiovascular disease",initial,2014-08-06,GCST002559,Vitamin B levels in ischemic stroke
2089,Asian,472.0,25096692.0,Chung WH,"Response to drug, Other disease",initial,2014-08-06,GCST002558,Phenytoin-induced severe cutaneous adverse reactions
1487,African American or Afro-Caribbean,23827.0,25102180.0,Ng MC,Metabolic disorder,initial,2014-08-07,GCST002560,Type 2 diabetes
11068,European,47117.0,25102180.0,Ng MC,Metabolic disorder,replication,2014-08-07,GCST002560,Type 2 diabetes
1395,African American or Afro-Caribbean,11544.0,25102180.0,Ng MC,Metabolic disorder,replication,2014-08-07,GCST002560,Type 2 diabetes
3729,Asian,6424.0,25105248.0,Wang H,Cancer,initial,2014-08-08,GCST002561,Colorectal cancer
10846,European,35034.0,25105248.0,Wang H,Cancer,replication,2014-08-08,GCST002561,Colorectal cancer
1268,African American or Afro-Caribbean,6596.0,25105248.0,Wang H,Cancer,initial,2014-08-08,GCST002561,Colorectal cancer
3430,Asian,4358.0,25108386.0,Hou S,Neurological disorder,replication,2014-08-10,GCST002562,Vogt-Koyanagi-Harada syndrome
1971,Asian,358.0,25108385.0,Yang SK,"Digestive system disorder, Other trait, Response to drug",replication,2014-08-10,GCST007229,Thiopurine-induced early leukopenia in Crohn's disease
8843,European,6492.0,25108383.0,Geller F,Other disease,initial,2014-08-10,GCST002563,Hypospadias
8004,European,3784.0,25108383.0,Geller F,Other disease,replication,2014-08-10,GCST002563,Hypospadias
1957,Asian,340.0,25108385.0,Yang SK,"Digestive system disorder, Other trait, Response to drug",initial,2014-08-10,GCST007229,Thiopurine-induced early leukopenia in Crohn's disease
3173,Asian,2783.0,25108386.0,Hou S,Neurological disorder,initial,2014-08-10,GCST002562,Vogt-Koyanagi-Harada syndrome
6869,European,1930.0,25111785.0,Jamain S,Neurological disorder,initial,2014-08-11,GCST002564,Bipolar disorder (early onset)
8937,European,6834.0,25109461.0,Ollila HM,Other measurement,replication,2014-08-11,GCST002565,Sleep duration
6876,European,1941.0,25109461.0,Ollila HM,Other measurement,initial,2014-08-11,GCST002565,Sleep duration
6243,European,1157.0,25111785.0,Jamain S,Neurological disorder,replication,2014-08-11,GCST002564,Bipolar disorder (early onset)
5538,European,642.0,25117820.0,Schneider BP,"Cancer, Cardiovascular disease, Response to drug",initial,2014-08-12,GCST002566,Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)
5539,European,642.0,25117820.0,Schneider BP,"Cancer, Cardiovascular disease, Response to drug",initial,2014-08-12,GCST002567,Response to chemotherapy in breast cancer (hypertension) (bevacizumab)
131,African,637.0,25014791.0,Govind N,Immune system disorder,initial,2014-08-14,GCST005562,Rheumatoid arthritis
4067,Asian,11124.0,25129146.0,Wu C,Cancer,initial,2014-08-17,GCST002568,Esophageal squamous cell carcinoma
4287,Asian,19712.0,25129146.0,Wu C,Cancer,replication,2014-08-17,GCST002568,Esophageal squamous cell carcinoma
5642,European,716.0,25138779.0,Mitchell LE,"Cardiovascular disease, Other measurement",initial,2014-08-18,GCST002574,Congenital left-sided heart lesions (maternal effect)
13568,Other/Mixed,207.0,25138779.0,Mitchell LE,"Cardiovascular disease, Other measurement",initial,2014-08-18,GCST002574,Congenital left-sided heart lesions (maternal effect)
13567,Other/Mixed,207.0,25138779.0,Mitchell LE,Cardiovascular disease,initial,2014-08-18,GCST002572,Congenital left-sided heart lesions
13436,Other/Mixed,24.0,25138779.0,Mitchell LE,"Cardiovascular disease, Other measurement",replication,2014-08-18,GCST002574,Congenital left-sided heart lesions (maternal effect)
3562,Asian,5344.0,25133637.0,Scannell Bryan M,"Other measurement, Body measurement",initial,2014-08-18,GCST002573,Height
13435,Other/Mixed,24.0,25138779.0,Mitchell LE,Cardiovascular disease,replication,2014-08-18,GCST002572,Congenital left-sided heart lesions
3273,Asian,3244.0,25133637.0,Scannell Bryan M,Body measurement,initial,2014-08-18,GCST002570,Overweight status
5641,European,716.0,25138779.0,Mitchell LE,Cardiovascular disease,initial,2014-08-18,GCST002572,Congenital left-sided heart lesions
3444,Asian,4474.0,25133637.0,Scannell Bryan M,Body measurement,initial,2014-08-18,GCST002569,Underweight status
3564,Asian,5354.0,25133637.0,Scannell Bryan M,"Body measurement, Other measurement",initial,2014-08-18,GCST002571,Body mass index
3515,Asian,4983.0,25133637.0,Scannell Bryan M,Body measurement,initial,2014-08-18,GCST002575,Body mass index (change over time)
5548,European,648.0,25138779.0,Mitchell LE,"Cardiovascular disease, Other measurement",replication,2014-08-18,GCST002574,Congenital left-sided heart lesions (maternal effect)
5547,European,648.0,25138779.0,Mitchell LE,Cardiovascular disease,replication,2014-08-18,GCST002572,Congenital left-sided heart lesions
3421,Asian,4255.0,25134534.0,Chen K,Cancer,replication,2014-08-19,GCST002576,Epithelial ovarian cancer
3018,Asian,2216.0,25134534.0,Chen K,Cancer,initial,2014-08-19,GCST002576,Epithelial ovarian cancer
1969,Asian,354.0,25145502.0,Tang S,"Other measurement, Cancer",initial,2014-08-22,GCST002577,Non-small cell lung cancer (survival)
1946,Asian,327.0,25145502.0,Tang S,"Other measurement, Cancer",replication,2014-08-22,GCST002577,Non-small cell lung cancer (survival)
2646,Asian,1496.0,25162662.0,Liao M,Other measurement,replication,2014-08-27,GCST002578,Ferritin levels
2924,Asian,1999.0,25162662.0,Liao M,Other measurement,initial,2014-08-27,GCST002578,Ferritin levels
6775,European,1778.0,25130324.0,Cai DC,Other measurement,initial,2014-08-29,GCST002579,Heschl's gyrus morphology
9876,European,13044.0,25173105.0,Gharahkhani P,Neurological disorder,replication,2014-08-31,GCST002582,Glaucoma (primary open-angle)
7664,European,3147.0,25173105.0,Gharahkhani P,Neurological disorder,initial,2014-08-31,GCST002582,Glaucoma (primary open-angle)
2908,Asian,1971.0,25173107.0,Chen Y,Neurological disorder,initial,2014-08-31,GCST002581,Glaucoma (high intraocular pressure)
10627,European,27558.0,25173106.0,Hysi PG,Other measurement,initial,2014-08-31,GCST002580,Intraocular pressure
3288,Asian,3377.0,25173107.0,Chen Y,Neurological disorder,replication,2014-08-31,GCST002581,Glaucoma (high intraocular pressure)
3857,Asian,7738.0,25173106.0,Hysi PG,Other measurement,initial,2014-08-31,GCST002580,Intraocular pressure
4850,European,216.0,25410890.0,Frau F,"Other measurement, Response to drug",replication,2014-09-01,GCST002583,Response to angiotensin II receptor blocker treatment (losartan) (change in systolic blood pressure levels)
557,African American or Afro-Caribbean,247.0,25072098.0,Bloom AJ,"Biological process, Other measurement",initial,2014-09-01,GCST002584,Exhaled carbon monoxide levels
5069,European,372.0,25410890.0,Frau F,"Other measurement, Response to drug",initial,2014-09-01,GCST002583,Response to angiotensin II receptor blocker treatment (losartan) (change in systolic blood pressure levels)
6534,European,1521.0,25072098.0,Bloom AJ,"Biological process, Other measurement",initial,2014-09-01,GCST002584,Exhaled carbon monoxide levels
4299,Asian,21345.0,25187374.0,Hwang JY,Other measurement,replication,2014-09-03,GCST002586,Fasting plasma glucose
4321,Asian,24740.0,25187374.0,Hwang JY,Other measurement,initial,2014-09-03,GCST002586,Fasting plasma glucose
3378,Asian,3963.0,25186300.0,Terao C,Other measurement,replication,2014-09-03,GCST002585,Antinuclear antibody levels
3269,Asian,3185.0,25186300.0,Terao C,Other measurement,initial,2014-09-03,GCST002585,Antinuclear antibody levels
6409,European,1357.0,25187353.0,Goldstein JI,"Response to drug, Other trait",initial,2014-09-04,GCST002595,Clozapine-induced agranulocytosis
10258,European,18509.0,25192705.0,Du M,"Other measurement, Cancer",initial,2014-09-05,GCST002596,Colorectal cancer (calcium intake interaction)
6778,European,1784.0,25442119.0,McLaughlin RL,Neurological disorder,initial,2014-09-06,GCST007144,Amyotrophic lateral sclerosis
6779,European,1784.0,25442119.0,McLaughlin RL,"Neurological disorder, Other measurement",initial,2014-09-06,GCST007145,Amyotrophic lateral sclerosis (age of onset)
6296,European,1204.0,25442119.0,McLaughlin RL,Neurological disorder,initial,2014-09-06,GCST007146,Amyotrophic lateral sclerosis
3538,Asian,5202.0,25194280.0,Wei Q,Cancer,replication,2014-09-07,GCST002597,Laryngeal squamous cell carcinoma
3236,Asian,2988.0,25194280.0,Wei Q,Cancer,initial,2014-09-07,GCST002597,Laryngeal squamous cell carcinoma
9708,European,11001.0,25200001.0,Robinson PC,Neurological disorder,initial,2014-09-08,GCST007362,Acute anterior uveitis (with or without ankylosing spondylitis)
11599,European,106736.0,25201988.0,Rietveld CA,Other measurement,initial,2014-09-08,GCST002598,Educational attainment
7568,European,2930.0,25200001.0,Robinson PC,"Immune system disorder, Neurological disorder",initial,2014-09-08,GCST007361,Acute anterior uveitis in ankylosing spondylitis
9546,European,9793.0,25199915.0,Broer L,Other measurement,initial,2014-09-08,GCST002599,Longevity (90 years and older)
602,African American or Afro-Caribbean,342.0,25201287.0,Del-Aguila JL,"Response to drug, Other trait",initial,2014-09-09,GCST002600,Response to thiazide diuretic treatment (hypokalemia)
5155,European,425.0,25201287.0,Del-Aguila JL,"Response to drug, Other trait",initial,2014-09-09,GCST002600,Response to thiazide diuretic treatment (hypokalemia)
7741,European,3244.0,25208887.0,Ma Q,Other measurement,initial,2014-09-10,GCST002601,Plasma plasminogen levels
7851,European,3412.0,25214527.0,Dube MP,"Cardiovascular measurement, Response to drug",initial,2014-09-11,GCST002603,Creatine kinase in statin users
7831,European,3389.0,25214527.0,Dube MP,"Cardiovascular measurement, Response to drug",replication,2014-09-11,GCST002603,Creatine kinase in statin users
6717,European,1718.0,25208829.0,Anderson D,Other measurement,initial,2014-09-11,GCST002602,Vitamin D levels
6629,European,1611.0,25224099.0,Gueant JL,Other measurement,initial,2014-09-12,GCST007161,beta-lactam allergy measurement
5570,European,661.0,25224099.0,Gueant JL,Other measurement,replication,2014-09-12,GCST007161,beta-lactam allergy measurement
4811,European,195.0,25223841.0,Li J,Neurological disorder,replication,2014-09-13,GCST002604,Schizophrenia (treatment resistant)
4760,European,174.0,25223841.0,Li J,Neurological disorder,initial,2014-09-13,GCST002604,Schizophrenia (treatment resistant)
7119,European,2207.0,25217962.0,Heap GA,"Digestive system disorder, Response to drug",initial,2014-09-14,GCST002607,Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine)
4619,European,78.0,25217962.0,Heap GA,"Digestive system disorder, Response to drug",replication,2014-09-14,GCST002607,Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine)
3771,Asian,6954.0,25217961.0,Al Olama AA,Cancer,initial,2014-09-14,GCST002606,Prostate cancer
6019,European,972.0,25218607.0,Coleman EA,"Digestive system disorder, Response to drug, Cancer",initial,2014-09-14,GCST002605,Response to chemotherapy in multiple myeloma (oral mucositis) (high-dose melphalan)
314,African,10463.0,25217961.0,Al Olama AA,Cancer,initial,2014-09-14,GCST002606,Prostate cancer
12869,Hispanic or Latin American,2080.0,25217961.0,Al Olama AA,Cancer,initial,2014-09-14,GCST002606,Prostate cancer
11298,European,67543.0,25217961.0,Al Olama AA,Cancer,initial,2014-09-14,GCST002606,Prostate cancer
991,African American or Afro-Caribbean,2347.0,25224454.0,Li J,Other measurement,initial,2014-09-15,GCST002609,Iron status biomarkers
5341,European,510.0,25221879.0,Wu K,"Other measurement, Other disease",initial,2014-09-15,GCST002608,Pulmonary function in asthmatics
590,African American or Afro-Caribbean,329.0,25224454.0,Li J,Other measurement,replication,2014-09-15,GCST002609,Iron status biomarkers
8864,European,6558.0,25226531.0,St Pourcain B,Biological process,replication,2014-09-16,GCST002611,Expressive vocabulary in infants
2315,Asian,776.0,25223902.0,Go MJ,Other measurement,replication,2014-09-16,GCST002610,Fasting plasma glucose (childhood)
9881,European,13150.0,25226531.0,St Pourcain B,Biological process,initial,2014-09-16,GCST002611,Expressive vocabulary in infants
2108,Asian,484.0,25223902.0,Go MJ,Other measurement,initial,2014-09-16,GCST002610,Fasting plasma glucose (childhood)
6401,European,1348.0,25234806.0,Dijkstra AE,Other trait,initial,2014-09-18,GCST002613,Chronic mucus hypersecretion
10066,European,15619.0,25233373.0,Simpson CL,Other trait,initial,2014-09-18,GCST002615,Myopia
5841,European,849.0,25234806.0,Dijkstra AE,"Other disease, Other trait",initial,2014-09-18,GCST002612,Chronic mucus hypersecretion in chronic obstructive pulmonary disease
9949,European,13912.0,25233373.0,Simpson CL,"Other trait, Neurological disorder",initial,2014-09-18,GCST002617,Hyperopia
7274,European,2443.0,25234806.0,Dijkstra AE,Other trait,replication,2014-09-18,GCST002613,Chronic mucus hypersecretion
8277,European,4581.0,25233373.0,Simpson CL,Other trait,replication,2014-09-18,GCST002615,Myopia
7645,European,3106.0,25234806.0,Dijkstra AE,"Other disease, Other trait",replication,2014-09-18,GCST002612,Chronic mucus hypersecretion in chronic obstructive pulmonary disease
5085,European,386.0,25240745.0,Lopez S,Other measurement,initial,2014-09-18,GCST002616,Mitochondrial DNA levels
6953,European,2036.0,25237182.0,Erickson SW,Cancer,initial,2014-09-18,GCST002614,Multiple myeloma
7689,European,3208.0,25233373.0,Simpson CL,"Other trait, Neurological disorder",replication,2014-09-18,GCST002617,Hyperopia
9002,European,7109.0,25352737.0,Ritchie MD,Other trait,initial,2014-09-19,GCST002619,Age-related cataracts
13548,Other/Mixed,174.0,25352737.0,Ritchie MD,Other trait,initial,2014-09-19,GCST002619,Age-related cataracts
13982,Other/Mixed,5503.0,25352737.0,Ritchie MD,"Other measurement, Other trait",initial,2014-09-19,GCST002618,Age-related cataracts (age at onset)
44,African,114.0,25352737.0,Ritchie MD,Other trait,initial,2014-09-19,GCST002619,Age-related cataracts
932,African American or Afro-Caribbean,1931.0,25241909.0,Lee JH,Other disease,initial,2014-09-21,GCST002625,Chronic bronchitis and chronic obstructive pulmonary disease
7985,European,3742.0,25245031.0,Luneburg N,"Cardiovascular measurement, Other measurement",initial,2014-09-21,GCST002620,Asymmetrical dimethylarginine levels
9032,European,7297.0,25241909.0,Lee JH,Other disease,initial,2014-09-21,GCST002624,Chronic obstructive pulmonary disease
6244,European,1159.0,25245031.0,Luneburg N,Other measurement,replication,2014-09-21,GCST002623,L-arginine levels
6238,European,1152.0,25245031.0,Luneburg N,"Cardiovascular measurement, Other measurement",replication,2014-09-21,GCST002622,Symmetrical dimethylarginine levels
8604,European,5439.0,25241909.0,Lee JH,Other disease,initial,2014-09-21,GCST002625,Chronic bronchitis and chronic obstructive pulmonary disease
6237,European,1151.0,25245031.0,Luneburg N,"Cardiovascular measurement, Other measurement",replication,2014-09-21,GCST002620,Asymmetrical dimethylarginine levels
8603,European,5439.0,25241909.0,Lee JH,Other disease,initial,2014-09-21,GCST002621,Chronic bronchitis in chronic obstructive pulmonary disease
7987,European,3747.0,25245031.0,Luneburg N,Other measurement,initial,2014-09-21,GCST002623,L-arginine levels
7986,European,3745.0,25245031.0,Luneburg N,"Cardiovascular measurement, Other measurement",initial,2014-09-21,GCST002622,Symmetrical dimethylarginine levels
2936,Asian,2026.0,25241763.0,Springelkamp H,Other measurement,replication,2014-09-22,GCST002626,Vertical cup-disc ratio
3096,Asian,2453.0,25241763.0,Springelkamp H,Other measurement,replication,2014-09-22,GCST002626,Vertical cup-disc ratio
10394,European,21094.0,25241763.0,Springelkamp H,Other measurement,initial,2014-09-22,GCST002626,Vertical cup-disc ratio
3052,Asian,2305.0,25241763.0,Springelkamp H,Other measurement,replication,2014-09-22,GCST002626,Vertical cup-disc ratio
4461,Asian,69146.0,25249183.0,Lu X,Other measurement,replication,2014-09-23,GCST002630,Systolic blood pressure
4462,Asian,69146.0,25249183.0,Lu X,Other measurement,replication,2014-09-23,GCST002631,Diastolic blood pressure
3997,Asian,9469.0,25249183.0,Lu X,Cardiovascular disease,initial,2014-09-23,GCST002627,Hypertension
8616,European,5466.0,25248455.0,Ek WE,Digestive system disorder,initial,2014-09-23,GCST002629,Irritable bowel syndrome
4106,Asian,11816.0,25249183.0,Lu X,Other measurement,initial,2014-09-23,GCST002631,Diastolic blood pressure
4460,Asian,69146.0,25249183.0,Lu X,Cardiovascular disease,replication,2014-09-23,GCST002627,Hypertension
6836,European,1868.0,25246029.0,DiStefano JK,"Metabolic disorder, Other measurement",initial,2014-09-23,GCST002628,Bilirubin levels in extreme obesity
6835,European,1868.0,25246029.0,DiStefano JK,"Lipid or lipoprotein measurement, Metabolic disorder",initial,2014-09-23,GCST002632,Hepatic lipid content in extreme obesity
7896,European,3511.0,25248455.0,Ek WE,Digestive system disorder,replication,2014-09-23,GCST002629,Irritable bowel syndrome
4105,Asian,11816.0,25249183.0,Lu X,Other measurement,initial,2014-09-23,GCST002630,Systolic blood pressure
5869,European,871.0,25256105.0,Freitag-Wolf S,"Digestive system disorder, Other measurement",replication,2014-09-25,GCST002635,Aggressive periodontitis (sex interaction)
2448,Asian,1026.0,25303641.0,Zhang F,Other disease,replication,2014-09-25,GCST002634,Kashin-Beck disease
8522,European,5165.0,25256182.0,Foroud T,Cardiovascular disease,initial,2014-09-25,GCST002633,Intracranial aneurysm
8938,European,6837.0,25256182.0,Foroud T,Cardiovascular disease,replication,2014-09-25,GCST002633,Intracranial aneurysm
2754,Asian,1717.0,25303641.0,Zhang F,Other disease,initial,2014-09-25,GCST002634,Kashin-Beck disease
6379,European,1312.0,25256105.0,Freitag-Wolf S,"Digestive system disorder, Other measurement",initial,2014-09-25,GCST002635,Aggressive periodontitis (sex interaction)
8723,European,5916.0,25261932.0,Cerhan JR,Cancer,replication,2014-09-28,GCST002636,Diffuse large B cell lymphoma
9761,European,11523.0,25261932.0,Cerhan JR,Cancer,initial,2014-09-28,GCST002636,Diffuse large B cell lymphoma
1770,Asian,178.0,25266886.0,Kim JJ,"Immune system disorder, Other measurement, Inflammatory measurement",initial,2014-09-30,GCST002640,Inflammatory biomarkers in Kawasaki disease
3925,Asian,8738.0,25317112.0,Oh S,Digestive system disorder,initial,2014-09-30,GCST002638,Gastritis
8394,European,4899.0,25534755.0,Chaste P,"Neurological disorder, Other measurement",initial,2014-09-30,GCST002639,Autism spectrum disorder-related traits
2572,Asian,1302.0,25317111.0,Seo I,"Biological process, Cardiovascular disease, Metabolic disorder",initial,2014-09-30,GCST002637,Medication adherence in chronic diseases
2090,Asian,473.0,25266886.0,Kim JJ,"Immune system disorder, Other measurement, Inflammatory measurement",replication,2014-09-30,GCST002640,Inflammatory biomarkers in Kawasaki disease
2149,Asian,548.0,25271088.0,Singh A,"Other measurement, Body measurement",initial,2014-10-01,GCST002641,Hip circumference (psychosocial stress interaction)
12806,Hispanic or Latin American,1250.0,25271088.0,Singh A,"Other measurement, Body measurement",initial,2014-10-01,GCST002641,Hip circumference (psychosocial stress interaction)
5430,European,562.0,25089948.0,Theusch E,"Other measurement, Response to drug",initial,2014-10-01,GCST002642,Response to simvastatin treatment (PCSK9 protein level change)
892,African American or Afro-Caribbean,1547.0,25271088.0,Singh A,"Other measurement, Body measurement",initial,2014-10-01,GCST002641,Hip circumference (psychosocial stress interaction)
7668,European,3157.0,25271088.0,Singh A,"Other measurement, Body measurement",replication,2014-10-01,GCST002641,Hip circumference (psychosocial stress interaction)
573,African American or Afro-Caribbean,287.0,25089948.0,Theusch E,"Other measurement, Response to drug",replication,2014-10-01,GCST002642,Response to simvastatin treatment (PCSK9 protein level change)
7286,European,2460.0,25271088.0,Singh A,"Other measurement, Body measurement",initial,2014-10-01,GCST002641,Hip circumference (psychosocial stress interaction)
9054,European,7381.0,25279986.0,Skibola CF,Cancer,replication,2014-10-02,GCST002643,Follicular lymphoma
9639,European,10486.0,25279986.0,Skibola CF,Cancer,initial,2014-10-02,GCST002643,Follicular lymphoma
2199,Asian,651.0,25281659.0,van der Valk RJ,Body measurement,replication,2014-10-03,GCST002644,Birth length
10643,European,28439.0,25281659.0,van der Valk RJ,Body measurement,initial,2014-10-03,GCST002644,Birth length
10095,European,16145.0,25281659.0,van der Valk RJ,Body measurement,replication,2014-10-03,GCST002644,Birth length
13598,Other/Mixed,280.0,25281659.0,van der Valk RJ,Body measurement,replication,2014-10-03,GCST002644,Birth length
13704,Other/Mixed,603.0,25281659.0,van der Valk RJ,Body measurement,replication,2014-10-03,GCST002644,Birth length
3822,Asian,7556.0,25281661.0,Matsuda K,Cancer,replication,2014-10-03,GCST002645,Bladder cancer
9359,European,8609.0,25281661.0,Matsuda K,Cancer,replication,2014-10-03,GCST002645,Bladder cancer
10639,European,28238.0,25281659.0,van der Valk RJ,Body measurement,initial,2014-10-03,GCST002646,Infant length
3692,Asian,6112.0,25281661.0,Matsuda K,Cancer,initial,2014-10-03,GCST002645,Bladder cancer
11409,European,80067.0,25282103.0,Wood AR,"Other measurement, Body measurement",replication,2014-10-05,GCST002647,Height
12119,European,253288.0,25282103.0,Wood AR,"Other measurement, Body measurement",initial,2014-10-05,GCST002647,Height
6280,European,1191.0,25284319.0,Sanchez-Mora C,Neurological disorder,initial,2014-10-06,GCST002648,Persistent attention-deficit hyperactivity disorder
8086,European,4005.0,25284319.0,Sanchez-Mora C,Neurological disorder,replication,2014-10-06,GCST002648,Persistent attention-deficit hyperactivity disorder
9909,European,13469.0,25288136.0,Cornelis MC,"Biological process, Other measurement",replication,2014-10-07,GCST002651,Coffee consumption
1162,African American or Afro-Caribbean,3845.0,25288136.0,Cornelis MC,"Biological process, Other measurement",replication,2014-10-07,GCST002651,Coffee consumption
1318,African American or Afro-Caribbean,7964.0,25288136.0,Cornelis MC,"Biological process, Other measurement",replication,2014-10-07,GCST002650,Coffee consumption (cups per day)
609,African American or Afro-Caribbean,364.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002649,Nicotine glucouronidation
10690,European,30062.0,25288136.0,Cornelis MC,"Biological process, Other measurement",replication,2014-10-07,GCST002650,Coffee consumption (cups per day)
610,African American or Afro-Caribbean,364.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002652,Cotinine glucuronidation
11544,European,91462.0,25288136.0,Cornelis MC,"Biological process, Other measurement",initial,2014-10-07,GCST002650,Coffee consumption (cups per day)
13605,Other/Mixed,311.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002649,Nicotine glucouronidation
5192,European,437.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002649,Nicotine glucouronidation
2221,Asian,674.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002652,Cotinine glucuronidation
13606,Other/Mixed,311.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002652,Cotinine glucuronidation
2220,Asian,674.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002649,Nicotine glucouronidation
11085,European,48528.0,25288136.0,Cornelis MC,"Biological process, Other measurement",initial,2014-10-07,GCST002651,Coffee consumption
12646,Hispanic or Latin American,453.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002652,Cotinine glucuronidation
12645,Hispanic or Latin American,453.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002649,Nicotine glucouronidation
5193,European,437.0,25293881.0,Patel YM,Other measurement,initial,2014-10-07,GCST002652,Cotinine glucuronidation
7033,European,2138.0,25411281.0,Dashti HS,Other measurement,initial,2014-10-08,GCST002653,Circulating phylloquinone levels
258,African,3485.0,25297839.0,Crosslin DR,"Other disease, Other measurement",initial,2014-10-09,GCST002654,Shingles
12695,Hispanic or Latin American,621.0,25297839.0,Crosslin DR,"Other disease, Other measurement",initial,2014-10-09,GCST002654,Shingles
10255,European,18423.0,25297839.0,Crosslin DR,"Other disease, Other measurement",initial,2014-10-09,GCST002654,Shingles
8284,European,4603.0,25305756.0,Kiryluk K,Other disease,initial,2014-10-12,GCST002655,IgA nephropathy
9521,European,9642.0,25305756.0,Kiryluk K,Other disease,replication,2014-10-12,GCST002655,IgA nephropathy
6439,European,1374.0,25451450.0,Jacobsen KK,"Cardiovascular disease, Neurological disorder",initial,2014-10-12,GCST002656,Migraine in bipolar disorder
3423,Asian,4271.0,25305756.0,Kiryluk K,Other disease,replication,2014-10-12,GCST002655,IgA nephropathy
6050,European,986.0,25451450.0,Jacobsen KK,"Cardiovascular disease, Neurological disorder",replication,2014-10-12,GCST002656,Migraine in bipolar disorder
2960,Asian,2096.0,25305756.0,Kiryluk K,Other disease,initial,2014-10-12,GCST002655,IgA nephropathy
2153,Asian,555.0,25310821.0,Kim JH,Digestive system disorder,initial,2014-10-13,GCST002658,Hirschsprung disease
6576,European,1550.0,25310577.0,Evans TJ,Cancer,initial,2014-10-13,GCST002657,Acute lymphoblastic leukemia (childhood)
6918,European,1983.0,25310577.0,Evans TJ,Cancer,replication,2014-10-13,GCST002657,Acute lymphoblastic leukemia (childhood)
2218,Asian,667.0,25328121.0,Lee JY,"Cardiovascular measurement, Cardiovascular disease",initial,2014-10-17,GCST002659,Coronary artery disease-related phenotypes
2363,Asian,853.0,25328121.0,Lee JY,"Cardiovascular measurement, Cardiovascular disease",replication,2014-10-17,GCST002659,Coronary artery disease-related phenotypes
5254,European,474.0,25457201.0,de Tayrac M,"Metabolic disorder, Other measurement",initial,2014-10-18,GCST002660,Hereditary hemochromatosis-related traits (HFE mutation homozygotes)
5696,European,746.0,25457201.0,de Tayrac M,"Metabolic disorder, Other measurement",replication,2014-10-18,GCST002660,Hereditary hemochromatosis-related traits (HFE mutation homozygotes)
7599,European,2996.0,25329471.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2014-10-20,GCST002661,HDL cholesterol (SNP x SNP interaction)
13090,Hispanic or Latin American,6614.0,25327703.0,Fejerman L,Cancer,replication,2014-10-20,GCST002662,Breast cancer
13021,Hispanic or Latin American,4710.0,25327703.0,Fejerman L,Cancer,initial,2014-10-20,GCST002662,Breast cancer
10029,European,15031.0,25329471.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2014-10-20,GCST002661,HDL cholesterol (SNP x SNP interaction)
13490,Other/Mixed,80.0,25729143.0,Ahmetov I,Other measurement,initial,2014-10-21,GCST002664,Maximal oxygen uptake response
2139,Asian,536.0,25335168.0,Hashimoto R,Other measurement,initial,2014-10-21,GCST002663,Superior frontal gyrus grey matter volume
647,African American or Afro-Caribbean,450.0,25338677.0,Kariuki SN,"Other measurement, Immune system disorder",replication,2014-10-23,GCST002666,Interferon alpha levels in systemic lupus erythematosus
5132,European,410.0,25338677.0,Kariuki SN,"Other measurement, Immune system disorder",initial,2014-10-23,GCST002666,Interferon alpha levels in systemic lupus erythematosus
5640,European,715.0,25338677.0,Kariuki SN,"Other measurement, Immune system disorder",replication,2014-10-23,GCST002666,Interferon alpha levels in systemic lupus erythematosus
9160,European,7916.0,25342443.0,Lindstrom S,"Other measurement, Cancer",initial,2014-10-24,GCST002669,Percent mammographic density
9519,European,9639.0,25343990.0,Cornelis MC,Other measurement,initial,2014-10-24,GCST002670,Blood and toenail selenium levels
5027,European,343.0,25342443.0,Lindstrom S,Other measurement,replication,2014-10-24,GCST002667,Mammographic density (dense area)
13872,Other/Mixed,1472.0,25342443.0,Lindstrom S,"Other measurement, Cancer",replication,2014-10-24,GCST002669,Percent mammographic density
13871,Other/Mixed,1472.0,25342443.0,Lindstrom S,Other measurement,replication,2014-10-24,GCST002668,Mammographic density (non-dense area)
13870,Other/Mixed,1472.0,25342443.0,Lindstrom S,Other measurement,replication,2014-10-24,GCST002667,Mammographic density (dense area)
5029,European,343.0,25342443.0,Lindstrom S,"Other measurement, Cancer",replication,2014-10-24,GCST002669,Percent mammographic density
5028,European,343.0,25342443.0,Lindstrom S,Other measurement,replication,2014-10-24,GCST002668,Mammographic density (non-dense area)
9101,European,7600.0,25342443.0,Lindstrom S,Other measurement,initial,2014-10-24,GCST002667,Mammographic density (dense area)
9102,European,7600.0,25342443.0,Lindstrom S,Other measurement,initial,2014-10-24,GCST002668,Mammographic density (non-dense area)
8144,European,4162.0,25343990.0,Cornelis MC,Other measurement,initial,2014-10-24,GCST002671,Toenail selenium levels
8764,European,6117.0,25344690.0,Feenstra B,Other trait,initial,2014-10-26,GCST002672,Febrile seizures
7631,European,3087.0,25344690.0,Feenstra B,Other trait,replication,2014-10-26,GCST002672,Febrile seizures
7632,European,3087.0,25344690.0,Feenstra B,Other trait,replication,2014-10-26,GCST002674,Febrile seizures (MMR vaccine-related)
8502,European,5118.0,25344690.0,Feenstra B,Other trait,initial,2014-10-26,GCST002673,Febrile seizures (MMR vaccine-unrelated)
8471,European,5047.0,25344690.0,Feenstra B,Other trait,initial,2014-10-26,GCST002674,Febrile seizures (MMR vaccine-related)
7438,European,2679.0,25344690.0,Feenstra B,Other trait,replication,2014-10-26,GCST002673,Febrile seizures (MMR vaccine-unrelated)
10498,European,23279.0,25350695.0,Postmus I,"Lipid or lipoprotein measurement, Response to drug",replication,2014-10-28,GCST002675,Response to statins (LDL cholesterol change)
10266,European,18596.0,25350695.0,Postmus I,"Lipid or lipoprotein measurement, Response to drug",initial,2014-10-28,GCST002675,Response to statins (LDL cholesterol change)
10528,European,23986.0,25352340.0,Benyamin B,Other measurement,initial,2014-10-29,GCST002679,Iron status biomarkers (iron levels)
10529,European,23986.0,25352340.0,Benyamin B,Other measurement,initial,2014-10-29,GCST002680,Iron status biomarkers (transferrin saturation)
10527,European,23986.0,25352340.0,Benyamin B,Other measurement,initial,2014-10-29,GCST002678,Iron status biomarkers (transferrin levels)
5260,European,478.0,25353672.0,Fernandez-Navarro P,Other measurement,initial,2014-10-29,GCST002676,Mammographic density
10526,European,23986.0,25352340.0,Benyamin B,Other measurement,initial,2014-10-29,GCST002677,Iron status biomarkers (ferritin levels)
10565,European,24986.0,25352340.0,Benyamin B,Other measurement,replication,2014-10-29,GCST002677,Iron status biomarkers (ferritin levels)
10566,European,24986.0,25352340.0,Benyamin B,Other measurement,replication,2014-10-29,GCST002678,Iron status biomarkers (transferrin levels)
10568,European,24986.0,25352340.0,Benyamin B,Other measurement,replication,2014-10-29,GCST002680,Iron status biomarkers (transferrin saturation)
10567,European,24986.0,25352340.0,Benyamin B,Other measurement,replication,2014-10-29,GCST002679,Iron status biomarkers (iron levels)
13722,Other/Mixed,640.0,25456346.0,Nievergelt CM,Neurological disorder,initial,2014-10-30,GCST002681,Post-traumatic stress disorder
2087,Asian,470.0,25456346.0,Nievergelt CM,Neurological disorder,initial,2014-10-30,GCST002681,Post-traumatic stress disorder
5297,European,491.0,25456346.0,Nievergelt CM,Neurological disorder,replication,2014-10-30,GCST002681,Post-traumatic stress disorder
7079,European,2179.0,25456346.0,Nievergelt CM,Neurological disorder,initial,2014-10-30,GCST002681,Post-traumatic stress disorder
535,African American or Afro-Caribbean,205.0,25456346.0,Nievergelt CM,Neurological disorder,initial,2014-10-30,GCST002681,Post-traumatic stress disorder
9454,European,9260.0,25158072.0,Yu D,Neurological disorder,initial,2014-10-31,GCST002682,Tourette's syndrome or obsessive-compulsive disorder
8039,European,3889.0,25409777.0,Thyagarajan B,Other measurement,initial,2014-11-01,GCST002683,Pulmonary function
2683,Asian,1540.0,25364816.0,Awata T,Metabolic disorder,replication,2014-11-03,GCST002684,Diabetic retinopathy in type 2 diabetes
2063,Asian,446.0,25364816.0,Awata T,Metabolic disorder,initial,2014-11-03,GCST002684,Diabetic retinopathy in type 2 diabetes
2999,Asian,2165.0,25367360.0,Li Q,Other trait,initial,2014-11-04,GCST002685,Refractive astigmatism
3685,Asian,6049.0,25367360.0,Li Q,Other trait,initial,2014-11-04,GCST002685,Refractive astigmatism
10904,European,37608.0,25367360.0,Li Q,Other trait,initial,2014-11-04,GCST002685,Refractive astigmatism
2912,Asian,1998.0,25367360.0,Li Q,Other trait,initial,2014-11-04,GCST002685,Refractive astigmatism
1022,African American or Afro-Caribbean,2701.0,25376901.0,Munir MS,Hematological measurement,initial,2014-11-05,GCST002686,Protein C levels
90,African,321.0,25372704.0,Mtatiro SN,"Neurological disorder, Hematological measurement",replication,2014-11-05,GCST002687,Fetal hemoglobin levels in sickle cell anemia
175,African,1213.0,25372704.0,Mtatiro SN,"Neurological disorder, Hematological measurement",initial,2014-11-05,GCST002687,Fetal hemoglobin levels in sickle cell anemia
9159,European,7915.0,25378659.0,Lemaitre RN,Lipid or lipoprotein measurement,initial,2014-11-06,GCST002689,Very long-chain saturated fatty acid levels (fatty acid 24:0)
9613,European,10129.0,25378659.0,Lemaitre RN,Lipid or lipoprotein measurement,initial,2014-11-06,GCST002690,Very long-chain saturated fatty acid levels (fatty acid 20:0)
9612,European,10129.0,25378659.0,Lemaitre RN,Lipid or lipoprotein measurement,initial,2014-11-06,GCST002688,Very long-chain saturated fatty acid levels (fatty acid 22:0)
12583,Hispanic or Latin American,209.0,25378290.0,McQueen MB,Body measurement,initial,2014-11-07,GCST002692,Body mass index (change over time)
13398,Other/Mixed,8.0,25378290.0,McQueen MB,Body measurement,initial,2014-11-07,GCST002692,Body mass index (change over time)
1626,Asian,73.0,25378290.0,McQueen MB,Body measurement,initial,2014-11-07,GCST002692,Body mass index (change over time)
5922,European,917.0,25378290.0,McQueen MB,Body measurement,initial,2014-11-07,GCST002692,Body mass index (change over time)
695,African American or Afro-Caribbean,677.0,25378290.0,McQueen MB,Body measurement,initial,2014-11-07,GCST002692,Body mass index (change over time)
456,African American or Afro-Caribbean,94.0,25670933.0,Hanchard NA,"Neurological disorder, Biological process",initial,2014-11-07,GCST002691,Alloimmunization response to red blood cell transfusion in sickle cell anemia
2431,Asian,981.0,25383971.0,Dunstan SJ,Other disease,replication,2014-11-10,GCST002693,Enteric fever
2343,Asian,819.0,25383971.0,Dunstan SJ,Other disease,replication,2014-11-10,GCST002693,Enteric fever
9001,European,7100.0,25383866.0,Kirkpatrick RM,Biological process,initial,2014-11-10,GCST002694,General cognitive ability
3095,Asian,2443.0,25383971.0,Dunstan SJ,Other disease,initial,2014-11-10,GCST002693,Enteric fever
13639,Other/Mixed,363.0,25385369.0,Ramanan VK,Biological process,replication,2014-11-11,GCST002695,Episodic memory
8556,European,5283.0,25385369.0,Ramanan VK,Biological process,initial,2014-11-11,GCST002695,Episodic memory
737,African American or Afro-Caribbean,817.0,25385369.0,Ramanan VK,Biological process,initial,2014-11-11,GCST002695,Episodic memory
8890,European,6687.0,25385369.0,Ramanan VK,Biological process,replication,2014-11-11,GCST002695,Episodic memory
711,African American or Afro-Caribbean,711.0,25385369.0,Ramanan VK,Biological process,replication,2014-11-11,GCST002695,Episodic memory
13710,Other/Mixed,605.0,25385369.0,Ramanan VK,Biological process,initial,2014-11-11,GCST002695,Episodic memory
685,African American or Afro-Caribbean,597.0,25390645.0,Otowa T,Neurological disorder,initial,2014-11-12,GCST002696,Anxiety disorder
6693,European,1697.0,25390645.0,Otowa T,Neurological disorder,initial,2014-11-12,GCST002696,Anxiety disorder
5667,European,736.0,25411163.0,Maitland ML,Other measurement,initial,2014-11-19,GCST002698,Serum VEGFR2 concentration
6106,European,1008.0,25407941.0,Sleiman PM,Digestive system disorder,replication,2014-11-19,GCST002697,Eosinophilic esophagitis
8172,European,4240.0,25407941.0,Sleiman PM,Digestive system disorder,initial,2014-11-19,GCST002697,Eosinophilic esophagitis
6003,European,959.0,25917933.0,Zai CC,"Biological process, Neurological disorder, Other measurement",initial,2014-11-20,GCST002699,Suicide in bipolar disorder
10075,European,15809.0,25420145.0,Debette S,Cardiovascular disease,initial,2014-11-24,GCST002700,Cervical artery dissection
7777,European,3307.0,25420145.0,Debette S,Cardiovascular disease,replication,2014-11-24,GCST002700,Cervical artery dissection
10668,European,29076.0,25648963.0,Debette S,Other measurement,initial,2014-11-25,GCST002701,Verbal declarative memory
1159,African American or Afro-Caribbean,3811.0,25648963.0,Debette S,Other measurement,replication,2014-11-25,GCST002701,Verbal declarative memory
9659,European,10617.0,25648963.0,Debette S,Other measurement,replication,2014-11-25,GCST002701,Verbal declarative memory
4448,Asian,57699.0,25429064.0,He M,"Other measurement, Body measurement",replication,2014-11-26,GCST002702,Height
4389,Asian,36227.0,25429064.0,He M,"Other measurement, Body measurement",initial,2014-11-26,GCST002702,Height
2134,Asian,523.0,25429627.0,Oryoji D,Immune system disorder,initial,2014-11-27,GCST002705,Hashimoto thyroiditis versus Graves' disease
2694,Asian,1575.0,25434496.0,Kim S,Other measurement,replication,2014-11-27,GCST002703,Prostate-specific antigen levels
2082,Asian,467.0,25429627.0,Oryoji D,Immune system disorder,replication,2014-11-27,GCST002705,Hashimoto thyroiditis versus Graves' disease
2152,Asian,554.0,25434496.0,Kim S,Other measurement,initial,2014-11-27,GCST002703,Prostate-specific antigen levels
6301,European,1211.0,25431337.0,Bouzigon E,Other measurement,initial,2014-11-27,GCST002704,Fractional exhaled nitric oxide levels
9460,European,9308.0,25431337.0,Bouzigon E,Other measurement,replication,2014-11-27,GCST002704,Fractional exhaled nitric oxide levels
8245,European,4469.0,25387707.0,Vaidyanathan U,Other measurement,initial,2014-12-01,GCST002710,Anti-saccade response
8228,European,4424.0,25387706.0,Vaidyanathan U,Other measurement,initial,2014-12-01,GCST002706,Electrodermal activity
605,African American or Afro-Caribbean,351.0,25436638.0,Malinowski JR,Other measurement,initial,2014-12-01,GCST002707,Serum thyroid-stimulating hormone levels
8256,European,4501.0,25436638.0,Malinowski JR,Other measurement,initial,2014-12-01,GCST002707,Serum thyroid-stimulating hormone levels
7786,European,3323.0,25387708.0,Vaidyanathan U,Other measurement,initial,2014-12-01,GCST002708,Acoustic startle blink response
8096,European,4026.0,25387704.0,Malone SM,Other measurement,initial,2014-12-01,GCST002709,Electroencephalogram traits
11069,European,47180.0,25469926.0,Gottlieb DJ,Other measurement,initial,2014-12-02,GCST002711,Sleep duration
12795,Hispanic or Latin American,1084.0,25468567.0,Perez-Andreu V,Cancer,initial,2014-12-02,GCST002713,Acute lymphoblastic leukemia (adolescents and young adults)
13941,Other/Mixed,3027.0,25468567.0,Perez-Andreu V,Cancer,initial,2014-12-02,GCST002713,Acute lymphoblastic leukemia (adolescents and young adults)
12667,Hispanic or Latin American,535.0,25468567.0,Perez-Andreu V,Cancer,replication,2014-12-02,GCST002713,Acute lymphoblastic leukemia (adolescents and young adults)
13686,Other/Mixed,558.0,25468567.0,Perez-Andreu V,Cancer,replication,2014-12-02,GCST002713,Acute lymphoblastic leukemia (adolescents and young adults)
805,African American or Afro-Caribbean,1085.0,25468567.0,Perez-Andreu V,Cancer,replication,2014-12-02,GCST002713,Acute lymphoblastic leukemia (adolescents and young adults)
869,African American or Afro-Caribbean,1378.0,25468567.0,Perez-Andreu V,Cancer,initial,2014-12-02,GCST002713,Acute lymphoblastic leukemia (adolescents and young adults)
6511,European,1480.0,25468567.0,Perez-Andreu V,Cancer,initial,2014-12-02,GCST002713,Acute lymphoblastic leukemia (adolescents and young adults)
1207,African American or Afro-Caribbean,4771.0,25469926.0,Gottlieb DJ,Other measurement,replication,2014-12-02,GCST002711,Sleep duration
7984,European,3739.0,25468567.0,Perez-Andreu V,Cancer,replication,2014-12-02,GCST002713,Acute lymphoblastic leukemia (adolescents and young adults)
8552,European,5275.0,25477429.0,Lieb W,Cardiovascular measurement,initial,2014-12-04,GCST002714,Plasma renin activity levels
12649,Hispanic or Latin American,454.0,25488688.0,Pino-Yanes M,Other measurement,replication,2014-12-06,GCST002717,Serum IgE levels
6500,European,1462.0,25476525.0,Germain M,Metabolic disorder,initial,2014-12-06,GCST002716,Diabetic nephropathy in type 1 diabetes
8818,European,6341.0,25476525.0,Germain M,Metabolic disorder,replication,2014-12-06,GCST002716,Diabetic nephropathy in type 1 diabetes
12934,Hispanic or Latin American,3334.0,25488688.0,Pino-Yanes M,Other measurement,initial,2014-12-06,GCST002717,Serum IgE levels
13946,Other/Mixed,3286.0,25483131.0,Ghassibe-Sabbagh M,Metabolic disorder,initial,2014-12-08,GCST002718,Type 2 diabetes
7752,European,3269.0,25562672.0,Byrne EM,Other measurement,initial,2014-12-09,GCST002719,Seasonality
5891,European,887.0,25562672.0,Byrne EM,Other measurement,replication,2014-12-09,GCST002719,Seasonality
10236,European,18028.0,25493955.0,Gorski M,"Other disease, Other measurement, Other trait",replication,2014-12-10,GCST002720,Kidney function decline traits
11037,European,45530.0,25493955.0,Gorski M,"Other disease, Other measurement, Other trait",initial,2014-12-10,GCST002720,Kidney function decline traits
12701,Hispanic or Latin American,657.0,25646338.0,Mozaffarian D,Lipid or lipoprotein measurement,replication,2014-12-10,GCST002721,Trans fatty acid levels
2219,Asian,669.0,25646338.0,Mozaffarian D,Lipid or lipoprotein measurement,replication,2014-12-10,GCST002721,Trans fatty acid levels
9188,European,8013.0,25646338.0,Mozaffarian D,Lipid or lipoprotein measurement,initial,2014-12-10,GCST002721,Trans fatty acid levels
800,African American or Afro-Caribbean,1082.0,25646338.0,Mozaffarian D,Lipid or lipoprotein measurement,replication,2014-12-10,GCST002721,Trans fatty acid levels
468,African American or Afro-Caribbean,116.0,25503805.0,Karnes JH,"Response to drug, Other trait",initial,2014-12-11,GCST002722,Heparin-induced thrombocytopenia
13389,Other/Mixed,7.0,25503805.0,Karnes JH,"Response to drug, Other trait",initial,2014-12-11,GCST002722,Heparin-induced thrombocytopenia
5774,European,811.0,25503805.0,Karnes JH,"Response to drug, Other trait",initial,2014-12-11,GCST002722,Heparin-induced thrombocytopenia
5157,European,426.0,25503805.0,Karnes JH,"Response to drug, Other trait",replication,2014-12-11,GCST002722,Heparin-induced thrombocytopenia
1517,Asian,1.0,25503805.0,Karnes JH,"Response to drug, Other trait",initial,2014-12-11,GCST002722,Heparin-induced thrombocytopenia
12498,Hispanic or Latin American,8.0,25503805.0,Karnes JH,"Response to drug, Other trait",initial,2014-12-11,GCST002722,Heparin-induced thrombocytopenia
6522,European,1504.0,25524241.0,Richter HE,Other trait,replication,2014-12-15,GCST002723,Urgency urinary incontinence
6525,European,1507.0,25524241.0,Richter HE,Other trait,initial,2014-12-15,GCST002723,Urgency urinary incontinence
8127,European,4108.0,25514360.0,Hansel NN,"Other disease, Other measurement",initial,2014-12-16,GCST002724,Airway responsiveness in chronic obstructive pulmonary disease
12996,Hispanic or Latin American,4176.0,25524916.0,Palmer ND,Other measurement,initial,2014-12-18,GCST002726,Glucose homeostasis traits
7499,European,2791.0,25521368.0,Tonjes A,Cardiovascular measurement,initial,2014-12-18,GCST004389,Circulating chemerin levels
5396,European,538.0,25533491.0,Rautanen A,"Other measurement, Other trait, Other disease",replication,2014-12-18,GCST002725,Sepsis from pneumonia (survival)
6583,European,1553.0,25533491.0,Rautanen A,"Other measurement, Other trait, Other disease",initial,2014-12-18,GCST002725,Sepsis from pneumonia (survival)
6537,European,1523.0,25526632.0,Rafiq S,"Other measurement, Cancer",replication,2014-12-19,GCST002727,Breast cancer (survival)
6395,European,1341.0,25526632.0,Rafiq S,"Other measurement, Cancer",initial,2014-12-19,GCST002727,Breast cancer (survival)
3244,Asian,3000.0,25705159.0,Hong Y,Other trait,initial,2014-12-31,GCST002730,Hepatitis
3870,Asian,7861.0,25705162.0,Oh JH,Hematological measurement,replication,2014-12-31,GCST002733,Platelet count
3952,Asian,8842.0,25705162.0,Oh JH,Hematological measurement,initial,2014-12-31,GCST002733,Platelet count
7675,European,3184.0,25552591.0,Lieb W,Cardiovascular measurement,replication,2014-12-31,GCST002731,Endothelial growth factor levels
7925,European,3574.0,25552591.0,Lieb W,Cardiovascular measurement,initial,2014-12-31,GCST002731,Endothelial growth factor levels
6360,European,1296.0,25557950.0,Alonso A,"Digestive system disorder, Immune system disorder, Other trait, Biological process",replication,2014-12-31,GCST002729,Crohn's disease-related phenotypes
6185,European,1090.0,25557950.0,Alonso A,"Digestive system disorder, Immune system disorder, Other trait, Biological process",initial,2014-12-31,GCST002729,Crohn's disease-related phenotypes
11422,European,80607.0,25551457.0,Baumert J,"Other measurement, Body measurement, Biological process, Hematological measurement",initial,2014-12-31,GCST002734,"Fibrinogen levels (smoking status, alcohol consumption or body mass index interaction)"
3951,Asian,8842.0,25705158.0,Shim U,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",initial,2014-12-31,GCST002732,Metabolic syndrome
1728,Asian,135.0,25824743.0,Haryono SJ,Cancer,initial,2015-01-01,GCST002735,Breast cancer
2517,Asian,1183.0,25489960.0,Yang SK,Digestive system disorder,initial,2015-01-01,GCST008485,Crohn's disease
2889,Asian,1925.0,25489960.0,Yang SK,Digestive system disorder,replication,2015-01-01,GCST008485,Crohn's disease
247,African,2790.0,25561047.0,Musani SK,Cardiovascular measurement,initial,2015-01-05,GCST002736,B-type natriuretic peptide levels
3256,Asian,3080.0,25566987.0,Hosgood HD 3rd,"Other measurement, Cancer",initial,2015-01-08,GCST002739,Lung cancer (household air pollution interaction)
8730,European,5946.0,25574825.0,Baurecht H,Immune system disorder,initial,2015-01-08,GCST002737,Atopic dermatitis
6415,European,1362.0,25569183.0,Vijai J,Cancer,replication,2015-01-08,GCST002742,Marginal zone lymphoma
9824,European,12244.0,25574825.0,Baurecht H,Immune system disorder,initial,2015-01-08,GCST002738,Psoriasis
2887,Asian,1922.0,25574032.0,Lee H,Other disease,initial,2015-01-08,GCST002741,Polycystic ovary syndrome
8985,European,7046.0,25569183.0,Vijai J,Cancer,initial,2015-01-08,GCST002742,Marginal zone lymphoma
10240,European,18190.0,25574825.0,Baurecht H,"Immune system disorder, Other disease",initial,2015-01-08,GCST002740,Inflammatory skin disease
2449,Asian,1027.0,25574032.0,Lee H,Other disease,replication,2015-01-08,GCST002741,Polycystic ovary syndrome
13917,Other/Mixed,2547.0,25884002.0,Moore CB,"Other disease, Hematological measurement",initial,2015-01-09,GCST002743,Neutrophil count in HIV-infection
13916,Other/Mixed,2547.0,25884002.0,Moore CB,"Lipid or lipoprotein measurement, Other disease",initial,2015-01-09,GCST002744,HDL Cholesterol in HIV-infection
13859,Other/Mixed,1376.0,25575512.0,Lu W,Lipid or lipoprotein measurement,initial,2015-01-09,GCST002746,Lipoprotein (a) - cholesterol levels
13918,Other/Mixed,2547.0,25884002.0,Moore CB,"Other disease, Other measurement",initial,2015-01-09,GCST002745,Total bilirubin levels in HIV-1 infection
7531,European,2845.0,25583994.0,Tardif JC,"Response to drug, Cardiovascular measurement, Cardiovascular disease",initial,2015-01-11,GCST002747,Response to Dalcetrapib treatment in acute coronary syndrome
11186,European,56254.0,25581431.0,Kuchenbaecker KB,Cancer,replication,2015-01-12,GCST002748,Epithelial ovarian cancer
9913,European,13491.0,25581431.0,Kuchenbaecker KB,Cancer,initial,2015-01-12,GCST002748,Epithelial ovarian cancer
12605,Hispanic or Latin American,337.0,25584925.0,Chen W,Other disease,replication,2015-01-13,GCST002750,Chronic obstructive pulmonary disease
455,African American or Afro-Caribbean,93.0,25628645.0,Tong Y,"Other measurement, Response to drug",initial,2015-01-13,GCST002749,Response to Homoharringtonine (cytotoxicity)
1657,Asian,94.0,25628645.0,Tong Y,"Other measurement, Response to drug",initial,2015-01-13,GCST002749,Response to Homoharringtonine (cytotoxicity)
4655,European,91.0,25628645.0,Tong Y,"Other measurement, Response to drug",initial,2015-01-13,GCST002749,Response to Homoharringtonine (cytotoxicity)
12801,Hispanic or Latin American,1188.0,25584925.0,Chen W,Other disease,initial,2015-01-13,GCST002750,Chronic obstructive pulmonary disease
13647,Other/Mixed,392.0,25599974.0,Zhang H,"Other measurement, Other trait",replication,2015-01-19,GCST002751,Spontaneous preterm birth (preterm birth)
13891,Other/Mixed,1881.0,25599974.0,Zhang H,"Other measurement, Other trait",initial,2015-01-19,GCST002752,Spontaneous preterm birth (preterm delivery)
13887,Other/Mixed,1851.0,25599974.0,Zhang H,"Other measurement, Other trait",initial,2015-01-19,GCST002751,Spontaneous preterm birth (preterm birth)
12572,Hispanic or Latin American,184.0,25599974.0,Zhang H,"Other measurement, Other trait",replication,2015-01-19,GCST002752,Spontaneous preterm birth (preterm delivery)
521,African American or Afro-Caribbean,194.0,25599974.0,Zhang H,"Other measurement, Other trait",replication,2015-01-19,GCST002752,Spontaneous preterm birth (preterm delivery)
13405,Other/Mixed,12.0,25599974.0,Zhang H,"Other measurement, Other trait",replication,2015-01-19,GCST002752,Spontaneous preterm birth (preterm delivery)
4685,European,103.0,25599974.0,Zhang H,"Other measurement, Other trait",replication,2015-01-19,GCST002752,Spontaneous preterm birth (preterm delivery)
9375,European,8683.0,25644374.0,Poirier JG,"Other measurement, Cancer",initial,2015-01-19,GCST002753,Lung cancer and family history of lung cancer
6201,European,1112.0,25604533.0,Renauer PA,Cardiovascular disease,initial,2015-01-20,GCST006575,Takayasu arteritis
13819,Other/Mixed,978.0,25604533.0,Renauer PA,Cardiovascular disease,initial,2015-01-20,GCST006575,Takayasu arteritis
10031,European,15130.0,25607358.0,Hibar DP,Other measurement,replication,2015-01-21,GCST002756,Subcortical brain region volumes
2145,Asian,545.0,25607358.0,Hibar DP,Other measurement,replication,2015-01-21,GCST002756,Subcortical brain region volumes
9883,European,13171.0,25607358.0,Hibar DP,Other measurement,initial,2015-01-21,GCST002756,Subcortical brain region volumes
12720,Hispanic or Latin American,736.0,25607358.0,Hibar DP,Other measurement,replication,2015-01-21,GCST002756,Subcortical brain region volumes
9093,European,7565.0,25608926.0,Betz RC,Other disease,initial,2015-01-22,GCST004866,Alopecia areata
7610,European,3020.0,25608926.0,Betz RC,Other disease,replication,2015-01-22,GCST004866,Alopecia areata
5727,European,773.0,25616667.0,Goris A,"Other measurement, Immune system disorder",initial,2015-01-22,GCST002757,Immunoglobulin G index levels in multiple sclerosis
7313,European,2507.0,25616667.0,Goris A,"Immune system disorder, Other measurement",initial,2015-01-22,GCST002758,Oligoclonal band status in multiple sclerosis
11411,European,80494.0,25628336.0,Hromatka BS,Other trait,initial,2015-01-26,GCST002759,Motion sickness
10771,European,33231.0,25625282.0,Mahajan A,Other measurement,initial,2015-01-27,GCST007858,Fasting blood glucose adjusted for BMI
10713,European,30825.0,25625282.0,Mahajan A,Other measurement,initial,2015-01-27,GCST007857,Fasting blood insulin adjusted for BMI
4995,European,325.0,25625606.0,Mather KA,Neurological disorder,initial,2015-01-27,GCST002760,Hippocampal atrophy
5317,European,498.0,25625606.0,Mather KA,Other measurement,initial,2015-01-27,GCST002761,Hippocampal volume
2975,Asian,2131.0,25631615.0,Springelkamp H,Other measurement,replication,2015-01-28,GCST002765,Optic disc area
2974,Asian,2131.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002763,Optic disc area
3029,Asian,2225.0,25631615.0,Springelkamp H,Other measurement,replication,2015-01-28,GCST002762,Optic cup area
10180,European,17218.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002762,Optic cup area
3054,Asian,2305.0,25631615.0,Springelkamp H,Other measurement,replication,2015-01-28,GCST002765,Optic disc area
10181,European,17218.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002764,Optic cup area
3053,Asian,2305.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002763,Optic disc area
3085,Asian,2405.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002763,Optic disc area
10182,European,17248.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002763,Optic disc area
3086,Asian,2405.0,25631615.0,Springelkamp H,Other measurement,replication,2015-01-28,GCST002765,Optic disc area
3028,Asian,2225.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002764,Optic cup area
3861,Asian,7810.0,25629512.0,Cheng CY,Neurological disorder,initial,2015-01-28,GCST002766,Exudative age-related macular degeneration
2933,Asian,2025.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002764,Optic cup area
3068,Asian,2363.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002764,Optic cup area
2934,Asian,2025.0,25631615.0,Springelkamp H,Other measurement,replication,2015-01-28,GCST002762,Optic cup area
4194,Asian,14515.0,25629512.0,Cheng CY,Neurological disorder,replication,2015-01-28,GCST002766,Exudative age-related macular degeneration
3069,Asian,2363.0,25631615.0,Springelkamp H,Other measurement,replication,2015-01-28,GCST002762,Optic cup area
10183,European,17248.0,25631615.0,Springelkamp H,Other measurement,initial,2015-01-28,GCST002765,Optic disc area
1401,African American or Afro-Caribbean,12738.0,25631608.0,Wessel J,Other measurement,initial,2015-01-29,GCST007898,Fasting blood insulin
11110,European,50900.0,25631608.0,Wessel J,Other measurement,initial,2015-01-29,GCST007899,Fasting blood glucose
10854,European,35380.0,25631608.0,Wessel J,Other measurement,initial,2015-01-29,GCST007898,Fasting blood insulin
1361,African American or Afro-Caribbean,9664.0,25631608.0,Wessel J,Other measurement,initial,2015-01-29,GCST007899,Fasting blood glucose
45,African,114.0,25637581.0,Derringer J,Other measurement,initial,2015-01-31,GCST002768,Behavioral disinhibition
12656,Hispanic or Latin American,477.0,25637581.0,Derringer J,Other measurement,initial,2015-01-31,GCST002768,Behavioral disinhibition
13453,Other/Mixed,40.0,25637581.0,Derringer J,Other measurement,initial,2015-01-31,GCST002768,Behavioral disinhibition
7826,European,3378.0,25637581.0,Derringer J,Other measurement,replication,2015-01-31,GCST002768,Behavioral disinhibition
6209,European,1129.0,25637581.0,Derringer J,Other measurement,initial,2015-01-31,GCST002768,Behavioral disinhibition
13455,Other/Mixed,42.0,25637581.0,Derringer J,Other measurement,initial,2015-01-31,GCST002768,Behavioral disinhibition
12570,Hispanic or Latin American,175.0,25461247.0,Lehmann DS,"Response to drug, Other measurement, Other disease",initial,2015-02-01,GCST002769,Response to abacavir-containing treatment in HIV-1 infection (virologic failure)
81,African,265.0,25461247.0,Lehmann DS,"Response to drug, Other measurement, Other disease",initial,2015-02-01,GCST002769,Response to abacavir-containing treatment in HIV-1 infection (virologic failure)
12598,Hispanic or Latin American,314.0,25461247.0,Lehmann DS,"Response to drug, Other measurement, Other disease",initial,2015-02-01,GCST002771,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)
5669,European,737.0,25461247.0,Lehmann DS,"Response to drug, Other measurement, Other disease",initial,2015-02-01,GCST002771,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)
5034,European,346.0,25461247.0,Lehmann DS,"Response to drug, Other measurement, Other disease",initial,2015-02-01,GCST002769,Response to abacavir-containing treatment in HIV-1 infection (virologic failure)
118,African,545.0,25461247.0,Lehmann DS,"Response to drug, Other measurement, Other disease",initial,2015-02-01,GCST002771,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)
5401,European,541.0,25637336.0,Chan JP,Other measurement,replication,2015-02-01,GCST002770,Hand grip strength
7008,European,2088.0,25637336.0,Chan JP,Other measurement,initial,2015-02-01,GCST002770,Hand grip strength
3078,Asian,2382.0,25646370.0,Matsuo H,Metabolic disorder,replication,2015-02-02,GCST002773,Gout
3880,Asian,8060.0,25642632.0,Liu H,Neurological disorder,initial,2015-02-02,GCST002772,Leprosy
2996,Asian,2158.0,25646370.0,Matsuo H,Metabolic disorder,initial,2015-02-02,GCST002773,Gout
4231,Asian,16270.0,25642632.0,Liu H,Neurological disorder,replication,2015-02-02,GCST002772,Leprosy
11155,European,53949.0,25644384.0,Davies G,"Biological process, Other measurement",initial,2015-02-03,GCST002774,Cognitive function
4624,European,80.0,25722978.0,Borghese B,Other disease,initial,2015-02-04,GCST002776,Endometriosis
5408,European,547.0,25722978.0,Borghese B,Other disease,replication,2015-02-04,GCST002776,Endometriosis
4652,European,90.0,25656473.0,de With SA,"Response to drug, Other measurement",initial,2015-02-05,GCST002777,Clozapine-induced cytotoxicity
6643,European,1629.0,25663231.0,Beecham GW,"Neurological disorder, Other measurement",initial,2015-02-06,GCST002778,Parkinson disease and lewy body pathology
2338,Asian,808.0,25672763.0,Ueta M,"Other disease, Response to drug",initial,2015-02-08,GCST002779,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement
1943,Asian,321.0,25672763.0,Ueta M,"Other disease, Response to drug",replication,2015-02-08,GCST002779,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement
1633,Asian,76.0,25672763.0,Ueta M,"Other disease, Response to drug",replication,2015-02-08,GCST002779,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement
12569,Hispanic or Latin American,174.0,25672763.0,Ueta M,"Other disease, Response to drug",replication,2015-02-08,GCST002779,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement
4735,European,156.0,25665007.0,Xu H,"Other trait, Neurological disorder, Response to drug",initial,2015-02-09,GCST002780,Cisplatin-induced hearing loss in brain tumor patients
3897,Asian,8345.0,25672891.0,Shimizu S,Digestive system disorder,replication,2015-02-11,GCST002781,Periodontitis
3998,Asian,9573.0,25672891.0,Shimizu S,Digestive system disorder,initial,2015-02-11,GCST002781,Periodontitis
1344,African American or Afro-Caribbean,8609.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST002782,Waist-to-hip ratio adjusted for body mass index
1343,African American or Afro-Caribbean,8609.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004067,Hip circumference adjusted for BMI
1342,African American or Afro-Caribbean,8609.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004066,Hip circumference
11817,European,142762.0,25673412.0,Shungin D,Body measurement,initial,2015-02-12,GCST004065,Waist circumference
1345,African American or Afro-Caribbean,8609.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST004063,Waist circumference adjusted for body mass index
11292,European,67326.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004065,Waist circumference
11821,European,142762.0,25673412.0,Shungin D,"Body measurement, Other measurement",initial,2015-02-12,GCST004063,Waist circumference adjusted for body mass index
1346,African American or Afro-Caribbean,8609.0,25673412.0,Shungin D,"Other measurement, Body measurement",replication,2015-02-12,GCST004064,Waist-hip ratio
1348,African American or Afro-Caribbean,8755.0,25673413.0,Locke AE,"Body measurement, Other measurement",replication,2015-02-12,GCST002783,Body mass index
756,African American or Afro-Caribbean,887.0,25673413.0,Locke AE,"Body measurement, Other measurement",initial,2015-02-12,GCST002783,Body mass index
11820,European,142762.0,25673412.0,Shungin D,"Body measurement, Other measurement",initial,2015-02-12,GCST002782,Waist-to-hip ratio adjusted for body mass index
2782,Asian,1747.0,25673413.0,Locke AE,"Body measurement, Other measurement",replication,2015-02-12,GCST002783,Body mass index
11819,European,142762.0,25673412.0,Shungin D,Body measurement,initial,2015-02-12,GCST004067,Hip circumference adjusted for BMI
3182,Asian,2791.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004066,Hip circumference
11818,European,142762.0,25673412.0,Shungin D,Body measurement,initial,2015-02-12,GCST004066,Hip circumference
11294,European,67326.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004067,Hip circumference adjusted for BMI
11293,European,67326.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004066,Hip circumference
11295,European,67326.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST002782,Waist-to-hip ratio adjusted for body mass index
2730,Asian,1650.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004067,Hip circumference adjusted for BMI
3181,Asian,2791.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004065,Waist circumference
104,African,461.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST002782,Waist-to-hip ratio adjusted for body mass index
2729,Asian,1650.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004066,Hip circumference
105,African,461.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST004063,Waist circumference adjusted for body mass index
103,African,461.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004067,Hip circumference adjusted for BMI
12809,Hispanic or Latin American,1276.0,25673413.0,Locke AE,"Body measurement, Other measurement",initial,2015-02-12,GCST002783,Body mass index
2728,Asian,1650.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004065,Waist circumference
11297,European,67326.0,25673412.0,Shungin D,"Other measurement, Body measurement",replication,2015-02-12,GCST004064,Waist-hip ratio
11296,European,67326.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST004063,Waist circumference adjusted for body mass index
2733,Asian,1650.0,25673412.0,Shungin D,"Other measurement, Body measurement",replication,2015-02-12,GCST004064,Waist-hip ratio
3186,Asian,2791.0,25673412.0,Shungin D,"Other measurement, Body measurement",replication,2015-02-12,GCST004064,Waist-hip ratio
3185,Asian,2791.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST004063,Waist circumference adjusted for body mass index
102,African,461.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004066,Hip circumference
106,African,461.0,25673412.0,Shungin D,"Other measurement, Body measurement",replication,2015-02-12,GCST004064,Waist-hip ratio
2732,Asian,1650.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST004063,Waist circumference adjusted for body mass index
3184,Asian,2791.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST002782,Waist-to-hip ratio adjusted for body mass index
12089,European,236781.0,25673413.0,Locke AE,"Body measurement, Other measurement",initial,2015-02-12,GCST002783,Body mass index
3183,Asian,2791.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004067,Hip circumference adjusted for BMI
3329,Asian,3622.0,25673413.0,Locke AE,"Body measurement, Other measurement",replication,2015-02-12,GCST002783,Body mass index
2731,Asian,1650.0,25673412.0,Shungin D,"Body measurement, Other measurement",replication,2015-02-12,GCST002782,Waist-to-hip ratio adjusted for body mass index
101,African,461.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004065,Waist circumference
1341,African American or Afro-Caribbean,8609.0,25673412.0,Shungin D,Body measurement,replication,2015-02-12,GCST004065,Waist circumference
11822,European,142762.0,25673412.0,Shungin D,"Other measurement, Body measurement",initial,2015-02-12,GCST004064,Waist-hip ratio
11497,European,88138.0,25673413.0,Locke AE,"Body measurement, Other measurement",replication,2015-02-12,GCST002783,Body mass index
6572,European,1545.0,25695618.0,Chittani M,"Other measurement, Response to drug, Cardiovascular disease",replication,2015-02-18,GCST002784,Blood pressure response to hydrochlorothiazide in hypertension
5272,European,485.0,25695618.0,Chittani M,"Other measurement, Response to drug, Cardiovascular disease",initial,2015-02-18,GCST002784,Blood pressure response to hydrochlorothiazide in hypertension
3859,Asian,7760.0,25706626.0,Aung T,Neurological disorder,replication,2015-02-23,GCST002787,Exfoliation syndrome
3152,Asian,2672.0,25706626.0,Aung T,Neurological disorder,initial,2015-02-23,GCST002787,Exfoliation syndrome
9854,European,12600.0,25706626.0,Aung T,Neurological disorder,replication,2015-02-23,GCST002787,Exfoliation syndrome
13867,Other/Mixed,1455.0,25706626.0,Aung T,Neurological disorder,replication,2015-02-23,GCST002787,Exfoliation syndrome
6249,European,1163.0,25713168.0,Leng S,Other measurement,initial,2015-02-23,GCST002786,Gene methylation in lung tissue
3462,Asian,4600.0,25706626.0,Aung T,Neurological disorder,replication,2015-02-23,GCST002787,Exfoliation syndrome
12611,Hispanic or Latin American,373.0,25706626.0,Aung T,Neurological disorder,replication,2015-02-23,GCST002787,Exfoliation syndrome
5644,European,718.0,25713168.0,Leng S,Other measurement,replication,2015-02-23,GCST002786,Gene methylation in lung tissue
7530,European,2844.0,25705849.0,Jacobs LC,Other measurement,initial,2015-02-23,GCST002785,Facial pigmentation
109,African,481.0,25706626.0,Aung T,Neurological disorder,replication,2015-02-23,GCST002787,Exfoliation syndrome
13498,Other/Mixed,99.0,25706626.0,Aung T,Neurological disorder,replication,2015-02-23,GCST002787,Exfoliation syndrome
7109,European,2197.0,25710614.0,Hong X,Other measurement,initial,2015-02-24,GCST002788,Milk allergy
7111,European,2197.0,25710614.0,Hong X,Other measurement,initial,2015-02-24,GCST002790,Food allergy
4840,European,209.0,25710658.0,Diouf B,"Response to drug, Cancer, Neurological disorder",initial,2015-02-24,GCST002792,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia
22,African,43.0,25710658.0,Diouf B,"Response to drug, Cancer, Neurological disorder",initial,2015-02-24,GCST002792,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia
4707,European,131.0,25710614.0,Hong X,Other measurement,replication,2015-02-24,GCST002791,Peanut allergy
12524,Hispanic or Latin American,44.0,25710658.0,Diouf B,"Response to drug, Cancer, Neurological disorder",initial,2015-02-24,GCST002792,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia
7110,European,2197.0,25710614.0,Hong X,Other measurement,initial,2015-02-24,GCST002789,Egg allergy
7112,European,2197.0,25710614.0,Hong X,Other measurement,initial,2015-02-24,GCST002791,Peanut allergy
1528,Asian,2.0,25710658.0,Diouf B,"Response to drug, Cancer, Neurological disorder",initial,2015-02-24,GCST002792,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia
12518,Hispanic or Latin American,36.0,25771307.0,Watson AL,Metabolic disorder,initial,2015-02-26,GCST008434,Type 2 diabetes
5368,European,521.0,25881214.0,Shah AA,Other trait,initial,2015-02-27,GCST002793,Vein graft stenosis in coronary artery bypass grafting
719,African American or Afro-Caribbean,754.0,25101718.0,Lee JH,"Other disease, Other trait",initial,2015-03-01,GCST002797,Pulmonary artery enlargement in chronic obstructive pulmonary disease
5199,European,439.0,25562107.0,Israel E,"Response to drug, Other disease",replication,2015-03-01,GCST002796,Bronchodilator response in asthma
8187,European,4287.0,25101718.0,Lee JH,"Other disease, Other trait",initial,2015-03-01,GCST002797,Pulmonary artery enlargement in chronic obstructive pulmonary disease
7977,European,3718.0,25101718.0,Lee JH,"Other disease, Other trait",initial,2015-03-01,GCST002798,Pulmonary artery enlargement and chronic obstructive pulmonary disease
8738,European,5993.0,25101718.0,Lee JH,Other disease,initial,2015-03-01,GCST002795,Chronic obstructive pulmonary disease
984,African American or Afro-Caribbean,2243.0,25101718.0,Lee JH,Other disease,initial,2015-03-01,GCST002795,Chronic obstructive pulmonary disease
6998,European,2076.0,25337690.0,Redler S,Other disease,replication,2015-03-01,GCST005539,Alopecia areata
7138,European,2242.0,25337690.0,Redler S,Other disease,initial,2015-03-01,GCST005539,Alopecia areata
5650,European,724.0,25562107.0,Israel E,"Response to drug, Other disease",initial,2015-03-01,GCST002796,Bronchodilator response in asthma
940,African American or Afro-Caribbean,2009.0,25101718.0,Lee JH,"Other disease, Other trait",initial,2015-03-01,GCST002798,Pulmonary artery enlargement and chronic obstructive pulmonary disease
2743,Asian,1686.0,25742292.0,Aschebrook-Kilfoy B,"Other measurement, Other trait",initial,2015-03-05,GCST002801,Number of children
2742,Asian,1686.0,25742292.0,Aschebrook-Kilfoy B,"Other measurement, Other trait",initial,2015-03-05,GCST002800,Number of children (6+ vs. 0 or 1)
2741,Asian,1686.0,25742292.0,Aschebrook-Kilfoy B,"Other measurement, Other trait",initial,2015-03-05,GCST002799,Number of pregnancies
10113,European,16335.0,25743335.0,Taylor PN,"Other measurement, Other trait",initial,2015-03-06,GCST008165,Thyroid stimulating hormone levels
9933,European,13651.0,25743335.0,Taylor PN,Other measurement,initial,2015-03-06,GCST008164,Free thyroxine concentration
12858,Hispanic or Latin American,1932.0,25758998.0,Rubicz R,Other measurement,initial,2015-03-11,GCST002804,Antibody level in response to infection
7137,European,2240.0,25758996.0,Pirastu N,Other measurement,initial,2015-03-11,GCST002802,White wine liking
13646,Other/Mixed,391.0,25760438.0,Anderson D,Metabolic disorder,initial,2015-03-11,GCST002806,Type 2 diabetes
13638,Other/Mixed,361.0,25760438.0,Anderson D,"Body measurement, Other measurement",initial,2015-03-11,GCST002805,Body mass index
7151,European,2271.0,25758996.0,Pirastu N,Other measurement,initial,2015-03-11,GCST002803,Red wine liking
6329,European,1246.0,25758996.0,Pirastu N,Other measurement,replication,2015-03-11,GCST002803,Red wine liking
13636,Other/Mixed,353.0,25758996.0,Pirastu N,Other measurement,replication,2015-03-11,GCST002803,Red wine liking
13627,Other/Mixed,335.0,25758996.0,Pirastu N,Other measurement,replication,2015-03-11,GCST002802,White wine liking
6343,European,1261.0,25758996.0,Pirastu N,Other measurement,replication,2015-03-11,GCST002802,White wine liking
8638,European,5595.0,25772935.0,Germain M,Cardiovascular disease,replication,2015-03-12,GCST002808,Venous thromboembolism
11230,European,60139.0,25772935.0,Germain M,Cardiovascular disease,initial,2015-03-12,GCST002808,Venous thromboembolism
6862,European,1911.0,25763902.0,Draaken M,Other disease,initial,2015-03-12,GCST002807,Classic bladder exstrophy
5996,European,951.0,25827505.0,Swaminathan S,Neurological disorder,initial,2015-03-14,GCST002809,Bipolar disorder
584,African American or Afro-Caribbean,317.0,25827505.0,Swaminathan S,Neurological disorder,initial,2015-03-14,GCST002809,Bipolar disorder
6320,European,1237.0,25827505.0,Swaminathan S,Neurological disorder,replication,2015-03-14,GCST002809,Bipolar disorder
9723,European,11137.0,25774636.0,Curtis J,"Other disease, Other measurement",initial,2015-03-16,GCST002810,Tuberculosis
275,African,4637.0,25774636.0,Curtis J,"Other disease, Other measurement",replication,2015-03-16,GCST002810,Tuberculosis
3320,Asian,3537.0,25775280.0,Sun Y,Other trait,replication,2015-03-16,GCST002811,Nonsyndromic cleft lip with or without cleft palate
2963,Asian,2106.0,25775280.0,Sun Y,Other trait,initial,2015-03-16,GCST002811,Nonsyndromic cleft lip with or without cleft palate
13967,Other/Mixed,3950.0,25774636.0,Curtis J,"Other disease, Other measurement",replication,2015-03-16,GCST002810,Tuberculosis
7257,European,2417.0,25778476.0,Jun G,Neurological disorder,replication,2015-03-17,GCST002817,Alzheimer's disease in APOE e4- carriers
8159,European,4203.0,25778476.0,Jun G,"Neurological disorder, Other measurement",replication,2015-03-17,GCST002814,Alzheimer's disease (APOE e4 interaction)
6782,European,1786.0,25778476.0,Jun G,Neurological disorder,replication,2015-03-17,GCST002813,Alzheimer's disease in APOE e4+ carriers
10178,European,17187.0,25781442.0,Nan H,"Cancer, Other measurement",initial,2015-03-17,GCST002816,Colorectal cancer (aspirin and/or NSAID use interaction)
13758,Other/Mixed,701.0,25781172.0,Avramopoulos D,"Neurological disorder, Other measurement",initial,2015-03-17,GCST002812,Schizophrenia (inflammation and infection response interaction)
13720,Other/Mixed,638.0,25781172.0,Avramopoulos D,"Neurological disorder, Other measurement",initial,2015-03-17,GCST002815,Bipolar disorder (inflammation and infection response interaction)
939,African American or Afro-Caribbean,2004.0,25786224.0,Johnson EO,"Immune system disorder, Other disease",initial,2015-03-18,GCST002818,HIV-1 susceptibility
5418,European,552.0,25784220.0,Sharma S,Other disease,replication,2015-03-18,GCST002819,Adolescent idiopathic scoliosis
924,African American or Afro-Caribbean,1852.0,25786224.0,Johnson EO,"Immune system disorder, Other disease",replication,2015-03-18,GCST002818,HIV-1 susceptibility
6213,European,1132.0,25786224.0,Johnson EO,"Immune system disorder, Other disease",initial,2015-03-18,GCST002818,HIV-1 susceptibility
5603,European,681.0,25786224.0,Johnson EO,"Immune system disorder, Other disease",replication,2015-03-18,GCST002818,HIV-1 susceptibility
6274,European,1184.0,25784220.0,Sharma S,Other disease,initial,2015-03-18,GCST002819,Adolescent idiopathic scoliosis
3122,Asian,2524.0,25784220.0,Sharma S,Other disease,replication,2015-03-18,GCST002819,Adolescent idiopathic scoliosis
5013,European,334.0,25866641.0,Xu W,"Cancer, Other measurement",initial,2015-03-19,GCST002822,Survival in colon cancer
5166,European,431.0,25866641.0,Xu W,"Other measurement, Cancer",initial,2015-03-19,GCST002820,Survival in microsatellite instability low/stable colorectal cancer
4751,European,171.0,25866641.0,Xu W,"Other measurement, Cancer",initial,2015-03-19,GCST002821,Survival in rectal cancer
13344,Other/Mixed,1.0,25799145.0,Kappen JH,Cardiovascular disease,initial,2015-03-23,GCST002824,Behcet's disease
13586,Other/Mixed,241.0,25799145.0,Kappen JH,Cardiovascular disease,initial,2015-03-23,GCST002824,Behcet's disease
13585,Other/Mixed,241.0,25799145.0,Kappen JH,Cardiovascular disease,initial,2015-03-23,GCST002823,Behcet's disease
13343,Other/Mixed,1.0,25799145.0,Kappen JH,Cardiovascular disease,initial,2015-03-23,GCST002823,Behcet's disease
4588,European,54.0,25799145.0,Kappen JH,Cardiovascular disease,initial,2015-03-23,GCST002823,Behcet's disease
7486,European,2764.0,25798622.0,Knowles JW,Other trait,initial,2015-03-23,GCST002825,Insulin resistance/response
4773,European,180.0,25799145.0,Kappen JH,Cardiovascular disease,replication,2015-03-23,GCST002823,Behcet's disease
12484,Hispanic or Latin American,1.0,25799145.0,Kappen JH,Cardiovascular disease,initial,2015-03-23,GCST002823,Behcet's disease
4589,European,54.0,25799145.0,Kappen JH,Cardiovascular disease,initial,2015-03-23,GCST002824,Behcet's disease
1519,Asian,1.0,25799145.0,Kappen JH,"Cardiovascular disease, Cardiovascular disease, Cardiovascular disease",initial,2015-03-23,GCST002824,Behcet's disease
12485,Hispanic or Latin American,1.0,25799145.0,Kappen JH,Cardiovascular disease,initial,2015-03-23,GCST002824,Behcet's disease
1518,Asian,1.0,25799145.0,Kappen JH,"Cardiovascular disease, Cardiovascular disease, Cardiovascular disease",initial,2015-03-23,GCST002823,Behcet's disease
12846,Hispanic or Latin American,1601.0,25798622.0,Knowles JW,Other trait,replication,2015-03-23,GCST002825,Insulin resistance/response
6340,European,1259.0,25798622.0,Knowles JW,Other trait,replication,2015-03-23,GCST002825,Insulin resistance/response
13963,Other/Mixed,3934.0,25799145.0,Kappen JH,Cardiovascular disease,replication,2015-03-23,GCST002824,Behcet's disease
10649,European,28610.0,25811787.0,Huffman JE,"Body measurement, Other measurement",initial,2015-03-26,GCST002827,Urate levels (BMI interaction)
10044,European,15282.0,25811787.0,Huffman JE,"Body measurement, Other measurement",initial,2015-03-26,GCST002830,Urate levels in lean individuals
9953,European,13959.0,25811787.0,Huffman JE,"Body measurement, Other measurement",replication,2015-03-26,GCST002827,Urate levels (BMI interaction)
10176,European,17078.0,25811787.0,Huffman JE,"Body measurement, Other measurement",initial,2015-03-26,GCST002829,Urate levels in overweight individuals
10166,European,16957.0,25817017.0,Carmona FD,Cardiovascular disease,initial,2015-03-26,GCST006198,Giant cell arteritis
10737,European,31950.0,25811787.0,Huffman JE,"Body measurement, Other measurement",initial,2015-03-26,GCST002826,Urate levels (BMI interaction)
9486,European,9445.0,25811787.0,Huffman JE,"Other measurement, Body measurement",initial,2015-03-26,GCST002828,Urate levels in obese individuals
9610,European,10114.0,25826619.0,Henrion MY,Cancer,replication,2015-03-31,GCST002835,Renal cell carcinoma
3274,Asian,3248.0,25823570.0,Miyake M,Other measurement,initial,2015-03-31,GCST002836,Axial length
3305,Asian,3460.0,25823570.0,Miyake M,Other measurement,replication,2015-03-31,GCST002836,Axial length
2369,Asian,876.0,25823687.0,Cao S,"Response to drug, Cancer, Other trait",replication,2015-03-31,GCST002833,Platinum-induced myelosuppression in non-small cell lung cancer
3703,Asian,6234.0,25823570.0,Miyake M,Other measurement,replication,2015-03-31,GCST002834,Corneal curvature
1947,Asian,328.0,25823687.0,Cao S,"Response to drug, Cancer, Other trait",initial,2015-03-31,GCST002833,Platinum-induced myelosuppression in non-small cell lung cancer
9698,European,10871.0,25826619.0,Henrion MY,Cancer,initial,2015-03-31,GCST002835,Renal cell carcinoma
6932,European,2007.0,25823570.0,Miyake M,Other measurement,replication,2015-03-31,GCST002834,Corneal curvature
11509,European,89677.0,25751625.0,Michailidou K,Cancer,initial,2015-04-01,GCST007236,Breast cancer
4579,European,49.0,25813999.0,Jeong S,"Response to drug, Other measurement",replication,2015-04-01,GCST002837,Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide)
11510,European,89677.0,25751625.0,Michailidou K,Cancer,replication,2015-04-01,GCST004950,Breast cancer
5900,European,890.0,25643325.0,Renton AE,"Neurological disorder, Other disease",replication,2015-04-01,GCST002838,Myasthenia gravis
10683,European,29652.0,25751624.0,Onengut-Gumuscu S,Metabolic disorder,initial,2015-04-01,GCST005536,Type 1 diabetes
7575,European,2949.0,25643325.0,Renton AE,"Neurological disorder, Other disease",initial,2015-04-01,GCST002838,Myasthenia gravis
4601,European,64.0,25813999.0,Jeong S,"Response to drug, Other measurement",initial,2015-04-01,GCST002837,Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide)
10811,European,33864.0,25751625.0,Michailidou K,Cancer,initial,2015-04-01,GCST004950,Breast cancer
5929,European,922.0,25839716.0,Ng E,Other measurement,initial,2015-04-02,GCST002839,Polychlorinated biphenyl levels
2748,Asian,1699.0,25848760.0,Sun Y,Other disease,replication,2015-04-07,GCST002841,Developmental dysplasia of the hip
2406,Asian,944.0,25848760.0,Sun Y,Other disease,initial,2015-04-07,GCST002841,Developmental dysplasia of the hip
8737,European,5992.0,25849990.0,Tapper W,Cancer,replication,2015-04-07,GCST002840,Myeloproliferative neoplasms
7682,European,3198.0,25849990.0,Tapper W,Cancer,initial,2015-04-07,GCST002840,Myeloproliferative neoplasms
12141,European,270930.0,25855136.0,Stacey SN,Cancer,initial,2015-04-09,GCST002842,Basal cell carcinoma
4308,Asian,22422.0,25854761.0,Zuo X,Immune system disorder,initial,2015-04-09,GCST008479,Psoriasis
10432,European,21590.0,25865494.0,Chan Y,Body measurement,initial,2015-04-09,GCST002843,Sitting height ratio
4293,Asian,20338.0,25854761.0,Zuo X,Immune system disorder,replication,2015-04-09,GCST008479,Psoriasis
8524,European,5170.0,25855136.0,Stacey SN,Cancer,replication,2015-04-09,GCST002842,Basal cell carcinoma
1136,African American or Afro-Caribbean,3545.0,25865494.0,Chan Y,Body measurement,initial,2015-04-09,GCST002843,Sitting height ratio
7647,European,3111.0,25865352.0,Schaarschmidt H,Immune system disorder,replication,2015-04-10,GCST002844,Atopic dermatitis
10138,European,16559.0,25861811.0,Li Z,Neurological disorder,replication,2015-04-10,GCST008391,Glaucoma (primary open-angle)
3237,Asian,2993.0,25861811.0,Li Z,Neurological disorder,replication,2015-04-10,GCST008391,Glaucoma (primary open-angle)
731,African American or Afro-Caribbean,801.0,25861811.0,Li Z,Neurological disorder,replication,2015-04-10,GCST008391,Glaucoma (primary open-angle)
3521,Asian,5050.0,25862617.0,Zhang Y,Immune system disorder,initial,2015-04-10,GCST002845,Systemic lupus erythematosus
4104,Asian,11760.0,25861811.0,Li Z,Neurological disorder,replication,2015-04-10,GCST008391,Glaucoma (primary open-angle)
13802,Other/Mixed,891.0,25861811.0,Li Z,Neurological disorder,replication,2015-04-10,GCST008391,Glaucoma (primary open-angle)
8778,European,6163.0,25865352.0,Schaarschmidt H,Immune system disorder,initial,2015-04-10,GCST002844,Atopic dermatitis
2353,Asian,837.0,25861811.0,Li Z,Neurological disorder,initial,2015-04-10,GCST008391,Glaucoma (primary open-angle)
2946,Asian,2042.0,25861811.0,Li Z,Neurological disorder,initial,2015-04-10,GCST008391,Glaucoma (primary open-angle)
828,African American or Afro-Caribbean,1226.0,25861811.0,Li Z,Neurological disorder,initial,2015-04-10,GCST008391,Glaucoma (primary open-angle)
2615,Asian,1425.0,25862617.0,Zhang Y,Immune system disorder,replication,2015-04-10,GCST002845,Systemic lupus erythematosus
3467,Asian,4628.0,25862617.0,Zhang Y,Immune system disorder,replication,2015-04-10,GCST002845,Systemic lupus erythematosus
3223,Asian,2949.0,25861811.0,Li Z,Neurological disorder,replication,2015-04-10,GCST008391,Glaucoma (primary open-angle)
3978,Asian,9145.0,25861811.0,Li Z,Neurological disorder,initial,2015-04-10,GCST008391,Glaucoma (primary open-angle)
6411,European,1358.0,25875332.0,Zayats T,Neurological disorder,initial,2015-04-13,GCST002848,Attention deficit hyperactivity disorder
2762,Asian,1732.0,25867717.0,Song N,"Cancer, Other measurement",initial,2015-04-13,GCST002847,Disease-free survival in breast cancer
2634,Asian,1494.0,25867717.0,Song N,"Cancer, Other measurement",replication,2015-04-13,GCST002847,Disease-free survival in breast cancer
10776,European,33337.0,25869804.0,Ibrahim-Verbaas CA,Biological process,initial,2015-04-14,GCST002850,Information processing speed
877,African American or Afro-Caribbean,1444.0,25869804.0,Ibrahim-Verbaas CA,Biological process,replication,2015-04-14,GCST002850,Information processing speed
9330,European,8436.0,25869804.0,Ibrahim-Verbaas CA,Biological process,replication,2015-04-14,GCST002850,Information processing speed
9908,European,13462.0,25869804.0,Ibrahim-Verbaas CA,Biological process,initial,2015-04-14,GCST002849,Executive function
10377,European,20720.0,25869804.0,Ibrahim-Verbaas CA,Biological process,replication,2015-04-14,GCST002849,Executive function
1092,African American or Afro-Caribbean,3146.0,25869804.0,Ibrahim-Verbaas CA,Biological process,replication,2015-04-14,GCST002849,Executive function
3357,Asian,3810.0,25888059.0,Cha S,Other trait,initial,2015-04-15,GCST002854,Sasang constitutional medicine type (So-Eum)
3356,Asian,3810.0,25888059.0,Cha S,Other trait,initial,2015-04-15,GCST002853,Sasang constitutional medicine type (Tae-Eum)
3355,Asian,3810.0,25888059.0,Cha S,Other trait,initial,2015-04-15,GCST002852,Sasang constitutional medicine type (So-Yang)
2737,Asian,1680.0,25888059.0,Cha S,Other trait,replication,2015-04-15,GCST002852,Sasang constitutional medicine type (So-Yang)
2736,Asian,1680.0,25888059.0,Cha S,Other trait,replication,2015-04-15,GCST002851,Sasang constitutional medicine type (Tae-Yang)
3354,Asian,3810.0,25888059.0,Cha S,Other trait,initial,2015-04-15,GCST002851,Sasang constitutional medicine type (Tae-Yang)
9189,European,8013.0,25877299.0,Kristiansen W,Cancer,initial,2015-04-15,GCST002855,Testicular germ cell tumor
2738,Asian,1680.0,25888059.0,Cha S,Other trait,replication,2015-04-15,GCST002853,Sasang constitutional medicine type (Tae-Eum)
2739,Asian,1680.0,25888059.0,Cha S,Other trait,replication,2015-04-15,GCST002854,Sasang constitutional medicine type (So-Eum)
7460,European,2709.0,25877299.0,Kristiansen W,Cancer,replication,2015-04-15,GCST002855,Testicular germ cell tumor
560,African American or Afro-Caribbean,257.0,25898001.0,Dong C,Other measurement,replication,2015-04-16,GCST002856,Carotid artery intima media thickness (sex interaction)
12776,Hispanic or Latin American,931.0,25898001.0,Dong C,Other measurement,initial,2015-04-16,GCST002856,Carotid artery intima media thickness (sex interaction)
4731,European,153.0,25898001.0,Dong C,Other measurement,replication,2015-04-16,GCST002856,Carotid artery intima media thickness (sex interaction)
7192,European,2317.0,25886283.0,Chang X,Other measurement,initial,2015-04-17,GCST002860,Magnesium levels
852,African American or Afro-Caribbean,1283.0,25886283.0,Chang X,Other measurement,initial,2015-04-17,GCST002860,Magnesium levels
4596,European,60.0,25896417.0,Nakada TA,"Inflammatory measurement, Response to drug",initial,2015-04-17,GCST002859,Cytokine-stimulated IL-6 production
8547,European,5261.0,25886283.0,Chang X,Other measurement,initial,2015-04-17,GCST002857,Calcium levels
1160,African American or Afro-Caribbean,3817.0,25886283.0,Chang X,Other measurement,initial,2015-04-17,GCST002857,Calcium levels
4597,European,60.0,25896417.0,Nakada TA,"Response to drug, Inflammatory measurement",initial,2015-04-17,GCST002858,Cytokine and corticosteroid-stimulated IL-6 production
10916,European,37954.0,25890600.0,Guo Q,"Other measurement, Cancer",initial,2015-04-18,GCST002861,Breast cancer (survival)
8914,European,6745.0,25898129.0,Shim H,"Lipid or lipoprotein measurement, Response to drug",replication,2015-04-21,GCST002865,Response to statin therapy (LDL cholesterol subfractions)
6838,European,1868.0,25898129.0,Shim H,"Lipid or lipoprotein measurement, Response to drug",initial,2015-04-21,GCST002865,Response to statin therapy (LDL cholesterol subfractions)
2162,Asian,567.0,25897834.0,Biernacka JM,"Response to drug, Neurological disorder",initial,2015-04-21,GCST002868,Response to serotonin reuptake inhibitors in major depressive disorder
4961,European,298.0,25897834.0,Biernacka JM,"Response to drug, Neurological disorder",initial,2015-04-21,GCST002868,Response to serotonin reuptake inhibitors in major depressive disorder
6837,European,1868.0,25898129.0,Shim H,Lipid or lipoprotein measurement,initial,2015-04-21,GCST002870,LDL cholesterol subfractions
8913,European,6745.0,25898129.0,Shim H,Lipid or lipoprotein measurement,replication,2015-04-21,GCST002870,LDL cholesterol subfractions
4894,European,245.0,25896534.0,Julia A,"Immune system disorder, Response to drug",replication,2015-04-21,GCST002869,"Response to anti-TNF treatment (adalimumab, etanercept or infliximab) in rheumatoid arthritis"
5055,European,361.0,25896534.0,Julia A,"Immune system disorder, Response to drug",initial,2015-04-21,GCST002869,"Response to anti-TNF treatment (adalimumab, etanercept or infliximab) in rheumatoid arthritis"
8061,European,3953.0,25898920.0,Korostishevsky M,Other measurement,initial,2015-04-22,GCST002872,Blood metabolite levels
7793,European,3330.0,25855579.0,Mancikova V,Cancer,replication,2015-04-22,GCST002873,Thyroid cancer
5906,European,900.0,25855579.0,Mancikova V,Cancer,initial,2015-04-22,GCST002873,Thyroid cancer
3531,Asian,5134.0,25903422.0,Yin X,Immune system disorder,initial,2015-04-23,GCST002874,Psoriasis
4047,Asian,10303.0,25903422.0,Yin X,Immune system disorder,replication,2015-04-23,GCST002874,Psoriasis
9374,European,8682.0,25903422.0,Yin X,Immune system disorder,initial,2015-04-23,GCST002874,Psoriasis
9686,European,10767.0,25903422.0,Yin X,Immune system disorder,replication,2015-04-23,GCST002874,Psoriasis
5905,European,898.0,25918132.0,Yucesoy B,"Biological process, Other disease",initial,2015-04-26,GCST002875,Diisocyanate-induced asthma
6159,European,1073.0,25936594.0,Tomer Y,"Immune system disorder, Metabolic disorder",initial,2015-04-27,GCST002876,Type 1 diabetes and autoimmune thyroid diseases
5381,European,525.0,25936594.0,Tomer Y,"Immune system disorder, Metabolic disorder",replication,2015-04-27,GCST002876,Type 1 diabetes and autoimmune thyroid diseases
7824,European,3373.0,25918841.0,Sanchez-Juan P,Neurological disorder,replication,2015-04-28,GCST002878,Creutzfeldt-Jakob disease (sporadic)
5318,European,498.0,25918995.0,Salvatore JE,Other measurement,replication,2015-04-28,GCST002877,Adult antisocial behavior
3331,Asian,3644.0,25802187.0,Jiang DK,Digestive system disorder,initial,2015-04-28,GCST002879,Chronic hepatitis B infection
5515,European,621.0,25918995.0,Salvatore JE,Other measurement,initial,2015-04-28,GCST002877,Adult antisocial behavior
7237,European,2373.0,25918841.0,Sanchez-Juan P,Neurological disorder,initial,2015-04-28,GCST002878,Creutzfeldt-Jakob disease (sporadic)
4198,Asian,14727.0,25802187.0,Jiang DK,Digestive system disorder,replication,2015-04-28,GCST002879,Chronic hepatitis B infection
2187,Asian,620.0,25920553.0,Coleman C,Immune system disorder,replication,2015-04-29,GCST008489,Celiac disease
10507,European,23649.0,25920553.0,Coleman C,Immune system disorder,replication,2015-04-29,GCST008489,Celiac disease
5881,European,878.0,25920553.0,Coleman C,Immune system disorder,initial,2015-04-29,GCST008489,Celiac disease
2328,Asian,797.0,25935106.0,Kim KW,Immune system disorder,initial,2015-04-30,GCST002880,Recalcitrant atopic dermatitis
7857,European,3423.0,25934476.0,de Vries PS,Other measurement,initial,2015-05-01,GCST002881,ADAMTS13 activity
6625,European,1607.0,25676789.0,Wen CC,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2015-05-01,GCST004751,Serum uric acid levels in response to allopurinol in gout
1868,Asian,238.0,25676789.0,Wen CC,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2015-05-01,GCST004751,Serum uric acid levels in response to allopurinol in gout
6946,European,2025.0,25934476.0,de Vries PS,Other measurement,replication,2015-05-01,GCST002881,ADAMTS13 activity
12537,Hispanic or Latin American,85.0,25676789.0,Wen CC,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2015-05-01,GCST004751,Serum uric acid levels in response to allopurinol in gout
445,African American or Afro-Caribbean,84.0,25676789.0,Wen CC,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2015-05-01,GCST004751,Serum uric acid levels in response to allopurinol in gout
6790,European,1794.0,25935875.0,Varenhorst C,"Cardiovascular disease, Other measurement",initial,2015-05-02,GCST002882,Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor
6866,European,1922.0,25935875.0,Varenhorst C,"Cardiovascular disease, Other measurement",replication,2015-05-02,GCST002883,AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor
13420,Other/Mixed,19.0,25935875.0,Varenhorst C,"Cardiovascular disease, Other measurement",replication,2015-05-02,GCST002882,Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor
6791,European,1794.0,25935875.0,Varenhorst C,"Cardiovascular disease, Other measurement",initial,2015-05-02,GCST002883,AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor
13421,Other/Mixed,19.0,25935875.0,Varenhorst C,"Cardiovascular disease, Other measurement",replication,2015-05-02,GCST002883,AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor
13416,Other/Mixed,18.0,25935875.0,Varenhorst C,"Cardiovascular disease, Other measurement",initial,2015-05-02,GCST002882,Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor
6865,European,1922.0,25935875.0,Varenhorst C,"Cardiovascular disease, Other measurement",replication,2015-05-02,GCST002882,Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor
13417,Other/Mixed,18.0,25935875.0,Varenhorst C,"Cardiovascular disease, Other measurement",initial,2015-05-02,GCST002883,AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor
5265,European,481.0,25827949.0,Kunz M,Immune system disorder,replication,2015-05-04,GCST002884,Cutaneous lupus erythematosus
6484,European,1439.0,25827949.0,Kunz M,Immune system disorder,initial,2015-05-04,GCST002884,Cutaneous lupus erythematosus
4946,European,290.0,25944848.0,Athanasiu L,"Response to drug, Neurological disorder, Other measurement",initial,2015-05-05,GCST002885,Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio)
10056,European,15402.0,25939597.0,Berndt SI,Cancer,replication,2015-05-05,GCST002890,Prostate cancer
5808,European,829.0,25944848.0,Athanasiu L,"Response to drug, Neurological disorder, Other measurement",initial,2015-05-05,GCST002888,Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)
4781,European,185.0,25944848.0,Athanasiu L,"Neurological disorder, Other measurement, Response to drug",initial,2015-05-05,GCST002887,Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio)
9172,European,7973.0,25939597.0,Berndt SI,"Cancer, Other measurement",replication,2015-05-05,GCST002886,Prostate cancer aggressiveness
10361,European,20440.0,25939698.0,Tsoi LC,Immune system disorder,replication,2015-05-05,GCST002889,Psoriasis
8264,European,4545.0,25939597.0,Berndt SI,"Cancer, Other measurement",initial,2015-05-05,GCST002886,Prostate cancer aggressiveness
4990,European,320.0,25944848.0,Athanasiu L,"Neurological disorder, Other measurement, Response to drug",initial,2015-05-05,GCST002891,Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio)
9090,European,7541.0,25939597.0,Berndt SI,Cancer,initial,2015-05-05,GCST002890,Prostate cancer
9774,European,11693.0,25939698.0,Tsoi LC,Immune system disorder,initial,2015-05-05,GCST002889,Psoriasis
5516,European,622.0,25948407.0,Kertai MD,"Other trait, Cardiovascular disease",replication,2015-05-06,GCST002892,Perioperative myocardial infarction in coronary artery bypass surgery
8048,European,3918.0,25953783.0,Warrington NM,"Body measurement, Other measurement",replication,2015-05-07,GCST002894,Body mass index
8047,European,3918.0,25953783.0,Warrington NM,Body measurement,replication,2015-05-07,GCST002893,Body mass index (age interaction)
11726,European,124013.0,25956309.0,Palomba G,Cancer,replication,2015-05-10,GCST002895,Breast cancer
7616,European,3025.0,25956309.0,Palomba G,Cancer,initial,2015-05-10,GCST002895,Breast cancer
11243,European,62166.0,25961943.0,Surakka I,Lipid or lipoprotein measurement,initial,2015-05-11,GCST002897,Triglycerides
8327,European,4723.0,25964295.0,Khan S,"Other measurement, Cancer, Response to drug",replication,2015-05-11,GCST002901,Survival in endocrine treated breast cancer (estrogen-receptor positive)
6403,European,1351.0,25964295.0,Khan S,"Other measurement, Cancer",replication,2015-05-11,GCST002902,Survival in breast cancer (estrogen-receptor negative)
11244,European,62166.0,25961943.0,Surakka I,Lipid or lipoprotein measurement,initial,2015-05-11,GCST002899,HDL cholesterol
11242,European,62166.0,25961943.0,Surakka I,Lipid or lipoprotein measurement,initial,2015-05-11,GCST002896,"Cholesterol, total"
6319,European,1236.0,25964295.0,Khan S,"Other measurement, Cancer, Response to drug",initial,2015-05-11,GCST002901,Survival in endocrine treated breast cancer (estrogen-receptor positive)
7823,European,3372.0,25964295.0,Khan S,"Other measurement, Cancer",replication,2015-05-11,GCST002903,Survival in breast cancer (estrogen-receptor positive)
11215,European,58358.0,25961943.0,Surakka I,"Lipid or lipoprotein measurement, Other measurement",initial,2015-05-11,GCST002898,LDL cholesterol
5533,European,639.0,25964295.0,Khan S,"Other measurement, Cancer",initial,2015-05-11,GCST002903,Survival in breast cancer (estrogen-receptor positive)
5477,European,597.0,25964295.0,Khan S,"Other measurement, Cancer",initial,2015-05-11,GCST002902,Survival in breast cancer (estrogen-receptor negative)
8700,European,5857.0,25963972.0,Liu F,Other trait,initial,2015-05-12,GCST002906,Skin colour saturation
7434,European,2668.0,25963972.0,Liu F,Immune system disorder,initial,2015-05-12,GCST002908,Skin sensitivity to sun
8555,European,5278.0,25963972.0,Liu F,Other trait,replication,2015-05-12,GCST002907,Perceived skin darkness
9464,European,9316.0,25963972.0,Liu F,Other trait,initial,2015-05-12,GCST002907,Perceived skin darkness
6172,European,1079.0,25963331.0,Hatzimanolis A,Other trait,initial,2015-05-12,GCST002905,Endophenotypes for schizophrenia in healthy individuals
6592,European,1563.0,25963331.0,Hatzimanolis A,Other trait,replication,2015-05-12,GCST002905,Endophenotypes for schizophrenia in healthy individuals
7061,European,2158.0,25972531.0,Carter TC,Other measurement,initial,2015-05-13,GCST006798,4-pyridoxic acid levels
3259,Asian,3103.0,25967671.0,Li C,Metabolic disorder,initial,2015-05-13,GCST002909,Gout
3808,Asian,7444.0,25967671.0,Li C,Metabolic disorder,replication,2015-05-13,GCST002909,Gout
7062,European,2158.0,25972531.0,Carter TC,Other measurement,initial,2015-05-13,GCST006799,Pyridoxal 5'-phosphate levels
7060,European,2158.0,25972531.0,Carter TC,Other measurement,initial,2015-05-13,GCST006797,Pyridoxal levels
3458,Asian,4558.0,25972035.0,Vinayagamoorthy N,Other measurement,initial,2015-05-14,GCST002911,Calcium levels
3397,Asian,4093.0,25972035.0,Vinayagamoorthy N,Other measurement,replication,2015-05-14,GCST002911,Calcium levels
5483,European,600.0,25914168.0,Esposito F,"Immune system disorder, Response to drug",replication,2015-05-14,GCST002910,Response to interferon beta in multiple sclerosis
4696,European,116.0,25914168.0,Esposito F,"Immune system disorder, Response to drug",initial,2015-05-14,GCST002910,Response to interferon beta in multiple sclerosis
2485,Asian,1109.0,25986216.0,Toyoda H,Neurological disorder,replication,2015-05-15,GCST002912,Narcolepsy with cataplexy
2909,Asian,1971.0,25986216.0,Toyoda H,Neurological disorder,initial,2015-05-15,GCST002912,Narcolepsy with cataplexy
1040,African American or Afro-Caribbean,2868.0,25988933.0,Almli LM,Neurological disorder,replication,2015-05-18,GCST002914,Post-traumatic stress disorder
1677,Asian,103.0,25985088.0,Oguchi T,"Immune system disorder, Other trait",initial,2015-05-18,GCST002913,Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis
13370,Other/Mixed,4.0,25988933.0,Almli LM,Neurological disorder,initial,2015-05-18,GCST002914,Post-traumatic stress disorder
4576,European,45.0,25988933.0,Almli LM,Neurological disorder,initial,2015-05-18,GCST002914,Post-traumatic stress disorder
1539,Asian,6.0,25988933.0,Almli LM,Neurological disorder,initial,2015-05-18,GCST002914,Post-traumatic stress disorder
13944,Other/Mixed,3126.0,25987655.0,Fernandez CA,"Cancer, Response to drug",initial,2015-05-18,GCST002915,Asparaginase hypersensitivity in acute lymphoblastic leukemia
13555,Other/Mixed,182.0,25987655.0,Fernandez CA,"Cancer, Response to drug",replication,2015-05-18,GCST002915,Asparaginase hypersensitivity in acute lymphoblastic leukemia
18,African,35.0,25988933.0,Almli LM,Neurological disorder,initial,2015-05-18,GCST002914,Post-traumatic stress disorder
12527,Hispanic or Latin American,57.0,25988933.0,Almli LM,Neurological disorder,initial,2015-05-18,GCST002914,Post-traumatic stress disorder
5729,European,775.0,25987243.0,Parham LR,"Digestive system disorder, Response to drug",initial,2015-05-19,GCST002918,Lapatinib-induced hepatotoxicity
8912,European,6744.0,25987507.0,Minica CC,"Neurological disorder, Biological process",initial,2015-05-19,GCST002916,Cannabis use (initiation)
8517,European,5148.0,25987507.0,Minica CC,"Biological process, Other measurement",initial,2015-05-19,GCST002917,Cannabis use (age at onset)
1863,Asian,236.0,25987243.0,Parham LR,"Digestive system disorder, Response to drug",initial,2015-05-19,GCST002918,Lapatinib-induced hepatotoxicity
10205,European,17556.0,25990418.0,Al-Tassan NA,Cancer,initial,2015-05-20,GCST002919,Colorectal cancer
11265,European,63661.0,25993607.0,de Moor MH,"Neurological disorder, Other measurement",initial,2015-05-20,GCST002920,Neuroticism
9544,European,9786.0,25993607.0,de Moor MH,"Neurological disorder, Other measurement",replication,2015-05-20,GCST002920,Neuroticism
7446,European,2697.0,26007630.0,Swaminathan B,"Other disease, Cancer",replication,2015-05-26,GCST002922,Multiple myeloma and monoclonal gammopathy
12081,European,224749.0,26007630.0,Swaminathan B,Cancer,initial,2015-05-26,GCST002921,Multiple myeloma
7445,European,2697.0,26007630.0,Swaminathan B,Cancer,replication,2015-05-26,GCST002921,Multiple myeloma
12182,European,296835.0,26007630.0,Swaminathan B,"Other disease, Cancer",initial,2015-05-26,GCST002922,Multiple myeloma and monoclonal gammopathy
1736,Asian,145.0,26015512.0,Komatsu M,"Response to drug, Neurological disorder, Other measurement",initial,2015-05-26,GCST002923,Paclitaxel-induced neuropathy
38,African,87.0,26015512.0,Komatsu M,"Other measurement, Response to drug",replication,2015-05-26,GCST002924,Paclitaxel-induced cytotoxicity
35,African,83.0,26015512.0,Komatsu M,"Other measurement, Response to drug",replication,2015-05-26,GCST002924,Paclitaxel-induced cytotoxicity
1692,Asian,116.0,26015512.0,Komatsu M,"Other measurement, Response to drug",initial,2015-05-26,GCST002924,Paclitaxel-induced cytotoxicity
4618,European,77.0,26015512.0,Komatsu M,"Other measurement, Response to drug",replication,2015-05-26,GCST002924,Paclitaxel-induced cytotoxicity
7556,European,2913.0,26014426.0,Ruth KS,Other measurement,initial,2015-05-27,GCST002925,Sex hormone levels
5292,European,489.0,26025128.0,Park HW,"Response to drug, Other disease, Other measurement",initial,2015-05-27,GCST002926,Bone mineral accretion in asthma (oral corticosteroid dose interaction)
5983,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002929,Chromium levels
5985,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002931,Aluminium levels
5986,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002932,Manganese levels
5982,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002928,Nickel levels
5987,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002934,Zinc levels
5988,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002935,Lead levels
5981,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002927,Mercury levels
5984,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002930,Cobalt levels
5990,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002937,Molybdenum levels
5989,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002936,Cadmium levels
1033,African American or Afro-Caribbean,2737.0,26058915.0,Tin A,Other measurement,initial,2015-05-29,GCST002933,Magnesium levels
768,African American or Afro-Caribbean,942.0,26058915.0,Tin A,Other measurement,replication,2015-05-29,GCST002933,Magnesium levels
5991,European,949.0,26025379.0,Ng E,Other measurement,initial,2015-05-29,GCST002938,Copper levels
6308,European,1221.0,26024889.0,Qayyum R,Biological process,replication,2015-05-30,GCST002939,Platelet aggregation
741,African American or Afro-Caribbean,825.0,26024889.0,Qayyum R,Biological process,initial,2015-05-30,GCST002939,Platelet aggregation
471,African American or Afro-Caribbean,119.0,26024889.0,Qayyum R,Biological process,replication,2015-05-30,GCST002939,Platelet aggregation
5293,European,489.0,26030142.0,Van Driest SL,"Response to drug, Other measurement",initial,2015-06-01,GCST002948,Peak creatinine levels in vancomycin therapy
3321,Asian,3559.0,26029870.0,Ye Z,Cancer,initial,2015-06-01,GCST002940,Sporadic pituitary adenoma
3696,Asian,6162.0,26029870.0,Ye Z,Cancer,replication,2015-06-01,GCST002940,Sporadic pituitary adenoma
4226,Asian,15898.0,26028593.0,Li M,Other disease,replication,2015-06-01,GCST002943,IgA nephropathy
1071,African American or Afro-Caribbean,3033.0,26030696.0,Cho MH,Other measurement,initial,2015-06-01,GCST002942,Percentage gas trapping
3271,Asian,3226.0,26034056.0,Hoffmann TJ,Cancer,initial,2015-06-01,GCST002944,Prostate cancer
1070,African American or Afro-Caribbean,3033.0,26030696.0,Cho MH,Other measurement,initial,2015-06-01,GCST002941,Airway imaging phenotypes
1072,African American or Afro-Caribbean,3033.0,26030696.0,Cho MH,Other measurement,initial,2015-06-01,GCST002945,Emphysema imaging phenotypes
5694,European,745.0,26030142.0,Van Driest SL,"Other measurement, Response to drug",initial,2015-06-01,GCST002946,Vancomycin trough in vancomycin therapy
12965,Hispanic or Latin American,3629.0,26034056.0,Hoffmann TJ,Cancer,initial,2015-06-01,GCST002944,Prostate cancer
4108,Asian,12095.0,26028593.0,Li M,Other disease,initial,2015-06-01,GCST002943,IgA nephropathy
10885,European,37272.0,26034056.0,Hoffmann TJ,Cancer,initial,2015-06-01,GCST002944,Prostate cancer
5031,European,343.0,26030142.0,Van Driest SL,"Response to drug, Other measurement",replication,2015-06-01,GCST002947,Renal elimination rate in vancomycin therapy
5030,European,343.0,26030142.0,Van Driest SL,"Other measurement, Response to drug",replication,2015-06-01,GCST002946,Vancomycin trough in vancomycin therapy
5200,European,439.0,26030142.0,Van Driest SL,"Response to drug, Other measurement",replication,2015-06-01,GCST002948,Peak creatinine levels in vancomycin therapy
9089,European,7539.0,26034056.0,Hoffmann TJ,Cancer,replication,2015-06-01,GCST002944,Prostate cancer
9424,European,8998.0,26030696.0,Cho MH,Other measurement,initial,2015-06-01,GCST002941,Airway imaging phenotypes
986,African American or Afro-Caribbean,2251.0,26034056.0,Hoffmann TJ,Cancer,initial,2015-06-01,GCST002944,Prostate cancer
1205,African American or Afro-Caribbean,4679.0,26034056.0,Hoffmann TJ,Cancer,replication,2015-06-01,GCST002944,Prostate cancer
9425,European,8998.0,26030696.0,Cho MH,Other measurement,initial,2015-06-01,GCST002945,Emphysema imaging phenotypes
5695,European,745.0,26030142.0,Van Driest SL,"Response to drug, Other measurement",initial,2015-06-01,GCST002947,Renal elimination rate in vancomycin therapy
8811,European,6305.0,26030696.0,Cho MH,Other measurement,initial,2015-06-01,GCST002942,Percentage gas trapping
2527,Asian,1211.0,26220383.0,Jang HW,Neurological disorder,initial,2015-06-02,GCST002950,Epilepsy
4903,European,259.0,26031901.0,Dahlin A,"Other measurement, Other disease, Response to drug",initial,2015-06-02,GCST002951,Response to zileuton treatment in asthma (FEV1 change interaction)
2489,Asian,1114.0,26220383.0,Jang HW,"Response to drug, Other disease, Neurological disorder",initial,2015-06-02,GCST002949,Epilepsy and lamotrigine-induced maculopapular eruptions
4789,European,187.0,26031901.0,Dahlin A,"Other measurement, Other disease, Response to drug",replication,2015-06-02,GCST002951,Response to zileuton treatment in asthma (FEV1 change interaction)
5913,European,908.0,26041818.0,Chesi A,Other measurement,initial,2015-06-03,GCST002952,Pediatric bone mineral content (radius)
5267,European,481.0,26041818.0,Chesi A,Other measurement,replication,2015-06-03,GCST002953,Pediatric areal bone mineral density (radius)
13511,Other/Mixed,126.0,26041818.0,Chesi A,Other measurement,initial,2015-06-03,GCST002952,Pediatric bone mineral content (radius)
595,African American or Afro-Caribbean,337.0,26041818.0,Chesi A,Other measurement,initial,2015-06-03,GCST002953,Pediatric areal bone mineral density (radius)
5266,European,481.0,26041818.0,Chesi A,Other measurement,replication,2015-06-03,GCST002952,Pediatric bone mineral content (radius)
594,African American or Afro-Caribbean,337.0,26041818.0,Chesi A,Other measurement,initial,2015-06-03,GCST002952,Pediatric bone mineral content (radius)
5914,European,908.0,26041818.0,Chesi A,Other measurement,initial,2015-06-03,GCST002953,Pediatric areal bone mineral density (radius)
13512,Other/Mixed,126.0,26041818.0,Chesi A,Other measurement,initial,2015-06-03,GCST002953,Pediatric areal bone mineral density (radius)
3889,Asian,8223.0,26049409.0,Hirano A,Neurological disorder,replication,2015-06-05,GCST002954,Alzheimer's disease (late onset)
3935,Asian,8808.0,26049409.0,Hirano A,Neurological disorder,initial,2015-06-05,GCST002954,Alzheimer's disease (late onset)
12643,Hispanic or Latin American,449.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002956,3-hydroxypropylmercapturic acid levels in smokers
2245,Asian,702.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002957,3-hydroxy-1-methylpropylmercapturic acid levels in smokers
606,African American or Afro-Caribbean,361.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002957,3-hydroxy-1-methylpropylmercapturic acid levels in smokers
13616,Other/Mixed,329.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002956,3-hydroxypropylmercapturic acid levels in smokers
2252,Asian,704.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002956,3-hydroxypropylmercapturic acid levels in smokers
5197,European,438.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002956,3-hydroxypropylmercapturic acid levels in smokers
13617,Other/Mixed,329.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002957,3-hydroxy-1-methylpropylmercapturic acid levels in smokers
607,African American or Afro-Caribbean,362.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002956,3-hydroxypropylmercapturic acid levels in smokers
5202,European,440.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002957,3-hydroxy-1-methylpropylmercapturic acid levels in smokers
12644,Hispanic or Latin American,452.0,26053186.0,Park SL,"Biological process, Other measurement",initial,2015-06-08,GCST002957,3-hydroxy-1-methylpropylmercapturic acid levels in smokers
13414,Other/Mixed,17.0,26067905.0,Bari R,"Immune system disorder, Biological process",replication,2015-06-11,GCST002958,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
4587,European,52.0,26067905.0,Bari R,"Immune system disorder, Biological process",initial,2015-06-11,GCST002958,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
13352,Other/Mixed,2.0,26067905.0,Bari R,"Immune system disorder, Biological process",initial,2015-06-11,GCST002958,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
4602,European,64.0,26067905.0,Bari R,"Immune system disorder, Biological process",replication,2015-06-11,GCST002958,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
1529,Asian,2.0,26067905.0,Bari R,"Immune system disorder, Biological process",replication,2015-06-11,GCST002958,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
1520,Asian,1.0,26067905.0,Bari R,"Immune system disorder, Biological process",initial,2015-06-11,GCST002958,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
12,African,17.0,26067905.0,Bari R,"Immune system disorder, Biological process",replication,2015-06-11,GCST002958,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
10,African,13.0,26067905.0,Bari R,"Immune system disorder, Biological process",initial,2015-06-11,GCST002958,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
9077,European,7478.0,26068415.0,Draisma HHM,Other measurement,initial,2015-06-12,GCST002966,Amino acid levels
6493,European,1456.0,26154020.0,Ferrari R,Neurological disorder,initial,2015-06-12,GCST002960,Frontotemporal dementia
5451,European,581.0,26073756.0,McGeachie MJ,Other measurement,initial,2015-06-12,GCST002962,Asthma exacerbations
155,African,949.0,26114229.0,Ashley-Koch AE,Neurological disorder,initial,2015-06-12,GCST002963,Post-traumatic stress disorder
9076,European,7478.0,26068415.0,Draisma HHM,Other measurement,initial,2015-06-12,GCST002961,Acylcarnitine levels
9075,European,7478.0,26068415.0,Draisma HHM,Other measurement,initial,2015-06-12,GCST002959,Hexose levels
9079,European,7478.0,26068415.0,Draisma HHM,"Other measurement, Lipid or lipoprotein measurement",initial,2015-06-12,GCST002965,Glycerophospholipid levels
9078,European,7478.0,26068415.0,Draisma HHM,"Other measurement, Lipid or lipoprotein measurement",initial,2015-06-12,GCST002964,Sphingolipid levels
6267,European,1182.0,26068415.0,Draisma HHM,Other measurement,replication,2015-06-12,GCST002959,Hexose levels
5715,European,759.0,26114229.0,Ashley-Koch AE,Neurological disorder,initial,2015-06-12,GCST002963,Post-traumatic stress disorder
6271,European,1182.0,26068415.0,Draisma HHM,"Other measurement, Lipid or lipoprotein measurement",replication,2015-06-12,GCST002965,Glycerophospholipid levels
6270,European,1182.0,26068415.0,Draisma HHM,"Other measurement, Lipid or lipoprotein measurement",replication,2015-06-12,GCST002964,Sphingolipid levels
541,African American or Afro-Caribbean,212.0,26073756.0,McGeachie MJ,Other measurement,replication,2015-06-12,GCST002962,Asthma exacerbations
6269,European,1182.0,26068415.0,Draisma HHM,Other measurement,replication,2015-06-12,GCST002966,Amino acid levels
5552,European,652.0,26073756.0,McGeachie MJ,Other measurement,replication,2015-06-12,GCST002962,Asthma exacerbations
6268,European,1182.0,26068415.0,Draisma HHM,Other measurement,replication,2015-06-12,GCST002961,Acylcarnitine levels
1785,Asian,190.0,25950743.0,Uttayamakul S,"Response to drug, Other disease, Other trait",replication,2015-06-15,GCST002968,Response to stavudine in HIV (lipoatrophy)
1734,Asian,141.0,25950743.0,Uttayamakul S,"Response to drug, Other disease, Other trait",initial,2015-06-15,GCST002968,Response to stavudine in HIV (lipoatrophy)
10500,European,23337.0,26075790.0,Kelemen LE,Cancer,initial,2015-06-15,GCST002967,Mucinous ovarian carcinoma
4900,European,253.0,26077402.0,de Rooy DP,"Immune system disorder, Other measurement",replication,2015-06-15,GCST003256,Joint damage progression in ACPA-negative rheumatoid arthritis
4904,European,262.0,26077402.0,de Rooy DP,"Immune system disorder, Other measurement",initial,2015-06-15,GCST003256,Joint damage progression in ACPA-negative rheumatoid arthritis
5052,European,358.0,26079190.0,Galfalvy H,"Neurological disorder, Other measurement",initial,2015-06-16,GCST002974,Suicide ideation score in major depressive disorder
6798,European,1810.0,26079190.0,Galfalvy H,Biological process,initial,2015-06-16,GCST002969,Suicide behavior
6577,European,1550.0,26079190.0,Galfalvy H,Biological process,initial,2015-06-16,GCST002973,Suicide
5426,European,557.0,26079190.0,Galfalvy H,"Biological process, Neurological disorder",initial,2015-06-16,GCST002972,Suicide attempts in major depressive disorder
4644,European,88.0,26083242.0,Dahlin A,"Other measurement, Other disease, Response to drug",initial,2015-06-17,GCST002979,Response to montelukast in asthma (change in FEV1)
28,African,61.0,26084801.0,Mirabello L,"Other measurement, Cancer",replication,2015-06-17,GCST002978,Metastasis at diagnosis in osteosarcoma
4683,European,101.0,26083242.0,Dahlin A,"Other measurement, Other disease, Response to drug",replication,2015-06-17,GCST002979,Response to montelukast in asthma (change in FEV1)
1598,Asian,50.0,26083242.0,Dahlin A,"Other measurement, Other disease, Response to drug",replication,2015-06-17,GCST002979,Response to montelukast in asthma (change in FEV1)
15,African,33.0,26083242.0,Dahlin A,"Other measurement, Other disease, Response to drug",replication,2015-06-17,GCST002979,Response to montelukast in asthma (change in FEV1)
8,African,10.0,26083242.0,Dahlin A,"Other measurement, Other disease, Response to drug",initial,2015-06-17,GCST002979,Response to montelukast in asthma (change in FEV1)
2140,Asian,538.0,26039976.0,Wei Z,"Biological process, Other measurement, Other disease",initial,2015-06-17,GCST002976,HIV-1 viral setpoint
5873,European,873.0,26083657.0,Stafford-Smith M,"Other trait, Other measurement",initial,2015-06-17,GCST002982,Acute kidney injury in coronary artery bypass surgery (creatinine rise)
2024,Asian,402.0,26083723.0,Park S,Cardiovascular measurement,initial,2015-06-17,GCST002980,Arterial stiffness (pulse-wave velocity)
4865,European,226.0,26084801.0,Mirabello L,"Other measurement, Cancer",replication,2015-06-17,GCST002978,Metastasis at diagnosis in osteosarcoma
5878,European,877.0,26385043.0,Kertai MD,"Other trait, Cardiovascular disease",initial,2015-06-17,GCST002975,Postoperative atrial fibrillation in coronary artery bypass grafting surgery
226,African,1737.0,26083729.0,Maruthur NM,"Other measurement, Metabolic disorder",initial,2015-06-17,GCST002977,Advanced glycation end-product levels
2525,Asian,1206.0,26083723.0,Park S,Cardiovascular measurement,replication,2015-06-17,GCST002980,Arterial stiffness (pulse-wave velocity)
5076,European,380.0,26083657.0,Stafford-Smith M,"Other trait, Other measurement",replication,2015-06-17,GCST002982,Acute kidney injury in coronary artery bypass surgery (creatinine rise)
5452,European,581.0,26083729.0,Maruthur NM,"Other measurement, Metabolic disorder",initial,2015-06-17,GCST002977,Advanced glycation end-product levels
1590,Asian,35.0,26083242.0,Dahlin A,"Other measurement, Other disease, Response to drug",initial,2015-06-17,GCST002979,Response to montelukast in asthma (change in FEV1)
12551,Hispanic or Latin American,107.0,26084801.0,Mirabello L,"Other measurement, Cancer",replication,2015-06-17,GCST002978,Metastasis at diagnosis in osteosarcoma
12744,Hispanic or Latin American,786.0,26339675.0,Tosto G,Neurological disorder,replication,2015-06-18,GCST002983,Alzheimer's disease (late onset)
10069,European,15668.0,26087016.0,Pappa I,Other measurement,initial,2015-06-18,GCST002984,Early childhood aggressive behavior
13002,Hispanic or Latin American,4514.0,26339675.0,Tosto G,Neurological disorder,initial,2015-06-18,GCST002983,Alzheimer's disease (late onset)
10284,European,18988.0,26087016.0,Pappa I,Other measurement,initial,2015-06-18,GCST002986,Childhood and early adolescence aggressive behavior
10112,European,16311.0,26087016.0,Pappa I,Other measurement,initial,2015-06-18,GCST002985,Middle childhood and early adolescence aggressive behavior
1419,African American or Afro-Caribbean,14746.0,26089329.0,Carty CL,Cardiovascular disease,initial,2015-06-18,GCST002987,Stroke
1417,African American or Afro-Caribbean,14519.0,26089329.0,Carty CL,"Cardiovascular disease, Other trait",initial,2015-06-18,GCST002988,Ischemic stroke
5398,European,540.0,26112879.0,Rudkowska I,"Lipid or lipoprotein measurement, Other measurement",initial,2015-06-20,GCST002989,LDL peak particle diameter (total fat intake interaction)
9042,European,7320.0,26098869.0,Childs EJ,Cancer,initial,2015-06-22,GCST002991,Pancreatic cancer
12044,European,208152.0,26098866.0,Helgason H,Cancer,initial,2015-06-22,GCST002992,Gastric cancer
12028,European,204576.0,26098866.0,Helgason H,Cancer,initial,2015-06-22,GCST002990,Gastric adenocarcinoma (histologically verified)
1948,Asian,329.0,26100964.0,Cao S,"Response to drug, Digestive system disorder, Cancer",initial,2015-06-23,GCST002993,Platinum-induced hepatotoxicity in non-small cell lung cancer
1991,Asian,375.0,26100964.0,Cao S,"Response to drug, Digestive system disorder, Cancer",replication,2015-06-23,GCST002993,Platinum-induced hepatotoxicity in non-small cell lung cancer
5424,European,555.0,26116289.0,Raginis-Zborowska A,Other trait,initial,2015-06-24,GCST002995,Dysphagia
13043,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST003005,Superior crus of antihelix expression
13035,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST002997,Helix rolling
13034,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST002996,Folding of antihelix
13033,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST002994,Ear protrusion
13040,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST003002,Tragus size
13039,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST003001,Ear morphology
13036,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST002998,Lobe attachment
13041,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST003003,Antitragus size
13037,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST002999,Lobe size
13038,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST003000,Darwin's tubercle
13042,Hispanic or Latin American,4919.0,26105758.0,Adhikari K,Other trait,initial,2015-06-24,GCST003004,Crus helix expression
4566,European,31.0,26121033.0,Grondin Y,Neurological disorder,initial,2015-06-29,GCST003006,Noise-induced hearing loss
12499,Hispanic or Latin American,10.0,26121033.0,Grondin Y,Neurological disorder,initial,2015-06-29,GCST003006,Noise-induced hearing loss
4590,European,55.0,26121980.0,Chauhan L,"Other measurement, Response to drug, Other trait",initial,2015-06-30,GCST003008,Triptolide cytotoxicity
3523,Asian,5058.0,26129866.0,Hu N,Cancer,initial,2015-06-30,GCST003010,Gastric cancer
4078,Asian,11286.0,26129866.0,Hu N,Cancer,replication,2015-06-30,GCST003009,Cardia gastric cancer
4070,Asian,11211.0,26129866.0,Hu N,Cancer,replication,2015-06-30,GCST003007,Non-cardia gastric cancer
3347,Asian,3735.0,26129866.0,Hu N,Cancer,initial,2015-06-30,GCST003007,Non-cardia gastric cancer
4209,Asian,14956.0,26129866.0,Hu N,Cancer,replication,2015-06-30,GCST003010,Gastric cancer
3362,Asian,3897.0,26129866.0,Hu N,Cancer,initial,2015-06-30,GCST003009,Cardia gastric cancer
13487,Other/Mixed,78.0,27186693.0,Aydin-Son Y,Immune system disorder,initial,2015-07-01,GCST003011,Arthritis (juvenile idiopathic)
2086,Asian,470.0,25325441.0,Baik I,Neurological disorder,initial,2015-07-01,GCST003012,Obstructive sleep apnea
542,African American or Afro-Caribbean,213.0,26138065.0,Schneider BP,"Cancer, Response to drug, Neurological disorder",initial,2015-07-02,GCST003627,Neuropathy in taxane-treated breast cancer
1803,Asian,204.0,25663218.0,Verhaaren BF,Other measurement,initial,2015-07-02,GCST003013,White matter hyperintensity burden
449,African American or Afro-Caribbean,90.0,26138065.0,Schneider BP,"Cancer, Response to drug, Neurological disorder",replication,2015-07-02,GCST003627,Neuropathy in taxane-treated breast cancer
1801,Asian,201.0,25663218.0,Verhaaren BF,Other measurement,initial,2015-07-02,GCST003013,White matter hyperintensity burden
6410,European,1357.0,26138065.0,Schneider BP,"Cancer, Response to drug, Neurological disorder",initial,2015-07-02,GCST003627,Neuropathy in taxane-treated breast cancer
10232,European,17936.0,25663218.0,Verhaaren BF,Other measurement,initial,2015-07-02,GCST003013,White matter hyperintensity burden
934,African American or Afro-Caribbean,1943.0,25663218.0,Verhaaren BF,Other measurement,initial,2015-07-02,GCST003013,White matter hyperintensity burden
5746,European,789.0,26138065.0,Schneider BP,"Cancer, Response to drug, Neurological disorder",replication,2015-07-02,GCST003627,Neuropathy in taxane-treated breast cancer
12747,Hispanic or Latin American,795.0,25663218.0,Verhaaren BF,Other measurement,initial,2015-07-02,GCST003013,White matter hyperintensity burden
5871,European,872.0,26256467.0,Wojczynski MK,"Lipid or lipoprotein measurement, Biological process",initial,2015-07-03,GCST003014,Postprandial triglyceride response to high fat diet meal
5826,European,843.0,26256467.0,Wojczynski MK,"Lipid or lipoprotein measurement, Biological process",replication,2015-07-03,GCST003014,Postprandial triglyceride response to high fat diet meal
5511,European,619.0,26146898.0,Clark SL,"Biological process, Other measurement",initial,2015-07-04,GCST003015,Alcohol consumption
5656,European,730.0,26146898.0,Clark SL,"Biological process, Other measurement",replication,2015-07-04,GCST003015,Alcohol consumption
5073,European,375.0,26207136.0,Cho CH,"Neurological disorder, Other trait",initial,2015-07-06,GCST003016,Hypersomnia during a major depressive episode in bipolar disorder
2163,Asian,567.0,26151496.0,Chen PL,"Immune system disorder, Response to drug, Other trait",replication,2015-07-07,GCST003018,Thionamide-induced agranulocytosis in Graves' disease
2227,Asian,683.0,26151496.0,Chen PL,"Immune system disorder, Response to drug, Other trait",initial,2015-07-07,GCST003018,Thionamide-induced agranulocytosis in Graves' disease
10917,European,37955.0,26151821.0,Schumacher FR,Cancer,initial,2015-07-07,GCST003017,Colorectal cancer
4197,Asian,14694.0,26151821.0,Schumacher FR,Cancer,replication,2015-07-07,GCST003017,Colorectal cancer
8997,European,7091.0,26184321.0,Lin BD,Other trait,initial,2015-07-13,GCST003022,Light vs. dark hair color
8998,European,7091.0,26184321.0,Lin BD,Other trait,initial,2015-07-13,GCST003023,Blond vs non-blond hair color
8995,European,7091.0,26184321.0,Lin BD,Other trait,initial,2015-07-13,GCST003020,Red vs non-red hair color
8994,European,7091.0,26184321.0,Lin BD,Other trait,initial,2015-07-13,GCST003019,Black vs. non-black hair color
8996,European,7091.0,26184321.0,Lin BD,Other trait,initial,2015-07-13,GCST003021,Brown vs. non-brown hair color
5262,European,479.0,26174813.0,Alemany S,"Neurological disorder, Other measurement",initial,2015-07-14,GCST003025,Attention function in attention deficit hyperactive disorder
8742,European,6007.0,26169577.0,Mosley JD,"Other trait, Response to drug",initial,2015-07-14,GCST003027,Cough in response to angiotensin-converting enzyme inhibitor drugs
8539,European,5231.0,26169577.0,Mosley JD,"Other trait, Response to drug",replication,2015-07-14,GCST003027,Cough in response to angiotensin-converting enzyme inhibitor drugs
147,African,879.0,26169577.0,Mosley JD,"Other trait, Response to drug",initial,2015-07-14,GCST003027,Cough in response to angiotensin-converting enzyme inhibitor drugs
1666,Asian,99.0,26174610.0,Kwak TJ,Other measurement,initial,2015-07-14,GCST003024,Ultraviolet-induced skin pigmentation (minimal erythema dose)
1688,Asian,112.0,26174610.0,Kwak TJ,Other measurement,replication,2015-07-14,GCST003024,Ultraviolet-induced skin pigmentation (minimal erythema dose)
2408,Asian,947.0,26169365.0,Huang KC,"Other trait, Metabolic disorder",initial,2015-07-14,GCST003026,Yu-Zhi constitution type in type 2 diabetes
13560,Other/Mixed,194.0,26169577.0,Mosley JD,"Other trait, Response to drug",initial,2015-07-14,GCST003027,Cough in response to angiotensin-converting enzyme inhibitor drugs
3280,Asian,3294.0,26174136.0,Setoh K,Other measurement,initial,2015-07-15,GCST003028,Serum alpha1-antitrypsin levels
3686,Asian,6065.0,26174136.0,Setoh K,Other measurement,replication,2015-07-15,GCST003028,Serum alpha1-antitrypsin levels
5508,European,612.0,26176695.0,Warrier V,Neurological disorder,initial,2015-07-15,GCST003029,Asperger syndrome
6250,European,1163.0,26183928.0,Leng S,"Biological process, Other measurement",initial,2015-07-16,GCST003031,MGMT methylation in smokers
4942,European,289.0,26183928.0,Leng S,"Biological process, Other measurement",replication,2015-07-16,GCST003031,MGMT methylation in smokers
5704,European,750.0,26184070.0,Aebi M,"Neurological disorder, Other measurement",initial,2015-07-16,GCST003030,Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder
12564,Hispanic or Latin American,141.0,26183928.0,Leng S,"Biological process, Other measurement",replication,2015-07-16,GCST003031,MGMT methylation in smokers
2097,Asian,481.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003034,Hearing function (8 kHz)
2099,Asian,481.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003036,Hearing function (low tone)
2096,Asian,481.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003033,Hearing function (medium tone)
2102,Asian,481.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003040,Hearing function (high tone)
5337,European,507.0,26186006.0,Abrantes P,Cardiovascular disease,replication,2015-07-17,GCST003038,Intracranial aneurysm
2100,Asian,481.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003037,Hearing function (0.5 kHz)
2095,Asian,481.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003032,Hearing function (2 kHz)
2101,Asian,481.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003039,Hearing function (0.25 kHz)
2103,Asian,481.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003041,Hearing function (1 kHz)
7053,European,2155.0,26188009.0,Vuckovic D,Other measurement,initial,2015-07-17,GCST003035,Hearing function (4 kHz)
8777,European,6162.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003041,Hearing function (1 kHz)
4915,European,270.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003037,Hearing function (0.5 kHz)
7051,European,2155.0,26188009.0,Vuckovic D,Other measurement,initial,2015-07-17,GCST003033,Hearing function (medium tone)
4916,European,270.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003039,Hearing function (0.25 kHz)
7050,European,2155.0,26188009.0,Vuckovic D,Other measurement,initial,2015-07-17,GCST003032,Hearing function (2 kHz)
7056,European,2155.0,26188009.0,Vuckovic D,Other measurement,initial,2015-07-17,GCST003039,Hearing function (0.25 kHz)
2098,Asian,481.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003035,Hearing function (4 kHz)
4914,European,270.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003036,Hearing function (low tone)
4913,European,270.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003034,Hearing function (8 kHz)
7057,European,2155.0,26188009.0,Vuckovic D,Other measurement,initial,2015-07-17,GCST003040,Hearing function (high tone)
7055,European,2155.0,26188009.0,Vuckovic D,Other measurement,initial,2015-07-17,GCST003037,Hearing function (0.5 kHz)
7058,European,2155.0,26188009.0,Vuckovic D,Other measurement,initial,2015-07-17,GCST003041,Hearing function (1 kHz)
4912,European,270.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003033,Hearing function (medium tone)
4911,European,270.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003032,Hearing function (2 kHz)
7052,European,2155.0,26188009.0,Vuckovic D,Other measurement,initial,2015-07-17,GCST003034,Hearing function (8 kHz)
8776,European,6162.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003035,Hearing function (4 kHz)
7054,European,2155.0,26188009.0,Vuckovic D,Other measurement,initial,2015-07-17,GCST003036,Hearing function (low tone)
4917,European,270.0,26188009.0,Vuckovic D,Other measurement,replication,2015-07-17,GCST003040,Hearing function (high tone)
4801,European,192.0,26186006.0,Abrantes P,Cardiovascular disease,initial,2015-07-17,GCST003038,Intracranial aneurysm
5466,European,583.0,26188370.0,Burdon KP,Metabolic disorder,replication,2015-07-19,GCST003042,Sight-threatening diabetic retinopathy in type 2 diabetes
2237,Asian,699.0,26188370.0,Burdon KP,Metabolic disorder,replication,2015-07-19,GCST003042,Sight-threatening diabetic retinopathy in type 2 diabetes
5831,European,844.0,26188370.0,Burdon KP,Metabolic disorder,initial,2015-07-19,GCST003042,Sight-threatening diabetic retinopathy in type 2 diabetes
5220,European,452.0,26194203.0,Ramachandran D,"Cardiovascular disease, Other trait",initial,2015-07-20,GCST003047,Atrioventricular septal defects in Down syndrome
3030,Asian,2229.0,26192919.0,Liu JZ,Immune system disorder,replication,2015-07-20,GCST003045,Ulcerative colitis
3574,Asian,5409.0,26192919.0,Liu JZ,Digestive system disorder,replication,2015-07-20,GCST003044,Crohn's disease
13771,Other/Mixed,739.0,26192919.0,Liu JZ,Immune system disorder,replication,2015-07-20,GCST003045,Ulcerative colitis
3087,Asian,2413.0,26192919.0,Liu JZ,"Digestive system disorder, Immune system disorder",replication,2015-07-20,GCST003043,Inflammatory bowel disease
10384,European,20883.0,26192919.0,Liu JZ,Digestive system disorder,initial,2015-07-20,GCST003044,Crohn's disease
10985,European,41309.0,26192919.0,Liu JZ,Digestive system disorder,replication,2015-07-20,GCST003044,Crohn's disease
10624,European,27432.0,26192919.0,Liu JZ,Immune system disorder,initial,2015-07-20,GCST003045,Ulcerative colitis
2510,Asian,1174.0,26192919.0,Liu JZ,Digestive system disorder,replication,2015-07-20,GCST003044,Crohn's disease
2766,Asian,1735.0,26190474.0,Dai Y,Biological process,replication,2015-07-20,GCST003046,Trichloroethylene-induced hypersensitivity syndrome
13801,Other/Mixed,890.0,26192919.0,Liu JZ,"Digestive system disorder, Immune system disorder",replication,2015-07-20,GCST003043,Inflammatory bowel disease
3740,Asian,6543.0,26192919.0,Liu JZ,"Digestive system disorder, Immune system disorder",replication,2015-07-20,GCST003043,Inflammatory bowel disease
10890,European,37394.0,26192919.0,Liu JZ,Immune system disorder,replication,2015-07-20,GCST003045,Ulcerative colitis
1796,Asian,196.0,26190474.0,Dai Y,Biological process,initial,2015-07-20,GCST003046,Trichloroethylene-induced hypersensitivity syndrome
11127,European,51988.0,26192919.0,Liu JZ,"Digestive system disorder, Immune system disorder",replication,2015-07-20,GCST003043,Inflammatory bowel disease
3508,Asian,4853.0,26192919.0,Liu JZ,Immune system disorder,replication,2015-07-20,GCST003045,Ulcerative colitis
10839,European,34652.0,26192919.0,Liu JZ,"Digestive system disorder, Immune system disorder",initial,2015-07-20,GCST003043,Inflammatory bowel disease
13677,Other/Mixed,493.0,26192919.0,Liu JZ,Digestive system disorder,replication,2015-07-20,GCST003044,Crohn's disease
13968,Other/Mixed,4058.0,26198764.0,Goes FS,Neurological disorder,initial,2015-07-21,GCST003050,Schizophrenia
6597,European,1572.0,26199339.0,Liu CY,"Cancer, Other measurement",initial,2015-07-21,GCST003049,Lung cancer (asbestos exposure interaction)
13823,Other/Mixed,1097.0,26198764.0,Goes FS,Neurological disorder,initial,2015-07-21,GCST003048,Schizophrenia
8640,European,5606.0,26199339.0,Liu CY,"Cancer, Other measurement",replication,2015-07-21,GCST003049,Lung cancer (asbestos exposure interaction)
5246,European,469.0,26198393.0,Ziv E,"Other measurement, Cancer",initial,2015-07-22,GCST003051,Multiple myeloma (survival)
12511,Hispanic or Latin American,27.0,26198393.0,Ziv E,"Other measurement, Cancer",initial,2015-07-22,GCST003051,Multiple myeloma (survival)
388,African American or Afro-Caribbean,25.0,26198393.0,Ziv E,"Other measurement, Cancer",initial,2015-07-22,GCST003051,Multiple myeloma (survival)
6186,European,1090.0,26198393.0,Ziv E,"Other measurement, Cancer",replication,2015-07-22,GCST003051,Multiple myeloma (survival)
13437,Other/Mixed,24.0,26198393.0,Ziv E,"Other measurement, Cancer",initial,2015-07-22,GCST003051,Multiple myeloma (survival)
3764,Asian,6947.0,26211971.0,Ogura Y,Other disease,replication,2015-07-23,GCST003052,Adolescent idiopathic scoliosis
4163,Asian,13249.0,26211971.0,Ogura Y,Other disease,initial,2015-07-23,GCST003052,Adolescent idiopathic scoliosis
5517,European,622.0,26209787.0,Barthold JS,Other disease,replication,2015-07-24,GCST003053,Cryptorchidism
7921,European,3562.0,26209787.0,Barthold JS,Other disease,initial,2015-07-24,GCST003053,Cryptorchidism
5362,European,520.0,26222057.0,Pander J,"Cancer, Response to drug, Other measurement",initial,2015-07-29,GCST003057,Progression free survival in metastatic colorectal cancer (chemotherapy interaction)
5363,European,520.0,26222057.0,Pander J,"Cancer, Response to drug, Other measurement",initial,2015-07-29,GCST003058,Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab)
2118,Asian,500.0,26227905.0,Hu Y,Neurological disorder,initial,2015-07-31,GCST003059,Parkinson's disease
13488,Other/Mixed,79.0,26233692.0,Gan-Or Z,"Neurological disorder, Other measurement",initial,2015-08-02,GCST003060,Parkinson's disease in GBA mutation carriers (age at onset)
13483,Other/Mixed,75.0,26233692.0,Gan-Or Z,"Neurological disorder, Other measurement",replication,2015-08-02,GCST003060,Parkinson's disease in GBA mutation carriers (age at onset)
10868,European,36077.0,26237428.0,Law MH,Cancer,initial,2015-08-03,GCST003061,Cutaneous malignant melanoma
6602,European,1576.0,26237428.0,Law MH,Cancer,replication,2015-08-03,GCST003061,Cutaneous malignant melanoma
1585,Asian,31.0,26237429.0,Aminkeng F,"Cardiovascular disease, Cancer, Response to drug",replication,2015-08-03,GCST003062,Anthracycline-induced cardiotoxicity in childhood cancer
4927,European,280.0,26237429.0,Aminkeng F,"Cardiovascular disease, Cancer, Response to drug",initial,2015-08-03,GCST003062,Anthracycline-induced cardiotoxicity in childhood cancer
13407,Other/Mixed,15.0,26237429.0,Aminkeng F,"Cardiovascular disease, Cancer, Response to drug",replication,2015-08-03,GCST003062,Anthracycline-induced cardiotoxicity in childhood cancer
12509,Hispanic or Latin American,23.0,26237429.0,Aminkeng F,"Cardiovascular disease, Cancer, Response to drug",replication,2015-08-03,GCST003062,Anthracycline-induced cardiotoxicity in childhood cancer
370,African American or Afro-Caribbean,11.0,26237429.0,Aminkeng F,"Cardiovascular disease, Cancer, Response to drug",replication,2015-08-03,GCST003062,Anthracycline-induced cardiotoxicity in childhood cancer
4667,European,96.0,26237429.0,Aminkeng F,"Cardiovascular disease, Cancer, Response to drug",replication,2015-08-03,GCST003062,Anthracycline-induced cardiotoxicity in childhood cancer
6377,European,1309.0,26239289.0,Nelson EC,Neurological disorder,replication,2015-08-04,GCST003614,Opioid dependence
6388,European,1328.0,26239289.0,Nelson EC,Neurological disorder,initial,2015-08-04,GCST003614,Opioid dependence
1713,Asian,128.0,26242244.0,Ma Y,Other measurement,initial,2015-08-05,GCST003064,Exploratory eye movement dysfunction in schizophrenia (cognitive search score)
1715,Asian,128.0,26242244.0,Ma Y,Other measurement,initial,2015-08-05,GCST003066,Exploratory eye movement dysfunction in schizophrenia (total eye scanning length)
1714,Asian,128.0,26242244.0,Ma Y,Other measurement,initial,2015-08-05,GCST003065,Exploratory eye movement dysfunction in schizophrenia (responsive search score)
1716,Asian,128.0,26242244.0,Ma Y,Other measurement,initial,2015-08-05,GCST003067,Exploratory eye movement dysfunction in schizophrenia (mean eye scanning length)
1717,Asian,128.0,26242244.0,Ma Y,Other measurement,initial,2015-08-05,GCST003068,Exploratory eye movement dysfunction in schizophrenia (number of eye fixations)
5253,European,472.0,26252872.0,Li QS,"Other measurement, Other trait",initial,2015-08-07,GCST003075,Cognitive decline rate in late mild cognitive impairment
6349,European,1275.0,26265699.0,Karol SE,"Other disease, Response to drug",initial,2015-08-11,GCST003083,Glucocorticoid-induced osteonecrosis (time dependent analysis)
1540,Asian,6.0,26265699.0,Karol SE,"Other disease, Response to drug",replication,2015-08-11,GCST003080,Glucocorticoid-induced osteonecrosis (time independent analysis)
558,African American or Afro-Caribbean,248.0,26265699.0,Karol SE,"Other disease, Response to drug",initial,2015-08-11,GCST003084,Glucocorticoid-induced osteonecrosis
1596,Asian,48.0,26265699.0,Karol SE,"Other disease, Response to drug",initial,2015-08-11,GCST003083,Glucocorticoid-induced osteonecrosis (time dependent analysis)
486,African American or Afro-Caribbean,139.0,26265699.0,Karol SE,"Other disease, Response to drug",initial,2015-08-11,GCST003083,Glucocorticoid-induced osteonecrosis (time dependent analysis)
5256,European,476.0,26265699.0,Karol SE,"Other disease, Response to drug",replication,2015-08-11,GCST003080,Glucocorticoid-induced osteonecrosis (time independent analysis)
6753,European,1751.0,26265699.0,Karol SE,"Other disease, Response to drug",initial,2015-08-11,GCST003084,Glucocorticoid-induced osteonecrosis
1601,Asian,54.0,26265699.0,Karol SE,"Other disease, Response to drug",initial,2015-08-11,GCST003084,Glucocorticoid-induced osteonecrosis
12687,Hispanic or Latin American,601.0,26265699.0,Karol SE,"Other disease, Response to drug",initial,2015-08-11,GCST003083,Glucocorticoid-induced osteonecrosis (time dependent analysis)
463,African American or Afro-Caribbean,109.0,26265699.0,Karol SE,"Other disease, Response to drug",replication,2015-08-11,GCST003080,Glucocorticoid-induced osteonecrosis (time independent analysis)
12521,Hispanic or Latin American,39.0,26265699.0,Karol SE,"Other disease, Response to drug",replication,2015-08-11,GCST003080,Glucocorticoid-induced osteonecrosis (time independent analysis)
12699,Hispanic or Latin American,640.0,26265699.0,Karol SE,"Other disease, Response to drug",initial,2015-08-11,GCST003084,Glucocorticoid-induced osteonecrosis
5309,European,495.0,26268530.0,Ramanan VK,Other measurement,initial,2015-08-11,GCST003082,Longitudinal change in brain amyloid plaque burden
12610,Hispanic or Latin American,367.0,26265036.0,Parra EJ,Response to drug,initial,2015-08-12,GCST003085,Warfarin maintenance dose
5759,European,798.0,26265036.0,Parra EJ,Response to drug,replication,2015-08-12,GCST003085,Warfarin maintenance dose
2705,Asian,1611.0,26265036.0,Parra EJ,Response to drug,replication,2015-08-12,GCST003085,Warfarin maintenance dose
516,African American or Afro-Caribbean,191.0,26265036.0,Parra EJ,Response to drug,replication,2015-08-12,GCST003085,Warfarin maintenance dose
6529,European,1516.0,26272072.0,Jiang X,"Other measurement, Immune system disorder",replication,2015-08-13,GCST006410,ACPA-positive rheumatoid arthritis (smoking interaction)
7381,European,2573.0,26272072.0,Jiang X,"Other measurement, Immune system disorder",initial,2015-08-13,GCST006410,ACPA-positive rheumatoid arthritis (smoking interaction)
7382,European,2573.0,26272072.0,Jiang X,"Other measurement, Immune system disorder",initial,2015-08-13,GCST006807,ACPA-negative rheumatoid arthritis (smoking interaction)
5470,European,587.0,26268663.0,Nalls MA,Neurological disorder,initial,2015-08-13,GCST005548,Parkinson's disease
12157,European,285019.0,26272126.0,Oddsson A,Other disease,initial,2015-08-14,GCST003086,Kidney stones
4188,Asian,14131.0,26278006.0,Ahmad S,Body measurement,initial,2015-08-17,GCST003087,Body mass index variance
5910,European,903.0,26284813.0,Hayes MG,"Other measurement, Other disease",initial,2015-08-18,GCST005271,Sex hormone-binding globulin levels in polycystic ovary syndrome
6530,European,1516.0,26284813.0,Hayes MG,"Other disease, Other measurement",replication,2015-08-18,GCST005272,Testosterone levels in polycystic ovary syndrome
8060,European,3948.0,26284813.0,Hayes MG,Other disease,initial,2015-08-18,GCST005273,Polycystic ovary syndrome
6239,European,1156.0,26284813.0,Hayes MG,"Other measurement, Other disease",replication,2015-08-18,GCST005271,Sex hormone-binding globulin levels in polycystic ovary syndrome
5546,European,647.0,26284813.0,Hayes MG,"Other measurement, Other disease",initial,2015-08-18,GCST005270,Follicule stimulating hormone levels in polycystic ovary syndrome
5499,European,607.0,26284813.0,Hayes MG,"Other disease, Other measurement",replication,2015-08-18,GCST005269,Luteinizing hormone levels in polycystic ovary syndrome
8278,European,4582.0,26284813.0,Hayes MG,Other disease,replication,2015-08-18,GCST005273,Polycystic ovary syndrome
6944,European,2021.0,26284813.0,Hayes MG,"Other disease, Other measurement",replication,2015-08-18,GCST005274,DHEAS levels in polycystic ovary syndrome
5496,European,606.0,26284813.0,Hayes MG,"Other measurement, Other disease",replication,2015-08-18,GCST005270,Follicule stimulating hormone levels in polycystic ovary syndrome
5541,European,645.0,26284813.0,Hayes MG,"Other disease, Other measurement",initial,2015-08-18,GCST005269,Luteinizing hormone levels in polycystic ovary syndrome
5999,European,957.0,26284813.0,Hayes MG,"Other disease, Other measurement",initial,2015-08-18,GCST005272,Testosterone levels in polycystic ovary syndrome
6044,European,984.0,26284813.0,Hayes MG,"Other disease, Other measurement",initial,2015-08-18,GCST005274,DHEAS levels in polycystic ovary syndrome
8835,European,6434.0,26291516.0,Miller FW,Immune system disorder,initial,2015-08-20,GCST003092,Myositis
5631,European,706.0,26297903.0,Fabbri C,"Other trait, Neurological disorder",initial,2015-08-20,GCST003089,Manic episodes in bipolar disorder
5649,European,723.0,26297903.0,Fabbri C,"Other measurement, Neurological disorder",initial,2015-08-20,GCST003091,Depressive episodes in bipolar disorder
1738,Asian,148.0,26289589.0,Nishizawa D,Neurological disorder,initial,2015-08-20,GCST003093,Nicotine dependence
5648,European,723.0,26297903.0,Fabbri C,"Other measurement, Neurological disorder",initial,2015-08-20,GCST003090,Depressive and manic episodes in bipolar disorder
699,African American or Afro-Caribbean,683.0,26293465.0,Durda P,Other measurement,initial,2015-08-20,GCST003088,Soluble interleukin-2 receptor subunit alpha
7582,European,2964.0,26293465.0,Durda P,Other measurement,initial,2015-08-20,GCST003088,Soluble interleukin-2 receptor subunit alpha
1990,Asian,374.0,26289589.0,Nishizawa D,Neurological disorder,replication,2015-08-20,GCST003093,Nicotine dependence
8240,European,4464.0,26293465.0,Durda P,Other measurement,replication,2015-08-20,GCST003088,Soluble interleukin-2 receptor subunit alpha
10152,European,16753.0,26301688.0,Li YR,"Immune system disorder, Digestive system disorder, Metabolic disorder",initial,2015-08-24,GCST003097,Pediatric autoimmune diseases
8035,European,3881.0,26301497.0,Dina C,Cardiovascular disease,initial,2015-08-24,GCST003094,Mitral valve prolapse
9217,European,8201.0,26301497.0,Dina C,Cardiovascular disease,replication,2015-08-24,GCST003094,Mitral valve prolapse
5671,European,737.0,26299439.0,Li WD,Other measurement,initial,2015-08-24,GCST003096,Adiponectin levels
5670,European,737.0,26299439.0,Li WD,Other measurement,initial,2015-08-24,GCST003095,Adiponectin levels (BMI-adjusted)
13798,Other/Mixed,857.0,26305897.0,Iyengar SK,Metabolic disorder,initial,2015-08-25,GCST003099,Diabetic kidney disease
5697,European,746.0,26305897.0,Iyengar SK,Metabolic disorder,initial,2015-08-25,GCST003098,Diabetic kidney disease
10241,European,18197.0,26307654.0,Szulkin R,"Cancer, Other measurement",replication,2015-08-25,GCST003100,Prostate cancer (survival)
13797,Other/Mixed,857.0,26305897.0,Iyengar SK,Metabolic disorder,initial,2015-08-25,GCST003098,Diabetic kidney disease
1110,African American or Afro-Caribbean,3221.0,26305897.0,Iyengar SK,Metabolic disorder,initial,2015-08-25,GCST003099,Diabetic kidney disease
1109,African American or Afro-Caribbean,3221.0,26305897.0,Iyengar SK,Metabolic disorder,initial,2015-08-25,GCST003098,Diabetic kidney disease
1043,African American or Afro-Caribbean,2887.0,26305897.0,Iyengar SK,Metabolic disorder,replication,2015-08-25,GCST003098,Diabetic kidney disease
13850,Other/Mixed,1297.0,26305897.0,Iyengar SK,Metabolic disorder,replication,2015-08-25,GCST003098,Diabetic kidney disease
5698,European,746.0,26305897.0,Iyengar SK,Metabolic disorder,initial,2015-08-25,GCST003099,Diabetic kidney disease
12817,Hispanic or Latin American,1373.0,26305897.0,Iyengar SK,Metabolic disorder,initial,2015-08-25,GCST003099,Diabetic kidney disease
12816,Hispanic or Latin American,1373.0,26305897.0,Iyengar SK,Metabolic disorder,initial,2015-08-25,GCST003098,Diabetic kidney disease
7815,European,3355.0,26305897.0,Iyengar SK,Metabolic disorder,replication,2015-08-25,GCST003098,Diabetic kidney disease
5120,European,407.0,26498133.0,Arya R,"Immune system disorder, Other measurement",initial,2015-08-26,GCST008643,Joint damage in rheumatoid arthritis
12703,Hispanic or Latin American,666.0,26498133.0,Arya R,"Immune system disorder, Other measurement",initial,2015-08-26,GCST008643,Joint damage in rheumatoid arthritis
12622,Hispanic or Latin American,408.0,26312577.0,Tan LJ,Other measurement,replication,2015-08-27,GCST003101,Bone mineral density (spine) and age at menarche
2348,Asian,826.0,26312577.0,Tan LJ,Other measurement,initial,2015-08-27,GCST003102,Bone mineral density (hip) and age at menarche
709,African American or Afro-Caribbean,709.0,26312577.0,Tan LJ,Other measurement,replication,2015-08-27,GCST003101,Bone mineral density (spine) and age at menarche
12623,Hispanic or Latin American,408.0,26312577.0,Tan LJ,Other measurement,replication,2015-08-27,GCST003102,Bone mineral density (hip) and age at menarche
6738,European,1728.0,26312577.0,Tan LJ,Other measurement,replication,2015-08-27,GCST003101,Bone mineral density (spine) and age at menarche
6739,European,1728.0,26312577.0,Tan LJ,Other measurement,replication,2015-08-27,GCST003102,Bone mineral density (hip) and age at menarche
2347,Asian,826.0,26312577.0,Tan LJ,Other measurement,initial,2015-08-27,GCST003101,Bone mineral density (spine) and age at menarche
710,African American or Afro-Caribbean,709.0,26312577.0,Tan LJ,Other measurement,replication,2015-08-27,GCST003102,Bone mineral density (hip) and age at menarche
6234,European,1148.0,26316170.0,Demirci FY,Immune system disorder,initial,2015-08-28,GCST003103,Systemic lupus erythematosus
2316,Asian,776.0,26314684.0,Liu X,Neurological disorder,initial,2015-08-28,GCST003104,Autism spectrum disorder
9929,European,13581.0,26316170.0,Demirci FY,Immune system disorder,replication,2015-08-28,GCST003103,Systemic lupus erythematosus
2726,Asian,1643.0,26314684.0,Liu X,Neurological disorder,replication,2015-08-28,GCST003104,Autism spectrum disorder
12048,European,209379.0,26235824.0,Styrkarsdottir U,Other measurement,initial,2015-08-29,GCST003106,Low bone mineral density (spine)
12047,European,209379.0,26235824.0,Styrkarsdottir U,Other measurement,initial,2015-08-29,GCST003105,Low bone mineral density (hip)
598,African American or Afro-Caribbean,338.0,26148204.0,Wanga V,"Other disease, Response to drug, Other measurement",initial,2015-09-01,GCST006072,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)
7,African,7.0,26177304.0,Waterman M,Immune system disorder,initial,2015-09-01,GCST006583,Ulcerative colitis
13690,Other/Mixed,568.0,26325155.0,Brehm JM,"Other measurement, Response to drug, Other disease",replication,2015-09-01,GCST003107,Post-bronchodilator lung function in asthma (FEV1/FVC)
4890,European,243.0,26148204.0,Wanga V,"Other disease, Response to drug",initial,2015-09-01,GCST006071,Tenofovir clearance in HIV infection (concomitant antiretroviral treatment interaction)
12548,Hispanic or Latin American,100.0,26148204.0,Wanga V,"Other disease, Response to drug",initial,2015-09-01,GCST006071,Tenofovir clearance in HIV infection (concomitant antiretroviral treatment interaction)
4889,European,243.0,26148204.0,Wanga V,"Other disease, Other measurement, Response to drug",initial,2015-09-01,GCST006074,Bilirubin levels in tenofovir-treated HIV infection
12549,Hispanic or Latin American,100.0,26148204.0,Wanga V,"Other disease, Response to drug",initial,2015-09-01,GCST006073,Tenofovir clearance in HIV infection
12577,Hispanic or Latin American,202.0,26148204.0,Wanga V,"Other disease, Response to drug, Other measurement",initial,2015-09-01,GCST006069,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)
5274,European,486.0,26148204.0,Wanga V,"Other disease, Response to drug, Other measurement",initial,2015-09-01,GCST006069,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)
5275,European,486.0,26148204.0,Wanga V,"Other disease, Response to drug, Other measurement",initial,2015-09-01,GCST006070,6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction)
5276,European,486.0,26148204.0,Wanga V,"Other disease, Response to drug, Other measurement",initial,2015-09-01,GCST006072,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)
5336,European,507.0,26177304.0,Waterman M,Immune system disorder,initial,2015-09-01,GCST006583,Ulcerative colitis
12579,Hispanic or Latin American,202.0,26148204.0,Wanga V,"Other disease, Response to drug, Other measurement",initial,2015-09-01,GCST006072,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)
12578,Hispanic or Latin American,202.0,26148204.0,Wanga V,"Other disease, Response to drug, Other measurement",initial,2015-09-01,GCST006070,6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction)
596,African American or Afro-Caribbean,338.0,26148204.0,Wanga V,"Other disease, Response to drug, Other measurement",initial,2015-09-01,GCST006069,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)
597,African American or Afro-Caribbean,338.0,26148204.0,Wanga V,"Other disease, Response to drug, Other measurement",initial,2015-09-01,GCST006070,6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction)
492,African American or Afro-Caribbean,149.0,26148204.0,Wanga V,"Other disease, Other measurement, Response to drug",initial,2015-09-01,GCST006074,Bilirubin levels in tenofovir-treated HIV infection
12547,Hispanic or Latin American,100.0,26148204.0,Wanga V,"Other disease, Other measurement, Response to drug",initial,2015-09-01,GCST006074,Bilirubin levels in tenofovir-treated HIV infection
1620,Asian,61.0,26177304.0,Waterman M,Immune system disorder,initial,2015-09-01,GCST006583,Ulcerative colitis
12890,Hispanic or Latin American,2414.0,26325155.0,Brehm JM,"Other measurement, Response to drug, Other disease",replication,2015-09-01,GCST003107,Post-bronchodilator lung function in asthma (FEV1/FVC)
4790,European,189.0,26323598.0,Brandl EJ,"Body measurement, Other trait",initial,2015-09-01,GCST003108,Antipsychotic drug-induced weight gain (time interaction)
12891,Hispanic or Latin American,2414.0,26325155.0,Brehm JM,"Other measurement, Response to drug, Other disease",replication,2015-09-01,GCST003110,Post-bronchodilator lung function in asthma (FEV1)
4791,European,189.0,26323598.0,Brandl EJ,Other trait,initial,2015-09-01,GCST003109,Antipsychotic drug-induced weight gain
12642,Hispanic or Latin American,447.0,26325155.0,Brehm JM,"Other measurement, Response to drug, Other disease",initial,2015-09-01,GCST003110,Post-bronchodilator lung function in asthma (FEV1)
12488,Hispanic or Latin American,2.0,26177304.0,Waterman M,Immune system disorder,initial,2015-09-01,GCST006583,Ulcerative colitis
13691,Other/Mixed,568.0,26325155.0,Brehm JM,"Other measurement, Response to drug, Other disease",replication,2015-09-01,GCST003110,Post-bronchodilator lung function in asthma (FEV1)
4891,European,243.0,26148204.0,Wanga V,"Other disease, Response to drug",initial,2015-09-01,GCST006073,Tenofovir clearance in HIV infection
4638,European,86.0,26323598.0,Brandl EJ,Other trait,replication,2015-09-01,GCST003109,Antipsychotic drug-induced weight gain
12641,Hispanic or Latin American,447.0,26325155.0,Brehm JM,"Other measurement, Response to drug, Other disease",initial,2015-09-01,GCST003107,Post-bronchodilator lung function in asthma (FEV1/FVC)
494,African American or Afro-Caribbean,149.0,26148204.0,Wanga V,"Other disease, Response to drug",initial,2015-09-01,GCST006073,Tenofovir clearance in HIV infection
493,African American or Afro-Caribbean,149.0,26148204.0,Wanga V,"Other disease, Response to drug",initial,2015-09-01,GCST006071,Tenofovir clearance in HIV infection (concomitant antiretroviral treatment interaction)
13390,Other/Mixed,7.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003111,Sleep duration
13391,Other/Mixed,7.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003112,Sleep duration
13371,Other/Mixed,4.0,26333835.0,Scheinfeldt LB,Other measurement,replication,2015-09-03,GCST003112,Sleep duration
7303,European,2484.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003112,Sleep duration
1594,Asian,43.0,26333835.0,Scheinfeldt LB,Other measurement,replication,2015-09-03,GCST003112,Sleep duration
13456,Other/Mixed,44.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003111,Sleep duration
13392,Other/Mixed,7.0,26333835.0,Scheinfeldt LB,Other measurement,replication,2015-09-03,GCST003112,Sleep duration
13354,Other/Mixed,2.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003112,Sleep duration
428,African American or Afro-Caribbean,70.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003111,Sleep duration
429,African American or Afro-Caribbean,70.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003112,Sleep duration
13457,Other/Mixed,44.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003112,Sleep duration
5485,European,602.0,26421299.0,Li J,Other measurement,initial,2015-09-03,GCST003113,Cingulate cortical amyloid beta load
7302,European,2484.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003111,Sleep duration
461,African American or Afro-Caribbean,98.0,26333835.0,Scheinfeldt LB,Other measurement,replication,2015-09-03,GCST003112,Sleep duration
1644,Asian,85.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003111,Sleep duration
13486,Other/Mixed,78.0,26333835.0,Scheinfeldt LB,Other measurement,replication,2015-09-03,GCST003112,Sleep duration
1645,Asian,85.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003112,Sleep duration
6130,European,1032.0,26333835.0,Scheinfeldt LB,Other measurement,replication,2015-09-03,GCST003112,Sleep duration
13353,Other/Mixed,2.0,26333835.0,Scheinfeldt LB,Other measurement,initial,2015-09-03,GCST003111,Sleep duration
2340,Asian,810.0,26343869.0,Xie G,"Other measurement, Cardiovascular measurement, Cardiovascular disease",initial,2015-09-05,GCST003114,Carotid intima media thickness
7579,European,2952.0,26350878.0,Tashjian RZ,Other disease,initial,2015-09-05,GCST003115,Rotator cuff tears
1047,African American or Afro-Caribbean,2908.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003117,Myocardial infarction
4327,Asian,25557.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003116,Coronary artery disease
3993,Asian,9396.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003117,Myocardial infarction
12964,Hispanic or Latin American,3615.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003117,Myocardial infarction
11737,European,126630.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003117,Myocardial infarction
13775,Other/Mixed,754.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003117,Myocardial infarction
4079,Asian,11323.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003116,Coronary artery disease
13908,Other/Mixed,2268.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003116,Coronary artery disease
12991,Hispanic or Latin American,4095.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003116,Coronary artery disease
4318,Asian,23156.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003117,Myocardial infarction
1090,African American or Afro-Caribbean,3139.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003116,Coronary artery disease
11809,European,141217.0,26343387.0,Nikpay M,Cardiovascular disease,initial,2015-09-07,GCST003116,Coronary artery disease
1856,Asian,230.0,26348319.0,Myung W,"Response to drug, Neurological disorder",replication,2015-09-08,GCST003118,Response to serotonin reuptake inhibitors in non-psychotic unipolar depression
2104,Asian,481.0,26348319.0,Myung W,"Response to drug, Neurological disorder",initial,2015-09-08,GCST003118,Response to serotonin reuptake inhibitors in non-psychotic unipolar depression
8029,European,3861.0,26352407.0,Raffler J,Other measurement,initial,2015-09-09,GCST003119,Urinary metabolites
6687,European,1691.0,26352407.0,Raffler J,Other measurement,replication,2015-09-09,GCST003119,Urinary metabolites
10140,European,16582.0,26362759.0,Rothwell S,Neurological disorder,initial,2015-09-11,GCST006052,Polymyositis
11259,European,63030.0,26362575.0,van den Berg SM,"Biological process, Other measurement",initial,2015-09-11,GCST003120,Extraversion
10242,European,18207.0,26362759.0,Rothwell S,Immune system disorder,initial,2015-09-11,GCST006051,Idiopathic inflammatory myopathy
10131,European,16530.0,26362759.0,Rothwell S,Neurological disorder,initial,2015-09-11,GCST006053,Dermatomyositis or juvenile dermatomyositis
9543,European,9783.0,26362575.0,van den Berg SM,"Biological process, Other measurement",replication,2015-09-11,GCST003120,Extraversion
8134,European,4131.0,26366553.0,Danjou F,Hematological measurement,replication,2015-09-14,GCST003122,Hemoglobin levels
9145,European,7842.0,26365420.0,Mbarek H,"Other measurement, Neurological disorder",initial,2015-09-14,GCST003121,Alcohol dependence
8871,European,6602.0,26366553.0,Danjou F,Hematological measurement,initial,2015-09-14,GCST003122,Hemoglobin levels
904,African American or Afro-Caribbean,1657.0,26051272.0,Fischer A,Other disease,replication,2015-09-15,GCST005538,Sarcoidosis
9146,European,7850.0,26051272.0,Fischer A,Other disease,replication,2015-09-15,GCST005538,Sarcoidosis
9025,European,7208.0,26051272.0,Fischer A,Other disease,initial,2015-09-15,GCST005538,Sarcoidosis
4736,European,156.0,26379185.0,Garcia-Etxebarria K,Other disease,initial,2015-09-17,GCST003125,Influenza A (H1N1) infection
5411,European,549.0,26379185.0,Garcia-Etxebarria K,Other disease,initial,2015-09-17,GCST003124,Mild influenza (H1N1) infection
4692,European,107.0,26379185.0,Garcia-Etxebarria K,Other disease,initial,2015-09-17,GCST003124,Mild influenza (H1N1) infection
5412,European,549.0,26379185.0,Garcia-Etxebarria K,Other disease,initial,2015-09-17,GCST003125,Influenza A (H1N1) infection
5410,European,549.0,26379185.0,Garcia-Etxebarria K,Other disease,initial,2015-09-17,GCST003123,Severe influenza A (H1N1) infection
4737,European,156.0,26379185.0,Garcia-Etxebarria K,Other measurement,initial,2015-09-17,GCST003126,Influenza A (H1N1) severity
1045,African American or Afro-Caribbean,2895.0,26377243.0,Li J,Lipid or lipoprotein measurement,initial,2015-09-17,GCST003127,Lipoprotein (a) levels
4580,European,49.0,26379185.0,Garcia-Etxebarria K,Other disease,initial,2015-09-17,GCST003123,Severe influenza A (H1N1) infection
4374,Asian,33126.0,26390057.0,Kato N,Cardiovascular disease,initial,2015-09-21,GCST003276,Hypertension
4368,Asian,31516.0,26390057.0,Kato N,Other measurement,initial,2015-09-21,GCST003275,Mean arterial pressure
4436,Asian,48268.0,26390057.0,Kato N,Other measurement,replication,2015-09-21,GCST003273,Diastolic blood pressure
4434,Asian,48268.0,26390057.0,Kato N,Cardiovascular measurement,replication,2015-09-21,GCST003274,Pulse pressure
4437,Asian,48268.0,26390057.0,Kato N,Other measurement,replication,2015-09-21,GCST003275,Mean arterial pressure
4237,Asian,16328.0,26390057.0,Kato N,Other measurement,replication,2015-09-21,GCST003275,Mean arterial pressure
4433,Asian,48268.0,26390057.0,Kato N,Cardiovascular disease,replication,2015-09-21,GCST003276,Hypertension
4236,Asian,16328.0,26390057.0,Kato N,Other measurement,replication,2015-09-21,GCST003273,Diastolic blood pressure
4235,Asian,16328.0,26390057.0,Kato N,Other measurement,replication,2015-09-21,GCST003272,Systolic blood pressure
4234,Asian,16328.0,26390057.0,Kato N,Cardiovascular measurement,replication,2015-09-21,GCST003274,Pulse pressure
4233,Asian,16328.0,26390057.0,Kato N,Cardiovascular disease,replication,2015-09-21,GCST003276,Hypertension
4378,Asian,33126.0,26390057.0,Kato N,Other measurement,initial,2015-09-21,GCST003275,Mean arterial pressure
11310,European,68456.0,26390057.0,Kato N,Other measurement,replication,2015-09-21,GCST003275,Mean arterial pressure
4377,Asian,33126.0,26390057.0,Kato N,Other measurement,initial,2015-09-21,GCST003273,Diastolic blood pressure
11309,European,68456.0,26390057.0,Kato N,Other measurement,replication,2015-09-21,GCST003273,Diastolic blood pressure
4435,Asian,48268.0,26390057.0,Kato N,Other measurement,replication,2015-09-21,GCST003272,Systolic blood pressure
11307,European,68456.0,26390057.0,Kato N,Cardiovascular measurement,replication,2015-09-21,GCST003274,Pulse pressure
10850,European,35352.0,26390057.0,Kato N,Cardiovascular measurement,initial,2015-09-21,GCST003274,Pulse pressure
11308,European,68456.0,26390057.0,Kato N,Other measurement,replication,2015-09-21,GCST003272,Systolic blood pressure
10851,European,35352.0,26390057.0,Kato N,Other measurement,initial,2015-09-21,GCST003272,Systolic blood pressure
4366,Asian,31516.0,26390057.0,Kato N,Other measurement,initial,2015-09-21,GCST003272,Systolic blood pressure
10852,European,35352.0,26390057.0,Kato N,Other measurement,initial,2015-09-21,GCST003273,Diastolic blood pressure
4375,Asian,33126.0,26390057.0,Kato N,Cardiovascular measurement,initial,2015-09-21,GCST003274,Pulse pressure
10853,European,35352.0,26390057.0,Kato N,Other measurement,initial,2015-09-21,GCST003275,Mean arterial pressure
4365,Asian,31516.0,26390057.0,Kato N,Cardiovascular measurement,initial,2015-09-21,GCST003274,Pulse pressure
4376,Asian,33126.0,26390057.0,Kato N,Other measurement,initial,2015-09-21,GCST003272,Systolic blood pressure
4367,Asian,31516.0,26390057.0,Kato N,Other measurement,initial,2015-09-21,GCST003273,Diastolic blood pressure
11306,European,68456.0,26390057.0,Kato N,Cardiovascular disease,replication,2015-09-21,GCST003276,Hypertension
10849,European,35352.0,26390057.0,Kato N,Cardiovascular disease,initial,2015-09-21,GCST003276,Hypertension
4364,Asian,31516.0,26390057.0,Kato N,Cardiovascular disease,initial,2015-09-21,GCST003276,Hypertension
9887,European,13239.0,26394269.0,Cordell HJ,Cancer,initial,2015-09-22,GCST003129,Primary biliary cholangitis
9183,European,7977.0,26394269.0,Cordell HJ,Cancer,replication,2015-09-22,GCST003129,Primary biliary cholangitis
3097,Asian,2459.0,26394188.0,Zhu Z,Other disease,initial,2015-09-22,GCST003128,Adolescent idiopathic scoliosis
3864,Asian,7832.0,26394188.0,Zhu Z,Other disease,replication,2015-09-22,GCST003128,Adolescent idiopathic scoliosis
2292,Asian,762.0,26398136.0,Kuo PH,Neurological disorder,replication,2015-09-23,GCST003130,Autism spectrum disorder
2619,Asian,1430.0,26398136.0,Kuo PH,Neurological disorder,initial,2015-09-23,GCST003130,Autism spectrum disorder
5931,European,923.0,26401656.0,Burkhardt R,Other measurement,replication,2015-09-24,GCST006879,Blood metabolite levels
7017,European,2107.0,26401656.0,Burkhardt R,Other measurement,initial,2015-09-24,GCST006879,Blood metabolite levels
6584,European,1554.0,26433762.0,Liu X,"Metabolic disorder, Neurological disorder",initial,2015-09-25,GCST003135,Bipolar disorder and eating disorder
7107,European,2190.0,26433762.0,Liu X,"Metabolic disorder, Neurological disorder",initial,2015-09-25,GCST003132,Eating disorder in bipolar disorder
7825,European,3376.0,26433762.0,Liu X,Neurological disorder,initial,2015-09-25,GCST003136,Bipolar disorder
9995,European,14647.0,26423011.0,Wain LV,Other measurement,initial,2015-09-27,GCST008662,Lung function in never smokers (low FEV1 vs high FEV1)
10004,European,14729.0,26423011.0,Wain LV,Other measurement,initial,2015-09-27,GCST008660,Lung function in never smokers (high FEV1 vs average FEV1)
9997,European,14654.0,26423011.0,Wain LV,Other measurement,initial,2015-09-27,GCST008659,Lung function in heavy smokers (low FEV1 vs high FEV1)
10674,European,29301.0,26423011.0,Wain LV,Other measurement,initial,2015-09-27,GCST008664,Lung function (low FEV1 vs high FEV1)
10323,European,19551.0,26423011.0,Wain LV,Other measurement,initial,2015-09-27,GCST008665,Lung function in heavy smokers (low FEV1 vs average FEV1)
10001,European,14709.0,26423011.0,Wain LV,Other measurement,initial,2015-09-27,GCST008661,Lung function in heavy smokers (high FEV1 vs average FEV1)
11092,European,48931.0,26423011.0,Wain LV,Other measurement,initial,2015-09-27,GCST008667,Smoking status (heavy vs never)
10675,European,29301.0,26423011.0,Wain LV,Other measurement,initial,2015-09-27,GCST008666,Lung function (low FEV1 vs high FEV1) x smoking interaction
10325,European,19572.0,26423011.0,Wain LV,Other measurement,initial,2015-09-27,GCST008663,Lung function in never smokers (low FEV1 vs average FEV1)
5691,European,744.0,26420894.0,Wuttke M,"Other disease, Other trait",initial,2015-09-28,GCST003142,Proteinuria in chronic kidney disease
6931,European,2005.0,26420894.0,Wuttke M,"Other disease, Other measurement",initial,2015-09-28,GCST003140,Chronic kidney disease
5690,European,744.0,26420894.0,Wuttke M,"Other disease, Other measurement",initial,2015-09-28,GCST003139,Glomerular filtration rate in chronic kidney disease
13650,Other/Mixed,397.0,26420894.0,Wuttke M,"Other disease, Other measurement",initial,2015-09-28,GCST003139,Glomerular filtration rate in chronic kidney disease
6991,European,2064.0,26422391.0,Yellin JL,Other trait,initial,2015-09-28,GCST003138,Juvenile osteochondritis dissecans
6655,European,1641.0,26420894.0,Wuttke M,"Other disease, Other trait",initial,2015-09-28,GCST003141,Proteinuria and chronic kidney disease
13651,Other/Mixed,397.0,26420894.0,Wuttke M,"Other disease, Other trait",initial,2015-09-28,GCST003142,Proteinuria in chronic kidney disease
11551,European,93055.0,26416764.0,Day FR,Other disease,replication,2015-09-29,GCST003144,Polycystic ovary syndrome
8758,European,6079.0,26417704.0,Corvol H,"Other disease, Other measurement",initial,2015-09-29,GCST003143,Lung disease severity in cystic fibrosis
11494,European,87943.0,26416764.0,Day FR,Other disease,initial,2015-09-29,GCST003144,Polycystic ovary syndrome
325,African,15483.0,26416757.0,Band G,Digestive system disorder,replication,2015-09-30,GCST003145,Severe malaria
313,African,10421.0,26416757.0,Band G,Digestive system disorder,initial,2015-09-30,GCST003145,Severe malaria
9206,European,8143.0,26367794.0,Zheng HF,Other measurement,initial,2015-10-01,GCST005546,Forearm bone mineral density
378,African American or Afro-Caribbean,19.0,26366535.0,Sood RF,Other measurement,initial,2015-10-01,GCST003146,Postburn hypertrophic scarring severity
11644,European,112279.0,26426971.0,Winkler TW,Body measurement,initial,2015-10-01,GCST005953,Body mass index (age <50)
5127,European,408.0,26366535.0,Sood RF,Other measurement,initial,2015-10-01,GCST003146,Postburn hypertrophic scarring severity
9765,European,11582.0,26424050.0,Kinnersley B,Cancer,initial,2015-10-01,GCST003228,Glioma
12214,European,309889.0,26426971.0,Winkler TW,"Body measurement, Other measurement",initial,2015-10-01,GCST005950,Body mass index x sex x age interaction (4df test)
12116,European,252375.0,26426971.0,Winkler TW,"Body measurement, Other measurement",initial,2015-10-01,GCST005960,Waist-to-hip ratio adjusted for BMI x sex x age interaction
1575,Asian,26.0,26366535.0,Sood RF,Other measurement,initial,2015-10-01,GCST003146,Postburn hypertrophic scarring severity
12114,European,252375.0,26426971.0,Winkler TW,Body measurement,initial,2015-10-01,GCST005956,Waist-to-hip ratio adjusted for BMI
10184,European,17253.0,26367794.0,Zheng HF,Other measurement,replication,2015-10-01,GCST005544,Femoral neck bone mineral density
13401,Other/Mixed,11.0,26366535.0,Sood RF,Other measurement,initial,2015-10-01,GCST003146,Postburn hypertrophic scarring severity
12118,European,252375.0,26426971.0,Winkler TW,"Body measurement, Other measurement",initial,2015-10-01,GCST005962,Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)
12213,European,309889.0,26426971.0,Winkler TW,"Body measurement, Other measurement",initial,2015-10-01,GCST005949,Body mass index x sex interaction
10760,European,32735.0,26367794.0,Zheng HF,Other measurement,initial,2015-10-01,GCST005544,Femoral neck bone mineral density
9447,European,9218.0,26424050.0,Kinnersley B,Cancer,initial,2015-10-01,GCST003220,Glioblastoma
12215,European,309889.0,26426971.0,Winkler TW,"Body measurement, Other measurement",initial,2015-10-01,GCST005951,Body mass index
12216,European,309889.0,26426971.0,Winkler TW,"Body measurement, Other measurement",initial,2015-10-01,GCST005954,Body mass index x age interaction
7430,European,2662.0,26367794.0,Zheng HF,Other measurement,replication,2015-10-01,GCST005546,Forearm bone mineral density
12016,European,197610.0,26426971.0,Winkler TW,Body measurement,initial,2015-10-01,GCST005952,Body mass index (age>50)
9548,European,9799.0,26424050.0,Kinnersley B,Cancer,initial,2015-10-01,GCST003227,Non-glioblastoma glioma
7690,European,3213.0,26424050.0,Kinnersley B,Cancer,replication,2015-10-01,GCST003220,Glioblastoma
11902,European,158073.0,26426971.0,Winkler TW,Body measurement,initial,2015-10-01,GCST005958,Waist-to-hip ratio adjusted for BMI (age >50)
11556,European,94302.0,26426971.0,Winkler TW,Body measurement,initial,2015-10-01,GCST005957,Waist-to-hip ratio adjusted for BMI (age <50)
7691,European,3213.0,26424050.0,Kinnersley B,Cancer,replication,2015-10-01,GCST003227,Non-glioblastoma glioma
7692,European,3213.0,26424050.0,Kinnersley B,Cancer,replication,2015-10-01,GCST003228,Glioma
12217,European,309889.0,26426971.0,Winkler TW,"Body measurement, Other measurement",initial,2015-10-01,GCST005955,Body mass index x sex x age interaction
10773,European,33297.0,26367794.0,Zheng HF,Other measurement,initial,2015-10-01,GCST005545,Lumbar spine bone mineral density
12115,European,252375.0,26426971.0,Winkler TW,"Body measurement, Other measurement",initial,2015-10-01,GCST005959,Waist-to-hip ratio adjusted for BMI x sex interaction
10106,European,16233.0,26367794.0,Zheng HF,Other measurement,replication,2015-10-01,GCST005545,Lumbar spine bone mineral density
12117,European,252375.0,26426971.0,Winkler TW,"Body measurement, Other measurement",initial,2015-10-01,GCST005961,Waist-to-hip ratio adjusted for BMI x age interaction
13471,Other/Mixed,57.0,26366535.0,Sood RF,Other measurement,initial,2015-10-01,GCST003146,Postburn hypertrophic scarring severity
8960,European,6901.0,26433129.0,Tin A,Other measurement,initial,2015-10-03,GCST003147,Plasma lactate levels
907,African American or Afro-Caribbean,1671.0,26433129.0,Tin A,Other measurement,replication,2015-10-03,GCST003147,Plasma lactate levels
9074,European,7469.0,26440539.0,Hancock DB,Neurological disorder,replication,2015-10-06,GCST003185,Nicotine dependence
10175,European,17074.0,26440539.0,Hancock DB,Neurological disorder,initial,2015-10-06,GCST003185,Nicotine dependence
3804,Asian,7394.0,26443449.0,Wang M,Cancer,initial,2015-10-07,GCST003148,Prostate cancer
3819,Asian,7524.0,26443449.0,Wang M,Cancer,replication,2015-10-07,GCST003148,Prostate cancer
9135,European,7773.0,26451028.0,Hofer E,Other measurement,initial,2015-10-08,GCST003152,White matter lesion progression (adjusted for white matter lesion burden at baseline)
11073,European,47564.0,26450422.0,DeLorenze GN,Other disease,initial,2015-10-08,GCST003149,Skin and soft tissue Staphylococcus aureus infection
9134,European,7773.0,26451028.0,Hofer E,Other measurement,initial,2015-10-08,GCST003151,White matter lesion progression
11102,European,50045.0,26450422.0,DeLorenze GN,Other disease,initial,2015-10-08,GCST003150,Staphylococcus aureus infection
7428,European,2660.0,26562150.0,Seldin MF,Neurological disorder,initial,2015-10-10,GCST003251,Late-onset myasthenia gravis
5607,European,685.0,26460308.0,Ghesquieres H,"Response to drug, Other measurement, Cancer",replication,2015-10-12,GCST003178,Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy
5844,European,852.0,26460308.0,Ghesquieres H,"Response to drug, Other measurement, Cancer",initial,2015-10-12,GCST003178,Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy
8781,European,6182.0,26490195.0,Cleynen I,"Digestive system disorder, Immune system disorder",replication,2015-10-18,GCST006960,Inflammatory bowel disease
10684,European,29838.0,26490195.0,Cleynen I,"Digestive system disorder, Immune system disorder",initial,2015-10-18,GCST006960,Inflammatory bowel disease
3994,Asian,9438.0,26482879.0,Paternoster L,Immune system disorder,initial,2015-10-19,GCST003184,Atopic dermatitis
7034,European,2138.0,26482880.0,Buch S,Cancer,initial,2015-10-19,GCST003153,Cirrhosis (alcohol related)
12123,European,257125.0,26482879.0,Paternoster L,Immune system disorder,replication,2015-10-19,GCST003184,Atopic dermatitis
12857,Hispanic or Latin American,1892.0,26482879.0,Paternoster L,Immune system disorder,initial,2015-10-19,GCST003184,Atopic dermatitis
850,African American or Afro-Caribbean,1266.0,26482879.0,Paternoster L,Immune system disorder,initial,2015-10-19,GCST003184,Atopic dermatitis
11588,European,103066.0,26482879.0,Paternoster L,Immune system disorder,initial,2015-10-19,GCST003184,Atopic dermatitis
855,African American or Afro-Caribbean,1288.0,26482879.0,Paternoster L,Immune system disorder,replication,2015-10-19,GCST003184,Atopic dermatitis
6994,European,2070.0,26482880.0,Buch S,Cancer,replication,2015-10-19,GCST003153,Cirrhosis (alcohol related)
3074,Asian,2374.0,26482879.0,Paternoster L,Immune system disorder,replication,2015-10-19,GCST003184,Atopic dermatitis
7325,European,2513.0,26480920.0,Sung YJ,"Other measurement, Body measurement",initial,2015-10-20,GCST003167,Visceral adipose tissue adjusted for BMI
7070,European,2171.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003162,Visceral adipose tissue/subcutaneous adipose tissue ratio
723,African American or Afro-Caribbean,772.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003165,Subcutaneous adipose tissue adjusted for BMI
722,African American or Afro-Caribbean,772.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003164,Subcutaneous adipose tissue
7323,European,2513.0,26480920.0,Sung YJ,Other measurement,initial,2015-10-20,GCST003173,Visceral adipose tissue/subcutaneous adipose tissue ratio
728,African American or Afro-Caribbean,772.0,26480920.0,Sung YJ,"Other measurement, Body measurement",replication,2015-10-20,GCST003167,Visceral adipose tissue adjusted for BMI
721,African American or Afro-Caribbean,772.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003162,Visceral adipose tissue/subcutaneous adipose tissue ratio
7315,European,2513.0,26480920.0,Sung YJ,Other measurement,initial,2015-10-20,GCST003162,Visceral adipose tissue/subcutaneous adipose tissue ratio
7321,European,2513.0,26480920.0,Sung YJ,Other measurement,initial,2015-10-20,GCST003170,Subcutaneous adipose tissue
7320,European,2513.0,26480920.0,Sung YJ,Other measurement,initial,2015-10-20,GCST003169,Total adipose tissue adjusted for BMI
7319,European,2513.0,26480920.0,Sung YJ,Other measurement,initial,2015-10-20,GCST003168,Total adipose tissue
7316,European,2513.0,26480920.0,Sung YJ,Other measurement,initial,2015-10-20,GCST003164,Subcutaneous adipose tissue
7317,European,2513.0,26480920.0,Sung YJ,Other measurement,initial,2015-10-20,GCST003165,Subcutaneous adipose tissue adjusted for BMI
724,African American or Afro-Caribbean,772.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003166,Visceral adipose tissue
7324,European,2513.0,26480920.0,Sung YJ,"Other measurement, Body measurement",initial,2015-10-20,GCST003163,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
7322,European,2513.0,26480920.0,Sung YJ,Other measurement,initial,2015-10-20,GCST003171,Visceral adipose tissue
7076,European,2171.0,26480920.0,Sung YJ,"Other measurement, Body measurement",replication,2015-10-20,GCST003163,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
727,African American or Afro-Caribbean,772.0,26480920.0,Sung YJ,"Other measurement, Body measurement",replication,2015-10-20,GCST003163,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
726,African American or Afro-Caribbean,772.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003169,Total adipose tissue adjusted for BMI
725,African American or Afro-Caribbean,772.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003168,Total adipose tissue
7077,European,2171.0,26480920.0,Sung YJ,"Other measurement, Body measurement",replication,2015-10-20,GCST003167,Visceral adipose tissue adjusted for BMI
7071,European,2171.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003164,Subcutaneous adipose tissue
7075,European,2171.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003169,Total adipose tissue adjusted for BMI
7074,European,2171.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003168,Total adipose tissue
7073,European,2171.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003166,Visceral adipose tissue
7318,European,2513.0,26480920.0,Sung YJ,Other measurement,initial,2015-10-20,GCST003166,Visceral adipose tissue
7326,European,2513.0,26480920.0,Sung YJ,"Other measurement, Body measurement",initial,2015-10-20,GCST003172,Visceral adipose tissue adjusted for BMI
7072,European,2171.0,26480920.0,Sung YJ,Other measurement,replication,2015-10-20,GCST003165,Subcutaneous adipose tissue adjusted for BMI
5261,European,478.0,26491034.0,Sarzynski MA,"Biological process, Lipid or lipoprotein measurement",initial,2015-10-21,GCST003207,Response to exercise (triglyceride level interaction)
4272,Asian,19131.0,26488411.0,Matsukura M,Cardiovascular disease,replication,2015-10-21,GCST003154,Peripheral artery disease
3409,Asian,4168.0,26488411.0,Matsukura M,Cardiovascular disease,initial,2015-10-21,GCST003154,Peripheral artery disease
10719,European,31149.0,26486471.0,van Loon J,Hematological measurement,initial,2015-10-21,GCST003210,Low vWF levels
9981,European,14267.0,26502338.0,Bentham J,Immune system disorder,initial,2015-10-26,GCST003156,Systemic lupus erythematosus
9413,European,8943.0,26502338.0,Bentham J,Immune system disorder,replication,2015-10-26,GCST003155,Systemic lupus erythematosus
9980,European,14267.0,26502338.0,Bentham J,Immune system disorder,initial,2015-10-26,GCST003155,Systemic lupus erythematosus
8727,European,5932.0,26503584.0,Litchfield K,Cancer,initial,2015-10-27,GCST003246,Testicular germ cell tumor
9642,European,10538.0,26503763.0,Song J,"Response to drug, Neurological disorder",initial,2015-10-27,GCST003158,Subjective response to lithium treatment
8728,European,5932.0,26503584.0,Litchfield K,Cancer,initial,2015-10-27,GCST003247,Testicular germ cell tumor
9725,European,11146.0,26503584.0,Litchfield K,Cancer,replication,2015-10-27,GCST003246,Testicular germ cell tumor
8977,European,7007.0,26503763.0,Song J,"Response to drug, Neurological disorder",initial,2015-10-27,GCST003159,Objective response to lithium treatment
7452,European,2698.0,26503763.0,Song J,"Response to drug, Neurological disorder",initial,2015-10-27,GCST003160,Subjective response to lithium treatment in bipolar disorder
6263,European,1176.0,26503763.0,Song J,"Response to drug, Neurological disorder",initial,2015-10-27,GCST003161,Objective response to lithium treatment in bipolar disorder
6257,European,1171.0,26516778.0,Bis JC,"Response to drug, Cardiovascular disease",replication,2015-10-30,GCST003201,Myocardial infarction in hypertension (beta blocker interaction)
6756,European,1751.0,26516778.0,Bis JC,"Response to drug, Other disease, Cardiovascular disease",replication,2015-10-30,GCST003203,Cardiovascular disease in hypertension (beta blocker interaction)
6255,European,1171.0,26516778.0,Bis JC,"Cardiovascular disease, Response to drug",replication,2015-10-30,GCST003187,Myocardial infarction in hypertension (ACE inhibitor interaction)
6755,European,1751.0,26516778.0,Bis JC,"Other disease, Cardiovascular disease, Response to drug",replication,2015-10-30,GCST003204,Cardiovascular disease in hypertension (diuretic interaction)
6754,European,1751.0,26516778.0,Bis JC,"Other disease, Cardiovascular disease, Response to drug",replication,2015-10-30,GCST003186,Cardiovascular disease in hypertension (ACE inhibitor interaction)
6258,European,1171.0,26516778.0,Bis JC,"Response to drug, Cardiovascular disease",replication,2015-10-30,GCST003206,Myocardial infarction in hypertension (calcium channel blocker interaction)
759,African American or Afro-Caribbean,898.0,26519441.0,Kim S,Cardiovascular measurement,initial,2015-10-30,GCST003157,Plasma homocysteine levels
6757,European,1751.0,26516778.0,Bis JC,"Response to drug, Other disease, Cardiovascular disease",replication,2015-10-30,GCST003205,Cardiovascular disease in hypertension (calcium channel blocker interaction)
156,African,960.0,26519441.0,Kim S,Cardiovascular measurement,initial,2015-10-30,GCST003157,Plasma homocysteine levels
6256,European,1171.0,26516778.0,Bis JC,"Cardiovascular disease, Response to drug",replication,2015-10-30,GCST003202,Myocardial infarction in hypertension (diuretic interaction)
1180,African American or Afro-Caribbean,4141.0,26516778.0,Bis JC,"Response to drug, Other disease, Cardiovascular disease",replication,2015-10-30,GCST003203,Cardiovascular disease in hypertension (beta blocker interaction)
10121,European,16375.0,26516778.0,Bis JC,"Response to drug, Cardiovascular disease",initial,2015-10-30,GCST003206,Myocardial infarction in hypertension (calcium channel blocker interaction)
10118,European,16375.0,26516778.0,Bis JC,"Other disease, Cardiovascular disease, Response to drug",initial,2015-10-30,GCST003186,Cardiovascular disease in hypertension (ACE inhibitor interaction)
1178,African American or Afro-Caribbean,4141.0,26516778.0,Bis JC,"Other disease, Cardiovascular disease, Response to drug",replication,2015-10-30,GCST003186,Cardiovascular disease in hypertension (ACE inhibitor interaction)
1179,African American or Afro-Caribbean,4141.0,26516778.0,Bis JC,"Other disease, Cardiovascular disease, Response to drug",replication,2015-10-30,GCST003204,Cardiovascular disease in hypertension (diuretic interaction)
10117,European,16375.0,26516778.0,Bis JC,"Cardiovascular disease, Response to drug",initial,2015-10-30,GCST003202,Myocardial infarction in hypertension (diuretic interaction)
10116,European,16375.0,26516778.0,Bis JC,"Cardiovascular disease, Response to drug",initial,2015-10-30,GCST003187,Myocardial infarction in hypertension (ACE inhibitor interaction)
10122,European,16375.0,26516778.0,Bis JC,"Response to drug, Other disease, Cardiovascular disease",initial,2015-10-30,GCST003203,Cardiovascular disease in hypertension (beta blocker interaction)
1181,African American or Afro-Caribbean,4141.0,26516778.0,Bis JC,"Response to drug, Other disease, Cardiovascular disease",replication,2015-10-30,GCST003205,Cardiovascular disease in hypertension (calcium channel blocker interaction)
10119,European,16375.0,26516778.0,Bis JC,"Other disease, Cardiovascular disease, Response to drug",initial,2015-10-30,GCST003204,Cardiovascular disease in hypertension (diuretic interaction)
10123,European,16375.0,26516778.0,Bis JC,"Response to drug, Other disease, Cardiovascular disease",initial,2015-10-30,GCST003205,Cardiovascular disease in hypertension (calcium channel blocker interaction)
10120,European,16375.0,26516778.0,Bis JC,"Response to drug, Cardiovascular disease",initial,2015-10-30,GCST003201,Myocardial infarction in hypertension (beta blocker interaction)
1042,African American or Afro-Caribbean,2885.0,26278503.0,Huang C,Digestive system disorder,initial,2015-11-01,GCST008730,Crohn's disease
8800,European,6252.0,26632684.0,Dong J,Biological process,initial,2015-11-01,GCST003174,Sense of smell
11328,European,69626.0,26414677.0,Day FR,Other measurement,initial,2015-11-01,GCST005312,Menopause (age at onset)
973,African American or Afro-Caribbean,2158.0,26278503.0,Huang C,Immune system disorder,initial,2015-11-01,GCST008732,Ulcerative colitis
8813,European,6307.0,26366551.0,Zoledziewska M,"Other measurement, Body measurement",initial,2015-11-01,GCST005354,Height
10550,European,24367.0,26366551.0,Zoledziewska M,"Other measurement, Body measurement",replication,2015-11-01,GCST005354,Height
11061,European,46638.0,26414677.0,Day FR,Other measurement,replication,2015-11-01,GCST005560,Menopause (age at onset)
1118,African American or Afro-Caribbean,3308.0,26278503.0,Huang C,"Digestive system disorder, Immune system disorder",initial,2015-11-01,GCST008731,Inflammatory bowel disease
7360,European,2545.0,26414677.0,Day FR,Other measurement,initial,2015-11-01,GCST005560,Menopause (age at onset)
1884,Asian,262.0,26434682.0,Lin YJ,"Immune system disorder, Cardiovascular disease",initial,2015-11-01,GCST003192,Coronary artery aneurysm in Kawasaki disease
8162,European,4216.0,26525574.0,Westerlind H,Immune system disorder,initial,2015-11-02,GCST005879,Collagenous colitis
5104,European,397.0,26525574.0,Westerlind H,Immune system disorder,replication,2015-11-02,GCST005879,Collagenous colitis
4659,European,93.0,26528553.0,Davenport ER,Other measurement,initial,2015-11-03,GCST003223,Gut microbiome composition (winter)
4703,European,127.0,26528553.0,Davenport ER,Other measurement,initial,2015-11-03,GCST003222,Gut microbiome composition (summer and winter)
4656,European,91.0,26528553.0,Davenport ER,Other measurement,initial,2015-11-03,GCST003221,Gut microbiome composition (summer)
6391,European,1335.0,26534935.0,Weng L,Cardiovascular disease,initial,2015-11-03,GCST008436,Nonobstructive coronary artery disease
8346,European,4773.0,26589003.0,Federoff M,Neurological disorder,initial,2015-11-05,GCST003179,Multiple system atrophy
12770,Hispanic or Latin American,911.0,26545240.0,Giri A,Other disease,initial,2015-11-06,GCST003226,Pelvic organ prolapse
9231,European,8281.0,26542096.0,Marenholz I,"Biological process, Immune system disorder, Other disease",replication,2015-11-06,GCST003180,Atopic march
1945,Asian,325.0,26546620.0,Xu CF,"Liver enzyme measurement, Response to drug, Cancer",initial,2015-11-06,GCST003232,Response to Pazopanib in cancer (hepatotoxicity)
9731,European,11181.0,26542096.0,Marenholz I,"Biological process, Immune system disorder, Other disease",initial,2015-11-06,GCST003180,Atopic march
12653,Hispanic or Latin American,468.0,26545240.0,Giri A,Other disease,initial,2015-11-06,GCST003225,Pelvic organ prolapse (moderate/severe)
1690,Asian,114.0,26546620.0,Xu CF,"Liver enzyme measurement, Response to drug, Cancer",replication,2015-11-06,GCST003232,Response to Pazopanib in cancer (hepatotoxicity)
809,African American or Afro-Caribbean,1102.0,26545240.0,Giri A,Other disease,initial,2015-11-06,GCST003225,Pelvic organ prolapse (moderate/severe)
5832,European,844.0,26546620.0,Xu CF,"Liver enzyme measurement, Response to drug, Cancer",initial,2015-11-06,GCST003232,Response to Pazopanib in cancer (hepatotoxicity)
914,African American or Afro-Caribbean,1741.0,26545240.0,Giri A,Other disease,initial,2015-11-06,GCST003226,Pelvic organ prolapse
5775,European,811.0,26546620.0,Xu CF,"Liver enzyme measurement, Response to drug, Cancer",replication,2015-11-06,GCST003232,Response to Pazopanib in cancer (hepatotoxicity)
8815,European,6315.0,26553974.0,McLaren PJ,"Other measurement, Other disease",initial,2015-11-09,GCST003183,Setpoint viral load in HIV-1 infection
11696,European,120246.0,26561523.0,de Vries PS,Hematological measurement,initial,2015-11-10,GCST003194,Fibrinogen levels
1860,Asian,234.0,26566055.0,Mieda T,Other measurement,replication,2015-11-13,GCST003200,Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours)
1693,Asian,116.0,26566055.0,Mieda T,Other measurement,initial,2015-11-13,GCST003200,Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours)
2463,Asian,1050.0,26531332.0,Kim LH,Neurological disorder,initial,2015-11-14,GCST003190,Schizophrenia
2392,Asian,914.0,26531332.0,Kim LH,Neurological disorder,replication,2015-11-14,GCST003190,Schizophrenia
12730,Hispanic or Latin American,761.0,26569114.0,Brown EL,Other measurement,initial,2015-11-16,GCST003182,Staphylococcus aureus nasal carriage (persistent)
12716,Hispanic or Latin American,717.0,26569114.0,Brown EL,Other measurement,initial,2015-11-16,GCST003181,Staphylococcus aureus nasal carriage (intermittent)
3895,Asian,8344.0,26582766.0,Lu X,Lipid or lipoprotein measurement,initial,2015-11-18,GCST003217,Triglycerides
3894,Asian,8344.0,26582766.0,Lu X,Lipid or lipoprotein measurement,initial,2015-11-18,GCST003215,HDL cholesterol
3896,Asian,8344.0,26582766.0,Lu X,"Lipid or lipoprotein measurement, Other measurement",initial,2015-11-18,GCST003216,LDL cholesterol
3893,Asian,8344.0,26582766.0,Lu X,Lipid or lipoprotein measurement,initial,2015-11-18,GCST003214,"Cholesterol, total"
4200,Asian,14739.0,26582766.0,Lu X,Lipid or lipoprotein measurement,replication,2015-11-18,GCST003215,HDL cholesterol
4199,Asian,14739.0,26582766.0,Lu X,Lipid or lipoprotein measurement,replication,2015-11-18,GCST003214,"Cholesterol, total"
4201,Asian,14739.0,26582766.0,Lu X,Lipid or lipoprotein measurement,replication,2015-11-18,GCST003217,Triglycerides
4202,Asian,14739.0,26582766.0,Lu X,"Lipid or lipoprotein measurement, Other measurement",replication,2015-11-18,GCST003216,LDL cholesterol
2088,Asian,470.0,26580837.0,Chen CJ,Neurological disorder,initial,2015-11-18,GCST003175,Amyotrophic lateral sclerosis
2596,Asian,1361.0,26584805.0,Dorajoo R,Lipid or lipoprotein measurement,initial,2015-11-19,GCST003242,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid)
7889,European,3494.0,26586795.0,Phipps AI,"Other measurement, Cancer",initial,2015-11-19,GCST003229,Survival in colorectal cancer
7529,European,2843.0,26586795.0,Phipps AI,"Other measurement, Cancer",initial,2015-11-19,GCST003231,Survival in colorectal cancer (non-distant metastatic)
7995,European,3764.0,26586795.0,Phipps AI,"Other measurement, Cancer",replication,2015-11-19,GCST003229,Survival in colorectal cancer
5236,European,462.0,26586795.0,Phipps AI,"Other measurement, Cancer",initial,2015-11-19,GCST003230,Survival in colorectal cancer (distant metastatic)
5191,European,435.0,26586795.0,Phipps AI,"Other measurement, Cancer",replication,2015-11-19,GCST003230,Survival in colorectal cancer (distant metastatic)
2590,Asian,1361.0,26584805.0,Dorajoo R,Lipid or lipoprotein measurement,initial,2015-11-19,GCST003236,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)
2597,Asian,1361.0,26584805.0,Dorajoo R,Other measurement,initial,2015-11-19,GCST003243,Delta-5 desaturase activity
2591,Asian,1361.0,26584805.0,Dorajoo R,Lipid or lipoprotein measurement,initial,2015-11-19,GCST003237,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)
2592,Asian,1361.0,26584805.0,Dorajoo R,Lipid or lipoprotein measurement,initial,2015-11-19,GCST003238,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)
2598,Asian,1361.0,26584805.0,Dorajoo R,Other measurement,initial,2015-11-19,GCST003244,Delta-6 desaturase activity
2593,Asian,1361.0,26584805.0,Dorajoo R,Lipid or lipoprotein measurement,initial,2015-11-19,GCST003239,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)
2595,Asian,1361.0,26584805.0,Dorajoo R,Lipid or lipoprotein measurement,initial,2015-11-19,GCST003241,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid)
2594,Asian,1361.0,26584805.0,Dorajoo R,Lipid or lipoprotein measurement,initial,2015-11-19,GCST003240,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)
7686,European,3205.0,26586795.0,Phipps AI,"Other measurement, Cancer",replication,2015-11-19,GCST003231,Survival in colorectal cancer (non-distant metastatic)
1670,Asian,100.0,26870257.0,Qu LS,"Digestive system disorder, Cancer",initial,2015-11-23,GCST003189,Hepatocellular carcinoma in hepatitis B infection
2158,Asian,560.0,26870257.0,Qu LS,"Digestive system disorder, Cancer",replication,2015-11-23,GCST003189,Hepatocellular carcinoma in hepatitis B infection
1667,Asian,99.0,26600424.0,MacInnis MJ,Cardiovascular disease,initial,2015-11-24,GCST003188,Acute mountain sickness
1802,Asian,202.0,26600424.0,MacInnis MJ,Cardiovascular disease,replication,2015-11-24,GCST003188,Acute mountain sickness
9740,European,11313.0,26604143.0,Felix JF,Body measurement,replication,2015-11-24,GCST003177,Childhood body mass index
5892,European,889.0,26620591.0,Barreto-Luis A,Other disease,initial,2015-11-24,GCST003176,Asthma
7118,European,2206.0,26620591.0,Barreto-Luis A,Other disease,replication,2015-11-24,GCST003176,Asthma
10840,European,34744.0,26604143.0,Felix JF,Body measurement,initial,2015-11-24,GCST003177,Childhood body mass index
13958,Other/Mixed,3710.0,26606652.0,Alarcon-Riquelme ME,Immune system disorder,initial,2015-11-25,GCST003252,Systemic lupus erythematosus
10438,European,21801.0,26626624.0,Stuart PE,Immune system disorder,replication,2015-11-28,GCST003268,Psoriasis vulgaris
7778,European,3309.0,26626624.0,Stuart PE,"Other measurement, Immune system disorder",initial,2015-11-28,GCST003271,Psoriatic arthritis vs Cutaneous psoriasis
10173,European,17062.0,26626624.0,Stuart PE,Immune system disorder,replication,2015-11-28,GCST003270,Psoriatic arthritis
8948,European,6880.0,26626624.0,Stuart PE,Immune system disorder,initial,2015-11-28,GCST003270,Psoriatic arthritis
9412,European,8941.0,26626624.0,Stuart PE,Immune system disorder,initial,2015-11-28,GCST003268,Psoriasis vulgaris
8782,European,6184.0,26626624.0,Stuart PE,"Other measurement, Immune system disorder",replication,2015-11-28,GCST003271,Psoriatic arthritis vs Cutaneous psoriasis
8806,European,6297.0,26626624.0,Stuart PE,"Other measurement, Immune system disorder",initial,2015-11-28,GCST003269,Cutaneous psoriasis
10191,European,17353.0,26626624.0,Stuart PE,"Other measurement, Immune system disorder",replication,2015-11-28,GCST003269,Cutaneous psoriasis
10423,European,21333.0,26621817.0,Cheng TH,Cancer,initial,2015-12-01,GCST003208,Colorectal or endometrial cancer
10720,European,31179.0,26621817.0,Cheng TH,Cancer,replication,2015-12-01,GCST003208,Colorectal or endometrial cancer
10424,European,21333.0,26621817.0,Cheng TH,Cancer,initial,2015-12-01,GCST003209,Colorectal or endometrial cancer
11042,European,46051.0,26631737.0,Teumer A,Other measurement,initial,2015-12-02,GCST003254,Urinary albumin-to-creatinine ratio in non-diabetics
11168,European,54450.0,26631737.0,Teumer A,Other measurement,initial,2015-12-02,GCST003255,Urinary albumin-to-creatinine ratio
6909,European,1962.0,26631737.0,Teumer A,"Other measurement, Metabolic disorder",replication,2015-12-02,GCST003250,Urinary albumin-to-creatinine ratio in diabetes
8695,European,5825.0,26631737.0,Teumer A,"Other measurement, Metabolic disorder",initial,2015-12-02,GCST003250,Urinary albumin-to-creatinine ratio in diabetes
11157,European,54116.0,26631737.0,Teumer A,Other trait,initial,2015-12-02,GCST003253,Microalbuminuria
739,African American or Afro-Caribbean,821.0,26634245.0,Lutz SM,"Other disease, Other measurement, Response to drug",initial,2015-12-03,GCST003265,Post bronchodilator FEV1/FVC ratio in COPD
1111,African American or Afro-Caribbean,3260.0,26634245.0,Lutz SM,"Other measurement, Response to drug",initial,2015-12-03,GCST003264,Post bronchodilator FEV1/FVC ratio
1112,African American or Afro-Caribbean,3260.0,26634245.0,Lutz SM,"Response to drug, Other measurement",initial,2015-12-03,GCST003262,Post bronchodilator FEV1
8606,European,5439.0,26634245.0,Lutz SM,"Other disease, Response to drug, Other measurement",initial,2015-12-03,GCST003263,Post bronchodilator FEV1 in COPD
740,African American or Afro-Caribbean,821.0,26634245.0,Lutz SM,"Other disease, Response to drug, Other measurement",initial,2015-12-03,GCST003263,Post bronchodilator FEV1 in COPD
8885,European,6659.0,26634245.0,Lutz SM,Other measurement,initial,2015-12-03,GCST003267,Pre bronchodilator FEV1/FVC ratio
9607,European,10094.0,26634245.0,Lutz SM,"Response to drug, Other measurement",initial,2015-12-03,GCST003262,Post bronchodilator FEV1
9606,European,10094.0,26634245.0,Lutz SM,"Other measurement, Response to drug",initial,2015-12-03,GCST003264,Post bronchodilator FEV1/FVC ratio
8605,European,5439.0,26634245.0,Lutz SM,"Other disease, Other measurement, Response to drug",initial,2015-12-03,GCST003265,Post bronchodilator FEV1/FVC ratio in COPD
8884,European,6659.0,26634245.0,Lutz SM,Other measurement,initial,2015-12-03,GCST003266,Pre bronchodilator FEV1
10919,European,38199.0,26635082.0,Soler Artigas M,Other measurement,initial,2015-12-04,GCST008480,Lung function (FEV1)
11170,European,54550.0,26635082.0,Soler Artigas M,Other measurement,replication,2015-12-04,GCST008480,Lung function (FEV1)
10920,European,38199.0,26635082.0,Soler Artigas M,Other measurement,initial,2015-12-04,GCST008481,Lung function (FEV1/FVC)
10921,European,38199.0,26635082.0,Soler Artigas M,Other measurement,initial,2015-12-04,GCST008482,Lung function (FVC)
11172,European,54550.0,26635082.0,Soler Artigas M,Other measurement,replication,2015-12-04,GCST008482,Lung function (FVC)
11171,European,54550.0,26635082.0,Soler Artigas M,Other measurement,replication,2015-12-04,GCST008481,Lung function (FEV1/FVC)
5016,European,337.0,26644207.0,Clarelli F,"Immune system disorder, Response to drug",initial,2015-12-08,GCST003193,Response to interferon beta in multiple sclerosis
2147,Asian,547.0,26656879.0,Yu H,"Neurological disorder, Other trait",replication,2015-12-09,GCST003579,Antipsychotic drug-induced weight gain in schizophrenia
2137,Asian,534.0,26656879.0,Yu H,"Neurological disorder, Other trait",initial,2015-12-09,GCST003579,Antipsychotic drug-induced weight gain in schizophrenia
3791,Asian,7263.0,26686025.0,Hwang JY,Other measurement,replication,2015-12-12,GCST003196,Calcaneal bone ultrasound measurement (speed of sound)
2883,Asian,1895.0,26686025.0,Hwang JY,Other measurement,initial,2015-12-12,GCST003196,Calcaneal bone ultrasound measurement (speed of sound)
2603,Asian,1387.0,26704534.0,Sapkota BR,Other measurement,initial,2015-12-15,GCST003191,Vitamin D levels
2994,Asian,2151.0,26704534.0,Sapkota BR,Other measurement,replication,2015-12-15,GCST003191,Vitamin D levels
3036,Asian,2252.0,26675016.0,Cha S,Body measurement,replication,2015-12-16,GCST003197,Thoracic-to-hip circumference ratio
7961,European,3670.0,26674333.0,Traylor M,"Other measurement, Other trait",initial,2015-12-16,GCST003245,White matter hyperintensities in ischemic stroke
3516,Asian,4988.0,26675016.0,Cha S,Body measurement,initial,2015-12-16,GCST003197,Thoracic-to-hip circumference ratio
12802,Hispanic or Latin American,1234.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003258,Ischemic stroke
3617,Asian,5615.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003257,Ischemic stroke (cardioembolic)
13985,Other/Mixed,6807.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003258,Ischemic stroke
2079,Asian,462.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003260,Ischemic stroke (small artery occlusion)
10691,European,30090.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003257,Ischemic stroke (cardioembolic)
10980,European,40990.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003258,Ischemic stroke
3591,Asian,5548.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003259,Ischemic stroke (large artery atherosclerosis)
13959,Other/Mixed,3735.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003260,Ischemic stroke (small artery occlusion)
13976,Other/Mixed,4440.0,26708676.0,Pulit SL,Other trait,initial,2015-12-18,GCST003261,Ischemic stroke (undetermined subtype)
13978,Other/Mixed,4963.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003258,Ischemic stroke
10841,European,34752.0,26708676.0,Pulit SL,Other trait,initial,2015-12-18,GCST003261,Ischemic stroke (undetermined subtype)
3826,Asian,7578.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003258,Ischemic stroke
13956,Other/Mixed,3574.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003259,Ischemic stroke (large artery atherosclerosis)
13952,Other/Mixed,3562.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003257,Ischemic stroke (cardioembolic)
12129,European,262805.0,26708676.0,Pulit SL,Other trait,replication,2015-12-18,GCST003261,Ischemic stroke (undetermined subtype)
3584,Asian,5507.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003260,Ischemic stroke (small artery occlusion)
13940,Other/Mixed,3015.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003257,Ischemic stroke (cardioembolic)
1961,Asian,346.0,26708676.0,Pulit SL,Other trait,replication,2015-12-18,GCST003261,Ischemic stroke (undetermined subtype)
13591,Other/Mixed,256.0,26708676.0,Pulit SL,Other trait,replication,2015-12-18,GCST003261,Ischemic stroke (undetermined subtype)
1977,Asian,363.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003259,Ischemic stroke (large artery atherosclerosis)
13595,Other/Mixed,272.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003259,Ischemic stroke (large artery atherosclerosis)
12289,European,368279.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003258,Ischemic stroke
12921,Hispanic or Latin American,2791.0,26708676.0,Pulit SL,Other trait,initial,2015-12-18,GCST003261,Ischemic stroke (undetermined subtype)
1975,Asian,360.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003257,Ischemic stroke (cardioembolic)
10664,European,29039.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003259,Ischemic stroke (large artery atherosclerosis)
10659,European,28942.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003260,Ischemic stroke (small artery occlusion)
13602,Other/Mixed,286.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003260,Ischemic stroke (small artery occlusion)
2150,Asian,548.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003258,Ischemic stroke
12718,Hispanic or Latin American,726.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003259,Ischemic stroke (large artery atherosclerosis)
12743,Hispanic or Latin American,783.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003257,Ischemic stroke (cardioembolic)
12908,Hispanic or Latin American,2575.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003259,Ischemic stroke (large artery atherosclerosis)
12072,European,219602.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003260,Ischemic stroke (small artery occlusion)
12738,Hispanic or Latin American,771.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003260,Ischemic stroke (small artery occlusion)
11984,European,178569.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003259,Ischemic stroke (large artery atherosclerosis)
12929,Hispanic or Latin American,2981.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003260,Ischemic stroke (small artery occlusion)
12148,European,277499.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",replication,2015-12-18,GCST003257,Ischemic stroke (cardioembolic)
12905,Hispanic or Latin American,2547.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003257,Ischemic stroke (cardioembolic)
12894,Hispanic or Latin American,2521.0,26708676.0,Pulit SL,"Cardiovascular disease, Other trait",initial,2015-12-18,GCST003258,Ischemic stroke
12754,Hispanic or Latin American,835.0,26708676.0,Pulit SL,Other trait,replication,2015-12-18,GCST003261,Ischemic stroke (undetermined subtype)
10818,European,33976.0,26691988.0,Fritsche LG,Neurological disorder,initial,2015-12-21,GCST003219,Advanced age-related macular degeneration
11350,European,72805.0,26686553.0,Jorgenson E,Other trait,initial,2015-12-21,GCST003198,Inguinal hernia
1634,Asian,77.0,26782385.0,Zhou TQ,Neurological disorder,initial,2015-12-21,GCST003199,Atrophic age-related macular degeneration
10067,European,15623.0,26685716.0,Chang X,Other measurement,replication,2015-12-21,GCST003195,Magnesium levels
98,African,413.0,26691988.0,Fritsche LG,Neurological disorder,replication,2015-12-21,GCST003219,Advanced age-related macular degeneration
2693,Asian,1572.0,26691988.0,Fritsche LG,Neurological disorder,replication,2015-12-21,GCST003219,Advanced age-related macular degeneration
1635,Asian,77.0,26865924.0,Lee M,"Body measurement, Other measurement",initial,2015-12-21,GCST003248,Body mass index
2043,Asian,426.0,26782385.0,Zhou TQ,Neurological disorder,replication,2015-12-21,GCST003199,Atrophic age-related macular degeneration
11549,European,92444.0,26686553.0,Jorgenson E,Other trait,replication,2015-12-21,GCST003198,Inguinal hernia
7147,European,2267.0,26685716.0,Chang X,Other measurement,initial,2015-12-21,GCST003195,Magnesium levels
1636,Asian,77.0,26865924.0,Lee M,Other measurement,initial,2015-12-21,GCST003249,Basal metabolic rate
3887,Asian,8201.0,26701879.0,Wang Z,Cancer,replication,2015-12-23,GCST003218,Non-cardia gastric cancer
3774,Asian,7001.0,26701879.0,Wang Z,Cancer,initial,2015-12-23,GCST003218,Non-cardia gastric cancer
75,African,258.0,26718567.0,Williams SR,"Hematological measurement, Other trait",initial,2015-12-30,GCST003212,Fibrinogen levels in ischemic stroke
78,African,258.0,26718567.0,Williams SR,"Other measurement, Other trait",initial,2015-12-30,GCST003234,Thrombomodulin levels in ischemic stroke
77,African,258.0,26718567.0,Williams SR,"Other measurement, Other trait",initial,2015-12-30,GCST003233,Thrombin-antithrombin complex levels in ischemic stroke
76,African,258.0,26718567.0,Williams SR,"Other measurement, Other trait",initial,2015-12-30,GCST003213,Creatinine levels in ischemic stroke
80,African,258.0,26718567.0,Williams SR,"Other trait, Inflammatory measurement",initial,2015-12-30,GCST003211,C-reactive protein levels in ischemic stroke
79,African,258.0,26718567.0,Williams SR,"Other measurement, Other trait",initial,2015-12-30,GCST003235,Prothrombin fragments F1+2 levels in ischemic stroke
6728,European,1725.0,26718567.0,Williams SR,"Hematological measurement, Other trait",initial,2015-12-30,GCST003212,Fibrinogen levels in ischemic stroke
6729,European,1725.0,26718567.0,Williams SR,"Other measurement, Other trait",initial,2015-12-30,GCST003213,Creatinine levels in ischemic stroke
6730,European,1725.0,26718567.0,Williams SR,"Other measurement, Other trait",initial,2015-12-30,GCST003233,Thrombin-antithrombin complex levels in ischemic stroke
6731,European,1725.0,26718567.0,Williams SR,"Other measurement, Other trait",initial,2015-12-30,GCST003234,Thrombomodulin levels in ischemic stroke
6732,European,1725.0,26718567.0,Williams SR,"Other measurement, Other trait",initial,2015-12-30,GCST003235,Prothrombin fragments F1+2 levels in ischemic stroke
6733,European,1725.0,26718567.0,Williams SR,"Other trait, Inflammatory measurement",initial,2015-12-30,GCST003211,C-reactive protein levels in ischemic stroke
4027,Asian,10095.0,26545403.0,Bei JX,Cancer,replication,2016-01-01,GCST005113,Nasopharyngeal carcinoma
10189,European,17348.0,27897004.0,Verma SS,"Other measurement, Hematological measurement, Liver enzyme measurement",replication,2016-01-01,GCST003540,Clinical laboratory measurements
3340,Asian,3674.0,26398853.0,Ye BD,Immune system disorder,replication,2016-01-01,GCST008483,Ulcerative colitis
3666,Asian,5892.0,26545403.0,Bei JX,Cancer,initial,2016-01-01,GCST005113,Nasopharyngeal carcinoma
9898,European,13329.0,26546613.0,Gutierrez-Achury J,Immune system disorder,initial,2016-01-01,GCST008644,Celiac disease and Rheumatoid arthritis
10188,European,17347.0,27897004.0,Verma SS,"Other measurement, Hematological measurement, Liver enzyme measurement",initial,2016-01-01,GCST003540,Clinical laboratory measurements
2376,Asian,880.0,26546613.0,Gutierrez-Achury J,Immune system disorder,initial,2016-01-01,GCST008644,Celiac disease and Rheumatoid arthritis
2876,Asian,1883.0,26398853.0,Ye BD,Immune system disorder,initial,2016-01-01,GCST008483,Ulcerative colitis
2475,Asian,1088.0,26845276.0,Ikeda M,"Other trait, Other measurement, Neurological disorder",initial,2016-01-01,GCST003319,Major depressive disorder (stressful life events interaction)
4152,Asian,13154.0,26732429.0,Wang Z,Cancer,initial,2016-01-04,GCST003325,Lung cancer
9502,European,9534.0,26732621.0,Ruth KS,Other measurement,initial,2016-01-04,GCST003334,Length of menstrual cycle
4153,Asian,13154.0,26732429.0,Wang Z,Cancer,initial,2016-01-04,GCST003326,Adenocarcinoma
4143,Asian,12924.0,26732429.0,Wang Z,Cancer,replication,2016-01-04,GCST003326,Adenocarcinoma
4142,Asian,12924.0,26732429.0,Wang Z,Cancer,replication,2016-01-04,GCST003325,Lung cancer
10237,European,18186.0,26732560.0,Cheng YC,Other trait,initial,2016-01-05,GCST003320,Ischemic stroke (undetermined subtype)
3496,Asian,4746.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",initial,2016-01-05,GCST003324,Ischemic stroke
631,African American or Afro-Caribbean,426.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",initial,2016-01-05,GCST003323,Ischemic stroke (cardioembolic)
632,African American or Afro-Caribbean,426.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",initial,2016-01-05,GCST003324,Ischemic stroke
10206,European,17565.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",initial,2016-01-05,GCST003322,Ischemic stroke (large artery atherosclerosis)
3540,Asian,5207.0,26732560.0,Cheng YC,Other trait,initial,2016-01-05,GCST003320,Ischemic stroke (undetermined subtype)
9386,European,8748.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",replication,2016-01-05,GCST003324,Ischemic stroke
669,African American or Afro-Caribbean,535.0,26732560.0,Cheng YC,Other trait,initial,2016-01-05,GCST003320,Ischemic stroke (undetermined subtype)
10217,European,17716.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",initial,2016-01-05,GCST003324,Ischemic stroke
10230,European,17831.0,26732560.0,Cheng YC,Cardiovascular disease,initial,2016-01-05,GCST003321,Small vessel stroke
616,African American or Afro-Caribbean,375.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",initial,2016-01-05,GCST003322,Ischemic stroke (large artery atherosclerosis)
3489,Asian,4685.0,26732560.0,Cheng YC,Cardiovascular disease,initial,2016-01-05,GCST003321,Small vessel stroke
3491,Asian,4710.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",initial,2016-01-05,GCST003322,Ischemic stroke (large artery atherosclerosis)
3495,Asian,4746.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",initial,2016-01-05,GCST003323,Ischemic stroke (cardioembolic)
633,African American or Afro-Caribbean,429.0,26732560.0,Cheng YC,Cardiovascular disease,initial,2016-01-05,GCST003321,Small vessel stroke
10216,European,17716.0,26732560.0,Cheng YC,"Cardiovascular disease, Other trait",initial,2016-01-05,GCST003323,Ischemic stroke (cardioembolic)
10352,European,20132.0,26733130.0,Styrkarsdottir U,Other measurement,initial,2016-01-06,GCST003388,Bone mineral density (spine)
13995,Other/Mixed,10092.0,26733130.0,Styrkarsdottir U,Other measurement,replication,2016-01-06,GCST003388,Bone mineral density (spine)
10353,European,20162.0,26733130.0,Styrkarsdottir U,Other measurement,initial,2016-01-06,GCST003389,Bone mineral density (hip)
13994,Other/Mixed,10037.0,26733130.0,Styrkarsdottir U,Other measurement,replication,2016-01-06,GCST003389,Bone mineral density (hip)
113,African,528.0,26741287.0,Milet J,Other measurement,initial,2016-01-07,GCST003460,IgG1 response to Plasmodium falciparum antigen (GLURP)
114,African,528.0,26741287.0,Milet J,Other measurement,initial,2016-01-07,GCST003461,"IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7)"
116,African,528.0,26741287.0,Milet J,Other measurement,initial,2016-01-07,GCST003463,IgG3 response to Plasmodium falciparum antigen (MSP2 3D7)
117,African,528.0,26741287.0,Milet J,Other measurement,initial,2016-01-07,GCST003464,IgG3 response to Plasmodium falciparum antigen (MSP2 FC27)
115,African,528.0,26741287.0,Milet J,Other measurement,initial,2016-01-07,GCST003462,IgG1 response to Plasmodium falciparum antigen (MSP1)
2081,Asian,465.0,26746183.0,Watanabe H,"Other measurement, Neurological disorder",initial,2016-01-08,GCST003333,Moderate functional decline in sporadic amyotrophic lateral sclerosis
2080,Asian,465.0,26746183.0,Watanabe H,"Other measurement, Neurological disorder",initial,2016-01-08,GCST003332,Rapid functional decline in sporadic amyotrophic lateral sclerosis
10886,European,37333.0,26752265.0,Bailey JN,Neurological disorder,initial,2016-01-11,GCST003342,Glaucoma (primary open-angle)
6841,European,1870.0,26752265.0,Bailey JN,Neurological disorder,initial,2016-01-11,GCST003343,Glaucoma (low intraocular pressure)
5059,European,363.0,26752265.0,Bailey JN,Neurological disorder,replication,2016-01-11,GCST003343,Glaucoma (low intraocular pressure)
9401,European,8836.0,26752265.0,Bailey JN,Neurological disorder,replication,2016-01-11,GCST003342,Glaucoma (primary open-angle)
803,African American or Afro-Caribbean,1083.0,26752167.0,Taylor JY,Other measurement,initial,2016-01-11,GCST003366,Diastolic blood pressure (cigarette smoking interaction)
3324,Asian,3580.0,26752265.0,Bailey JN,Neurological disorder,replication,2016-01-11,GCST003342,Glaucoma (primary open-angle)
10777,European,33365.0,26752265.0,Bailey JN,Neurological disorder,initial,2016-01-11,GCST003344,Glaucoma (high intraocular pressure)
873,African American or Afro-Caribbean,1427.0,26752167.0,Taylor JY,Other measurement,replication,2016-01-11,GCST003366,Diastolic blood pressure (cigarette smoking interaction)
872,African American or Afro-Caribbean,1427.0,26752167.0,Taylor JY,Other measurement,replication,2016-01-11,GCST003365,Systolic blood pressure (cigarette smoking interaction)
802,African American or Afro-Caribbean,1083.0,26752167.0,Taylor JY,Other measurement,initial,2016-01-11,GCST003365,Systolic blood pressure (cigarette smoking interaction)
2326,Asian,795.0,26599303.0,Cheung CL,"Response to drug, Other trait",initial,2016-01-12,GCST003580,Antithyroid drug-induced agranulocytosis
2015,Asian,391.0,26599303.0,Cheung CL,"Response to drug, Other trait",replication,2016-01-12,GCST003580,Antithyroid drug-induced agranulocytosis
10187,European,17310.0,26754954.0,Otowa T,Neurological disorder,initial,2016-01-12,GCST003370,Anxiety disorder
10238,European,18186.0,26754954.0,Otowa T,Other measurement,initial,2016-01-12,GCST003369,Anxiety disorder (factor score)
3953,Asian,8842.0,26763874.0,Ryu D,Other measurement,initial,2016-01-14,GCST003331,Sex ratio
6354,European,1283.0,26766742.0,Garcia-Albeniz X,"Cancer, Other trait",initial,2016-01-14,GCST003386,Colorectal cancer (oestrogen-progestogen hormone therapy interaction)
3751,Asian,6805.0,26763881.0,Kurano M,Lipid or lipoprotein measurement,replication,2016-01-14,GCST003361,LDL cholesterol levels
3752,Asian,6805.0,26763881.0,Kurano M,Lipid or lipoprotein measurement,replication,2016-01-14,GCST003362,Phospholipid levels
13687,Other/Mixed,558.0,26767831.0,Grant AV,"Other disease, Other measurement",initial,2016-01-14,GCST003451,Tuberculosis
3239,Asian,2994.0,26763881.0,Kurano M,Lipid or lipoprotein measurement,initial,2016-01-14,GCST003361,LDL cholesterol levels
3240,Asian,2994.0,26763881.0,Kurano M,Lipid or lipoprotein measurement,initial,2016-01-14,GCST003362,Phospholipid levels
3241,Asian,2994.0,26763881.0,Kurano M,Lipid or lipoprotein measurement,initial,2016-01-14,GCST003363,HDL cholesterol levels
3754,Asian,6805.0,26763881.0,Kurano M,Lipid or lipoprotein measurement,replication,2016-01-14,GCST003364,Triglyceride levels
13818,Other/Mixed,967.0,26767831.0,Grant AV,"Other disease, Other measurement",replication,2016-01-14,GCST003451,Tuberculosis
3242,Asian,2994.0,26763881.0,Kurano M,Lipid or lipoprotein measurement,initial,2016-01-14,GCST003364,Triglyceride levels
2400,Asian,935.0,26763874.0,Ryu D,Other measurement,replication,2016-01-14,GCST003331,Sex ratio
7829,European,3384.0,26766742.0,Garcia-Albeniz X,"Cancer, Other trait",initial,2016-01-14,GCST003385,Colorectal cancer (menopausal hormone therapy interaction)
6624,European,1606.0,26766742.0,Garcia-Albeniz X,"Cancer, Other trait",initial,2016-01-14,GCST003387,Colorectal cancer (oestrogen hormone therapy interaction)
3753,Asian,6805.0,26763881.0,Kurano M,Lipid or lipoprotein measurement,replication,2016-01-14,GCST003363,HDL cholesterol levels
2062,Asian,444.0,26776603.0,Honne K,"Immune system disorder, Response to drug",initial,2016-01-18,GCST003329,Response to anti-TNF therapy in rheumatoid arthritis
13135,Hispanic or Latin American,7876.0,26780889.0,Below JE,Lipid or lipoprotein measurement,replication,2016-01-19,GCST003301,Triglycerides
13000,Hispanic or Latin American,4383.0,26780889.0,Below JE,Lipid or lipoprotein measurement,initial,2016-01-19,GCST003304,HDL cholesterol
13136,Hispanic or Latin American,7876.0,26780889.0,Below JE,Lipid or lipoprotein measurement,replication,2016-01-19,GCST003302,"Cholesterol, total"
12998,Hispanic or Latin American,4383.0,26780889.0,Below JE,Lipid or lipoprotein measurement,initial,2016-01-19,GCST003301,Triglycerides
13001,Hispanic or Latin American,4383.0,26780889.0,Below JE,"Lipid or lipoprotein measurement, Other measurement",initial,2016-01-19,GCST003303,LDL cholesterol
13138,Hispanic or Latin American,7876.0,26780889.0,Below JE,"Lipid or lipoprotein measurement, Other measurement",replication,2016-01-19,GCST003303,LDL cholesterol
13137,Hispanic or Latin American,7876.0,26780889.0,Below JE,Lipid or lipoprotein measurement,replication,2016-01-19,GCST003304,HDL cholesterol
12999,Hispanic or Latin American,4383.0,26780889.0,Below JE,Lipid or lipoprotein measurement,initial,2016-01-19,GCST003302,"Cholesterol, total"
4291,Asian,20137.0,26785701.0,Wen W,"Body measurement, Other measurement",replication,2016-01-20,GCST003338,Waist-to-hip ratio adjusted for body mass index
4325,Asian,25553.0,26785701.0,Wen W,Body measurement,replication,2016-01-20,GCST003335,Waist circumference
4425,Asian,44609.0,26785701.0,Wen W,Body measurement,initial,2016-01-20,GCST003335,Waist circumference
4426,Asian,44609.0,26785701.0,Wen W,"Body measurement, Other measurement",initial,2016-01-20,GCST003336,Waist circumference adjusted for body mass index
4326,Asian,25553.0,26785701.0,Wen W,"Other measurement, Body measurement",replication,2016-01-20,GCST003337,Waist-hip ratio
4416,Asian,39869.0,26785701.0,Wen W,"Other measurement, Body measurement",initial,2016-01-20,GCST003337,Waist-hip ratio
4415,Asian,39869.0,26785701.0,Wen W,"Body measurement, Other measurement",initial,2016-01-20,GCST003338,Waist-to-hip ratio adjusted for body mass index
4320,Asian,24146.0,26785701.0,Wen W,"Body measurement, Other measurement",replication,2016-01-20,GCST003336,Waist circumference adjusted for body mass index
11677,European,117165.0,26831199.0,Pattaro C,"Other disease, Other measurement",initial,2016-01-21,GCST003374,Chronic kidney disease
8439,European,4955.0,26831199.0,Pattaro C,"Other measurement, Metabolic disorder",replication,2016-01-21,GCST003373,Glomerular filtration rate in diabetics (creatinine)
11765,European,133413.0,26831199.0,Pattaro C,Other measurement,initial,2016-01-21,GCST003372,Glomerular filtration rate (creatinine)
13118,Hispanic or Latin American,7170.0,26805783.0,Schick UM,Hematological measurement,replication,2016-01-21,GCST003383,Platelet count
13233,Hispanic or Latin American,12491.0,26805783.0,Schick UM,Hematological measurement,initial,2016-01-21,GCST003383,Platelet count
1584,Asian,29.0,26908625.0,Johansson A,Cardiovascular measurement,initial,2016-01-21,GCST003298,NT-proBNP levels in acute coronary syndrome
10024,European,14930.0,26831199.0,Pattaro C,Other measurement,replication,2016-01-21,GCST003375,Glomerular filtration rate (cystatin C)
13,African,20.0,26908625.0,Johansson A,Cardiovascular measurement,initial,2016-01-21,GCST003298,NT-proBNP levels in acute coronary syndrome
11764,European,133413.0,26831199.0,Pattaro C,Other measurement,initial,2016-01-21,GCST003371,Glomerular filtration rate (creatinine)
10995,European,42166.0,26831199.0,Pattaro C,Other measurement,replication,2016-01-21,GCST003372,Glomerular filtration rate (creatinine)
4419,Asian,42296.0,26831199.0,Pattaro C,Other measurement,replication,2016-01-21,GCST003372,Glomerular filtration rate (creatinine)
7969,European,3691.0,26908625.0,Johansson A,Cardiovascular measurement,initial,2016-01-21,GCST003298,NT-proBNP levels in acute coronary syndrome
16,African,33.0,26908625.0,Johansson A,Cardiovascular measurement,replication,2016-01-21,GCST003298,NT-proBNP levels in acute coronary syndrome
11686,European,118448.0,26831199.0,Pattaro C,Other measurement,initial,2016-01-21,GCST003401,Glomerular filtration rate in non diabetics (creatinine)
1602,Asian,54.0,26908625.0,Johansson A,Cardiovascular measurement,replication,2016-01-21,GCST003298,NT-proBNP levels in acute coronary syndrome
10874,European,36433.0,26831199.0,Pattaro C,Other measurement,replication,2016-01-21,GCST003401,Glomerular filtration rate in non diabetics (creatinine)
10763,European,32834.0,26831199.0,Pattaro C,Other measurement,initial,2016-01-21,GCST003375,Glomerular filtration rate (cystatin C)
9760,European,11522.0,26831199.0,Pattaro C,"Other measurement, Metabolic disorder",initial,2016-01-21,GCST003373,Glomerular filtration rate in diabetics (creatinine)
8595,European,5404.0,26908625.0,Johansson A,Cardiovascular measurement,replication,2016-01-21,GCST003298,NT-proBNP levels in acute coronary syndrome
326,African,16471.0,26831199.0,Pattaro C,Other measurement,replication,2016-01-21,GCST003372,Glomerular filtration rate (creatinine)
327,African,16840.0,26831199.0,Pattaro C,Other measurement,initial,2016-01-21,GCST003371,Glomerular filtration rate (creatinine)
10817,European,33972.0,26831199.0,Pattaro C,"Other disease, Other measurement",replication,2016-01-21,GCST003374,Chronic kidney disease
13919,Other/Mixed,2563.0,26806518.0,Hou L,"Response to drug, Neurological disorder",initial,2016-01-22,GCST003378,Response to lithium treatment in bipolar disorder
9776,European,11708.0,27179730.0,Allen NB,Other trait,initial,2016-01-23,GCST003279,Ideal cardiovascular health (clinical)
9775,European,11708.0,27179730.0,Allen NB,Other trait,initial,2016-01-23,GCST003278,Ideal cardiovascular health (clinical and behavioural)
5370,European,522.0,27179730.0,Allen NB,Other trait,replication,2016-01-23,GCST003278,Ideal cardiovascular health (clinical and behavioural)
5371,European,522.0,27179730.0,Allen NB,Other trait,replication,2016-01-23,GCST003279,Ideal cardiovascular health (clinical)
5006,European,331.0,26811534.0,Wang X,"Cardiovascular disease, Cancer",initial,2016-01-25,GCST003299,Cardiomyopathy in childhood cancer survivors
5007,European,331.0,26811534.0,Wang X,"Cardiovascular disease, Cancer, Response to drug",initial,2016-01-25,GCST003300,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction)
13424,Other/Mixed,21.0,26811534.0,Wang X,"Cardiovascular disease, Cancer",replication,2016-01-25,GCST003299,Cardiomyopathy in childhood cancer survivors
13425,Other/Mixed,21.0,26811534.0,Wang X,"Cardiovascular disease, Cancer, Response to drug",replication,2016-01-25,GCST003300,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction)
4561,European,21.0,26811534.0,Wang X,"Cardiovascular disease, Cancer",replication,2016-01-25,GCST003299,Cardiomyopathy in childhood cancer survivors
12500,Hispanic or Latin American,12.0,26811534.0,Wang X,"Cardiovascular disease, Cancer",replication,2016-01-25,GCST003299,Cardiomyopathy in childhood cancer survivors
12501,Hispanic or Latin American,12.0,26811534.0,Wang X,"Cardiovascular disease, Cancer, Response to drug",replication,2016-01-25,GCST003300,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction)
4562,European,21.0,26811534.0,Wang X,"Cardiovascular disease, Cancer, Response to drug",replication,2016-01-25,GCST003300,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction)
6404,European,1352.0,26818729.0,Weinsheimer S,Cancer,replication,2016-01-27,GCST003318,Brain arteriovenous malformations (sporadic)
6702,European,1706.0,26818729.0,Weinsheimer S,Cancer,initial,2016-01-27,GCST003318,Brain arteriovenous malformations (sporadic)
6264,European,1178.0,26815016.0,Julia A,"Other measurement, Immune system disorder",initial,2016-01-27,GCST003330,Rheumatoid factor seropositivity in rheumatoid arthritis
12861,Hispanic or Latin American,1956.0,26819262.0,Zhou Y,Other measurement,initial,2016-01-27,GCST003339,Epstein Barr virus nuclear antigen 1 IgG levels
12860,Hispanic or Latin American,1956.0,26819262.0,Zhou Y,"Immune system disorder, Other measurement",initial,2016-01-27,GCST003340,Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis
5572,European,662.0,26815016.0,Julia A,"Other measurement, Immune system disorder",replication,2016-01-27,GCST003330,Rheumatoid factor seropositivity in rheumatoid arthritis
10215,European,17698.0,26819262.0,Zhou Y,"Immune system disorder, Other measurement",initial,2016-01-27,GCST003340,Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis
13143,Hispanic or Latin American,8214.0,26818947.0,Imamura M,Metabolic disorder,replication,2016-01-28,GCST003400,Type 2 diabetes
11905,European,160850.0,26818947.0,Imamura M,Metabolic disorder,replication,2016-01-28,GCST003400,Type 2 diabetes
4322,Asian,24965.0,26818947.0,Imamura M,Metabolic disorder,replication,2016-01-28,GCST003400,Type 2 diabetes
4417,Asian,41646.0,26818947.0,Imamura M,Metabolic disorder,initial,2016-01-28,GCST003400,Type 2 diabetes
4423,Asian,43412.0,26818947.0,Imamura M,Metabolic disorder,replication,2016-01-28,GCST003400,Type 2 diabetes
4622,European,79.0,26821981.0,Koga AT,"Other measurement, Neurological disorder",initial,2016-01-28,GCST003341,antipsychotic drug dosage in schizophrenia or schizoaffective disorder
8832,European,6410.0,26829030.0,Asgari MM,Cancer,replication,2016-01-29,GCST003327,Squamous cell carcinoma
1769,Asian,176.0,26824906.0,Rankinen T,Other measurement,initial,2016-01-29,GCST003459,Endurance athleticism
2230,Asian,688.0,26824906.0,Rankinen T,Other measurement,replication,2016-01-29,GCST003458,World class endurance athleticism
6802,European,1815.0,26824906.0,Rankinen T,Other measurement,replication,2016-01-29,GCST003458,World class endurance athleticism
2345,Asian,825.0,26824906.0,Rankinen T,Other measurement,replication,2016-01-29,GCST003459,Endurance athleticism
11240,European,61457.0,26829030.0,Asgari MM,Cancer,initial,2016-01-29,GCST003327,Squamous cell carcinoma
6803,European,1815.0,26824906.0,Rankinen T,Other measurement,replication,2016-01-29,GCST003459,Endurance athleticism
99,African,415.0,26824906.0,Rankinen T,Other measurement,replication,2016-01-29,GCST003458,World class endurance athleticism
1768,Asian,176.0,26824906.0,Rankinen T,Other measurement,initial,2016-01-29,GCST003458,World class endurance athleticism
130,African,618.0,26824906.0,Rankinen T,Other measurement,replication,2016-01-29,GCST003459,Endurance athleticism
6011,European,965.0,26840454.0,French JD,"Response to drug, Other measurement, Cancer",replication,2016-01-31,GCST003328,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
4926,European,279.0,26840454.0,French JD,"Response to drug, Other measurement, Cancer",initial,2016-01-31,GCST003328,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
807,African American or Afro-Caribbean,1089.0,26833246.0,Lu Y,Body measurement,replication,2016-02-01,GCST003435,Body fat percentage
10243,European,18226.0,26833098.0,Kilpelainen TO,Other measurement,replication,2016-02-01,GCST003367,circulating leptin levels
3986,Asian,9289.0,26833246.0,Lu Y,Body measurement,initial,2016-02-01,GCST003435,Body fat percentage
8265,European,4548.0,26833182.0,Ware JJ,Other measurement,initial,2016-02-01,GCST003466,Cotinine levels in current smokers
10244,European,18226.0,26833098.0,Kilpelainen TO,Other measurement,replication,2016-02-01,GCST003368,circulating leptin levels adjusted for BMI
5711,European,755.0,26833182.0,Ware JJ,Other measurement,replication,2016-02-01,GCST003466,Cotinine levels in current smokers
13975,Other/Mixed,4431.0,26708285.0,Wakil SM,Cardiovascular disease,initial,2016-02-01,GCST003471,Myocardial infarction
13846,Other/Mixed,1273.0,26708285.0,Wakil SM,Cardiovascular disease,replication,2016-02-01,GCST003470,Coronary artery disease
10820,European,33987.0,26833098.0,Kilpelainen TO,Other measurement,initial,2016-02-01,GCST003367,circulating leptin levels
11280,European,65831.0,26833246.0,Lu Y,Body measurement,initial,2016-02-01,GCST003435,Body fat percentage
13983,Other/Mixed,5668.0,26708285.0,Wakil SM,Cardiovascular disease,initial,2016-02-01,GCST003470,Coronary artery disease
10502,European,23469.0,26833246.0,Lu Y,Body measurement,replication,2016-02-01,GCST003435,Body fat percentage
3060,Asian,2333.0,26833246.0,Lu Y,Body measurement,initial,2016-02-01,GCST003435,Body fat percentage
13840,Other/Mixed,1237.0,26708285.0,Wakil SM,Cardiovascular disease,replication,2016-02-01,GCST003471,Myocardial infarction
629,African American or Afro-Caribbean,416.0,26833246.0,Lu Y,Body measurement,initial,2016-02-01,GCST003435,Body fat percentage
10821,European,33987.0,26833098.0,Kilpelainen TO,Other measurement,initial,2016-02-01,GCST003368,circulating leptin levels adjusted for BMI
11507,European,89283.0,26835600.0,Hu Y,Biological process,initial,2016-02-02,GCST003429,Morning vs. evening chronotype
11714,European,122125.0,26835600.0,Hu Y,"Biological process, Other measurement",initial,2016-02-02,GCST003428,Chronotype
7903,European,3524.0,26830138.0,Herold C,"Neurological disorder, Other measurement",initial,2016-02-02,GCST003427,Alzheimer disease and age of onset
5357,European,516.0,27333618.0,Sekula P,Other disease,replication,2016-02-04,GCST003402,Membranous nephropathy
5582,European,668.0,27333618.0,Sekula P,Other disease,initial,2016-02-04,GCST003402,Membranous nephropathy
5203,European,441.0,26861389.0,D'Adamo CR,Other measurement,initial,2016-02-06,GCST003433,Serum lycopene concentrations
3224,Asian,2951.0,26853712.0,Zhang YB,Other disease,initial,2016-02-08,GCST004412,Craniofacial microsomia
2967,Asian,2112.0,26853712.0,Zhang YB,Other disease,replication,2016-02-08,GCST004412,Craniofacial microsomia
12125,European,258962.0,26908601.0,Hinds DA,"Other trait, Cardiovascular disease",initial,2016-02-09,GCST003390,Thrombosis
4639,European,86.0,26856250.0,Sacchetti E,Response to drug,initial,2016-02-09,GCST003432,Early response to risperidone in schizophrenia
3229,Asian,2955.0,26876947.0,Saito T,"Response to drug, Neurological disorder, Other trait",initial,2016-02-11,GCST003450,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia
6174,European,1082.0,26908436.0,Siiskonen SJ,Cancer,replication,2016-02-12,GCST003422,Squamous cell carcinoma
9914,European,13550.0,26908436.0,Siiskonen SJ,Cancer,initial,2016-02-12,GCST003422,Squamous cell carcinoma
13862,Other/Mixed,1413.0,26879886.0,Wakil SM,Lipid or lipoprotein measurement,replication,2016-02-16,GCST003391,Low high density lipoprotein cholesterol levels
13970,Other/Mixed,4082.0,26879886.0,Wakil SM,Lipid or lipoprotein measurement,initial,2016-02-16,GCST003391,Low high density lipoprotein cholesterol levels
682,African American or Afro-Caribbean,578.0,26888256.0,Hernandez W,Cardiovascular disease,initial,2016-02-17,GCST003377,Venous thromboembolism
500,African American or Afro-Caribbean,159.0,26888256.0,Hernandez W,Cardiovascular disease,replication,2016-02-17,GCST003377,Venous thromboembolism
2467,Asian,1067.0,26887379.0,Tang W,Digestive system disorder,initial,2016-02-18,GCST008016,Hirschsprung disease
3149,Asian,2644.0,26891255.0,Jung ES,Digestive system disorder,initial,2016-02-18,GCST003360,Crohn's disease
2574,Asian,1308.0,26891255.0,Jung ES,Digestive system disorder,replication,2016-02-18,GCST003360,Crohn's disease
11668,European,116470.0,26913989.0,Traylor M,"Neurological disorder, Cardiovascular disease",initial,2016-02-23,GCST003423,Alzheimer's disease or small vessel stroke
3346,Asian,3725.0,26902266.0,Giri AK,Cardiovascular measurement,replication,2016-02-23,GCST003359,Serum uric acid levels
2486,Asian,1109.0,26902266.0,Giri AK,Cardiovascular measurement,initial,2016-02-23,GCST003359,Serum uric acid levels
7506,European,2800.0,26910538.0,Choi SH,Cardiovascular measurement,replication,2016-02-24,GCST003403,Vascular endothelial growth factor levels
9896,European,13312.0,26910538.0,Choi SH,Cardiovascular measurement,initial,2016-02-24,GCST003403,Vascular endothelial growth factor levels
6135,European,1042.0,26911590.0,Mullin BH,Other measurement,initial,2016-02-25,GCST003379,Bone mineral density (hip)
8657,European,5654.0,26911590.0,Mullin BH,Other measurement,replication,2016-02-25,GCST003380,Bone mineral density (spine)
8658,European,5654.0,26911590.0,Mullin BH,Other measurement,replication,2016-02-25,GCST003381,Bone mineral density (femoral neck)
6136,European,1042.0,26911590.0,Mullin BH,Other measurement,initial,2016-02-25,GCST003380,Bone mineral density (spine)
6137,European,1042.0,26911590.0,Mullin BH,Other measurement,initial,2016-02-25,GCST003381,Bone mineral density (femoral neck)
8656,European,5654.0,26911590.0,Mullin BH,Other measurement,replication,2016-02-25,GCST003379,Bone mineral density (hip)
3448,Asian,4477.0,26912274.0,Zeng Y,Other measurement,initial,2016-02-25,GCST003425,Longevity
408,African American or Afro-Caribbean,49.0,26921259.0,Baurley JW,Other measurement,initial,2016-02-27,GCST003376,Nicotine metabolite ratio
1600,Asian,51.0,26921259.0,Baurley JW,Other measurement,initial,2016-02-27,GCST003376,Nicotine metabolite ratio
4849,European,215.0,26921259.0,Baurley JW,Other measurement,initial,2016-02-27,GCST003376,Nicotine metabolite ratio
12923,Hispanic or Latin American,2922.0,26926045.0,Adhikari K,Other measurement,initial,2016-03-01,GCST003476,Eyebrow thickness
12922,Hispanic or Latin American,2922.0,26926045.0,Adhikari K,Other measurement,initial,2016-03-01,GCST003475,Beard thickness
12924,Hispanic or Latin American,2922.0,26926045.0,Adhikari K,Other measurement,initial,2016-03-01,GCST003477,Monobrow thickness
13086,Hispanic or Latin American,6357.0,26926045.0,Adhikari K,Other measurement,initial,2016-03-01,GCST003478,Hair greying
13085,Hispanic or Latin American,6357.0,26926045.0,Adhikari K,Other measurement,initial,2016-03-01,GCST003474,Scalp hair shape
13088,Hispanic or Latin American,6357.0,26926045.0,Adhikari K,"Other measurement, Other trait",initial,2016-03-01,GCST003479,Hair color
13087,Hispanic or Latin American,6357.0,26926045.0,Adhikari K,Other measurement,initial,2016-03-01,GCST003480,Balding
10903,European,37561.0,26950853.0,Dehghan A,Cardiovascular disease,replication,2016-03-07,GCST003430,Incident myocardial infarction
10532,European,24024.0,26950853.0,Dehghan A,Cardiovascular disease,initial,2016-03-07,GCST003431,Incident coronary heart disease
10494,European,23188.0,26950853.0,Dehghan A,Cardiovascular disease,initial,2016-03-07,GCST003430,Incident myocardial infarction
10718,European,31146.0,26950853.0,Dehghan A,Cardiovascular disease,replication,2016-03-07,GCST003431,Incident coronary heart disease
1322,African American or Afro-Caribbean,8201.0,26950853.0,Dehghan A,Cardiovascular disease,replication,2016-03-07,GCST003430,Incident myocardial infarction
6025,European,975.0,26962152.0,Offenbacher S,Other measurement,initial,2016-03-08,GCST008439,Periodontal disease related phenotype (PCT2)
6027,European,975.0,26962152.0,Offenbacher S,Other measurement,initial,2016-03-08,GCST008441,Periodontal disease related phenotype (PCT4)
6030,European,975.0,26962152.0,Offenbacher S,"Other measurement, Digestive system disorder",initial,2016-03-08,GCST003484,Periodontal disease-related phenotype (Socransky)
6029,European,975.0,26962152.0,Offenbacher S,Other measurement,initial,2016-03-08,GCST008443,Periodontal disease related phenotype (PCT6)
4297,Asian,21096.0,26965516.0,Zeng C,Cancer,initial,2016-03-08,GCST003799,Colorectal cancer
6026,European,975.0,26962152.0,Offenbacher S,Other measurement,initial,2016-03-08,GCST008440,Periodontal disease related phenotype (PCT3)
4371,Asian,32599.0,26965516.0,Zeng C,Cancer,replication,2016-03-08,GCST003799,Colorectal cancer
6028,European,975.0,26962152.0,Offenbacher S,Other measurement,initial,2016-03-08,GCST008442,Periodontal disease related phenotype (PCT5)
2222,Asian,674.0,26959369.0,Haiman CA,"Biological process, Other measurement",initial,2016-03-09,GCST003483,S-phenylmercapturic acid levels in smokers
7751,European,3268.0,26965164.0,Hanchard NA,Cardiovascular disease,initial,2016-03-09,GCST003419,Congenital left-sided heart lesions
12647,Hispanic or Latin American,453.0,26959369.0,Haiman CA,"Biological process, Other measurement",initial,2016-03-09,GCST003483,S-phenylmercapturic acid levels in smokers
5194,European,437.0,26959369.0,Haiman CA,"Biological process, Other measurement",initial,2016-03-09,GCST003483,S-phenylmercapturic acid levels in smokers
9732,European,11208.0,26959717.0,Nicoletti P,"Response to drug, Digestive system disorder",initial,2016-03-09,GCST003426,Drug-induced liver injury
8630,European,5526.0,26965164.0,Hanchard NA,Cardiovascular disease,replication,2016-03-09,GCST003419,Congenital left-sided heart lesions
13607,Other/Mixed,311.0,26959369.0,Haiman CA,"Biological process, Other measurement",initial,2016-03-09,GCST003483,S-phenylmercapturic acid levels in smokers
9687,European,10767.0,26956414.0,Berndt SI,Cancer,initial,2016-03-09,GCST003468,Chronic lymphocytic leukemia
11580,European,100420.0,26955885.0,Lane JM,"Biological process, Other measurement",initial,2016-03-09,GCST003453,Chronotype
10859,European,35672.0,26955885.0,Lane JM,Biological process,initial,2016-03-09,GCST003454,Morning vs. evening chronotype
611,African American or Afro-Caribbean,364.0,26959369.0,Haiman CA,"Biological process, Other measurement",initial,2016-03-09,GCST003483,S-phenylmercapturic acid levels in smokers
11691,European,119688.0,26961502.0,Wood AR,"Body measurement, Other measurement",initial,2016-03-10,GCST006802,Body mass index
11683,European,117775.0,26961502.0,Wood AR,Metabolic disorder,initial,2016-03-10,GCST006801,Type 2 diabetes
10513,European,23689.0,26969751.0,Parmar PG,Other measurement,initial,2016-03-11,GCST003671,Diastolic blood pressure
10512,European,23689.0,26969751.0,Parmar PG,Other measurement,initial,2016-03-11,GCST003670,Systolic blood pressure
11480,European,86475.0,26974007.0,Ellinghaus D,"Immune system disorder, Digestive system disorder",initial,2016-03-14,GCST005537,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)"
1820,Asian,214.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",replication,2016-03-15,GCST003673,Obstructive sleep apnea (average oxygen saturation during sleep)
1822,Asian,214.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",replication,2016-03-15,GCST003675,Obstructive sleep apnea trait (average respiratory event duration)
818,African American or Afro-Caribbean,1183.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",replication,2016-03-15,GCST003673,Obstructive sleep apnea (average oxygen saturation during sleep)
8650,European,5638.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",replication,2016-03-15,GCST003673,Obstructive sleep apnea (average oxygen saturation during sleep)
8651,European,5638.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",replication,2016-03-15,GCST003674,Obstructive sleep apnea trait (apnea hypopnea index)
13241,Hispanic or Latin American,12557.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",initial,2016-03-15,GCST003673,Obstructive sleep apnea (average oxygen saturation during sleep)
819,African American or Afro-Caribbean,1183.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",replication,2016-03-15,GCST003674,Obstructive sleep apnea trait (apnea hypopnea index)
820,African American or Afro-Caribbean,1183.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",replication,2016-03-15,GCST003675,Obstructive sleep apnea trait (average respiratory event duration)
13178,Hispanic or Latin American,10238.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",initial,2016-03-15,GCST003675,Obstructive sleep apnea trait (average respiratory event duration)
1821,Asian,214.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",replication,2016-03-15,GCST003674,Obstructive sleep apnea trait (apnea hypopnea index)
1687,Asian,109.0,26980576.0,Kim K,"Immune system disorder, Response to drug",initial,2016-03-15,GCST003445,Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis
13245,Hispanic or Latin American,12558.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",initial,2016-03-15,GCST003674,Obstructive sleep apnea trait (apnea hypopnea index)
8652,European,5638.0,26977737.0,Cade BE,"Other measurement, Neurological disorder",replication,2016-03-15,GCST003675,Obstructive sleep apnea trait (average respiratory event duration)
5909,European,902.0,26989097.0,Coleman JR,"Other trait, Neurological disorder",initial,2016-03-17,GCST003469,Response to cognitive-behavioural therapy in anxiety disorder
10754,European,32528.0,26997408.0,Demirkan A,Other measurement,initial,2016-03-21,GCST003667,Depressive symptoms measurement (somatic complaints domain)
10755,European,32528.0,26997408.0,Demirkan A,Other measurement,initial,2016-03-21,GCST003668,Depressive symptoms measurement (lack of positive affect domain)
8930,European,6813.0,26997408.0,Demirkan A,Other measurement,replication,2016-03-21,GCST003669,Depressive symptoms measurement (lack of negative affect domain)
1639,Asian,79.0,27001664.0,Yoo J,Other measurement,initial,2016-03-21,GCST003607,knee peak torque response
10756,European,32528.0,26997408.0,Demirkan A,Other measurement,initial,2016-03-21,GCST003669,Depressive symptoms measurement (lack of negative affect domain)
1640,Asian,79.0,27001664.0,Yoo J,Other measurement,initial,2016-03-21,GCST003608,Maximal oxygen uptake response
8928,European,6813.0,26997408.0,Demirkan A,Other measurement,replication,2016-03-21,GCST003667,Depressive symptoms measurement (somatic complaints domain)
8929,European,6813.0,26997408.0,Demirkan A,Other measurement,replication,2016-03-21,GCST003668,Depressive symptoms measurement (lack of positive affect domain)
7544,European,2888.0,27005825.0,Finkel TH,Immune system disorder,initial,2016-03-22,GCST003424,Arthritis (juvenile idiopathic)
2179,Asian,616.0,27001270.0,Vishal M,Neurological disorder,replication,2016-03-22,GCST003446,Glaucoma (primary open-angle)
2243,Asian,701.0,27001270.0,Vishal M,Neurological disorder,initial,2016-03-22,GCST003446,Glaucoma (primary open-angle)
9137,European,7778.0,27005825.0,Finkel TH,Immune system disorder,replication,2016-03-22,GCST003424,Arthritis (juvenile idiopathic)
10562,European,24925.0,27005778.0,Kettunen J,Other measurement,initial,2016-03-23,GCST003666,Metabolite levels (small molecules and protein measures)
10162,European,16852.0,27008869.0,Chen MM,Cancer,initial,2016-03-23,GCST003436,Endometrial cancer
11135,European,52776.0,27015805.0,Pilling LC,Other measurement,initial,2016-03-23,GCST003393,Parental longevity (mother's age at death)
11038,European,45627.0,27015805.0,Pilling LC,Other measurement,initial,2016-03-23,GCST003394,Parental longevity (combined parental age at death)
11267,European,63775.0,27015805.0,Pilling LC,Other measurement,initial,2016-03-23,GCST003392,Parental longevity (father's age at death)
11000,European,42273.0,27015805.0,Pilling LC,Other measurement,initial,2016-03-23,GCST003395,Parental extreme longevity (95 years and older)
10560,European,24925.0,27005778.0,Kettunen J,Other measurement,initial,2016-03-23,GCST003664,Metabolite levels (lipid measures)
10561,European,24925.0,27005778.0,Kettunen J,Other measurement,initial,2016-03-23,GCST003665,Metabolite levels (lipoprotein measures)
715,African American or Afro-Caribbean,736.0,27022141.0,Liu L,"Hematological measurement, Other disease",initial,2016-03-27,GCST006251,High fetal hemoglobin in sickle cell disease
1016,African American or Afro-Caribbean,2660.0,27023175.0,Stringer S,Biological process,replication,2016-03-29,GCST003382,Cannabis use
10964,European,40036.0,27020472.0,Fan Q,Other measurement,initial,2016-03-29,GCST003455,Spherical equivalent (joint analysis main effects and education interaction)
3039,Asian,2256.0,27020472.0,Fan Q,Other measurement,initial,2016-03-29,GCST003455,Spherical equivalent (joint analysis main effects and education interaction)
7583,European,2967.0,27023175.0,Stringer S,Biological process,replication,2016-03-29,GCST003382,Cannabis use
2697,Asian,1584.0,27206850.0,Wang M,Cancer,initial,2016-03-29,GCST003384,Bladder cancer
3731,Asian,6467.0,27206850.0,Wang M,Cancer,replication,2016-03-29,GCST003384,Bladder cancer
2957,Asian,2088.0,27020472.0,Fan Q,Other measurement,initial,2016-03-29,GCST003455,Spherical equivalent (joint analysis main effects and education interaction)
5992,European,949.0,27021820.0,Roostaei T,"Other measurement, Other trait",replication,2016-03-29,GCST003399,Cognitive impairment (brain beta-amyloid deposition interaction)
10747,European,32330.0,27023175.0,Stringer S,Biological process,initial,2016-03-29,GCST003382,Cannabis use
6151,European,1060.0,27021288.0,Brevik EJ,"Neurological disorder, Other measurement",initial,2016-03-29,GCST003473,Aggressiveness in attention deficit hyperactivity disorder
5597,European,678.0,27021820.0,Roostaei T,"Other measurement, Other trait",initial,2016-03-29,GCST003399,Cognitive impairment (brain beta-amyloid deposition interaction)
3669,Asian,5971.0,27020472.0,Fan Q,Other measurement,initial,2016-03-29,GCST003455,Spherical equivalent (joint analysis main effects and education interaction)
5447,European,579.0,27023328.0,Kulkarni D,"Other trait, Response to drug, Cancer",initial,2016-03-29,GCST003456,Adverse response to dabrafenib or dabrafenib-trametinib treatment in melanoma (pyrexia)
1243,African American or Afro-Caribbean,6000.0,27028160.0,Sherva R,Other measurement,initial,2016-03-30,GCST003465,Cannabis dependence symptom count
6859,European,1893.0,27028160.0,Sherva R,Other measurement,replication,2016-03-30,GCST003465,Cannabis dependence symptom count
9392,European,8754.0,27028160.0,Sherva R,Other measurement,initial,2016-03-30,GCST003465,Cannabis dependence symptom count
133,African,681.0,27029810.0,Joshi PK,Other measurement,replication,2016-03-31,GCST005078,Mortality
771,African American or Afro-Caribbean,962.0,27029810.0,Joshi PK,Other measurement,replication,2016-03-31,GCST005078,Mortality
10545,European,24168.0,27029810.0,Joshi PK,Other measurement,replication,2016-03-31,GCST005078,Mortality
12142,European,272081.0,27029810.0,Joshi PK,Other measurement,initial,2016-03-31,GCST005078,Mortality
1955,Asian,338.0,27029810.0,Joshi PK,Other measurement,replication,2016-03-31,GCST005078,Mortality
2706,Asian,1613.0,27029810.0,Joshi PK,Other measurement,replication,2016-03-31,GCST005078,Mortality
1258,African American or Afro-Caribbean,6480.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003663,"Cholesterol, total"
1026,African American or Afro-Caribbean,2710.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2016-04-01,GCST003661,Triglycerides
1253,African American or Afro-Caribbean,6237.0,27036123.0,van Leeuwen EM,"Lipid or lipoprotein measurement, Other measurement",initial,2016-04-01,GCST003662,LDL cholesterol
4024,Asian,9992.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2016-04-01,GCST003660,HDL cholesterol
11343,European,71921.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2016-04-01,GCST003660,HDL cholesterol
11109,European,50823.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003660,HDL cholesterol
2246,Asian,702.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003663,"Cholesterol, total"
4025,Asian,10000.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2016-04-01,GCST003663,"Cholesterol, total"
2250,Asian,703.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003660,HDL cholesterol
1257,African American or Afro-Caribbean,6476.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003660,HDL cholesterol
12818,Hispanic or Latin American,1381.0,27036123.0,van Leeuwen EM,"Lipid or lipoprotein measurement, Other measurement",initial,2016-04-01,GCST003662,LDL cholesterol
11236,European,60827.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2016-04-01,GCST003661,Triglycerides
11117,European,51430.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003663,"Cholesterol, total"
11229,European,60078.0,27036123.0,van Leeuwen EM,"Lipid or lipoprotein measurement, Other measurement",replication,2016-04-01,GCST003662,LDL cholesterol
14031,Other/Mixed,71032.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2016-04-01,GCST003663,"Cholesterol, total"
1255,African American or Afro-Caribbean,6287.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003661,Triglycerides
1019,African American or Afro-Caribbean,2679.0,27036123.0,van Leeuwen EM,"Lipid or lipoprotein measurement, Other measurement",replication,2016-04-01,GCST003662,LDL cholesterol
1021,African American or Afro-Caribbean,2685.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2016-04-01,GCST003660,HDL cholesterol
10981,European,41142.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003661,Triglycerides
2253,Asian,705.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003661,Triglycerides
12826,Hispanic or Latin American,1415.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003661,Triglycerides
12824,Hispanic or Latin American,1412.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003663,"Cholesterol, total"
2231,Asian,689.0,27036123.0,van Leeuwen EM,"Lipid or lipoprotein measurement, Other measurement",initial,2016-04-01,GCST003662,LDL cholesterol
12822,Hispanic or Latin American,1407.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,initial,2016-04-01,GCST003660,HDL cholesterol
4006,Asian,9729.0,27036123.0,van Leeuwen EM,"Lipid or lipoprotein measurement, Other measurement",replication,2016-04-01,GCST003662,LDL cholesterol
10974,European,40473.0,27036123.0,van Leeuwen EM,"Lipid or lipoprotein measurement, Other measurement",initial,2016-04-01,GCST003662,LDL cholesterol
1024,African American or Afro-Caribbean,2707.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2016-04-01,GCST003663,"Cholesterol, total"
4014,Asian,9982.0,27036123.0,van Leeuwen EM,Lipid or lipoprotein measurement,replication,2016-04-01,GCST003661,Triglycerides
1918,Asian,295.0,27064256.0,Khor CC,Neurological disorder,replication,2016-04-04,GCST003467,Glaucoma (primary angle closure)
2513,Asian,1180.0,27064256.0,Khor CC,Neurological disorder,replication,2016-04-04,GCST003467,Glaucoma (primary angle closure)
3204,Asian,2875.0,27064256.0,Khor CC,Neurological disorder,initial,2016-04-04,GCST003467,Glaucoma (primary angle closure)
7923,European,3563.0,27064256.0,Khor CC,Neurological disorder,replication,2016-04-04,GCST003467,Glaucoma (primary angle closure)
3700,Asian,6205.0,27064256.0,Khor CC,Neurological disorder,replication,2016-04-04,GCST003467,Glaucoma (primary angle closure)
12600,Hispanic or Latin American,323.0,27064256.0,Khor CC,Neurological disorder,replication,2016-04-04,GCST003467,Glaucoma (primary angle closure)
13901,Other/Mixed,2050.0,27064256.0,Khor CC,Neurological disorder,replication,2016-04-04,GCST003467,Glaucoma (primary angle closure)
8629,European,5516.0,27064256.0,Khor CC,Neurological disorder,initial,2016-04-04,GCST003467,Glaucoma (primary angle closure)
4256,Asian,18063.0,27064256.0,Khor CC,Neurological disorder,initial,2016-04-04,GCST003467,Glaucoma (primary angle closure)
11641,European,112067.0,27046643.0,Davies G,Other measurement,initial,2016-04-05,GCST003497,Memory performance
11630,European,111114.0,27046643.0,Davies G,Other measurement,initial,2016-04-05,GCST003496,Educational attainment
10863,European,36035.0,27046643.0,Davies G,Biological process,initial,2016-04-05,GCST003498,Verbal-numerical reasoning
11632,European,111483.0,27046643.0,Davies G,Other measurement,initial,2016-04-05,GCST003499,Reaction time
9947,European,13886.0,27130862.0,Sarnowski C,"Other disease, Other measurement",initial,2016-04-06,GCST008838,Asthma (time to onset)
10314,European,19468.0,27068588.0,Chauhan G,"Cardiovascular disease, Other trait",replication,2016-04-07,GCST003492,Ischemic stroke
6937,European,2012.0,27068588.0,Chauhan G,Cardiovascular disease,replication,2016-04-07,GCST003491,Stroke
12539,Hispanic or Latin American,90.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005948,Cleft palate
10287,European,19094.0,27068588.0,Chauhan G,"Cardiovascular disease, Other trait",replication,2016-04-07,GCST003490,Ischemic stroke (cardioembolic)
12721,Hispanic or Latin American,737.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005947,Cleft palate
14026,Other/Mixed,37969.0,27068588.0,Chauhan G,Other trait,replication,2016-04-07,GCST003493,Ischemic stroke (non-cardioembolic)
6871,European,1931.0,27018472.0,Leslie EJ,Other trait,replication,2016-04-07,GCST005947,Cleft palate
6870,European,1931.0,27018472.0,Leslie EJ,Other trait,replication,2016-04-07,GCST005946,Cleft palate
12700,Hispanic or Latin American,647.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005946,Cleft palate
8209,European,4348.0,27068588.0,Chauhan G,Cardiovascular disease,initial,2016-04-07,GCST003491,Stroke
11434,European,82383.0,27068588.0,Chauhan G,Other trait,initial,2016-04-07,GCST003493,Ischemic stroke (non-cardioembolic)
14024,Other/Mixed,35900.0,27068588.0,Chauhan G,"Cardiovascular disease, Other trait",replication,2016-04-07,GCST003490,Ischemic stroke (cardioembolic)
7619,European,3028.0,27068588.0,Chauhan G,"Cardiovascular disease, Other trait",initial,2016-04-07,GCST003492,Ischemic stroke
10300,European,19215.0,27068588.0,Chauhan G,Other trait,replication,2016-04-07,GCST003493,Ischemic stroke (non-cardioembolic)
14029,Other/Mixed,49324.0,27068588.0,Chauhan G,"Cardiovascular disease, Other trait",replication,2016-04-07,GCST003492,Ischemic stroke
0,African,1.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005946,Cleft palate
1695,Asian,117.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005948,Cleft palate
1707,Asian,125.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005946,Cleft palate
6304,European,1215.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005947,Cleft palate
41,African,98.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005947,Cleft palate
1,African,1.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005947,Cleft palate
368,African American or Afro-Caribbean,7.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005947,Cleft palate
5024,European,342.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005948,Cleft palate
367,African American or Afro-Caribbean,7.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005946,Cleft palate
5874,European,873.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005946,Cleft palate
5486,European,602.0,27068588.0,Chauhan G,"Cardiovascular disease, Other trait",initial,2016-04-07,GCST003490,Ischemic stroke (cardioembolic)
1871,Asian,242.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005947,Cleft palate
1593,Asian,41.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005947,Cleft palate
1592,Asian,38.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005946,Cleft palate
1532,Asian,3.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005948,Cleft palate
11,African,15.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005948,Cleft palate
36,African,83.0,27018472.0,Leslie EJ,Other trait,initial,2016-04-07,GCST005946,Cleft palate
4695,European,114.0,27060151.0,Magrangeas F,"Response to drug, Neurological disorder, Cancer",replication,2016-04-08,GCST003438,Bortezomib-induced peripheral neuropathy in multiple myeloma
5247,European,469.0,27060151.0,Magrangeas F,"Response to drug, Neurological disorder, Cancer",initial,2016-04-08,GCST003438,Bortezomib-induced peripheral neuropathy in multiple myeloma
83,African,296.0,27064253.0,Zhou W,Other measurement,initial,2016-04-11,GCST003421,Mosaic loss of chromosome Y
9779,European,11749.0,27064253.0,Zhou W,Other measurement,initial,2016-04-11,GCST003421,Mosaic loss of chromosome Y
11543,European,91370.0,27067015.0,Smith DJ,"Neurological disorder, Other measurement",initial,2016-04-12,GCST003447,Neuroticism
6412,European,1359.0,27207532.0,Roshandel D,"Metabolic disorder, Other measurement",initial,2016-04-12,GCST003418,Skin fluorescence in type 1 diabetes
6637,European,1623.0,27082954.0,Ward-Caviness CK,"Cardiovascular disease, Other measurement",initial,2016-04-15,GCST004482,Peripheral arterial disease (traffic-related air pollution interaction)
678,African American or Afro-Caribbean,554.0,27082954.0,Ward-Caviness CK,"Cardiovascular disease, Other measurement",initial,2016-04-15,GCST004482,Peripheral arterial disease (traffic-related air pollution interaction)
11268,European,63872.0,27094239.0,Joshi AD,Digestive system disorder,initial,2016-04-16,GCST003725,Gallstone disease
1389,African American or Afro-Caribbean,10644.0,27094239.0,Joshi AD,Digestive system disorder,replication,2016-04-16,GCST003725,Gallstone disease
11320,European,69286.0,27094239.0,Joshi AD,Digestive system disorder,replication,2016-04-16,GCST003725,Gallstone disease
12942,Hispanic or Latin American,3459.0,27094239.0,Joshi AD,Digestive system disorder,replication,2016-04-16,GCST003725,Gallstone disease
11728,European,125667.0,27089180.0,Day FR,Other measurement,initial,2016-04-18,GCST007335,Age at first sexual intercourse
12185,European,298420.0,27089181.0,Okbay A,Other measurement,initial,2016-04-18,GCST003766,Subjective well-being
11987,European,180281.0,27089181.0,Okbay A,Other measurement,initial,2016-04-18,GCST003768,Positive affect
12290,European,368890.0,27089181.0,Okbay A,"Neurological disorder, Other measurement",replication,2016-04-18,GCST003769,Depression
11956,European,170911.0,27089181.0,Okbay A,"Neurological disorder, Other measurement",initial,2016-04-18,GCST003770,Neuroticism
13066,Hispanic or Latin American,5941.0,27207650.0,Schmit SL,Cancer,initial,2016-04-18,GCST003420,Colorectal cancer
11989,European,180866.0,27089181.0,Okbay A,"Neurological disorder, Other measurement",initial,2016-04-18,GCST003769,Depression
12128,European,262097.0,27089180.0,Day FR,Other measurement,replication,2016-04-18,GCST007336,Age at first birth
11282,European,66310.0,27089180.0,Day FR,Other measurement,initial,2016-04-18,GCST007336,Age at first birth
11930,European,166205.0,27089181.0,Okbay A,Other measurement,initial,2016-04-18,GCST003767,Life satisfaction
8116,European,4077.0,28459102.0,Zhang S,Other trait,initial,2016-04-20,GCST004198,Severe gingival inflammation
11721,European,123671.0,27197191.0,Fehringer G,Cancer,initial,2016-04-20,GCST003587,Cancer
11722,European,123671.0,27197191.0,Fehringer G,Cancer,initial,2016-04-20,GCST003588,Cancer (pleiotropy)
8145,European,4163.0,27098658.0,Muller-Calleja N,Other measurement,initial,2016-04-21,GCST003563,Presence of antiphospholipid antibodies
9461,European,9314.0,27106561.0,Cornelis MC,"Biological process, Other measurement",initial,2016-04-23,GCST003489,Food addiction
1668,Asian,99.0,27114598.0,Liu C,"Cancer, Digestive system disorder",initial,2016-04-25,GCST003501,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time)
93,African,350.0,27114598.0,Liu C,"Cancer, Digestive system disorder",initial,2016-04-25,GCST003501,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time)
7628,European,3069.0,27114598.0,Liu C,"Cancer, Digestive system disorder",initial,2016-04-25,GCST003501,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time)
12800,Hispanic or Latin American,1177.0,27114598.0,Liu C,"Cancer, Digestive system disorder",initial,2016-04-25,GCST003501,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time)
10307,European,19291.0,27117709.0,Couch FJ,Cancer,initial,2016-04-27,GCST003845,Breast cancer
11277,European,65053.0,27117709.0,Couch FJ,Cancer,replication,2016-04-27,GCST003845,Breast cancer
10306,European,19291.0,27117709.0,Couch FJ,Cancer,initial,2016-04-27,GCST003842,Breast cancer (estrogen-receptor negative)
11100,European,49801.0,27117709.0,Couch FJ,Cancer,replication,2016-04-27,GCST003842,Breast cancer (estrogen-receptor negative)
5876,European,874.0,27126917.0,Spada J,Other measurement,initial,2016-04-29,GCST003518,Daytime sleep phenotypes
5975,European,941.0,27126917.0,Spada J,Other measurement,initial,2016-04-29,GCST003542,Night sleep phenotypes
6140,European,1048.0,26651848.0,Rivera NV,Other disease,initial,2016-05-01,GCST005541,Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)
8518,European,5152.0,26651848.0,Rivera NV,Other disease,replication,2016-05-01,GCST005540,Sarcoidosis (Lofgren's syndrome)
3576,Asian,5420.0,26663301.0,Lessard CJ,Immune system disorder,initial,2016-05-01,GCST003599,Systemic lupus erythematosus
8661,European,5664.0,26651848.0,Rivera NV,Other disease,replication,2016-05-01,GCST005543,Sarcoidosis (non-Lofgren's syndrome)
7233,European,2370.0,26651848.0,Rivera NV,Other disease,initial,2016-05-01,GCST005540,Sarcoidosis (Lofgren's syndrome)
5259,European,477.0,26651848.0,Rivera NV,Other disease,replication,2016-05-01,GCST005541,Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)
7335,European,2537.0,26651848.0,Rivera NV,Other disease,initial,2016-05-01,GCST005542,Sarcoidosis (non-Lofgren's syndrome without extrapulmonary manifestations)
3130,Asian,2561.0,26663301.0,Lessard CJ,Immune system disorder,replication,2016-05-01,GCST003599,Systemic lupus erythematosus
905,African American or Afro-Caribbean,1657.0,26651848.0,Rivera NV,Other disease,replication,2016-05-01,GCST005543,Sarcoidosis (non-Lofgren's syndrome)
7390,European,2593.0,26651848.0,Rivera NV,Other disease,initial,2016-05-01,GCST005543,Sarcoidosis (non-Lofgren's syndrome)
10742,European,32153.0,27135401.0,Cheng TH,Cancer,replication,2016-05-02,GCST003525,Endometrial endometrioid carcinoma
9781,European,11756.0,27135401.0,Cheng TH,Cancer,initial,2016-05-02,GCST003524,Endometrial cancer
9769,European,11626.0,27135401.0,Cheng TH,Cancer,initial,2016-05-02,GCST003525,Endometrial endometrioid carcinoma
10769,European,33125.0,27135401.0,Cheng TH,Cancer,replication,2016-05-02,GCST003524,Endometrial cancer
829,African American or Afro-Caribbean,1227.0,27142222.0,White MJ,Other disease,initial,2016-05-03,GCST003482,Asthma (childhood onset)
8594,European,5392.0,27157822.0,Hallberg P,"Other trait, Biological process",initial,2016-05-03,GCST003526,Non-chemotherapy drug induced agranulocytosis
8533,European,5208.0,27157822.0,Hallberg P,"Response to drug, Other trait",initial,2016-05-03,GCST003527,Anti-thyroid drug induced agranulocytosis
5519,European,623.0,27143689.0,Hertz DL,"Cancer, Neurological disorder, Response to drug",initial,2016-05-03,GCST003672,Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer
10703,European,30377.0,27142678.0,Amin N,Other measurement,replication,2016-05-04,GCST003481,Sleep latency
8173,European,4242.0,27142678.0,Amin N,Other measurement,initial,2016-05-04,GCST003481,Sleep latency
5054,European,360.0,27445529.0,Berube JC,Other disease,initial,2016-05-04,GCST003521,Asthma
6001,European,958.0,27445529.0,Berube JC,Other disease,replication,2016-05-04,GCST003521,Asthma
6842,European,1870.0,27149122.0,Smith JG,"Other measurement, Cardiovascular disease",replication,2016-05-05,GCST003539,Mortality in heart failure
12200,European,300945.0,27132594.0,Mbarek H,Biological process,replication,2016-05-05,GCST004413,Spontaneous dizygotic twinning
3058,Asian,2329.0,27145994.0,Wang M,Cancer,initial,2016-05-05,GCST003494,Colorectal cancer
836,African American or Afro-Caribbean,1233.0,27151647.0,Chen G,Other measurement,initial,2016-05-05,GCST003538,Alcohol dependence symptom count
4109,Asian,12204.0,27145994.0,Wang M,Cancer,replication,2016-05-05,GCST003494,Colorectal cancer
6366,European,1300.0,27149984.0,Degenhardt F,Other measurement,initial,2016-05-05,GCST003523,Coenzyme Q10 levels
7398,European,2605.0,27151647.0,Chen G,Other measurement,initial,2016-05-05,GCST003538,Alcohol dependence symptom count
7024,European,2122.0,27145994.0,Wang M,Cancer,replication,2016-05-05,GCST003494,Colorectal cancer
10026,European,14933.0,27132594.0,Mbarek H,Biological process,initial,2016-05-05,GCST004413,Spontaneous dizygotic twinning
7520,European,2828.0,27149122.0,Smith JG,"Other measurement, Cardiovascular disease",initial,2016-05-05,GCST003539,Mortality in heart failure
2747,Asian,1693.0,27153935.0,Zhang CE,Neurological disorder,initial,2016-05-06,GCST003522,Dermatomyositis
5294,European,489.0,27173062.0,Azad AK,"Other measurement, Cancer",initial,2016-05-09,GCST003541,Survival in head and neck cancer
1604,Asian,57.0,27173062.0,Azad AK,"Other measurement, Cancer",replication,2016-05-09,GCST003541,Survival in head and neck cancer
5249,European,470.0,27173062.0,Azad AK,"Other measurement, Cancer",replication,2016-05-09,GCST003541,Survival in head and neck cancer
13141,Hispanic or Latin American,8195.0,27159506.0,Dunn EC,"Other measurement, Other trait",replication,2016-05-09,GCST003562,Anxiety
371,African American or Afro-Caribbean,11.0,27173062.0,Azad AK,"Other measurement, Cancer",replication,2016-05-09,GCST003541,Survival in head and neck cancer
13230,Hispanic or Latin American,12282.0,27159506.0,Dunn EC,"Other measurement, Other trait",initial,2016-05-09,GCST003562,Anxiety
13444,Other/Mixed,28.0,27173062.0,Azad AK,"Other measurement, Cancer",replication,2016-05-09,GCST003541,Survival in head and neck cancer
13442,Other/Mixed,26.0,27173062.0,Azad AK,"Other measurement, Cancer",initial,2016-05-09,GCST003541,Survival in head and neck cancer
856,African American or Afro-Caribbean,1312.0,27167565.0,Stein MB,Neurological disorder,initial,2016-05-11,GCST003495,Post-traumatic stress disorder
12804,Hispanic or Latin American,1242.0,27167565.0,Stein MB,Neurological disorder,replication,2016-05-11,GCST003495,Post-traumatic stress disorder
8088,European,4007.0,27167565.0,Stein MB,Neurological disorder,replication,2016-05-11,GCST003495,Post-traumatic stress disorder
694,African American or Afro-Caribbean,667.0,27167565.0,Stein MB,Neurological disorder,replication,2016-05-11,GCST003495,Post-traumatic stress disorder
8473,European,5049.0,27167565.0,Stein MB,Neurological disorder,initial,2016-05-11,GCST003495,Post-traumatic stress disorder
12825,Hispanic or Latin American,1413.0,27167565.0,Stein MB,Neurological disorder,initial,2016-05-11,GCST003495,Post-traumatic stress disorder
1745,Asian,157.0,27171184.0,Kuo HC,"Immune system disorder, Cardiovascular disease",initial,2016-05-12,GCST003560,Coronary artery aneurysm in Kawasaki disease
1176,African American or Afro-Caribbean,4001.0,27393504.0,Zanetti KA,Cancer,initial,2016-05-13,GCST003777,Squamous cell lung carcinoma
2325,Asian,786.0,27191271.0,Hu Q,Cardiovascular disease,initial,2016-05-13,GCST003561,Coronary artery disease
860,African American or Afro-Caribbean,1329.0,27393504.0,Zanetti KA,Cancer,replication,2016-05-13,GCST003777,Squamous cell lung carcinoma
1206,African American or Afro-Caribbean,4737.0,27393504.0,Zanetti KA,Other measurement,initial,2016-05-13,GCST003779,Smoking behaviour (cigarettes smoked per day)
1153,African American or Afro-Caribbean,3777.0,27393504.0,Zanetti KA,Other measurement,initial,2016-05-13,GCST003778,Smoking status (current vs former)
906,African American or Afro-Caribbean,1662.0,27393504.0,Zanetti KA,Cancer,replication,2016-05-13,GCST003775,Lung cancer
1226,African American or Afro-Caribbean,5339.0,27393504.0,Zanetti KA,Cancer,initial,2016-05-13,GCST003775,Lung cancer
880,African American or Afro-Caribbean,1448.0,27393504.0,Zanetti KA,Cancer,replication,2016-05-13,GCST003776,Lung adenocarcinoma
3974,Asian,9127.0,27191271.0,Hu Q,Cardiovascular disease,replication,2016-05-13,GCST003561,Coronary artery disease
1190,African American or Afro-Caribbean,4340.0,27393504.0,Zanetti KA,Cancer,initial,2016-05-13,GCST003776,Lung adenocarcinoma
11286,European,67023.0,27182965.0,Pickrell JK,Other measurement,initial,2016-05-16,GCST003999,Nose size
10202,European,17500.0,27182965.0,Pickrell JK,"Other measurement, Other disease",initial,2016-05-16,GCST003983,Male-pattern baldness
12248,European,334141.0,27182965.0,Pickrell JK,Neurological disorder,initial,2016-05-16,GCST003984,Parkinson's disease
11183,European,55871.0,27182965.0,Pickrell JK,Other measurement,initial,2016-05-16,GCST003994,Age at voice drop
11341,European,71489.0,27182965.0,Pickrell JK,Other measurement,initial,2016-05-16,GCST003989,Chin dimples
11574,European,99695.0,27182965.0,Pickrell JK,Other trait,initial,2016-05-16,GCST003992,Photic sneeze reflex
10807,European,33790.0,27182965.0,Pickrell JK,Body measurement,initial,2016-05-16,GCST003985,Breast size
12156,European,283985.0,27182965.0,Pickrell JK,Cardiovascular disease,initial,2016-05-16,GCST003986,Migraine
11711,European,121810.0,27182965.0,Pickrell JK,Other measurement,initial,2016-05-16,GCST003991,Childhood ear infection
11378,European,76831.0,27182965.0,Pickrell JK,Other measurement,initial,2016-05-16,GCST003993,Menarche (age at onset)
11777,European,134641.0,27182965.0,Pickrell JK,Other disease,initial,2016-05-16,GCST003988,Hypothyroidism
11319,European,69284.0,27182965.0,Pickrell JK,Other measurement,initial,2016-05-16,GCST003996,Monobrow
12005,European,191843.0,27182965.0,Pickrell JK,Other trait,initial,2016-05-16,GCST003997,Myopia
11975,European,173421.0,27182965.0,Pickrell JK,Other measurement,initial,2016-05-16,GCST003995,Tonsillectomy
11896,European,157242.0,27182965.0,Pickrell JK,Other disease,initial,2016-05-16,GCST003987,Asthma
11988,European,180741.0,27182965.0,Pickrell JK,Immune system disorder,initial,2016-05-16,GCST003990,Allergy
11270,European,64143.0,27182965.0,Pickrell JK,Other measurement,initial,2016-05-16,GCST003998,Joint mobility (Beighton score)
11316,European,69033.0,27189021.0,Cook JP,Metabolic disorder,replication,2016-05-18,GCST003619,Type 2 diabetes
11203,European,56799.0,27189021.0,Cook JP,Metabolic disorder,initial,2016-05-18,GCST003619,Type 2 diabetes
11128,European,52107.0,27193031.0,Marquez A,Immune system disorder,replication,2016-05-18,GCST003620,Systemic lupus erythematosus or rheumatoid arthritis
10133,European,16546.0,27193031.0,Marquez A,Immune system disorder,initial,2016-05-18,GCST003620,Systemic lupus erythematosus or rheumatoid arthritis
13089,Hispanic or Latin American,6499.0,27189021.0,Cook JP,Metabolic disorder,initial,2016-05-18,GCST003619,Type 2 diabetes
1137,African American or Afro-Caribbean,3571.0,27189021.0,Cook JP,Metabolic disorder,initial,2016-05-18,GCST003619,Type 2 diabetes
3492,Asian,4735.0,27189021.0,Cook JP,Metabolic disorder,initial,2016-05-18,GCST003619,Type 2 diabetes
13073,Hispanic or Latin American,5958.0,27193062.0,Adhikari K,Other measurement,initial,2016-05-19,GCST003638,upper facial morphology traits (ordinal measurement)
13070,Hispanic or Latin American,5958.0,27193062.0,Adhikari K,Other measurement,initial,2016-05-19,GCST003633,middle facial morphology traits (ordinal measurement)
13072,Hispanic or Latin American,5958.0,27193062.0,Adhikari K,Other measurement,initial,2016-05-19,GCST003637,facial morphology traits (multivariate analysis)
12925,Hispanic or Latin American,2955.0,27193062.0,Adhikari K,Other measurement,initial,2016-05-19,GCST003635,middle facial morphology traits (quantitative measurement)
13071,Hispanic or Latin American,5958.0,27193062.0,Adhikari K,Other measurement,initial,2016-05-19,GCST003634,lower facial morphology traits (ordinal measurement)
12662,Hispanic or Latin American,501.0,27193062.0,Adhikari K,Other measurement,replication,2016-05-19,GCST003633,middle facial morphology traits (ordinal measurement)
3243,Asian,2994.0,27195777.0,Sano M,Cardiovascular measurement,initial,2016-05-19,GCST003630,Left ventricular QRS voltage
12926,Hispanic or Latin American,2955.0,27193062.0,Adhikari K,Other measurement,initial,2016-05-19,GCST003636,lower facial morphology traits (quantitative measurement)
4048,Asian,10318.0,27195708.0,Scott WR,"Body measurement, Other measurement",initial,2016-05-19,GCST003564,Waist-to-hip ratio adjusted for body mass index
3222,Asian,2941.0,27195777.0,Sano M,Cardiovascular measurement,replication,2016-05-19,GCST003630,Left ventricular QRS voltage
2888,Asian,1922.0,27195708.0,Scott WR,"Body measurement, Other measurement",replication,2016-05-19,GCST003564,Waist-to-hip ratio adjusted for body mass index
5382,European,525.0,27203581.0,Sousa I,Other trait,replication,2016-05-20,GCST003618,Primary spontaneous pneumothorax
4852,European,221.0,27203581.0,Sousa I,Other trait,initial,2016-05-20,GCST003618,Primary spontaneous pneumothorax
9767,European,11611.0,27519822.0,Power RA,Neurological disorder,initial,2016-05-24,GCST003558,Major depressive disorder
3589,Asian,5537.0,27519822.0,Power RA,Neurological disorder,replication,2016-05-24,GCST003558,Major depressive disorder
11592,European,104402.0,27519822.0,Power RA,Neurological disorder,replication,2016-05-24,GCST003558,Major depressive disorder
12340,European,405072.0,27225129.0,Okbay A,Other measurement,initial,2016-05-26,GCST003676,Educational attainment (years of education)
4740,European,161.0,28090565.0,Tsai EA,"Neurological disorder, Digestive system disorder",initial,2016-05-26,GCST003616,Liver disease severity in Alagille syndrome
12149,European,280007.0,27225129.0,Okbay A,Other measurement,initial,2016-05-26,GCST003677,Educational attainment (college completion)
8178,European,4256.0,27244217.0,Fogh I,"Other measurement, Neurological disorder",initial,2016-05-31,GCST003632,Survival in sporadic amyotrophic lateral sclerosis
3790,Asian,7261.0,27244555.0,Li Y,"Digestive system disorder, Immune system disorder",replication,2016-05-31,GCST003615,Susceptibility to persistent hepatitis B virus infection
3055,Asian,2308.0,27244555.0,Li Y,"Digestive system disorder, Immune system disorder",initial,2016-05-31,GCST003615,Susceptibility to persistent hepatitis B virus infection
5397,European,539.0,27304844.0,Khong JJ,"Neurological disorder, Immune system disorder",replication,2016-06-01,GCST003640,Thyroid-associated orbitopathy in graves' disease
5136,European,412.0,27304844.0,Khong JJ,"Neurological disorder, Immune system disorder",initial,2016-06-01,GCST003640,Thyroid-associated orbitopathy in graves' disease
253,African,3106.0,27236921.0,Rautanen A,Other disease,initial,2016-06-02,GCST003649,Pneumococcal bacteremia
269,African,4213.0,27236921.0,Rautanen A,Other disease,initial,2016-06-02,GCST003650,Bacteremia
227,African,1770.0,27236921.0,Rautanen A,Other disease,replication,2016-06-02,GCST003650,Bacteremia
194,African,1449.0,27236921.0,Rautanen A,Other disease,replication,2016-06-02,GCST003649,Pneumococcal bacteremia
8040,European,3893.0,27262462.0,Teerlink CC,Cancer,initial,2016-06-04,GCST003586,Prostate cancer
7314,European,2511.0,27262462.0,Teerlink CC,"Cancer, Other measurement",initial,2016-06-04,GCST003585,Aggressive prostate cancer
7435,European,2671.0,27285765.0,Chen D,Cancer,replication,2016-06-07,GCST003565,Cervical cancer
8757,European,6076.0,27285765.0,Chen D,Cancer,initial,2016-06-07,GCST003565,Cervical cancer
13575,Other/Mixed,230.0,28025368.0,Janicki PK,Neurological disorder,initial,2016-06-10,GCST003930,Complex regional pain syndrome
13576,Other/Mixed,230.0,28025368.0,Janicki PK,Neurological disorder,replication,2016-06-10,GCST003930,Complex regional pain syndrome
12939,Hispanic or Latin American,3379.0,27296613.0,Salinas YD,"Body measurement, Other measurement",replication,2016-06-13,GCST003647,Body mass index
893,African American or Afro-Caribbean,1549.0,27296613.0,Salinas YD,"Body measurement, Other measurement",initial,2016-06-13,GCST003647,Body mass index
2254,Asian,706.0,27296613.0,Salinas YD,"Body measurement, Other measurement",initial,2016-06-13,GCST003647,Body mass index
1279,African American or Afro-Caribbean,6871.0,27296613.0,Salinas YD,"Body measurement, Other measurement",replication,2016-06-13,GCST003647,Body mass index
7248,European,2395.0,27296613.0,Salinas YD,"Body measurement, Other measurement",initial,2016-06-13,GCST003647,Body mass index
12803,Hispanic or Latin American,1235.0,27296613.0,Salinas YD,"Body measurement, Other measurement",initial,2016-06-13,GCST003647,Body mass index
6481,European,1431.0,27315593.0,Lang M,Neurological disorder,initial,2016-06-14,GCST003648,Pathological gambling
745,African American or Afro-Caribbean,845.0,27311723.0,Pei YF,Other measurement,replication,2016-06-16,GCST003559,Bone mineral density (hip)
12637,Hispanic or Latin American,446.0,27311723.0,Pei YF,Other measurement,replication,2016-06-16,GCST003559,Bone mineral density (hip)
8964,European,6912.0,27311723.0,Pei YF,Other measurement,initial,2016-06-16,GCST003559,Bone mineral density (hip)
6017,European,971.0,27311723.0,Pei YF,Other measurement,replication,2016-06-16,GCST003559,Bone mineral density (hip)
8790,European,6226.0,27386562.0,Andlauer TF,Immune system disorder,replication,2016-06-17,GCST003566,Multiple sclerosis
10046,European,15283.0,27386562.0,Andlauer TF,Immune system disorder,initial,2016-06-17,GCST003566,Multiple sclerosis
11875,European,151215.0,27322543.0,Gormley P,Cardiovascular disease,initial,2016-06-20,GCST003722,Migraine with aura
11843,European,147790.0,27322543.0,Gormley P,Cardiovascular disease,initial,2016-06-20,GCST003721,Migraine without aura
12306,European,375752.0,27322543.0,Gormley P,Cardiovascular disease,initial,2016-06-20,GCST003720,Migraine
10844,European,34950.0,27329760.0,Hou L,Neurological disorder,initial,2016-06-21,GCST003724,Bipolar disorder
9557,European,9822.0,27325353.0,Matteini AM,Other measurement,initial,2016-06-21,GCST004493,Lower body strength
10628,European,27581.0,27325353.0,Matteini AM,Other measurement,initial,2016-06-21,GCST004494,Hand grip strength
5325,European,502.0,27327535.0,Laville V,Other measurement,initial,2016-06-21,GCST003591,Severity of facial solar lentigines
8575,European,5305.0,27329760.0,Hou L,Neurological disorder,replication,2016-06-21,GCST003724,Bipolar disorder
4176,Asian,13905.0,27354352.0,Han MR,Cancer,initial,2016-06-27,GCST003520,Breast cancer
6012,European,966.0,27347659.0,Vaysse A,"Cancer, Other measurement",initial,2016-06-27,GCST003639,Breslow thickness in cutaneous melanoma
6573,European,1546.0,27347659.0,Vaysse A,"Cancer, Other measurement",replication,2016-06-27,GCST003639,Breslow thickness in cutaneous melanoma
4217,Asian,15148.0,27354352.0,Han MR,Cancer,replication,2016-06-27,GCST003520,Breast cancer
4268,Asian,18817.0,27362418.0,Zhang H,Metabolic disorder,replication,2016-06-30,GCST005716,Type 2 diabetes
11756,European,130990.0,27362418.0,Zhang H,Metabolic disorder,initial,2016-06-30,GCST005716,Type 2 diabetes
12608,Hispanic or Latin American,350.0,27002377.0,Irvin MR,"Lipid or lipoprotein measurement, Response to drug",replication,2016-07-01,GCST003487,Response to fenofibrate (total cholesterol levels)
12609,Hispanic or Latin American,350.0,27002377.0,Irvin MR,"Response to drug, Lipid or lipoprotein measurement",replication,2016-07-01,GCST003488,Response to fenofibrate (triglyceride levels)
6618,European,1594.0,27002377.0,Irvin MR,"Response to drug, Lipid or lipoprotein measurement",initial,2016-07-01,GCST003488,Response to fenofibrate (triglyceride levels)
6617,European,1594.0,27002377.0,Irvin MR,"Lipid or lipoprotein measurement, Response to drug",initial,2016-07-01,GCST003487,Response to fenofibrate (total cholesterol levels)
12094,European,241704.0,27363682.0,Mitchell JS,Cancer,initial,2016-07-01,GCST004483,Multiple myeloma
12607,Hispanic or Latin American,350.0,27002377.0,Irvin MR,"Lipid or lipoprotein measurement, Response to drug",replication,2016-07-01,GCST003486,Response to fenofibrate (LDL cholesterol levels)
9045,European,7350.0,27363682.0,Mitchell JS,Cancer,replication,2016-07-01,GCST004483,Multiple myeloma
6616,European,1594.0,27002377.0,Irvin MR,"Lipid or lipoprotein measurement, Response to drug",initial,2016-07-01,GCST003486,Response to fenofibrate (LDL cholesterol levels)
481,African American or Afro-Caribbean,138.0,27002377.0,Irvin MR,"Response to drug, Lipid or lipoprotein measurement",replication,2016-07-01,GCST003488,Response to fenofibrate (triglyceride levels)
480,African American or Afro-Caribbean,138.0,27002377.0,Irvin MR,"Lipid or lipoprotein measurement, Response to drug",replication,2016-07-01,GCST003487,Response to fenofibrate (total cholesterol levels)
479,African American or Afro-Caribbean,138.0,27002377.0,Irvin MR,"Lipid or lipoprotein measurement, Response to drug",replication,2016-07-01,GCST003486,Response to fenofibrate (LDL cholesterol levels)
478,African American or Afro-Caribbean,138.0,27002377.0,Irvin MR,"Lipid or lipoprotein measurement, Response to drug",replication,2016-07-01,GCST003485,Response to fenofibrate (HDL cholesterol levels)
12606,Hispanic or Latin American,350.0,27002377.0,Irvin MR,"Lipid or lipoprotein measurement, Response to drug",replication,2016-07-01,GCST003485,Response to fenofibrate (HDL cholesterol levels)
6615,European,1594.0,27002377.0,Irvin MR,"Lipid or lipoprotein measurement, Response to drug",initial,2016-07-01,GCST003485,Response to fenofibrate (HDL cholesterol levels)
13921,Other/Mixed,2672.0,27523435.0,Mosteller M,"Response to drug, Other measurement, Other disease",initial,2016-07-05,GCST003567,Response to inhaled corticosteroid treatment in asthma (change in FEV1)
6640,European,1625.0,27387956.0,Murk W,Other disease,initial,2016-07-07,GCST003682,Asthma (SNP x SNP interaction)
746,African American or Afro-Caribbean,845.0,27397699.0,Pei YF,Other measurement,initial,2016-07-07,GCST003654,Bone mineral density (Ward's triangle area)
6649,European,1634.0,27387956.0,Murk W,Other disease,replication,2016-07-07,GCST003682,Asthma (SNP x SNP interaction)
8198,European,4305.0,27397699.0,Pei YF,Other measurement,initial,2016-07-07,GCST003654,Bone mineral density (Ward's triangle area)
2696,Asian,1579.0,27397699.0,Pei YF,Other measurement,initial,2016-07-07,GCST003654,Bone mineral density (Ward's triangle area)
12638,Hispanic or Latin American,446.0,27397699.0,Pei YF,Other measurement,initial,2016-07-07,GCST003654,Bone mineral density (Ward's triangle area)
7225,European,2363.0,27402877.0,Hill-Burns EM,"Neurological disorder, Other measurement",replication,2016-07-11,GCST003651,"Parkinson's disease (non-familial, age at onset)"
5672,European,737.0,27402877.0,Hill-Burns EM,"Neurological disorder, Other measurement",replication,2016-07-11,GCST003652,"Parkinson's disease (familial, age at onset)"
6920,European,1985.0,27402877.0,Hill-Burns EM,"Neurological disorder, Other measurement",initial,2016-07-11,GCST003653,Parkinson's disease (age of onset)
7639,European,3100.0,27402877.0,Hill-Burns EM,"Neurological disorder, Other measurement",replication,2016-07-11,GCST003653,Parkinson's disease (age of onset)
3522,Asian,5057.0,27399966.0,Morris DL,Immune system disorder,initial,2016-07-11,GCST003622,Systemic lupus erythematosus
3883,Asian,8117.0,27399966.0,Morris DL,Immune system disorder,replication,2016-07-11,GCST003622,Systemic lupus erythematosus
9771,European,11675.0,27399966.0,Morris DL,Immune system disorder,replication,2016-07-11,GCST003622,Systemic lupus erythematosus
9707,European,10995.0,27399966.0,Morris DL,Immune system disorder,initial,2016-07-11,GCST003622,Systemic lupus erythematosus
6585,European,1554.0,27402877.0,Hill-Burns EM,"Neurological disorder, Other measurement",initial,2016-07-11,GCST003651,"Parkinson's disease (non-familial, age at onset)"
5167,European,431.0,27402877.0,Hill-Burns EM,"Neurological disorder, Other measurement",initial,2016-07-11,GCST003652,"Parkinson's disease (familial, age at onset)"
7148,European,2267.0,27412012.0,Lamina C,Lipid or lipoprotein measurement,replication,2016-07-12,GCST003590,Apolipoprotein A-IV levels
9943,European,13813.0,27412012.0,Lamina C,Lipid or lipoprotein measurement,initial,2016-07-12,GCST003590,Apolipoprotein A-IV levels
8655,European,5649.0,27400856.0,Legge SE,"Response to drug, Neurological disorder, Other trait",initial,2016-07-12,GCST003628,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia
5923,European,917.0,27412988.0,Tise CG,Other measurement,initial,2016-07-13,GCST003723,Serum sulfate level
10154,European,16753.0,27416945.0,Walford GA,"Body measurement, Other measurement",initial,2016-07-14,GCST003659,Modified Stumvoll Insulin Sensitivity Index (BMI interaction)
10153,European,16753.0,27416945.0,Walford GA,"Body measurement, Other measurement",initial,2016-07-14,GCST003658,Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI)
9903,European,13354.0,27416945.0,Walford GA,Other measurement,replication,2016-07-14,GCST005178,Modified Stumvoll Insulin Sensitivity Index
9902,European,13354.0,27416945.0,Walford GA,"Body measurement, Other measurement",replication,2016-07-14,GCST003659,Modified Stumvoll Insulin Sensitivity Index (BMI interaction)
9901,European,13354.0,27416945.0,Walford GA,"Body measurement, Other measurement",replication,2016-07-14,GCST003658,Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI)
9855,European,12601.0,27418160.0,van 't Hof FN,Cardiovascular disease,initial,2016-07-14,GCST003683,"Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy)"
10155,European,16753.0,27416945.0,Walford GA,Other measurement,initial,2016-07-14,GCST005178,Modified Stumvoll Insulin Sensitivity Index
2686,Asian,1547.0,27424934.0,Choi HJ,Other measurement,replication,2016-07-15,GCST003610,Bone mineral density (spine)
3160,Asian,2729.0,27424934.0,Choi HJ,Other measurement,initial,2016-07-15,GCST003612,Bone mineral density (femoral neck)
7735,European,3237.0,27424934.0,Choi HJ,Other measurement,replication,2016-07-15,GCST003610,Bone mineral density (spine)
7736,European,3237.0,27424934.0,Choi HJ,Other measurement,replication,2016-07-15,GCST003611,Bone mineral density (total hip)
7737,European,3237.0,27424934.0,Choi HJ,Other measurement,replication,2016-07-15,GCST003612,Bone mineral density (femoral neck)
2688,Asian,1547.0,27424934.0,Choi HJ,Other measurement,replication,2016-07-15,GCST003612,Bone mineral density (femoral neck)
2687,Asian,1547.0,27424934.0,Choi HJ,Other measurement,replication,2016-07-15,GCST003611,Bone mineral density (total hip)
3159,Asian,2729.0,27424934.0,Choi HJ,Other measurement,initial,2016-07-15,GCST003611,Bone mineral density (total hip)
3158,Asian,2729.0,27424934.0,Choi HJ,Other measurement,initial,2016-07-15,GCST003610,Bone mineral density (spine)
12162,European,287137.0,27424798.0,Chahal HS,Cancer,initial,2016-07-18,GCST003655,Cutaneous squamous cell carcinoma
9830,European,12343.0,27424798.0,Chahal HS,Cancer,replication,2016-07-18,GCST003655,Cutaneous squamous cell carcinoma
4066,Asian,11054.0,27436580.0,Cui Q,Cancer,replication,2016-07-19,GCST003578,Nasopharyngeal carcinoma
3459,Asian,4562.0,27436580.0,Cui Q,Cancer,initial,2016-07-19,GCST003578,Nasopharyngeal carcinoma
6328,European,1245.0,27515689.0,Kerns SL,"Cancer, Biological process, Other trait",initial,2016-07-20,GCST003581,Toxicity response to radiotherapy in prostate cancer (decreased urine stream) (time to event)
6512,European,1487.0,27515689.0,Kerns SL,"Cancer, Biological process",initial,2016-07-20,GCST003584,"Response to radiotherapy in prostate cancer (toxicity, rectal bleeding)"
6471,European,1409.0,27515689.0,Kerns SL,"Cancer, Biological process",initial,2016-07-20,GCST003582,"Response to radiotherapy in prostate cancer (toxicity, urinary frequency)"
6400,European,1346.0,27515689.0,Kerns SL,"Cancer, Biological process, Other disease",initial,2016-07-20,GCST003583,Response to radiotherapy in prostate cancer (overall toxicity)
9457,European,9291.0,27439200.0,Nieuwenhuis MA,Other disease,replication,2016-07-20,GCST003589,Bronchial hyperresponsiveness in asthma
6212,European,1131.0,26202629.0,Johnson EO,Neurological disorder,replication,2016-07-23,GCST003601,Drug abuse
720,African American or Afro-Caribbean,755.0,26202629.0,Johnson EO,Neurological disorder,replication,2016-07-23,GCST003601,Drug abuse
8939,European,6845.0,26202629.0,Johnson EO,Neurological disorder,initial,2016-07-23,GCST003601,Drug abuse
1148,African American or Afro-Caribbean,3742.0,26202629.0,Johnson EO,Neurological disorder,initial,2016-07-23,GCST003601,Drug abuse
10864,European,36052.0,27455348.0,van Rheenen W,Neurological disorder,initial,2016-07-25,GCST004692,Amyotrophic lateral sclerosis
13943,Other/Mixed,3072.0,27455349.0,Minster RL,"Body measurement, Other measurement",initial,2016-07-25,GCST005181,Body mass index
13902,Other/Mixed,2102.0,27455349.0,Minster RL,"Body measurement, Other measurement",replication,2016-07-25,GCST005181,Body mass index
8583,European,5346.0,27455348.0,van Rheenen W,Neurological disorder,replication,2016-07-25,GCST004692,Amyotrophic lateral sclerosis
4943,European,289.0,27339598.0,Ulveling D,"Other disease, Digestive system disorder, Other trait",initial,2016-07-29,GCST003606,Liver fibrosis severity in HIV/hepatitis C co-infection
2861,Asian,1876.0,27271309.0,Li C,Other measurement,initial,2016-08-01,GCST006115,Systolic blood pressure x sodium interaction (1df test)
2307,Asian,775.0,27271309.0,Li C,Other measurement,replication,2016-08-01,GCST006115,Systolic blood pressure x sodium interaction (1df test)
2304,Asian,775.0,27271309.0,Li C,Other measurement,replication,2016-08-01,GCST006112,Diastolic blood pressure x sodium interaction (1df test)
2305,Asian,775.0,27271309.0,Li C,Other measurement,replication,2016-08-01,GCST006113,Systolic blood pressure x sodium interaction (2df test)
2309,Asian,775.0,27271309.0,Li C,"Other measurement, Cardiovascular measurement",replication,2016-08-01,GCST006117,Pulse pressure x sodium interaction (1df test)
2303,Asian,775.0,27271309.0,Li C,Other measurement,replication,2016-08-01,GCST006111,Diastolic blood pressure x sodium interaction (2df test)
2306,Asian,775.0,27271309.0,Li C,Other measurement,replication,2016-08-01,GCST006114,Mean arterial pressure x sodium interaction (2df test)
2310,Asian,775.0,27271309.0,Li C,"Other measurement, Cardiovascular measurement",replication,2016-08-01,GCST006118,Pulse pressure x sodium interaction (2df test)
2860,Asian,1876.0,27271309.0,Li C,Other measurement,initial,2016-08-01,GCST006114,Mean arterial pressure x sodium interaction (2df test)
2308,Asian,775.0,27271309.0,Li C,Other measurement,replication,2016-08-01,GCST006116,Mean arterial pressure x sodium interaction (1df test)
8369,European,4835.0,27492634.0,Du Y,Cancer,initial,2016-08-01,GCST003786,Small intestine neuroendocrine tumor
8324,European,4698.0,27492634.0,Du Y,Cancer,initial,2016-08-01,GCST003788,Pancreatic neuroendocrine tumor
11877,European,152127.0,27479909.0,Hyde CL,Neurological disorder,replication,2016-08-01,GCST006041,Major depressive disorder
8308,European,4670.0,27492634.0,Du Y,Cancer,initial,2016-08-01,GCST003787,Bronchial neuroendocrine tumor
2859,Asian,1876.0,27271309.0,Li C,Other measurement,initial,2016-08-01,GCST006113,Systolic blood pressure x sodium interaction (2df test)
2857,Asian,1876.0,27271309.0,Li C,Other measurement,initial,2016-08-01,GCST006111,Diastolic blood pressure x sodium interaction (2df test)
2862,Asian,1876.0,27271309.0,Li C,Other measurement,initial,2016-08-01,GCST006116,Mean arterial pressure x sodium interaction (1df test)
9952,European,13952.0,27579533.0,Zhang M,Cancer,initial,2016-08-01,GCST003758,Pancreatic cancer
2863,Asian,1876.0,27271309.0,Li C,"Other measurement, Cardiovascular measurement",initial,2016-08-01,GCST006117,Pulse pressure x sodium interaction (1df test)
12235,European,326113.0,27479909.0,Hyde CL,Neurological disorder,initial,2016-08-01,GCST006041,Major depressive disorder
2864,Asian,1876.0,27271309.0,Li C,"Other measurement, Cardiovascular measurement",initial,2016-08-01,GCST006118,Pulse pressure x sodium interaction (2df test)
8590,European,5374.0,27492634.0,Du Y,Cancer,initial,2016-08-01,GCST003785,Neuroendocrine tumor
2858,Asian,1876.0,27271309.0,Li C,Other measurement,initial,2016-08-01,GCST006112,Diastolic blood pressure x sodium interaction (1df test)
2130,Asian,518.0,27480026.0,Liu X,Cardiovascular disease,initial,2016-08-02,GCST003613,Hypertension
4301,Asian,21472.0,27480026.0,Liu X,Cardiovascular disease,replication,2016-08-02,GCST003613,Hypertension
13608,Other/Mixed,311.0,27488534.0,Patel YM,"Biological process, Other measurement",initial,2016-08-03,GCST003629,nicotine metabolite ratio in current smokers
5195,European,437.0,27488534.0,Patel YM,"Biological process, Other measurement",initial,2016-08-03,GCST003629,nicotine metabolite ratio in current smokers
12648,Hispanic or Latin American,453.0,27488534.0,Patel YM,"Biological process, Other measurement",initial,2016-08-03,GCST003629,nicotine metabolite ratio in current smokers
612,African American or Afro-Caribbean,364.0,27488534.0,Patel YM,"Biological process, Other measurement",initial,2016-08-03,GCST003629,nicotine metabolite ratio in current smokers
2223,Asian,674.0,27488534.0,Patel YM,"Biological process, Other measurement",initial,2016-08-03,GCST003629,nicotine metabolite ratio in current smokers
6197,European,1109.0,27490719.0,Bacelis J,Other measurement,initial,2016-08-04,GCST003686,Gestational age at birth (child effect)
4862,European,225.0,27490719.0,Bacelis J,Other measurement,initial,2016-08-04,GCST003689,Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect)
5014,European,336.0,27490719.0,Bacelis J,Other measurement,initial,2016-08-04,GCST003685,Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect)
6749,European,1743.0,27490719.0,Bacelis J,Other measurement,initial,2016-08-04,GCST003688,Gestational age at birth (maternal effect)
6468,European,1407.0,27490719.0,Bacelis J,Other measurement,initial,2016-08-04,GCST003684,Gestational age at birth in labor-initiated deliveries (maternal effect)
5887,European,884.0,27490719.0,Bacelis J,Other measurement,initial,2016-08-04,GCST003687,Gestational age at birth in labor-initiated deliveries (child effect)
11626,European,110188.0,27494321.0,Jones SE,Other measurement,initial,2016-08-05,GCST006686,Sleep duration (undersleepers)
10940,European,39082.0,27494321.0,Jones SE,Other measurement,initial,2016-08-05,GCST003840,Sleep duration (oversleepers vs undersleepers)
11541,European,91306.0,27494321.0,Jones SE,Other measurement,initial,2016-08-05,GCST006685,Sleep duration (oversleepers)
11745,European,127898.0,27494321.0,Jones SE,"Biological process, Other measurement",initial,2016-08-05,GCST003837,Chronotype
11742,European,127573.0,27494321.0,Jones SE,Other measurement,initial,2016-08-05,GCST003839,Sleep duration
11657,European,114765.0,27494321.0,Jones SE,Biological process,initial,2016-08-05,GCST003838,Morning vs. evening chronotype
2744,Asian,1686.0,27503288.0,Song IW,Neurological disorder,initial,2016-08-08,GCST003604,Sjgren's syndrome
4195,Asian,14610.0,27503288.0,Song IW,Neurological disorder,replication,2016-08-08,GCST003604,Sjgren's syndrome
3206,Asian,2876.0,27506219.0,Wang W,Other disease,replication,2016-08-09,GCST003819,Endometriosis
1671,Asian,100.0,27506219.0,Wang W,Other disease,initial,2016-08-09,GCST003819,Endometriosis
3519,Asian,5030.0,27501781.0,Shiraishi K,Cancer,initial,2016-08-09,GCST003605,EGFR mutation-positive lung adenocarcinoma
4165,Asian,13301.0,27501781.0,Shiraishi K,Cancer,replication,2016-08-09,GCST003605,EGFR mutation-positive lung adenocarcinoma
10499,European,23326.0,27527254.0,Gharahkhani P,Digestive system disorder,initial,2016-08-12,GCST003738,Barrett's esophagus
10396,European,21271.0,27527254.0,Gharahkhani P,Cancer,initial,2016-08-12,GCST003739,Esophageal adenocarcinoma
10625,European,27438.0,27527254.0,Gharahkhani P,"Digestive system disorder, Cancer",initial,2016-08-12,GCST003740,Barrett's esophagus  or Esophageal adenocarcinoma
2049,Asian,439.0,27529621.0,Otowa T,"Neurological disorder, Other measurement",replication,2016-08-16,GCST003836,Depressive symptoms
1942,Asian,320.0,27529621.0,Otowa T,Other measurement,initial,2016-08-16,GCST003835,Depressive symptoms (stressful life events interaction)
1941,Asian,320.0,27529621.0,Otowa T,"Neurological disorder, Other measurement",initial,2016-08-16,GCST003836,Depressive symptoms
2050,Asian,439.0,27529621.0,Otowa T,Other measurement,replication,2016-08-16,GCST003835,Depressive symptoms (stressful life events interaction)
979,African American or Afro-Caribbean,2173.0,27531626.0,Polimanti R,"Other measurement, Neurological disorder",initial,2016-08-17,GCST003860,Risky sexual behaviors (alcohol dependence interaction)
6758,European,1751.0,27531626.0,Polimanti R,"Other measurement, Neurological disorder",initial,2016-08-17,GCST003860,Risky sexual behaviors (alcohol dependence interaction)
6330,European,1250.0,27568811.0,Marinelli M,Other measurement,replication,2016-08-19,GCST003741,Sleep duration
10170,European,17044.0,27539887.0,Chahal HS,Cancer,replication,2016-08-19,GCST003726,Basal cell carcinoma
12163,European,287197.0,27539887.0,Chahal HS,Cancer,initial,2016-08-19,GCST003726,Basal cell carcinoma
9643,European,10554.0,27568811.0,Marinelli M,Other measurement,initial,2016-08-19,GCST003741,Sleep duration
5666,European,735.0,27548383.0,Ortiz-Fernandez L,Cardiovascular disease,replication,2016-08-22,GCST007551,Behcet's disease
6793,European,1795.0,27548383.0,Ortiz-Fernandez L,Cardiovascular disease,initial,2016-08-22,GCST007551,Behcet's disease
2242,Asian,700.0,27545300.0,Hao J,"Body measurement, Other disease, Other measurement",replication,2016-08-22,GCST003727,Joint destruction and growth retardation
2755,Asian,1717.0,27545300.0,Hao J,"Body measurement, Other disease, Other measurement",initial,2016-08-22,GCST003727,Joint destruction and growth retardation
7996,European,3768.0,27559109.0,Bustamante M,Other trait,replication,2016-08-23,GCST003626,diarrhoeal disease at age 1
7899,European,3516.0,27559109.0,Bustamante M,Other trait,replication,2016-08-23,GCST003623,diarrhoeal disease at age 2
8792,European,6233.0,27559109.0,Bustamante M,Other trait,initial,2016-08-23,GCST003624,diarrhoeal disease at age 2 with doctor diagnosis
9131,European,7722.0,27559109.0,Bustamante M,Other trait,replication,2016-08-23,GCST003624,diarrhoeal disease at age 2 with doctor diagnosis
8642,European,5608.0,27559109.0,Bustamante M,Other trait,initial,2016-08-23,GCST003623,diarrhoeal disease at age 2
9070,European,7465.0,27559109.0,Bustamante M,Other trait,replication,2016-08-23,GCST003625,diarrhoeal disease at age 1 with doctor diagnosis
8831,European,6403.0,27559109.0,Bustamante M,Other trait,initial,2016-08-23,GCST003625,diarrhoeal disease at age 1 with doctor diagnosis
8679,European,5758.0,27559109.0,Bustamante M,Other trait,initial,2016-08-23,GCST003626,diarrhoeal disease at age 1
1887,Asian,267.0,27558924.0,Kim HS,"Digestive system disorder, Other trait, Response to drug",initial,2016-08-24,GCST003603,Thiopurine-induced leukopenia in inflammatory bowel disease
2293,Asian,767.0,27558924.0,Kim HS,"Digestive system disorder, Other trait, Response to drug",replication,2016-08-24,GCST003603,Thiopurine-induced leukopenia in inflammatory bowel disease
7278,European,2447.0,27560520.0,Shaffer JR,Other measurement,initial,2016-08-25,GCST003644,Lip morphology
3582,Asian,5480.0,27569725.0,Yang SK,"Digestive system disorder, Immune system disorder",replication,2016-08-25,GCST003602,Inflammatory bowel disease
7277,European,2447.0,27560520.0,Shaffer JR,Other measurement,initial,2016-08-25,GCST003643,Nose morphology
7276,European,2447.0,27560520.0,Shaffer JR,Other measurement,initial,2016-08-25,GCST003642,Eye morphology
3590,Asian,5546.0,27569725.0,Yang SK,"Digestive system disorder, Immune system disorder",initial,2016-08-25,GCST003602,Inflammatory bowel disease
6709,European,1713.0,27561104.0,Pirastu N,"Biological process, Other measurement",replication,2016-08-25,GCST003621,Coffee consumption
7275,European,2447.0,27560520.0,Shaffer JR,Other measurement,initial,2016-08-25,GCST003641,Cranial base width
5592,European,671.0,27560520.0,Shaffer JR,Other measurement,replication,2016-08-25,GCST003646,Facial depth
5591,European,671.0,27560520.0,Shaffer JR,Other measurement,replication,2016-08-25,GCST003645,Lower facial height
5590,European,671.0,27560520.0,Shaffer JR,Other measurement,replication,2016-08-25,GCST003644,Lip morphology
5587,European,671.0,27560520.0,Shaffer JR,Other measurement,replication,2016-08-25,GCST003641,Cranial base width
5588,European,671.0,27560520.0,Shaffer JR,Other measurement,replication,2016-08-25,GCST003642,Eye morphology
5589,European,671.0,27560520.0,Shaffer JR,Other measurement,replication,2016-08-25,GCST003643,Nose morphology
7280,European,2447.0,27560520.0,Shaffer JR,Other measurement,initial,2016-08-25,GCST003646,Facial depth
6303,European,1213.0,27561104.0,Pirastu N,"Biological process, Other measurement",initial,2016-08-25,GCST003621,Coffee consumption
7279,European,2447.0,27560520.0,Shaffer JR,Other measurement,initial,2016-08-25,GCST003645,Lower facial height
12589,Hispanic or Latin American,251.0,27564568.0,Liu C,"Response to drug, Other measurement, Cancer",initial,2016-08-26,GCST003609,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines
5121,European,407.0,27564568.0,Liu C,"Response to drug, Other measurement, Cancer",initial,2016-08-26,GCST003609,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines
51,African,138.0,27564568.0,Liu C,"Response to drug, Other measurement, Cancer",initial,2016-08-26,GCST003609,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines
1605,Asian,57.0,27564568.0,Liu C,"Response to drug, Other measurement, Cancer",initial,2016-08-26,GCST003609,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines
1383,African American or Afro-Caribbean,10305.0,28580392.0,Taylor KC,Other disease,initial,2016-08-27,GCST004403,Bone fracture in osteoporosis
1402,African American or Afro-Caribbean,13031.0,27577874.0,Evans DS,Cardiovascular measurement,initial,2016-08-29,GCST003598,QRS duration
10973,European,40407.0,27577874.0,Evans DS,Cardiovascular measurement,initial,2016-08-29,GCST003598,QRS duration
6389,European,1328.0,27576016.0,Zhao B,"Other measurement, Other trait",initial,2016-08-30,GCST003656,Acute kidney injury in critical illness
6630,European,1612.0,27576016.0,Zhao B,"Other measurement, Other trait",replication,2016-08-30,GCST003656,Acute kidney injury in critical illness
6433,European,1373.0,27500523.0,Zhou K,"Response to drug, Other measurement, Metabolic disorder",initial,2016-09-01,GCST004522,Response to metformin in type 2 diabetes (HbA1c reduction)
13277,Hispanic or Latin American,16325.0,27588450.0,Mahajan A,Other measurement,initial,2016-09-01,GCST003790,Glomerular filtration rate
12723,Hispanic or Latin American,743.0,27500523.0,Zhou K,"Response to drug, Other measurement, Metabolic disorder",replication,2016-09-01,GCST004522,Response to metformin in type 2 diabetes (HbA1c reduction)
2191,Asian,627.0,27500523.0,Zhou K,"Response to drug, Other measurement, Metabolic disorder",replication,2016-09-01,GCST004522,Response to metformin in type 2 diabetes (HbA1c reduction)
1333,African American or Afro-Caribbean,8224.0,27588450.0,Mahajan A,Other measurement,initial,2016-09-01,GCST003790,Glomerular filtration rate
10159,European,16769.0,27587472.0,Postmus I,"Lipid or lipoprotein measurement, Response to drug",initial,2016-09-01,GCST003617,Response to statins (HDL cholesterol change)
10504,European,23553.0,27588450.0,Mahajan A,Other measurement,initial,2016-09-01,GCST003790,Glomerular filtration rate
822,African American or Afro-Caribbean,1196.0,27500523.0,Zhou K,"Response to drug, Other measurement, Metabolic disorder",replication,2016-09-01,GCST004522,Response to metformin in type 2 diabetes (HbA1c reduction)
9704,European,10951.0,27587472.0,Postmus I,"Lipid or lipoprotein measurement, Response to drug",replication,2016-09-01,GCST003617,Response to statins (HDL cholesterol change)
4319,Asian,23536.0,27588450.0,Mahajan A,Other measurement,initial,2016-09-01,GCST003790,Glomerular filtration rate
9443,European,9184.0,27500523.0,Zhou K,"Response to drug, Other measurement, Metabolic disorder",replication,2016-09-01,GCST004522,Response to metformin in type 2 diabetes (HbA1c reduction)
183,African,1335.0,28171663.0,Huo D,Cancer,initial,2016-09-04,GCST003782,Breast cancer
1230,African American or Afro-Caribbean,5499.0,28171663.0,Huo D,Cancer,initial,2016-09-04,GCST003780,Breast cancer (estrogen-receptor negative)
1241,African American or Afro-Caribbean,5945.0,28171663.0,Huo D,Cancer,initial,2016-09-04,GCST003781,Breast cancer (estrogen-receptor positive)
1131,African American or Afro-Caribbean,3512.0,28171663.0,Huo D,Cancer,replication,2016-09-04,GCST003780,Breast cancer (estrogen-receptor negative)
1210,African American or Afro-Caribbean,4923.0,28171663.0,Huo D,Cancer,replication,2016-09-04,GCST003782,Breast cancer
134,African,723.0,28171663.0,Huo D,Cancer,initial,2016-09-04,GCST003781,Breast cancer (estrogen-receptor positive)
1319,African American or Afro-Caribbean,8112.0,28171663.0,Huo D,Cancer,initial,2016-09-04,GCST003782,Breast cancer
1177,African American or Afro-Caribbean,4032.0,28171663.0,Huo D,Cancer,replication,2016-09-04,GCST003781,Breast cancer (estrogen-receptor positive)
132,African,666.0,28171663.0,Huo D,Cancer,initial,2016-09-04,GCST003780,Breast cancer (estrogen-receptor negative)
5448,European,579.0,27595289.0,Goyal RK,Immune system disorder,initial,2016-09-05,GCST003941,Acute graft versus host disease in bone marrow transplantation (recipient effect)
5562,European,656.0,27595289.0,Goyal RK,"Immune system disorder, Other measurement",initial,2016-09-05,GCST003942,Acute graft versus host disease in bone marrow transplantation (donor effect)
9827,European,12287.0,27476799.0,Nielson CM,Other measurement,initial,2016-09-06,GCST007014,Lumbar spine bone mineral density (trabecular)
8221,European,4402.0,27601451.0,Sanders AE,Other measurement,replication,2016-09-06,GCST003744,Chronic periodontitis (mean interproximal clinical attachment level)
9718,European,11080.0,27476799.0,Nielson CM,Other measurement,initial,2016-09-06,GCST007015,Lumbar spine bone mineral density (integral)
13184,Hispanic or Latin American,10935.0,27601451.0,Sanders AE,Other measurement,initial,2016-09-06,GCST003744,Chronic periodontitis (mean interproximal clinical attachment level)
761,African American or Afro-Caribbean,908.0,27601451.0,Sanders AE,Other measurement,replication,2016-09-06,GCST003744,Chronic periodontitis (mean interproximal clinical attachment level)
13971,Other/Mixed,4086.0,27599772.0,Ram R,"Metabolic disorder, Lipid or lipoprotein measurement",initial,2016-09-07,GCST003743,Hypertriglyceridemia
13863,Other/Mixed,1415.0,27599772.0,Ram R,"Metabolic disorder, Lipid or lipoprotein measurement",replication,2016-09-07,GCST003743,Hypertriglyceridemia
1227,African American or Afro-Caribbean,5372.0,27611488.0,Almoguera B,Other disease,initial,2016-09-09,GCST003832,Asthma (childhood onset)
1290,African American or Afro-Caribbean,7397.0,27611488.0,Almoguera B,Other disease,initial,2016-09-09,GCST003831,Asthma
9977,European,14247.0,27611488.0,Almoguera B,Other disease,initial,2016-09-09,GCST003831,Asthma
943,African American or Afro-Caribbean,2025.0,27611488.0,Almoguera B,Other disease,initial,2016-09-09,GCST003833,Adult asthma
8554,European,5277.0,27611488.0,Almoguera B,Other disease,initial,2016-09-09,GCST003832,Asthma (childhood onset)
9421,European,8970.0,27611488.0,Almoguera B,Other disease,initial,2016-09-09,GCST003833,Adult asthma
1009,African American or Afro-Caribbean,2600.0,27643478.0,Powers A,Other measurement,initial,2016-09-09,GCST003765,Emotional dysregulation
4669,European,96.0,28173075.0,Niu N,"Other measurement, Response to drug",initial,2016-09-11,GCST003791,Response to metformin (IC50)
460,African American or Afro-Caribbean,96.0,28173075.0,Niu N,"Other measurement, Response to drug",initial,2016-09-11,GCST003791,Response to metformin (IC50)
1663,Asian,96.0,28173075.0,Niu N,"Other measurement, Response to drug",initial,2016-09-11,GCST003791,Response to metformin (IC50)
11806,European,140886.0,27618452.0,Ehret GB,Other measurement,replication,2016-09-12,GCST006259,Systolic blood pressure
11805,European,140886.0,27618452.0,Ehret GB,Other measurement,replication,2016-09-12,GCST006258,Diastolic blood pressure
12023,European,201529.0,27618452.0,Ehret GB,Other measurement,initial,2016-09-12,GCST006259,Systolic blood pressure
12022,European,201529.0,27618452.0,Ehret GB,Other measurement,initial,2016-09-12,GCST006258,Diastolic blood pressure
9527,European,9688.0,27622933.0,Li QS,"Response to drug, Neurological disorder",initial,2016-09-13,GCST003801,Response to selective serotonin reuptake inhibitors in depression
40,African,96.0,27623284.0,Verma SS,Neurological disorder,initial,2016-09-13,GCST003745,Glaucoma (primary open-angle)
12017,European,197744.0,27622933.0,Li QS,"Response to drug, Neurological disorder",initial,2016-09-13,GCST003809,Response to selective serotonin reuptake inhibitors and depression
12020,European,198990.0,27622933.0,Li QS,"Neurological disorder, Response to drug",initial,2016-09-13,GCST003813,Response to antidepressants and depression
12014,European,195222.0,27622933.0,Li QS,"Response to drug, Neurological disorder",initial,2016-09-13,GCST003808,Non-response to selective serotonin reuptake inhibitors and depression
8325,European,4698.0,27622933.0,Li QS,"Neurological disorder, Response to drug",initial,2016-09-13,GCST003802,Response to citalopram or escitalopram in depression
12013,European,194909.0,27622933.0,Li QS,"Neurological disorder, Response to drug",initial,2016-09-13,GCST003811,Response to citalopram or escitalopram and depression
8371,European,4840.0,27623284.0,Verma SS,Neurological disorder,initial,2016-09-13,GCST003745,Glaucoma (primary open-angle)
9434,European,9106.0,27622933.0,Li QS,"Neurological disorder, Response to drug",initial,2016-09-13,GCST003803,Response to antidepressants in depression
8262,European,4536.0,27622933.0,Li QS,"Neurological disorder, Response to drug",initial,2016-09-13,GCST003800,Response to bupropion in depression
12012,European,194673.0,27622933.0,Li QS,"Neurological disorder, Response to drug",initial,2016-09-13,GCST003806,Response to bupropion and depression
13518,Other/Mixed,154.0,27623284.0,Verma SS,Neurological disorder,initial,2016-09-13,GCST003745,Glaucoma (primary open-angle)
12010,European,193931.0,27622933.0,Li QS,"Neurological disorder, Response to drug",initial,2016-09-13,GCST003804,Non-response to bupropion and depression
12011,European,194088.0,27622933.0,Li QS,"Neurological disorder, Response to drug",initial,2016-09-13,GCST003810,Non-response to citalopram or escitalopram and depression
12008,European,193489.0,27622933.0,Li QS,"Neurological disorder, Response to drug",initial,2016-09-13,GCST003812,Non-response to antidepressants and depression
2109,Asian,484.0,27623749.0,Hwang JY,"Body measurement, Other measurement",initial,2016-09-14,GCST003789,Body mass index
4051,Asian,10390.0,27623749.0,Hwang JY,"Body measurement, Other measurement",replication,2016-09-14,GCST003789,Body mass index
8349,European,4782.0,27629089.0,Sailer A,Neurological disorder,initial,2016-09-14,GCST003784,Multiple system atrophy
8143,European,4159.0,27629089.0,Sailer A,Neurological disorder,initial,2016-09-14,GCST003783,Multiple system atrophy (pathologically confirmed)
9342,European,8490.0,27629369.0,Gao J,Other measurement,initial,2016-09-15,GCST003772,Loneliness (linear analysis)
742,African American or Afro-Caribbean,825.0,27629369.0,Gao J,Other measurement,initial,2016-09-15,GCST003771,Loneliness
832,African American or Afro-Caribbean,1228.0,27629369.0,Gao J,Other measurement,initial,2016-09-15,GCST003773,Loneliness (multivariate analysis)
12762,Hispanic or Latin American,867.0,27629369.0,Gao J,Other measurement,initial,2016-09-15,GCST003773,Loneliness (multivariate analysis)
5679,European,740.0,27639821.0,Scherag A,"Other measurement, Other trait",initial,2016-09-15,GCST003817,Mortality in sepsis
12761,Hispanic or Latin American,867.0,27629369.0,Gao J,Other measurement,initial,2016-09-15,GCST003772,Loneliness (linear analysis)
9343,European,8490.0,27629369.0,Gao J,Other measurement,initial,2016-09-15,GCST003773,Loneliness (multivariate analysis)
831,African American or Afro-Caribbean,1228.0,27629369.0,Gao J,Other measurement,initial,2016-09-15,GCST003772,Loneliness (linear analysis)
8732,European,5950.0,27629369.0,Gao J,Other measurement,initial,2016-09-15,GCST003771,Loneliness
12696,Hispanic or Latin American,621.0,27629369.0,Gao J,Other measurement,initial,2016-09-15,GCST003771,Loneliness
7385,European,2585.0,27632927.0,Einarsdottir E,Neurological disorder,initial,2016-09-16,GCST003828,Otitis media (chronic)
7490,European,2775.0,27632927.0,Einarsdottir E,Neurological disorder,initial,2016-09-16,GCST003829,Otitis media (recurrent)
7541,European,2876.0,27632927.0,Einarsdottir E,Neurological disorder,initial,2016-09-16,GCST003827,Otitis media
7414,European,2632.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",initial,2016-09-19,GCST003861,Kidney disease (end stage renal disease vs normoalbuminuria) in type 1 diabetes
7380,European,2568.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",initial,2016-09-19,GCST003863,Chronic kidney disease (severe chronic kidney disease vs normal kidney function) in type 1 diabetes
7284,European,2458.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",initial,2016-09-19,GCST003865,Kidney disease (early stage) in type 1 diabetes
6180,European,1087.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",replication,2016-09-19,GCST003862,Kidney disease (end stage renal disease vs non-end stage renal disease) in type 1 diabetes
5647,European,721.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",replication,2016-09-19,GCST003861,Kidney disease (end stage renal disease vs normoalbuminuria) in type 1 diabetes
7850,European,3410.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",initial,2016-09-19,GCST003866,Kidney disease (late stage) in type 1 diabetes
5886,European,883.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",replication,2016-09-19,GCST003864,Kidney disease (early and late stages) in type 1 diabetes
8092,European,4019.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",initial,2016-09-19,GCST003862,Kidney disease (end stage renal disease vs non-end stage renal disease) in type 1 diabetes
8071,European,3971.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",initial,2016-09-19,GCST003864,Kidney disease (early and late stages) in type 1 diabetes
7932,European,3584.0,27647854.0,Sandholm N,"Other disease, Metabolic disorder",initial,2016-09-19,GCST003867,Chronic kidney disease (chronic kidney disease vs normal or mildly reduced eGFR) in type 1 diabetes
13220,Hispanic or Latin American,12226.0,27650483.0,Kramer HJ,Other measurement,initial,2016-09-20,GCST003774,Urinary albumin-to-creatinine ratio
2605,Asian,1394.0,27656708.0,Zhang W,Other measurement,initial,2016-09-22,GCST003793,L-arginine levels
5404,European,546.0,27656889.0,Alemany S,Other measurement,replication,2016-09-22,GCST003719,Attention function
6670,European,1655.0,27656889.0,Alemany S,Other measurement,initial,2016-09-22,GCST003719,Attention function
6076,European,1000.0,27656708.0,Zhang W,Other measurement,replication,2016-09-22,GCST003793,L-arginine levels
5907,European,901.0,27656708.0,Zhang W,Other measurement,initial,2016-09-22,GCST003793,L-arginine levels
5602,European,679.0,27671502.0,Blokland GAM,"Other measurement, Biological process",initial,2016-09-23,GCST003698,Brain activation in response to working memory task
2065,Asian,448.0,27664181.0,Kawamura R,Other measurement,initial,2016-09-23,GCST003759,Resistin levels
3389,Asian,4059.0,27664181.0,Kawamura R,Other measurement,replication,2016-09-23,GCST003759,Resistin levels
71,African,244.0,27671213.0,Petros Z,"Response to drug, Other disease, Digestive system disorder",replication,2016-09-26,GCST003792,Liver injury in anti-tuberculosis drug treatment
1058,African American or Afro-Caribbean,2955.0,27669027.0,Boueiz A,"Biological process, Other measurement",initial,2016-09-26,GCST003761,Emphysema distribution in smoking
5798,European,824.0,27669027.0,Boueiz A,"Biological process, Other measurement",initial,2016-09-26,GCST003761,Emphysema distribution in smoking
8786,European,6215.0,27669027.0,Boueiz A,"Biological process, Other measurement",initial,2016-09-26,GCST003761,Emphysema distribution in smoking
1623,Asian,70.0,27669169.0,Chang IS,"Response to drug, Other measurement, Cancer",replication,2016-09-26,GCST003794,Progression free survival in EGFR-mutation-positive never-smoking lung adenocarcinoma treated with gefitinib or erlotinib
1606,Asian,57.0,27665939.0,Liang KH,"Biological process, Digestive system disorder",initial,2016-09-26,GCST003718,Hepatitis B (viral clearance)
1718,Asian,128.0,27669169.0,Chang IS,"Response to drug, Other measurement, Cancer",initial,2016-09-26,GCST003794,Progression free survival in EGFR-mutation-positive never-smoking lung adenocarcinoma treated with gefitinib or erlotinib
97,African,402.0,27671213.0,Petros Z,"Response to drug, Other disease, Digestive system disorder",initial,2016-09-26,GCST003792,Liver injury in anti-tuberculosis drug treatment
1924,Asian,302.0,27665939.0,Liang KH,"Biological process, Digestive system disorder",replication,2016-09-26,GCST003718,Hepatitis B (viral clearance)
11218,European,58862.0,27659466.0,van der Harst P,Cardiovascular measurement,initial,2016-09-27,GCST003871,QRS complex (Cornell)
11231,European,60255.0,27659466.0,van der Harst P,Cardiovascular measurement,initial,2016-09-27,GCST003844,QRS duration
11090,European,48632.0,27659466.0,van der Harst P,Cardiovascular measurement,initial,2016-09-27,GCST003872,QRS complex (12-leadsum)
470,African American or Afro-Caribbean,117.0,27670767.0,Chang SW,"Response to drug, Cardiovascular disease, Metabolic disorder",replication,2016-09-27,GCST003797,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction)
1139,African American or Afro-Caribbean,3603.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003870,QRS complex (Sokolow-Lyon)
3463,Asian,4619.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003844,QRS duration
3464,Asian,4619.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003870,QRS complex (Sokolow-Lyon)
1140,African American or Afro-Caribbean,3603.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003871,QRS complex (Cornell)
9890,European,13263.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003871,QRS complex (Cornell)
9889,European,13263.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003870,QRS complex (Sokolow-Lyon)
9891,European,13263.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003872,QRS complex (12-leadsum)
1141,African American or Afro-Caribbean,3603.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003872,QRS complex (12-leadsum)
5133,European,410.0,27670397.0,Reyes-Gibby CC,"Other trait, Cancer",replication,2016-09-27,GCST003760,Pre-treatment pain in head and neck squamous cell carcinoma
9888,European,13263.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003844,QRS duration
3466,Asian,4619.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003872,QRS complex (12-leadsum)
3465,Asian,4619.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003871,QRS complex (Cornell)
1138,African American or Afro-Caribbean,3603.0,27659466.0,van der Harst P,Cardiovascular measurement,replication,2016-09-27,GCST003844,QRS duration
12654,Hispanic or Latin American,471.0,27670767.0,Chang SW,"Response to drug, Cardiovascular disease, Metabolic disorder",replication,2016-09-27,GCST003797,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction)
5419,European,552.0,27670767.0,Chang SW,"Response to drug, Cardiovascular disease, Metabolic disorder",initial,2016-09-27,GCST003797,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction)
11177,European,54993.0,27659466.0,van der Harst P,Cardiovascular measurement,initial,2016-09-27,GCST003870,QRS complex (Sokolow-Lyon)
6002,European,958.0,27670397.0,Reyes-Gibby CC,"Other trait, Cancer",initial,2016-09-27,GCST003760,Pre-treatment pain in head and neck squamous cell carcinoma
6822,European,1846.0,27769005.0,Nassan M,Neurological disorder,replication,2016-09-30,GCST003742,Bipolar disorder (early onset)
7254,European,2411.0,27769005.0,Nassan M,Neurological disorder,initial,2016-09-30,GCST003742,Bipolar disorder (early onset)
1474,African American or Afro-Caribbean,21503.0,27618448.0,Liu C,Other measurement,initial,2016-10-01,GCST006227,Diastolic blood pressure
13003,Hispanic or Latin American,4586.0,27618448.0,Liu C,Cardiovascular disease,initial,2016-10-01,GCST006229,Hypertension
1476,African American or Afro-Caribbean,21503.0,27618448.0,Liu C,Other measurement,initial,2016-10-01,GCST006231,Mean arterial pressure
11895,European,157090.0,27618447.0,Surendran P,Cardiovascular disease,initial,2016-10-01,GCST006023,Hypertension
11885,European,154543.0,27618448.0,Liu C,Other measurement,replication,2016-10-01,GCST006228,Systolic blood pressure
11884,European,154543.0,27618448.0,Liu C,Other measurement,replication,2016-10-01,GCST006227,Diastolic blood pressure
1482,African American or Afro-Caribbean,22077.0,27618447.0,Surendran P,Cardiovascular disease,replication,2016-10-01,GCST006023,Hypertension
1483,African American or Afro-Caribbean,22077.0,27618447.0,Surendran P,Cardiovascular measurement,replication,2016-10-01,GCST006022,Pulse pressure
1484,African American or Afro-Caribbean,22077.0,27618447.0,Surendran P,Other measurement,replication,2016-10-01,GCST006020,Diastolic blood pressure
1485,African American or Afro-Caribbean,22077.0,27618447.0,Surendran P,Other measurement,replication,2016-10-01,GCST006021,Systolic blood pressure
11883,European,154543.0,27618448.0,Liu C,Cardiovascular measurement,replication,2016-10-01,GCST006230,Pulse pressure
11882,European,154543.0,27618448.0,Liu C,Cardiovascular disease,replication,2016-10-01,GCST006229,Hypertension
1473,African American or Afro-Caribbean,21503.0,27618448.0,Liu C,Cardiovascular measurement,initial,2016-10-01,GCST006230,Pulse pressure
13010,Hispanic or Latin American,4632.0,27618447.0,Surendran P,Other measurement,replication,2016-10-01,GCST006020,Diastolic blood pressure
4329,Asian,26183.0,27618447.0,Surendran P,Cardiovascular disease,initial,2016-10-01,GCST006023,Hypertension
13009,Hispanic or Latin American,4632.0,27618447.0,Surendran P,Cardiovascular measurement,replication,2016-10-01,GCST006022,Pulse pressure
13008,Hispanic or Latin American,4632.0,27618447.0,Surendran P,Cardiovascular disease,replication,2016-10-01,GCST006023,Hypertension
4330,Asian,26183.0,27618448.0,Liu C,Cardiovascular disease,replication,2016-10-01,GCST006229,Hypertension
13007,Hispanic or Latin American,4586.0,27618448.0,Liu C,Other measurement,initial,2016-10-01,GCST006231,Mean arterial pressure
13006,Hispanic or Latin American,4586.0,27618448.0,Liu C,Other measurement,initial,2016-10-01,GCST006228,Systolic blood pressure
4331,Asian,26183.0,27618448.0,Liu C,Cardiovascular measurement,replication,2016-10-01,GCST006230,Pulse pressure
4332,Asian,26183.0,27618448.0,Liu C,Other measurement,replication,2016-10-01,GCST006227,Diastolic blood pressure
4333,Asian,26183.0,27618448.0,Liu C,Other measurement,replication,2016-10-01,GCST006228,Systolic blood pressure
4340,Asian,27487.0,27618447.0,Surendran P,Cardiovascular measurement,initial,2016-10-01,GCST006022,Pulse pressure
4341,Asian,27487.0,27618447.0,Surendran P,Other measurement,initial,2016-10-01,GCST006020,Diastolic blood pressure
4342,Asian,27487.0,27618447.0,Surendran P,Other measurement,initial,2016-10-01,GCST006021,Systolic blood pressure
13005,Hispanic or Latin American,4586.0,27618448.0,Liu C,Other measurement,initial,2016-10-01,GCST006227,Diastolic blood pressure
13004,Hispanic or Latin American,4586.0,27618448.0,Liu C,Cardiovascular measurement,initial,2016-10-01,GCST006230,Pulse pressure
13011,Hispanic or Latin American,4632.0,27618447.0,Surendran P,Other measurement,replication,2016-10-01,GCST006021,Systolic blood pressure
1472,African American or Afro-Caribbean,21503.0,27618448.0,Liu C,Cardiovascular disease,initial,2016-10-01,GCST006229,Hypertension
1475,African American or Afro-Caribbean,21503.0,27618448.0,Liu C,Other measurement,initial,2016-10-01,GCST006228,Systolic blood pressure
11731,European,125713.0,27618447.0,Surendran P,Other measurement,replication,2016-10-01,GCST006020,Diastolic blood pressure
11700,European,120473.0,27618448.0,Liu C,Cardiovascular measurement,initial,2016-10-01,GCST006230,Pulse pressure
11699,European,120473.0,27618448.0,Liu C,Cardiovascular disease,initial,2016-10-01,GCST006229,Hypertension
3148,Asian,2641.0,27618447.0,Surendran P,Other measurement,replication,2016-10-01,GCST006021,Systolic blood pressure
11729,European,125713.0,27618447.0,Surendran P,Cardiovascular disease,replication,2016-10-01,GCST006023,Hypertension
11927,European,165276.0,27618447.0,Surendran P,Other measurement,initial,2016-10-01,GCST006020,Diastolic blood pressure
11928,European,165276.0,27618447.0,Surendran P,Other measurement,initial,2016-10-01,GCST006021,Systolic blood pressure
3147,Asian,2641.0,27618447.0,Surendran P,Other measurement,replication,2016-10-01,GCST006020,Diastolic blood pressure
7403,European,2618.0,27696742.0,Yau MS,Other disease,replication,2016-10-01,GCST003820,Knee osteoarthritis
11703,European,120473.0,27618448.0,Liu C,Other measurement,initial,2016-10-01,GCST006231,Mean arterial pressure
8235,European,4448.0,27696742.0,Yau MS,Other disease,initial,2016-10-01,GCST003820,Knee osteoarthritis
11730,European,125713.0,27618447.0,Surendran P,Cardiovascular measurement,replication,2016-10-01,GCST006022,Pulse pressure
11732,European,125713.0,27618447.0,Surendran P,Other measurement,replication,2016-10-01,GCST006021,Systolic blood pressure
3146,Asian,2641.0,27618447.0,Surendran P,Cardiovascular measurement,replication,2016-10-01,GCST006022,Pulse pressure
3145,Asian,2641.0,27618447.0,Surendran P,Cardiovascular disease,replication,2016-10-01,GCST006023,Hypertension
11926,European,165276.0,27618447.0,Surendran P,Cardiovascular measurement,initial,2016-10-01,GCST006022,Pulse pressure
11701,European,120473.0,27618448.0,Liu C,Other measurement,initial,2016-10-01,GCST006227,Diastolic blood pressure
11702,European,120473.0,27618448.0,Liu C,Other measurement,initial,2016-10-01,GCST006228,Systolic blood pressure
8578,European,5323.0,27702941.0,Cornelis MC,Other measurement,initial,2016-10-03,GCST003851,"Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio)"
5799,European,824.0,27702941.0,Cornelis MC,Other measurement,replication,2016-10-03,GCST003849,"Caffeine metabolism (plasma 3,7-dimethylxanthine (theobromine) level)"
7546,European,2891.0,27694927.0,Vijayakrishnan J,Cancer,replication,2016-10-03,GCST003798,Acute lymphoblastic leukemia in childhood (B cell precursor)
5388,European,530.0,27694959.0,Bonder MJ,Other measurement,replication,2016-10-03,GCST003854,Gut microbiota (functional units)
9408,European,8911.0,27702941.0,Cornelis MC,Other measurement,initial,2016-10-03,GCST003849,"Caffeine metabolism (plasma 3,7-dimethylxanthine (theobromine) level)"
9428,European,9054.0,27702941.0,Cornelis MC,Other measurement,initial,2016-10-03,GCST003846,"Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level)"
5789,European,822.0,27702941.0,Cornelis MC,Other measurement,replication,2016-10-03,GCST003846,"Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level)"
8548,European,5261.0,27702941.0,Cornelis MC,Other measurement,initial,2016-10-03,GCST003848,"Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level)"
9407,European,8882.0,27694927.0,Vijayakrishnan J,Cancer,initial,2016-10-03,GCST003798,Acute lymphoblastic leukemia in childhood (B cell precursor)
5800,European,824.0,27702941.0,Cornelis MC,Other measurement,replication,2016-10-03,GCST003851,"Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio)"
5140,European,414.0,27702942.0,Tang CS,Digestive system disorder,initial,2016-10-03,GCST003764,Hirschsprung disease
12847,Hispanic or Latin American,1605.0,27694991.0,Adams HH,Other measurement,replication,2016-10-03,GCST003834,Intracranial volume
5804,European,826.0,27702941.0,Cornelis MC,Other measurement,replication,2016-10-03,GCST003848,"Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level)"
2568,Asian,1294.0,27702942.0,Tang CS,Digestive system disorder,initial,2016-10-03,GCST003764,Hirschsprung disease
5812,European,833.0,27702941.0,Cornelis MC,Other measurement,replication,2016-10-03,GCST003847,"Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) level)"
5389,European,530.0,27694959.0,Bonder MJ,Other measurement,replication,2016-10-03,GCST003855,Gut microbiota (bacterial taxa)
10608,European,26577.0,27694991.0,Adams HH,Other measurement,initial,2016-10-03,GCST003834,Intracranial volume
2418,Asian,955.0,27694991.0,Adams HH,Other measurement,replication,2016-10-03,GCST003834,Intracranial volume
6045,European,984.0,27694959.0,Bonder MJ,Other measurement,initial,2016-10-03,GCST003854,Gut microbiota (functional units)
7224,European,2362.0,27694991.0,Adams HH,Other measurement,replication,2016-10-03,GCST003834,Intracranial volume
766,African American or Afro-Caribbean,938.0,27694991.0,Adams HH,Other measurement,replication,2016-10-03,GCST003834,Intracranial volume
6046,European,984.0,27694959.0,Bonder MJ,Other measurement,initial,2016-10-03,GCST003855,Gut microbiota (bacterial taxa)
8585,European,5353.0,27702941.0,Cornelis MC,Other measurement,initial,2016-10-03,GCST003847,"Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) level)"
7922,European,3562.0,27702941.0,Cornelis MC,Other measurement,initial,2016-10-03,GCST003850,"Caffeine metabolism (plasma 1,3,7-trimethyluric acid level)"
12508,Hispanic or Latin American,18.0,27704462.0,Moura Rodrigues R,"Other disease, Response to drug",initial,2016-10-04,GCST003852,Response to dendritic cell-based immunotherapy in HIV infection
6598,European,1572.0,27701424.0,Castano-Betancourt MC,Other measurement,replication,2016-10-04,GCST003853,Hip minimal joint space width
4559,European,15.0,27704462.0,Moura Rodrigues R,"Other disease, Response to drug",initial,2016-10-04,GCST003852,Response to dendritic cell-based immunotherapy in HIV infection
8847,European,6523.0,27701424.0,Castano-Betancourt MC,Other measurement,initial,2016-10-04,GCST003853,Hip minimal joint space width
488,African American or Afro-Caribbean,140.0,27758888.0,Ingle JN,"Cancer, Response to drug, Other measurement",initial,2016-10-10,GCST003816,Breast cancer-free interval (treatment with aromatase inhibitor)
5068,European,371.0,27723756.0,Wang J,Other measurement,replication,2016-10-10,GCST003876,Gut microbiota (beta diversity)
1610,Asian,59.0,27758888.0,Ingle JN,"Cancer, Response to drug, Other measurement",initial,2016-10-10,GCST003816,Breast cancer-free interval (treatment with aromatase inhibitor)
1751,Asian,160.0,27723809.0,Matsunami K,"Response to drug, Digestive system disorder, Other measurement",replication,2016-10-10,GCST003824,Depression in response to interferon-based therapy in chronic hepatitis C
6799,European,1812.0,27723756.0,Wang J,Other measurement,initial,2016-10-10,GCST003875,Gut microbiota (bacterial taxa)
4769,European,176.0,28364478.0,Sulkava S,Other measurement,initial,2016-10-10,GCST003868,Job-related exhaustion in shift workers
5446,European,577.0,28364478.0,Sulkava S,Other measurement,replication,2016-10-10,GCST003868,Job-related exhaustion in shift workers
8842,European,6487.0,27723758.0,Bronson PG,Immune system disorder,initial,2016-10-10,GCST003814,Selective IgA deficiency
1837,Asian,224.0,27723809.0,Matsunami K,"Response to drug, Digestive system disorder, Other measurement",initial,2016-10-10,GCST003824,Depression in response to interferon-based therapy in chronic hepatitis C
10161,European,16823.0,27723779.0,Gong J,"Cancer, Other measurement",initial,2016-10-10,GCST003873,Colorectal cancer (alcohol consumption interaction)
10477,European,22601.0,27723779.0,Gong J,"Other measurement, Cancer",initial,2016-10-10,GCST003874,Colorectal cancer (smoking interaction)
6800,European,1812.0,27723756.0,Wang J,Other measurement,initial,2016-10-10,GCST003876,Gut microbiota (beta diversity)
8238,European,4459.0,27758888.0,Ingle JN,"Cancer, Response to drug, Other measurement",initial,2016-10-10,GCST003816,Breast cancer-free interval (treatment with aromatase inhibitor)
10110,European,16288.0,27680694.0,Horikoshi M,Body measurement,replication,2016-10-13,GCST005146,Birth weight
2622,Asian,1449.0,27680694.0,Horikoshi M,Body measurement,replication,2016-10-13,GCST005146,Birth weight
10111,European,16288.0,27680694.0,Horikoshi M,Body measurement,replication,2016-10-13,GCST007557,Birth weight
13648,Other/Mixed,395.0,27680694.0,Horikoshi M,Body measurement,initial,2016-10-13,GCST005146,Birth weight
13315,Hispanic or Latin American,19706.0,27736895.0,Franceschini N,Other measurement,initial,2016-10-13,GCST007238,Diastolic blood pressure
1271,African American or Afro-Caribbean,6635.0,27680694.0,Horikoshi M,Body measurement,initial,2016-10-13,GCST005146,Birth weight
13660,Other/Mixed,420.0,27680694.0,Horikoshi M,Body measurement,initial,2016-10-13,GCST005146,Birth weight
1444,African American or Afro-Caribbean,18744.0,27736895.0,Franceschini N,Other measurement,initial,2016-10-13,GCST007238,Diastolic blood pressure
2354,Asian,840.0,27680694.0,Horikoshi M,Body measurement,initial,2016-10-13,GCST005146,Birth weight
13314,Hispanic or Latin American,19706.0,27736895.0,Franceschini N,Other measurement,initial,2016-10-13,GCST007237,Systolic blood pressure
11774,European,133903.0,27680694.0,Horikoshi M,Body measurement,initial,2016-10-13,GCST005146,Birth weight
11775,European,133903.0,27680694.0,Horikoshi M,Body measurement,initial,2016-10-13,GCST007557,Birth weight
13640,Other/Mixed,365.0,27680694.0,Horikoshi M,Body measurement,initial,2016-10-13,GCST005146,Birth weight
1443,African American or Afro-Caribbean,18744.0,27736895.0,Franceschini N,Other measurement,initial,2016-10-13,GCST007237,Systolic blood pressure
9381,European,8727.0,27764800.0,Cox DG,"Cancer, Other measurement",initial,2016-10-14,GCST003821,Estrogen receptor status in breast cancer
3232,Asian,2961.0,27964859.0,Zhang M,Other trait,initial,2016-10-14,GCST003843,Petaloid toenail
13763,Other/Mixed,721.0,27964859.0,Zhang M,Other trait,initial,2016-10-14,GCST003843,Petaloid toenail
8611,European,5452.0,27764800.0,Cox DG,"Cancer, Other measurement",initial,2016-10-14,GCST003823,Estrogen receptor status in HER2 negative breast cancer
7754,European,3275.0,27764800.0,Cox DG,"Cancer, Other measurement",initial,2016-10-14,GCST003822,Estrogen receptor status in HER2 positive breast cancer
9378,European,8701.0,27749845.0,Lesseur C,Cancer,initial,2016-10-17,GCST003858,Oral cavity cancer
9344,European,8490.0,27749845.0,Lesseur C,Cancer,initial,2016-10-17,GCST003859,Oropharynx cancer
12705,Hispanic or Latin American,683.0,27980656.0,Justice AE,Other measurement,initial,2016-10-18,GCST003825,Systolic blood pressure change trajectories
10552,European,24442.0,27890468.0,van Hulzen KJE,Neurological disorder,initial,2016-10-18,GCST004002,Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder
10657,European,28925.0,27890468.0,van Hulzen KJE,Neurological disorder,initial,2016-10-18,GCST004001,Bipolar disorder or attention deficit hyperactivity disorder
13062,Hispanic or Latin American,5696.0,27764096.0,Hoffmann TJ,Neurological disorder,replication,2016-10-20,GCST003763,Age-related hearing impairment
1232,African American or Afro-Caribbean,5609.0,27770636.0,Mez J,Neurological disorder,initial,2016-10-20,GCST003815,Late-onset Alzheimer's disease
3578,Asian,5438.0,27764096.0,Hoffmann TJ,Neurological disorder,replication,2016-10-20,GCST003763,Age-related hearing impairment
10304,European,19265.0,27764105.0,Lemmela S,Other trait,replication,2016-10-20,GCST003869,Sciatica
8063,European,3962.0,27764105.0,Lemmela S,Other trait,initial,2016-10-20,GCST003869,Sciatica
989,African American or Afro-Caribbean,2279.0,27764096.0,Hoffmann TJ,Neurological disorder,replication,2016-10-20,GCST003763,Age-related hearing impairment
11133,European,52409.0,27764096.0,Hoffmann TJ,Neurological disorder,initial,2016-10-20,GCST003763,Age-related hearing impairment
7011,European,2094.0,27797806.0,Muller SH,Other trait,replication,2016-10-20,GCST003762,Essential tremor
9009,European,7154.0,27797806.0,Muller SH,Other trait,initial,2016-10-20,GCST003762,Essential tremor
6302,European,1212.0,27770449.0,Tamm R,Other measurement,initial,2016-10-22,GCST003841,Thiopurine S-methyltransferase activity
12618,Hispanic or Latin American,399.0,27777418.0,Wong ML,Neurological disorder,initial,2016-10-25,GCST005547,Major depressive disorder
732,African American or Afro-Caribbean,811.0,26503814.0,Hardin M,"Other disease, Response to drug, Other measurement",initial,2016-10-27,GCST003830,Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)
8681,European,5766.0,26503814.0,Hardin M,"Other disease, Response to drug, Other measurement",initial,2016-10-27,GCST003830,Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)
6747,European,1739.0,27802415.0,Salvi E,"Other measurement, Response to drug, Cardiovascular disease",initial,2016-10-31,GCST003805,Diastolic blood pressure response to hydrochlorothiazide in hypertension
225,African,1734.0,27798624.0,Eppinga RN,Cardiovascular measurement,initial,2016-10-31,GCST003818,Resting heart rate
634,African American or Afro-Caribbean,430.0,27802415.0,Salvi E,"Other measurement, Response to drug, Cardiovascular disease",replication,2016-10-31,GCST003805,Diastolic blood pressure response to hydrochlorothiazide in hypertension
635,African American or Afro-Caribbean,430.0,27802415.0,Salvi E,"Other measurement, Response to drug, Cardiovascular disease",replication,2016-10-31,GCST003807,Systolic blood pressure response to hydrochlorothiazide in hypertension
6748,European,1739.0,27802415.0,Salvi E,"Other measurement, Response to drug, Cardiovascular disease",initial,2016-10-31,GCST003807,Systolic blood pressure response to hydrochlorothiazide in hypertension
12241,European,329139.0,27798627.0,Barban N,Other measurement,initial,2016-10-31,GCST003796,Number of children ever born
13731,Other/Mixed,684.0,27798624.0,Eppinga RN,Cardiovascular measurement,initial,2016-10-31,GCST003818,Resting heart rate
11746,European,127919.0,27798624.0,Eppinga RN,Cardiovascular measurement,initial,2016-10-31,GCST003818,Resting heart rate
12092,European,238064.0,27798627.0,Barban N,Other measurement,initial,2016-10-31,GCST003795,Age at first birth
11083,European,48408.0,27798627.0,Barban N,Other measurement,initial,2016-10-31,GCST006044,Age at first birth
3102,Asian,2478.0,27798624.0,Eppinga RN,Cardiovascular measurement,initial,2016-10-31,GCST003818,Resting heart rate
11589,European,103909.0,27798627.0,Barban N,Other measurement,initial,2016-10-31,GCST006046,Number of children ever born
11751,European,130795.0,27798624.0,Eppinga RN,Cardiovascular measurement,replication,2016-10-31,GCST003818,Resting heart rate
12001,European,189656.0,27798627.0,Barban N,Other measurement,initial,2016-10-31,GCST006045,Age at first birth
12085,European,225230.0,27798627.0,Barban N,Other measurement,initial,2016-10-31,GCST006047,Number of children ever born
11587,European,102505.0,27668658.0,Iotchkova V,"Hematological measurement, Cardiovascular measurement, Lipid or lipoprotein measurement, Other measurement",replication,2016-11-01,GCST006101,Cardiometabolic and hematological traits
9801,European,11891.0,27454463.0,Jones AV,Other measurement,initial,2016-11-01,GCST003927,Dysmenorrheic pain
10966,European,40258.0,27723757.0,Jin Y,Immune system disorder,initial,2016-11-01,GCST004785,Vitiligo
3213,Asian,2899.0,27487801.0,Wu S,"Other measurement, Other trait",initial,2016-11-01,GCST006468,Straight vs curly hair
8089,European,4008.0,27723757.0,Jin Y,Immune system disorder,replication,2016-11-01,GCST004785,Vitiligo
10862,European,35981.0,27668658.0,Iotchkova V,"Hematological measurement, Cardiovascular measurement, Lipid or lipoprotein measurement, Other measurement",initial,2016-11-01,GCST006101,Cardiometabolic and hematological traits
13759,Other/Mixed,709.0,27487801.0,Wu S,"Other measurement, Other trait",replication,2016-11-01,GCST006468,Straight vs curly hair
11570,European,96900.0,27818178.0,Hill WD,Other trait,initial,2016-11-03,GCST007155,Household income
9516,European,9618.0,27790247.0,He L,"Hematological measurement, Body measurement, Other measurement, Cardiovascular disease, Cancer, Lipid or lipoprotein measurement, Cardiovascular measurement, Metabolic disorder",initial,2016-11-03,GCST004045,"Age-related diseases, mortality and associated endophenotypes"
9515,European,9618.0,27790247.0,He L,"Hematological measurement, Body measurement, Lipid or lipoprotein measurement, Other measurement, Cardiovascular measurement",initial,2016-11-03,GCST004046,Age-related disease endophenotypes
9517,European,9618.0,27790247.0,He L,"Other measurement, Cardiovascular disease, Cancer, Metabolic disorder",initial,2016-11-03,GCST004044,Age-related diseases and mortality
10335,European,19796.0,27790247.0,He L,"Hematological measurement, Body measurement, Other measurement, Cardiovascular disease, Cancer, Lipid or lipoprotein measurement, Cardiovascular measurement, Metabolic disorder",replication,2016-11-03,GCST004045,"Age-related diseases, mortality and associated endophenotypes"
10336,European,19796.0,27790247.0,He L,"Other measurement, Cardiovascular disease, Cancer, Metabolic disorder",replication,2016-11-03,GCST004044,Age-related diseases and mortality
11638,European,112005.0,27818178.0,Hill WD,Other trait,initial,2016-11-03,GCST007156,Social deprivation
10334,European,19796.0,27790247.0,He L,"Hematological measurement, Body measurement, Lipid or lipoprotein measurement, Other measurement, Cardiovascular measurement",replication,2016-11-03,GCST004046,Age-related disease endophenotypes
8470,European,5034.0,27816938.0,Tanaka T,Other measurement,initial,2016-11-05,GCST003882,Parental longevity (at least one long-lived parent)
696,African American or Afro-Caribbean,682.0,27816938.0,Tanaka T,Other measurement,initial,2016-11-05,GCST003882,Parental longevity (at least one long-lived parent)
11676,European,117109.0,27824142.0,Lin H,Cardiovascular disease,replication,2016-11-08,GCST004018,Atrial fibrillation (SNPxSNP interaction)
11354,European,73410.0,27824142.0,Lin H,Cardiovascular disease,initial,2016-11-08,GCST004018,Atrial fibrillation (SNPxSNP interaction)
6454,European,1390.0,27846195.0,Li Q,"Neurological disorder, Other measurement, Response to drug",initial,2016-11-11,GCST004043,Response to paliperidone in schizophrenia (Multivariate)
6452,European,1390.0,27846195.0,Li Q,"Neurological disorder, Other measurement, Response to drug",initial,2016-11-11,GCST004041,Response to paliperidone in schizophrenia (negative Marder score)
6114,European,1016.0,27839851.0,Lind L,Other measurement,initial,2016-11-11,GCST003923,"DDT metabolite (p,p'-DDE levels)"
6453,European,1390.0,27846195.0,Li Q,"Neurological disorder, Other measurement, Response to drug",initial,2016-11-11,GCST004042,Response to paliperidone in schizophrenia (PANSS score)
6450,European,1390.0,27846195.0,Li Q,"Neurological disorder, Other measurement, Response to drug",initial,2016-11-11,GCST004039,Response to paliperidone in schizophrenia (CGI-S score)
6451,European,1390.0,27846195.0,Li Q,"Neurological disorder, Other measurement, Response to drug",initial,2016-11-11,GCST004040,Response to paliperidone in schizophrenia (positive Marder score)
12178,European,295529.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007096,Pulse pressure
12180,European,295529.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007099,Systolic blood pressure
3162,Asian,2735.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007096,Pulse pressure
13144,Hispanic or Latin American,8231.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007096,Pulse pressure
13145,Hispanic or Latin American,8231.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007097,Pulse pressure
13146,Hispanic or Latin American,8231.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007094,Diastolic blood pressure
3163,Asian,2735.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007094,Diastolic blood pressure
12179,European,295529.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007094,Diastolic blood pressure
3164,Asian,2735.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007099,Systolic blood pressure
13147,Hispanic or Latin American,8231.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007095,Systolic blood pressure
13149,Hispanic or Latin American,8231.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007099,Systolic blood pressure
13148,Hispanic or Latin American,8231.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007098,Diastolic blood pressure
1075,African American or Afro-Caribbean,3058.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007097,Pulse pressure
3787,Asian,7243.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007097,Pulse pressure
3788,Asian,7243.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007095,Systolic blood pressure
3789,Asian,7243.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007098,Diastolic blood pressure
3840,Asian,7701.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007096,Pulse pressure
3841,Asian,7701.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007094,Diastolic blood pressure
3842,Asian,7701.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007099,Systolic blood pressure
2076,Asian,461.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007097,Pulse pressure
2077,Asian,461.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007095,Systolic blood pressure
2078,Asian,461.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007098,Diastolic blood pressure
230,African,2029.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007094,Diastolic blood pressure
11426,European,80792.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007098,Diastolic blood pressure
1074,African American or Afro-Caribbean,3058.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007096,Pulse pressure
1076,African American or Afro-Caribbean,3058.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007094,Diastolic blood pressure
1077,African American or Afro-Caribbean,3058.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007095,Systolic blood pressure
229,African,2029.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007096,Pulse pressure
1079,African American or Afro-Caribbean,3058.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007099,Systolic blood pressure
11425,European,80792.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007095,Systolic blood pressure
11424,European,80792.0,27841878.0,Hoffmann TJ,Cardiovascular measurement,initial,2016-11-14,GCST007097,Pulse pressure
1078,African American or Afro-Caribbean,3058.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007098,Diastolic blood pressure
231,African,2029.0,27841878.0,Hoffmann TJ,Other measurement,initial,2016-11-14,GCST007099,Systolic blood pressure
7771,European,3299.0,27846281.0,Galesloot TE,Other measurement,initial,2016-11-15,GCST003945,Hepcidin/transferrin saturation ratio
7769,European,3299.0,27846281.0,Galesloot TE,Other measurement,initial,2016-11-15,GCST003943,Hepcidin levels
7770,European,3299.0,27846281.0,Galesloot TE,Other measurement,initial,2016-11-15,GCST003944,Hepcidin/ferritin ratio
12961,Hispanic or Latin American,3584.0,28171582.0,Gao X,Other measurement,initial,2016-11-15,GCST003856,Central corneal thickness
6116,European,1018.0,27846281.0,Galesloot TE,Other measurement,replication,2016-11-15,GCST003943,Hepcidin levels
12777,Hispanic or Latin American,931.0,28171582.0,Gao X,Other measurement,replication,2016-11-15,GCST003856,Central corneal thickness
11968,European,172433.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004602,Mean corpuscular volume
11972,European,172952.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004601,Red blood cell count
11971,European,172925.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004615,Hemoglobin concentration
11951,European,170690.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004619,Reticulocyte fraction of red cells
11970,European,172851.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004605,Mean corpuscular hemoglobin concentration
11969,European,172435.0,27863252.0,Astle WJ,"Hematological measurement, Inflammatory measurement",initial,2016-11-17,GCST004610,White blood cell count
11952,European,170702.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004629,Neutrophil count
11963,European,171846.0,27863252.0,Astle WJ,Inflammatory measurement,initial,2016-11-17,GCST004618,White blood cell count (basophil)
11958,European,171529.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004621,Red cell distribution width
11953,European,170721.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004625,Monocyte count
11962,European,171771.0,27863252.0,Astle WJ,"Inflammatory measurement, Hematological measurement",initial,2016-11-17,GCST004624,Sum eosinophil basophil counts
11973,European,173039.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004604,Hematocrit
11966,European,172332.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004630,Mean corpuscular hemoglobin
11955,European,170763.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004612,High light scatter reticulocyte percentage of red cells
11960,European,171643.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004627,Lymphocyte counts
11961,European,171748.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004632,Lymphocyte percentage of white cells
11967,European,172378.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004600,Eosinophil percentage of white cells
11954,European,170761.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004611,High light scatter reticulocyte count
11959,European,171542.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004633,Neutrophil percentage of white cells
11964,European,171996.0,27863252.0,Astle WJ,Inflammatory measurement,initial,2016-11-17,GCST004631,Basophil percentage of white cells
11950,European,170672.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004623,Neutrophil percentage of granulocytes
11929,European,166066.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004603,Platelet count
11945,European,170384.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004613,Sum neutrophil eosinophil counts
11915,European,164454.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004599,Mean platelet volume
11914,European,164433.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004616,Platelet distribution width
11942,European,169822.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004614,Granulocyte count
11965,European,172275.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004606,Eosinophil counts
11946,European,170494.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004609,Monocyte percentage of white cells
11943,European,170143.0,27863252.0,Astle WJ,"Inflammatory measurement, Hematological measurement",initial,2016-11-17,GCST004620,Sum basophil neutrophil counts
11913,European,164339.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004607,Plateletcrit
11940,European,169219.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004626,Myeloid white cell count
11944,European,170223.0,27863252.0,Astle WJ,Inflammatory measurement,initial,2016-11-17,GCST004634,Basophil percentage of granulocytes
11941,European,169545.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004608,Granulocyte percentage of myeloid white cells
11949,European,170641.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004622,Reticulocyte count
11947,European,170536.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004617,Eosinophil percentage of granulocytes
11948,European,170548.0,27863252.0,Astle WJ,Hematological measurement,initial,2016-11-17,GCST004628,Immature fraction of reticulocytes
1726,Asian,133.0,28031287.0,Sasayama D,Other measurement,initial,2016-11-26,GCST004000,Cerebrospinal fluid biomarker levels
10855,European,35438.0,27911795.0,Schumann G,"Biological process, Other measurement",replication,2016-11-28,GCST004026,Alcohol consumption
11364,European,74711.0,27911795.0,Schumann G,Other measurement,initial,2016-11-28,GCST004027,Alcohol consumption (heavy vs. light/non-drinkers)
10716,European,31021.0,27911795.0,Schumann G,Other measurement,replication,2016-11-28,GCST004027,Alcohol consumption (heavy vs. light/non-drinkers)
11335,European,70460.0,27911795.0,Schumann G,"Biological process, Other measurement",initial,2016-11-28,GCST004026,Alcohol consumption
6813,European,1833.0,27899376.0,Nakayama A,Metabolic disorder,replication,2016-11-29,GCST003925,Gout
8505,European,5127.0,27899403.0,Jones GT,Cardiovascular disease,replication,2016-11-29,GCST003877,Abdominal aortic aneurysm
11593,European,104830.0,27899403.0,Jones GT,Cardiovascular disease,initial,2016-11-29,GCST003877,Abdominal aortic aneurysm
2834,Asian,1832.0,27899376.0,Nakayama A,Metabolic disorder,initial,2016-11-29,GCST003926,Renal underexcretion gout
2795,Asian,1773.0,27899376.0,Nakayama A,Metabolic disorder,initial,2016-11-29,GCST003924,Renal overload gout
10327,European,19596.0,27898682.0,Lotta LA,Other measurement,initial,2016-11-29,GCST006077,Branched-chain amino acid levels (Isoleucine)
2997,Asian,2158.0,27899376.0,Nakayama A,Metabolic disorder,initial,2016-11-29,GCST003925,Gout
10326,European,19596.0,27898682.0,Lotta LA,Other measurement,initial,2016-11-29,GCST006076,Branched-chain amino acid levels (Leucine)
2906,Asian,1964.0,27899376.0,Nakayama A,Metabolic disorder,replication,2016-11-29,GCST003926,Renal underexcretion gout
13874,Other/Mixed,1536.0,27899376.0,Nakayama A,Metabolic disorder,replication,2016-11-29,GCST003925,Gout
3150,Asian,2664.0,27899376.0,Nakayama A,Metabolic disorder,replication,2016-11-29,GCST003925,Gout
10328,European,19596.0,27898682.0,Lotta LA,Other measurement,initial,2016-11-29,GCST006078,Branched-chain amino acid levels (Valine)
2877,Asian,1886.0,27899376.0,Nakayama A,Metabolic disorder,replication,2016-11-29,GCST003924,Renal overload gout
6784,European,1788.0,27901618.0,Gref A,"Other disease, Other measurement",replication,2016-11-30,GCST003975,Childhood onset asthma (traffic air pollution exposure interaction)
6554,European,1534.0,27901618.0,Gref A,"Other disease, Other measurement",initial,2016-11-30,GCST003975,Childhood onset asthma (traffic air pollution exposure interaction)
9465,European,9320.0,27915449.0,Corre T,Other measurement,initial,2016-12-03,GCST003929,Urinary electrolytes (magnesium/calcium ratio)
2013,Asian,390.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006546,Pericardial fat
2012,Asian,390.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST006544,Pericardial adipose tissue adjusted for height and weight
10021,European,14863.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST003967,Visceral adipose tissue adjusted for BMI
11793,European,137994.0,27918536.0,Lo MT,"Neurological disorder, Other measurement",replication,2016-12-05,GCST004017,Neuroticism
11718,European,122886.0,27918536.0,Lo MT,"Biological process, Other measurement",initial,2016-12-05,GCST004015,Extraversion
2294,Asian,768.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST003968,Pericardial adipose tissue adjusted for height and weight
1999,Asian,378.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006545,Pericardial fat
1998,Asian,378.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST006543,Pericardial adipose tissue adjusted for height and weight
2295,Asian,768.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003971,Pericardial fat
10007,European,14780.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003965,Subcutaneous adipose tissue
10020,European,14863.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003966,Visceral adipose tissue
787,African American or Afro-Caribbean,1034.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006538,Subcutaneous adipose tissue
9998,European,14668.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003972,Visceral adipose tissue/subcutaneous adipose tissue ratio
975,African American or Afro-Caribbean,2161.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003971,Pericardial fat
976,African American or Afro-Caribbean,2163.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006537,Subcutaneous adipose tissue
977,African American or Afro-Caribbean,2163.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006542,Visceral adipose tissue
978,African American or Afro-Caribbean,2163.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST006533,Visceral adipose tissue adjusted for BMI
983,African American or Afro-Caribbean,2205.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006551,Visceral adipose tissue/subcutaneous adipose tissue ratio
8986,European,7050.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006552,Visceral adipose tissue/subcutaneous adipose tissue ratio
8987,European,7050.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST006554,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
9055,European,7381.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006538,Subcutaneous adipose tissue
9059,European,7399.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006537,Subcutaneous adipose tissue
12706,Hispanic or Latin American,699.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST006543,Pericardial adipose tissue adjusted for height and weight
9065,European,7431.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006542,Visceral adipose tissue
9067,European,7432.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006540,Visceral adipose tissue
9068,European,7432.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST006534,Visceral adipose tissue adjusted for BMI
9110,European,7618.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006551,Visceral adipose tissue/subcutaneous adipose tissue ratio
9111,European,7618.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST006553,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
9150,European,7866.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST003968,Pericardial adipose tissue adjusted for height and weight
9999,European,14668.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST003973,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
9151,European,7866.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003971,Pericardial fat
11369,European,76551.0,27918536.0,Lo MT,Other measurement,initial,2016-12-05,GCST004013,Agreeableness
11370,European,76551.0,27918536.0,Lo MT,Other measurement,initial,2016-12-05,GCST004014,Conscientiousness
9066,European,7431.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST006533,Visceral adipose tissue adjusted for BMI
12707,Hispanic or Latin American,699.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006545,Pericardial fat
12724,Hispanic or Latin American,746.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST006544,Pericardial adipose tissue adjusted for height and weight
12725,Hispanic or Latin American,746.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006546,Pericardial fat
789,African American or Afro-Caribbean,1036.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006540,Visceral adipose tissue
790,African American or Afro-Caribbean,1036.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST006534,Visceral adipose tissue adjusted for BMI
793,African American or Afro-Caribbean,1041.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003969,Visceral adipose tissue attenuation (Hounslow unit scale)
794,African American or Afro-Caribbean,1041.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003970,Subcutaneous adipose tissue attenuation (Hounsfield unit scale)
846,African American or Afro-Caribbean,1261.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST003968,Pericardial adipose tissue adjusted for height and weight
853,African American or Afro-Caribbean,1284.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST006544,Pericardial adipose tissue adjusted for height and weight
854,African American or Afro-Caribbean,1284.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006546,Pericardial fat
12833,Hispanic or Latin American,1445.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003971,Pericardial fat
12832,Hispanic or Latin American,1445.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST003968,Pericardial adipose tissue adjusted for height and weight
858,African American or Afro-Caribbean,1324.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006552,Visceral adipose tissue/subcutaneous adipose tissue ratio
859,African American or Afro-Caribbean,1324.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST006554,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
8664,European,5699.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006549,Subcutaneous adipose tissue attenuation (Hounsfield unit scale)
8665,European,5699.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006550,Subcutaneous adipose tissue attenuation (Hounsfield unit scale)
755,African American or Afro-Caribbean,877.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006545,Pericardial fat
754,African American or Afro-Caribbean,877.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST006543,Pericardial adipose tissue adjusted for height and weight
8672,European,5729.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006548,Visceral adipose tissue attenuation (Hounslow unit scale)
8674,European,5749.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006547,Visceral adipose tissue attenuation (Hounslow unit scale)
684,African American or Afro-Caribbean,592.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006550,Subcutaneous adipose tissue attenuation (Hounsfield unit scale)
683,African American or Afro-Caribbean,592.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006548,Visceral adipose tissue attenuation (Hounslow unit scale)
11056,European,46621.0,27918536.0,Lo MT,"Biological process, Other measurement",replication,2016-12-05,GCST004015,Extraversion
11055,European,46581.0,27918536.0,Lo MT,Other measurement,replication,2016-12-05,GCST004014,Conscientiousness
11372,European,76581.0,27918536.0,Lo MT,Other measurement,initial,2016-12-05,GCST004016,Openness
646,African American or Afro-Caribbean,449.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006549,Subcutaneous adipose tissue attenuation (Hounsfield unit scale)
11716,European,122867.0,27918536.0,Lo MT,"Neurological disorder, Other measurement",initial,2016-12-05,GCST004017,Neuroticism
9746,European,11398.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003970,Subcutaneous adipose tissue attenuation (Hounsfield unit scale)
9754,European,11478.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003969,Visceral adipose tissue attenuation (Hounslow unit scale)
645,African American or Afro-Caribbean,449.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006547,Visceral adipose tissue attenuation (Hounslow unit scale)
8036,European,3888.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST006543,Pericardial adipose tissue adjusted for height and weight
8037,European,3888.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006545,Pericardial fat
1135,African American or Afro-Caribbean,3529.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST006553,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
1134,African American or Afro-Caribbean,3529.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST003973,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI
1133,African American or Afro-Caribbean,3529.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003972,Visceral adipose tissue/subcutaneous adipose tissue ratio
8074,European,3978.0,27918534.0,Chu AY,"Body measurement, Other measurement",initial,2016-12-05,GCST006544,Pericardial adipose tissue adjusted for height and weight
8075,European,3978.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST006546,Pericardial fat
1130,African American or Afro-Caribbean,3469.0,27918534.0,Chu AY,"Other measurement, Body measurement",initial,2016-12-05,GCST003967,Visceral adipose tissue adjusted for BMI
1129,African American or Afro-Caribbean,3469.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003966,Visceral adipose tissue
1128,African American or Afro-Caribbean,3467.0,27918534.0,Chu AY,Other measurement,initial,2016-12-05,GCST003965,Subcutaneous adipose tissue
4081,Asian,11382.0,27922604.0,Yu H,Neurological disorder,replication,2016-12-06,GCST003880,Schizophrenia
4032,Asian,10154.0,27922604.0,Yu H,Neurological disorder,initial,2016-12-06,GCST003880,Schizophrenia
8844,European,6502.0,27927781.0,Robinson-Cohen C,Other measurement,replication,2016-12-07,GCST003879,Serum parathyroid hormone levels
10481,European,22653.0,27927781.0,Robinson-Cohen C,Other measurement,initial,2016-12-07,GCST003879,Serum parathyroid hormone levels
11331,European,70017.0,28049566.0,Direk N,"Neurological disorder, Other measurement",initial,2016-12-08,GCST004024,Depressive symptom measurement or major depressive disorder
4053,Asian,10640.0,28049566.0,Direk N,"Neurological disorder, Other measurement",replication,2016-12-08,GCST004024,Depressive symptom measurement or major depressive disorder
10644,European,28489.0,28049566.0,Direk N,"Neurological disorder, Other measurement",replication,2016-12-08,GCST004024,Depressive symptom measurement or major depressive disorder
9912,European,13483.0,27941131.0,Feenstra B,Other measurement,initial,2016-12-09,GCST003974,Tonsillectomy
2124,Asian,504.0,27936112.0,Kalsi G,Neurological disorder,initial,2016-12-09,GCST003878,Heroin dependence
7573,European,2942.0,27941131.0,Feenstra B,Other measurement,replication,2016-12-09,GCST003974,Tonsillectomy
7917,European,3557.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004443,Interleukin-13 levels
13269,Hispanic or Latin American,15124.0,27958378.0,Floyd JS,"Cardiovascular measurement, Response to drug",initial,2016-12-13,GCST004033,QRS interval (sulfonylurea treatment interaction)
7951,European,3636.0,27989323.0,Ahola-Olli AV,Inflammatory measurement,initial,2016-12-13,GCST004441,Interleukin-18 levels
7868,European,3454.0,27989323.0,Ahola-Olli AV,Inflammatory measurement,initial,2016-12-13,GCST004426,Tumor necrosis factor alpha levels
6586,European,1559.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004425,Tumor necrosis factor beta levels
7882,European,3475.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004455,Interleukin-2 levels
7847,European,3409.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004451,Interleukin-7 levels
7855,European,3421.0,27989323.0,Ahola-Olli AV,Inflammatory measurement,initial,2016-12-13,GCST004431,RANTES levels
7911,European,3531.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004421,beta-nerve growth factor levels
7894,European,3505.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004457,Growth-regulated protein alpha levels
13268,Hispanic or Latin American,15124.0,27958378.0,Floyd JS,"Cardiovascular measurement, Response to drug",initial,2016-12-13,GCST004031,QT interval (sulfonylurea treatment interaction)
7902,European,3522.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004434,Macrophage inflammatory protein 1a levels
7905,European,3526.0,27989323.0,Ahola-Olli AV,"Other measurement, Inflammatory measurement",initial,2016-12-13,GCST004445,Interleukin-8 levels
7949,European,3634.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004450,Interleukin-9 levels
7948,European,3631.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004420,CTACK levels
7884,European,3483.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004430,Interleukin-16 levels
8740,European,5998.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004427,Stromal-cell-derived factor 1 alpha levels
9205,European,8124.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004453,Interleukin-4 levels
7964,European,3677.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004454,Interleukin-2 receptor antagonist levels
9209,European,8153.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004460,Eotaxin levels
9214,European,8186.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004424,TRAIL levels
9215,European,8189.0,27989323.0,Ahola-Olli AV,Inflammatory measurement,initial,2016-12-13,GCST004446,Interleukin-6 levels
9154,European,7904.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004458,Granulocyte-colony stimulating factor levels
9228,European,8243.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004433,Macrophage inflammatory protein 1b levels
9229,European,8270.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004439,Interleukin-12p70 levels
9233,European,8290.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004429,Stem cell factor levels
9133,European,7760.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004442,Interleukin-17 levels
9127,European,7701.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004456,Interferon gamma levels
7952,European,3638.0,27989323.0,Ahola-Olli AV,Inflammatory measurement,initial,2016-12-13,GCST004447,Interleukin-1-receptor antagonist levels
9123,European,7681.0,27989323.0,Ahola-Olli AV,Inflammatory measurement,initial,2016-12-13,GCST004444,Interleukin-10 levels
9235,European,8293.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004432,Platelet-derived growth factor BB levels
9094,European,7565.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004459,Fibroblast growth factor basic levels
9236,European,8293.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004438,Monocyte chemoattractant protein-1 levels
7819,European,3364.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004452,Interleukin-5 levels
9004,European,7118.0,27989323.0,Ahola-Olli AV,Cardiovascular measurement,initial,2016-12-13,GCST004422,Vascular endothelial growth factor levels
13270,Hispanic or Latin American,15124.0,27958378.0,Floyd JS,"Response to drug, Cardiovascular measurement",initial,2016-12-13,GCST004032,JT interval (sulfonylurea treatment interaction)
7968,European,3685.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004440,Interferon gamma-induced protein 10 levels
7967,European,3685.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004435,Monokine induced by gamma interferon levels
7965,European,3682.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004428,Stem cell growth factor beta levels
9234,European,8292.0,27989323.0,Ahola-Olli AV,Cardiovascular measurement,initial,2016-12-13,GCST004449,Hepatocyte growth factor levels
7779,European,3309.0,27989323.0,Ahola-Olli AV,Inflammatory measurement,initial,2016-12-13,GCST004448,Interleukin-1-beta levels
7890,European,3494.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004423,Macrophage Migration Inhibitory Factor levels
11035,European,45002.0,27958378.0,Floyd JS,"Response to drug, Cardiovascular measurement",initial,2016-12-13,GCST004032,JT interval (sulfonylurea treatment interaction)
5823,European,840.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004436,Macrophage colony stimulating factor levels
5827,European,843.0,27989323.0,Ahola-Olli AV,Other measurement,initial,2016-12-13,GCST004437,Monocyte chemoattractant protein-3 levels
1398,African American or Afro-Caribbean,11731.0,27958378.0,Floyd JS,"Response to drug, Cardiovascular measurement",initial,2016-12-13,GCST004032,JT interval (sulfonylurea treatment interaction)
11033,European,45002.0,27958378.0,Floyd JS,"Cardiovascular measurement, Response to drug",initial,2016-12-13,GCST004031,QT interval (sulfonylurea treatment interaction)
1397,African American or Afro-Caribbean,11731.0,27958378.0,Floyd JS,"Cardiovascular measurement, Response to drug",initial,2016-12-13,GCST004033,QRS interval (sulfonylurea treatment interaction)
11034,European,45002.0,27958378.0,Floyd JS,"Cardiovascular measurement, Response to drug",initial,2016-12-13,GCST004033,QRS interval (sulfonylurea treatment interaction)
1396,African American or Afro-Caribbean,11731.0,27958378.0,Floyd JS,"Cardiovascular measurement, Response to drug",initial,2016-12-13,GCST004031,QT interval (sulfonylurea treatment interaction)
5231,European,458.0,27957625.0,Bacchelli E,"Other measurement, Other trait",initial,2016-12-13,GCST003900,Cluster headache
2045,Asian,434.0,28000841.0,Baek SH,Other disease,initial,2016-12-14,GCST003918,Idiopathic osteonecrosis of the femoral head
4253,Asian,17450.0,27976721.0,Wang Z,Neurological disorder,replication,2016-12-15,GCST004009,Leprosy
3712,Asian,6316.0,27976721.0,Wang Z,Neurological disorder,initial,2016-12-15,GCST004009,Leprosy
1691,Asian,115.0,27981573.0,Zhong WP,"Cardiovascular disease, Cardiovascular measurement, Response to drug",initial,2016-12-16,GCST003899,Response to clopidogrel therapy in coronary heart disease
10023,European,14890.0,27992413.0,Ji SG,Digestive system disorder,initial,2016-12-19,GCST004030,Primary sclerosing cholangitis
11634,European,111648.0,27992416.0,Lane JM,Other measurement,initial,2016-12-19,GCST003979,Excessive daytime sleepiness
11220,European,59128.0,27992416.0,Lane JM,"Neurological disorder, Other measurement",initial,2016-12-19,GCST003981,Insomnia
11637,European,111975.0,27992416.0,Lane JM,Other measurement,initial,2016-12-19,GCST003980,Sleep duration
5833,European,845.0,27993963.0,Schneider BP,"Cardiovascular disease, Cancer, Response to drug",initial,2016-12-19,GCST003939,Adverse response to chemotherapy (congestive heart failure) in breast cancer
5730,European,775.0,27993963.0,Schneider BP,"Cardiovascular disease, Cancer, Response to drug",replication,2016-12-19,GCST003939,Adverse response to chemotherapy (congestive heart failure) in breast cancer
11646,European,112586.0,27992416.0,Lane JM,"Biological process, Other measurement",initial,2016-12-19,GCST003982,Sleep traits (multi-trait analysis)
9565,European,9861.0,27992413.0,Ji SG,Digestive system disorder,replication,2016-12-19,GCST004030,Primary sclerosing cholangitis
10988,European,41544.0,27997041.0,Traylor M,"Cardiovascular disease, Other trait",replication,2016-12-20,GCST004021,Ischemic stroke (cardioembolic)
10289,European,19100.0,27997041.0,Traylor M,Cardiovascular disease,replication,2016-12-20,GCST004022,Large artery stroke
9956,European,14000.0,27997041.0,Traylor M,"Cardiovascular disease, Other trait",initial,2016-12-20,GCST004021,Ischemic stroke (cardioembolic)
10970,European,40371.0,27997041.0,Traylor M,Cardiovascular disease,replication,2016-12-20,GCST004020,Small vessel stroke
10467,European,22495.0,27997041.0,Traylor M,"Cardiovascular disease, Other trait",initial,2016-12-20,GCST004023,Ischemic stroke
9991,European,14560.0,27997041.0,Traylor M,Cardiovascular disease,initial,2016-12-20,GCST004020,Small vessel stroke
10589,European,25713.0,27997041.0,Traylor M,"Cardiovascular disease, Other trait",replication,2016-12-20,GCST004023,Ischemic stroke
9966,European,14162.0,27997041.0,Traylor M,Cardiovascular disease,initial,2016-12-20,GCST004022,Large artery stroke
1165,African American or Afro-Caribbean,3964.0,28078323.0,Raj T,Other trait,initial,2016-12-21,GCST003901,Cognitive decline (age-related)
2178,Asian,611.0,28011148.0,Zhang M,Other measurement,initial,2016-12-21,GCST003940,Trans-epidermal water loss
1980,Asian,366.0,28011148.0,Zhang M,Other measurement,replication,2016-12-21,GCST003940,Trans-epidermal water loss
14003,Other/Mixed,16389.0,28017375.0,van Rooij FJA,Hematological measurement,replication,2016-12-22,GCST004003,Hematocrit
10969,European,40258.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004008,Red blood cell count
10968,European,40258.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004005,Hemoglobin levels
10967,European,40258.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004003,Hematocrit
13685,Other/Mixed,540.0,28011710.0,Benyamin B,Other measurement,initial,2016-12-22,GCST004038,Circulating chromogranin peptide levels
14006,Other/Mixed,16389.0,28017375.0,van Rooij FJA,Hematological measurement,replication,2016-12-22,GCST004006,Mean corpuscular hemoglobin
14005,Other/Mixed,16389.0,28017375.0,van Rooij FJA,Hematological measurement,replication,2016-12-22,GCST004005,Hemoglobin levels
1245,African American or Afro-Caribbean,6150.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004004,Mean corpuscular volume
14008,Other/Mixed,16389.0,28017375.0,van Rooij FJA,Hematological measurement,replication,2016-12-22,GCST004008,Red blood cell count
10682,European,29646.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004004,Mean corpuscular volume
1142,African American or Afro-Caribbean,3621.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004006,Mean corpuscular hemoglobin
1143,African American or Afro-Caribbean,3621.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004007,Mean corpuscular hemoglobin concentration
14007,Other/Mixed,16389.0,28017375.0,van Rooij FJA,Hematological measurement,replication,2016-12-22,GCST004007,Mean corpuscular hemoglobin concentration
2070,Asian,455.0,28011712.0,Foo JN,Neurological disorder,replication,2016-12-22,GCST003922,Parkinson's disease
14004,Other/Mixed,16389.0,28017375.0,van Rooij FJA,Hematological measurement,replication,2016-12-22,GCST004004,Mean corpuscular volume
10391,European,21020.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004006,Mean corpuscular hemoglobin
5183,European,433.0,28002826.0,D'Adamo CR,Other measurement,initial,2016-12-22,GCST003936,Vitamin E levels (gamma-tocopherol)
5181,European,433.0,28002826.0,D'Adamo CR,Other measurement,initial,2016-12-22,GCST003934,Carotenoid levels (cryptoxanthin)
4306,Asian,22274.0,28011712.0,Foo JN,Neurological disorder,replication,2016-12-22,GCST003922,Parkinson's disease
5184,European,433.0,28002826.0,D'Adamo CR,Other measurement,initial,2016-12-22,GCST003937,Retinol levels
5185,European,433.0,28002826.0,D'Adamo CR,Other measurement,initial,2016-12-22,GCST003938,Carotenoid levels (alpha-carotene)
1428,African American or Afro-Caribbean,16128.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004003,Hematocrit
5180,European,433.0,28002826.0,D'Adamo CR,Other measurement,initial,2016-12-22,GCST003933,Carotenoid levels (zeaxanthin)
4220,Asian,15252.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004008,Red blood cell count
5179,European,433.0,28002826.0,D'Adamo CR,Other measurement,initial,2016-12-22,GCST003932,Carotenoid levels (lutein)
4219,Asian,15252.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004005,Hemoglobin levels
4218,Asian,15252.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004003,Hematocrit
5182,European,433.0,28002826.0,D'Adamo CR,Other measurement,initial,2016-12-22,GCST003935,Vitamin E levels (alpha-tocopherol)
4215,Asian,15074.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004004,Mean corpuscular volume
4214,Asian,15062.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004007,Mean corpuscular hemoglobin concentration
1430,African American or Afro-Caribbean,16128.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004008,Red blood cell count
10392,European,21020.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004007,Mean corpuscular hemoglobin concentration
4213,Asian,15062.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004006,Mean corpuscular hemoglobin
4181,Asian,14006.0,28011712.0,Foo JN,Neurological disorder,initial,2016-12-22,GCST003922,Parkinson's disease
5178,European,433.0,28002826.0,D'Adamo CR,Other measurement,initial,2016-12-22,GCST003931,Carotenoid levels (beta-carotene)
1429,African American or Afro-Caribbean,16128.0,28017375.0,van Rooij FJA,Hematological measurement,initial,2016-12-22,GCST004005,Hemoglobin levels
6259,European,1172.0,28008999.0,Ostrowski J,Digestive system disorder,initial,2016-12-23,GCST003959,Crohn's disease
6198,European,1110.0,28008999.0,Ostrowski J,Immune system disorder,initial,2016-12-23,GCST003960,Ulcerative colitis
5427,European,558.0,28008999.0,Ostrowski J,Immune system disorder,replication,2016-12-23,GCST003960,Ulcerative colitis
5655,European,729.0,28008999.0,Ostrowski J,"Digestive system disorder, Immune system disorder",replication,2016-12-23,GCST003958,Inflammatory bowel disease
5375,European,523.0,28008999.0,Ostrowski J,Digestive system disorder,replication,2016-12-23,GCST003959,Crohn's disease
6982,European,2059.0,28012008.0,Lu S,Other measurement,initial,2016-12-23,GCST003919,Spine bone mineral density and alcohol drinking
6983,European,2059.0,28012008.0,Lu S,Other measurement,initial,2016-12-23,GCST003920,Hip bone mineral density and alcohol drinking
5532,European,636.0,28011674.0,Ruhle F,Cardiovascular disease,initial,2016-12-23,GCST004012,Venous thromboembolism
6696,European,1700.0,28008999.0,Ostrowski J,"Digestive system disorder, Immune system disorder",initial,2016-12-23,GCST003958,Inflammatory bowel disease
6984,European,2059.0,28012008.0,Lu S,Other measurement,initial,2016-12-23,GCST003921,Whole body bone mineral density and alcohol drinking
7929,European,3582.0,28029757.0,Merkel PA,Immune system disorder,initial,2016-12-28,GCST003977,Vasculitis associated with antineutrophil cytoplasmic antibody reactive to myeloperoxidase
6954,European,2036.0,28029757.0,Merkel PA,Immune system disorder,initial,2016-12-28,GCST003976,Antineutrophil cytoplasmic antibody-associated vasculitis
6882,European,1944.0,28029757.0,Merkel PA,Immune system disorder,initial,2016-12-28,GCST003978,Vasculitis associated with antineutrophil cytoplasmic antibody reactive to proteinase-3
6594,European,1564.0,28040410.0,Meyers JL,Other measurement,initial,2016-12-28,GCST003902,Fast beta electroencephalogram
8248,European,4479.0,28029757.0,Merkel PA,Immune system disorder,initial,2016-12-28,GCST003976,Antineutrophil cytoplasmic antibody-associated vasculitis
8140,European,4140.0,28029757.0,Merkel PA,Immune system disorder,initial,2016-12-28,GCST003978,Vasculitis associated with antineutrophil cytoplasmic antibody reactive to proteinase-3
6532,European,1519.0,28029757.0,Merkel PA,Immune system disorder,initial,2016-12-28,GCST003977,Vasculitis associated with antineutrophil cytoplasmic antibody reactive to myeloperoxidase
9737,European,11259.0,28041642.0,Carmona FD,Cardiovascular disease,initial,2016-12-29,GCST003928,Giant cell arteritis
1380,African American or Afro-Caribbean,10235.0,28039329.0,Noordam R,"Cardiovascular measurement, Response to drug",initial,2016-12-30,GCST004010,QT interval (tricyclic/tetracyclic antidepressant use interaction)
13338,Hispanic or Latin American,69749.0,28039329.0,Noordam R,"Cardiovascular measurement, Response to drug",initial,2016-12-30,GCST004010,QT interval (tricyclic/tetracyclic antidepressant use interaction)
1381,African American or Afro-Caribbean,10235.0,28039329.0,Noordam R,"Cardiovascular measurement, Response to drug",initial,2016-12-30,GCST004011,RR interval (tricyclic/tetracyclic antidepressant use interaction)
11039,European,45706.0,28039329.0,Noordam R,"Cardiovascular measurement, Response to drug",initial,2016-12-30,GCST004011,RR interval (tricyclic/tetracyclic antidepressant use interaction)
5344,European,511.0,28039263.0,Wheeler HE,"Other trait, Response to drug",initial,2016-12-30,GCST003898,Cisplatin-induced ototoxicity
13262,Hispanic or Latin American,13808.0,28039329.0,Noordam R,"Cardiovascular measurement, Response to drug",initial,2016-12-30,GCST004011,RR interval (tricyclic/tetracyclic antidepressant use interaction)
9657,European,10602.0,28043905.0,Nicoletti P,"Digestive system disorder, Response to drug",initial,2016-12-30,GCST004078,Drug-induced liver injury (terbinafine)
9703,European,10911.0,28043905.0,Nicoletti P,Digestive system disorder,initial,2016-12-30,GCST004081,Drug-induced cholestatic/mixed liver injury
9661,European,10631.0,28043905.0,Nicoletti P,"Digestive system disorder, Response to drug",initial,2016-12-30,GCST004085,Drug-induced liver injury (fluoroquinolones)
10993,European,41951.0,28039329.0,Noordam R,"Cardiovascular measurement, Response to drug",initial,2016-12-30,GCST004010,QT interval (tricyclic/tetracyclic antidepressant use interaction)
9665,European,10655.0,28043905.0,Nicoletti P,"Digestive system disorder, Response to drug",initial,2016-12-30,GCST004084,Drug-induced liver injury (anti-tuberculosis drugs)
9663,European,10652.0,28043905.0,Nicoletti P,"Digestive system disorder, Response to drug",initial,2016-12-30,GCST004082,Drug-induced liver injury (nitrofurantoin)
9717,European,11062.0,28043905.0,Nicoletti P,Digestive system disorder,initial,2016-12-30,GCST004079,Drug-induced hepatocellular liver injury
9680,European,10732.0,28043905.0,Nicoletti P,"Digestive system disorder, Response to drug",initial,2016-12-30,GCST004087,Drug-induced liver injury (nonsteroidal anti-inflammatory drugs)
9749,European,11450.0,28043905.0,Nicoletti P,"Response to drug, Digestive system disorder",initial,2016-12-30,GCST004086,Drug-induced liver injury
9664,European,10655.0,28043905.0,Nicoletti P,"Digestive system disorder, Response to drug",initial,2016-12-30,GCST004083,Drug-induced liver injury (diclofenac)
9662,European,10647.0,28043905.0,Nicoletti P,"Digestive system disorder, Response to drug",initial,2016-12-30,GCST004080,Drug-induced liver injury (statins)
2948,Asian,2058.0,28952330.0,Chen SP,Cardiovascular disease,initial,2017-01-01,GCST004900,Migraine without aura
12963,Hispanic or Latin American,3596.0,28061514.0,Nannini DR,Other measurement,initial,2017-01-01,GCST004047,Optic nerve measurement (cup-to-disc ratio)
13849,Other/Mixed,1279.0,28222112.0,Dumitrescu L,Cardiovascular disease,initial,2017-01-01,GCST004163,Resistance to antihypertensive treatment in hypertension
2758,Asian,1724.0,28952330.0,Chen SP,Cardiovascular disease,replication,2017-01-01,GCST004900,Migraine without aura
5543,European,646.0,28317148.0,Campo C,"Response to drug, Neurological disorder, Cancer",initial,2017-01-01,GCST003964,Bortezomib-induced peripheral neuropathy in multiple myeloma
12778,Hispanic or Latin American,941.0,28061514.0,Nannini DR,Other measurement,replication,2017-01-01,GCST004047,Optic nerve measurement (cup-to-disc ratio)
7263,European,2427.0,28222112.0,Dumitrescu L,Cardiovascular disease,initial,2017-01-01,GCST004163,Resistance to antihypertensive treatment in hypertension
3556,Asian,5292.0,28046027.0,Kim T,Lipid or lipoprotein measurement,initial,2017-01-03,GCST004036,LDL cholesterol to HDL cholesterol ratio
3557,Asian,5292.0,28046027.0,Kim T,Lipid or lipoprotein measurement,initial,2017-01-03,GCST004037,Triglyceride to HDL cholesterol ratio
3133,Asian,2567.0,28046027.0,Kim T,Lipid or lipoprotein measurement,replication,2017-01-03,GCST004037,Triglyceride to HDL cholesterol ratio
3132,Asian,2567.0,28046027.0,Kim T,Lipid or lipoprotein measurement,replication,2017-01-03,GCST004036,LDL cholesterol to HDL cholesterol ratio
3555,Asian,5292.0,28046027.0,Kim T,Lipid or lipoprotein measurement,initial,2017-01-03,GCST004035,NHDL cholesterol to HDL cholesterol ratio
3131,Asian,2567.0,28046027.0,Kim T,Lipid or lipoprotein measurement,replication,2017-01-03,GCST004035,NHDL cholesterol to HDL cholesterol ratio
2327,Asian,796.0,28045058.0,Kim SW,Cardiovascular disease,initial,2017-01-03,GCST004019,Behcet's disease
2263,Asian,725.0,28045058.0,Kim SW,Cardiovascular disease,replication,2017-01-03,GCST004019,Behcet's disease
13796,Other/Mixed,846.0,28054174.0,Leslie EJ,Other trait,initial,2017-01-04,GCST004052,Cleft palate
2428,Asian,977.0,28054174.0,Leslie EJ,Other trait,initial,2017-01-04,GCST004052,Cleft palate
13945,Other/Mixed,3161.0,28054174.0,Leslie EJ,Other trait,initial,2017-01-04,GCST004050,Cleft lip with or without cleft palate
3349,Asian,3763.0,28054174.0,Leslie EJ,Other trait,initial,2017-01-04,GCST004050,Cleft lip with or without cleft palate
8070,European,3969.0,28054174.0,Leslie EJ,Other trait,initial,2017-01-04,GCST004050,Cleft lip with or without cleft palate
3461,Asian,4579.0,28054174.0,Leslie EJ,"Other trait, Other measurement, Other disease",initial,2017-01-04,GCST004051,Orofacial clefts
13948,Other/Mixed,3303.0,28054174.0,Leslie EJ,"Other trait, Other measurement, Other disease",initial,2017-01-04,GCST004051,Orofacial clefts
8384,European,4865.0,28054174.0,Leslie EJ,"Other trait, Other measurement, Other disease",initial,2017-01-04,GCST004051,Orofacial clefts
6767,European,1761.0,28054174.0,Leslie EJ,Other trait,initial,2017-01-04,GCST004052,Cleft palate
1883,Asian,261.0,28065765.0,Nagao Y,"Other disease, Digestive system disorder",initial,2017-01-05,GCST004090,Lichen planus in hepatitis C
68,African,233.0,28062682.0,Carr DF,"Other disease, Response to drug",initial,2017-01-05,GCST004115,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis)
39,African,87.0,28062682.0,Carr DF,"Other disease, Response to drug",replication,2017-01-05,GCST004117,Nevirapine-induced hypersensitivity in HIV (rash)
50,African,122.0,28062682.0,Carr DF,"Other disease, Immune system disorder, Response to drug",replication,2017-01-05,GCST004118,Nevirapine-induced hypersensitivity in HIV
20,African,35.0,28062682.0,Carr DF,"Other disease, Response to drug",replication,2017-01-05,GCST004115,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis)
19,African,35.0,28062682.0,Carr DF,"Other disease, Digestive system disorder, Response to drug",replication,2017-01-05,GCST004114,Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury)
61,African,205.0,28062682.0,Carr DF,"Other disease, Immune system disorder, Response to drug",initial,2017-01-05,GCST004116,Nevirapine-induced hypersensitivity in HIV (hypersensitivity syndrome)
31,African,76.0,28062682.0,Carr DF,"Other disease, Digestive system disorder, Response to drug",replication,2017-01-05,GCST004114,Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury)
29,African,71.0,28062682.0,Carr DF,"Other disease, Response to drug",replication,2017-01-05,GCST004115,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis)
96,African,398.0,28062682.0,Carr DF,"Other disease, Response to drug",initial,2017-01-05,GCST004117,Nevirapine-induced hypersensitivity in HIV (rash)
3777,Asian,7024.0,28062665.0,Kawashima M,Cancer,replication,2017-01-05,GCST004145,Primary biliary cholangitis
3210,Asian,2886.0,28062665.0,Kawashima M,Cancer,initial,2017-01-05,GCST004145,Primary biliary cholangitis
60,African,203.0,28062682.0,Carr DF,"Other disease, Digestive system disorder, Response to drug",initial,2017-01-05,GCST004114,Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury)
4577,European,45.0,28065765.0,Nagao Y,"Other disease, Digestive system disorder",replication,2017-01-05,GCST004090,Lichen planus in hepatitis C
91,African,333.0,28062682.0,Carr DF,"Other disease, Immune system disorder, Response to drug",initial,2017-01-05,GCST004118,Nevirapine-induced hypersensitivity in HIV
1648,Asian,90.0,28059113.0,Hao J,Other disease,initial,2017-01-06,GCST004091,Palmar length-width ratio in Kashin-Beck disease
6147,European,1054.0,28056976.0,Paziewska A,Digestive system disorder,initial,2017-01-06,GCST004119,Primary sclerosing cholangitis
6443,European,1377.0,28056976.0,Paziewska A,Cancer,initial,2017-01-06,GCST004120,Primary biliary cholangitis
2025,Asian,403.0,28059113.0,Hao J,Other disease,replication,2017-01-06,GCST004091,Palmar length-width ratio in Kashin-Beck disease
10518,European,23825.0,28067910.0,Luo Y,Immune system disorder,initial,2017-01-09,GCST008658,Ulcerative colitis
7472,European,2734.0,28067912.0,Lee JC,"Digestive system disorder, Other measurement",initial,2017-01-09,GCST004053,Poor prognosis in Crohn's disease
11931,European,167078.0,28067910.0,Luo Y,Immune system disorder,replication,2017-01-09,GCST008658,Ulcerative colitis
10520,European,23899.0,28073927.0,Springelkamp H,Other measurement,initial,2017-01-10,GCST004075,Vertical cup-disc ratio
992,African American or Afro-Caribbean,2382.0,28070124.0,Meyers JL,Other measurement,initial,2017-01-10,GCST004048,Fast beta electroencephalogram
7388,European,2588.0,28077804.0,Ben-Avraham D,Other measurement,replication,2017-01-10,GCST004110,Gait speed in old age
3885,Asian,8168.0,28073927.0,Springelkamp H,Other measurement,replication,2017-01-10,GCST004075,Vertical cup-disc ratio
8920,European,6789.0,28073367.0,Zeng X,Other measurement,replication,2017-01-10,GCST004073,Cough
10680,European,29578.0,28073927.0,Springelkamp H,Other measurement,initial,2017-01-10,GCST004074,Intraocular pressure
8922,European,6789.0,28073367.0,Zeng X,Other measurement,replication,2017-01-10,GCST004112,Dyspnea
8921,European,6789.0,28073367.0,Zeng X,Other measurement,replication,2017-01-10,GCST004111,Phlegm
3800,Asian,7333.0,28073927.0,Springelkamp H,Other measurement,replication,2017-01-10,GCST004137,Optic cup area
3796,Asian,7302.0,28073927.0,Springelkamp H,Other measurement,replication,2017-01-10,GCST004076,Optic disc area
9176,European,7976.0,28073367.0,Zeng X,Other measurement,initial,2017-01-10,GCST004111,Phlegm
9175,European,7976.0,28073367.0,Zeng X,Other measurement,initial,2017-01-10,GCST004073,Cough
3898,Asian,8352.0,28073927.0,Springelkamp H,Other measurement,replication,2017-01-10,GCST004074,Intraocular pressure
9177,European,7976.0,28073367.0,Zeng X,Other measurement,initial,2017-01-10,GCST004112,Dyspnea
10770,European,33181.0,28072414.0,Charney AW,Neurological disorder,initial,2017-01-10,GCST003962,Bipolar disorder
10728,European,31478.0,28077804.0,Ben-Avraham D,Other measurement,initial,2017-01-10,GCST004110,Gait speed in old age
10466,European,22484.0,28073927.0,Springelkamp H,Other measurement,initial,2017-01-10,GCST004137,Optic cup area
10468,European,22504.0,28073927.0,Springelkamp H,Other measurement,initial,2017-01-10,GCST004076,Optic disc area
2370,Asian,876.0,28076899.0,Taylor KE,Neurological disorder,initial,2017-01-11,GCST004061,Sjgren's syndrome
13482,Other/Mixed,74.0,27883235.0,Martino DJ,Other measurement,replication,2017-01-11,GCST003881,Peanut allergy
13443,Other/Mixed,27.0,27883235.0,Martino DJ,Other measurement,initial,2017-01-11,GCST003881,Peanut allergy
4750,European,170.0,27883235.0,Martino DJ,Other measurement,initial,2017-01-11,GCST003881,Peanut allergy
2698,Asian,1585.0,28076899.0,Taylor KE,Neurological disorder,initial,2017-01-11,GCST004062,Sjgren's syndrome
13652,Other/Mixed,401.0,28076899.0,Taylor KE,Neurological disorder,initial,2017-01-11,GCST004061,Sjgren's syndrome
1573,Asian,24.0,27883235.0,Martino DJ,Other measurement,initial,2017-01-11,GCST003881,Peanut allergy
119,African,546.0,28076899.0,Taylor KE,Neurological disorder,initial,2017-01-11,GCST004061,Sjgren's syndrome
8534,European,5212.0,27883235.0,Martino DJ,Other measurement,replication,2017-01-11,GCST003881,Peanut allergy
8135,European,4131.0,28076899.0,Taylor KE,Neurological disorder,initial,2017-01-11,GCST004061,Sjgren's syndrome
8643,European,5613.0,28081371.0,Sanders AE,Other disease,replication,2017-01-12,GCST004034,Temporomandibular joint disorder
13177,Hispanic or Latin American,10153.0,28081371.0,Sanders AE,Other disease,initial,2017-01-12,GCST004034,Temporomandibular joint disorder
1023,African American or Afro-Caribbean,2706.0,28082259.0,Pankow JS,Hematological measurement,initial,2017-01-12,GCST006119,Protein C levels
12698,Hispanic or Latin American,636.0,28081371.0,Sanders AE,Other disease,replication,2017-01-12,GCST004034,Temporomandibular joint disorder
9690,European,10778.0,28082259.0,Pankow JS,Hematological measurement,initial,2017-01-12,GCST006119,Protein C levels
8146,European,4167.0,28081215.0,Pardo LM,"Cancer, Other measurement",initial,2017-01-12,GCST004134,Multiple keratinocyte cancers
13345,Other/Mixed,1.0,28084903.0,Hallberg P,"Other trait, Response to drug",initial,2017-01-13,GCST004049,Cough in response to angiotensin-converting enzyme inhibitor drugs
6229,European,1145.0,28087736.0,Ludwig KU,Other trait,replication,2017-01-13,GCST004088,Nonsyndromic cleft lip with or without cleft palate
12655,Hispanic or Latin American,475.0,28087736.0,Ludwig KU,Other trait,replication,2017-01-13,GCST004088,Nonsyndromic cleft lip with or without cleft palate
4698,European,123.0,28084903.0,Hallberg P,"Other trait, Response to drug",initial,2017-01-13,GCST004049,Cough in response to angiotensin-converting enzyme inhibitor drugs
3081,Asian,2385.0,28087736.0,Ludwig KU,Other trait,initial,2017-01-13,GCST004088,Nonsyndromic cleft lip with or without cleft palate
13700,Other/Mixed,589.0,28087736.0,Ludwig KU,Other trait,replication,2017-01-13,GCST004088,Nonsyndromic cleft lip with or without cleft palate
7976,European,3715.0,28087736.0,Ludwig KU,Other trait,initial,2017-01-13,GCST004088,Nonsyndromic cleft lip with or without cleft palate
4668,European,96.0,28108127.0,Eitel I,Cardiovascular disease,initial,2017-01-15,GCST004095,Takotsubo syndrome
13468,Other/Mixed,56.0,28090653.0,Liu Y,"Liver enzyme measurement, Cancer, Response to drug",initial,2017-01-16,GCST004250,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)
464,African American or Afro-Caribbean,111.0,28090653.0,Liu Y,"Liver enzyme measurement, Cancer, Response to drug",initial,2017-01-16,GCST004250,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)
7848,European,3409.0,28060188.0,Hamet P,Metabolic disorder,initial,2017-01-16,GCST004125,Type 2 diabetes (age of onset)
12528,Hispanic or Latin American,60.0,28090653.0,Liu Y,"Liver enzyme measurement, Cancer, Response to drug",initial,2017-01-16,GCST004250,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)
5290,European,488.0,28090653.0,Liu Y,"Liver enzyme measurement, Cancer, Response to drug",initial,2017-01-16,GCST004250,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)
12737,Hispanic or Latin American,768.0,28095793.0,Chittoor G,Other measurement,initial,2017-01-17,GCST004057,Creatinine clearance
12736,Hispanic or Latin American,768.0,28095793.0,Chittoor G,Other measurement,initial,2017-01-17,GCST004056,Urinary uric acid to urinary creatinine ratio
12735,Hispanic or Latin American,768.0,28095793.0,Chittoor G,Cardiovascular measurement,initial,2017-01-17,GCST004058,Uric acid clearance
12734,Hispanic or Latin American,768.0,28095793.0,Chittoor G,Cardiovascular measurement,initial,2017-01-17,GCST004055,Fractional excretion of uric acid
12733,Hispanic or Latin American,768.0,28095793.0,Chittoor G,Cardiovascular measurement,initial,2017-01-17,GCST004054,Glomerular load of uric acid
10848,European,35298.0,28093568.0,Trampush JW,"Biological process, Other measurement",initial,2017-01-17,GCST004077,Cognitive function
8030,European,3863.0,28098162.0,Hibar DP,Other measurement,replication,2017-01-18,GCST003961,Hippocampal volume
12823,Hispanic or Latin American,1411.0,28098162.0,Hibar DP,Other measurement,replication,2017-01-18,GCST003961,Hippocampal volume
2378,Asian,886.0,28098162.0,Hibar DP,Other measurement,replication,2017-01-18,GCST003961,Hippocampal volume
4870,European,229.0,28109725.0,Fuchs O,Other measurement,initial,2017-01-18,GCST004059,Exhaled nitric oxide levels
4871,European,229.0,28109725.0,Fuchs O,Other measurement,initial,2017-01-18,GCST004060,Exhaled nitric oxide output
5238,European,463.0,28100725.0,Chen J,Other measurement,initial,2017-01-18,GCST004092,Plasma t-tau levels
10612,European,26814.0,28098162.0,Hibar DP,Other measurement,initial,2017-01-18,GCST003961,Hippocampal volume
681,African American or Afro-Caribbean,562.0,28098162.0,Hibar DP,Other measurement,replication,2017-01-18,GCST003961,Hippocampal volume
1970,Asian,354.0,28100913.0,Ueta M,"Other disease, Response to drug",replication,2017-01-19,GCST004072,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications
2336,Asian,805.0,28100913.0,Ueta M,"Other disease, Response to drug",initial,2017-01-19,GCST004072,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications
11547,European,91953.0,28107422.0,de Vries PS,Hematological measurement,initial,2017-01-20,GCST004122,Fibrinogen levels
11546,European,91953.0,28107422.0,de Vries PS,Hematological measurement,initial,2017-01-20,GCST004121,Fibrinogen levels
5135,European,411.0,28128768.0,Ferrari R,"Neurological disorder, Other measurement",initial,2017-01-23,GCST004096,Frontotemporal dementia (age at onset)
9986,European,14421.0,28112199.0,Law PJ,Cancer,initial,2017-01-23,GCST004099,"B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)"
13680,Other/Mixed,504.0,28118524.0,Saxena R,Immune system disorder,replication,2017-01-24,GCST004172,Rheumatoid arthritis
13681,Other/Mixed,506.0,28118524.0,Saxena R,Immune system disorder,initial,2017-01-24,GCST004173,Rheumatoid arthritis (rheumatoid factor and anti-cyclic citrullinated peptide seronegative)
619,African American or Afro-Caribbean,383.0,28115739.0,Smith AH,"Neurological disorder, Other measurement",initial,2017-01-24,GCST004136,Methadone dose in opioid dependence
13597,Other/Mixed,279.0,28118524.0,Saxena R,Immune system disorder,replication,2017-01-24,GCST004173,Rheumatoid arthritis (rheumatoid factor and anti-cyclic citrullinated peptide seronegative)
13799,Other/Mixed,863.0,28118524.0,Saxena R,Immune system disorder,initial,2017-01-24,GCST004172,Rheumatoid arthritis
13760,Other/Mixed,709.0,28118524.0,Saxena R,"Other measurement, Immune system disorder",initial,2017-01-24,GCST004174,Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive)
6125,European,1027.0,28115739.0,Smith AH,"Neurological disorder, Other measurement",initial,2017-01-24,GCST004136,Methadone dose in opioid dependence
13667,Other/Mixed,459.0,28118524.0,Saxena R,"Other measurement, Immune system disorder",replication,2017-01-24,GCST004174,Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive)
4458,Asian,64851.0,28115744.0,Ikeda M,Neurological disorder,initial,2017-01-24,GCST004139,Bipolar disorder
10150,European,16731.0,28115744.0,Ikeda M,Neurological disorder,initial,2017-01-24,GCST004139,Bipolar disorder
1839,Asian,226.0,28120872.0,Li X,"Cancer, Response to drug",initial,2017-01-25,GCST004097,Response to platinum-based neoadjuvant chemotherapy in cervical cancer
1987,Asian,370.0,28120872.0,Li X,"Cancer, Response to drug",replication,2017-01-25,GCST004097,Response to platinum-based neoadjuvant chemotherapy in cervical cancer
2320,Asian,780.0,28130311.0,Tan W,Digestive system disorder,initial,2017-01-27,GCST004165,Acute-on-chronic liver failure in hepatitis B
3138,Asian,2587.0,28130311.0,Tan W,Digestive system disorder,replication,2017-01-27,GCST004165,Acute-on-chronic liver failure in hepatitis B
11804,European,140882.0,28135244.0,Warren HR,Other measurement,initial,2017-01-30,GCST004279,Systolic blood pressure
11807,European,140886.0,28135244.0,Warren HR,Cardiovascular measurement,initial,2017-01-30,GCST004278,Pulse pressure
11808,European,140886.0,28135244.0,Warren HR,Other measurement,initial,2017-01-30,GCST004280,Diastolic blood pressure
12002,European,190318.0,28135244.0,Warren HR,Cardiovascular measurement,replication,2017-01-30,GCST004278,Pulse pressure
12003,European,190318.0,28135244.0,Warren HR,Other measurement,replication,2017-01-30,GCST004279,Systolic blood pressure
12004,European,190318.0,28135244.0,Warren HR,Other measurement,replication,2017-01-30,GCST004280,Diastolic blood pressure
12914,Hispanic or Latin American,2716.0,28139693.0,Hoffmann TJ,Other measurement,replication,2017-01-31,GCST004093,Prostate-specific antigen levels
3119,Asian,2518.0,28139693.0,Hoffmann TJ,Other measurement,replication,2017-01-31,GCST004094,Prostate-specific antigen levels (conditioned on lead SNPs)
6873,European,1936.0,28139761.0,Pasanen A,Other trait,replication,2017-01-31,GCST004140,Bronchiolitis
10646,European,28503.0,28139693.0,Hoffmann TJ,Other measurement,initial,2017-01-31,GCST004094,Prostate-specific antigen levels (conditioned on lead SNPs)
8783,European,6193.0,28139693.0,Hoffmann TJ,Other measurement,replication,2017-01-31,GCST004094,Prostate-specific antigen levels (conditioned on lead SNPs)
3118,Asian,2518.0,28139693.0,Hoffmann TJ,Other measurement,replication,2017-01-31,GCST004093,Prostate-specific antigen levels
9795,European,11796.0,28139693.0,Hoffmann TJ,Other measurement,replication,2017-01-31,GCST004093,Prostate-specific antigen levels
6065,European,995.0,28139761.0,Pasanen A,Other trait,initial,2017-01-31,GCST004140,Bronchiolitis
896,African American or Afro-Caribbean,1585.0,28139693.0,Hoffmann TJ,Other measurement,replication,2017-01-31,GCST004094,Prostate-specific antigen levels (conditioned on lead SNPs)
12915,Hispanic or Latin American,2716.0,28139693.0,Hoffmann TJ,Other measurement,replication,2017-01-31,GCST004094,Prostate-specific antigen levels (conditioned on lead SNPs)
10645,European,28503.0,28139693.0,Hoffmann TJ,Other measurement,initial,2017-01-31,GCST004093,Prostate-specific antigen levels
5094,European,393.0,27903959.0,Lv H,Cancer,initial,2017-01-31,GCST008413,Core binding factor acute myeloid leukemia
895,African American or Afro-Caribbean,1585.0,28139693.0,Hoffmann TJ,Other measurement,replication,2017-01-31,GCST004093,Prostate-specific antigen levels
13210,Hispanic or Latin American,11809.0,28158719.0,Jain D,"Hematological measurement, Inflammatory measurement",initial,2017-02-01,GCST004126,White blood cell count
13208,Hispanic or Latin American,11809.0,28158719.0,Jain D,Hematological measurement,initial,2017-02-01,GCST004130,White blood cell count (lymphocyte)
13209,Hispanic or Latin American,11809.0,28158719.0,Jain D,Hematological measurement,initial,2017-02-01,GCST004135,White blood cell count (eosinophil)
13119,Hispanic or Latin American,7200.0,28158719.0,Jain D,Hematological measurement,replication,2017-02-01,GCST004128,White blood cell count (neutrophil)
13207,Hispanic or Latin American,11809.0,28158719.0,Jain D,Hematological measurement,initial,2017-02-01,GCST004129,White blood cell count (monocyte)
13206,Hispanic or Latin American,11809.0,28158719.0,Jain D,Hematological measurement,initial,2017-02-01,GCST004128,White blood cell count (neutrophil)
6959,European,2045.0,28053049.0,Sennblad B,Hematological measurement,replication,2017-02-01,GCST004124,Factor XI
13120,Hispanic or Latin American,7200.0,28158719.0,Jain D,Hematological measurement,replication,2017-02-01,GCST004129,White blood cell count (monocyte)
13121,Hispanic or Latin American,7200.0,28158719.0,Jain D,Hematological measurement,replication,2017-02-01,GCST004130,White blood cell count (lymphocyte)
13211,Hispanic or Latin American,11809.0,28158719.0,Jain D,Inflammatory measurement,initial,2017-02-01,GCST004127,White blood cell count (basophil)
13122,Hispanic or Latin American,7200.0,28158719.0,Jain D,Hematological measurement,replication,2017-02-01,GCST004135,White blood cell count (eosinophil)
13124,Hispanic or Latin American,7200.0,28158719.0,Jain D,Inflammatory measurement,replication,2017-02-01,GCST004127,White blood cell count (basophil)
13123,Hispanic or Latin American,7200.0,28158719.0,Jain D,"Hematological measurement, Inflammatory measurement",replication,2017-02-01,GCST004126,White blood cell count
10097,European,16169.0,28053049.0,Sennblad B,Hematological measurement,initial,2017-02-01,GCST004124,Factor XI
1958,Asian,340.0,28163062.0,Matsuura K,"Other measurement, Response to drug, Cancer",replication,2017-02-02,GCST004160,Hepatocellular carcinoma in post hepatitis C eradication by interferon therapy
2072,Asian,457.0,28163062.0,Matsuura K,"Other measurement, Response to drug, Cancer",initial,2017-02-02,GCST004160,Hepatocellular carcinoma in post hepatitis C eradication by interferon therapy
6979,European,2053.0,28256260.0,Siitonen A,Neurological disorder,initial,2017-02-02,GCST004138,Early-onset Parkinson's disease
2174,Asian,599.0,28155865.0,Chen H,Biological process,replication,2017-02-03,GCST004123,Mathematical ability
2436,Asian,998.0,28155865.0,Chen H,Biological process,initial,2017-02-03,GCST004123,Mathematical ability
5311,European,497.0,28167095.0,Forno E,"Other measurement, Other disease",replication,2017-02-04,GCST004107,Lung function (FEV1) in asthma (dust mite allergen exposure interaction)
5312,European,497.0,28167095.0,Forno E,"Other measurement, Other disease",replication,2017-02-04,GCST004108,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction)
12692,Hispanic or Latin American,605.0,28167095.0,Forno E,"Other measurement, Other disease",replication,2017-02-04,GCST004108,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction)
12691,Hispanic or Latin American,605.0,28167095.0,Forno E,"Other measurement, Other disease",replication,2017-02-04,GCST004107,Lung function (FEV1) in asthma (dust mite allergen exposure interaction)
12635,Hispanic or Latin American,440.0,28167095.0,Forno E,"Other measurement, Other disease",initial,2017-02-04,GCST004108,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction)
12634,Hispanic or Latin American,440.0,28167095.0,Forno E,"Other measurement, Other disease",initial,2017-02-04,GCST004107,Lung function (FEV1) in asthma (dust mite allergen exposure interaction)
12686,Hispanic or Latin American,600.0,28166215.0,Hobbs BD,Other disease,initial,2017-02-06,GCST004147,Chronic obstructive pulmonary disease
9780,European,11751.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004248,Alzheimer's disease in APOE e4+ carriers
965,African American or Afro-Caribbean,2106.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004248,Alzheimer's disease in APOE e4+ carriers
13507,Other/Mixed,115.0,28183528.0,Jun GR,"Neurological disorder, Other measurement",initial,2017-02-06,GCST004247,Alzheimer's disease (APOE e4 interaction)
11206,European,57176.0,28166213.0,Wain LV,Other measurement,replication,2017-02-06,GCST004184,Lung function (FVC)
11078,European,47856.0,28166215.0,Hobbs BD,Other disease,initial,2017-02-06,GCST004147,Chronic obstructive pulmonary disease
11207,European,57176.0,28166213.0,Wain LV,Other measurement,replication,2017-02-06,GCST004185,Lung function (FEV1/FVC)
2503,Asian,1159.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004249,Alzheimer's disease in APOE e4- carriers
1972,Asian,358.0,28166215.0,Hobbs BD,Other disease,replication,2017-02-06,GCST004147,Chronic obstructive pulmonary disease
11205,European,57176.0,28166213.0,Wain LV,Other measurement,replication,2017-02-06,GCST004183,Lung function (FEV1)
13505,Other/Mixed,115.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004246,Alzheimer's disease
11094,European,48943.0,28166213.0,Wain LV,Other measurement,initial,2017-02-06,GCST004184,Lung function (FVC)
11095,European,48943.0,28166213.0,Wain LV,Other measurement,initial,2017-02-06,GCST004185,Lung function (FEV1/FVC)
3761,Asian,6940.0,28166215.0,Hobbs BD,Other disease,initial,2017-02-06,GCST004147,Chronic obstructive pulmonary disease
1211,African American or Afro-Caribbean,4983.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004246,Alzheimer's disease
8763,European,6107.0,28165464.0,Law PJ,Cancer,replication,2017-02-06,GCST004146,Chronic lymphocytic leukemia
11093,European,48943.0,28166213.0,Wain LV,Other measurement,initial,2017-02-06,GCST004183,Lung function (FEV1)
13506,Other/Mixed,115.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004249,Alzheimer's disease in APOE e4- carriers
9978,European,14248.0,28183528.0,Jun GR,Neurological disorder,replication,2017-02-06,GCST004249,Alzheimer's disease in APOE e4- carriers
10600,European,26320.0,28183528.0,Jun GR,"Neurological disorder, Other measurement",initial,2017-02-06,GCST004247,Alzheimer's disease (APOE e4 interaction)
1041,African American or Afro-Caribbean,2877.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004249,Alzheimer's disease in APOE e4- carriers
9992,European,14569.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004249,Alzheimer's disease in APOE e4- carriers
10599,European,26320.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004246,Alzheimer's disease
10597,European,26287.0,28183528.0,Jun GR,"Neurological disorder, Other measurement",replication,2017-02-06,GCST004247,Alzheimer's disease (APOE e4 interaction)
10596,European,26287.0,28183528.0,Jun GR,Neurological disorder,replication,2017-02-06,GCST004246,Alzheimer's disease
2847,Asian,1845.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004246,Alzheimer's disease
10493,European,23162.0,28166215.0,Hobbs BD,Other disease,replication,2017-02-06,GCST004147,Chronic obstructive pulmonary disease
9814,European,12039.0,28183528.0,Jun GR,Neurological disorder,replication,2017-02-06,GCST004248,Alzheimer's disease in APOE e4+ carriers
10213,European,17691.0,28165464.0,Law PJ,Cancer,initial,2017-02-06,GCST004146,Chronic lymphocytic leukemia
2228,Asian,686.0,28183528.0,Jun GR,Neurological disorder,initial,2017-02-06,GCST004248,Alzheimer's disease in APOE e4+ carriers
2848,Asian,1845.0,28183528.0,Jun GR,"Neurological disorder, Other measurement",initial,2017-02-06,GCST004247,Alzheimer's disease (APOE e4 interaction)
1132,African American or Afro-Caribbean,3522.0,28166215.0,Hobbs BD,Other disease,initial,2017-02-06,GCST004147,Chronic obstructive pulmonary disease
1212,African American or Afro-Caribbean,4983.0,28183528.0,Jun GR,"Neurological disorder, Other measurement",initial,2017-02-06,GCST004247,Alzheimer's disease (APOE e4 interaction)
8828,European,6392.0,28167838.0,Deckert J,Other measurement,replication,2017-02-07,GCST004109,Agoraphobic traits
6430,European,1370.0,28167838.0,Deckert J,Other measurement,initial,2017-02-07,GCST004109,Agoraphobic traits
5950,European,933.0,28181694.0,Chesi A,Other measurement,initial,2017-02-09,GCST004176,Pediatric areal bone mineral density (radius)
5281,European,486.0,28181694.0,Chesi A,Other measurement,replication,2017-02-09,GCST004179,Pediatric bone mineral content (femoral neck)
5955,European,933.0,28181694.0,Chesi A,Other measurement,initial,2017-02-09,GCST004181,Pediatric bone mineral density (spine)
5278,European,486.0,28181694.0,Chesi A,Other measurement,replication,2017-02-09,GCST004176,Pediatric areal bone mineral density (radius)
5279,European,486.0,28181694.0,Chesi A,Other measurement,replication,2017-02-09,GCST004177,Pediatric bone mineral density (femoral neck)
12176,European,291407.0,28212542.0,Ransohoff KJ,Cancer,initial,2017-02-09,GCST004142,Melanoma
5282,European,486.0,28181694.0,Chesi A,Other measurement,replication,2017-02-09,GCST004180,Pediatric bone mineral content (hip)
5956,European,933.0,28181694.0,Chesi A,Other measurement,initial,2017-02-09,GCST004182,Pediatric bone mineral content (spine)
5280,European,486.0,28181694.0,Chesi A,Other measurement,replication,2017-02-09,GCST004178,Pediatric bone mineral density (hip)
5284,European,486.0,28181694.0,Chesi A,Other measurement,replication,2017-02-09,GCST004182,Pediatric bone mineral content (spine)
5283,European,486.0,28181694.0,Chesi A,Other measurement,replication,2017-02-09,GCST004181,Pediatric bone mineral density (spine)
5951,European,933.0,28181694.0,Chesi A,Other measurement,initial,2017-02-09,GCST004177,Pediatric bone mineral density (femoral neck)
7523,European,2830.0,28212542.0,Ransohoff KJ,Cancer,replication,2017-02-09,GCST004142,Melanoma
5277,European,486.0,28181694.0,Chesi A,Other measurement,replication,2017-02-09,GCST004175,Pediatric bone mineral content (radius)
5949,European,933.0,28181694.0,Chesi A,Other measurement,initial,2017-02-09,GCST004175,Pediatric bone mineral content (radius)
5953,European,933.0,28181694.0,Chesi A,Other measurement,initial,2017-02-09,GCST004179,Pediatric bone mineral content (femoral neck)
5954,European,933.0,28181694.0,Chesi A,Other measurement,initial,2017-02-09,GCST004180,Pediatric bone mineral content (hip)
5952,European,933.0,28181694.0,Chesi A,Other measurement,initial,2017-02-09,GCST004178,Pediatric bone mineral density (hip)
5745,European,785.0,28187132.0,Kiryluk K,Other measurement,replication,2017-02-10,GCST004159,Serum galactose-deficient IgA1 levels
2201,Asian,653.0,28187132.0,Kiryluk K,Other measurement,replication,2017-02-10,GCST004159,Serum galactose-deficient IgA1 levels
4895,European,245.0,28187132.0,Kiryluk K,Other measurement,initial,2017-02-10,GCST004159,Serum galactose-deficient IgA1 levels
2409,Asian,950.0,28187132.0,Kiryluk K,Other measurement,initial,2017-02-10,GCST004159,Serum galactose-deficient IgA1 levels
11136,European,52874.0,28196072.0,Hagenaars SP,"Other measurement, Other disease",initial,2017-02-14,GCST006661,Male-pattern baldness
12174,European,290551.0,28195142.0,Gudmundsson J,Cancer,initial,2017-02-14,GCST004144,Thyroid cancer
8711,European,5892.0,28193307.0,Lin BD,Hematological measurement,initial,2017-02-14,GCST004170,Monocyte-lymphocyte ratio
8710,European,5892.0,28193307.0,Lin BD,Hematological measurement,initial,2017-02-14,GCST004164,Monocyte count
11620,European,108976.0,28194004.0,Deary V,Other measurement,initial,2017-02-14,GCST004158,Self-reported tiredness
1225,African American or Afro-Caribbean,5334.0,28203683.0,Heit JA,Cardiovascular disease,initial,2017-02-16,GCST004068,Venous thromboembolism adjusted for sickle cell variant rs77121243-T
4431,Asian,45953.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,replication,2017-02-21,GCST004234,HDL cholesterol levels
11974,European,173082.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004233,LDL cholesterol levels
4369,Asian,32285.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004233,LDL cholesterol levels
4370,Asian,32576.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004235,Total cholesterol levels
4385,Asian,34930.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004232,HDL cholesterol levels
3907,Asian,8478.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,replication,2017-02-21,GCST004233,LDL cholesterol levels
4323,Asian,25169.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004234,HDL cholesterol levels
3929,Asian,8741.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,replication,2017-02-21,GCST004232,HDL cholesterol levels
4260,Asian,18421.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004238,Triglyceride levels
4447,Asian,57490.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,replication,2017-02-21,GCST004231,Total cholesterol levels
4344,Asian,28183.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004237,Triglyceride levels
4406,Asian,37842.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,replication,2017-02-21,GCST004236,LDL cholesterol levels
4059,Asian,10857.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,replication,2017-02-21,GCST004237,Triglyceride levels
4058,Asian,10855.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,replication,2017-02-21,GCST004235,Total cholesterol levels
11983,European,177861.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004237,Triglyceride levels
4407,Asian,38060.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,replication,2017-02-21,GCST004238,Triglyceride levels
11992,European,187167.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004232,HDL cholesterol levels
11993,European,187365.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004235,Total cholesterol levels
4312,Asian,22526.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004236,LDL cholesterol levels
4317,Asian,22814.0,28334899.0,Spracklen CN,Lipid or lipoprotein measurement,initial,2017-02-21,GCST004231,Total cholesterol levels
12206,European,304241.0,28177523.0,Lin Y,Cancer,initial,2017-02-22,GCST004113,Basal cell carcinoma
12166,European,287338.0,28223688.0,Bjornsdottir G,"Other trait, Other disease, Other measurement",initial,2017-02-22,GCST004098,Sciatica caused by lumbar disc herniation (treated with microdiscectomy)
9442,European,9179.0,28224759.0,Pei YF,Other measurement,initial,2017-02-22,GCST004141,Body fat mass
9379,European,8703.0,28649644.0,Pivot X,"Cancer, Other measurement",initial,2017-02-23,GCST004528,HER2 status in breast cancer
3688,Asian,6084.0,28232668.0,Yu Y,Other trait,initial,2017-02-24,GCST004166,Nonsyndromic cleft lip with cleft palate
9022,European,7189.0,28282560.0,Pott J,Cardiovascular measurement,initial,2017-02-24,GCST004162,Carotid plaque burden
3665,Asian,5888.0,28232668.0,Yu Y,Other trait,replication,2017-02-24,GCST004166,Nonsyndromic cleft lip with cleft palate
6376,European,1306.0,28250457.0,Scerri TS,Neurological disorder,replication,2017-02-27,GCST004171,Macular telangiectasia type 2
2439,Asian,1001.0,28334792.0,Nongmaithem SS,Other measurement,initial,2017-02-27,GCST004161,Vitamin B12 levels
7120,European,2209.0,28250457.0,Scerri TS,Neurological disorder,initial,2017-02-27,GCST004171,Macular telangiectasia type 2
6069,European,997.0,28240269.0,Suhre K,"Other measurement, Hematological measurement, Lipid or lipoprotein measurement, Cardiovascular measurement, Liver enzyme measurement, Inflammatory measurement",initial,2017-02-27,GCST004365,Blood protein levels
13629,Other/Mixed,338.0,28240269.0,Suhre K,"Other measurement, Hematological measurement, Lipid or lipoprotein measurement, Cardiovascular measurement, Liver enzyme measurement, Inflammatory measurement",replication,2017-02-27,GCST004365,Blood protein levels
3296,Asian,3418.0,28334792.0,Nongmaithem SS,Other measurement,replication,2017-02-27,GCST004161,Vitamin B12 levels
3322,Asian,3560.0,28334814.0,Zhu Z,Other disease,initial,2017-02-28,GCST004288,Adolescent idiopathic scoliosis
4052,Asian,10464.0,28334814.0,Zhu Z,Other disease,replication,2017-02-28,GCST004288,Adolescent idiopathic scoliosis
6887,European,1950.0,28253294.0,Vonk JM,Other disease,initial,2017-03-02,GCST004221,Adult onset asthma in non-smokers
13125,Hispanic or Latin American,7746.0,28254843.0,Qi Q,Metabolic disorder,initial,2017-03-02,GCST004758,Type 2 diabetes
7018,European,2107.0,28253294.0,Vonk JM,"Biological process, Other disease",initial,2017-03-02,GCST004222,Adult onset asthma in ever-smokers
8109,European,4057.0,28253294.0,Vonk JM,"Biological process, Other disease",initial,2017-03-02,GCST004220,Adult onset asthma (smoking interaction)
9842,European,12475.0,28253294.0,Vonk JM,"Biological process, Other disease",replication,2017-03-02,GCST004220,Adult onset asthma (smoking interaction)
9087,European,7496.0,28253294.0,Vonk JM,"Biological process, Other disease",replication,2017-03-02,GCST004222,Adult onset asthma in ever-smokers
8446,European,4979.0,28253294.0,Vonk JM,Other disease,replication,2017-03-02,GCST004221,Adult onset asthma in non-smokers
2359,Asian,848.0,28274756.0,Mhatre S,Cancer,replication,2017-03-03,GCST004201,Gallbladder cancer
3171,Asian,2751.0,28274756.0,Mhatre S,Cancer,initial,2017-03-03,GCST004201,Gallbladder cancer
3942,Asian,8839.0,28273873.0,Park YM,Cardiovascular disease,initial,2017-03-05,GCST004143,Hypertension
12590,Hispanic or Latin American,254.0,28262088.0,Melroy-Greif WE,"Other measurement, Biological process",initial,2017-03-06,GCST005550,Post traumatic stress disorder symptom count in trauma-exposed individuals
9730,European,11170.0,28265093.0,Malik R,Cardiovascular disease,initial,2017-03-06,GCST007991,Large artery stroke
13592,Other/Mixed,258.0,28262088.0,Melroy-Greif WE,"Other measurement, Biological process",initial,2017-03-06,GCST005550,Post traumatic stress disorder symptom count in trauma-exposed individuals
2589,Asian,1354.0,28265093.0,Malik R,Cardiovascular disease,initial,2017-03-06,GCST007991,Large artery stroke
10320,European,19546.0,28270201.0,Nagy R,Cardiovascular measurement,initial,2017-03-07,GCST004205,Pulse pressure
12932,Hispanic or Latin American,3238.0,28265120.0,Polimanti R,Other measurement,initial,2017-03-07,GCST004225,Alcohol misuse (trauma interaction)
1189,African American or Afro-Caribbean,4329.0,28265120.0,Polimanti R,Other measurement,replication,2017-03-07,GCST004225,Alcohol misuse (trauma interaction)
10322,European,19547.0,28270201.0,Nagy R,Other measurement,initial,2017-03-07,GCST004204,Systolic blood pressure
9681,European,10732.0,28265120.0,Polimanti R,Other measurement,initial,2017-03-07,GCST004225,Alcohol misuse (trauma interaction)
6999,European,2077.0,28270201.0,Nagy R,"Metabolic disorder, Other measurement",initial,2017-03-07,GCST004211,Urate levels
10321,European,19546.0,28270201.0,Nagy R,Other measurement,initial,2017-03-07,GCST004203,Diastolic blood pressure
10346,European,19900.0,28270201.0,Nagy R,"Body measurement, Other measurement",initial,2017-03-07,GCST004208,Body mass index
10331,European,19695.0,28270201.0,Nagy R,"Body measurement, Other measurement",initial,2017-03-07,GCST004216,Waist-to-hip ratio adjusted for body mass index
7991,European,3755.0,28265120.0,Polimanti R,Other measurement,replication,2017-03-07,GCST004225,Alcohol misuse (trauma interaction)
10303,European,19259.0,28270201.0,Nagy R,Lipid or lipoprotein measurement,initial,2017-03-07,GCST004209,"Cholesterol, total"
10347,European,19920.0,28270201.0,Nagy R,Cardiovascular measurement,initial,2017-03-07,GCST004213,Resting heart rate
10309,European,19293.0,28270201.0,Nagy R,Other measurement,initial,2017-03-07,GCST004215,Urea levels
10099,European,16174.0,28270201.0,Nagy R,Other measurement,initial,2017-03-07,GCST004206,Fasting plasma glucose
10315,European,19480.0,28270201.0,Nagy R,Body measurement,initial,2017-03-07,GCST004210,Body fat percentage
10348,European,19965.0,28270201.0,Nagy R,"Other measurement, Body measurement",initial,2017-03-07,GCST004212,Height
10301,European,19223.0,28270201.0,Nagy R,Lipid or lipoprotein measurement,initial,2017-03-07,GCST004207,HDL cholesterol
10114,European,16347.0,28270201.0,Nagy R,Other measurement,initial,2017-03-07,GCST004214,Creatinine levels
993,African American or Afro-Caribbean,2391.0,28265120.0,Polimanti R,Other measurement,initial,2017-03-07,GCST004225,Alcohol misuse (trauma interaction)
10470,European,22518.0,28272467.0,Heilmann-Heimbach S,"Other measurement, Other disease",initial,2017-03-08,GCST007815,Male-pattern baldness
5524,European,626.0,28439531.0,Aslibekyan S,Other measurement,initial,2017-03-08,GCST004484,Plasma trimethylamine N-oxide levels
5569,European,660.0,28781888.0,Mobuchon L,Cancer,initial,2017-03-10,GCST004661,Uveal melanoma
5020,European,339.0,28283553.0,Srinivasan L,Other trait,initial,2017-03-10,GCST004230,Sepsis in extremely premature infants
5233,European,460.0,28781888.0,Mobuchon L,Cancer,replication,2017-03-10,GCST004661,Uveal melanoma
1220,African American or Afro-Caribbean,5146.0,28295283.0,Wang H,Cancer,initial,2017-03-13,GCST004169,Rectal cancer
1269,African American or Afro-Caribbean,6597.0,28295283.0,Wang H,Cancer,initial,2017-03-13,GCST004168,Colorectal cancer
875,African American or Afro-Caribbean,1434.0,28295283.0,Wang H,Cancer,replication,2017-03-13,GCST004169,Rectal cancer
956,African American or Afro-Caribbean,2041.0,28295283.0,Wang H,Cancer,replication,2017-03-13,GCST004168,Colorectal cancer
1355,African American or Afro-Caribbean,9020.0,28296344.0,Chen G,"Body measurement, Other measurement",replication,2017-03-13,GCST004255,Body mass index
13067,Hispanic or Latin American,5941.0,28295283.0,Wang H,Cancer,replication,2017-03-13,GCST004168,Colorectal cancer
1246,African American or Afro-Caribbean,6154.0,28295283.0,Wang H,Cancer,initial,2017-03-13,GCST004167,Colon cancer
915,African American or Afro-Caribbean,1753.0,28295283.0,Wang H,Cancer,replication,2017-03-13,GCST004167,Colon cancer
186,African,1411.0,28296344.0,Chen G,"Body measurement, Other measurement",replication,2017-03-13,GCST004255,Body mass index
207,African,1570.0,28296344.0,Chen G,"Body measurement, Other measurement",initial,2017-03-13,GCST004255,Body mass index
587,African American or Afro-Caribbean,327.0,28292921.0,Boldry EJ,Other measurement,initial,2017-03-14,GCST004254,"Urinary 1,3-butadiene metabolite levels in smokers"
5099,European,396.0,28292921.0,Boldry EJ,Other measurement,initial,2017-03-14,GCST004254,"Urinary 1,3-butadiene metabolite levels in smokers"
1964,Asian,349.0,28292921.0,Boldry EJ,Other measurement,initial,2017-03-14,GCST004254,"Urinary 1,3-butadiene metabolite levels in smokers"
8285,European,4610.0,28179588.0,Fagerholm R,"Cancer, Other measurement",replication,2017-03-14,GCST004229,Survival in breast cancer (TP53 expression interaction)
4738,European,157.0,28179588.0,Fagerholm R,"Cancer, Other measurement",initial,2017-03-14,GCST004228,Survival in TP53 positive breast cancer
5439,European,572.0,28179588.0,Fagerholm R,"Cancer, Other measurement",initial,2017-03-14,GCST004229,Survival in breast cancer (TP53 expression interaction)
3318,Asian,3521.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004341,Nervonic acid (24:1n-9) levels
9813,European,12020.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004342,Vaccenic acid (18:1n-7) levels
9810,European,12020.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004337,Gondoic acid (20:1n-9) levels
3314,Asian,3521.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004337,Gondoic acid (20:1n-9) levels
3315,Asian,3521.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004338,Oleic acid (18:1n-9) levels
3316,Asian,3521.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004339,Palmitoleic acid (16:1n-7) levels
3317,Asian,3521.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004340,Erucic acid (22:1n-9) levels
3319,Asian,3521.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004342,Vaccenic acid (18:1n-7) levels
9811,European,12020.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004340,Erucic acid (22:1n-9) levels
9812,European,12020.0,28298293.0,Hu Y,Lipid or lipoprotein measurement,initial,2017-03-15,GCST004341,Nervonic acid (24:1n-9) levels
12596,Hispanic or Latin American,285.0,28300201.0,Hernandez-Pacheco N,"Other trait, Other measurement",initial,2017-03-16,GCST004219,Skin pigmentation
613,African American or Afro-Caribbean,373.0,28300201.0,Hernandez-Pacheco N,"Other trait, Other measurement",replication,2017-03-16,GCST004219,Skin pigmentation
9802,European,11907.0,28314753.0,Terao C,Neurological disorder,replication,2017-03-17,GCST004202,Systemic sclerosis
7213,European,2340.0,28314753.0,Terao C,Neurological disorder,initial,2017-03-17,GCST004202,Systemic sclerosis
3090,Asian,2427.0,28314753.0,Terao C,Neurological disorder,replication,2017-03-17,GCST004202,Systemic sclerosis
3106,Asian,2497.0,28314753.0,Terao C,Neurological disorder,initial,2017-03-17,GCST004202,Systemic sclerosis
1744,Asian,152.0,28415562.0,Li X,Other disease,initial,2017-03-18,GCST004200,High-altitude pulmonary edema
2123,Asian,503.0,28415562.0,Li X,Other disease,replication,2017-03-18,GCST004200,High-altitude pulmonary edema
6384,European,1322.0,28317342.0,Hivert MF,Other measurement,initial,2017-03-20,GCST004289,Adiponectin levels in pregnancy
12054,European,212171.0,28319091.0,Styrkarsdottir U,"Other disease, Other measurement",initial,2017-03-20,GCST004199,Osteoarthritis (with total hip replacement)
5616,European,696.0,28317342.0,Hivert MF,Other measurement,replication,2017-03-20,GCST004289,Adiponectin levels in pregnancy
7156,European,2283.0,28322352.0,Ran S,Other measurement,replication,2017-03-21,GCST004218,Lean body mass
10744,European,32241.0,28322246.0,McLaughlin RL,Neurological disorder,initial,2017-03-21,GCST004252,Amyotrophic lateral sclerosis or schizophrenia (pleiotropy)
6077,European,1000.0,28322352.0,Ran S,Other measurement,initial,2017-03-21,GCST004218,Lean body mass
14033,Other/Mixed,79845.0,28322246.0,McLaughlin RL,Neurological disorder,initial,2017-03-21,GCST004252,Amyotrophic lateral sclerosis or schizophrenia (pleiotropy)
7600,European,2998.0,28386217.0,Ritter ML,Neurological disorder,initial,2017-03-23,GCST004223,Attention deficit hyperactivity disorder and obsessive compulsive disorder
1665,Asian,98.0,28352666.0,Liu TC,"Digestive system disorder, Other measurement",initial,2017-03-23,GCST004251,Paneth cell defects in Crohn's disease
6683,European,1680.0,28333968.0,Nielsen TR,Other measurement,initial,2017-03-23,GCST004276,Plasma thyroid-stimulating hormone levels
6684,European,1680.0,28333968.0,Nielsen TR,Other measurement,initial,2017-03-23,GCST004277,Free thyroxine concentration
7026,European,2129.0,28333968.0,Nielsen TR,Other measurement,replication,2017-03-23,GCST004276,Plasma thyroid-stimulating hormone levels
7027,European,2129.0,28333968.0,Nielsen TR,Other measurement,replication,2017-03-23,GCST004277,Free thyroxine concentration
11020,European,43751.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004418,Endometrioid ovarian cancer
9837,European,12412.0,28346442.0,Phelan CM,"Other measurement, Cancer",initial,2017-03-27,GCST004416,Ovarian cancer in BRCA2 mutation carriers
312,African,10401.0,28346466.0,Chen G,Metabolic disorder,replication,2017-03-27,GCST007620,Type 2 diabetes
11156,European,53978.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004480,High-grade serous ovarian cancer
11464,European,85426.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004462,Epithelial ovarian cancer
10285,European,19036.0,28346442.0,Phelan CM,"Other measurement, Cancer",initial,2017-03-27,GCST004414,Ovarian cancer in BRCA1 mutation carriers
2884,Asian,1908.0,28346466.0,Chen G,Metabolic disorder,initial,2017-03-27,GCST007620,Type 2 diabetes
8520,European,5161.0,28030426.0,Mahmoudpour SH,Response to drug,initial,2017-03-27,GCST004029,Angiotensin-converting enzyme inhibitor intolerance
11016,European,43507.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004419,Mucinous ovarian carcinoma
10994,European,41953.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004461,Low-grade serous ovarian cancer
11009,European,42895.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004479,Serous borderline ovarian cancer
11001,European,42307.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004417,Ovarian clear cell cancer
10551,European,24381.0,28346443.0,Melin BS,Cancer,initial,2017-03-27,GCST004349,Glioblastoma
10709,European,30659.0,28346443.0,Melin BS,Cancer,initial,2017-03-27,GCST004347,Glioma
11023,European,43907.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004481,Low-grade serous and serous borderline ovarian cancer
11176,European,54990.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004478,Serous invasive ovarian cancer
10531,European,24009.0,28346443.0,Melin BS,Cancer,initial,2017-03-27,GCST004348,Non-glioblastoma glioma
11261,European,63347.0,28346442.0,Phelan CM,Cancer,initial,2017-03-27,GCST004415,Invasive epithelial ovarian cancer
2818,Asian,1790.0,28355295.0,Hong EP,"Other disease, Other measurement",initial,2017-03-29,GCST004226,Tuberculosis
2225,Asian,679.0,28355295.0,Hong EP,"Other disease, Other measurement",replication,2017-03-29,GCST004226,Tuberculosis
6590,European,1562.0,28355232.0,Ward-Caviness CK,Other measurement,initial,2017-03-29,GCST004224,Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction)
670,African American or Afro-Caribbean,538.0,28355232.0,Ward-Caviness CK,Other measurement,initial,2017-03-29,GCST004224,Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction)
11041,European,45889.0,28360221.0,Boger CA,Other measurement,initial,2017-03-30,GCST004267,Blood osmolality (transformed sodium)
4062,Asian,10978.0,28371326.0,Zhu Y,Lipid or lipoprotein measurement,replication,2017-03-30,GCST004242,HDL cholesterol
11441,European,83264.0,28358823.0,Kim SK,Other disease,initial,2017-03-30,GCST004263,Achilles tendinopathy
2092,Asian,476.0,28358823.0,Kim SK,Other disease,initial,2017-03-30,GCST004263,Achilles tendinopathy
4060,Asian,10978.0,28371326.0,Zhu Y,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",replication,2017-03-30,GCST004239,Metabolic syndrome
3414,Asian,4219.0,28371326.0,Zhu Y,"Other measurement, Body measurement",replication,2017-03-30,GCST004244,Waist-hip ratio
4061,Asian,10978.0,28371326.0,Zhu Y,Lipid or lipoprotein measurement,replication,2017-03-30,GCST004241,Triglyceride levels
3413,Asian,4219.0,28371326.0,Zhu Y,"Body measurement, Other measurement",replication,2017-03-30,GCST004245,Body mass index
3815,Asian,7518.0,28358823.0,Kim SK,Other disease,initial,2017-03-30,GCST004263,Achilles tendinopathy
3816,Asian,7518.0,28358823.0,Kim SK,Other disease,initial,2017-03-30,GCST004265,Anterior cruciate ligament rupture
3932,Asian,8765.0,28360221.0,Boger CA,Other measurement,initial,2017-03-30,GCST004267,Blood osmolality (transformed sodium)
6488,European,1449.0,28358029.0,Afshari NA,Neurological disorder,replication,2017-03-30,GCST004217,Fuchs's corneal dystrophy
1094,African American or Afro-Caribbean,3161.0,28358823.0,Kim SK,Other disease,initial,2017-03-30,GCST004263,Achilles tendinopathy
2774,Asian,1742.0,28371326.0,Zhu Y,"Other measurement, Body measurement",initial,2017-03-30,GCST004244,Waist-hip ratio
2773,Asian,1742.0,28371326.0,Zhu Y,Other measurement,initial,2017-03-30,GCST004240,Fasting blood glucose
2772,Asian,1742.0,28371326.0,Zhu Y,Lipid or lipoprotein measurement,initial,2017-03-30,GCST004243,LDL cholesterol levels
13156,Hispanic or Latin American,8560.0,28358823.0,Kim SK,Other disease,initial,2017-03-30,GCST004265,Anterior cruciate ligament rupture
2771,Asian,1742.0,28371326.0,Zhu Y,Lipid or lipoprotein measurement,initial,2017-03-30,GCST004242,HDL cholesterol
13155,Hispanic or Latin American,8560.0,28358823.0,Kim SK,Other disease,initial,2017-03-30,GCST004263,Achilles tendinopathy
2770,Asian,1742.0,28371326.0,Zhu Y,Lipid or lipoprotein measurement,initial,2017-03-30,GCST004241,Triglyceride levels
2769,Asian,1742.0,28371326.0,Zhu Y,"Body measurement, Other measurement",initial,2017-03-30,GCST004245,Body mass index
11442,European,83264.0,28358823.0,Kim SK,Other disease,initial,2017-03-30,GCST004265,Anterior cruciate ligament rupture
2768,Asian,1742.0,28371326.0,Zhu Y,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",initial,2017-03-30,GCST004239,Metabolic syndrome
2700,Asian,1589.0,28371326.0,Zhu Y,Lipid or lipoprotein measurement,replication,2017-03-30,GCST004243,LDL cholesterol levels
1287,African American or Afro-Caribbean,7215.0,28360221.0,Boger CA,Other measurement,initial,2017-03-30,GCST004267,Blood osmolality (transformed sodium)
10208,European,17637.0,28360221.0,Boger CA,Other measurement,replication,2017-03-30,GCST004267,Blood osmolality (transformed sodium)
2701,Asian,1589.0,28371326.0,Zhu Y,Other measurement,replication,2017-03-30,GCST004240,Fasting blood glucose
8068,European,3968.0,28358029.0,Afshari NA,Neurological disorder,initial,2017-03-30,GCST004217,Fuchs's corneal dystrophy
9325,European,8424.0,28333195.0,Uimari O,Other disease,initial,2017-04-01,GCST004370,Deep ovarian and/or rectovaginal disease with dense adhesions
7369,European,2555.0,28289848.0,Haralambieva IH,Response to drug,initial,2017-04-01,GCST004269,Immune response to measles vaccine (measles-specific neutralising antibody titre)
7368,European,2555.0,28289848.0,Haralambieva IH,Response to drug,initial,2017-04-01,GCST004268,Immune response to measles vaccine (measles-induced IFN gamma)
30,African,73.0,28388302.0,Petros Z,"Response to drug, Other disease, Digestive system disorder",replication,2017-04-01,GCST004261,Liver injury in anti-retroviral drug treated HIV
11317,European,69057.0,28199695.0,Jones AV,Other measurement,initial,2017-04-01,GCST004865,Itch intensity from mosquito bite adjusted by bite size
88,African,307.0,28388302.0,Petros Z,"Response to drug, Other disease, Digestive system disorder",initial,2017-04-01,GCST004261,Liver injury in anti-retroviral drug treated HIV
57,African,186.0,28388302.0,Petros Z,"Response to drug, Other disease, Digestive system disorder",initial,2017-04-01,GCST004262,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis
10139,European,16576.0,28199695.0,Jones AV,Other measurement,initial,2017-04-01,GCST004864,Perceived unattractiveness to mosquitoes
11693,European,120158.0,28373160.0,Klarin D,Cardiovascular disease,initial,2017-04-01,GCST004256,Venous thromboembolism
11058,European,46629.0,28348047.0,Li C,Other measurement,replication,2017-04-01,GCST004257,Systolic blood pressure (long-term average)
4262,Asian,18422.0,28348047.0,Li C,Other measurement,initial,2017-04-01,GCST004257,Systolic blood pressure (long-term average)
4263,Asian,18422.0,28348047.0,Li C,Other measurement,initial,2017-04-01,GCST004258,Diastolic blood pressure (long-term average)
4264,Asian,18422.0,28348047.0,Li C,Other measurement,initial,2017-04-01,GCST004259,Mean arterial pressure (long-term average)
49,African,116.0,28388302.0,Petros Z,"Response to drug, Other disease, Digestive system disorder",replication,2017-04-01,GCST004262,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis
5353,European,513.0,28207573.0,Backman JD,Other measurement,initial,2017-04-01,GCST004264,Clopidogrel active metabolite levels
5354,European,513.0,28207573.0,Backman JD,"Response to drug, Cardiovascular measurement",initial,2017-04-01,GCST004266,Response to clopidogrel therapy
9384,European,8746.0,28333195.0,Uimari O,Other disease,initial,2017-04-01,GCST004369,Ovarian disease with few adhesions
11060,European,46629.0,28348047.0,Li C,Other measurement,replication,2017-04-01,GCST004259,Mean arterial pressure (long-term average)
11059,European,46629.0,28348047.0,Li C,Other measurement,replication,2017-04-01,GCST004258,Diastolic blood pressure (long-term average)
11057,European,46629.0,28348047.0,Li C,Cardiovascular measurement,replication,2017-04-01,GCST004260,Pulse pressure (long-term average)
4261,Asian,18422.0,28348047.0,Li C,Cardiovascular measurement,initial,2017-04-01,GCST004260,Pulse pressure (long-term average)
11452,European,84724.0,28199695.0,Jones AV,Other measurement,initial,2017-04-01,GCST004861,Itch intensity from mosquito bite
11454,European,84724.0,28199695.0,Jones AV,Other measurement,initial,2017-04-01,GCST004863,Mosquito bite size
586,African American or Afro-Caribbean,317.0,28289848.0,Haralambieva IH,Response to drug,initial,2017-04-01,GCST004269,Immune response to measles vaccine (measles-specific neutralising antibody titre)
11453,European,84724.0,28199695.0,Jones AV,Other measurement,initial,2017-04-01,GCST004862,Itch intensity from mosquito bite adjusted by bite size
9619,European,10254.0,28333195.0,Uimari O,Other disease,initial,2017-04-01,GCST004368,Endometriosis
585,African American or Afro-Caribbean,317.0,28289848.0,Haralambieva IH,Response to drug,initial,2017-04-01,GCST004268,Immune response to measles vaccine (measles-induced IFN gamma)
4039,Asian,10295.0,28373541.0,Yang J,Biological process,initial,2017-04-03,GCST006054,High altitude adaptation
1571,Asian,23.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004283,Midgestational circulating levels of PCBs
12603,Hispanic or Latin American,329.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004285,Midgestational circulating levels of PBDEs
12602,Hispanic or Latin American,329.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004283,Midgestational circulating levels of PCBs
12601,Hispanic or Latin American,329.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004281,Midgestational circulating levels of organochlorine pesticides
1572,Asian,23.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004285,Midgestational circulating levels of PBDEs
1703,Asian,122.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004281,Midgestational circulating levels of organochlorine pesticides
13779,Other/Mixed,764.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004286,Midgestational circulating levels of PBDEs (fetal genetic effect)
13777,Other/Mixed,764.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004282,Midgestational circulating levels of organochlorine pesticides (fetal genetic effect)
13778,Other/Mixed,764.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004284,Midgestational circulating levels of PCBs (fetal genetic effect)
13430,Other/Mixed,22.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004285,Midgestational circulating levels of PBDEs
1570,Asian,23.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004281,Midgestational circulating levels of organochlorine pesticides
4920,European,273.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004283,Midgestational circulating levels of PCBs
4919,European,273.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004281,Midgestational circulating levels of organochlorine pesticides
13429,Other/Mixed,22.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004283,Midgestational circulating levels of PCBs
382,African American or Afro-Caribbean,21.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004281,Midgestational circulating levels of organochlorine pesticides
383,African American or Afro-Caribbean,21.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004283,Midgestational circulating levels of PCBs
1704,Asian,122.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004283,Midgestational circulating levels of PCBs
13428,Other/Mixed,22.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004281,Midgestational circulating levels of organochlorine pesticides
4921,European,273.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004285,Midgestational circulating levels of PBDEs
1705,Asian,122.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004285,Midgestational circulating levels of PBDEs
384,African American or Afro-Caribbean,21.0,28235828.0,Traglia M,Other measurement,initial,2017-04-03,GCST004285,Midgestational circulating levels of PBDEs
6542,European,1528.0,28375557.0,Thomsen H,Other disease,initial,2017-04-04,GCST004287,Monoclonal gammopathy of undetermined significance
8431,European,4942.0,28374850.0,Ellinghaus E,Other trait,initial,2017-04-04,GCST004343,Chronic venous disease
8496,European,5092.0,28374850.0,Ellinghaus E,Other trait,replication,2017-04-04,GCST004343,Chronic venous disease
10440,European,21852.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004649,Isovolumetric relaxation time
10445,European,21852.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004656,Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.
10441,European,21852.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004650,Diastolic dysfunction with preserved ejection pressure
10443,European,21852.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004653,Peak velocity of the mitral E-wave
10010,European,14787.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004652,Peak velocity of the mitral A-wave
10015,European,14787.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004658,Peak velocity of excursion of lateral mitral annulus in early diastolic phase
10014,European,14787.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004657,Ratio of the peak velocity of the excursion of the lateral mitral annulus in the early diastolic phase and the peak velocity of the mitral E-wave
10013,European,14787.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004656,Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.
10012,European,14787.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004654,Deceleration time of the mitral E-wave
10011,European,14787.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004653,Peak velocity of the mitral E-wave
10009,European,14787.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004650,Diastolic dysfunction with preserved ejection pressure
10008,European,14787.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004649,Isovolumetric relaxation time
10444,European,21852.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004654,Deceleration time of the mitral E-wave
10699,European,30201.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004659,Left ventricular mass
9957,European,14002.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004645,Left ventricular fractional shortening
9958,European,14002.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004651,Aortic root size
9959,European,14002.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004655,Left ventricle diastolic internal dimension
9960,European,14002.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004659,Left ventricular mass
10016,European,14787.0,28394258.0,Wild PS,Cardiovascular measurement,replication,2017-04-10,GCST004660,Heart failure with preserved ejection fraction
10442,European,21852.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004652,Peak velocity of the mitral A-wave
10698,European,30201.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004655,Left ventricle diastolic internal dimension
10448,European,21852.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004660,Heart failure with preserved ejection fraction
10447,European,21852.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004658,Peak velocity of excursion of lateral mitral annulus in early diastolic phase
10693,European,30201.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004645,Left ventricular fractional shortening
10694,European,30201.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004646,Left ventricle wall thickness
10696,European,30201.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004648,Left  ventricle systolic dysfunction
10446,European,21852.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004657,Ratio of the peak velocity of the excursion of the lateral mitral annulus in the early diastolic phase and the peak velocity of the mitral E-wave
10695,European,30201.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004647,Left atrial antero-posterior diameter
10697,European,30201.0,28394258.0,Wild PS,Cardiovascular measurement,initial,2017-04-10,GCST004651,Aortic root size
3874,Asian,7935.0,28406950.0,Kim J,Metabolic disorder,initial,2017-04-13,GCST004304,Prevalent type 2 diabetes
3875,Asian,7935.0,28406950.0,Kim J,Metabolic disorder,initial,2017-04-13,GCST004305,Type 2 diabetes
4671,European,98.0,28437668.0,Jung J,"Neurological disorder, Response to drug",initial,2017-04-14,GCST004270,Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks)
4675,European,98.0,28437668.0,Jung J,"Neurological disorder, Response to drug",initial,2017-04-14,GCST004274,Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks)
4674,European,98.0,28437668.0,Jung J,"Neurological disorder, Response to drug",initial,2017-04-14,GCST004273,Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks)
4673,European,98.0,28437668.0,Jung J,"Neurological disorder, Response to drug",initial,2017-04-14,GCST004272,Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 12 weeks)
4672,European,98.0,28437668.0,Jung J,"Neurological disorder, Response to drug",initial,2017-04-14,GCST004271,Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks)
4676,European,98.0,28437668.0,Jung J,"Neurological disorder, Response to drug",initial,2017-04-14,GCST004275,Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)
1237,African American or Afro-Caribbean,5875.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004295,Atrial fibrillation
11690,European,118755.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004297,Atrial fibrillation
11688,European,118755.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004295,Atrial fibrillation
11631,European,111432.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004301,Prevalent atrial fibrillation
11689,European,118755.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004296,Atrial fibrillation
12938,Hispanic or Latin American,3358.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004296,Atrial fibrillation
3403,Asian,4133.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004298,Atrial fibrillation
11749,European,129712.0,28416822.0,Low SK,Cardiovascular disease,replication,2017-04-17,GCST004373,Atrial fibrillation
12937,Hispanic or Latin American,3358.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004295,Atrial fibrillation
4401,Asian,36792.0,28416822.0,Low SK,Cardiovascular disease,initial,2017-04-17,GCST004373,Atrial fibrillation
4400,Asian,36792.0,28416818.0,Christophersen IE,Cardiovascular disease,replication,2017-04-17,GCST004298,Atrial fibrillation
4399,Asian,36792.0,28416818.0,Christophersen IE,Cardiovascular disease,replication,2017-04-17,GCST004295,Atrial fibrillation
3401,Asian,4130.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004295,Atrial fibrillation
1239,African American or Afro-Caribbean,5875.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004299,Atrial fibrillation
1238,African American or Afro-Caribbean,5875.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004296,Atrial fibrillation
11625,European,110099.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004300,Incident atrial fibrillation
4512,Asian,128184.0,28416822.0,Low SK,Cardiovascular disease,replication,2017-04-17,GCST004373,Atrial fibrillation
3402,Asian,4130.0,28416818.0,Christophersen IE,Cardiovascular disease,initial,2017-04-17,GCST004296,Atrial fibrillation
757,African American or Afro-Caribbean,889.0,28416818.0,Christophersen IE,Cardiovascular disease,replication,2017-04-17,GCST004299,Atrial fibrillation
2393,Asian,922.0,28416812.0,Yang L,"Neurological disorder, Other measurement",replication,2017-04-18,GCST004336,Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder
4898,European,251.0,28421636.0,Dennis J,Other measurement,initial,2017-04-18,GCST004344,Tissue factor pathway inhibitor levels
2321,Asian,780.0,28416812.0,Yang L,"Neurological disorder, Other measurement",initial,2017-04-18,GCST004336,Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder
6131,European,1033.0,28421636.0,Dennis J,Other measurement,replication,2017-04-18,GCST004344,Tissue factor pathway inhibitor levels
1562,Asian,15.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004363,Plasma androstenedione levels in resected early stage-receptor positive breast cancer
1561,Asian,15.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004362,Plasma estrone levels in resected estrogen-receptor positive breast cancer
3537,Asian,5158.0,28425483.0,Qiu F,Cancer,initial,2017-04-20,GCST004302,Primary biliary cholangitis
2138,Asian,534.0,28424481.0,Sugiura-Ogasawara M,Immune system disorder,initial,2017-04-20,GCST004227,Obstetric antiphospholipid syndrome
410,African American or Afro-Caribbean,52.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004360,Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer
5633,European,707.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004359,Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer
5634,European,707.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004360,Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer
5635,European,707.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004361,Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer
1558,Asian,15.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004359,Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer
409,African American or Afro-Caribbean,52.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004359,Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer
412,African American or Afro-Caribbean,52.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004362,Plasma estrone levels in resected estrogen-receptor positive breast cancer
1560,Asian,15.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004361,Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer
413,African American or Afro-Caribbean,52.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004363,Plasma androstenedione levels in resected early stage-receptor positive breast cancer
5636,European,707.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004362,Plasma estrone levels in resected estrogen-receptor positive breast cancer
3250,Asian,3034.0,28425483.0,Qiu F,Cancer,replication,2017-04-20,GCST004302,Primary biliary cholangitis
5637,European,707.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004363,Plasma androstenedione levels in resected early stage-receptor positive breast cancer
411,African American or Afro-Caribbean,52.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004361,Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer
1559,Asian,15.0,28429243.0,Dudenkov TM,"Cancer, Other measurement",initial,2017-04-20,GCST004360,Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer
12229,European,322154.0,28430825.0,Ng MCY,Body measurement,replication,2017-04-21,GCST004519,Body mass index (adult)
1506,African American or Afro-Caribbean,46696.0,28430825.0,Ng MCY,Body measurement,initial,2017-04-21,GCST004519,Body mass index (adult)
12050,European,210086.0,28430825.0,Ng MCY,"Body measurement, Other measurement",replication,2017-04-21,GCST004518,Waist-to-hip ratio adjusted for body mass index
168,African,1056.0,28430825.0,Ng MCY,Body measurement,initial,2017-04-21,GCST004519,Body mass index (adult)
1452,African American or Afro-Caribbean,20384.0,28430825.0,Ng MCY,"Body measurement, Other measurement",initial,2017-04-21,GCST004518,Waist-to-hip ratio adjusted for body mass index
311,African,10143.0,28430825.0,Ng MCY,Body measurement,replication,2017-04-21,GCST004519,Body mass index (adult)
1027,African American or Afro-Caribbean,2711.0,28430825.0,Ng MCY,"Body measurement, Other measurement",replication,2017-04-21,GCST004518,Waist-to-hip ratio adjusted for body mass index
4888,European,242.0,28560309.0,Lee E,"Neurological disorder, Other measurement, Other trait",initial,2017-04-23,GCST004253,Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction)
7104,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004328,"Facial morphology (factor 1, breadth of lateral portion of upper face)"
7091,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004315,"Facial morphology (factor 11, projection of the nose)"
7082,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004306,"Facial morphology (factor 2, vertical position of orbits relative to midface)"
7083,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004307,"Facial morphology (factor 3, length of philtrum)"
7084,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004308,"Facial morphology (factor 4, facial height related to vertical position of gnathion)"
7103,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004327,Facial morphology (factor 23)
10002,European,14713.0,28440896.0,Yin X,Neurological disorder,initial,2017-04-25,GCST004294,Nicotine dependence
7087,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004311,"Facial morphology (factor 7, width of cartilaginous portion of nose)"
7088,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004312,"Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion)"
7102,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004326,Facial morphology (factor 22)
7101,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004325,"Facial morphology (factor 21, depth of nasal alae)"
7093,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004317,"Facial morphology (factor 13, vertical position of alar curvature relative to upper lip)"
7085,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004309,"Facial morphology (factor 5, width of mouth relative to central midface)"
7094,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004318,"Facial morphology (factor 14, intercanthal width)"
7089,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004313,"Facial morphology (factor 9, facial height related to vertical position of nasion)"
1122,African American or Afro-Caribbean,3369.0,28440896.0,Yin X,Neurological disorder,initial,2017-04-25,GCST004294,Nicotine dependence
7096,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004320,Facial morphology (factor 16)
7097,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004321,"Facial morphology (factor 17, height of vermillion upper lip)"
7086,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004310,"Facial morphology (factor 6, height of vermillion lower lip)"
7098,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004322,Facial morphology (factor 18)
7100,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004324,Facial morphology (factor 20)
7092,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004316,"Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface)"
13783,Other/Mixed,787.0,28449029.0,Munz M,Digestive system disorder,initial,2017-04-25,GCST004303,Aggressive periodontitis
6035,European,979.0,28441426.0,White CC,Biological process,initial,2017-04-25,GCST004291,Residual cognition
7090,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004314,"Facial morphology (factor 10, width of nasal floor)"
9125,European,7687.0,28449029.0,Munz M,Digestive system disorder,initial,2017-04-25,GCST004303,Aggressive periodontitis
7099,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004323,Facial morphology (factor 19)
7095,European,2187.0,28441456.0,Lee MK,Other measurement,initial,2017-04-25,GCST004319,"Facial morphology (factor 15, philtrum width)"
12974,Hispanic or Latin American,3787.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004508,Waist-to-hip ratio adjusted for BMI in non-smokers
12973,Hispanic or Latin American,3787.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004504,Waist circumference adjusted for BMI in non-smokers
11748,European,129415.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004499,BMI in non-smokers
3916,Asian,8678.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004497,Body mass index (joint analysis main effects and smoking interaction)
3846,Asian,7711.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004508,Waist-to-hip ratio adjusted for BMI in non-smokers
3915,Asian,8678.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004496,BMI (smoking interaction)
2677,Asian,1526.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004499,BMI in non-smokers
12972,Hispanic or Latin American,3787.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004499,BMI in non-smokers
3914,Asian,8678.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004495,BMI (adjusted for smoking behaviour)
2422,Asian,967.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004503,Waist circumference adjusted for BMI in smokers
4922,European,275.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004408,HIV-associated neurocognitive disorder (mild neurocognitive disorder)
10579,European,25372.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004509,Waist-to-hip ratio adjusted for BMI in smokers
11796,European,139141.0,28443625.0,Justice AE,Body measurement,replication,2017-04-26,GCST004508,Waist-to-hip ratio adjusted for BMI in non-smokers
11923,European,164513.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004506,Waist-to-hip ratio adjusted for BMI (smoking interaction)
11795,European,139141.0,28443625.0,Justice AE,Body measurement,replication,2017-04-26,GCST004504,Waist circumference adjusted for BMI in non-smokers
5205,European,443.0,28447399.0,Jia P,"Other disease, Other measurement",initial,2017-04-26,GCST004406,Neurocognitive impairment in HIV-1 infection (continuous)
1406,African American or Afro-Caribbean,13206.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004497,Body mass index (joint analysis main effects and smoking interaction)
11917,European,164513.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004496,BMI (smoking interaction)
11939,European,168375.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004497,Body mass index (joint analysis main effects and smoking interaction)
11938,European,168375.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004496,BMI (smoking interaction)
11918,European,164513.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004497,Body mass index (joint analysis main effects and smoking interaction)
11734,European,126046.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004508,Waist-to-hip ratio adjusted for BMI in non-smokers
11937,European,168375.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004495,BMI (adjusted for smoking behaviour)
11934,European,167121.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004502,Waist circumference adjusted for BMI (smoking interaction)
1405,African American or Afro-Caribbean,13206.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004496,BMI (smoking interaction)
1407,African American or Afro-Caribbean,13206.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004500,Waist circumference adjusted for BMI (adjusted for smoking behaviour)
11919,European,164513.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004500,Waist circumference adjusted for BMI (adjusted for smoking behaviour)
1408,African American or Afro-Caribbean,13206.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004501,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
11932,European,167121.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004500,Waist circumference adjusted for BMI (adjusted for smoking behaviour)
1409,African American or Afro-Caribbean,13206.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004502,Waist circumference adjusted for BMI (smoking interaction)
1410,African American or Afro-Caribbean,13206.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004505,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
11924,European,164513.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004507,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
11920,European,164513.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004501,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
11921,European,164513.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004502,Waist circumference adjusted for BMI (smoking interaction)
1411,African American or Afro-Caribbean,13206.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004506,Waist-to-hip ratio adjusted for BMI (smoking interaction)
11933,European,167121.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004501,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
3917,Asian,8678.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004500,Waist circumference adjusted for BMI (adjusted for smoking behaviour)
1404,African American or Afro-Caribbean,13206.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004495,BMI (adjusted for smoking behaviour)
11916,European,164513.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004495,BMI (adjusted for smoking behaviour)
3918,Asian,8678.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004501,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
11747,European,129288.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004504,Waist circumference adjusted for BMI in non-smokers
3919,Asian,8678.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004502,Waist circumference adjusted for BMI (smoking interaction)
10578,European,25372.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004503,Waist circumference adjusted for BMI in smokers
3920,Asian,8678.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004505,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
3921,Asian,8678.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004506,Waist-to-hip ratio adjusted for BMI (smoking interaction)
3922,Asian,8678.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004507,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
10577,European,25372.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004498,BMI in smokers
11909,European,163276.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004505,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
3845,Asian,7711.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004504,Waist circumference adjusted for BMI in non-smokers
11910,European,163276.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004506,Waist-to-hip ratio adjusted for BMI (smoking interaction)
12773,Hispanic or Latin American,921.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004498,BMI in smokers
11922,European,164513.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004505,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
5077,European,380.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004410,HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment)
12774,Hispanic or Latin American,921.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004503,Waist circumference adjusted for BMI in smokers
2421,Asian,967.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004498,BMI in smokers
12775,Hispanic or Latin American,921.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004509,Waist-to-hip ratio adjusted for BMI in smokers
5207,European,443.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004409,HIV-associated neurocognitive disorder
5206,European,443.0,28447399.0,Jia P,"Other disease, Other measurement",initial,2017-04-26,GCST004407,Neurocognitive impairment in HIV-1 infection (dichotomous)
588,African American or Afro-Caribbean,327.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004408,HIV-associated neurocognitive disorder (mild neurocognitive disorder)
11911,European,163276.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004507,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
3844,Asian,7711.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004499,BMI in non-smokers
1387,African American or Afro-Caribbean,10602.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004504,Waist circumference adjusted for BMI in non-smokers
1388,African American or Afro-Caribbean,10602.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004508,Waist-to-hip ratio adjusted for BMI in non-smokers
2824,Asian,1793.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004502,Waist circumference adjusted for BMI (smoking interaction)
2823,Asian,1793.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004501,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
2822,Asian,1793.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004500,Waist circumference adjusted for BMI (adjusted for smoking behaviour)
2821,Asian,1793.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004497,Body mass index (joint analysis main effects and smoking interaction)
2820,Asian,1793.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004496,BMI (smoking interaction)
1030,African American or Afro-Caribbean,2720.0,28443625.0,Justice AE,Body measurement,replication,2017-04-26,GCST004508,Waist-to-hip ratio adjusted for BMI in non-smokers
2819,Asian,1793.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004495,BMI (adjusted for smoking behaviour)
1029,African American or Afro-Caribbean,2720.0,28443625.0,Justice AE,Body measurement,replication,2017-04-26,GCST004504,Waist circumference adjusted for BMI in non-smokers
1028,African American or Afro-Caribbean,2720.0,28443625.0,Justice AE,Body measurement,replication,2017-04-26,GCST004499,BMI in non-smokers
2825,Asian,1793.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004505,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
2678,Asian,1526.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004504,Waist circumference adjusted for BMI in non-smokers
654,African American or Afro-Caribbean,461.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004503,Waist circumference adjusted for BMI in smokers
655,African American or Afro-Caribbean,461.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004509,Waist-to-hip ratio adjusted for BMI in smokers
659,African American or Afro-Caribbean,482.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004411,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment)
661,African American or Afro-Caribbean,489.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004409,HIV-associated neurocognitive disorder
662,African American or Afro-Caribbean,490.0,28447399.0,Jia P,"Other disease, Other measurement",initial,2017-04-26,GCST004406,Neurocognitive impairment in HIV-1 infection (continuous)
663,African American or Afro-Caribbean,490.0,28447399.0,Jia P,"Other disease, Other measurement",initial,2017-04-26,GCST004407,Neurocognitive impairment in HIV-1 infection (dichotomous)
1012,African American or Afro-Caribbean,2604.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004503,Waist circumference adjusted for BMI in smokers
1011,African American or Afro-Caribbean,2604.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004498,BMI in smokers
10867,European,36054.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004509,Waist-to-hip ratio adjusted for BMI in smokers
653,African American or Afro-Caribbean,461.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004498,BMI in smokers
2826,Asian,1793.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004506,Waist-to-hip ratio adjusted for BMI (smoking interaction)
10876,European,36657.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004503,Waist circumference adjusted for BMI in smokers
2827,Asian,1793.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004507,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
1108,African American or Afro-Caribbean,3181.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004507,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
1107,African American or Afro-Caribbean,3181.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004506,Waist-to-hip ratio adjusted for BMI (smoking interaction)
1106,African American or Afro-Caribbean,3181.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004505,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
1105,African American or Afro-Caribbean,3181.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004502,Waist circumference adjusted for BMI (smoking interaction)
1104,African American or Afro-Caribbean,3181.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004501,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
11794,European,139141.0,28443625.0,Justice AE,Body measurement,replication,2017-04-26,GCST004499,BMI in non-smokers
1103,African American or Afro-Caribbean,3181.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004500,Waist circumference adjusted for BMI (adjusted for smoking behaviour)
1102,African American or Afro-Caribbean,3181.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004497,Body mass index (joint analysis main effects and smoking interaction)
1101,African American or Afro-Caribbean,3181.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004496,BMI (smoking interaction)
1100,African American or Afro-Caribbean,3181.0,28443625.0,Justice AE,"Biological process, Body measurement",replication,2017-04-26,GCST004495,BMI (adjusted for smoking behaviour)
12526,Hispanic or Latin American,46.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004408,HIV-associated neurocognitive disorder (mild neurocognitive disorder)
12534,Hispanic or Latin American,78.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004410,HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment)
12541,Hispanic or Latin American,95.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004411,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment)
5156,European,425.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004411,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment)
10914,European,37784.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004498,BMI in smokers
12544,Hispanic or Latin American,99.0,28447399.0,Jia P,"Other disease, Other measurement",initial,2017-04-26,GCST004406,Neurocognitive impairment in HIV-1 infection (continuous)
12545,Hispanic or Latin American,99.0,28447399.0,Jia P,"Other disease, Other measurement",initial,2017-04-26,GCST004407,Neurocognitive impairment in HIV-1 infection (dichotomous)
12546,Hispanic or Latin American,99.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004409,HIV-associated neurocognitive disorder
1888,Asian,267.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004498,BMI in smokers
1889,Asian,267.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004503,Waist circumference adjusted for BMI in smokers
1890,Asian,267.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004509,Waist-to-hip ratio adjusted for BMI in smokers
1010,African American or Afro-Caribbean,2602.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004509,Waist-to-hip ratio adjusted for BMI in smokers
13020,Hispanic or Latin American,4708.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004507,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
648,African American or Afro-Caribbean,452.0,28447399.0,Jia P,Other measurement,initial,2017-04-26,GCST004410,HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment)
13015,Hispanic or Latin American,4708.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004500,Waist circumference adjusted for BMI (adjusted for smoking behaviour)
13014,Hispanic or Latin American,4708.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004497,Body mass index (joint analysis main effects and smoking interaction)
13019,Hispanic or Latin American,4708.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004506,Waist-to-hip ratio adjusted for BMI (smoking interaction)
2423,Asian,967.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004509,Waist-to-hip ratio adjusted for BMI in smokers
13017,Hispanic or Latin American,4708.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004502,Waist circumference adjusted for BMI (smoking interaction)
13018,Hispanic or Latin American,4708.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004505,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
13016,Hispanic or Latin American,4708.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004501,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
1385,African American or Afro-Caribbean,10602.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004507,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
13012,Hispanic or Latin American,4708.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004495,BMI (adjusted for smoking behaviour)
1386,African American or Afro-Caribbean,10602.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004499,BMI in non-smokers
2679,Asian,1526.0,28443625.0,Justice AE,Body measurement,initial,2017-04-26,GCST004508,Waist-to-hip ratio adjusted for BMI in non-smokers
13013,Hispanic or Latin American,4708.0,28443625.0,Justice AE,"Biological process, Body measurement",initial,2017-04-26,GCST004496,BMI (smoking interaction)
10898,European,37487.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004576,Waist-to-hip ratio adjusted for body mass index
10899,European,37487.0,28448500.0,Graff M,"Body measurement, Other measurement, Biological process",replication,2017-04-27,GCST004568,Body mass index (physical activity interaction)
1172,African American or Afro-Caribbean,3975.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004566,Waist-to-hip ratio adjusted for BMI (physical activity interaction)
1217,African American or Afro-Caribbean,5072.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004559,Body mass index in physically active individuals
3851,Asian,7713.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004563,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)
3852,Asian,7713.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004566,Waist-to-hip ratio adjusted for BMI (physical activity interaction)
1218,African American or Afro-Caribbean,5072.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004564,Waist circumference adjusted for BMI in active individuals
3854,Asian,7713.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004576,Waist-to-hip ratio adjusted for body mass index
11829,European,146049.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004561,Waist circumference adjusted for BMI (physical activity interaction)
11831,European,146049.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004563,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)
8227,European,4421.0,28445677.0,Steri M,Immune system disorder,initial,2017-04-27,GCST004290,Multiple sclerosis
3853,Asian,7713.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004567,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
3061,Asian,2334.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004559,Body mass index in physically active individuals
3566,Asian,5379.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004560,Body mass index in physically inactive individuals
3567,Asian,5379.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004565,Waist circumference adjusted for BMI in inactive individuals
3568,Asian,5379.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004577,Waist-to-hip ratio adjusted for BMI in inactive individuals
3062,Asian,2334.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004564,Waist circumference adjusted for BMI in active individuals
10618,European,26887.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004578,Waist-to-hip ratio adjusted for BMI in active individuals
2931,Asian,2012.0,28460022.0,Lee JY,Cardiovascular disease,replication,2017-04-27,GCST004352,Early onset atrial fibrillation
11830,European,146049.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004562,Waist circumference adjusted for body mass index
10897,European,37487.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004567,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
10895,European,37487.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004563,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)
10896,European,37487.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004566,Waist-to-hip ratio adjusted for BMI (physical activity interaction)
3431,Asian,4372.0,28460022.0,Lee JY,Cardiovascular disease,initial,2017-04-27,GCST004352,Early onset atrial fibrillation
3847,Asian,7713.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004557,Body mass index
1171,African American or Afro-Caribbean,3975.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004563,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)
9653,European,10600.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004560,Body mass index in physically inactive individuals
10616,European,26887.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004559,Body mass index in physically active individuals
10891,European,37487.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004557,Body mass index
3848,Asian,7713.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004558,Body mass index (joint analysis main effects and physical activity interaction)
9654,European,10600.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004565,Waist circumference adjusted for BMI in inactive individuals
1170,African American or Afro-Caribbean,3975.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004562,Waist circumference adjusted for body mass index
9655,European,10600.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004577,Waist-to-hip ratio adjusted for BMI in inactive individuals
3849,Asian,7713.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004561,Waist circumference adjusted for BMI (physical activity interaction)
1097,African American or Afro-Caribbean,3163.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004578,Waist-to-hip ratio adjusted for BMI in active individuals
1173,African American or Afro-Caribbean,3975.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004567,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
11663,European,115827.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004559,Body mass index in physically active individuals
10892,European,37487.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004558,Body mass index (joint analysis main effects and physical activity interaction)
11813,European,142227.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004566,Waist-to-hip ratio adjusted for BMI (physical activity interaction)
11661,European,115058.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004564,Waist circumference adjusted for BMI in active individuals
11814,European,142227.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004567,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
1095,African American or Afro-Caribbean,3163.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004559,Body mass index in physically active individuals
10893,European,37487.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004561,Waist circumference adjusted for BMI (physical activity interaction)
10894,European,37487.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004562,Waist circumference adjusted for body mass index
11815,European,142227.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004576,Waist-to-hip ratio adjusted for body mass index
10617,European,26887.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004564,Waist circumference adjusted for BMI in active individuals
1175,African American or Afro-Caribbean,3975.0,28448500.0,Graff M,"Body measurement, Other measurement, Biological process",initial,2017-04-27,GCST004568,Body mass index (physical activity interaction)
1174,African American or Afro-Caribbean,3975.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004576,Waist-to-hip ratio adjusted for body mass index
3850,Asian,7713.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004562,Waist circumference adjusted for body mass index
1096,African American or Afro-Caribbean,3163.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004564,Waist circumference adjusted for BMI in active individuals
1267,African American or Afro-Caribbean,6573.0,28448500.0,Graff M,"Body measurement, Other measurement, Biological process",replication,2017-04-27,GCST004568,Body mass index (physical activity interaction)
11836,European,146942.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004558,Body mass index (joint analysis main effects and physical activity interaction)
3855,Asian,7713.0,28448500.0,Graff M,"Body measurement, Other measurement, Biological process",initial,2017-04-27,GCST004568,Body mass index (physical activity interaction)
10017,European,14789.0,28445677.0,Steri M,Immune system disorder,replication,2017-04-27,GCST004290,Multiple sclerosis
2806,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004578,Waist-to-hip ratio adjusted for BMI in active individuals
2805,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004576,Waist-to-hip ratio adjusted for body mass index
2804,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004567,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
1266,African American or Afro-Caribbean,6573.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004576,Waist-to-hip ratio adjusted for body mass index
1968,Asian,352.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004577,Waist-to-hip ratio adjusted for BMI in inactive individuals
1259,African American or Afro-Caribbean,6573.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004557,Body mass index
3063,Asian,2334.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004578,Waist-to-hip ratio adjusted for BMI in active individuals
2802,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004564,Waist circumference adjusted for BMI in active individuals
2801,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004563,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)
1967,Asian,352.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004565,Waist circumference adjusted for BMI in inactive individuals
2800,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004562,Waist circumference adjusted for body mass index
1260,African American or Afro-Caribbean,6573.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004558,Body mass index (joint analysis main effects and physical activity interaction)
1966,Asian,352.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004560,Body mass index in physically inactive individuals
1263,African American or Afro-Caribbean,6573.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004563,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)
2799,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004561,Waist circumference adjusted for BMI (physical activity interaction)
1262,African American or Afro-Caribbean,6573.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004562,Waist circumference adjusted for body mass index
1261,African American or Afro-Caribbean,6573.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004561,Waist circumference adjusted for BMI (physical activity interaction)
2798,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004559,Body mass index in physically active individuals
2797,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004558,Body mass index (joint analysis main effects and physical activity interaction)
2796,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004557,Body mass index
734,African American or Afro-Caribbean,812.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004560,Body mass index in physically inactive individuals
2807,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement, Biological process",initial,2017-04-27,GCST004568,Body mass index (physical activity interaction)
2803,Asian,1773.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004566,Waist-to-hip ratio adjusted for BMI (physical activity interaction)
1265,African American or Afro-Caribbean,6573.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004567,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
10717,European,31133.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004577,Waist-to-hip ratio adjusted for BMI in inactive individuals
1264,African American or Afro-Caribbean,6573.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004566,Waist-to-hip ratio adjusted for BMI (physical activity interaction)
886,African American or Afro-Caribbean,1501.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004560,Body mass index in physically inactive individuals
887,African American or Afro-Caribbean,1501.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004565,Waist circumference adjusted for BMI in inactive individuals
888,African American or Afro-Caribbean,1501.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004577,Waist-to-hip ratio adjusted for BMI in inactive individuals
1219,African American or Afro-Caribbean,5072.0,28448500.0,Graff M,"Body measurement, Other measurement",replication,2017-04-27,GCST004578,Waist-to-hip ratio adjusted for BMI in active individuals
1168,African American or Afro-Caribbean,3975.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004558,Body mass index (joint analysis main effects and physical activity interaction)
1167,African American or Afro-Caribbean,3975.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004557,Body mass index
11640,European,112031.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004578,Waist-to-hip ratio adjusted for BMI in active individuals
11835,European,146942.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004557,Body mass index
10735,European,31928.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004565,Waist circumference adjusted for BMI in inactive individuals
10738,European,32052.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004560,Body mass index in physically inactive individuals
736,African American or Afro-Caribbean,812.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004577,Waist-to-hip ratio adjusted for BMI in inactive individuals
735,African American or Afro-Caribbean,812.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004565,Waist circumference adjusted for BMI in inactive individuals
11837,European,146942.0,28448500.0,Graff M,"Body measurement, Other measurement, Biological process",initial,2017-04-27,GCST004568,Body mass index (physical activity interaction)
1169,African American or Afro-Caribbean,3975.0,28448500.0,Graff M,"Body measurement, Other measurement",initial,2017-04-27,GCST004561,Waist circumference adjusted for BMI (physical activity interaction)
13025,Hispanic or Latin American,4772.0,28453575.0,Hodonsky CJ,Hematological measurement,replication,2017-04-28,GCST004334,Mean corpuscular hemoglobin
13236,Hispanic or Latin American,12502.0,28453575.0,Hodonsky CJ,Hematological measurement,initial,2017-04-28,GCST004331,Hemoglobin
13235,Hispanic or Latin American,12502.0,28453575.0,Hodonsky CJ,Hematological measurement,initial,2017-04-28,GCST004330,Hematocrit
13026,Hispanic or Latin American,4772.0,28453575.0,Hodonsky CJ,Hematological measurement,replication,2017-04-28,GCST004335,Mean corpuscular volume
13024,Hispanic or Latin American,4772.0,28453575.0,Hodonsky CJ,Hematological measurement,replication,2017-04-28,GCST004333,Red cell distribution width
13234,Hispanic or Latin American,12502.0,28453575.0,Hodonsky CJ,Hematological measurement,initial,2017-04-28,GCST004329,Mean corpuscular hemoglobin concentration
13023,Hispanic or Latin American,4772.0,28453575.0,Hodonsky CJ,Hematological measurement,replication,2017-04-28,GCST004332,Red blood cell count
13237,Hispanic or Latin American,12502.0,28453575.0,Hodonsky CJ,Hematological measurement,initial,2017-04-28,GCST004332,Red blood cell count
13022,Hispanic or Latin American,4772.0,28453575.0,Hodonsky CJ,Hematological measurement,replication,2017-04-28,GCST004329,Mean corpuscular hemoglobin concentration
10535,European,24063.0,28452372.0,Gorski M,Other measurement,initial,2017-04-28,GCST004293,Glomerular filtration rate (cystatin C)
13238,Hispanic or Latin American,12502.0,28453575.0,Hodonsky CJ,Hematological measurement,initial,2017-04-28,GCST004333,Red cell distribution width
11628,European,110517.0,28452372.0,Gorski M,Other measurement,initial,2017-04-28,GCST004292,Glomerular filtration rate (creatinine)
4635,European,84.0,28453389.0,Koga A,"Response to drug, Neurological disorder, Other measurement",initial,2017-04-28,GCST004374,Resistance to antipsychotic treatment in schizophrenia (childhood trauma interaction)
4634,European,84.0,28453389.0,Koga A,"Response to drug, Neurological disorder",initial,2017-04-28,GCST004375,Resistance to antipsychotic treatment in schizophrenia
13116,Hispanic or Latin American,7106.0,28453575.0,Hodonsky CJ,Hematological measurement,replication,2017-04-28,GCST004330,Hematocrit
13239,Hispanic or Latin American,12502.0,28453575.0,Hodonsky CJ,Hematological measurement,initial,2017-04-28,GCST004334,Mean corpuscular hemoglobin
13240,Hispanic or Latin American,12502.0,28453575.0,Hodonsky CJ,Hematological measurement,initial,2017-04-28,GCST004335,Mean corpuscular volume
13117,Hispanic or Latin American,7106.0,28453575.0,Hodonsky CJ,Hematological measurement,replication,2017-04-28,GCST004331,Hemoglobin
13047,Hispanic or Latin American,5037.0,28461288.0,Yan Q,Other disease,initial,2017-05-01,GCST004390,Asthma
2563,Asian,1283.0,28471803.0,Choe EK,Other measurement,replication,2017-05-03,GCST004345,Elevated serum prostate-specific antigen levels in healthy men
3199,Asian,2841.0,28471803.0,Choe EK,Other measurement,initial,2017-05-03,GCST004345,Elevated serum prostate-specific antigen levels in healthy men
5864,European,868.0,28470677.0,Tang H,"Other measurement, Cancer",initial,2017-05-03,GCST004485,Survival in pancreatic cancer
5785,European,820.0,28470677.0,Tang H,"Other measurement, Cancer",replication,2017-05-03,GCST004485,Survival in pancreatic cancer
10144,European,16627.0,28472463.0,Mullin BH,Other measurement,initial,2017-05-04,GCST004350,Bone ultrasound measurement (velocity of sound)
10145,European,16627.0,28472463.0,Mullin BH,Other measurement,initial,2017-05-04,GCST004351,Bone ultrasound measurement (broadband ultrasound attenuation)
13659,Other/Mixed,419.0,28476931.0,Piaggi P,Other measurement,initial,2017-05-05,GCST004524,Energy expenditure (24h)
13682,Other/Mixed,509.0,28476931.0,Piaggi P,Other measurement,initial,2017-05-05,GCST004523,Resting metabolic rate
11338,European,71071.0,28485404.0,Jorgenson E,"Biological process, Other measurement",initial,2017-05-09,GCST004404,Alcohol consumption (drinkers vs non-drinkers)
999,African American or Afro-Caribbean,2475.0,28485404.0,Jorgenson E,"Biological process, Other measurement",initial,2017-05-09,GCST004404,Alcohol consumption (drinkers vs non-drinkers)
1000,African American or Afro-Caribbean,2475.0,28485404.0,Jorgenson E,"Biological process, Other measurement",initial,2017-05-09,GCST004405,Alcohol consumption (drinks per week)
13114,Hispanic or Latin American,7047.0,28485404.0,Jorgenson E,"Biological process, Other measurement",initial,2017-05-09,GCST004404,Alcohol consumption (drinkers vs non-drinkers)
3684,Asian,6034.0,28485404.0,Jorgenson E,"Biological process, Other measurement",initial,2017-05-09,GCST004405,Alcohol consumption (drinks per week)
13115,Hispanic or Latin American,7047.0,28485404.0,Jorgenson E,"Biological process, Other measurement",initial,2017-05-09,GCST004405,Alcohol consumption (drinks per week)
11339,European,71071.0,28485404.0,Jorgenson E,"Biological process, Other measurement",initial,2017-05-09,GCST004405,Alcohol consumption (drinks per week)
3683,Asian,6034.0,28485404.0,Jorgenson E,"Biological process, Other measurement",initial,2017-05-09,GCST004404,Alcohol consumption (drinkers vs non-drinkers)
13626,Other/Mixed,332.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006681,Insulin disposition index (BMI adjusted)
5682,European,741.0,28490609.0,Wood AR,Other measurement,replication,2017-05-10,GCST004575,Acute insulin response
5683,European,741.0,28490609.0,Wood AR,Other measurement,replication,2017-05-10,GCST006677,Acute insulin response (insulin secretion adjusted)
5684,European,741.0,28490609.0,Wood AR,Other measurement,replication,2017-05-10,GCST006678,Acute insulin response (insulin secretion and BMI adjusted)
6957,European,2042.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006681,Insulin disposition index (BMI adjusted)
13625,Other/Mixed,332.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006678,Acute insulin response (insulin secretion and BMI adjusted)
7006,European,2087.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006678,Acute insulin response (insulin secretion and BMI adjusted)
13624,Other/Mixed,332.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006677,Acute insulin response (insulin secretion adjusted)
7004,European,2087.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004575,Acute insulin response
13623,Other/Mixed,332.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006676,Peak insulin response (insulin secretion adjusted)
13622,Other/Mixed,332.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006675,Peak insulin response (BMI and insulin secretion adjusted)
7065,European,2159.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004487,Peak insulin response
13621,Other/Mixed,332.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004575,Acute insulin response
7066,European,2159.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006675,Peak insulin response (BMI and insulin secretion adjusted)
7067,European,2159.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006676,Peak insulin response (insulin secretion adjusted)
13619,Other/Mixed,332.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004487,Peak insulin response
13620,Other/Mixed,332.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004489,Insulin disposition index
7005,European,2087.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006677,Acute insulin response (insulin secretion adjusted)
5384,European,527.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004488,Insulin secretion rate
5685,European,741.0,28490609.0,Wood AR,Other measurement,replication,2017-05-10,GCST006681,Insulin disposition index (BMI adjusted)
6956,European,2042.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004489,Insulin disposition index
12883,Hispanic or Latin American,2337.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006676,Peak insulin response (insulin secretion adjusted)
12882,Hispanic or Latin American,2337.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006675,Peak insulin response (BMI and insulin secretion adjusted)
12887,Hispanic or Latin American,2346.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004575,Acute insulin response
12888,Hispanic or Latin American,2346.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006677,Acute insulin response (insulin secretion adjusted)
12889,Hispanic or Latin American,2346.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006678,Acute insulin response (insulin secretion and BMI adjusted)
5675,European,739.0,28490609.0,Wood AR,Other measurement,replication,2017-05-10,GCST006675,Peak insulin response (BMI and insulin secretion adjusted)
12885,Hispanic or Latin American,2345.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004489,Insulin disposition index
12881,Hispanic or Latin American,2337.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST004487,Peak insulin response
5681,European,741.0,28490609.0,Wood AR,Other measurement,replication,2017-05-10,GCST004489,Insulin disposition index
5676,European,739.0,28490609.0,Wood AR,Other measurement,replication,2017-05-10,GCST006676,Peak insulin response (insulin secretion adjusted)
12886,Hispanic or Latin American,2345.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006681,Insulin disposition index (BMI adjusted)
5674,European,739.0,28490609.0,Wood AR,Other measurement,replication,2017-05-10,GCST004487,Peak insulin response
5385,European,527.0,28490609.0,Wood AR,Other measurement,initial,2017-05-10,GCST006679,insulin secretion rate (BMI adjusted)
1939,Asian,319.0,28492228.0,Parks T,Cardiovascular disease,initial,2017-05-11,GCST004366,Rheumatic heart disease
13907,Other/Mixed,2229.0,28492228.0,Parks T,Cardiovascular disease,initial,2017-05-11,GCST004366,Rheumatic heart disease
13604,Other/Mixed,307.0,28492228.0,Parks T,Cardiovascular disease,initial,2017-05-11,GCST004366,Rheumatic heart disease
242,African,2375.0,28498854.0,Liang J,Cardiovascular disease,replication,2017-05-12,GCST004384,Hypertension
3345,Asian,3718.0,28498854.0,Liang J,Cardiovascular disease,replication,2017-05-12,GCST004384,Hypertension
13224,Hispanic or Latin American,12278.0,28498854.0,Liang J,"Other measurement, Cardiovascular disease, Cardiovascular measurement",replication,2017-05-12,GCST004388,Blood pressure traits (multi-trait analysis)
13222,Hispanic or Latin American,12278.0,28498854.0,Liang J,Other measurement,replication,2017-05-12,GCST004385,Systolic blood pressure
349,African,31155.0,28498854.0,Liang J,Cardiovascular measurement,initial,2017-05-12,GCST004387,Pulse pressure
351,African,31155.0,28498854.0,Liang J,Other measurement,initial,2017-05-12,GCST004386,Diastolic blood pressure
329,African,18440.0,28498854.0,Liang J,Cardiovascular disease,initial,2017-05-12,GCST004384,Hypertension
350,African,31155.0,28498854.0,Liang J,Other measurement,initial,2017-05-12,GCST004385,Systolic blood pressure
13223,Hispanic or Latin American,12278.0,28498854.0,Liang J,Other measurement,replication,2017-05-12,GCST004386,Diastolic blood pressure
352,African,31155.0,28498854.0,Liang J,"Other measurement, Cardiovascular disease, Cardiovascular measurement",initial,2017-05-12,GCST004388,Blood pressure traits (multi-trait analysis)
9470,European,9348.0,28498854.0,Liang J,Cardiovascular disease,replication,2017-05-12,GCST004384,Hypertension
265,African,4187.0,28498854.0,Liang J,Cardiovascular measurement,replication,2017-05-12,GCST004387,Pulse pressure
13221,Hispanic or Latin American,12278.0,28498854.0,Liang J,Cardiovascular measurement,replication,2017-05-12,GCST004387,Pulse pressure
4182,Asian,14016.0,28498854.0,Liang J,Cardiovascular measurement,replication,2017-05-12,GCST004387,Pulse pressure
10524,European,23914.0,28498854.0,Liang J,"Other measurement, Cardiovascular disease, Cardiovascular measurement",replication,2017-05-12,GCST004388,Blood pressure traits (multi-trait analysis)
4185,Asian,14016.0,28498854.0,Liang J,"Other measurement, Cardiovascular disease, Cardiovascular measurement",replication,2017-05-12,GCST004388,Blood pressure traits (multi-trait analysis)
10523,European,23914.0,28498854.0,Liang J,Other measurement,replication,2017-05-12,GCST004386,Diastolic blood pressure
10522,European,23914.0,28498854.0,Liang J,Other measurement,replication,2017-05-12,GCST004385,Systolic blood pressure
10521,European,23914.0,28498854.0,Liang J,Cardiovascular measurement,replication,2017-05-12,GCST004387,Pulse pressure
4184,Asian,14016.0,28498854.0,Liang J,Other measurement,replication,2017-05-12,GCST004386,Diastolic blood pressure
12941,Hispanic or Latin American,3445.0,28498854.0,Liang J,Cardiovascular disease,replication,2017-05-12,GCST004384,Hypertension
4183,Asian,14016.0,28498854.0,Liang J,Other measurement,replication,2017-05-12,GCST004385,Systolic blood pressure
267,African,4187.0,28498854.0,Liang J,Other measurement,replication,2017-05-12,GCST004386,Diastolic blood pressure
266,African,4187.0,28498854.0,Liang J,Other measurement,replication,2017-05-12,GCST004385,Systolic blood pressure
9990,European,14477.0,28494655.0,Duncan L,Metabolic disorder,initial,2017-05-12,GCST004367,Anorexia nervosa
4882,European,237.0,28500057.0,Bluett J,"Other disease, Immune system disorder, Response to drug",initial,2017-05-12,GCST004358,Methotrexate-induced interstitial lung disease in rheumatoid arthritis
268,African,4187.0,28498854.0,Liang J,"Other measurement, Cardiovascular disease, Cardiovascular measurement",replication,2017-05-12,GCST004388,Blood pressure traits (multi-trait analysis)
5830,European,843.0,28641921.0,Li J,Other measurement,initial,2017-05-15,GCST004492,Cerebrospinal fluid AB1-42 levels
13248,Hispanic or Latin American,12589.0,28334935.0,Raffield LM,Other measurement,initial,2017-05-15,GCST004572,Iron status biomarkers (transferrin saturation)
5829,European,843.0,28641921.0,Li J,Other measurement,initial,2017-05-15,GCST004491,Cerebrospinal fluid t-tau levels
5828,European,843.0,28641921.0,Li J,Other measurement,initial,2017-05-15,GCST004490,Cerebrospinal fluid t-tau:AB1-42 ratio
13247,Hispanic or Latin American,12586.0,28334935.0,Raffield LM,Other measurement,initial,2017-05-15,GCST004571,Iron status biomarkers (total iron binding capacity)
13246,Hispanic or Latin American,12580.0,28334935.0,Raffield LM,Other measurement,initial,2017-05-15,GCST004570,Iron status biomarkers (iron levels)
13232,Hispanic or Latin American,12375.0,28334935.0,Raffield LM,Other measurement,initial,2017-05-15,GCST004573,Iron status biomarkers (ferritin levels)
9939,European,13781.0,28512139.0,Mack S,Lipid or lipoprotein measurement,initial,2017-05-16,GCST004399,Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms
2257,Asian,711.0,28512992.0,Joo YB,Other measurement,initial,2017-05-16,GCST004400,Bone erosion in rheumatoid arthritis
9938,European,13781.0,28512139.0,Mack S,Lipid or lipoprotein measurement,initial,2017-05-16,GCST004398,Lipoprotein (a) levels
13050,Hispanic or Latin American,5085.0,28520984.0,Saccone NL,Other measurement,initial,2017-05-17,GCST004512,Smoking status (heavy vs light)
6574,European,1548.0,28520984.0,Saccone NL,Other measurement,replication,2017-05-17,GCST004511,Smoking status (daily vs non-daily)
13051,Hispanic or Latin American,5119.0,28520984.0,Saccone NL,Other measurement,initial,2017-05-17,GCST004513,Smoking status (current vs former)
12633,Hispanic or Latin American,428.0,28520984.0,Saccone NL,Other measurement,replication,2017-05-17,GCST004511,Smoking status (daily vs non-daily)
13250,Hispanic or Latin American,12735.0,28520984.0,Saccone NL,"Biological process, Other measurement",initial,2017-05-17,GCST004514,Smoking status (ever vs never smokers)
848,African American or Afro-Caribbean,1264.0,28520984.0,Saccone NL,Other measurement,replication,2017-05-17,GCST004511,Smoking status (daily vs non-daily)
12907,Hispanic or Latin American,2564.0,28520984.0,Saccone NL,Other measurement,initial,2017-05-17,GCST004511,Smoking status (daily vs non-daily)
7608,European,3013.0,28521775.0,Manichaikul A,Other measurement,replication,2017-05-18,GCST004526,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan)
7267,European,2434.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004527,Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan)
7266,European,2434.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004526,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan)
7265,European,2434.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004525,Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan)
2249,Asian,702.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004527,Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan)
2248,Asian,702.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004526,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan)
2247,Asian,702.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004525,Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan)
7609,European,3013.0,28521775.0,Manichaikul A,Other measurement,replication,2017-05-18,GCST004527,Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan)
6300,European,1210.0,28545128.0,McDaniel LD,Cancer,replication,2017-05-18,GCST004510,Sporadic neuroblastoma
12866,Hispanic or Latin American,2065.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004525,Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan)
12867,Hispanic or Latin American,2065.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004526,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan)
12868,Hispanic or Latin American,2065.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004527,Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan)
1039,African American or Afro-Caribbean,2856.0,28545128.0,McDaniel LD,Cancer,replication,2017-05-18,GCST004510,Sporadic neuroblastoma
8810,European,6303.0,28545128.0,McDaniel LD,Cancer,initial,2017-05-18,GCST004510,Sporadic neuroblastoma
998,African American or Afro-Caribbean,2470.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004527,Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan)
997,African American or Afro-Caribbean,2470.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004526,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan)
996,African American or Afro-Caribbean,2470.0,28521775.0,Manichaikul A,Other measurement,initial,2017-05-18,GCST004525,Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan)
8014,European,3820.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004684,Psychosis proneness (revised physical anhedonia scale and revised social anhedonia scale)
8010,European,3812.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004688,Psychosis proneness (perceptual aberration scale and revised physical anhedonia scale)
8158,European,4191.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004687,Psychosis proneness (schizoidia scale)
8005,European,3787.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004681,Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale)
8015,European,3824.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004679,Psychosis proneness (hypomanic personality scale and perceptual aberration scale)
8031,European,3868.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004683,Psychosis proneness (perceptual aberration scale and revised social anhedonia scale)
8110,European,4057.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004685,Psychosis proneness (perceptual aberration scale)
8095,European,4025.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004686,Psychosis proneness (revised social anhedonia scale)
8021,European,3837.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004682,Psychosis proneness (hypomanic personality scale and revised social anhedonia scale)
8067,European,3967.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004678,Psychosis proneness (hypomanic personality scale)
8083,European,3988.0,28525603.0,Ortega-Alonso A,Other measurement,initial,2017-05-19,GCST004680,Psychosis proneness (revised physical anhedonia scale)
11395,European,78308.0,28530673.0,Sniekers S,Biological process,initial,2017-05-22,GCST004364,Intelligence
9916,European,13574.0,28540026.0,Anney RJL,Neurological disorder,initial,2017-05-22,GCST004520,Autism spectrum disorder
9917,European,13574.0,28540026.0,Anney RJL,Neurological disorder,initial,2017-05-22,GCST004521,Autism spectrum disorder or schizophrenia
11891,European,155828.0,28540026.0,Anney RJL,Neurological disorder,replication,2017-05-22,GCST004520,Autism spectrum disorder
8306,European,4664.0,28533516.0,Cantor RM,"Other measurement, Neurological disorder",initial,2017-05-23,GCST004377,Restricted and repetitive behaviours in autism spectrum disorder
1521,Asian,1.0,28542097.0,Wells QS,"Other trait, Response to drug",initial,2017-05-24,GCST004353,Left ventricular function change in anthracycline treatment
386,African American or Afro-Caribbean,23.0,28542097.0,Wells QS,"Other trait, Response to drug",replication,2017-05-24,GCST004353,Left ventricular function change in anthracycline treatment
1533,Asian,3.0,28542097.0,Wells QS,"Other trait, Response to drug",replication,2017-05-24,GCST004353,Left ventricular function change in anthracycline treatment
3422,Asian,4262.0,28537267.0,Sapkota Y,Other disease,initial,2017-05-24,GCST004549,Endometriosis
10257,European,18478.0,28537254.0,Tsoi LC,Immune system disorder,replication,2017-05-24,GCST004346,Psoriasis
391,African American or Afro-Caribbean,30.0,28542097.0,Wells QS,"Other trait, Response to drug",initial,2017-05-24,GCST004353,Left ventricular function change in anthracycline treatment
12029,European,204641.0,28537267.0,Sapkota Y,Other disease,initial,2017-05-24,GCST004549,Endometriosis
12165,European,287323.0,28537254.0,Tsoi LC,Immune system disorder,initial,2017-05-24,GCST004346,Psoriasis
4728,European,152.0,28542097.0,Wells QS,"Other trait, Response to drug",replication,2017-05-24,GCST004353,Left ventricular function change in anthracycline treatment
12490,Hispanic or Latin American,4.0,28542097.0,Wells QS,"Other trait, Response to drug",initial,2017-05-24,GCST004353,Left ventricular function change in anthracycline treatment
5017,European,337.0,28542097.0,Wells QS,"Other trait, Response to drug",initial,2017-05-24,GCST004353,Left ventricular function change in anthracycline treatment
8845,European,6507.0,28540843.0,Mbarek H,Neurological disorder,initial,2017-05-25,GCST004486,Major depressive disorder
7703,European,3213.0,28548082.0,Southam L,Hematological measurement,initial,2017-05-26,GCST004543,Mean corpuscular hemoglobin concentration
7702,European,3213.0,28548082.0,Southam L,Hematological measurement,initial,2017-05-26,GCST004542,Mean corpuscular hemoglobin
7701,European,3213.0,28548082.0,Southam L,Hematological measurement,initial,2017-05-26,GCST004536,Hemoglobin
7700,European,3213.0,28548082.0,Southam L,Hematological measurement,initial,2017-05-26,GCST004535,Hematocrit
7697,European,3213.0,28548082.0,Southam L,"Body measurement, Other measurement",initial,2017-05-26,GCST004529,Body mass index
7698,European,3213.0,28548082.0,Southam L,"Body measurement, Other measurement",initial,2017-05-26,GCST004552,Waist circumference adjusted for body mass index
7696,European,3213.0,28548082.0,Southam L,Body measurement,initial,2017-05-26,GCST004760,Hip bone size adjusted for BMI
7695,European,3213.0,28548082.0,Southam L,Body measurement,initial,2017-05-26,GCST004554,Weight
7694,European,3213.0,28548082.0,Southam L,Body measurement,initial,2017-05-26,GCST004551,Waist circumference
7693,European,3213.0,28548082.0,Southam L,Body measurement,initial,2017-05-26,GCST004538,Hip bone size
7704,European,3213.0,28548082.0,Southam L,Hematological measurement,initial,2017-05-26,GCST004544,Mean corpuscular volume
7699,European,3213.0,28548082.0,Southam L,"Body measurement, Other measurement",initial,2017-05-26,GCST004556,Waist-to-hip ratio adjusted for body mass index
7705,European,3213.0,28548082.0,Southam L,Hematological measurement,initial,2017-05-26,GCST004545,Platelet count
7721,European,3213.0,28548082.0,Southam L,"Other measurement, Body measurement",initial,2017-05-26,GCST004534,Height
7706,European,3213.0,28548082.0,Southam L,Hematological measurement,initial,2017-05-26,GCST004546,Red blood cell count
7719,European,3213.0,28548082.0,Southam L,Other measurement,initial,2017-05-26,GCST004761,Fasting blood glucose adjusted for BMI
7713,European,3213.0,28548082.0,Southam L,Lipid or lipoprotein measurement,initial,2017-05-26,GCST004759,Very low density lipoprotein cholesterol levels
7723,European,3213.0,28548082.0,Southam L,"Other measurement, Other trait",initial,2017-05-26,GCST004539,Homeostasis model assessment of insulin resistance
7716,European,3213.0,28548082.0,Southam L,Other measurement,initial,2017-05-26,GCST004533,Fasting blood insulin
7715,European,3213.0,28548082.0,Southam L,Other measurement,initial,2017-05-26,GCST004532,Fasting blood glucose
7711,European,3213.0,28548082.0,Southam L,Lipid or lipoprotein measurement,initial,2017-05-26,GCST004548,Total cholesterol levels
7712,European,3213.0,28548082.0,Southam L,Lipid or lipoprotein measurement,initial,2017-05-26,GCST004550,Triglyceride levels
7717,European,3213.0,28548082.0,Southam L,Other measurement,initial,2017-05-26,GCST004540,Homeostasis model assessment of insulin resistance adjusted for BMI
7718,European,3213.0,28548082.0,Southam L,Other measurement,initial,2017-05-26,GCST004547,Systolic blood pressure
7709,European,3213.0,28548082.0,Southam L,Lipid or lipoprotein measurement,initial,2017-05-26,GCST004537,High density lipoprotein cholesterol levels
7708,European,3213.0,28548082.0,Southam L,Inflammatory measurement,initial,2017-05-26,GCST004530,C-reactive protein levels
7707,European,3213.0,28548082.0,Southam L,"Hematological measurement, Inflammatory measurement",initial,2017-05-26,GCST004553,White blood cell count
7722,European,3213.0,28548082.0,Southam L,"Other measurement, Body measurement",initial,2017-05-26,GCST004555,Waist-hip ratio
7714,European,3213.0,28548082.0,Southam L,Other measurement,initial,2017-05-26,GCST004531,Diastolic blood pressure
7720,European,3213.0,28548082.0,Southam L,Other measurement,initial,2017-05-26,GCST004762,Fasting blood insulin adjusted for BMI
7710,European,3213.0,28548082.0,Southam L,Lipid or lipoprotein measurement,initial,2017-05-26,GCST004541,Low density lipoprotein cholesterol levels
11903,European,159208.0,28566273.0,Scott RA,Metabolic disorder,initial,2017-05-31,GCST004773,Type 2 diabetes
11149,European,53539.0,28566273.0,Scott RA,Metabolic disorder,replication,2017-05-31,GCST004773,Type 2 diabetes
11904,European,159208.0,28566273.0,Scott RA,Metabolic disorder,initial,2017-05-31,GCST004774,Type 2 diabetes
11399,European,79001.0,28566273.0,Scott RA,Metabolic disorder,replication,2017-05-31,GCST004774,Type 2 diabetes
6588,European,1560.0,28577822.0,Deters KD,Other measurement,initial,2017-05-31,GCST004372,Language performance in older adults (adjusted for episodic memory)
11143,European,53255.0,28552196.0,Tachmazidou I,"Body measurement, Other measurement",initial,2017-06-01,GCST008158,Body mass index
11635,European,111749.0,27864402.0,Harris SE,Other trait,initial,2017-06-01,GCST006620,Self-rated health
9796,European,11801.0,28552196.0,Tachmazidou I,Other measurement,initial,2017-06-01,GCST008153,Lean body mass
12030,European,205003.0,28552196.0,Tachmazidou I,"Other measurement, Body measurement",replication,2017-06-01,GCST008163,Height
9798,European,11802.0,28552196.0,Tachmazidou I,Other measurement,initial,2017-06-01,GCST008157,Body fat mass
12035,European,205909.0,28552196.0,Tachmazidou I,Body measurement,replication,2017-06-01,GCST008162,Hip circumference
6382,European,1317.0,28468790.0,Agopian AJ,Cardiovascular disease,initial,2017-06-01,GCST004722,Left ventricular obstructive tract defect (maternal effect)
11985,European,179022.0,28552196.0,Tachmazidou I,Body measurement,replication,2017-06-01,GCST008152,Weight
11150,European,53588.0,28552196.0,Tachmazidou I,"Other measurement, Body measurement",initial,2017-06-01,GCST008163,Height
5680,European,741.0,28468790.0,Agopian AJ,Cardiovascular disease,initial,2017-06-01,GCST004719,Left ventricular obstructive tract defect (inherited effect)
9669,European,10670.0,28552196.0,Tachmazidou I,Other measurement,replication,2017-06-01,GCST008157,Body fat mass
11148,European,53484.0,28552196.0,Tachmazidou I,Body measurement,initial,2017-06-01,GCST008152,Weight
12036,European,206045.0,28552196.0,Tachmazidou I,Body measurement,replication,2017-06-01,GCST008159,Waist-to-hip ratio adjusted for BMI
9671,European,10676.0,28552196.0,Tachmazidou I,Other measurement,replication,2017-06-01,GCST008153,Lean body mass
9870,European,12838.0,28552196.0,Tachmazidou I,Other measurement,initial,2017-06-01,GCST008154,Trunk fat mass
7816,European,3357.0,28468790.0,Agopian AJ,Cardiovascular disease,initial,2017-06-01,GCST004721,Congenital heart disease (maternal effect)
10808,European,33811.0,28552196.0,Tachmazidou I,Body measurement,initial,2017-06-01,GCST008159,Waist-to-hip ratio adjusted for BMI
10812,European,33865.0,28552196.0,Tachmazidou I,Body measurement,initial,2017-06-01,GCST008156,Hip circumference adjusted for BMI
8911,European,6739.0,28468790.0,Agopian AJ,Cardiovascular disease,initial,2017-06-01,GCST004718,Congenital heart disease (inherited effect)
10822,European,34004.0,28552196.0,Tachmazidou I,Body measurement,initial,2017-06-01,GCST008162,Hip circumference
10824,European,34088.0,28552196.0,Tachmazidou I,"Other measurement, Body measurement",initial,2017-06-01,GCST008155,Waist-hip ratio
8367,European,4831.0,28468790.0,Agopian AJ,Cardiovascular disease,initial,2017-06-01,GCST004720,Conotruncal heart defects (inherited effects)
9668,European,10667.0,28552196.0,Tachmazidou I,Other measurement,replication,2017-06-01,GCST008154,Trunk fat mass
11064,European,47095.0,28552196.0,Tachmazidou I,"Body measurement, Other measurement",initial,2017-06-01,GCST008161,Waist circumference adjusted for body mass index
12034,European,205905.0,28552196.0,Tachmazidou I,Body measurement,replication,2017-06-01,GCST008156,Hip circumference adjusted for BMI
12046,European,209191.0,28552196.0,Tachmazidou I,"Body measurement, Other measurement",replication,2017-06-01,GCST008158,Body mass index
11075,European,47593.0,28552196.0,Tachmazidou I,Body measurement,initial,2017-06-01,GCST008151,Waist circumference
12037,European,206053.0,28552196.0,Tachmazidou I,"Other measurement, Body measurement",replication,2017-06-01,GCST008155,Waist-hip ratio
12040,European,206737.0,28552196.0,Tachmazidou I,Body measurement,replication,2017-06-01,GCST008160,Waist circumference
12038,European,206723.0,28552196.0,Tachmazidou I,"Body measurement, Other measurement",replication,2017-06-01,GCST008161,Waist circumference adjusted for body mass index
7327,European,2514.0,28468790.0,Agopian AJ,Cardiovascular disease,initial,2017-06-01,GCST004723,Conotruncal heart defects (maternal effects)
11076,European,47593.0,28552196.0,Tachmazidou I,Body measurement,initial,2017-06-01,GCST008160,Waist circumference
12039,European,206737.0,28552196.0,Tachmazidou I,Body measurement,replication,2017-06-01,GCST008151,Waist circumference
182,African,1293.0,28584135.0,Chaturvedi S,"Neurological disorder, Other measurement",initial,2017-06-05,GCST004644,Vaso-occlusive pain in sickle-cell anemia
9423,European,8990.0,28585551.0,Sigurdsson S,Digestive system disorder,replication,2017-06-06,GCST008257,Diverticular disease
11508,European,89553.0,28584286.0,Warrier V,Other measurement,initial,2017-06-06,GCST005755,Cognitive empathy
12106,European,248715.0,28585551.0,Sigurdsson S,Digestive system disorder,initial,2017-06-06,GCST008256,Diverticulitis
12113,European,251377.0,28585551.0,Sigurdsson S,Digestive system disorder,initial,2017-06-06,GCST008257,Diverticular disease
954,African American or Afro-Caribbean,2030.0,28588231.0,Li M,Other measurement,replication,2017-06-06,GCST004643,"1,5-anhydroglucitol levels"
9092,European,7550.0,28588231.0,Li M,Other measurement,initial,2017-06-06,GCST004643,"1,5-anhydroglucitol levels"
9398,European,8790.0,28588231.0,Li M,Other measurement,replication,2017-06-06,GCST004643,"1,5-anhydroglucitol levels"
10022,European,14889.0,28749367.0,Gondalia R,"Other measurement, Cardiovascular measurement",initial,2017-06-08,GCST004642,QT interval (ambient particulate matter interaction)
1233,African American or Afro-Caribbean,5707.0,28749367.0,Gondalia R,"Other measurement, Cardiovascular measurement",initial,2017-06-08,GCST004642,QT interval (ambient particulate matter interaction)
12843,Hispanic or Latin American,1562.0,28749367.0,Gondalia R,"Other measurement, Cardiovascular measurement",initial,2017-06-08,GCST004642,QT interval (ambient particulate matter interaction)
579,African American or Afro-Caribbean,300.0,28598419.0,Hong X,"Body measurement, Other measurement, Other trait",replication,2017-06-09,GCST004843,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction)
911,African American or Afro-Caribbean,1733.0,28598419.0,Hong X,Other measurement,initial,2017-06-09,GCST004844,Gestational age at birth (maternal effect)
912,African American or Afro-Caribbean,1733.0,28598419.0,Hong X,"Other measurement, Other trait",initial,2017-06-09,GCST004841,Preterm birth (maternal effect)
9496,European,9483.0,28598434.0,Scelo G,Cancer,replication,2017-06-09,GCST004710,Renal cell carcinoma
885,African American or Afro-Caribbean,1496.0,28598419.0,Hong X,"Other trait, Other measurement",initial,2017-06-09,GCST004845,Spontaneous preterm birth (maternal effect)
5605,European,683.0,28598419.0,Hong X,"Other measurement, Other trait",replication,2017-06-09,GCST004841,Preterm birth (maternal effect)
10721,European,31190.0,28598434.0,Scelo G,Cancer,initial,2017-06-09,GCST004710,Renal cell carcinoma
5604,European,683.0,28598419.0,Hong X,"Body measurement, Other measurement, Other trait",replication,2017-06-09,GCST004843,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction)
897,African American or Afro-Caribbean,1586.0,28598419.0,Hong X,"Body measurement, Other measurement, Other trait",initial,2017-06-09,GCST004843,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction)
729,African American or Afro-Caribbean,782.0,28598419.0,Hong X,"Other measurement, Other trait",replication,2017-06-09,GCST004841,Preterm birth (maternal effect)
929,African American or Afro-Caribbean,1886.0,28598419.0,Hong X,"Body measurement, Other measurement, Other trait",initial,2017-06-09,GCST004842,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction)
1208,African American or Afro-Caribbean,4771.0,28610988.0,Kerr KF,Cardiovascular measurement,replication,2017-06-10,GCST004715,Heart rate
1048,African American or Afro-Caribbean,2908.0,28610988.0,Kerr KF,Cardiovascular measurement,replication,2017-06-10,GCST004714,Heart rate variability traits (SDNN)
8992,European,7073.0,28610988.0,Kerr KF,Cardiovascular measurement,replication,2017-06-10,GCST004715,Heart rate
1049,African American or Afro-Caribbean,2908.0,28610988.0,Kerr KF,Cardiovascular measurement,replication,2017-06-10,GCST004716,Heart rate variability traits (RMSSD)
13261,Hispanic or Latin American,13767.0,28610988.0,Kerr KF,Cardiovascular measurement,initial,2017-06-10,GCST004716,Heart rate variability traits (RMSSD)
8991,European,7073.0,28610988.0,Kerr KF,Cardiovascular measurement,replication,2017-06-10,GCST004714,Heart rate variability traits (SDNN)
13252,Hispanic or Latin American,13184.0,28610988.0,Kerr KF,Cardiovascular measurement,initial,2017-06-10,GCST004715,Heart rate
13251,Hispanic or Latin American,13184.0,28610988.0,Kerr KF,Cardiovascular measurement,initial,2017-06-10,GCST004714,Heart rate variability traits (SDNN)
8330,European,4730.0,28610988.0,Kerr KF,Cardiovascular measurement,replication,2017-06-10,GCST004716,Heart rate variability traits (RMSSD)
11649,European,113006.0,28604731.0,Hammerschlag AR,Neurological disorder,initial,2017-06-12,GCST004695,Insomnia complaints
11648,European,112866.0,28604731.0,Hammerschlag AR,Other measurement,initial,2017-06-12,GCST004697,Ease of getting up in the morning
11224,European,59367.0,28604731.0,Hammerschlag AR,Neurological disorder,initial,2017-06-12,GCST006487,Insomnia complaints
10965,European,40187.0,28604730.0,McKay JD,"Other measurement, Cancer",initial,2017-06-12,GCST004749,Lung cancer in ever smokers
11651,European,113006.0,28604731.0,Hammerschlag AR,Neurological disorder,initial,2017-06-12,GCST004701,Insomnia complaints (continuous)
11647,European,112717.0,28604731.0,Hammerschlag AR,Other measurement,initial,2017-06-12,GCST004699,Daytime sleepiness
11645,European,112411.0,28604731.0,Hammerschlag AR,Other measurement,initial,2017-06-12,GCST004694,Sleep duration
11652,European,113054.0,28604731.0,Hammerschlag AR,Other measurement,initial,2017-06-12,GCST004693,Daytime nap
11468,European,85716.0,28604730.0,McKay JD,Cancer,initial,2017-06-12,GCST004748,Lung cancer
11260,European,63053.0,28604730.0,McKay JD,Cancer,initial,2017-06-12,GCST004750,Squamous cell lung carcinoma
11650,European,113006.0,28604731.0,Hammerschlag AR,Neurological disorder,initial,2017-06-12,GCST004700,Insomnia complaints (sex interaction)
10555,European,24573.0,28604728.0,Litchfield K,Cancer,initial,2017-06-12,GCST004635,Testicular germ cell tumor
9095,European,7565.0,28604731.0,Hammerschlag AR,Neurological disorder,replication,2017-06-12,GCST004695,Insomnia complaints
11225,European,59512.0,28604731.0,Hammerschlag AR,Neurological disorder,initial,2017-06-12,GCST004702,Insomnia complaints (dichotomous)
9096,European,7565.0,28604731.0,Hammerschlag AR,Neurological disorder,replication,2017-06-12,GCST006487,Insomnia complaints
9097,European,7565.0,28604731.0,Hammerschlag AR,Neurological disorder,replication,2017-06-12,GCST006488,Insomnia complaints
11583,European,101185.0,28604731.0,Hammerschlag AR,"Biological process, Other measurement",initial,2017-06-12,GCST004696,Chronotype
10204,European,17528.0,28604732.0,Wang Z,Cancer,initial,2017-06-12,GCST004713,Testicular germ cell tumor
11285,European,66756.0,28604730.0,McKay JD,Cancer,initial,2017-06-12,GCST004744,Lung adenocarcinoma
11597,European,105377.0,28604731.0,Hammerschlag AR,Other measurement,initial,2017-06-12,GCST004698,Snoring
8696,European,5828.0,28604728.0,Litchfield K,Cancer,replication,2017-06-12,GCST004635,Testicular germ cell tumor
10538,European,24108.0,28604730.0,McKay JD,Cancer,initial,2017-06-12,GCST004746,Small cell lung carcinoma
9564,European,9859.0,28604730.0,McKay JD,"Other measurement, Cancer",initial,2017-06-12,GCST004747,Lung cancer in never smokers
11151,European,53639.0,28604731.0,Hammerschlag AR,Neurological disorder,initial,2017-06-12,GCST006488,Insomnia complaints
8124,European,4097.0,28608620.0,Coleman JRI,Other measurement,initial,2017-06-13,GCST004731,Facial emotion recognition (fearful faces)
8120,European,4097.0,28608620.0,Coleman JRI,Other measurement,initial,2017-06-13,GCST004727,Facial emotion recognition
8122,European,4097.0,28608620.0,Coleman JRI,Other measurement,initial,2017-06-13,GCST004729,Facial emotion recognition (happy faces)
8123,European,4097.0,28608620.0,Coleman JRI,Other measurement,initial,2017-06-13,GCST004730,Facial emotion recognition (sad faces)
8121,European,4097.0,28608620.0,Coleman JRI,Other measurement,initial,2017-06-13,GCST004728,Facial emotion recognition (angry faces)
12620,Hispanic or Latin American,404.0,28613276.0,Nolte IM,Cardiovascular measurement,replication,2017-06-14,GCST004732,Heart rate variability traits (pvRSA/HF)
10539,European,24125.0,28613276.0,Nolte IM,Cardiovascular measurement,replication,2017-06-14,GCST004734,Heart rate variability traits (SDNN)
9477,European,9377.0,28613276.0,Nolte IM,Cardiovascular measurement,replication,2017-06-14,GCST004732,Heart rate variability traits (pvRSA/HF)
13194,Hispanic or Latin American,11234.0,28613276.0,Nolte IM,Cardiovascular measurement,replication,2017-06-14,GCST004733,Heart rate variability traits (RMSSD)
930,African American or Afro-Caribbean,1901.0,28613276.0,Nolte IM,Cardiovascular measurement,replication,2017-06-14,GCST004732,Heart rate variability traits (pvRSA/HF)
1281,African American or Afro-Caribbean,6899.0,28613276.0,Nolte IM,Cardiovascular measurement,replication,2017-06-14,GCST004734,Heart rate variability traits (SDNN)
10635,European,27850.0,28613276.0,Nolte IM,Cardiovascular measurement,initial,2017-06-14,GCST004734,Heart rate variability traits (SDNN)
10607,European,26523.0,28613276.0,Nolte IM,Cardiovascular measurement,initial,2017-06-14,GCST004733,Heart rate variability traits (RMSSD)
13195,Hispanic or Latin American,11234.0,28613276.0,Nolte IM,Cardiovascular measurement,replication,2017-06-14,GCST004734,Heart rate variability traits (SDNN)
10537,European,24088.0,28613276.0,Nolte IM,Cardiovascular measurement,initial,2017-06-14,GCST004732,Heart rate variability traits (pvRSA/HF)
1280,African American or Afro-Caribbean,6895.0,28613276.0,Nolte IM,Cardiovascular measurement,replication,2017-06-14,GCST004733,Heart rate variability traits (RMSSD)
10360,European,20429.0,28613276.0,Nolte IM,Cardiovascular measurement,replication,2017-06-14,GCST004733,Heart rate variability traits (RMSSD)
12504,Hispanic or Latin American,13.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004708,Fear of minor pain
6425,European,1367.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004709,Fear of severe pain
12503,Hispanic or Latin American,13.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004707,Fear of medical pain (dental)
501,African American or Afro-Caribbean,159.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004706,Fear of pain
12502,Hispanic or Latin American,13.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004706,Fear of pain
502,African American or Afro-Caribbean,159.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004707,Fear of medical pain (dental)
503,African American or Afro-Caribbean,159.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004708,Fear of minor pain
504,African American or Afro-Caribbean,159.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004709,Fear of severe pain
13434,Other/Mixed,23.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004709,Fear of severe pain
6423,European,1367.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004707,Fear of medical pain (dental)
13432,Other/Mixed,23.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004707,Fear of medical pain (dental)
13431,Other/Mixed,23.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004706,Fear of pain
12505,Hispanic or Latin American,13.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004709,Fear of severe pain
6424,European,1367.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004708,Fear of minor pain
13433,Other/Mixed,23.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004708,Fear of minor pain
6422,European,1367.0,28701861.0,Randall CL,Other measurement,initial,2017-06-15,GCST004706,Fear of pain
9973,European,14183.0,28628107.0,Jonsson S,Other measurement,initial,2017-06-19,GCST008573,Composite immunoglobulin trait (IgA/IgM)
6402,European,1350.0,28627999.0,Ikram MA,Other measurement,replication,2017-06-19,GCST004376,Cerebral blood flow
7039,European,2146.0,28628107.0,Jonsson S,Other measurement,replication,2017-06-19,GCST008569,Composite immunoglobulin trait (IgA x IgG x IgM)
7042,European,2146.0,28628107.0,Jonsson S,Other measurement,replication,2017-06-19,GCST008572,Composite immunoglobulin trait (IgA/IgG)
7043,European,2146.0,28628107.0,Jonsson S,Other measurement,replication,2017-06-19,GCST008573,Composite immunoglobulin trait (IgA/IgM)
7044,European,2146.0,28628107.0,Jonsson S,Other measurement,replication,2017-06-19,GCST008574,Composite immunoglobulin trait (IgG/IgM)
9969,European,14183.0,28628107.0,Jonsson S,Other measurement,initial,2017-06-19,GCST008569,Composite immunoglobulin trait (IgA x IgG x IgM)
9970,European,14183.0,28628107.0,Jonsson S,Other measurement,initial,2017-06-19,GCST008570,Composite immunoglobulin trait (IgA x IgG/IgM)
9971,European,14183.0,28628107.0,Jonsson S,Other measurement,initial,2017-06-19,GCST008571,Composite immunoglobulin trait (IgA x IgG)
9972,European,14183.0,28628107.0,Jonsson S,Other measurement,initial,2017-06-19,GCST008572,Composite immunoglobulin trait (IgA/IgG)
7041,European,2146.0,28628107.0,Jonsson S,Other measurement,replication,2017-06-19,GCST008571,Composite immunoglobulin trait (IgA x IgG)
9974,European,14183.0,28628107.0,Jonsson S,Other measurement,initial,2017-06-19,GCST008574,Composite immunoglobulin trait (IgG/IgM)
7040,European,2146.0,28628107.0,Jonsson S,Other measurement,replication,2017-06-19,GCST008570,Composite immunoglobulin trait (IgA x IgG/IgM)
7046,European,2151.0,28628107.0,Jonsson S,Other measurement,replication,2017-06-19,GCST008568,IgA levels
8246,European,4472.0,28627999.0,Ikram MA,Other measurement,initial,2017-06-19,GCST004376,Cerebral blood flow
10061,European,15536.0,28628107.0,Jonsson S,Other measurement,initial,2017-06-19,GCST008576,IgG levels
8180,European,4262.0,28630421.0,Li D,Metabolic disorder,initial,2017-06-19,GCST004585,Anorexia nervosa (excluding migration to or from binge-eating disorder or bulimia nervosa)
10164,European,16883.0,28628107.0,Jonsson S,Other measurement,initial,2017-06-19,GCST008568,IgA levels
7738,European,3238.0,29296746.0,Ma Q,Other measurement,initial,2017-06-19,GCST005945,ADAMTS13 levels
7059,European,2157.0,28628107.0,Jonsson S,Other measurement,replication,2017-06-19,GCST008575,IgM levels
7063,European,2158.0,28628107.0,Jonsson S,Other measurement,replication,2017-06-19,GCST008576,IgG levels
9988,European,14442.0,28628107.0,Jonsson S,Other measurement,initial,2017-06-19,GCST008575,IgM levels
7358,European,2543.0,28632202.0,Witt SH,Other trait,initial,2017-06-20,GCST004641,Borderline personality disorder
12567,Hispanic or Latin American,157.0,28654678.0,Mandage R,Other disease,initial,2017-06-27,GCST004735,Epstein-Barr virus copy number in lymphoblastoid cell lines
5299,European,492.0,28654678.0,Mandage R,Other disease,initial,2017-06-27,GCST004735,Epstein-Barr virus copy number in lymphoblastoid cell lines
422,African American or Afro-Caribbean,59.0,28654678.0,Mandage R,Other disease,initial,2017-06-27,GCST004735,Epstein-Barr virus copy number in lymphoblastoid cell lines
1783,Asian,189.0,28654678.0,Mandage R,Other disease,initial,2017-06-27,GCST004735,Epstein-Barr virus copy number in lymphoblastoid cell lines
108,African,467.0,28654678.0,Mandage R,Other disease,initial,2017-06-27,GCST004735,Epstein-Barr virus copy number in lymphoblastoid cell lines
2011,Asian,389.0,28654678.0,Mandage R,Other disease,initial,2017-06-27,GCST004735,Epstein-Barr virus copy number in lymphoblastoid cell lines
11327,European,69603.0,28658209.0,Huang H,"Digestive system disorder, Immune system disorder",initial,2017-06-28,GCST005837,Inflammatory bowel disease
7641,European,3103.0,28656603.0,Na R,"Other disease, Other trait",initial,2017-06-28,GCST004638,Benign prostatic hyperplasia and/or lower urinary tract symptoms
6004,European,960.0,28656603.0,Na R,"Other disease, Other trait",replication,2017-06-28,GCST004638,Benign prostatic hyperplasia and/or lower urinary tract symptoms
1907,Asian,278.0,28662289.0,Lin YY,"Digestive system disorder, Cancer",initial,2017-06-29,GCST004736,Familial hepatitis B virus-related hepatocellular carcinoma
276,African,4758.0,28234671.0,Nandakumar P,Other measurement,initial,2017-07-01,GCST007828,Diastolic blood pressure
9589,European,9896.0,28641744.0,Guo W,Neurological disorder,initial,2017-07-01,GCST004703,Obsessive-compulsive disorder or autism spectrum disorder
1391,African American or Afro-Caribbean,11156.0,28234671.0,Nandakumar P,Other measurement,initial,2017-07-01,GCST007828,Diastolic blood pressure
1392,African American or Afro-Caribbean,11156.0,28234671.0,Nandakumar P,Other measurement,initial,2017-07-01,GCST007829,Systolic blood pressure
277,African,4758.0,28234671.0,Nandakumar P,Other measurement,initial,2017-07-01,GCST007829,Systolic blood pressure
8435,European,4949.0,28672053.0,Meng W,"Cancer, Neurological disorder, Metabolic disorder",initial,2017-07-03,GCST004725,Foot ulcer and neuropathy in diabetes
7837,European,3394.0,28672053.0,Meng W,"Cancer, Neurological disorder, Metabolic disorder",initial,2017-07-03,GCST004724,Foot ulcer in diabetes and neuropathy
9482,European,9410.0,29731509.0,Zabaneh D,Biological process,initial,2017-07-04,GCST005626,Extremely high intelligence
3667,Asian,5937.0,28680059.0,Song X,"Cancer, Other trait",replication,2017-07-05,GCST004799,Family history of upper gastrointestinal cancer in esophageal squamous cell carcinoma
3281,Asian,3302.0,28680059.0,Song X,"Cancer, Other trait",initial,2017-07-05,GCST004799,Family history of upper gastrointestinal cancer in esophageal squamous cell carcinoma
593,African American or Afro-Caribbean,330.0,28686080.0,Liu N,Response to drug,replication,2017-07-07,GCST008374,Warfarin maintenance dose (adjusted for clinical factors)
671,African American or Afro-Caribbean,539.0,28686080.0,Liu N,Response to drug,initial,2017-07-07,GCST008374,Warfarin maintenance dose (adjusted for clinical factors)
4710,European,137.0,28686080.0,Liu N,Response to drug,replication,2017-07-07,GCST008374,Warfarin maintenance dose (adjusted for clinical factors)
5623,European,701.0,28686080.0,Liu N,Response to drug,initial,2017-07-07,GCST008374,Warfarin maintenance dose (adjusted for clinical factors)
4834,European,205.0,28696415.0,Maciukiewicz M,"Neurological disorder, Biological process",initial,2017-07-11,GCST004743,Placebo response in major depressive disorder (responder/non-responder status)
4784,European,186.0,28696415.0,Maciukiewicz M,"Neurological disorder, Response to drug",initial,2017-07-11,GCST004740,Duloxetine response in major depressive disorder (remitter/non-remitter status)
4785,European,186.0,28696415.0,Maciukiewicz M,"Neurological disorder, Response to drug",initial,2017-07-11,GCST004741,Duloxetine response in major depressive disorder (responder/non-responder status)
6359,European,1291.0,28698626.0,Lopez-Mejias R,Immune system disorder,initial,2017-07-11,GCST004745,Immunoglobulin A vasculitis
4783,European,186.0,28696415.0,Maciukiewicz M,"Neurological disorder, Response to drug",initial,2017-07-11,GCST004738,Duloxetine response in major depressive disorder (% change in symptom score)
4833,European,205.0,28696415.0,Maciukiewicz M,"Neurological disorder, Biological process",initial,2017-07-11,GCST004742,Placebo response in major depressive disorder (remitter/non-remitter status)
4832,European,205.0,28696415.0,Maciukiewicz M,"Neurological disorder, Biological process",initial,2017-07-11,GCST004739,Placebo response in major depressive disorder (% change in symptom score)
11141,European,53145.0,29313844.0,Willems SM,Other measurement,replication,2017-07-12,GCST005235,Hand grip strength
11812,European,142035.0,29313844.0,Willems SM,Other measurement,initial,2017-07-12,GCST005235,Hand grip strength
3923,Asian,8689.0,28703219.0,Son HY,Cancer,initial,2017-07-13,GCST004753,Papillary thyroid cancer
2530,Asian,1220.0,28703219.0,Son HY,Cancer,replication,2017-07-13,GCST004798,Differentiated thyroid cancer
10291,European,19108.0,28706201.0,Wei WH,Immune system disorder,initial,2017-07-13,GCST005826,Sero-negative rheumatoid arthritis
3931,Asian,8749.0,28703219.0,Son HY,Cancer,initial,2017-07-13,GCST004798,Differentiated thyroid cancer
2520,Asian,1192.0,28703219.0,Son HY,Cancer,replication,2017-07-13,GCST004753,Papillary thyroid cancer
1664,Asian,97.0,28700999.0,Yang CK,"Digestive system disorder, Cancer",replication,2017-07-13,GCST007514,Hepatitis B virus-related hepatocellular carcinoma
3892,Asian,8339.0,28703219.0,Son HY,Cancer,initial,2017-07-13,GCST004754,Follicular thyroid cancer
1793,Asian,195.0,28700999.0,Yang CK,"Digestive system disorder, Cancer",initial,2017-07-13,GCST007514,Hepatitis B virus-related hepatocellular carcinoma
2623,Asian,1451.0,28703135.0,Ruamviboonsuk P,Neurological disorder,initial,2017-07-13,GCST004737,Neovascular age-related macular degeneration
2193,Asian,633.0,28703219.0,Son HY,Cancer,replication,2017-07-13,GCST004754,Follicular thyroid cancer
2358,Asian,845.0,28703135.0,Ruamviboonsuk P,Neurological disorder,replication,2017-07-13,GCST004737,Neovascular age-related macular degeneration
7746,European,3260.0,28714907.0,Treutlein J,"Digestive system disorder, Cancer",initial,2017-07-17,GCST004755,Chronic alcoholic pancreatitis or alcohol-related cirrhosis
11697,European,120286.0,28714974.0,Klarin D,Cardiovascular disease,initial,2017-07-17,GCST007990,Coronary artery disease
10246,European,18264.0,28714469.0,Langefeld CD,Immune system disorder,initial,2017-07-17,GCST005752,Systemic lupus erythematosus
1229,African American or Afro-Caribbean,5422.0,28714469.0,Langefeld CD,Immune system disorder,initial,2017-07-17,GCST005752,Systemic lupus erythematosus
12975,Hispanic or Latin American,3888.0,28714469.0,Langefeld CD,Immune system disorder,initial,2017-07-17,GCST005752,Systemic lupus erythematosus
10247,European,18264.0,28714469.0,Langefeld CD,Immune system disorder,initial,2017-07-17,GCST007400,Systemic lupus erythematosus
7747,European,3265.0,28714907.0,Treutlein J,"Other measurement, Neurological disorder",initial,2017-07-17,GCST004756,Alcohol dependence
8347,European,4775.0,28714907.0,Treutlein J,"Neurological disorder, Digestive system disorder, Cancer",initial,2017-07-17,GCST004757,Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis
10926,European,38292.0,28724990.0,Zillikens MC,Other measurement,initial,2017-07-19,GCST005036,Lean body mass
3067,Asian,2350.0,28724990.0,Zillikens MC,Other measurement,replication,2017-07-19,GCST005037,Appendicular lean mass
3879,Asian,8034.0,28724990.0,Zillikens MC,Other measurement,replication,2017-07-19,GCST005036,Lean body mass
10642,European,28330.0,28724990.0,Zillikens MC,Other measurement,initial,2017-07-19,GCST005037,Appendicular lean mass
11070,European,47227.0,28724990.0,Zillikens MC,Other measurement,replication,2017-07-19,GCST005036,Lean body mass
617,African American or Afro-Caribbean,380.0,28724990.0,Zillikens MC,Other measurement,replication,2017-07-19,GCST005036,Lean body mass
618,African American or Afro-Caribbean,380.0,28724990.0,Zillikens MC,Other measurement,replication,2017-07-19,GCST005037,Appendicular lean mass
3865,Asian,7834.0,28724990.0,Zillikens MC,Other measurement,replication,2017-07-19,GCST005036,Lean body mass
11002,European,42360.0,28724990.0,Zillikens MC,Other measurement,replication,2017-07-19,GCST005037,Appendicular lean mass
10978,European,40832.0,28757204.0,Manousaki D,Other measurement,initial,2017-07-21,GCST004726,Vitamin D levels
5739,European,781.0,28736931.0,Rotroff DM,"Lipid or lipoprotein measurement, Response to drug, Metabolic disorder",initial,2017-07-24,GCST004765,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
482,African American or Afro-Caribbean,138.0,28736931.0,Rotroff DM,"Lipid or lipoprotein measurement, Response to drug, Metabolic disorder",initial,2017-07-24,GCST004763,HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
5737,European,781.0,28736931.0,Rotroff DM,"Lipid or lipoprotein measurement, Response to drug, Metabolic disorder",initial,2017-07-24,GCST004763,HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
484,African American or Afro-Caribbean,138.0,28736931.0,Rotroff DM,"Lipid or lipoprotein measurement, Response to drug, Metabolic disorder",initial,2017-07-24,GCST004765,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
11870,European,150134.0,28739976.0,Wain LV,Other measurement,initial,2017-07-24,GCST004777,Diastolic blood pressure
483,African American or Afro-Caribbean,138.0,28736931.0,Rotroff DM,"Lipid or lipoprotein measurement, Response to drug, Metabolic disorder",initial,2017-07-24,GCST004764,LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
6240,European,1156.0,28738859.0,de Jong K,Other measurement,replication,2017-07-24,GCST004800,Forced expiratory volume in 1 second (environmental tobacco smoke interaction)
11869,European,150134.0,28739976.0,Wain LV,Other measurement,initial,2017-07-24,GCST004776,Systolic blood pressure
5740,European,781.0,28736931.0,Rotroff DM,"Response to drug, Lipid or lipoprotein measurement, Metabolic disorder",initial,2017-07-24,GCST004766,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes
485,African American or Afro-Caribbean,138.0,28736931.0,Rotroff DM,"Response to drug, Lipid or lipoprotein measurement, Metabolic disorder",initial,2017-07-24,GCST004766,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes
11487,European,87359.0,28739976.0,Wain LV,Other measurement,replication,2017-07-24,GCST004776,Systolic blood pressure
9694,European,10817.0,28738859.0,de Jong K,Other measurement,initial,2017-07-24,GCST004800,Forced expiratory volume in 1 second (environmental tobacco smoke interaction)
11486,European,87359.0,28739976.0,Wain LV,Cardiovascular measurement,replication,2017-07-24,GCST004775,Pulse pressure
11868,European,150134.0,28739976.0,Wain LV,Cardiovascular measurement,initial,2017-07-24,GCST004775,Pulse pressure
11488,European,87359.0,28739976.0,Wain LV,Other measurement,replication,2017-07-24,GCST004777,Diastolic blood pressure
5738,European,781.0,28736931.0,Rotroff DM,"Lipid or lipoprotein measurement, Response to drug, Metabolic disorder",initial,2017-07-24,GCST004764,LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes
11642,European,112117.0,28937693.0,Clarke TK,"Biological process, Other measurement",initial,2017-07-25,GCST004886,Alcohol consumption
1779,Asian,185.0,28744025.0,Woolston AL,"Neurological disorder, Other measurement",initial,2017-07-25,GCST004767,Schizophrenia (age at onset)
11615,European,108309.0,28937693.0,Clarke TK,Other measurement,initial,2017-07-25,GCST004887,Alcohol consumption in current drinkers
13996,Other/Mixed,10874.0,28753643.0,Yeo A,"Cardiovascular disease, Cardiovascular measurement, Response to drug",initial,2017-07-28,GCST004966,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease
13772,Other/Mixed,740.0,28753643.0,Yeo A,"Cardiovascular disease, Response to drug",initial,2017-07-28,GCST004964,Myocardial infarction in darapladib-treated cardiovascular disease (time to event)
13876,Other/Mixed,1573.0,28753643.0,Yeo A,"Cardiovascular disease, Response to drug",initial,2017-07-28,GCST004959,Myocardial infarction in cardiovascular disease (time to event) (darapladib treatment interaction)
14016,Other/Mixed,22156.0,28753643.0,Yeo A,"Lipid or lipoprotein measurement, Cardiovascular disease",initial,2017-07-28,GCST004963,Lipoprotein phospholipase A2 activity in cardiovascular disease
2115,Asian,490.0,28754176.0,Wang Z,Other measurement,initial,2017-07-28,GCST004768,Motor development (prenatal lead exposure interaction)
12615,Hispanic or Latin American,390.0,28754176.0,Wang Z,Other measurement,initial,2017-07-28,GCST004768,Motor development (prenatal lead exposure interaction)
2116,Asian,490.0,28754176.0,Wang Z,Other measurement,initial,2017-07-28,GCST004769,Mental development (prenatal lead exposure interaction)
12616,Hispanic or Latin American,390.0,28754176.0,Wang Z,Other measurement,initial,2017-07-28,GCST004769,Mental development (prenatal lead exposure interaction)
13930,Other/Mixed,2758.0,28753643.0,Yeo A,"Cardiovascular measurement, Cardiovascular disease, Response to drug",initial,2017-07-28,GCST004958,Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction)
5268,European,481.0,28753643.0,Yeo A,"Cardiovascular disease, Other trait, Response to drug",initial,2017-07-28,GCST004962,Diarrhoea in darapladib-treated cardiovascular disease (time to event)
13997,Other/Mixed,10874.0,28753643.0,Yeo A,"Cardiovascular disease, Cardiovascular measurement, Response to drug",initial,2017-07-28,GCST004968,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease (adjusted for baseline)
9184,European,7999.0,28754779.0,Rosendahl J,Digestive system disorder,initial,2017-07-28,GCST004860,Alcoholic chronic pancreatitis
13889,Other/Mixed,1867.0,28753643.0,Yeo A,"Cardiovascular disease, Response to drug, Other measurement",initial,2017-07-28,GCST004960,Odor events in darapladib-treated cardiovascular disease (time to event)
13794,Other/Mixed,833.0,28753643.0,Yeo A,"Cardiovascular disease, Biological process",initial,2017-07-28,GCST004965,Myocardial infarction in placebo-treated cardiovascular disease (time to event)
4846,European,212.0,28753643.0,Yeo A,"Cardiovascular disease, Other trait, Response to drug",initial,2017-07-28,GCST004967,Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event)
13853,Other/Mixed,1318.0,28753643.0,Yeo A,"Cardiovascular measurement, Cardiovascular disease, Response to drug",initial,2017-07-28,GCST004957,Major coronary event in darapladib-treated cardiovascular disease (time to event)
13866,Other/Mixed,1440.0,28753643.0,Yeo A,"Cardiovascular measurement, Cardiovascular disease, Biological process",initial,2017-07-28,GCST004961,Major coronary event in placebo-treated cardiovascular disease (time to event)
3534,Asian,5152.0,28761973.0,Peng C,"Cancer, Other measurement",initial,2017-07-31,GCST004837,Lumbar spine bone mineral density or breast cancer (pleiotropy)
5762,European,800.0,28763429.0,Serie DJ,"Cardiovascular measurement, Response to drug",initial,2017-07-31,GCST004790,Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer
3535,Asian,5152.0,28761973.0,Peng C,"Other measurement, Cancer",initial,2017-07-31,GCST004836,Femoral neck bone mineral density or breast cancer (pleiotropy)
6281,European,1191.0,28763429.0,Serie DJ,"Cardiovascular measurement, Response to drug",initial,2017-07-31,GCST004788,Change in LVEF in response to paclitaxel and in response to paclitaxel and trastuzumab in HER+ breast cancer
5093,European,391.0,28763429.0,Serie DJ,"Cardiovascular measurement, Response to drug",initial,2017-07-31,GCST004789,Change in LVEF in response to paclitaxel in HER2+ breast cancer
13562,Other/Mixed,205.0,28763065.0,Xia K,"Other measurement, Other measurement, Other measurement, Other measurement",initial,2017-08-01,GCST004795,Brain volume in infants (white matter)
10732,European,31764.0,28813576.0,Persad PJ,Neurological disorder,initial,2017-08-01,GCST004871,Age-related macular degeneration (SNP x mitochondrial G12771A interaction)
10731,European,31757.0,28813576.0,Persad PJ,Neurological disorder,initial,2017-08-01,GCST004869,Age-related macular degeneration (SNP x mitochondrial T5004C interaction)
10819,European,33976.0,28813576.0,Persad PJ,Neurological disorder,initial,2017-08-01,GCST004868,Advanced age-related macular degeneration
10913,European,37776.0,28813576.0,Persad PJ,Neurological disorder,initial,2017-08-01,GCST004872,Age-related macular degeneration (SNP x mitochondrial C16069T interaction)
1399,African American or Afro-Caribbean,11782.0,29117387.0,Conti DV,Cancer,initial,2017-08-01,GCST004982,Prostate cancer
13561,Other/Mixed,205.0,28763065.0,Xia K,"Other measurement, Other measurement, Other measurement, Other measurement",initial,2017-08-01,GCST004794,Brain volume in infants (intracranial brain volume)
10814,European,33932.0,28813576.0,Persad PJ,Neurological disorder,initial,2017-08-01,GCST004870,Age-related macular degeneration (SNP x mitochondrial A4917G interaction)
13563,Other/Mixed,205.0,28763065.0,Xia K,"Other measurement, Other measurement, Other measurement, Other measurement",initial,2017-08-01,GCST004796,Brain volume in infants (cerebrospinal fluid)
154,African,932.0,29117387.0,Conti DV,Cancer,initial,2017-08-01,GCST004982,Prostate cancer
10816,European,33955.0,28794112.0,Christophersen IE,Cardiovascular measurement,initial,2017-08-01,GCST004824,P wave terminal force
5049,European,356.0,28763065.0,Xia K,Other measurement,initial,2017-08-01,GCST004797,Brain volume in infants (grey matter)
5047,European,356.0,28763065.0,Xia K,Other measurement,initial,2017-08-01,GCST004795,Brain volume in infants (white matter)
5046,European,356.0,28763065.0,Xia K,Other measurement,initial,2017-08-01,GCST004794,Brain volume in infants (intracranial brain volume)
1275,African American or Afro-Caribbean,6778.0,28794112.0,Christophersen IE,Cardiovascular measurement,initial,2017-08-01,GCST004826,P wave duration
10907,European,37678.0,28794112.0,Christophersen IE,Cardiovascular measurement,initial,2017-08-01,GCST004826,P wave duration
1274,African American or Afro-Caribbean,6778.0,28794112.0,Christophersen IE,Cardiovascular measurement,initial,2017-08-01,GCST004824,P wave terminal force
11719,European,123195.0,28870582.0,Wang XF,"Neurological disorder, Metabolic disorder",initial,2017-08-01,GCST004880,Alzheimer's disease or type 2 diabetes (pleiotropy)
8532,European,5206.0,28762467.0,Wadelius M,"Other trait, Response to drug",initial,2017-08-01,GCST004781,Sulfasalazine-induced agranulocytosis
5048,European,356.0,28763065.0,Xia K,Other measurement,initial,2017-08-01,GCST004796,Brain volume in infants (cerebrospinal fluid)
13564,Other/Mixed,205.0,28763065.0,Xia K,"Other measurement, Other measurement, Other measurement, Other measurement",initial,2017-08-01,GCST004797,Brain volume in infants (grey matter)
12632,Hispanic or Latin American,420.0,28840121.0,Villalobos-Comparan M,Other measurement,replication,2017-08-03,GCST004835,Femoral neck bone geometry
12627,Hispanic or Latin American,411.0,28840121.0,Villalobos-Comparan M,Other measurement,initial,2017-08-03,GCST004835,Femoral neck bone geometry
1760,Asian,168.0,28775256.0,Kawashima-Kumagai K,"Neurological disorder, Other measurement",replication,2017-08-03,GCST004813,Laterality in neovascular age-related macular degeneration
1676,Asian,102.0,28775256.0,Kawashima-Kumagai K,"Neurological disorder, Other measurement",replication,2017-08-03,GCST004813,Laterality in neovascular age-related macular degeneration
12626,Hispanic or Latin American,411.0,28840121.0,Villalobos-Comparan M,Other measurement,initial,2017-08-03,GCST004834,Lumbar spine bone mineral density
2492,Asian,1124.0,28775256.0,Kawashima-Kumagai K,"Neurological disorder, Other measurement",initial,2017-08-03,GCST004813,Laterality in neovascular age-related macular degeneration
12631,Hispanic or Latin American,420.0,28840121.0,Villalobos-Comparan M,Other measurement,replication,2017-08-03,GCST004834,Lumbar spine bone mineral density
7604,European,3007.0,28779025.0,Alberts R,"Digestive system disorder, Cancer",initial,2017-08-04,GCST005857,Gallbladder carcinoma in primary sclerosing cholangitis
7603,European,3006.0,28779025.0,Alberts R,"Digestive system disorder, Cancer",initial,2017-08-04,GCST005858,Hepatocellular carcinoma in primary sclerosing cholangitis
7797,European,3335.0,28779025.0,Alberts R,"Digestive system disorder, Cancer",initial,2017-08-04,GCST005855,Cholangiocarcinoma in primary sclerosing cholangitis
7798,European,3335.0,28779025.0,Alberts R,"Digestive system disorder, Other measurement, Cancer",initial,2017-08-04,GCST005860,Cholangiocarcinoma in primary sclerosing cholangitis (time to event)
7576,European,2949.0,28779025.0,Alberts R,"Digestive system disorder, Cancer",initial,2017-08-04,GCST005856,Colorectal carcinoma in primary sclerosing cholangitis
7733,European,3234.0,28779025.0,Alberts R,Digestive system disorder,initial,2017-08-04,GCST005854,Primary sclerosing cholangitis (small duct vs large duct)
7782,European,3316.0,28779025.0,Alberts R,Digestive system disorder,initial,2017-08-04,GCST005852,Colectomy in primary sclerosing cholangitis
7749,European,3266.0,28779025.0,Alberts R,"Immune system disorder, Digestive system disorder",initial,2017-08-04,GCST005853,Autoimmune hepatitis in primary sclerosing cholangitis
4779,European,183.0,28776448.0,Beaudoin JJ,Digestive system disorder,initial,2017-08-04,GCST004784,Alcoholic hepatitis
7783,European,3318.0,28779025.0,Alberts R,"Digestive system disorder, Other measurement",initial,2017-08-04,GCST005859,Liver transplant-free survival in primary sclerosing cholangitis (time to event)
4821,European,200.0,28783044.0,Ware JS,Other trait,replication,2017-08-07,GCST004786,Thiazide-induced hyponatremia
7580,European,2953.0,28783044.0,Ware JS,Other trait,initial,2017-08-07,GCST004786,Thiazide-induced hyponatremia
10650,European,28676.0,28989979.0,Howard DM,Biological process,replication,2017-08-10,GCST008861,General cognitive ability
10311,European,19326.0,28989979.0,Howard DM,Biological process,initial,2017-08-10,GCST008861,General cognitive ability
5218,European,448.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005139,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1)
5219,European,448.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005140,Sotalol-induced IKr potassium channel inhibition  (ventricular repolarization duration change)
5214,European,448.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005135,Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change)
5216,European,448.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005137,Sotalol-induced IKr potassium channel inhibition (T wave morphology notching)
5213,European,448.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005134,Sotalol-induced IKr potassium channel inhibition  (T wave peak and end interval change)
5215,European,448.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005136,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2)
5217,European,448.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005138,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3)
5168,European,431.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005134,Sotalol-induced IKr potassium channel inhibition  (T wave peak and end interval change)
13459,Other/Mixed,47.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005135,Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change)
13478,Other/Mixed,64.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005139,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1)
8956,European,6898.0,28800603.0,Arpawong TE,Other measurement,replication,2017-08-11,GCST004828,Verbal memory performance (immediate recall level)
8957,European,6898.0,28800603.0,Arpawong TE,Other measurement,replication,2017-08-11,GCST004829,Verbal memory performance (residualized delayed recall level)
8958,European,6898.0,28800603.0,Arpawong TE,Other measurement,replication,2017-08-11,GCST004830,Verbal memory performance (residualized delayed recall change)
5170,European,431.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005136,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2)
9984,European,14384.0,28800603.0,Arpawong TE,Other measurement,initial,2017-08-11,GCST004830,Verbal memory performance (residualized delayed recall change)
5171,European,431.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005137,Sotalol-induced IKr potassium channel inhibition (T wave morphology notching)
5172,European,431.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005138,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3)
5173,European,431.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005139,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1)
13473,Other/Mixed,64.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005134,Sotalol-induced IKr potassium channel inhibition  (T wave peak and end interval change)
13464,Other/Mixed,47.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005140,Sotalol-induced IKr potassium channel inhibition  (ventricular repolarization duration change)
13474,Other/Mixed,64.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005135,Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change)
5174,European,431.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005140,Sotalol-induced IKr potassium channel inhibition  (ventricular repolarization duration change)
13479,Other/Mixed,64.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005140,Sotalol-induced IKr potassium channel inhibition  (ventricular repolarization duration change)
13463,Other/Mixed,47.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005139,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1)
13475,Other/Mixed,64.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005136,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2)
13458,Other/Mixed,47.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005134,Sotalol-induced IKr potassium channel inhibition  (T wave peak and end interval change)
9082,European,7486.0,28800603.0,Arpawong TE,Other measurement,initial,2017-08-11,GCST004827,Verbal memory performance (immediate recall change)
9083,European,7486.0,28800603.0,Arpawong TE,Other measurement,initial,2017-08-11,GCST004828,Verbal memory performance (immediate recall level)
9084,European,7486.0,28800603.0,Arpawong TE,Other measurement,initial,2017-08-11,GCST004829,Verbal memory performance (residualized delayed recall level)
9085,European,7486.0,28800603.0,Arpawong TE,Other measurement,initial,2017-08-11,GCST004831,Verbal memory performance (delayed recall level)
9086,European,7486.0,28800603.0,Arpawong TE,Other measurement,initial,2017-08-11,GCST004832,Verbal memory performance (delayed recall change)
13462,Other/Mixed,47.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005138,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3)
13477,Other/Mixed,64.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005138,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3)
13460,Other/Mixed,47.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005136,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2)
13476,Other/Mixed,64.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005137,Sotalol-induced IKr potassium channel inhibition (T wave morphology notching)
13461,Other/Mixed,47.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",initial,2017-08-11,GCST005137,Sotalol-induced IKr potassium channel inhibition (T wave morphology notching)
5169,European,431.0,28800628.0,Salem JE,"Response to drug, Cardiovascular measurement",replication,2017-08-11,GCST005135,Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change)
8955,European,6898.0,28800603.0,Arpawong TE,Other measurement,replication,2017-08-11,GCST004827,Verbal memory performance (immediate recall change)
9128,European,7703.0,28843169.0,Neumann A,Other measurement,initial,2017-08-12,GCST004780,Cortisol levels (saliva)
1908,Asian,278.0,28808816.0,Xu C,"Biological process, Other measurement",initial,2017-08-14,GCST004823,Cognitive function
9469,European,9347.0,28806749.0,Leo PJ,Cancer,initial,2017-08-14,GCST004833,Cervical cancer
3211,Asian,2888.0,28809852.0,Liu L,Neurological disorder,replication,2017-08-15,GCST004778,Attention deficit hyperactivity disorder
2910,Asian,1983.0,28809852.0,Liu L,Neurological disorder,initial,2017-08-15,GCST004778,Attention deficit hyperactivity disorder
13497,Other/Mixed,96.0,28817678.0,Archer NP,Cancer,initial,2017-08-17,GCST007727,Acute lymphoblastic leukemia (childhood)
13599,Other/Mixed,281.0,28828242.0,Dajani R,Metabolic disorder,initial,2017-08-17,GCST004782,Type 2 diabetes
8406,European,4912.0,28828242.0,Dajani R,Metabolic disorder,replication,2017-08-17,GCST004782,Type 2 diabetes
12580,Hispanic or Latin American,203.0,28817678.0,Archer NP,Cancer,initial,2017-08-17,GCST007727,Acute lymphoblastic leukemia (childhood)
14021,Other/Mixed,30482.0,28843344.0,Lv WQ,"Cardiovascular disease, Body measurement",initial,2017-08-23,GCST004838,Coronary artery disease and/or body mass index (pleiotropy)
11484,European,86995.0,28843344.0,Lv WQ,"Cardiovascular disease, Body measurement",replication,2017-08-23,GCST004838,Coronary artery disease and/or body mass index (pleiotropy)
1349,African American or Afro-Caribbean,8763.0,28836065.0,Hellwege JN,Cancer,initial,2017-08-23,GCST004779,Uterine fibroids
1807,Asian,205.0,28835685.0,Yamashiro K,"Neurological disorder, Response to drug, Other measurement",replication,2017-08-23,GCST004803,Response to ranibizumab in age-related macular degeneration (additional treatment requirement)
1805,Asian,205.0,28835685.0,Yamashiro K,"Neurological disorder, Response to drug, Other measurement",replication,2017-08-23,GCST004801,Response to ranibizumab in age-related macular degeneration (visual acuity)
1881,Asian,256.0,28835685.0,Yamashiro K,"Neurological disorder, Response to drug, Other measurement",initial,2017-08-23,GCST004803,Response to ranibizumab in age-related macular degeneration (additional treatment requirement)
1880,Asian,256.0,28835685.0,Yamashiro K,"Neurological disorder, Response to drug, Other measurement",initial,2017-08-23,GCST004802,Response to ranibizumab in age-related macular degeneration (dry maculae)
1879,Asian,256.0,28835685.0,Yamashiro K,"Neurological disorder, Response to drug, Other measurement",initial,2017-08-23,GCST004801,Response to ranibizumab in age-related macular degeneration (visual acuity)
1806,Asian,205.0,28835685.0,Yamashiro K,"Neurological disorder, Response to drug, Other measurement",replication,2017-08-23,GCST004802,Response to ranibizumab in age-related macular degeneration (dry maculae)
12111,European,249796.0,28843344.0,Lv WQ,"Cardiovascular disease, Body measurement",initial,2017-08-23,GCST004838,Coronary artery disease and/or body mass index (pleiotropy)
13134,Hispanic or Latin American,7820.0,28838971.0,Mercader JM,Metabolic disorder,replication,2017-08-24,GCST006145,Type 2 diabetes
4761,European,174.0,28839172.0,Mahlman M,"Other disease, Other trait",initial,2017-08-24,GCST004783,Bronchopulmonary dysplasia in preterm infants
13162,Hispanic or Latin American,8658.0,28838971.0,Mercader JM,Metabolic disorder,initial,2017-08-24,GCST006145,Type 2 diabetes
2445,Asian,1012.0,29088834.0,Kimura M,Cardiovascular disease,replication,2017-08-24,GCST004947,Pulmonary arterial hypertension
32,African,76.0,28839172.0,Mahlman M,"Other disease, Other trait",replication,2017-08-24,GCST004783,Bronchopulmonary dysplasia in preterm infants
13974,Other/Mixed,4377.0,28838971.0,Mercader JM,Metabolic disorder,replication,2017-08-24,GCST006145,Type 2 diabetes
5863,European,867.0,28839172.0,Mahlman M,"Other disease, Other trait",replication,2017-08-24,GCST004783,Bronchopulmonary dysplasia in preterm infants
2935,Asian,2025.0,29088834.0,Kimura M,Cardiovascular disease,initial,2017-08-24,GCST004947,Pulmonary arterial hypertension
7644,European,3105.0,28881265.0,Sobalska-Kwapis M,Other disease,initial,2017-09-01,GCST004873,Endometriosis
10826,European,34174.0,28714976.0,Sims R,Neurological disorder,initial,2017-09-01,GCST005549,Alzheimer's disease (late onset)
3333,Asian,3647.0,28776340.0,Son CN,"Cardiovascular measurement, Metabolic disorder",initial,2017-09-01,GCST004825,Hyperuricemia
11113,European,50959.0,28714976.0,Sims R,Neurological disorder,replication,2017-09-01,GCST005549,Alzheimer's disease (late onset)
1477,African American or Afro-Caribbean,22000.0,28871152.0,Sofer T,Cardiovascular disease,replication,2017-09-04,GCST004889,Hypertension
11886,European,155786.0,28871152.0,Sofer T,Cardiovascular disease,replication,2017-09-04,GCST004889,Hypertension
12920,Hispanic or Latin American,2764.0,28871152.0,Sofer T,Other measurement,replication,2017-09-04,GCST004891,Mean arterial pressure
11887,European,155786.0,28871152.0,Sofer T,Cardiovascular measurement,replication,2017-09-04,GCST004892,Pulse pressure
11888,European,155786.0,28871152.0,Sofer T,Other measurement,replication,2017-09-04,GCST004888,Systolic blood pressure
2465,Asian,1050.0,28869801.0,Takahashi Y,Cancer,initial,2017-09-04,GCST004840,Colorectal cancer
13227,Hispanic or Latin American,12278.0,28871152.0,Sofer T,Other measurement,initial,2017-09-04,GCST004888,Systolic blood pressure
12919,Hispanic or Latin American,2764.0,28871152.0,Sofer T,Other measurement,replication,2017-09-04,GCST004890,Diastolic blood pressure
12918,Hispanic or Latin American,2764.0,28871152.0,Sofer T,Other measurement,replication,2017-09-04,GCST004888,Systolic blood pressure
1479,African American or Afro-Caribbean,22000.0,28871152.0,Sofer T,Other measurement,replication,2017-09-04,GCST004888,Systolic blood pressure
1480,African American or Afro-Caribbean,22000.0,28871152.0,Sofer T,Other measurement,replication,2017-09-04,GCST004890,Diastolic blood pressure
1478,African American or Afro-Caribbean,22000.0,28871152.0,Sofer T,Cardiovascular measurement,replication,2017-09-04,GCST004892,Pulse pressure
4172,Asian,13532.0,28869590.0,Zhao W,Metabolic disorder,initial,2017-09-04,GCST004894,Type 2 diabetes
11816,European,142487.0,28869591.0,Kemp JP,Other measurement,initial,2017-09-04,GCST006288,Heel bone mineral density
13229,Hispanic or Latin American,12278.0,28871152.0,Sofer T,Other measurement,initial,2017-09-04,GCST004891,Mean arterial pressure
11889,European,155786.0,28871152.0,Sofer T,Other measurement,replication,2017-09-04,GCST004890,Diastolic blood pressure
3190,Asian,2798.0,28869801.0,Takahashi Y,Cancer,replication,2017-09-04,GCST004840,Colorectal cancer
4345,Asian,28567.0,28869590.0,Zhao W,Metabolic disorder,replication,2017-09-04,GCST004894,Type 2 diabetes
7298,European,2479.0,28869590.0,Zhao W,Metabolic disorder,replication,2017-09-04,GCST004894,Type 2 diabetes
3287,Asian,3373.0,28869801.0,Takahashi Y,Cancer,replication,2017-09-04,GCST004839,Colorectal cancer
13228,Hispanic or Latin American,12278.0,28871152.0,Sofer T,Other measurement,initial,2017-09-04,GCST004890,Diastolic blood pressure
4443,Asian,50981.0,28869590.0,Zhao W,Metabolic disorder,replication,2017-09-04,GCST004894,Type 2 diabetes
13225,Hispanic or Latin American,12278.0,28871152.0,Sofer T,Cardiovascular disease,initial,2017-09-04,GCST004889,Hypertension
2464,Asian,1050.0,28869801.0,Takahashi Y,Cancer,initial,2017-09-04,GCST004839,Colorectal cancer
11890,European,155786.0,28871152.0,Sofer T,Other measurement,replication,2017-09-04,GCST004891,Mean arterial pressure
13226,Hispanic or Latin American,12278.0,28871152.0,Sofer T,Cardiovascular measurement,initial,2017-09-04,GCST004892,Pulse pressure
10356,European,20298.0,28869590.0,Zhao W,Metabolic disorder,initial,2017-09-04,GCST004894,Type 2 diabetes
12916,Hispanic or Latin American,2764.0,28871152.0,Sofer T,Cardiovascular disease,replication,2017-09-04,GCST004889,Hypertension
1481,African American or Afro-Caribbean,22000.0,28871152.0,Sofer T,Other measurement,replication,2017-09-04,GCST004891,Mean arterial pressure
12917,Hispanic or Latin American,2764.0,28871152.0,Sofer T,Cardiovascular measurement,replication,2017-09-04,GCST004892,Pulse pressure
6905,European,1960.0,28878392.0,Shen X,Other measurement,initial,2017-09-06,GCST004931,IgG disialylation phenotypes (multivariate analysis)
6899,European,1960.0,28878392.0,Shen X,Other measurement,initial,2017-09-06,GCST004925,IgG N-glycosylation phenotypes (multivariate analysis)
6900,European,1960.0,28878392.0,Shen X,Other measurement,initial,2017-09-06,GCST004926,IgG digalactosylation phenotypes (multivariate analysis)
6901,European,1960.0,28878392.0,Shen X,Other measurement,initial,2017-09-06,GCST004927,IgG galactosylation phenotypes (multivariate analysis)
6902,European,1960.0,28878392.0,Shen X,Other measurement,initial,2017-09-06,GCST004928,IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis)
6903,European,1960.0,28878392.0,Shen X,Other measurement,initial,2017-09-06,GCST004929,IgG fucosylation phenotypes (multivariate analysis)
6898,European,1960.0,28878392.0,Shen X,Other measurement,initial,2017-09-06,GCST004924,IgG monogalactosylation phenotypes (multivariate analysis)
6906,European,1960.0,28878392.0,Shen X,Other measurement,initial,2017-09-06,GCST004932,IgG monosialylation phenotypes (multivariate analysis)
6904,European,1960.0,28878392.0,Shen X,Other measurement,initial,2017-09-06,GCST004930,IgG sialylation phenotypes (multivariate analysis)
9358,European,8599.0,28877031.0,Zhang G,"Other measurement, Other trait",replication,2017-09-07,GCST004898,Preterm birth (maternal effect)
11017,European,43567.0,28877031.0,Zhang G,"Other measurement, Other trait",initial,2017-09-07,GCST004898,Preterm birth (maternal effect)
11018,European,43568.0,28877031.0,Zhang G,Other measurement,initial,2017-09-07,GCST004899,Gestational age at birth (maternal effect)
9369,European,8643.0,28877031.0,Zhang G,Other measurement,replication,2017-09-07,GCST004899,Gestational age at birth (maternal effect)
9352,European,8557.0,28886342.0,Ng M,Other disease,initial,2017-09-07,GCST004858,Dupuytren's disease
9581,European,9888.0,28887542.0,Prins BP,Other measurement,replication,2017-09-08,GCST005059,Serum albumin level
9505,European,9541.0,28887542.0,Prins BP,Inflammatory measurement,initial,2017-09-08,GCST005067,C-reactive protein levels
9534,European,9732.0,28887542.0,Prins BP,Other measurement,initial,2017-09-08,GCST005071,Insulin-like growth factor 1 levels
9582,European,9888.0,28887542.0,Prins BP,Other measurement,replication,2017-09-08,GCST005063,Glomerular filtration rate
9533,European,9731.0,28887542.0,Prins BP,Liver enzyme measurement,initial,2017-09-08,GCST004940,Alanine transaminase levels
9584,European,9888.0,28887542.0,Prins BP,Other measurement,replication,2017-09-08,GCST005070,Urea levels
9579,European,9888.0,28887542.0,Prins BP,Other measurement,replication,2017-09-08,GCST004939,Glycated hemoglobin levels
9583,European,9888.0,28887542.0,Prins BP,Other measurement,replication,2017-09-08,GCST005066,Creatinine levels
9580,European,9888.0,28887542.0,Prins BP,Other measurement,replication,2017-09-08,GCST004941,Dehydroepiandrosterone sulphate levels
9483,European,9436.0,28887542.0,Prins BP,Other measurement,initial,2017-09-08,GCST004939,Glycated hemoglobin levels
9578,European,9888.0,28887542.0,Prins BP,Liver enzyme measurement,replication,2017-09-08,GCST005069,Gamma glutamyl transferase levels
9523,European,9667.0,28887542.0,Prins BP,Hematological measurement,initial,2017-09-08,GCST005060,Hemoglobin levels
9586,European,9888.0,28887542.0,Prins BP,Other measurement,replication,2017-09-08,GCST005072,Ferritin levels
8179,European,4259.0,28887542.0,Prins BP,Other measurement,initial,2017-09-08,GCST005074,Testosterone levels
9532,European,9722.0,28887542.0,Prins BP,Other measurement,initial,2017-09-08,GCST004941,Dehydroepiandrosterone sulphate levels
9577,European,9888.0,28887542.0,Prins BP,Liver enzyme measurement,replication,2017-09-08,GCST005064,Aspartate aminotransferase levels
9538,European,9745.0,28887542.0,Prins BP,Lipid or lipoprotein measurement,initial,2017-09-08,GCST005073,Triglyceride levels
9569,European,9888.0,28887542.0,Prins BP,Hematological measurement,replication,2017-09-08,GCST005062,Fibrinogen levels
9568,European,9888.0,28887542.0,Prins BP,Hematological measurement,replication,2017-09-08,GCST005060,Hemoglobin levels
9571,European,9888.0,28887542.0,Prins BP,Lipid or lipoprotein measurement,replication,2017-09-08,GCST005058,HDL cholesterol
7757,European,3280.0,29296818.0,Clay-Gilmour AI,Cancer,initial,2017-09-08,GCST005968,B cell acute lymphoblastic leukaemia (abnormal cytogenetics)
9572,European,9888.0,28887542.0,Prins BP,Lipid or lipoprotein measurement,replication,2017-09-08,GCST005065,"Cholesterol, total"
9597,European,9961.0,28887542.0,Prins BP,Other measurement,initial,2017-09-08,GCST005063,Glomerular filtration rate
9555,European,9818.0,28887542.0,Prins BP,Other measurement,initial,2017-09-08,GCST005072,Ferritin levels
9573,European,9888.0,28887542.0,Prins BP,Lipid or lipoprotein measurement,replication,2017-09-08,GCST005073,Triglyceride levels
7670,European,3161.0,29296818.0,Clay-Gilmour AI,Cancer,initial,2017-09-08,GCST005969,Acute lymphoblastic leukemia in childhood (B cell precursor)
9554,European,9818.0,28887542.0,Prins BP,Other measurement,initial,2017-09-08,GCST005070,Urea levels
9553,European,9817.0,28887542.0,Prins BP,Lipid or lipoprotein measurement,initial,2017-09-08,GCST005065,"Cholesterol, total"
9551,European,9803.0,28887542.0,Prins BP,Other measurement,initial,2017-09-08,GCST005066,Creatinine levels
9574,European,9888.0,28887542.0,Prins BP,"Lipid or lipoprotein measurement, Other measurement",replication,2017-09-08,GCST005068,LDL cholesterol
7674,European,3179.0,29296818.0,Clay-Gilmour AI,Cancer,initial,2017-09-08,GCST005971,B cell acute lymphoblastic leukaemia in adulthood
9575,European,9888.0,28887542.0,Prins BP,Liver enzyme measurement,replication,2017-09-08,GCST004940,Alanine transaminase levels
9585,European,9888.0,28887542.0,Prins BP,Other measurement,replication,2017-09-08,GCST005071,Insulin-like growth factor 1 levels
7679,European,3187.0,29296818.0,Clay-Gilmour AI,Cancer,initial,2017-09-08,GCST005970,B cell acute lymphoblastic leukaemia in young adulthood
7726,European,3220.0,29296818.0,Clay-Gilmour AI,Cancer,initial,2017-09-08,GCST005965,B cell acute lymphoblastic leukaemia (normal cytogenetics)
9587,European,9888.0,28887542.0,Prins BP,Other measurement,replication,2017-09-08,GCST005074,Testosterone levels
9547,European,9796.0,28887542.0,Prins BP,Lipid or lipoprotein measurement,initial,2017-09-08,GCST005058,HDL cholesterol
9540,European,9762.0,28887542.0,Prins BP,Hematological measurement,initial,2017-09-08,GCST005062,Fibrinogen levels
9539,European,9747.0,28887542.0,Prins BP,Liver enzyme measurement,initial,2017-09-08,GCST005069,Gamma glutamyl transferase levels
9596,European,9961.0,28887542.0,Prins BP,"Lipid or lipoprotein measurement, Other measurement",initial,2017-09-08,GCST005068,LDL cholesterol
9576,European,9888.0,28887542.0,Prins BP,Liver enzyme measurement,replication,2017-09-08,GCST005061,Serum alkaline phosphatase levels
9570,European,9888.0,28887542.0,Prins BP,Inflammatory measurement,replication,2017-09-08,GCST005067,C-reactive protein levels
9535,European,9733.0,28887542.0,Prins BP,Liver enzyme measurement,initial,2017-09-08,GCST005061,Serum alkaline phosphatase levels
9558,European,9824.0,28887542.0,Prins BP,Other measurement,initial,2017-09-08,GCST005059,Serum albumin level
9494,European,9463.0,28887542.0,Prins BP,Liver enzyme measurement,initial,2017-09-08,GCST005064,Aspartate aminotransferase levels
2553,Asian,1249.0,28886140.0,Kwon YC,Immune system disorder,initial,2017-09-08,GCST004859,Kawasaki disease
7881,European,3473.0,29296818.0,Clay-Gilmour AI,Cancer,initial,2017-09-08,GCST005972,Acute lymphoblastic leukemia (B-cell precursor)
7861,European,3437.0,29296818.0,Clay-Gilmour AI,Cancer,initial,2017-09-08,GCST005966,B cell acute lymphoblastic leukaemia (hyperdiploid negative)
3587,Asian,5514.0,28886140.0,Kwon YC,Immune system disorder,replication,2017-09-08,GCST004859,Kawasaki disease
7818,European,3360.0,29296818.0,Clay-Gilmour AI,Cancer,initial,2017-09-08,GCST005967,B cell acute lymphoblastic leukaemia (Philadelphia chromosome negative)
12352,European,417508.0,28892059.0,Chang D,Neurological disorder,initial,2017-09-11,GCST004902,Parkinson's disease
9777,European,11717.0,28892059.0,Chang D,Neurological disorder,replication,2017-09-11,GCST004902,Parkinson's disease
4547,Asian,158284.0,28892062.0,Akiyama M,"Body measurement, Other measurement",initial,2017-09-11,GCST004904,Body mass index
4216,Asian,15146.0,28892062.0,Akiyama M,"Body measurement, Other measurement",replication,2017-09-11,GCST004904,Body mass index
12230,European,322154.0,28892062.0,Akiyama M,"Body measurement, Other measurement",replication,2017-09-11,GCST004904,Body mass index
3071,Asian,2366.0,28898252.0,Wheeler E,Other measurement,replication,2017-09-12,GCST004903,Glycated hemoglobin levels
10772,European,33238.0,28898252.0,Wheeler E,Other measurement,replication,2017-09-12,GCST004903,Glycated hemoglobin levels
2573,Asian,1302.0,28898252.0,Wheeler E,Other measurement,replication,2017-09-12,GCST004903,Glycated hemoglobin levels
1295,African American or Afro-Caribbean,7564.0,28898252.0,Wheeler E,Other measurement,initial,2017-09-12,GCST007952,Glycated hemoglobin levels
11499,European,88355.0,28898252.0,Wheeler E,Other measurement,initial,2017-09-12,GCST007954,Glycated hemoglobin levels
11498,European,88355.0,28898252.0,Wheeler E,Other measurement,initial,2017-09-12,GCST004903,Glycated hemoglobin levels
3825,Asian,7572.0,28898252.0,Wheeler E,Other measurement,initial,2017-09-12,GCST007951,Glycated hemoglobin levels
4266,Asian,18472.0,28898252.0,Wheeler E,Other measurement,initial,2017-09-12,GCST007953,Glycated hemoglobin levels
4265,Asian,18472.0,28898252.0,Wheeler E,Other measurement,initial,2017-09-12,GCST004903,Glycated hemoglobin levels
3824,Asian,7572.0,28898252.0,Wheeler E,Other measurement,initial,2017-09-12,GCST004903,Glycated hemoglobin levels
1294,African American or Afro-Caribbean,7564.0,28898252.0,Wheeler E,Other measurement,initial,2017-09-12,GCST004903,Glycated hemoglobin levels
12859,Hispanic or Latin American,1940.0,28902444.0,Stein MB,Biological process,initial,2017-09-13,GCST004893,Suicide attempts
228,African,1772.0,28902444.0,Stein MB,Biological process,initial,2017-09-13,GCST004893,Suicide attempts
144,African,840.0,28902444.0,Stein MB,Biological process,replication,2017-09-13,GCST004893,Suicide attempts
8314,European,4683.0,28902444.0,Stein MB,Biological process,replication,2017-09-13,GCST004893,Suicide attempts
12565,Hispanic or Latin American,149.0,28902444.0,Stein MB,Biological process,replication,2017-09-13,GCST004893,Suicide attempts
8854,European,6539.0,28902444.0,Stein MB,Biological process,initial,2017-09-13,GCST004893,Suicide attempts
12566,Hispanic or Latin American,156.0,28918882.0,Wattacheril J,Digestive system disorder,initial,2017-09-14,GCST004943,Pediatric nonalcoholic steatohepatitis
12582,Hispanic or Latin American,208.0,28918882.0,Wattacheril J,"Other trait, Digestive system disorder",initial,2017-09-14,GCST004938,Liver fibrosis in pediatric non-alcoholic fatty acid liver disease
12581,Hispanic or Latin American,208.0,28918882.0,Wattacheril J,"Cancer, Other measurement, Digestive system disorder",initial,2017-09-14,GCST004942,Pediatric non-alcoholic fatty liver disease activity score
824,African American or Afro-Caribbean,1217.0,28916551.0,Liu Y,Other disease,initial,2017-09-15,GCST004881,Knee osteoarthritis
4040,Asian,10300.0,29212154.0,Lin E,Body measurement,initial,2017-09-16,GCST005872,Waist circumference
4042,Asian,10300.0,29212154.0,Lin E,Lipid or lipoprotein measurement,initial,2017-09-16,GCST005873,Triglyceride levels
4043,Asian,10300.0,29212154.0,Lin E,Lipid or lipoprotein measurement,initial,2017-09-16,GCST005874,HDL cholesterol
4044,Asian,10300.0,29212154.0,Lin E,Other measurement,initial,2017-09-16,GCST005875,Diastolic blood pressure
4045,Asian,10300.0,29212154.0,Lin E,Other measurement,initial,2017-09-16,GCST005876,Systolic blood pressure
4046,Asian,10300.0,29212154.0,Lin E,Other measurement,initial,2017-09-16,GCST005877,Fasting blood glucose
4041,Asian,10300.0,29212154.0,Lin E,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",initial,2017-09-16,GCST005871,Metabolic syndrome
658,African American or Afro-Caribbean,480.0,28921760.0,Chenoweth MJ,"Biological process, Other measurement",replication,2017-09-16,GCST004976,nicotine metabolite ratio in current smokers
2480,Asian,1098.0,28921602.0,Lee MH,"Cancer, Digestive system disorder",replication,2017-09-16,GCST006037,Hepatocellular carcinoma in hepatitis C infection
6676,European,1660.0,28927820.0,Sugier PE,Immune system disorder,initial,2017-09-16,GCST006040,Atopy
770,African American or Afro-Caribbean,954.0,28921760.0,Chenoweth MJ,"Biological process, Other measurement",initial,2017-09-16,GCST004976,nicotine metabolite ratio in current smokers
6214,European,1138.0,28927820.0,Sugier PE,Immune system disorder,replication,2017-09-16,GCST006040,Atopy
5212,European,446.0,28927820.0,Sugier PE,Immune system disorder,replication,2017-09-16,GCST006040,Atopy
2554,Asian,1251.0,28921602.0,Lee MH,"Cancer, Digestive system disorder",initial,2017-09-16,GCST006037,Hepatocellular carcinoma in hepatitis C infection
1848,Asian,227.0,28924203.0,Ren HY,"Other measurement, Neurological disorder",initial,2017-09-18,GCST004994,White matter microstructure in first episode schizophrenia (left anterior cingulate cortex)
1846,Asian,227.0,28924203.0,Ren HY,"Other measurement, Neurological disorder",initial,2017-09-18,GCST004992,White matter microstructure in first episode schizophrenia (right posterior cingulate cortex)
1849,Asian,227.0,28924203.0,Ren HY,"Other measurement, Neurological disorder",initial,2017-09-18,GCST004995,White matter microstructure in first episode schizophrenia (left posterior cingulate cortex)
1850,Asian,227.0,28924203.0,Ren HY,"Other measurement, Neurological disorder",initial,2017-09-18,GCST004996,Total mean fractional anisotropy measurement in first episode schizophrenia
5097,European,395.0,28924153.0,Chang X,Cancer,initial,2017-09-18,GCST004882,Neuroblastoma (11q deletion vs 11q undeleted and MYCN amplification)
6885,European,1946.0,28924153.0,Chang X,Cancer,replication,2017-09-18,GCST004883,Neuroblastoma (11q deletion)
1851,Asian,227.0,28924203.0,Ren HY,"Other measurement, Neurological disorder",initial,2017-09-18,GCST004997,Abnormal white matter microstructure in first episode schizophrenia (multivariate analysis)
1847,Asian,227.0,28924203.0,Ren HY,"Other measurement, Neurological disorder",initial,2017-09-18,GCST004993,White matter microstructure in first episode schizophrenia (right anterior cingulate cortex)
1845,Asian,227.0,28924203.0,Ren HY,"Other measurement, Neurological disorder",initial,2017-09-18,GCST004991,White matter microstructure in first episode schizophrenia (left inferior parietal cortex)
8587,European,5369.0,28924153.0,Chang X,Cancer,initial,2017-09-18,GCST004885,Neuroblastoma (MYCN amplification)
8526,European,5178.0,28924153.0,Chang X,Cancer,initial,2017-09-18,GCST004884,Neuroblastoma (1p deletion)
4944,European,289.0,28935272.0,Moore KN,"Response to drug, Other measurement, Cancer",initial,2017-09-18,GCST004896,Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin
8537,European,5222.0,28924153.0,Chang X,Cancer,initial,2017-09-18,GCST004883,Neuroblastoma (11q deletion)
4723,European,147.0,28935272.0,Moore KN,"Response to drug, Other measurement, Cancer",initial,2017-09-18,GCST004897,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
11778,European,134863.0,28928442.0,Tian C,"Other disease, Other measurement",initial,2017-09-19,GCST005001,Shingles
11252,European,62445.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005005,Plantar warts
11461,European,84913.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005021,Chronic sinus infection
11477,European,85903.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005002,Mononucleosis
11363,European,74504.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005007,Strep throat
11466,European,85498.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005016,Measles
11712,European,121810.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005013,Childhood ear infection
11706,European,120649.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005008,Scarlet fever
4987,European,315.0,28922980.0,Konte B,"Neurological disorder, Other measurement",initial,2017-09-19,GCST004953,Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia
11463,European,85380.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005003,Mumps
11724,European,123751.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST004999,Chickenpox
11506,European,89227.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005015,Myringotomy
11976,European,173421.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005014,Tonsillectomy
11500,European,88440.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005000,Cold sores
11750,European,130639.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005009,Pneumonia
11503,European,88716.0,28928442.0,Tian C,"Other disease, Other measurement",initial,2017-09-19,GCST005006,Tuberculosis
11505,European,89191.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005018,Rheumatic fever
11253,European,62453.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005011,Yeast infection
12073,European,219605.0,28928442.0,Tian C,"Digestive system disorder, Other measurement",initial,2017-09-19,GCST005004,Hepatitis B
11445,European,83597.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005020,Rubella
11226,European,59546.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005019,Number of common colds
11446,European,83620.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005010,Bacterial meningitis
12071,European,219579.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005017,Hepatitis A
11311,European,68478.0,28928442.0,Tian C,Other measurement,initial,2017-09-19,GCST005012,Urinary tract infection frequency
10865,European,36052.0,28931804.0,Benyamin B,Neurological disorder,initial,2017-09-20,GCST004901,Amyotrophic lateral sclerosis (sporadic)
7157,European,2283.0,28979897.0,Zeller T,Cardiovascular disease,replication,2017-09-20,GCST004918,Coronary artery disease severity measurement
8421,European,4931.0,28979897.0,Zeller T,Cardiovascular disease,initial,2017-09-20,GCST004918,Coronary artery disease severity measurement
10866,European,36052.0,28931804.0,Benyamin B,Neurological disorder,initial,2017-09-20,GCST008472,Amyotrophic lateral sclerosis (sporadic)
3395,Asian,4084.0,28931804.0,Benyamin B,Neurological disorder,initial,2017-09-20,GCST004901,Amyotrophic lateral sclerosis (sporadic)
3396,Asian,4084.0,28931804.0,Benyamin B,Neurological disorder,initial,2017-09-20,GCST008472,Amyotrophic lateral sclerosis (sporadic)
10210,European,17675.0,28941034.0,Smith CE,"Body measurement, Biological process",replication,2017-09-21,GCST006173,BMI x dairy intake interaction (1df interaction test)
10584,European,25513.0,28941034.0,Smith CE,"Body measurement, Biological process",initial,2017-09-21,GCST006173,BMI x dairy intake interaction (1df interaction test)
245,African,2698.0,29036319.0,Qi H,"Other disease, Other measurement",initial,2017-09-26,GCST004922,Tuberculosis
3886,Asian,8187.0,29036319.0,Qi H,"Other disease, Other measurement",replication,2017-09-26,GCST004923,Tuberculosis
3114,Asian,2509.0,29036319.0,Qi H,"Other disease, Other measurement",initial,2017-09-26,GCST004922,Tuberculosis
3115,Asian,2509.0,29036319.0,Qi H,"Other disease, Other measurement",initial,2017-09-26,GCST004923,Tuberculosis
10530,European,24003.0,28960316.0,Tanskanen T,Cancer,replication,2017-09-28,GCST004895,Colorectal cancer
11670,European,116666.0,28957414.0,Pilling LC,Hematological measurement,initial,2017-09-28,GCST006804,Red cell distribution width
10074,European,15783.0,28960316.0,Tanskanen T,Cancer,initial,2017-09-28,GCST004895,Colorectal cancer
13157,Hispanic or Latin American,8560.0,28957384.0,Kim SK,Other disease,initial,2017-09-28,GCST004952,Ankle injury
3817,Asian,7518.0,28957384.0,Kim SK,Other disease,initial,2017-09-28,GCST004952,Ankle injury
11443,European,83264.0,28957384.0,Kim SK,Other disease,initial,2017-09-28,GCST004952,Ankle injury
10651,European,28677.0,28972577.0,Hancock DB,Neurological disorder,initial,2017-10-03,GCST008496,Nicotine dependence
1374,African American or Afro-Caribbean,9925.0,28972577.0,Hancock DB,Neurological disorder,initial,2017-10-03,GCST008496,Nicotine dependence
8988,European,7054.0,28979981.0,Tielbeek JJ,Other measurement,initial,2017-10-04,GCST006489,Antisocial behavior
10028,European,14980.0,28979981.0,Tielbeek JJ,Other measurement,initial,2017-10-04,GCST004954,Antisocial behavior
9165,European,7926.0,28979981.0,Tielbeek JJ,Other measurement,initial,2017-10-04,GCST006490,Antisocial behavior
2084,Asian,469.0,28983962.0,Cheung JPY,Other disease,initial,2017-10-06,GCST004945,Lumbar spinal stenosis
9144,European,7827.0,28990592.0,Warrington NM,Other measurement,replication,2017-10-09,GCST005031,Gestational weight gain (fetal effect)
9353,European,8559.0,28990592.0,Warrington NM,Other measurement,initial,2017-10-09,GCST005032,Early gestational weight gain (fetal effect)
9124,European,7681.0,28990592.0,Warrington NM,Other measurement,initial,2017-10-09,GCST005034,Late gestational weight gain (maternal effect)
10126,European,16434.0,28990592.0,Warrington NM,Other measurement,initial,2017-10-09,GCST005031,Gestational weight gain (fetal effect)
9129,European,7704.0,28990592.0,Warrington NM,Other measurement,initial,2017-10-09,GCST005029,Early gestation weight gain (maternal effect)
6662,European,1646.0,28990592.0,Warrington NM,Other measurement,replication,2017-10-09,GCST005034,Late gestational weight gain (maternal effect)
9738,European,11280.0,28990592.0,Warrington NM,Other measurement,replication,2017-10-09,GCST005033,Gestational weight gain (maternal effect)
6518,European,1491.0,29228715.0,Hofer P,Cancer,initial,2017-10-09,GCST005153,Colorectal adenoma (advanced)
8420,European,4930.0,29228715.0,Hofer P,Cancer,initial,2017-10-09,GCST005151,Colorectal adenoma (advanced)
7292,European,2469.0,29228715.0,Hofer P,Cancer,initial,2017-10-09,GCST005148,Colorectal cancer
5734,European,779.0,28990592.0,Warrington NM,Other measurement,replication,2017-10-09,GCST005030,Late gestational weight gain (fetal effect)
4328,Asian,26026.0,28991256.0,Li Z,Neurological disorder,initial,2017-10-09,GCST004946,Schizophrenia
8551,European,5272.0,29228715.0,Hofer P,Cancer,initial,2017-10-09,GCST005149,Colorectal cancer
9644,European,10555.0,28990592.0,Warrington NM,Other measurement,initial,2017-10-09,GCST005033,Gestational weight gain (maternal effect)
980,African American or Afro-Caribbean,2173.0,28990359.0,Polimanti R,"Other measurement, Neurological disorder",initial,2017-10-09,GCST004956,Risky sexual behaviors (alcohol dependence interaction)
891,African American or Afro-Caribbean,1541.0,28990359.0,Polimanti R,"Neurological disorder, Other measurement",initial,2017-10-09,GCST004955,Risky sexual behaviors in alcohol dependence
7760,European,3289.0,28990592.0,Warrington NM,Other measurement,replication,2017-10-09,GCST005032,Early gestational weight gain (fetal effect)
9368,European,8641.0,28990592.0,Warrington NM,Other measurement,initial,2017-10-09,GCST005030,Late gestational weight gain (fetal effect)
6759,European,1751.0,28990359.0,Polimanti R,"Other measurement, Neurological disorder",initial,2017-10-09,GCST004956,Risky sexual behaviors (alcohol dependence interaction)
8190,European,4294.0,29228715.0,Hofer P,Other trait,initial,2017-10-09,GCST005147,Colonoscopy-negative controls vs population controls
11433,European,82315.0,28991256.0,Li Z,Neurological disorder,initial,2017-10-09,GCST004946,Schizophrenia
8721,European,5908.0,29228715.0,Hofer P,Cancer,initial,2017-10-09,GCST005150,Colorectal cancer
6828,European,1854.0,28990592.0,Warrington NM,Other measurement,replication,2017-10-09,GCST005029,Early gestation weight gain (maternal effect)
6814,European,1833.0,29228715.0,Hofer P,Cancer,initial,2017-10-09,GCST005152,Colorectal cancer
4033,Asian,10154.0,28991256.0,Li Z,Neurological disorder,replication,2017-10-09,GCST004946,Schizophrenia
6482,European,1436.0,28990359.0,Polimanti R,"Neurological disorder, Other measurement",initial,2017-10-09,GCST004955,Risky sexual behaviors in alcohol dependence
8258,European,4506.0,29030101.0,Asai Y,Other measurement,initial,2017-10-10,GCST006038,Food allergy
8218,European,4395.0,29030101.0,Asai Y,Other measurement,initial,2017-10-10,GCST006039,Peanut allergy
8352,European,4792.0,29018042.0,Schierding W,Other measurement,initial,2017-10-10,GCST004951,Post-term birth
2256,Asian,708.0,29031612.0,Hirata J,Immune system disorder,initial,2017-10-12,GCST006036,Psoriasis vulgaris
2901,Asian,1942.0,29031612.0,Hirata J,Immune system disorder,replication,2017-10-12,GCST006036,Psoriasis vulgaris
12443,European,586626.0,29030599.0,Joshi PK,Other measurement,initial,2017-10-13,GCST004983,Parental lifespan
1445,African American or Afro-Caribbean,19433.0,29030599.0,Joshi PK,Other measurement,initial,2017-10-13,GCST004983,Parental lifespan
2897,Asian,1937.0,29016859.0,Ogura Y,"Other disease, Other measurement",initial,2017-10-15,GCST004981,Curve progression in adolescent idiopathic scoliosis
2175,Asian,606.0,29016859.0,Ogura Y,"Other disease, Other measurement",replication,2017-10-15,GCST004981,Curve progression in adolescent idiopathic scoliosis
13827,Other/Mixed,1158.0,29045471.0,Robiou-du-Pont S,Other measurement,initial,2017-10-18,GCST007577,Blood pressure (parental or offspring effect)
7436,European,2675.0,29051540.0,Marenholz I,Other measurement,initial,2017-10-20,GCST004977,Hen's egg allergy
8261,European,4529.0,29059373.0,Li Y,"Biological process, Cancer",initial,2017-10-20,GCST005911,Smoking interaction in squamous cell lung cancer (1df test)
8981,European,7015.0,29059373.0,Li Y,"Biological process, Cancer",initial,2017-10-20,GCST005909,Smoking interaction in lung adenocarcinoma (1df test)
7370,European,2556.0,29051540.0,Marenholz I,Other measurement,initial,2017-10-20,GCST004978,Cow's milk allergy
7920,European,3560.0,29051540.0,Marenholz I,Other measurement,replication,2017-10-20,GCST004979,Food allergy
7402,European,2617.0,29051540.0,Marenholz I,Other measurement,initial,2017-10-20,GCST004980,Peanut allergy
7543,European,2884.0,29051540.0,Marenholz I,Other measurement,initial,2017-10-20,GCST004979,Food allergy
9049,European,7353.0,29066090.0,Allen RJ,Cancer,replication,2017-10-20,GCST004986,Idiopathic pulmonary fibrosis
7562,European,2926.0,29051540.0,Marenholz I,Other measurement,replication,2017-10-20,GCST004977,Hen's egg allergy
9899,European,13336.0,29059373.0,Li Y,"Biological process, Cancer",initial,2017-10-20,GCST005910,Smoking interaction in non-small cell lung cancer (1df test)
7552,European,2900.0,29051540.0,Marenholz I,Other measurement,replication,2017-10-20,GCST004978,Cow's milk allergy
8069,European,3968.0,29066090.0,Allen RJ,Cancer,initial,2017-10-20,GCST004986,Idiopathic pulmonary fibrosis
7574,European,2948.0,29051540.0,Marenholz I,Other measurement,replication,2017-10-20,GCST004980,Peanut allergy
11140,European,53143.0,29058716.0,Milne RL,Cancer,replication,2017-10-23,GCST005077,Breast cancer
10357,European,20328.0,29058377.0,Sanchez-Roige S,Other measurement,initial,2017-10-23,GCST004990,Alcohol consumption over the past year
1864,Asian,236.0,29058489.0,Ogata S,"Other measurement, Biological process",replication,2017-10-23,GCST004984,White coat effect (clinic systolic blood pressure minus home systolic blood pressure)
5188,European,434.0,29064910.0,Kure Fischer E,"Response to drug, Neurological disorder, Cardiovascular measurement",initial,2017-10-23,GCST004987,Antipsychotic drug-induced QTc interval change in schizophrenia
10062,European,15566.0,29058716.0,Milne RL,"Cancer, Other measurement",initial,2017-10-23,GCST005075,Breast Cancer in BRCA1 mutation carriers
1865,Asian,236.0,29058489.0,Ogata S,"Other measurement, Biological process",replication,2017-10-23,GCST004985,White coat effect (clinic diastolic blood pressure minus home diastolic blood pressure)
11346,European,72261.0,29058716.0,Milne RL,Cancer,initial,2017-10-23,GCST005076,Breast cancer (estrogen-receptor negative)
13426,Other/Mixed,21.0,29057527.0,Ballantine JL,Digestive system disorder,initial,2017-10-23,GCST004989,Early childhood caries
425,African American or Afro-Caribbean,67.0,29057527.0,Ballantine JL,Digestive system disorder,initial,2017-10-23,GCST004989,Early childhood caries
11101,European,49801.0,29058716.0,Milne RL,Cancer,replication,2017-10-23,GCST005076,Breast cancer (estrogen-receptor negative)
11797,European,139274.0,29059683.0,Michailidou K,Cancer,initial,2017-10-23,GCST004988,Breast cancer
59,African,202.0,29064910.0,Kure Fischer E,"Response to drug, Neurological disorder, Cardiovascular measurement",initial,2017-10-23,GCST004987,Antipsychotic drug-induced QTc interval change in schizophrenia
4186,Asian,14068.0,29059683.0,Michailidou K,Cancer,replication,2017-10-23,GCST004988,Breast cancer
1919,Asian,295.0,29058489.0,Ogata S,"Other measurement, Biological process",initial,2017-10-23,GCST004984,White coat effect (clinic systolic blood pressure minus home systolic blood pressure)
1920,Asian,295.0,29058489.0,Ogata S,"Other measurement, Biological process",initial,2017-10-23,GCST004985,White coat effect (clinic diastolic blood pressure minus home diastolic blood pressure)
11493,European,87827.0,29058716.0,Milne RL,Cancer,initial,2017-10-23,GCST005077,Breast cancer
12531,Hispanic or Latin American,74.0,29057527.0,Ballantine JL,Digestive system disorder,initial,2017-10-23,GCST004989,Early childhood caries
4581,European,49.0,29057527.0,Ballantine JL,Digestive system disorder,initial,2017-10-23,GCST004989,Early childhood caries
11511,European,89677.0,29059683.0,Michailidou K,Cancer,replication,2017-10-23,GCST004988,Breast cancer
7800,European,3342.0,29058716.0,Milne RL,"Cancer, Other measurement",replication,2017-10-23,GCST005075,Breast Cancer in BRCA1 mutation carriers
5061,European,367.0,29064472.0,Lencer R,"Neurological disorder, Other measurement",initial,2017-10-24,GCST005026,Initial pursuit acceleration in psychotic disorders
65,African,224.0,29064472.0,Lencer R,"Neurological disorder, Other measurement",initial,2017-10-24,GCST005027,Anti-saccade error rate in psychotic disorders
64,African,224.0,29064472.0,Lencer R,"Neurological disorder, Other measurement",initial,2017-10-24,GCST005026,Initial pursuit acceleration in psychotic disorders
84,African,300.0,29064472.0,Lencer R,Other measurement,initial,2017-10-24,GCST005023,Initial pursuit acceleration
85,African,300.0,29064472.0,Lencer R,Other measurement,initial,2017-10-24,GCST005024,Pursuit maintenance gain
66,African,224.0,29064472.0,Lencer R,"Neurological disorder, Other measurement",initial,2017-10-24,GCST005028,Pursuit maintenance gain in psychotic disorders
5063,European,367.0,29064472.0,Lencer R,"Neurological disorder, Other measurement",initial,2017-10-24,GCST005028,Pursuit maintenance gain in psychotic disorders
5414,European,549.0,29064472.0,Lencer R,Other measurement,initial,2017-10-24,GCST005024,Pursuit maintenance gain
5415,European,549.0,29064472.0,Lencer R,Other measurement,initial,2017-10-24,GCST005025,Anti-saccade response
5062,European,367.0,29064472.0,Lencer R,"Neurological disorder, Other measurement",initial,2017-10-24,GCST005027,Anti-saccade error rate in psychotic disorders
86,African,300.0,29064472.0,Lencer R,Other measurement,initial,2017-10-24,GCST005025,Anti-saccade response
8549,European,5262.0,29065852.0,Hallengren E,Other measurement,replication,2017-10-24,GCST005035,Fasting growth hormone levels
5413,European,549.0,29064472.0,Lencer R,Other measurement,initial,2017-10-24,GCST005023,Initial pursuit acceleration
8136,European,4134.0,29065852.0,Hallengren E,Other measurement,initial,2017-10-24,GCST005035,Fasting growth hormone levels
1073,African American or Afro-Caribbean,3041.0,29071344.0,Zhou H,Neurological disorder,initial,2017-10-25,GCST005022,Major depression and alcohol dependence
6578,European,1551.0,29071344.0,Zhou H,Neurological disorder,replication,2017-10-25,GCST005022,Major depression and alcohol dependence
901,African American or Afro-Caribbean,1612.0,29071344.0,Zhou H,Neurological disorder,replication,2017-10-25,GCST005022,Major depression and alcohol dependence
6635,European,1618.0,29071344.0,Zhou H,Neurological disorder,initial,2017-10-25,GCST005022,Major depression and alcohol dependence
1869,Asian,238.0,29065906.0,Joo YB,"Immune system disorder, Other measurement",initial,2017-10-25,GCST004998,Severe progression in rheumatoid arthritis
9821,European,12169.0,29107063.0,Yashin AI,"Neurological disorder, Other measurement",initial,2017-10-26,GCST006120,Alzheimer's disease (age of onset)
240,African,2329.0,29107063.0,Yashin AI,Neurological disorder,initial,2017-10-26,GCST006121,Alzheimer's disease
5786,European,820.0,29229094.0,Condreay L,"Other disease, Response to drug",initial,2017-10-26,GCST005115,Response to mepolizumab in severe asthma
10088,European,16063.0,29107063.0,Yashin AI,Neurological disorder,initial,2017-10-26,GCST006121,Alzheimer's disease
233,African,2078.0,29107063.0,Yashin AI,"Neurological disorder, Other measurement",initial,2017-10-26,GCST006120,Alzheimer's disease (age of onset)
827,African American or Afro-Caribbean,1221.0,29077507.0,Chen H,"Other measurement, Neurological disorder",initial,2017-10-27,GCST005051,Obstructive sleep apnea trait (apnea hypopnea index)
825,African American or Afro-Caribbean,1221.0,29077507.0,Chen H,Other measurement,initial,2017-10-27,GCST005049,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index)
826,African American or Afro-Caribbean,1221.0,29077507.0,Chen H,Other measurement,initial,2017-10-27,GCST005050,Obstructive sleep apnea during REM sleep (apnea hypopnea index)
8591,European,5382.0,29077507.0,Chen H,Other measurement,replication,2017-10-27,GCST005049,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index)
539,African American or Afro-Caribbean,206.0,29077507.0,Chen H,Other measurement,replication,2017-10-27,GCST005049,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index)
1852,Asian,228.0,29077507.0,Chen H,Other measurement,initial,2017-10-27,GCST005049,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index)
1854,Asian,228.0,29077507.0,Chen H,"Other measurement, Neurological disorder",initial,2017-10-27,GCST005051,Obstructive sleep apnea trait (apnea hypopnea index)
8669,European,5727.0,29077507.0,Chen H,Other measurement,initial,2017-10-27,GCST005049,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index)
1853,Asian,228.0,29077507.0,Chen H,Other measurement,initial,2017-10-27,GCST005050,Obstructive sleep apnea during REM sleep (apnea hypopnea index)
3187,Asian,2792.0,29077507.0,Chen H,Other measurement,replication,2017-10-27,GCST005049,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index)
8670,European,5727.0,29077507.0,Chen H,Other measurement,initial,2017-10-27,GCST005050,Obstructive sleep apnea during REM sleep (apnea hypopnea index)
13242,Hispanic or Latin American,12557.0,29077507.0,Chen H,Other measurement,initial,2017-10-27,GCST005049,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index)
13243,Hispanic or Latin American,12557.0,29077507.0,Chen H,Other measurement,initial,2017-10-27,GCST005050,Obstructive sleep apnea during REM sleep (apnea hypopnea index)
8671,European,5727.0,29077507.0,Chen H,"Other measurement, Neurological disorder",initial,2017-10-27,GCST005051,Obstructive sleep apnea trait (apnea hypopnea index)
13244,Hispanic or Latin American,12557.0,29077507.0,Chen H,"Other measurement, Neurological disorder",initial,2017-10-27,GCST005051,Obstructive sleep apnea trait (apnea hypopnea index)
9247,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005442,Apolipoprotein B levels
9257,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005452,Triglyceride levels in very large VLDL
9256,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005451,Phospholipid levels in very large VLDL
43,African,108.0,29082582.0,Almli LM,"Other measurement, Biological process",replication,2017-10-30,GCST005236,Problematic alcohol use in trauma-exposed individuals
9255,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005450,Very large VLDL particle concentration
9313,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005508,Small HDL particle concentration
9253,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005448,Serum total cholesterol levels
9248,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005443,Ratio of apolipoprotein A1 to apolipoprotein B
9252,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005447,Total cholesterol levels in LDL
9251,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005446,Total cholesterol levels in HDL
791,African American or Afro-Caribbean,1036.0,29082582.0,Almli LM,"Other measurement, Biological process",initial,2017-10-30,GCST005236,Problematic alcohol use in trauma-exposed individuals
13600,Other/Mixed,282.0,29082582.0,Almli LM,"Other measurement, Biological process",replication,2017-10-30,GCST005236,Problematic alcohol use in trauma-exposed individuals
5807,European,828.0,29082582.0,Almli LM,"Other measurement, Biological process",replication,2017-10-30,GCST005236,Problematic alcohol use in trauma-exposed individuals
9250,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005445,Free cholesterol levels
9249,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005444,Esterified cholesterol levels
9254,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005449,Total triglycerides levels
12281,European,360838.0,29083406.0,Ferreira MA,"Other disease, Immune system disorder",initial,2017-10-30,GCST005038,"Allergic disease (asthma, hay fever or eczema)"
9314,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005509,Triglyceride levels in small HDL
9259,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005454,Phospholipid levels in large VLDL
9258,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005453,Very large VLDL particle concentration
9291,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005486,Medium LDL particle concentration
9292,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005487,Phospholipid levels in medium LDL
9293,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005488,Total cholesterol levels in medium LDL
9294,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005489,Cholesterol ester levels in medium LDL
9295,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005490,Small LDL particle concentration
9296,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005491,Total cholesterol levels in small LDL
9297,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005492,Very large HDL particle concentration
9298,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005493,Phospholipid levels in very large HDL
9299,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005494,Total cholesterol levels in very large HDL
9300,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005495,Cholesterol ester levels in very large HDL
9301,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005496,Free cholesterol levels in very large HDL
9302,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005497,Large HDL particle concentration
9303,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005498,Triglyceride levels in very large HDL
9304,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005499,Phospholipid levels in large HDL
9305,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005500,Total cholesterol levels in large HDL
9306,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005501,Cholesterol ester levels in very large HDL
9307,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005502,Free cholesterol levels in large HDL
9308,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005503,Medium HDL particle concentration
9309,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005504,Phospholipid levels in medium HDL
9310,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005505,Total cholesterol levels in medium HDL
9311,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005506,Cholesterol ester levels in medium HDL
9312,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005507,Free cholesterol levels in medium HDL
9318,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005513,Apolipoprotein A1 levels
9317,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005512,Triglyceride levels in chylomicrons and largest VLDL
9316,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005511,Phospholipid levels in chylomicrons and largest VLDL
9315,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005510,Chylomicron and largest VLDL particle concentration
9289,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005484,Cholesterol ester levels in large LDL
9288,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005483,Total cholesterol levels in large LDL
9290,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005485,Free cholesterol levels in large LDL
9272,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005467,Triglyceride levels in medium VLDL
9260,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005455,Mean diameter of HDL particles
9261,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005456,Mean diameter of LDL particles
9262,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005457,Mean diameter of VLDL particles
9263,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005458,Total cholesterol levels in large VLDL
9265,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005460,Triglyceride levels in large VLDL
9266,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005461,Cholesterol ester levels in large VLDL
9267,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005462,Medium VLDL particle concentration
9268,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005463,Phospholipid levels in medium VLDL
1541,Asian,6.0,29082582.0,Almli LM,"Other measurement, Biological process",replication,2017-10-30,GCST005236,Problematic alcohol use in trauma-exposed individuals
9269,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005464,Total cholesterol levels in medium VLDL
9270,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005465,Cholesterol ester levels in medium VLDL
9271,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005466,Free cholesterol levels in medium VLDL
9287,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005482,Phospholipid levels in large LDL
9273,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005468,Small VLDL particle concentration
9264,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005459,Free cholesterol levels in large VLDL
9275,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005470,Total cholesterol levels in small VLDL
9286,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005481,Large LDL particle concentration
9285,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005480,Triglyceride levels in IDL
9284,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005479,Free cholesterol levels in IDL
9283,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005478,IDL particle concentration
9282,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005477,Phospholipid levels in IDL
9274,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005469,Phospholipid levels in small VLDL
9280,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005475,Triglyceride levels in very small VLDL
9281,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005476,IDL particle concentration
9278,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005473,Very small VLDL particle concentration
9277,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005472,Triglyceride levels in small VLDL
9276,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005471,Free cholesterol levels in small VLDL
9279,European,8372.0,29084231.0,Davis JP,Lipid or lipoprotein measurement,initial,2017-10-30,GCST005474,Phospholipid levels in very small VLDL
2044,Asian,428.0,29104669.0,Chen L,Other disease,initial,2017-11-01,GCST005043,Polycystic ovary syndrome
3957,Asian,8842.0,29095316.0,Suh Y,Other measurement,initial,2017-11-01,GCST005131,Lung function (forced vital capacity)
11629,European,110851.0,29029846.0,Schormair B,Neurological disorder,initial,2017-11-01,GCST005042,Restless legs syndrome
9179,European,7976.0,29093028.0,Corre T,Other measurement,initial,2017-11-01,GCST005126,Fractional excretion of magnesium
12224,European,317683.0,29029846.0,Schormair B,Neurological disorder,replication,2017-11-01,GCST005042,Restless legs syndrome
3958,Asian,8842.0,29095316.0,Suh Y,Other measurement,initial,2017-11-01,GCST005132,Lung function (forced expiratory volume in 1 second)
5522,European,624.0,29059430.0,Morton LM,"Cancer, Biological process",initial,2017-11-01,GCST005112,Breast cancer in childhood cancer survivors treated with more than 10 gray radiotherapy
9178,European,7976.0,29093028.0,Corre T,Other measurement,initial,2017-11-01,GCST005125,Serum magnesium levels
7589,European,2981.0,29059430.0,Morton LM,Cancer,initial,2017-11-01,GCST005111,Breast cancer in childhood cancer survivors
3956,Asian,8842.0,29095316.0,Suh Y,Other measurement,initial,2017-11-01,GCST005130,Lung function (FEV1/FVC)
9431,European,9099.0,29093028.0,Corre T,Other measurement,initial,2017-11-01,GCST005124,Urinary magnesium-to-creatinine ratio
8714,European,5901.0,29066854.0,Lin BD,Hematological measurement,initial,2017-11-01,GCST005052,Platelet-to-lymphocyte ratio
3954,Asian,8842.0,29095316.0,Suh Y,Other measurement,initial,2017-11-01,GCST005127,Lung function (maximal voluntary ventilation)
8716,European,5901.0,29066854.0,Lin BD,Hematological measurement,initial,2017-11-01,GCST005054,Platelet count
7122,European,2213.0,29059430.0,Morton LM,Cancer,initial,2017-11-01,GCST005110,Breast cancer in childhood cancer survivors treated with less than 10 gray radiotherapy
8717,European,5901.0,29066854.0,Lin BD,Hematological measurement,initial,2017-11-01,GCST005055,Lymphocyte counts
8718,European,5901.0,29066854.0,Lin BD,Hematological measurement,initial,2017-11-01,GCST005056,Neutrophil count
2704,Asian,1600.0,29104669.0,Chen L,Other disease,replication,2017-11-01,GCST005043,Polycystic ovary syndrome
3955,Asian,8842.0,29095316.0,Suh Y,Other measurement,initial,2017-11-01,GCST005129,Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity)
8715,European,5901.0,29066854.0,Lin BD,Hematological measurement,initial,2017-11-01,GCST005053,Neutrophil-to-lymphocyte ratio
4983,European,314.0,29097388.0,Magvanjav O,"Response to drug, Other measurement",initial,2017-11-02,GCST005040,Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic)
4853,European,221.0,29097388.0,Magvanjav O,"Other measurement, Response to drug",replication,2017-11-02,GCST005039,Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic)
4854,European,221.0,29097388.0,Magvanjav O,"Response to drug, Other measurement",replication,2017-11-02,GCST005040,Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic)
4982,European,314.0,29097388.0,Magvanjav O,"Other measurement, Response to drug",initial,2017-11-02,GCST005039,Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic)
4984,European,314.0,29097388.0,Magvanjav O,"Response to drug, Other measurement",initial,2017-11-02,GCST005041,Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic)
7801,European,3344.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005159,Insulin levels in response to oral glucose tolerance test (fasting)
4855,European,221.0,29097388.0,Magvanjav O,"Response to drug, Other measurement",replication,2017-11-02,GCST005041,Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic)
7807,European,3344.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005165,GLP-1 levels in response to oral glucose tolerance test (120 minutes)
7806,European,3344.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005164,GLP-1 levels in response to oral glucose tolerance test (fasting)
7805,European,3344.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005163,Glucagon levels in response to oral glucose tolerance test (120 minutes)
7804,European,3344.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005162,Glucagon levels in response to oral glucose tolerance test (fasting)
7803,European,3344.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005161,Insulin levels in response to oral glucose tolerance test (120 minutes)
7802,European,3344.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005160,Insulin levels in response to oral glucose tolerance test (30 minutes)
7809,European,3344.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005167,GIP levels in response to oral glucose tolerance test (fasting)
7808,European,3344.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005166,GIP levels in response to oral glucose tolerance test (120 minutes)
2165,Asian,568.0,29109912.0,Rawofi L,"Other trait, Other measurement",replication,2017-11-02,GCST005084,Skin pigmentation
8396,European,4905.0,29093273.0,Almgren P,Other measurement,initial,2017-11-02,GCST005161,Insulin levels in response to oral glucose tolerance test (120 minutes)
8399,European,4905.0,29093273.0,Almgren P,Other measurement,replication,2017-11-02,GCST005162,Glucagon levels in response to oral glucose tolerance test (fasting)
12576,Hispanic or Latin American,193.0,29097388.0,Magvanjav O,"Response to drug, Other measurement",replication,2017-11-02,GCST005041,Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic)
1997,Asian,377.0,29109912.0,Rawofi L,"Other trait, Other measurement",initial,2017-11-02,GCST005084,Skin pigmentation
12575,Hispanic or Latin American,193.0,29097388.0,Magvanjav O,"Response to drug, Other measurement",replication,2017-11-02,GCST005040,Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic)
1996,Asian,377.0,29109912.0,Rawofi L,"Other measurement, Other trait",initial,2017-11-02,GCST005096,Iris color (b* coordinate)
8400,European,4905.0,29093273.0,Almgren P,Other measurement,replication,2017-11-02,GCST005163,Glucagon levels in response to oral glucose tolerance test (120 minutes)
1995,Asian,377.0,29109912.0,Rawofi L,"Other measurement, Other trait",initial,2017-11-02,GCST005095,Iris heterochromicity
12574,Hispanic or Latin American,193.0,29097388.0,Magvanjav O,"Other measurement, Response to drug",replication,2017-11-02,GCST005039,Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic)
1994,Asian,377.0,29109912.0,Rawofi L,"Other measurement, Other trait",initial,2017-11-02,GCST005094,Iris color (L* coordinate)
8404,European,4905.0,29093273.0,Almgren P,Other measurement,replication,2017-11-02,GCST005167,GIP levels in response to oral glucose tolerance test (fasting)
8403,European,4905.0,29093273.0,Almgren P,Other measurement,replication,2017-11-02,GCST005166,GIP levels in response to oral glucose tolerance test (120 minutes)
8398,European,4905.0,29093273.0,Almgren P,Other measurement,replication,2017-11-02,GCST005160,Insulin levels in response to oral glucose tolerance test (30 minutes)
8402,European,4905.0,29093273.0,Almgren P,Other measurement,replication,2017-11-02,GCST005165,GLP-1 levels in response to oral glucose tolerance test (120 minutes)
8401,European,4905.0,29093273.0,Almgren P,Other measurement,replication,2017-11-02,GCST005164,GLP-1 levels in response to oral glucose tolerance test (fasting)
8397,European,4905.0,29093273.0,Almgren P,Other measurement,replication,2017-11-02,GCST005159,Insulin levels in response to oral glucose tolerance test (fasting)
1993,Asian,377.0,29109912.0,Rawofi L,"Other measurement, Other trait",initial,2017-11-02,GCST005093,Iris color (a* coordinate)
7108,European,2192.0,29097723.0,Darlow JM,Other disease,initial,2017-11-06,GCST005044,Primary vesicoureteric reflux
8427,European,4936.0,29097723.0,Darlow JM,Other disease,initial,2017-11-06,GCST005045,Primary vesicoureteric reflux
7235,European,2372.0,29112194.0,Agrawal A,Neurological disorder,replication,2017-11-07,GCST005133,Cannabis dependence
3220,Asian,2928.0,29209388.0,Cho CH,Neurological disorder,initial,2017-11-07,GCST005107,Restless legs syndrome
9347,European,8515.0,29112194.0,Agrawal A,Neurological disorder,initial,2017-11-07,GCST005133,Cannabis dependence
1034,African American or Afro-Caribbean,2801.0,29112194.0,Agrawal A,Neurological disorder,replication,2017-11-07,GCST005133,Cannabis dependence
2071,Asian,456.0,29209388.0,Cho CH,Neurological disorder,replication,2017-11-07,GCST005107,Restless legs syndrome
9196,European,8050.0,29112194.0,Agrawal A,Other measurement,initial,2017-11-07,GCST005128,Cannabis dependence symptom count
4452,Asian,60650.0,29118346.0,Sakamoto Y,Other disease,initial,2017-11-08,GCST005048,Idiopathic osteonecrosis of the femoral head
3592,Asian,5556.0,29124443.0,Yasukochi Y,"Cardiovascular measurement, Metabolic disorder",replication,2017-11-09,GCST007916,Hyperuricemia
3664,Asian,5847.0,29124443.0,Yasukochi Y,Cardiovascular measurement,initial,2017-11-09,GCST007918,Serum uric acid levels
7226,European,2366.0,29121268.0,Amare AT,"Response to drug, Neurological disorder",initial,2017-11-09,GCST005081,Bipolar disorder lithium response (continuous) or schizophrenia
3293,Asian,3402.0,29124443.0,Yasukochi Y,"Other disease, Other measurement",replication,2017-11-09,GCST007920,Chronic kidney disease
7227,European,2366.0,29121268.0,Amare AT,"Response to drug, Neurological disorder",initial,2017-11-09,GCST005082,Bipolar disorder lithium response (categorical) or schizophrenia
3583,Asian,5487.0,29124443.0,Yasukochi Y,"Cardiovascular measurement, Metabolic disorder",initial,2017-11-09,GCST007916,Hyperuricemia
1825,Asian,220.0,29121268.0,Amare AT,"Response to drug, Neurological disorder",initial,2017-11-09,GCST005081,Bipolar disorder lithium response (continuous) or schizophrenia
2627,Asian,1453.0,29123153.0,Lee TH,Cardiovascular disease,replication,2017-11-09,GCST005057,Small vessel stroke
1840,Asian,226.0,29121268.0,Amare AT,"Response to drug, Neurological disorder",initial,2017-11-09,GCST005082,Bipolar disorder lithium response (categorical) or schizophrenia
3625,Asian,5636.0,29124443.0,Yasukochi Y,Other measurement,initial,2017-11-09,GCST007917,Estimated glomerular filtration rate
3626,Asian,5636.0,29124443.0,Yasukochi Y,Other measurement,initial,2017-11-09,GCST007919,Creatinine levels
2951,Asian,2073.0,29123153.0,Lee TH,Cardiovascular disease,initial,2017-11-09,GCST005057,Small vessel stroke
2727,Asian,1646.0,29124443.0,Yasukochi Y,"Other disease, Other measurement",initial,2017-11-09,GCST007920,Chronic kidney disease
12794,Hispanic or Latin American,1050.0,29124805.0,Carlson JC,"Other trait, Other disease",initial,2017-11-10,GCST005079,Orofacial clefts (cleft lip vs. cleft lip and palate)
3755,Asian,6805.0,29127183.0,Seyerle AA,Cardiovascular measurement,replication,2017-11-10,GCST005080,PR interval
2143,Asian,542.0,29124805.0,Carlson JC,"Other trait, Other disease",replication,2017-11-10,GCST005079,Orofacial clefts (cleft lip vs. cleft lip and palate)
12652,Hispanic or Latin American,463.0,29124805.0,Carlson JC,"Other trait, Other disease",replication,2017-11-10,GCST005079,Orofacial clefts (cleft lip vs. cleft lip and palate)
52,African,147.0,29124805.0,Carlson JC,"Other trait, Other disease",initial,2017-11-10,GCST005079,Orofacial clefts (cleft lip vs. cleft lip and palate)
1981,Asian,367.0,29124805.0,Carlson JC,"Other trait, Other disease",initial,2017-11-10,GCST005079,Orofacial clefts (cleft lip vs. cleft lip and palate)
2395,Asian,927.0,29124805.0,Carlson JC,"Other trait, Other disease",replication,2017-11-10,GCST005079,Orofacial clefts (cleft lip vs. cleft lip and palate)
8192,European,4296.0,29127183.0,Seyerle AA,Cardiovascular measurement,replication,2017-11-10,GCST005080,PR interval
13267,Hispanic or Latin American,14756.0,29127183.0,Seyerle AA,Cardiovascular measurement,initial,2017-11-10,GCST005080,PR interval
1152,African American or Afro-Caribbean,3763.0,29127183.0,Seyerle AA,Cardiovascular measurement,replication,2017-11-10,GCST005080,PR interval
5444,European,576.0,29124805.0,Carlson JC,"Other trait, Other disease",initial,2017-11-10,GCST005079,Orofacial clefts (cleft lip vs. cleft lip and palate)
5480,European,598.0,29124805.0,Carlson JC,"Other trait, Other disease",replication,2017-11-10,GCST005079,Orofacial clefts (cleft lip vs. cleft lip and palate)
5497,European,606.0,29130521.0,Christopher L,Other measurement,initial,2017-11-11,GCST006632,Decline in glucose metabolism in posterior cingulate cortex
12441,European,585478.0,29145611.0,Hu Y,"Other disease, Metabolic disorder",initial,2017-11-14,GCST005114,Osteoporosis or obesity (pleiotropy)
9852,European,12596.0,29147026.0,Chen CH,Other measurement,initial,2017-11-16,GCST005083,Putamen volume
10572,European,25218.0,29146897.0,Pirastu N,"Other measurement, Other disease",replication,2017-11-17,GCST005116,Male-pattern baldness
11019,European,43590.0,29146897.0,Pirastu N,"Other measurement, Other disease",initial,2017-11-17,GCST005116,Male-pattern baldness
3525,Asian,5075.0,29151059.0,Delgado DA,Other measurement,initial,2017-11-18,GCST005143,Telomere length
4934,European,286.0,29158487.0,Heckerman D,Other measurement,initial,2017-11-20,GCST005117,Activities of daily living score
4940,European,286.0,29158487.0,Heckerman D,Other measurement,initial,2017-11-20,GCST005123,Cognitive performance
4935,European,286.0,29158487.0,Heckerman D,Other measurement,initial,2017-11-20,GCST005118,Mid-arm muscle circumference
4938,European,286.0,29158487.0,Heckerman D,Other measurement,initial,2017-11-20,GCST005121,Short physical performance battery score
6148,European,1055.0,29158487.0,Heckerman D,Other measurement,replication,2017-11-20,GCST005120,Four meter walk test score
4936,European,286.0,29158487.0,Heckerman D,Other measurement,initial,2017-11-20,GCST005119,Calf circumference
4937,European,286.0,29158487.0,Heckerman D,Other measurement,initial,2017-11-20,GCST005120,Four meter walk test score
4939,European,286.0,29158487.0,Heckerman D,Other measurement,initial,2017-11-20,GCST005122,Hand grip strength
6368,European,1301.0,29158497.0,Kadalayil L,"Other measurement, Cancer",replication,2017-11-21,GCST005106,Breast cancer (survival)
6809,European,1828.0,29160301.0,Fabbri C,Response to drug,initial,2017-11-21,GCST007042,Response to SSRI (symptom improvement)
7037,European,2145.0,29160301.0,Fabbri C,Response to drug,initial,2017-11-21,GCST007059,Response to antidepressants (symptom improvement)
6507,European,1472.0,29160301.0,Fabbri C,Response to drug,replication,2017-11-21,GCST007042,Response to SSRI (symptom improvement)
8334,European,4739.0,29158497.0,Kadalayil L,"Other measurement, Cancer",initial,2017-11-21,GCST005106,Breast cancer (survival)
6810,European,1828.0,29160301.0,Fabbri C,Response to drug,initial,2017-11-21,GCST007060,Response to SSRI (symptom remission)
6399,European,1345.0,29160300.0,Oetting WS,"Other trait, Other measurement",initial,2017-11-21,GCST005144,Tacrolimus trough concentration in kidney transplant patients
7038,European,2145.0,29160301.0,Fabbri C,Response to drug,initial,2017-11-21,GCST007061,Response to antidepressants (symptom remission)
6176,European,1085.0,29168253.0,Seielstad M,Biological process,initial,2017-11-22,GCST005157,Alloimmunization response to pregnancy (HLA class II)
6078,European,1000.0,29168253.0,Seielstad M,Biological process,initial,2017-11-22,GCST005156,Alloimmunization response to pregnancy (HLA class I)
6523,European,1505.0,29168253.0,Seielstad M,Biological process,initial,2017-11-22,GCST005155,Alloimmunization response to pregnancy
5978,European,946.0,29168253.0,Seielstad M,Biological process,initial,2017-11-22,GCST005154,Alloimmunization response to pregnancy (HLA class I and II)
3843,Asian,7704.0,29170429.0,Hachiya T,Other measurement,initial,2017-11-23,GCST005145,Glycated hemoglobin levels
8712,European,5893.0,29170203.0,Alonso N,Other disease,initial,2017-11-23,GCST005097,Fractures (vertebral)
7505,European,2799.0,29170203.0,Alonso N,Other disease,replication,2017-11-23,GCST005097,Fractures (vertebral)
10293,European,19136.0,29299148.0,Liu W,Cancer,initial,2017-11-25,GCST005275,Cancer
12260,European,338460.0,29413154.0,Shadrin AA,"Neurological disorder, Other measurement",initial,2017-11-26,GCST006216,Attention deficit hyperactivity disorder or educational attainment (years of education) (pleiotropy)
12785,Hispanic or Latin American,983.0,29178545.0,Gao C,Other measurement,initial,2017-11-27,GCST005089,Visceral adipose tissue/subcutaneous adipose tissue ratio
12782,Hispanic or Latin American,983.0,29178545.0,Gao C,Other measurement,initial,2017-11-27,GCST005085,Visceral adipose tissue
203,African,1562.0,29868224.0,Sallah N,Other measurement,initial,2017-11-27,GCST005944,Viral capsid antigen IgG seropositivity
7514,European,2811.0,29186428.0,Tonjes A,Other measurement,initial,2017-11-27,GCST005109,Progranulin levels
12783,Hispanic or Latin American,983.0,29178545.0,Gao C,Other measurement,initial,2017-11-27,GCST005086,Visceral adipose tissue (sex interaction)
6794,European,1800.0,29186428.0,Tonjes A,Other measurement,replication,2017-11-27,GCST005109,Progranulin levels
12709,Hispanic or Latin American,707.0,29178545.0,Gao C,Other measurement,replication,2017-11-27,GCST005085,Visceral adipose tissue
12784,Hispanic or Latin American,983.0,29178545.0,Gao C,Other measurement,initial,2017-11-27,GCST005088,Visceral adipose tissue adjusted for BMI (sex interaction)
12714,Hispanic or Latin American,707.0,29178545.0,Gao C,"Other measurement, Body measurement",replication,2017-11-27,GCST005087,Visceral adipose tissue adjusted for BMI
12711,Hispanic or Latin American,707.0,29178545.0,Gao C,Other measurement,replication,2017-11-27,GCST005088,Visceral adipose tissue adjusted for BMI (sex interaction)
12712,Hispanic or Latin American,707.0,29178545.0,Gao C,Other measurement,replication,2017-11-27,GCST005089,Visceral adipose tissue/subcutaneous adipose tissue ratio
202,African,1562.0,29868224.0,Sallah N,Other measurement,initial,2017-11-27,GCST005941,Epstein Barr virus nuclear antigen 1 IgG seropositivity
12787,Hispanic or Latin American,983.0,29178545.0,Gao C,Other measurement,initial,2017-11-27,GCST005091,Subcutaneous adipose tissue
7068,European,2162.0,29868224.0,Sallah N,Other measurement,initial,2017-11-27,GCST005963,Epstein Barr virus nuclear antigen 1 IgG levels
12710,Hispanic or Latin American,707.0,29178545.0,Gao C,Other measurement,replication,2017-11-27,GCST005086,Visceral adipose tissue (sex interaction)
12788,Hispanic or Latin American,983.0,29178545.0,Gao C,Other measurement,initial,2017-11-27,GCST005092,Subcutaneous adipose tissue (sex interaction)
12713,Hispanic or Latin American,707.0,29178545.0,Gao C,Other measurement,replication,2017-11-27,GCST005090,Visceral adipose tissue/subcutaneous adipose tissue ratio (sex interaction)
197,African,1473.0,29868224.0,Sallah N,Other measurement,initial,2017-11-27,GCST005963,Epstein Barr virus nuclear antigen 1 IgG levels
196,African,1473.0,29868224.0,Sallah N,Other measurement,initial,2017-11-27,GCST005943,Epstein-Barr virus immune response (multivariate analysis)
12789,Hispanic or Latin American,983.0,29178545.0,Gao C,"Other measurement, Body measurement",initial,2017-11-27,GCST005087,Visceral adipose tissue adjusted for BMI
195,African,1473.0,29868224.0,Sallah N,Other measurement,initial,2017-11-27,GCST005942,Viral capsid antigen IgG levels
12786,Hispanic or Latin American,983.0,29178545.0,Gao C,Other measurement,initial,2017-11-27,GCST005090,Visceral adipose tissue/subcutaneous adipose tissue ratio (sex interaction)
7585,European,2971.0,29423119.0,Khan S,"Other measurement, Cancer",initial,2017-11-28,GCST005901,Survival in breast cancer (estrogen-receptor positive)
12363,European,436124.0,29186694.0,Lam M,"Other measurement, Biological process",initial,2017-11-28,GCST005141,Cognitive ability (MTAG)
11600,European,107207.0,29186694.0,Lam M,Biological process,initial,2017-11-28,GCST005142,Cognitive ability
7410,European,2629.0,29423119.0,Khan S,"Other measurement, Cancer, Response to drug",initial,2017-11-28,GCST005900,Survival in endocrine treated breast cancer (estrogen-receptor positive)
688,African American or Afro-Caribbean,613.0,29185836.0,Chen MH,Biological process,replication,2017-11-29,GCST008171,Platelet aggregation
6275,European,1184.0,29185836.0,Chen MH,Biological process,replication,2017-11-29,GCST008171,Platelet aggregation
8161,European,4213.0,29185836.0,Chen MH,Biological process,initial,2017-11-29,GCST008171,Platelet aggregation
70,African,240.0,29195075.0,Martin AR,"Other trait, Other measurement",replication,2017-11-30,GCST005188,Skin pigmentation
437,African American or Afro-Caribbean,74.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005244,Putamen volume in trauma-exposed individuals
10571,European,25035.0,29187746.0,Howard DM,Neurological disorder,replication,2017-11-30,GCST005108,Major depressive disorder
11590,European,104103.0,29187730.0,Ward J,Other measurement,initial,2017-11-30,GCST005237,Mood instability
13049,Hispanic or Latin American,5062.0,29198719.0,Shaffer JR,Other trait,initial,2017-11-30,GCST005193,Lobe attachment (rater scored)
13048,Hispanic or Latin American,5062.0,29198719.0,Shaffer JR,Other trait,initial,2017-11-30,GCST005192,Lobe attachment (rater-scored or self-reported)
11656,European,113968.0,29187730.0,Ward J,Other measurement,initial,2017-11-30,GCST005238,Mood instability
438,African American or Afro-Caribbean,74.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005245,Thalamus volume in trauma-exposed individuals
436,African American or Afro-Caribbean,74.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005243,Hippocampal volume in trauma-exposed individuals
4632,European,83.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005244,Putamen volume in trauma-exposed individuals
4630,European,83.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005242,Pallidum volume in trauma-exposed individuals
432,African American or Afro-Caribbean,74.0,29187748.0,Morey RA,"Biological process, Other measurement",initial,2017-11-30,GCST005286,Lateral ventricle volume in trauma-exposed individuals
433,African American or Afro-Caribbean,74.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005239,Amygdala volume in trauma-exposed individuals
4628,European,83.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005239,Amygdala volume in trauma-exposed individuals
69,African,240.0,29195075.0,Martin AR,Other trait,replication,2017-11-30,GCST005189,Tanning
434,African American or Afro-Caribbean,74.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005241,Nucleus accumbens volume in trauma-exposed individuals
4627,European,83.0,29187748.0,Morey RA,"Biological process, Other measurement",initial,2017-11-30,GCST005286,Lateral ventricle volume in trauma-exposed individuals
4626,European,83.0,29187748.0,Morey RA,"Biological process, Other measurement",initial,2017-11-30,GCST005240,Caudate volume in trauma-exposed individuals
10277,European,18773.0,29187746.0,Howard DM,Neurological disorder,initial,2017-11-30,GCST005108,Major depressive disorder
435,African American or Afro-Caribbean,74.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005242,Pallidum volume in trauma-exposed individuals
4631,European,83.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005243,Hippocampal volume in trauma-exposed individuals
4629,European,83.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005241,Nucleus accumbens volume in trauma-exposed individuals
6786,European,1791.0,29198719.0,Shaffer JR,Other trait,initial,2017-11-30,GCST005193,Lobe attachment (rater scored)
62,African,216.0,29195075.0,Martin AR,Other trait,initial,2017-11-30,GCST005189,Tanning
431,African American or Afro-Caribbean,74.0,29187748.0,Morey RA,"Biological process, Other measurement",initial,2017-11-30,GCST005240,Caudate volume in trauma-exposed individuals
4633,European,83.0,29187748.0,Morey RA,"Other measurement, Biological process",initial,2017-11-30,GCST005245,Thalamus volume in trauma-exposed individuals
11284,European,66741.0,29198719.0,Shaffer JR,Other trait,initial,2017-11-30,GCST005192,Lobe attachment (rater-scored or self-reported)
3200,Asian,2857.0,29198719.0,Shaffer JR,Other trait,initial,2017-11-30,GCST005192,Lobe attachment (rater-scored or self-reported)
3201,Asian,2857.0,29198719.0,Shaffer JR,Other trait,initial,2017-11-30,GCST005193,Lobe attachment (rater scored)
63,African,216.0,29195075.0,Martin AR,"Other trait, Other measurement",initial,2017-11-30,GCST005188,Skin pigmentation
8422,European,4932.0,29237677.0,Salo PP,Cardiovascular measurement,initial,2017-12-01,GCST005205,N-terminal pro B-type natriuretic peptide levels
8423,European,4932.0,29237677.0,Salo PP,Cardiovascular measurement,initial,2017-12-01,GCST005206,B-type natriuretic peptide levels
12102,European,246941.0,29227965.0,Pilling LC,Other measurement,initial,2017-12-01,GCST006699,Parental longevity (mother's age at death)
8424,European,4932.0,29237677.0,Salo PP,Cardiovascular measurement,initial,2017-12-01,GCST005207,Midregional pro atrial natriuretic peptide levels
8425,European,4932.0,29237677.0,Salo PP,Cardiovascular measurement,initial,2017-12-01,GCST005208,B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio
12351,European,415311.0,29227965.0,Pilling LC,Other measurement,initial,2017-12-01,GCST006701,Parental longevity (father's attained age)
6434,European,1373.0,29237677.0,Salo PP,Cardiovascular measurement,replication,2017-12-01,GCST005205,N-terminal pro B-type natriuretic peptide levels
5960,European,934.0,29251981.0,Weafer J,Other measurement,initial,2017-12-01,GCST005246,Inhibitory control
12043,European,208118.0,29227965.0,Pilling LC,Other measurement,initial,2017-12-01,GCST006702,Parental longevity (combined parental age at death)
12223,European,317652.0,29227965.0,Pilling LC,Other measurement,initial,2017-12-01,GCST006700,Parental longevity (father's age at death)
6435,European,1373.0,29237677.0,Salo PP,Cardiovascular measurement,replication,2017-12-01,GCST005206,B-type natriuretic peptide levels
10065,European,15603.0,29196614.0,Sud A,Cancer,initial,2017-12-01,GCST005211,Nodular sclerosis Hodgkin lymphoma
6436,European,1373.0,29237677.0,Salo PP,Cardiovascular measurement,replication,2017-12-01,GCST005207,Midregional pro atrial natriuretic peptide levels
6437,European,1373.0,29237677.0,Salo PP,Cardiovascular measurement,replication,2017-12-01,GCST005208,B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio
12349,European,412937.0,29227965.0,Pilling LC,Other measurement,initial,2017-12-01,GCST006696,Parental longevity (mother's attained age)
12323,European,389166.0,29227965.0,Pilling LC,Other measurement,initial,2017-12-01,GCST006697,"Parental longevity (combined parental attained age, Martingale residuals)"
10033,European,15143.0,29196614.0,Sud A,Cancer,initial,2017-12-01,GCST005210,Mixed cellularity Hodgkin lymphoma
8754,European,6049.0,29212897.0,Salminen A,Inflammatory measurement,initial,2017-12-01,GCST005187,Matrix metalloproteinase-8 levels
11482,European,86949.0,29227965.0,Pilling LC,Other measurement,initial,2017-12-01,GCST006698,Parental longevity (both parents in top 10%)
10156,European,16757.0,29196614.0,Sud A,Cancer,initial,2017-12-01,GCST005209,Hodgkin's lymphoma
11698,European,120286.0,29237688.0,Weng LC,Cardiovascular disease,initial,2017-12-01,GCST008486,Atrial fibrillation
11144,European,53293.0,29325848.0,Martin J,Neurological disorder,initial,2017-12-02,GCST005362,Attention deficit hyperactivity disorder
10288,European,19099.0,29325848.0,Martin J,"Neurological disorder, Other trait",initial,2017-12-02,GCST005363,Sex difference in attention deficit hyperactivity disorder
11145,European,53293.0,29325848.0,Martin J,"Neurological disorder, Other measurement",initial,2017-12-02,GCST005361,Attention deficit hyperactivity disorder (sex interaction)
575,African American or Afro-Caribbean,288.0,29206233.0,Shendre A,Cardiovascular measurement,initial,2017-12-04,GCST005182,Common carotid intima-media thickness in HIV negative individuals
697,African American or Afro-Caribbean,682.0,29206233.0,Shendre A,"Other disease, Cardiovascular measurement",initial,2017-12-04,GCST005184,Common carotid intima-media thickness in HIV infection
773,African American or Afro-Caribbean,970.0,29206233.0,Shendre A,Cardiovascular measurement,initial,2017-12-04,GCST005183,Common carotid intima-media thickness
2868,Asian,1876.0,29212900.0,Li C,"Other measurement, Cardiovascular measurement",initial,2017-12-06,GCST005201,Pulse pressure (dietary potassium intake interaction)
2867,Asian,1876.0,29212900.0,Li C,Other measurement,initial,2017-12-06,GCST005204,Systolic blood pressure (dietary potassium intake interaction)
2312,Asian,775.0,29212900.0,Li C,Other measurement,replication,2017-12-06,GCST005203,Mean arterial pressure (dietary potassium intake interaction)
13761,Other/Mixed,709.0,29220522.0,Liu F,Other measurement,replication,2017-12-06,GCST005191,Hair shape
2865,Asian,1876.0,29212900.0,Li C,Other measurement,initial,2017-12-06,GCST005202,Diastolic blood pressure (dietary potassium intake interaction)
7214,European,2340.0,29220522.0,Liu F,Other measurement,replication,2017-12-06,GCST005191,Hair shape
2311,Asian,775.0,29212900.0,Li C,Other measurement,replication,2017-12-06,GCST005202,Diastolic blood pressure (dietary potassium intake interaction)
2314,Asian,775.0,29212900.0,Li C,"Other measurement, Cardiovascular measurement",replication,2017-12-06,GCST005201,Pulse pressure (dietary potassium intake interaction)
3214,Asian,2899.0,29220522.0,Liu F,Other measurement,replication,2017-12-06,GCST005191,Hair shape
2985,Asian,2146.0,29208002.0,Kim M,Other measurement,initial,2017-12-06,GCST005169,Diastolic blood pressure
2313,Asian,775.0,29212900.0,Li C,Other measurement,replication,2017-12-06,GCST005204,Systolic blood pressure (dietary potassium intake interaction)
2984,Asian,2146.0,29208002.0,Kim M,Other measurement,initial,2017-12-06,GCST005168,Systolic blood pressure
2866,Asian,1876.0,29212900.0,Li C,Other measurement,initial,2017-12-06,GCST005203,Mean arterial pressure (dietary potassium intake interaction)
1696,Asian,117.0,29207912.0,Nishizawa D,"Response to drug, Other measurement",initial,2017-12-06,GCST005364,Opioid requirements during laparoscopic-assisted colectomy
13275,Hispanic or Latin American,15997.0,29213071.0,Mendez-Giraldez R,Cardiovascular measurement,initial,2017-12-06,GCST005171,QT interval
1861,Asian,234.0,29207912.0,Nishizawa D,"Response to drug, Other measurement",replication,2017-12-06,GCST005364,Opioid requirements during laparoscopic-assisted colectomy
12552,Hispanic or Latin American,109.0,29210060.0,Koster R,"Cancer, Other measurement",replication,2017-12-06,GCST005158,Overall survival in osteosarcoma
13084,Hispanic or Latin American,6238.0,29220522.0,Liu F,Other measurement,replication,2017-12-06,GCST005191,Hair shape
13408,Other/Mixed,15.0,29220522.0,Liu F,"Other measurement, Other measurement",replication,2017-12-06,GCST005191,Hair shape
5376,European,523.0,29210060.0,Koster R,"Cancer, Other measurement",initial,2017-12-06,GCST005158,Overall survival in osteosarcoma
10157,European,16763.0,29220522.0,Liu F,Other measurement,initial,2017-12-06,GCST005191,Hair shape
7182,European,2308.0,29217827.0,Sanders AR,Other trait,initial,2017-12-07,GCST005247,Male sexual orientation
700,African American or Afro-Caribbean,691.0,29221444.0,Divers J,"Other trait, Metabolic disorder",initial,2017-12-08,GCST005173,Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes
537,African American or Afro-Caribbean,205.0,29221444.0,Divers J,"Other trait, Metabolic disorder",replication,2017-12-08,GCST005174,Coronary artery calcified atherosclerotic plaque score in type 2 diabetes
701,African American or Afro-Caribbean,691.0,29221444.0,Divers J,"Other trait, Metabolic disorder",initial,2017-12-08,GCST005174,Coronary artery calcified atherosclerotic plaque score in type 2 diabetes
702,African American or Afro-Caribbean,691.0,29221444.0,Divers J,"Other trait, Metabolic disorder",initial,2017-12-08,GCST005175,Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes
538,African American or Afro-Caribbean,205.0,29221444.0,Divers J,"Other trait, Metabolic disorder",replication,2017-12-08,GCST005175,Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes
536,African American or Afro-Caribbean,205.0,29221444.0,Divers J,"Other trait, Metabolic disorder",replication,2017-12-08,GCST005173,Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes
10492,European,23127.0,29230059.0,Sanchez-Roige S,Other measurement,initial,2017-12-11,GCST005248,Delayed reward discounting
5942,European,928.0,29230059.0,Sanchez-Roige S,Other measurement,replication,2017-12-11,GCST005248,Delayed reward discounting
11204,European,56819.0,29235454.0,Choquet H,Other measurement,initial,2017-12-13,GCST005170,Intraocular pressure
14025,Other/Mixed,37930.0,29235454.0,Choquet H,Other measurement,replication,2017-12-13,GCST005170,Intraocular pressure
960,African American or Afro-Caribbean,2070.0,29235454.0,Choquet H,Other measurement,initial,2017-12-13,GCST005170,Intraocular pressure
13063,Hispanic or Latin American,5748.0,29235454.0,Choquet H,Other measurement,initial,2017-12-13,GCST005170,Intraocular pressure
3527,Asian,5119.0,29235454.0,Choquet H,Other measurement,initial,2017-12-13,GCST005170,Intraocular pressure
13670,Other/Mixed,466.0,29240982.0,Mitchell JA,Other measurement,initial,2017-12-14,GCST006247,Pediatric areal bone mineral density (radius vs spine & hip discordant skeletal phenotype)
5287,European,486.0,29240982.0,Mitchell JA,Other measurement,replication,2017-12-14,GCST006247,Pediatric areal bone mineral density (radius vs spine & hip discordant skeletal phenotype)
532,African American or Afro-Caribbean,202.0,29253144.0,Voigt EA,"Response to drug, Inflammatory measurement",initial,2017-12-14,GCST005176,Rubella-specific interleukin-6 secretion
533,African American or Afro-Caribbean,202.0,29253144.0,Voigt EA,"Response to drug, Other measurement",initial,2017-12-14,GCST005177,Rubella-specific interferon-gamma secretion
13669,Other/Mixed,466.0,29240982.0,Mitchell JA,Other measurement,initial,2017-12-14,GCST006130,Pediatric areal bone mineral density (concordant skeletal phenotype)
5285,European,486.0,29240982.0,Mitchell JA,Other measurement,replication,2017-12-14,GCST006129,Pediatric areal bone mineral density (spine vs radius & hip discordant skeletal phenotype)
5957,European,933.0,29240982.0,Mitchell JA,Other measurement,initial,2017-12-14,GCST006129,Pediatric areal bone mineral density (spine vs radius & hip discordant skeletal phenotype)
13668,Other/Mixed,466.0,29240982.0,Mitchell JA,Other measurement,initial,2017-12-14,GCST006129,Pediatric areal bone mineral density (spine vs radius & hip discordant skeletal phenotype)
5286,European,486.0,29240982.0,Mitchell JA,Other measurement,replication,2017-12-14,GCST006130,Pediatric areal bone mineral density (concordant skeletal phenotype)
5959,European,933.0,29240982.0,Mitchell JA,Other measurement,initial,2017-12-14,GCST006247,Pediatric areal bone mineral density (radius vs spine & hip discordant skeletal phenotype)
6657,European,1643.0,29253144.0,Voigt EA,"Response to drug, Other measurement",initial,2017-12-14,GCST005177,Rubella-specific interferon-gamma secretion
5958,European,933.0,29240982.0,Mitchell JA,Other measurement,initial,2017-12-14,GCST006130,Pediatric areal bone mineral density (concordant skeletal phenotype)
6656,European,1643.0,29253144.0,Voigt EA,"Response to drug, Inflammatory measurement",initial,2017-12-14,GCST005176,Rubella-specific interleukin-6 secretion
13231,Hispanic or Latin American,12310.0,29505938.0,Dunn EC,"Neurological disorder, Other measurement",initial,2017-12-16,GCST006174,Depressive symptoms
13140,Hispanic or Latin American,8048.0,29505938.0,Dunn EC,"Neurological disorder, Other measurement",replication,2017-12-16,GCST006174,Depressive symptoms
5741,European,782.0,29253858.0,Bohman A,Neurological disorder,initial,2017-12-18,GCST005268,Chronic rhinosinusitis with nasal polyps
11717,European,122867.0,29255261.0,Luciano M,"Neurological disorder, Other measurement",replication,2017-12-18,GCST005232,Neuroticism
12243,European,329821.0,29255261.0,Luciano M,"Neurological disorder, Other measurement",initial,2017-12-18,GCST005232,Neuroticism
407,African American or Afro-Caribbean,48.0,29266176.0,Inaba H,"Cancer, Other measurement, Response to drug",initial,2017-12-19,GCST005214,Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia
4875,European,235.0,29266176.0,Inaba H,"Cancer, Other measurement, Response to drug",initial,2017-12-19,GCST005214,Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia
5454,European,581.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST006997,Cerebrospinal fluid t-tau levels in mild cognitive impairment
4795,European,190.0,29274321.0,Chung J,"Neurological disorder, Other measurement",initial,2017-12-20,GCST006994,Logical memory (immediate recall) in Alzheimer's disease dementia
4972,European,305.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007004,Hippocampal volume in normal cognition
4971,European,305.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007003,Cerebrospinal fluid p-tau levels in normal cognition
4970,European,305.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007002,Cerebrospinal fluid t-tau levels in normal cognition
4794,European,190.0,29274321.0,Chung J,"Neurological disorder, Other measurement",initial,2017-12-20,GCST006993,Hippocampal volume in Alzheimer's disease dementia
4969,European,305.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007001,Cerebrospinal AB1-42 levels in normal cognition
4796,European,190.0,29274321.0,Chung J,"Neurological disorder, Other measurement",initial,2017-12-20,GCST006995,Logical memory (delayed recall) in Alzheimer's disease dementia
4793,European,190.0,29274321.0,Chung J,"Neurological disorder, Other measurement",initial,2017-12-20,GCST006990,Cerebrospinal AB1-42 levels in Alzheimer's disease dementia
3762,Asian,6942.0,29263402.0,Han Y,Cardiovascular disease,initial,2017-12-20,GCST005172,Coronary artery disease
6166,European,1076.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007009,Hippocampal volume
6165,European,1076.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007008,Cerebrospinal fluid p-tau levels
3139,Asian,2603.0,29263402.0,Han Y,Cardiovascular disease,initial,2017-12-20,GCST005172,Coronary artery disease
6169,European,1076.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007012,Cerebrospinal fluid AB1-42 levels
4797,European,190.0,29274321.0,Chung J,"Other measurement, Neurological disorder",initial,2017-12-20,GCST006991,Cerebrospinal fluid t-tau levels in Alzheimer's disease dementia
4973,European,305.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007005,Logical memory (immediate recall) in normal cognition
6167,European,1076.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007010,Logical memory (delayed recall)
5455,European,581.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST006998,Cerebrospinal fluid p-tau levels in mild cognitive impairment
2979,Asian,2139.0,29263402.0,Han Y,Cardiovascular disease,replication,2017-12-20,GCST005172,Coronary artery disease
5456,European,581.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST006999,Logical memory (immediate recall) in mild cognitive impairment
5457,European,581.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007000,Logical memory (delayed recall) in mild cognitive impairment
4974,European,305.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007006,Logical memory (delayed recall) in normal cognition
5458,European,581.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007013,Hippocampal volume in mild cognitive impairment
5453,European,581.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST006996,Cerebrospinal AB1-42 levels in mild cognitive impairment
6164,European,1076.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007007,Cerebrospinal fluid t-tau levels
6168,European,1076.0,29274321.0,Chung J,Other measurement,initial,2017-12-20,GCST007011,Logical memory (immediate recall)
4798,European,190.0,29274321.0,Chung J,"Other measurement, Neurological disorder",initial,2017-12-20,GCST006992,Cerebrospinal fluid p-tau levels in Alzheimer's disease dementia
3351,Asian,3767.0,29273593.0,Duan L,Cardiovascular disease,replication,2017-12-22,GCST005575,Moyamoya disease
3542,Asian,5215.0,29273806.0,Demenais F,Other disease,initial,2017-12-22,GCST005212,Asthma
4350,Asian,29398.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008127,Body mass index
4351,Asian,29398.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008129,Body mass index
3174,Asian,2786.0,29273593.0,Duan L,Cardiovascular disease,initial,2017-12-22,GCST005575,Moyamoya disease
3543,Asian,5215.0,29273806.0,Demenais F,Other disease,initial,2017-12-22,GCST005213,Asthma (childhood onset)
10380,European,20762.0,29273806.0,Demenais F,Other disease,initial,2017-12-22,GCST005213,Asthma (childhood onset)
12386,European,449889.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008129,Body mass index
12385,European,449886.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008128,Body mass index
1499,African American or Afro-Caribbean,27610.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008129,Body mass index
11743,European,127669.0,29273806.0,Demenais F,Other disease,initial,2017-12-22,GCST005212,Asthma
11744,European,127669.0,29273806.0,Demenais F,Other disease,initial,2017-12-22,GCST006862,Asthma
12006,European,192226.0,29273807.0,Turcot V,"Body measurement, Other measurement",replication,2017-12-22,GCST008124,Body mass index
12819,Hispanic or Latin American,1398.0,29273806.0,Demenais F,Other disease,initial,2017-12-22,GCST005212,Asthma
12820,Hispanic or Latin American,1398.0,29273806.0,Demenais F,Other disease,initial,2017-12-22,GCST005213,Asthma (childhood onset)
12007,European,192226.0,29273807.0,Turcot V,"Body measurement, Other measurement",replication,2017-12-22,GCST008128,Body mass index
12015,European,196766.0,29273807.0,Turcot V,"Body measurement, Other measurement",replication,2017-12-22,GCST008129,Body mass index
1498,African American or Afro-Caribbean,27610.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008124,Body mass index
3944,Asian,8839.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008129,Body mass index
13182,Hispanic or Latin American,10772.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008125,Body mass index
3943,Asian,8839.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008126,Body mass index
13183,Hispanic or Latin American,10772.0,29273807.0,Turcot V,"Body measurement, Other measurement",initial,2017-12-22,GCST008129,Body mass index
4841,European,209.0,29278698.0,Zagajewska K,Neurological disorder,initial,2017-12-23,GCST005347,Pseudoexfoliation syndrome
3435,Asian,4409.0,29271184.0,Chung GE,Digestive system disorder,initial,2017-12-26,GCST005190,Nonalcoholic fatty liver disease
2874,Asian,1881.0,29271184.0,Chung GE,Digestive system disorder,replication,2017-12-26,GCST005190,Nonalcoholic fatty liver disease
1641,Asian,80.0,29288229.0,McCormack M,"Response to drug, Other disease",initial,2017-12-29,GCST005200,Phenytoin-induced maculopapular exanthema
6009,European,964.0,29288229.0,McCormack M,"Other disease, Response to drug",initial,2017-12-29,GCST005198,Carbamazepine-induced maculopapular exanthema
4684,European,101.0,29288229.0,McCormack M,"Response to drug, Other disease",replication,2017-12-29,GCST005200,Phenytoin-induced maculopapular exanthema
6325,European,1238.0,29288229.0,McCormack M,"Other disease, Response to drug",initial,2017-12-29,GCST005197,Antiepileptic drug-induced maculopapular exanthema
1914,Asian,282.0,29288229.0,McCormack M,"Other disease, Response to drug",initial,2017-12-29,GCST005198,Carbamazepine-induced maculopapular exanthema
2073,Asian,458.0,29288229.0,McCormack M,"Other disease, Response to drug",initial,2017-12-29,GCST005197,Antiepileptic drug-induced maculopapular exanthema
1597,Asian,48.0,29288229.0,McCormack M,"Response to drug, Other disease",initial,2017-12-29,GCST005199,Lamotrigine-induced maculopapular exanthema
5378,European,524.0,29288229.0,McCormack M,"Response to drug, Other disease",initial,2017-12-29,GCST005200,Phenytoin-induced maculopapular exanthema
5947,European,930.0,29288229.0,McCormack M,"Response to drug, Other disease",initial,2017-12-29,GCST005199,Lamotrigine-induced maculopapular exanthema
2617,Asian,1426.0,29354237.0,Kim HA,Other disease,initial,2018-01-01,GCST005278,Lumbar spondylosis (presence and severity of osteophytes)
12261,European,339154.0,29364747.0,Jonsson L,Digestive system disorder,initial,2018-01-01,GCST005391,Tooth agenesis (maxillary lateral incisors)
12266,European,340498.0,29364747.0,Jonsson L,Digestive system disorder,initial,2018-01-01,GCST005389,Tooth agenesis
12263,European,339750.0,29364747.0,Jonsson L,Digestive system disorder,initial,2018-01-01,GCST005390,Tooth agenesis (mandibular second premolars)
12262,European,339154.0,29364747.0,Jonsson L,Digestive system disorder,initial,2018-01-01,GCST005392,Tooth agenesis (maxillary second premolars)
6278,European,1190.0,29263008.0,Guerreiro R,Other trait,replication,2018-01-01,GCST005276,Dementia with Lewy bodies
8779,European,6170.0,29364747.0,Jonsson L,Digestive system disorder,replication,2018-01-01,GCST005389,Tooth agenesis
2614,Asian,1424.0,29354237.0,Kim HA,Other disease,initial,2018-01-01,GCST005277,Lumbar spondylosis (Kellgren-Lawrence grade)
12321,European,388538.0,29292387.0,Turley P,Other measurement,initial,2018-01-01,GCST005325,Subjective well-being (MTAG)
12322,European,388538.0,29292387.0,Turley P,Other measurement,initial,2018-01-01,GCST005328,Subjective well-being
12276,European,354862.0,29292387.0,Turley P,Other measurement,initial,2018-01-01,GCST005323,Depressive symptoms (MTAG)
11936,European,168105.0,29292387.0,Turley P,Other measurement,initial,2018-01-01,GCST005326,Neuroticism (MTAG)
11935,European,168105.0,29292387.0,Turley P,"Neurological disorder, Other measurement",initial,2018-01-01,GCST005327,Neuroticism
2616,Asian,1425.0,29354237.0,Kim HA,Other disease,initial,2018-01-01,GCST005279,Lumbar spondylosis (disc space narrowing)
8463,European,5007.0,29263008.0,Guerreiro R,Other trait,initial,2018-01-01,GCST005276,Dementia with Lewy bodies
8331,European,4733.0,29364747.0,Jonsson L,Digestive system disorder,replication,2018-01-01,GCST005390,Tooth agenesis (mandibular second premolars)
4976,European,306.0,29364747.0,Jonsson L,Digestive system disorder,replication,2018-01-01,GCST005391,Tooth agenesis (maxillary lateral incisors)
12275,European,354862.0,29292387.0,Turley P,"Neurological disorder, Other measurement",initial,2018-01-01,GCST005324,Depressive symptoms
8105,European,4040.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005553,Diffuse cutaneous systemic sclerosis
569,African American or Afro-Caribbean,281.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005333,Systemic sclerosis (anti-centromere-positive)
8138,European,4137.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005333,Systemic sclerosis (anti-centromere-positive)
570,African American or Afro-Caribbean,281.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005552,Systemic sclerosis (anti-centromere-positive)
4682,European,100.0,29293525.0,Gudmundsdottir V,Other measurement,replication,2018-01-02,GCST005353,GLP-1-stimulated insulin secretion
8573,European,5299.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005336,Systemic sclerosis
8104,European,4040.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005335,Diffuse cutaneous systemic sclerosis
8574,European,5299.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005554,Systemic sclerosis
8139,European,4137.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005552,Systemic sclerosis (anti-centromere-positive)
603,African American or Afro-Caribbean,342.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005334,Limited cutaneous systemic scleroderma
8012,European,3813.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005551,Systemic sclerosis (anti-topoisomerase-positive)
676,African American or Afro-Caribbean,551.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005336,Systemic sclerosis
677,African American or Afro-Caribbean,551.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005554,Systemic sclerosis
591,African American or Afro-Caribbean,329.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005332,Systemic sclerosis (anti-topoisomerase-positive)
8011,European,3813.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005332,Systemic sclerosis (anti-topoisomerase-positive)
656,African American or Afro-Caribbean,461.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005335,Diffuse cutaneous systemic sclerosis
604,African American or Afro-Caribbean,342.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005555,Limited cutaneous systemic scleroderma
657,African American or Afro-Caribbean,461.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005553,Diffuse cutaneous systemic sclerosis
8268,European,4553.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005555,Limited cutaneous systemic scleroderma
8267,European,4553.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005334,Limited cutaneous systemic scleroderma
592,African American or Afro-Caribbean,329.0,29293537.0,Gorlova OY,Neurological disorder,initial,2018-01-02,GCST005551,Systemic sclerosis (anti-topoisomerase-positive)
10250,European,18319.0,29309628.0,Beaumont RN,"Body measurement, Other measurement",replication,2018-01-03,GCST005314,Offspring birth weight
11305,European,68258.0,29309628.0,Beaumont RN,"Body measurement, Other measurement",initial,2018-01-03,GCST005314,Offspring birth weight
11302,European,67944.0,29290336.0,Nielsen JB,Cardiovascular disease,initial,2018-01-04,GCST005306,Atrial fibrillation
11187,European,56284.0,29304378.0,Medina-Gomez C,Other measurement,initial,2018-01-04,GCST005348,Total body bone mineral density
12212,European,309574.0,29290336.0,Nielsen JB,Cardiovascular disease,replication,2018-01-04,GCST005306,Atrial fibrillation
10278,European,18805.0,29304378.0,Medina-Gomez C,Other measurement,initial,2018-01-04,GCST005350,Total body bone mineral density (age 45-60)
861,African American or Afro-Caribbean,1333.0,29304378.0,Medina-Gomez C,Other measurement,initial,2018-01-04,GCST005348,Total body bone mineral density
8492,European,5086.0,29310926.0,Sharma A,"Other measurement, Metabolic disorder",initial,2018-01-05,GCST006197,Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)
8491,European,5086.0,29310926.0,Sharma A,"Other measurement, Metabolic disorder",initial,2018-01-05,GCST006196,Type 1 diabetes in high risk HLA genotype individuals (time to event)
871,African American or Afro-Caribbean,1419.0,29317701.0,Rappoport N,"Other measurement, Other trait",replication,2018-01-09,GCST005313,Spontaneous preterm birth (preterm birth)
5008,European,331.0,29317701.0,Rappoport N,"Other measurement, Other trait",replication,2018-01-09,GCST005313,Spontaneous preterm birth (preterm birth)
1611,Asian,59.0,29317701.0,Rappoport N,"Other measurement, Other trait",initial,2018-01-09,GCST005313,Spontaneous preterm birth (preterm birth)
9098,European,7570.0,29325096.0,Eriksson AL,Other measurement,initial,2018-01-09,GCST005827,Estrone levels
4603,European,64.0,29315502.0,Tamraz B,Other measurement,initial,2018-01-09,GCST006203,Atazanavir levels
12558,Hispanic or Latin American,130.0,29315502.0,Tamraz B,Other measurement,initial,2018-01-09,GCST006203,Atazanavir levels
12930,Hispanic or Latin American,3133.0,29317701.0,Rappoport N,"Other measurement, Other trait",replication,2018-01-09,GCST005313,Spontaneous preterm birth (preterm birth)
9588,European,9890.0,29317701.0,Rappoport N,"Other measurement, Other trait",initial,2018-01-09,GCST005313,Spontaneous preterm birth (preterm birth)
927,African American or Afro-Caribbean,1874.0,29317701.0,Rappoport N,"Other measurement, Other trait",initial,2018-01-09,GCST005313,Spontaneous preterm birth (preterm birth)
12856,Hispanic or Latin American,1847.0,29317701.0,Rappoport N,"Other measurement, Other trait",initial,2018-01-09,GCST005313,Spontaneous preterm birth (preterm birth)
522,African American or Afro-Caribbean,194.0,29315502.0,Tamraz B,Other measurement,initial,2018-01-09,GCST006203,Atazanavir levels
12954,Hispanic or Latin American,3485.0,29325163.0,Hong J,Other measurement,initial,2018-01-09,GCST005782,Serum 25-Hydroxyvitamin D levels
1339,African American or Afro-Caribbean,8541.0,29325163.0,Hong J,Other measurement,initial,2018-01-09,GCST005782,Serum 25-Hydroxyvitamin D levels
9720,European,11097.0,29325096.0,Eriksson AL,Other measurement,initial,2018-01-09,GCST005828,Estradiol levels
1875,Asian,249.0,29317701.0,Rappoport N,"Other measurement, Other trait",initial,2018-01-09,GCST005313,Spontaneous preterm birth (preterm birth)
1552,Asian,10.0,29315502.0,Tamraz B,Other measurement,initial,2018-01-09,GCST006203,Atazanavir levels
10091,European,16124.0,29325163.0,Hong J,Other measurement,initial,2018-01-09,GCST005782,Serum 25-Hydroxyvitamin D levels
10947,European,39556.0,29317602.0,Hall LS,Neurological disorder,initial,2018-01-10,GCST005230,Recurrent major depressive disorder
4947,European,290.0,29317604.0,Liu D,"Neurological disorder, Other measurement",initial,2018-01-10,GCST005342,Plasma kynurenine levels in major depressive disorder
11011,European,43055.0,29317602.0,Hall LS,Neurological disorder,initial,2018-01-10,GCST005231,Major depressive disorder
4948,European,290.0,29317604.0,Liu D,"Neurological disorder, Other measurement",initial,2018-01-10,GCST005343,Plasma kynurenine to tryptophan ratio in major depressive disorder
7626,European,3058.0,29478698.0,Cheng Z,Neurological disorder,initial,2018-01-11,GCST005368,Opioid dependence
941,African American or Afro-Caribbean,2014.0,29478698.0,Cheng Z,Neurological disorder,replication,2018-01-11,GCST005368,Opioid dependence
11707,European,120934.0,29326435.0,Hill WD,Biological process,initial,2018-01-11,GCST005316,Intelligence (MTAG)
3732,Asian,6506.0,29331962.0,Kochi Y,Neurological disorder,initial,2018-01-13,GCST005340,Polymyositis
3742,Asian,6610.0,29331962.0,Kochi Y,Neurological disorder,initial,2018-01-13,GCST005339,Dermatomyositis
3710,Asian,6303.0,29331962.0,Kochi Y,Neurological disorder,initial,2018-01-13,GCST005338,Clinically amyopathic dermatomyositis
3756,Asian,6846.0,29331962.0,Kochi Y,Immune system disorder,initial,2018-01-13,GCST005341,Idiopathic inflammatory myopathy
4688,European,105.0,29331962.0,Kochi Y,Neurological disorder,replication,2018-01-13,GCST005338,Clinically amyopathic dermatomyositis
7465,European,2721.0,29346644.0,Yan Q,"Neurological disorder, Other measurement",initial,2018-01-15,GCST005360,Disease progression to geographic atrophy form in age-related macular degeneration
7464,European,2721.0,29346644.0,Yan Q,"Neurological disorder, Other measurement",initial,2018-01-15,GCST005359,Disease progression in age-related macular degeneration
7463,European,2721.0,29346644.0,Yan Q,"Neurological disorder, Other measurement",initial,2018-01-15,GCST005358,Disease progression to choroidal neovascularization form in age-related macular degeneration
7021,European,2113.0,29343764.0,Jiang X,Other measurement,replication,2018-01-17,GCST005366,Vitamin D levels (dietary vitamin D intake interaction)
10951,European,39868.0,29343764.0,Jiang X,Other measurement,initial,2018-01-17,GCST005366,Vitamin D levels (dietary vitamin D intake interaction)
11405,European,79366.0,29343764.0,Jiang X,Other measurement,initial,2018-01-17,GCST005367,Vitamin D levels
12791,Hispanic or Latin American,1041.0,29348612.0,Wiemels JL,Cancer,replication,2018-01-18,GCST005315,Acute lymphoblastic leukemia (childhood)
1166,African American or Afro-Caribbean,3972.0,29348612.0,Wiemels JL,Cancer,initial,2018-01-18,GCST005315,Acute lymphoblastic leukemia (childhood)
7931,European,3583.0,29348612.0,Wiemels JL,Cancer,replication,2018-01-18,GCST005315,Acute lymphoblastic leukemia (childhood)
8332,European,4735.0,29348612.0,Wiemels JL,Cancer,initial,2018-01-18,GCST005315,Acute lymphoblastic leukemia (childhood)
13181,Hispanic or Latin American,10533.0,29348612.0,Wiemels JL,Cancer,initial,2018-01-18,GCST005315,Acute lymphoblastic leukemia (childhood)
6880,European,1943.0,29360470.0,Miron J,Neurological disorder,initial,2018-01-19,GCST006806,Late-onset Alzheimer's disease
166,African,1040.0,29356057.0,Du Z,Cancer,initial,2018-01-21,GCST005786,Prostate cancer
12955,Hispanic or Latin American,3490.0,29358691.0,Bonas-Guarch S,Metabolic disorder,replication,2018-01-22,GCST005898,Type 2 diabetes
11334,European,70127.0,29358691.0,Bonas-Guarch S,Metabolic disorder,initial,2018-01-22,GCST005413,Type 2 diabetes
11211,European,57968.0,29358691.0,Bonas-Guarch S,Metabolic disorder,initial,2018-01-22,GCST005899,Type 2 diabetes
4269,Asian,18817.0,29358691.0,Bonas-Guarch S,Metabolic disorder,initial,2018-01-22,GCST005414,Type 2 diabetes
11367,European,75670.0,29358691.0,Bonas-Guarch S,Metabolic disorder,replication,2018-01-22,GCST005899,Type 2 diabetes
10388,European,20979.0,29358691.0,Bonas-Guarch S,Metabolic disorder,initial,2018-01-22,GCST005898,Type 2 diabetes
12911,Hispanic or Latin American,2583.0,29358691.0,Bonas-Guarch S,Metabolic disorder,initial,2018-01-22,GCST005414,Type 2 diabetes
11739,European,127001.0,29358691.0,Bonas-Guarch S,Metabolic disorder,initial,2018-01-22,GCST005414,Type 2 diabetes
9452,European,9253.0,29358691.0,Bonas-Guarch S,Metabolic disorder,replication,2018-01-22,GCST005898,Type 2 diabetes
14009,Other/Mixed,16857.0,29358691.0,Bonas-Guarch S,Metabolic disorder,replication,2018-01-22,GCST005899,Type 2 diabetes
4290,Asian,20019.0,29358691.0,Bonas-Guarch S,Metabolic disorder,initial,2018-01-22,GCST005414,Type 2 diabetes
3711,Asian,6312.0,29367735.0,Nakagawa-Senda H,"Biological process, Other measurement",initial,2018-01-24,GCST005329,Coffee consumption
4574,European,42.0,29367611.0,Gao B,"Cancer, Response to drug",initial,2018-01-24,GCST005351,Carboplatin disposition in epthelial ovarian cancer
3511,Asian,4949.0,29367735.0,Nakagawa-Senda H,"Biological process, Other measurement",replication,2018-01-24,GCST005329,Coffee consumption
4604,European,66.0,29367611.0,Gao B,"Cancer, Response to drug",initial,2018-01-24,GCST005352,Paclitaxel disposition in epithelial ovarian cancer
1555,Asian,14.0,29367611.0,Gao B,"Cancer, Response to drug",initial,2018-01-24,GCST005351,Carboplatin disposition in epthelial ovarian cancer
1556,Asian,14.0,29367611.0,Gao B,"Cancer, Response to drug",initial,2018-01-24,GCST005352,Paclitaxel disposition in epithelial ovarian cancer
4073,Asian,11261.0,29367735.0,Nakagawa-Senda H,"Biological process, Other measurement",initial,2018-01-24,GCST005330,Coffee consumption
784,African American or Afro-Caribbean,1023.0,29374233.0,Lu AT,Biological process,replication,2018-01-26,GCST005287,Intrinsic epigenetic age acceleration
12660,Hispanic or Latin American,491.0,29374233.0,Lu AT,Biological process,replication,2018-01-26,GCST005288,Extrinsic epigenetic age acceleration
785,African American or Afro-Caribbean,1023.0,29374233.0,Lu AT,Biological process,replication,2018-01-26,GCST005288,Extrinsic epigenetic age acceleration
12659,Hispanic or Latin American,491.0,29374233.0,Lu AT,Biological process,replication,2018-01-26,GCST005287,Intrinsic epigenetic age acceleration
9321,European,8393.0,29374233.0,Lu AT,Biological process,initial,2018-01-26,GCST005287,Intrinsic epigenetic age acceleration
9322,European,8393.0,29374233.0,Lu AT,Biological process,initial,2018-01-26,GCST005288,Extrinsic epigenetic age acceleration
6383,European,1319.0,29379196.0,Fadista J,Digestive system disorder,replication,2018-01-29,GCST005289,Hirschsprung disease
164,African,1017.0,29404214.0,Andaleon A,"Lipid or lipoprotein measurement, Other measurement",initial,2018-01-29,GCST006307,LDL cholesterol
159,African,1017.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006306,HDL cholesterol
160,African,1017.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006308,Triglycerides
161,African,1017.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006469,"Cholesterol, total"
8390,European,4887.0,29379196.0,Fadista J,Digestive system disorder,initial,2018-01-29,GCST005289,Hirschsprung disease
158,African,1017.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006305,"Cholesterol, total"
2790,Asian,1765.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006470,HDL cholesterol
165,African,1017.0,29404214.0,Andaleon A,"Lipid or lipoprotein measurement, Other measurement",initial,2018-01-29,GCST006471,LDL cholesterol
2789,Asian,1765.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006469,"Cholesterol, total"
162,African,1017.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006470,HDL cholesterol
163,African,1017.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006472,Triglyceride levels
2788,Asian,1765.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006308,Triglycerides
2791,Asian,1765.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006472,Triglyceride levels
2792,Asian,1765.0,29404214.0,Andaleon A,"Lipid or lipoprotein measurement, Other measurement",initial,2018-01-29,GCST006307,LDL cholesterol
2793,Asian,1765.0,29404214.0,Andaleon A,"Lipid or lipoprotein measurement, Other measurement",initial,2018-01-29,GCST006471,LDL cholesterol
2786,Asian,1765.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006305,"Cholesterol, total"
2787,Asian,1765.0,29404214.0,Andaleon A,Lipid or lipoprotein measurement,initial,2018-01-29,GCST006306,HDL cholesterol
4755,European,173.0,29382897.0,Pagerols M,"Neurological disorder, Response to drug",initial,2018-01-30,GCST005318,Response to methylphenidate treatment in attention-deficit/hyperactivity disorder
12573,Hispanic or Latin American,189.0,29382897.0,Pagerols M,"Neurological disorder, Response to drug",replication,2018-01-30,GCST005318,Response to methylphenidate treatment in attention-deficit/hyperactivity disorder
151,African,914.0,29381699.0,Ravenhall M,Digestive system disorder,initial,2018-01-30,GCST005357,Severe malaria (adjusted for sickle cell variant rs334)
150,African,914.0,29381699.0,Ravenhall M,Digestive system disorder,initial,2018-01-30,GCST005356,Severe malaria
2164,Asian,567.0,29385134.0,Kawaguchi T,Other measurement,initial,2018-01-31,GCST005310,Brunt grade in nonalcoholic fatty liver disease
3856,Asian,7730.0,29385134.0,Kawaguchi T,"Cancer, Digestive system disorder",initial,2018-01-31,GCST005309,Nonalcoholic steatohepatitis-derived hepatocellular carcinoma
2091,Asian,474.0,29385134.0,Kawaguchi T,Other measurement,initial,2018-01-31,GCST005307,Brunt stage in nonalcoholic fatty liver disease
12078,European,223782.0,29397368.0,Meng W,Other trait,initial,2018-01-31,GCST005337,Headache
2352,Asian,834.0,29385134.0,Kawaguchi T,Other measurement,initial,2018-01-31,GCST005311,Hepatocyte fat droplet content in nonalcoholic fatty liver disease
3908,Asian,8574.0,29385134.0,Kawaguchi T,Digestive system disorder,initial,2018-01-31,GCST005308,Nonalcoholic fatty liver disease
7116,European,2204.0,29392897.0,Hernandez-Fuentes MP,Other measurement,initial,2018-02-01,GCST005429,Graft survival time in renal transplantation (donor effect)
487,African American or Afro-Caribbean,139.0,29278617.0,Sucheston-Campbell LE,"Cancer, Response to drug, Neurological disorder",initial,2018-02-01,GCST005804,Taxane-induced peripheral neuropathy in breast cancer
7441,European,2689.0,29392897.0,Hernandez-Fuentes MP,Other measurement,initial,2018-02-01,GCST005428,Graft survival time in renal transplantation (recipient effect)
7194,European,2318.0,29392897.0,Hernandez-Fuentes MP,Other measurement,initial,2018-02-01,GCST005432,Acute graft rejection in renal transplantation (donor effect)
7443,European,2695.0,29392897.0,Hernandez-Fuentes MP,Other measurement,initial,2018-02-01,GCST005431,Acute graft rejection in renal transplantation (recipient effect)
9604,European,10088.0,29392897.0,Hernandez-Fuentes MP,"Other disease, Other measurement",initial,2018-02-01,GCST005427,End stage renal failure in renal transplantation (recipient effect)
7025,European,2123.0,29278617.0,Sucheston-Campbell LE,"Cancer, Response to drug, Neurological disorder",initial,2018-02-01,GCST005804,Taxane-induced peripheral neuropathy in breast cancer
9603,European,10088.0,29392897.0,Hernandez-Fuentes MP,Cardiovascular disease,initial,2018-02-01,GCST005426,Intracranial haemorrhage in renal transplantation (donors)
2266,Asian,731.0,29581620.0,Fujii R,Immune system disorder,initial,2018-02-01,GCST005556,Pollinosis
8466,European,5027.0,29392897.0,Hernandez-Fuentes MP,Other measurement,replication,2018-02-01,GCST005429,Graft survival time in renal transplantation (donor effect)
2159,Asian,560.0,29581620.0,Fujii R,Immune system disorder,replication,2018-02-01,GCST005556,Pollinosis
7648,European,3116.0,29378355.0,Stanne TM,Other measurement,initial,2018-02-01,GCST005412,Thrombin-activatable fibrinolysis inhibitor levels
8157,European,4188.0,29392897.0,Hernandez-Fuentes MP,Other measurement,initial,2018-02-01,GCST005430,Graft survival time in renal transplantation (donor-recipient interaction)
6575,European,1548.0,29398083.0,Lores-Motta L,Hematological measurement,initial,2018-02-01,GCST005365,Serum C3d:C3 ratio (systemic complement activation)
6195,European,1098.0,29392897.0,Hernandez-Fuentes MP,Other measurement,initial,2018-02-01,GCST005433,Acute graft rejection in renal transplantation (donor-recipient interaction)
7651,European,3124.0,29378355.0,Stanne TM,Hematological measurement,initial,2018-02-01,GCST005411,Thrombin-activatable fibrinolysis inhibitor activation peptide
7665,European,3148.0,29392897.0,Hernandez-Fuentes MP,Other measurement,replication,2018-02-01,GCST005431,Acute graft rejection in renal transplantation (recipient effect)
7667,European,3148.0,29392897.0,Hernandez-Fuentes MP,Other measurement,replication,2018-02-01,GCST005433,Acute graft rejection in renal transplantation (donor-recipient interaction)
7666,European,3148.0,29392897.0,Hernandez-Fuentes MP,Other measurement,replication,2018-02-01,GCST005432,Acute graft rejection in renal transplantation (donor effect)
8705,European,5866.0,29392897.0,Hernandez-Fuentes MP,Other measurement,replication,2018-02-01,GCST005428,Graft survival time in renal transplantation (recipient effect)
8704,European,5866.0,29392897.0,Hernandez-Fuentes MP,"Other disease, Other measurement",replication,2018-02-01,GCST005427,End stage renal failure in renal transplantation (recipient effect)
5617,European,697.0,29398083.0,Lores-Motta L,Hematological measurement,replication,2018-02-01,GCST005365,Serum C3d:C3 ratio (systemic complement activation)
8465,European,5027.0,29392897.0,Hernandez-Fuentes MP,Cardiovascular disease,replication,2018-02-01,GCST005426,Intracranial haemorrhage in renal transplantation (donors)
9733,European,11218.0,29392897.0,Hernandez-Fuentes MP,Other measurement,replication,2018-02-01,GCST005430,Graft survival time in renal transplantation (donor-recipient interaction)
13179,Hispanic or Latin American,10403.0,29394082.0,Burkart KM,Other measurement,initial,2018-02-02,GCST005416,Airflow obstruction
753,African American or Afro-Caribbean,876.0,29394082.0,Burkart KM,Other measurement,replication,2018-02-02,GCST005419,Lung function (FEV1/FVC)
752,African American or Afro-Caribbean,876.0,29394082.0,Burkart KM,Other measurement,replication,2018-02-02,GCST005418,FEV1
12994,Hispanic or Latin American,4162.0,29394082.0,Burkart KM,Other measurement,replication,2018-02-02,GCST005418,FEV1
12995,Hispanic or Latin American,4162.0,29394082.0,Burkart KM,Other measurement,replication,2018-02-02,GCST005419,Lung function (FEV1/FVC)
13057,Hispanic or Latin American,5616.0,29394082.0,Burkart KM,Other disease,initial,2018-02-02,GCST005417,Chronic obstructive pulmonary disease
11564,European,94612.0,29394082.0,Burkart KM,Other measurement,replication,2018-02-02,GCST005418,FEV1
11565,European,94612.0,29394082.0,Burkart KM,Other measurement,replication,2018-02-02,GCST005419,Lung function (FEV1/FVC)
6628,European,1610.0,29391396.0,McElroy SL,"Metabolic disorder, Neurological disorder",initial,2018-02-02,GCST005387,Binge eating behaviour in bipolar disorder
13216,Hispanic or Latin American,11822.0,29394082.0,Burkart KM,Other measurement,initial,2018-02-02,GCST005418,FEV1
3194,Asian,2818.0,29408531.0,Zhang D,Cardiovascular measurement,replication,2018-02-02,GCST005369,Serum uric acid levels
13217,Hispanic or Latin American,11822.0,29394082.0,Burkart KM,Other measurement,initial,2018-02-02,GCST005419,Lung function (FEV1/FVC)
11667,European,116255.0,29391395.0,Strawbridge RJ,Biological process,initial,2018-02-02,GCST005415,Self-reported risk-taking behaviour
11798,European,139473.0,29391395.0,Strawbridge RJ,Biological process,replication,2018-02-02,GCST005415,Self-reported risk-taking behaviour
2723,Asian,1634.0,29408531.0,Zhang D,Cardiovascular measurement,initial,2018-02-02,GCST005369,Serum uric acid levels
7121,European,2209.0,29391396.0,McElroy SL,"Metabolic disorder, Neurological disorder",initial,2018-02-02,GCST005386,Binge eating behaviour and bipolar disorder
4491,Asian,105597.0,29403010.0,Kanai M,Lipid or lipoprotein measurement,initial,2018-02-05,GCST006003,Triglyceride levels
4505,Asian,113509.0,29403010.0,Kanai M,"Hematological measurement, Other measurement",initial,2018-02-05,GCST005989,Serum total protein level
4506,Asian,118309.0,29403010.0,Kanai M,Liver enzyme measurement,initial,2018-02-05,GCST006019,Gamma glutamyl transferase levels
4509,Asian,126319.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST006013,Lactate dehydrogenase levels
4510,Asian,126402.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST006030,Chloride levels
4422,Asian,42793.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005981,Phosphorus levels
4511,Asian,127304.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST006032,Sodium levels
4421,Asian,42790.0,29403010.0,Kanai M,"Other measurement, Hematological measurement",initial,2018-02-05,GCST006001,Hemoglobin A1c levels
4405,Asian,37767.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST006018,Activated partial thromboplastin time
4518,Asian,132938.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST006031,Potassium levels
4519,Asian,134154.0,29403010.0,Kanai M,Liver enzyme measurement,initial,2018-02-05,GCST005999,Aspartate aminotransferase levels
10461,European,22250.0,29422769.0,Shah RL,"Neurological disorder, Other trait",initial,2018-02-05,GCST005803,Corneal astigmatism
4520,Asian,134182.0,29403010.0,Kanai M,Liver enzyme measurement,initial,2018-02-05,GCST005998,Alanine transaminase levels
4529,Asian,136249.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006009,Pulse pressure
4532,Asian,136482.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST006010,Mean arterial pressure
4533,Asian,136597.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005979,Systolic blood pressure
4534,Asian,136615.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005978,Diastolic blood pressure
4535,Asian,139818.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005986,Blood urea nitrogen levels
3910,Asian,8600.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006024,E/A ratio
4540,Asian,142097.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005985,Creatinine levels
4513,Asian,128305.0,29403010.0,Kanai M,Lipid or lipoprotein measurement,initial,2018-02-05,GCST006034,Total cholesterol levels
4502,Asian,110207.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005980,Total bilirubin levels
4500,Asian,108794.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005996,Red blood cell count
4488,Asian,105030.0,29403010.0,Kanai M,Liver enzyme measurement,initial,2018-02-05,GCST006016,Serum alkaline phosphatase levels
3973,Asian,9120.0,29422769.0,Shah RL,"Neurological disorder, Other trait",initial,2018-02-05,GCST005803,Corneal astigmatism
4487,Asian,102223.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005988,Serum albumin level
4486,Asian,98626.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST005987,Albumin-globulin ratio
4485,Asian,98538.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005990,Non-albumin protein levels
4492,Asian,106080.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006014,Creatine kinase levels
4475,Asian,93146.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST006002,Blood sugar levels
4493,Asian,107964.0,29403010.0,Kanai M,"Hematological measurement, Inflammatory measurement",initial,2018-02-05,GCST005973,White blood cell count
4467,Asian,75391.0,29403010.0,Kanai M,Inflammatory measurement,initial,2018-02-05,GCST006012,C-reactive protein levels
4466,Asian,72866.0,29403010.0,Kanai M,Lipid or lipoprotein measurement,initial,2018-02-05,GCST006004,Low density lipoprotein cholesterol levels
4465,Asian,71701.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005982,Calcium levels
4494,Asian,108054.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005993,Mean corpuscular hemoglobin
4501,Asian,109029.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST005983,Serum uric acid levels
4495,Asian,108208.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005991,Platelet count
4464,Asian,70657.0,29403010.0,Kanai M,Lipid or lipoprotein measurement,initial,2018-02-05,GCST006005,High density lipoprotein cholesterol levels
4457,Asian,62076.0,29403010.0,Kanai M,Inflammatory measurement,initial,2018-02-05,GCST005976,White blood cell count (basophil)
4456,Asian,62076.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005997,Lymphocyte counts
4455,Asian,62076.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005977,Monocyte count
6520,European,1497.0,29404672.0,Roshandel D,"Other measurement, Metabolic disorder",initial,2018-02-05,GCST005437,Random C-peptide levels in type I diabetes
4454,Asian,62076.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005975,Eosinophil counts
4497,Asian,108728.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005992,Mean corpuscular hemoglobin concentration
4498,Asian,108757.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005994,Hematocrit
4453,Asian,62076.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005974,Neutrophil count
4449,Asian,58110.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST006017,Prothrombin time
4499,Asian,108769.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST005995,Hemoglobin
4496,Asian,108256.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST006011,Mean corpuscular volume
4286,Asian,19676.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006008,Left ventricular internal dimension in diastole
4541,Asian,143658.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST005984,Glomerular filtration rate
7883,European,3479.0,29404672.0,Roshandel D,"Other measurement, Metabolic disorder",initial,2018-02-05,GCST005436,C-peptide levels in type I diabetes
4275,Asian,19373.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006027,Posterior wall thickness
4276,Asian,19516.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006006,Ejection fraction
4278,Asian,19580.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006029,Fractional shortening
4279,Asian,19586.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006007,Left ventricular internal dimension in systole
4110,Asian,12303.0,29403010.0,Kanai M,Other measurement,initial,2018-02-05,GCST006000,Immunoglobulin measurement (zinc sulfate turbidity test)
4255,Asian,17837.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006025,Left ventricular mass index
4259,Asian,18348.0,29403010.0,Kanai M,Hematological measurement,initial,2018-02-05,GCST006015,Fibrinogen levels
6941,European,2019.0,29404672.0,Roshandel D,"Other measurement, Metabolic disorder",initial,2018-02-05,GCST005438,Fasting C-peptide levels in type I diabetes
4274,Asian,19318.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006028,Interventricular septum thickness
4273,Asian,19311.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006033,Relative wall thickness
4270,Asian,19076.0,29403010.0,Kanai M,Cardiovascular measurement,initial,2018-02-05,GCST006026,Left ventricular mass
6369,European,1303.0,29404672.0,Roshandel D,"Other measurement, Metabolic disorder",initial,2018-02-05,GCST005435,Stimulated C-peptide levels in type I diabetes
11263,European,63556.0,29436472.0,Casalone E,Other disease,replication,2018-02-07,GCST005573,Osteoarthritis of the hip or knee
9820,European,12127.0,29436472.0,Casalone E,Other disease,initial,2018-02-07,GCST005574,Osteoarthritis of the knee (with total joint replacement)
10052,European,15353.0,29436472.0,Casalone E,Other disease,initial,2018-02-07,GCST005571,Osteoarthritis of the hip or knee (with total joint replacement)
9841,European,12456.0,29436472.0,Casalone E,Other disease,initial,2018-02-07,GCST005572,Osteoarthritis of the hip (with total joint replacement)
10053,European,15353.0,29436472.0,Casalone E,Other disease,initial,2018-02-07,GCST005573,Osteoarthritis of the hip or knee
11601,European,107364.0,29436472.0,Casalone E,Other disease,replication,2018-02-07,GCST005571,Osteoarthritis of the hip or knee (with total joint replacement)
9752,European,11475.0,29436472.0,Casalone E,Other disease,replication,2018-02-07,GCST005572,Osteoarthritis of the hip (with total joint replacement)
9753,European,11475.0,29436472.0,Casalone E,Other disease,replication,2018-02-07,GCST005574,Osteoarthritis of the knee (with total joint replacement)
46,African,114.0,29432556.0,Brooke RJ,Other disease,initial,2018-02-08,GCST005518,Premature menopause in childhood cancer survivors
10430,European,21536.0,29422604.0,Klein AP,Cancer,initial,2018-02-08,GCST005434,Pancreatic cancer
5608,European,685.0,29432556.0,Brooke RJ,Other disease,initial,2018-02-08,GCST005518,Premature menopause in childhood cancer survivors
608,African American or Afro-Caribbean,362.0,29425463.0,Bime C,Other disease,replication,2018-02-09,GCST005805,Acute respiratory distress syndrome
621,African American or Afro-Caribbean,394.0,29425463.0,Bime C,Other disease,initial,2018-02-09,GCST005805,Acute respiratory distress syndrome
5500,European,607.0,29425463.0,Bime C,Other disease,replication,2018-02-09,GCST005805,Acute respiratory distress syndrome
874,African American or Afro-Caribbean,1432.0,29452408.0,Shiga Y,Neurological disorder,replication,2018-02-14,GCST005388,Glaucoma (primary open-angle)
4316,Asian,22795.0,29452408.0,Shiga Y,Neurological disorder,initial,2018-02-14,GCST005388,Glaucoma (primary open-angle)
10975,European,40480.0,29452408.0,Shiga Y,Neurological disorder,replication,2018-02-14,GCST005388,Glaucoma (primary open-angle)
249,African,2946.0,29452408.0,Shiga Y,Neurological disorder,replication,2018-02-14,GCST005388,Glaucoma (primary open-angle)
4313,Asian,22567.0,29452408.0,Shiga Y,Neurological disorder,replication,2018-02-14,GCST005388,Glaucoma (primary open-angle)
2837,Asian,1835.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
4118,Asian,12475.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
178,African,1229.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
2836,Asian,1835.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
4084,Asian,11603.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
177,African,1229.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
1490,African American or Afro-Caribbean,25814.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
4117,Asian,12475.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
13164,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
2835,Asian,1835.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
4089,Asian,11603.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
1489,African American or Afro-Caribbean,25814.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
4091,Asian,11603.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
13165,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
4116,Asian,12475.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
1488,African American or Afro-Caribbean,25814.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
4090,Asian,11603.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
4086,Asian,11603.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
4087,Asian,11603.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
4088,Asian,11603.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
176,African,1229.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
4085,Asian,11603.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
10804,European,33720.0,29449654.0,Gharahkhani P,"Other measurement, Neurological disorder",initial,2018-02-15,GCST005409,Open-angle glaucoma and vertical cup-disc ratio
12208,European,305832.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
12194,European,300070.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
2415,Asian,952.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
2416,Asian,952.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
2417,Asian,952.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
12209,European,305832.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
2412,Asian,952.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
2411,Asian,952.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
2410,Asian,952.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
1494,African American or Afro-Caribbean,25887.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
1493,African American or Afro-Caribbean,25887.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
2840,Asian,1835.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
2841,Asian,1835.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
1495,African American or Afro-Caribbean,25887.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
2842,Asian,1835.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
2839,Asian,1835.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
1247,African American or Afro-Caribbean,6180.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
1496,African American or Afro-Caribbean,25889.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
1492,African American or Afro-Caribbean,25887.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
1250,African American or Afro-Caribbean,6180.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
3715,Asian,6340.0,29246937.0,Li Y,"Digestive system disorder, Cancer",replication,2018-02-15,GCST005570,Hepatitis B virus-related hepatocellular carcinoma
2838,Asian,1835.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
1491,African American or Afro-Caribbean,25814.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
9556,European,9821.0,29449654.0,Gharahkhani P,Neurological disorder,initial,2018-02-15,GCST005407,Glaucoma (primary open-angle)
1249,African American or Afro-Caribbean,6180.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
10745,European,32310.0,29449654.0,Gharahkhani P,"Other measurement, Neurological disorder",initial,2018-02-15,GCST005406,Open-angle glaucoma and optic cup area
1248,African American or Afro-Caribbean,6180.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
10746,European,32325.0,29449654.0,Gharahkhani P,"Other measurement, Neurological disorder",initial,2018-02-15,GCST005410,Open-angle glaucoma and optic disc area
179,African,1229.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
12197,European,300070.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
12196,European,300070.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
12195,European,300070.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
1497,African American or Afro-Caribbean,25889.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
13166,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
4119,Asian,12475.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
2414,Asian,952.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
4521,Asian,135505.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
181,African,1229.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
13304,Hispanic or Latin American,17936.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
1307,African American or Afro-Caribbean,7786.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
3801,Asian,7339.0,29449654.0,Gharahkhani P,"Other measurement, Neurological disorder",initial,2018-02-15,GCST005406,Open-angle glaucoma and optic cup area
1306,African American or Afro-Caribbean,7786.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
4123,Asian,12475.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
1305,African American or Afro-Caribbean,7785.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
1304,African American or Afro-Caribbean,7785.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
1303,African American or Afro-Caribbean,7785.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
1302,African American or Afro-Caribbean,7785.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
4122,Asian,12475.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
3797,Asian,7307.0,29449654.0,Gharahkhani P,"Other measurement, Neurological disorder",initial,2018-02-15,GCST005410,Open-angle glaucoma and optic disc area
11412,European,80542.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
11413,European,80542.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
4522,Asian,135505.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
11414,European,80542.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
4523,Asian,135505.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
13302,Hispanic or Latin American,17936.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
4171,Asian,13438.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
4170,Asian,13438.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
4125,Asian,12481.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
4531,Asian,136451.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
3900,Asian,8373.0,29449654.0,Gharahkhani P,"Other measurement, Neurological disorder",initial,2018-02-15,GCST005409,Open-angle glaucoma and vertical cup-disc ratio
3899,Asian,8352.0,29449654.0,Gharahkhani P,"Other measurement, Neurological disorder",initial,2018-02-15,GCST005408,Open-angle glaucoma and intra-ocular pressure
10945,European,39399.0,29449654.0,Gharahkhani P,"Other measurement, Neurological disorder",initial,2018-02-15,GCST005408,Open-angle glaucoma and intra-ocular pressure
4530,Asian,136451.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
4124,Asian,12481.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
4528,Asian,135505.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
4527,Asian,135505.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
4526,Asian,135505.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
4525,Asian,135505.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
4524,Asian,135505.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
13301,Hispanic or Latin American,17936.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006186,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)
13303,Hispanic or Latin American,17936.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
4121,Asian,12475.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
2413,Asian,952.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
180,African,1229.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
11415,European,80542.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
13172,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006194,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)
13171,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006193,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)
13170,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
4120,Asian,12475.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
2561,Asian,1274.0,29246937.0,Li Y,"Digestive system disorder, Cancer",initial,2018-02-15,GCST005570,Hepatitis B virus-related hepatocellular carcinoma
12161,European,285041.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
13169,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
13309,Hispanic or Latin American,17947.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
13168,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
11420,European,80552.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006187,Diastolic blood pressure (cigarette smoking interaction)
11421,European,80552.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
13310,Hispanic or Latin American,17947.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006188,Systolic blood pressure (cigarette smoking interaction)
13167,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
11419,European,80551.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
13308,Hispanic or Latin American,17943.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006192,Systolic blood pressure x smoking status (ever vs never) interaction (2df test)
11418,European,80551.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
12159,European,285041.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
12158,European,285041.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
13305,Hispanic or Latin American,17943.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
11416,European,80551.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006189,Systolic blood pressure x smoking status (ever vs never) interaction (1df test)
11417,European,80551.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
12160,European,285041.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
13173,Hispanic or Latin American,8805.0,29455858.0,Sung YJ,Other measurement,initial,2018-02-15,GCST006195,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)
13307,Hispanic or Latin American,17943.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006191,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)
13306,Hispanic or Latin American,17943.0,29455858.0,Sung YJ,Other measurement,replication,2018-02-15,GCST006190,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)
2635,Asian,1494.0,29453348.0,Chen CJ,Metabolic disorder,initial,2018-02-16,GCST005801,Gout vs. Hyperuricemia
2342,Asian,811.0,29453196.0,Sato Y,Other measurement,initial,2018-02-16,GCST005798,Sperm motility
3196,Asian,2818.0,29453348.0,Chen CJ,Metabolic disorder,initial,2018-02-16,GCST005799,Gout
3195,Asian,2818.0,29453348.0,Chen CJ,"Cardiovascular measurement, Metabolic disorder",initial,2018-02-16,GCST005802,Hyperuricemia
2319,Asian,779.0,29453196.0,Sato Y,Other measurement,replication,2018-02-16,GCST005798,Sperm motility
4065,Asian,11046.0,29471430.0,Tanikawa C,Cancer,replication,2018-02-17,GCST005591,Colorectal cancer
4383,Asian,33870.0,29471430.0,Tanikawa C,Cancer,initial,2018-02-17,GCST005591,Colorectal cancer
6718,European,1719.0,29459680.0,Claes P,Other measurement,replication,2018-02-19,GCST007989,Facial morphology traits (63 three-dimensional facial segments)
7207,European,2329.0,29459680.0,Claes P,Other measurement,initial,2018-02-19,GCST007989,Facial morphology traits (63 three-dimensional facial segments)
8321,European,4687.0,29496196.0,McCoy TH Jr.,Other measurement,initial,2018-02-20,GCST005759,Dimensional psychopathology (Social)
8320,European,4687.0,29496196.0,McCoy TH Jr.,Other measurement,initial,2018-02-20,GCST005758,Dimensional psychopathology (Arousal)
8322,European,4687.0,29496196.0,McCoy TH Jr.,Other measurement,initial,2018-02-20,GCST005760,Dimensional psychopathology (Cognitive)
8319,European,4687.0,29496196.0,McCoy TH Jr.,Other measurement,initial,2018-02-20,GCST005757,Dimensional psychopathology (Positive)
7937,European,3598.0,29458411.0,Chung J,"Metabolic disorder, Other measurement",initial,2018-02-20,GCST005515,Neuritic plaques or cerebral amyloid angiopathy (pleiotropy)
2459,Asian,1045.0,29460428.0,Gelernter J,"Biological process, Other measurement",initial,2018-02-20,GCST005441,Alcohol consumption (max-drinks)
7936,European,3598.0,29458411.0,Chung J,"Metabolic disorder, Other measurement",initial,2018-02-20,GCST005514,Neuritic plaques or neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy)
2458,Asian,1045.0,29460428.0,Gelernter J,Biological process,initial,2018-02-20,GCST005439,Response to alcohol consumption (flushing response)
7939,European,3598.0,29458411.0,Chung J,Other measurement,initial,2018-02-20,GCST005516,Neuritic plaques or neurofibrillary tangles (pleiotropy)
7938,European,3598.0,29458411.0,Chung J,"Metabolic disorder, Other measurement",initial,2018-02-20,GCST005517,Neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy)
8318,European,4687.0,29496196.0,McCoy TH Jr.,Other measurement,initial,2018-02-20,GCST005756,Dimensional psychopathology (Negative)
2460,Asian,1045.0,29460428.0,Gelernter J,Other measurement,initial,2018-02-20,GCST005440,Alcohol dependence symptom count
4298,Asian,21198.0,29472232.0,Li Y,Cardiovascular disease,replication,2018-02-22,GCST005582,Coronary artery disease
2192,Asian,630.0,29472232.0,Li Y,Cardiovascular disease,initial,2018-02-22,GCST005582,Coronary artery disease
8276,European,4577.0,29472613.0,Warrier V,Other measurement,initial,2018-02-22,GCST005797,Theory of mind score in adolescence (Emotional Triangles Task)
5158,European,426.0,29478026.0,Shahin MH,"Cardiovascular measurement, Response to drug",initial,2018-02-24,GCST005519,Heart rate response to beta blockers
566,African American or Afro-Caribbean,273.0,29478026.0,Shahin MH,"Cardiovascular measurement, Response to drug",initial,2018-02-24,GCST005519,Heart rate response to beta blockers
506,African American or Afro-Caribbean,168.0,29478026.0,Shahin MH,"Cardiovascular measurement, Response to drug",replication,2018-02-24,GCST005519,Heart rate response to beta blockers
472,African American or Afro-Caribbean,127.0,29478026.0,Shahin MH,"Cardiovascular measurement, Response to drug",initial,2018-02-24,GCST005520,Heart rate response to beta blockers (atenolol add-on therapy)
491,African American or Afro-Caribbean,146.0,29478026.0,Shahin MH,"Cardiovascular measurement, Response to drug",initial,2018-02-24,GCST005521,Heart rate response to beta blockers (atenolol monotherapy)
4822,European,200.0,29478026.0,Shahin MH,"Cardiovascular measurement, Response to drug",replication,2018-02-24,GCST005519,Heart rate response to beta blockers
4815,European,198.0,29478026.0,Shahin MH,"Cardiovascular measurement, Response to drug",initial,2018-02-24,GCST005520,Heart rate response to beta blockers (atenolol add-on therapy)
4867,European,228.0,29478026.0,Shahin MH,"Cardiovascular measurement, Response to drug",initial,2018-02-24,GCST005521,Heart rate response to beta blockers (atenolol monotherapy)
11825,European,144368.0,29483656.0,Pardinas AF,Neurological disorder,replication,2018-02-26,GCST006803,Schizophrenia
13551,Other/Mixed,177.0,29535761.0,Haaland OA,"Other measurement, Other trait",initial,2018-02-26,GCST005653,Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction)
3248,Asian,3027.0,29535761.0,Haaland OA,"Other measurement, Other trait",initial,2018-02-26,GCST005653,Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction)
11596,European,105318.0,29483656.0,Pardinas AF,Neurological disorder,initial,2018-02-26,GCST006803,Schizophrenia
3255,Asian,3072.0,29535761.0,Haaland OA,"Other measurement, Other trait",initial,2018-02-26,GCST005652,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction)
3249,Asian,3027.0,29535761.0,Haaland OA,"Other measurement, Other trait",initial,2018-02-26,GCST005654,Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction)
6817,European,1836.0,29535710.0,Wahl A,Other measurement,replication,2018-02-26,GCST005656,IgG glycosylation patterns
7297,European,2475.0,29535761.0,Haaland OA,"Other measurement, Other trait",initial,2018-02-26,GCST005654,Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction)
7296,European,2475.0,29535761.0,Haaland OA,"Other measurement, Other trait",initial,2018-02-26,GCST005653,Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction)
7295,European,2475.0,29535761.0,Haaland OA,"Other measurement, Other trait",initial,2018-02-26,GCST005652,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction)
13552,Other/Mixed,177.0,29535761.0,Haaland OA,"Other measurement, Other trait",initial,2018-02-26,GCST005654,Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction)
916,African American or Afro-Caribbean,1800.0,29495422.0,Xu H,Cardiovascular disease,initial,2018-02-26,GCST005588,Idiopathic dilated cardiomyopathy
6807,European,1823.0,29535710.0,Wahl A,Other measurement,initial,2018-02-26,GCST005656,IgG glycosylation patterns
13550,Other/Mixed,177.0,29535761.0,Haaland OA,"Other measurement, Other trait",initial,2018-02-26,GCST005652,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction)
748,African American or Afro-Caribbean,849.0,29499414.0,Pei YF,Other measurement,initial,2018-02-27,GCST005795,Femoral neck bone mineral density
12640,Hispanic or Latin American,446.0,29499414.0,Pei YF,Other measurement,initial,2018-02-27,GCST005796,Lumbar spine bone mineral density
12639,Hispanic or Latin American,446.0,29499414.0,Pei YF,Other measurement,initial,2018-02-27,GCST005795,Femoral neck bone mineral density
10905,European,37657.0,29499414.0,Pei YF,Other measurement,initial,2018-02-27,GCST005795,Femoral neck bone mineral density
10906,European,37657.0,29499414.0,Pei YF,Other measurement,initial,2018-02-27,GCST005796,Lumbar spine bone mineral density
2682,Asian,1539.0,29499414.0,Pei YF,Other measurement,initial,2018-02-27,GCST005796,Lumbar spine bone mineral density
749,African American or Afro-Caribbean,849.0,29499414.0,Pei YF,Other measurement,initial,2018-02-27,GCST005796,Lumbar spine bone mineral density
2681,Asian,1539.0,29499414.0,Pei YF,Other measurement,initial,2018-02-27,GCST005795,Femoral neck bone mineral density
4859,European,223.0,29535370.0,Kleinstein SE,Other measurement,initial,2018-02-28,GCST005559,Virologic severity in Herpes simplex virus type 2 infection
7378,European,2565.0,29562276.0,Venkateswaran S,Immune system disorder,initial,2018-03-01,GCST005815,Childhood onset ulcerative colitis
13672,Other/Mixed,468.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005846,Heart rate response to recovery post exercise (10 sec)
2,African,1.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005706,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies)
1523,Asian,1.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005707,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels)
13493,Other/Mixed,84.0,29545823.0,O'Brien KM,Other measurement,replication,2018-03-01,GCST005729,Serum 25-Hydroxyvitamin D levels
5933,European,926.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005707,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels)
5932,European,926.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005706,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies)
2601,Asian,1379.0,29503163.0,Yu H,"Response to drug, Neurological disorder",replication,2018-03-01,GCST006292,Response to antipsychotic treatment in schizophrenia
6603,European,1576.0,29545823.0,O'Brien KM,Other measurement,initial,2018-03-01,GCST005729,Serum 25-Hydroxyvitamin D levels
3037,Asian,2252.0,29494758.0,Liu L,Immune system disorder,initial,2018-03-01,GCST005754,Systemic lupus erythematosus
12535,Hispanic or Latin American,81.0,29545823.0,O'Brien KM,Other measurement,initial,2018-03-01,GCST005729,Serum 25-Hydroxyvitamin D levels
13671,Other/Mixed,468.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005845,Heart rate increase in response to exercise
1789,Asian,192.0,29503163.0,Yu H,"Response to drug, Neurological disorder",initial,2018-03-01,GCST006298,Response to haloperidol in schizophrenia
1790,Asian,193.0,29503163.0,Yu H,"Response to drug, Neurological disorder",initial,2018-03-01,GCST006297,Response to perphenazine in schizophrenia
13675,Other/Mixed,468.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005849,Heart rate response to recovery post exercise (40 sec)
1522,Asian,1.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005706,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies)
5050,European,356.0,30207284.0,Galvan-Femenia I,"Response to drug, Cancer, Other measurement",replication,2018-03-01,GCST007358,Response to platinum-based chemotherapy in non-small-cell lung cancer (progression)
2775,Asian,1744.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005845,Heart rate increase in response to exercise
1525,Asian,1.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005709,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels)
11163,European,54137.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005850,Heart rate response to recovery post exercise (30 sec)
2780,Asian,1744.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005850,Heart rate response to recovery post exercise (30 sec)
11162,European,54137.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005849,Heart rate response to recovery post exercise (40 sec)
2779,Asian,1744.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005849,Heart rate response to recovery post exercise (40 sec)
2157,Asian,559.0,29503163.0,Yu H,"Response to drug, Neurological disorder",replication,2018-03-01,GCST006294,Response to risperidone in schizophrenia
2778,Asian,1744.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005848,Heart rate response to recovery post exercise (50 sec)
188,African,1445.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005845,Heart rate increase in response to exercise
12494,Hispanic or Latin American,7.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005706,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies)
12495,Hispanic or Latin American,7.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005707,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels)
12496,Hispanic or Latin American,7.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005708,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years)
11161,European,54137.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005848,Heart rate response to recovery post exercise (50 sec)
1524,Asian,1.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005708,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years)
534,African American or Afro-Caribbean,204.0,29545823.0,O'Brien KM,Other measurement,replication,2018-03-01,GCST005729,Serum 25-Hydroxyvitamin D levels
11159,European,54137.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005846,Heart rate response to recovery post exercise (10 sec)
11158,European,54137.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005845,Heart rate increase in response to exercise
12497,Hispanic or Latin American,7.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005709,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels)
5935,European,926.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005709,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels)
2777,Asian,1744.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005847,Heart rate response to recovery post exercise (20 sec)
2776,Asian,1744.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005846,Heart rate response to recovery post exercise (10 sec)
3,African,1.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005707,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels)
5723,European,770.0,29489655.0,Liu X,Other measurement,initial,2018-03-01,GCST005726,Milk allergy (parent-of-origin effect)
189,African,1445.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005846,Heart rate response to recovery post exercise (10 sec)
5722,European,770.0,29489655.0,Liu X,Other measurement,initial,2018-03-01,GCST005722,Milk allergy (maternal genetic effects)
5934,European,926.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005708,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years)
11160,European,54137.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005847,Heart rate response to recovery post exercise (20 sec)
10797,European,33431.0,29615537.0,Kulminski AM,Other measurement,initial,2018-03-01,GCST005777,Systolic blood pressure
10798,European,33431.0,29615537.0,Kulminski AM,Other trait,initial,2018-03-01,GCST005762,Death
5816,European,835.0,29489655.0,Liu X,Other measurement,initial,2018-03-01,GCST005723,Peanut allergy (maternal genetic effects)
5817,European,835.0,29489655.0,Liu X,Other measurement,initial,2018-03-01,GCST005727,Peanut allergy (parent-of-origin effect)
10789,European,33431.0,29615537.0,Kulminski AM,Lipid or lipoprotein measurement,initial,2018-03-01,GCST005780,Triglyceride levels
10788,European,33431.0,29615537.0,Kulminski AM,Lipid or lipoprotein measurement,initial,2018-03-01,GCST005776,High density lipoprotein cholesterol levels
5,African,1.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005709,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels)
10787,European,33431.0,29615537.0,Kulminski AM,Inflammatory measurement,initial,2018-03-01,GCST005770,C-reactive protein levels
10786,European,33431.0,29615537.0,Kulminski AM,Hematological measurement,initial,2018-03-01,GCST005775,Hematocrit
10785,European,33431.0,29615537.0,Kulminski AM,Cardiovascular measurement,initial,2018-03-01,GCST005774,Heart rate
10784,European,33431.0,29615537.0,Kulminski AM,Cardiovascular disease,initial,2018-03-01,GCST005778,Atrial fibrillation
10783,European,33431.0,29615537.0,Kulminski AM,Cardiovascular disease,initial,2018-03-01,GCST005767,Coronary heart disease
10782,European,33431.0,29615537.0,Kulminski AM,Cardiovascular disease,initial,2018-03-01,GCST005765,Heart failure
10781,European,33431.0,29615537.0,Kulminski AM,Cardiovascular disease,initial,2018-03-01,GCST005764,Stroke
12553,Hispanic or Latin American,113.0,29545823.0,O'Brien KM,Other measurement,replication,2018-03-01,GCST005729,Serum 25-Hydroxyvitamin D levels
10780,European,33431.0,29615537.0,Kulminski AM,Cancer,initial,2018-03-01,GCST005768,Cancer
10790,European,33431.0,29615537.0,Kulminski AM,Lipid or lipoprotein measurement,initial,2018-03-01,GCST005781,Total cholesterol levels
10779,European,33431.0,29615537.0,Kulminski AM,"Body measurement, Other measurement",initial,2018-03-01,GCST005769,Body mass index
13673,Other/Mixed,468.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005847,Heart rate response to recovery post exercise (20 sec)
5431,European,563.0,29489655.0,Liu X,Other measurement,initial,2018-03-01,GCST005725,Egg allergy (parent-of-origin effect)
5432,European,563.0,29489655.0,Liu X,Other measurement,initial,2018-03-01,GCST005728,Egg allergy (maternal genetic effects)
3088,Asian,2413.0,29503163.0,Yu H,"Response to drug, Neurological disorder",initial,2018-03-01,GCST006292,Response to antipsychotic treatment in schizophrenia
4776,European,181.0,30207284.0,Galvan-Femenia I,"Response to drug, Cancer, Other measurement",initial,2018-03-01,GCST007358,Response to platinum-based chemotherapy in non-small-cell lung cancer (progression)
13674,Other/Mixed,468.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005848,Heart rate response to recovery post exercise (50 sec)
192,African,1445.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005849,Heart rate response to recovery post exercise (40 sec)
6645,European,1630.0,29489655.0,Liu X,Other measurement,initial,2018-03-01,GCST005724,Food allergy (maternal genetic effects)
476,African American or Afro-Caribbean,134.0,29545823.0,O'Brien KM,Other measurement,initial,2018-03-01,GCST005729,Serum 25-Hydroxyvitamin D levels
7466,European,2722.0,29545823.0,O'Brien KM,Other measurement,replication,2018-03-01,GCST005729,Serum 25-Hydroxyvitamin D levels
13676,Other/Mixed,468.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005850,Heart rate response to recovery post exercise (30 sec)
6644,European,1630.0,29489655.0,Liu X,Other measurement,initial,2018-03-01,GCST005721,Food allergy (parent-of-origin effect)
191,African,1445.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005848,Heart rate response to recovery post exercise (50 sec)
193,African,1445.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005850,Heart rate response to recovery post exercise (30 sec)
190,African,1445.0,29497042.0,Verweij N,Cardiovascular measurement,initial,2018-03-01,GCST005847,Heart rate response to recovery post exercise (20 sec)
2009,Asian,386.0,29503163.0,Yu H,"Response to drug, Neurological disorder",initial,2018-03-01,GCST006295,Response to quetiapine in schizophrenia
10793,European,33431.0,29615537.0,Kulminski AM,Other measurement,initial,2018-03-01,GCST005763,Blood glucose levels
2042,Asian,425.0,29503163.0,Yu H,"Response to drug, Neurological disorder",initial,2018-03-01,GCST006294,Response to risperidone in schizophrenia
4103,Asian,11755.0,29494758.0,Liu L,Immune system disorder,replication,2018-03-01,GCST005754,Systemic lupus erythematosus
4,African,1.0,29521573.0,Buck D,"Immune system disorder, Response to drug, Other measurement",initial,2018-03-01,GCST005708,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years)
2032,Asian,415.0,29503163.0,Yu H,"Response to drug, Neurological disorder",replication,2018-03-01,GCST006293,Response to olanzapine in schizophrenia
10796,European,33431.0,29615537.0,Kulminski AM,Other measurement,initial,2018-03-01,GCST005773,Lung function (forced vital capacity)
2031,Asian,412.0,29503163.0,Yu H,"Response to drug, Neurological disorder",initial,2018-03-01,GCST006293,Response to olanzapine in schizophrenia
2028,Asian,408.0,29503163.0,Yu H,"Response to drug, Neurological disorder",initial,2018-03-01,GCST006296,Response to ziprazidone in schizophrenia
2026,Asian,405.0,29503163.0,Yu H,"Response to drug, Neurological disorder",replication,2018-03-01,GCST006285,Response to aripiprazole in schizophrenia
13451,Other/Mixed,38.0,29545823.0,O'Brien KM,Other measurement,initial,2018-03-01,GCST005729,Serum 25-Hydroxyvitamin D levels
2017,Asian,397.0,29503163.0,Yu H,"Response to drug, Neurological disorder",initial,2018-03-01,GCST006285,Response to aripiprazole in schizophrenia
10795,European,33431.0,29615537.0,Kulminski AM,Other measurement,initial,2018-03-01,GCST005772,Diastolic blood pressure
10792,European,33431.0,29615537.0,Kulminski AM,Neurological disorder,initial,2018-03-01,GCST005779,Alzheimer's disease
10794,European,33431.0,29615537.0,Kulminski AM,Other measurement,initial,2018-03-01,GCST005771,Creatinine levels
10791,European,33431.0,29615537.0,Kulminski AM,Metabolic disorder,initial,2018-03-01,GCST005766,Diabetes mellitus
12301,European,372869.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006950,Feeling worry
12295,European,371318.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006952,Feeling tense
12287,European,366726.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006941,Irritable mood
3999,Asian,9599.0,29495898.0,Peterson RE,Neurological disorder,initial,2018-03-02,GCST005691,Major depressive disorder
3772,Asian,6971.0,29495898.0,Peterson RE,Neurological disorder,initial,2018-03-02,GCST005689,Major depressive disorder (unexposed to adversity)
12305,European,374971.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006947,Feeling fed-up
12304,European,373733.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006944,Experiencing mood swings
3141,Asian,2628.0,29495898.0,Peterson RE,Neurological disorder,initial,2018-03-02,GCST005690,Major depressive disorder (exposed to adversity)
12300,European,372047.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006951,Feeling hurt
12313,European,380506.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006940,Neurociticism
12307,European,376097.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006943,Feeling miserable
12309,European,376352.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006942,Feeling lonely
12303,European,373380.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006945,Feeling guilty
12302,European,373121.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006948,Feeling nervous
12288,European,367725.0,29500382.0,Nagel M,Other measurement,initial,2018-03-02,GCST006946,Worry too long after an embarrassing experience
12291,European,369499.0,29500382.0,Nagel M,Neurological disorder,initial,2018-03-02,GCST006949,Suffering from nerves
11375,European,76627.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007141,Low density lipoprotein cholesterol levels
2058,Asian,439.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007143,Total cholesterol levels
2051,Asian,439.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007131,Low density lipoprotein cholesterol levels
1066,African American or Afro-Caribbean,2958.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007143,Total cholesterol levels
1064,African American or Afro-Caribbean,2958.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007141,Low density lipoprotein cholesterol levels
1059,African American or Afro-Caribbean,2958.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007131,Low density lipoprotein cholesterol levels
1060,African American or Afro-Caribbean,2958.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007132,High density lipoprotein cholesterol levels
2053,Asian,439.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007133,Triglycerides
11376,European,76627.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007142,Triglycerides
1062,African American or Afro-Caribbean,2958.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007134,Total cholesterol levels
2054,Asian,439.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007134,Total cholesterol levels
11374,European,76627.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007140,High density lipoprotein cholesterol levels
2055,Asian,439.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007140,High density lipoprotein cholesterol levels
2056,Asian,439.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007141,Low density lipoprotein cholesterol levels
11377,European,76627.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007143,Total cholesterol levels
2057,Asian,439.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007142,Triglycerides
1063,African American or Afro-Caribbean,2958.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007140,High density lipoprotein cholesterol levels
2052,Asian,439.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007132,High density lipoprotein cholesterol levels
1061,African American or Afro-Caribbean,2958.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007133,Triglycerides
1065,African American or Afro-Caribbean,2958.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007142,Triglycerides
13126,Hispanic or Latin American,7795.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007131,Low density lipoprotein cholesterol levels
13127,Hispanic or Latin American,7795.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007132,High density lipoprotein cholesterol levels
12136,European,265204.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007134,Total cholesterol levels
12135,European,265204.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007133,Triglycerides
12134,European,265204.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007132,High density lipoprotein cholesterol levels
12133,European,265204.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007131,Low density lipoprotein cholesterol levels
13132,Hispanic or Latin American,7795.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007142,Triglycerides
13131,Hispanic or Latin American,7795.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007141,Low density lipoprotein cholesterol levels
13130,Hispanic or Latin American,7795.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007140,High density lipoprotein cholesterol levels
13133,Hispanic or Latin American,7795.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007143,Total cholesterol levels
13129,Hispanic or Latin American,7795.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007134,Total cholesterol levels
13128,Hispanic or Latin American,7795.0,29507422.0,Hoffmann TJ,Lipid or lipoprotein measurement,initial,2018-03-05,GCST007133,Triglycerides
1909,Asian,278.0,29559957.0,Wang W,Cardiovascular measurement,initial,2018-03-06,GCST005557,Serum uric acid levels
5473,European,590.0,29513936.0,Haasnoot AJW,"Neurological disorder, Immune system disorder",initial,2018-03-07,GCST006127,Uveitis (juvenile idiopathic arthritis-associated)
12273,European,351799.0,29511194.0,Helgadottir A,Cardiovascular disease,initial,2018-03-07,GCST005561,Aortic valve stenosis
12274,European,353586.0,29511167.0,Theriault S,Cardiovascular disease,replication,2018-03-07,GCST005785,Calcific aortic valve stenosis
12401,European,456581.0,29511194.0,Helgadottir A,Cardiovascular disease,replication,2018-03-07,GCST005561,Aortic valve stenosis
5927,European,920.0,29513936.0,Haasnoot AJW,Immune system disorder,initial,2018-03-07,GCST006128,Arthritis (juvenile idiopathic)
5372,European,522.0,29513936.0,Haasnoot AJW,"Neurological disorder, Immune system disorder",initial,2018-03-07,GCST006126,Uveitis in juvenile idiopathic arthritis
2500,Asian,1142.0,29514873.0,Mychaleckyj JC,"Lipid or lipoprotein measurement, Other measurement",initial,2018-03-07,GCST005587,Breast milk fatty acid composition (infant genotype effect)
2499,Asian,1142.0,29514873.0,Mychaleckyj JC,"Lipid or lipoprotein measurement, Other measurement",initial,2018-03-07,GCST005586,Breast milk fatty acid composition (maternal genotype effect)
6947,European,2026.0,29511167.0,Theriault S,Cardiovascular disease,initial,2018-03-07,GCST005785,Calcific aortic valve stenosis
1700,Asian,119.0,29518117.0,Lee HS,"Biological process, Other measurement",initial,2018-03-08,GCST006133,Bone mineral density x blood lead interaction in current smokers (2df test)
1699,Asian,119.0,29518117.0,Lee HS,"Biological process, Other measurement",initial,2018-03-08,GCST006132,Bone mineral density x blood lead interaction in current smokers (1df test)
1020,African American or Afro-Caribbean,2679.0,29520036.0,Stein MB,"Neurological disorder, Other measurement",initial,2018-03-08,GCST005566,Insomnia
9750,European,11473.0,29520036.0,Stein MB,"Neurological disorder, Other measurement",initial,2018-03-08,GCST005566,Insomnia
12956,Hispanic or Latin American,3499.0,29520036.0,Stein MB,"Neurological disorder, Other measurement",initial,2018-03-08,GCST005566,Insomnia
11489,European,87740.0,29520040.0,Coleman JRI,Biological process,initial,2018-03-08,GCST007044,Extremely high intelligence
248,African,2857.0,29523850.0,Gilchrist JJ,Other disease,initial,2018-03-09,GCST005590,Nontyphoidal Salmonella bacteraemia
4857,European,222.0,29523524.0,Singh S,"Cardiovascular disease, Other measurement, Response to drug",replication,2018-03-09,GCST005577,Change in glucose in response to thiazide diuretic treatment in hypertension
135,African,734.0,29523850.0,Gilchrist JJ,Other disease,replication,2018-03-09,GCST005590,Nontyphoidal Salmonella bacteraemia
4765,European,175.0,29523524.0,Singh S,"Cardiovascular disease, Other measurement, Response to drug",initial,2018-03-09,GCST005577,Change in glucose in response to thiazide diuretic treatment in hypertension
489,African American or Afro-Caribbean,140.0,29523524.0,Singh S,"Cardiovascular disease, Other measurement, Response to drug",replication,2018-03-09,GCST005577,Change in glucose in response to thiazide diuretic treatment in hypertension
477,African American or Afro-Caribbean,135.0,29523524.0,Singh S,"Cardiovascular disease, Other measurement, Response to drug",initial,2018-03-09,GCST005577,Change in glucose in response to thiazide diuretic treatment in hypertension
8749,European,6035.0,29631748.0,McCoy TH Jr.,Neurological disorder,initial,2018-03-10,GCST005851,Delirium
12842,Hispanic or Latin American,1557.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005838,Stroke
1421,African American or Afro-Caribbean,15405.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005840,Ischemic stroke (large artery atherosclerosis)
1982,Asian,367.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005840,Ischemic stroke (large artery atherosclerosis)
1978,Asian,364.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005842,Ischemic stroke (cardioembolic)
1423,African American or Afro-Caribbean,15560.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005842,Ischemic stroke (cardioembolic)
2236,Asian,698.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005838,Stroke
2083,Asian,467.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005841,Ischemic stroke (small-vessel)
1427,African American or Afro-Caribbean,15840.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005841,Ischemic stroke (small-vessel)
12380,European,446696.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST006906,Stroke
11873,European,150765.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST006907,Ischemic stroke (large artery atherosclerosis)
3977,Asian,9144.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005843,Ischemic stroke
3976,Asian,9144.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005838,Stroke
12052,European,211763.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005842,Ischemic stroke (cardioembolic)
12745,Hispanic or Latin American,791.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005842,Ischemic stroke (cardioembolic)
12741,Hispanic or Latin American,778.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005841,Ischemic stroke (small-vessel)
12719,Hispanic or Latin American,733.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005840,Ischemic stroke (large artery atherosclerosis)
12805,Hispanic or Latin American,1247.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005843,Ischemic stroke
4347,Asian,29042.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005842,Ischemic stroke (cardioembolic)
11872,European,150765.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005840,Ischemic stroke (large artery atherosclerosis)
4352,Asian,29821.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005840,Ischemic stroke (large artery atherosclerosis)
4428,Asian,45564.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005838,Stroke
11062,European,46861.0,29527006.0,Warrier V,Other measurement,initial,2018-03-12,GCST005751,Empathy quotient
4429,Asian,45564.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005843,Ischemic stroke
3785,Asian,7129.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005842,Ischemic stroke (cardioembolic)
12019,European,198048.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST006909,Ischemic stroke (small-vessel)
3776,Asian,7021.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005841,Ischemic stroke (small-vessel)
12018,European,198048.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005841,Ischemic stroke (small-vessel)
6884,European,1945.0,29531279.0,Zhou S,Cardiovascular disease,initial,2018-03-12,GCST005576,Intracranial aneurysm
4379,Asian,33291.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005841,Ischemic stroke (small-vessel)
3780,Asian,7062.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005840,Ischemic stroke (large artery atherosclerosis)
12053,European,211763.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST006910,Ischemic stroke (cardioembolic)
12379,European,446696.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005838,Stroke
2154,Asian,555.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005843,Ischemic stroke
12367,European,440328.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST006908,Ischemic stroke
1455,African American or Afro-Caribbean,20687.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005843,Ischemic stroke
12366,European,440328.0,29531354.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-03-12,GCST005843,Ischemic stroke
1456,African American or Afro-Caribbean,20695.0,29531354.0,Malik R,Cardiovascular disease,initial,2018-03-12,GCST005838,Stroke
8848,European,6524.0,29531327.0,Meijsen JJ,"Biological process, Other measurement",initial,2018-03-13,GCST008590,Cognitive performance (processing speed)
8980,European,7012.0,29531327.0,Meijsen JJ,"Other measurement, Neurological disorder",initial,2018-03-13,GCST008584,Cognitive performance (language ability) x major depressive disorder status interaction
8850,European,6524.0,29531327.0,Meijsen JJ,Other measurement,initial,2018-03-13,GCST008588,Cognitive performance (language ability)
9044,European,7344.0,29532581.0,Hallfors J,Other measurement,replication,2018-03-13,GCST006299,Smoking behaviour (cigarettes smoked per day)
8979,European,7012.0,29531327.0,Meijsen JJ,Other measurement,initial,2018-03-13,GCST008587,Cognitive performance (language ability)
8851,European,6524.0,29531327.0,Meijsen JJ,"Other measurement, Neurological disorder",initial,2018-03-13,GCST008585,Cognitive performance (language ability) x major depressive disorder status interaction
6698,European,1703.0,29532581.0,Hallfors J,Other measurement,initial,2018-03-13,GCST006303,Nicotine withdrawal symptom count
1098,African American or Afro-Caribbean,3166.0,29534260.0,Kim SK,"Other trait, Cancer",initial,2018-03-13,GCST005558,Plantar fascial disorders
6699,European,1703.0,29532581.0,Hallfors J,Other measurement,initial,2018-03-13,GCST006869,Nicotine withdrawal
11444,European,83264.0,29534260.0,Kim SK,"Other trait, Cancer",initial,2018-03-13,GCST005558,Plantar fascial disorders
8849,European,6524.0,29531327.0,Meijsen JJ,"Neurological disorder, Biological process, Other measurement",initial,2018-03-13,GCST008583,Cognitive performance (processing speed) x major depressive disorder status interaction
6707,European,1711.0,29532581.0,Hallfors J,Other measurement,initial,2018-03-13,GCST006300,Smoking behaviour (maximum cigarettes in a 24 hour period)
6711,European,1715.0,29532581.0,Hallfors J,Neurological disorder,initial,2018-03-13,GCST006302,Nicotine dependence
2521,Asian,1193.0,29534301.0,Nishida N,"Response to drug, Other measurement",initial,2018-03-13,GCST005606,Response to hepatitis B vaccine
6713,European,1715.0,29532581.0,Hallfors J,Other measurement,initial,2018-03-13,GCST006301,Nicotine dependence symptom count
13158,Hispanic or Latin American,8560.0,29534260.0,Kim SK,"Other trait, Cancer",initial,2018-03-13,GCST005558,Plantar fascial disorders
3818,Asian,7518.0,29534260.0,Kim SK,"Other trait, Cancer",initial,2018-03-13,GCST005558,Plantar fascial disorders
6119,European,1021.0,29531327.0,Meijsen JJ,"Neurological disorder, Biological process, Other measurement",initial,2018-03-13,GCST008586,Cognitive performance (processing speed) x major depressive disorder type interaction
6712,European,1715.0,29532581.0,Hallfors J,Other measurement,initial,2018-03-13,GCST006299,Smoking behaviour (cigarettes smoked per day)
6120,European,1021.0,29531327.0,Meijsen JJ,"Neurological disorder, Biological process, Other measurement",initial,2018-03-13,GCST008589,Cognitive performance (processing speed) in major depressive disorder
7602,European,3002.0,29547969.0,Chen X,Other measurement,initial,2018-03-14,GCST005761,Immunoglobulin M against phosphorylcholine (IgM anti-PC) levels
12559,Hispanic or Latin American,136.0,29538362.0,Jilling T,"Other trait, Digestive system disorder",initial,2018-03-14,GCST005800,Surgical necrotising enterocolitis in extremely premature birth
5544,European,646.0,29547969.0,Chen X,Other measurement,replication,2018-03-14,GCST005761,Immunoglobulin M against phosphorylcholine (IgM anti-PC) levels
4711,European,137.0,29538362.0,Jilling T,"Other trait, Digestive system disorder",initial,2018-03-14,GCST005800,Surgical necrotising enterocolitis in extremely premature birth
580,African American or Afro-Caribbean,303.0,29538362.0,Jilling T,"Other trait, Digestive system disorder",initial,2018-03-14,GCST005800,Surgical necrotising enterocolitis in extremely premature birth
8241,European,4466.0,29551738.0,Dong J,"Body measurement, Cancer",initial,2018-03-15,GCST006525,Esophageal adenocarcinoma x BMI interaction
5122,European,407.0,29551627.0,Hawcutt DB,"Other measurement, Response to drug",initial,2018-03-15,GCST005924,Corticosteroid-induced adrenal suppression (peak cortisol < 500 nmol/L)
6225,European,1143.0,29545352.0,Li Y,"Other disease, Other measurement",initial,2018-03-15,GCST005666,Fractional excretion of metabolites in chronic kidney disease
6223,European,1143.0,29545352.0,Li Y,"Other disease, Other measurement",initial,2018-03-15,GCST005650,Serum metabolite ratios in chronic kidney disease
8563,European,5286.0,29551738.0,Dong J,"Body measurement, Digestive system disorder",initial,2018-03-15,GCST006529,Barrett's esophagus x BMI interaction
5124,European,407.0,29551627.0,Hawcutt DB,"Response to drug, Other measurement, Other disease",initial,2018-03-15,GCST005925,Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma
8242,European,4466.0,29551738.0,Dong J,"Cancer, Digestive system disorder",initial,2018-03-15,GCST006531,Esophageal adenocarcinoma x gastroesophageal reflux disease interaction
8565,European,5286.0,29551738.0,Dong J,"Other measurement, Digestive system disorder",initial,2018-03-15,GCST006527,Barrett's esophagus x smoking interaction
8566,European,5286.0,29551738.0,Dong J,"Other measurement, Digestive system disorder",initial,2018-03-15,GCST006528,Barrett's esophagus x pack-years of smoking exposure interaction
8243,European,4466.0,29551738.0,Dong J,"Other measurement, Cancer",initial,2018-03-15,GCST006530,Esophageal adenocarcinoma x smoking interaction
6221,European,1143.0,29545352.0,Li Y,"Other disease, Other measurement",initial,2018-03-15,GCST005648,Serum metabolite concentrations in chronic kidney disease
5123,European,407.0,29551627.0,Hawcutt DB,"Other measurement, Response to drug",initial,2018-03-15,GCST005927,Corticosteroid-induced adrenal suppression (peak cortisol < 350 nmol/L)
8564,European,5286.0,29551738.0,Dong J,Digestive system disorder,initial,2018-03-15,GCST006526,Barrett's esophagus x gastroesophageal reflux disease interaction
8244,European,4466.0,29551738.0,Dong J,"Other measurement, Cancer",initial,2018-03-15,GCST006532,Esophageal adenocarcinoma x pack-years of smoking exposure interaction
6222,European,1143.0,29545352.0,Li Y,"Other disease, Other measurement",initial,2018-03-15,GCST005649,Urinary metabolite ratios in chronic kidney disease
5125,European,407.0,29551627.0,Hawcutt DB,"Response to drug, Other measurement, Other disease",initial,2018-03-15,GCST005926,Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma
6224,European,1143.0,29545352.0,Li Y,"Other disease, Other measurement",initial,2018-03-15,GCST005651,Urinary metabolite concentrations in chronic kidney disease
7897,European,3513.0,29555444.0,Hamer MA,Other trait,initial,2018-03-16,GCST006981,Facial wrinkles
5481,European,599.0,29555444.0,Hamer MA,Other trait,replication,2018-03-16,GCST006981,Facial wrinkles
8731,European,5947.0,29743933.0,Wu B,Other measurement,initial,2018-03-18,GCST006404,Glycemic traits (multi-trait analysis)
3734,Asian,6509.0,29558500.0,Lee J,Other measurement,replication,2018-03-20,GCST005792,Glomerular filtration rate
11107,European,50508.0,29559693.0,Zengini E,Other disease,initial,2018-03-20,GCST005814,Osteoarthritis (hospital diagnosed)
3733,Asian,6509.0,29558500.0,Lee J,Other measurement,replication,2018-03-20,GCST005791,Creatinine levels
3343,Asian,3703.0,29558500.0,Lee J,Cardiovascular measurement,replication,2018-03-20,GCST005793,Uric acid levels
10767,European,32970.0,29559693.0,Zengini E,Other disease,initial,2018-03-20,GCST005812,Osteoarthritis of the hip or knee (hospital diagnosed)
3735,Asian,6509.0,29558500.0,Lee J,Other measurement,replication,2018-03-20,GCST005794,Blood urea nitrogen levels
13986,Other/Mixed,7064.0,29558500.0,Lee J,Other measurement,initial,2018-03-20,GCST005794,Blood urea nitrogen levels
3781,Asian,7064.0,29558500.0,Lee J,Cardiovascular measurement,initial,2018-03-20,GCST005793,Uric acid levels
3782,Asian,7064.0,29558500.0,Lee J,Other measurement,initial,2018-03-20,GCST005791,Creatinine levels
3783,Asian,7064.0,29558500.0,Lee J,Other measurement,initial,2018-03-20,GCST005792,Glomerular filtration rate
11982,European,177463.0,29559693.0,Zengini E,Other disease,replication,2018-03-20,GCST005813,Osteoarthritis of the knee (hospital diagnosed)
10462,European,22347.0,29559693.0,Zengini E,Other disease,initial,2018-03-20,GCST005813,Osteoarthritis of the knee (hospital diagnosed)
12045,European,208850.0,29559693.0,Zengini E,Other disease,replication,2018-03-20,GCST005812,Osteoarthritis of the hip or knee (hospital diagnosed)
4083,Asian,11409.0,29559738.0,Sasayama D,Other trait,initial,2018-03-20,GCST005809,Photic sneeze reflex
12031,European,205135.0,29559693.0,Zengini E,Other disease,replication,2018-03-20,GCST005810,Osteoarthritis of the hip (hospital diagnosed)
9808,European,11989.0,29559693.0,Zengini E,Other disease,initial,2018-03-20,GCST005810,Osteoarthritis of the hip (hospital diagnosed)
12132,European,264362.0,29559693.0,Zengini E,Other disease,replication,2018-03-20,GCST005814,Osteoarthritis (hospital diagnosed)
11264,European,63556.0,29559693.0,Zengini E,Other disease,initial,2018-03-20,GCST005811,Osteoarthritis (self-reported)
11152,European,53731.0,29563502.0,Fejzo MS,Other measurement,initial,2018-03-21,GCST005929,Severity of nausea and vomiting of pregnancy
6665,European,1648.0,29563502.0,Fejzo MS,Other disease,replication,2018-03-21,GCST005930,Hyperemesis gravidarum
10174,European,17062.0,29563502.0,Fejzo MS,Other disease,initial,2018-03-21,GCST005930,Hyperemesis gravidarum
11423,European,80610.0,29566793.0,Nicolas A,Neurological disorder,initial,2018-03-21,GCST005647,Amyotrophic lateral sclerosis
6361,European,1297.0,29563342.0,Li XS,Hematological measurement,initial,2018-03-22,GCST005670,Plasma trimethyllysine levels
2127,Asian,512.0,29572449.0,Gurung RL,"Hematological measurement, Metabolic disorder",replication,2018-03-23,GCST005807,Urinary haptoglobin levels in type 2 diabetes
5768,European,807.0,29628937.0,Jiang J,Hematological measurement,replication,2018-03-23,GCST005711,Growth differentiation factor-15 levels
5769,European,807.0,29628937.0,Jiang J,Hematological measurement,replication,2018-03-23,GCST005712,Growth differentiation factor-15 levels (conditioned on rs888663)
8296,European,4633.0,29628937.0,Jiang J,Hematological measurement,initial,2018-03-23,GCST005712,Growth differentiation factor-15 levels (conditioned on rs888663)
1607,Asian,57.0,29572449.0,Gurung RL,"Hematological measurement, Metabolic disorder",replication,2018-03-23,GCST005807,Urinary haptoglobin levels in type 2 diabetes
1608,Asian,57.0,29572449.0,Gurung RL,"Hematological measurement, Metabolic disorder",replication,2018-03-23,GCST005808,Plasma haptoglobin levels in type 2 diabetes
8295,European,4633.0,29628937.0,Jiang J,Hematological measurement,initial,2018-03-23,GCST005711,Growth differentiation factor-15 levels
1866,Asian,236.0,29572449.0,Gurung RL,"Hematological measurement, Metabolic disorder",initial,2018-03-23,GCST005807,Urinary haptoglobin levels in type 2 diabetes
1867,Asian,236.0,29572449.0,Gurung RL,"Hematological measurement, Metabolic disorder",initial,2018-03-23,GCST005808,Plasma haptoglobin levels in type 2 diabetes
12057,European,214493.0,29590334.0,Bjornsson T,Cardiovascular disease,replication,2018-03-24,GCST005687,Aortic coarctation
11803,European,140700.0,29590334.0,Bjornsson T,Cardiovascular disease,initial,2018-03-24,GCST005687,Aortic coarctation
4848,European,214.0,29580174.0,Ala-Mutka EM,"Cardiovascular measurement, Response to drug, Cardiovascular disease",initial,2018-03-27,GCST005646,Change in serum uric acid levels in response to thiazide diuretic treatment (hydrochlorothiazide) in hypertension
5240,European,465.0,29580174.0,Ala-Mutka EM,"Cardiovascular measurement, Response to drug, Cardiovascular disease",replication,2018-03-27,GCST005646,Change in serum uric acid levels in response to thiazide diuretic treatment (hydrochlorothiazide) in hypertension
5545,European,646.0,29594489.0,Apewokin S,"Other disease, Cancer",initial,2018-03-28,GCST005686,Clostridium difficile infection in multiple myeloma
11662,European,115486.0,29617998.0,Gao XR,Other measurement,initial,2018-03-28,GCST005580,Intraocular pressure
817,African American or Afro-Caribbean,1178.0,29596498.0,Charles BA,Hematological measurement,initial,2018-03-29,GCST005578,Low white blood cell count (conditioned on rs2814778)
938,African American or Afro-Caribbean,1997.0,29596498.0,Charles BA,Hematological measurement,initial,2018-03-29,GCST005579,Low white blood cell count
1878,Asian,254.0,29603369.0,Naito T,"Other measurement, Digestive system disorder",initial,2018-03-30,GCST005784,Bone mineral density (femoral neck) in inflammatory bowel disease
406,African American or Afro-Caribbean,42.0,29608535.0,Kuehn MH,Cardiovascular disease,initial,2018-03-30,GCST005688,Idiopathic intracranial hypertension
4700,European,124.0,29608535.0,Kuehn MH,Cardiovascular disease,initial,2018-03-30,GCST005688,Idiopathic intracranial hypertension
1530,Asian,2.0,29608535.0,Kuehn MH,Cardiovascular disease,initial,2018-03-30,GCST005688,Idiopathic intracranial hypertension
1877,Asian,254.0,29603369.0,Naito T,"Digestive system disorder, Other measurement",initial,2018-03-30,GCST005783,Bone mineral density (lumbar spine) in inflammatory bowel disease
13393,Other/Mixed,7.0,29608535.0,Kuehn MH,Cardiovascular disease,initial,2018-03-30,GCST005688,Idiopathic intracranial hypertension
8868,European,6579.0,29603866.0,Pain O,Other measurement,initial,2018-03-31,GCST005718,Anhedonia
7222,European,2359.0,29603866.0,Pain O,Other measurement,replication,2018-03-31,GCST005718,Anhedonia
8807,European,6297.0,29603866.0,Pain O,Other measurement,initial,2018-03-31,GCST005719,Cognitive disorganisation
9608,European,10098.0,29603866.0,Pain O,Other measurement,initial,2018-03-31,GCST005720,Parent-rated negative symptoms
9372,European,8665.0,29603866.0,Pain O,Other measurement,initial,2018-03-31,GCST005717,Paranoia and hallucinations
5234,European,461.0,29650764.0,McDonough CW,Cardiovascular measurement,initial,2018-04-01,GCST006043,Plasma renin activity levels
577,African American or Afro-Caribbean,297.0,29650764.0,McDonough CW,Cardiovascular measurement,initial,2018-04-01,GCST006043,Plasma renin activity levels
4725,European,150.0,29650764.0,McDonough CW,Cardiovascular measurement,replication,2018-04-01,GCST006043,Plasma renin activity levels
13193,Hispanic or Latin American,11185.0,29618737.0,Napier MD,Cardiovascular disease,initial,2018-04-04,GCST005937,Ventricular ectopy
13192,Hispanic or Latin American,11185.0,29618737.0,Napier MD,Cardiovascular disease,initial,2018-04-04,GCST005936,Supraventricular ectopy
13191,Hispanic or Latin American,11185.0,29618737.0,Napier MD,Cardiovascular disease,initial,2018-04-04,GCST005935,Ventricular ectopy or supraventricular ectopy (pleiotropy)
307,African,9274.0,29618737.0,Napier MD,Cardiovascular disease,initial,2018-04-04,GCST005935,Ventricular ectopy or supraventricular ectopy (pleiotropy)
4714,European,139.0,29670602.0,Moreau K,"Other disease, Cardiovascular disease",initial,2018-04-04,GCST006805,Infective endocarditis in Staphylococcus aureus infection
308,African,9274.0,29618737.0,Napier MD,Cardiovascular disease,initial,2018-04-04,GCST005936,Supraventricular ectopy
309,African,9274.0,29618737.0,Napier MD,Cardiovascular disease,initial,2018-04-04,GCST005937,Ventricular ectopy
4774,European,180.0,29670602.0,Moreau K,"Other disease, Cardiovascular disease",replication,2018-04-04,GCST006805,Infective endocarditis in Staphylococcus aureus infection
10469,European,22517.0,29618737.0,Napier MD,Cardiovascular disease,initial,2018-04-04,GCST005936,Supraventricular ectopy
10509,European,23672.0,29618737.0,Napier MD,Cardiovascular disease,initial,2018-04-04,GCST005935,Ventricular ectopy or supraventricular ectopy (pleiotropy)
10510,European,23672.0,29618737.0,Napier MD,Cardiovascular disease,initial,2018-04-04,GCST005937,Ventricular ectopy
250,African,3057.0,29622589.0,Tereshchenko LG,Cardiovascular measurement,initial,2018-04-05,GCST005905,Global electrical heterogeneity phenotypes
9689,European,10769.0,29622589.0,Tereshchenko LG,Cardiovascular measurement,initial,2018-04-05,GCST005905,Global electrical heterogeneity phenotypes
3636,Asian,5731.0,29621232.0,Spracklen CN,Metabolic disorder,initial,2018-04-05,GCST005912,Type 2 diabetes
3763,Asian,6943.0,29621232.0,Spracklen CN,Other measurement,initial,2018-04-05,GCST005914,Glycated hemoglobin levels
3661,Asian,5786.0,29621232.0,Spracklen CN,Other measurement,initial,2018-04-05,GCST005913,Fasting blood glucose
3662,Asian,5786.0,29621232.0,Spracklen CN,Other measurement,initial,2018-04-05,GCST005915,Fasting blood insulin
3341,Asian,3694.0,29632305.0,Lee HS,Metabolic disorder,replication,2018-04-09,GCST005878,Metabolic syndrome (multivariate analysis)
12187,European,298957.0,29632382.0,Mahajan A,Metabolic disorder,initial,2018-04-09,GCST007516,Type 2 diabetes (adjusted for BMI)
12188,European,298957.0,29632382.0,Mahajan A,Metabolic disorder,initial,2018-04-09,GCST007517,Type 2 diabetes
12189,European,298957.0,29632382.0,Mahajan A,Metabolic disorder,initial,2018-04-09,GCST007518,Type 2 diabetes (adjusted for BMI)
14041,Other/Mixed,153287.0,29632382.0,Mahajan A,Metabolic disorder,initial,2018-04-09,GCST007516,Type 2 diabetes (adjusted for BMI)
3901,Asian,8373.0,29632305.0,Lee HS,Metabolic disorder,initial,2018-04-09,GCST005878,Metabolic syndrome (multivariate analysis)
14040,Other/Mixed,153287.0,29632382.0,Mahajan A,Metabolic disorder,initial,2018-04-09,GCST007515,Type 2 diabetes
12186,European,298957.0,29632382.0,Mahajan A,Metabolic disorder,initial,2018-04-09,GCST007515,Type 2 diabetes
10171,European,17051.0,29632299.0,Vijayakrishnan J,Cancer,initial,2018-04-09,GCST005832,Acute lymphoblastic leukemia in childhood (B cell precursor)
8094,European,4024.0,29631575.0,Obeidat M,"Other disease, Other measurement",initial,2018-04-10,GCST005916,Cotinine levels in smokers with chronic obstructive pulmonary disease
7533,European,2854.0,29631575.0,Obeidat M,"Other disease, Other measurement",initial,2018-04-10,GCST005917,Current cigarettes per day in chronic obstructive pulmonary disease
7459,European,2706.0,29631575.0,Obeidat M,"Other disease, Other measurement",initial,2018-04-10,GCST005919,Exhaled carbon monoxide levels in smokers with chronic obstructive pulmonary disease
7547,European,2892.0,29631575.0,Obeidat M,"Other disease, Biological process",initial,2018-04-10,GCST005918,Smoking cessation in chronic obstructive pulmonary disease
7392,European,2596.0,30134803.0,Matana A,Other measurement,initial,2018-04-11,GCST006431,Plasma parathyroid hormone levels
1748,Asian,158.0,29674289.0,Cheon EJ,Lipid or lipoprotein measurement,replication,2018-04-12,GCST005671,Cholesterol efflux capacity
9983,European,14382.0,29659830.0,Warrington NM,Body measurement,initial,2018-04-12,GCST005749,Digit length ratio (left hand)
5834,European,845.0,29650774.0,Rotroff DM,"Response to drug, Other measurement, Metabolic disorder",initial,2018-04-12,GCST005753,Change in HbA1c levels in response to metformin treatment in type 2 diabetes
780,African American or Afro-Caribbean,1015.0,29650774.0,Rotroff DM,"Response to drug, Other measurement, Metabolic disorder",replication,2018-04-12,GCST005753,Change in HbA1c levels in response to metformin treatment in type 2 diabetes
9850,European,12586.0,29659830.0,Warrington NM,Body measurement,initial,2018-04-12,GCST005750,Digit length ratio
2176,Asian,607.0,29674289.0,Cheon EJ,Lipid or lipoprotein measurement,initial,2018-04-12,GCST005671,Cholesterol efflux capacity
9860,European,12636.0,29659830.0,Warrington NM,Body measurement,initial,2018-04-12,GCST005748,Digit length ratio (right hand)
8970,European,6963.0,29650774.0,Rotroff DM,"Response to drug, Other measurement, Metabolic disorder",replication,2018-04-12,GCST005753,Change in HbA1c levels in response to metformin treatment in type 2 diabetes
548,African American or Afro-Caribbean,222.0,29650774.0,Rotroff DM,"Response to drug, Other measurement, Metabolic disorder",initial,2018-04-12,GCST005753,Change in HbA1c levels in response to metformin treatment in type 2 diabetes
5326,European,502.0,29654602.0,Laville V,Other measurement,initial,2018-04-13,GCST006365,Upper eyelid sagging severity
12231,European,322580.0,29662059.0,Howard DM,Neurological disorder,initial,2018-04-16,GCST005902,Depression (broad)
12175,European,290891.0,29662168.0,Hysi PG,"Other measurement, Other trait",initial,2018-04-16,GCST006075,Hair color
11978,European,174519.0,29662059.0,Howard DM,Neurological disorder,initial,2018-04-16,GCST005904,Major depressive disorder (probable)
10636,European,27865.0,29662168.0,Hysi PG,"Other measurement, Other trait",replication,2018-04-16,GCST006075,Hair color
12065,European,217584.0,29662059.0,Howard DM,Neurological disorder,initial,2018-04-16,GCST005903,Major depressive disorder (ICD-10 coded)
3721,Asian,6403.0,29665250.0,Shimanoe C,Other measurement,initial,2018-04-17,GCST006821,Problem solving
3723,Asian,6403.0,29665250.0,Shimanoe C,Other measurement,initial,2018-04-17,GCST006823,Emotional coping (emotional expression/emotional support seeking)
3720,Asian,6403.0,29665250.0,Shimanoe C,Other measurement,initial,2018-04-17,GCST006820,Positive reappraisal
3833,Asian,7685.0,29665250.0,Shimanoe C,Other measurement,replication,2018-04-17,GCST006821,Problem solving
3832,Asian,7685.0,29665250.0,Shimanoe C,Other measurement,replication,2018-04-17,GCST006820,Positive reappraisal
3831,Asian,7685.0,29665250.0,Shimanoe C,Other measurement,replication,2018-04-17,GCST006819,Emotional support seeking
3834,Asian,7685.0,29665250.0,Shimanoe C,Other measurement,replication,2018-04-17,GCST006822,Disengagement
3719,Asian,6403.0,29665250.0,Shimanoe C,Other measurement,initial,2018-04-17,GCST006819,Emotional support seeking
3836,Asian,7685.0,29665250.0,Shimanoe C,Other measurement,replication,2018-04-17,GCST006824,Approach coping (positive reappraisal/problem solving)
3835,Asian,7685.0,29665250.0,Shimanoe C,Other measurement,replication,2018-04-17,GCST006823,Emotional coping (emotional expression/emotional support seeking)
3726,Asian,6403.0,29665250.0,Shimanoe C,Other measurement,initial,2018-04-17,GCST006826,Emotional expression
3725,Asian,6403.0,29665250.0,Shimanoe C,Other measurement,initial,2018-04-17,GCST006825,Perceived stress
3724,Asian,6403.0,29665250.0,Shimanoe C,Other measurement,initial,2018-04-17,GCST006824,Approach coping (positive reappraisal/problem solving)
3838,Asian,7685.0,29665250.0,Shimanoe C,Other measurement,replication,2018-04-17,GCST006826,Emotional expression
3837,Asian,7685.0,29665250.0,Shimanoe C,Other measurement,replication,2018-04-17,GCST006825,Perceived stress
3722,Asian,6403.0,29665250.0,Shimanoe C,Other measurement,initial,2018-04-17,GCST006822,Disengagement
7411,European,2629.0,29678681.0,Matana A,Other measurement,initial,2018-04-18,GCST008367,Plasma anti-thyroglobulin and anti-thyroid peroxidase levels (bivariate analysis)
12282,European,360838.0,29679657.0,Ferreira MA,"Other disease, Immune system disorder",initial,2018-04-18,GCST007732,"Allergic disease (asthma, hay fever or eczema)"
7412,European,2629.0,29678681.0,Matana A,Other measurement,initial,2018-04-18,GCST008369,Plasma anti-thyroglobulin levels
7404,European,2618.0,29678681.0,Matana A,Other measurement,initial,2018-04-18,GCST008368,Plasma anti-thyroid peroxidase levels
9721,European,11103.0,29673008.0,Bonfiglio F,Digestive system disorder,initial,2018-04-19,GCST006535,Irritable bowel syndrome
393,African American or Afro-Caribbean,31.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006221,White matter growth
5461,European,581.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006222,Cerebellum growth
5462,European,581.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006223,Cerebral cortical growth
5460,European,581.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006221,White matter growth
5463,European,581.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006224,Right lateral prefrontal cortical growth
5459,European,581.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006220,Basal ganglia growth
13410,Other/Mixed,15.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006221,White matter growth
13413,Other/Mixed,15.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006224,Right lateral prefrontal cortical growth
1548,Asian,8.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006224,Right lateral prefrontal cortical growth
1547,Asian,8.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006223,Cerebral cortical growth
394,African American or Afro-Caribbean,31.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006222,Cerebellum growth
13412,Other/Mixed,15.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006223,Cerebral cortical growth
392,African American or Afro-Caribbean,31.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006220,Basal ganglia growth
1546,Asian,8.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006222,Cerebellum growth
13411,Other/Mixed,15.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006222,Cerebellum growth
13409,Other/Mixed,15.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006220,Basal ganglia growth
395,African American or Afro-Caribbean,31.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006223,Cerebral cortical growth
1545,Asian,8.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006221,White matter growth
396,African American or Afro-Caribbean,31.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006224,Right lateral prefrontal cortical growth
1544,Asian,8.0,29682794.0,Szekely E,Other measurement,initial,2018-04-22,GCST006220,Basal ganglia growth
1252,African American or Afro-Caribbean,6224.0,29691896.0,Keaton JM,Metabolic disorder,initial,2018-04-24,GCST006495,"Type 2 diabetes (SNP x SNP interaction, 2df)"
11633,European,111610.0,29691431.0,Tikkanen E,Other measurement,replication,2018-04-24,GCST005829,Hand grip strength
12076,European,223215.0,29691431.0,Tikkanen E,Other measurement,initial,2018-04-24,GCST005829,Hand grip strength
1251,African American or Afro-Caribbean,6224.0,29691896.0,Keaton JM,Metabolic disorder,initial,2018-04-24,GCST006494,"Type 2 diabetes (SNP x SNP interaction, 1df)"
12249,European,334825.0,29691431.0,Tikkanen E,Other measurement,initial,2018-04-24,GCST005830,Hand grip strength
7918,European,3557.0,29695241.0,Charmet R,"Cardiovascular disease, Metabolic disorder",initial,2018-04-25,GCST006281,Coronary artery disease in type 1 diabetes
8224,European,4419.0,29698431.0,Roosenboom J,Other measurement,initial,2018-04-26,GCST005938,Maximum cranial length
7479,European,2754.0,29698419.0,Pande M,Cancer,initial,2018-04-26,GCST006035,Breast cancer and/or colorectal cancer
8225,European,4419.0,29698431.0,Roosenboom J,Other measurement,initial,2018-04-26,GCST005939,Cephalic index
12423,European,480359.0,29700475.0,Wray NR,"Neurological disorder, Other measurement",initial,2018-04-26,GCST005839,Depression
8226,European,4419.0,29698431.0,Roosenboom J,Other measurement,initial,2018-04-26,GCST005940,Maximum cranial width
1761,Asian,169.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005885,End-stage renal disease in type 2 diabetes
9699,European,10875.0,29703844.0,van Zuydam NR,Metabolic disorder,initial,2018-04-27,GCST005881,Diabetic kidney disease in diabetes
7281,European,2447.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",initial,2018-04-27,GCST005885,End-stage renal disease in type 2 diabetes
1754,Asian,165.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005882,Chronic kidney disease in type 2 diabetes
2094,Asian,480.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005882,Chronic kidney disease in type 2 diabetes
9563,European,9853.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005888,Late diabetic kidney disease in diabetes
3709,Asian,6287.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005882,Chronic kidney disease in type 2 diabetes
3586,Asian,5508.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005890,Early diabetic kidney disease in diabetes
3708,Asian,6287.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005880,Chronic kidney disease in diabetes
8543,European,5248.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005883,Chronic kidney disease and diabetic kidney disease in type 2 diabetes
3570,Asian,5387.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005893,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD)
2093,Asian,480.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005880,Chronic kidney disease in diabetes
8667,European,5717.0,29703844.0,van Zuydam NR,Metabolic disorder,initial,2018-04-27,GCST005895,Diabetic kidney disease in type 2 diabetes
9670,European,10674.0,29703846.0,Wei WQ,"Cardiovascular measurement, Response to drug",initial,2018-04-27,GCST006217,Coronary heart disease events during statin therapy
1772,Asian,180.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005889,Early diabetic kidney disease in type 2 diabetes
2007,Asian,384.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005891,Glomerular filtration rate in diabetes
8830,European,6400.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005886,End-stage renal disease in diabetes
2425,Asian,975.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005891,Glomerular filtration rate in diabetes
9484,European,9443.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005894,Diabetic kidney disease in diabetes (ESRD vs. no ESRD)
4227,Asian,16047.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005881,Diabetic kidney disease in diabetes
2426,Asian,975.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005892,Glomerular filtration rate in type 2 diabetes
9468,European,9333.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005892,Glomerular filtration rate in type 2 diabetes
2060,Asian,440.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005890,Early diabetic kidney disease in diabetes
6844,European,1877.0,29703947.0,Jawinski P,Other measurement,initial,2018-04-27,GCST006138,Resting-state electroencephalogram vigilance
9835,European,12356.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005895,Diabetic kidney disease in type 2 diabetes
1762,Asian,169.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005886,End-stage renal disease in diabetes
3659,Asian,5738.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005886,End-stage renal disease in diabetes
1678,Asian,103.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005887,Late diabetic kidney disease in type 2 diabetes
2059,Asian,440.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005889,Early diabetic kidney disease in type 2 diabetes
1679,Asian,103.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005888,Late diabetic kidney disease in diabetes
8659,European,5655.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",initial,2018-04-27,GCST005886,End-stage renal disease in diabetes
2008,Asian,384.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005892,Glomerular filtration rate in type 2 diabetes
9965,European,14150.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005882,Chronic kidney disease in type 2 diabetes
9964,European,14150.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005880,Chronic kidney disease in diabetes
1753,Asian,165.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005880,Chronic kidney disease in diabetes
4054,Asian,10640.0,29728651.0,Li X,Neurological disorder,initial,2018-04-27,GCST005907,Major depressive disorder
1773,Asian,180.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005890,Early diabetic kidney disease in diabetes
3658,Asian,5738.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005885,End-stage renal disease in type 2 diabetes
9198,European,8063.0,29703844.0,van Zuydam NR,Metabolic disorder,initial,2018-04-27,GCST005888,Late diabetic kidney disease in diabetes
4178,Asian,13915.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005888,Late diabetic kidney disease in diabetes
9562,European,9853.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005887,Late diabetic kidney disease in type 2 diabetes
3569,Asian,5387.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005894,Diabetic kidney disease in diabetes (ESRD vs. no ESRD)
6210,European,1129.0,29703846.0,Wei WQ,"Cardiovascular measurement, Response to drug",replication,2018-04-27,GCST006217,Coronary heart disease events during statin therapy
1829,Asian,222.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005895,Diabetic kidney disease in type 2 diabetes
12236,European,326113.0,29728651.0,Li X,Neurological disorder,initial,2018-04-27,GCST005907,Major depressive disorder
1954,Asian,332.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005888,Late diabetic kidney disease in diabetes
1953,Asian,332.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005887,Late diabetic kidney disease in type 2 diabetes
8601,European,5433.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",initial,2018-04-27,GCST005884,Chronic kidney disease and diabetic kidney disease in diabetes
9113,European,7626.0,29703844.0,van Zuydam NR,Metabolic disorder,initial,2018-04-27,GCST005890,Early diabetic kidney disease in diabetes
1828,Asian,222.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005881,Diabetic kidney disease in diabetes
1930,Asian,307.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005891,Glomerular filtration rate in diabetes
8544,European,5248.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005884,Chronic kidney disease and diabetic kidney disease in diabetes
7974,European,3711.0,29703844.0,van Zuydam NR,Metabolic disorder,initial,2018-04-27,GCST005887,Late diabetic kidney disease in type 2 diabetes
4228,Asian,16047.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005895,Diabetic kidney disease in type 2 diabetes
1931,Asian,307.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005892,Glomerular filtration rate in type 2 diabetes
2034,Asian,418.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005893,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD)
8741,European,6000.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",initial,2018-04-27,GCST005882,Chronic kidney disease in type 2 diabetes
8165,European,4227.0,29703844.0,van Zuydam NR,Metabolic disorder,initial,2018-04-27,GCST005889,Early diabetic kidney disease in type 2 diabetes
9614,European,10164.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",initial,2018-04-27,GCST005880,Chronic kidney disease in diabetes
7886,European,3485.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005890,Early diabetic kidney disease in diabetes
3805,Asian,7405.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005891,Glomerular filtration rate in diabetes
3806,Asian,7405.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005892,Glomerular filtration rate in type 2 diabetes
1730,Asian,137.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005889,Early diabetic kidney disease in type 2 diabetes
8829,European,6400.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005885,End-stage renal disease in type 2 diabetes
3585,Asian,5508.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005889,Early diabetic kidney disease in type 2 diabetes
9485,European,9443.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005893,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD)
10345,European,19896.0,29728651.0,Li X,Neurological disorder,replication,2018-04-27,GCST005907,Major depressive disorder
2183,Asian,619.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005881,Diabetic kidney disease in diabetes
1792,Asian,194.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005884,Chronic kidney disease and diabetic kidney disease in diabetes
7177,European,2298.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",initial,2018-04-27,GCST005883,Chronic kidney disease and diabetic kidney disease in type 2 diabetes
7885,European,3485.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005889,Early diabetic kidney disease in type 2 diabetes
9445,European,9197.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",initial,2018-04-27,GCST005892,Glomerular filtration rate in type 2 diabetes
9467,European,9333.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",replication,2018-04-27,GCST005891,Glomerular filtration rate in diabetes
1750,Asian,159.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005882,Chronic kidney disease in type 2 diabetes
1749,Asian,159.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005880,Chronic kidney disease in diabetes
1731,Asian,137.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005890,Early diabetic kidney disease in diabetes
8372,European,4842.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",initial,2018-04-27,GCST005893,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD)
2385,Asian,900.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005884,Chronic kidney disease and diabetic kidney disease in diabetes
2384,Asian,900.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005883,Chronic kidney disease and diabetic kidney disease in type 2 diabetes
2184,Asian,619.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005895,Diabetic kidney disease in type 2 diabetes
4177,Asian,13915.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005887,Late diabetic kidney disease in type 2 diabetes
1833,Asian,223.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005895,Diabetic kidney disease in type 2 diabetes
9882,European,13158.0,29703844.0,van Zuydam NR,"Other measurement, Metabolic disorder",initial,2018-04-27,GCST005891,Glomerular filtration rate in diabetes
1791,Asian,194.0,29703844.0,van Zuydam NR,"Other disease, Metabolic disorder",replication,2018-04-27,GCST005883,Chronic kidney disease and diabetic kidney disease in type 2 diabetes
9834,European,12356.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005881,Diabetic kidney disease in diabetes
1832,Asian,223.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005881,Diabetic kidney disease in diabetes
2033,Asian,418.0,29703844.0,van Zuydam NR,Metabolic disorder,replication,2018-04-27,GCST005894,Diabetic kidney disease in diabetes (ESRD vs. no ESRD)
9522,European,9650.0,29703844.0,van Zuydam NR,Metabolic disorder,initial,2018-04-27,GCST005894,Diabetic kidney disease in diabetes (ESRD vs. no ESRD)
6934,European,2008.0,29724592.0,Pottier C,Neurological disorder,replication,2018-04-30,GCST006154,Frontotemporal dementia
4843,European,210.0,29724592.0,Pottier C,"Neurological disorder, Other measurement",replication,2018-04-30,GCST006147,Frontotemporal dementia (age at onset)
4606,European,67.0,29724592.0,Pottier C,"Neurological disorder, Other measurement",replication,2018-04-30,GCST006149,Frontotemporal dementia with GRN mutation (age at onset)
5081,European,382.0,29724592.0,Pottier C,"Neurological disorder, Other measurement",initial,2018-04-30,GCST006149,Frontotemporal dementia with GRN mutation (age at onset)
6546,European,1528.0,29724592.0,Pottier C,"Neurological disorder, Other measurement",initial,2018-04-30,GCST006147,Frontotemporal dementia (age at onset)
6544,European,1528.0,29724592.0,Pottier C,Neurological disorder,initial,2018-04-30,GCST006150,Frontotemporal dementia
6877,European,1941.0,29724592.0,Pottier C,Neurological disorder,replication,2018-04-30,GCST006150,Frontotemporal dementia
6543,European,1528.0,29724592.0,Pottier C,Neurological disorder,initial,2018-04-30,GCST006148,Frontotemporal dementia with GRN mutation
5080,European,382.0,29724592.0,Pottier C,"Neurological disorder, Biological process",initial,2018-04-30,GCST006146,Behavioural changes in frontotemporal lobe dementia
6545,European,1528.0,29724592.0,Pottier C,Neurological disorder,initial,2018-04-30,GCST006154,Frontotemporal dementia
5079,European,382.0,29724592.0,Pottier C,Neurological disorder,initial,2018-04-30,GCST006153,Parkinsonism in frontotemporal lobe dementia
6833,European,1865.0,29724592.0,Pottier C,Neurological disorder,replication,2018-04-30,GCST006148,Frontotemporal dementia with GRN mutation
5082,European,382.0,29724592.0,Pottier C,"Neurological disorder, Other trait",initial,2018-04-30,GCST006151,Memory dysfunction in frontotemporal lobe dementia
5078,European,382.0,29724592.0,Pottier C,Neurological disorder,initial,2018-04-30,GCST006152,Language impairment in frontotemporal lobe dementia
12987,Hispanic or Latin American,4038.0,29847655.0,Fan BJ,Other measurement,replication,2018-05-01,GCST006050,Central corneal thickness
12986,Hispanic or Latin American,4038.0,29847655.0,Fan BJ,Other measurement,replication,2018-05-01,GCST006049,Central corneal thickness
8962,European,6911.0,29847655.0,Fan BJ,Other measurement,replication,2018-05-01,GCST006050,Central corneal thickness
7761,European,3290.0,29748315.0,Pott J,Other measurement,initial,2018-05-01,GCST006284,Plasma proprotein convertase subtilisin/kexin type 9 levels in stable coronary artery disease
8358,European,4806.0,29847655.0,Fan BJ,Other measurement,replication,2018-05-01,GCST006049,Central corneal thickness
2674,Asian,1520.0,29847655.0,Fan BJ,Other measurement,replication,2018-05-01,GCST006050,Central corneal thickness
1794,Asian,195.0,29847655.0,Fan BJ,Other measurement,initial,2018-05-01,GCST006049,Central corneal thickness
1795,Asian,195.0,29847655.0,Fan BJ,Other measurement,initial,2018-05-01,GCST006050,Central corneal thickness
4908,European,264.0,29730043.0,Li J,"Response to drug, Neurological disorder",initial,2018-05-02,GCST006248,Response to lurasidone in schizophrenia
499,African American or Afro-Caribbean,158.0,29730043.0,Li J,"Response to drug, Neurological disorder",initial,2018-05-02,GCST006248,Response to lurasidone in schizophrenia
4697,European,119.0,29998114.0,Gadad BS,"Neurological disorder, Response to drug",initial,2018-05-03,GCST006818,Remission after antidepressant treatment in major depression
12387,European,450406.0,30271922.0,Clifton EAD,"Biological process, Other measurement",initial,2018-05-03,GCST006812,Smoking status (ever vs never smokers)
4844,European,210.0,29998114.0,Gadad BS,"Neurological disorder, Response to drug",initial,2018-05-03,GCST006817,Response to antidepressants in depression
3279,Asian,3279.0,29725004.0,Hosoda Y,Other measurement,replication,2018-05-03,GCST005715,Myopic maculopathy
12364,European,436236.0,30271922.0,Clifton EAD,Biological process,initial,2018-05-03,GCST006810,Self-reported risk-taking behaviour
3447,Asian,4476.0,29725004.0,Hosoda Y,Other measurement,initial,2018-05-03,GCST005715,Myopic maculopathy
5627,European,705.0,29739359.0,Graham PS,Metabolic disorder,initial,2018-05-08,GCST006282,Diabetic macular edema in type 2 diabetes
9100,European,7582.0,29738550.0,de Oliveira Otto MC,Lipid or lipoprotein measurement,initial,2018-05-08,GCST005861,Circulating odd-numbered chain saturated fatty acid levels (C23:0)
11180,European,55382.0,29739929.0,Visconti A,Other trait,replication,2018-05-08,GCST005897,Low tan response
5506,European,611.0,29739359.0,Graham PS,Metabolic disorder,initial,2018-05-08,GCST006283,Proliferative diabetic retinopathy in type 2 diabetes
8743,European,6016.0,29738550.0,de Oliveira Otto MC,Lipid or lipoprotein measurement,initial,2018-05-08,GCST005866,Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0)
11708,European,121296.0,29739929.0,Visconti A,Other trait,initial,2018-05-08,GCST005897,Low tan response
9755,European,11494.0,29738550.0,de Oliveira Otto MC,Lipid or lipoprotein measurement,initial,2018-05-08,GCST005869,Circulating odd-numbered chain saturated fatty acid levels (C15:0)
6861,European,1910.0,29738550.0,de Oliveira Otto MC,Lipid or lipoprotein measurement,initial,2018-05-08,GCST005862,Circulating odd-numbered chain saturated fatty acid levels (C19:0)
8744,European,6016.0,29738550.0,de Oliveira Otto MC,Lipid or lipoprotein measurement,initial,2018-05-08,GCST005868,Circulating odd-numbered chain saturated fatty acid levels (C17:0)
10271,European,18723.0,29743610.0,Ostrom QT,Cancer,initial,2018-05-09,GCST005931,Glioma
9937,European,13722.0,29743610.0,Ostrom QT,Cancer,initial,2018-05-09,GCST005933,Non-glioblastoma glioma
10034,European,15203.0,29743610.0,Ostrom QT,Cancer,initial,2018-05-09,GCST005932,Glioblastoma
5386,European,527.0,29747637.0,Li JQ,Other measurement,initial,2018-05-10,GCST005713,Plasma neurofilament light levels
8112,European,4061.0,29750799.0,Chao MJ,"Neurological disorder, Other measurement",initial,2018-05-11,GCST007113,Huntington's disease (age at onset)
9226,European,8239.0,29752348.0,Rutten-Jacobs LCA,Other measurement,initial,2018-05-11,GCST006063,White matter integrity (fractional anisotropy)
9328,European,8429.0,29752348.0,Rutten-Jacobs LCA,Other measurement,initial,2018-05-11,GCST006062,White matter hyperintensity volume
5021,European,340.0,29751835.0,Hu H,Other measurement,initial,2018-05-11,GCST005714,Cerebrospinal fluid beta-site APP cleaving enzyme levels
9227,European,8239.0,29752348.0,Rutten-Jacobs LCA,Other measurement,initial,2018-05-11,GCST006064,White matter integrity (mean diffusivity)
12612,Hispanic or Latin American,374.0,29750799.0,Chao MJ,"Neurological disorder, Other measurement",initial,2018-05-11,GCST007113,Huntington's disease (age at onset)
5364,European,520.0,29762745.0,Claus EB,Cancer,replication,2018-05-12,GCST005870,Meningioma
9747,European,11429.0,29762745.0,Claus EB,Cancer,initial,2018-05-12,GCST005870,Meningioma
3881,Asian,8107.0,29760442.0,Iglesias AI,Other measurement,initial,2018-05-14,GCST005667,Central corneal thickness
10226,European,17803.0,29760442.0,Iglesias AI,Other measurement,initial,2018-05-14,GCST005667,Central corneal thickness
10227,European,17803.0,29760442.0,Iglesias AI,Other measurement,initial,2018-05-14,GCST006366,Central corneal thickness
3882,Asian,8107.0,29760442.0,Iglesias AI,Other measurement,initial,2018-05-14,GCST006367,Central corneal thickness
4662,European,95.0,29766673.0,Fusco JP,"Biological process, Cancer",initial,2018-05-15,GCST005747,Non-small cell lung cancer in heavy smokers
1116,African American or Afro-Caribbean,3280.0,29767774.0,Lutz SM,"Other disease, Other measurement",initial,2018-05-15,GCST006042,Current cigarettes per day in chronic obstructive pulmonary disease
4708,European,133.0,29766673.0,Fusco JP,"Biological process, Cancer",replication,2018-05-15,GCST005747,Non-small cell lung cancer in heavy smokers
8883,European,6658.0,29767774.0,Lutz SM,"Other disease, Other measurement",initial,2018-05-15,GCST006042,Current cigarettes per day in chronic obstructive pulmonary disease
11287,European,67062.0,29769521.0,Ramirez J,Cardiovascular measurement,initial,2018-05-16,GCST005789,Resting heart rate
11291,European,67257.0,29769521.0,Ramirez J,Cardiovascular measurement,initial,2018-05-16,GCST005788,Heart rate response to recovery post exercise
5383,European,526.0,29769526.0,Estrada K,Immune system disorder,replication,2018-05-16,GCST006937,Neuromyelitis optica (AQP4-IgG-positive)
11290,European,67257.0,29769521.0,Ramirez J,Cardiovascular measurement,initial,2018-05-16,GCST005787,Heart rate response to exercise
5842,European,850.0,29769526.0,Estrada K,Immune system disorder,initial,2018-05-16,GCST006937,Neuromyelitis optica (AQP4-IgG-positive)
5405,European,546.0,29769526.0,Estrada K,Immune system disorder,replication,2018-05-16,GCST005964,Neuromyelitis optica
5919,European,913.0,29769526.0,Estrada K,Immune system disorder,initial,2018-05-16,GCST005964,Neuromyelitis optica
2148,Asian,547.0,29769613.0,Sun X,"Neurological disorder, Other measurement",initial,2018-05-16,GCST006219,Executive function in ADHD
5835,European,847.0,29769526.0,Estrada K,Immune system disorder,initial,2018-05-16,GCST006938,Neuromyelitis optica (AQP4-IgG-negative)
11351,European,73265.0,29771307.0,Aponte JL,Other measurement,initial,2018-05-16,GCST005790,Rosacea symptom severity
1910,Asian,278.0,29868124.0,Wu Y,Body measurement,initial,2018-05-16,GCST006430,Body mass index and waist-hip ratio (pleiotropy)
5264,European,480.0,29769526.0,Estrada K,Immune system disorder,replication,2018-05-16,GCST006938,Neuromyelitis optica (AQP4-IgG-negative)
4356,Asian,30266.0,29773799.0,Horikoshi M,Other measurement,initial,2018-05-17,GCST005865,Early age at menarche
4324,Asian,25432.0,29773799.0,Horikoshi M,Other measurement,initial,2018-05-17,GCST005864,Late age at menarche
8156,European,4187.0,30271932.0,Oskarsson GR,Other measurement,initial,2018-05-17,GCST006536,Serum erythropoietin levels
4459,Asian,67029.0,29773799.0,Horikoshi M,Other measurement,initial,2018-05-17,GCST005867,Menarche (age at onset)
11353,European,73397.0,29773799.0,Horikoshi M,Other measurement,replication,2018-05-17,GCST005867,Menarche (age at onset)
10758,European,32545.0,29773799.0,Horikoshi M,Other measurement,replication,2018-05-17,GCST005863,Menopause (age at onset)
4607,European,68.0,30271932.0,Oskarsson GR,Other measurement,replication,2018-05-17,GCST006536,Serum erythropoietin levels
4424,Asian,43861.0,29773799.0,Horikoshi M,Other measurement,initial,2018-05-17,GCST005863,Menopause (age at onset)
12126,European,260279.0,29777097.0,Marioni RE,Other measurement,initial,2018-05-18,GCST005920,Paternal history of Alzheimer's disease
4077,Asian,11283.0,29779033.0,Hishida A,Other measurement,initial,2018-05-18,GCST006393,Serum creatinine levels
12218,European,314278.0,29777097.0,Marioni RE,"Neurological disorder, Other measurement",initial,2018-05-18,GCST005922,Alzheimer's disease or family history of Alzheimer's disease
4076,Asian,11283.0,29779033.0,Hishida A,Other measurement,initial,2018-05-18,GCST006392,Estimated glomerular filtration rate
12219,European,314278.0,29777097.0,Marioni RE,Other measurement,initial,2018-05-18,GCST005921,Family history of Alzheimer's disease
4544,Asian,148829.0,29779033.0,Hishida A,"Other disease, Other measurement",initial,2018-05-18,GCST006391,Chronic kidney disease
4075,Asian,11283.0,29779033.0,Hishida A,"Other disease, Other measurement",initial,2018-05-18,GCST006391,Chronic kidney disease
4546,Asian,148829.0,29779033.0,Hishida A,Other measurement,initial,2018-05-18,GCST006393,Serum creatinine levels
4545,Asian,148829.0,29779033.0,Hishida A,Other measurement,initial,2018-05-18,GCST006392,Estimated glomerular filtration rate
12171,European,288676.0,29777097.0,Marioni RE,Other measurement,initial,2018-05-18,GCST005923,Maternal history of Alzheimer's disease
12120,European,253288.0,29782485.0,Rueger S,"Other measurement, Body measurement",initial,2018-05-21,GCST005908,Height
6396,European,1341.0,29787419.0,Hrdlickova B,Digestive system disorder,replication,2018-05-21,GCST005928,Refractory celiac disease type II
11799,European,139555.0,29785010.0,Khawaja AP,Other measurement,initial,2018-05-21,GCST006412,Intraocular pressure
2462,Asian,1048.0,29784950.0,Sawai H,"Digestive system disorder, Cancer",replication,2018-05-21,GCST005746,Hepatocellular carcinoma in hepatitis B infection
2435,Asian,989.0,29784950.0,Sawai H,"Digestive system disorder, Cancer",initial,2018-05-21,GCST005746,Hepatocellular carcinoma in hepatitis B infection
11529,European,90853.0,29785011.0,Zhu Z,Other disease,initial,2018-05-21,GCST007562,Asthma
11669,European,116538.0,29785011.0,Zhu Z,"Other disease, Immune system disorder",initial,2018-05-21,GCST007564,Asthma or allergic disease (pleiotropy)
2005,Asian,383.0,29784950.0,Sawai H,"Digestive system disorder, Cancer",replication,2018-05-21,GCST005746,Hepatocellular carcinoma in hepatitis B infection
5888,European,884.0,29787419.0,Hrdlickova B,Digestive system disorder,initial,2018-05-21,GCST005928,Refractory celiac disease type II
12254,European,336474.0,29782485.0,Rueger S,"Other measurement, Body measurement",replication,2018-05-21,GCST005908,Height
11586,European,102453.0,29785011.0,Zhu Z,"Other disease, Immune system disorder",initial,2018-05-21,GCST007563,"Allergic disease (asthma, hay fever or eczema)"
5747,European,790.0,29786918.0,Vonk JM,"Other disease, Other trait",initial,2018-05-22,GCST007423,Clinical remission in asthma
5580,European,667.0,29786918.0,Vonk JM,"Other disease, Other trait",initial,2018-05-22,GCST007424,Complete remission in asthma
5025,European,342.0,29786918.0,Vonk JM,"Other disease, Other trait",replication,2018-05-22,GCST007424,Complete remission in asthma
5229,European,456.0,29786918.0,Vonk JM,"Other disease, Other trait",replication,2018-05-22,GCST007423,Clinical remission in asthma
4212,Asian,15044.0,29808027.0,Tedja MS,"Other measurement, Other trait",initial,2018-05-28,GCST006291,Spherical equivalent or myopia (age of diagnosis)
11567,European,95505.0,29808027.0,Tedja MS,"Other measurement, Other trait",replication,2018-05-28,GCST006291,Spherical equivalent or myopia (age of diagnosis)
11846,European,148485.0,29808027.0,Tedja MS,"Other measurement, Other trait",initial,2018-05-28,GCST006291,Spherical equivalent or myopia (age of diagnosis)
4211,Asian,15044.0,29808027.0,Tedja MS,Other measurement,initial,2018-05-28,GCST006289,Spherical equivalent
11027,European,44192.0,29808027.0,Tedja MS,Other measurement,initial,2018-05-28,GCST006289,Spherical equivalent
2966,Asian,2110.0,29808027.0,Tedja MS,"Other measurement, Other trait",initial,2018-05-28,GCST006291,Spherical equivalent or myopia (age of diagnosis)
2965,Asian,2110.0,29808027.0,Tedja MS,Other measurement,initial,2018-05-28,GCST006289,Spherical equivalent
11591,European,104293.0,29808027.0,Tedja MS,"Other measurement, Other trait",initial,2018-05-28,GCST006290,Myopia (age of diagnosis)
3046,Asian,2275.0,29808027.0,Tedja MS,Other measurement,initial,2018-05-28,GCST006289,Spherical equivalent
3047,Asian,2275.0,29808027.0,Tedja MS,"Other measurement, Other trait",initial,2018-05-28,GCST006291,Spherical equivalent or myopia (age of diagnosis)
3112,Asian,2506.0,29808027.0,Tedja MS,Other measurement,initial,2018-05-28,GCST006289,Spherical equivalent
3113,Asian,2506.0,29808027.0,Tedja MS,"Other measurement, Other trait",initial,2018-05-28,GCST006291,Spherical equivalent or myopia (age of diagnosis)
9118,European,7647.0,29844224.0,Loomis SJ,Other measurement,initial,2018-05-29,GCST006059,Fasting blood glucose
9119,European,7647.0,29844224.0,Loomis SJ,"Other measurement, Hematological measurement",initial,2018-05-29,GCST006060,Hemoglobin A1c levels
6374,European,1304.0,29844224.0,Loomis SJ,Other measurement,replication,2018-05-29,GCST006057,Percent glycated albumin
6373,European,1304.0,29844224.0,Loomis SJ,Other measurement,replication,2018-05-29,GCST006056,Fructosamine levels
12244,European,330069.0,29844566.0,Davies G,Other measurement,initial,2018-05-29,GCST006268,Reaction time
128,African,608.0,29844224.0,Loomis SJ,Other measurement,replication,2018-05-29,GCST006056,Fructosamine levels
129,African,608.0,29844224.0,Loomis SJ,Other measurement,replication,2018-05-29,GCST006057,Percent glycated albumin
9117,European,7647.0,29844224.0,Loomis SJ,Other measurement,initial,2018-05-29,GCST006058,Total glycated albumin levels
9116,European,7647.0,29844224.0,Loomis SJ,Other measurement,initial,2018-05-29,GCST006057,Percent glycated albumin
236,African,2104.0,29844224.0,Loomis SJ,Other measurement,initial,2018-05-29,GCST006058,Total glycated albumin levels
9115,European,7647.0,29844224.0,Loomis SJ,Other measurement,initial,2018-05-29,GCST006056,Fructosamine levels
234,African,2104.0,29844224.0,Loomis SJ,Other measurement,initial,2018-05-29,GCST006056,Fructosamine levels
235,African,2104.0,29844224.0,Loomis SJ,Other measurement,initial,2018-05-29,GCST006057,Percent glycated albumin
2560,Asian,1271.0,29857070.0,Gao J,Immune system disorder,initial,2018-05-29,GCST006584,Pemphigus vulgaris
12199,European,300486.0,29844566.0,Davies G,Biological process,initial,2018-05-29,GCST006269,General cognitive ability
3297,Asian,3418.0,29844195.0,Hosoda Y,Other measurement,initial,2018-05-29,GCST006068,Sub-foveal choroidal thickness
3155,Asian,2692.0,29844195.0,Hosoda Y,Other measurement,replication,2018-05-29,GCST006068,Sub-foveal choroidal thickness
237,African,2104.0,29844224.0,Loomis SJ,Other measurement,initial,2018-05-29,GCST006059,Fasting blood glucose
238,African,2104.0,29844224.0,Loomis SJ,"Other measurement, Hematological measurement",initial,2018-05-29,GCST006060,Hemoglobin A1c levels
2962,Asian,2104.0,29857070.0,Gao J,Immune system disorder,replication,2018-05-29,GCST006584,Pemphigus vulgaris
6766,European,1760.0,30680360.0,McCoy TH Jr,Other disease,initial,2018-05-29,GCST007250,Nonunion in individuals with fractures
5936,European,926.0,29860282.0,Scelsi MA,Other measurement,initial,2018-05-30,GCST006134,Hippocampal volume
5977,European,944.0,29860282.0,Scelsi MA,Other measurement,initial,2018-05-30,GCST006136,Alzheimer's disease progression score
10167,European,16966.0,29848360.0,Julia A,Immune system disorder,initial,2018-05-30,GCST005831,Systemic lupus erythematosus
5966,European,936.0,29860282.0,Scelsi MA,Other measurement,initial,2018-05-30,GCST006135,Cortical amyloid beta load
3610,Asian,5614.0,29855537.0,Hirata T,"Other trait, Other measurement",replication,2018-05-31,GCST006638,Menstruation quality of life impact (fever)
3611,Asian,5614.0,29855537.0,Hirata T,"Other trait, Other measurement",replication,2018-05-31,GCST006639,Heavy vaginal discharge
3612,Asian,5614.0,29855537.0,Hirata T,"Other trait, Other measurement",replication,2018-05-31,GCST006643,Menstruation quality of life impact (bowel movement)
3609,Asian,5614.0,29855537.0,Hirata T,Other trait,replication,2018-05-31,GCST006654,Vaginal discharge (smell)
3608,Asian,5614.0,29855537.0,Hirata T,Other trait,replication,2018-05-31,GCST006653,Vaginal discharge (itching)
3607,Asian,5614.0,29855537.0,Hirata T,"Other measurement, Other disease",replication,2018-05-31,GCST006645,Menstruation quality of life impact (edema)
3606,Asian,5614.0,29855537.0,Hirata T,Other measurement,replication,2018-05-31,GCST006656,Dysmenorrheic pain severity
3605,Asian,5614.0,29855537.0,Hirata T,Other measurement,replication,2018-05-31,GCST006637,Pain medicine use during menstruation
3604,Asian,5614.0,29855537.0,Hirata T,Other measurement,replication,2018-05-31,GCST006636,Menstruation quality of life impact (dysmenorrhea)
3603,Asian,5614.0,29855537.0,Hirata T,"Other disease, Other measurement",replication,2018-05-31,GCST006640,Menstruation quality of life impact (acne)
3602,Asian,5614.0,29855537.0,Hirata T,"Neurological disorder, Other measurement",replication,2018-05-31,GCST006651,Menstruation quality of life impact (sleepiness)
3601,Asian,5614.0,29855537.0,Hirata T,"Neurological disorder, Other measurement",replication,2018-05-31,GCST006644,Menstruation quality of life impact (depression)
8683,European,5781.0,30273415.0,Hatzikotoulas K,Other disease,replication,2018-05-31,GCST006566,Developmental dysplasia of the hip
3600,Asian,5614.0,29855537.0,Hirata T,"Body measurement, Other measurement",replication,2018-05-31,GCST006650,Menstruation quality of life impact (pressure in breast)
3599,Asian,5614.0,29855537.0,Hirata T,"Biological process, Other measurement",replication,2018-05-31,GCST006642,Menstruation quality of life impact (increased appetite)
3598,Asian,5614.0,29855537.0,Hirata T,"Biological process, Other measurement",replication,2018-05-31,GCST006641,Menstruation quality of life impact (aggressiveness)
3597,Asian,5609.0,29855537.0,Hirata T,Body measurement,initial,2018-05-31,GCST006655,Breast size
12519,Hispanic or Latin American,36.0,29855589.0,Chernus J,Other trait,initial,2018-05-31,GCST006280,Velopharyngeal dysfunction
5598,European,678.0,29852030.0,Lores-Motta L,"Neurological disorder, Response to drug, Other measurement",initial,2018-05-31,GCST006808,Response to anti-VEGF treatment in neovascular age-related macular degeneration (visual acuity)
3613,Asian,5614.0,29855537.0,Hirata T,"Other trait, Other measurement",replication,2018-05-31,GCST006646,Menstruation quality of life impact (headache)
3614,Asian,5614.0,29855537.0,Hirata T,"Other trait, Other measurement",replication,2018-05-31,GCST006647,Menstruation quality of life impact (joint pain)
3646,Asian,5734.0,29855537.0,Hirata T,Other measurement,initial,2018-05-31,GCST006637,Pain medicine use during menstruation
3651,Asian,5734.0,29855537.0,Hirata T,Other trait,initial,2018-05-31,GCST006657,Vaginal discharge (metrorrhagia)
3650,Asian,5734.0,29855537.0,Hirata T,Other trait,initial,2018-05-31,GCST006654,Vaginal discharge (smell)
3654,Asian,5734.0,29855537.0,Hirata T,"Other trait, Other measurement",initial,2018-05-31,GCST006643,Menstruation quality of life impact (bowel movement)
3649,Asian,5734.0,29855537.0,Hirata T,Other trait,initial,2018-05-31,GCST006653,Vaginal discharge (itching)
3648,Asian,5734.0,29855537.0,Hirata T,"Other measurement, Other disease",initial,2018-05-31,GCST006645,Menstruation quality of life impact (edema)
3655,Asian,5734.0,29855537.0,Hirata T,"Other trait, Other measurement",initial,2018-05-31,GCST006646,Menstruation quality of life impact (headache)
8137,European,4134.0,30273415.0,Hatzikotoulas K,Other disease,initial,2018-05-31,GCST006566,Developmental dysplasia of the hip
3647,Asian,5734.0,29855537.0,Hirata T,Other measurement,initial,2018-05-31,GCST006656,Dysmenorrheic pain severity
3656,Asian,5734.0,29855537.0,Hirata T,"Other trait, Other measurement",initial,2018-05-31,GCST006647,Menstruation quality of life impact (joint pain)
3652,Asian,5734.0,29855537.0,Hirata T,"Other trait, Other measurement",initial,2018-05-31,GCST006638,Menstruation quality of life impact (fever)
3657,Asian,5734.0,29855537.0,Hirata T,"Other trait, Other measurement",initial,2018-05-31,GCST006652,Menstruation quality of life impact (stiff neck)
3645,Asian,5734.0,29855537.0,Hirata T,Other measurement,initial,2018-05-31,GCST006636,Menstruation quality of life impact (dysmenorrhea)
3644,Asian,5734.0,29855537.0,Hirata T,"Other disease, Other measurement",initial,2018-05-31,GCST006640,Menstruation quality of life impact (acne)
3653,Asian,5734.0,29855537.0,Hirata T,"Other trait, Other measurement",initial,2018-05-31,GCST006639,Heavy vaginal discharge
3643,Asian,5734.0,29855537.0,Hirata T,"Neurological disorder, Other measurement",initial,2018-05-31,GCST006651,Menstruation quality of life impact (sleepiness)
3642,Asian,5734.0,29855537.0,Hirata T,"Neurological disorder, Other measurement",initial,2018-05-31,GCST006649,Menstruation quality of life impact (nervousness)
3641,Asian,5734.0,29855537.0,Hirata T,"Neurological disorder, Other measurement",initial,2018-05-31,GCST006648,Menstruation quality of life impact (loss of concentration)
3615,Asian,5614.0,29855537.0,Hirata T,"Other trait, Other measurement",replication,2018-05-31,GCST006652,Menstruation quality of life impact (stiff neck)
3640,Asian,5734.0,29855537.0,Hirata T,"Neurological disorder, Other measurement",initial,2018-05-31,GCST006644,Menstruation quality of life impact (depression)
3639,Asian,5734.0,29855537.0,Hirata T,"Body measurement, Other measurement",initial,2018-05-31,GCST006650,Menstruation quality of life impact (pressure in breast)
3638,Asian,5734.0,29855537.0,Hirata T,"Biological process, Other measurement",initial,2018-05-31,GCST006642,Menstruation quality of life impact (increased appetite)
3637,Asian,5734.0,29855537.0,Hirata T,"Biological process, Other measurement",initial,2018-05-31,GCST006641,Menstruation quality of life impact (aggressiveness)
4885,European,240.0,29967566.0,Roberts CH,Other measurement,initial,2018-06-03,GCST006225,Chlamydia trachomatis seropositivity
6445,European,1380.0,29883787.0,Gregson CL,Other measurement,initial,2018-06-05,GCST006142,Lumbar spine bone mineral density
8713,European,5899.0,29883787.0,Gregson CL,Other measurement,initial,2018-06-05,GCST006141,High bone mineral density
7019,European,2110.0,29883787.0,Gregson CL,Other measurement,initial,2018-06-05,GCST006143,Bone mineral density (total hip)
448,African American or Afro-Caribbean,89.0,29875475.0,Montalvo-Ortiz JL,Biological process,replication,2018-06-06,GCST006175,Cannabis-related aggression
7366,European,2546.0,29875475.0,Montalvo-Ortiz JL,Biological process,initial,2018-06-06,GCST006175,Cannabis-related aggression
1081,African American or Afro-Caribbean,3076.0,29885931.0,Langefeld CD,"Other disease, Other measurement",initial,2018-06-06,GCST006815,End stage renal disease in APOL1 risk genotype-negative individuals
1015,African American or Afro-Caribbean,2649.0,29885931.0,Langefeld CD,"Other disease, Other measurement",initial,2018-06-06,GCST006813,End stage renal disease x APOL1 genotype interaction
1113,African American or Afro-Caribbean,3269.0,29875475.0,Montalvo-Ortiz JL,Biological process,initial,2018-06-06,GCST006175,Cannabis-related aggression
7772,European,3301.0,29875488.0,Sun BB,"Other measurement, Hematological measurement, Lipid or lipoprotein measurement, Cardiovascular measurement, Liver enzyme measurement, Inflammatory measurement",initial,2018-06-06,GCST005806,Blood protein levels
833,African American or Afro-Caribbean,1229.0,29885931.0,Langefeld CD,"Other disease, Other measurement",initial,2018-06-06,GCST006816,End stage renal disease in APOL1 risk genotype-positive individuals
1187,African American or Afro-Caribbean,4306.0,29885931.0,Langefeld CD,Other disease,initial,2018-06-06,GCST006814,End-stage renal disease
6138,European,1043.0,29884837.0,Reyes-Gibby CC,"Cancer, Other trait",initial,2018-06-08,GCST005934,Neuropathic pain in head and neck cancer
13953,Other/Mixed,3571.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006065,Glaucoma (primary open-angle)
11355,European,73475.0,29892016.0,Schumacher FR,Cancer,initial,2018-06-11,GCST006083,Prostate cancer (advanced)
922,African American or Afro-Caribbean,1847.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006066,Glaucoma (primary open-angle)
921,African American or Afro-Caribbean,1847.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006065,Glaucoma (primary open-angle)
12056,European,214102.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006065,Glaucoma (primary open-angle)
13954,Other/Mixed,3571.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006067,Glaucoma (primary open-angle)
6547,European,1528.0,30134812.0,Chattopadhyay S,Other disease,initial,2018-06-11,GCST006917,Monoclonal gammopathy of undetermined significance
1353,African American or Afro-Caribbean,8967.0,29892015.0,Roselli C,Cardiovascular disease,initial,2018-06-11,GCST006061,Atrial fibrillation
11125,European,51901.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006066,Glaucoma (primary open-angle)
923,African American or Afro-Caribbean,1847.0,29891935.0,Choquet H,Neurological disorder,replication,2018-06-11,GCST006067,Glaucoma (primary open-angle)
3565,Asian,5370.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006065,Glaucoma (primary open-angle)
11216,European,58751.0,29892016.0,Schumacher FR,Cancer,initial,2018-06-11,GCST006082,Prostate cancer aggressiveness (high vs low/intermediate)
11126,European,51901.0,29891935.0,Choquet H,Neurological disorder,replication,2018-06-11,GCST006067,Glaucoma (primary open-angle)
12430,European,537409.0,29892015.0,Roselli C,Cardiovascular disease,initial,2018-06-11,GCST006061,Atrial fibrillation
11907,European,162201.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006067,Glaucoma (primary open-angle)
11908,European,162201.0,29891935.0,Choquet H,Neurological disorder,replication,2018-06-11,GCST006066,Glaucoma (primary open-angle)
280,African,5103.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006065,Glaucoma (primary open-angle)
3530,Asian,5120.0,29891935.0,Choquet H,Neurological disorder,replication,2018-06-11,GCST006066,Glaucoma (primary open-angle)
11114,European,51244.0,29892016.0,Schumacher FR,Cancer,initial,2018-06-11,GCST006089,Prostate cancer (early onset)
2381,Asian,895.0,29891935.0,Choquet H,Neurological disorder,replication,2018-06-11,GCST006066,Glaucoma (primary open-angle)
11801,European,140254.0,29892016.0,Schumacher FR,Cancer,initial,2018-06-11,GCST006085,Prostate cancer
2380,Asian,895.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006067,Glaucoma (primary open-angle)
11241,European,61978.0,29892016.0,Schumacher FR,Cancer,initial,2018-06-11,GCST006084,Prostate cancer (Gleason score)
13046,Hispanic or Latin American,5022.0,29892015.0,Roselli C,Cardiovascular disease,initial,2018-06-11,GCST006061,Atrial fibrillation
13053,Hispanic or Latin American,5189.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006065,Glaucoma (primary open-angle)
281,African,5103.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006067,Glaucoma (primary open-angle)
3528,Asian,5120.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006065,Glaucoma (primary open-angle)
13955,Other/Mixed,3571.0,29891935.0,Choquet H,Neurological disorder,replication,2018-06-11,GCST006066,Glaucoma (primary open-angle)
3529,Asian,5120.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006067,Glaucoma (primary open-angle)
3445,Asian,4475.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006066,Glaucoma (primary open-angle)
13054,Hispanic or Latin American,5189.0,29891935.0,Choquet H,Neurological disorder,initial,2018-06-11,GCST006066,Glaucoma (primary open-angle)
11373,European,76581.0,29892016.0,Schumacher FR,Cancer,initial,2018-06-11,GCST006081,Prostate cancer (advanced vs non-advanced)
282,African,5103.0,29891935.0,Choquet H,Neurological disorder,replication,2018-06-11,GCST006066,Glaucoma (primary open-angle)
4402,Asian,36792.0,29892015.0,Roselli C,Cardiovascular disease,initial,2018-06-11,GCST006061,Atrial fibrillation
3446,Asian,4475.0,29891935.0,Choquet H,Neurological disorder,replication,2018-06-11,GCST006067,Glaucoma (primary open-angle)
13055,Hispanic or Latin American,5189.0,29891935.0,Choquet H,Neurological disorder,replication,2018-06-11,GCST006067,Glaucoma (primary open-angle)
10574,European,25300.0,29892016.0,Schumacher FR,Cancer,initial,2018-06-11,GCST006080,Prostate cancer aggressiveness (high vs low)
1580,Asian,28.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006928,Visual memory
13359,Other/Mixed,2.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006928,Visual memory
1577,Asian,28.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006932,Reasoning
1581,Asian,28.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006929,Attention function
4802,European,192.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006930,Working memory
3616,Asian,5614.0,29895819.0,Endo C,Other measurement,initial,2018-06-12,GCST006092,Double-edged eyelids
4803,European,192.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006932,Reasoning
1576,Asian,28.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006930,Working memory
13355,Other/Mixed,2.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006930,Working memory
4805,European,192.0,29907492.0,Nakahara S,"Biological process, Other measurement",initial,2018-06-12,GCST006933,Cognitive function
4804,European,192.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006934,Information processing speed
13356,Other/Mixed,2.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006932,Reasoning
1582,Asian,28.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006931,Verbal memory
13360,Other/Mixed,2.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006929,Attention function
399,African American or Afro-Caribbean,37.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006932,Reasoning
3455,Asian,4538.0,29895819.0,Endo C,Other trait,initial,2018-06-12,GCST006090,Excessive sweating
398,African American or Afro-Caribbean,37.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006930,Working memory
400,African American or Afro-Caribbean,37.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006934,Information processing speed
401,African American or Afro-Caribbean,37.0,29907492.0,Nakahara S,"Biological process, Other measurement",initial,2018-06-12,GCST006933,Cognitive function
402,African American or Afro-Caribbean,37.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006928,Visual memory
403,African American or Afro-Caribbean,37.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006929,Attention function
4806,European,192.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006928,Visual memory
13376,Other/Mixed,4.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006928,Visual memory
3374,Asian,3941.0,29895819.0,Endo C,Other measurement,initial,2018-06-12,GCST006093,Thick vs thin eyebrows
404,African American or Afro-Caribbean,37.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006931,Verbal memory
4808,European,192.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006931,Verbal memory
13358,Other/Mixed,2.0,29907492.0,Nakahara S,"Biological process, Other measurement",initial,2018-06-12,GCST006933,Cognitive function
13361,Other/Mixed,2.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006931,Verbal memory
3510,Asian,4878.0,29895819.0,Endo C,"Other measurement, Other trait",initial,2018-06-12,GCST006094,Straight vs curly hair
4069,Asian,11182.0,29895819.0,Endo C,Other trait,initial,2018-06-12,GCST006091,Freckles
4071,Asian,11244.0,29895819.0,Endo C,Other trait,initial,2018-06-12,GCST006095,Excessive hairiness
4072,Asian,11253.0,29895819.0,Endo C,Other measurement,initial,2018-06-12,GCST006096,Age spots
13357,Other/Mixed,2.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006934,Information processing speed
4807,European,192.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006929,Attention function
13374,Other/Mixed,4.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006934,Information processing speed
13377,Other/Mixed,4.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006929,Attention function
13378,Other/Mixed,4.0,29907492.0,Nakahara S,Other measurement,initial,2018-06-12,GCST006931,Verbal memory
13373,Other/Mixed,4.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006932,Reasoning
1579,Asian,28.0,29907492.0,Nakahara S,"Biological process, Other measurement",initial,2018-06-12,GCST006933,Cognitive function
13372,Other/Mixed,4.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006930,Working memory
13375,Other/Mixed,4.0,29907492.0,Nakahara S,"Biological process, Other measurement",initial,2018-06-12,GCST006933,Cognitive function
1578,Asian,28.0,29907492.0,Nakahara S,Biological process,initial,2018-06-12,GCST006934,Information processing speed
12272,European,350492.0,29899525.0,Klimentidis YC,Other measurement,initial,2018-06-13,GCST006100,Strenuous sports or other exercises
12127,European,261055.0,29899525.0,Klimentidis YC,Other measurement,initial,2018-06-13,GCST006098,Vigorous physical activity
11530,European,91084.0,29899525.0,Klimentidis YC,Other measurement,initial,2018-06-13,GCST006099,Accelerometer-based physical activity measurement (average acceleration)
5330,European,505.0,29942513.0,Penney ME,Cancer,initial,2018-06-13,GCST006411,Mucinous adenocarcinoma in colorectal cancer
11528,European,90667.0,29899525.0,Klimentidis YC,Other measurement,initial,2018-06-13,GCST006079,Accelerometer-based physical activity measurement (fraction of time with accelerations >425 milli-gravities)
6883,European,1944.0,29898447.0,Alaraudanjoki VK,Other measurement,initial,2018-06-13,GCST006218,Erosive tooth wear (severe vs non-severe)
6233,European,1147.0,29898447.0,Alaraudanjoki VK,Other measurement,initial,2018-06-13,GCST006226,Erosive tooth wear (severe vs none or mild)
12310,European,377234.0,29899525.0,Klimentidis YC,Other measurement,initial,2018-06-13,GCST006097,Moderate to vigorous physical activity levels
112,African,510.0,29903748.0,Debiec H,Other disease,initial,2018-06-14,GCST006252,Childhood steroid-sensitive nephrotic syndrome
13632,Other/Mixed,346.0,29903748.0,Debiec H,Other disease,initial,2018-06-14,GCST006252,Childhood steroid-sensitive nephrotic syndrome
7504,European,2796.0,29903748.0,Debiec H,Other disease,initial,2018-06-14,GCST006252,Childhood steroid-sensitive nephrotic syndrome
11239,European,61335.0,29917119.0,Schmit SL,Cancer,replication,2018-06-16,GCST006131,Colorectal cancer
4302,Asian,21630.0,29917119.0,Schmit SL,Cancer,replication,2018-06-16,GCST006131,Colorectal cancer
1270,African American or Afro-Caribbean,6597.0,29917119.0,Schmit SL,Cancer,initial,2018-06-16,GCST006131,Colorectal cancer
11301,European,67812.0,29917119.0,Schmit SL,Cancer,initial,2018-06-16,GCST006131,Colorectal cancer
13068,Hispanic or Latin American,5941.0,29917119.0,Schmit SL,Cancer,replication,2018-06-16,GCST006131,Colorectal cancer
2816,Asian,1789.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006170,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
795,African American or Afro-Caribbean,1062.0,29912962.0,Feitosa MF,"Cardiovascular measurement, Other measurement",replication,2018-06-18,GCST006171,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)
1468,African American or Afro-Caribbean,21416.0,29912962.0,Feitosa MF,"Biological process, Cardiovascular measurement",initial,2018-06-18,GCST006168,Pulse pressure x alcohol consumption interaction (2df test)
4112,Asian,12365.0,29912962.0,Feitosa MF,"Biological process, Cardiovascular measurement",initial,2018-06-18,GCST006168,Pulse pressure x alcohol consumption interaction (2df test)
1470,African American or Afro-Caribbean,21416.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006167,Mean arterial pressure x alcohol consumption interaction (2df test)
310,African,9725.0,29912962.0,Feitosa MF,"Cardiovascular measurement, Other measurement",initial,2018-06-18,GCST006171,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)
11199,European,56705.0,29912962.0,Feitosa MF,"Cardiovascular measurement, Other measurement",initial,2018-06-18,GCST006171,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)
4868,European,228.0,29915124.0,Marini S,Cardiovascular disease,initial,2018-06-18,GCST006139,Hematoma volume in lobar spontaneous intracerebral hemorrhage
11200,European,56705.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006169,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
4748,European,169.0,29915124.0,Marini S,Cardiovascular disease,replication,2018-06-18,GCST006140,Hematoma volume in non-lobar spontaneous intracerebral hemorrhage
11201,European,56705.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006170,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
2814,Asian,1789.0,29912962.0,Feitosa MF,"Cardiovascular measurement, Other measurement",initial,2018-06-18,GCST006171,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)
798,African American or Afro-Caribbean,1062.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006172,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
4113,Asian,12365.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006166,Diastolic blood pressure x alcohol consumption interaction (2df test)
797,African American or Afro-Caribbean,1062.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006170,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
4745,European,166.0,29915124.0,Marini S,Cardiovascular disease,initial,2018-06-18,GCST006140,Hematoma volume in non-lobar spontaneous intracerebral hemorrhage
4114,Asian,12365.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006167,Mean arterial pressure x alcohol consumption interaction (2df test)
4115,Asian,12365.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006434,Systolic blood pressure x alcohol consumption interaction (2df test)
11202,European,56705.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006172,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
2815,Asian,1789.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006169,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
796,African American or Afro-Caribbean,1062.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006169,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
1471,African American or Afro-Caribbean,21417.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006434,Systolic blood pressure x alcohol consumption interaction (2df test)
1469,African American or Afro-Caribbean,21416.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006166,Diastolic blood pressure x alcohol consumption interaction (2df test)
2817,Asian,1789.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006172,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
13029,Hispanic or Latin American,4812.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006169,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
11531,European,91099.0,29912962.0,Feitosa MF,"Biological process, Cardiovascular measurement",initial,2018-06-18,GCST006168,Pulse pressure x alcohol consumption interaction (2df test)
12151,European,281318.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006434,Systolic blood pressure x alcohol consumption interaction (2df test)
12152,European,281371.0,29912962.0,Feitosa MF,"Biological process, Cardiovascular measurement",replication,2018-06-18,GCST006168,Pulse pressure x alcohol consumption interaction (2df test)
12153,European,281376.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006166,Diastolic blood pressure x alcohol consumption interaction (2df test)
12671,Hispanic or Latin American,535.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006172,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
4610,European,71.0,29915124.0,Marini S,Cardiovascular disease,replication,2018-06-18,GCST006139,Hematoma volume in lobar spontaneous intracerebral hemorrhage
12670,Hispanic or Latin American,535.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006169,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
12669,Hispanic or Latin American,535.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006170,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
11539,European,91110.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006167,Mean arterial pressure x alcohol consumption interaction (2df test)
4557,Asian,306423.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006172,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
12668,Hispanic or Latin American,535.0,29912962.0,Feitosa MF,"Cardiovascular measurement, Other measurement",replication,2018-06-18,GCST006171,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)
11532,European,91099.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006166,Diastolic blood pressure x alcohol consumption interaction (2df test)
13151,Hispanic or Latin American,8470.0,29912962.0,Feitosa MF,"Biological process, Cardiovascular measurement",initial,2018-06-18,GCST006168,Pulse pressure x alcohol consumption interaction (2df test)
13152,Hispanic or Latin American,8470.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006167,Mean arterial pressure x alcohol consumption interaction (2df test)
13153,Hispanic or Latin American,8471.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006166,Diastolic blood pressure x alcohol consumption interaction (2df test)
13031,Hispanic or Latin American,4812.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006172,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
13154,Hispanic or Latin American,8471.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006434,Systolic blood pressure x alcohol consumption interaction (2df test)
13030,Hispanic or Latin American,4812.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006170,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
13028,Hispanic or Latin American,4812.0,29912962.0,Feitosa MF,"Cardiovascular measurement, Other measurement",initial,2018-06-18,GCST006171,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)
11533,European,91102.0,29912962.0,Feitosa MF,"Biological process, Other measurement",initial,2018-06-18,GCST006434,Systolic blood pressure x alcohol consumption interaction (2df test)
4556,Asian,306423.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006170,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
12150,European,281311.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006167,Mean arterial pressure x alcohol consumption interaction (2df test)
4554,Asian,306423.0,29912962.0,Feitosa MF,"Cardiovascular measurement, Other measurement",replication,2018-06-18,GCST006171,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)
4539,Asian,141026.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006434,Systolic blood pressure x alcohol consumption interaction (2df test)
4538,Asian,141024.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006166,Diastolic blood pressure x alcohol consumption interaction (2df test)
4537,Asian,141023.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006167,Mean arterial pressure x alcohol consumption interaction (2df test)
13253,Hispanic or Latin American,13370.0,29912962.0,Feitosa MF,"Biological process, Cardiovascular measurement",replication,2018-06-18,GCST006168,Pulse pressure x alcohol consumption interaction (2df test)
13254,Hispanic or Latin American,13371.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006166,Diastolic blood pressure x alcohol consumption interaction (2df test)
13255,Hispanic or Latin American,13371.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006167,Mean arterial pressure x alcohol consumption interaction (2df test)
13256,Hispanic or Latin American,13377.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006434,Systolic blood pressure x alcohol consumption interaction (2df test)
4536,Asian,141023.0,29912962.0,Feitosa MF,"Biological process, Cardiovascular measurement",replication,2018-06-18,GCST006168,Pulse pressure x alcohol consumption interaction (2df test)
1213,African American or Afro-Caribbean,5041.0,29912962.0,Feitosa MF,"Biological process, Cardiovascular measurement",replication,2018-06-18,GCST006168,Pulse pressure x alcohol consumption interaction (2df test)
1214,African American or Afro-Caribbean,5041.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006166,Diastolic blood pressure x alcohol consumption interaction (2df test)
4555,Asian,306423.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006169,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
1360,African American or Afro-Caribbean,9565.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006170,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
1359,African American or Afro-Caribbean,9565.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006169,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
1364,African American or Afro-Caribbean,9725.0,29912962.0,Feitosa MF,Other measurement,initial,2018-06-18,GCST006172,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
1216,African American or Afro-Caribbean,5041.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006434,Systolic blood pressure x alcohol consumption interaction (2df test)
11674,European,116836.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006169,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
11673,European,116835.0,29912962.0,Feitosa MF,"Cardiovascular measurement, Other measurement",replication,2018-06-18,GCST006171,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)
11671,European,116778.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006172,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)
11672,European,116784.0,29912962.0,Feitosa MF,Other measurement,replication,2018-06-18,GCST006170,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)
1215,African American or Afro-Caribbean,5041.0,29912962.0,Feitosa MF,"Biological process, Other measurement",replication,2018-06-18,GCST006167,Mean arterial pressure x alcohol consumption interaction (2df test)
2529,Asian,1215.0,29923122.0,Kakuta Y,"Digestive system disorder, Other trait, Response to drug",initial,2018-06-19,GCST006215,Thiopurine-induced acute severe leukopenia in inflammatory bowel disease (conditioned on rs116855232)
2528,Asian,1215.0,29923122.0,Kakuta Y,"Digestive system disorder, Other trait, Response to drug",initial,2018-06-19,GCST006205,Thiopurine-induced acute severe leukopenia in inflammatory bowel disease
3619,Asian,5634.0,29921221.0,Cha S,Other measurement,initial,2018-06-19,GCST006105,Eye morphology
10749,European,32338.0,29924316.0,Byun J,"Other measurement, Cancer",initial,2018-06-19,GCST006087,Familial lung adenocarcinoma
10736,European,31930.0,29924316.0,Byun J,"Other measurement, Cancer",initial,2018-06-19,GCST006088,Familial squamous cell lung carcinoma
3621,Asian,5634.0,29921221.0,Cha S,Other measurement,initial,2018-06-19,GCST006107,Upper eyelid morphology
2531,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Other disease, Response to drug",initial,2018-06-19,GCST006199,Thiopurine-induced severe alopecia in inflammatory bowel disease (conditioned on rs116855232)
3622,Asian,5634.0,29921221.0,Cha S,Other measurement,initial,2018-06-19,GCST006109,Lip morphology
2890,Asian,1926.0,29921221.0,Cha S,Other measurement,replication,2018-06-19,GCST006105,Eye morphology
3623,Asian,5634.0,29921221.0,Cha S,Other measurement,initial,2018-06-19,GCST006110,Nose morphology
3624,Asian,5634.0,29921221.0,Cha S,"Other trait, Other measurement",initial,2018-06-19,GCST006108,Facial morphology
3620,Asian,5634.0,29921221.0,Cha S,Other measurement,initial,2018-06-19,GCST006106,Forehead morphology
2532,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Other disease, Response to drug",initial,2018-06-19,GCST006206,Thiopurine-induced alopecia in inflammatory bowel disease
2891,Asian,1926.0,29921221.0,Cha S,Other measurement,replication,2018-06-19,GCST006106,Forehead morphology
2544,Asian,1220.0,29923122.0,Kakuta Y,"Other trait, Digestive system disorder, Response to drug",initial,2018-06-19,GCST006209,Thiopurine-induced fever in inflammatory bowel disease
2541,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Response to drug, Other disease",initial,2018-06-19,GCST006210,Thiopurine-induced digestive symptoms in inflammatory bowel disease
2540,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Response to drug",initial,2018-06-19,GCST006212,Thiopurine-induced liver dysfunction in inflammatory bowel disease
2539,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Response to drug",initial,2018-06-19,GCST006208,Thiopurine-induced pancreatitis in inflammatory bowel disease
2538,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Other trait, Response to drug",initial,2018-06-19,GCST006204,Thiopurine-induced severe leukopenia in inflammatory bowel disease
2537,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Other trait, Response to drug",initial,2018-06-19,GCST006202,Thiopurine-induced leukopenia in inflammatory bowel disease (conditioned on rs116855232)
2536,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Other trait, Response to drug",initial,2018-06-19,GCST006201,Thiopurine-induced leukopenia in inflammatory bowel disease
2542,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Response to drug, Other measurement",initial,2018-06-19,GCST006211,Thiopurine-induced infection in inflammatory bowel disease
2892,Asian,1926.0,29921221.0,Cha S,Other measurement,replication,2018-06-19,GCST006107,Upper eyelid morphology
2894,Asian,1926.0,29921221.0,Cha S,"Other trait, Other measurement",replication,2018-06-19,GCST006108,Facial morphology
2899,Asian,1940.0,29921221.0,Cha S,Other measurement,replication,2018-06-19,GCST006110,Nose morphology
2535,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Other trait, Response to drug",initial,2018-06-19,GCST006200,Thiopurine-induced severe leukopenia in inflammatory bowel disease (conditioned on rs116855232)
2534,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Other disease, Response to drug",initial,2018-06-19,GCST006214,Thiopurine-induced alopecia in inflammatory bowel disease (conditioned on rs116855232)
2533,Asian,1220.0,29923122.0,Kakuta Y,"Digestive system disorder, Other disease, Response to drug",initial,2018-06-19,GCST006207,Thiopurine-induced severe alopecia in inflammatory bowel disease
10861,European,35953.0,29924316.0,Byun J,"Other measurement, Cancer",initial,2018-06-19,GCST006086,Familial lung cancer
2893,Asian,1926.0,29921221.0,Cha S,Other measurement,replication,2018-06-19,GCST006109,Lip morphology
2543,Asian,1220.0,29923122.0,Kakuta Y,"Other disease, Digestive system disorder, Response to drug",initial,2018-06-19,GCST006213,Thiopurine-induced skin symptoms in inflammatory bowel disease
9900,European,13353.0,29931343.0,Haworth S,Digestive system disorder,initial,2018-06-20,GCST006311,Childhood dental caries in permanent teeth
10169,European,17037.0,29931343.0,Haworth S,Digestive system disorder,initial,2018-06-20,GCST006312,Childhood dental caries in primary teeth
4753,European,172.0,29934777.0,Witten A,"Response to drug, Other trait",initial,2018-06-22,GCST006144,Heparin-induced thrombocytopenia
4809,European,192.0,29934777.0,Witten A,"Response to drug, Other trait",initial,2018-06-22,GCST006144,Heparin-induced thrombocytopenia
12427,European,504130.0,29936532.0,Colodro-Conde L,Other measurement,initial,2018-06-23,GCST007421,Population density of place of residence
12398,European,456426.0,29936532.0,Colodro-Conde L,Other measurement,initial,2018-06-23,GCST007422,Socioeconomic status of place of residence
12271,European,348219.0,29942085.0,Nagel M,"Other measurement, Other trait",initial,2018-06-25,GCST006478,Worry
12279,European,357957.0,29942085.0,Nagel M,Neurological disorder,initial,2018-06-25,GCST006475,Depressed affect
12383,European,449484.0,29942085.0,Nagel M,"Neurological disorder, Other measurement",initial,2018-06-25,GCST006476,Neuroticism
12137,European,269867.0,29942086.0,Savage JE,Biological process,initial,2018-06-25,GCST006250,Intelligence
12453,European,688809.0,29942085.0,Nagel M,"Neurological disorder, Other measurement",initial,2018-06-25,GCST006477,Depression
2925,Asian,1999.0,29953918.0,Deng C,Other measurement,initial,2018-06-25,GCST006137,Serum folate levels
1672,Asian,100.0,30065583.0,Choi MR,Other measurement,initial,2018-06-28,GCST006939,Skin hydration
4842,European,209.0,29959729.0,Zhong XL,Other measurement,initial,2018-06-29,GCST006279,Cerebrospinal fluid -synuclein levels
4147,Asian,13112.0,30304924.0,Kim HJ,Immune system disorder,replication,2018-06-30,GCST006809,Kawasaki disease
2569,Asian,1296.0,30304924.0,Kim HJ,Immune system disorder,initial,2018-06-30,GCST006809,Kawasaki disease
1008,African American or Afro-Caribbean,2589.0,30134085.0,Zhang H,Other measurement,initial,2018-07-01,GCST006406,Cognitive flexibility
7158,European,2284.0,30134085.0,Zhang H,Other measurement,initial,2018-07-01,GCST006406,Cognitive flexibility
3940,Asian,8832.0,30045251.0,Lee MR,"Body measurement, Other measurement",initial,2018-07-01,GCST006369,Body mass index
2126,Asian,511.0,30004843.0,Ge S,Other measurement,initial,2018-07-01,GCST006257,Elevated fasting plasma glucose
2322,Asian,781.0,29967481.0,Joo YB,"Immune system disorder, Other measurement",initial,2018-07-02,GCST006260,Childhood onset systemic lupus erythematosus
12425,European,487647.0,29970889.0,Day FR,Other measurement,initial,2018-07-03,GCST006924,Loneliness (MTAG)
12390,European,452302.0,29970889.0,Day FR,Other measurement,initial,2018-07-03,GCST006920,Regular attendance at a gym or sports club
12392,European,452302.0,29970889.0,Day FR,Other measurement,initial,2018-07-03,GCST006922,Regular attendance at a religious group
12372,European,445024.0,29970889.0,Day FR,Other measurement,initial,2018-07-03,GCST006923,Loneliness
12391,European,452302.0,29970889.0,Day FR,Other measurement,initial,2018-07-03,GCST006921,Regular attendance at a pub or social club
2712,Asian,1623.0,29970928.0,Zhu Z,Other measurement,initial,2018-07-03,GCST006254,Short-term memory (visuospatial task)
2856,Asian,1862.0,29970928.0,Zhu Z,Other measurement,replication,2018-07-03,GCST006256,Long-term memory (delayed word recall task)
12172,European,288950.0,29970889.0,Day FR,Other measurement,initial,2018-07-03,GCST006918,Social isolation
2676,Asian,1522.0,29970928.0,Zhu Z,Other measurement,initial,2018-07-03,GCST006256,Long-term memory (delayed word recall task)
12202,European,302567.0,29970889.0,Day FR,Other measurement,initial,2018-07-03,GCST006919,Ability to confide in someone
3179,Asian,2790.0,29970928.0,Zhu Z,Other measurement,replication,2018-07-03,GCST006254,Short-term memory (visuospatial task)
2713,Asian,1623.0,29970928.0,Zhu Z,Other measurement,initial,2018-07-03,GCST006255,Short-term memory (shared component of digit-span and visuospatial tasks)
3180,Asian,2790.0,29970928.0,Zhu Z,Other measurement,replication,2018-07-03,GCST006255,Short-term memory (shared component of digit-span and visuospatial tasks)
3175,Asian,2788.0,29970928.0,Zhu Z,"Biological process, Other measurement",replication,2018-07-03,GCST006253,Short-term memory (digit-span task)
10648,European,28599.0,29971594.0,Rosenberger A,"Cancer, Other measurement",initial,2018-07-03,GCST006413,Lung cancer x radon exposure interaction (1df)
2709,Asian,1621.0,29970928.0,Zhu Z,"Biological process, Other measurement",initial,2018-07-03,GCST006253,Short-term memory (digit-span task)
4830,European,204.0,29973135.0,Rimpela JM,"Other measurement, Cardiovascular disease",initial,2018-07-04,GCST006273,Diastolic blood pressure night-to-day ratio in hypertension
4831,European,204.0,29973135.0,Rimpela JM,"Other measurement, Cardiovascular disease",initial,2018-07-04,GCST006274,Systolic blood pressure night-to-day ratio in hypertension
1799,Asian,200.0,29975729.0,Kim TH,"Digestive system disorder, Other measurement",initial,2018-07-05,GCST006364,Hepatitis B surface antigen seroclearance in chronic hepatitis B infection
5189,European,434.0,29981864.0,Mohammadnejad A,"Immune system disorder, Other measurement",initial,2018-07-05,GCST008138,Allergic rhinitis x sex interaction
2039,Asian,421.0,30034349.0,Lin E,"Response to drug, Neurological disorder",initial,2018-07-06,GCST006267,Response to selective serotonin reuptake inhibitors in depression
2038,Asian,421.0,30034349.0,Lin E,"Response to drug, Neurological disorder",initial,2018-07-06,GCST006266,Remission after SSRI treatment in major depression
6144,European,1053.0,30289108.0,Li W,"Cancer, Other measurement",initial,2018-07-07,GCST008493,Prostate cancer mortality
6580,European,1552.0,30289108.0,Li W,"Cancer, Other measurement",replication,2018-07-07,GCST008493,Prostate cancer mortality
11540,European,91114.0,29988085.0,Merino J,Biological process,initial,2018-07-09,GCST006388,Dietary macronutrient intake
11981,European,177315.0,29988085.0,Merino J,Biological process,replication,2018-07-09,GCST006388,Dietary macronutrient intake
10068,European,15666.0,30003307.0,Fall T,"Cardiovascular disease, Metabolic disorder",initial,2018-07-12,GCST006405,Coronary artery disease in diabetes
10564,European,24953.0,30003630.0,Minica CC,"Biological process, Other measurement",initial,2018-07-13,GCST006386,Cannabis use (age at onset)
7981,European,3735.0,30003630.0,Minica CC,"Biological process, Other measurement",replication,2018-07-13,GCST006386,Cannabis use (age at onset)
4726,European,151.0,30013178.0,Kowalec K,"Immune system disorder, Response to drug, Digestive system disorder",initial,2018-07-16,GCST006270,Drug-induced liver injury in interferon-beta-treated multiple sclerosis
2401,Asian,935.0,30012571.0,Jia X,Other disease,initial,2018-07-16,GCST006246,Childhood steroid-sensitive nephrotic syndrome
4892,European,243.0,30014611.0,Weiss RB,"Neurological disorder, Other measurement",initial,2018-07-16,GCST006286,Age at loss of ambulation in Duchenne muscular dystrophy
2195,Asian,636.0,30012571.0,Jia X,Other disease,initial,2018-07-16,GCST006246,Childhood steroid-sensitive nephrotic syndrome
4567,European,31.0,30013178.0,Kowalec K,"Immune system disorder, Response to drug, Digestive system disorder",replication,2018-07-16,GCST006270,Drug-induced liver injury in interferon-beta-treated multiple sclerosis
1300,African American or Afro-Caribbean,7695.0,30012220.0,Prins BP,Cardiovascular measurement,initial,2018-07-17,GCST007104,QRS duration
1301,African American or Afro-Caribbean,7695.0,30012220.0,Prins BP,Cardiovascular measurement,initial,2018-07-17,GCST007105,QRS duration
11392,European,77898.0,30012220.0,Prins BP,Cardiovascular measurement,initial,2018-07-17,GCST007103,QRS duration
11636,European,111874.0,30012220.0,Prins BP,Cardiovascular measurement,replication,2018-07-17,GCST007104,QRS duration
5658,European,732.0,30145303.0,Kimbrel NA,Biological process,initial,2018-07-17,GCST006428,Suicide attempts
11393,European,77898.0,30012220.0,Prins BP,Cardiovascular measurement,initial,2018-07-17,GCST007104,QRS duration
5663,European,733.0,30145303.0,Kimbrel NA,"Biological process, Other measurement",initial,2018-07-17,GCST006429,Suicidal ideation
5009,European,331.0,30031151.0,Virtanen VB,Digestive system disorder,replication,2018-07-18,GCST006272,Hirschsprung disease
5298,European,491.0,30031151.0,Virtanen VB,Digestive system disorder,initial,2018-07-18,GCST006272,Hirschsprung disease
5223,European,454.0,30031151.0,Virtanen VB,Digestive system disorder,initial,2018-07-18,GCST006271,Hirschsprung disease
7475,European,2740.0,30079052.0,Rujescu D,Neurological disorder,initial,2018-07-20,GCST006275,Vestibular neuritis
12124,European,257841.0,30038396.0,Lee JJ,Other measurement,initial,2018-07-23,GCST006572,Cognitive performance
12335,European,402382.0,30038396.0,Lee JJ,Other measurement,initial,2018-07-23,GCST006570,Cognitive performance (MTAG)
12452,European,670471.0,30038396.0,Lee JJ,Biological process,initial,2018-07-23,GCST006569,Self-reported math ability (MTAG)
12477,European,1131881.0,30038396.0,Lee JJ,Other measurement,initial,2018-07-23,GCST006442,Educational attainment (years of education)
12436,European,564698.0,30038396.0,Lee JJ,Biological process,initial,2018-07-23,GCST006573,Self-reported math ability
12476,European,1131438.0,30038396.0,Lee JJ,Other measurement,initial,2018-07-23,GCST006571,Educational attainment (MTAG)
12465,European,811539.0,30038396.0,Lee JJ,Biological process,initial,2018-07-23,GCST006568,Highest math class taken (MTAG)
12359,European,430445.0,30038396.0,Lee JJ,Biological process,initial,2018-07-23,GCST006574,Highest math class taken
11548,European,92340.0,30046033.0,van Setten J,Cardiovascular measurement,initial,2018-07-25,GCST007045,PR interval
12330,European,394929.0,30048462.0,Kim SK,Other measurement,initial,2018-07-26,GCST006433,Heel bone mineral density
9319,European,8372.0,30049742.0,Terzikhan N,Other measurement,initial,2018-07-26,GCST006473,Diffusing capacity of the lung for carbon monoxide traits
12397,European,455607.0,30054458.0,Xue A,Metabolic disorder,initial,2018-07-27,GCST006868,Type 2 diabetes
11766,European,133492.0,30054594.0,MacGregor S,Other measurement,initial,2018-07-27,GCST006394,Intraocular pressure
11792,European,137086.0,30054594.0,MacGregor S,Neurological disorder,initial,2018-07-27,GCST006395,Glaucoma
12449,European,655666.0,30054458.0,Xue A,Metabolic disorder,initial,2018-07-27,GCST006867,Type 2 diabetes
2110,Asian,485.0,30054556.0,Akiyama M,"Neurological disorder, Response to drug",replication,2018-07-27,GCST006277,Response to ranibizumab in age-related macular degeneration (exudative)
6093,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006356,Anti-hepatitis B virus surface antigen (HBs) IgG seropositivity
6092,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006343,Anti-hepatitis B virus core antigen (HBc) IgG seropositivity
4766,European,175.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006363,Anti-Helicobacter pylori IgG levels
4657,European,91.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006345,Anti-Epstein-Barr virus early antigen (EA) IgG levels
6097,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006360,IgA levels
6079,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006330,Anti-Epstein-Barr virus early antigen (EA) IgG seropositivity
5998,European,956.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006362,Anti-Epstein-Barr virus viral capsid antigen (VCA) IgG levels
2046,Asian,434.0,30054556.0,Akiyama M,"Neurological disorder, Response to drug",initial,2018-07-27,GCST006277,Response to ranibizumab in age-related macular degeneration (exudative)
6080,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006331,Anti-cytomegalovirus IgG seropositivity
6082,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006333,Anti-Epstein-Barr virus viral capsid antigen (VCA) IgG seropositivity
6081,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006332,Anti-Epstein-Barr virus nuclear antigen (EBNA) IgG seropositivity
6087,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006338,Anti-Toxoplasma gondii IgG seropositivity
6088,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006339,Anti-influenza A virus IgG seropositivity
5339,European,508.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006354,Anti-hepatitis B virus surface antigen (HBs) IgG levels
6086,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006337,Anti-Helicobacter pylori IgG seropositivity
6084,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006335,Anti-herpes simplex virus 2 IgG seropositivity
6094,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006357,IgG levels
6095,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006358,IgE levels
4839,European,208.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006347,Anti-herpes simplex virus 2 IgG levels
6090,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006341,Anti-mumps virus IgG seropositivity
6091,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006342,Anti-rubella virus IgG seropositivity
5542,European,645.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006346,Anti-herpes simplex virus 1 IgG levels
3337,Asian,3650.0,30054458.0,Xue A,Metabolic disorder,initial,2018-07-27,GCST006867,Type 2 diabetes
6096,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006359,IgM levels
4560,European,15.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006355,Anti-hepatitis B virus core antigen (HBc) IgG levels
6083,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006334,Anti-herpes simplex virus 1 IgG seropositivity
6085,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006336,Anti-varicella zoster virus IgG seropositivity
5918,European,912.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006352,Anti-mumps virus IgG levels
5889,European,885.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006351,Anti-measles virus IgG levels
5732,European,777.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006350,Anti-influenza A virus IgG levels
1960,Asian,344.0,30060048.0,Wang SC,"Neurological disorder, Other measurement",initial,2018-07-27,GCST006856,Methadone dose in opioid dependence
5428,European,559.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006349,Anti-Toxoplasma gondii IgG levels
5962,European,935.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006353,Anti-rubella virus IgG levels
5948,European,931.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006348,Anti-varicella zoster virus IgG levels
6089,European,1000.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006340,Anti-measles virus IgG seropositivity
5920,European,914.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006361,Anti-Epstein-Barr virus nuclear antigen (EBNA) IgG levels
5037,European,347.0,30053915.0,Scepanovic P,Other measurement,initial,2018-07-27,GCST006344,Anti-cytomegalovirus IgG levels
11233,European,60552.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006481,Lung function (FEV1)
11234,European,60552.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006482,Lung function (FEV1/FVC)
11235,European,60552.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006483,Lung function (FVC)
12473,European,1030836.0,30061737.0,Nielsen JB,Cardiovascular disease,initial,2018-07-30,GCST006414,Atrial fibrillation
13205,Hispanic or Latin American,11775.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006483,Lung function (FVC)
4011,Asian,9959.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006481,Lung function (FEV1)
304,African,8429.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006482,Lung function (FEV1/FVC)
303,African,8429.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006481,Lung function (FEV1)
13204,Hispanic or Latin American,11775.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006482,Lung function (FEV1/FVC)
13203,Hispanic or Latin American,11775.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006481,Lung function (FEV1)
4012,Asian,9959.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006482,Lung function (FEV1/FVC)
4013,Asian,9959.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006483,Lung function (FVC)
305,African,8429.0,30061609.0,Wyss AB,Other measurement,initial,2018-07-30,GCST006483,Lung function (FVC)
5313,European,497.0,30066433.0,Jabbari E,Neurological disorder,initial,2018-07-31,GCST006276,Non-Richardson's syndrome vs Richardson's syndrome in progressive supranuclear palsy
8567,European,5293.0,30369316.0,Low-Kam C,Lipid or lipoprotein measurement,initial,2018-08-01,GCST007114,Cholesterol efflux capacity
8568,European,5293.0,30369316.0,Low-Kam C,Lipid or lipoprotein measurement,initial,2018-08-01,GCST007115,Cholesterol efflux capacity (cAMP stimulated assay)
7150,European,2270.0,30067744.0,Howe LJ,Other trait,initial,2018-08-01,GCST006415,Nonsyndromic cleft lip with or without cleft palate
6024,European,973.0,30098192.0,Shaaban S,Neurological disorder,initial,2018-08-01,GCST008738,Accommodative esotropia
5001,European,330.0,30098192.0,Shaaban S,Neurological disorder,replication,2018-08-01,GCST008738,Accommodative esotropia
2064,Asian,447.0,30067105.0,Chang LC,"Response to drug, Immune system disorder",initial,2018-08-01,GCST006278,Adverse response to antithyroid drugs in Graves disease
7032,European,2137.0,30098192.0,Shaaban S,Neurological disorder,replication,2018-08-01,GCST008741,Non-accommodative esotropia
7291,European,2467.0,30098192.0,Shaaban S,Other trait,replication,2018-08-01,GCST008737,Esotropia
8774,European,6136.0,30067744.0,Howe LJ,Other measurement,initial,2018-08-01,GCST006407,Philtrum width
8351,European,4790.0,30098192.0,Shaaban S,Other trait,initial,2018-08-01,GCST008737,Esotropia
8013,European,3817.0,30098192.0,Shaaban S,Neurological disorder,initial,2018-08-01,GCST008741,Non-accommodative esotropia
7003,European,2086.0,30098192.0,Shaaban S,Neurological disorder,initial,2018-08-01,GCST008739,Amblyopia
8569,European,5293.0,30369316.0,Low-Kam C,Lipid or lipoprotein measurement,initial,2018-08-01,GCST007116,Cholesterol efflux capacity (ABCA-1 dependent assay)
6986,European,2061.0,30098192.0,Shaaban S,"Other trait, Neurological disorder",initial,2018-08-01,GCST008740,Hyperopia
6660,European,1645.0,30068317.0,Li X,"Other measurement, Biological process",initial,2018-08-01,GCST006309,Post bronchodilator percent predicted FEV1 in smoking
5858,European,862.0,30098192.0,Shaaban S,"Other trait, Neurological disorder",replication,2018-08-01,GCST008740,Hyperopia
8570,European,5293.0,30369316.0,Low-Kam C,Lipid or lipoprotein measurement,initial,2018-08-01,GCST007117,Cholesterol efflux capacity (BHK stimulated assay)
4863,European,225.0,30098192.0,Shaaban S,Neurological disorder,replication,2018-08-01,GCST008739,Amblyopia
1776,Asian,182.0,30067105.0,Chang LC,"Response to drug, Immune system disorder",replication,2018-08-01,GCST006278,Adverse response to antithyroid drugs in Graves disease
6661,European,1645.0,30068317.0,Li X,"Other measurement, Biological process",initial,2018-08-01,GCST006310,Post bronchodilator FEV1/FVC ratio in smoking
10276,European,18770.0,30071075.0,Jiang L,Other measurement,initial,2018-08-02,GCST006403,Energy expenditure
5809,European,830.0,30196823.0,Blum S,Immune system disorder,initial,2018-08-02,GCST006836,Guillain-Barr syndrome
10275,European,18770.0,30071075.0,Jiang L,Other measurement,initial,2018-08-02,GCST006402,Energy intake
7685,European,3200.0,30072576.0,Emilsson V,"Other measurement, Hematological measurement, Lipid or lipoprotein measurement, Cardiovascular measurement, Liver enzyme measurement, Inflammatory measurement",initial,2018-08-02,GCST006585,Blood protein levels
8125,European,4098.0,30073298.0,Schellevis RL,Neurological disorder,initial,2018-08-02,GCST006416,Chronic central serous retinopathy
7652,European,3126.0,30070759.0,Olsson M,Other measurement,initial,2018-08-02,GCST006417,Plasma factor VII activating protease levels
12533,Hispanic or Latin American,77.0,30092369.0,Mainali B,Other disease,initial,2018-08-06,GCST008308,Infection persistence (>18 months) in genital human papillomavirus 16 infection
4653,European,90.0,30092369.0,Mainali B,Other disease,initial,2018-08-06,GCST008308,Infection persistence (>18 months) in genital human papillomavirus 16 infection
2648,Asian,1502.0,30099483.0,Hwangbo Y,Other disease,initial,2018-08-06,GCST006387,Thyroid nodules
3526,Asian,5081.0,30099483.0,Hwangbo Y,Other disease,replication,2018-08-06,GCST006387,Thyroid nodules
387,African American or Afro-Caribbean,24.0,30092369.0,Mainali B,Other disease,initial,2018-08-06,GCST008308,Infection persistence (>18 months) in genital human papillomavirus 16 infection
4677,European,98.0,30087447.0,Aubart M,"Neurological disorder, Cardiovascular disease",initial,2018-08-07,GCST006957,Severe aortic features in Marfan syndrome
10547,European,24196.0,30087453.0,Yilmaz Z,"Neurological disorder, Metabolic disorder",initial,2018-08-07,GCST006576,Anorexia nervosa or obsessive-compulsive disorder
9829,European,12308.0,30089514.0,Chen JA,Neurological disorder,initial,2018-08-08,GCST006418,Progressive supranuclear palsy
11713,European,121885.0,30093612.0,O'Mara TA,Cancer,initial,2018-08-09,GCST006464,Endometrial cancer
11175,European,54884.0,30093612.0,O'Mara TA,Cancer,initial,2018-08-09,GCST006465,Endometrial cancer (endometrioid histology)
8333,European,4735.0,30093639.0,Machiela MJ,Cancer,replication,2018-08-09,GCST006467,Ewing sarcoma
10877,European,36677.0,30093612.0,O'Mara TA,Cancer,initial,2018-08-09,GCST006466,Endometrial cancer (Non-endometrioid histology)
7001,European,2079.0,30093639.0,Machiela MJ,Cancer,initial,2018-08-09,GCST006467,Ewing sarcoma
4179,Asian,13980.0,30102679.0,Hara M,Biological process,initial,2018-08-10,GCST006857,Leisure-time exercise behaviour
2945,Asian,2036.0,30102679.0,Hara M,Biological process,initial,2018-08-10,GCST006858,Leisure-time exercise behaviour (age-stratified)
4180,Asian,13980.0,30102679.0,Hara M,Biological process,initial,2018-08-10,GCST006858,Leisure-time exercise behaviour (age-stratified)
2944,Asian,2036.0,30102679.0,Hara M,Biological process,initial,2018-08-10,GCST006857,Leisure-time exercise behaviour
12341,European,407757.0,30104761.0,Zhou W,Cancer,initial,2018-08-13,GCST008371,Thyroid cancer
10595,European,26271.0,30104567.0,Ji X,"Other measurement, Cancer",replication,2018-08-13,GCST006400,Lung cancer in ever smokers
12334,European,402223.0,30104761.0,Zhou W,Neurological disorder,initial,2018-08-13,GCST008373,Glaucoma
5210,European,444.0,30103242.0,Karhausen JA,Other trait,initial,2018-08-13,GCST006435,Thrombocytopenia in coronary artery bypass surgery
5065,European,368.0,30102696.0,Chen Y,Digestive system disorder,replication,2018-08-13,GCST006390,Biliary atresia
12319,European,387318.0,30104761.0,Zhou W,Cancer,initial,2018-08-13,GCST008372,Colorectal cancer
10753,European,32465.0,30104567.0,Ji X,Cancer,replication,2018-08-13,GCST006399,Lung cancer
12343,European,408458.0,30104761.0,Zhou W,Cardiovascular disease,initial,2018-08-13,GCST008370,Coronary artery disease
5716,European,759.0,30104601.0,Ren H,"Other measurement, Neurological disorder",initial,2018-08-13,GCST006927,Anhedonia in major depressive disorder
6985,European,2059.0,30102696.0,Chen Y,Digestive system disorder,initial,2018-08-13,GCST006390,Biliary atresia
9373,European,8669.0,30104567.0,Ji X,"Other measurement, Cancer",initial,2018-08-13,GCST006400,Lung cancer in ever smokers
9636,European,10473.0,30104567.0,Ji X,Cancer,initial,2018-08-13,GCST006398,Lung cancer (SNP x SNP interaction)
9637,European,10473.0,30104567.0,Ji X,Cancer,initial,2018-08-13,GCST006399,Lung cancer
4743,European,164.0,30103242.0,Karhausen JA,Other trait,initial,2018-08-13,GCST006435,Thrombocytopenia in coronary artery bypass surgery
1080,African American or Afro-Caribbean,3069.0,30108127.0,Hoffmann TJ,"Body measurement, Other measurement",initial,2018-08-14,GCST006368,Body mass index
5002,European,330.0,30108209.0,Ganjgahi H,Other measurement,initial,2018-08-14,GCST006389,Brain imaging measurements
13858,Other/Mixed,1353.0,30108155.0,Hebbar P,Lipid or lipoprotein measurement,initial,2018-08-14,GCST006439,Total cholesterol levels
3984,Asian,9275.0,30108127.0,Hoffmann TJ,"Body measurement, Other measurement",replication,2018-08-14,GCST006368,Body mass index
13813,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,"Other measurement, Body measurement",initial,2018-08-14,GCST007056,Waist-hip ratio
12221,European,315347.0,30108127.0,Hoffmann TJ,"Body measurement, Other measurement",initial,2018-08-14,GCST006368,Body mass index
302,African,8261.0,30108127.0,Hoffmann TJ,"Body measurement, Other measurement",replication,2018-08-14,GCST006368,Body mass index
13830,Other/Mixed,1176.0,30108155.0,Hebbar P,Lipid or lipoprotein measurement,replication,2018-08-14,GCST006438,High density lipoprotein cholesterol levels
13831,Other/Mixed,1176.0,30108155.0,Hebbar P,Lipid or lipoprotein measurement,replication,2018-08-14,GCST006439,Total cholesterol levels
13150,Hispanic or Latin American,8322.0,30108127.0,Hoffmann TJ,"Body measurement, Other measurement",initial,2018-08-14,GCST006368,Body mass index
11389,European,77440.0,30120083.0,Ferguson A,Biological process,initial,2018-08-14,GCST006397,Relative amplitude of rest-activity cycles
13828,Other/Mixed,1176.0,30108155.0,Hebbar P,Lipid or lipoprotein measurement,replication,2018-08-14,GCST006436,Triglyceride levels
13808,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,Body measurement,initial,2018-08-14,GCST007055,Waist circumference
13807,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,Body measurement,initial,2018-08-14,GCST007054,Weight
13810,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,"Body measurement, Other measurement",initial,2018-08-14,GCST007053,Body mass index
13814,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,"Other measurement, Body measurement",initial,2018-08-14,GCST007057,Height
13809,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,Body measurement,initial,2018-08-14,GCST007058,Hip circumference
13855,Other/Mixed,1353.0,30108155.0,Hebbar P,Lipid or lipoprotein measurement,initial,2018-08-14,GCST006436,Triglyceride levels
3793,Asian,7290.0,30108127.0,Hoffmann TJ,"Body measurement, Other measurement",initial,2018-08-14,GCST006368,Body mass index
12360,European,431743.0,30108127.0,Hoffmann TJ,"Body measurement, Other measurement",replication,2018-08-14,GCST006368,Body mass index
2831,Asian,1822.0,30108127.0,Hoffmann TJ,"Body measurement, Other measurement",replication,2018-08-14,GCST006368,Body mass index
2074,Asian,459.0,30108127.0,Hoffmann TJ,"Body measurement, Other measurement",initial,2018-08-14,GCST006368,Body mass index
13829,Other/Mixed,1176.0,30108155.0,Hebbar P,Lipid or lipoprotein measurement,replication,2018-08-14,GCST006437,Low density lipoprotein cholesterol levels
13812,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,Lipid or lipoprotein measurement,initial,2018-08-14,GCST007052,Lipoprotein (a) levels
13856,Other/Mixed,1353.0,30108155.0,Hebbar P,Lipid or lipoprotein measurement,initial,2018-08-14,GCST006437,Low density lipoprotein cholesterol levels
13857,Other/Mixed,1353.0,30108155.0,Hebbar P,Lipid or lipoprotein measurement,initial,2018-08-14,GCST006438,High density lipoprotein cholesterol levels
11342,European,71500.0,30120083.0,Ferguson A,Biological process,initial,2018-08-14,GCST006396,Disrupted circadian rhythm (low relative amplitude of rest-activity cycles)
13811,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,Cardiovascular measurement,initial,2018-08-14,GCST007051,Pulse rate
8193,European,4298.0,30111768.0,Yao C,"Other measurement, Hematological measurement, Lipid or lipoprotein measurement, Cardiovascular measurement, Liver enzyme measurement, Inflammatory measurement",replication,2018-08-15,GCST007128,Blood protein levels
8941,European,6861.0,30111768.0,Yao C,"Other measurement, Hematological measurement, Lipid or lipoprotein measurement, Cardiovascular measurement, Liver enzyme measurement, Inflammatory measurement",initial,2018-08-15,GCST007128,Blood protein levels
13755,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006517,Nose morphology (partial least square model)
13756,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006518,Mouth morphology (partial least square model)
13738,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006500,Nosetip height
13545,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006517,Nose morphology (partial least square model)
4771,European,177.0,30113228.0,Torgerson DG,"Other disease, Other trait",initial,2018-08-16,GCST006460,Bronchopulmonary dysplasia in preterm infants
13753,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006515,Side of face morphology (partial least square model)
11105,European,50264.0,30116032.0,Erlangsen A,Biological process,initial,2018-08-16,GCST006419,Suicide attempts
13746,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006508,Eye morphology (principal component model)
13754,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006516,Cheek morphology (partial least square model)
13546,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006518,Mouth morphology (partial least square model)
13745,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006507,Lower face length
13751,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006513,Brow ridge morphology (partial least square model)
13748,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006510,Cheek morphology (principal component model)
13741,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006503,Eye length
13740,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006502,Nasal root height
13742,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006504,Interorbital distance
13747,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006509,Side of face morphology (principal component model)
13744,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006506,Lip thickness
13737,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006499,Nose length
2650,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006498,Brow ridge morphology (principal component model)
13752,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006514,Eye morphology (partial least square model)
2651,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006499,Nose length
10207,European,17596.0,30116032.0,Erlangsen A,"Biological process, Neurological disorder",initial,2018-08-16,GCST006420,Affective disorder and suicide attempts
2649,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006497,Nose wing breadth
13749,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006511,Nose morphology (principal component model)
2652,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006500,Nosetip height
2653,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006501,Nasal root breadth
2654,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006502,Nasal root height
13739,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006501,Nasal root breadth
13750,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006512,Mouth morphology (principal component model)
12400,European,456426.0,30124842.0,Yengo L,"Other measurement, Body measurement",initial,2018-08-16,GCST006901,Height
12399,European,456426.0,30124842.0,Yengo L,"Body measurement, Other measurement",initial,2018-08-16,GCST006900,Body mass index
13542,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006514,Eye morphology (partial least square model)
2656,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006504,Interorbital distance
13525,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006497,Nose wing breadth
13526,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006498,Brow ridge morphology (principal component model)
13527,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006499,Nose length
13528,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006500,Nosetip height
12522,Hispanic or Latin American,42.0,30113228.0,Torgerson DG,"Other disease, Other trait",initial,2018-08-16,GCST006460,Bronchopulmonary dysplasia in preterm infants
2660,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006508,Eye morphology (principal component model)
13529,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006501,Nasal root breadth
13530,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006502,Nasal root height
2669,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006517,Nose morphology (partial least square model)
2655,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006503,Eye length
13531,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006503,Eye length
13532,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006504,Interorbital distance
13537,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006509,Side of face morphology (principal component model)
2667,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006515,Side of face morphology (partial least square model)
13533,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006505,Labial fissure length
2666,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006514,Eye morphology (partial least square model)
2665,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006513,Brow ridge morphology (partial least square model)
13534,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006506,Lip thickness
2668,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006516,Cheek morphology (partial least square model)
13535,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006507,Lower face length
2670,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006518,Mouth morphology (partial least square model)
13539,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006511,Nose morphology (principal component model)
2664,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006512,Mouth morphology (principal component model)
2657,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006505,Labial fissure length
13544,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006516,Cheek morphology (partial least square model)
13735,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006497,Nose wing breadth
13736,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006498,Brow ridge morphology (principal component model)
13743,Other/Mixed,694.0,30174134.0,Qiao L,Other measurement,initial,2018-08-16,GCST006505,Labial fissure length
13538,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006510,Cheek morphology (principal component model)
2658,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006506,Lip thickness
13541,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006513,Brow ridge morphology (partial least square model)
2659,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006507,Lower face length
13540,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006512,Mouth morphology (principal component model)
13543,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006515,Side of face morphology (partial least square model)
2662,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006510,Cheek morphology (principal component model)
2661,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006509,Side of face morphology (principal component model)
475,African American or Afro-Caribbean,133.0,30113228.0,Torgerson DG,"Other disease, Other trait",initial,2018-08-16,GCST006460,Bronchopulmonary dysplasia in preterm infants
2663,Asian,1504.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006511,Nose morphology (principal component model)
13536,Other/Mixed,171.0,30174134.0,Qiao L,Other measurement,replication,2018-08-16,GCST006508,Eye morphology (principal component model)
1758,Asian,166.0,30120336.0,Kikuchi M,Other measurement,initial,2018-08-17,GCST006458,Eye movement (horizontal position gain)
1757,Asian,166.0,30120336.0,Kikuchi M,Other measurement,initial,2018-08-17,GCST006456,Eye movement (scanpath length)
1756,Asian,166.0,30120336.0,Kikuchi M,Other measurement,initial,2018-08-17,GCST006453,Eye movement (duration of fixations)
1755,Asian,166.0,30120336.0,Kikuchi M,Other measurement,initial,2018-08-17,GCST006450,Eye movement (integrated eye movement score)
1841,Asian,226.0,30120336.0,Kikuchi M,Other measurement,initial,2018-08-17,GCST006449,Eye movement (integrated eye movement score)
1619,Asian,60.0,30120336.0,Kikuchi M,"Neurological disorder, Other measurement",initial,2018-08-17,GCST006459,Eye movement in schizophrenia (scanpath length)
12651,Hispanic or Latin American,462.0,30120420.0,Sun R,Other measurement,initial,2018-08-17,GCST006441,Mental composite score
1842,Asian,226.0,30120336.0,Kikuchi M,Other measurement,initial,2018-08-17,GCST006452,Eye movement (duration of fixations)
1843,Asian,226.0,30120336.0,Kikuchi M,Other measurement,initial,2018-08-17,GCST006455,Eye movement (scanpath length)
1844,Asian,226.0,30120336.0,Kikuchi M,Other measurement,initial,2018-08-17,GCST006457,Eye movement (horizontal position gain)
1618,Asian,60.0,30120336.0,Kikuchi M,"Neurological disorder, Other measurement",initial,2018-08-17,GCST006454,Eye movement in schizophrenia (duration of fixations)
12650,Hispanic or Latin American,462.0,30120420.0,Sun R,Other measurement,initial,2018-08-17,GCST006440,Motor composite score
1616,Asian,60.0,30120336.0,Kikuchi M,"Neurological disorder, Other measurement",initial,2018-08-17,GCST006448,Eye movement in schizophrenia (horizontal position gain)
4609,European,70.0,30120429.0,Schlauch KA,Metabolic disorder,initial,2018-08-17,GCST006492,Obesity without metabolic disease
2120,Asian,502.0,30120420.0,Sun R,Other measurement,initial,2018-08-17,GCST006440,Motor composite score
1617,Asian,60.0,30120336.0,Kikuchi M,"Neurological disorder, Other measurement",initial,2018-08-17,GCST006451,Eye movement in schizophrenia (integrated eye movement score)
2121,Asian,502.0,30120420.0,Sun R,Other measurement,initial,2018-08-17,GCST006441,Mental composite score
13496,Other/Mixed,92.0,30130595.0,Dominguez-Cruz MG,Metabolic disorder,initial,2018-08-18,GCST006484,Type 2 diabetes
13785,Other/Mixed,790.0,30134952.0,Traglia M,Other measurement,initial,2018-08-22,GCST006625,Neonatal cytokine/chemokine levels (maternal genetic effect)
2986,Asian,2148.0,30132804.0,Kim M,Lipid or lipoprotein measurement,initial,2018-08-22,GCST006860,Low HDL-cholesterol levels
13780,Other/Mixed,764.0,30134952.0,Traglia M,Other measurement,initial,2018-08-22,GCST006623,Midgestational cytokine/chemokine levels (fetal genetic effect)
13781,Other/Mixed,764.0,30134952.0,Traglia M,"Other measurement, Inflammatory measurement",initial,2018-08-22,GCST006622,Neonatal cytokine/chemokine levels (fetal genetic effect)
13786,Other/Mixed,790.0,30134952.0,Traglia M,"Other measurement, Inflammatory measurement",initial,2018-08-22,GCST006621,Midgestational cytokine/chemokine levels (maternal genetic effect)
3449,Asian,4477.0,30294719.0,Zeng Y,Other measurement,initial,2018-08-24,GCST006658,Longevity
11991,European,184756.0,30150663.0,Pasman JA,Biological process,initial,2018-08-27,GCST006421,Cannabis use
10687,European,29928.0,30169657.0,Ashar FN,Cardiovascular disease,initial,2018-08-28,GCST006401,Sudden cardiac arrest
2041,Asian,424.0,30169657.0,Ashar FN,Cardiovascular disease,replication,2018-08-28,GCST006401,Sudden cardiac arrest
14028,Other/Mixed,40333.0,30169657.0,Ashar FN,Cardiovascular disease,replication,2018-08-28,GCST006401,Sudden cardiac arrest
7662,European,3146.0,30153862.0,Maxwell TJ,Other measurement,initial,2018-08-28,GCST007129,Cerebrospinal fluid t-tau:AB1-42 ratio
589,African American or Afro-Caribbean,328.0,30169657.0,Ashar FN,Cardiovascular disease,replication,2018-08-28,GCST006401,Sudden cardiac arrest
7663,European,3146.0,30153862.0,Maxwell TJ,Other measurement,initial,2018-08-28,GCST007130,Cerebrospinal fluid t-tau:AB1-42 ratio
13869,Other/Mixed,1468.0,30158200.0,Trajanoska K,Other disease,replication,2018-08-29,GCST006422,Fractures
11025,European,44108.0,30158200.0,Trajanoska K,Other disease,replication,2018-08-29,GCST006422,Fractures
2331,Asian,800.0,30158200.0,Trajanoska K,Other disease,initial,2018-08-29,GCST006422,Fractures
2332,Asian,800.0,30158200.0,Trajanoska K,Other disease,initial,2018-08-29,GCST006423,Fractures
3554,Asian,5281.0,30158200.0,Trajanoska K,Other disease,replication,2018-08-29,GCST006422,Fractures
12183,European,297285.0,30158200.0,Trajanoska K,Other disease,replication,2018-08-29,GCST006423,Fractures
12131,European,264173.0,30158200.0,Trajanoska K,Other disease,initial,2018-08-29,GCST006423,Fractures
12130,European,264173.0,30158200.0,Trajanoska K,Other disease,initial,2018-08-29,GCST006422,Fractures
1906,Asian,275.0,30161160.0,Onishi H,"Other measurement, Cancer, Response to drug",initial,2018-08-30,GCST006615,Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer
7166,European,2286.0,30172743.0,Liang X,Other measurement,initial,2018-08-30,GCST006447,Bone mineral density (spine)
7165,European,2286.0,30172743.0,Liang X,Other measurement,initial,2018-08-30,GCST006446,Ulna and radius bone mineral density
7164,European,2286.0,30172743.0,Liang X,Other measurement,initial,2018-08-30,GCST006445,Femoral neck bone mineral density
12251,European,336107.0,30166351.0,Galvan-Femenia I,Other measurement,replication,2018-08-30,GCST007490,Anthropometric traits (multi-trait analysis)
7163,European,2286.0,30172743.0,Liang X,Other measurement,initial,2018-08-30,GCST006444,Bone mineral density (hip)
1625,Asian,72.0,30161160.0,Onishi H,"Other measurement, Cancer, Response to drug",replication,2018-08-30,GCST006615,Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer
8453,European,4988.0,30166351.0,Galvan-Femenia I,Other trait,initial,2018-08-30,GCST007482,Handedness
7162,European,2286.0,30172743.0,Liang X,Other measurement,initial,2018-08-30,GCST006443,Total body bone mineral density
13346,Other/Mixed,1.0,30160337.0,Asleh R,"Other measurement, Biological process",initial,2018-08-30,GCST006496,Glomerular filtration rate change in heart transplantation
4893,European,243.0,30160337.0,Asleh R,"Other measurement, Biological process",initial,2018-08-30,GCST006496,Glomerular filtration rate change in heart transplantation
8452,European,4988.0,30166351.0,Galvan-Femenia I,Other trait,initial,2018-08-30,GCST007480,Disorders of lipid metabolism
8450,European,4988.0,30166351.0,Galvan-Femenia I,Other measurement,initial,2018-08-30,GCST007490,Anthropometric traits (multi-trait analysis)
8451,European,4988.0,30166351.0,Galvan-Femenia I,"Other measurement, Body measurement",initial,2018-08-30,GCST007485,Anthropometric traits
12252,European,336107.0,30166351.0,Galvan-Femenia I,"Other measurement, Body measurement",replication,2018-08-30,GCST007485,Anthropometric traits
12055,European,212444.0,30172742.0,Hu Y,"Other measurement, Metabolic disorder",initial,2018-08-30,GCST006861,Femoral neck bone mineral density or type 2 diabetes (pleiotropy)
8455,European,4988.0,30166351.0,Galvan-Femenia I,Other trait,initial,2018-08-30,GCST007489,Eye color traits
8454,European,4988.0,30166351.0,Galvan-Femenia I,Other trait,initial,2018-08-30,GCST007488,Skin pigmentation traits
8448,European,4988.0,30166351.0,Galvan-Femenia I,Cardiovascular measurement,initial,2018-08-30,GCST007481,Heart rate
8449,European,4988.0,30166351.0,Galvan-Femenia I,Other measurement,initial,2018-08-30,GCST007486,Hair morphology traits
6705,European,1709.0,30166627.0,Massey J,"Other trait, Immune system disorder, Response to drug",initial,2018-08-31,GCST006608,Response to TNF inhibitor in rheumatoid arthritis (change in patient global heath assessment score)
6595,European,1569.0,30166627.0,Massey J,"Immune system disorder, Response to drug, Other measurement",initial,2018-08-31,GCST006610,Response to TNF inhibitor in rheumatoid arthritis (change in disease activity score)
6725,European,1723.0,30166627.0,Massey J,"Immune system disorder, Response to drug, Other measurement",initial,2018-08-31,GCST006609,Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count)
6724,European,1723.0,30166627.0,Massey J,"Immune system disorder, Response to drug, Other measurement",initial,2018-08-31,GCST006606,Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)
2466,Asian,1052.0,30169916.0,Sun Y,Immune system disorder,replication,2018-08-31,GCST006521,Pemphigus vulgaris
2389,Asian,909.0,30169916.0,Sun Y,Immune system disorder,initial,2018-08-31,GCST006520,Pemphigus foliaceus
2461,Asian,1045.0,30169916.0,Sun Y,Immune system disorder,replication,2018-08-31,GCST006520,Pemphigus foliaceus
6527,European,1514.0,30166627.0,Massey J,"Inflammatory measurement, Immune system disorder, Response to drug",initial,2018-08-31,GCST006607,Response to TNF inhibitor in rheumatoid arthritis (erythrocyte sedimentation rate)
2407,Asian,945.0,30169916.0,Sun Y,Immune system disorder,initial,2018-08-31,GCST006521,Pemphigus vulgaris
13851,Other/Mixed,1301.0,30196971.0,Bray MJ,Other measurement,initial,2018-09-01,GCST006618,Uterine fibroid size (maximum dimension)
1786,Asian,190.0,30088374.0,Park HW,Other disease,replication,2018-09-01,GCST008492,Severe cutaneous adverse drug reactions
1959,Asian,340.0,30088374.0,Park HW,Other disease,initial,2018-09-01,GCST008492,Severe cutaneous adverse drug reactions
12345,European,409728.0,30177863.0,Maguire LH,Digestive system disorder,initial,2018-09-03,GCST006479,Diverticular disease
3779,Asian,7031.0,30181555.0,Strawbridge RJ,Biological process,replication,2018-09-04,GCST006461,Self-reported risk-taking behaviour
1293,African American or Afro-Caribbean,7480.0,30181555.0,Strawbridge RJ,Biological process,replication,2018-09-04,GCST006461,Self-reported risk-taking behaviour
12240,European,328339.0,30181555.0,Strawbridge RJ,Biological process,initial,2018-09-04,GCST006461,Self-reported risk-taking behaviour
11080,European,47983.0,30181555.0,Strawbridge RJ,Biological process,replication,2018-09-04,GCST006461,Self-reported risk-taking behaviour
8428,European,4941.0,30181573.0,Jing J,"Other disease, Metabolic disorder",initial,2018-09-04,GCST006425,Gout in chronic kidney disease
8429,European,4941.0,30181573.0,Jing J,"Other disease, Other measurement",initial,2018-09-04,GCST006426,Serum urate levels in chronic kidney disease
8307,European,4666.0,30178632.0,Meng W,Metabolic disorder,initial,2018-09-04,GCST006424,Severe diabetic retinopathy in type 2 diabetes
664,African American or Afro-Caribbean,492.0,30185882.0,Zeiger AM,Other measurement,initial,2018-09-05,GCST006485,Telomere length
12203,European,302687.0,30220432.0,Haas ME,Other trait,initial,2018-09-06,GCST006463,Urinary albumin excretion (no hypertensive medication)
12314,European,382500.0,30220432.0,Haas ME,Other trait,initial,2018-09-06,GCST006586,Urinary albumin excretion
1091,African American or Afro-Caribbean,3140.0,30219690.0,Heinzman JT,"Biological process, Neurological disorder",initial,2018-09-07,GCST006427,Depression in smokers
12431,European,539925.0,30194396.0,Rafnar T,Cancer,initial,2018-09-07,GCST006462,Uterine fibroids
11032,European,44871.0,30202859.0,Laisk T,Other measurement,initial,2018-09-07,GCST006958,Length of menstrual cycle
8867,European,6576.0,30219690.0,Heinzman JT,"Biological process, Neurological disorder",initial,2018-09-07,GCST006427,Depression in smokers
10631,European,27750.0,30194254.0,Sud A,Cancer,initial,2018-09-07,GCST007062,Hodgkin's lymphoma
11894,European,156028.0,30270018.0,Zhang Q,"Cardiovascular disease, Metabolic disorder",initial,2018-09-09,GCST007359,Type 2 diabetes or coronary artery disease (pleiotropy)
6219,European,1141.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",replication,2018-09-10,GCST008102,Pulmonary function (FEV1) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
121,African,546.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",replication,2018-09-10,GCST008100,Pulmonary function (FVC) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
140,African,797.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",initial,2018-09-10,GCST008102,Pulmonary function (FEV1) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
9726,European,11165.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",initial,2018-09-10,GCST008099,Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
5209,European,443.0,30201983.0,Tulstrup M,"Response to drug, Cancer, Other measurement",initial,2018-09-10,GCST007151,DNA-incorporated thioguanine to erythrocyte thioguanine ratio in 6-mercaptopurine-treated acute lymphoblastic leukaemia
139,African,797.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",initial,2018-09-10,GCST008101,Pulmonary function (FEV1) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
120,African,546.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",replication,2018-09-10,GCST008099,Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
6216,European,1141.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",replication,2018-09-10,GCST008099,Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
9728,European,11165.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",initial,2018-09-10,GCST008101,Pulmonary function (FEV1) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
123,African,546.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",replication,2018-09-10,GCST008102,Pulmonary function (FEV1) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
6217,European,1141.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",replication,2018-09-10,GCST008100,Pulmonary function (FVC) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
4709,European,136.0,30201983.0,Tulstrup M,"Response to drug, Cancer, Other measurement",replication,2018-09-10,GCST007151,DNA-incorporated thioguanine to erythrocyte thioguanine ratio in 6-mercaptopurine-treated acute lymphoblastic leukaemia
5224,European,454.0,30201983.0,Tulstrup M,"Response to drug, Cancer, Other measurement",initial,2018-09-10,GCST007149,Erythrocyte methylated 6-mercaptopurine metabolite concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia
6218,European,1141.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",replication,2018-09-10,GCST008101,Pulmonary function (FEV1) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
5221,European,452.0,30201983.0,Tulstrup M,"Response to drug, Cancer, Other measurement",initial,2018-09-10,GCST007148,Erythrocyte thioguanine concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia
5208,European,443.0,30201983.0,Tulstrup M,"Response to drug, Cancer, Other measurement",initial,2018-09-10,GCST007150,DNA-incorporated thioguanine levels in 6-mercaptopurine-treated acute lymphoblastic leukaemia
137,African,797.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",initial,2018-09-10,GCST008099,Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
122,African,546.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",replication,2018-09-10,GCST008101,Pulmonary function (FEV1) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
9729,European,11165.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",initial,2018-09-10,GCST008102,Pulmonary function (FEV1) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)
138,African,797.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",initial,2018-09-10,GCST008100,Pulmonary function (FVC) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
6552,European,1533.0,30202041.0,Otani T,"Cardiovascular disease, Biological process, Cardiovascular measurement",initial,2018-09-10,GCST007366,Homocysteine level response to multivitamin in cerebral infarction
9727,European,11165.0,30199657.0,Xu J,"Other measurement, Lipid or lipoprotein measurement",initial,2018-09-10,GCST008100,Pulmonary function (FVC) x omega-3 PUFA (docosapentaenoic acid) interaction (2df)
8405,European,4910.0,30206230.0,Offenbacher S,Inflammatory measurement,initial,2018-09-11,GCST007542,High IL-1beta levels in gingival crevicular fluid
769,African American or Afro-Caribbean,949.0,30206298.0,Spear ML,"Response to drug, Other disease",initial,2018-09-12,GCST007360,Bronchodilator response in asthma
12628,Hispanic or Latin American,416.0,30206298.0,Spear ML,"Response to drug, Other disease",replication,2018-09-12,GCST007360,Bronchodilator response in asthma
12855,Hispanic or Latin American,1830.0,30206298.0,Spear ML,"Response to drug, Other disease",initial,2018-09-12,GCST007360,Bronchodilator response in asthma
902,African American or Afro-Caribbean,1615.0,30206298.0,Spear ML,"Response to drug, Other disease",replication,2018-09-12,GCST007360,Bronchodilator response in asthma
9149,European,7865.0,30213928.0,Went M,Cancer,replication,2018-09-13,GCST006432,Multiple myeloma
4238,Asian,16533.0,30219835.0,Lin WY,"Biological process, Other measurement",initial,2018-09-13,GCST007618,Blood pressure (smoking interaction)
12110,European,249665.0,30213928.0,Went M,Cancer,initial,2018-09-13,GCST006432,Multiple myeloma
4239,Asian,16543.0,30219835.0,Lin WY,Other measurement,initial,2018-09-13,GCST007617,Blood pressure x alcohol consumption interaction
8026,European,3844.0,30217971.0,Ho KWD,"Neurological disorder, Other measurement",initial,2018-09-14,GCST007101,Seasonality in depression
7255,European,2412.0,30218097.0,Munz M,Digestive system disorder,replication,2018-09-14,GCST006486,Periodontitis
9851,European,12591.0,30218097.0,Munz M,Digestive system disorder,initial,2018-09-14,GCST006486,Periodontitis
1624,Asian,71.0,30277654.0,Yokoshima Y,"Cancer, Response to drug",initial,2018-09-14,GCST007106,Response to opioid analgesics in cancer (pain decrease)
8199,European,4317.0,30217971.0,Ho KWD,"Neurological disorder, Other measurement",initial,2018-09-14,GCST007102,Seasonality and depression
10142,European,16624.0,30217807.0,Robinson-Cohen C,Other measurement,initial,2018-09-14,GCST006491,Circulating fibroblast growth factor 23 levels
273,African,4443.0,30217807.0,Robinson-Cohen C,Other measurement,replication,2018-09-14,GCST006491,Circulating fibroblast growth factor 23 levels
5555,European,653.0,31277774.0,Lipunova N,"Cancer, Other measurement",initial,2018-09-15,GCST008220,Non-muscle-invasive bladder cancer tumour stage (Tis/T1 vs Ta)
5540,European,643.0,31277774.0,Lipunova N,"Cancer, Other measurement",initial,2018-09-15,GCST008221,Non-muscle-invasive bladder cancer tumour grade (G3 vs G2/G1)
6385,European,1323.0,31277774.0,Lipunova N,"Cancer, Other measurement",replication,2018-09-15,GCST008221,Non-muscle-invasive bladder cancer tumour grade (G3 vs G2/G1)
5528,European,633.0,31277774.0,Lipunova N,"Cancer, Other measurement",initial,2018-09-15,GCST008216,Non-muscle-invasive bladder cancer tumour size
4966,European,302.0,31277774.0,Lipunova N,"Cancer, Other measurement",replication,2018-09-15,GCST008216,Non-muscle-invasive bladder cancer tumour size
5554,European,653.0,31277774.0,Lipunova N,"Cancer, Other measurement",initial,2018-09-15,GCST008218,Non-muscle-invasive bladder cancer age at diagnosis (< 70 years vs  70 years)
4967,European,302.0,31277774.0,Lipunova N,"Cancer, Other measurement",replication,2018-09-15,GCST008219,Non-muscle-invasive bladder cancer tumour size (< 3 cm vs  3 cm)
6502,European,1470.0,31277774.0,Lipunova N,"Cancer, Other measurement",replication,2018-09-15,GCST008217,Non-muscle-invasive bladder cancer age at diagnosis
5556,European,653.0,31277774.0,Lipunova N,"Cancer, Other measurement",initial,2018-09-15,GCST008222,Non-muscle-invasive bladder cancer EORTC risk category
5553,European,653.0,31277774.0,Lipunova N,"Cancer, Other measurement",initial,2018-09-15,GCST008217,Non-muscle-invasive bladder cancer age at diagnosis
5529,European,633.0,31277774.0,Lipunova N,"Cancer, Other measurement",initial,2018-09-15,GCST008219,Non-muscle-invasive bladder cancer tumour size (< 3 cm vs  3 cm)
6503,European,1470.0,31277774.0,Lipunova N,"Cancer, Other measurement",replication,2018-09-15,GCST008218,Non-muscle-invasive bladder cancer age at diagnosis (< 70 years vs  70 years)
6504,European,1470.0,31277774.0,Lipunova N,"Cancer, Other measurement",replication,2018-09-15,GCST008220,Non-muscle-invasive bladder cancer tumour stage (Tis/T1 vs Ta)
12458,European,757601.0,30224653.0,Evangelou E,Cardiovascular measurement,initial,2018-09-17,GCST006629,Pulse pressure
12462,European,757601.0,30224653.0,Evangelou E,Other measurement,initial,2018-09-17,GCST006630,Diastolic blood pressure
12107,European,249262.0,30224653.0,Evangelou E,Cardiovascular measurement,replication,2018-09-17,GCST006629,Pulse pressure
5795,European,823.0,30255771.0,Sarnowski C,"Response to drug, Other measurement, Lipid or lipoprotein measurement",initial,2018-09-17,GCST007660,Triglyceride levels in response to fenofibrate treatment (parental genotype effect)
5791,European,823.0,30255771.0,Sarnowski C,"Other measurement, Lipid or lipoprotein measurement",initial,2018-09-17,GCST007658,Triglyceride levels (parental genotype effect)
5793,European,823.0,30255771.0,Sarnowski C,"Response to drug, Lipid or lipoprotein measurement",initial,2018-09-17,GCST007663,Triglyceride change in response to fenofibrate treatment
6925,European,1999.0,30223776.0,Hwang LD,Biological process,initial,2018-09-17,GCST006703,Bitter taste perception (multivariate analysis)
12109,European,249262.0,30224653.0,Evangelou E,Other measurement,replication,2018-09-17,GCST006630,Diastolic blood pressure
12459,European,757601.0,30224653.0,Evangelou E,Other measurement,initial,2018-09-17,GCST006624,Systolic blood pressure
12461,European,757601.0,30224653.0,Evangelou E,Other measurement,initial,2018-09-17,GCST006628,Systolic blood pressure
12108,European,249262.0,30224653.0,Evangelou E,Other measurement,replication,2018-09-17,GCST006624,Systolic blood pressure
5790,European,823.0,30255771.0,Sarnowski C,Lipid or lipoprotein measurement,initial,2018-09-17,GCST007661,Triglyceride levels
12457,European,757601.0,30224653.0,Evangelou E,Cardiovascular measurement,initial,2018-09-17,GCST006626,Pulse pressure
12460,European,757601.0,30224653.0,Evangelou E,Other measurement,initial,2018-09-17,GCST006627,Diastolic blood pressure
5792,European,823.0,30255771.0,Sarnowski C,"Response to drug, Lipid or lipoprotein measurement",initial,2018-09-17,GCST007662,Triglyceride levels in response to fenofibrate
6926,European,1999.0,30223776.0,Hwang LD,Biological process,initial,2018-09-17,GCST006704,Bitter taste perception
5794,European,823.0,30255771.0,Sarnowski C,"Response to drug, Other measurement, Lipid or lipoprotein measurement",initial,2018-09-17,GCST007659,Triglyceride change in response to fenofibrate (parental genotype effect)
5359,European,517.0,30324795.0,Moen GH,Other measurement,initial,2018-09-18,GCST007179,Fasting glucose in pregnancy (gestational week 14-16)
5314,European,497.0,30324795.0,Moen GH,Other measurement,initial,2018-09-18,GCST007183,General glucose level in pregnancy (gestational week 14-16)
5315,European,497.0,30324795.0,Moen GH,Other measurement,initial,2018-09-18,GCST007185,Timing of glucose curve peak in pregnancy (gestational week 14-16)
5334,European,506.0,30324795.0,Moen GH,Other measurement,initial,2018-09-18,GCST007184,General glucose level in pregnancy (gestational week 30-32)
5352,European,512.0,30324795.0,Moen GH,Other measurement,initial,2018-09-18,GCST007182,Two-hour glucose in pregnancy (gestational week 30-32)
1025,African American or Afro-Caribbean,2709.0,30226466.0,Valimaki N,Cancer,replication,2018-09-18,GCST007548,Uterine fibroids
5333,European,506.0,30324795.0,Moen GH,Other measurement,initial,2018-09-18,GCST007181,Two-hour glucose in pregnancy (gestational week 14-16)
5335,European,506.0,30324795.0,Moen GH,Other measurement,initial,2018-09-18,GCST007186,Timing of glucose curve peak in pregnancy (gestational week 30-32)
5369,European,521.0,30324795.0,Moen GH,Other measurement,initial,2018-09-18,GCST007180,Fasting glucose in pregnancy (gestational week 30-32)
3172,Asian,2770.0,30226466.0,Valimaki N,Cancer,replication,2018-09-18,GCST007548,Uterine fibroids
200,African,1552.0,30226466.0,Valimaki N,Cancer,replication,2018-09-18,GCST007548,Uterine fibroids
12356,European,424481.0,30226466.0,Valimaki N,Cancer,initial,2018-09-18,GCST007548,Uterine fibroids
2269,Asian,744.0,30228239.0,Wojcik GL,Other disease,initial,2018-09-18,GCST007109,Diarrhoea-associated Entamoeba histolytica infection
10433,European,21637.0,30226466.0,Valimaki N,Cancer,replication,2018-09-18,GCST007548,Uterine fibroids
2196,Asian,636.0,30230522.0,Zhang S,Immune system disorder,replication,2018-09-19,GCST008067,Pemphigus foliaceus
2166,Asian,573.0,30230522.0,Zhang S,Immune system disorder,initial,2018-09-19,GCST008067,Pemphigus foliaceus
2281,Asian,750.0,30230522.0,Zhang S,Immune system disorder,replication,2018-09-19,GCST008069,Pemphigus
2361,Asian,851.0,30230522.0,Zhang S,Immune system disorder,initial,2018-09-19,GCST008069,Pemphigus
2283,Asian,756.0,30230522.0,Zhang S,Immune system disorder,initial,2018-09-19,GCST008068,Pemphigus vulgaris
2258,Asian,715.0,30230522.0,Zhang S,Immune system disorder,replication,2018-09-19,GCST008068,Pemphigus vulgaris
5928,European,920.0,30237584.0,El Rouby N,Cardiovascular disease,initial,2018-09-20,GCST007135,Resistant hypertension
7258,European,2417.0,30237584.0,El Rouby N,Cardiovascular disease,replication,2018-09-20,GCST007135,Resistant hypertension
5563,European,657.0,30237584.0,El Rouby N,Cardiovascular disease,initial,2018-09-20,GCST007136,Resistant hypertension
12672,Hispanic or Latin American,537.0,30237584.0,El Rouby N,Cardiovascular disease,initial,2018-09-20,GCST007136,Resistant hypertension
4907,European,263.0,30237584.0,El Rouby N,Cardiovascular disease,replication,2018-09-20,GCST007136,Resistant hypertension
12599,Hispanic or Latin American,322.0,30237584.0,El Rouby N,Cardiovascular disease,replication,2018-09-20,GCST007136,Resistant hypertension
12760,Hispanic or Latin American,859.0,30237584.0,El Rouby N,Cardiovascular disease,initial,2018-09-20,GCST007135,Resistant hypertension
2270,Asian,744.0,30242048.0,Chen B,Other measurement,replication,2018-09-21,GCST007178,Perceptual rivalry (voluntary modulation strength)
2280,Asian,748.0,30242048.0,Chen B,Other measurement,replication,2018-09-21,GCST007176,Perceptual rivalry (Necker cube stimulus)
3454,Asian,4527.0,30242241.0,Hachiya T,Other measurement,initial,2018-09-21,GCST007108,Systolic blood pressure x sodium interaction (1df test)
3453,Asian,4527.0,30242241.0,Hachiya T,Other measurement,initial,2018-09-21,GCST007107,Diastolic blood pressure x sodium interaction (1df test)
3419,Asian,4241.0,30242241.0,Hachiya T,Other measurement,replication,2018-09-21,GCST007107,Diastolic blood pressure x sodium interaction (1df test)
3420,Asian,4241.0,30242241.0,Hachiya T,Other measurement,replication,2018-09-21,GCST007108,Systolic blood pressure x sodium interaction (1df test)
13903,Other/Mixed,2107.0,30247649.0,Gonzalez-Serna D,Neurological disorder,initial,2018-09-21,GCST006493,Systemic sclerosis
2366,Asian,870.0,30242048.0,Chen B,Other measurement,replication,2018-09-21,GCST007177,Perceptual rivalry (binocular rivalry task)
2869,Asian,1876.0,30242048.0,Chen B,Other measurement,initial,2018-09-21,GCST007178,Perceptual rivalry (voluntary modulation strength)
2961,Asian,2097.0,30242048.0,Chen B,Other measurement,initial,2018-09-21,GCST007177,Perceptual rivalry (binocular rivalry task)
2870,Asian,1880.0,30242048.0,Chen B,Other measurement,initial,2018-09-21,GCST007176,Perceptual rivalry (Necker cube stimulus)
3233,Asian,2961.0,30248107.0,Wu S,Other measurement,initial,2018-09-24,GCST006706,Eyebrow thickness
8223,European,4411.0,30248107.0,Wu S,Other measurement,replication,2018-09-24,GCST006706,Eyebrow thickness
12879,Hispanic or Latin American,2301.0,30248107.0,Wu S,Other measurement,initial,2018-09-24,GCST006706,Eyebrow thickness
6408,European,1355.0,30251476.0,Lopez-Mejias R,"Immune system disorder, Other measurement",initial,2018-09-24,GCST007040,Carotid intima media thickness in rheumatoid arthritis
7592,European,2989.0,30251476.0,Lopez-Mejias R,"Other disease, Immune system disorder",initial,2018-09-24,GCST007041,Cardiovascular event in rheumatoid arthritis
7591,European,2989.0,30251476.0,Lopez-Mejias R,"Immune system disorder, Cardiovascular disease",initial,2018-09-24,GCST007088,Ischemic heart disease in rheumatoid arthritis
6407,European,1355.0,30251476.0,Lopez-Mejias R,"Immune system disorder, Cardiovascular disease",initial,2018-09-24,GCST007425,Carotid plaques in rheumatoid arthritis
13764,Other/Mixed,721.0,30248107.0,Wu S,Other measurement,initial,2018-09-24,GCST006706,Eyebrow thickness
9884,European,13175.0,30254083.0,Cousminer DL,Metabolic disorder,initial,2018-09-25,GCST007246,Latent autoimmune diabetes vs. type 2 diabetes
7856,European,3422.0,30254083.0,Cousminer DL,Metabolic disorder,initial,2018-09-25,GCST007247,Latent autoimmune diabetes vs. type 1 diabetes
6362,European,1297.0,30252935.0,Smith AH,Neurological disorder,initial,2018-09-25,GCST008137,Alcohol withdrawal symptoms
6935,European,2009.0,30254083.0,Cousminer DL,Metabolic disorder,replication,2018-09-25,GCST007245,Latent autoimmune diabetes
834,African American or Afro-Caribbean,1231.0,30252935.0,Smith AH,Neurological disorder,initial,2018-09-25,GCST008136,Alcohol withdrawal symptoms
4777,European,181.0,30252935.0,Smith AH,Neurological disorder,replication,2018-09-25,GCST008137,Alcohol withdrawal symptoms
9356,European,8581.0,30254083.0,Cousminer DL,Metabolic disorder,initial,2018-09-25,GCST007245,Latent autoimmune diabetes
883,African American or Afro-Caribbean,1488.0,30258056.0,Vojinovic D,Other measurement,initial,2018-09-26,GCST007147,Lateral ventricular volume in normal aging
10452,European,22045.0,30258056.0,Vojinovic D,Other measurement,initial,2018-09-26,GCST007147,Lateral ventricular volume in normal aging
7362,European,2545.0,30363675.0,Cha EDK,Other measurement,initial,2018-09-27,GCST007188,Visceral adipose tissue/subcutaneous adipose tissue ratio
7363,European,2545.0,30363675.0,Cha EDK,Other measurement,initial,2018-09-27,GCST007189,visceral adipose tissue/total adipose tissue ratio
7364,European,2545.0,30363675.0,Cha EDK,Other measurement,initial,2018-09-27,GCST007190,Subcutaneous adipose tissue
11901,European,158025.0,30261039.0,Suri P,Other trait,initial,2018-09-27,GCST007152,Chronic back pain
6051,European,986.0,30265060.0,MacKillop J,Other measurement,initial,2018-09-27,GCST007153,Delayed reward discounting
7361,European,2545.0,30363675.0,Cha EDK,Other measurement,initial,2018-09-27,GCST007187,Visceral adipose tissue
12154,European,283752.0,30261039.0,Suri P,Other trait,replication,2018-09-27,GCST007152,Chronic back pain
1186,African American or Afro-Caribbean,4271.0,30266756.0,Chang X,Cardiovascular disease,replication,2018-09-28,GCST007154,Paediatric migraine
2259,Asian,716.0,30266950.0,Miyagawa T,Neurological disorder,replication,2018-09-28,GCST007191,Hypersomnia (HLA-DQB1*06:02 negative)
2749,Asian,1701.0,30266950.0,Miyagawa T,Neurological disorder,initial,2018-09-28,GCST007191,Hypersomnia (HLA-DQB1*06:02 negative)
1003,African American or Afro-Caribbean,2509.0,30266756.0,Chang X,Cardiovascular disease,initial,2018-09-28,GCST007154,Paediatric migraine
9166,European,7926.0,30266756.0,Chang X,Cardiovascular disease,initial,2018-09-28,GCST007154,Paediatric migraine
12059,European,215551.0,30275531.0,Klarin D,Lipid or lipoprotein measurement,initial,2018-10-01,GCST006613,Triglycerides
1510,African American or Afro-Caribbean,57332.0,30275531.0,Klarin D,Lipid or lipoprotein measurement,initial,2018-10-01,GCST006613,Triglycerides
12060,European,215551.0,30275531.0,Klarin D,Lipid or lipoprotein measurement,initial,2018-10-01,GCST006614,Total cholesterol levels
12061,European,215551.0,30275531.0,Klarin D,"Lipid or lipoprotein measurement, Other measurement",initial,2018-10-01,GCST006612,LDL cholesterol
148,African,892.0,30276832.0,Edwards AC,Biological process,initial,2018-10-01,GCST006633,Initial alcohol sensitivity
1509,African American or Afro-Caribbean,57332.0,30275531.0,Klarin D,Lipid or lipoprotein measurement,initial,2018-10-01,GCST006611,HDL cholesterol
1511,African American or Afro-Caribbean,57332.0,30275531.0,Klarin D,Lipid or lipoprotein measurement,initial,2018-10-01,GCST006614,Total cholesterol levels
1512,African American or Afro-Caribbean,57332.0,30275531.0,Klarin D,"Lipid or lipoprotein measurement, Other measurement",initial,2018-10-01,GCST006612,LDL cholesterol
12058,European,215551.0,30275531.0,Klarin D,Lipid or lipoprotein measurement,initial,2018-10-01,GCST006611,HDL cholesterol
8750,European,6039.0,30276832.0,Edwards AC,Biological process,initial,2018-10-01,GCST006633,Initial alcohol sensitivity
13334,Hispanic or Latin American,24743.0,30275531.0,Klarin D,Lipid or lipoprotein measurement,initial,2018-10-01,GCST006614,Total cholesterol levels
13335,Hispanic or Latin American,24743.0,30275531.0,Klarin D,"Lipid or lipoprotein measurement, Other measurement",initial,2018-10-01,GCST006612,LDL cholesterol
546,African American or Afro-Caribbean,215.0,30357299.0,De T,Response to drug,initial,2018-10-01,GCST007137,Warfarin-associated bleeding
13332,Hispanic or Latin American,24743.0,30275531.0,Klarin D,Lipid or lipoprotein measurement,initial,2018-10-01,GCST006611,HDL cholesterol
13333,Hispanic or Latin American,24743.0,30275531.0,Klarin D,Lipid or lipoprotein measurement,initial,2018-10-01,GCST006613,Triglycerides
513,African American or Afro-Caribbean,188.0,30357299.0,De T,Response to drug,replication,2018-10-01,GCST007137,Warfarin-associated bleeding
12874,Hispanic or Latin American,2153.0,30305239.0,Macias-Kauffer LR,Cardiovascular measurement,initial,2018-10-01,GCST006905,Serum uric acid levels
12624,Hispanic or Latin American,408.0,30276832.0,Edwards AC,Biological process,initial,2018-10-01,GCST006633,Initial alcohol sensitivity
10402,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006874,Hippocampal subfield CA1 volume (corrected for total hippocampal volume)
12807,Hispanic or Latin American,1266.0,30281099.0,Fadista J,Digestive system disorder,replication,2018-10-02,GCST006705,Infantile hypertrophic pyloric stenosis
10401,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006873,Subiculum volume (corrected for total hippocampal volume)
10400,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006872,Presubiculum volume (corrected for total hippocampal volume)
12075,European,221575.0,30279531.0,Baselmans BML,Other measurement,initial,2018-10-02,GCST006634,Hedonic well-being
10405,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006877,Dentate gyrus granule cell layer volume (corrected for total hippocampal volume)
10398,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006870,Hippocampal tail volume
10420,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006893,Fimbria volume
7959,European,3669.0,30281099.0,Fadista J,Digestive system disorder,replication,2018-10-02,GCST006705,Infantile hypertrophic pyloric stenosis
10421,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006894,HATA volume
10422,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006895,Parasubiculum volume
8697,European,5833.0,30281099.0,Fadista J,Digestive system disorder,initial,2018-10-02,GCST006705,Infantile hypertrophic pyloric stenosis
10399,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006871,Total hippocampal volume
10406,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006878,Dentate gyrus molecular layer volume (corrected for total hippocampal volume)
10407,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006880,Hippocampal fissure volume (corrected for total hippocampal volume)
10403,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006875,Hippocampal subfield CA3 volume (corrected for total hippocampal volume)
10404,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006876,Hippocampal subfield CA4 volume (corrected for total hippocampal volume)
10408,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006881,Hippocampal tail volume (corrected for total hippocampal volume)
10409,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006882,Fimbria volume (corrected for total hippocampal volume)
10410,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006883,HATA volume (corrected for total hippocampal volume)
11614,European,108154.0,30279531.0,Baselmans BML,Other measurement,initial,2018-10-02,GCST006635,Eudaimonic well-being
10419,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006892,Hippocampal fissure volume
10412,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006885,Presubiculum volume
10411,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006884,Parasubiculum volume (corrected for total hippocampal volume)
10413,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006886,Subiculum volume
10414,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006887,Hippocampal subfield CA1 volume
10415,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006888,Hippocampal subfield CA3 volume
10416,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006889,Hippocampal subfield CA4 volume
10417,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006890,Dentate gyrus granule cell layer volume
10418,European,21297.0,30279459.0,van der Meer D,Other measurement,initial,2018-10-02,GCST006891,Dentate gyrus molecular layer volume
4380,Asian,33349.0,30281874.0,Tanikawa C,Cancer,initial,2018-10-03,GCST006707,Gastric cancer
5819,European,838.0,30284222.0,Brcic L,Immune system disorder,initial,2018-10-03,GCST007138,Hashimoto thyroiditis
4427,Asian,45528.0,30285260.0,Ikeda M,Neurological disorder,initial,2018-10-03,GCST007201,Schizophrenia
5493,European,605.0,30284222.0,Brcic L,Immune system disorder,replication,2018-10-03,GCST007138,Hashimoto thyroiditis
3989,Asian,9348.0,30285260.0,Ikeda M,Neurological disorder,initial,2018-10-03,GCST007205,Schizophrenia
4246,Asian,17062.0,30281874.0,Tanikawa C,Cancer,replication,2018-10-03,GCST006707,Gastric cancer
11384,European,77096.0,30285260.0,Ikeda M,Neurological disorder,replication,2018-10-03,GCST007201,Schizophrenia
4450,Asian,58541.0,30285260.0,Ikeda M,Neurological disorder,replication,2018-10-03,GCST007205,Schizophrenia
5186,European,433.0,30284742.0,Bevilacqua L,Digestive system disorder,initial,2018-10-04,GCST007195,Chronic periodontitis (slight)
5000,European,329.0,30284742.0,Bevilacqua L,Digestive system disorder,initial,2018-10-04,GCST007194,Chronic periodontitis (severe)
2947,Asian,2053.0,30287856.0,Zheng R,"Other disease, Other measurement",initial,2018-10-04,GCST006619,Tuberculosis
5064,European,367.0,30284742.0,Bevilacqua L,Digestive system disorder,initial,2018-10-04,GCST007197,Chronic periodontitis (localised)
5098,European,395.0,30284742.0,Bevilacqua L,Digestive system disorder,initial,2018-10-04,GCST007193,Chronic periodontitis (generalised)
5849,European,857.0,30287865.0,Pinar A,Other measurement,initial,2018-10-04,GCST007243,Intra-individual response time variability (selective attention)
3672,Asian,5986.0,30287856.0,Zheng R,"Other disease, Other measurement",replication,2018-10-04,GCST006619,Tuberculosis
5850,European,857.0,30287865.0,Pinar A,Other measurement,initial,2018-10-04,GCST007244,Intra-individual response time variability (response selection)
1147,African American or Afro-Caribbean,3724.0,30287806.0,Zhou H,Other measurement,initial,2018-10-04,GCST006631,Nicotine dependence and major depression (severity of comorbidity)
5487,European,602.0,30284742.0,Bevilacqua L,Digestive system disorder,initial,2018-10-04,GCST007196,Chronic periodontitis
12446,European,630791.0,30289880.0,Qi G,Other measurement,initial,2018-10-05,GCST006665,Social science traits (pleiotropy) (HIPO component 1)
11995,European,188577.0,30289880.0,Qi G,Lipid or lipoprotein measurement,initial,2018-10-05,GCST006667,Lipid traits (pleiotropy) (HIPO component 2)
11994,European,188577.0,30289880.0,Qi G,Lipid or lipoprotein measurement,initial,2018-10-05,GCST006666,Lipid traits (pleiotropy) (HIPO component 1)
6888,European,1950.0,30338293.0,Wallen ZD,"Neurological disorder, Other measurement",initial,2018-10-05,GCST007198,Parkinson's disease (age at diagnosis)
5652,European,726.0,30338293.0,Wallen ZD,"Neurological disorder, Other measurement",replication,2018-10-05,GCST007198,Parkinson's disease (age at diagnosis)
3560,Asian,5304.0,30297428.0,Jorgenson E,Other disease,replication,2018-10-08,GCST007118,Erectile dysfunction
259,African,3634.0,30297428.0,Jorgenson E,Other disease,replication,2018-10-08,GCST007118,Erectile dysfunction
10686,European,29859.0,30297428.0,Jorgenson E,Other disease,initial,2018-10-08,GCST007118,Erectile dysfunction
804,African American or Afro-Caribbean,1083.0,30297428.0,Jorgenson E,Other disease,initial,2018-10-08,GCST007118,Erectile dysfunction
10935,European,38763.0,30298529.0,Stanaway IB,"Other disease, Other measurement",initial,2018-10-08,GCST007139,Shingles
2226,Asian,680.0,30297428.0,Jorgenson E,Other disease,replication,2018-10-08,GCST007118,Erectile dysfunction
12928,Hispanic or Latin American,2970.0,30297428.0,Jorgenson E,Other disease,initial,2018-10-08,GCST007118,Erectile dysfunction
3165,Asian,2737.0,30297428.0,Jorgenson E,Other disease,initial,2018-10-08,GCST007118,Erectile dysfunction
1278,African American or Afro-Caribbean,6831.0,30298529.0,Stanaway IB,"Other disease, Other measurement",initial,2018-10-08,GCST007139,Shingles
12049,European,209758.0,30297428.0,Jorgenson E,Other disease,replication,2018-10-08,GCST007118,Erectile dysfunction
2284,Asian,756.0,30298529.0,Stanaway IB,"Other disease, Other measurement",initial,2018-10-08,GCST007139,Shingles
5879,European,877.0,30305637.0,McMaster ML,Cancer,replication,2018-10-10,GCST006982,Waldenstrm macroglobulinemia / lymphoplasmacytic lymphoma
8091,European,4015.0,30305637.0,McMaster ML,Cancer,initial,2018-10-10,GCST006982,Waldenstrm macroglobulinemia / lymphoplasmacytic lymphoma
8214,European,4386.0,30305740.0,Elliott LT,Other measurement,replication,2018-10-10,GCST006777,Brain imaging measurements
11479,European,86335.0,30306274.0,Shah RL,"Neurological disorder, Other trait",initial,2018-10-10,GCST007159,Corneal astigmatism
11478,European,86335.0,30306274.0,Shah RL,"Neurological disorder, Other trait",initial,2018-10-10,GCST007157,Corneal astigmatism
11495,European,88005.0,30306274.0,Shah RL,Other trait,initial,2018-10-10,GCST007158,Refractive astigmatism
11496,European,88005.0,30306274.0,Shah RL,Other trait,initial,2018-10-10,GCST007160,Refractive astigmatism
9327,European,8428.0,30305740.0,Elliott LT,Other measurement,initial,2018-10-10,GCST006777,Brain imaging measurements
262,African,3723.0,30317457.0,Bonnemaijer PWM,Neurological disorder,replication,2018-10-13,GCST007199,Glaucoma (primary open-angle)
13596,Other/Mixed,275.0,30317457.0,Bonnemaijer PWM,Neurological disorder,initial,2018-10-13,GCST007199,Glaucoma (primary open-angle)
1228,African American or Afro-Caribbean,5408.0,30317457.0,Bonnemaijer PWM,Neurological disorder,replication,2018-10-13,GCST007199,Glaucoma (primary open-angle)
146,African,864.0,30317457.0,Bonnemaijer PWM,Neurological disorder,initial,2018-10-13,GCST007199,Glaucoma (primary open-angle)
917,African American or Afro-Caribbean,1800.0,30317457.0,Bonnemaijer PWM,Neurological disorder,initial,2018-10-13,GCST007199,Glaucoma (primary open-angle)
3809,Asian,7448.0,30323354.0,Lee JY,Cancer,initial,2018-10-15,GCST006719,BRCA1/2-negative high-risk breast cancer
9616,European,10217.0,30320955.0,Baird DA,Body measurement,initial,2018-10-15,GCST006903,Hip shape (DXA scan)
8443,European,4976.0,30327367.0,Jung SY,"Other measurement, Other trait",initial,2018-10-16,GCST007753,Homeostasis model assessment of insulin resistance in higher physical activity
7859,European,3431.0,30327367.0,Jung SY,"Metabolic disorder, Other measurement",initial,2018-10-16,GCST007768,Hyperinsulinemia in obesity
1923,Asian,301.0,30326835.0,Li Z,Other measurement,initial,2018-10-16,GCST006936,Mitochondrial DNA levels
9786,European,11794.0,30327367.0,Jung SY,"Lipid or lipoprotein measurement, Other measurement",initial,2018-10-16,GCST007759,Hyperglycemia x saturated fatty acids interaction
6181,European,1087.0,30327367.0,Jung SY,"Lipid or lipoprotein measurement, Other measurement",initial,2018-10-16,GCST007750,Hyperglycemia in less-fat diet
6182,European,1087.0,30327367.0,Jung SY,"Lipid or lipoprotein measurement, Other measurement",initial,2018-10-16,GCST007773,Hyperinsulinemia in less-fat diet
12257,European,337208.0,30325047.0,Gellert-Kristensen H,Digestive system disorder,initial,2018-10-16,GCST007364,Gallstone disease
8932,European,6818.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007747,Hyperglycemia in lower physical activity
9784,European,11794.0,30327367.0,Jung SY,"Body measurement, Other measurement",initial,2018-10-16,GCST007762,Hyperinsulinemia x BMI interaction
9794,European,11794.0,30327367.0,Jung SY,"Other measurement, Other trait",initial,2018-10-16,GCST007765,Homeostasis model assessment of insulin resistance x physical activity interaction
9783,European,11794.0,30327367.0,Jung SY,"Body measurement, Other measurement",initial,2018-10-16,GCST007757,Hyperglycemia x BMI interaction
7858,European,3431.0,30327367.0,Jung SY,"Metabolic disorder, Other measurement",initial,2018-10-16,GCST007745,Hyperglycemia in obesity
9790,European,11794.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007758,Hyperglycemia x physical activity interaction
9244,European,8363.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007746,Hyperglycemia in non-obese individuals
9785,European,11794.0,30327367.0,Jung SY,"Body measurement, Other trait",initial,2018-10-16,GCST007763,Homeostasis model assessment of insulin resistance x BMI interaction
9245,European,8363.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007769,Hyperinsulinemia in non-obese individuals
6183,European,1087.0,30327367.0,Jung SY,"Lipid or lipoprotein measurement, Other trait",initial,2018-10-16,GCST007756,Homeostasis model assessment of insulin resistance in less-fat diet
9789,European,11794.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007744,Hyperglycemia
9791,European,11794.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007760,Hyperinsulinemia
9674,European,10707.0,30327367.0,Jung SY,"Lipid or lipoprotein measurement, Other measurement",initial,2018-10-16,GCST007749,Hyperglycemia in more-fat diet
9675,European,10707.0,30327367.0,Jung SY,"Lipid or lipoprotein measurement, Other measurement",initial,2018-10-16,GCST007772,Hyperinsulinemia in more-fat diet
10333,European,19788.0,30325047.0,Gellert-Kristensen H,Digestive system disorder,replication,2018-10-16,GCST007364,Gallstone disease
8934,European,6818.0,30327367.0,Jung SY,"Other measurement, Other trait",initial,2018-10-16,GCST007754,Homeostasis model assessment of insulin resistance in lower physical activity
9788,European,11794.0,30327367.0,Jung SY,"Lipid or lipoprotein measurement, Other trait",initial,2018-10-16,GCST007767,Homeostasis model assessment of insulin resistance x saturated fatty acids interaction
9787,European,11794.0,30327367.0,Jung SY,"Lipid or lipoprotein measurement, Other measurement",initial,2018-10-16,GCST007766,Hyperinsulinemia x saturated fatty acids interaction
9246,European,8363.0,30327367.0,Jung SY,Other trait,initial,2018-10-16,GCST007752,Homeostasis model assessment of insulin resistance in non-obese individuals
9676,European,10707.0,30327367.0,Jung SY,"Lipid or lipoprotein measurement, Other trait",initial,2018-10-16,GCST007755,Homeostasis model assessment of insulin resistance in more-fat diet
8441,European,4976.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007748,Hyperglycemia in higher physical activity
8442,European,4976.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007770,Hyperinsulinemia in higher physical activity
9792,European,11794.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007764,Hyperinsulinemia x physical activity interaction
8933,European,6818.0,30327367.0,Jung SY,Other measurement,initial,2018-10-16,GCST007771,Hyperinsulinemia in lower physical activity
9793,European,11794.0,30327367.0,Jung SY,"Other measurement, Other trait",initial,2018-10-16,GCST007761,Homeostasis model assessment of insulin resistance
7860,European,3431.0,30327367.0,Jung SY,"Metabolic disorder, Other trait",initial,2018-10-16,GCST007751,Homeostasis model assessment of insulin resistance in obesity
11811,European,141932.0,30336701.0,Sanchez-Roige S,Other measurement,initial,2018-10-19,GCST006716,Alcohol use disorder (total score)
11709,European,121604.0,30336701.0,Sanchez-Roige S,Other measurement,initial,2018-10-19,GCST006717,Alcohol use disorder (dependence and problematic use scores)
2040,Asian,422.0,30343302.0,Kim SH,Other disease,initial,2018-10-19,GCST006659,Polycystic ovary syndrome
7128,European,2232.0,30339177.0,Shane B,Cardiovascular measurement,initial,2018-10-19,GCST007578,Plasma homocysteine levels
7129,European,2232.0,30339177.0,Shane B,Other measurement,initial,2018-10-19,GCST007579,Serum folate levels
7130,European,2232.0,30339177.0,Shane B,Other measurement,initial,2018-10-19,GCST007580,Red blood cell folate levels
11710,European,121604.0,30336701.0,Sanchez-Roige S,Other measurement,initial,2018-10-19,GCST006718,Alcohol use disorder (consumption score)
4949,European,290.0,30353303.0,Seo M,"Other disease, Response to drug",initial,2018-10-23,GCST007558,Response to long-term oxygen therapy in chronic obstructive pulmonary disease
556,African American or Afro-Caribbean,244.0,30367910.0,Levin AM,"Response to drug, Other measurement",initial,2018-10-24,GCST008230,Asthma control x inhaled corticosteroid treatment interaction (2df)
555,African American or Afro-Caribbean,244.0,30367910.0,Levin AM,"Response to drug, Other measurement",initial,2018-10-24,GCST008229,Asthma control x inhaled corticosteroid treatment interaction (1df)
554,African American or Afro-Caribbean,244.0,30367910.0,Levin AM,Other measurement,initial,2018-10-24,GCST008228,Asthma control
4680,European,98.0,30367910.0,Levin AM,"Response to drug, Other measurement",replication,2018-10-24,GCST008230,Asthma control x inhaled corticosteroid treatment interaction (2df)
866,African American or Afro-Caribbean,1366.0,30367910.0,Levin AM,Other measurement,replication,2018-10-24,GCST008228,Asthma control
868,African American or Afro-Caribbean,1366.0,30367910.0,Levin AM,"Response to drug, Other measurement",replication,2018-10-24,GCST008230,Asthma control x inhaled corticosteroid treatment interaction (2df)
867,African American or Afro-Caribbean,1366.0,30367910.0,Levin AM,"Response to drug, Other measurement",replication,2018-10-24,GCST008229,Asthma control x inhaled corticosteroid treatment interaction (1df)
4678,European,98.0,30367910.0,Levin AM,Other measurement,replication,2018-10-24,GCST008228,Asthma control
4679,European,98.0,30367910.0,Levin AM,"Response to drug, Other measurement",replication,2018-10-24,GCST008229,Asthma control x inhaled corticosteroid treatment interaction (1df)
12835,Hispanic or Latin American,1461.0,30367910.0,Levin AM,Other measurement,replication,2018-10-24,GCST008228,Asthma control
12837,Hispanic or Latin American,1461.0,30367910.0,Levin AM,"Response to drug, Other measurement",replication,2018-10-24,GCST008230,Asthma control x inhaled corticosteroid treatment interaction (2df)
12836,Hispanic or Latin American,1461.0,30367910.0,Levin AM,"Response to drug, Other measurement",replication,2018-10-24,GCST008229,Asthma control x inhaled corticosteroid treatment interaction (1df)
6042,European,983.0,30361487.0,Yan Q,Other measurement,initial,2018-10-25,GCST006904,Cerebral amyloid deposition (PET imaging)
11165,European,54288.0,30367059.0,Teumer A,"Other measurement, Other trait",initial,2018-10-26,GCST006899,Thyroid stimulating hormone levels
10463,European,22383.0,30367059.0,Teumer A,Other measurement,replication,2018-10-26,GCST006896,Free thyroxine concentration
11098,European,49269.0,30367059.0,Teumer A,Other measurement,initial,2018-10-26,GCST006896,Free thyroxine concentration
10464,European,22383.0,30367059.0,Teumer A,"Other measurement, Other trait",replication,2018-10-26,GCST006899,Thyroid stimulating hormone levels
11124,European,51823.0,30367059.0,Teumer A,Other disease,initial,2018-10-26,GCST006897,Hyperthyroidism
11147,European,53323.0,30367059.0,Teumer A,Other disease,initial,2018-10-26,GCST006898,Hypothyroidism
8586,European,5364.0,30373671.0,Hayden LP,"Other measurement, Other disease",initial,2018-10-29,GCST007508,Self-reported childhood asthma in adult smokers
12442,European,586030.0,30374069.0,Styrkarsdottir U,Other disease,initial,2018-10-29,GCST006925,Knee osteoarthritis
1017,African American or Afro-Caribbean,2667.0,30373671.0,Hayden LP,"Other measurement, Other disease",initial,2018-10-29,GCST007508,Self-reported childhood asthma in adult smokers
12444,European,613790.0,30374069.0,Styrkarsdottir U,Other disease,initial,2018-10-29,GCST006926,Osteoarthritis (hip)
1732,Asian,139.0,30377885.0,Fujimori S,"Response to drug, Digestive system disorder",initial,2018-10-30,GCST007258,Non-steroidal anti-inflammatory drug-induced enteropathy
7260,European,2421.0,30378284.0,Smajlagic D,"Biological process, Other trait",initial,2018-10-31,GCST007403,Verbal intelligence quotient (cesarean section interaction)
7262,European,2421.0,30378284.0,Smajlagic D,"Biological process, Other trait",initial,2018-10-31,GCST007405,Full scale intelligence quotient (cesarean section interaction)
7261,European,2421.0,30378284.0,Smajlagic D,"Biological process, Other trait",initial,2018-10-31,GCST007404,Performance intelligence quotient (cesarean section interaction)
4858,European,222.0,30596066.0,Kong LL,Other measurement,initial,2018-11-01,GCST007206,Brain glucose metabolism (fluorodeoxyglucose uptake)
3198,Asian,2838.0,30382898.0,Moon S,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",replication,2018-11-01,GCST007738,Metabolic syndrome
14036,Other/Mixed,101040.0,30383316.0,Malik R,Cardiovascular disease,initial,2018-11-01,GCST007248,Stroke
2576,Asian,1311.0,30480742.0,Miki A,Neurological disorder,initial,2018-11-01,GCST007296,Chronic central serous retinopathy
12466,European,813375.0,30383316.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-11-01,GCST007249,Ischemic stroke
4451,Asian,59552.0,30395268.0,Khanshour AM,Other disease,replication,2018-11-01,GCST006902,Adolescent idiopathic scoliosis
14032,Other/Mixed,74463.0,30383316.0,Malik R,"Cardiovascular disease, Other trait",initial,2018-11-01,GCST007249,Ischemic stroke
12468,European,821100.0,30383316.0,Malik R,Cardiovascular disease,initial,2018-11-01,GCST007248,Stroke
11844,European,148164.0,30388399.0,Ligthart S,Inflammatory measurement,initial,2018-11-01,GCST007615,C-reactive protein levels
3038,Asian,2254.0,30480742.0,Miki A,Neurological disorder,replication,2018-11-01,GCST007296,Chronic central serous retinopathy
7830,European,3387.0,30395268.0,Khanshour AM,Other disease,replication,2018-11-01,GCST006902,Adolescent idiopathic scoliosis
3786,Asian,7198.0,30382898.0,Moon S,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",initial,2018-11-01,GCST007738,Metabolic syndrome
12026,European,204402.0,30388399.0,Ligthart S,Inflammatory measurement,initial,2018-11-01,GCST007614,C-reactive protein levels
10351,European,20097.0,30395268.0,Khanshour AM,Other disease,initial,2018-11-01,GCST006902,Adolescent idiopathic scoliosis
4169,Asian,13379.0,30395268.0,Khanshour AM,Other disease,initial,2018-11-01,GCST006902,Adolescent idiopathic scoliosis
12267,European,340793.0,30392061.0,Orlova E,Immune system disorder,replication,2018-11-03,GCST007595,Appendicitis
11772,European,133680.0,30392061.0,Orlova E,Immune system disorder,initial,2018-11-03,GCST007595,Appendicitis
12177,European,295351.0,30410027.0,Gudmundsson J,"Other disease, Other trait",initial,2018-11-08,GCST007512,Benign prostatic hyperplasia and lower urinary tract symptoms (prostate cancer excluded)
12181,European,295892.0,30410027.0,Gudmundsson J,Cancer,initial,2018-11-08,GCST007506,Prostate cancer
12201,European,301162.0,30410027.0,Gudmundsson J,"Other disease, Other trait",initial,2018-11-08,GCST007507,Benign prostatic hyperplasia and lower urinary tract symptoms
10801,European,33572.0,30410027.0,Gudmundsson J,Other measurement,initial,2018-11-08,GCST007513,Prostate-specific antigen levels
3497,Asian,4756.0,30412241.0,Takeuchi F,Cancer,replication,2018-11-09,GCST007119,Cervical cancer
3798,Asian,7321.0,30412241.0,Takeuchi F,Cancer,initial,2018-11-09,GCST007119,Cervical cancer
12482,European,1432180.0,30413934.0,Broce IJ,"Cardiovascular disease, Body measurement, Neurological disorder, Lipid or lipoprotein measurement, Metabolic disorder",initial,2018-11-09,GCST007303,Alzheimer's disease or cardiovascular risk factors (pleiotropy)
12326,European,394156.0,30586722.0,Aragam KG,Cardiovascular disease,initial,2018-11-11,GCST007715,Heart failure
10179,European,17195.0,30586722.0,Aragam KG,Cardiovascular disease,replication,2018-11-11,GCST007714,Nonischemic cardiomyopathy
9866,European,12819.0,30586722.0,Aragam KG,Cardiovascular disease,replication,2018-11-11,GCST007715,Heart failure
12324,European,390142.0,30586722.0,Aragam KG,Cardiovascular disease,initial,2018-11-11,GCST007714,Nonischemic cardiomyopathy
12568,Hispanic or Latin American,159.0,30431558.0,Smith SB,Other disease,initial,2018-11-13,GCST007619,Temporomandibular joint disorder
990,African American or Afro-Caribbean,2308.0,30423114.0,Laufer VA,Immune system disorder,initial,2018-11-13,GCST006959,Rheumatoid arthritis
13218,Hispanic or Latin American,11975.0,30431558.0,Smith SB,Other disease,replication,2018-11-13,GCST007619,Temporomandibular joint disorder
11827,European,144750.0,30431558.0,Smith SB,Other disease,replication,2018-11-13,GCST007619,Temporomandibular joint disorder
1834,Asian,223.0,30431558.0,Smith SB,Other disease,initial,2018-11-13,GCST007619,Temporomandibular joint disorder
11428,European,80888.0,30423114.0,Laufer VA,Immune system disorder,replication,2018-11-13,GCST006959,Rheumatoid arthritis
13399,Other/Mixed,8.0,30431558.0,Smith SB,Other disease,initial,2018-11-13,GCST007619,Temporomandibular joint disorder
10843,European,34932.0,30699873.0,van der Merwe C,"Other measurement, Neurological disorder",initial,2018-11-13,GCST007775,Anxiety disorder or brain volume (pleiotropy)
13379,Other/Mixed,4.0,30431558.0,Smith SB,Other disease,initial,2018-11-13,GCST007619,Temporomandibular joint disorder
10482,European,22708.0,30699873.0,van der Merwe C,"Other measurement, Neurological disorder",initial,2018-11-13,GCST007776,Post-traumatic stress disorder or brain volume (pleiotropy)
704,African American or Afro-Caribbean,701.0,30431558.0,Smith SB,Other disease,initial,2018-11-13,GCST007619,Temporomandibular joint disorder
4310,Asian,22514.0,30423114.0,Laufer VA,Immune system disorder,replication,2018-11-13,GCST006959,Rheumatoid arthritis
6829,European,1859.0,30431558.0,Smith SB,Other disease,initial,2018-11-13,GCST007619,Temporomandibular joint disorder
11502,European,88583.0,30429480.0,Duffy DL,"Cancer, Other measurement",initial,2018-11-14,GCST007505,Nevus count or cutaneous melanoma
11134,European,52506.0,30429480.0,Duffy DL,Other measurement,initial,2018-11-14,GCST007504,Nevus count
1911,Asian,278.0,30498476.0,Liu H,Lipid or lipoprotein measurement,initial,2018-11-15,GCST007202,High density lipoprotein cholesterol levels
9182,European,7976.0,30449631.0,Zeng X,Other measurement,initial,2018-11-15,GCST008671,"Phlegm x occupational exposure (biological dust, mineral dust, gases and fumes, pesticides, aromatic solvents, chlorinated solvents, other solvents or metals) interaction"
8923,European,6789.0,30449631.0,Zeng X,Other measurement,replication,2018-11-15,GCST008669,"Cough x occupational exposure (biological dust, mineral dust, gases and fumes, pesticides, aromatic solvents, chlorinated solvents, other solvents or metals) interaction"
9181,European,7976.0,30449631.0,Zeng X,Other measurement,initial,2018-11-15,GCST008670,"Dyspnea x occupational exposure (biological dust, mineral dust, gases and fumes, pesticides, aromatic solvents, chlorinated solvents, other solvents or metals) interaction"
1912,Asian,278.0,30498476.0,Liu H,Lipid or lipoprotein measurement,initial,2018-11-15,GCST007203,Total cholesterol levels
8924,European,6789.0,30449631.0,Zeng X,Other measurement,replication,2018-11-15,GCST008670,"Dyspnea x occupational exposure (biological dust, mineral dust, gases and fumes, pesticides, aromatic solvents, chlorinated solvents, other solvents or metals) interaction"
1913,Asian,278.0,30498476.0,Liu H,Lipid or lipoprotein measurement,initial,2018-11-15,GCST007204,Low density lipoprotein cholesterol levels
9180,European,7976.0,30449631.0,Zeng X,Other measurement,initial,2018-11-15,GCST008669,"Cough x occupational exposure (biological dust, mineral dust, gases and fumes, pesticides, aromatic solvents, chlorinated solvents, other solvents or metals) interaction"
8925,European,6789.0,30449631.0,Zeng X,Other measurement,replication,2018-11-15,GCST008671,"Phlegm x occupational exposure (biological dust, mineral dust, gases and fumes, pesticides, aromatic solvents, chlorinated solvents, other solvents or metals) interaction"
5743,European,783.0,30453627.0,Marklund M,Other measurement,initial,2018-11-17,GCST007636,Fatty acid desaturase activity (adipose tissue)
6492,European,1453.0,30453627.0,Marklund M,Other measurement,initial,2018-11-17,GCST007635,Fatty acid desaturase activity (serum)
5810,European,831.0,30450575.0,Hojfeldt SG,"Cancer, Response to drug",initial,2018-11-18,GCST007540,PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia
5763,European,803.0,30450575.0,Hojfeldt SG,"Cancer, Other measurement",initial,2018-11-18,GCST007539,Silent asparaginase inactivation in childhood acute lymphoblastic leukaemia
5882,European,878.0,30450575.0,Hojfeldt SG,"Cancer, Response to drug",initial,2018-11-18,GCST007541,PEG-asparaginase hypersensitivity in childhood acute lymphoblastic leukaemia (allergic reaction grade 2 or more)
251,African,3073.0,30452639.0,Butali A,Other trait,initial,2018-11-19,GCST007510,Cleft lip with or without cleft palate
167,African,1049.0,30452639.0,Butali A,Other trait,replication,2018-11-19,GCST007510,Cleft lip with or without cleft palate
564,African American or Afro-Caribbean,265.0,30452639.0,Butali A,Other trait,replication,2018-11-19,GCST007509,Cleft palate
241,African,2364.0,30452639.0,Butali A,Other trait,initial,2018-11-19,GCST007509,Cleft palate
136,African,748.0,30452639.0,Butali A,Other trait,replication,2018-11-19,GCST007509,Cleft palate
5391,European,534.0,30453346.0,Tunjungputri RN,"Hematological measurement, Cardiovascular measurement",initial,2018-11-19,GCST007652,Platelet count and reactivity phenotypes
581,African American or Afro-Caribbean,307.0,30452639.0,Butali A,Other trait,replication,2018-11-19,GCST007510,Cleft lip with or without cleft palate
9567,European,9870.0,30456828.0,Khramtsova EA,"Neurological disorder, Other measurement",initial,2018-11-20,GCST007207,Obsessive-compulsive disorder x sex interaction
1202,African American or Afro-Caribbean,4500.0,30586737.0,Sabater-Lleal M,"Hematological measurement, Other measurement",initial,2018-11-20,GCST007447,vWF and FVIII levels
12594,Hispanic or Latin American,275.0,30586737.0,Sabater-Lleal M,Hematological measurement,initial,2018-11-20,GCST007446,vWF levels
12828,Hispanic or Latin American,1440.0,30586737.0,Sabater-Lleal M,Hematological measurement,initial,2018-11-20,GCST007445,Factor VIII levels
1144,African American or Afro-Caribbean,3700.0,30586737.0,Sabater-Lleal M,Hematological measurement,initial,2018-11-20,GCST007446,vWF levels
12829,Hispanic or Latin American,1440.0,30586737.0,Sabater-Lleal M,"Hematological measurement, Other measurement",initial,2018-11-20,GCST007447,vWF and FVIII levels
11004,European,42379.0,30586737.0,Sabater-Lleal M,"Hematological measurement, Other measurement",initial,2018-11-20,GCST007447,vWF and FVIII levels
2299,Asian,773.0,30586737.0,Sabater-Lleal M,Hematological measurement,initial,2018-11-20,GCST007445,Factor VIII levels
2300,Asian,773.0,30586737.0,Sabater-Lleal M,"Hematological measurement, Other measurement",initial,2018-11-20,GCST007447,vWF and FVIII levels
11003,European,42379.0,30586737.0,Sabater-Lleal M,Hematological measurement,initial,2018-11-20,GCST007446,vWF levels
10590,European,25897.0,30586737.0,Sabater-Lleal M,Hematological measurement,initial,2018-11-20,GCST007445,Factor VIII levels
1201,African American or Afro-Caribbean,4500.0,30586737.0,Sabater-Lleal M,Hematological measurement,initial,2018-11-20,GCST007445,Factor VIII levels
9566,European,9870.0,30456828.0,Khramtsova EA,Neurological disorder,initial,2018-11-20,GCST007208,Obsessive-compulsive disorder
94,African,371.0,30467376.0,Wilker S,Neurological disorder,replication,2018-11-22,GCST007651,Post-traumatic stress disorder
152,African,924.0,30467376.0,Wilker S,Neurological disorder,initial,2018-11-22,GCST007651,Post-traumatic stress disorder
6752,European,1746.0,30470734.0,Hackinger S,"Neurological disorder, Metabolic disorder",initial,2018-11-23,GCST007223,Schizophrenia vs type 2 diabetes
6387,European,1327.0,30470734.0,Hackinger S,"Neurological disorder, Metabolic disorder",initial,2018-11-23,GCST007224,Type 2 diabetes vs schizophrenia and type 2 diabetes
6478,European,1429.0,30470734.0,Hackinger S,"Neurological disorder, Metabolic disorder",initial,2018-11-23,GCST007222,Schizophrenia vs schizophrenia and type 2 diabetes
7728,European,3226.0,30468137.0,Fabbri C,"Neurological disorder, Response to drug",initial,2018-11-23,GCST007665,Treatment resistant depression
7185,European,2312.0,30468137.0,Fabbri C,"Other measurement, Response to drug",initial,2018-11-23,GCST007666,Depressive symptom improvement
7184,European,2312.0,30468137.0,Fabbri C,"Neurological disorder, Response to drug",initial,2018-11-23,GCST007667,Treatment resistant depression
6646,European,1630.0,30470734.0,Hackinger S,"Neurological disorder, Metabolic disorder",initial,2018-11-23,GCST007220,Schizophrenia and type 2 diabetes
6977,European,2049.0,30470734.0,Hackinger S,Neurological disorder,initial,2018-11-23,GCST007219,Schizophrenia
6886,European,1947.0,30470734.0,Hackinger S,Metabolic disorder,initial,2018-11-23,GCST007221,Type 2 diabetes
11146,European,53293.0,30478444.0,Demontis D,Neurological disorder,initial,2018-11-26,GCST007543,Attention deficit hyperactivity disorder
11779,European,136207.0,30478444.0,Demontis D,Neurological disorder,replication,2018-11-26,GCST007543,Attention deficit hyperactivity disorder
8545,European,5248.0,30475886.0,Mekli K,Other measurement,replication,2018-11-26,GCST007716,Frailty index
2898,Asian,1937.0,30478444.0,Demontis D,Neurological disorder,initial,2018-11-26,GCST007543,Attention deficit hyperactivity disorder
9225,European,8232.0,30475886.0,Mekli K,Other measurement,initial,2018-11-26,GCST007716,Frailty index
6299,European,1207.0,30488612.0,Xiang B,Neurological disorder,initial,2018-11-28,GCST007657,Alcohol and nicotine co-dependence
4516,Asian,130777.0,30487518.0,Takeuchi F,Other measurement,initial,2018-11-28,GCST007704,Diastolic blood pressure
4442,Asian,50792.0,30487518.0,Takeuchi F,Cardiovascular disease,initial,2018-11-28,GCST007707,Hypertension
4515,Asian,130777.0,30487518.0,Takeuchi F,Other measurement,initial,2018-11-28,GCST007703,Systolic blood pressure
12913,Hispanic or Latin American,2710.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007292,Diabetic retinopathy (all NPDR and PDR)
8311,European,4677.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007290,Diabetic retinopathy (moderate NPDR and PDR)
4514,Asian,130777.0,30487518.0,Takeuchi F,Cardiovascular measurement,initial,2018-11-28,GCST007705,Pulse pressure
3911,Asian,8607.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007290,Diabetic retinopathy (moderate NPDR and PDR)
12810,Hispanic or Latin American,1280.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007291,Proliferative diabetic retinopathy (vs no DR)
925,African American or Afro-Caribbean,1852.0,30487263.0,Pollack S,Metabolic disorder,initial,2018-11-28,GCST007292,Diabetic retinopathy (all NPDR and PDR)
4489,Asian,105253.0,30487518.0,Takeuchi F,Cardiovascular measurement,replication,2018-11-28,GCST007705,Pulse pressure
4490,Asian,105253.0,30487518.0,Takeuchi F,Other measurement,replication,2018-11-28,GCST007706,Mean arterial pressure
3105,Asian,2484.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007291,Proliferative diabetic retinopathy (vs no DR)
11137,European,53008.0,30487518.0,Takeuchi F,Cardiovascular disease,replication,2018-11-28,GCST007707,Hypertension
11138,European,53008.0,30487518.0,Takeuchi F,Cardiovascular measurement,replication,2018-11-28,GCST007705,Pulse pressure
11139,European,53008.0,30487518.0,Takeuchi F,Other measurement,replication,2018-11-28,GCST007706,Mean arterial pressure
9399,European,8821.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007289,Proliferative diabetic retinopathy (vs NPDR and no DR)
2956,Asian,2085.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007289,Proliferative diabetic retinopathy (vs NPDR and no DR)
10084,European,15918.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007292,Diabetic retinopathy (all NPDR and PDR)
955,African American or Afro-Caribbean,2038.0,30487263.0,Pollack S,Metabolic disorder,initial,2018-11-28,GCST007291,Proliferative diabetic retinopathy (vs no DR)
4517,Asian,130777.0,30487518.0,Takeuchi F,Other measurement,initial,2018-11-28,GCST007706,Mean arterial pressure
7743,European,3246.0,30487263.0,Pollack S,Metabolic disorder,initial,2018-11-28,GCST007289,Proliferative diabetic retinopathy (vs NPDR and no DR)
4309,Asian,22472.0,30487518.0,Takeuchi F,Cardiovascular disease,replication,2018-11-28,GCST007707,Hypertension
12877,Hispanic or Latin American,2254.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007290,Diabetic retinopathy (moderate NPDR and PDR)
7980,European,3731.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007291,Proliferative diabetic retinopathy (vs no DR)
909,African American or Afro-Caribbean,1709.0,30487263.0,Pollack S,Metabolic disorder,initial,2018-11-28,GCST007290,Diabetic retinopathy (moderate NPDR and PDR)
7400,European,2614.0,30487263.0,Pollack S,Metabolic disorder,initial,2018-11-28,GCST007290,Diabetic retinopathy (moderate NPDR and PDR)
1013,African American or Afro-Caribbean,2611.0,30487263.0,Pollack S,Metabolic disorder,initial,2018-11-28,GCST007289,Proliferative diabetic retinopathy (vs NPDR and no DR)
11594,European,105253.0,30487518.0,Takeuchi F,Other measurement,replication,2018-11-28,GCST007703,Systolic blood pressure
11595,European,105253.0,30487518.0,Takeuchi F,Other measurement,replication,2018-11-28,GCST007704,Diastolic blood pressure
7229,European,2368.0,30487263.0,Pollack S,Metabolic disorder,initial,2018-11-28,GCST007291,Proliferative diabetic retinopathy (vs no DR)
4444,Asian,53008.0,30487518.0,Takeuchi F,Other measurement,replication,2018-11-28,GCST007703,Systolic blood pressure
964,African American or Afro-Caribbean,2094.0,30488612.0,Xiang B,Neurological disorder,initial,2018-11-28,GCST007657,Alcohol and nicotine co-dependence
4174,Asian,13703.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007292,Diabetic retinopathy (all NPDR and PDR)
5599,European,678.0,30488612.0,Xiang B,Neurological disorder,replication,2018-11-28,GCST007657,Alcohol and nicotine co-dependence
2296,Asian,771.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007292,Diabetic retinopathy (all NPDR and PDR)
7636,European,3094.0,30487263.0,Pollack S,Metabolic disorder,initial,2018-11-28,GCST007292,Diabetic retinopathy (all NPDR and PDR)
12892,Hispanic or Latin American,2426.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007289,Proliferative diabetic retinopathy (vs NPDR and no DR)
2433,Asian,984.0,30487263.0,Pollack S,Metabolic disorder,replication,2018-11-28,GCST007292,Diabetic retinopathy (all NPDR and PDR)
4445,Asian,53008.0,30487518.0,Takeuchi F,Other measurement,replication,2018-11-28,GCST007704,Diastolic blood pressure
3134,Asian,2569.0,30498034.0,Terao C,Cardiovascular disease,initial,2018-11-29,GCST006984,Takayasu arteritis
2711,Asian,1622.0,30500874.0,Kakuta Y,Digestive system disorder,replication,2018-11-29,GCST007216,Crohn's disease
3380,Asian,3989.0,30498034.0,Terao C,Cardiovascular disease,replication,2018-11-29,GCST006984,Takayasu arteritis
3188,Asian,2796.0,30500874.0,Kakuta Y,Digestive system disorder,initial,2018-11-29,GCST007216,Crohn's disease
12463,European,764012.0,30504769.0,Ferkingstad E,Digestive system disorder,initial,2018-11-30,GCST007209,Gallstone disease
12258,European,337536.0,30566020.0,Fukaya E,Other trait,initial,2018-12-01,GCST007225,Varicose veins
12450,European,660648.0,30575882.0,Lotta LA,Body measurement,initial,2018-12-01,GCST008733,Waist-to-hip ratio adjusted for BMI
12451,European,663598.0,30575882.0,Lotta LA,"Other measurement, Body measurement",initial,2018-12-01,GCST008734,Waist-hip ratio
565,African American or Afro-Caribbean,267.0,30578281.0,Williams LM,"Neurological disorder, Biological process",initial,2018-12-01,GCST007210,Alloimmunization response to red blood cell transfusion in sickle cell anemia
474,African American or Afro-Caribbean,130.0,30578281.0,Williams LM,"Neurological disorder, Biological process",replication,2018-12-01,GCST007210,Alloimmunization response to red blood cell transfusion in sickle cell anemia
11694,European,120184.0,30510241.0,Huyghe JR,Cancer,initial,2018-12-03,GCST007856,Colorectal cancer or advanced adenoma
899,African American or Afro-Caribbean,1607.0,30510082.0,Qian M,Cancer,replication,2018-12-03,GCST007276,Acute lymphoblastic leukemia (B-cell precursor)
8212,European,4367.0,30510082.0,Qian M,Cancer,replication,2018-12-03,GCST007276,Acute lymphoblastic leukemia (B-cell precursor)
11340,European,71128.0,30510157.0,Franceschini N,"Other measurement, Cardiovascular measurement, Cardiovascular disease",initial,2018-12-03,GCST007436,Carotid intima media thickness
2501,Asian,1143.0,30511388.0,Yan W,Other disease,replication,2018-12-03,GCST007699,Developmental dysplasia of the hip
12682,Hispanic or Latin American,585.0,30510082.0,Qian M,Cancer,replication,2018-12-03,GCST007276,Acute lymphoblastic leukemia (B-cell precursor)
2379,Asian,886.0,30511388.0,Yan W,Other disease,initial,2018-12-03,GCST007699,Developmental dysplasia of the hip
12841,Hispanic or Latin American,1521.0,30510082.0,Qian M,Cancer,initial,2018-12-03,GCST007276,Acute lymphoblastic leukemia (B-cell precursor)
3558,Asian,5294.0,30510241.0,Huyghe JR,Cancer,initial,2018-12-03,GCST007856,Colorectal cancer or advanced adenoma
11084,European,48434.0,30510157.0,Franceschini N,Cardiovascular disease,initial,2018-12-03,GCST007435,Carotid plaque
8469,European,5031.0,30514930.0,Mukherjee S,Neurological disorder,initial,2018-12-04,GCST007333,Alzheimer's disease with no specific cognitive domain impairment
8062,European,3957.0,30514930.0,Mukherjee S,Neurological disorder,initial,2018-12-04,GCST007334,Alzheimer's disease with language domain impairment
8270,European,4554.0,30514930.0,Mukherjee S,"Neurological disorder, Other trait",initial,2018-12-04,GCST007330,Alzheimer's disease with memory domain impairment
8059,European,3944.0,30514930.0,Mukherjee S,Neurological disorder,initial,2018-12-04,GCST007318,Alzheimer's disease with visuospatial domain impairment
7971,European,3695.0,30514930.0,Mukherjee S,"Neurological disorder, Other trait",initial,2018-12-04,GCST007332,Alzheimer's disease with multiple cognitive domain impairments
8708,European,5878.0,30514930.0,Mukherjee S,Neurological disorder,initial,2018-12-04,GCST007331,Alzheimer's disease
9778,European,11744.0,30527956.0,Rhodes CJ,Cardiovascular disease,initial,2018-12-05,GCST007228,Pulmonary arterial hypertension
5026,European,342.0,30563176.0,Westermair AL,"Cardiovascular disease, Neurological disorder",initial,2018-12-05,GCST007230,Severe depressive disorders in coronary artery disease
12361,European,433216.0,30679032.0,Brazel DM,"Other measurement, Biological process",initial,2018-12-06,GCST008810,Smoking initiation (ever regular vs never regular)
4463,Asian,70506.0,30529582.0,Lu Y,Cancer,initial,2018-12-06,GCST007552,Colorectal cancer
11874,European,150993.0,30679032.0,Brazel DM,Other measurement,initial,2018-12-06,GCST008803,Smoking behaviour (cigarette pack-years)
306,African,8974.0,30679032.0,Brazel DM,"Other measurement, Biological process",initial,2018-12-06,GCST008806,Smoking initiation (ever regular vs never regular)
244,African,2685.0,30679032.0,Brazel DM,Other measurement,initial,2018-12-06,GCST008804,Smoking behaviour (cigarettes smoked per day)
299,African,7594.0,30679032.0,Brazel DM,"Biological process, Other measurement",initial,2018-12-06,GCST008805,Alcohol consumption (drinks per week)
12278,European,357857.0,30679032.0,Brazel DM,"Biological process, Other measurement",initial,2018-12-06,GCST008811,Alcohol consumption (drinks per week)
11832,European,146117.0,30679032.0,Brazel DM,"Other measurement, Biological process",initial,2018-12-06,GCST008802,Smoking behaviour (age at first cigarette)
246,African,2705.0,30679032.0,Brazel DM,"Other measurement, Biological process",initial,2018-12-06,GCST008807,Smoking behaviour (age at first cigarette)
11881,European,153918.0,30679032.0,Brazel DM,Other measurement,initial,2018-12-06,GCST008809,Smoking behaviour (cigarettes smoked per day)
9360,European,8609.0,30535121.0,Gao XR,Other measurement,replication,2018-12-07,GCST006976,Macular thickness
11228,European,59814.0,30535121.0,Gao XR,Other measurement,initial,2018-12-07,GCST006976,Macular thickness
5035,European,346.0,30531935.0,Crowley JJ,Metabolic disorder,initial,2018-12-07,GCST007233,Fragile X syndrome
1018,African American or Afro-Caribbean,2670.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007352,Focal epilepsy
3286,Asian,3365.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007352,Focal epilepsy
1014,African American or Afro-Caribbean,2645.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007353,Generalized epilepsy
11536,European,91105.0,30531941.0,Doherty A,Other measurement,initial,2018-12-10,GCST006914,Sleep duration
11537,European,91105.0,30531941.0,Doherty A,Other measurement,initial,2018-12-10,GCST006915,Physical activity (moderate intensity activity duration)
11538,European,91105.0,30531941.0,Doherty A,Other measurement,initial,2018-12-10,GCST007110,Physical activity (walking duration)
10637,European,27926.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007353,Generalized epilepsy
10621,European,26969.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007351,Focal epilepsy (with lesion other than hippocampal sclerosis)
10614,European,26878.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007349,Focal epilepsy (lesion negative)
10933,European,38752.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007343,Epilepsy
11535,European,91105.0,30531941.0,Doherty A,Other measurement,initial,2018-12-10,GCST006913,Sedentary behaviour duration
10569,European,24996.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007345,Childhood absence epilepsy
3205,Asian,2875.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007353,Generalized epilepsy
10563,European,24927.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007350,Focal epilepsy (with hippocampal sclerosis)
10556,European,24633.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007346,Juvenile absence epilepsy
10553,European,24443.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007348,"Epilepsy (generalized, with tonic-clonic seizures alone)"
12155,European,283920.0,30531825.0,Morgan MD,Other trait,initial,2018-12-10,GCST006989,Brown vs. black hair color
12193,European,299651.0,30531825.0,Morgan MD,Other trait,initial,2018-12-10,GCST006986,Red vs. brown/black hair color
1032,African American or Afro-Caribbean,2731.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007343,Epilepsy
12232,European,323317.0,30531825.0,Morgan MD,Other trait,initial,2018-12-10,GCST006988,Blond vs. brown/black hair color
11534,European,91105.0,30531941.0,Doherty A,Other measurement,initial,2018-12-10,GCST006912,Physical activity (overall physical activity time)
10580,European,25395.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007347,Juvenile myoclonic epilepsy
10774,European,33313.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007352,Focal epilepsy
3294,Asian,3406.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Neurological disorder,initial,2018-12-10,GCST007343,Epilepsy
10615,European,26885.0,30552067.0,Shrine N,Other disease,replication,2018-12-11,GCST006911,Asthma (moderate or severe)
10712,European,30810.0,30552067.0,Shrine N,Other disease,initial,2018-12-11,GCST006911,Asthma (moderate or severe)
10610,European,26722.0,30542056.0,Petridis C,Other disease,initial,2018-12-12,GCST007234,Acne (severe)
5638,European,708.0,30584014.0,Huang M,Other measurement,initial,2018-12-12,GCST008491,Whole-brain volume
10431,European,21536.0,30541042.0,Walsh N,Cancer,initial,2018-12-12,GCST007235,Pancreatic ductal adenocarcinoma
2224,Asian,676.0,30552108.0,Kawabata Y,Metabolic disorder,initial,2018-12-14,GCST007433,Fulminant type 1 diabetes
4654,European,90.0,30552317.0,Guo W,"Neurological disorder, Response to drug, Other measurement",initial,2018-12-14,GCST007317,Response to ketamine in bipolar disorder or major depression (dissociation effects)
4739,European,157.0,30552317.0,Guo W,"Neurological disorder, Response to drug, Other measurement",initial,2018-12-14,GCST007316,Response to ketamine in bipolar disorder or major depression (antidepressant effects)
7114,European,2198.0,30552173.0,Aterido A,Immune system disorder,initial,2018-12-14,GCST007043,Psoriatic arthritis
5365,European,520.0,30556296.0,Alblooshi H,Neurological disorder,replication,2018-12-16,GCST007700,Substance use disorder
13679,Other/Mixed,502.0,30556296.0,Alblooshi H,Neurological disorder,initial,2018-12-16,GCST007700,Substance use disorder
4257,Asian,18173.0,30557369.0,Yodsurang V,Cancer,initial,2018-12-17,GCST007239,Ovarian cancer
7678,European,3186.0,30631343.0,Rolfe S,Other measurement,initial,2018-12-18,GCST007450,Normal facial asymmetry (deformation magnitude)
2029,Asian,408.0,30662464.0,Yang C,"Other measurement, Cancer",initial,2018-12-18,GCST008104,Nucleoside diphosphate kinase A levels in hepatocellular carcinoma
6686,European,1688.0,30563984.0,Hawi Z,Neurological disorder,initial,2018-12-18,GCST006916,Attention deficit hyperactivity disorder
7677,European,3186.0,30631343.0,Rolfe S,Other measurement,initial,2018-12-18,GCST007449,Normal facial asymmetry (angle of deformation score)
7676,European,3186.0,30631343.0,Rolfe S,Other measurement,initial,2018-12-18,GCST007448,Normal facial asymmetry (angle of surface orientation score)
3903,Asian,8401.0,30566433.0,Taira M,Metabolic disorder,initial,2018-12-19,GCST007021,Type 2 diabetes nephropathy
3470,Asian,4634.0,30566433.0,Taira M,"Other trait, Metabolic disorder",replication,2018-12-19,GCST007022,Type 2 diabetes nephropathy including microalbuminuria
3904,Asian,8401.0,30566433.0,Taira M,"Other trait, Metabolic disorder",initial,2018-12-19,GCST007022,Type 2 diabetes nephropathy including microalbuminuria
11169,European,54543.0,30578877.0,Dahlin A,Other disease,initial,2018-12-19,GCST007596,Adult asthma
3469,Asian,4634.0,30566433.0,Taira M,Metabolic disorder,replication,2018-12-19,GCST007021,Type 2 diabetes nephropathy
11653,European,113238.0,30566500.0,Day F,Other disease,initial,2018-12-19,GCST007089,Polycystic ovary syndrome
10605,European,26475.0,30578877.0,Dahlin A,Other disease,replication,2018-12-19,GCST007598,Adult asthma
3702,Asian,6227.0,30578877.0,Dahlin A,Other disease,initial,2018-12-19,GCST007598,Adult asthma
13056,Hispanic or Latin American,5327.0,30578877.0,Dahlin A,Other disease,initial,2018-12-19,GCST007597,Adult asthma
1005,African American or Afro-Caribbean,2526.0,30578877.0,Dahlin A,Other disease,initial,2018-12-19,GCST007599,Adult asthma
10603,European,26475.0,30578877.0,Dahlin A,Other disease,replication,2018-12-19,GCST007596,Adult asthma
10604,European,26475.0,30578877.0,Dahlin A,Other disease,replication,2018-12-19,GCST007597,Adult asthma
10606,European,26475.0,30578877.0,Dahlin A,Other disease,replication,2018-12-19,GCST007599,Adult asthma
10491,European,23092.0,30571770.0,Arnau-Soler A,"Neurological disorder, Other measurement",initial,2018-12-20,GCST008507,Stress sensitivity (neuroticism score x major depressive disorder status interaction)
10701,European,30247.0,30571770.0,Arnau-Soler A,"Neurological disorder, Other measurement",initial,2018-12-20,GCST008508,Stress sensitivity (neuroticism score x major depressive disorder status interaction)
10702,European,30247.0,30571770.0,Arnau-Soler A,"Neurological disorder, Other measurement",initial,2018-12-20,GCST008510,Neuroticism
10727,European,31382.0,30573655.0,Acosta-Herrera M,"Neurological disorder, Immune system disorder",initial,2018-12-20,GCST007278,Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies)
12032,European,205327.0,30573740.0,Yap CX,"Other measurement, Other disease",initial,2018-12-20,GCST007020,Male-pattern baldness
9010,European,7155.0,30571770.0,Arnau-Soler A,"Neurological disorder, Other measurement",initial,2018-12-20,GCST008506,Stress sensitivity (neuroticism score x major depressive disorder status interaction)
10700,European,30247.0,30571770.0,Arnau-Soler A,Neurological disorder,initial,2018-12-20,GCST008509,Major depressive disorder
12079,European,223805.0,30583798.0,Bovijn J,Other disease,initial,2018-12-21,GCST006956,Erectile dysfunction
358,African,63490.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007270,Systolic blood pressure
12084,European,225112.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007271,Diastolic blood pressure
359,African,63490.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007271,Diastolic blood pressure
12083,European,225112.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007270,Systolic blood pressure
357,African,63490.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007268,Diastolic blood pressure
355,African,63490.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007272,Pulse pressure
13331,Hispanic or Latin American,22802.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007271,Diastolic blood pressure
13330,Hispanic or Latin American,22802.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007270,Systolic blood pressure
13329,Hispanic or Latin American,22802.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007268,Diastolic blood pressure
13328,Hispanic or Latin American,22802.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007267,Systolic blood pressure
13327,Hispanic or Latin American,22802.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007272,Pulse pressure
13326,Hispanic or Latin American,22802.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007269,Pulse pressure
356,African,63490.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007267,Systolic blood pressure
12285,European,365998.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007267,Systolic blood pressure
354,African,63490.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007269,Pulse pressure
13927,Other/Mixed,2695.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007271,Diastolic blood pressure
13926,Other/Mixed,2695.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007270,Systolic blood pressure
13925,Other/Mixed,2695.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007268,Diastolic blood pressure
13924,Other/Mixed,2695.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007267,Systolic blood pressure
13923,Other/Mixed,2695.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007272,Pulse pressure
13922,Other/Mixed,2695.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007269,Pulse pressure
12286,European,365998.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007268,Diastolic blood pressure
12082,European,225112.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007272,Pulse pressure
12284,European,365998.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007269,Pulse pressure
3500,Asian,4792.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007269,Pulse pressure
3504,Asian,4792.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007270,Systolic blood pressure
3503,Asian,4792.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007268,Diastolic blood pressure
3502,Asian,4792.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007267,Systolic blood pressure
3501,Asian,4792.0,30578418.0,Giri A,Cardiovascular measurement,initial,2018-12-21,GCST007272,Pulse pressure
12190,European,299024.0,30578418.0,Giri A,Cardiovascular measurement,replication,2018-12-21,GCST007269,Pulse pressure
12191,European,299024.0,30578418.0,Giri A,Other measurement,replication,2018-12-21,GCST007267,Systolic blood pressure
3505,Asian,4792.0,30578418.0,Giri A,Other measurement,initial,2018-12-21,GCST007271,Diastolic blood pressure
12192,European,299024.0,30578418.0,Giri A,Other measurement,replication,2018-12-21,GCST007268,Diastolic blood pressure
5301,European,493.0,30583557.0,Loohuis LM,Other measurement,initial,2018-12-22,GCST007261,Cerebrospinal fluid pyridoxal phosphate levels
5300,European,493.0,30583557.0,Loohuis LM,Other measurement,initial,2018-12-22,GCST007260,B6 vitamer levels (multivariate analysis)
5302,European,493.0,30583557.0,Loohuis LM,Other measurement,initial,2018-12-22,GCST007262,Plasma pyridoxal phosphate levels
5305,European,493.0,30583557.0,Loohuis LM,Other measurement,initial,2018-12-22,GCST007265,Plasma pyridoxic acid to pyridoxal phosphate ratio
5304,European,493.0,30583557.0,Loohuis LM,Other measurement,initial,2018-12-22,GCST007264,Plasma pyridoxal phosphate to pyridoxal ratio
5303,European,493.0,30583557.0,Loohuis LM,Other measurement,initial,2018-12-22,GCST007263,Cerebrospinal fluid pyridoxal phosphate to pyridoxal ratio
3593,Asian,5571.0,30591961.0,Huang L,Other measurement,initial,2018-12-24,GCST007998,Intraocular pressure
3235,Asian,2981.0,30591961.0,Huang L,Other measurement,initial,2018-12-24,GCST007998,Intraocular pressure
12657,Hispanic or Latin American,486.0,30593799.0,Vergara C,"Other trait, Digestive system disorder",initial,2018-12-26,GCST007631,Hepatitis C (spontaneous viral clearance)
12658,Hispanic or Latin American,486.0,30593799.0,Vergara C,"Other trait, Digestive system disorder",initial,2018-12-26,GCST007634,Hepatitis C (spontaneous viral clearance)
982,African American or Afro-Caribbean,2201.0,30593799.0,Vergara C,"Other trait, Digestive system disorder",initial,2018-12-26,GCST007632,Hepatitis C (spontaneous viral clearance)
6746,European,1736.0,30593799.0,Vergara C,"Other trait, Digestive system disorder",initial,2018-12-26,GCST007633,Hepatitis C (spontaneous viral clearance)
981,African American or Afro-Caribbean,2201.0,30593799.0,Vergara C,"Other trait, Digestive system disorder",initial,2018-12-26,GCST007631,Hepatitis C (spontaneous viral clearance)
6745,European,1736.0,30593799.0,Vergara C,"Other trait, Digestive system disorder",initial,2018-12-26,GCST007631,Hepatitis C (spontaneous viral clearance)
12299,European,372000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007081,Lung function (FVC)
12411,European,459000.0,30595370.0,Kichaev G,Metabolic disorder,initial,2018-12-27,GCST007077,Type 2 diabetes
12410,European,459000.0,30595370.0,Kichaev G,Immune system disorder,initial,2018-12-27,GCST007071,Autoimmune traits
12414,European,459000.0,30595370.0,Kichaev G,Other disease,initial,2018-12-27,GCST007076,Respiratory diseases
12415,European,459000.0,30595370.0,Kichaev G,Other trait,initial,2018-12-27,GCST007075,Eczema
12405,European,458000.0,30595370.0,Kichaev G,"Other measurement, Body measurement",initial,2018-12-27,GCST007841,Height
12404,European,458000.0,30595370.0,Kichaev G,"Other measurement, Body measurement",initial,2018-12-27,GCST007067,Waist-hip ratio
12403,European,458000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007085,Smoking status
12402,European,458000.0,30595370.0,Kichaev G,"Body measurement, Other measurement",initial,2018-12-27,GCST007039,Body mass index
12394,European,455000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007037,Educational attainment (years of education)
12389,European,452000.0,30595370.0,Kichaev G,"Other measurement, Other trait",initial,2018-12-27,GCST007082,Hair color
12373,European,446000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007066,Heel bone mineral density
12270,European,344000.0,30595370.0,Kichaev G,Other disease,initial,2018-12-27,GCST007086,Sunburns
12369,European,444000.0,30595370.0,Kichaev G,"Hematological measurement, Inflammatory measurement",initial,2018-12-27,GCST007070,White blood cell count
12368,European,443000.0,30595370.0,Kichaev G,Hematological measurement,initial,2018-12-27,GCST007068,Mean corpuscular hemoglobin
12365,European,440000.0,30595370.0,Kichaev G,Hematological measurement,initial,2018-12-27,GCST007065,Eosinophil counts
12355,European,422000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007087,Systolic blood pressure
12095,European,242000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007078,Menarche (age at onset)
12346,European,410000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007083,Morning person
12293,European,370000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007080,Lung function (FEV1/FVC)
12298,European,372000.0,30595370.0,Kichaev G,"Neurological disorder, Other measurement",initial,2018-12-27,GCST007084,Neuroticism
12371,European,445000.0,30595370.0,Kichaev G,Hematological measurement,initial,2018-12-27,GCST007074,Red cell distribution width
12370,European,445000.0,30595370.0,Kichaev G,Hematological measurement,initial,2018-12-27,GCST007069,Red blood cell count
12413,European,459000.0,30595370.0,Kichaev G,Other disease,initial,2018-12-27,GCST007073,Hypothyroidism
12412,European,459000.0,30595370.0,Kichaev G,Other disease,initial,2018-12-27,GCST007072,Cardiovascular disease
5575,European,665.0,30595539.0,Wallace HJ,Other measurement,initial,2018-12-27,GCST007251,Postburn scar height
12042,European,208000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007038,Balding type 1
5576,European,665.0,30595539.0,Wallace HJ,Other measurement,initial,2018-12-27,GCST007252,Postburn scar pliability
11823,European,143000.0,30595370.0,Kichaev G,Other measurement,initial,2018-12-27,GCST007079,Age at menopause
11892,European,155961.0,30593698.0,Hubel C,Body measurement,initial,2018-12-28,GCST007064,Body fat percentage
11893,European,155961.0,30593698.0,Hubel C,Other measurement,initial,2018-12-28,GCST007063,Fat-free mass
7553,European,2900.0,30685440.0,Silbernagel G,Lipid or lipoprotein measurement,initial,2018-12-28,GCST007955,Low density lipoprotein triglyceride levels
12456,European,731819.0,30598549.0,Morris JA,Other disease,replication,2018-12-31,GCST006980,Fractures
12357,European,426795.0,30598549.0,Morris JA,Other disease,initial,2018-12-31,GCST006980,Fractures
12358,European,426824.0,30598549.0,Morris JA,Other measurement,initial,2018-12-31,GCST006979,Heel bone mineral density
6310,European,1225.0,30582445.0,Mola-Caminal M,"Other trait, Other measurement",initial,2019-01-01,GCST006935,3-month functional outcome in ischaemic stroke (modified Rankin score)
6787,European,1791.0,30582445.0,Mola-Caminal M,"Other trait, Other measurement",replication,2019-01-01,GCST006935,3-month functional outcome in ischaemic stroke (modified Rankin score)
572,African American or Afro-Caribbean,285.0,30610941.0,Wang AW,Other measurement,initial,2019-01-02,GCST007726,Anti-Toxoplasma gondii IgG seropositivity
5748,European,790.0,30610941.0,Wang AW,Other measurement,initial,2019-01-02,GCST007726,Anti-Toxoplasma gondii IgG seropositivity
11776,European,134070.0,30604766.0,Morris AP,Other measurement,initial,2019-01-03,GCST007344,Estimated glomerular filtration rate
13337,Hispanic or Latin American,26344.0,30604766.0,Morris AP,Other measurement,initial,2019-01-03,GCST007344,Estimated glomerular filtration rate
4542,Asian,143658.0,30604766.0,Morris AP,Other measurement,initial,2019-01-03,GCST007344,Estimated glomerular filtration rate
1334,African American or Afro-Caribbean,8224.0,30604766.0,Morris AP,Other measurement,initial,2019-01-03,GCST007344,Estimated glomerular filtration rate
11440,European,83129.0,30610198.0,Soler Artigas M,"Neurological disorder, Biological process",initial,2019-01-04,GCST006983,Attention deficit hyperactivity disorder or cannabis use
5143,European,418.0,30621171.0,Coltell O,"Other measurement, Metabolic disorder",initial,2019-01-04,GCST007017,Serum bilirubin levels x Mediterranean diet adherence interaction in metabolic syndrome
14034,Other/Mixed,82315.0,30610197.0,Smeland OB,"Biological process, Neurological disorder",initial,2019-01-04,GCST007782,Schizophrenia or intelligence (pleiotropy)
10554,European,24546.0,30610202.0,Ruderfer DM,Other measurement,initial,2019-01-04,GCST006977,Predicted suicide risk
11120,European,51710.0,30610197.0,Smeland OB,"Biological process, Neurological disorder",initial,2019-01-04,GCST007781,Bipolar disorder or intelligence (pleiotropy)
5164,European,430.0,30621171.0,Coltell O,"Metabolic disorder, Other measurement",initial,2019-01-04,GCST007018,Serum bilirubin levels in metabolic syndrome
12256,European,337199.0,30610202.0,Ruderfer DM,Biological process,initial,2019-01-04,GCST006978,Suicide attempts
5163,European,430.0,30621171.0,Coltell O,"Metabolic disorder, Other measurement",initial,2019-01-04,GCST007016,Serum bilirubin levels x sex interaction in metabolic syndrome
14039,Other/Mixed,131892.0,30617275.0,Erzurumluoglu AM,Other measurement,initial,2019-01-07,GCST007601,Smoking behaviour (cigarette pack-years)
12308,European,376113.0,30617256.0,Jansen IE,Other measurement,initial,2019-01-07,GCST007321,Family history of Alzheimer's disease
12396,European,455258.0,30617256.0,Jansen IE,"Neurological disorder, Other measurement",initial,2019-01-07,GCST007320,Alzheimer's disease or family history of Alzheimer's disease
12233,European,324851.0,30617275.0,Erzurumluoglu AM,Biological process,initial,2019-01-07,GCST007603,Smoking initiation
4303,Asian,21962.0,30617275.0,Erzurumluoglu AM,Biological process,initial,2019-01-07,GCST007603,Smoking initiation
11403,European,79145.0,30617256.0,Jansen IE,Neurological disorder,initial,2019-01-07,GCST007319,Alzheimer's disease (late onset)
12145,European,275596.0,30617275.0,Erzurumluoglu AM,Biological process,replication,2019-01-07,GCST007604,Smoking cessation
12146,European,275596.0,30617275.0,Erzurumluoglu AM,Other measurement,replication,2019-01-07,GCST007601,Smoking behaviour (cigarette pack-years)
12147,European,275596.0,30617275.0,Erzurumluoglu AM,Other measurement,replication,2019-01-07,GCST007602,Smoking behaviour (cigarettes smoked per day)
14037,Other/Mixed,121543.0,30617275.0,Erzurumluoglu AM,Biological process,initial,2019-01-07,GCST007604,Smoking cessation
14038,Other/Mixed,128746.0,30617275.0,Erzurumluoglu AM,Other measurement,initial,2019-01-07,GCST007602,Smoking behaviour (cigarettes smoked per day)
12144,European,275596.0,30617275.0,Erzurumluoglu AM,Biological process,replication,2019-01-07,GCST007603,Smoking initiation
11481,European,86748.0,30626913.0,Amare AT,Neurological disorder,initial,2019-01-09,GCST007255,Broad depression or bipolar disorder
12312,European,377371.0,30626913.0,Amare AT,Neurological disorder,initial,2019-01-09,GCST007254,Broad depression or major depressive disorder (self-reported)
4055,Asian,10640.0,30626913.0,Amare AT,Neurological disorder,initial,2019-01-09,GCST007256,Broad depression or major depressive disorder (recurrent)
11333,European,70017.0,30626913.0,Amare AT,Neurological disorder,initial,2019-01-09,GCST007257,Broad depression or schizophrenia
11332,European,70017.0,30626913.0,Amare AT,Neurological disorder,initial,2019-01-09,GCST007256,Broad depression or major depressive disorder (recurrent)
10201,European,17480.0,30636644.0,Nazarian A,Neurological disorder,initial,2019-01-12,GCST007600,Alzheimer's disease
12435,European,557923.0,30643258.0,Karlsson Linner R,Biological process,initial,2019-01-14,GCST007324,Adventurousness
12347,European,410603.0,30643256.0,Baselmans BML,Other measurement,initial,2019-01-14,GCST007338,Positive affect
12483,European,2083151.0,30643256.0,Baselmans BML,Other measurement,initial,2019-01-14,GCST007341,Well-being spectrum (multivariate analysis)
12350,European,414343.0,30643258.0,Karlsson Linner R,"Biological process, Other measurement",initial,2019-01-14,GCST007328,Alcohol consumption (drinks per week)
12471,European,941280.0,30643251.0,Liu M,"Biological process, Other measurement",initial,2019-01-14,GCST007461,Alcohol consumption (drinks per week)
1127,African American or Afro-Caribbean,3420.0,30642921.0,de Vries PS,Other measurement,initial,2019-01-14,GCST007402,Factor VII activity or levels
1242,African American or Afro-Caribbean,5984.0,30642363.0,Hoffman J,Cancer,replication,2019-01-14,GCST006985,Breast cancer
12269,European,341427.0,30643251.0,Liu M,"Biological process, Other measurement",initial,2019-01-14,GCST007458,Age of smoking initiation
12470,European,939908.0,30643258.0,Karlsson Linner R,Biological process,initial,2019-01-14,GCST007322,General risk tolerance
12467,European,820192.0,30643251.0,Liu M,Biological process,initial,2019-01-14,GCST007464,Smoking cessation (MTAG)
12294,European,370711.0,30643258.0,Karlsson Linner R,Other measurement,initial,2019-01-14,GCST007326,Number of sexual partners
12469,European,931815.0,30643251.0,Liu M,Biological process,initial,2019-01-14,GCST007462,Age of smoking initiation (MTAG)
12164,European,287239.0,30643256.0,Baselmans BML,Other measurement,replication,2019-01-14,GCST007341,Well-being spectrum (multivariate analysis)
12976,Hispanic or Latin American,3992.0,30642363.0,Hoffman J,Cancer,replication,2019-01-14,GCST006985,Breast cancer
12481,European,1359002.0,30643251.0,Liu M,Other measurement,initial,2019-01-14,GCST007468,Smoking initiation (ever regular vs never regular) (MTAG)
3924,Asian,8719.0,30642363.0,Hoffman J,Cancer,replication,2019-01-14,GCST006985,Breast cancer
13163,Hispanic or Latin American,8801.0,30642363.0,Hoffman J,Cancer,initial,2019-01-14,GCST006985,Breast cancer
12478,European,1232091.0,30643251.0,Liu M,"Other measurement, Biological process",initial,2019-01-14,GCST007474,Smoking initiation (ever regular vs never regular)
12464,European,765694.0,30643255.0,Kristjansson RP,Neurological disorder,initial,2019-01-14,GCST007444,Chronic rhinosinusitis
11427,European,80852.0,30643256.0,Baselmans BML,Other measurement,initial,2019-01-14,GCST007337,Life satisfaction
12432,European,547219.0,30643251.0,Liu M,Biological process,initial,2019-01-14,GCST007460,Smoking cessation
12311,European,377334.0,30643251.0,Liu M,Other measurement,initial,2019-01-14,GCST007459,Smoking behaviour (cigarettes smoked per day)
12455,European,719047.0,30643255.0,Kristjansson RP,Cancer,initial,2019-01-14,GCST007443,Nasal polyps
12086,European,228033.0,30643256.0,Baselmans BML,"Neurological disorder, Other measurement",replication,2019-01-14,GCST007340,Depressive symptoms
11222,European,59206.0,30643256.0,Baselmans BML,"Neurological disorder, Other measurement",replication,2019-01-14,GCST007339,Neuroticism
7810,European,3344.0,30649302.0,Ruth KS,Other measurement,initial,2019-01-14,GCST007363,Anti-Mullerian hormone levels in pre-menopausal women of late reproductive age
12428,European,518633.0,30643258.0,Karlsson Linner R,"Biological process, Other measurement",initial,2019-01-14,GCST007327,Smoking status (ever vs never smokers)
10349,European,20014.0,30642921.0,de Vries PS,Other measurement,initial,2019-01-14,GCST007401,Factor VII activity
12472,European,975353.0,30643258.0,Karlsson Linner R,Biological process,initial,2019-01-14,GCST007325,General risk tolerance (MTAG)
10856,European,35445.0,30643258.0,Karlsson Linner R,Biological process,replication,2019-01-14,GCST007322,General risk tolerance
12475,European,1067913.0,30643256.0,Baselmans BML,"Neurological disorder, Other measurement",initial,2019-01-14,GCST007340,Depressive symptoms
12474,European,1039210.0,30643251.0,Liu M,Other measurement,initial,2019-01-14,GCST007472,Alcohol consumption (drinks per week) (MTAG)
12429,European,523783.0,30643256.0,Baselmans BML,"Neurological disorder, Other measurement",initial,2019-01-14,GCST007339,Neuroticism
10536,European,24075.0,30642921.0,de Vries PS,Other measurement,initial,2019-01-14,GCST007402,Factor VII activity or levels
1126,African American or Afro-Caribbean,3420.0,30642921.0,de Vries PS,Other measurement,initial,2019-01-14,GCST007401,Factor VII activity
12338,European,403928.0,30643251.0,Liu M,Other measurement,initial,2019-01-14,GCST007463,Cigarettes smoked per day (MTAG)
12339,European,404291.0,30643258.0,Karlsson Linner R,Biological process,initial,2019-01-14,GCST007329,Automobile speeding propensity
12222,European,315894.0,30643258.0,Karlsson Linner R,Biological process,initial,2019-01-14,GCST007323,Risk-taking tendency (4-domain principal component model)
3323,Asian,3574.0,30643196.0,Hitomi Y,Cancer,initial,2019-01-14,GCST007036,Primary biliary cholangitis
124,African,552.0,30647433.0,Legge SE,"Response to drug, Neurological disorder, Hematological measurement",initial,2019-01-15,GCST006987,Neutrophil level response to clozapine in treatment-resistant schizophrenia
776,African American or Afro-Caribbean,994.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007729,Small subcortical brain infarct
8819,European,6341.0,30651383.0,Chauhan G,Cardiovascular disease,replication,2019-01-16,GCST007730,Brain infarct
10059,European,15464.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007729,Small subcortical brain infarct
8673,European,5748.0,30651383.0,Chauhan G,Cardiovascular disease,replication,2019-01-16,GCST007729,Small subcortical brain infarct
8966,European,6932.0,30649180.0,Luo Q,Other measurement,initial,2019-01-16,GCST007357,Voxel-wise structural brain imaging measurements
10233,European,17956.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007730,Brain infarct
6722,European,1721.0,30649180.0,Luo Q,Other measurement,initial,2019-01-16,GCST007357,Voxel-wise structural brain imaging measurements
5531,European,634.0,30648747.0,Dudenkov TM,"Response to drug, Cancer",initial,2019-01-16,GCST007664,Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer
920,African American or Afro-Caribbean,1834.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007730,Brain infarct
405,African American or Afro-Caribbean,40.0,30648747.0,Dudenkov TM,"Response to drug, Cancer",initial,2019-01-16,GCST007664,Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer
1797,Asian,196.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007729,Small subcortical brain infarct
12708,Hispanic or Latin American,699.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007729,Small subcortical brain infarct
1809,Asian,207.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007730,Brain infarct
1810,Asian,208.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007729,Small subcortical brain infarct
1823,Asian,215.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007730,Brain infarct
12722,Hispanic or Latin American,737.0,30651383.0,Chauhan G,Cardiovascular disease,initial,2019-01-16,GCST007730,Brain infarct
1553,Asian,13.0,30648747.0,Dudenkov TM,"Response to drug, Cancer",initial,2019-01-16,GCST007664,Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer
2132,Asian,521.0,30651383.0,Chauhan G,Cardiovascular disease,replication,2019-01-16,GCST007730,Brain infarct
7269,European,2439.0,30655502.0,Levey DF,Other measurement,initial,2019-01-17,GCST007019,Suicide attempt severity
884,African American or Afro-Caribbean,1488.0,30655502.0,Levey DF,Other measurement,replication,2019-01-17,GCST007019,Suicide attempt severity
9478,European,9382.0,30655502.0,Levey DF,Other measurement,replication,2019-01-17,GCST007019,Suicide attempt severity
5766,European,804.0,30868120.0,Berghuis B,"Response to drug, Other trait, Neurological disorder",initial,2019-01-17,GCST007810,Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy
6128,European,1031.0,30868120.0,Berghuis B,"Other trait, Response to drug, Neurological disorder",initial,2019-01-17,GCST007811,Carbamazepine-induced hyponatremia in epilepsy
6334,European,1252.0,30868120.0,Berghuis B,"Response to drug, Other trait, Neurological disorder",initial,2019-01-17,GCST007809,Carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy
12927,Hispanic or Latin American,2963.0,30655502.0,Levey DF,Other measurement,replication,2019-01-17,GCST007019,Suicide attempt severity
4960,European,297.0,30868120.0,Berghuis B,"Response to drug, Other trait, Neurological disorder",initial,2019-01-17,GCST007812,Oxcarbazepine-induced hyponatremia in epilepsy
6333,European,1252.0,30868120.0,Berghuis B,"Other measurement, Neurological disorder",initial,2019-01-17,GCST007814,Sodium levels in epilepsy
5245,European,468.0,30868120.0,Berghuis B,"Other measurement, Neurological disorder",initial,2019-01-17,GCST007813,"Carbamazepine metabolism (carbamazepine-10,11-diol to carbamazepine ratio) in epilepsy"
1164,African American or Afro-Caribbean,3881.0,30655502.0,Levey DF,Other measurement,initial,2019-01-17,GCST007019,Suicide attempt severity
6230,European,1145.0,30654714.0,Hurst Z,"Biological process, Cancer",initial,2019-01-18,GCST008107,Radioiodine-refractory disease in thyroid cancer
6988,European,2062.0,30891314.0,Saad MN,Immune system disorder,initial,2019-01-18,GCST007843,Rheumatoid arthritis
13791,Other/Mixed,815.0,30713548.0,Schurz H,Other disease,initial,2019-01-18,GCST007232,Tuberculosis (SNP x SNP interaction)
13792,Other/Mixed,815.0,30713548.0,Schurz H,"Other disease, Other measurement",initial,2019-01-18,GCST007231,Tuberculosis
419,African American or Afro-Caribbean,55.0,30654714.0,Hurst Z,"Biological process, Cancer",initial,2019-01-18,GCST008107,Radioiodine-refractory disease in thyroid cancer
9734,European,11226.0,30659137.0,Traylor M,Other measurement,initial,2019-01-18,GCST007305,White matter hyperintensity volume
2419,Asian,959.0,30657218.0,Park SY,Other disease,initial,2019-01-18,GCST007520,Asthma-chronic obstructive pulmonary disease overlap syndrome in asthma
2216,Asian,665.0,30659259.0,Imaizumi A,Other measurement,replication,2019-01-18,GCST007384,Plasma free proline levels
2217,Asian,665.0,30659259.0,Imaizumi A,Other measurement,replication,2019-01-18,GCST007386,Plasma free asparagine levels
3694,Asian,6143.0,30657218.0,Park SY,Other disease,initial,2019-01-18,GCST007521,Asthma-chronic obstructive  pulmonary disease overlap syndrome
9822,European,12203.0,30664875.0,Cirulli ET,"Response to drug, Digestive system disorder",initial,2019-01-18,GCST007774,Drug-induced liver injury
12093,European,239417.0,30664875.0,Cirulli ET,"Response to drug, Digestive system disorder",replication,2019-01-18,GCST007774,Drug-induced liver injury
12753,Hispanic or Latin American,827.0,30664875.0,Cirulli ET,"Response to drug, Digestive system disorder",initial,2019-01-18,GCST007774,Drug-induced liver injury
2585,Asian,1338.0,30659259.0,Imaizumi A,Other measurement,initial,2019-01-18,GCST007386,Plasma free asparagine levels
10000,European,14689.0,30659475.0,Arias-Vasquez A,Other measurement,initial,2019-01-18,GCST007279,Attention deficit hyperactivity disorder symptom score
6293,European,1202.0,30659137.0,Traylor M,Other measurement,replication,2019-01-18,GCST007305,White matter hyperintensity volume
2584,Asian,1338.0,30659259.0,Imaizumi A,Other measurement,initial,2019-01-18,GCST007385,Plasma free amino acid levels
2583,Asian,1338.0,30659259.0,Imaizumi A,Other measurement,initial,2019-01-18,GCST007384,Plasma free proline levels
2582,Asian,1338.0,30659259.0,Imaizumi A,Other measurement,initial,2019-01-18,GCST007383,Plasma free amino acid levels (adjusted for one other PFAA)
3792,Asian,7271.0,30657218.0,Park SY,Other disease,initial,2019-01-18,GCST007519,Adult asthma
2581,Asian,1338.0,30659259.0,Imaizumi A,Other measurement,initial,2019-01-18,GCST007382,Plasma free amino acid levels (adjusted for twenty other PFAAs)
879,African American or Afro-Caribbean,1447.0,30664875.0,Cirulli ET,"Response to drug, Digestive system disorder",initial,2019-01-18,GCST007774,Drug-induced liver injury
9658,European,10603.0,30661239.0,Nicoletti P,Digestive system disorder,initial,2019-01-19,GCST007607,Drug-induced liver injury (amoxicillin)
9651,European,10594.0,30661239.0,Nicoletti P,Digestive system disorder,initial,2019-01-19,GCST007608,Drug-induced liver injury (isoxazolyl penicillins)
12388,European,451099.0,30661054.0,Schafmayer C,Digestive system disorder,initial,2019-01-19,GCST008105,Diverticular disease
8984,European,7032.0,30661239.0,Nicoletti P,Digestive system disorder,initial,2019-01-19,GCST007606,Drug-induced liver injury (flucloxacillin)
10869,European,36089.0,30661054.0,Schafmayer C,Digestive system disorder,replication,2019-01-19,GCST008105,Diverticular disease
12100,European,246360.0,30664634.0,Rask-Andersen M,Body measurement,replication,2019-01-21,GCST007295,Body fat distribution (leg fat ratio)
12099,European,246360.0,30664634.0,Rask-Andersen M,Body measurement,replication,2019-01-21,GCST007294,Body fat distribution (trunk fat ratio)
12098,European,246360.0,30664634.0,Rask-Andersen M,Body measurement,replication,2019-01-21,GCST007293,Body fat distribution (arm fat ratio)
12336,European,403124.0,30664745.0,Tachmazidou I,Other disease,initial,2019-01-21,GCST007090,Knee osteoarthritis
11666,European,116138.0,30664634.0,Rask-Andersen M,Body measurement,initial,2019-01-21,GCST007295,Body fat distribution (leg fat ratio)
11665,European,116138.0,30664634.0,Rask-Andersen M,Body measurement,initial,2019-01-21,GCST007294,Body fat distribution (trunk fat ratio)
13083,Hispanic or Latin American,6236.0,30664655.0,Adhikari K,"Other trait, Other measurement",initial,2019-01-21,GCST007452,Skin pigmentation
12353,European,417596.0,30664745.0,Tachmazidou I,Other disease,initial,2019-01-21,GCST007092,Osteoarthritis of the hip or knee
12325,European,393873.0,30664745.0,Tachmazidou I,Other disease,initial,2019-01-21,GCST007091,Osteoarthritis (hip)
13082,Hispanic or Latin American,6236.0,30664655.0,Adhikari K,"Other measurement, Other trait",initial,2019-01-21,GCST007454,Hair color
13081,Hispanic or Latin American,6236.0,30664655.0,Adhikari K,"Other measurement, Other trait",initial,2019-01-21,GCST007453,Eye color
13080,Hispanic or Latin American,6236.0,30664655.0,Adhikari K,Other measurement,initial,2019-01-21,GCST007457,Eye color (saturation)
13079,Hispanic or Latin American,6236.0,30664655.0,Adhikari K,Other measurement,initial,2019-01-21,GCST007456,Eye color (hue)
13078,Hispanic or Latin American,6236.0,30664655.0,Adhikari K,Other measurement,initial,2019-01-21,GCST007455,Eye color (brightness)
12395,European,455221.0,30664745.0,Tachmazidou I,Other disease,initial,2019-01-21,GCST007093,Osteoarthritis
13077,Hispanic or Latin American,6236.0,30664655.0,Adhikari K,Other measurement,initial,2019-01-21,GCST007451,"Skin, hair and eye pigmentation (multivariate analysis)"
11664,European,116138.0,30664634.0,Rask-Andersen M,Body measurement,initial,2019-01-21,GCST007293,Body fat distribution (arm fat ratio)
2987,Asian,2148.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
11345,European,72102.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
11344,European,72102.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
2988,Asian,2148.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
210,African,1606.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
2989,Asian,2149.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
11390,European,77688.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
2990,Asian,2149.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
2991,Asian,2149.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
13197,Hispanic or Latin American,11239.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
2992,Asian,2149.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
13196,Hispanic or Latin American,11239.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
969,African American or Afro-Caribbean,2120.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
968,African American or Afro-Caribbean,2120.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
963,African American or Afro-Caribbean,2092.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
962,African American or Afro-Caribbean,2092.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
13198,Hispanic or Latin American,11421.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
212,African,1606.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
208,African,1606.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
13200,Hispanic or Latin American,11422.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
1448,African American or Afro-Caribbean,20021.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
1449,African American or Afro-Caribbean,20021.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
1450,African American or Afro-Caribbean,20126.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
1451,African American or Afro-Caribbean,20126.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
1453,African American or Afro-Caribbean,20487.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
1454,African American or Afro-Caribbean,20487.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
1154,African American or Afro-Caribbean,3778.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
13061,Hispanic or Latin American,5652.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
3441,Asian,4442.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
3440,Asian,4442.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
3439,Asian,4441.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
13060,Hispanic or Latin American,5652.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
3438,Asian,4441.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
13059,Hispanic or Latin American,5624.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
3434,Asian,4401.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
1155,African American or Afro-Caribbean,3778.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
3433,Asian,4401.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
13058,Hispanic or Latin American,5624.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
209,African,1606.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
3717,Asian,6355.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
3718,Asian,6355.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
11430,European,81966.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
3727,Asian,6403.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
13201,Hispanic or Latin American,11422.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
3728,Asian,6403.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
13199,Hispanic or Latin American,11421.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
11431,European,81966.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
11391,European,77688.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
11460,European,84902.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
11611,European,107617.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
13175,Hispanic or Latin American,9187.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
211,African,1606.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
213,African,1606.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
11459,European,84902.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
11450,European,84608.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007284,LDL cholesterol x physical activity interaction (2df test)
11449,European,84608.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007283,LDL cholesterol x physical activity interaction (1df test)
11612,European,107617.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007282,HDL cholesterol x physical activity interaction (2df test)
13174,Hispanic or Latin American,9187.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",initial,2019-01-22,GCST007281,HDL cholesterol x physical activity interaction (1df test)
3137,Asian,2579.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007286,Triglycerides x physical activity interaction (2df test)
3136,Asian,2579.0,30670697.0,Kilpelainen TO,"Lipid or lipoprotein measurement, Biological process",replication,2019-01-22,GCST007285,Triglycerides x physical activity interaction (1df test)
8290,European,4622.0,30674623.0,Syreeni A,"Other measurement, Metabolic disorder",initial,2019-01-23,GCST007605,Glycated hemoglobin levels in type 1 diabetes
10372,European,20623.0,30674883.0,Jin Y,Immune system disorder,initial,2019-01-23,GCST007112,Vitiligo (late onset)
13815,Other/Mixed,920.0,30674050.0,Spiegel AM,Other disease,initial,2019-01-23,GCST007956,Maternal chorioamnionitis
6812,European,1830.0,30674883.0,Jin Y,Immune system disorder,replication,2019-01-23,GCST007111,Vitiligo (early onset)
10342,European,19860.0,30674883.0,Jin Y,Immune system disorder,initial,2019-01-23,GCST007111,Vitiligo (early onset)
6700,European,1704.0,30674883.0,Jin Y,Immune system disorder,replication,2019-01-23,GCST007112,Vitiligo (late onset)
10611,European,26794.0,30679814.0,van Setten J,Cardiovascular measurement,initial,2019-01-24,GCST007218,QT interval
10640,European,28246.0,30677029.0,Riveros-McKay F,"Metabolic disorder, Body measurement",replication,2019-01-24,GCST007241,Obesity (extreme)
10730,European,31695.0,30679814.0,van Setten J,Cardiovascular measurement,initial,2019-01-24,GCST007226,PR interval
9716,European,11058.0,30677029.0,Riveros-McKay F,Body measurement,replication,2019-01-24,GCST007240,Obese vs. thin
7565,European,2927.0,30677029.0,Riveros-McKay F,Body measurement,initial,2019-01-24,GCST007240,Obese vs. thin
10653,European,28698.0,30679814.0,van Setten J,Cardiovascular measurement,initial,2019-01-24,GCST007217,RR interval (heart rate)
10740,European,32132.0,30679814.0,van Setten J,Cardiovascular measurement,replication,2019-01-24,GCST007227,QRS duration
10759,European,32597.0,30679814.0,van Setten J,Cardiovascular measurement,replication,2019-01-24,GCST007218,QT interval
9161,European,7916.0,30677029.0,Riveros-McKay F,"Metabolic disorder, Body measurement",initial,2019-01-24,GCST007241,Obesity (extreme)
961,African American or Afro-Caribbean,2070.0,30679814.0,van Setten J,Cardiovascular measurement,replication,2019-01-24,GCST007226,PR interval
9168,European,7931.0,30677029.0,Riveros-McKay F,Body measurement,initial,2019-01-24,GCST007242,Normal body mass index vs. thin
958,African American or Afro-Caribbean,2048.0,30679814.0,van Setten J,Cardiovascular measurement,replication,2019-01-24,GCST007227,QRS duration
957,African American or Afro-Caribbean,2048.0,30679814.0,van Setten J,Cardiovascular measurement,replication,2019-01-24,GCST007218,QT interval
10549,European,24252.0,30677029.0,Riveros-McKay F,Body measurement,replication,2019-01-24,GCST007242,Normal body mass index vs. thin
10751,European,32405.0,30679814.0,van Setten J,Cardiovascular measurement,replication,2019-01-24,GCST007226,PR interval
10583,European,25509.0,30679814.0,van Setten J,Cardiovascular measurement,initial,2019-01-24,GCST007227,QRS duration
11279,European,65534.0,30692689.0,Schork AJ,"Neurological disorder, Metabolic disorder",initial,2019-01-28,GCST007777,Psychiatric disorder
12796,Hispanic or Latin American,1095.0,30692554.0,Bustos BI,Digestive system disorder,initial,2019-01-28,GCST007050,Gallstone disease
8760,European,6092.0,30692554.0,Bustos BI,Digestive system disorder,replication,2019-01-28,GCST007050,Gallstone disease
12848,Hispanic or Latin American,1643.0,30692554.0,Bustos BI,Digestive system disorder,replication,2019-01-28,GCST007050,Gallstone disease
4102,Asian,11706.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008077,LDL cholesterol levels
4478,Asian,96276.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
4477,Asian,96276.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
4476,Asian,96276.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
13101,Hispanic or Latin American,6622.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
13100,Hispanic or Latin American,6622.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
4479,Asian,96276.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
4480,Asian,96276.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
4481,Asian,96276.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
4482,Asian,96276.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008070,HDL cholesterol levels
13292,Hispanic or Latin American,17366.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008077,LDL cholesterol levels
4483,Asian,96276.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008076,Triglyceride levels
4484,Asian,96276.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008077,LDL cholesterol levels
4100,Asian,11706.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008070,HDL cholesterol levels
13284,Hispanic or Latin American,17366.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
13285,Hispanic or Latin American,17366.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
863,African American or Afro-Caribbean,1349.0,30694715.0,Sakornsakolpat P,Other measurement,initial,2019-01-29,GCST007637,Diffusing capacity of carbon monoxide
13159,Hispanic or Latin American,8606.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
13160,Hispanic or Latin American,8606.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
13286,Hispanic or Latin American,17366.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
4094,Asian,11706.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
8636,European,5586.0,30694715.0,Sakornsakolpat P,Other measurement,initial,2019-01-29,GCST007637,Diffusing capacity of carbon monoxide
4095,Asian,11706.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
13098,Hispanic or Latin American,6622.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
13099,Hispanic or Latin American,6622.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
4096,Asian,11706.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
4097,Asian,11706.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
13161,Hispanic or Latin American,8606.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008087,Triglyceride levels in current drinkers
13287,Hispanic or Latin American,17366.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
13288,Hispanic or Latin American,17366.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
13289,Hispanic or Latin American,17366.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
13290,Hispanic or Latin American,17366.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008070,HDL cholesterol levels
4098,Asian,11706.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
4099,Asian,11706.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
13291,Hispanic or Latin American,17366.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008076,Triglyceride levels
4101,Asian,11706.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008076,Triglyceride levels
13102,Hispanic or Latin American,6622.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
950,African American or Afro-Caribbean,2028.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
4023,Asian,9986.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008077,LDL cholesterol levels
12900,Hispanic or Latin American,2528.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
12901,Hispanic or Latin American,2528.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
12902,Hispanic or Latin American,2528.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
12981,Hispanic or Latin American,3994.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
4018,Asian,9986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
12903,Hispanic or Latin American,2528.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
4017,Asian,9986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
12980,Hispanic or Latin American,3994.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
12979,Hispanic or Latin American,3994.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
12982,Hispanic or Latin American,3994.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
12978,Hispanic or Latin American,3994.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
4016,Asian,9986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
4015,Asian,9986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
12757,Hispanic or Latin American,854.0,30697902.0,Hernandez-Pacheco N,"Response to drug, Other measurement",initial,2019-01-29,GCST007100,Asthma exacerbations in inhaled corticosteroid treatment
944,African American or Afro-Caribbean,2028.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
945,African American or Afro-Caribbean,2028.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
946,African American or Afro-Caribbean,2028.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008087,Triglyceride levels in current drinkers
948,African American or Afro-Caribbean,2028.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
952,African American or Afro-Caribbean,2028.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
951,African American or Afro-Caribbean,2028.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
12977,Hispanic or Latin American,3994.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
13103,Hispanic or Latin American,6622.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
12899,Hispanic or Latin American,2528.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
12984,Hispanic or Latin American,3994.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008076,Triglyceride levels
4022,Asian,9986.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008076,Triglyceride levels
4398,Asian,36673.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
4397,Asian,36673.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
4396,Asian,36673.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
4021,Asian,9986.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008070,HDL cholesterol levels
949,African American or Afro-Caribbean,2028.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
4020,Asian,9986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
4395,Asian,36673.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
12895,Hispanic or Latin American,2528.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
12983,Hispanic or Latin American,3994.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008070,HDL cholesterol levels
4394,Asian,36673.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
4392,Asian,36673.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008087,Triglyceride levels in current drinkers
12896,Hispanic or Latin American,2528.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
4391,Asian,36673.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
665,African American or Afro-Caribbean,493.0,30697902.0,Hernandez-Pacheco N,"Response to drug, Other measurement",initial,2019-01-29,GCST007100,Asthma exacerbations in inhaled corticosteroid treatment
4390,Asian,36673.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
12897,Hispanic or Latin American,2528.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008087,Triglyceride levels in current drinkers
12898,Hispanic or Latin American,2528.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
4019,Asian,9986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
12985,Hispanic or Latin American,3994.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008077,LDL cholesterol levels
4393,Asian,36673.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
947,African American or Afro-Caribbean,2028.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
3002,Asian,2169.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
1196,African American or Afro-Caribbean,4475.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
3007,Asian,2169.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008076,Triglyceride levels
3006,Asian,2169.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008070,HDL cholesterol levels
3005,Asian,2169.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
3004,Asian,2169.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
3003,Asian,2169.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
3001,Asian,2169.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
3008,Asian,2169.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008077,LDL cholesterol levels
3000,Asian,2169.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
2206,Asian,662.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
12104,European,248100.0,30696823.0,Jones SE,Other measurement,replication,2019-01-29,GCST007565,Morning person
2207,Asian,662.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
12103,European,248098.0,30696823.0,Jones SE,"Biological process, Other measurement",replication,2019-01-29,GCST007576,Chronotype
2208,Asian,662.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008087,Triglyceride levels in current drinkers
2209,Asian,662.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
1200,African American or Afro-Caribbean,4475.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008077,LDL cholesterol levels
3019,Asian,2224.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
1373,African American or Afro-Caribbean,9870.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
3021,Asian,2224.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008087,Triglyceride levels in current drinkers
11610,European,107548.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
1460,African American or Afro-Caribbean,20989.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
1461,African American or Afro-Caribbean,20989.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
1462,African American or Afro-Caribbean,20989.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
1463,African American or Afro-Caribbean,20989.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
1464,African American or Afro-Caribbean,20989.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
1465,African American or Afro-Caribbean,20989.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008070,HDL cholesterol levels
3027,Asian,2224.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
1466,African American or Afro-Caribbean,20989.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008076,Triglyceride levels
3026,Asian,2224.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
3025,Asian,2224.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
1467,African American or Afro-Caribbean,20989.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008077,LDL cholesterol levels
3024,Asian,2224.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
3023,Asian,2224.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
3022,Asian,2224.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
2210,Asian,662.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
2211,Asian,662.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
2212,Asian,662.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
2213,Asian,662.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
11790,European,136986.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008077,LDL cholesterol levels
2271,Asian,744.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
2272,Asian,744.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
2273,Asian,744.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
2274,Asian,744.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
2275,Asian,744.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
2276,Asian,744.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
2277,Asian,744.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008070,HDL cholesterol levels
2278,Asian,744.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008076,Triglyceride levels
2279,Asian,744.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008077,LDL cholesterol levels
1368,African American or Afro-Caribbean,9870.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
1369,African American or Afro-Caribbean,9870.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
1370,African American or Afro-Caribbean,9870.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
1371,African American or Afro-Caribbean,9870.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
1372,African American or Afro-Caribbean,9870.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
11789,European,136986.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008076,Triglyceride levels
11609,European,107548.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
11788,European,136986.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008070,HDL cholesterol levels
11786,European,136986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
2214,Asian,662.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
1199,African American or Afro-Caribbean,4475.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008076,Triglyceride levels
1198,African American or Afro-Caribbean,4475.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,replication,2019-01-29,GCST008070,HDL cholesterol levels
1197,African American or Afro-Caribbean,4475.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
1195,African American or Afro-Caribbean,4475.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
1194,African American or Afro-Caribbean,4475.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
1193,African American or Afro-Caribbean,4475.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
1192,African American or Afro-Caribbean,4475.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
1365,African American or Afro-Caribbean,9870.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
1366,African American or Afro-Caribbean,9870.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
1367,African American or Afro-Caribbean,9870.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008087,Triglyceride levels in current drinkers
11782,European,136986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
11783,European,136986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
11784,European,136986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
11785,European,136986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
11787,European,136986.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
11608,European,107548.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
3020,Asian,2224.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
11606,European,107548.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
1896,Asian,267.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
11192,European,56505.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
11193,European,56505.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
11194,European,56505.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
1897,Asian,267.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
11195,European,56505.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
1898,Asian,267.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
11191,European,56505.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
11607,European,107548.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
3371,Asian,3905.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
3370,Asian,3905.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008075,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
3369,Asian,3905.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008074,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
3368,Asian,3905.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008073,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
3367,Asian,3905.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
3366,Asian,3905.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
3365,Asian,3905.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008087,Triglyceride levels in current drinkers
1899,Asian,267.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
1895,Asian,267.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008072,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
1894,Asian,267.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
1893,Asian,267.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008087,Triglyceride levels in current drinkers
11188,European,56505.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
6694,European,1697.0,30697902.0,Hernandez-Pacheco N,"Response to drug, Other measurement",replication,2019-01-29,GCST007100,Asthma exacerbations in inhaled corticosteroid treatment
12384,European,449734.0,30696823.0,Jones SE,"Biological process, Other measurement",initial,2019-01-29,GCST007576,Chronotype
11512,European,89893.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
11513,European,89893.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008080,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
11514,European,89893.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008081,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
11515,European,89893.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008082,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df)
11516,European,89893.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008083,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
11517,European,89893.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008084,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
11518,European,89893.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008070,HDL cholesterol levels
11519,European,89893.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008076,Triglyceride levels
11520,European,89893.0,30698716.0,de Vries PS,Lipid or lipoprotein measurement,initial,2019-01-29,GCST008077,LDL cholesterol levels
12337,European,403195.0,30696823.0,Jones SE,Other measurement,initial,2019-01-29,GCST007565,Morning person
1891,Asian,267.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
11189,European,56505.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
11190,European,56505.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008087,Triglyceride levels in current drinkers
1892,Asian,267.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
3364,Asian,3905.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
3363,Asian,3905.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
11196,European,56505.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",initial,2019-01-29,GCST008078,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)
1459,African American or Afro-Caribbean,20989.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",initial,2019-01-29,GCST008079,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)
11605,European,107548.0,30698716.0,de Vries PS,"Lipid or lipoprotein measurement, Other measurement",replication,2019-01-29,GCST008071,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df)
11603,European,107548.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008086,LDL cholesterol levels in current drinkers
11602,European,107548.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008085,HDL cholesterol levels in current drinkers
11604,European,107548.0,30698716.0,de Vries PS,"Biological process, Lipid or lipoprotein measurement",replication,2019-01-29,GCST008087,Triglyceride levels in current drinkers
252,African,3073.0,30729179.0,Zenin A,Other measurement,replication,2019-01-30,GCST007406,Healthspan
2613,Asian,1422.0,30729179.0,Zenin A,Other measurement,replication,2019-01-30,GCST007406,Healthspan
4568,European,31.0,30711515.0,Hallberg P,"Neurological disorder, Response to drug",replication,2019-01-30,GCST007779,Pandemrix-induced narcolepsy
11429,European,81099.0,30729179.0,Zenin A,Other measurement,replication,2019-01-30,GCST007406,Healthspan
12198,European,300447.0,30729179.0,Zenin A,Other measurement,initial,2019-01-30,GCST007406,Healthspan
8426,European,4932.0,30711515.0,Hallberg P,"Neurological disorder, Response to drug",initial,2019-01-30,GCST007779,Pandemrix-induced narcolepsy
3760,Asian,6921.0,30729179.0,Zenin A,Other measurement,replication,2019-01-30,GCST007406,Healthspan
1158,African American or Afro-Caribbean,3799.0,30729179.0,Zenin A,Other measurement,replication,2019-01-30,GCST007406,Healthspan
4050,Asian,10330.0,30705256.0,Koshimizu H,Other measurement,initial,2019-01-31,GCST007297,Psychological distress
5003,European,330.0,30706531.0,Tao F,"Neurological disorder, Other measurement",initial,2019-01-31,GCST007304,Reduced foot dorsiflexion strength in Charcot-Marie-Tooth disease type 1A
7866,European,3452.0,30700811.0,Wigmore EM,Response to drug,initial,2019-01-31,GCST007355,Antidepressant treatment resistance (> 2 drugs prescribed)
7867,European,3452.0,30700811.0,Wigmore EM,Response to drug,initial,2019-01-31,GCST007356,Antidepressant treatment resistance (number of drugs prescribed)
7954,European,3647.0,30704525.0,Guyatt AL,Other measurement,initial,2019-01-31,GCST007393,Mitochondrial DNA copy number
1642,Asian,80.0,30706531.0,Tao F,"Neurological disorder, Other measurement",replication,2019-01-31,GCST007304,Reduced foot dorsiflexion strength in Charcot-Marie-Tooth disease type 1A
8614,European,5461.0,30704525.0,Guyatt AL,Other measurement,initial,2019-01-31,GCST007395,Mitochondrial DNA copy number
7846,European,3405.0,30704525.0,Guyatt AL,Other measurement,initial,2019-01-31,GCST007398,Mitochondrial DNA copy number (white blood cells)
7845,European,3405.0,30704525.0,Guyatt AL,Other measurement,initial,2019-01-31,GCST007396,Mitochondrial DNA copy number (white blood cells)
8615,European,5461.0,30704525.0,Guyatt AL,Other measurement,initial,2019-01-31,GCST007399,Mitochondrial DNA copy number
7015,European,2102.0,30704525.0,Guyatt AL,Other measurement,initial,2019-01-31,GCST007394,Mitochondrial DNA copy number
7898,European,3514.0,30794219.0,MacInnes SJ,"Other trait, Other disease",initial,2019-02-01,GCST007549,Osteolysis in total hip arthroplasty
6194,European,1096.0,30794219.0,MacInnes SJ,"Other trait, Other disease, Other measurement",initial,2019-02-01,GCST007550,Osteolysis in total hip arthroplasty (time to prosthesis revision)
5925,European,919.0,30806694.0,Walker GJ,"Digestive system disorder, Response to drug, Other trait",initial,2019-02-01,GCST008801,Thiopurine-induced myelosuppression in inflammatory bowel disease
10488,European,22795.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007625,Negative urgency
3677,Asian,6000.0,30718733.0,Moon S,Lipid or lipoprotein measurement,replication,2019-02-04,GCST007442,Low density lipoprotein cholesterol levels
10484,European,22745.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007621,Sensation seeking
3766,Asian,6949.0,30718733.0,Moon S,Lipid or lipoprotein measurement,initial,2019-02-04,GCST007438,High density lipoprotein cholesterol levels
3675,Asian,6000.0,30718733.0,Moon S,Lipid or lipoprotein measurement,replication,2019-02-04,GCST007438,High density lipoprotein cholesterol levels
3765,Asian,6949.0,30718733.0,Moon S,Lipid or lipoprotein measurement,initial,2019-02-04,GCST007437,Triglyceride levels
10486,European,22774.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007623,Lack of premeditation
3674,Asian,6000.0,30718733.0,Moon S,Lipid or lipoprotein measurement,replication,2019-02-04,GCST007437,Triglyceride levels
2928,Asian,2000.0,30714141.0,Chen H,Cancer,initial,2019-02-04,GCST007842,Glioma
12479,European,1306354.0,30718901.0,Howard DM,"Neurological disorder, Other measurement",replication,2019-02-04,GCST007342,Depression
3676,Asian,6000.0,30718733.0,Moon S,Lipid or lipoprotein measurement,replication,2019-02-04,GCST007441,Total cholesterol levels
8410,European,4919.0,30718454.0,Arnau-Soler A,"Neurological disorder, Other measurement",initial,2019-02-04,GCST007407,Depressive symptoms
3679,Asian,6000.0,30718733.0,Moon S,Liver enzyme measurement,replication,2019-02-04,GCST007440,Alanine aminotransferase levels
3768,Asian,6949.0,30718733.0,Moon S,Lipid or lipoprotein measurement,initial,2019-02-04,GCST007442,Low density lipoprotein cholesterol levels
11573,European,99057.0,30718454.0,Arnau-Soler A,Other measurement,initial,2019-02-04,GCST007409,Depressive symptoms x stressful life events interaction (2df test)
10429,European,21495.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007622,Impulsivity
11572,European,99057.0,30718454.0,Arnau-Soler A,Other measurement,initial,2019-02-04,GCST007408,Depressive symptoms x stressful life events interaction (1df test)
11571,European,99057.0,30718454.0,Arnau-Soler A,"Neurological disorder, Other measurement",initial,2019-02-04,GCST007407,Depressive symptoms
10436,European,21786.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007629,Impulsivity (non-planning)
10450,European,21876.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007627,Impulsivity (attentional)
3580,Asian,5479.0,30714141.0,Chen H,Cancer,replication,2019-02-04,GCST007842,Glioma
3767,Asian,6949.0,30718733.0,Moon S,Lipid or lipoprotein measurement,initial,2019-02-04,GCST007441,Total cholesterol levels
8415,European,4919.0,30718454.0,Arnau-Soler A,Other measurement,initial,2019-02-04,GCST007412,Depressive symptoms x independent stressful life events interaction (1df test)
8414,European,4919.0,30718454.0,Arnau-Soler A,Other measurement,initial,2019-02-04,GCST007411,Depressive symptoms x dependent stressful life events interaction (2df test)
8412,European,4919.0,30718454.0,Arnau-Soler A,Other measurement,initial,2019-02-04,GCST007409,Depressive symptoms x stressful life events interaction (2df test)
8413,European,4919.0,30718454.0,Arnau-Soler A,Other measurement,initial,2019-02-04,GCST007410,Depressive symptoms x dependent stressful life events interaction (1df test)
10489,European,22861.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007626,Lack of perseverance
10439,European,21806.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007628,Impulsivity (motor)
12378,European,446238.0,30718901.0,Howard DM,"Neurological disorder, Other measurement",initial,2019-02-04,GCST007342,Depression
3770,Asian,6949.0,30718733.0,Moon S,Liver enzyme measurement,initial,2019-02-04,GCST007440,Alanine aminotransferase levels
8416,European,4919.0,30718454.0,Arnau-Soler A,Other measurement,initial,2019-02-04,GCST007413,Depressive symptoms x independent stressful life events interaction (2df test)
3769,Asian,6949.0,30718733.0,Moon S,Liver enzyme measurement,initial,2019-02-04,GCST007439,Aspartate aminotransferase levels
10476,European,22572.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007630,Drug experimentation measurement
10483,European,22738.0,30718321.0,Sanchez-Roige S,Other measurement,initial,2019-02-04,GCST007624,Positive urgency
3678,Asian,6000.0,30718733.0,Moon S,Liver enzyme measurement,replication,2019-02-04,GCST007439,Aspartate aminotransferase levels
8411,European,4919.0,30718454.0,Arnau-Soler A,Other measurement,initial,2019-02-04,GCST007408,Depressive symptoms x stressful life events interaction (1df test)
4552,Asian,191764.0,30718926.0,Suzuki K,Metabolic disorder,initial,2019-02-04,GCST007847,Type 2 diabetes
11577,European,100234.0,30745170.0,Strawbridge RJ,Other measurement,initial,2019-02-07,GCST007391,Deliberate self-harm
11715,European,122808.0,30745170.0,Strawbridge RJ,Other measurement,initial,2019-02-07,GCST007389,Suicidality
11613,European,108090.0,30745170.0,Strawbridge RJ,Other measurement,initial,2019-02-07,GCST007390,Suicidality (suicidal ideation/attempts)
3207,Asian,2885.0,30753327.0,Hishida A,Other measurement,replication,2019-02-08,GCST008709,Pepsinogen-I levels
3209,Asian,2885.0,30753327.0,Hishida A,Other measurement,replication,2019-02-08,GCST008716,Anti-Helicobacter pylori IgG seropositivity
3208,Asian,2885.0,30753327.0,Hishida A,Other measurement,replication,2019-02-08,GCST008712,Pepsinogen I/II ratio
8045,European,3902.0,30737484.0,Thomsen H,Other disease,initial,2019-02-08,GCST007824,Monoclonal gammopathy of undetermined significance
2562,Asian,1275.0,30753327.0,Hishida A,Digestive system disorder,replication,2019-02-08,GCST008714,Gastric atrophy
2377,Asian,880.0,30753327.0,Hishida A,Digestive system disorder,initial,2019-02-08,GCST008713,Severe gastric atrophy
2551,Asian,1239.0,30753327.0,Hishida A,Digestive system disorder,initial,2019-02-08,GCST008714,Gastric atrophy
3290,Asian,3385.0,30753327.0,Hishida A,Other measurement,initial,2019-02-08,GCST008712,Pepsinogen I/II ratio
3289,Asian,3385.0,30753327.0,Hishida A,Other measurement,initial,2019-02-08,GCST008709,Pepsinogen-I levels
3291,Asian,3385.0,30753327.0,Hishida A,Other measurement,initial,2019-02-08,GCST008716,Anti-Helicobacter pylori IgG seropositivity
2185,Asian,619.0,30753327.0,Hishida A,Digestive system disorder,replication,2019-02-08,GCST008713,Severe gastric atrophy
5074,European,379.0,30738427.0,Penney ME,"Cancer, Other measurement",initial,2019-02-09,GCST007434,Metastasis in stage I-III microsatellite instability low/stable colorectal cancer (time to event)
7375,European,2562.0,30741946.0,Gialluisi A,Biological process,initial,2019-02-11,GCST007473,Rapid automised naming of pictures
7877,European,3468.0,30741946.0,Gialluisi A,Biological process,initial,2019-02-11,GCST007479,Reading ability (multivariate)
7876,European,3468.0,30741946.0,Gialluisi A,Biological process,initial,2019-02-11,GCST007466,Word reading
7376,European,2563.0,30741946.0,Gialluisi A,Biological process,initial,2019-02-11,GCST007469,Rapid automised naming of digits
7377,European,2563.0,30741946.0,Gialluisi A,Biological process,initial,2019-02-11,GCST007470,Rapid automised naming of letters
7840,European,3399.0,30741946.0,Gialluisi A,Biological process,initial,2019-02-11,GCST007467,Word spelling
7635,European,3093.0,30741946.0,Gialluisi A,Biological process,initial,2019-02-11,GCST007465,Phoneme awareness
7389,European,2591.0,30741946.0,Gialluisi A,"Biological process, Other measurement",initial,2019-02-11,GCST007471,Short-term memory (digit-span task)
7849,European,3409.0,30741946.0,Gialluisi A,Biological process,initial,2019-02-11,GCST007478,Non-word reading
12354,European,418553.0,30760885.0,Mbarek H,Other measurement,initial,2019-02-13,GCST007280,Number of twin births
1630,Asian,74.0,30767168.0,Shin JH,Other measurement,initial,2019-02-14,GCST007538,Cellular nuclear factor (erythroid-derived 2)-like 2 levels
11900,European,157516.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007503,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
12168,European,288492.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007484,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
11897,European,157516.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007500,Waist-to-hip ratio adjusted for BMI (additive genetic model)
12167,European,288492.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007483,Waist-to-hip ratio adjusted for BMI (additive genetic model)
11248,European,62368.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007500,Waist-to-hip ratio adjusted for BMI (additive genetic model)
11250,European,62368.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007502,Waist-to-hip ratio adjusted for BMI (additive genetic model)
11899,European,157516.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007502,Waist-to-hip ratio adjusted for BMI (additive genetic model)
11256,European,62500.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007494,Waist-to-hip ratio adjusted for BMI (additive genetic model)
14044,Other/Mixed,180131.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007500,Waist-to-hip ratio adjusted for BMI (additive genetic model)
11249,European,62368.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007501,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
11255,European,62500.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007493,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
11254,European,62500.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007492,Waist-to-hip ratio adjusted for BMI (additive genetic model)
11251,European,62368.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007503,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
1425,African American or Afro-Caribbean,15687.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007483,Waist-to-hip ratio adjusted for BMI (additive genetic model)
11898,European,157516.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007501,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
1426,African American or Afro-Caribbean,15687.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007484,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
12989,Hispanic or Latin American,4075.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007484,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
3748,Asian,6800.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007484,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
11761,European,132177.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007491,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
11760,European,132177.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007487,Waist-to-hip ratio adjusted for BMI (additive genetic model)
11759,European,132177.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007484,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
11758,European,132177.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007483,Waist-to-hip ratio adjusted for BMI (additive genetic model)
14043,Other/Mixed,164238.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007493,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
11755,European,130976.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007496,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
4348,Asian,29315.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007483,Waist-to-hip ratio adjusted for BMI (additive genetic model)
11754,European,130976.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007494,Waist-to-hip ratio adjusted for BMI (additive genetic model)
11753,European,130976.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007493,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
4349,Asian,29315.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007484,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
11752,European,130976.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007492,Waist-to-hip ratio adjusted for BMI (additive genetic model)
14042,Other/Mixed,164238.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007492,Waist-to-hip ratio adjusted for BMI (additive genetic model)
12170,European,288492.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007491,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
3747,Asian,6800.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007483,Waist-to-hip ratio adjusted for BMI (additive genetic model)
12988,Hispanic or Latin American,4075.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007483,Waist-to-hip ratio adjusted for BMI (additive genetic model)
12169,European,288492.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007487,Waist-to-hip ratio adjusted for BMI (additive genetic model)
14045,Other/Mixed,180131.0,30778226.0,Justice AE,Body measurement,initial,2019-02-18,GCST007501,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
11257,European,62500.0,30778226.0,Justice AE,Body measurement,replication,2019-02-18,GCST007496,Waist-to-hip ratio adjusted for BMI (recessive genetic model)
6318,European,1235.0,30801552.0,Oetting WS,"Other trait, Response to drug, Metabolic disorder",initial,2019-02-19,GCST008578,New onset diabetes in calcineurin inhibitor treated kidney transplant patients (time to event)
457,African American or Afro-Caribbean,94.0,30801552.0,Oetting WS,"Other trait, Response to drug, Metabolic disorder",replication,2019-02-19,GCST008578,New onset diabetes in calcineurin inhibitor treated kidney transplant patients (time to event)
4599,European,63.0,30801552.0,Oetting WS,"Other trait, Other measurement, Response to drug",replication,2019-02-19,GCST008581,Nephrotoxicity in cyclosporine-treated kidney transplant patients (time to event)
6781,European,1785.0,30801552.0,Oetting WS,"Other trait, Response to drug",initial,2019-02-19,GCST008580,Anemia in mycophenolic acid treated kidney transplant patients (time to event)
6780,European,1785.0,30801552.0,Oetting WS,"Other trait, Response to drug",initial,2019-02-19,GCST008579,Leukopenia in mycophenolic acid treated kidney transplant patients (time to event)
510,African American or Afro-Caribbean,171.0,30801552.0,Oetting WS,"Other trait, Response to drug",replication,2019-02-19,GCST008579,Leukopenia in mycophenolic acid treated kidney transplant patients (time to event)
5564,European,657.0,30801552.0,Oetting WS,"Other trait, Response to drug",replication,2019-02-19,GCST008579,Leukopenia in mycophenolic acid treated kidney transplant patients (time to event)
5289,European,487.0,30801552.0,Oetting WS,"Other trait, Response to drug, Metabolic disorder",replication,2019-02-19,GCST008578,New onset diabetes in calcineurin inhibitor treated kidney transplant patients (time to event)
3858,Asian,7742.0,30779856.0,Lu HF,Other measurement,initial,2019-02-19,GCST007616,Calcaneus stiffness index
509,African American or Afro-Caribbean,171.0,30801552.0,Oetting WS,"Other trait, Other measurement",replication,2019-02-19,GCST008577,Tacrolimus trough concentration in kidney transplant patients
5255,European,475.0,30801552.0,Oetting WS,"Other trait, Other measurement, Response to drug",initial,2019-02-19,GCST008581,Nephrotoxicity in cyclosporine-treated kidney transplant patients (time to event)
5504,European,609.0,30801552.0,Oetting WS,"Other trait, Other measurement",replication,2019-02-19,GCST008577,Tacrolimus trough concentration in kidney transplant patients
599,African American or Afro-Caribbean,338.0,30801552.0,Oetting WS,"Other trait, Response to drug",initial,2019-02-19,GCST008579,Leukopenia in mycophenolic acid treated kidney transplant patients (time to event)
578,African American or Afro-Caribbean,299.0,30801552.0,Oetting WS,"Other trait, Other measurement",initial,2019-02-19,GCST008577,Tacrolimus trough concentration in kidney transplant patients
3230,Asian,2955.0,30779856.0,Lu HF,Other measurement,replication,2019-02-19,GCST007616,Calcaneus stiffness index
5198,European,438.0,30801552.0,Oetting WS,"Other trait, Response to drug",replication,2019-02-19,GCST008580,Anemia in mycophenolic acid treated kidney transplant patients (time to event)
6405,European,1352.0,30801552.0,Oetting WS,"Other trait, Other measurement, Response to drug",initial,2019-02-19,GCST008582,Nephrotoxicity in tacrolimus-treated kidney transplant patients (time to event)
559,African American or Afro-Caribbean,256.0,30801552.0,Oetting WS,"Other trait, Response to drug, Metabolic disorder",initial,2019-02-19,GCST008578,New onset diabetes in calcineurin inhibitor treated kidney transplant patients (time to event)
6417,European,1363.0,30801552.0,Oetting WS,"Other trait, Other measurement",initial,2019-02-19,GCST008577,Tacrolimus trough concentration in kidney transplant patients
5505,European,609.0,30801552.0,Oetting WS,"Other trait, Other measurement, Response to drug",replication,2019-02-19,GCST008582,Nephrotoxicity in tacrolimus-treated kidney transplant patients (time to event)
13052,Hispanic or Latin American,5136.0,30787307.0,Daya M,Other disease,initial,2019-02-20,GCST007266,Adult asthma
1358,African American or Afro-Caribbean,9518.0,30787307.0,Daya M,Other disease,initial,2019-02-20,GCST007266,Adult asthma
11271,European,64171.0,30787463.0,Escala-Garcia M,"Other measurement, Cancer",initial,2019-02-21,GCST007475,Breast cancer specific mortality in estrogen receptor positive breast cancer
10098,European,16172.0,30787463.0,Escala-Garcia M,"Other measurement, Cancer",initial,2019-02-21,GCST007476,Breast cancer specific mortality in estrogen receptor negative breast cancer
11569,European,96661.0,30787463.0,Escala-Garcia M,"Other measurement, Cancer",initial,2019-02-21,GCST007477,Breast cancer specific mortality in breast cancer
4363,Asian,31230.0,30810208.0,Nishiyama T,Other measurement,initial,2019-02-22,GCST008770,Sleep duration
3533,Asian,5140.0,30810208.0,Nishiyama T,Other measurement,replication,2019-02-22,GCST008770,Sleep duration
12480,European,1331010.0,30804565.0,Jansen PR,"Neurological disorder, Other measurement",initial,2019-02-25,GCST007988,Insomnia
11047,European,46350.0,30804558.0,Grove J,Neurological disorder,initial,2019-02-25,GCST007553,Autism and major depressive disorder (MTAG)
11598,European,105912.0,30805717.0,Zhu Z,"Neurological disorder, Other measurement",initial,2019-02-25,GCST007826,Alzheimer's disease or fasting insulin levels (pleiotropy)
10548,European,24218.0,30804560.0,Shrine N,Other measurement,initial,2019-02-25,GCST007430,Peak expiratory flow
12225,European,321047.0,30804560.0,Shrine N,Other measurement,initial,2019-02-25,GCST007429,Lung function (FVC)
12226,European,321047.0,30804560.0,Shrine N,Other measurement,initial,2019-02-25,GCST007430,Peak expiratory flow
11401,European,79005.0,30804560.0,Shrine N,Other measurement,initial,2019-02-25,GCST007431,Lung function (FEV1/FVC)
11400,European,79005.0,30804560.0,Shrine N,Other measurement,initial,2019-02-25,GCST007429,Lung function (FVC)
11398,European,78990.0,30804566.0,Lane JM,Other measurement,replication,2019-02-25,GCST007388,Insomnia symptoms (never/rarely vs. usually)
5573,European,662.0,30801121.0,O'Donnell S,"Digestive system disorder, Other measurement",initial,2019-02-25,GCST007497,Crohn's disease (time to progression)
11643,European,112209.0,30805717.0,Zhu Z,"Neurological disorder, Other measurement",initial,2019-02-25,GCST007825,Alzheimer's disease or fasting glucose levels (pleiotropy)
12228,European,321047.0,30804560.0,Shrine N,Other measurement,initial,2019-02-25,GCST007432,FEV1
11050,European,46350.0,30804558.0,Grove J,"Other measurement, Neurological disorder",initial,2019-02-25,GCST007554,Autism and educational attainment (MTAG)
12227,European,321047.0,30804560.0,Shrine N,Other measurement,initial,2019-02-25,GCST007431,Lung function (FEV1/FVC)
12280,European,359916.0,30804565.0,Jansen PR,Other measurement,initial,2019-02-25,GCST007985,Snoring
11397,European,78990.0,30804566.0,Lane JM,Other measurement,replication,2019-02-25,GCST007387,Insomnia symptoms (never/rarely vs. sometimes/usually)
12091,European,237627.0,30804566.0,Lane JM,Other measurement,initial,2019-02-25,GCST007388,Insomnia symptoms (never/rarely vs. usually)
12315,European,384317.0,30804565.0,Jansen PR,Other measurement,initial,2019-02-25,GCST007982,Sleep duration
12393,European,453379.0,30804566.0,Lane JM,Other measurement,initial,2019-02-25,GCST007387,Insomnia symptoms (never/rarely vs. sometimes/usually)
2146,Asian,546.0,30823506.0,Hong EP,Cardiovascular disease,initial,2019-02-25,GCST007354,Intracranial aneurysm
6345,European,1263.0,30801121.0,O'Donnell S,"Digestive system disorder, Other measurement",initial,2019-02-25,GCST007499,Crohn's disease (indolent vs progressive)
11049,European,46350.0,30804558.0,Grove J,Neurological disorder,initial,2019-02-25,GCST007556,Autism spectrum disorder
11660,European,114974.0,30805717.0,Zhu Z,"Neurological disorder, Lipid or lipoprotein measurement",initial,2019-02-25,GCST007827,Alzheimer's disease or HDL levels (pleiotropy)
12362,European,434835.0,30804565.0,Jansen PR,Other measurement,initial,2019-02-25,GCST007983,Morningness
6413,European,1360.0,30801121.0,O'Donnell S,"Digestive system disorder, Other measurement",initial,2019-02-25,GCST007498,Crohn's disease (time to first abdominal surgery)
11048,European,46350.0,30804558.0,Grove J,Neurological disorder,initial,2019-02-25,GCST007555,Autism and schizophrenia (MTAG)
11826,European,144498.0,30804558.0,Grove J,Neurological disorder,replication,2019-02-25,GCST007556,Autism spectrum disorder
11402,European,79005.0,30804560.0,Shrine N,Other measurement,initial,2019-02-25,GCST007432,FEV1
12316,European,385949.0,30804565.0,Jansen PR,Other measurement,initial,2019-02-25,GCST007986,Ease of getting up in the morning
12317,European,386548.0,30804565.0,Jansen PR,Other measurement,initial,2019-02-25,GCST007984,Daytime sleepiness
12318,European,386577.0,30804565.0,Jansen PR,Other measurement,initial,2019-02-25,GCST007987,Daytime nap
5442,European,574.0,30809046.0,Schmitz B,"Cardiovascular disease, Other disease, Other measurement",replication,2019-02-26,GCST007495,Estimated glomerular filtration rate in coronary artery disease and impaired kidney function
6811,European,1829.0,30808802.0,Freidin M,Other trait,initial,2019-02-26,GCST007537,Modic changes
9053,European,7379.0,30808845.0,Thio CHL,Other measurement,replication,2019-02-26,GCST007536,Serum urea levels
5320,European,499.0,30809046.0,Schmitz B,"Cardiovascular disease, Other disease, Other measurement",initial,2019-02-26,GCST007495,Estimated glomerular filtration rate in coronary artery disease and impaired kidney function
9897,European,13312.0,30808845.0,Thio CHL,Other measurement,initial,2019-02-26,GCST007536,Serum urea levels
8917,European,6770.0,30807572.0,Gong J,Digestive system disorder,initial,2019-02-26,GCST007367,Meconium ileus in cystic fibrosis
7561,European,2921.0,30920136.0,Stapleton CP,Other measurement,initial,2019-02-27,GCST007649,Estimated glomerular filtration rate after 5 years in renal transplantation (recipient effect)
8729,European,5935.0,30920136.0,Stapleton CP,Other measurement,initial,2019-02-27,GCST007645,Estimated glomerular filtration rate after 1 year in renal transplantation (recipient effect)
8247,European,4475.0,30920136.0,Stapleton CP,Other measurement,initial,2019-02-27,GCST007644,Estimated glomerular filtration rate after 1 year in renal transplantation (donor effect)
7178,European,2298.0,30920136.0,Stapleton CP,Other measurement,initial,2019-02-27,GCST007646,Estimated glomerular filtration rate change in renal transplantation (donor effect)
7179,European,2298.0,30920136.0,Stapleton CP,Other measurement,initial,2019-02-27,GCST007647,Estimated glomerular filtration rate change in renal transplantation (recipient effect)
7560,European,2921.0,30920136.0,Stapleton CP,Other measurement,initial,2019-02-27,GCST007648,Estimated glomerular filtration rate after 5 years in renal transplantation (donor effect)
11269,European,63926.0,30820047.0,Kunkle BW,Neurological disorder,initial,2019-02-28,GCST007511,Alzheimer's disease (late onset)
10706,European,30511.0,30820047.0,Kunkle BW,Neurological disorder,replication,2019-02-28,GCST007511,Alzheimer's disease (late onset)
10533,European,24024.0,30818988.0,Klein M,Other measurement,initial,2019-03-01,GCST007589,Intracranial volume
12739,Hispanic or Latin American,773.0,30945665.0,Bandesh K,Other measurement,replication,2019-03-01,GCST008641,C-peptide levels
1983,Asian,367.0,30945673.0,Prasad G,"Other measurement, Cancer",initial,2019-03-01,GCST007650,Postoperative survival time in hepatocellular carcinoma
6205,European,1121.0,30824882.0,Gunjaca I,Other measurement,initial,2019-03-01,GCST007428,Thyroxine levels
10557,European,24704.0,30818988.0,Klein M,Other measurement,initial,2019-03-01,GCST007590,Hippocampal volume
2833,Asian,1829.0,30945665.0,Bandesh K,Other measurement,replication,2019-03-01,GCST008641,C-peptide levels
11274,European,64939.0,30818988.0,Klein M,"Other measurement, Neurological disorder",initial,2019-03-01,GCST007582,Attention deficit hyperactivity disorder or putamen volume (pleiotropy)
11388,European,77317.0,30818988.0,Klein M,"Neurological disorder, Other measurement",initial,2019-03-01,GCST007586,Attention deficit hyperactivity disorder or intracranial volume (pleiotropy)
9982,European,14307.0,30818990.0,Yu D,Neurological disorder,initial,2019-03-01,GCST007277,Tourette syndrome
11273,European,64933.0,30818988.0,Klein M,"Other measurement, Neurological disorder",initial,2019-03-01,GCST007585,Attention deficit hyperactivity disorder or pallidum volume (pleiotropy)
11275,European,64987.0,30818988.0,Klein M,"Other measurement, Neurological disorder",initial,2019-03-01,GCST007584,Attention deficit hyperactivity disorder or thalamus volume (pleiotropy)
11394,European,77997.0,30818988.0,Klein M,"Neurological disorder, Other measurement",initial,2019-03-01,GCST007587,Attention deficit hyperactivity disorder or hippocampal volume (pleiotropy)
11288,European,67083.0,30818988.0,Klein M,"Other measurement, Neurological disorder",initial,2019-03-01,GCST007583,Attention deficit hyperactivity disorder or nucleus accumbens volume (pleiotropy)
2374,Asian,877.0,30945665.0,Bandesh K,Other measurement,initial,2019-03-01,GCST008641,C-peptide levels
5521,European,623.0,30824882.0,Gunjaca I,Other measurement,initial,2019-03-01,GCST007427,Triiodothyronine/thyroxine ratio
11276,European,65050.0,30818988.0,Klein M,"Other measurement, Neurological disorder",initial,2019-03-01,GCST007588,Attention deficit hyperactivity disorder or amygdala volume (pleiotropy)
2288,Asian,758.0,30945673.0,Prasad G,"Other measurement, Cancer",replication,2019-03-01,GCST007650,Postoperative survival time in hepatocellular carcinoma
5520,European,623.0,30824882.0,Gunjaca I,Other measurement,initial,2019-03-01,GCST007426,Triiodothyronine levels
8918,European,6774.0,30818990.0,Yu D,Neurological disorder,replication,2019-03-01,GCST007277,Tourette syndrome
11278,European,65065.0,30818988.0,Klein M,"Neurological disorder, Other measurement",initial,2019-03-01,GCST007591,Attention deficit hyperactivity disorder or caudate nucleus volume (pleiotropy)
12333,European,401656.0,30833571.0,Wiberg A,Neurological disorder,initial,2019-03-04,GCST007581,Carpal tunnel syndrome
11408,European,80003.0,30837465.0,Wittemans LBL,Other measurement,initial,2019-03-05,GCST007638,Glycine levels
8861,European,6545.0,31201950.0,Lutz MW,Other trait,initial,2019-03-06,GCST008235,Cognitive impairment
8860,European,6545.0,31201950.0,Lutz MW,"Lipid or lipoprotein measurement, Other trait",initial,2019-03-06,GCST008233,Cognitive impairment and LDL levels (pleiotropy)
8859,European,6545.0,31201950.0,Lutz MW,"Lipid or lipoprotein measurement, Other trait",initial,2019-03-06,GCST008232,Cognitive impairment and total cholesterol levels (pleiotropy)
8858,European,6545.0,31201950.0,Lutz MW,Lipid or lipoprotein measurement,initial,2019-03-06,GCST008239,Serum total cholesterol levels
8857,European,6545.0,31201950.0,Lutz MW,Lipid or lipoprotein measurement,initial,2019-03-06,GCST008238,Low density lipoprotein cholesterol levels
8856,European,6545.0,31201950.0,Lutz MW,Lipid or lipoprotein measurement,initial,2019-03-06,GCST008237,High density lipoprotein cholesterol levels
8855,European,6545.0,31201950.0,Lutz MW,Inflammatory measurement,initial,2019-03-06,GCST008236,C-reactive protein levels
8862,European,6545.0,31201950.0,Lutz MW,"Other trait, Inflammatory measurement",initial,2019-03-06,GCST008234,Cognitive impairment and C-reactive protein levels (pleiotropy)
6742,European,1731.0,30843173.0,Popovic M,"Other measurement, Other trait",initial,2019-03-07,GCST007681,Thyroid stimulating hormone levels
8487,European,5070.0,30845926.0,van der Plaat DA,Other measurement,initial,2019-03-07,GCST008247,Airway obstruction (FEV1/FVC<70%) in never smokers
6911,European,1966.0,30845926.0,van der Plaat DA,Other measurement,replication,2019-03-07,GCST008246,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers
3016,Asian,2197.0,30866520.0,Er LK,Cardiovascular measurement,initial,2019-03-07,GCST007900,Chemerin levels
5796,European,823.0,30845926.0,van der Plaat DA,Other measurement,initial,2019-03-07,GCST008242,Airway obstruction (FEV1/FVC<lower limit of normal) in ever smokers
12374,European,446118.0,30846698.0,Dashti HS,Other measurement,initial,2019-03-07,GCST007559,Sleep duration (short sleep)
8486,European,5070.0,30845926.0,van der Plaat DA,Other measurement,initial,2019-03-07,GCST008246,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers
6714,European,1715.0,30843173.0,Popovic M,Other measurement,initial,2019-03-07,GCST007682,Thyroxine levels
5797,European,823.0,30845926.0,van der Plaat DA,Other measurement,initial,2019-03-07,GCST008243,Airway obstruction (FEV1/FVC<70%) in ever smokers
12265,European,339926.0,30846698.0,Dashti HS,Other measurement,initial,2019-03-07,GCST007560,Sleep duration (long sleep)
6740,European,1729.0,30843173.0,Popovic M,Other measurement,initial,2019-03-07,GCST007680,Triiodothyronine levels and thyroxine levels
12375,European,446118.0,30846698.0,Dashti HS,Other measurement,initial,2019-03-07,GCST007561,Sleep duration
6741,European,1729.0,30843173.0,Popovic M,Other measurement,initial,2019-03-07,GCST007683,Triiodothyronine levels
6912,European,1966.0,30845926.0,van der Plaat DA,Other measurement,replication,2019-03-07,GCST008247,Airway obstruction (FEV1/FVC<70%) in never smokers
5176,European,432.0,30845926.0,van der Plaat DA,Other measurement,initial,2019-03-07,GCST008240,Airway obstruction (FEV1/FVC<70%) in never smokers
8376,European,4855.0,30845926.0,van der Plaat DA,Other measurement,initial,2019-03-07,GCST008244,Airway obstruction (FEV1/FVC<70%) in ever smokers
5177,European,432.0,30845926.0,van der Plaat DA,Other measurement,initial,2019-03-07,GCST008241,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers
7654,European,3134.0,30845926.0,van der Plaat DA,Other measurement,replication,2019-03-07,GCST008244,Airway obstruction (FEV1/FVC<70%) in ever smokers
8377,European,4855.0,30845926.0,van der Plaat DA,Other measurement,initial,2019-03-07,GCST008245,Airway obstruction (FEV1/FVC<lower limit of normal) in ever smokers
7655,European,3134.0,30845926.0,van der Plaat DA,Other measurement,replication,2019-03-07,GCST008245,Airway obstruction (FEV1/FVC<lower limit of normal) in ever smokers
8521,European,5161.0,30850646.0,Tziotzios C,Other disease,initial,2019-03-08,GCST007713,Frontal fibrosing alopecia
5067,European,369.0,30852652.0,Schlicht K,Other measurement,initial,2019-03-09,GCST007690,Metabolic coherence (transcriptomic)
8002,European,3783.0,30852652.0,Schlicht K,Other measurement,replication,2019-03-09,GCST007690,Metabolic coherence (transcriptomic)
2556,Asian,1252.0,30854688.0,Wang C,"Cancer, Other measurement",replication,2019-03-10,GCST007737,Anti-sp100 seropositivity in primary biliary cholangitis
2390,Asian,912.0,30854688.0,Wang C,"Cancer, Other measurement",initial,2019-03-10,GCST007736,Anti-gp210 seropositivity in primary biliary cholangitis
2394,Asian,922.0,30854688.0,Wang C,"Cancer, Other measurement",initial,2019-03-10,GCST007737,Anti-sp100 seropositivity in primary biliary cholangitis
2555,Asian,1252.0,30854688.0,Wang C,"Cancer, Other measurement",replication,2019-03-10,GCST007736,Anti-gp210 seropositivity in primary biliary cholangitis
12066,European,217634.0,30910378.0,Zanetti D,Other trait,initial,2019-03-12,GCST007719,Albuminuria
11618,European,108800.0,30910378.0,Zanetti D,Other trait,replication,2019-03-12,GCST007719,Albuminuria
11619,European,108942.0,30910378.0,Zanetti D,Other measurement,replication,2019-03-12,GCST007717,Urinary sodium to potassium ratio
11623,European,109178.0,30910378.0,Zanetti D,Other measurement,replication,2019-03-12,GCST007721,Urinary potassium to creatinine ratio
11624,European,109530.0,30910378.0,Zanetti D,Other measurement,replication,2019-03-12,GCST007718,Urinary albumin-to-creatinine ratio
11622,European,109166.0,30910378.0,Zanetti D,Other measurement,replication,2019-03-12,GCST007778,Urinary sodium to creatinine ratio
12067,European,217996.0,30910378.0,Zanetti D,Other measurement,initial,2019-03-12,GCST007717,Urinary sodium to potassium ratio
12069,European,218450.0,30910378.0,Zanetti D,Other measurement,initial,2019-03-12,GCST007778,Urinary sodium to creatinine ratio
12068,European,218435.0,30910378.0,Zanetti D,Other measurement,initial,2019-03-12,GCST007721,Urinary potassium to creatinine ratio
12070,European,218759.0,30910378.0,Zanetti D,Other measurement,initial,2019-03-12,GCST007718,Urinary albumin-to-creatinine ratio
12139,European,270059.0,30867560.0,Hill WD,Other measurement,initial,2019-03-13,GCST007709,General factor of neuroticism
12140,European,270059.0,30867560.0,Hill WD,Other measurement,initial,2019-03-13,GCST007710,Anxiety/tension (special factor of neuroticism)
12138,European,270059.0,30867560.0,Hill WD,Other measurement,initial,2019-03-13,GCST007708,Worry/vulnerability (special factor of neuroticism)
4956,European,294.0,30889042.0,Innocenti F,"Immune system disorder, Response to drug, Cancer",initial,2019-03-18,GCST007643,Gemcitabine-induced early high-grade neutropenia in pancreatic cancer
6763,European,1758.0,30886212.0,Eszlari N,Biological process,initial,2019-03-18,GCST007677,Rumination (response to stress)
6764,European,1758.0,30886212.0,Eszlari N,Biological process,initial,2019-03-18,GCST007678,Brooding (response to stress)
6765,European,1758.0,30886212.0,Eszlari N,Biological process,initial,2019-03-18,GCST007679,Reflection (response to stress)
3799,Asian,7321.0,30898391.0,Lawrenson K,Cancer,initial,2019-03-19,GCST007728,Epithelial ovarian cancer
8770,European,6125.0,30894546.0,Ivarsdottir EV,Other measurement,initial,2019-03-20,GCST008319,Intraocular pressure (corneal compensated)
8768,European,6125.0,30894546.0,Ivarsdottir EV,Other measurement,initial,2019-03-20,GCST008317,Central corneal thickness
8766,European,6125.0,30894546.0,Ivarsdottir EV,Other measurement,initial,2019-03-20,GCST008315,Corneal hysteresis
8767,European,6125.0,30894546.0,Ivarsdottir EV,Other measurement,initial,2019-03-20,GCST008316,Corneal endothelial cell size variation coefficient
8771,European,6125.0,30894546.0,Ivarsdottir EV,Other measurement,initial,2019-03-20,GCST008320,Intraocular pressure (Goldman correlated)
8769,European,6125.0,30894546.0,Ivarsdottir EV,Other measurement,initial,2019-03-20,GCST008318,Corneal resistance factor
8772,European,6125.0,30894546.0,Ivarsdottir EV,Other measurement,initial,2019-03-20,GCST008321,Corneal endothelial cell shape (percentage of hexagonally shaped cells)
6497,European,1459.0,30894546.0,Ivarsdottir EV,Other measurement,replication,2019-03-20,GCST008317,Central corneal thickness
8773,European,6125.0,30894546.0,Ivarsdottir EV,Other measurement,initial,2019-03-20,GCST008339,Corneal endothelial cell density
3863,Asian,7830.0,30899057.0,Lee MG,Metabolic disorder,replication,2019-03-21,GCST008139,Gout
1951,Asian,329.0,30895295.0,Jonnalagadda M,"Other measurement, Other trait",initial,2019-03-21,GCST007742,Iris heterochromicity
1950,Asian,329.0,30895295.0,Jonnalagadda M,"Other measurement, Other trait",initial,2019-03-21,GCST007741,Iris color (b* coordinate)
1949,Asian,329.0,30895295.0,Jonnalagadda M,"Other measurement, Other trait",initial,2019-03-21,GCST007740,Iris color (a* coordinate)
3784,Asian,7094.0,30899057.0,Lee MG,Metabolic disorder,initial,2019-03-21,GCST008139,Gout
3295,Asian,3417.0,30899065.0,Wang M,Other trait,initial,2019-03-21,GCST007687,Photic sneeze reflex
2262,Asian,720.0,30895295.0,Jonnalagadda M,Other measurement,initial,2019-03-21,GCST007739,Skin reflectance (Melanin index)
1952,Asian,329.0,30895295.0,Jonnalagadda M,"Other measurement, Other trait",initial,2019-03-21,GCST007743,Iris color (L* coordinate)
10739,European,32131.0,30902966.0,Mufford M,"Other measurement, Neurological disorder",initial,2019-03-22,GCST008908,Social disinhibition in Tourette syndrome or subcortical volume measurements (pleiotropy)
10741,European,32136.0,30902966.0,Mufford M,"Other measurement, Neurological disorder",initial,2019-03-22,GCST008909,Symmetry behaviour in Tourette syndrome or subcortical volume measurements (pleiotropy)
11024,European,44056.0,30902966.0,Mufford M,"Other measurement, Neurological disorder",initial,2019-03-22,GCST008907,Tourette syndrome or brain region volumes (pleiotropy)
3418,Asian,4235.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007702,Triglyceride levels
13988,Other/Mixed,7898.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007688,Total cholesterol levels
13991,Other/Mixed,7898.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007702,Triglyceride levels
2453,Asian,1036.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,initial,2019-03-25,GCST007689,Low density lipoprotein cholesterol levels
2454,Asian,1036.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,initial,2019-03-25,GCST007701,High density lipoprotein cholesterol levels
2452,Asian,1036.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,initial,2019-03-25,GCST007688,Total cholesterol levels
11999,European,188577.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007702,Triglyceride levels
11998,European,188577.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007701,High density lipoprotein cholesterol levels
13989,Other/Mixed,7898.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007689,Low density lipoprotein cholesterol levels
3417,Asian,4235.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007701,High density lipoprotein cholesterol levels
13990,Other/Mixed,7898.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007701,High density lipoprotein cholesterol levels
11996,European,188577.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007688,Total cholesterol levels
3416,Asian,4235.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007689,Low density lipoprotein cholesterol levels
3415,Asian,4235.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007688,Total cholesterol levels
2455,Asian,1036.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,initial,2019-03-25,GCST007702,Triglyceride levels
11997,European,188577.0,30911093.0,Bandesh K,Lipid or lipoprotein measurement,replication,2019-03-25,GCST007689,Low density lipoprotein cholesterol levels
12554,Hispanic or Latin American,114.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2019-03-28,GCST008147,Response to allopurinol in gout (change in serum uric acid levels)
1927,Asian,303.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2019-03-28,GCST008148,Response to allopurinol in gout (change in serum uric acid levels)
2565,Asian,1288.0,30921371.0,Choi SY,Other trait,replication,2019-03-28,GCST007711,Severe coronary artery calcification
10654,European,28835.0,30929738.0,Ferreira MAR,"Other disease, Other measurement",initial,2019-03-28,GCST007797,Asthma onset (childhood vs adult)
12863,Hispanic or Latin American,1970.0,30920090.0,Trochet H,"Neurological disorder, Immune system disorder, Response to drug, Cardiovascular disease, Digestive system disorder, Other disease, Biological process",initial,2019-03-28,GCST008910,Multiple traits (pleiotropy)
1926,Asian,303.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2019-03-28,GCST008147,Response to allopurinol in gout (change in serum uric acid levels)
13693,Other/Mixed,574.0,30921485.0,Bejaoui Y,Immune system disorder,replication,2019-03-28,GCST008096,Psoriasis
11071,European,47299.0,30929738.0,Ferreira MAR,"Other disease, Other measurement",replication,2019-03-28,GCST007797,Asthma onset (childhood vs adult)
11153,European,53842.0,30920090.0,Trochet H,"Neurological disorder, Immune system disorder, Response to drug, Cardiovascular disease, Digestive system disorder, Other disease, Biological process",initial,2019-03-28,GCST008910,Multiple traits (pleiotropy)
270,African,4213.0,30920090.0,Trochet H,"Neurological disorder, Immune system disorder, Response to drug, Cardiovascular disease, Digestive system disorder, Other disease, Biological process",initial,2019-03-28,GCST008910,Multiple traits (pleiotropy)
5787,European,820.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",replication,2019-03-28,GCST008147,Response to allopurinol in gout (change in serum uric acid levels)
7421,European,2647.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2019-03-28,GCST008148,Response to allopurinol in gout (change in serum uric acid levels)
12268,European,341215.0,30929738.0,Ferreira MAR,Other disease,initial,2019-03-28,GCST007798,Asthma
2955,Asian,2078.0,30920090.0,Trochet H,"Neurological disorder, Immune system disorder, Response to drug, Cardiovascular disease, Digestive system disorder, Other disease, Biological process",initial,2019-03-28,GCST008910,Multiple traits (pleiotropy)
7420,European,2647.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2019-03-28,GCST008147,Response to allopurinol in gout (change in serum uric acid levels)
5043,European,355.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",replication,2019-03-28,GCST008148,Response to allopurinol in gout (change in serum uric acid levels)
12101,European,246649.0,30929738.0,Ferreira MAR,Other disease,replication,2019-03-28,GCST007800,Asthma (childhood onset)
12237,European,327253.0,30929738.0,Ferreira MAR,Other disease,initial,2019-03-28,GCST007799,Asthma (adult onset)
2023,Asian,400.0,30921371.0,Choi SY,Other trait,initial,2019-03-28,GCST007711,Severe coronary artery calcification
12555,Hispanic or Latin American,114.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2019-03-28,GCST008148,Response to allopurinol in gout (change in serum uric acid levels)
12088,European,234008.0,30929738.0,Ferreira MAR,Other disease,replication,2019-03-28,GCST007799,Asthma (adult onset)
12220,European,314633.0,30929738.0,Ferreira MAR,Other disease,initial,2019-03-28,GCST007800,Asthma (childhood onset)
466,African American or Afro-Caribbean,115.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2019-03-28,GCST008148,Response to allopurinol in gout (change in serum uric acid levels)
465,African American or Afro-Caribbean,115.0,30924126.0,Brackman DJ,"Cardiovascular measurement, Metabolic disorder, Response to drug",initial,2019-03-28,GCST008147,Response to allopurinol in gout (change in serum uric acid levels)
13713,Other/Mixed,631.0,30921485.0,Bejaoui Y,Immune system disorder,initial,2019-03-28,GCST008096,Psoriasis
11437,European,82522.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008676,LDL cholesterol levels
11436,European,82518.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008687,LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
11435,European,82518.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008686,LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
4504,Asian,111921.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008699,Triglyceride levels x smoking (ever vs never smokers) interaction (1df test)
11313,European,68719.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008689,LDL cholesterol levels in non smokers
11379,European,77043.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008694,Triglyceride levels x smoking (current vs non smokers) interaction (1df test)
11439,European,82522.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008691,LDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
13108,Hispanic or Latin American,6646.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008691,LDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
13096,Hispanic or Latin American,6620.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008694,Triglyceride levels x smoking (current vs non smokers) interaction (1df test)
13107,Hispanic or Latin American,6646.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008690,LDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
10977,European,40797.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008684,HDL cholesterol levels in never smokers
13095,Hispanic or Latin American,6620.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008682,HDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
11010,European,42899.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008700,Triglyceride levels in ever smokers
13094,Hispanic or Latin American,6620.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008681,HDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
13093,Hispanic or Latin American,6620.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008678,HDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
13110,Hispanic or Latin American,6705.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008694,Triglyceride levels x smoking (current vs non smokers) interaction (1df test)
13104,Hispanic or Latin American,6646.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008676,LDL cholesterol levels
11438,European,82522.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008690,LDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
316,African,11700.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008693,LDL cholesterol levels in never smokers
10825,European,34148.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008701,Triglyceride levels in never smokers
12992,Hispanic or Latin American,4095.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008693,LDL cholesterol levels in never smokers
11099,European,49475.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008683,HDL cholesterol levels in ever smokers
11266,European,63740.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008697,Triglyceride levels in non smokers
13105,Hispanic or Latin American,6646.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008686,LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
315,African,11649.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008692,LDL cholesterol levels in ever smokers
4438,Asian,48349.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008686,LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
11382,European,77047.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008698,Triglyceride levels x smoking (ever vs never smokers) interaction (2df test)
4441,Asian,48349.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008691,LDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
4439,Asian,48349.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008687,LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
13064,Hispanic or Latin American,5873.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008680,HDL cholesterol levels in non smokers
318,African,11777.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008701,Triglyceride levels in never smokers
4440,Asian,48349.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008690,LDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
13065,Hispanic or Latin American,5894.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008689,LDL cholesterol levels in non smokers
11381,European,77047.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008702,Triglyceride levels
11380,European,77043.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008695,Triglyceride levels x smoking (current vs non smokers) interaction (2df test)
13069,Hispanic or Latin American,5941.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008697,Triglyceride levels in non smokers
12993,Hispanic or Latin American,4123.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008701,Triglyceride levels in never smokers
11383,European,77047.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008699,Triglyceride levels x smoking (ever vs never smokers) interaction (1df test)
319,African,11866.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008684,HDL cholesterol levels in never smokers
317,African,11735.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008700,Triglyceride levels in ever smokers
13109,Hispanic or Latin American,6705.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008702,Triglyceride levels
13097,Hispanic or Latin American,6620.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008695,Triglyceride levels x smoking (current vs non smokers) interaction (2df test)
13113,Hispanic or Latin American,6705.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008699,Triglyceride levels x smoking (ever vs never smokers) interaction (1df test)
13112,Hispanic or Latin American,6705.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008698,Triglyceride levels x smoking (ever vs never smokers) interaction (2df test)
13111,Hispanic or Latin American,6705.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008695,Triglyceride levels x smoking (current vs non smokers) interaction (2df test)
4473,Asian,81517.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008682,HDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
4503,Asian,111921.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008698,Triglyceride levels x smoking (ever vs never smokers) interaction (2df test)
12990,Hispanic or Latin American,4076.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008684,HDL cholesterol levels in never smokers
10881,European,37016.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008693,LDL cholesterol levels in never smokers
4470,Asian,81517.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008677,HDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
4471,Asian,81517.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008678,HDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
13106,Hispanic or Latin American,6646.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008687,LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
4472,Asian,81517.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008681,HDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
11036,European,45506.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008692,LDL cholesterol levels in ever smokers
11365,European,75138.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008680,HDL cholesterol levels in non smokers
13091,Hispanic or Latin American,6620.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008685,HDL cholesterol levels
12909,Hispanic or Latin American,2582.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008700,Triglyceride levels in ever smokers
2339,Asian,808.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008696,Triglyceride levels in current smokers
264,African,3750.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008699,Triglyceride levels x smoking (ever vs never smokers) interaction (1df test)
345,African,23761.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008677,HDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
13280,Hispanic or Latin American,16996.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008686,LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
334,African,23353.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008676,LDL cholesterol levels
333,African,23348.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008687,LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
13281,Hispanic or Latin American,16996.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008687,LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
13282,Hispanic or Latin American,16996.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008690,LDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
3083,Asian,2394.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008679,HDL cholesterol levels in current smokers
332,African,23348.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008686,LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
11838,European,147060.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008681,HDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
12726,Hispanic or Latin American,747.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008679,HDL cholesterol levels in current smokers
290,African,5612.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008681,HDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
12732,Hispanic or Latin American,764.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008696,Triglyceride levels in current smokers
13283,Hispanic or Latin American,16996.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008691,LDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
5117,European,405.0,30926877.0,Brcic L,"Other measurement, Immune system disorder",initial,2019-03-29,GCST007851,Anti-thyroid peroxidase (TPOAb) and anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis
5116,European,405.0,30926877.0,Brcic L,"Other measurement, Immune system disorder",initial,2019-03-29,GCST007830,Anti-thyroid peroxidase (TPOAb) levels in Hashimoto's thyroiditis
3477,Asian,4649.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008699,Triglyceride levels x smoking (ever vs never smokers) interaction (1df test)
291,African,5612.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008682,HDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
7595,European,2989.0,30922102.0,Pardinas AF,"Response to drug, Neurological disorder",initial,2019-03-29,GCST007686,Plasma norclozapine levels in treatment-resistant schizophrenia
3476,Asian,4649.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008698,Triglyceride levels x smoking (ever vs never smokers) interaction (2df test)
3972,Asian,9118.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008693,LDL cholesterol levels in never smokers
12728,Hispanic or Latin American,755.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008688,LDL cholesterol levels in current smokers
11839,European,147060.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008682,HDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
11841,European,147211.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008677,HDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
11842,European,147211.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008678,HDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
284,African,5120.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008679,HDL cholesterol levels in current smokers
336,African,23353.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008691,LDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
337,African,23503.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008694,Triglyceride levels x smoking (current vs non smokers) interaction (1df test)
9895,European,13303.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008696,Triglyceride levels in current smokers
338,African,23503.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008695,Triglyceride levels x smoking (current vs non smokers) interaction (2df test)
263,African,3750.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008698,Triglyceride levels x smoking (ever vs never smokers) interaction (2df test)
339,African,23508.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008702,Triglyceride levels
9941,European,13799.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008688,LDL cholesterol levels in current smokers
261,African,3718.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008691,LDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
13265,Hispanic or Latin American,14710.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008698,Triglyceride levels x smoking (ever vs never smokers) interaction (2df test)
13266,Hispanic or Latin American,14710.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008699,Triglyceride levels x smoking (ever vs never smokers) interaction (1df test)
260,African,3718.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008690,LDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
10030,European,15129.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008679,HDL cholesterol levels in current smokers
287,African,5324.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008686,LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
340,African,23508.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008698,Triglyceride levels x smoking (ever vs never smokers) interaction (2df test)
341,African,23508.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008699,Triglyceride levels x smoking (ever vs never smokers) interaction (1df test)
342,African,23753.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008682,HDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
288,African,5324.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008687,LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
2509,Asian,1172.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008700,Triglyceride levels in ever smokers
320,African,11893.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008683,HDL cholesterol levels in ever smokers
343,African,23753.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008681,HDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
344,African,23761.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008685,HDL cholesterol levels
3075,Asian,2375.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008688,LDL cholesterol levels in current smokers
3979,Asian,9146.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008684,HDL cholesterol levels in never smokers
13092,Hispanic or Latin American,6620.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008677,HDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
7594,European,2989.0,30922102.0,Pardinas AF,"Response to drug, Neurological disorder",initial,2019-03-29,GCST007685,Plasma clozapine levels in treatment-resistant schizophrenia
13294,Hispanic or Latin American,17522.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008677,HDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
279,African,5022.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008696,Triglyceride levels in current smokers
4157,Asian,13171.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008678,HDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
4158,Asian,13171.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008681,HDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
4159,Asian,13171.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008682,HDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
13296,Hispanic or Latin American,17522.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008681,HDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
4160,Asian,13171.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008694,Triglyceride levels x smoking (current vs non smokers) interaction (1df test)
13297,Hispanic or Latin American,17522.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008682,HDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
4161,Asian,13171.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008695,Triglyceride levels x smoking (current vs non smokers) interaction (2df test)
346,African,23761.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008678,HDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
328,African,18384.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008689,LDL cholesterol levels in non smokers
298,African,7217.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008678,HDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
11527,European,90272.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008682,HDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
11526,European,90272.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008681,HDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
11525,European,90272.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008685,HDL cholesterol levels
11524,European,90266.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008695,Triglyceride levels x smoking (current vs non smokers) interaction (2df test)
11523,European,90266.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008694,Triglyceride levels x smoking (current vs non smokers) interaction (1df test)
11522,European,90266.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008678,HDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
11521,European,90266.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008677,HDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
347,African,23761.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008694,Triglyceride levels x smoking (current vs non smokers) interaction (1df test)
12904,Hispanic or Latin American,2544.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008683,HDL cholesterol levels in ever smokers
348,African,23761.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008695,Triglyceride levels x smoking (current vs non smokers) interaction (2df test)
12906,Hispanic or Latin American,2554.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008692,LDL cholesterol levels in ever smokers
278,African,4973.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008688,LDL cholesterol levels in current smokers
4156,Asian,13171.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008677,HDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
5115,European,405.0,30926877.0,Brcic L,"Immune system disorder, Other measurement",initial,2019-03-29,GCST007831,Anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis
4155,Asian,13171.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008685,HDL cholesterol levels
4151,Asian,13117.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008691,LDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
3307,Asian,3477.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008701,Triglyceride levels in never smokers
3359,Asian,3841.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008697,Triglyceride levels in non smokers
7593,European,2989.0,30922102.0,Pardinas AF,"Response to drug, Neurological disorder",initial,2019-03-29,GCST007684,Plasma clozapine-norclozapine ratio in treatment-resistant schizophrenia
3475,Asian,4649.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008695,Triglyceride levels x smoking (current vs non smokers) interaction (2df test)
3382,Asian,3999.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008692,LDL cholesterol levels in ever smokers
11682,European,117440.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008687,LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
11681,European,117440.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008686,LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
13295,Hispanic or Latin American,17522.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008678,HDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
11679,European,117167.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008691,LDL cholesterol levels x smoking (ever vs never smokers) interaction (2df test)
11678,European,117167.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008690,LDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
3474,Asian,4649.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008694,Triglyceride levels x smoking (current vs non smokers) interaction (1df test)
4154,Asian,13171.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008676,LDL cholesterol levels
3473,Asian,4649.0,30926973.0,Bentley AR,Lipid or lipoprotein measurement,initial,2019-03-29,GCST008702,Triglyceride levels
4056,Asian,10742.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008689,LDL cholesterol levels in non smokers
3385,Asian,4025.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008683,HDL cholesterol levels in ever smokers
4057,Asian,10777.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008680,HDL cholesterol levels in non smokers
11617,European,108591.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008699,Triglyceride levels x smoking (ever vs never smokers) interaction (1df test)
11616,European,108591.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008698,Triglyceride levels x smoking (ever vs never smokers) interaction (2df test)
297,African,7217.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",replication,2019-03-29,GCST008677,HDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
330,African,18489.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008697,Triglyceride levels in non smokers
4148,Asian,13117.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008686,LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)
4149,Asian,13117.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008687,LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)
4150,Asian,13117.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008690,LDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
331,African,18641.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008680,HDL cholesterol levels in non smokers
335,African,23353.0,30926973.0,Bentley AR,"Other measurement, Lipid or lipoprotein measurement",initial,2019-03-29,GCST008690,LDL cholesterol levels x smoking (ever vs never smokers) interaction (1df test)
6190,European,1094.0,30929638.0,Matana A,Other measurement,initial,2019-03-30,GCST008170,Thyroglobulin plasma levels
11867,European,149899.0,30476138.0,Benonisdottir S,Other measurement,initial,2019-04-01,GCST008616,Urine pH measurement
11802,European,140260.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008606,Glucosuria (mild)
11828,European,145547.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008610,Proteinuria
11810,European,141621.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008605,Glucosuria (moderate to severe)
11800,European,139555.0,30476138.0,Benonisdottir S,Other measurement,initial,2019-04-01,GCST008604,Urine specific gravity measurement
11781,European,136954.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008613,Hematuria
11780,European,136698.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008607,Ketonuria
11695,European,120230.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008612,Proteinuria (mild)
11685,European,118115.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008617,Hematuria (moderate to severe)
11833,European,146369.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008614,Glucosuria
11680,European,117371.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008608,Ketonuria (moderate to severe)
11659,European,114895.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008609,Ketonuria (mild)
11407,European,79850.0,30476138.0,Benonisdottir S,Other measurement,initial,2019-04-01,GCST008619,Signs of urinary tract infection (nitrites and leukocyte esterase)
11490,European,87742.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008618,Hematuria (mild)
11675,European,116855.0,30476138.0,Benonisdottir S,Other trait,initial,2019-04-01,GCST008611,Proteinuria (moderate to severe)
11845,European,148199.0,30476138.0,Benonisdottir S,Other measurement,initial,2019-04-01,GCST008615,Low urine pH
1784,Asian,189.0,30940813.0,Kranzler HR,Other measurement,initial,2019-04-02,GCST008258,Alcohol use disorder (consumption score)
12409,European,458969.0,30940143.0,Zhu Z,"Other disease, Cardiovascular measurement",initial,2019-04-02,GCST007656,Chronic obstructive pulmonary disease or resting heart rate (pleiotropy)
1787,Asian,190.0,30940813.0,Kranzler HR,"Neurological disorder, Other measurement",initial,2019-04-02,GCST008259,Alcohol use disorder
12381,European,446696.0,30940143.0,Zhu Z,"Other disease, Cardiovascular disease",initial,2019-04-02,GCST007613,Chronic obstructive pulmonary disease or stroke (pleiotropy)
1508,African American or Afro-Caribbean,56648.0,30940813.0,Kranzler HR,"Neurological disorder, Other measurement",initial,2019-04-02,GCST008259,Alcohol use disorder
12406,European,458554.0,30940143.0,Zhu Z,Cardiovascular disease,initial,2019-04-02,GCST007610,Hypertension
12407,European,458554.0,30940143.0,Zhu Z,"Other disease, Other measurement, Cardiovascular disease",initial,2019-04-02,GCST007611,Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)
1507,African American or Afro-Caribbean,56495.0,30940813.0,Kranzler HR,Other measurement,initial,2019-04-02,GCST008258,Alcohol use disorder (consumption score)
12408,European,458969.0,30940143.0,Zhu Z,Cardiovascular measurement,initial,2019-04-02,GCST007609,Resting heart rate
13263,Hispanic or Latin American,14112.0,30940813.0,Kranzler HR,Other measurement,initial,2019-04-02,GCST008258,Alcohol use disorder (consumption score)
13264,Hispanic or Latin American,14175.0,30940813.0,Kranzler HR,"Neurological disorder, Other measurement",initial,2019-04-02,GCST008259,Alcohol use disorder
12024,European,202004.0,30940813.0,Kranzler HR,"Neurological disorder, Other measurement",initial,2019-04-02,GCST008259,Alcohol use disorder
12021,European,200680.0,30940813.0,Kranzler HR,Other measurement,initial,2019-04-02,GCST008258,Alcohol use disorder (consumption score)
2599,Asian,1366.0,30940813.0,Kranzler HR,Other measurement,initial,2019-04-02,GCST008258,Alcohol use disorder (consumption score)
2600,Asian,1374.0,30940813.0,Kranzler HR,"Neurological disorder, Other measurement",initial,2019-04-02,GCST008259,Alcohol use disorder
5146,European,420.0,30958311.0,Tao F,"Other trait, Neurological disorder",initial,2019-04-03,GCST008533,Decreased fine motor function in Charcot-Marie-Tooth disease 1A (eating with utensils)
9383,European,8736.0,30944420.0,Liu L,Other measurement,initial,2019-04-03,GCST007816,Trunk fat mass adjusted for trunk lean mass
4950,European,291.0,30958311.0,Tao F,"Neurological disorder, Other measurement",initial,2019-04-03,GCST008544,Reduced foot dorsiflexion strength in Charcot-Marie-Tooth disease type 1A
747,African American or Afro-Caribbean,847.0,30944420.0,Liu L,Other measurement,initial,2019-04-03,GCST007816,Trunk fat mass adjusted for trunk lean mass
5145,European,420.0,30958311.0,Tao F,"Neurological disorder, Other trait",initial,2019-04-03,GCST008537,Decreased sensory function in Charcot-Marie-Tooth disease type 1A
5151,European,423.0,30958311.0,Tao F,"Other trait, Neurological disorder",initial,2019-04-03,GCST008540,"Decreased fine motor function in Charcot-Marie-Tooth disease 1A (buttons, zippers, fasteners, bottles)"
5141,European,417.0,30958311.0,Tao F,"Neurological disorder, Other trait",initial,2019-04-03,GCST008541,Foot deformity in Charcot-Marie-Tooth disease 1A
5153,European,424.0,30958311.0,Tao F,"Other trait, Neurological disorder",initial,2019-04-03,GCST008543,Walking difficulty in Charcot-Marie-Tooth disease 1A
5060,European,364.0,30958311.0,Tao F,Neurological disorder,initial,2019-04-03,GCST008534,Hearing loss in Charcot-Marie-Tooth disease 1A
4823,European,200.0,30958311.0,Tao F,"Neurological disorder, Other measurement",initial,2019-04-03,GCST008542,First dorsal interosseous strength in Charcot-Marie-Tooth disease 1A
5137,European,412.0,30958311.0,Tao F,"Neurological disorder, Other measurement",initial,2019-04-03,GCST008539,Foot plantar flexion strength in Charcot-Marie-Tooth disease 1A
5131,European,409.0,30958311.0,Tao F,"Other trait, Neurological disorder",initial,2019-04-03,GCST008535,Arthritic-like pain in Charcot-Marie-Tooth type 1A
6612,European,1589.0,30942860.0,Shin J,Other measurement,initial,2019-04-03,GCST008473,Visceral fat
5130,European,409.0,30958311.0,Tao F,"Other disease, Neurological disorder",initial,2019-04-03,GCST008536,Scoliosis in Charcot-Marie-Tooth disease 1A
5250,European,471.0,30958311.0,Tao F,Neurological disorder,initial,2019-04-03,GCST008530,Neuropathy in Charcot-Marie-Tooth disease type 1A
2684,Asian,1541.0,30944420.0,Liu L,Other measurement,initial,2019-04-03,GCST007816,Trunk fat mass adjusted for trunk lean mass
5139,European,413.0,30958311.0,Tao F,"Neurological disorder, Other trait",initial,2019-04-03,GCST008538,Balance difficulty in Charcot-Marie-Tooth disease type 1A
12636,Hispanic or Latin American,445.0,30944420.0,Liu L,Other measurement,initial,2019-04-03,GCST007816,Trunk fat mass adjusted for trunk lean mass
5118,European,406.0,30958311.0,Tao F,Neurological disorder,initial,2019-04-03,GCST008532,Burning or tingling in extremities in Charcot-Marie-Tooth disease type 1A
4847,European,213.0,30946739.0,Hu B,Other measurement,replication,2019-04-04,GCST007822,Facial attractiveness (male raters)
5228,European,455.0,30946739.0,Hu B,Other measurement,replication,2019-04-04,GCST007818,Facial attractiveness (female raters)
6788,European,1792.0,30946739.0,Hu B,Other measurement,initial,2019-04-04,GCST007821,Facial attractiveness (female raters)
6789,European,1792.0,30946739.0,Hu B,Other measurement,initial,2019-04-04,GCST007823,Facial attractiveness (male raters)
8054,European,3928.0,30946739.0,Hu B,Other measurement,initial,2019-04-04,GCST007817,Facial attractiveness (male raters)
13832,Other/Mixed,1176.0,30946743.0,Li Z,Immune system disorder,initial,2019-04-04,GCST007844,Ankylosing spondylitis
3945,Asian,8839.0,31006500.0,Liu M,Lipid or lipoprotein measurement,initial,2019-04-04,GCST007840,Low HDL-cholesterol levels
1984,Asian,367.0,30945699.0,Wei J,"Other measurement, Cancer",initial,2019-04-04,GCST007731,Postoperative survival time in hepatocellular carcinoma
13886,Other/Mixed,1828.0,30946743.0,Li Z,Immune system disorder,initial,2019-04-04,GCST007844,Ankylosing spondylitis
8049,European,3921.0,30946739.0,Hu B,Other measurement,initial,2019-04-04,GCST007819,Facial attractiveness (male raters)
6989,European,2062.0,30946739.0,Hu B,Other measurement,initial,2019-04-04,GCST007820,Facial attractiveness (female raters)
6990,European,2062.0,30946739.0,Hu B,Other measurement,initial,2019-04-04,GCST007822,Facial attractiveness (male raters)
8055,European,3928.0,30946739.0,Hu B,Other measurement,initial,2019-04-04,GCST007818,Facial attractiveness (female raters)
2289,Asian,758.0,30945699.0,Wei J,"Other measurement, Cancer",replication,2019-04-04,GCST007731,Postoperative survival time in hepatocellular carcinoma
5719,European,762.0,30952644.0,El Charif O,"Cancer, Response to drug, Other trait",initial,2019-04-05,GCST007796,Tinnitus in cisplatin-treated testicular cancer
8690,European,5819.0,30952852.0,Jones SE,Other measurement,replication,2019-04-05,GCST007802,Sleep duration (variability)
8689,European,5819.0,30952852.0,Jones SE,Other measurement,replication,2019-04-05,GCST007801,Sleep duration
8693,European,5819.0,30952852.0,Jones SE,Other measurement,replication,2019-04-05,GCST007806,Time to most active 10 hours
11467,European,85670.0,30952852.0,Jones SE,Other measurement,initial,2019-04-05,GCST007806,Time to most active 10 hours
11465,European,85449.0,30952852.0,Jones SE,Other measurement,initial,2019-04-05,GCST007801,Sleep duration
8219,European,4401.0,30952852.0,Jones SE,Other measurement,replication,2019-04-05,GCST007804,Sleep (number of episodes)
8220,European,4401.0,30952852.0,Jones SE,Other measurement,replication,2019-04-05,GCST007808,Diurnal inactivity
8691,European,5819.0,30952852.0,Jones SE,Other measurement,replication,2019-04-05,GCST007803,Sleep efficiency
8692,European,5819.0,30952852.0,Jones SE,Other measurement,replication,2019-04-05,GCST007805,Sleep (time to least active 5 hours)
11462,European,85205.0,30952852.0,Jones SE,Other measurement,initial,2019-04-05,GCST007805,Sleep (time to least active 5 hours)
11458,European,84810.0,30952852.0,Jones SE,Other measurement,initial,2019-04-05,GCST007807,Sleep (time to midpoint)
11457,European,84810.0,30952852.0,Jones SE,Other measurement,initial,2019-04-05,GCST007804,Sleep (number of episodes)
11456,European,84810.0,30952852.0,Jones SE,Other measurement,initial,2019-04-05,GCST007803,Sleep efficiency
11455,European,84757.0,30952852.0,Jones SE,Other measurement,initial,2019-04-05,GCST007808,Diurnal inactivity
8694,European,5819.0,30952852.0,Jones SE,Other measurement,replication,2019-04-05,GCST007807,Sleep (time to midpoint)
11447,European,84441.0,30952852.0,Jones SE,Other measurement,initial,2019-04-05,GCST007802,Sleep duration (variability)
3327,Asian,3617.0,30955190.0,Yun S,Other disease,initial,2019-04-06,GCST007734,Incident chronic kidney disease
3328,Asian,3617.0,30955190.0,Yun S,Other measurement,initial,2019-04-06,GCST008837,Estimated glomerular filtration rate reduction (30%)
4136,Asian,12680.0,31003110.0,Kim S,Other measurement,initial,2019-04-08,GCST008265,Psychological wellbeing (social role performance and self-confidence)
11584,European,101293.0,30993211.0,Nakatochi M,Cardiovascular measurement,replication,2019-04-08,GCST007725,Serum uric acid levels
11501,European,88461.0,30993211.0,Nakatochi M,Cardiovascular measurement,initial,2019-04-08,GCST007733,Serum uric acid levels
11738,European,126936.0,31151762.0,Gelernter J,Other measurement,initial,2019-04-08,GCST008675,Maximum habitual alcohol consumption
4138,Asian,12680.0,31003110.0,Kim S,Other measurement,initial,2019-04-08,GCST008267,Psychological wellbeing index (total score)
4137,Asian,12680.0,31003110.0,Kim S,Other measurement,initial,2019-04-08,GCST008266,Psychological wellbeing (health and vitality)
1437,African American or Afro-Caribbean,17029.0,31151762.0,Gelernter J,Other measurement,initial,2019-04-08,GCST008675,Maximum habitual alcohol consumption
4132,Asian,12680.0,31003110.0,Kim S,Other measurement,initial,2019-04-08,GCST008261,Psychological wellbeing (depressiveness)
4133,Asian,12680.0,31003110.0,Kim S,Other measurement,initial,2019-04-08,GCST008262,Psychological wellbeing index 1 (lack of subjective wellbeing and health)
4508,Asian,121745.0,30993211.0,Nakatochi M,Cardiovascular measurement,initial,2019-04-08,GCST007733,Serum uric acid levels
4507,Asian,121745.0,30993211.0,Nakatochi M,Cardiovascular measurement,initial,2019-04-08,GCST007725,Serum uric acid levels
4134,Asian,12680.0,31003110.0,Kim S,Other measurement,initial,2019-04-08,GCST008263,Psychological wellbeing index 3 (fatigue and loss of appetite)
4135,Asian,12680.0,31003110.0,Kim S,Other measurement,initial,2019-04-08,GCST008264,Psychological wellbeing index 12 (lack of enjoying daily life)
7301,European,2481.0,30999091.0,Wang Y,"Other measurement, Biological process",initial,2019-04-09,GCST008270,Post-traumatic stress disorder symptoms in trauma-exposed soldiers
5241,European,465.0,30972912.0,Wei L,"Response to drug, Digestive system disorder",initial,2019-04-10,GCST008514,Peginterferon alfa-2a treatment response in chronic hepatitis B infection
2483,Asian,1108.0,30972912.0,Wei L,"Response to drug, Digestive system disorder",initial,2019-04-10,GCST008514,Peginterferon alfa-2a treatment response in chronic hepatitis B infection
3691,Asian,6106.0,30975718.0,Tanikawa C,Other disease,replication,2019-04-11,GCST007833,Urolithiasis
8891,European,6692.0,31070471.0,Akinkuolie AO,"Other measurement, Inflammatory measurement",initial,2019-04-11,GCST008260,group IIA secretory phospholipase A2 levels in individuals with elevated hsCRP
11757,European,131686.0,31070453.0,Zekavat SM,Cardiovascular measurement,initial,2019-04-11,GCST007846,Arterial stiffness
1921,Asian,296.0,30971808.0,Kim JJ,"Immune system disorder, Other trait",initial,2019-04-11,GCST008314,Response to intravenous immunoglobulin treatment in Kawasaki disease
2552,Asian,1242.0,30971808.0,Kim JJ,"Immune system disorder, Other trait",replication,2019-04-11,GCST008314,Response to intravenous immunoglobulin treatment in Kawasaki disease
4553,Asian,198769.0,30975718.0,Tanikawa C,Other disease,initial,2019-04-11,GCST007833,Urolithiasis
12246,European,331037.0,30980028.0,de Kovel CGF,Other trait,initial,2019-04-12,GCST007593,Ambidextrousness
12245,European,331037.0,30980028.0,de Kovel CGF,Other trait,initial,2019-04-12,GCST007592,Handedness (Left-handed vs. non-left-handed)
12247,European,331037.0,30980028.0,de Kovel CGF,Other trait,initial,2019-04-12,GCST007594,Handedness (Right-handed vs. non-right-handed)
9402,European,8857.0,30988330.0,Hellwege JN,Other disease,initial,2019-04-15,GCST008169,Benign prostatic hyperplasia
13589,Other/Mixed,249.0,31040861.0,Thomson RJ,Other measurement,initial,2019-04-16,GCST007832,Urinary albumin-to-creatinine ratio
13678,Other/Mixed,497.0,31040861.0,Thomson RJ,Other measurement,replication,2019-04-16,GCST007832,Urinary albumin-to-creatinine ratio
8946,European,6879.0,30992453.0,Bjornsdottir G,Other measurement,initial,2019-04-16,GCST008312,Sural nerve amplitude potential
8973,European,6979.0,30992453.0,Bjornsdottir G,Other measurement,initial,2019-04-16,GCST008313,Sural nerve conduction velocity
641,African American or Afro-Caribbean,441.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007862,Latent naming speed
642,African American or Afro-Caribbean,441.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007863,Rapid alternating stimulus test for letters/numbers
643,African American or Afro-Caribbean,441.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007864,Rapid automised naming of letters
644,African American or Afro-Caribbean,441.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007865,Rapid automised naming of objects
12768,Hispanic or Latin American,883.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007865,Rapid automised naming of objects
639,African American or Afro-Caribbean,441.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007859,Rapid automised naming and rapid alternating stimulus test performance
12763,Hispanic or Latin American,883.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007859,Rapid automised naming and rapid alternating stimulus test performance
12764,Hispanic or Latin American,883.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007860,Latent naming speed
12765,Hispanic or Latin American,883.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007861,Latent naming speed
12766,Hispanic or Latin American,883.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007863,Rapid alternating stimulus test for letters/numbers
12767,Hispanic or Latin American,883.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007864,Rapid automised naming of letters
640,African American or Afro-Caribbean,441.0,30995994.0,Truong DT,Biological process,initial,2019-04-17,GCST007860,Latent naming speed
12342,European,408455.0,30998689.0,Shadrina AS,Other trait,initial,2019-04-18,GCST008057,Varicose veins
9023,European,7192.0,31009812.0,Hung RJ,"Other measurement, Cancer",initial,2019-04-19,GCST008375,Adenocarcinoma in never smokers
9194,European,8031.0,31009812.0,Hung RJ,"Other measurement, Cancer",initial,2019-04-19,GCST008376,Lung cancer in never smokers
6860,European,1900.0,31009812.0,Hung RJ,"Other measurement, Cancer",replication,2019-04-19,GCST008376,Lung cancer in never smokers
6631,European,1612.0,31009812.0,Hung RJ,"Other measurement, Cancer",replication,2019-04-19,GCST008375,Adenocarcinoma in never smokers
12487,Hispanic or Latin American,1.0,31006051.0,Kharazmi M,"Response to drug, Other disease",initial,2019-04-20,GCST008098,Atypical femoral fracture in phosphonate treatment
12486,Hispanic or Latin American,1.0,31006051.0,Kharazmi M,"Response to drug, Other disease",initial,2019-04-20,GCST008097,Bisphosphonate-associated atypical femoral fracture
8430,European,4941.0,31006051.0,Kharazmi M,"Response to drug, Other disease",initial,2019-04-20,GCST008097,Bisphosphonate-associated atypical femoral fracture
5072,European,374.0,31006051.0,Kharazmi M,"Response to drug, Other disease",initial,2019-04-20,GCST008098,Atypical femoral fracture in phosphonate treatment
5610,European,686.0,31005972.0,Hwang LD,Other measurement,initial,2019-04-21,GCST008761,Sucrose liking
11977,European,174424.0,31005972.0,Hwang LD,Other measurement,initial,2019-04-21,GCST008759,Intake of total sugars
10428,European,21447.0,31005972.0,Hwang LD,Other measurement,initial,2019-04-21,GCST008762,Intake of sweets
5760,European,799.0,31009096.0,Meda SA,"Neurological disorder, Other measurement",initial,2019-04-22,GCST008911,Alcohol use disorder
4543,Asian,143658.0,31015462.0,Graham SE,Other measurement,initial,2019-04-23,GCST007876,Estimated glomerular filtration rate
12096,European,242659.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007925,Medication use (vasodilators used in cardiac diseases)
12143,European,272602.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007933,Medication use (immunosuppressants)
12173,European,290385.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007931,Medication use (HMG CoA reductase inhibitors)
12205,European,304162.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007940,Medication use (antidepressants)
11878,European,152380.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007926,Medication use (antihypertensives)
12090,European,237530.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007930,Medication use (agents acting on the renin-angiotensin system)
11396,European,78808.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007936,Medication use (opioids)
11326,European,69591.0,31015462.0,Graham SE,Other measurement,initial,2019-04-23,GCST007877,Creatinine levels
11299,European,67619.0,31015462.0,Graham SE,"Other disease, Other measurement",initial,2019-04-23,GCST007879,Chronic kidney disease
12210,European,305913.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007923,Medication use (drugs used in diabetes)
12087,European,229086.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007928,Medication use (diuretics)
12207,European,305582.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007932,Medication use (thyroid preparations)
12062,European,215668.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007935,Medication use (drugs affecting bone structure and mineralization)
11876,European,151636.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007943,Medication use (antihistamines for systemic use)
11925,European,164520.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007934,"Medication use (anti-inflammatory and antirheumatic products, non-steroids)"
11762,European,132367.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007922,Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease)
10375,European,20700.0,31015462.0,Graham SE,Other measurement,initial,2019-04-23,GCST007878,Urea levels
11692,European,119844.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007939,Medication use (antimigraine preparations)
11980,European,176445.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007941,"Medication use (adrenergics, inhalants)"
12080,European,224024.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007927,Medication use (beta blocking agents)
11986,European,179810.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007938,Medication use (anilides)
12025,European,204378.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007929,Medication use (calcium channel blockers)
11880,European,153639.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007924,Medication use (antithrombotic agents)
11639,European,112010.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007937,Medication use (salicylic acid and derivatives)
12033,European,205700.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007942,Medication use (glucocorticoids)
12041,European,206856.0,31015462.0,Graham SE,Other measurement,initial,2019-04-23,GCST007876,Estimated glomerular filtration rate
11581,European,100868.0,31015401.0,Wu Y,Other measurement,initial,2019-04-23,GCST007944,Medication use (antiglaucoma preparations and miotics)
4730,European,152.0,31241743.0,Jaeger M,Other disease,replication,2019-04-24,GCST008106,Candidemia
4741,European,161.0,31241743.0,Jaeger M,Other disease,initial,2019-04-24,GCST008106,Candidemia
9630,European,10395.0,31014085.0,Welsh P,Cardiovascular measurement,initial,2019-04-24,GCST008310,Cardiac Troponin-T levels
2036,Asian,419.0,31020675.0,Omae Y,Other measurement,initial,2019-04-24,GCST007948,KANNO antigen negativity
9993,European,14579.0,31014085.0,Welsh P,Cardiovascular measurement,initial,2019-04-24,GCST008309,Cardiac troponin-I levels
11044,European,46186.0,31021400.0,Masotti M,Other measurement,initial,2019-04-25,GCST008674,Glycemic traits (pleiotropy)
217,African,1625.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008325,Platelet count
5373,European,522.0,31028280.0,Ierodiakonou D,"Other measurement, Other disease",initial,2019-04-26,GCST008272,Post-bronchodilator FEV1 x air pollution (CO) interaction in childhood asthma
219,African,1625.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008330,Mean corpuscular volume
204,African,1565.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008326,Lymphocyte counts
214,African,1624.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008336,Mean platelet volume
220,African,1625.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008331,Mean corpuscular hemoglobin
221,African,1625.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008332,Mean corpuscular hemoglobin concentration
12239,European,328113.0,31036433.0,Pividori M,Other disease,initial,2019-04-26,GCST007996,Chronic obstructive pulmonary disease
223,African,1625.0,31080455.0,Fatumo S,"Hematological measurement, Inflammatory measurement",initial,2019-04-26,GCST008322,White blood cell count
206,African,1565.0,31080455.0,Fatumo S,Inflammatory measurement,initial,2019-04-26,GCST008328,Basophil count
10915,European,37846.0,31036433.0,Pividori M,Other disease,initial,2019-04-26,GCST007994,Asthma (age of onset)
215,African,1625.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008323,Hematocrit
205,African,1565.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008327,Monocyte count
447,African American or Afro-Caribbean,88.0,31028280.0,Ierodiakonou D,"Other measurement, Other disease",replication,2019-04-26,GCST008273,Post-bronchodilator FEV1 x air pollution (NO2) interaction in childhood asthma
5374,European,522.0,31028280.0,Ierodiakonou D,"Other measurement, Other disease",initial,2019-04-26,GCST008273,Post-bronchodilator FEV1 x air pollution (NO2) interaction in childhood asthma
12238,European,327670.0,31036433.0,Pividori M,Other disease,initial,2019-04-26,GCST007995,Asthma (childhood onset)
222,African,1625.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008333,Red cell distribution width
12264,European,339801.0,31036433.0,Pividori M,Other disease,initial,2019-04-26,GCST007993,Asthma (adult onset)
218,African,1625.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008329,Red blood cell count
294,African,6407.0,31080455.0,Fatumo S,"Hematological measurement, Inflammatory measurement",initial,2019-04-26,GCST008337,Blood cell traits (multivariate analysis)
295,African,6407.0,31080455.0,Fatumo S,"Hematological measurement, Inflammatory measurement",initial,2019-04-26,GCST008338,Blood cell traits (multivariate analysis)
187,African,1415.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008334,Neutrophil count
201,African,1555.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008335,Eosinophil counts
216,African,1625.0,31080455.0,Fatumo S,Hematological measurement,initial,2019-04-26,GCST008324,Hemoglobin
8263,European,4543.0,31040135.0,Dahlin AM,Cancer,initial,2019-04-30,GCST008912,Glioma (pediatric/youth onset)
1603,Asian,54.0,31039275.0,Park SH,"Digestive system disorder, Response to drug",replication,2019-04-30,GCST008397,Infliximab-induced mucosal healing in Crohn's disease
1609,Asian,58.0,31039275.0,Park SH,"Digestive system disorder, Response to drug",initial,2019-04-30,GCST008397,Infliximab-induced mucosal healing in Crohn's disease
6127,European,1030.0,31118946.0,Jiao H,Metabolic disorder,initial,2019-05-01,GCST007997,Obesity (extreme) (SNP x SNP interaction)
13793,Other/Mixed,815.0,31043758.0,Warrington NM,Body measurement,initial,2019-05-01,GCST008362,Birth weight
1746,Asian,157.0,31058715.0,St Jean PL,"Response to drug, Immune system disorder",initial,2019-05-01,GCST008307,Response to belimumab (SLE response index) in systemic lupus erythematosus
10842,European,34779.0,31043756.0,Stahl EA,Neurological disorder,initial,2019-05-01,GCST008116,Bipolar II disorder
1299,African American or Afro-Caribbean,7687.0,31043758.0,Warrington NM,Body measurement,initial,2019-05-01,GCST008362,Birth weight
1804,Asian,204.0,31058715.0,St Jean PL,"Response to drug, Immune system disorder",replication,2019-05-01,GCST008307,Response to belimumab (SLE response index) in systemic lupus erythematosus
10748,European,32335.0,31043756.0,Stahl EA,Neurological disorder,initial,2019-05-01,GCST008117,Schizoaffective disorder-bipolar type
11046,European,46237.0,31043756.0,Stahl EA,Neurological disorder,initial,2019-05-01,GCST008115,Bipolar I disorder
8113,European,4064.0,31250797.0,Brick LA,Neurological disorder,initial,2019-05-01,GCST008424,Opioid dependence
11840,European,147172.0,31043756.0,Stahl EA,Neurological disorder,replication,2019-05-01,GCST008103,Bipolar disorder
3142,Asian,2629.0,31043758.0,Warrington NM,Body measurement,initial,2019-05-01,GCST008362,Birth weight
2355,Asian,840.0,31043758.0,Warrington NM,Body measurement,initial,2019-05-01,GCST008362,Birth weight
12184,European,298142.0,31043758.0,Warrington NM,Body measurement,initial,2019-05-01,GCST008362,Birth weight
12051,European,210267.0,31043758.0,Warrington NM,"Body measurement, Other measurement",initial,2019-05-01,GCST008363,Offspring birth weight
11121,European,51710.0,31043756.0,Stahl EA,Neurological disorder,initial,2019-05-01,GCST008103,Bipolar disorder
12693,Hispanic or Latin American,612.0,31043758.0,Warrington NM,Body measurement,initial,2019-05-01,GCST008362,Birth weight
13641,Other/Mixed,365.0,31043758.0,Warrington NM,Body measurement,initial,2019-05-01,GCST008362,Birth weight
11472,European,85852.0,31046077.0,Zhong VW,Other measurement,initial,2019-05-02,GCST008524,Bitter non-alcoholic beverage consumption
4598,European,62.0,31043678.0,Aterido A,"Digestive system disorder, Response to drug",initial,2019-05-02,GCST008271,Anti-adalimumab antibody production in response to treatment in Crohn's disease
10952,European,39924.0,31046077.0,Zhong VW,"Biological process, Other measurement",replication,2019-05-02,GCST008526,Coffee consumption
4645,European,88.0,31043678.0,Aterido A,"Digestive system disorder, Response to drug",replication,2019-05-02,GCST008271,Anti-adalimumab antibody production in response to treatment in Crohn's disease
12250,European,335909.0,31046077.0,Zhong VW,"Biological process, Other measurement",initial,2019-05-02,GCST008526,Coffee consumption
12253,European,336448.0,31046077.0,Zhong VW,Other measurement,initial,2019-05-02,GCST008522,Bitter alcoholic beverage consumption
12255,European,336898.0,31046077.0,Zhong VW,Other measurement,initial,2019-05-02,GCST008529,Tea consumption
10954,European,39924.0,31046077.0,Zhong VW,Other measurement,replication,2019-05-02,GCST008522,Bitter alcoholic beverage consumption
11471,European,85852.0,31046077.0,Zhong VW,Other measurement,initial,2019-05-02,GCST008523,Pure non-grapefruit juice consumption
10956,European,39924.0,31046077.0,Zhong VW,Other measurement,replication,2019-05-02,GCST008524,Bitter non-alcoholic beverage consumption
10957,European,39924.0,31046077.0,Zhong VW,Other measurement,replication,2019-05-02,GCST008525,Artificially sweetened beverage consumption
10955,European,39924.0,31046077.0,Zhong VW,Other measurement,replication,2019-05-02,GCST008523,Pure non-grapefruit juice consumption
10959,European,39924.0,31046077.0,Zhong VW,Other measurement,replication,2019-05-02,GCST008528,Sweet beverage consumption
11470,European,85852.0,31046077.0,Zhong VW,Other measurement,initial,2019-05-02,GCST008521,Bitter beverage consumption
11473,European,85852.0,31046077.0,Zhong VW,Other measurement,initial,2019-05-02,GCST008525,Artificially sweetened beverage consumption
11474,European,85852.0,31046077.0,Zhong VW,Other measurement,initial,2019-05-02,GCST008527,Sugar-sweetened beverage consumption
11475,European,85852.0,31046077.0,Zhong VW,Other measurement,initial,2019-05-02,GCST008528,Sweet beverage consumption
11476,European,85852.0,31046077.0,Zhong VW,Other measurement,initial,2019-05-02,GCST008531,Grapefruit juice consumption
10958,European,39924.0,31046077.0,Zhong VW,Other measurement,replication,2019-05-02,GCST008527,Sugar-sweetened beverage consumption
10953,European,39924.0,31046077.0,Zhong VW,Other measurement,replication,2019-05-02,GCST008521,Bitter beverage consumption
10961,European,39924.0,31046077.0,Zhong VW,Other measurement,replication,2019-05-02,GCST008531,Grapefruit juice consumption
271,African,4347.0,31049640.0,Chen J,Metabolic disorder,initial,2019-05-02,GCST008114,Type 2 diabetes
10960,European,39924.0,31046077.0,Zhong VW,Other measurement,replication,2019-05-02,GCST008529,Tea consumption
10666,European,29059.0,31053729.0,Styrkarsdottir U,Other measurement,initial,2019-05-03,GCST008282,Spine bone size
10660,European,28944.0,31053729.0,Styrkarsdottir U,Body measurement,initial,2019-05-03,GCST008279,Trochanter size
8822,European,6351.0,31053729.0,Styrkarsdottir U,Body measurement,replication,2019-05-03,GCST008278,Femoral neck size
10661,European,28954.0,31053729.0,Styrkarsdottir U,Body measurement,initial,2019-05-03,GCST008278,Femoral neck size
3716,Asian,6345.0,31053729.0,Styrkarsdottir U,Other measurement,replication,2019-05-03,GCST008282,Spine bone size
3634,Asian,5711.0,31053729.0,Styrkarsdottir U,Body measurement,replication,2019-05-03,GCST008279,Trochanter size
10658,European,28936.0,31053729.0,Styrkarsdottir U,Body measurement,initial,2019-05-03,GCST008280,Intertrochanteric region size
10656,European,28900.0,31053729.0,Styrkarsdottir U,Body measurement,initial,2019-05-03,GCST008281,Hip bone size
3631,Asian,5696.0,31053729.0,Styrkarsdottir U,Body measurement,replication,2019-05-03,GCST008280,Intertrochanteric region size
2624,Asian,1451.0,31050781.0,Zhao SX,"Immune system disorder, Metabolic disorder",replication,2019-05-03,GCST008365,Thyrotoxic hypokalemic periodic paralysis and Graves disease
10025,European,14932.0,31053729.0,Styrkarsdottir U,Other measurement,replication,2019-05-03,GCST008282,Spine bone size
2695,Asian,1575.0,31050781.0,Zhao SX,"Immune system disorder, Metabolic disorder",initial,2019-05-03,GCST008364,Thyrotoxic hypokalemic periodic paralysis in Graves disease
3632,Asian,5699.0,31053729.0,Styrkarsdottir U,Body measurement,replication,2019-05-03,GCST008281,Hip bone size
3059,Asian,2331.0,31050781.0,Zhao SX,"Immune system disorder, Metabolic disorder",initial,2019-05-03,GCST008365,Thyrotoxic hypokalemic periodic paralysis and Graves disease
3992,Asian,9383.0,31053729.0,Styrkarsdottir U,Body measurement,replication,2019-05-03,GCST008278,Femoral neck size
9199,European,8065.0,31053729.0,Styrkarsdottir U,Body measurement,replication,2019-05-03,GCST008279,Trochanter size
9157,European,7912.0,31053729.0,Styrkarsdottir U,Body measurement,replication,2019-05-03,GCST008280,Intertrochanteric region size
9158,European,7912.0,31053729.0,Styrkarsdottir U,Body measurement,replication,2019-05-03,GCST008281,Hip bone size
9697,European,10870.0,31055733.0,Nazarian A,"Neurological disorder, Cardiovascular disease",initial,2019-05-05,GCST008438,Alzheimer's disease in hypertension
8359,European,4806.0,31055733.0,Nazarian A,Neurological disorder,initial,2019-05-05,GCST008437,Alzheimer's disease in hypertension-negative individuals
8336,European,4755.0,31059154.0,Chen Z,Neurological disorder,initial,2019-05-06,GCST007845,Progressive supranuclear palsy
9333,European,8454.0,31066027.0,Nicoletti P,"Other disease, Response to drug",initial,2019-05-07,GCST008385,Carbamazepine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)
9332,European,8450.0,31066027.0,Nicoletti P,"Digestive system disorder, Response to drug",initial,2019-05-07,GCST008383,Carbamazepine-induced liver injury
9040,European,7310.0,31065058.0,Rongve A,Other trait,initial,2019-05-07,GCST007881,Dementia with Lewy bodies
9684,European,10744.0,31066027.0,Nicoletti P,"Other disease, Response to drug",initial,2019-05-07,GCST008386,Carbamazepine-induced serious cutaneous adverse reaction
9678,European,10726.0,31066027.0,Nicoletti P,"Immune system disorder, Response to drug",initial,2019-05-07,GCST008384,Carbamazepine-induced reaction with eosinophilia and systemic symptoms
11366,European,75653.0,31065058.0,Rongve A,Other trait,replication,2019-05-07,GCST007881,Dementia with Lewy bodies
10692,European,30118.0,31070104.0,Jia Q,Other measurement,initial,2019-05-09,GCST007836,Glycine levels
9709,European,11006.0,31070104.0,Jia Q,Other measurement,initial,2019-05-09,GCST007837,Glycine levels
10292,European,19112.0,31070104.0,Jia Q,Other measurement,initial,2019-05-09,GCST007838,Glycine levels
5433,European,563.0,31085060.0,Gisbert L,"Neurological disorder, Other measurement",initial,2019-05-10,GCST007880,Emotional lability in attention deficit hyperactivity disorder
6874,European,1939.0,31081985.0,Stein MB,Other measurement,initial,2019-05-13,GCST007947,Psychological resilience (outcome-based)
8163,European,4216.0,31135556.0,Wyles CC,Other disease,initial,2019-05-13,GCST008913,Idiopathic osteonecrosis of the femoral head
363,African American or Afro-Caribbean,2.0,31135556.0,Wyles CC,Other disease,replication,2019-05-13,GCST008913,Idiopathic osteonecrosis of the femoral head
5316,European,497.0,31135556.0,Wyles CC,Other disease,replication,2019-05-13,GCST008913,Idiopathic osteonecrosis of the femoral head
9751,European,11473.0,31081985.0,Stein MB,Other measurement,initial,2019-05-13,GCST007946,Psychological resilience (self-assessed)
369,African American or Afro-Caribbean,9.0,31135556.0,Wyles CC,Other disease,initial,2019-05-13,GCST008913,Idiopathic osteonecrosis of the femoral head
5464,European,581.0,31081985.0,Stein MB,Other measurement,initial,2019-05-13,GCST007945,Psychological resilience (outcome-based) in high deployment stress exposure
1531,Asian,2.0,31135556.0,Wyles CC,Other disease,initial,2019-05-13,GCST008913,Idiopathic osteonecrosis of the femoral head
1534,Asian,3.0,31135556.0,Wyles CC,Other disease,replication,2019-05-13,GCST008913,Idiopathic osteonecrosis of the femoral head
8482,European,5053.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008289,Alcohol dependence (giving up activities)
8176,European,4244.0,31090166.0,Lai D,"Other measurement, Neurological disorder",replication,2019-05-14,GCST008284,Alcohol dependence
1053,African American or Afro-Caribbean,2940.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008285,Alcohol dependence (tolerance)
2200,Asian,651.0,31089239.0,Choe EK,Other trait,replication,2019-05-14,GCST007921,Right-sided colonic diverticulosis
1052,African American or Afro-Caribbean,2940.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008283,Alcohol dependence symptom count
9033,European,7305.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008286,Alcohol dependence (withdrawal)
9038,European,7309.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008288,Alcohol dependence (desire to cut drinking)
9037,European,7308.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008289,Alcohol dependence (giving up activities)
1089,African American or Afro-Caribbean,3137.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008288,Alcohol dependence (desire to cut drinking)
1088,African American or Afro-Caribbean,3136.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008290,Alcohol dependence (time spent drinking)
1087,African American or Afro-Caribbean,3136.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008289,Alcohol dependence (giving up activities)
1085,African American or Afro-Caribbean,3134.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008287,Alcohol dependence (drinking more than intended)
1099,African American or Afro-Caribbean,3175.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008283,Alcohol dependence symptom count
9036,European,7307.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008291,Alcohol dependence (drinking despite problems)
1084,African American or Afro-Caribbean,3134.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008285,Alcohol dependence (tolerance)
1051,African American or Afro-Caribbean,2939.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008291,Alcohol dependence (drinking despite problems)
9035,European,7306.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008287,Alcohol dependence (drinking more than intended)
1082,African American or Afro-Caribbean,3130.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008286,Alcohol dependence (withdrawal)
9034,European,7306.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008285,Alcohol dependence (tolerance)
919,African American or Afro-Caribbean,1831.0,31090166.0,Lai D,"Other measurement, Neurological disorder",initial,2019-05-14,GCST008284,Alcohol dependence
1050,African American or Afro-Caribbean,2938.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008287,Alcohol dependence (drinking more than intended)
2907,Asian,1968.0,31089239.0,Choe EK,Other trait,initial,2019-05-14,GCST007921,Right-sided colonic diverticulosis
1086,African American or Afro-Caribbean,3135.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008291,Alcohol dependence (drinking despite problems)
1057,African American or Afro-Caribbean,2940.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008290,Alcohol dependence (time spent drinking)
8479,European,5053.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008283,Alcohol dependence symptom count
8478,European,5052.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008291,Alcohol dependence (drinking despite problems)
8481,European,5053.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008288,Alcohol dependence (desire to cut drinking)
8480,European,5053.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008286,Alcohol dependence (withdrawal)
11550,European,92967.0,31089142.0,Law PJ,Cancer,initial,2019-05-14,GCST007992,Colorectal cancer
1054,African American or Afro-Caribbean,2940.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008286,Alcohol dependence (withdrawal)
8374,European,4849.0,31090166.0,Lai D,"Other measurement, Neurological disorder",initial,2019-05-14,GCST008284,Alcohol dependence
1031,African American or Afro-Caribbean,2726.0,31090166.0,Lai D,"Other measurement, Neurological disorder",replication,2019-05-14,GCST008284,Alcohol dependence
1056,African American or Afro-Caribbean,2940.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008289,Alcohol dependence (giving up activities)
1055,African American or Afro-Caribbean,2940.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008288,Alcohol dependence (desire to cut drinking)
8483,European,5053.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008290,Alcohol dependence (time spent drinking)
9063,European,7418.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008283,Alcohol dependence symptom count
8477,European,5052.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008285,Alcohol dependence (tolerance)
9039,European,7309.0,31090166.0,Lai D,Other measurement,initial,2019-05-14,GCST008290,Alcohol dependence (time spent drinking)
8475,European,5050.0,31090166.0,Lai D,Other measurement,replication,2019-05-14,GCST008287,Alcohol dependence (drinking more than intended)
1384,African American or Afro-Caribbean,10409.0,31092297.0,Guan M,Metabolic disorder,initial,2019-05-15,GCST007949,Type 2 diabetes and end-stage kidney disease
1351,African American or Afro-Caribbean,8827.0,31092297.0,Guan M,"Metabolic disorder, Other measurement",initial,2019-05-15,GCST007950,Type 2 diabetes and end-stage kidney disease in APOL1 risk genotype negative individuals
7944,European,3619.0,31095341.0,Kerns SL,"Cancer, Other trait, Biological process",initial,2019-05-16,GCST008380,Toxicity response to radiotherapy in prostate cancer (hematuria) (time to event)
7880,European,3470.0,31095341.0,Kerns SL,"Cancer, Biological process, Other trait",initial,2019-05-16,GCST008378,Toxicity response to radiotherapy in prostate cancer (decreased urine stream) (time to event)
8001,European,3782.0,31095341.0,Kerns SL,"Cancer, Biological process, Other trait",initial,2019-05-16,GCST008382,Toxicity response to radiotherapy in prostate cancer (increased urinary frequency) (time to event)
8033,European,3871.0,31095341.0,Kerns SL,"Cancer, Biological process, Other disease",initial,2019-05-16,GCST008379,Response to radiotherapy in prostate cancer (overall toxicity)
2141,Asian,538.0,31095341.0,Kerns SL,"Cancer, Other trait, Biological process",replication,2019-05-16,GCST008380,Toxicity response to radiotherapy in prostate cancer (hematuria) (time to event)
7827,European,3379.0,31095341.0,Kerns SL,"Cancer, Biological process, Other trait",initial,2019-05-16,GCST008381,Toxicity response to radiotherapy in prostate cancer (rectal bleeding) (time to event)
6667,European,1650.0,31099175.0,Wetherill L,Neurological disorder,replication,2019-05-17,GCST008914,Alcohol or illicit drug dependence
9030,European,7291.0,31099175.0,Wetherill L,Neurological disorder,initial,2019-05-17,GCST008914,Alcohol or illicit drug dependence
6626,European,1609.0,31102405.0,Labreche K,Cancer,initial,2019-05-17,GCST007896,Primary central nervous system lymphoma
1035,African American or Afro-Caribbean,2812.0,31099175.0,Wetherill L,Neurological disorder,replication,2019-05-17,GCST008914,Alcohol or illicit drug dependence
1083,African American or Afro-Caribbean,3132.0,31099175.0,Wetherill L,Neurological disorder,initial,2019-05-17,GCST008914,Alcohol or illicit drug dependence
1938,Asian,318.0,31109976.0,Suvichapanich S,"Response to drug, Other disease, Digestive system disorder",initial,2019-05-20,GCST007897,Liver injury in anti-tuberculosis drug treatment
5377,European,523.0,31113495.0,Evans KL,"Other trait, Cardiovascular measurement, Cardiovascular disease",initial,2019-05-21,GCST007999,Heart rate in heart failure with reduced ejection fraction
667,African American or Afro-Caribbean,520.0,31113495.0,Evans KL,"Other trait, Cardiovascular measurement, Cardiovascular disease",initial,2019-05-21,GCST007999,Heart rate in heart failure with reduced ejection fraction
10734,European,31880.0,31116379.0,Meier SM,Neurological disorder,initial,2019-05-22,GCST008559,Anxiety and stress-related disorders
10665,European,29056.0,31116379.0,Meier SM,Neurological disorder,initial,2019-05-22,GCST008567,Stress-related disorders
10630,European,27742.0,31116379.0,Meier SM,Neurological disorder,initial,2019-05-22,GCST008565,Anxiety and stress-related disorders (excluding adjustment disorder)
10711,European,30785.0,31116379.0,Meier SM,Neurological disorder,initial,2019-05-22,GCST008564,Anxiety and stress-related disorders (excluding co-morbid schizophrenia)
10679,European,29536.0,31116379.0,Meier SM,Neurological disorder,initial,2019-05-22,GCST008562,Anxiety and stress-related disorders (psychiatric co-morbidity weighting design)
10495,European,23198.0,31116379.0,Meier SM,Neurological disorder,initial,2019-05-22,GCST008560,Anxiety and stress-related disorders (propensity-score-matching design)
10516,European,23809.0,31116379.0,Meier SM,Neurological disorder,initial,2019-05-22,GCST008566,Anxiety disorders
11166,European,54311.0,31116379.0,Meier SM,Neurological disorder,initial,2019-05-22,GCST008561,Anxiety and stress-related disorders (psychiatric co-morbidity covariate model)
10761,European,32758.0,31116379.0,Meier SM,Neurological disorder,initial,2019-05-22,GCST008563,Anxiety and stress-related disorders (including obsessive-compulsive disorder)
1203,African American or Afro-Caribbean,4560.0,31118516.0,Flannick J,Metabolic disorder,initial,2019-05-22,GCST008833,Type 2 diabetes
13219,Hispanic or Latin American,12154.0,31118516.0,Flannick J,Metabolic disorder,initial,2019-05-22,GCST008833,Type 2 diabetes
3680,Asian,6019.0,31118516.0,Flannick J,Metabolic disorder,initial,2019-05-22,GCST008833,Type 2 diabetes
3668,Asian,5961.0,31118516.0,Flannick J,Metabolic disorder,initial,2019-05-22,GCST008833,Type 2 diabetes
9026,European,7218.0,31118516.0,Flannick J,Metabolic disorder,initial,2019-05-22,GCST008833,Type 2 diabetes
6021,European,972.0,31123309.0,Rayner C,"Other trait, Neurological disorder",initial,2019-05-23,GCST008360,Response to cognitive-behavioural therapy in anxiety disorder
5963,European,935.0,31120506.0,Grassmann F,"Other measurement, Neurological disorder",initial,2019-05-23,GCST008356,Geographic atrophy lesion growth rate in age-related macular degeneration
6020,European,972.0,31123309.0,Rayner C,"Other trait, Neurological disorder",initial,2019-05-23,GCST008358,Response to cognitive-behavioural therapy in anxiety and major depressive disorders
3335,Asian,3648.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008395,End-stage kidney disease
13939,Other/Mixed,2988.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008395,End-stage kidney disease
8523,European,5168.0,31127053.0,Tang Y,"Metabolic disorder, Neurological disorder",initial,2019-05-24,GCST008223,Diabetic peripheral neuropathy in type 2 diabetes
13719,Other/Mixed,637.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008394,Mild to moderate chronic kidney disease
3398,Asian,4115.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008394,Mild to moderate chronic kidney disease
13318,Hispanic or Latin American,20653.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008394,Mild to moderate chronic kidney disease
5993,European,949.0,31127053.0,Tang Y,"Metabolic disorder, Neurological disorder",replication,2019-05-24,GCST008223,Diabetic peripheral neuropathy in type 2 diabetes
13465,Other/Mixed,50.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008395,End-stage kidney disease
862,African American or Afro-Caribbean,1345.0,31127053.0,Tang Y,"Metabolic disorder, Neurological disorder",replication,2019-05-24,GCST008223,Diabetic peripheral neuropathy in type 2 diabetes
1354,African American or Afro-Caribbean,9013.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008395,End-stage kidney disease
13949,Other/Mixed,3500.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008394,Mild to moderate chronic kidney disease
13817,Other/Mixed,966.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008395,End-stage kidney disease
1420,African American or Afro-Caribbean,15293.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008394,Mild to moderate chronic kidney disease
13821,Other/Mixed,993.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008394,Mild to moderate chronic kidney disease
13276,Hispanic or Latin American,16134.0,31178898.0,Lin BM,Other disease,initial,2019-05-24,GCST008395,End-stage kidney disease
1415,African American or Afro-Caribbean,13842.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008066,Estimated glomerular filtration rate
3536,Asian,5152.0,31152121.0,Zhu M,Metabolic disorder,replication,2019-05-31,GCST008377,Type 1 diabetes
12445,European,625219.0,31152163.0,Wuttke M,"Other disease, Other measurement",initial,2019-05-31,GCST008065,Chronic kidney disease
4549,Asian,165726.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008058,Estimated glomerular filtration rate
4550,Asian,165726.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008060,Estimated glomerular filtration rate
12439,European,567460.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008058,Estimated glomerular filtration rate
4167,Asian,13359.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008061,Estimated glomerular filtration rate
13044,Hispanic or Latin American,4961.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008058,Estimated glomerular filtration rate
4166,Asian,13359.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008058,Estimated glomerular filtration rate
1414,African American or Afro-Caribbean,13842.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008058,Estimated glomerular filtration rate
12440,European,567460.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008059,Estimated glomerular filtration rate
12097,European,243029.0,31152163.0,Wuttke M,Other measurement,initial,2019-05-31,GCST008063,Blood urea nitrogen levels
12064,European,216518.0,31152163.0,Wuttke M,Other measurement,replication,2019-05-31,GCST008059,Estimated glomerular filtration rate
360,African,64204.0,31152163.0,Wuttke M,Other measurement,replication,2019-05-31,GCST008058,Estimated glomerular filtration rate
12063,European,216518.0,31152163.0,Wuttke M,Other measurement,replication,2019-05-31,GCST008058,Estimated glomerular filtration rate
3040,Asian,2262.0,31152121.0,Zhu M,Metabolic disorder,initial,2019-05-31,GCST008377,Type 1 diabetes
5735,European,779.0,31189108.0,O'Connor D,"Response to drug, Other measurement",replication,2019-06-01,GCST008499,Meningococcal C functional antibody titers post childhood immunization
6036,European,980.0,31189108.0,O'Connor D,"Response to drug, Other measurement",replication,2019-06-01,GCST008498,Meningococcal C IgG concentrations post childhood immunization
5416,European,549.0,31189108.0,O'Connor D,"Response to drug, Other measurement",initial,2019-06-01,GCST008500,Tetanus toxoid IgG concentrations post childhood immunization
6013,European,967.0,31189108.0,O'Connor D,"Response to drug, Other measurement",initial,2019-06-01,GCST008501,Haemophilus influenza type b polyribosylribitol phosphate IgG concentrations post childhood immunization
6370,European,1303.0,31189108.0,O'Connor D,"Response to drug, Other measurement",replication,2019-06-01,GCST008500,Tetanus toxoid IgG concentrations post childhood immunization
6107,European,1011.0,31189108.0,O'Connor D,"Response to drug, Other measurement",replication,2019-06-01,GCST008501,Haemophilus influenza type b polyribosylribitol phosphate IgG concentrations post childhood immunization
8684,European,5783.0,31250787.0,Fawns-Ritchie C,Other measurement,initial,2019-06-01,GCST008513,Health literacy
6295,European,1203.0,31189108.0,O'Connor D,"Response to drug, Other measurement",initial,2019-06-01,GCST008498,Meningococcal C IgG concentrations post childhood immunization
6609,European,1585.0,31189108.0,O'Connor D,"Response to drug, Other measurement",initial,2019-06-01,GCST008499,Meningococcal C functional antibody titers post childhood immunization
13366,Other/Mixed,3.0,31155012.0,Nakahara S,Other measurement,initial,2019-06-03,GCST008558,Dentate gyrus volume
1586,Asian,31.0,31155012.0,Nakahara S,"Neurological disorder, Other measurement",initial,2019-06-03,GCST008557,Dentate gyrus volume x schizophrenia interaction
13362,Other/Mixed,2.0,31155012.0,Nakahara S,"Neurological disorder, Other measurement",initial,2019-06-03,GCST008557,Dentate gyrus volume x schizophrenia interaction
13363,Other/Mixed,2.0,31155012.0,Nakahara S,Other measurement,initial,2019-06-03,GCST008558,Dentate gyrus volume
1587,Asian,31.0,31155012.0,Nakahara S,Other measurement,initial,2019-06-03,GCST008558,Dentate gyrus volume
13365,Other/Mixed,3.0,31155012.0,Nakahara S,"Neurological disorder, Other measurement",initial,2019-06-03,GCST008557,Dentate gyrus volume x schizophrenia interaction
4816,European,199.0,31155012.0,Nakahara S,"Neurological disorder, Other measurement",initial,2019-06-03,GCST008557,Dentate gyrus volume x schizophrenia interaction
4817,European,199.0,31155012.0,Nakahara S,Other measurement,initial,2019-06-03,GCST008558,Dentate gyrus volume
10296,European,19172.0,31164008.0,Mullins N,"Biological process, Neurological disorder",initial,2019-06-05,GCST008121,Suicide attempts in major depressive disorder or bipolar disorder
12283,European,363705.0,31168069.0,Ward J,Other measurement,initial,2019-06-05,GCST008357,Mood instability
8079,European,3984.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008410,Diastolic blood pressure x physical activity (least vs most active quartile) interaction (2df)
8894,European,6704.0,31167214.0,Osazuwa-Peters OL,Other measurement,initial,2019-06-05,GCST008390,DIastolic blood pressure x physical activity interaction (2df)
9631,European,10408.0,31164008.0,Mullins N,"Biological process, Neurological disorder",initial,2019-06-05,GCST008118,Suicide attempts in major depressive disorder
9393,European,8764.0,31164008.0,Mullins N,"Biological process, Neurological disorder",initial,2019-06-05,GCST008119,Suicide attempts in bipolar disorder
8895,European,6704.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008406,Diastolic blood pressure x physical activity (less vs more active half) interaction (1df)
8896,European,6704.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008407,Diastolic blood pressure x physical activity (least active quartile vs others) interaction (1df)
8898,European,6704.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008412,Diastolic blood pressure x physical activity (least active quartile vs others) interaction (2df)
10515,European,23801.0,31164008.0,Mullins N,"Biological process, Neurological disorder",initial,2019-06-05,GCST008123,Suicide attempts in major depressive disorder or bipolar disorder or schizophrenia
8893,European,6704.0,31167214.0,Osazuwa-Peters OL,Other measurement,initial,2019-06-05,GCST008389,Diastolic blood pressure x physical activity interaction (1df)
8904,European,6705.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008409,Systolic blood pressure x physical activity (least active quartile vs others) interaction (2df)
8901,European,6705.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008401,Systolic blood pressure x physical activity (less vs more active half) interaction (1df)
8897,European,6704.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008411,Diastolic blood pressure x physical activity (less vs more active half) interaction (2df)
8293,European,4629.0,31164008.0,Mullins N,"Biological process, Neurological disorder",initial,2019-06-05,GCST008120,Suicide attempts in schizophrenia
8076,European,3984.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008400,Systolic blood pressure x physical activity (least vs most active quartile) interaction (1df)
8903,European,6705.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008408,Systolic blood pressure x physical activity (less vs more active half) interaction (2df)
8902,European,6705.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008404,Systolic blood pressure x physical activity (least active quartile vs others) interaction (1df)
8899,European,6705.0,31167214.0,Osazuwa-Peters OL,Other measurement,initial,2019-06-05,GCST008392,Systolic blood pressure x physical activity interaction (1df)
9905,European,13393.0,31164008.0,Mullins N,"Biological process, Neurological disorder",initial,2019-06-05,GCST008122,Suicide attempts in bipolar disorder or schizophrenia
8900,European,6705.0,31167214.0,Osazuwa-Peters OL,Other measurement,initial,2019-06-05,GCST008393,Systolic blood pressure x physical activity interaction (2df)
8078,European,3984.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008405,Diastolic blood pressure x physical activity (least vs most active quartile) interaction (1df)
11217,European,58853.0,31164008.0,Mullins N,"Biological process, Neurological disorder",replication,2019-06-05,GCST008121,Suicide attempts in major depressive disorder or bipolar disorder
8077,European,3984.0,31167214.0,Osazuwa-Peters OL,"Other measurement, Biological process",initial,2019-06-05,GCST008402,Systolic blood pressure x physical activity (least vs most active quartile) interaction (2df)
7406,European,2619.0,31169883.0,Pott J,Other measurement,initial,2019-06-06,GCST008885,Progesterone levels
10900,European,37505.0,31171785.0,Dorajoo R,Other measurement,replication,2019-06-06,GCST008366,Leukocyte telomere length
3479,Asian,4659.0,31170924.0,Kong S,Lipid or lipoprotein measurement,initial,2019-06-06,GCST008141,HDL cholesterol
2852,Asian,1850.0,31170924.0,Kong S,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",initial,2019-06-06,GCST008140,Metabolic syndrome
3482,Asian,4659.0,31170924.0,Kong S,Other measurement,initial,2019-06-06,GCST008143,Diastolic blood pressure
3481,Asian,4659.0,31170924.0,Kong S,Other measurement,initial,2019-06-06,GCST008142,Systolic blood pressure
3483,Asian,4659.0,31170924.0,Kong S,Other measurement,initial,2019-06-06,GCST008144,Fasting plasma glucose
3714,Asian,6337.0,31171785.0,Dorajoo R,Other measurement,replication,2019-06-06,GCST008366,Leukocyte telomere length
3480,Asian,4659.0,31170924.0,Kong S,Lipid or lipoprotein measurement,initial,2019-06-06,GCST008150,Triglyceride levels
6995,European,2070.0,31169883.0,Pott J,Other measurement,initial,2019-06-06,GCST008879,17-hydroxyprogesterone (17-OHP) levels
3549,Asian,5273.0,31170924.0,Kong S,Lipid or lipoprotein measurement,replication,2019-06-06,GCST008141,HDL cholesterol
3202,Asian,2857.0,31170924.0,Kong S,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",initial,2019-06-06,GCST008146,Metabolic syndrome
9114,European,7643.0,31169883.0,Pott J,Other measurement,initial,2019-06-06,GCST008884,Testosterone levels
9120,European,7659.0,31169883.0,Pott J,Other measurement,initial,2019-06-06,GCST008883,DHEAS levels
9121,European,7667.0,31169883.0,Pott J,Other measurement,initial,2019-06-06,GCST008882,Cortisol levels (plasma)
4243,Asian,16759.0,31171785.0,Dorajoo R,Other measurement,initial,2019-06-06,GCST008366,Leukocyte telomere length
3548,Asian,5273.0,31170924.0,Kong S,Body measurement,replication,2019-06-06,GCST008145,Waist circumference
6996,European,2070.0,31169883.0,Pott J,Other measurement,initial,2019-06-06,GCST008886,Androstenedione levels
3553,Asian,5273.0,31170924.0,Kong S,Other measurement,replication,2019-06-06,GCST008144,Fasting plasma glucose
6923,European,1993.0,31169883.0,Pott J,Other measurement,initial,2019-06-06,GCST008880,Aldosterone levels
3552,Asian,5273.0,31170924.0,Kong S,Other measurement,replication,2019-06-06,GCST008143,Diastolic blood pressure
8926,European,6798.0,31169883.0,Pott J,Other measurement,initial,2019-06-06,GCST008881,Estradiol levels
3551,Asian,5273.0,31170924.0,Kong S,Other measurement,replication,2019-06-06,GCST008142,Systolic blood pressure
3550,Asian,5273.0,31170924.0,Kong S,Lipid or lipoprotein measurement,replication,2019-06-06,GCST008150,Triglyceride levels
3478,Asian,4659.0,31170924.0,Kong S,Body measurement,initial,2019-06-06,GCST008145,Waist circumference
2970,Asian,2118.0,31170924.0,Kong S,"Body measurement, Lipid or lipoprotein measurement, Other measurement, Metabolic disorder",replication,2019-06-06,GCST008140,Metabolic syndrome
12448,European,651138.0,31174203.0,Liyanage UE,Cancer,initial,2019-06-07,GCST008871,Basal cell carcinoma
12447,European,635331.0,31174203.0,Liyanage UE,Cancer,initial,2019-06-07,GCST008872,Squamous cell carcinoma
9107,European,7611.0,31188284.0,Bae H,Other measurement,initial,2019-06-10,GCST008149,Age at menopause
2609,Asian,1402.0,31186284.0,Liu Y,"Lipid or lipoprotein measurement, Cardiovascular disease",initial,2019-06-11,GCST008433,Lipoprotein (a) levels in coronary artery disease (percutaneous coronary intervention)
11352,European,73302.0,31249589.0,Edwards TL,Cancer,initial,2019-06-12,GCST008423,Uterine fibroids
11871,European,150588.0,31249589.0,Edwards TL,Cancer,replication,2019-06-12,GCST008423,Uterine fibroids
255,African,3192.0,31249589.0,Edwards TL,Cancer,replication,2019-06-12,GCST008423,Uterine fibroids
1675,Asian,100.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008168,Platelet count
12561,Hispanic or Latin American,138.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008166,Mean corpuscular volume
1674,Asian,100.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008167,Mean platelet volume
1673,Asian,100.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008166,Mean corpuscular volume
12562,Hispanic or Latin American,138.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008167,Mean platelet volume
416,African American or Afro-Caribbean,53.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008168,Platelet count
415,African American or Afro-Caribbean,53.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008167,Mean platelet volume
414,African American or Afro-Caribbean,53.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008166,Mean corpuscular volume
1554,Asian,13.0,31219150.0,Ekenberg C,"Other measurement, Other disease",initial,2019-06-13,GCST008758,Pre-treatment viral load in HIV-1 infection
9803,European,11963.0,31190057.0,Dashti HS,Other measurement,initial,2019-06-13,GCST008556,Breakfast skipping
5577,European,666.0,31194736.0,Tiensuu H,Other measurement,initial,2019-06-13,GCST008176,Gestational age at birth (child effect)
5578,European,666.0,31194736.0,Tiensuu H,"Other measurement, Other trait",initial,2019-06-13,GCST008177,Spontaneous preterm birth (preterm birth)
12563,Hispanic or Latin American,138.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008168,Platelet count
10160,European,16815.0,31194737.0,Johnston KJA,Other trait,initial,2019-06-13,GCST008511,Chronic widespread pain
8151,European,4175.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008168,Platelet count
12630,Hispanic or Latin American,418.0,31219150.0,Ekenberg C,"Other measurement, Other disease",initial,2019-06-13,GCST008758,Pre-treatment viral load in HIV-1 infection
13446,Other/Mixed,30.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008166,Mean corpuscular volume
13447,Other/Mixed,30.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008167,Mean platelet volume
126,African,572.0,31219150.0,Ekenberg C,"Other measurement, Other disease",initial,2019-06-13,GCST008758,Pre-treatment viral load in HIV-1 infection
13448,Other/Mixed,30.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008168,Platelet count
8149,European,4175.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008166,Mean corpuscular volume
8150,European,4175.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008167,Mean platelet volume
12619,Hispanic or Latin American,401.0,31196165.0,Lee E,"Other trait, Cancer, Biological process",initial,2019-06-13,GCST008388,Acute post-radiotherapy pain in breast cancer
12320,European,387649.0,31194737.0,Johnston KJA,Other trait,initial,2019-06-13,GCST008512,Multisite chronic pain
13402,Other/Mixed,11.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008166,Mean corpuscular volume
5366,European,520.0,31194736.0,Tiensuu H,Other trait,initial,2019-06-13,GCST008181,Spontaneous preterm birth without premature rupture of membranes
13403,Other/Mixed,11.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008167,Mean platelet volume
13472,Other/Mixed,58.0,31196165.0,Lee E,"Other trait, Cancer, Biological process",initial,2019-06-13,GCST008388,Acute post-radiotherapy pain in breast cancer
5307,European,494.0,31194736.0,Tiensuu H,Other trait,initial,2019-06-13,GCST008179,Moderate-to-late spontaneous preterm birth
5051,European,357.0,31196165.0,Lee E,"Other trait, Cancer, Biological process",initial,2019-06-13,GCST008388,Acute post-radiotherapy pain in breast cancer
6461,European,1398.0,31219150.0,Ekenberg C,"Other measurement, Other disease",initial,2019-06-13,GCST008758,Pre-treatment viral load in HIV-1 infection
12009,European,193860.0,31190057.0,Dashti HS,Other measurement,initial,2019-06-13,GCST008555,Breakfast cereal skipping frequency
5474,European,591.0,31194736.0,Tiensuu H,Other trait,initial,2019-06-13,GCST008178,Early spontaneous preterm birth
13404,Other/Mixed,11.0,31194788.0,Read RW,Hematological measurement,initial,2019-06-13,GCST008168,Platelet count
5420,European,552.0,31194736.0,Tiensuu H,"Other trait, Other disease",initial,2019-06-13,GCST008180,Spontaneous preterm birth with premature rupture of membranes
12968,Hispanic or Latin American,3693.0,31207883.0,Rivera-Paredez B,Cardiovascular measurement,replication,2019-06-14,GCST008445,Serum uric acid levels
12617,Hispanic or Latin American,396.0,31207883.0,Rivera-Paredez B,Cardiovascular measurement,initial,2019-06-14,GCST008445,Serum uric acid levels
13614,Other/Mixed,327.0,31163085.0,Sharapov SZ,Other measurement,replication,2019-06-15,GCST008108,N-glycan levels
4957,European,294.0,31163085.0,Sharapov SZ,Other measurement,replication,2019-06-15,GCST008108,N-glycan levels
8825,European,6378.0,31212010.0,Cabana-Dominguez J,Neurological disorder,initial,2019-06-15,GCST008399,Cocaine dependence
11096,European,48985.0,31209380.0,Demontis D,Neurological disorder,initial,2019-06-17,GCST008416,Psychiatric disorder without cannabis use disorder
7622,European,3034.0,31206164.0,Richards AL,"Biological process, Neurological disorder",initial,2019-06-17,GCST008387,Cognitive ability in schizophrenia
12211,European,306542.0,31209380.0,Demontis D,"Other disease, Neurological disorder",replication,2019-06-17,GCST008414,Cannabis use disorder
11116,European,51372.0,31209380.0,Demontis D,"Other disease, Neurological disorder",initial,2019-06-17,GCST008414,Cannabis use disorder
8152,European,4176.0,31209380.0,Demontis D,"Neurological disorder, Other disease",initial,2019-06-17,GCST008415,Cannabis use disorder vs schizophrenia
11115,European,51372.0,31209380.0,Demontis D,"Neurological disorder, Metabolic disorder",initial,2019-06-17,GCST008417,Psychiatric disorder
5811,European,831.0,31206233.0,Real LM,Other trait,initial,2019-06-17,GCST008502,Low susceptibility to hepatitis C infection
5225,European,454.0,31209788.0,Li HQ,Other trait,initial,2019-06-18,GCST008275,Cerebral microbleeds
13027,Hispanic or Latin American,4777.0,31213470.0,Moon JY,Other measurement,replication,2019-06-18,GCST008398,Glycated hemoglobin levels
13928,Other/Mixed,2700.0,31211820.0,Deek R,Lipid or lipoprotein measurement,initial,2019-06-18,GCST008444,High density lipoprotein cholesterol levels
6526,European,1513.0,31226389.0,Wilman HR,Other measurement,replication,2019-06-18,GCST008172,Liver iron content
9232,European,8289.0,31226389.0,Wilman HR,Other measurement,initial,2019-06-18,GCST008172,Liver iron content
4729,European,152.0,31209788.0,Li HQ,"Other trait, Other measurement",initial,2019-06-18,GCST008274,Cerebral microbleed progression
13176,Hispanic or Latin American,9636.0,31213470.0,Moon JY,Other measurement,initial,2019-06-18,GCST008398,Glycated hemoglobin levels
13578,Other/Mixed,231.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008042,PR interval
13724,Other/Mixed,647.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008041,Height
13725,Other/Mixed,647.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008053,Height
13577,Other/Mixed,230.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008043,QT interval
13701,Other/Mixed,591.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008037,Low density lipoprotein cholesterol levels
13694,Other/Mixed,574.0,31217584.0,Wojcik GL,Inflammatory measurement,initial,2019-06-19,GCST008055,C-reactive protein levels
13703,Other/Mixed,602.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008030,Estimated glomerular filtration rate
13603,Other/Mixed,288.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008027,Smoking behaviour (cigarettes smoked per day)
13649,Other/Mixed,395.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008033,Fasting blood insulin
13705,Other/Mixed,603.0,31217584.0,Wojcik GL,Hematological measurement,initial,2019-06-19,GCST008039,Platelet count
13708,Other/Mixed,604.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008045,Total cholesterol levels
13709,Other/Mixed,604.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008046,Triglyceride levels
13711,Other/Mixed,606.0,31217584.0,Wojcik GL,"Hematological measurement, Inflammatory measurement",initial,2019-06-19,GCST008049,White blood cell count
13712,Other/Mixed,619.0,31217584.0,Wojcik GL,Metabolic disorder,initial,2019-06-19,GCST008048,Type 2 diabetes
13699,Other/Mixed,585.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008052,Waist-hip ratio
13716,Other/Mixed,635.0,31217584.0,Wojcik GL,Cardiovascular disease,initial,2019-06-19,GCST008036,Hypertension
13717,Other/Mixed,636.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008029,Diastolic blood pressure
13698,Other/Mixed,585.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008050,Waist-hip ratio
13718,Other/Mixed,636.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008044,Systolic blood pressure
13697,Other/Mixed,582.0,31217584.0,Wojcik GL,"Biological process, Other measurement",initial,2019-06-19,GCST008028,Coffee consumption (cups per day)
13721,Other/Mixed,639.0,31217584.0,Wojcik GL,"Other disease, Other measurement",initial,2019-06-19,GCST008026,Chronic kidney disease
13573,Other/Mixed,226.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008054,QRS duration
13723,Other/Mixed,645.0,31217584.0,Wojcik GL,"Body measurement, Other measurement",initial,2019-06-19,GCST008025,Body mass index
13657,Other/Mixed,412.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008032,Fasting blood glucose
13707,Other/Mixed,604.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008035,High density lipoprotein cholesterol levels
3484,Asian,4663.0,31217584.0,Wojcik GL,Cardiovascular disease,initial,2019-06-19,GCST008036,Hypertension
13894,Other/Mixed,1912.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008035,High density lipoprotein cholesterol levels
810,African American or Afro-Caribbean,1146.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008051,Waist-hip ratio
2142,Asian,541.0,31217584.0,Wojcik GL,Hematological measurement,initial,2019-06-19,GCST008039,Platelet count
2144,Asian,543.0,31217584.0,Wojcik GL,"Hematological measurement, Inflammatory measurement",initial,2019-06-19,GCST008049,White blood cell count
2472,Asian,1086.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008029,Diastolic blood pressure
2473,Asian,1086.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008044,Systolic blood pressure
13879,Other/Mixed,1715.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008050,Waist-hip ratio
8562,European,5284.0,31217265.0,Sliz E,Other measurement,initial,2019-06-19,GCST008207,Interleukin-1-alpha levels
13966,Other/Mixed,3939.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008053,Height
13965,Other/Mixed,3939.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008041,Height
13964,Other/Mixed,3936.0,31217584.0,Wojcik GL,"Body measurement, Other measurement",initial,2019-06-19,GCST008025,Body mass index
13961,Other/Mixed,3857.0,31217584.0,Wojcik GL,"Biological process, Other measurement",initial,2019-06-19,GCST008028,Coffee consumption (cups per day)
13957,Other/Mixed,3705.0,31217584.0,Wojcik GL,Cardiovascular disease,initial,2019-06-19,GCST008036,Hypertension
13893,Other/Mixed,1900.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008037,Low density lipoprotein cholesterol levels
3487,Asian,4680.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008053,Height
13885,Other/Mixed,1777.0,31217584.0,Wojcik GL,Inflammatory measurement,initial,2019-06-19,GCST008055,C-reactive protein levels
8561,European,5284.0,31217265.0,Sliz E,Other measurement,initial,2019-06-19,GCST008206,Plasminogen activator inhibitor-1 (PAI-1) levels
8560,European,5284.0,31217265.0,Sliz E,Other measurement,initial,2019-06-19,GCST008196,Soluble VCAM-1 levels
8559,European,5284.0,31217265.0,Sliz E,Inflammatory measurement,initial,2019-06-19,GCST008208,Soluble CD40 ligand levels
1651,Asian,92.0,31217584.0,Wojcik GL,"Other measurement, Hematological measurement",initial,2019-06-19,GCST008034,Hemoglobin A1c levels
1335,African American or Afro-Caribbean,8261.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008030,Estimated glomerular filtration rate
1711,Asian,126.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008054,QRS duration
12997,Hispanic or Latin American,4198.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008027,Smoking behaviour (cigarettes smoked per day)
1712,Asian,127.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008043,QT interval
680,African American or Afro-Caribbean,559.0,31217584.0,Wojcik GL,"Other measurement, Hematological measurement",initial,2019-06-19,GCST008034,Hemoglobin A1c levels
1719,Asian,128.0,31217584.0,Wojcik GL,Hematological measurement,initial,2019-06-19,GCST008038,Mean corpuscular hemoglobin concentration
1721,Asian,129.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008042,PR interval
9919,European,13577.0,31217265.0,Sliz E,Inflammatory measurement,initial,2019-06-19,GCST008200,Interleukin-6 levels
1741,Asian,150.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008030,Estimated glomerular filtration rate
1286,African American or Afro-Caribbean,7171.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008027,Smoking behaviour (cigarettes smoked per day)
1256,African American or Afro-Caribbean,6457.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008032,Fasting blood glucose
8557,European,5284.0,31217265.0,Sliz E,Cardiovascular measurement,initial,2019-06-19,GCST008210,Soluble ICAM-1
1231,African American or Afro-Caribbean,5525.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008033,Fasting blood insulin
8558,European,5284.0,31217265.0,Sliz E,Inflammatory measurement,initial,2019-06-19,GCST008202,Soluble E-selectin levels
3486,Asian,4680.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008041,Height
1115,African American or Afro-Caribbean,3274.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008054,QRS duration
1117,African American or Afro-Caribbean,3293.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008043,QT interval
1121,African American or Afro-Caribbean,3360.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008042,PR interval
3082,Asian,2387.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008045,Total cholesterol levels
3077,Asian,2381.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008046,Triglyceride levels
3076,Asian,2378.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008035,High density lipoprotein cholesterol levels
3057,Asian,2316.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008037,Low density lipoprotein cholesterol levels
12121,European,253288.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008041,Height
1151,African American or Afro-Caribbean,3750.0,31217584.0,Wojcik GL,Hematological measurement,initial,2019-06-19,GCST008038,Mean corpuscular hemoglobin concentration
13950,Other/Mixed,3500.0,31217584.0,Wojcik GL,"Other disease, Other measurement",initial,2019-06-19,GCST008026,Chronic kidney disease
13951,Other/Mixed,3551.0,31217584.0,Wojcik GL,Metabolic disorder,initial,2019-06-19,GCST008048,Type 2 diabetes
9922,European,13577.0,31217265.0,Sliz E,Inflammatory measurement,initial,2019-06-19,GCST008211,Tumor necrosis factor alpha levels
2886,Asian,1918.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008032,Fasting blood glucose
2885,Asian,1918.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008027,Smoking behaviour (cigarettes smoked per day)
2845,Asian,1843.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008050,Waist-hip ratio
2830,Asian,1811.0,31217584.0,Wojcik GL,Inflammatory measurement,initial,2019-06-19,GCST008055,C-reactive protein levels
9921,European,13577.0,31217265.0,Sliz E,Inflammatory measurement,initial,2019-06-19,GCST008209,Interleukin-1-beta levels
9918,European,13577.0,31217265.0,Sliz E,Cardiovascular measurement,initial,2019-06-19,GCST008198,Vascular endothelial growth factor levels
9923,European,13577.0,31217265.0,Sliz E,Other measurement,initial,2019-06-19,GCST008199,Interferon gamma-induced protein 10 levels
13032,Hispanic or Latin American,4917.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008051,Waist-hip ratio
9924,European,13577.0,31217265.0,Sliz E,Other measurement,initial,2019-06-19,GCST008201,Interleukin-4 levels
12204,European,303288.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008040,Height
13895,Other/Mixed,1915.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008045,Total cholesterol levels
3472,Asian,4647.0,31217584.0,Wojcik GL,"Body measurement, Other measurement",initial,2019-06-19,GCST008025,Body mass index
13896,Other/Mixed,1915.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008046,Triglyceride levels
3460,Asian,4576.0,31217584.0,Wojcik GL,Metabolic disorder,initial,2019-06-19,GCST008048,Type 2 diabetes
13906,Other/Mixed,2176.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008027,Smoking behaviour (cigarettes smoked per day)
3399,Asian,4124.0,31217584.0,Wojcik GL,"Other disease, Other measurement",initial,2019-06-19,GCST008026,Chronic kidney disease
2689,Asian,1547.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008033,Fasting blood insulin
3350,Asian,3764.0,31217584.0,Wojcik GL,"Biological process, Other measurement",initial,2019-06-19,GCST008028,Coffee consumption (cups per day)
3325,Asian,3600.0,31217584.0,Wojcik GL,Other disease,initial,2019-06-19,GCST008031,End-stage renal disease
3311,Asian,3500.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008052,Waist-hip ratio
2734,Asian,1657.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008051,Waist-hip ratio
13937,Other/Mixed,2946.0,31217584.0,Wojcik GL,Other disease,initial,2019-06-19,GCST008031,End-stage renal disease
13942,Other/Mixed,3061.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008052,Waist-hip ratio
9927,European,13577.0,31217265.0,Sliz E,"Other measurement, Inflammatory measurement",initial,2019-06-19,GCST008197,Interleukin-8 levels
9926,European,13577.0,31217265.0,Sliz E,Other measurement,initial,2019-06-19,GCST008205,Interleukin-17 levels
9925,European,13577.0,31217265.0,Sliz E,Other measurement,initial,2019-06-19,GCST008204,Monocyte chemoattractant protein-1 levels
1337,African American or Afro-Caribbean,8349.0,31217584.0,Wojcik GL,Inflammatory measurement,initial,2019-06-19,GCST008055,C-reactive protein levels
9920,European,13577.0,31217265.0,Sliz E,Inflammatory measurement,initial,2019-06-19,GCST008203,Interleukin-1-receptor antagonist levels
13259,Hispanic or Latin American,13698.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008043,QT interval
13257,Hispanic or Latin American,13420.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008054,QRS duration
1382,African American or Afro-Caribbean,10286.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008052,Waist-hip ratio
13258,Hispanic or Latin American,13556.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008032,Fasting blood glucose
13312,Hispanic or Latin American,18548.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008030,Estimated glomerular filtration rate
13380,Other/Mixed,4.0,31217584.0,Wojcik GL,"Other measurement, Hematological measurement",initial,2019-06-19,GCST008034,Hemoglobin A1c levels
1379,African American or Afro-Caribbean,10137.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008045,Total cholesterol levels
13325,Hispanic or Latin American,22192.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008053,Height
13324,Hispanic or Latin American,22192.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008041,Height
1378,African American or Afro-Caribbean,10085.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008035,High density lipoprotein cholesterol levels
13260,Hispanic or Latin American,13702.0,31217584.0,Wojcik GL,Cardiovascular measurement,initial,2019-06-19,GCST008042,PR interval
1357,African American or Afro-Caribbean,9140.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008050,Waist-hip ratio
13323,Hispanic or Latin American,21955.0,31217584.0,Wojcik GL,"Body measurement, Other measurement",initial,2019-06-19,GCST008025,Body mass index
1363,African American or Afro-Caribbean,9720.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008037,Low density lipoprotein cholesterol levels
13322,Hispanic or Latin American,21936.0,31217584.0,Wojcik GL,Cardiovascular disease,initial,2019-06-19,GCST008036,Hypertension
13321,Hispanic or Latin American,21549.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008044,Systolic blood pressure
13272,Hispanic or Latin American,15522.0,31217584.0,Wojcik GL,Hematological measurement,initial,2019-06-19,GCST008038,Mean corpuscular hemoglobin concentration
13273,Hispanic or Latin American,15837.0,31217584.0,Wojcik GL,"Biological process, Other measurement",initial,2019-06-19,GCST008028,Coffee consumption (cups per day)
13320,Hispanic or Latin American,21549.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008029,Diastolic blood pressure
13274,Hispanic or Latin American,15912.0,31217584.0,Wojcik GL,Inflammatory measurement,initial,2019-06-19,GCST008055,C-reactive protein levels
13278,Hispanic or Latin American,16405.0,31217584.0,Wojcik GL,Other disease,initial,2019-06-19,GCST008031,End-stage renal disease
13311,Hispanic or Latin American,18251.0,31217584.0,Wojcik GL,"Hematological measurement, Inflammatory measurement",initial,2019-06-19,GCST008049,White blood cell count
13279,Hispanic or Latin American,16472.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008052,Waist-hip ratio
13293,Hispanic or Latin American,17373.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008037,Low density lipoprotein cholesterol levels
13300,Hispanic or Latin American,17856.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008046,Triglyceride levels
1350,African American or Afro-Caribbean,8825.0,31217584.0,Wojcik GL,"Hematological measurement, Inflammatory measurement",initial,2019-06-19,GCST008049,White blood cell count
13249,Hispanic or Latin American,12687.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008033,Fasting blood insulin
13299,Hispanic or Latin American,17802.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008045,Total cholesterol levels
1356,African American or Afro-Caribbean,9065.0,31217584.0,Wojcik GL,Other disease,initial,2019-06-19,GCST008031,End-stage renal disease
1393,African American or Afro-Caribbean,11380.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008029,Diastolic blood pressure
13319,Hispanic or Latin American,20920.0,31217584.0,Wojcik GL,"Other disease, Other measurement",initial,2019-06-19,GCST008026,Chronic kidney disease
1441,African American or Afro-Caribbean,17286.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008053,Height
13861,Other/Mixed,1400.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008032,Fasting blood glucose
13860,Other/Mixed,1397.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008033,Fasting blood insulin
13467,Other/Mixed,53.0,31217584.0,Wojcik GL,Other disease,initial,2019-06-19,GCST008031,End-stage renal disease
1440,African American or Afro-Caribbean,17286.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008041,Height
13180,Hispanic or Latin American,10408.0,31217584.0,Wojcik GL,"Other measurement, Hematological measurement",initial,2019-06-19,GCST008034,Hemoglobin A1c levels
1352,African American or Afro-Caribbean,8850.0,31217584.0,Wojcik GL,Hematological measurement,initial,2019-06-19,GCST008039,Platelet count
1439,African American or Afro-Caribbean,17152.0,31217584.0,Wojcik GL,Cardiovascular disease,initial,2019-06-19,GCST008036,Hypertension
13317,Hispanic or Latin American,20480.0,31217584.0,Wojcik GL,Metabolic disorder,initial,2019-06-19,GCST008048,Type 2 diabetes
13298,Hispanic or Latin American,17751.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008035,High density lipoprotein cholesterol levels
1424,African American or Afro-Caribbean,15601.0,31217584.0,Wojcik GL,Metabolic disorder,initial,2019-06-19,GCST008048,Type 2 diabetes
1375,African American or Afro-Caribbean,9980.0,31217584.0,Wojcik GL,Lipid or lipoprotein measurement,initial,2019-06-19,GCST008046,Triglyceride levels
13854,Other/Mixed,1346.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008051,Waist-hip ratio
1394,African American or Afro-Caribbean,11380.0,31217584.0,Wojcik GL,Other measurement,initial,2019-06-19,GCST008044,Systolic blood pressure
13202,Hispanic or Latin American,11555.0,31217584.0,Wojcik GL,"Other measurement, Body measurement",initial,2019-06-19,GCST008050,Waist-hip ratio
13422,Other/Mixed,20.0,31217584.0,Wojcik GL,Hematological measurement,initial,2019-06-19,GCST008038,Mean corpuscular hemoglobin concentration
1400,African American or Afro-Caribbean,11862.0,31217584.0,Wojcik GL,"Biological process, Other measurement",initial,2019-06-19,GCST008028,Coffee consumption (cups per day)
13313,Hispanic or Latin American,18949.0,31217584.0,Wojcik GL,Hematological measurement,initial,2019-06-19,GCST008039,Platelet count
1438,African American or Afro-Caribbean,17127.0,31217584.0,Wojcik GL,"Body measurement, Other measurement",initial,2019-06-19,GCST008025,Body mass index
1422,African American or Afro-Caribbean,15522.0,31217584.0,Wojcik GL,"Other disease, Other measurement",initial,2019-06-19,GCST008026,Chronic kidney disease
4637,European,85.0,31220337.0,Carr DF,"Other disease, Response to drug",initial,2019-06-20,GCST008551,Simvastatin-induced myopathy
4569,European,32.0,31220337.0,Carr DF,"Other disease, Response to drug",initial,2019-06-20,GCST008553,Statin-induced myopathy (severe)
4704,European,128.0,31220337.0,Carr DF,"Other disease, Response to drug",initial,2019-06-20,GCST008552,Statin-induced myopathy
12845,Hispanic or Latin American,1577.0,31219225.0,Young KA,Liver enzyme measurement,initial,2019-06-20,GCST008175,Gamma glutamyl transferase levels
12966,Hispanic or Latin American,3644.0,31219225.0,Young KA,Liver enzyme measurement,initial,2019-06-20,GCST008174,Aspartate aminotransferase levels
4564,European,28.0,31220337.0,Carr DF,"Response to drug, Other disease",initial,2019-06-20,GCST008554,Atorvastatin-induced myopathy
12962,Hispanic or Latin American,3595.0,31219225.0,Young KA,Liver enzyme measurement,initial,2019-06-20,GCST008173,Alanine aminotransferase levels
13139,Hispanic or Latin American,7953.0,31226226.0,Du Z,Cancer,initial,2019-06-21,GCST008231,Prostate cancer
9204,European,8113.0,31231134.0,Laskar RS,Cancer,replication,2019-06-23,GCST008226,Renal cell carcinoma
9207,European,8143.0,31231134.0,Laskar RS,Cancer,initial,2019-06-23,GCST008226,Renal cell carcinoma
7586,European,2974.0,31231134.0,Laskar RS,Cancer,replication,2019-06-23,GCST008225,Renal cell carcinoma
9719,European,11087.0,31231134.0,Laskar RS,"Cancer, Other measurement",replication,2019-06-23,GCST008224,Renal cell carcinoma x sex interaction
8493,European,5087.0,31231134.0,Laskar RS,Cancer,initial,2019-06-23,GCST008225,Renal cell carcinoma
9886,European,13230.0,31231134.0,Laskar RS,"Cancer, Other measurement",initial,2019-06-23,GCST008224,Renal cell carcinoma x sex interaction
12417,European,461031.0,31235808.0,Shungin D,Other measurement,initial,2019-06-24,GCST008303,Painful gums
12416,European,461031.0,31235808.0,Shungin D,Other measurement,initial,2019-06-24,GCST008297,Loose teeth
12419,European,461031.0,31235808.0,Shungin D,Other trait,initial,2019-06-24,GCST008304,Mouth ulcers
12418,European,461031.0,31235808.0,Shungin D,Other trait,initial,2019-06-24,GCST008301,Bleeding gums
12420,European,461031.0,31235808.0,Shungin D,Other trait,initial,2019-06-24,GCST008305,Toothache
4250,Asian,17350.0,31235808.0,Shungin D,Digestive system disorder,initial,2019-06-24,GCST008300,Periodontitis
12422,European,476007.0,31235808.0,Shungin D,"Digestive system disorder, Other trait",initial,2019-06-24,GCST008295,"Number of decayed, missing and filled tooth surfaces or use of dentures"
13215,Hispanic or Latin American,11816.0,31235808.0,Shungin D,Other measurement,initial,2019-06-24,GCST008298,Number of natural teeth
13214,Hispanic or Latin American,11816.0,31235808.0,Shungin D,"Digestive system disorder, Other trait",initial,2019-06-24,GCST008295,"Number of decayed, missing and filled tooth surfaces or use of dentures"
13213,Hispanic or Latin American,11816.0,31235808.0,Shungin D,Digestive system disorder,initial,2019-06-24,GCST008302,"Number of decayed, missing and filled tooth surfaces"
13212,Hispanic or Latin American,11816.0,31235808.0,Shungin D,Digestive system disorder,initial,2019-06-24,GCST008299,Number of decayed and filled tooth surfaces per available tooth surface
13186,Hispanic or Latin American,10948.0,31235808.0,Shungin D,"Other measurement, Digestive system disorder",initial,2019-06-24,GCST008296,Periodontitis or loose teeth
11740,European,127121.0,31235810.0,Fung K,Cardiovascular measurement,initial,2019-06-24,GCST008403,Arterial stiffness index
4251,Asian,17350.0,31235808.0,Shungin D,"Other measurement, Digestive system disorder",initial,2019-06-24,GCST008296,Periodontitis or loose teeth
10192,European,17353.0,31235808.0,Shungin D,Digestive system disorder,initial,2019-06-24,GCST008300,Periodontitis
12421,European,461031.0,31235808.0,Shungin D,Other trait,initial,2019-06-24,GCST008306,Dentures
10094,European,16133.0,31235808.0,Shungin D,Other measurement,initial,2019-06-24,GCST008298,Number of natural teeth
10027,European,14976.0,31235808.0,Shungin D,Digestive system disorder,initial,2019-06-24,GCST008302,"Number of decayed, missing and filled tooth surfaces"
10003,European,14717.0,31235808.0,Shungin D,Digestive system disorder,initial,2019-06-24,GCST008299,Number of decayed and filled tooth surfaces per available tooth surface
12426,European,495646.0,31235808.0,Shungin D,"Other measurement, Digestive system disorder",initial,2019-06-24,GCST008296,Periodontitis or loose teeth
13185,Hispanic or Latin American,10948.0,31235808.0,Shungin D,Digestive system disorder,initial,2019-06-24,GCST008300,Periodontitis
7244,European,2384.0,31246245.0,Khawaja AP,Other measurement,replication,2019-06-27,GCST008276,Corneal resistance factor
7245,European,2384.0,31246245.0,Khawaja AP,Other measurement,replication,2019-06-27,GCST008277,Corneal hysteresis
3758,Asian,6867.0,31243853.0,Chung S,"Response to drug, Other measurement",initial,2019-06-27,GCST008435,Response to hepatitis B vaccine
3140,Asian,2610.0,31243853.0,Chung S,"Response to drug, Other measurement",replication,2019-06-27,GCST008435,Response to hepatitis B vaccine
13271,Hispanic or Latin American,15124.0,31251759.0,Swenson BR,Cardiovascular measurement,initial,2019-06-28,GCST008422,QRS duration
13839,Other/Mixed,1209.0,31299468.0,Condreay LD,"Other disease, Other disease, Response to drug, Response to drug, Other measurement, Other measurement",initial,2019-06-29,GCST008292,Change in quality of life in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
13838,Other/Mixed,1188.0,31299468.0,Condreay LD,"Other disease, Other disease, Response to drug, Response to drug, Other measurement, Other measurement",initial,2019-06-29,GCST008294,Response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
1526,Asian,1.0,31299468.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-06-29,GCST008293,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
13394,Other/Mixed,7.0,31299468.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-06-29,GCST008293,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
13381,Other/Mixed,4.0,31299468.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-06-29,GCST008293,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
13367,Other/Mixed,3.0,31299468.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-06-29,GCST008293,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
1588,Asian,33.0,31299468.0,Condreay LD,"Other disease, Other disease, Response to drug, Response to drug, Other measurement, Other measurement",initial,2019-06-29,GCST008293,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
6839,European,1869.0,31299468.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-06-29,GCST008293,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease
8287,European,4611.0,31598132.0,Donati G,Biological process,initial,2019-06-30,GCST008892,Working memory
5964,European,935.0,31262040.0,Pujol-Moix N,Cardiovascular measurement,initial,2019-06-30,GCST008457,Platelet reactivity measurement (collagen-epinephrine)
5965,European,935.0,31262040.0,Pujol-Moix N,Cardiovascular measurement,initial,2019-06-30,GCST008458,Platelet reactivity measurement (collagen-ADP)
8288,European,4611.0,31598132.0,Donati G,"Biological process, Other measurement",initial,2019-06-30,GCST008891,Cognitive performance (processing speed)
8289,European,4611.0,31598132.0,Donati G,Other measurement,initial,2019-06-30,GCST008893,Inhibitory control
9216,European,8195.0,31263163.0,Liu CT,Other measurement,initial,2019-07-01,GCST008505,Fasting glucose change (short-term)
8756,European,6064.0,31263063.0,Dufek S,Other disease,initial,2019-07-01,GCST008456,Childhood steroid-sensitive nephrotic syndrome
13841,Other/Mixed,1258.0,31260374.0,Pedergnana V,"Response to drug, Digestive system disorder",initial,2019-07-01,GCST008517,Response to interferon treatment in hepatitis C virus genotype 3
7960,European,3669.0,31263163.0,Liu CT,Other measurement,initial,2019-07-01,GCST008504,Fasting glucose change (long-term)
12297,European,371428.0,31263887.0,Adams MJ,Other trait,initial,2019-07-01,GCST008550,Mental health study participation (completed survey)
13656,Other/Mixed,409.0,31260374.0,Pedergnana V,"Response to drug, Digestive system disorder",initial,2019-07-01,GCST008520,Response to direct-acting antiviral treatment in hepatitis C virus genotype 3
13873,Other/Mixed,1498.0,31260374.0,Pedergnana V,"Other measurement, Digestive system disorder",initial,2019-07-01,GCST008515,Pre-treatment viral load in hepatitis C virus genotype 3
9942,European,13807.0,31263163.0,Liu CT,Other measurement,initial,2019-07-01,GCST008503,Fasting glucose change
12296,European,371417.0,31263887.0,Adams MJ,Other trait,initial,2019-07-01,GCST008549,Mental health study participation (provided email address)
6819,European,1843.0,31264924.0,Meng W,"Metabolic disorder, Other measurement",initial,2019-07-02,GCST008545,Diabetic maculopathy with decreased visual acuity in type 2 diabetes
7401,European,2614.0,31264924.0,Meng W,Metabolic disorder,initial,2019-07-02,GCST008546,Diabetic maculopathy in type 2 diabetes
1824,Asian,218.0,31269844.0,Wu NN,Metabolic disorder,initial,2019-07-03,GCST008448,Diabetes (gestational)
889,African American or Afro-Caribbean,1527.0,31270906.0,Lai D,Biological process,initial,2019-07-03,GCST008446,Number of alcoholic drinks required to feel an effect (first five times drinking)
507,African American or Afro-Caribbean,169.0,31270906.0,Lai D,Biological process,replication,2019-07-03,GCST008446,Number of alcoholic drinks required to feel an effect (first five times drinking)
3258,Asian,3092.0,31268507.0,Periyasamy S,Neurological disorder,initial,2019-07-03,GCST008459,Schizophrenia
508,African American or Afro-Caribbean,169.0,31270906.0,Lai D,Biological process,replication,2019-07-03,GCST008447,Number of alcoholic drinks required to feel an effect (long-term average)
8329,European,4723.0,31270906.0,Lai D,Biological process,initial,2019-07-03,GCST008447,Number of alcoholic drinks required to feel an effect (long-term average)
8328,European,4723.0,31270906.0,Lai D,Biological process,initial,2019-07-03,GCST008446,Number of alcoholic drinks required to feel an effect (first five times drinking)
890,African American or Afro-Caribbean,1527.0,31270906.0,Lai D,Biological process,initial,2019-07-03,GCST008447,Number of alcoholic drinks required to feel an effect (long-term average)
4978,European,306.0,31270906.0,Lai D,Biological process,replication,2019-07-03,GCST008447,Number of alcoholic drinks required to feel an effect (long-term average)
4977,European,306.0,31270906.0,Lai D,Biological process,replication,2019-07-03,GCST008446,Number of alcoholic drinks required to feel an effect (first five times drinking)
6241,European,1156.0,31271701.0,Thibord F,"Cardiovascular disease, Other measurement",replication,2019-07-04,GCST008461,Plasma factor V levels in venous thrombosis
5343,European,510.0,31271701.0,Thibord F,"Cardiovascular disease, Other measurement",initial,2019-07-04,GCST008462,Plasma factor V levels in venous thrombosis (conditioned on rs6027)
5342,European,510.0,31271701.0,Thibord F,"Cardiovascular disease, Other measurement",initial,2019-07-04,GCST008461,Plasma factor V levels in venous thrombosis
6242,European,1156.0,31271701.0,Thibord F,"Cardiovascular disease, Other measurement",replication,2019-07-04,GCST008462,Plasma factor V levels in venous thrombosis (conditioned on rs6027)
1628,Asian,73.0,31295674.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-07-05,GCST008269,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease
1627,Asian,73.0,31295674.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-07-05,GCST008268,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease
4131,Asian,12603.0,31320941.0,Igarashi M,Other measurement,initial,2019-07-05,GCST008597,Fish intake frequency
13418,Other/Mixed,18.0,31295674.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-07-05,GCST008268,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease
364,African American or Afro-Caribbean,5.0,31295674.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-07-05,GCST008268,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease
365,African American or Afro-Caribbean,5.0,31295674.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-07-05,GCST008269,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease
13419,Other/Mixed,18.0,31295674.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-07-05,GCST008269,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease
5328,European,504.0,31295674.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-07-05,GCST008268,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease
5329,European,504.0,31295674.0,Condreay LD,"Other disease, Response to drug, Other measurement",initial,2019-07-05,GCST008269,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease
9904,European,13382.0,31285632.0,Klarin D,Cardiovascular measurement,initial,2019-07-08,GCST008475,Minimum anklebrachial index
13316,Hispanic or Latin American,20210.0,31285632.0,Klarin D,Cardiovascular disease,initial,2019-07-08,GCST008474,Peripheral artery disease
353,African,47858.0,31285632.0,Klarin D,Cardiovascular disease,initial,2019-07-08,GCST008474,Peripheral artery disease
2903,Asian,1948.0,31289104.0,Kawamura Y,Metabolic disorder,initial,2019-07-08,GCST008460,Gout vs. Hyperuricemia
11979,European,174992.0,31285632.0,Klarin D,Cardiovascular disease,initial,2019-07-08,GCST008474,Peripheral artery disease
256,African,3284.0,31285632.0,Klarin D,Cardiovascular measurement,initial,2019-07-08,GCST008475,Minimum anklebrachial index
12328,European,394408.0,31285632.0,Klarin D,Cardiovascular disease,replication,2019-07-08,GCST008474,Peripheral artery disease
12790,Hispanic or Latin American,998.0,31285632.0,Klarin D,Cardiovascular measurement,initial,2019-07-08,GCST008475,Minimum anklebrachial index
3390,Asian,4061.0,31289104.0,Kawamura Y,Metabolic disorder,replication,2019-07-08,GCST008460,Gout vs. Hyperuricemia
8978,European,7010.0,31294817.0,Chen J,Other measurement,replication,2019-07-11,GCST008548,Fagerstrm test for nicotine dependence
5862,European,866.0,31296530.0,Trendowski MR,"Other measurement, Response to drug",initial,2019-07-11,GCST008756,Serum platinum levels after completion of cisplatin chemotherapy
10265,European,18567.0,31294817.0,Chen J,Other measurement,initial,2019-07-11,GCST008547,Time to smoke first cigarette in the morning
10313,European,19431.0,31294817.0,Chen J,Other measurement,initial,2019-07-11,GCST008548,Fagerstrm test for nicotine dependence
9600,European,10061.0,31294817.0,Chen J,Other measurement,replication,2019-07-11,GCST008547,Time to smoke first cigarette in the morning
5403,European,545.0,31295725.0,Wang ZT,Other measurement,initial,2019-07-11,GCST008497,Change in neurofilament light levels
4175,Asian,13855.0,31319653.0,Jeon C,Cardiovascular disease,initial,2019-07-12,GCST008816,Ischemic heart disease
4381,Asian,33598.0,31319653.0,Jeon C,Other measurement,initial,2019-07-12,GCST008817,Bilirubin levels
11347,European,72517.0,31308545.0,Watson HJ,Metabolic disorder,initial,2019-07-15,GCST008465,Anorexia nervosa
9524,European,9677.0,31311600.0,Namjou B,Digestive system disorder,initial,2019-07-17,GCST008468,Nonalcoholic fatty liver disease
9525,European,9677.0,31311600.0,Namjou B,Digestive system disorder,initial,2019-07-17,GCST008470,Nonalcoholic fatty liver disease (SNP x SNP interaction)
13732,Other/Mixed,684.0,31315583.0,Lona-Durazo F,Other measurement,initial,2019-07-17,GCST008516,Skin pigmentation (conditioned on rs1426654 and rs35397)
614,African American or Afro-Caribbean,373.0,31315583.0,Lona-Durazo F,Other measurement,initial,2019-07-17,GCST008516,Skin pigmentation (conditioned on rs1426654 and rs35397)
615,African American or Afro-Caribbean,373.0,31315583.0,Lona-Durazo F,"Other trait, Other measurement",initial,2019-07-17,GCST008519,Skin pigmentation
13733,Other/Mixed,684.0,31315583.0,Lona-Durazo F,"Other trait, Other measurement",initial,2019-07-17,GCST008519,Skin pigmentation
4877,European,235.0,31311600.0,Namjou B,"Other trait, Digestive system disorder",initial,2019-07-17,GCST008469,Liver fibrosis in non-alcoholic fatty acid liver disease
6161,European,1075.0,31311600.0,Namjou B,"Liver enzyme measurement, Digestive system disorder",initial,2019-07-17,GCST008466,Alanine aminotransferase levels in non-alcoholic fatty liver disease
8648,European,5628.0,31346403.0,Massrali A,Other measurement,initial,2019-07-17,GCST008484,Autistic traits score (Social and Communication Disorders Checklist)
12731,Hispanic or Latin American,762.0,31315583.0,Lona-Durazo F,"Other trait, Other measurement",initial,2019-07-17,GCST008518,Skin pigmentation
4304,Asian,22090.0,31326317.0,Dai J,Cancer,initial,2019-07-17,GCST008836,Lung adenocarcinoma
10383,European,20846.0,31326317.0,Dai J,Cancer,initial,2019-07-17,GCST008836,Lung adenocarcinoma
6162,European,1075.0,31311600.0,Namjou B,"Liver enzyme measurement, Digestive system disorder",initial,2019-07-17,GCST008467,Aspartate aminotransferase levels in non-alcoholic fatty liver disease
12792,Hispanic or Latin American,1047.0,31315583.0,Lona-Durazo F,Other measurement,initial,2019-07-17,GCST008516,Skin pigmentation (conditioned on rs1426654 and rs35397)
12793,Hispanic or Latin American,1047.0,31315583.0,Lona-Durazo F,"Other trait, Other measurement",initial,2019-07-17,GCST008519,Skin pigmentation
4335,Asian,26655.0,31326317.0,Dai J,Cancer,initial,2019-07-17,GCST008834,Non-small cell lung cancer
4876,European,235.0,31311600.0,Namjou B,Other measurement,initial,2019-07-17,GCST008471,Non-alcoholic fatty liver disease activity score
4248,Asian,17188.0,31326317.0,Dai J,Cancer,initial,2019-07-17,GCST008835,Squamous cell lung carcinoma
10259,European,18517.0,31326317.0,Dai J,Cancer,initial,2019-07-17,GCST008835,Squamous cell lung carcinoma
10634,European,27820.0,31326317.0,Dai J,Cancer,initial,2019-07-17,GCST008834,Non-small cell lung cancer
5705,European,750.0,31320639.0,Hillary RF,Other measurement,initial,2019-07-18,GCST008478,Neurological blood protein biomarker levels
813,African American or Afro-Caribbean,1158.0,31324189.0,Kim W,Other measurement,initial,2019-07-19,GCST008477,Emphysema annual change measurement in smokers (adjusted lung density)
812,African American or Afro-Caribbean,1158.0,31324189.0,Kim W,Other measurement,initial,2019-07-19,GCST008476,Emphysema annual change measurement in smokers (percent low attenuation area)
243,African,2578.0,31324766.0,Adeyemo AA,Metabolic disorder,replication,2019-07-19,GCST008463,Type 2 diabetes
8229,European,4427.0,31324189.0,Kim W,Other measurement,initial,2019-07-19,GCST008476,Emphysema annual change measurement in smokers (percent low attenuation area)
285,African,5231.0,31324766.0,Adeyemo AA,Metabolic disorder,initial,2019-07-19,GCST008463,Type 2 diabetes
8230,European,4427.0,31324189.0,Kim W,Other measurement,initial,2019-07-19,GCST008477,Emphysema annual change measurement in smokers (adjusted lung density)
286,African,5231.0,31324766.0,Adeyemo AA,Metabolic disorder,initial,2019-07-19,GCST008464,Type 2 diabetes
1340,African American or Afro-Caribbean,8599.0,31324766.0,Adeyemo AA,Metabolic disorder,initial,2019-07-19,GCST008464,Type 2 diabetes
3670,Asian,5975.0,31345160.0,Jia H,"Biological process, Other measurement",replication,2019-07-26,GCST008487,Coffee consumption
3705,Asian,6264.0,31345160.0,Jia H,"Biological process, Other measurement",initial,2019-07-26,GCST008487,Coffee consumption
1447,African American or Afro-Caribbean,19983.0,31358989.0,Gelernter J,Other measurement,initial,2019-07-29,GCST008490,Post-traumatic stress disorder (re-experiencing symptoms)
12424,European,480842.0,31358974.0,Evangelou E,"Biological process, Other measurement",initial,2019-07-29,GCST008757,Alcohol consumption
11684,European,117900.0,31358989.0,Gelernter J,Other measurement,replication,2019-07-29,GCST008490,Post-traumatic stress disorder (re-experiencing symptoms)
11834,European,146660.0,31358989.0,Gelernter J,Other measurement,initial,2019-07-29,GCST008490,Post-traumatic stress disorder (re-experiencing symptoms)
878,African American or Afro-Caribbean,1445.0,31362332.0,Cheng Z,Other measurement,initial,2019-07-30,GCST008596,Opioid overdose severity score
13609,Other/Mixed,312.0,31417607.0,Gazal S,Cardiovascular disease,initial,2019-07-30,GCST008708,Chronic mountain sickness
6948,European,2032.0,31362332.0,Cheng Z,Other measurement,initial,2019-07-30,GCST008596,Opioid overdose severity score
10558,European,24776.0,31367044.0,Locke AE,"Other measurement, Body measurement, Lipid or lipoprotein measurement, Cardiovascular measurement, Inflammatory measurement",replication,2019-07-31,GCST008673,Cardiometabolic traits
10308,European,19292.0,31367044.0,Locke AE,"Other measurement, Body measurement, Lipid or lipoprotein measurement, Cardiovascular measurement, Inflammatory measurement",initial,2019-07-31,GCST008673,Cardiometabolic traits
10310,European,19325.0,31467194.0,Ganna A,Biological process,initial,2019-08-01,GCST008657,proportion of same-sex sexual behaviour among non-heterosexuals
12259,European,338218.0,31467194.0,Ganna A,Biological process,initial,2019-08-01,GCST008653,same-sex sexual behaviour
11705,European,120552.0,31374203.0,Lam M,"Other measurement, Biological process, Neurological disorder",initial,2019-08-01,GCST008595,"Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)"
12242,European,329546.0,31467194.0,Ganna A,Biological process,initial,2019-08-01,GCST008652,same-sex sexual behaviour
9625,European,10305.0,31467194.0,Ganna A,Biological process,replication,2019-08-01,GCST008652,same-sex sexual behaviour
4991,European,321.0,31370031.0,Dou KX,Other measurement,initial,2019-08-01,GCST008642,Annualised percent change of cerebrospinal fluid AB1-42 levels
12344,European,408995.0,31467194.0,Ganna A,Biological process,initial,2019-08-01,GCST008651,same-sex sexual behaviour
9122,European,7675.0,31467194.0,Ganna A,Biological process,initial,2019-08-01,GCST008655,proportion of same-sex sexual behaviour among non-heterosexuals
9867,European,12834.0,31467194.0,Ganna A,Biological process,replication,2019-08-01,GCST008651,same-sex sexual behaviour
9868,European,12834.0,31467194.0,Ganna A,Biological process,replication,2019-08-01,GCST008653,same-sex sexual behaviour
9869,European,12834.0,31467194.0,Ganna A,Biological process,replication,2019-08-01,GCST008654,same-sex sexual behaviour
12000,European,188825.0,31467194.0,Ganna A,Biological process,initial,2019-08-01,GCST008649,same-sex sexual behaviour
12454,European,695908.0,31467194.0,Ganna A,Biological process,initial,2019-08-01,GCST008654,same-sex sexual behaviour
8698,European,5838.0,31467194.0,Ganna A,Biological process,initial,2019-08-01,GCST008656,proportion of same-sex sexual behaviour among non-heterosexuals
12074,European,220170.0,31467194.0,Ganna A,Biological process,initial,2019-08-01,GCST008650,same-sex sexual behaviour
626,African American or Afro-Caribbean,405.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008717,Frontal lobe volume
9397,European,8789.0,31396565.0,van der Lee SJ,Other measurement,replication,2019-08-02,GCST008715,Frontal lobe volume
9396,European,8789.0,31396565.0,van der Lee SJ,Other measurement,replication,2019-08-02,GCST008705,Temporal lobe volume
9395,European,8789.0,31396565.0,van der Lee SJ,Other measurement,replication,2019-08-02,GCST008704,Parietal lobe volume
9394,European,8789.0,31396565.0,van der Lee SJ,Other measurement,replication,2019-08-02,GCST008703,Occipital lobe volume
1814,Asian,211.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008717,Frontal lobe volume
1813,Asian,211.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008711,Temporal lobe volume
1811,Asian,211.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008707,Occipital lobe volume
625,African American or Afro-Caribbean,405.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008711,Temporal lobe volume
624,African American or Afro-Caribbean,405.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008710,Parietal lobe volume
623,African American or Afro-Caribbean,405.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008707,Occipital lobe volume
10042,European,15269.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008717,Frontal lobe volume
1812,Asian,211.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008710,Parietal lobe volume
10041,European,15269.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008715,Frontal lobe volume
1722,Asian,131.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008707,Occipital lobe volume
1723,Asian,131.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008710,Parietal lobe volume
1724,Asian,131.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008711,Temporal lobe volume
10035,European,15269.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008703,Occipital lobe volume
10036,European,15269.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008704,Parietal lobe volume
1725,Asian,131.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008717,Frontal lobe volume
10037,European,15269.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008705,Temporal lobe volume
10040,European,15269.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008711,Temporal lobe volume
10038,European,15269.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008707,Occipital lobe volume
10039,European,15269.0,31396565.0,van der Lee SJ,Other measurement,initial,2019-08-02,GCST008710,Parietal lobe volume
3982,Asian,9197.0,31383772.0,Yan C,Cancer,initial,2019-08-05,GCST008646,Gastric cancer
4221,Asian,15358.0,31383772.0,Yan C,Cancer,replication,2019-08-05,GCST008646,Gastric cancer
13190,Hispanic or Latin American,11103.0,31393916.0,Andaleon A,Lipid or lipoprotein measurement,initial,2019-08-08,GCST008594,Total cholesterol levels
13188,Hispanic or Latin American,11103.0,31393916.0,Andaleon A,Lipid or lipoprotein measurement,initial,2019-08-08,GCST008592,High density lipoprotein cholesterol levels
13187,Hispanic or Latin American,11103.0,31393916.0,Andaleon A,Lipid or lipoprotein measurement,initial,2019-08-08,GCST008591,Triglyceride levels
13189,Hispanic or Latin American,11103.0,31393916.0,Andaleon A,Lipid or lipoprotein measurement,initial,2019-08-08,GCST008593,Low density lipoprotein cholesterol levels
10813,European,33880.0,31407831.0,Din L,"Immune system disorder, Cancer",initial,2019-08-13,GCST008723,Marginal zone lymphoma or multiple sclerosis
300,African,7612.0,31409800.0,Pazoki R,Other measurement,replication,2019-08-13,GCST008647,Urinary sodium excretion
12376,European,446230.0,31409800.0,Pazoki R,Other measurement,initial,2019-08-13,GCST008648,Urinary potassium excretion
10764,European,32855.0,31407831.0,Din L,"Immune system disorder, Cancer",initial,2019-08-13,GCST008727,Chronic lymphocytic leukemia or systemic lupus erythematosus
10688,European,29942.0,31407831.0,Din L,"Cancer, Immune system disorder",initial,2019-08-13,GCST008729,Marginal zone lymphoma or systemic lupus erythematosus
10286,European,19054.0,31407831.0,Din L,"Immune system disorder, Cancer",initial,2019-08-13,GCST008725,Diffuse large B-cell lymphoma or rheumatoid arthritis
10264,European,18566.0,31407831.0,Din L,Immune system disorder,initial,2019-08-13,GCST008719,Follicular lymphoma or rheumatoid arthritis
10209,European,17645.0,31407831.0,Din L,"Immune system disorder, Cancer",initial,2019-08-13,GCST008724,Chronic lymphocytic leukemia or rheumatoid arthritis
10006,European,14732.0,31407831.0,Din L,"Immune system disorder, Cancer",initial,2019-08-13,GCST008726,Marginal zone lymphoma or rheumatoid arthritis
12377,European,446237.0,31409800.0,Pazoki R,Other measurement,initial,2019-08-13,GCST008647,Urinary sodium excretion
10827,European,34264.0,31407831.0,Din L,"Immune system disorder, Cancer",initial,2019-08-13,GCST008728,Diffuse large B-cell lymphoma or systemic lupus erythematosus
10805,European,33776.0,31407831.0,Din L,Immune system disorder,initial,2019-08-13,GCST008720,Follicular lymphoma or systemic lupus erythematosus
301,African,7612.0,31409800.0,Pazoki R,Other measurement,replication,2019-08-13,GCST008648,Urinary potassium excretion
10909,European,37714.0,31407831.0,Din L,Immune system disorder,initial,2019-08-13,GCST008718,Follicular lymphoma or multiple sclerosis
10922,European,38202.0,31407831.0,Din L,"Immune system disorder, Cancer",initial,2019-08-13,GCST008722,Diffuse large B-cell lymphoma or multiple sclerosis
10880,European,36793.0,31407831.0,Din L,"Immune system disorder, Cancer",initial,2019-08-13,GCST008721,Chronic lymphocytic leukemia or multiple sclerosis
4028,Asian,10095.0,31409800.0,Pazoki R,Other measurement,replication,2019-08-13,GCST008647,Urinary sodium excretion
4029,Asian,10095.0,31409800.0,Pazoki R,Other measurement,replication,2019-08-13,GCST008648,Urinary potassium excretion
3450,Asian,4477.0,31413261.0,Deelen J,Other measurement,initial,2019-08-14,GCST008600,Longevity (age >90th survival percentile)
9091,European,7544.0,31413261.0,Deelen J,Other measurement,replication,2019-08-14,GCST008598,Longevity (age >90th survival percentile)
10878,European,36745.0,31413261.0,Deelen J,Other measurement,initial,2019-08-14,GCST008598,Longevity (age >90th survival percentile)
10663,European,28967.0,31413261.0,Deelen J,Other measurement,initial,2019-08-14,GCST008601,Longevity (age >99th survival percentile)
620,African American or Afro-Caribbean,388.0,31413261.0,Deelen J,Other measurement,initial,2019-08-14,GCST008600,Longevity (age >90th survival percentile)
10662,European,28967.0,31413261.0,Deelen J,Other measurement,initial,2019-08-14,GCST008599,Longevity (age >99th survival percentile)
10879,European,36745.0,31413261.0,Deelen J,Other measurement,initial,2019-08-14,GCST008600,Longevity (age >90th survival percentile)
3451,Asian,4477.0,31413261.0,Deelen J,Other measurement,initial,2019-08-14,GCST008601,Longevity (age >99th survival percentile)
8959,European,6898.0,31413261.0,Deelen J,Other measurement,replication,2019-08-14,GCST008599,Longevity (age >99th survival percentile)
4469,Asian,79211.0,31417091.0,Kou I,Other disease,initial,2019-08-15,GCST008789,Adolescent idiopathic scoliosis
4411,Asian,38683.0,31417091.0,Kou I,Other disease,initial,2019-08-15,GCST008788,Adolescent idiopathic scoliosis
6582,European,1552.0,31423876.0,Singh S,"Other measurement, Response to drug, Cardiovascular disease",replication,2019-08-19,GCST008736,Response to beta blocker use in hypertension (systolic blood pressure)
6335,European,1254.0,31423876.0,Singh S,"Other measurement, Response to drug, Cardiovascular disease",initial,2019-08-19,GCST008735,Response to beta blocker use in hypertension (diastolic blood pressure)
582,African American or Afro-Caribbean,315.0,31423876.0,Singh S,"Other measurement, Response to drug, Cardiovascular disease",replication,2019-08-19,GCST008735,Response to beta blocker use in hypertension (diastolic blood pressure)
583,African American or Afro-Caribbean,315.0,31423876.0,Singh S,"Other measurement, Response to drug, Cardiovascular disease",replication,2019-08-19,GCST008736,Response to beta blocker use in hypertension (systolic blood pressure)
6336,European,1254.0,31423876.0,Singh S,"Other measurement, Response to drug, Cardiovascular disease",initial,2019-08-19,GCST008736,Response to beta blocker use in hypertension (systolic blood pressure)
6581,European,1552.0,31423876.0,Singh S,"Other measurement, Response to drug, Cardiovascular disease",replication,2019-08-19,GCST008735,Response to beta blocker use in hypertension (diastolic blood pressure)
7901,European,3519.0,31430377.0,Chung J,Cardiovascular disease,initial,2019-08-20,GCST008878,Intracerebral hemorrhage
7462,European,2716.0,31430377.0,Chung J,Cardiovascular disease,initial,2019-08-20,GCST008876,Non-lobar intracerebral hemorrhage (MTAG)
7461,European,2716.0,31430377.0,Chung J,Cardiovascular disease,initial,2019-08-20,GCST008873,Non-lobar intracerebral hemorrhage
7289,European,2466.0,31430377.0,Chung J,Cardiovascular disease,initial,2019-08-20,GCST008877,Lobar intracerebral hemorrhage (MTAG)
7288,European,2466.0,31430377.0,Chung J,Cardiovascular disease,initial,2019-08-20,GCST008874,Lobar intracerebral hemorrhage
7900,European,3519.0,31430377.0,Chung J,Cardiovascular disease,initial,2019-08-20,GCST008875,Intracerebral hemorrhage (MTAG)
1504,African American or Afro-Caribbean,36369.0,31451708.0,Hellwege JN,Other measurement,initial,2019-08-26,GCST008745,Estimated glomerular filtration rate in non-diabetics
12077,European,223386.0,31451708.0,Hellwege JN,Other measurement,initial,2019-08-26,GCST008747,Estimated glomerular filtration rate
1416,African American or Afro-Caribbean,13842.0,31451708.0,Hellwege JN,Other measurement,replication,2019-08-26,GCST008747,Estimated glomerular filtration rate
1458,African American or Afro-Caribbean,20967.0,31451708.0,Hellwege JN,"Other measurement, Metabolic disorder",initial,2019-08-26,GCST008746,Estimated glomerular filtration rate in diabetes
4551,Asian,165726.0,31451708.0,Hellwege JN,Other measurement,replication,2019-08-26,GCST008747,Estimated glomerular filtration rate
1513,African American or Afro-Caribbean,57336.0,31451708.0,Hellwege JN,Other measurement,initial,2019-08-26,GCST008747,Estimated glomerular filtration rate
13045,Hispanic or Latin American,4961.0,31451708.0,Hellwege JN,Other measurement,replication,2019-08-26,GCST008747,Estimated glomerular filtration rate
11879,European,152624.0,31451708.0,Hellwege JN,Other measurement,initial,2019-08-26,GCST008745,Estimated glomerular filtration rate in non-diabetics
12438,European,567401.0,31451708.0,Hellwege JN,Other measurement,replication,2019-08-26,GCST008747,Estimated glomerular filtration rate
11336,European,70762.0,31451708.0,Hellwege JN,"Other measurement, Metabolic disorder",initial,2019-08-26,GCST008746,Estimated glomerular filtration rate in diabetes
4168,Asian,13359.0,31451708.0,Hellwege JN,Other measurement,replication,2019-08-26,GCST008747,Estimated glomerular filtration rate
3695,Asian,6155.0,31462767.0,Sun Y,Neurological disorder,initial,2019-08-28,GCST008645,Alcohol dependence or heroin dependence or methamphetamine dependence
3360,Asian,3858.0,31462767.0,Sun Y,Neurological disorder,replication,2019-08-28,GCST008645,Alcohol dependence or heroin dependence or methamphetamine dependence
6555,European,1534.0,31455332.0,Zhang Y,Response to drug,initial,2019-08-28,GCST008755,Phenylephrine infusion rate during anesthesia
11957,European,171516.0,31482140.0,Meng W,Other trait,initial,2019-08-28,GCST008672,Knee pain
498,African American or Afro-Caribbean,156.0,31466081.0,Luo A,"Biological process, Other measurement",initial,2019-08-29,GCST008748,Epigenetic age acceleration in alcohol use disorder
82,African,291.0,31482010.0,Liu C,Metabolic disorder,initial,2019-08-29,GCST008668,Proliferative diabetic retinopathy
426,African American or Afro-Caribbean,69.0,31482010.0,Liu C,Metabolic disorder,replication,2019-08-29,GCST008668,Proliferative diabetic retinopathy
4733,European,154.0,31466081.0,Luo A,"Biological process, Other measurement",initial,2019-08-29,GCST008748,Epigenetic age acceleration in alcohol use disorder
142,African,815.0,31469255.0,Lule SA,Other measurement,initial,2019-08-30,GCST008749,Systolic blood pressure
143,African,815.0,31469255.0,Lule SA,Other measurement,initial,2019-08-30,GCST008750,Diastolic blood pressure
7456,European,2701.0,31497858.0,Dumitrescu L,Other measurement,initial,2019-09-01,GCST008822,Neuritic plaque
8735,European,5976.0,31497858.0,Dumitrescu L,Other measurement,initial,2019-09-01,GCST008829,Neuritic plaque
7755,European,3275.0,31497858.0,Dumitrescu L,Other measurement,initial,2019-09-01,GCST008830,Neurofibrillary tangles
7455,European,2701.0,31497858.0,Dumitrescu L,Other measurement,initial,2019-09-01,GCST008821,Neurofibrillary tangles
11451,European,84689.0,31477735.0,Liu X,Other measurement,initial,2019-09-02,GCST008751,Gestational age at birth (child effect)
11238,European,61287.0,31477735.0,Liu X,Other trait,initial,2019-09-02,GCST008753,Early spontaneous preterm birth
8805,European,6296.0,31477735.0,Liu X,Other measurement,replication,2019-09-02,GCST008752,Post-term birth
4207,Asian,14795.0,31476763.0,Otsuka I,Biological process,initial,2019-09-02,GCST008772,Suicide
11304,European,68036.0,31477735.0,Liu X,Other measurement,initial,2019-09-02,GCST008752,Post-term birth
11272,European,64923.0,31477735.0,Liu X,"Other measurement, Other trait",initial,2019-09-02,GCST008754,Spontaneous preterm birth (preterm birth)
2261,Asian,719.0,31476763.0,Otsuka I,Other measurement,initial,2019-09-02,GCST008771,Age at suicide
6022,European,972.0,31477735.0,Liu X,Other trait,replication,2019-09-02,GCST008753,Early spontaneous preterm birth
9458,European,9291.0,31477735.0,Liu X,Other measurement,replication,2019-09-02,GCST008751,Gestational age at birth (child effect)
8599,European,5421.0,31508503.0,Warrier V,Other measurement,initial,2019-09-03,GCST008890,Autistic traits score (Social and Communication Disorders Checklist)
11119,European,51564.0,31508503.0,Warrier V,Other measurement,initial,2019-09-03,GCST008887,Systemising
10592,European,26063.0,31508503.0,Warrier V,Other measurement,initial,2019-09-03,GCST008888,Systemising
10582,European,25501.0,31508503.0,Warrier V,Other measurement,initial,2019-09-03,GCST008889,Systemising
12331,European,401198.0,31504236.0,Wiberg A,Other trait,initial,2019-09-05,GCST008818,Handedness (Left-handed vs. non-left-handed)
12332,European,401198.0,31504236.0,Wiberg A,Other trait,initial,2019-09-05,GCST008820,Handedness (non-right-handed vs right-handed)
12329,European,394889.0,31504236.0,Wiberg A,Other trait,initial,2019-09-05,GCST008819,Handedness (left-handed vs. right-handed)
8364,European,4822.0,31498392.0,Kusic DM,"Body measurement, Other measurement",initial,2019-09-09,GCST008823,Body mass index
12234,European,325153.0,31501611.0,Karlsson T,Other measurement,initial,2019-09-09,GCST008744,Predicted visceral adipose tissue
13662,Other/Mixed,429.0,31498392.0,Kusic DM,"Body measurement, Other measurement",initial,2019-09-09,GCST008823,Body mass index
11912,European,163984.0,31501611.0,Karlsson T,Other measurement,initial,2019-09-09,GCST008743,Predicted visceral adipose tissue
11906,European,161168.0,31501611.0,Karlsson T,Other measurement,initial,2019-09-09,GCST008742,Predicted visceral adipose tissue
14030,Other/Mixed,51541.0,31511532.0,Teumer A,"Other measurement, Metabolic disorder",initial,2019-09-11,GCST008792,Urinary albumin-to-creatinine ratio in diabetes
1276,African American or Afro-Caribbean,6795.0,31511532.0,Teumer A,Other measurement,initial,2019-09-11,GCST008790,Urinary albumin-to-creatinine ratio
1277,African American or Afro-Caribbean,6795.0,31511532.0,Teumer A,Other measurement,initial,2019-09-11,GCST008793,Urinary albumin-to-creatinine ratio
14046,Other/Mixed,348954.0,31511532.0,Teumer A,Other trait,initial,2019-09-11,GCST008791,Microalbuminuria
12433,European,547361.0,31511532.0,Teumer A,Other measurement,initial,2019-09-11,GCST008790,Urinary albumin-to-creatinine ratio
12434,European,547361.0,31511532.0,Teumer A,Other measurement,initial,2019-09-11,GCST008794,Urinary albumin-to-creatinine ratio
3713,Asian,6324.0,31511532.0,Teumer A,Other measurement,initial,2019-09-11,GCST008790,Urinary albumin-to-creatinine ratio
12830,Hispanic or Latin American,1442.0,31511532.0,Teumer A,Other measurement,initial,2019-09-11,GCST008790,Urinary albumin-to-creatinine ratio
3065,Asian,2335.0,31511532.0,Teumer A,Other measurement,initial,2019-09-11,GCST008790,Urinary albumin-to-creatinine ratio
3962,Asian,8842.0,31513605.0,Jeon S,Metabolic disorder,initial,2019-09-12,GCST008827,Type 2 diabetes
3959,Asian,8842.0,31513605.0,Jeon S,Body measurement,initial,2019-09-12,GCST008826,Waist circumference
3960,Asian,8842.0,31513605.0,Jeon S,"Body measurement, Other measurement",initial,2019-09-12,GCST008825,Body mass index
3961,Asian,8842.0,31513605.0,Jeon S,Cardiovascular disease,initial,2019-09-12,GCST008828,Hypertension
3963,Asian,8842.0,31513605.0,Jeon S,Other measurement,initial,2019-09-12,GCST008824,Subscapular skin fold thickness
5854,European,858.0,31519223.0,Scepanovic P,Other measurement,initial,2019-09-13,GCST008903,Gut microbiota relative abundance (bacterial taxa)
5853,European,858.0,31519223.0,Scepanovic P,Other measurement,initial,2019-09-13,GCST008902,Gut microbiota (bacterial taxa)
5851,European,858.0,31519223.0,Scepanovic P,Other measurement,initial,2019-09-13,GCST008900,Gut microbiota (alpha diversity)
5852,European,858.0,31519223.0,Scepanovic P,Other measurement,initial,2019-09-13,GCST008901,Gut microbiota (beta diversity)
11866,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008859,Depressive symptom (anhedonia) (binary trait)
11847,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008840,Depressive symptom (depressed mood) (binary trait)
11849,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008842,Depressive symptom (fatigue) (binary trait)
11848,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008841,Depressive symptom (sleep problems) (binary trait)
11851,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008844,Depressive symptom (low self-esteem) (binary trait)
11865,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008858,Depressive symptom (depressed mood) (ordinal trait)
11864,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008857,Depressive symptom (anhedonia) (ordinal trait)
11863,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008856,Depressive symptom (suicidal ideation) (ordinal trait)
11862,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008855,Depressive symptom (psychomotor changes) (ordinal trait)
11861,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008854,Depressive symptom (concentration problems) (ordinal trait)
11850,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008843,Depressive symptom (appetite changes) (binary trait)
11859,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008852,Depressive symptom (appetite changes) (ordinal trait)
11860,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008853,Depressive symptom (low self-esteem) (ordinal trait)
11857,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008850,Depressive symptom (sleep problems) (ordinal trait)
11856,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008849,Depressive symptoms (binary sum-score)
11855,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008848,Depressive symptoms (sum-score)
11854,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008847,Depressive symptom (suicidal ideation) (binary trait)
11853,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008846,Depressive symptom (psychomotor changes) (binary trait)
11852,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008845,Depressive symptom (concentration problems) (binary trait)
11858,European,148752.0,31530331.0,Thorp JG,Other measurement,initial,2019-09-18,GCST008851,Depressive symptom (fatigue) (ordinal trait)
6972,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008934,Sterol levels
6976,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008938,Total cholesterol levels
6975,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008937,Triglyceride levels
6974,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008936,High density lipoprotein cholesterol levels
6973,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008935,Low density lipoprotein cholesterol levels
6971,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008933,Sphingomyelin levels
6965,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008927,Phosphatidylcholine levels
6969,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008931,Phosphatidylinositol levels
6964,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008926,Lysophosphatidylethanolamine levels
6963,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008925,Lysophosphatidylcholine levels
6962,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008924,Diacylglyceride levels
6966,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008928,Phosphatidylcholine-ether levels
6967,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008929,Phosphatidylethanolamine levels
6970,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008932,Cholesteryl ester levels
6960,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008922,Triacylglyceride levels
6968,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008930,Phosphatidylethanolamine-ether levels
6961,European,2045.0,31551469.0,Tabassum R,Lipid or lipoprotein measurement,initial,2019-09-24,GCST008923,Ceramide levels
11720,European,123522.0,31553412.0,Legge SE,Other trait,initial,2019-09-25,GCST008896,Psychotic experience (distressing)
11727,European,124716.0,31553412.0,Legge SE,Other trait,initial,2019-09-25,GCST008897,Psychotic experience (multiple occurrences)
11741,European,127502.0,31553412.0,Legge SE,Other trait,initial,2019-09-25,GCST008895,Psychotic experience
13336,Hispanic or Latin American,25847.0,31564439.0,Fang H,"Other measurement, Body measurement",initial,2019-09-26,GCST008904,Height
783,African American or Afro-Caribbean,1019.0,31579629.0,Fiorica PN,Neurological disorder,initial,2019-09-26,GCST008905,Bipolar disorder
12122,European,253918.0,31564434.0,Wells HRR,Neurological disorder,initial,2019-09-26,GCST008898,Adult hearing aid use
12112,European,250389.0,31564434.0,Wells HRR,Neurological disorder,initial,2019-09-26,GCST008899,Adult hearing difficulty
1514,African American or Afro-Caribbean,68155.0,31564439.0,Fang H,"Other measurement, Body measurement",initial,2019-09-26,GCST008904,Height
3254,Asian,3054.0,31564439.0,Fang H,"Other measurement, Body measurement",initial,2019-09-26,GCST008904,Height
10845,European,35004.0,31564434.0,Wells HRR,Neurological disorder,replication,2019-09-26,GCST008898,Adult hearing aid use
12105,European,248507.0,31564439.0,Fang H,"Other measurement, Body measurement",initial,2019-09-26,GCST008904,Height
10710,European,30765.0,31564434.0,Wells HRR,Neurological disorder,replication,2019-09-26,GCST008899,Adult hearing difficulty
987,African American or Afro-Caribbean,2256.0,31579629.0,Fiorica PN,Neurological disorder,initial,2019-09-26,GCST008906,Schizophrenia
4223,Asian,15770.0,31562322.0,Takata R,Cancer,initial,2019-09-27,GCST008860,Prostate cancer
4373,Asian,32692.0,31562340.0,Akiyama M,"Other measurement, Body measurement",replication,2019-09-27,GCST008839,Height
4468,Asian,78079.0,31562322.0,Takata R,Cancer,replication,2019-09-27,GCST008860,Prostate cancer
4548,Asian,159095.0,31562340.0,Akiyama M,"Other measurement, Body measurement",initial,2019-09-27,GCST008839,Height
6992,European,2064.0,31587654.0,Torres-Aguila NP,"Hematological measurement, Other trait",initial,2019-10-07,GCST008915,Leukocyte count in ischemic stroke
5126,European,407.0,31587654.0,Torres-Aguila NP,"Hematological measurement, Other trait",replication,2019-10-07,GCST008915,Leukocyte count in ischemic stroke
12437,European,567288.0,31619474.0,Zhu Z,"Other disease, Neurological disorder",initial,2019-10-17,GCST008921,Asthma and major depressive disorder
12277,European,357157.0,31619474.0,Zhu Z,Other disease,initial,2019-10-17,GCST008917,Asthma (childhood onset)
12382,European,447576.0,31619474.0,Zhu Z,"Neurological disorder, Other disease",initial,2019-10-17,GCST008919,Asthma and attention deficit hyperactivity disorder
12292,European,369777.0,31619474.0,Zhu Z,Other disease,initial,2019-10-17,GCST008918,Asthma (adult onset)
12327,European,394283.0,31619474.0,Zhu Z,Other disease,initial,2019-10-17,GCST008916,Asthma
12348,European,411593.0,31619474.0,Zhu Z,"Other disease, Neurological disorder",initial,2019-10-17,GCST008920,Asthma and anxiety disorder
